data_1pla_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1pla _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 109.908 -0.405 . . . . 0.0 109.908 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -131.17 122.15 26.1 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.823 -0.751 . . . . 0.0 110.835 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.6 t -115.15 126.59 72.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 119.966 -0.694 . . . . 0.0 110.33 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 22.1 mtmt -101.72 116.15 32.1 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.918 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.0 mt -79.56 114.64 18.64 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.167 -1.013 . . . . 0.0 109.971 178.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.499 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 96.83 108.02 2.49 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.491 -1.338 . . . . 0.0 109.787 -179.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.0 p . . . . . 0 C--N 1.305 -1.349 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.934 -179.354 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.2 mt . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 120.438 0.161 . . . . 0.0 110.658 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.7 m -150.48 158.11 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 119.009 -1.076 . . . . 0.0 110.999 179.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.535 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 16.7 m-85 -78.8 111.96 15.45 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 177.628 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.0 m -114.4 107.62 51.06 Favored Pre-proline 0 N--CA 1.484 1.264 0 C-N-CA 119.421 -0.911 . . . . 0.0 112.226 -177.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.413 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.0 OUTLIER -67.64 176.58 25.44 Favored 'Cis proline' 0 C--N 1.362 1.275 0 C-N-CA 125.4 -0.667 . . . . 0.0 111.6 -0.555 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -92.49 -58.8 2.25 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.014 179.118 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.2 t -124.06 138.55 54.43 Favored 'General case' 0 N--CA 1.487 1.4 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.265 178.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.41 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 9.0 p90 -159.72 136.06 8.96 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 118.328 -1.349 . . . . 0.0 111.706 -178.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -85.98 150.67 24.32 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.329 179.436 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.3 m -144.21 177.79 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.179 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -98.05 145.79 26.18 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.68 -0.808 . . . . 0.0 110.365 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.4 88.9 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.122 -1.031 . . . . 0.0 110.934 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 139.16 19.73 0.46 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -96.28 137.67 35.0 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.715 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 54.1 mttm -84.89 120.11 26.1 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.248 -0.981 . . . . 0.0 110.924 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.7 mt -109.27 110.88 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.038 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 30.3 p -106.2 116.92 32.77 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.379 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -85.86 103.59 14.74 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.023 178.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.6 tttm -101.7 135.19 43.66 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.758 -0.777 . . . . 0.0 112.218 -177.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.471 ' OD1' ' N ' ' A' ' 31' ' ' ASN . 1.3 m-20 -76.71 126.24 30.64 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.935 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 0.9 OUTLIER -106.78 -32.62 7.88 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.086 -1.046 . . . . 0.0 113.136 -178.371 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 178.11 11.94 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.387 0 C-N-CA 119.052 -1.059 . . . . 0.0 111.729 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -124.88 49.68 0.9 Allowed Glycine 0 N--CA 1.5 2.931 0 C-N-CA 119.35 -1.405 . . . . 0.0 112.104 -178.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.596 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -91.06 161.31 35.63 Favored Pre-proline 0 N--CA 1.488 1.428 0 C-N-CA 118.35 -1.34 . . . . 0.0 110.291 178.805 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -78.17 142.42 69.6 Favored 'Cis proline' 0 C--O 1.215 -0.658 0 C-N-CA 124.004 -1.248 . . . . 0.0 111.825 -1.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.524 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 36.9 m-70 -107.26 162.38 13.95 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.596 -0.842 . . . . 0.0 111.016 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -144.6 137.76 26.94 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 119.607 -0.837 . . . . 0.0 109.852 179.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.4 mp -127.29 117.46 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.16 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.58 142.84 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.765 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 7.5 m-85 -95.08 117.74 30.7 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.738 -178.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.513 ' C ' ' H ' ' A' ' 44' ' ' ASP . 21.6 t0 -55.4 99.33 0.03 OUTLIER 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.374 179.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -64.01 5.26 0.25 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.446 -0.902 . . . . 0.0 111.392 -179.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.513 ' H ' ' C ' ' A' ' 42' ' ' ASP . 9.6 m-20 -99.78 -8.67 23.91 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.915 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -134.6 16.33 3.65 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.957 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -95.53 147.03 32.36 Favored Pre-proline 0 N--CA 1.49 1.529 0 N-CA-C 108.957 -0.756 . . . . 0.0 108.957 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -47.84 142.73 14.3 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.958 1.105 . . . . 0.0 111.799 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.2 70.64 1.63 Allowed 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.712 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.46 -37.75 0.12 Allowed Glycine 0 N--CA 1.488 2.102 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.077 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.4 t -86.22 104.9 14.15 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.789 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -48.28 147.7 2.18 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.738 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -99.46 -5.81 28.73 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.918 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.07 -30.45 17.7 Favored 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.511 -0.876 . . . . 0.0 111.19 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 36.0 mttt -69.25 -29.91 67.92 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.148 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.1 pt -94.16 -37.52 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.748 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 57.7 m -64.01 159.62 19.68 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.537 -0.865 . . . . 0.0 111.253 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.611 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -139.66 75.67 31.15 Favored Pre-proline 0 N--CA 1.486 1.361 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.398 179.635 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -57.63 -21.76 48.62 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 121.262 1.308 . . . . 0.0 111.567 -179.078 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.21 95.67 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.021 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -42.71 163.11 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.799 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -150.09 111.64 4.48 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 118.862 -1.135 . . . . 0.0 111.878 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -106.33 21.66 17.03 Favored 'General case' 0 N--CA 1.488 1.475 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.918 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -83.65 137.66 16.5 Favored Glycine 0 N--CA 1.494 2.53 0 C-N-CA 119.355 -1.403 . . . . 0.0 110.655 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -82.32 114.48 20.82 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.533 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.07 -13.67 66.62 Favored Glycine 0 N--CA 1.488 2.147 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.506 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.25 150.34 26.05 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.209 -0.996 . . . . 0.0 110.31 179.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.57 168.75 19.88 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 118.981 -1.087 . . . . 0.0 111.884 -179.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.611 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 29.3 t80 -135.29 129.88 34.24 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.555 179.228 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.96 152.86 21.01 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.306 -178.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.1 t -151.79 130.78 3.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 CA-C-N 115.105 -0.952 . . . . 0.0 108.844 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 20.6 m -129.86 93.93 3.62 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.652 -0.819 . . . . 0.0 111.226 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 13.7 mt -79.39 157.98 27.49 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.213 -0.995 . . . . 0.0 109.507 179.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' THR . . . . . 0.437 ' OG1' ' O ' ' A' ' 73' ' ' THR . 2.2 t -149.94 46.07 0.92 Allowed 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 118.793 -1.163 . . . . 0.0 111.649 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.416 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 5.6 tt0 -144.93 99.98 3.42 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 118.977 -1.089 . . . . 0.0 109.913 179.048 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.404 ' C ' ' O ' ' A' ' 74' ' ' GLU . 0.0 OUTLIER -39.45 112.48 0.26 Allowed 'General case' 0 N--CA 1.484 1.239 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.344 -179.124 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.76 -148.88 10.0 Favored Glycine 0 N--CA 1.484 1.849 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.004 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.96 132.34 25.09 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.922 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.562 ' N ' ' CD1' ' A' ' 78' ' ' TYR . 1.2 m-85 -120.8 126.01 49.03 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.66 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.442 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -100.4 114.11 27.39 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.78 -179.361 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.594 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -125.02 169.74 11.83 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.09 178.686 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -171.25 -179.76 2.76 Favored 'General case' 0 C--N 1.297 -1.694 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.073 -179.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 2.1 t -106.39 115.31 29.99 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.504 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.563 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 tt0 -66.87 -40.38 29.77 Favored Pre-proline 0 C--N 1.3 -1.576 0 C-N-CA 119.379 -0.928 . . . . 0.0 112.724 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.563 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.4 Cg_endo -68.95 -47.69 1.12 Allowed 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 120.822 1.015 . . . . 0.0 112.03 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -87.87 12.15 13.84 Favored 'General case' 0 N--CA 1.487 1.423 0 C-N-CA 119.238 -0.985 . . . . 0.0 111.296 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.72 -24.4 61.42 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.771 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -62.24 -22.19 62.8 Favored Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.514 -1.327 . . . . 0.0 110.414 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.92 -31.83 14.8 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.621 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 117.21 30.22 1.96 Allowed Glycine 0 N--CA 1.495 2.611 0 C-N-CA 119.991 -1.1 . . . . 0.0 110.495 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.3 mtp -77.88 105.52 9.12 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.862 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.535 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 0.6 OUTLIER -127.61 166.89 17.19 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 119.956 -0.698 . . . . 0.0 110.777 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -147.83 148.44 19.98 Favored Glycine 0 N--CA 1.488 2.104 0 C-N-CA 119.018 -1.563 . . . . 0.0 111.286 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -153.63 141.64 20.28 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.625 179.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.2 p -136.87 125.26 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.624 179.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 95.8 m -103.32 98.71 8.58 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.409 -0.916 . . . . 0.0 110.645 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 41.1 t -80.03 148.3 5.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.255 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 6.7 m-80 . . . . . 0 C--N 1.304 -1.41 0 CA-C-O 116.344 -1.789 . . . . 0.0 111.007 -179.554 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.105 0 CA-C-O 120.792 0.33 . . . . 0.0 110.197 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -130.19 121.46 26.27 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.54 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.8 t -112.87 122.02 66.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.682 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 60.8 mttt -94.53 116.61 28.98 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.761 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.434 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 8.5 mt -76.21 102.4 5.79 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 118.615 -1.234 . . . . 0.0 109.525 178.18 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 121.25 155.7 9.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.031 -1.627 . . . . 0.0 109.031 -178.204 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.2 p . . . . . 0 C--N 1.301 -1.528 0 C-N-CA 119.039 -1.064 . . . . 0.0 111.047 -179.395 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 80.1 mt . . . . . 0 N--CA 1.488 1.426 0 N-CA-C 110.382 -0.229 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 m -149.71 154.78 8.77 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 C-N-CA 118.74 -1.184 . . . . 0.0 111.072 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' A' ' 16' ' ' PRO . 17.2 m-85 -78.2 110.16 12.94 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.7 m -115.0 109.01 47.5 Favored Pre-proline 0 CA--C 1.562 1.41 0 C-N-CA 119.369 -0.933 . . . . 0.0 112.503 -177.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.421 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.9 Cg_endo -66.66 178.35 17.84 Favored 'Cis proline' 0 C--N 1.364 1.348 0 C-N-CA 125.27 -0.721 . . . . 0.0 111.484 -0.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.6 p -94.94 -60.43 1.69 Allowed 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.933 179.177 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.2 p -121.05 135.41 55.2 Favored 'General case' 0 N--CA 1.486 1.34 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.076 178.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.465 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 14.4 p90 -157.88 140.74 14.89 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 118.528 -1.269 . . . . 0.0 111.49 -178.729 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -87.77 153.45 21.33 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.357 -0.937 . . . . 0.0 110.633 179.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.1 m -145.94 158.76 11.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.105 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.421 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -75.04 145.88 42.02 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.211 -0.996 . . . . 0.0 110.427 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.27 73.03 0.12 Allowed 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.459 -0.896 . . . . 0.0 110.9 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 160.98 11.15 0.04 OUTLIER Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -98.81 157.14 16.49 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.913 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.4 mmtp -95.48 134.2 38.6 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.33 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.9 mt -107.09 104.36 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 120.076 -0.649 . . . . 0.0 109.358 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 52.3 p -101.41 117.57 35.21 Favored 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 119.553 -0.859 . . . . 0.0 112.612 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -91.16 109.76 21.03 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.12 178.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 31.0 tttt -103.14 135.14 45.37 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.58 -178.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 1.0 OUTLIER -84.67 106.11 15.98 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.258 -0.977 . . . . 0.0 110.108 179.237 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.434 ' OD1' ' O ' ' A' ' 5' ' ' LEU . 4.3 p-10 -93.36 -28.6 16.07 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.208 -0.997 . . . . 0.0 112.016 -178.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 175.44 133.57 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 118.55 -1.26 . . . . 0.0 111.371 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 111.48 5.97 25.73 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.782 -1.199 . . . . 0.0 111.579 179.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.452 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -52.47 162.54 0.89 Allowed Pre-proline 0 N--CA 1.488 1.437 0 C-N-CA 118.188 -1.405 . . . . 0.0 109.744 179.814 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -78.76 161.62 88.95 Favored 'Cis proline' 0 C--O 1.212 -0.798 0 C-N-CA 124.38 -1.091 . . . . 0.0 112.636 -0.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -125.75 172.7 9.6 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.952 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.418 HD21 ' CG2' ' A' ' 40' ' ' VAL . 0.7 OUTLIER -153.49 117.53 4.81 Favored 'General case' 0 N--CA 1.492 1.67 0 C-N-CA 118.978 -1.089 . . . . 0.0 110.622 179.185 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.586 ' N ' ' CD1' ' A' ' 39' ' ' ILE . 2.4 mp -96.18 129.71 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.146 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.418 ' CG2' HD21 ' A' ' 38' ' ' ASN . 2.6 t -143.31 138.63 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 C-N-CA 119.679 -0.808 . . . . 0.0 110.427 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -98.33 118.26 34.59 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.206 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.524 ' OD2' ' N ' ' A' ' 45' ' ' GLU . 11.2 t70 -53.1 120.4 5.86 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.348 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -73.57 0.47 12.51 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.433 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.404 ' N ' ' OD2' ' A' ' 42' ' ' ASP . 14.6 m-20 -107.99 4.2 24.92 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.813 -0.755 . . . . 0.0 111.135 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.524 ' N ' ' OD2' ' A' ' 42' ' ' ASP . 34.5 mt-10 -146.18 52.56 1.14 Allowed 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 119.486 -0.886 . . . . 0.0 110.835 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -137.03 148.36 62.52 Favored Pre-proline 0 N--CA 1.493 1.676 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -49.58 145.78 16.31 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 121.061 1.174 . . . . 0.0 111.678 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.89 81.92 2.8 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.709 -0.796 . . . . 0.0 111.025 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 161.54 -41.95 0.4 Allowed Glycine 0 N--CA 1.489 2.174 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.312 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 92.0 t -81.96 95.94 3.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.348 -0.941 . . . . 0.0 110.84 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -44.94 143.76 1.39 Allowed 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.969 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.412 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -95.54 -2.04 49.3 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.625 -0.83 . . . . 0.0 110.898 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -86.55 -35.13 19.7 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.98 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 30.7 mttt -68.75 -34.38 75.5 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.581 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.1 pt -89.94 -29.68 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 C-N-CA 118.938 -1.105 . . . . 0.0 111.062 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.412 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 7.6 m -58.95 -178.63 0.05 Allowed 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.928 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.614 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 61.2 mt-30 -146.38 73.19 13.02 Favored Pre-proline 0 N--CA 1.484 1.274 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.031 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -62.39 -4.52 5.5 Favored 'Trans proline' 0 C--N 1.321 -0.879 0 C-N-CA 121.094 1.196 . . . . 0.0 110.984 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.405 ' H ' ' C ' ' A' ' 57' ' ' GLN . 16.0 mt-10 -100.31 99.98 10.71 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.828 -0.749 . . . . 0.0 110.545 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -47.54 164.49 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.411 -0.916 . . . . 0.0 110.92 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.1 pp -142.32 135.95 29.21 Favored 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.96 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -135.46 42.41 2.7 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.664 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -102.5 128.28 9.49 Favored Glycine 0 N--CA 1.495 2.595 0 C-N-CA 119.584 -1.293 . . . . 0.0 110.532 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -78.06 108.22 11.19 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.628 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.51 -6.37 59.14 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.325 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -71.96 157.69 37.37 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.555 179.835 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 4.9 p -148.64 163.29 37.71 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.051 -1.059 . . . . 0.0 111.229 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.614 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 28.5 t80 -134.7 139.16 45.02 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.651 179.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.411 ' CD ' ' H ' ' A' ' 69' ' ' GLU . 1.7 mp0 -102.76 148.5 25.53 Favored 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 119.434 -0.907 . . . . 0.0 112.252 -178.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -142.82 126.05 14.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 115.124 -0.943 . . . . 0.0 108.748 179.208 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.0 m -117.47 112.82 21.15 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.61 -0.836 . . . . 0.0 112.039 -178.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 58.3 mt -95.88 161.7 13.89 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.47 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 87.9 m -150.57 42.61 0.81 Allowed 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 118.662 -1.215 . . . . 0.0 112.044 -179.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -147.9 102.97 3.45 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 118.658 -1.217 . . . . 0.0 110.33 179.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.472 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 11.5 pttt -43.97 120.2 2.0 Allowed 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.723 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.446 ' C ' ' HG1' ' A' ' 77' ' ' THR . . . 169.45 -147.01 10.58 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' THR . . . . . 0.446 ' HG1' ' C ' ' A' ' 76' ' ' GLY . 0.1 OUTLIER -143.25 128.85 19.16 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.405 -0.918 . . . . 0.0 111.248 -179.864 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.562 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -115.73 136.87 52.64 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.422 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.412 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -107.86 116.27 31.64 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.634 -0.826 . . . . 0.0 111.541 -179.348 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.489 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 2.4 p90 -130.26 166.8 19.58 Favored 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.082 178.485 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -170.46 -172.74 1.3 Allowed 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.682 -178.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -107.32 126.08 51.99 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.756 179.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.499 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.9 mt-10 -68.78 -47.11 33.18 Favored Pre-proline 0 C--N 1.305 -1.336 0 C-N-CA 119.593 -0.843 . . . . 0.0 112.599 -179.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.499 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.9 Cg_endo -64.72 -47.77 4.89 Favored 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 120.719 0.946 . . . . 0.0 111.746 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -90.84 19.88 5.21 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.808 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.44 -14.23 11.63 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.346 -0.942 . . . . 0.0 110.462 179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -93.76 -12.47 56.75 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.151 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.01 -13.53 38.59 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.597 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 96.96 25.6 11.23 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.605 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.64 99.77 10.42 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.234 -0.987 . . . . 0.0 111.022 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -120.97 159.7 25.06 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.793 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.74 143.03 11.47 Favored Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.337 -1.411 . . . . 0.0 111.071 -179.049 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -150.68 144.74 25.39 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.35 179.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.0 p -135.24 125.73 44.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.689 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 55.0 m -101.67 98.22 8.54 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.274 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 41.2 t -79.75 152.51 4.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 118.587 -1.245 . . . . 0.0 110.734 -178.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 116.283 -1.818 . . . . 0.0 110.826 -179.688 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.118 0 CA-C-O 120.78 0.324 . . . . 0.0 110.142 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.439 ' OE1' ' O ' ' A' ' 28' ' ' THR . 3.1 mm-40 -140.19 121.0 14.43 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.618 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -108.72 120.54 60.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 C-N-CA 119.917 -0.713 . . . . 0.0 110.509 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.7 mttt -91.16 114.55 27.11 Favored 'General case' 0 C--N 1.299 -1.59 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.992 -179.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.0 mt -74.51 113.84 12.22 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.239 178.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.47 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 99.28 124.13 5.12 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.488 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.44 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 16.6 p . . . . . 0 C--N 1.302 -1.46 0 C-N-CA 119.324 -0.951 . . . . 0.0 110.428 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.3 mt . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 120.402 0.144 . . . . 0.0 110.983 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.4 m -144.25 155.86 15.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 C-N-CA 119.098 -1.041 . . . . 0.0 110.674 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.401 ' O ' ' C ' ' A' ' 16' ' ' PRO . 16.6 m-85 -77.36 112.98 14.67 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 177.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.8 m -114.89 108.46 48.66 Favored Pre-proline 0 CA--C 1.558 1.283 0 C-N-CA 119.219 -0.992 . . . . 0.0 112.007 -177.348 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.401 ' C ' ' O ' ' A' ' 14' ' ' PHE . 3.2 Cg_exo -67.5 170.71 46.55 Favored 'Cis proline' 0 C--N 1.362 1.269 0 C-N-CA 125.321 -0.7 . . . . 0.0 111.597 -0.536 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.5 t -90.23 -64.51 1.12 Allowed 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.543 178.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.35 139.58 50.25 Favored 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.199 178.69 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.401 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 9.5 p90 -167.95 139.45 2.91 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 118.468 -1.293 . . . . 0.0 111.424 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -85.06 159.12 20.26 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.623 -0.831 . . . . 0.0 111.411 -179.591 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 25.9 m -146.69 -177.75 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.059 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.87 148.95 21.76 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.438 -0.905 . . . . 0.0 111.015 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.39 68.48 0.54 Allowed 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.042 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 159.21 14.03 0.04 OUTLIER Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -97.36 155.95 16.67 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.907 -0.717 . . . . 0.0 111.038 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 13.7 mttp -95.44 138.53 33.0 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.76 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.9 mt -117.65 127.58 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.443 179.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.439 ' O ' ' OE1' ' A' ' 2' ' ' GLU . 7.6 p -125.51 119.07 27.18 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.544 -0.862 . . . . 0.0 112.17 -178.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -84.91 110.37 18.81 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.489 -0.885 . . . . 0.0 109.024 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 50.0 tttp -101.45 139.13 37.54 Favored 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.158 -178.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -86.45 112.57 21.62 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.47 179.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.484 ' O ' ' CB ' ' A' ' 33' ' ' ALA . 1.0 OUTLIER -95.66 -30.8 13.57 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 119.224 -0.991 . . . . 0.0 111.543 -179.227 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.484 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 164.69 118.08 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 119.349 -0.94 . . . . 0.0 111.182 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 138.6 -1.03 2.57 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.957 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.409 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -47.69 164.66 0.24 Allowed Pre-proline 0 C--N 1.307 -1.281 0 C-N-CA 118.839 -1.144 . . . . 0.0 110.137 -179.835 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_endo -75.99 138.9 57.6 Favored 'Cis proline' 0 C--O 1.214 -0.722 0 C-N-CA 124.292 -1.128 . . . . 0.0 112.633 -0.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.5 m-70 -110.3 156.4 20.77 Favored 'General case' 0 N--CA 1.485 1.295 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.205 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.429 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 6.2 t30 -148.42 116.23 6.35 Favored 'General case' 0 C--N 1.3 -1.58 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.136 179.251 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.7 mp -96.64 137.22 25.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.652 -178.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.429 ' CG2' ' ND2' ' A' ' 38' ' ' ASN . 1.5 t -146.54 149.42 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.987 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -107.58 118.28 36.32 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.712 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.516 ' OD2' ' N ' ' A' ' 45' ' ' GLU . 1.6 t70 -55.58 119.32 5.5 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 119.576 -0.849 . . . . 0.0 110.28 179.47 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -75.5 14.21 0.65 Allowed 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 119.393 -0.923 . . . . 0.0 111.55 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.414 ' H ' ' C ' ' A' ' 42' ' ' ASP . 4.0 m-20 -115.39 2.1 13.86 Favored 'General case' 0 N--CA 1.495 1.779 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.049 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.548 ' OE1' ' NZ ' ' A' ' 79' ' ' LYS . 11.8 mm-40 -140.6 19.3 2.36 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 119.657 -0.817 . . . . 0.0 110.446 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -107.69 147.12 34.76 Favored Pre-proline 0 N--CA 1.488 1.471 0 CA-C-N 115.23 -0.895 . . . . 0.0 108.856 179.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -48.6 145.24 12.76 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 120.804 1.003 . . . . 0.0 111.718 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.35 50.56 0.79 Allowed 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.935 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -160.6 -31.11 0.02 OUTLIER Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 86.3 t -96.18 90.69 2.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.745 -0.782 . . . . 0.0 110.638 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -45.95 139.89 4.05 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.888 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.08 -26.35 36.33 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.62 -0.832 . . . . 0.0 111.109 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -67.48 -19.89 65.39 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.456 -0.898 . . . . 0.0 110.93 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -78.03 -38.01 45.62 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.876 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.7 pt -94.26 -26.41 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.306 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.0 m -72.35 155.89 39.67 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.431 -0.908 . . . . 0.0 111.297 -179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.621 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.1 OUTLIER -137.95 75.98 40.8 Favored Pre-proline 0 C--N 1.303 -1.432 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.972 179.484 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . 0.412 ' O ' ' OD1' ' A' ' 38' ' ' ASN . 5.2 Cg_exo -56.5 -29.07 76.82 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 121.234 1.289 . . . . 0.0 111.496 -178.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -52.96 103.67 0.08 Allowed 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 118.813 -1.155 . . . . 0.0 109.844 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 46.8 m-85 -42.63 161.56 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.69 -0.804 . . . . 0.0 111.105 -179.388 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.475 ' C ' ' CD1' ' A' ' 61' ' ' LEU . 0.3 OUTLIER -143.65 148.08 35.27 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.542 -0.863 . . . . 0.0 110.239 -179.644 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.664 HD21 ' N ' ' A' ' 63' ' ' GLY . 0.0 OUTLIER -148.2 -12.56 0.36 Allowed 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.265 -179.83 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.664 ' N ' HD21 ' A' ' 62' ' ' ASN . . . -48.74 115.82 2.84 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.203 -1.475 . . . . 0.0 110.403 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.51 119.92 10.1 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.962 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.85 -21.29 27.62 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.639 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -58.05 153.76 13.98 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.048 -1.061 . . . . 0.0 110.326 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -140.68 170.01 16.56 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 119.329 -0.948 . . . . 0.0 111.67 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.621 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 22.8 t80 -130.96 130.98 44.11 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.284 179.361 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -93.33 150.76 20.23 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 119.081 -1.048 . . . . 0.0 112.716 -178.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -151.59 136.52 10.28 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-N 115.127 -0.942 . . . . 0.0 108.933 179.246 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.3 m -127.31 104.65 8.05 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.521 -0.871 . . . . 0.0 111.503 -179.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 49.6 mt -88.17 155.14 19.92 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.001 179.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 4.8 p -150.92 47.32 0.85 Allowed 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.935 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.439 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 1.5 mm-40 -144.18 108.48 4.81 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.099 -1.041 . . . . 0.0 110.722 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.508 ' H ' ' HZ2' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -49.79 114.33 1.05 Allowed 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 119.372 -0.931 . . . . 0.0 110.854 -179.572 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 165.28 -137.74 4.86 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.183 -1.484 . . . . 0.0 110.235 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -149.46 143.0 25.4 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.286 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.563 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -127.34 123.74 37.02 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.37 179.716 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.548 ' NZ ' ' OE1' ' A' ' 45' ' ' GLU . 1.2 mptm? -95.43 119.67 34.34 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.728 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.551 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.2 p90 -130.31 171.91 12.4 Favored 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 119.571 -0.852 . . . . 0.0 109.978 177.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 42.5 p90 -171.83 -175.33 1.5 Allowed 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.922 -178.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -108.82 117.18 33.51 Favored 'General case' 0 C--N 1.31 -1.112 0 C-N-CA 119.856 -0.738 . . . . 0.0 109.713 178.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.561 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.4 tt0 -68.3 -39.59 17.0 Favored Pre-proline 0 C--N 1.303 -1.455 0 C-N-CA 119.431 -0.907 . . . . 0.0 112.89 -178.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.561 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.0 Cg_endo -68.99 -43.78 3.07 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 120.638 0.892 . . . . 0.0 111.699 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . 0.463 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.4 m80 -94.15 14.83 18.83 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.306 -0.958 . . . . 0.0 111.173 -179.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.52 0.27 1.65 Allowed 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.089 -1.044 . . . . 0.0 110.687 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.463 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -86.92 -18.05 58.62 Favored Glycine 0 N--CA 1.49 2.238 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.215 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -97.97 -19.99 17.7 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 119.615 -0.834 . . . . 0.0 110.675 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.73 22.0 6.2 Favored Glycine 0 N--CA 1.497 2.74 0 C-N-CA 119.877 -1.154 . . . . 0.0 110.624 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 9.6 ttt -71.22 108.72 4.85 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.494 -0.882 . . . . 0.0 110.832 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.406 ' CG ' ' N ' ' A' ' 92' ' ' GLY . 30.9 ttpt -137.13 159.91 40.53 Favored 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 119.754 -0.778 . . . . 0.0 111.299 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' A' ' 91' ' ' LYS . . . -140.84 156.97 25.71 Favored Glycine 0 N--CA 1.497 2.757 0 C-N-CA 119.688 -1.244 . . . . 0.0 111.559 -178.484 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -157.15 145.94 19.82 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 120.027 -0.669 . . . . 0.0 110.639 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.8 p -139.94 124.91 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 C-N-CA 119.106 -1.038 . . . . 0.0 110.937 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 34.0 m -102.68 103.17 13.41 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.543 -0.863 . . . . 0.0 110.582 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.497 ' C ' HD21 ' A' ' 97' ' ' ASN . 26.2 t -85.71 146.31 6.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 118.866 -1.133 . . . . 0.0 110.622 -178.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.497 HD21 ' C ' ' A' ' 96' ' ' VAL . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 116.375 -1.774 . . . . 0.0 110.661 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.17 0 CA-C-O 120.821 0.343 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -96.73 119.89 36.05 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.702 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 73.4 t -108.31 122.38 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.07 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 76.9 mttt -88.31 111.46 21.73 Favored 'General case' 0 C--N 1.297 -1.706 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.865 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 11.6 mt -73.91 110.08 7.92 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 118.539 -1.264 . . . . 0.0 109.763 178.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.54 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 98.86 126.51 5.64 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -179.109 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 24.5 p . . . . . 0 C--N 1.305 -1.334 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.581 179.907 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.0 mt . . . . . 0 N--CA 1.487 1.419 0 CA-C-O 120.644 0.259 . . . . 0.0 110.756 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 23.6 m -150.83 157.91 5.33 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.65 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.533 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 35.9 m-85 -78.15 113.63 16.28 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 177.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 18.5 m -115.54 109.77 45.53 Favored Pre-proline 0 CA--C 1.56 1.355 0 C-N-CA 119.515 -0.874 . . . . 0.0 112.187 -177.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -65.98 170.58 39.44 Favored 'Cis proline' 0 C--N 1.361 1.232 0 C-N-CA 125.123 -0.782 . . . . 0.0 111.567 -0.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.03 -68.64 0.79 Allowed 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.836 178.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.6 m -110.12 132.92 53.73 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.652 178.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 36.0 p90 -162.15 141.49 9.59 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 118.681 -1.208 . . . . 0.0 111.323 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -85.23 160.28 19.91 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.545 -0.862 . . . . 0.0 111.3 -179.577 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.4 m -149.29 179.11 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.645 179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -96.0 148.29 22.81 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 119.476 -0.89 . . . . 0.0 110.931 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.38 71.1 0.18 Allowed 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.229 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 157.52 16.19 0.04 OUTLIER Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 -102.8 154.89 18.74 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.682 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.3 mtpt -95.33 141.18 29.2 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.419 -0.912 . . . . 0.0 111.386 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.5 mt -119.78 114.81 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.435 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.4 p -111.41 120.97 43.96 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.53 -0.868 . . . . 0.0 112.616 -178.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -85.57 111.72 20.29 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.876 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.7 tttp -102.89 138.77 39.32 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 119.575 -0.85 . . . . 0.0 111.455 -178.078 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.466 ' ND2' ' O ' ' A' ' 66' ' ' GLU . 77.3 m-20 -80.53 110.54 16.1 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.805 179.678 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.54 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 2.0 t30 -98.34 -31.23 12.15 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.225 -0.99 . . . . 0.0 111.673 -179.318 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 170.52 128.19 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.383 -0.927 . . . . 0.0 111.214 179.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 119.5 11.08 7.48 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.789 -1.196 . . . . 0.0 111.355 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.431 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -60.62 163.44 9.15 Favored Pre-proline 0 N--CA 1.484 1.265 0 C-N-CA 118.391 -1.324 . . . . 0.0 110.042 179.819 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -76.92 146.33 83.6 Favored 'Cis proline' 0 C--O 1.217 -0.564 0 C-N-CA 124.145 -1.189 . . . . 0.0 112.636 -0.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 35.3 m-70 -110.67 -179.66 3.82 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.119 179.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -155.67 142.6 19.02 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.015 179.153 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 mt -125.2 121.78 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.247 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.0 t -144.8 143.86 22.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.149 179.395 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -96.32 135.99 37.41 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.877 -179.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.546 ' C ' ' H ' ' A' ' 44' ' ' ASP . 7.8 t0 -71.95 111.24 7.04 Favored 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.671 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -71.4 35.22 0.05 Allowed 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 119.526 -0.869 . . . . 0.0 110.858 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.546 ' H ' ' C ' ' A' ' 42' ' ' ASP . 13.6 m-20 -111.34 -15.65 13.55 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 120.092 -0.643 . . . . 0.0 111.364 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -145.81 -5.39 0.63 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 118.261 -1.376 . . . . 0.0 112.464 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -52.51 142.31 31.45 Favored Pre-proline 0 C--N 1.285 -2.216 0 C-N-CA 118.628 -1.229 . . . . 0.0 108.112 179.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -49.09 148.03 10.2 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 120.895 1.063 . . . . 0.0 112.236 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.25 64.55 2.06 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.722 -0.791 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.58 -39.48 0.06 OUTLIER Glycine 0 N--CA 1.488 2.147 0 C-N-CA 119.57 -1.3 . . . . 0.0 109.863 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 98.8 t -92.16 97.1 6.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.336 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -44.61 162.33 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.447 -0.901 . . . . 0.0 111.155 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -102.91 -29.01 11.69 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.919 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -78.97 -14.15 59.38 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.146 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 1.8 mptp? -81.9 -37.69 26.47 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.064 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -90.87 -17.93 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 C-N-CA 119.199 -1.0 . . . . 0.0 111.019 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 73.6 m -76.55 -177.44 4.19 Favored 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.256 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.638 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -159.96 78.55 2.67 Favored Pre-proline 0 C--N 1.304 -1.405 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.788 179.635 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -60.56 0.99 0.59 Allowed 'Trans proline' 0 C--O 1.213 -0.747 0 C-N-CA 121.372 1.381 . . . . 0.0 112.216 -178.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.485 ' H ' ' C ' ' A' ' 57' ' ' GLN . 6.9 tt0 -82.9 100.44 10.39 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 118.878 -1.129 . . . . 0.0 110.249 179.387 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.43 ' O ' ' O ' ' A' ' 59' ' ' GLU . 43.9 m-85 -41.92 164.79 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.932 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.0 pp -147.3 124.47 11.47 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.103 -1.039 . . . . 0.0 111.037 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.585 ' N ' ' ND2' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -120.8 32.55 5.93 Favored 'General case' 0 N--CA 1.496 1.875 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.706 -179.963 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -97.02 120.87 6.86 Favored Glycine 0 N--CA 1.494 2.56 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.8 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -68.67 118.5 11.74 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.544 -0.862 . . . . 0.0 110.774 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.03 -19.75 40.48 Favored Glycine 0 N--CA 1.488 2.159 0 C-N-CA 119.419 -1.372 . . . . 0.0 110.374 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.466 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 34.8 tt0 -56.99 153.7 10.84 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.22 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -144.88 169.37 18.19 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.212 -0.995 . . . . 0.0 111.579 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.638 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 29.2 t80 -134.73 139.06 44.9 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.141 178.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.486 ' H ' ' CD ' ' A' ' 69' ' ' GLU . 1.3 mp0 -100.32 148.24 24.9 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.181 -1.008 . . . . 0.0 112.755 -178.046 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.3 t -145.74 131.31 13.18 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 114.924 -1.035 . . . . 0.0 108.721 179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.1 m -123.2 113.69 19.28 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.905 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 46.2 mt -98.77 159.12 15.17 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.526 178.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.95 34.45 0.59 Allowed 'General case' 0 C--N 1.297 -1.702 0 C-N-CA 118.824 -1.151 . . . . 0.0 111.64 -178.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.446 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 2.3 mm-40 -137.87 102.38 4.7 Favored 'General case' 0 N--CA 1.492 1.654 0 C-N-CA 119.092 -1.043 . . . . 0.0 110.624 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.431 ' CG ' ' O ' ' A' ' 75' ' ' LYS . 11.2 pttm -43.57 114.59 0.66 Allowed 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.884 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.18 -145.33 7.78 Favored Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.487 -1.34 . . . . 0.0 110.129 -179.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.06 128.93 20.61 Favored 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 119.303 -0.959 . . . . 0.0 111.557 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.578 ' N ' ' CD1' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -121.66 138.85 54.17 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 115.242 -0.89 . . . . 0.0 108.922 179.303 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 12.4 mttp -111.19 127.77 55.7 Favored 'General case' 0 N--CA 1.493 1.689 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.767 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.541 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.6 OUTLIER -129.05 159.81 34.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.048 177.753 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -167.93 178.44 5.16 Favored 'General case' 0 C--N 1.286 -2.171 0 C-N-CA 119.621 -0.832 . . . . 0.0 110.593 -178.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -104.4 131.77 51.39 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.27 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.496 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.6 mt-10 -71.48 -46.22 13.26 Favored Pre-proline 0 C--N 1.306 -1.308 0 C-N-CA 119.364 -0.934 . . . . 0.0 112.843 -179.596 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.0 Cg_endo -67.01 -45.1 4.33 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 120.902 1.068 . . . . 0.0 111.87 -179.402 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -93.52 22.81 5.04 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.886 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -68.5 -13.67 62.48 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.739 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -87.27 -12.3 67.88 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.261 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.54 -12.16 30.21 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.406 -0.918 . . . . 0.0 110.819 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.16 10.79 38.44 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.743 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -66.68 101.6 0.82 Allowed 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.364 -0.935 . . . . 0.0 111.081 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.533 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 18.4 mttp -129.11 173.18 10.7 Favored 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.349 -179.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -155.58 152.09 23.59 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.333 -1.413 . . . . 0.0 111.444 -178.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -155.75 144.95 20.76 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.789 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.4 p -136.46 124.33 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.809 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 68.6 m -100.73 97.92 8.52 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.254 179.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.7 t -79.53 151.9 4.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 119.097 -1.041 . . . . 0.0 110.622 -178.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 10.8 m120 . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 116.319 -1.8 . . . . 0.0 110.783 -179.99 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.087 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -134.31 118.37 17.45 Favored 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.685 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.2 t -102.76 123.51 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 C-N-CA 119.713 -0.795 . . . . 0.0 110.51 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.451 ' CD ' ' HZ1' ' A' ' 30' ' ' LYS . 1.5 mmmm -95.42 117.55 30.56 Favored 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.111 -179.431 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 3.6 mt -86.52 109.85 19.38 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.012 -1.075 . . . . 0.0 110.013 178.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.433 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 101.42 93.56 2.19 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.844 -1.17 . . . . 0.0 110.214 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.6 p . . . . . 0 C--N 1.307 -1.256 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.932 -179.755 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt . . . . . 0 N--CA 1.485 1.296 0 N-CA-C 110.628 -0.138 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.7 m -150.4 158.39 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 118.624 -1.23 . . . . 0.0 111.57 179.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.447 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 18.2 m-85 -78.84 110.45 14.04 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 177.274 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 38.7 m -116.35 108.48 45.51 Favored Pre-proline 0 C--N 1.304 -1.394 0 C-N-CA 119.54 -0.864 . . . . 0.0 112.08 -177.382 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -66.0 175.0 24.47 Favored 'Cis proline' 0 C--N 1.357 0.98 0 C-N-CA 125.312 -0.703 . . . . 0.0 111.8 -0.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.41 ' HG ' ' N ' ' A' ' 18' ' ' SER . 2.2 t -95.71 -64.96 1.01 Allowed 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.706 178.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.41 ' N ' ' HG ' ' A' ' 17' ' ' SER . 81.4 p -118.63 128.3 54.41 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.958 178.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.476 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 12.6 p90 -156.23 145.68 20.8 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 118.477 -1.289 . . . . 0.0 111.255 -178.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -87.46 158.67 18.91 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 119.376 -0.93 . . . . 0.0 111.278 -179.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.0 m -147.39 169.18 4.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.569 179.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -85.83 147.36 26.33 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.664 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.99 73.02 0.18 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.309 -179.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 154.47 15.83 0.05 OUTLIER Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -98.8 154.82 17.72 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.667 -0.813 . . . . 0.0 110.983 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 12.7 mttm -95.43 136.92 35.19 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.549 -0.86 . . . . 0.0 111.136 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 85.6 mt -115.19 104.92 17.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.611 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 26.7 p -99.98 114.65 28.07 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.532 -0.867 . . . . 0.0 112.215 -178.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -85.07 127.74 34.35 Favored 'General case' 0 C--N 1.309 -1.188 0 C-N-CA 119.277 -0.969 . . . . 0.0 109.241 178.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.451 ' HZ1' ' CD ' ' A' ' 4' ' ' LYS . 23.7 tttm -124.41 131.49 53.5 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 119.892 -0.723 . . . . 0.0 111.341 -179.059 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.625 HD22 ' H ' ' A' ' 66' ' ' GLU . 31.3 p-10 -90.15 127.26 36.06 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.355 -0.938 . . . . 0.0 109.792 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.433 ' OD1' ' O ' ' A' ' 6' ' ' GLY . 2.6 p-10 -127.65 -6.4 5.73 Favored 'General case' 0 N--CA 1.495 1.787 0 C-N-CA 118.939 -1.104 . . . . 0.0 112.871 -178.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 177.7 90.74 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 117.982 -1.487 . . . . 0.0 112.184 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 135.73 28.83 0.38 Allowed Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.455 -1.355 . . . . 0.0 111.114 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.596 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -75.95 162.29 72.35 Favored Pre-proline 0 N--CA 1.483 1.191 0 C-N-CA 118.297 -1.361 . . . . 0.0 109.829 179.627 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -79.88 148.55 79.37 Favored 'Cis proline' 0 C--O 1.211 -0.853 0 C-N-CA 124.185 -1.173 . . . . 0.0 112.531 -0.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -110.64 170.96 7.75 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.914 -0.715 . . . . 0.0 110.162 178.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.432 ' OD1' ' CD2' ' A' ' 60' ' ' TYR . 1.0 OUTLIER -149.46 151.87 34.7 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.193 -1.003 . . . . 0.0 110.646 179.525 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.4 mt -132.74 114.51 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 C-N-CA 119.771 -0.772 . . . . 0.0 111.019 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.0 t -131.14 141.97 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.732 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -100.02 120.12 39.33 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 119.278 -0.969 . . . . 0.0 112.085 -179.109 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.556 ' C ' ' H ' ' A' ' 44' ' ' ASP . 1.6 t0 -65.77 114.42 5.03 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.39 -0.924 . . . . 0.0 109.709 178.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.35 15.1 0.06 Allowed 'General case' 0 N--CA 1.491 1.609 0 C-N-CA 119.274 -0.97 . . . . 0.0 111.592 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.556 ' H ' ' C ' ' A' ' 42' ' ' ASP . 3.0 m-20 -101.86 -2.79 29.14 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.224 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -143.1 14.64 1.87 Allowed 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.213 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -96.83 145.51 29.71 Favored Pre-proline 0 C--N 1.299 -1.599 0 C-N-CA 119.868 -0.733 . . . . 0.0 109.107 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -52.9 154.1 13.72 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 120.785 0.99 . . . . 0.0 111.63 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.53 44.08 0.78 Allowed 'General case' 0 C--N 1.307 -1.278 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.584 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -147.68 -38.39 0.04 OUTLIER Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 86.9 t -98.93 94.05 3.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 C-N-CA 119.775 -0.77 . . . . 0.0 110.339 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -44.57 155.36 0.1 Allowed 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.955 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -93.89 -11.66 30.59 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.177 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -89.49 -9.25 50.75 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.92 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 3.0 mmpt? -88.03 -28.62 21.27 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.402 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -105.49 -5.51 9.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.739 -179.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.0 m -74.23 171.53 13.45 Favored 'General case' 0 C--N 1.308 -1.218 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.355 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.617 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 56.3 mt-30 -123.95 80.04 57.38 Favored Pre-proline 0 N--CA 1.49 1.536 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.35 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -61.41 -16.11 45.22 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 120.722 0.948 . . . . 0.0 110.852 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -100.49 119.73 38.94 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.81 -0.756 . . . . 0.0 110.679 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.432 ' CD2' ' OD1' ' A' ' 38' ' ' ASN . 38.4 m-85 -69.04 174.98 4.03 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.839 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.4 pp -144.38 123.31 12.75 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.221 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -116.13 -14.63 11.15 Favored 'General case' 0 N--CA 1.501 2.112 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.184 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.508 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . -52.07 137.5 32.63 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.036 -1.554 . . . . 0.0 110.633 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.64 106.37 5.37 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.661 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 97.61 12.64 46.94 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.519 -1.325 . . . . 0.0 110.004 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.625 ' H ' HD22 ' A' ' 31' ' ' ASN . 1.9 mm-40 -66.02 158.37 28.47 Favored 'General case' 0 N--CA 1.484 1.242 0 C-N-CA 119.229 -0.989 . . . . 0.0 110.244 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.4 p -147.48 160.01 43.08 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 118.805 -1.158 . . . . 0.0 111.979 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.617 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 42.9 t80 -135.8 178.07 7.34 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.371 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.586 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 8.4 mt-10 -140.62 149.74 42.7 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 118.916 -1.113 . . . . 0.0 111.929 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -150.07 132.7 6.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-N 115.322 -0.853 . . . . 0.0 109.218 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.3 m -127.21 106.28 9.14 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.424 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 30.3 mt -91.79 159.72 15.67 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.249 -0.98 . . . . 0.0 110.117 179.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 6.4 p -150.63 46.36 0.87 Allowed 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.098 -1.041 . . . . 0.0 111.544 -179.354 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.433 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 2.0 mm-40 -143.84 101.6 3.77 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 118.995 -1.082 . . . . 0.0 110.565 179.475 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 19.5 tttm -43.96 108.03 0.1 Allowed 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.657 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.71 -143.71 6.76 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.193 -1.479 . . . . 0.0 110.202 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.03 133.17 21.5 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.918 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.58 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.3 m-85 -119.62 157.35 28.61 Favored 'General case' 0 N--CA 1.485 1.29 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.134 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.1 mmtm -124.62 123.81 40.86 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.545 -0.862 . . . . 0.0 112.224 -179.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.574 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.0 OUTLIER -135.25 163.89 28.96 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.099 178.408 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -169.49 179.59 3.78 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 119.165 -1.014 . . . . 0.0 111.223 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -102.17 116.87 33.57 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.778 -0.769 . . . . 0.0 109.651 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.58 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 7.0 tt0 -71.99 -36.08 3.96 Favored Pre-proline 0 C--N 1.304 -1.374 0 C-N-CA 118.941 -1.104 . . . . 0.0 112.901 -179.223 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.58 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -70.2 -52.48 0.29 Allowed 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 120.429 0.753 . . . . 0.0 111.144 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . 0.514 ' C ' ' H ' ' A' ' 87' ' ' GLY . 35.1 m170 -82.14 13.91 3.17 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.829 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.25 -6.14 0.14 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.659 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.514 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -80.55 -27.6 50.73 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.575 -1.298 . . . . 0.0 110.327 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.73 -32.56 23.43 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.4 -0.92 . . . . 0.0 110.392 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 114.94 23.23 4.69 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.926 -1.131 . . . . 0.0 110.903 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 28.6 mtp -65.14 107.68 1.63 Allowed 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.869 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.447 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 17.4 pttp -124.97 159.0 32.26 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 119.975 -0.69 . . . . 0.0 110.461 179.501 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.47 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.86 145.6 15.13 Favored Glycine 0 N--CA 1.497 2.729 0 C-N-CA 119.053 -1.546 . . . . 0.0 111.742 -178.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 51.3 tt0 -150.8 144.7 25.25 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.317 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.2 p -136.99 124.6 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 C-N-CA 119.121 -1.031 . . . . 0.0 111.179 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 41.4 m -100.61 99.51 10.09 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.672 179.406 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.7 t -79.79 146.23 8.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.374 -179.067 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.486 1.346 0 CA-C-O 116.412 -1.756 . . . . 0.0 110.999 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.893 0.377 . . . . 0.0 110.077 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -97.32 122.06 39.92 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.809 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 43.9 t -107.7 121.56 60.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.149 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 45.6 mtpt -92.05 117.36 29.76 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.157 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 16.8 mt -78.15 111.71 14.36 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.558 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.554 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 97.33 120.45 4.02 Favored Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.789 -1.196 . . . . 0.0 110.227 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 18.3 p . . . . . 0 C--N 1.301 -1.5 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.609 179.669 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.3 mt . . . . . 0 N--CA 1.483 1.182 0 CA-C-O 120.525 0.202 . . . . 0.0 110.668 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.4 m -150.89 158.39 4.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 C-N-CA 118.918 -1.113 . . . . 0.0 110.872 179.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.415 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 58.0 m-85 -78.75 112.83 16.28 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 177.093 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 53.8 m -115.0 110.9 45.51 Favored Pre-proline 0 N--CA 1.485 1.316 0 C-N-CA 119.315 -0.954 . . . . 0.0 112.431 -177.089 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -65.82 170.95 37.19 Favored 'Cis proline' 0 C--N 1.362 1.284 0 C-N-CA 125.228 -0.738 . . . . 0.0 111.51 -0.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.424 ' HG ' ' H ' ' A' ' 18' ' ' SER . 6.0 p -94.86 -67.95 0.83 Allowed 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.055 179.082 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.424 ' H ' ' HG ' ' A' ' 17' ' ' SER . 0.3 OUTLIER -109.67 137.32 47.66 Favored 'General case' 0 N--CA 1.486 1.326 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.672 179.198 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -163.57 134.9 4.75 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 118.456 -1.298 . . . . 0.0 111.658 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -85.54 152.88 22.82 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.237 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -144.84 173.78 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.677 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.518 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -94.1 139.22 31.25 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.452 -0.899 . . . . 0.0 110.357 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.19 77.79 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.319 -0.953 . . . . 0.0 110.888 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 158.12 13.83 0.04 OUTLIER Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -104.05 149.69 24.96 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 120.102 -0.639 . . . . 0.0 110.767 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 78.0 mttt -94.91 137.56 33.82 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.105 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mp -115.9 150.47 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 68.5 p -141.75 121.89 13.82 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 118.92 -1.112 . . . . 0.0 112.1 -179.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -87.18 120.93 28.97 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.373 -0.931 . . . . 0.0 108.895 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.5 ttmm -110.99 136.81 49.43 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.669 -0.812 . . . . 0.0 111.742 -178.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.631 ' ND2' ' CD1' ' A' ' 35' ' ' PHE . 19.2 t30 -80.42 104.27 10.85 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 115.109 -0.95 . . . . 0.0 109.723 179.146 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.554 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 1.2 t30 -101.27 -32.03 10.7 Favored 'General case' 0 N--CA 1.491 1.575 0 C-N-CA 118.838 -1.145 . . . . 0.0 112.389 -178.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 177.27 143.06 0.09 Allowed 'General case' 0 N--CA 1.502 2.134 0 C-N-CA 119.503 -0.879 . . . . 0.0 111.166 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 100.89 8.54 48.01 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 119.338 -1.411 . . . . 0.0 112.299 178.286 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.631 ' CD1' ' ND2' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -55.45 162.88 2.06 Favored Pre-proline 0 C--N 1.308 -1.229 0 C-N-CA 117.763 -1.575 . . . . 0.0 109.478 179.569 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_endo -76.67 140.76 67.11 Favored 'Cis proline' 0 C--O 1.215 -0.64 0 C-N-CA 124.285 -1.131 . . . . 0.0 112.521 -0.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.3 m-70 -109.91 163.46 13.53 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.801 179.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.61 HD21 ' H ' ' A' ' 39' ' ' ILE . 1.6 t-20 -148.12 139.79 23.77 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.682 179.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.61 ' H ' HD21 ' A' ' 38' ' ' ASN . 2.7 mp -116.45 118.01 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 120.046 -0.662 . . . . 0.0 111.045 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 28.3 t -129.8 162.37 37.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.899 179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -121.09 122.0 39.1 Favored 'General case' 0 N--CA 1.494 1.755 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.552 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.43 ' C ' ' H ' ' A' ' 44' ' ' ASP . 14.7 t70 -54.13 117.48 3.28 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.346 -179.691 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.451 ' O ' ' OD1' ' A' ' 44' ' ' ASP . 9.2 mt-10 -76.38 39.06 0.19 Allowed 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.297 -179.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.451 ' OD1' ' O ' ' A' ' 43' ' ' GLU . 75.4 m-20 -148.91 -3.22 0.45 Allowed 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.157 -1.017 . . . . 0.0 110.975 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -130.71 8.62 4.92 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.821 -0.752 . . . . 0.0 109.885 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -95.8 148.06 33.97 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 115.027 -0.988 . . . . 0.0 108.79 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -49.45 151.1 7.42 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 120.89 1.06 . . . . 0.0 111.827 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.34 54.84 1.47 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.864 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -165.06 -40.93 0.02 OUTLIER Glycine 0 N--CA 1.489 2.197 0 C-N-CA 119.465 -1.35 . . . . 0.0 110.322 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 46.3 t -86.56 93.95 4.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.969 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -47.14 158.25 0.15 Allowed 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.649 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.64 -25.01 16.3 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.786 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 90.7 mt-10 -71.71 -13.22 61.66 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.884 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.9 mmpp? -87.6 -39.75 14.81 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.775 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.0 pt -91.62 -25.86 5.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.242 -0.983 . . . . 0.0 111.258 -179.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.7 m -55.52 -176.98 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 119.124 -1.031 . . . . 0.0 110.686 179.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.617 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 13.9 tt0 -144.95 78.12 12.78 Favored Pre-proline 0 C--N 1.302 -1.464 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.528 -179.556 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -59.51 -24.51 75.24 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 120.971 1.114 . . . . 0.0 111.532 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -77.9 99.57 6.04 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.201 -1.0 . . . . 0.0 110.484 179.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -56.99 167.28 0.84 Allowed 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.045 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -135.61 105.27 6.11 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 119.729 -0.788 . . . . 0.0 110.708 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -107.26 4.93 27.13 Favored 'General case' 0 N--CA 1.488 1.426 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.701 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -90.88 139.38 14.81 Favored Glycine 0 N--CA 1.489 2.216 0 C-N-CA 119.386 -1.388 . . . . 0.0 110.433 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -74.19 123.55 24.69 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.722 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.19 -8.99 59.32 Favored Glycine 0 N--CA 1.498 2.826 0 C-N-CA 119.547 -1.311 . . . . 0.0 110.983 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -55.83 150.65 12.67 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.976 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 3.2 p -150.59 160.11 44.03 Favored 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 118.829 -1.149 . . . . 0.0 111.667 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.617 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 53.5 t80 -135.68 177.39 7.86 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.898 -0.721 . . . . 0.0 109.745 179.092 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.506 ' O ' ' CE2' ' A' ' 68' ' ' TYR . 9.0 mt-10 -144.99 151.94 39.37 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.118 -1.033 . . . . 0.0 111.554 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.444 ' O ' ' CG1' ' A' ' 70' ' ' VAL . 1.8 p -158.76 127.78 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 C-N-CA 119.552 -0.859 . . . . 0.0 109.981 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.6 m -115.03 93.87 4.5 Favored 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.058 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 11.8 mt -79.15 156.07 28.41 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 118.81 -1.156 . . . . 0.0 109.353 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.2 p -150.86 38.37 0.67 Allowed 'General case' 0 C--N 1.293 -1.886 0 C-N-CA 118.902 -1.119 . . . . 0.0 111.559 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.437 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 0.5 OUTLIER -124.2 96.4 4.91 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 119.482 -0.887 . . . . 0.0 109.62 179.202 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.418 ' C ' ' O ' ' A' ' 74' ' ' GLU . 16.3 mtmm -39.52 99.75 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.292 -178.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.34 -135.4 2.64 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 119.257 -1.449 . . . . 0.0 110.359 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.3 m -150.36 142.56 24.15 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.145 -1.022 . . . . 0.0 111.225 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.611 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.7 m-85 -128.47 125.48 38.55 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.606 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 6.2 mptt -99.23 116.33 31.17 Favored 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.23 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.573 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -123.5 168.87 12.01 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.082 178.74 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -170.73 -176.81 2.15 Favored 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.683 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.5 t -105.86 127.1 52.9 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.775 -0.77 . . . . 0.0 109.865 179.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.567 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 tm-20 -74.59 -37.14 2.75 Favored Pre-proline 0 CA--C 1.558 1.259 0 C-N-CA 119.161 -1.016 . . . . 0.0 113.318 -178.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.1 Cg_endo -71.03 -50.04 0.35 Allowed 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 120.716 0.944 . . . . 0.0 111.416 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -83.72 16.29 2.79 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.594 -0.842 . . . . 0.0 110.888 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.89 -6.21 5.63 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.671 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.83 -11.94 64.8 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.146 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -97.16 -42.41 7.85 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.794 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.25 30.61 0.72 Allowed Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -79.43 110.99 15.25 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.212 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.415 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 1.0 OUTLIER -133.96 162.62 31.55 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.237 -179.808 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -144.1 152.12 23.99 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.675 -1.25 . . . . 0.0 110.661 -178.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -154.13 146.74 24.14 Favored 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 119.105 -1.038 . . . . 0.0 111.29 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.4 p -143.74 126.52 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.261 0 C-N-CA 119.016 -1.074 . . . . 0.0 110.334 178.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 99.4 m -105.61 102.49 11.95 Favored 'General case' 0 N--CA 1.494 1.76 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.723 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.9 t -82.67 141.36 15.06 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.226 -179.172 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 . . . . . 0 C--N 1.302 -1.458 0 CA-C-O 116.344 -1.788 . . . . 0.0 110.857 -179.85 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.114 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -107.66 118.99 38.2 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.741 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 t -108.22 120.01 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 C-N-CA 119.866 -0.734 . . . . 0.0 110.642 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -95.01 116.52 28.8 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.414 -0.914 . . . . 0.0 110.861 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.1 mt -77.2 113.36 14.87 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 118.891 -1.123 . . . . 0.0 109.993 178.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.487 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 101.64 131.75 7.49 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.1 p . . . . . 0 C--N 1.304 -1.388 0 C-N-CA 119.225 -0.99 . . . . 0.0 110.62 179.998 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.9 mt . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 120.634 0.254 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.7 m -151.01 155.2 7.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.828 179.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.402 ' O ' ' C ' ' A' ' 16' ' ' PRO . 67.2 m-85 -78.31 110.53 13.41 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 177.598 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 59.4 m -113.37 110.06 50.82 Favored Pre-proline 0 CA--C 1.557 1.246 0 C-N-CA 119.377 -0.929 . . . . 0.0 112.504 -177.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.402 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.3 Cg_endo -67.62 170.2 49.26 Favored 'Cis proline' 0 C--N 1.363 1.31 0 C-N-CA 125.344 -0.69 . . . . 0.0 111.414 -0.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.4 m -94.0 -70.64 0.7 Allowed 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.441 -0.904 . . . . 0.0 109.648 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.3 t -107.46 129.65 54.92 Favored 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.311 178.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 13.1 p90 -157.22 144.12 18.39 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 118.237 -1.385 . . . . 0.0 111.898 -179.081 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 19.9 m -84.43 157.02 21.51 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.859 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.5 m -150.66 168.28 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 C-N-CA 119.737 -0.785 . . . . 0.0 110.941 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -89.38 148.64 23.39 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.559 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.93 73.57 0.19 Allowed 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.079 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 156.38 16.04 0.04 OUTLIER Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -97.85 153.97 17.95 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.795 -0.762 . . . . 0.0 111.055 -179.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.0 mtmm -95.17 127.52 41.29 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.069 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.0 mt -107.25 103.26 15.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 C-N-CA 120.069 -0.653 . . . . 0.0 109.87 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 52.5 p -100.99 115.12 29.73 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 119.656 -0.818 . . . . 0.0 112.382 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -85.5 109.83 18.76 Favored 'General case' 0 N--CA 1.489 1.485 0 C-N-CA 119.668 -0.813 . . . . 0.0 109.228 178.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.7 tttp -105.61 137.69 43.05 Favored 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 119.46 -0.896 . . . . 0.0 112.122 -178.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.456 ' ND2' ' N ' ' A' ' 31' ' ' ASN . 0.1 OUTLIER -79.64 114.15 18.34 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.272 179.177 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.487 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 0.7 OUTLIER -97.71 -31.04 12.47 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.181 -1.008 . . . . 0.0 111.634 -179.238 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.483 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 165.47 114.38 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.246 -0.981 . . . . 0.0 111.148 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 139.51 3.61 1.56 Allowed Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.434 -1.365 . . . . 0.0 110.863 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.523 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -53.16 163.08 0.96 Allowed Pre-proline 0 C--N 1.304 -1.372 0 C-N-CA 118.704 -1.199 . . . . 0.0 109.741 -179.874 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -77.1 141.26 68.5 Favored 'Cis proline' 0 C--O 1.214 -0.691 0 C-N-CA 124.194 -1.169 . . . . 0.0 112.509 -0.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -107.2 178.23 4.61 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.967 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.534 HD21 ' H ' ' A' ' 83' ' ' GLU . 15.5 t30 -158.09 139.64 13.67 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.618 -0.833 . . . . 0.0 110.212 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.7 mp -128.07 114.74 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 C-N-CA 119.789 -0.765 . . . . 0.0 111.311 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 66.6 t -130.08 134.48 62.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.921 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -87.07 129.18 35.02 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.147 -1.021 . . . . 0.0 111.446 -179.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.648 ' C ' ' H ' ' A' ' 44' ' ' ASP . 31.1 t0 -65.75 94.29 0.2 Allowed 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.646 -178.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -55.37 5.35 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.858 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.373 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.648 ' H ' ' C ' ' A' ' 42' ' ' ASP . 73.8 m-20 -82.85 -68.18 0.73 Allowed 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.557 179.272 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -98.51 25.51 6.32 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.471 -0.892 . . . . 0.0 112.131 -177.031 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -89.16 154.41 49.32 Favored Pre-proline 0 N--CA 1.489 1.5 0 C-N-CA 119.204 -0.998 . . . . 0.0 108.374 178.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -51.13 144.01 30.42 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 121.017 1.145 . . . . 0.0 112.061 -179.065 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.47 69.38 5.72 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.791 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.73 -43.24 0.08 OUTLIER Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 46.5 t -84.18 83.39 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.078 179.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . 0.48 ' ND2' ' H ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER -44.74 140.87 2.31 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.525 -179.652 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.39 -26.33 60.94 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.539 -0.865 . . . . 0.0 111.293 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' A' ' 53' ' ' GLU . 3.7 mp0 -65.34 -3.17 3.77 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.938 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.0 mmpp? -97.44 -40.92 8.45 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.022 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.3 pt -99.13 -13.99 7.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.638 -0.825 . . . . 0.0 111.087 -179.587 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 68.9 m -73.06 173.11 9.82 Favored 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.855 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.63 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 70.3 mt-30 -136.65 80.3 38.26 Favored Pre-proline 0 N--CA 1.488 1.469 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.623 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -60.92 -20.83 68.73 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.121 1.214 . . . . 0.0 111.443 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -94.56 108.7 20.64 Favored 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.525 179.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 38.9 m-85 -51.51 177.24 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.887 -0.725 . . . . 0.0 111.035 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.8 pp -143.69 139.19 29.4 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.822 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.415 ' OD1' ' N ' ' A' ' 62' ' ' ASN . 2.9 p-10 -134.97 42.95 2.75 Favored 'General case' 0 N--CA 1.489 1.498 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.399 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -105.31 159.54 15.49 Favored Glycine 0 N--CA 1.493 2.461 0 C-N-CA 119.797 -1.192 . . . . 0.0 110.429 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -110.64 110.89 21.76 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 119.989 -0.685 . . . . 0.0 110.726 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.34 -14.21 64.67 Favored Glycine 0 N--CA 1.49 2.285 0 C-N-CA 119.437 -1.364 . . . . 0.0 110.367 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.414 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 1.2 mm-40 -69.82 160.15 32.29 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.269 -0.973 . . . . 0.0 110.345 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -147.22 172.27 14.09 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.669 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.63 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 43.9 t80 -133.61 129.45 36.95 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.082 179.125 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -91.46 149.75 21.55 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 118.892 -1.123 . . . . 0.0 112.461 -178.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -150.28 131.72 5.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.994 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.0 m -127.04 106.54 9.34 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.836 -0.745 . . . . 0.0 111.504 -178.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 20.5 mt -90.58 157.7 17.37 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.837 179.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 8.7 p -150.67 48.37 0.87 Allowed 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.072 -1.051 . . . . 0.0 111.412 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -146.67 100.74 3.37 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.151 179.36 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.469 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 2.0 ptpt -41.77 118.76 1.15 Allowed 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 119.65 -0.82 . . . . 0.0 111.041 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 164.87 -147.22 12.23 Favored Glycine 0 N--CA 1.484 1.9 0 C-N-CA 119.506 -1.331 . . . . 0.0 109.878 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.71 132.96 24.68 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.462 -0.895 . . . . 0.0 111.2 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.585 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.5 OUTLIER -116.81 127.36 54.25 Favored 'General case' 0 N--CA 1.486 1.333 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.342 179.712 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.476 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 2.5 mptp? -101.2 110.72 22.78 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.538 -0.865 . . . . 0.0 111.388 -179.404 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.2 p90 -123.78 168.0 13.3 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.896 -0.722 . . . . 0.0 109.922 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 46.0 p90 -171.43 -173.92 1.32 Allowed 'General case' 0 C--N 1.296 -1.758 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.033 -178.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -107.97 129.5 55.11 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.001 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.534 ' H ' HD21 ' A' ' 38' ' ' ASN . 1.9 mt-10 -69.91 -45.4 23.35 Favored Pre-proline 0 N--CA 1.486 1.374 0 C-N-CA 119.541 -0.864 . . . . 0.0 113.073 -179.385 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.518 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.7 Cg_endo -67.79 -53.17 0.45 Allowed 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 121.066 1.177 . . . . 0.0 111.771 -179.047 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.3 m80 -82.42 16.36 2.12 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.407 -0.917 . . . . 0.0 111.05 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.28 -18.42 58.37 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.365 -0.934 . . . . 0.0 110.809 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.19 -19.6 78.28 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.405 -1.379 . . . . 0.0 110.573 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.97 -4.69 52.23 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.577 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.64 9.67 62.58 Favored Glycine 0 N--CA 1.489 2.178 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.571 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -55.85 102.31 0.07 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.707 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.8 ptmt -126.64 157.48 38.85 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 119.929 -0.708 . . . . 0.0 111.221 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -140.24 133.86 6.21 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.971 -1.109 . . . . 0.0 110.391 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -139.21 148.79 43.59 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.634 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.4 p -141.84 132.47 25.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 119.065 -1.054 . . . . 0.0 110.219 178.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 99.6 m -110.31 104.99 13.85 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.26 -0.976 . . . . 0.0 110.338 179.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 31.4 t -84.83 152.31 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 118.555 -1.258 . . . . 0.0 110.774 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 60.8 m-20 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 116.324 -1.798 . . . . 0.0 110.816 -179.792 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.199 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -130.51 122.59 27.9 Favored 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 120.053 -0.659 . . . . 0.0 110.642 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -99.11 154.4 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.635 -179.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.2 mttt -120.59 106.95 12.25 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.074 -0.967 . . . . 0.0 110.479 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.9 mt -74.77 111.47 10.01 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 118.625 -1.23 . . . . 0.0 110.207 179.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.536 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 112.03 136.32 6.81 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -178.675 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 79.7 p . . . . . 0 C--N 1.3 -1.556 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.806 -179.909 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mt . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.5 m -150.84 155.47 7.3 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 C-N-CA 118.853 -1.139 . . . . 0.0 111.281 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.49 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 57.2 m-85 -78.7 109.84 13.3 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 177.449 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.9 m -115.3 108.19 48.19 Favored Pre-proline 0 CA--C 1.565 1.552 0 C-N-CA 119.596 -0.841 . . . . 0.0 112.875 -176.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -66.23 175.09 25.08 Favored 'Cis proline' 0 C--N 1.368 1.571 0 C-N-CA 125.128 -0.78 . . . . 0.0 111.142 -1.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.521 ' OG ' ' N ' ' A' ' 18' ' ' SER . 0.1 OUTLIER -102.91 -67.84 0.86 Allowed 'General case' 0 N--CA 1.488 1.442 0 C-N-CA 119.704 -0.799 . . . . 0.0 110.305 179.428 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.521 ' N ' ' OG ' ' A' ' 17' ' ' SER . 34.2 t -105.74 133.45 50.46 Favored 'General case' 0 N--CA 1.488 1.433 0 C-N-CA 120.069 -0.652 . . . . 0.0 109.843 179.323 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 32.6 p90 -160.65 137.13 8.69 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 118.817 -1.153 . . . . 0.0 111.177 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -87.77 159.57 18.4 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 119.271 -0.972 . . . . 0.0 111.183 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 30.6 m -148.93 176.35 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.315 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -97.37 150.41 21.03 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.568 -0.853 . . . . 0.0 110.722 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.03 71.67 0.17 Allowed 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.99 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.405 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 164.4 10.02 0.03 OUTLIER Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.405 ' H ' ' H ' ' A' ' 24' ' ' GLY . 3.9 tp10 -104.37 146.59 28.61 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.105 -0.638 . . . . 0.0 110.543 -179.638 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.6 pttt -94.33 153.29 18.08 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.394 -0.922 . . . . 0.0 111.039 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 mt -122.94 145.51 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.486 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.7 p -137.8 118.13 13.69 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.274 -0.97 . . . . 0.0 112.165 -178.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -84.63 126.59 33.49 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.642 -0.823 . . . . 0.0 109.059 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.16 130.76 54.74 Favored 'General case' 0 N--CA 1.493 1.705 0 C-N-CA 119.604 -0.838 . . . . 0.0 111.853 -178.085 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.601 HD22 ' CD1' ' A' ' 61' ' ' LEU . 6.2 m-20 -70.2 125.41 26.71 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.517 -0.873 . . . . 0.0 109.101 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.536 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 0.2 OUTLIER -103.7 -32.24 9.47 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 118.861 -1.136 . . . . 0.0 112.798 -178.533 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.439 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 170.01 -5.16 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 118.019 -1.472 . . . . 0.0 112.016 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.506 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -107.6 41.81 2.1 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.411 -1.376 . . . . 0.0 112.02 -178.798 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -76.14 160.78 77.37 Favored Pre-proline 0 N--CA 1.483 1.218 0 C-N-CA 117.917 -1.513 . . . . 0.0 109.564 179.019 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -74.38 176.98 40.33 Favored 'Cis proline' 0 C--O 1.207 -1.037 0 C-N-CA 124.163 -1.182 . . . . 0.0 111.784 -0.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.506 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 43.0 m-70 -150.98 168.92 23.09 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.567 -0.853 . . . . 0.0 110.794 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.788 HD22 ' H ' ' A' ' 83' ' ' GLU . 4.8 p-10 -154.54 152.89 30.6 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 119.381 -0.928 . . . . 0.0 110.079 178.244 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.0 mp -129.14 97.78 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.652 -179.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -112.39 143.41 22.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.163 178.579 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -99.04 138.5 36.06 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.097 -1.041 . . . . 0.0 112.354 -178.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -75.83 110.81 10.57 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.241 -0.983 . . . . 0.0 108.981 178.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -72.56 49.68 0.22 Allowed 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.405 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -142.5 3.57 1.5 Allowed 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.968 -0.693 . . . . 0.0 110.2 179.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -142.99 8.13 1.65 Allowed 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.721 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 44.3 t -94.63 143.75 26.76 Favored Pre-proline 0 C--N 1.291 -1.968 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -50.94 148.56 16.53 Favored 'Trans proline' 0 C--O 1.216 -0.593 0 C-N-CA 120.868 1.045 . . . . 0.0 112.251 -179.081 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.11 78.25 2.94 Favored 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.503 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 168.32 -43.13 0.23 Allowed Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 55.5 t -79.35 94.21 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.528 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -44.93 139.85 2.9 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.696 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -96.34 -1.46 47.73 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.561 -0.856 . . . . 0.0 110.937 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.439 ' N ' ' OE1' ' A' ' 53' ' ' GLU . 11.0 mp0 -90.33 -15.82 30.41 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.303 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -89.88 -27.47 19.87 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.01 -1.076 . . . . 0.0 111.437 -179.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 15.8 pt -92.74 -27.76 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 C-N-CA 119.106 -1.038 . . . . 0.0 110.918 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 9.0 m -60.75 -168.15 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.655 -0.818 . . . . 0.0 111.43 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.634 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 47.8 mt-30 -150.07 74.27 9.21 Favored Pre-proline 0 C--N 1.305 -1.336 0 C-N-CA 119.867 -0.733 . . . . 0.0 110.626 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -60.18 -12.26 19.01 Favored 'Trans proline' 0 C--N 1.325 -0.695 0 C-N-CA 121.202 1.268 . . . . 0.0 111.256 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' A' ' 60' ' ' TYR . 45.0 mt-10 -100.13 95.48 6.85 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.834 -0.746 . . . . 0.0 110.414 179.425 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.44 ' O ' ' O ' ' A' ' 59' ' ' GLU . 71.3 m-85 -43.97 171.19 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.916 -0.714 . . . . 0.0 111.17 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.601 ' CD1' HD22 ' A' ' 31' ' ' ASN . 1.9 pp -139.74 150.3 44.64 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.833 -0.747 . . . . 0.0 110.644 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -149.06 53.26 0.97 Allowed 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.891 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.27 126.98 6.29 Favored Glycine 0 N--CA 1.498 2.774 0 C-N-CA 119.95 -1.119 . . . . 0.0 110.402 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.67 128.78 37.56 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.833 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.47 -14.99 10.13 Favored Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.371 -1.395 . . . . 0.0 110.859 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 -56.44 154.83 7.88 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.336 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -147.99 164.57 33.4 Favored 'General case' 0 N--CA 1.489 1.522 0 C-N-CA 119.016 -1.074 . . . . 0.0 111.788 -179.069 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.634 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 36.0 t80 -136.14 146.45 46.94 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -108.03 154.74 21.22 Favored 'General case' 0 N--CA 1.498 1.935 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.794 -178.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -155.24 135.91 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 CA-C-N 115.086 -0.961 . . . . 0.0 108.936 179.287 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.2 m -128.07 104.16 7.62 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.667 -0.813 . . . . 0.0 111.769 -179.365 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.4 mt -88.22 157.74 18.7 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.237 -0.985 . . . . 0.0 109.614 179.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.71 48.42 0.87 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 118.865 -1.134 . . . . 0.0 111.351 -179.25 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.447 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -142.58 105.08 4.48 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.272 -0.971 . . . . 0.0 110.011 178.996 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 32.0 mtmt -46.59 110.31 0.27 Allowed 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.162 -179.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 171.08 -141.76 6.67 Favored Glycine 0 N--CA 1.485 1.912 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -146.38 137.5 24.39 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.924 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.573 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.4 m-85 -122.32 152.3 40.27 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.131 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 31.2 mttm -115.5 132.42 56.63 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.625 -0.83 . . . . 0.0 112.335 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.516 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -141.9 153.37 44.36 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.843 176.956 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 30.5 p90 -168.48 177.64 5.19 Favored 'General case' 0 C--N 1.285 -2.221 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.55 -178.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . 0.464 ' SG ' ' OD1' ' A' ' 38' ' ' ASN . 1.3 t -101.62 120.65 40.66 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.246 -0.981 . . . . 0.0 109.233 179.424 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.788 ' H ' HD22 ' A' ' 38' ' ' ASN . 6.6 tt0 -65.15 -40.56 46.1 Favored Pre-proline 0 C--N 1.3 -1.548 0 N-CA-C 113.774 1.027 . . . . 0.0 113.774 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.502 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.7 Cg_endo -68.95 -52.41 0.39 Allowed 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 120.401 0.734 . . . . 0.0 111.694 -179.363 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . 0.449 ' C ' ' H ' ' A' ' 87' ' ' GLY . 30.3 m80 -79.78 13.87 1.97 Allowed 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.906 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.31 -2.26 2.1 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.317 -0.953 . . . . 0.0 110.659 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.449 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -88.01 -18.18 56.44 Favored Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.514 -1.326 . . . . 0.0 110.231 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.32 -41.09 10.05 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.631 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 133.69 15.3 1.24 Allowed Glycine 0 N--CA 1.495 2.628 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.456 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.75 100.79 0.31 Allowed 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.392 -0.923 . . . . 0.0 111.017 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.49 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 32.4 mttm -125.99 164.5 20.68 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.9 -0.72 . . . . 0.0 111.497 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -148.58 143.89 11.57 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.927 -179.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -149.13 146.92 27.91 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.484 -0.886 . . . . 0.0 111.131 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.417 ' CG1' ' O ' ' A' ' 94' ' ' VAL . 12.5 p -140.05 119.63 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.53 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 94.5 m -99.07 101.25 12.56 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.628 179.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.436 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 41.8 t -79.61 142.74 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 C-N-CA 118.963 -1.095 . . . . 0.0 110.444 -179.014 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 96' ' ' VAL . 81.2 m-20 . . . . . 0 C--N 1.304 -1.38 0 CA-C-O 116.335 -1.793 . . . . 0.0 110.728 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.109 0 N-CA-C 110.145 -0.316 . . . . 0.0 110.145 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 20.7 mp0 -121.78 122.0 38.5 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 120.128 -0.629 . . . . 0.0 110.652 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.8 t -106.69 119.06 55.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 C-N-CA 119.768 -0.773 . . . . 0.0 110.853 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -91.82 117.63 29.96 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 119.335 -0.946 . . . . 0.0 110.883 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.429 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 4.8 mt -84.27 106.36 15.82 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 119.264 -0.975 . . . . 0.0 110.702 179.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.519 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 106.75 86.64 1.89 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 2.9 p . . . . . 0 C--N 1.304 -1.37 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.389 -179.59 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.1 mt . . . . . 0 N--CA 1.488 1.449 0 CA-C-O 120.326 0.108 . . . . 0.0 110.814 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.0 m -146.73 161.38 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 118.804 -1.159 . . . . 0.0 111.427 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -78.58 113.79 16.93 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 177.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.1 m -116.7 107.45 46.46 Favored Pre-proline 0 CA--C 1.559 1.292 0 C-N-CA 119.39 -0.924 . . . . 0.0 111.881 -177.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -66.11 176.38 21.23 Favored 'Cis proline' 0 C--N 1.36 1.153 0 C-N-CA 125.227 -0.739 . . . . 0.0 111.46 -0.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.7 p -95.76 -48.86 5.59 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.205 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 47.9 t -137.07 137.12 38.99 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.601 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 11.3 p90 -163.3 143.68 9.02 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 118.563 -1.255 . . . . 0.0 111.528 -179.117 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -86.44 157.43 19.82 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.896 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.3 m -146.48 146.89 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.313 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.437 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -61.45 141.58 57.58 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.697 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.75 74.21 0.07 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.184 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 154.25 18.89 0.05 OUTLIER Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.364 -1.398 . . . . 0.0 109.922 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 21.7 tt0 -103.63 157.1 17.29 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.947 -0.701 . . . . 0.0 110.8 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 29.1 mttt -94.38 142.07 27.84 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.714 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mt -124.81 125.52 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 C-N-CA 119.992 -0.683 . . . . 0.0 109.519 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.6 p -119.68 129.33 54.5 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.528 -0.869 . . . . 0.0 112.368 -178.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -91.71 131.48 37.07 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.226 178.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.5 tptm -120.94 131.01 54.09 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 120.017 -0.673 . . . . 0.0 111.249 -178.408 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -90.77 94.68 9.78 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.594 -0.842 . . . . 0.0 109.547 178.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 40.1 p-10 -91.26 -23.17 20.25 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.24 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -177.36 162.23 1.87 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 118.999 -1.08 . . . . 0.0 111.219 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.03 12.49 76.68 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.393 -1.384 . . . . 0.0 112.583 178.035 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -63.05 159.93 43.08 Favored Pre-proline 0 C--N 1.308 -1.199 0 C-N-CA 117.283 -1.767 . . . . 0.0 109.378 179.489 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -79.13 147.05 79.27 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 124.13 -1.196 . . . . 0.0 112.195 -0.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 40.5 m-70 -111.3 -175.43 2.7 Favored 'General case' 0 N--CA 1.495 1.805 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.377 179.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.58 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -160.63 146.06 14.67 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.446 179.262 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.58 ' N ' HD21 ' A' ' 38' ' ' ASN . 3.7 mp -134.17 107.27 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.971 -179.376 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.3 t -133.48 144.17 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.849 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -97.42 118.24 33.45 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.962 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -52.28 118.52 3.59 Favored 'General case' 0 C--N 1.308 -1.202 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.281 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -76.09 47.94 0.47 Allowed 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.121 -1.032 . . . . 0.0 111.047 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -147.75 2.68 0.71 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.652 -0.819 . . . . 0.0 109.94 179.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -144.56 21.39 1.67 Allowed 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 119.69 -0.804 . . . . 0.0 110.614 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -104.88 148.13 35.61 Favored Pre-proline 0 N--CA 1.493 1.693 0 CA-C-N 115.45 -0.795 . . . . 0.0 109.28 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -49.66 143.12 22.97 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 120.951 1.101 . . . . 0.0 111.715 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.85 69.37 2.5 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.942 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.0 -43.27 0.1 Allowed Glycine 0 N--CA 1.49 2.238 0 C-N-CA 119.44 -1.362 . . . . 0.0 110.018 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 77.5 t -78.44 97.32 2.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.372 179.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -44.71 139.68 2.83 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.66 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -94.8 2.66 55.5 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.441 -179.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -87.72 -33.22 18.8 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.932 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.1 mmtm -76.41 -32.2 58.36 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.911 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -90.64 -16.09 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 C-N-CA 118.993 -1.083 . . . . 0.0 111.682 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.8 m -79.97 170.72 16.07 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.264 -0.974 . . . . 0.0 110.782 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.65 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 5.8 mt-30 -134.68 73.44 67.36 Favored Pre-proline 0 N--CA 1.487 1.393 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.523 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -61.36 -4.26 3.99 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 121.402 1.401 . . . . 0.0 111.459 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 60' ' ' TYR . 37.8 mt-10 -99.86 100.67 11.63 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.716 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.473 ' CD2' ' OD1' ' A' ' 38' ' ' ASN . 84.7 m-85 -45.82 171.49 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.623 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.2 pp -149.39 126.54 11.34 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.248 -0.981 . . . . 0.0 110.499 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -120.86 33.61 5.51 Favored 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 120.175 -0.61 . . . . 0.0 110.663 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -87.91 168.19 37.22 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.308 -1.425 . . . . 0.0 110.876 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -121.62 101.27 7.49 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.363 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.94 -7.94 55.5 Favored Glycine 0 N--CA 1.49 2.248 0 C-N-CA 119.622 -1.275 . . . . 0.0 110.063 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -71.1 157.55 38.0 Favored 'General case' 0 N--CA 1.486 1.359 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.226 179.665 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -141.69 173.27 11.66 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.27 -0.972 . . . . 0.0 112.041 -179.077 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.65 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 56.7 t80 -134.66 178.23 7.17 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-N 115.498 -0.773 . . . . 0.0 109.623 178.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.516 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 5.1 mt-10 -145.92 149.34 34.03 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 118.912 -1.115 . . . . 0.0 112.012 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -159.04 133.87 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.659 178.57 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.1 m -122.53 96.34 4.99 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 119.828 -0.749 . . . . 0.0 111.035 -179.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.3 mt -79.75 158.64 26.84 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.448 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 97.0 m -150.96 47.12 0.85 Allowed 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.552 -1.259 . . . . 0.0 112.362 -178.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.446 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 5.9 tp10 -146.2 107.25 4.16 Favored 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 118.746 -1.182 . . . . 0.0 109.95 178.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.62 ' CD ' ' H ' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -43.36 116.32 0.91 Allowed 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.199 -0.909 . . . . 0.0 111.184 -178.972 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.6 -151.22 16.68 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.359 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.17 131.15 34.29 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.846 -0.741 . . . . 0.0 110.677 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.538 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 3.7 m-85 -118.19 121.58 40.86 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 36.8 mmtt -100.19 127.48 46.45 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.524 -0.87 . . . . 0.0 112.839 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.448 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 5.6 p90 -139.87 171.46 14.18 Favored 'General case' 0 C--N 1.312 -1.025 0 C-N-CA 119.616 -0.833 . . . . 0.0 110.433 177.673 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -170.55 -175.71 1.94 Allowed 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 119.437 -0.905 . . . . 0.0 111.178 -178.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -106.7 123.26 47.86 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.757 179.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.532 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.4 OUTLIER -64.05 -45.16 79.79 Favored Pre-proline 0 C--N 1.307 -1.253 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.466 -179.874 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.532 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.3 Cg_endo -66.93 -48.36 1.97 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.994 1.129 . . . . 0.0 112.47 -178.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . 0.51 ' C ' ' H ' ' A' ' 87' ' ' GLY . 34.4 m80 -91.69 23.19 3.68 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.152 -179.196 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -71.19 12.29 0.33 Allowed 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.893 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.51 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -107.15 -18.35 10.54 Favored Glycine 0 N--CA 1.498 2.79 0 C-N-CA 119.746 -1.216 . . . . 0.0 110.682 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -95.1 -16.11 22.88 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.232 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 108.17 17.76 10.5 Favored Glycine 0 N--CA 1.498 2.78 0 C-N-CA 119.777 -1.202 . . . . 0.0 110.242 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.7 ttt -69.99 90.78 0.65 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.215 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 15.4 ttmt -118.39 162.17 18.75 Favored 'General case' 0 N--CA 1.498 1.944 0 C-N-CA 120.045 -0.662 . . . . 0.0 111.16 -179.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -141.74 150.99 22.42 Favored Glycine 0 N--CA 1.495 2.608 0 C-N-CA 119.349 -1.405 . . . . 0.0 111.6 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -157.57 145.43 18.85 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.75 -0.78 . . . . 0.0 110.919 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.2 p -138.55 123.06 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.346 178.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 97.7 m -99.61 103.23 14.92 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.594 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 22.0 t -80.05 142.86 13.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 C-N-CA 118.423 -1.311 . . . . 0.0 110.46 -179.145 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.3 m120 . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 116.358 -1.782 . . . . 0.0 110.764 -179.76 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.221 0 CA-C-O 120.7 0.286 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 89.2 mt-10 -115.08 121.34 42.77 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.586 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 t -102.49 123.61 55.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.915 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 39.1 mttp -88.92 112.9 23.86 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.902 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.1 mt -75.82 107.43 8.0 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 118.229 -1.388 . . . . 0.0 109.4 178.104 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.535 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.64 130.4 6.98 Favored Glycine 0 N--CA 1.486 1.986 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -178.819 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.3 p . . . . . 0 C--N 1.302 -1.476 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.663 179.619 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.4 mt . . . . . 0 N--CA 1.487 1.422 0 CA-C-O 120.374 0.131 . . . . 0.0 110.827 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.2 m -150.12 153.97 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.868 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.423 ' O ' ' O ' ' A' ' 16' ' ' PRO . 69.7 m-85 -78.45 110.61 13.68 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 177.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.2 m -115.59 110.39 44.75 Favored Pre-proline 0 CA--C 1.562 1.419 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.723 -177.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.423 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.7 Cg_exo -64.79 174.7 21.0 Favored 'Cis proline' 0 C--N 1.365 1.43 0 C-N-CA 125.103 -0.79 . . . . 0.0 111.829 -0.157 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.9 t -102.82 -66.36 0.94 Allowed 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.455 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 61.6 m -119.08 131.88 55.97 Favored 'General case' 0 N--CA 1.492 1.634 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.008 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.436 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 16.7 p90 -161.23 170.94 19.28 Favored 'General case' 0 N--CA 1.487 1.391 0 C-N-CA 118.655 -1.218 . . . . 0.0 111.324 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.4 p -102.88 161.45 13.74 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.992 -0.683 . . . . 0.0 111.193 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.9 m -149.23 151.0 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.946 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.519 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -78.82 142.06 37.21 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.274 -0.971 . . . . 0.0 110.359 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.01 77.35 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.51 -0.876 . . . . 0.0 111.395 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 153.79 15.32 0.06 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -103.94 145.0 30.78 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.754 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ptpt -95.45 136.34 35.95 Favored 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.383 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.1 mt -109.16 113.79 45.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.631 179.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.3 p -107.3 116.47 31.98 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.775 -0.77 . . . . 0.0 112.336 -178.547 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 69.2 m-85 -85.16 118.81 24.94 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 119.526 -0.87 . . . . 0.0 109.05 178.293 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.0 tttp -111.74 138.16 48.7 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.657 -0.817 . . . . 0.0 111.482 -178.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.482 HD22 ' CD1' ' A' ' 61' ' ' LEU . 2.6 m-20 -77.65 109.92 12.03 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.413 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.535 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 1.4 t30 -96.51 -30.96 13.03 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 119.147 -1.021 . . . . 0.0 110.703 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.444 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 165.13 129.12 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.806 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 127.98 -9.01 6.75 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.687 -1.244 . . . . 0.0 110.91 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.478 ' CD1' ' ND2' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -45.92 160.64 0.28 Allowed Pre-proline 0 N--CA 1.482 1.142 0 C-N-CA 118.52 -1.272 . . . . 0.0 109.695 -179.881 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -77.3 141.55 68.84 Favored 'Cis proline' 0 C--O 1.214 -0.68 0 C-N-CA 124.139 -1.192 . . . . 0.0 112.241 0.008 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 40.6 m-70 -108.55 -177.24 3.26 Favored 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.072 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.576 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -161.16 141.54 11.06 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.875 -0.73 . . . . 0.0 109.872 178.829 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.576 ' N ' HD21 ' A' ' 38' ' ' ASN . 3.6 mp -129.63 124.69 59.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.438 -179.542 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -143.53 146.99 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.385 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.161 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -97.23 134.56 40.38 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.248 -0.981 . . . . 0.0 111.04 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.659 ' O ' ' N ' ' A' ' 44' ' ' ASP . 44.5 p-10 -73.1 93.81 1.85 Allowed 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.529 -0.868 . . . . 0.0 111.063 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.445 ' O ' ' CG ' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -50.45 78.84 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 O-C-N 124.063 0.852 . . . . 0.0 109.803 179.385 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.659 ' N ' ' O ' ' A' ' 42' ' ' ASP . 59.4 m-20 -157.01 -67.04 0.1 Allowed 'General case' 0 C--N 1.283 -2.3 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.682 -177.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -96.24 17.37 15.94 Favored 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.191 -1.003 . . . . 0.0 112.139 -177.399 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -86.07 143.96 38.12 Favored Pre-proline 0 C--N 1.291 -1.959 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.458 ' C ' ' H ' ' A' ' 49' ' ' GLY . 2.7 Cg_exo -48.81 152.21 4.68 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 120.815 1.01 . . . . 0.0 111.797 -179.252 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.68 31.15 0.36 Allowed 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.645 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.458 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -136.27 -35.34 0.21 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.5 t -96.46 93.2 3.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.986 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -45.26 144.48 1.37 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.671 179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -87.99 -29.85 20.44 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.84 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.03 -1.05 21.02 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.747 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -97.62 -35.03 10.73 Favored 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.753 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -96.2 -16.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 C-N-CA 119.404 -0.918 . . . . 0.0 111.102 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 36.7 m -68.27 170.07 9.38 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.733 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.64 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 5.0 mt-30 -137.09 73.37 51.87 Favored Pre-proline 0 N--CA 1.489 1.489 0 C-N-CA 119.811 -0.756 . . . . 0.0 110.901 -179.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -57.28 -27.73 76.51 Favored 'Trans proline' 0 C--N 1.322 -0.836 0 C-N-CA 121.038 1.159 . . . . 0.0 110.933 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -65.65 114.1 4.73 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.088 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 -60.72 173.26 0.77 Allowed 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 119.479 -0.888 . . . . 0.0 111.073 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.482 ' CD1' HD22 ' A' ' 31' ' ' ASN . 2.5 pp -149.15 144.63 26.73 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.682 -0.807 . . . . 0.0 110.158 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.581 ' N ' ' ND2' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -128.28 -73.53 0.59 Allowed 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 119.88 -0.728 . . . . 0.0 111.72 -178.992 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.519 ' H ' ' CG ' ' A' ' 62' ' ' ASN . . . -24.2 127.19 0.02 OUTLIER Glycine 0 N--CA 1.511 3.642 0 O-C-N 123.993 0.808 . . . . 0.0 112.612 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.525 ' C ' ' H ' ' A' ' 66' ' ' GLU . . . -62.33 156.76 21.47 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.207 179.394 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 71.28 -14.62 1.65 Allowed Glycine 0 N--CA 1.492 2.376 0 C-N-CA 119.109 -1.519 . . . . 0.0 110.6 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.525 ' H ' ' C ' ' A' ' 64' ' ' ALA . 12.9 tt0 -61.13 101.8 0.18 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.286 -0.966 . . . . 0.0 109.97 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 37.4 p -106.99 162.19 14.06 Favored 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.575 -0.85 . . . . 0.0 112.225 -178.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.64 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 29.7 t80 -136.17 143.57 44.52 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.323 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -104.84 154.6 19.84 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.589 -178.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -151.59 130.75 3.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.945 -1.025 . . . . 0.0 108.942 179.272 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.4 m -124.6 112.06 16.37 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.693 -0.803 . . . . 0.0 111.585 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 34.3 mt -98.61 156.85 16.6 Favored 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.772 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 11.1 p -150.93 47.98 0.85 Allowed 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 118.714 -1.194 . . . . 0.0 112.274 -179.122 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.429 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 1.4 tp10 -144.49 106.29 4.3 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.781 -1.168 . . . . 0.0 110.467 178.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -44.96 110.84 0.26 Allowed 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.913 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.93 -148.28 10.35 Favored Glycine 0 N--CA 1.487 2.053 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.077 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.92 135.37 32.75 Favored 'General case' 0 N--CA 1.483 1.176 0 C-N-CA 119.424 -0.91 . . . . 0.0 111.095 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.569 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -124.36 159.04 31.23 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 179.565 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 12.2 mtpt -136.5 125.48 24.31 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 118.612 -1.235 . . . . 0.0 112.871 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.542 ' O ' ' N ' ' A' ' 92' ' ' GLY . 3.9 p90 -129.43 162.34 28.3 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.35 178.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 22.7 p90 -166.94 -179.5 4.72 Favored 'General case' 0 C--N 1.285 -2.232 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.496 -178.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -107.34 112.93 25.99 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.49 -0.884 . . . . 0.0 109.573 178.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.487 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.9 OUTLIER -59.37 -42.99 95.58 Favored Pre-proline 0 C--N 1.298 -1.635 0 C-N-CA 119.471 -0.892 . . . . 0.0 112.581 -179.407 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.487 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.4 Cg_endo -66.3 -47.88 2.92 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 120.283 0.655 . . . . 0.0 111.839 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -92.82 10.1 32.42 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.447 -179.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.07 -15.8 15.71 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.559 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -77.91 -20.47 73.31 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.421 -1.371 . . . . 0.0 110.377 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.63 -9.34 47.32 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.694 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 104.54 10.78 32.57 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.67 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.51 105.05 1.72 Allowed 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 118.989 -1.085 . . . . 0.0 110.952 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.422 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 43.9 pttt -135.54 168.34 19.43 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.29 -179.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.04 153.0 24.93 Favored Glycine 0 N--CA 1.485 1.941 0 C-N-CA 119.372 -1.394 . . . . 0.0 111.053 -179.05 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -155.91 145.9 21.39 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.3 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.8 p -141.62 131.29 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 C-N-CA 118.955 -1.098 . . . . 0.0 110.652 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.0 m -109.46 105.15 14.38 Favored 'General case' 0 N--CA 1.493 1.722 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.825 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 37.2 t -79.68 152.93 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 C-N-CA 118.553 -1.259 . . . . 0.0 110.526 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 60.9 m-20 . . . . . 0 C--N 1.307 -1.277 0 CA-C-O 116.284 -1.817 . . . . 0.0 110.932 179.99 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.127 0 N-CA-C 110.071 -0.344 . . . . 0.0 110.071 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -113.92 122.41 46.9 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 120.076 -0.649 . . . . 0.0 110.856 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.3 t -110.4 150.11 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.393 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 10.9 mtpt -124.6 117.69 24.87 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.865 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.2 mt -76.74 109.1 10.24 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.067 -1.053 . . . . 0.0 109.995 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 117.42 162.01 12.36 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.021 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.442 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 59.4 p . . . . . 0 C--N 1.302 -1.491 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.813 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.3 mt . . . . . 0 N--CA 1.485 1.287 0 CA-C-O 120.59 0.234 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.9 m -144.82 155.37 14.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 119.111 -1.035 . . . . 0.0 110.415 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.425 ' O ' ' O ' ' A' ' 16' ' ' PRO . 5.4 m-85 -78.71 111.99 15.37 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 178.311 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.3 m -114.44 108.59 49.55 Favored Pre-proline 0 C--N 1.303 -1.415 0 C-N-CA 119.734 -0.786 . . . . 0.0 112.007 -177.44 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -67.26 177.9 20.57 Favored 'Cis proline' 0 C--N 1.36 1.149 0 C-N-CA 125.35 -0.688 . . . . 0.0 111.423 -0.205 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.7 m -92.62 -47.78 6.93 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.414 -0.914 . . . . 0.0 109.996 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.63 135.42 31.69 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.756 179.279 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.479 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 13.5 p90 -153.69 146.61 24.44 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.608 -1.237 . . . . 0.0 111.545 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.43 151.25 20.88 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.042 179.579 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.4 158.82 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.933 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.532 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -73.09 137.28 45.15 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.176 -1.01 . . . . 0.0 110.347 179.515 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -59.91 78.82 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.934 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 150.39 18.38 0.07 OUTLIER Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -96.18 158.42 15.45 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.577 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 40.5 mttm -93.5 120.29 33.59 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.093 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.9 mt -105.52 120.52 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.68 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.1 p -118.42 116.6 27.05 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.64 -0.824 . . . . 0.0 112.283 -178.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -87.87 120.31 29.07 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.508 -0.877 . . . . 0.0 109.022 178.336 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 13.0 ttmt -112.21 136.2 51.93 Favored 'General case' 0 N--CA 1.492 1.658 0 C-N-CA 119.697 -0.801 . . . . 0.0 111.75 -178.475 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -80.31 115.57 19.92 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.157 178.688 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.442 ' ND2' ' O ' ' A' ' 7' ' ' SER . 0.1 OUTLIER -100.22 -31.38 11.4 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.257 -0.977 . . . . 0.0 112.141 -178.995 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.44 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 169.02 120.74 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 C-N-CA 118.882 -1.127 . . . . 0.0 111.359 -179.75 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 131.57 -1.19 5.19 Favored Glycine 0 N--CA 1.496 2.667 0 C-N-CA 119.661 -1.257 . . . . 0.0 111.187 179.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -46.84 163.97 0.23 Allowed Pre-proline 0 N--CA 1.487 1.377 0 C-N-CA 118.942 -1.103 . . . . 0.0 110.028 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -75.74 143.0 75.66 Favored 'Cis proline' 0 C--O 1.212 -0.81 0 C-N-CA 124.306 -1.122 . . . . 0.0 112.45 -0.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 31.7 m-70 -113.92 160.72 18.48 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.769 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.56 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 8.9 t30 -145.69 133.28 20.92 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 119.426 -0.909 . . . . 0.0 109.945 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.57 ' N ' ' CD1' ' A' ' 39' ' ' ILE . 1.7 mp -115.19 121.41 67.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 C-N-CA 119.767 -0.773 . . . . 0.0 111.405 -179.562 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.56 ' CG2' ' ND2' ' A' ' 38' ' ' ASN . 1.7 t -139.07 154.8 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.068 179.454 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -106.56 134.34 49.85 Favored 'General case' 0 N--CA 1.49 1.533 0 C-N-CA 119.287 -0.965 . . . . 0.0 112.019 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.54 ' C ' ' H ' ' A' ' 44' ' ' ASP . 4.3 t0 -74.32 107.0 6.21 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.188 -1.005 . . . . 0.0 109.179 178.654 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -69.32 33.83 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.833 -178.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.54 ' H ' ' C ' ' A' ' 42' ' ' ASP . 14.9 m-20 -110.23 -9.98 14.65 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.855 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -142.5 -5.8 0.93 Allowed 'General case' 0 N--CA 1.497 1.889 0 C-N-CA 118.865 -1.134 . . . . 0.0 111.634 179.609 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -69.98 146.17 94.88 Favored Pre-proline 0 C--N 1.286 -2.153 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 178.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -51.48 159.32 3.26 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.712 0.941 . . . . 0.0 112.323 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -89.17 40.4 0.98 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 119.722 -0.791 . . . . 0.0 110.374 179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -143.18 -44.63 0.05 OUTLIER Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 50.9 t -83.14 86.29 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 119.384 -0.926 . . . . 0.0 110.18 179.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -45.0 139.59 3.07 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.634 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.425 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -76.99 -28.48 55.1 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.679 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -66.33 -15.56 63.35 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.379 -0.928 . . . . 0.0 111.13 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.95 -42.89 17.08 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.838 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -93.32 -41.59 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.212 -179.779 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.425 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 42.9 m -48.53 165.98 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.154 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.594 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.3 mt-30 -138.23 78.55 33.55 Favored Pre-proline 0 N--CA 1.487 1.412 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.561 -179.593 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -61.67 -22.91 75.51 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 121.405 1.403 . . . . 0.0 112.003 -179.068 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -76.08 119.83 20.56 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.122 -1.031 . . . . 0.0 110.585 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -55.86 168.56 0.44 Allowed 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.126 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.449 ' C ' ' CD1' ' A' ' 61' ' ' LEU . 0.4 OUTLIER -144.61 141.91 29.76 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.189 179.329 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.413 ' ND2' ' O ' ' A' ' 62' ' ' ASN . 4.1 p-10 -146.51 32.7 0.96 Allowed 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.198 -179.263 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -97.26 112.26 4.43 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.482 -1.342 . . . . 0.0 110.539 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.15 111.6 1.58 Allowed 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.22 -0.992 . . . . 0.0 110.571 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.7 -12.5 66.02 Favored Glycine 0 N--CA 1.489 2.23 0 C-N-CA 119.464 -1.351 . . . . 0.0 110.203 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -63.04 151.22 40.49 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.335 -0.946 . . . . 0.0 110.302 179.689 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.73 166.72 23.88 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.214 -0.995 . . . . 0.0 111.511 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.594 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 31.6 t80 -135.83 138.32 42.41 Favored 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.524 179.246 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -98.16 152.94 18.82 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.885 -178.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -149.61 133.69 8.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.34 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.6 m -125.92 100.3 6.32 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.304 -179.23 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 54.2 mt -81.0 165.43 21.72 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.173 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' THR . . . . . 0.478 ' CG2' ' O ' ' A' ' 73' ' ' THR . 81.1 m -150.43 31.01 0.67 Allowed 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 118.608 -1.237 . . . . 0.0 112.589 -178.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.456 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 2.5 mt-10 -143.39 124.28 14.3 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 118.781 -1.168 . . . . 0.0 110.35 178.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 14.4 pttt -58.69 128.14 35.72 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.221 -0.992 . . . . 0.0 111.281 -179.271 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 156.31 174.59 26.28 Favored Glycine 0 N--CA 1.488 2.116 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.223 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.79 105.35 15.34 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.914 -0.715 . . . . 0.0 110.281 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.463 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.8 m-30 -89.58 156.54 18.54 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 118.591 -1.244 . . . . 0.0 107.981 -179.261 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 71.1 mttt -115.19 127.77 55.74 Favored 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.165 -1.014 . . . . 0.0 112.782 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.469 ' O ' ' N ' ' A' ' 92' ' ' GLY . 1.7 p90 -138.14 157.5 46.19 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.834 -0.746 . . . . 0.0 109.526 176.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 33.8 p90 -169.8 -175.23 2.03 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.523 -178.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -110.14 116.31 31.31 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.398 179.265 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.563 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tp10 -69.67 -39.34 11.46 Favored Pre-proline 0 C--N 1.305 -1.358 0 C-N-CA 119.518 -0.873 . . . . 0.0 112.435 -179.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.563 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 4.4 Cg_exo -66.17 -41.92 11.84 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 120.394 0.729 . . . . 0.0 111.268 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . 0.475 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.8 m80 -97.71 18.91 14.57 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.518 -0.873 . . . . 0.0 110.638 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.37 0.21 1.09 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.853 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.475 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -94.31 -13.38 54.3 Favored Glycine 0 N--CA 1.487 2.081 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.449 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.45 -47.55 6.81 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.377 -0.929 . . . . 0.0 110.57 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 141.27 18.22 0.35 Allowed Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.629 -1.272 . . . . 0.0 110.271 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 12.8 mtp -71.55 100.41 2.25 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.16 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.465 ' O ' ' CD ' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -129.17 148.48 51.11 Favored 'General case' 0 N--CA 1.495 1.792 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.221 179.489 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -136.29 153.78 21.7 Favored Glycine 0 N--CA 1.499 2.889 0 C-N-CA 119.508 -1.33 . . . . 0.0 112.211 -178.057 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -154.68 149.37 26.49 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 120.314 -0.555 . . . . 0.0 109.937 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.484 ' CG1' ' O ' ' A' ' 94' ' ' VAL . 12.2 p -139.32 114.88 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 C-N-CA 119.079 -1.048 . . . . 0.0 111.07 -179.327 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 16.0 m -89.84 93.55 9.47 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.096 -1.042 . . . . 0.0 110.616 179.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 14.0 t -78.77 148.31 6.23 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.617 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 17.8 p30 . . . . . 0 C--N 1.307 -1.277 0 CA-C-O 116.309 -1.805 . . . . 0.0 110.818 -179.744 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.103 0 CA-C-O 120.873 0.368 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -107.86 120.63 42.81 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 120.033 -0.667 . . . . 0.0 110.687 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.8 t -98.52 122.35 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.651 179.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.7 mptt -90.0 114.72 26.62 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.983 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.43 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 5.3 mp -80.45 100.03 8.3 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 118.572 -1.251 . . . . 0.0 109.62 178.507 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.425 ' C ' HD22 ' A' ' 32' ' ' ASN . . . 122.6 146.6 7.25 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -178.718 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.55 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 53.5 p . . . . . 0 C--N 1.302 -1.477 0 C-N-CA 119.439 -0.905 . . . . 0.0 110.709 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.0 mt . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 110.357 -0.238 . . . . 0.0 110.357 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.9 m -145.38 156.27 13.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.022 0 C-N-CA 118.996 -1.082 . . . . 0.0 111.075 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -78.59 111.54 14.77 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 178.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -114.5 108.34 49.8 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 119.566 -0.854 . . . . 0.0 112.232 -177.106 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -68.04 173.48 37.72 Favored 'Cis proline' 0 C--N 1.359 1.085 0 C-N-CA 125.45 -0.646 . . . . 0.0 111.503 -0.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 p -88.9 -45.22 9.87 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 119.307 -0.957 . . . . 0.0 109.76 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.76 140.5 34.81 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.55 179.114 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -162.41 147.3 12.34 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 118.356 -1.338 . . . . 0.0 111.598 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.24 151.71 19.64 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.275 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -146.06 169.24 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.809 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.76 146.48 28.14 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.257 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.27 71.26 0.42 Allowed 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.32 -0.952 . . . . 0.0 110.848 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 165.51 11.08 0.03 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -101.92 145.89 28.61 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.841 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.1 mttm -84.97 134.87 34.23 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.288 -0.965 . . . . 0.0 110.671 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mp -115.94 118.31 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 36.2 p -110.6 121.51 45.49 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.471 -0.891 . . . . 0.0 113.299 -177.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -84.88 111.12 19.37 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 45.5 tttt -109.9 131.62 54.89 Favored 'General case' 0 N--CA 1.496 1.83 0 C-N-CA 119.431 -0.907 . . . . 0.0 111.76 -177.2 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.414 ' ND2' ' CD1' ' A' ' 61' ' ' LEU . 7.8 m-20 -90.06 117.39 28.82 Favored 'General case' 0 C--N 1.294 -1.82 0 C-N-CA 119.335 -0.946 . . . . 0.0 111.329 -179.536 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 7' ' ' SER . 25.3 p-10 -101.01 -29.54 12.12 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.968 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 174.09 137.59 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.373 -0.931 . . . . 0.0 110.935 -179.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.403 ' O ' ' C ' ' A' ' 35' ' ' PHE . . . 122.22 -6.99 9.98 Favored Glycine 0 N--CA 1.498 2.774 0 C-N-CA 119.524 -1.322 . . . . 0.0 111.626 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.403 ' C ' ' O ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -45.87 163.1 0.23 Allowed Pre-proline 0 N--CA 1.485 1.312 0 C-N-CA 118.423 -1.311 . . . . 0.0 109.908 -179.834 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -76.76 138.43 54.24 Favored 'Cis proline' 0 C--O 1.213 -0.734 0 C-N-CA 124.122 -1.199 . . . . 0.0 112.443 -0.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 32.5 m-70 -102.28 179.79 4.21 Favored 'General case' 0 N--CA 1.488 1.462 0 C-N-CA 119.751 -0.78 . . . . 0.0 111.106 179.576 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -159.56 142.11 13.76 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.782 179.293 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -135.11 117.12 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.045 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.4 t -139.25 150.24 22.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.386 179.043 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -99.3 135.08 41.24 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.856 -178.816 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.573 ' C ' ' H ' ' A' ' 44' ' ' ASP . 59.6 t0 -70.62 104.36 2.79 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.284 -0.966 . . . . 0.0 109.519 178.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.465 ' N ' ' CD ' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -68.42 27.27 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.789 -0.765 . . . . 0.0 111.785 -179.229 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.573 ' H ' ' C ' ' A' ' 42' ' ' ASP . 73.3 m-20 -111.26 -7.02 14.46 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.079 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -143.82 -1.46 0.99 Allowed 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 119.218 -0.993 . . . . 0.0 111.721 -179.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -68.56 144.9 96.76 Favored Pre-proline 0 C--N 1.285 -2.21 0 C-N-CA 119.269 -0.972 . . . . 0.0 108.726 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -59.08 160.5 18.61 Favored 'Trans proline' 0 C--O 1.216 -0.603 0 C-N-CA 121.062 1.175 . . . . 0.0 112.243 -178.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.63 145.16 41.29 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.567 -0.853 . . . . 0.0 109.66 178.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 95.26 -59.13 1.65 Allowed Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.238 -1.458 . . . . 0.0 109.849 -179.439 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.4 t -68.52 87.18 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 119.114 -1.035 . . . . 0.0 110.339 179.509 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -44.86 154.51 0.13 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.001 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.25 -25.66 16.26 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.332 179.385 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -81.4 -15.93 53.69 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.611 -0.836 . . . . 0.0 110.774 179.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.18 -21.61 46.16 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.568 -0.853 . . . . 0.0 111.408 -179.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.5 pt -111.04 -19.22 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 C-N-CA 119.753 -0.779 . . . . 0.0 111.312 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.7 m -79.58 169.47 17.97 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.575 -0.85 . . . . 0.0 111.81 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.634 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.8 OUTLIER -150.03 73.24 9.42 Favored Pre-proline 0 C--N 1.306 -1.32 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.785 179.113 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -56.74 -26.45 65.97 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.501 1.467 . . . . 0.0 111.947 -178.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.35 102.82 0.08 Allowed 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 118.94 -1.104 . . . . 0.0 110.145 179.251 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -42.46 161.75 0.02 OUTLIER 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 119.581 -0.848 . . . . 0.0 111.103 -179.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.415 ' CD1' ' C ' ' A' ' 61' ' ' LEU . 0.8 OUTLIER -143.3 147.8 35.32 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.614 -0.835 . . . . 0.0 110.459 -179.977 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -145.01 20.99 1.6 Allowed 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.351 -0.939 . . . . 0.0 110.952 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -77.81 119.51 5.27 Favored Glycine 0 N--CA 1.487 2.034 0 C-N-CA 119.182 -1.485 . . . . 0.0 110.199 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.11 106.15 4.85 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.276 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.72 -10.72 49.35 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -68.11 154.85 40.82 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.256 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.87 170.04 16.64 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 119.133 -1.027 . . . . 0.0 111.335 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.634 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 40.7 t80 -135.24 142.49 45.98 Favored 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.487 179.412 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -113.78 151.19 32.35 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 119.404 -0.918 . . . . 0.0 112.335 -178.708 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.6 p -153.78 132.07 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.34 178.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.7 m -119.06 94.5 4.46 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 119.749 -0.78 . . . . 0.0 111.493 -179.153 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.5 mt -79.72 157.77 27.09 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.224 178.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.5 p -150.63 52.68 0.88 Allowed 'General case' 0 C--N 1.3 -1.587 0 C-N-CA 118.536 -1.266 . . . . 0.0 111.949 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.434 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 2.9 tt0 -150.73 99.41 2.73 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 118.73 -1.188 . . . . 0.0 109.934 178.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 74' ' ' GLU . 0.8 OUTLIER -39.87 108.96 0.1 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.255 -178.908 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.51 -148.46 8.43 Favored Glycine 0 N--CA 1.485 1.921 0 C-N-CA 119.29 -1.433 . . . . 0.0 110.302 -179.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -141.49 129.99 22.58 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.472 -0.891 . . . . 0.0 111.218 -179.799 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.61 ' N ' ' CD1' ' A' ' 78' ' ' TYR . 0.6 OUTLIER -119.64 161.6 20.4 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.426 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 32.2 mttt -128.98 131.96 47.5 Favored 'General case' 0 N--CA 1.49 1.567 0 C-N-CA 119.187 -1.005 . . . . 0.0 111.958 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.544 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -139.25 158.75 43.62 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.829 177.712 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -167.78 -175.11 2.64 Favored 'General case' 0 C--N 1.288 -2.079 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.989 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -111.98 119.75 39.54 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.913 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.576 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.3 tt0 -65.41 -42.37 57.35 Favored Pre-proline 0 N--CA 1.486 1.326 0 C-N-CA 119.931 -0.708 . . . . 0.0 112.724 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.576 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.1 Cg_endo -69.45 -48.2 0.84 Allowed 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 121.108 1.205 . . . . 0.0 112.035 -179.381 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -90.03 10.39 24.31 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.647 -179.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.08 -35.45 62.09 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 118.906 -1.117 . . . . 0.0 110.475 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -62.23 -21.14 61.53 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.199 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -85.3 -17.29 37.31 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.278 179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.23 23.79 9.42 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 119.716 -1.23 . . . . 0.0 110.731 179.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -75.95 101.01 5.04 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.131 -1.028 . . . . 0.0 110.979 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.32 149.67 46.31 Favored 'General case' 0 N--CA 1.49 1.56 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.751 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -137.76 149.13 20.25 Favored Glycine 0 N--CA 1.496 2.655 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.352 -178.827 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -155.63 148.87 24.7 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 120.004 -0.678 . . . . 0.0 110.395 179.45 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -139.08 128.99 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.81 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.9 m -104.91 98.55 8.25 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.159 179.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 42.4 t -79.13 150.63 5.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 118.632 -1.227 . . . . 0.0 110.453 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 89.2 m-20 . . . . . 0 N--CA 1.489 1.489 0 CA-C-O 116.333 -1.794 . . . . 0.0 110.894 -179.761 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.128 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -112.62 118.67 35.71 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 120.029 -0.668 . . . . 0.0 110.535 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 83.9 t -102.34 119.9 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.705 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 8.5 mptt -87.12 110.28 20.01 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.959 -179.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 11.9 mt -76.27 104.37 6.76 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.753 177.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 104.23 107.59 3.21 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.1 p . . . . . 0 C--N 1.304 -1.38 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.442 179.861 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.0 mt . . . . . 0 N--CA 1.484 1.235 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.2 m -149.71 160.41 4.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 C-N-CA 119.064 -1.054 . . . . 0.0 110.955 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.456 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 59.3 m-85 -79.02 113.11 16.88 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 176.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.9 m -114.74 110.87 46.24 Favored Pre-proline 0 N--CA 1.485 1.293 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.935 -177.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.44 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.9 Cg_endo -65.56 176.1 20.2 Favored 'Cis proline' 0 C--N 1.363 1.324 0 C-N-CA 125.254 -0.728 . . . . 0.0 111.751 -0.254 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.5 ' HG ' ' H ' ' A' ' 18' ' ' SER . 3.2 p -96.34 -60.86 1.53 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.467 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.5 ' H ' ' HG ' ' A' ' 17' ' ' SER . 60.7 p -123.74 136.69 54.59 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.752 179.168 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 p90 -163.08 146.45 10.75 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 118.583 -1.247 . . . . 0.0 111.443 -179.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -89.62 153.49 20.71 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.445 -0.902 . . . . 0.0 111.075 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.3 m -145.87 176.46 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.641 179.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.03 150.79 21.29 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.589 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.12 66.85 0.87 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.997 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 166.75 11.73 0.03 OUTLIER Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -97.99 155.2 17.21 Favored 'General case' 0 C--N 1.307 -1.276 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.078 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.52 133.47 39.49 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.033 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.7 mt -115.3 114.53 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 C-N-CA 120.022 -0.671 . . . . 0.0 109.614 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 73.2 p -106.87 117.04 32.99 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.782 -0.767 . . . . 0.0 112.417 -178.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -84.17 107.02 16.26 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.6 ttmt -96.59 142.98 28.0 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.054 -1.058 . . . . 0.0 111.295 -177.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.553 ' OD1' ' CD1' ' A' ' 35' ' ' PHE . 19.9 t-20 -100.12 121.23 41.09 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.509 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -132.83 -8.79 3.12 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.961 -1.095 . . . . 0.0 112.13 -179.571 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -168.61 132.25 1.49 Allowed 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 117.986 -1.485 . . . . 0.0 112.711 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.79 59.99 2.87 Favored Glycine 0 N--CA 1.49 2.296 0 C-N-CA 119.868 -1.158 . . . . 0.0 113.805 177.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.553 ' CD1' ' OD1' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -97.06 165.12 16.42 Favored Pre-proline 0 N--CA 1.493 1.685 0 C-N-CA 118.978 -1.089 . . . . 0.0 108.382 176.86 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.5 Cg_endo -77.97 147.41 83.33 Favored 'Cis proline' 0 C--O 1.214 -0.685 0 C-N-CA 124.615 -0.994 . . . . 0.0 112.938 -0.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -103.0 175.21 5.55 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.299 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.566 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.3 OUTLIER -150.81 124.71 9.21 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 119.205 -0.998 . . . . 0.0 110.764 179.703 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.566 ' N ' HD21 ' A' ' 38' ' ' ASN . 0.1 OUTLIER -107.85 115.68 49.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.71 179.78 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.8 t -140.23 141.7 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.194 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.3 m-85 -99.73 122.24 42.43 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 119.457 -0.897 . . . . 0.0 111.864 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.548 ' C ' ' H ' ' A' ' 44' ' ' ASP . 0.7 OUTLIER -64.96 111.86 3.04 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.029 179.183 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -66.64 11.12 0.1 Allowed 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.134 -1.026 . . . . 0.0 111.108 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.548 ' H ' ' C ' ' A' ' 42' ' ' ASP . 50.2 m-20 -93.35 -15.35 25.82 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 119.318 -0.953 . . . . 0.0 111.185 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -141.05 50.22 1.64 Allowed 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 119.635 -0.826 . . . . 0.0 110.495 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -128.41 144.86 53.54 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.931 179.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -48.28 150.65 5.15 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 120.831 1.02 . . . . 0.0 111.959 -179.384 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.53 47.65 0.85 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.926 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -157.78 -44.28 0.02 OUTLIER Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.456 -1.354 . . . . 0.0 109.975 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.6 t -83.57 84.42 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.313 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -44.48 142.48 1.59 Allowed 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.841 -0.743 . . . . 0.0 111.191 -179.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -86.9 -9.74 54.98 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.872 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -85.78 -11.99 52.09 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.853 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.29 -36.24 12.67 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.014 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -89.91 -21.43 6.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 C-N-CA 119.253 -0.979 . . . . 0.0 111.191 -179.774 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 51.6 m -74.43 178.19 5.42 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.415 -0.914 . . . . 0.0 111.142 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.636 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.3 pm0 -159.17 77.37 3.06 Favored Pre-proline 0 C--N 1.303 -1.424 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.018 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -57.78 -0.41 0.39 Allowed 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 121.09 1.193 . . . . 0.0 111.575 -178.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.537 ' H ' ' C ' ' A' ' 57' ' ' GLN . 2.7 mm-40 -80.8 92.39 6.07 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.17 -1.012 . . . . 0.0 110.046 178.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.401 ' O ' ' O ' ' A' ' 59' ' ' GLU . 38.3 m-85 -41.02 162.19 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.521 -179.388 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -135.07 108.63 7.92 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.488 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -104.72 3.51 31.47 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.907 -0.717 . . . . 0.0 110.956 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -73.64 117.74 5.88 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.378 -1.391 . . . . 0.0 110.558 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -59.38 108.68 0.74 Allowed 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.638 -0.825 . . . . 0.0 111.012 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.48 -6.21 59.11 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 119.516 -1.326 . . . . 0.0 110.817 179.595 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -62.23 149.98 40.28 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 118.996 -1.081 . . . . 0.0 110.674 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -140.8 164.44 30.21 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.421 -0.912 . . . . 0.0 111.625 -179.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.636 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 17.5 t80 -136.05 130.16 33.06 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.343 179.482 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -94.82 154.38 17.28 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 119.124 -1.03 . . . . 0.0 112.236 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.2 t -152.62 130.97 2.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 114.952 -1.022 . . . . 0.0 108.735 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.3 m -121.04 103.35 8.97 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.68 -178.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 65.7 mt -86.59 158.41 19.51 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.247 -0.981 . . . . 0.0 109.751 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.03 40.94 0.73 Allowed 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 118.845 -1.142 . . . . 0.0 111.614 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.417 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 14.3 mm-40 -142.97 102.18 3.96 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 118.787 -1.165 . . . . 0.0 110.801 179.453 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -43.24 114.44 0.62 Allowed 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.18 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 173.04 -145.36 8.36 Favored Glycine 0 N--CA 1.486 2.0 0 C-N-CA 119.395 -1.383 . . . . 0.0 110.038 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.7 127.83 17.59 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.444 -0.902 . . . . 0.0 110.893 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.566 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -114.72 167.14 11.02 Favored 'General case' 0 N--CA 1.481 1.12 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.123 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 20.4 mmtp -134.96 123.47 23.4 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.421 -0.912 . . . . 0.0 112.338 -178.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.543 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -132.72 161.73 33.25 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.774 -0.77 . . . . 0.0 110.359 178.033 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 34.3 p90 -170.35 -174.08 1.61 Allowed 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.382 -178.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.6 t -113.27 134.51 54.56 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.527 179.483 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.5 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.3 mt-10 -75.61 -46.16 4.21 Favored Pre-proline 0 C--N 1.308 -1.224 0 C-N-CA 119.571 -0.852 . . . . 0.0 112.927 -179.376 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -67.62 -41.97 7.66 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.901 1.067 . . . . 0.0 112.266 -179.192 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -93.99 20.71 7.49 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.447 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -74.27 -11.74 60.36 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.126 -1.03 . . . . 0.0 110.548 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -74.83 -18.48 80.11 Favored Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.345 -1.407 . . . . 0.0 110.247 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.72 -49.48 5.59 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.54 -0.864 . . . . 0.0 110.539 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 143.91 23.55 0.16 Allowed Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.467 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.7 103.54 3.1 Favored 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.052 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 6.5 mtpp -130.93 168.49 17.23 Favored 'General case' 0 N--CA 1.494 1.748 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.384 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -153.62 147.29 16.5 Favored Glycine 0 N--CA 1.493 2.492 0 C-N-CA 119.258 -1.449 . . . . 0.0 111.614 -179.068 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -152.66 146.3 25.05 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 120.004 -0.678 . . . . 0.0 109.979 179.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.4 p -137.64 127.59 36.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 C-N-CA 119.1 -1.04 . . . . 0.0 111.148 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 48.2 m -102.0 98.14 8.39 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.346 179.097 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.48 145.63 9.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 118.726 -1.19 . . . . 0.0 110.489 -178.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 . . . . . 0 C--N 1.306 -1.303 0 CA-C-O 116.337 -1.792 . . . . 0.0 110.649 -179.938 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.206 0 N-CA-C 110.148 -0.315 . . . . 0.0 110.148 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -105.16 136.48 44.59 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.829 -0.749 . . . . 0.0 110.825 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.8 t -117.87 143.7 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.931 179.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 13.3 mttm -113.39 107.57 16.04 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.797 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.8 mp -74.69 110.38 8.94 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 118.527 -1.269 . . . . 0.0 109.701 178.437 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.422 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.01 129.17 6.59 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 -179.217 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.3 p . . . . . 0 C--N 1.302 -1.463 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.716 -179.988 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 mt . . . . . 0 N--CA 1.486 1.338 0 CA-C-O 120.665 0.269 . . . . 0.0 110.58 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.9 m -150.03 155.72 7.61 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 119.139 -1.024 . . . . 0.0 110.996 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.414 ' O ' ' O ' ' A' ' 16' ' ' PRO . 61.2 m-85 -78.54 108.44 11.93 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 29.3 m -113.15 110.6 50.98 Favored Pre-proline 0 C--N 1.305 -1.359 0 C-N-CA 119.719 -0.792 . . . . 0.0 112.173 -177.619 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.414 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.2 Cg_endo -67.02 174.56 29.76 Favored 'Cis proline' 0 C--N 1.36 1.137 0 C-N-CA 125.337 -0.693 . . . . 0.0 111.626 -0.215 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.402 ' HG ' ' H ' ' A' ' 18' ' ' SER . 0.2 OUTLIER -95.13 -66.06 0.94 Allowed 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 119.494 -0.883 . . . . 0.0 109.985 179.079 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.402 ' H ' ' HG ' ' A' ' 17' ' ' SER . 19.6 t -114.92 132.53 56.52 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.42 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.448 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 11.1 p90 -157.25 137.8 13.04 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 118.596 -1.242 . . . . 0.0 111.227 -179.137 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -82.28 161.79 22.52 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.184 -1.006 . . . . 0.0 111.082 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.3 m -148.97 162.49 4.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.098 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.457 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -77.05 142.6 39.78 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.872 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.11 76.76 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.066 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.85 19.77 0.1 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -102.74 162.39 12.97 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.793 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -95.59 150.85 19.89 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.529 -0.869 . . . . 0.0 111.371 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.8 mm -124.26 103.4 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.002 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.3 p -100.58 114.08 27.45 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.536 -0.866 . . . . 0.0 112.745 -178.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -83.8 122.32 28.52 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 177.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.3 tttp -121.34 121.56 37.91 Favored 'General case' 0 N--CA 1.502 2.129 0 C-N-CA 119.396 -0.922 . . . . 0.0 112.104 -177.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 0.6 OUTLIER -69.94 113.13 6.87 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.737 179.551 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.422 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 1.9 t30 -100.34 -27.87 13.25 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.685 -179.282 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 175.85 141.33 0.06 Allowed 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 119.256 -0.978 . . . . 0.0 111.122 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 103.2 0.12 47.52 Favored Glycine 0 N--CA 1.494 2.505 0 C-N-CA 119.428 -1.368 . . . . 0.0 112.194 178.626 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -48.16 162.66 0.32 Allowed Pre-proline 0 N--CA 1.487 1.386 0 C-N-CA 118.013 -1.475 . . . . 0.0 109.614 179.766 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -78.59 154.06 91.76 Favored 'Cis proline' 0 C--O 1.215 -0.635 0 C-N-CA 124.354 -1.102 . . . . 0.0 112.288 -0.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 43.8 m-70 -115.62 -177.02 3.05 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.016 178.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -159.75 108.54 1.78 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.41 178.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.2 mp -91.65 121.35 42.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.011 -1.076 . . . . 0.0 111.906 -179.103 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.2 t -134.76 142.37 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.716 179.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.55 ' H ' ' HG ' ' A' ' 56' ' ' SER . 8.0 m-85 -99.48 123.82 44.09 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.309 -0.956 . . . . 0.0 111.577 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.547 ' C ' ' H ' ' A' ' 44' ' ' ASP . 10.5 t0 -68.75 112.0 5.2 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.911 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -72.67 25.46 0.06 Allowed 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.546 -0.861 . . . . 0.0 111.132 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.547 ' H ' ' C ' ' A' ' 42' ' ' ASP . 32.0 m-20 -108.56 -7.9 15.61 Favored 'General case' 0 N--CA 1.49 1.557 0 C-N-CA 119.888 -0.725 . . . . 0.0 110.812 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -142.75 13.4 1.91 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.706 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -93.05 144.37 28.27 Favored Pre-proline 0 C--N 1.298 -1.658 0 C-N-CA 119.559 -0.856 . . . . 0.0 109.693 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -49.15 148.52 9.78 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.931 1.087 . . . . 0.0 112.09 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.79 74.91 5.31 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 119.651 -0.82 . . . . 0.0 110.49 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.66 -51.12 0.19 Allowed Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 84.4 t -72.3 87.09 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.006 179.088 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -44.47 139.23 2.86 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.77 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -91.14 -16.05 28.41 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.878 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -81.13 -11.74 59.4 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.699 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.9 mtmt -91.89 -27.3 18.01 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.299 -0.96 . . . . 0.0 111.071 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.2 pt -92.31 -30.44 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 C-N-CA 119.149 -1.02 . . . . 0.0 110.727 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.55 ' HG ' ' H ' ' A' ' 41' ' ' PHE . 19.1 m -71.07 167.58 18.96 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.095 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.609 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -136.17 81.1 39.14 Favored Pre-proline 0 C--N 1.302 -1.46 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.567 179.285 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_exo -56.05 -16.34 16.34 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 121.317 1.345 . . . . 0.0 112.114 -178.315 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.414 ' O ' ' O ' ' A' ' 60' ' ' TYR . 9.6 mt-10 -73.24 103.32 3.91 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.001 179.157 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.414 ' O ' ' O ' ' A' ' 59' ' ' GLU . 83.6 m-85 -43.71 168.39 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 119.6 -0.84 . . . . 0.0 111.148 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.1 pp -147.53 139.17 23.96 Favored 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.379 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -141.15 28.86 1.86 Allowed 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.843 -179.354 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -92.11 115.24 4.74 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.203 -1.475 . . . . 0.0 110.614 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.37 110.33 1.22 Allowed 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.857 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 98.74 -13.02 62.7 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.521 -1.323 . . . . 0.0 110.414 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 38.9 tt0 -62.65 148.95 44.8 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.246 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.11 164.81 29.16 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.244 -0.982 . . . . 0.0 111.371 -179.643 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.609 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 36.9 t80 -135.53 133.16 38.13 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 120.011 -0.676 . . . . 0.0 109.492 179.566 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -94.83 152.88 18.03 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.184 -178.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 t -150.59 135.38 9.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.267 179.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.5 m -127.65 102.4 6.81 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.417 -0.913 . . . . 0.0 112.254 -178.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 19.9 mt -89.47 155.81 19.06 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.184 -1.006 . . . . 0.0 109.02 178.37 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' THR . . . . . 0.408 ' CG2' ' O ' ' A' ' 73' ' ' THR . 67.2 m -150.94 47.81 0.85 Allowed 'General case' 0 C--N 1.293 -1.854 0 C-N-CA 118.878 -1.129 . . . . 0.0 111.79 -179.05 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.438 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 5.2 tp10 -145.91 103.07 3.72 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 118.95 -1.1 . . . . 0.0 110.017 179.204 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.425 ' N ' ' OE2' ' A' ' 74' ' ' GLU . 0.0 OUTLIER -40.69 114.19 0.44 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.49 -179.25 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 170.93 -148.93 11.72 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.169 -1.491 . . . . 0.0 110.372 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -140.32 133.07 28.99 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.926 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.589 ' N ' ' CD1' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -119.41 154.3 33.89 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.477 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 15.2 mmtm -126.01 128.41 47.41 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.239 -0.985 . . . . 0.0 112.113 -178.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.556 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -137.23 165.44 26.11 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.063 -0.972 . . . . 0.0 110.357 178.463 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.9 p90 -170.58 -175.72 1.93 Allowed 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 119.724 -0.791 . . . . 0.0 110.277 -178.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.2 t -110.38 126.77 54.63 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.498 -0.881 . . . . 0.0 109.95 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.547 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 3.9 tm-20 -73.17 -36.72 3.39 Favored Pre-proline 0 N--CA 1.486 1.366 0 C-N-CA 119.181 -1.008 . . . . 0.0 113.689 -178.462 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.547 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -70.66 -52.39 0.26 Allowed 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 120.527 0.818 . . . . 0.0 110.998 179.701 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -80.25 12.82 2.67 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.759 -0.776 . . . . 0.0 110.791 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.45 -13.43 8.71 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.53 -0.868 . . . . 0.0 110.862 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.26 -18.19 79.45 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.277 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.28 -32.19 13.75 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.921 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.53 8.35 9.21 Favored Glycine 0 N--CA 1.497 2.711 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -50.27 105.26 0.09 Allowed 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.951 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.6 pttp -129.53 160.69 32.43 Favored 'General case' 0 N--CA 1.497 1.883 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.329 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.22 152.21 24.1 Favored Glycine 0 N--CA 1.497 2.742 0 C-N-CA 119.458 -1.354 . . . . 0.0 111.372 -178.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 72.1 tt0 -154.25 148.69 26.16 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.654 -0.818 . . . . 0.0 110.83 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 10.8 p -140.04 125.63 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 C-N-CA 119.205 -0.998 . . . . 0.0 110.449 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 41.4 m -102.89 99.82 9.76 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.459 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 43.3 t -79.22 147.11 6.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 C-N-CA 118.558 -1.257 . . . . 0.0 110.597 -178.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.401 ' OD1' ' N ' ' A' ' 97' ' ' ASN . 12.0 p-10 . . . . . 0 C--N 1.305 -1.338 0 CA-C-O 116.275 -1.822 . . . . 0.0 110.787 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 CA-C-O 120.783 0.325 . . . . 0.0 110.169 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -133.14 130.27 38.98 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 120.021 -0.672 . . . . 0.0 110.575 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.1 t -125.55 126.76 70.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.974 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 21.7 mttm -99.83 119.37 38.08 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.985 -179.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.442 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 77.8 mt -79.35 104.01 9.67 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.142 178.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.437 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 116.31 138.35 6.3 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -178.63 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 58.2 p . . . . . 0 C--N 1.304 -1.403 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.073 -179.627 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 28.1 mt . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 110.426 -0.213 . . . . 0.0 110.426 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.6 m -150.07 155.85 7.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 C-N-CA 118.807 -1.157 . . . . 0.0 111.109 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 18.6 m-85 -78.37 112.1 15.05 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.45 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.8 m -116.17 107.96 46.74 Favored Pre-proline 0 CA--C 1.56 1.354 0 C-N-CA 119.496 -0.882 . . . . 0.0 111.968 -177.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.405 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.3 Cg_endo -65.91 175.53 22.77 Favored 'Cis proline' 0 C--N 1.362 1.268 0 C-N-CA 125.221 -0.741 . . . . 0.0 111.448 0.119 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.01 -45.82 6.12 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.65 -0.82 . . . . 0.0 110.056 179.415 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -137.66 135.18 36.27 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.525 179.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 18.4 p90 -161.5 143.76 11.91 Favored 'General case' 0 N--CA 1.485 1.285 0 C-N-CA 118.577 -1.249 . . . . 0.0 111.497 -179.093 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.3 p -87.27 156.55 19.59 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.331 -0.948 . . . . 0.0 110.957 179.77 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.8 m -148.61 173.12 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.896 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.416 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -88.8 149.43 23.42 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.415 179.635 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.8 74.32 0.1 Allowed 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.981 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 156.08 16.42 0.04 OUTLIER Glycine 0 N--CA 1.488 2.16 0 C-N-CA 119.562 -1.304 . . . . 0.0 109.983 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -95.52 151.26 19.47 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.914 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ptmt -95.34 123.58 38.94 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.527 -0.869 . . . . 0.0 111.114 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.0 mt -101.86 108.07 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.696 179.6 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 p -104.48 112.42 25.47 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.653 -0.819 . . . . 0.0 112.572 -178.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -84.83 116.74 23.46 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.142 178.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.1 ttpt -113.1 126.31 55.32 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.389 -178.036 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -68.11 113.97 6.22 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.737 178.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.453 ' O ' ' CB ' ' A' ' 33' ' ' ALA . 2.4 p-10 -107.31 -22.3 12.64 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 119.171 -1.011 . . . . 0.0 111.15 179.552 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.453 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 169.38 114.46 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 118.926 -1.11 . . . . 0.0 111.113 179.511 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 129.15 7.73 3.93 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.124 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.514 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -57.68 161.63 6.01 Favored Pre-proline 0 C--N 1.306 -1.292 0 C-N-CA 118.521 -1.272 . . . . 0.0 109.95 -179.947 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -80.01 152.68 85.23 Favored 'Cis proline' 0 C--O 1.213 -0.731 0 C-N-CA 124.037 -1.235 . . . . 0.0 112.326 -1.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 45.1 m-70 -113.06 165.19 12.6 Favored 'General case' 0 N--CA 1.493 1.722 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.246 178.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.403 ' C ' ' ND2' ' A' ' 38' ' ' ASN . 1.2 t-20 -149.6 99.76 2.91 Favored 'General case' 0 N--CA 1.49 1.549 0 C-N-CA 118.974 -1.09 . . . . 0.0 110.783 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.8 mp -84.95 135.65 24.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 119.279 -0.969 . . . . 0.0 111.472 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -143.55 143.56 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.004 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -101.56 123.0 44.88 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.539 -0.864 . . . . 0.0 111.702 -179.396 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -66.33 118.06 9.46 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 119.404 -0.918 . . . . 0.0 109.994 179.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.504 ' CD ' ' H ' ' A' ' 43' ' ' GLU . 1.5 pm0 -71.32 -6.65 41.55 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 119.454 -0.898 . . . . 0.0 112.211 -178.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -95.58 5.89 50.35 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.174 -1.01 . . . . 0.0 111.574 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -143.22 16.67 1.89 Allowed 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.702 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -105.19 151.64 39.61 Favored Pre-proline 0 N--CA 1.489 1.481 0 CA-C-N 115.241 -0.89 . . . . 0.0 108.635 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -46.37 151.04 1.9 Allowed 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 121.173 1.249 . . . . 0.0 112.131 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.93 72.12 6.67 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.859 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.58 -35.39 0.14 Allowed Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.548 -1.31 . . . . 0.0 110.054 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 72.8 t -90.34 95.24 5.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.612 179.661 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 66.0 m-20 -50.15 152.9 1.57 Allowed 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.167 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.509 ' C ' ' H ' ' A' ' 54' ' ' LYS . . . -83.09 -38.25 22.74 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.468 179.641 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -63.69 0.52 0.77 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.387 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.509 ' H ' ' C ' ' A' ' 52' ' ' ALA . 0.0 OUTLIER -91.36 -45.68 8.45 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.583 179.973 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -94.46 -25.35 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.875 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 37.3 m -48.74 164.63 0.06 Allowed 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.503 -0.879 . . . . 0.0 110.902 179.695 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.624 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 8.0 mt-30 -138.05 73.96 44.26 Favored Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 120.021 -0.671 . . . . 0.0 110.845 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -61.46 -25.6 80.01 Favored 'Trans proline' 0 C--N 1.324 -0.721 0 C-N-CA 121.301 1.334 . . . . 0.0 111.325 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -68.28 97.76 0.76 Allowed 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.421 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 47.5 m-85 -48.19 162.89 0.07 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.509 -0.877 . . . . 0.0 111.219 -179.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -142.22 106.32 4.76 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.751 179.631 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -114.23 21.45 14.69 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.075 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -90.85 118.64 5.42 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.281 -1.438 . . . . 0.0 110.525 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -58.42 111.35 1.2 Allowed 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.63 179.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.82 -13.35 57.76 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.732 -1.223 . . . . 0.0 110.407 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -60.81 148.04 40.58 Favored 'General case' 0 N--CA 1.487 1.402 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.456 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 2.3 p -145.83 165.4 28.99 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.275 -0.97 . . . . 0.0 111.3 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.624 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 38.3 t80 -136.15 146.99 47.51 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.868 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.42 ' CD ' ' N ' ' A' ' 69' ' ' GLU . 2.1 mp0 -106.88 154.1 21.54 Favored 'General case' 0 N--CA 1.496 1.874 0 C-N-CA 119.431 -0.908 . . . . 0.0 112.164 -179.053 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -151.18 134.23 7.02 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.137 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 12.5 m -129.44 114.24 15.9 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.735 -0.786 . . . . 0.0 111.125 -179.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 17.1 mt -97.6 163.44 12.84 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.696 -0.802 . . . . 0.0 110.079 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 62.3 m -150.38 51.95 0.89 Allowed 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 118.939 -1.104 . . . . 0.0 111.468 -179.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.419 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 0.4 OUTLIER -152.72 105.8 3.01 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 118.916 -1.114 . . . . 0.0 110.658 179.533 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -48.85 110.43 0.35 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.958 -1.097 . . . . 0.0 110.609 -179.695 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.39 -142.66 6.29 Favored Glycine 0 N--CA 1.488 2.139 0 C-N-CA 119.218 -1.468 . . . . 0.0 110.078 -179.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.58 129.25 19.23 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.357 -0.937 . . . . 0.0 111.114 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.568 ' N ' ' CD1' ' A' ' 78' ' ' TYR . 1.5 m-85 -116.03 122.86 46.45 Favored 'General case' 0 N--CA 1.484 1.236 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.535 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.425 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -95.04 113.99 25.75 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.992 -178.843 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.555 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -122.83 165.39 16.71 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.608 178.307 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 30.9 p90 -170.78 -177.62 2.34 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.971 -178.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -110.28 113.27 25.81 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.462 178.483 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.541 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.8 tt0 -65.79 -39.75 33.86 Favored Pre-proline 0 C--N 1.303 -1.427 0 C-N-CA 119.416 -0.914 . . . . 0.0 112.891 -178.735 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.541 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.5 Cg_endo -68.53 -50.39 0.68 Allowed 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 120.499 0.8 . . . . 0.0 111.804 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -83.26 15.8 2.76 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.998 -179.579 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.97 -1.97 4.73 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.636 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -72.4 -27.46 69.68 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.307 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.77 -50.48 5.13 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.561 -0.856 . . . . 0.0 110.456 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.84 30.67 0.12 Allowed Glycine 0 N--CA 1.486 1.987 0 C-N-CA 119.618 -1.277 . . . . 0.0 110.492 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 2.5 mtp -72.17 97.65 1.99 Allowed 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.149 -1.02 . . . . 0.0 111.02 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.481 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -122.76 168.06 12.7 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.66 179.688 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -150.53 146.33 15.25 Favored Glycine 0 N--CA 1.487 2.082 0 C-N-CA 118.883 -1.627 . . . . 0.0 111.563 -178.658 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -149.51 140.87 23.23 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 119.808 -0.757 . . . . 0.0 110.535 179.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.4 p -131.96 120.57 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.729 179.484 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.6 m -94.92 96.97 9.66 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.23 179.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.6 t -79.98 153.01 4.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.639 -178.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.307 -1.251 0 CA-C-O 116.349 -1.786 . . . . 0.0 110.775 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.138 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 -103.74 152.43 21.86 Favored 'General case' 0 N--CA 1.49 1.525 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.856 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.3 t -134.03 145.72 32.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 C-N-CA 119.718 -0.793 . . . . 0.0 110.591 179.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -114.74 109.15 17.76 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 115.118 -0.947 . . . . 0.0 110.609 -179.502 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.438 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 3.9 mt -78.9 106.49 10.96 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.131 -1.027 . . . . 0.0 109.848 179.044 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.427 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 115.29 138.18 6.48 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -178.609 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.437 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 32.1 p . . . . . 0 C--N 1.302 -1.458 0 C-N-CA 119.363 -0.935 . . . . 0.0 111.383 -179.411 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.7 mt . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.9 m -139.73 161.45 26.8 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 C-N-CA 119.376 -0.929 . . . . 0.0 111.501 -178.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.422 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 22.4 m-85 -78.41 110.46 13.48 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 177.793 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 5.6 m -115.67 106.32 50.42 Favored Pre-proline 0 N--CA 1.486 1.348 0 C-N-CA 119.775 -0.77 . . . . 0.0 111.315 -178.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.402 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.7 Cg_endo -66.78 174.61 28.67 Favored 'Cis proline' 0 C--N 1.356 0.94 0 C-N-CA 125.326 -0.698 . . . . 0.0 112.075 0.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -93.3 -55.05 3.45 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.885 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 69.8 m -125.15 140.36 52.94 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.541 179.022 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.438 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 10.4 p90 -156.69 132.06 9.28 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 118.649 -1.22 . . . . 0.0 111.397 -179.315 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.5 p -87.86 152.58 21.98 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.081 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.4 m -147.0 176.13 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.865 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -90.14 155.89 18.73 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.506 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.49 61.21 0.68 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.565 -0.854 . . . . 0.0 111.296 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 170.77 11.91 0.02 OUTLIER Glycine 0 N--CA 1.489 2.216 0 C-N-CA 119.569 -1.3 . . . . 0.0 109.91 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.408 ' OE1' ' O ' ' A' ' 26' ' ' LYS . 5.7 tm-20 -104.61 123.37 47.44 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.969 -0.693 . . . . 0.0 110.831 -179.636 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.408 ' O ' ' OE1' ' A' ' 25' ' ' GLU . 1.3 pttp -69.73 150.31 47.07 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.25 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mt -122.86 147.45 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.2 p -139.22 117.56 11.99 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.218 -0.993 . . . . 0.0 111.626 -179.321 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -84.28 150.58 25.32 Favored 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 119.267 -0.973 . . . . 0.0 109.796 179.058 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -144.55 138.72 27.69 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 118.999 -1.08 . . . . 0.0 111.707 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.613 HD22 ' CB ' ' A' ' 66' ' ' GLU . 0.5 OUTLIER -85.31 131.27 34.44 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.423 178.839 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 5' ' ' LEU . 5.6 p-10 -111.56 -32.38 6.7 Favored 'General case' 0 N--CA 1.505 2.281 0 C-N-CA 119.107 -1.037 . . . . 0.0 112.587 -179.631 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 176.42 30.48 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 118.941 -1.104 . . . . 0.0 110.819 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.493 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -138.78 40.3 1.47 Allowed Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.229 -1.462 . . . . 0.0 111.233 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.596 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -86.2 161.58 48.82 Favored Pre-proline 0 C--N 1.309 -1.194 0 C-N-CA 118.442 -1.303 . . . . 0.0 109.999 179.226 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -78.65 135.82 38.54 Favored 'Cis proline' 0 C--O 1.215 -0.649 0 C-N-CA 124.075 -1.219 . . . . 0.0 111.568 -0.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.493 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 40.4 m-70 -100.21 -177.1 3.42 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.749 179.589 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.619 ' ND2' ' N ' ' A' ' 39' ' ' ILE . 1.7 t-20 -161.11 146.86 14.36 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.3 -0.96 . . . . 0.0 110.916 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.619 ' N ' ' ND2' ' A' ' 38' ' ' ASN . 3.5 mt -131.0 114.91 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.779 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.449 ' CG2' HD22 ' A' ' 38' ' ' ASN . 3.0 t -137.15 137.24 46.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.124 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 44.1 m-85 -93.67 127.63 39.46 Favored 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.236 -0.986 . . . . 0.0 111.413 -179.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.4 125.77 25.28 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.895 179.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -57.47 -49.94 74.64 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 -177.143 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -85.21 8.23 19.11 Favored 'General case' 0 N--CA 1.498 1.936 0 C-N-CA 118.941 -1.104 . . . . 0.0 113.855 -176.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -126.86 40.35 3.74 Favored 'General case' 0 N--CA 1.495 1.781 0 C-N-CA 119.341 -0.944 . . . . 0.0 110.568 179.347 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -135.59 156.33 77.7 Favored Pre-proline 0 N--CA 1.487 1.399 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 179.279 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -48.04 148.06 7.24 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 120.916 1.077 . . . . 0.0 111.73 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.57 70.37 6.03 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.644 -0.822 . . . . 0.0 111.035 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.37 -22.78 0.09 OUTLIER Glycine 0 N--CA 1.489 2.211 0 C-N-CA 119.342 -1.409 . . . . 0.0 110.435 179.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 44.6 t -97.42 99.78 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.809 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -46.75 149.66 0.81 Allowed 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.256 -0.978 . . . . 0.0 110.715 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.435 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -94.64 -5.69 45.09 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.623 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -86.14 -29.6 23.16 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.107 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 21.4 mmtt -71.87 -27.55 62.94 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.463 -0.895 . . . . 0.0 111.481 -179.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 10.7 pt -105.15 -14.95 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 C-N-CA 119.559 -0.857 . . . . 0.0 111.944 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.435 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 4.7 m -67.32 173.62 3.83 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.241 -0.983 . . . . 0.0 110.827 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.656 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 12.9 tt0 -136.93 76.01 47.14 Favored Pre-proline 0 C--N 1.306 -1.321 0 C-N-CA 120.072 -0.651 . . . . 0.0 110.354 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -60.02 -22.33 68.85 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 121.359 1.373 . . . . 0.0 111.985 -178.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 38.8 mm-40 -89.89 106.83 18.74 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.139 -1.024 . . . . 0.0 110.652 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 30.9 m-85 -56.37 170.5 0.35 Allowed 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.728 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.5 pp -140.26 129.48 23.75 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.098 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -127.68 10.33 6.59 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.521 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.48 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . -77.85 118.78 5.08 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.412 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.9 105.12 0.52 Allowed 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.759 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.24 -2.77 43.66 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.559 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.613 ' CB ' HD22 ' A' ' 31' ' ' ASN . 2.8 tp10 -63.16 161.14 14.05 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 118.916 -1.113 . . . . 0.0 110.229 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 66.8 p -147.45 163.14 37.45 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.556 -179.138 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.656 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 76.0 t80 -135.62 139.14 43.57 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.751 179.05 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -107.59 153.17 23.27 Favored 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 119.513 -0.875 . . . . 0.0 112.577 -178.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 p -161.51 132.9 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.391 178.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.8 m -119.81 95.6 4.84 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.733 -178.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 12.2 mt -80.46 158.49 25.88 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.384 -0.926 . . . . 0.0 109.226 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.0 p -151.14 28.44 0.67 Allowed 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 118.65 -1.22 . . . . 0.0 112.253 -179.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.506 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -114.5 97.75 6.49 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.024 179.599 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.8 tttt -41.68 98.0 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.958 -179.674 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 74' ' ' GLU . . . 177.56 -134.17 2.4 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.176 -1.488 . . . . 0.0 110.257 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -145.31 142.0 29.05 Favored 'General case' 0 C--N 1.309 -1.165 0 C-N-CA 119.216 -0.994 . . . . 0.0 111.519 -179.683 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.574 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.2 m-85 -128.05 128.31 44.72 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.386 -0.825 . . . . 0.0 108.779 179.359 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -105.77 118.97 37.96 Favored 'General case' 0 N--CA 1.488 1.453 0 C-N-CA 119.243 -0.983 . . . . 0.0 111.318 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -124.31 172.91 8.73 Favored 'General case' 0 C--O 1.206 -1.205 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.56 178.532 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -171.06 175.3 4.39 Favored 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 118.932 -1.107 . . . . 0.0 111.577 -178.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.4 t -99.66 127.06 45.77 Favored 'General case' 0 C--N 1.3 -1.587 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.287 179.494 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.593 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 3.2 tm-20 -73.88 -34.95 2.25 Favored Pre-proline 0 N--CA 1.492 1.661 0 C-N-CA 118.85 -1.14 . . . . 0.0 113.667 -178.498 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.1 Cg_endo -72.68 -52.31 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 120.671 0.914 . . . . 0.0 110.99 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 34.4 m80 -81.39 14.72 2.32 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.879 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -62.89 -6.19 3.56 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.187 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.31 -21.43 62.5 Favored Glycine 0 N--CA 1.49 2.267 0 C-N-CA 119.339 -1.41 . . . . 0.0 110.307 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.73 -22.36 18.15 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.956 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.426 ' O ' ' N ' ' A' ' 91' ' ' LYS . . . 109.27 11.82 21.15 Favored Glycine 0 N--CA 1.497 2.754 0 C-N-CA 119.964 -1.112 . . . . 0.0 110.364 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 6.1 ttt -53.9 92.62 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.474 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.584 ' CB ' ' HZ1' ' A' ' 91' ' ' LYS . 0.1 OUTLIER -117.1 158.73 23.7 Favored 'General case' 0 N--CA 1.5 2.039 0 C-N-CA 119.855 -0.738 . . . . 0.0 111.386 -179.73 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.23 146.53 18.45 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.027 -1.082 . . . . 0.0 111.052 -178.676 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -148.85 147.1 28.32 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.842 179.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.4 p -140.05 129.89 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.195 179.131 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 90.4 m -106.09 100.78 10.31 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.656 -0.818 . . . . 0.0 110.964 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 47.1 t -82.48 142.99 12.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.364 -179.071 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 17.3 p30 . . . . . 0 C--N 1.307 -1.253 0 CA-C-O 116.328 -1.796 . . . . 0.0 110.952 -179.688 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.905 0.383 . . . . 0.0 110.036 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -92.7 131.46 37.76 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.404 -0.918 . . . . 0.0 110.562 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 t -122.29 121.72 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.404 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.58 118.83 31.86 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.186 179.46 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.8 mt -78.54 98.83 6.26 Favored 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.9 179.019 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.464 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 113.59 131.6 5.39 Favored Glycine 0 N--CA 1.488 2.151 0 CA-C-N 114.546 -1.206 . . . . 0.0 110.323 -179.135 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 56.3 p . . . . . 0 C--N 1.302 -1.48 0 C-N-CA 119.299 -0.96 . . . . 0.0 110.548 179.578 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.7 mt . . . . . 0 N--CA 1.492 1.625 0 CA-C-O 120.471 0.177 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.0 m -150.39 157.06 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 118.979 -1.088 . . . . 0.0 110.954 179.45 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.419 ' O ' ' O ' ' A' ' 16' ' ' PRO . 62.2 m-85 -78.27 110.83 13.63 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 16.5 m -114.2 111.62 47.28 Favored Pre-proline 0 CA--C 1.56 1.341 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.948 -177.459 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.419 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.3 Cg_exo -65.83 174.18 26.4 Favored 'Cis proline' 0 C--N 1.36 1.158 0 C-N-CA 125.105 -0.79 . . . . 0.0 111.611 -0.343 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.9 m -97.45 -65.87 0.94 Allowed 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.098 179.256 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 m -114.39 137.68 51.51 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.734 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 34.5 p90 -168.2 147.4 4.58 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 118.49 -1.284 . . . . 0.0 111.656 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 44.2 p -83.31 161.55 21.4 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.193 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 31.5 m -149.32 148.72 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.228 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.662 179.541 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.539 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -76.51 140.74 41.29 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.294 -0.962 . . . . 0.0 110.751 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -58.78 78.39 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.242 0 C-N-CA 119.657 -0.817 . . . . 0.0 110.937 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 148.21 21.22 0.09 OUTLIER Glycine 0 N--CA 1.487 2.071 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -102.56 150.34 23.5 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.924 -0.71 . . . . 0.0 110.733 -179.718 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 74.9 mttt -95.2 117.69 30.69 Favored 'General case' 0 C--N 1.303 -1.434 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.055 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.5 mt -93.22 98.35 8.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 119.501 -0.88 . . . . 0.0 108.962 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 55.0 p -94.34 117.43 30.11 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 119.493 -0.883 . . . . 0.0 112.821 -177.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -84.68 143.62 29.08 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.049 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 11.4 ttpt -135.3 125.55 26.33 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.387 -178.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.525 ' OD1' ' CD1' ' A' ' 35' ' ' PHE . 36.5 t-20 -79.39 115.8 19.24 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 119.792 -0.763 . . . . 0.0 110.009 179.354 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.464 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 3.0 p-10 -120.29 -22.23 6.63 Favored 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.307 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -177.45 123.43 0.13 Allowed 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 118.358 -1.337 . . . . 0.0 112.188 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 104.17 48.6 1.13 Allowed Glycine 0 N--CA 1.495 2.618 0 C-N-CA 119.272 -1.442 . . . . 0.0 112.849 177.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.623 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -87.54 164.83 33.39 Favored Pre-proline 0 C--N 1.304 -1.37 0 C-N-CA 118.573 -1.251 . . . . 0.0 108.936 177.91 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -77.2 140.13 62.6 Favored 'Cis proline' 0 C--O 1.215 -0.642 0 C-N-CA 124.555 -1.019 . . . . 0.0 112.917 -0.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 33.6 m-70 -108.15 161.28 15.12 Favored 'General case' 0 N--CA 1.495 1.794 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.952 178.607 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.721 HD22 ' H ' ' A' ' 83' ' ' GLU . 4.0 p-10 -153.52 163.18 40.4 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 119.049 -1.061 . . . . 0.0 110.684 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -133.78 124.35 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.841 -0.743 . . . . 0.0 110.758 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.7 t -137.48 141.31 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.264 179.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -96.39 130.75 43.45 Favored 'General case' 0 C--N 1.303 -1.455 0 C-N-CA 119.574 -0.85 . . . . 0.0 111.706 -178.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -73.9 117.19 15.4 Favored 'General case' 0 N--CA 1.485 1.279 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.789 179.034 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -69.56 0.3 5.57 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.435 -0.906 . . . . 0.0 112.013 -178.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 62.3 m-20 -99.76 -5.79 28.08 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.357 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 31.0 mm-40 -123.37 -2.38 8.52 Favored 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.615 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 42.2 t -95.99 144.93 28.66 Favored Pre-proline 0 C--N 1.285 -2.216 0 N-CA-C 107.256 -1.386 . . . . 0.0 107.256 178.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -61.09 165.2 12.82 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 CA-C-N 119.024 0.687 . . . . 0.0 111.89 -178.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.8 38.89 0.72 Allowed 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.381 -0.928 . . . . 0.0 110.239 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.18 -57.83 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . 0.454 ' CG1' ' O ' ' A' ' 50' ' ' VAL . 9.8 p -84.46 101.99 9.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.722 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -48.97 153.81 0.82 Allowed 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.681 -0.808 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -98.29 -10.16 24.35 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.443 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -88.1 -10.46 50.02 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.652 -0.819 . . . . 0.0 110.579 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.4 13.2 16.19 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.465 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.1 pt -147.38 -29.09 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 C-N-CA 119.503 -0.879 . . . . 0.0 110.814 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 2.1 m -48.58 174.25 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.948 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.624 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 36.5 mt-30 -135.5 78.95 49.23 Favored Pre-proline 0 N--CA 1.489 1.491 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.022 -179.833 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -60.58 -7.86 7.97 Favored 'Trans proline' 0 N--CA 1.456 -0.686 0 C-N-CA 120.78 0.987 . . . . 0.0 110.641 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.406 ' H ' ' C ' ' A' ' 57' ' ' GLN . 51.2 mt-10 -98.01 127.61 44.06 Favored 'General case' 0 N--CA 1.483 1.179 0 C-N-CA 119.778 -0.769 . . . . 0.0 110.227 179.309 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.435 ' CD1' ' N ' ' A' ' 60' ' ' TYR . 32.4 m-85 -88.59 173.58 8.56 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.917 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -137.94 106.53 5.87 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.658 179.644 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.617 ' H ' ' ND2' ' A' ' 62' ' ' ASN . 0.3 OUTLIER -101.67 3.65 39.97 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.912 179.993 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -65.83 -140.58 0.04 OUTLIER Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.392 -1.385 . . . . 0.0 110.413 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -159.42 99.61 1.46 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.68 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.44 -1.12 43.01 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 119.815 -1.183 . . . . 0.0 110.44 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -63.03 158.74 18.72 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.56 179.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.2 p -147.26 155.48 42.09 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.828 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.624 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 41.0 t80 -136.97 153.51 50.67 Favored 'General case' 0 N--CA 1.488 1.444 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.443 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.411 ' O ' ' CE1' ' A' ' 68' ' ' TYR . 3.6 mt-10 -113.41 149.18 34.52 Favored 'General case' 0 N--CA 1.501 2.082 0 C-N-CA 119.44 -0.904 . . . . 0.0 112.224 -179.076 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -144.62 126.04 9.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.182 179.033 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.9 m -119.22 100.11 7.12 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.82 -0.752 . . . . 0.0 111.268 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 65.9 mt -79.55 161.28 26.08 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.65 179.171 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.9 p -150.07 48.53 0.91 Allowed 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 118.819 -1.152 . . . . 0.0 111.742 -178.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.4 ' O ' ' C ' ' A' ' 75' ' ' LYS . 3.6 mm-40 -148.17 98.26 2.9 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.567 179.416 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 74' ' ' GLU . 0.0 OUTLIER -43.67 107.8 0.09 Allowed 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.596 -179.784 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 176.48 -141.91 5.7 Favored Glycine 0 C--N 1.294 -1.773 0 C-N-CA 119.066 -1.54 . . . . 0.0 110.094 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.52 136.67 26.22 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.476 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.592 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.2 OUTLIER -128.78 137.64 51.64 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.488 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.37 108.64 16.78 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.932 179.759 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.504 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 2.1 p90 -109.87 170.95 7.74 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.202 179.445 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -171.18 179.84 2.9 Favored 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 119.362 -0.935 . . . . 0.0 112.068 -178.454 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . 0.465 ' SG ' ' OD1' ' A' ' 38' ' ' ASN . 1.5 t -108.96 124.45 50.71 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.205 179.122 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.721 ' H ' HD22 ' A' ' 38' ' ' ASN . 0.3 OUTLIER -68.46 -39.4 15.51 Favored Pre-proline 0 N--CA 1.488 1.442 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -178.283 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.3 Cg_endo -73.35 -51.67 0.16 Allowed 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 121.02 1.147 . . . . 0.0 111.84 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -81.4 8.49 9.17 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.286 -0.966 . . . . 0.0 111.328 -179.327 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.03 -17.28 64.31 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.198 -1.001 . . . . 0.0 110.686 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -65.05 -22.98 69.28 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.493 -1.336 . . . . 0.0 110.248 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.25 -39.82 10.78 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.562 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 135.65 20.89 0.67 Allowed Glycine 0 N--CA 1.493 2.461 0 C-N-CA 119.744 -1.217 . . . . 0.0 110.34 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.98 106.2 2.26 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.312 -0.955 . . . . 0.0 111.19 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.409 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 2.1 pttp -135.15 169.5 17.35 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.938 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.462 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -150.51 150.17 22.14 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 119.013 -1.565 . . . . 0.0 111.417 -178.467 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -150.09 143.52 25.15 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.519 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.6 p -141.03 126.34 18.77 Favored 'Isoleucine or valine' 0 C--O 1.205 -1.285 0 C-N-CA 119.244 -0.982 . . . . 0.0 110.746 179.703 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 22.7 m -103.45 103.41 13.38 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.647 -0.821 . . . . 0.0 110.423 179.432 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 21.6 t -79.55 143.15 12.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 118.714 -1.194 . . . . 0.0 110.018 -179.36 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 . . . . . 0 N--CA 1.489 1.488 0 CA-C-O 116.314 -1.803 . . . . 0.0 110.818 -179.602 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.096 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -140.21 122.49 15.92 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.748 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 98.4 t -114.52 132.54 63.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 C-N-CA 119.848 -0.741 . . . . 0.0 111.127 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -100.56 111.75 24.03 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.736 -0.786 . . . . 0.0 110.684 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.433 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 9.5 mt -75.68 105.07 6.52 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.923 178.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 112.39 131.68 5.66 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -178.61 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.4 p . . . . . 0 C--N 1.306 -1.309 0 C-N-CA 119.256 -0.978 . . . . 0.0 111.092 -179.63 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.9 mt . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 120.629 0.252 . . . . 0.0 110.915 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.6 m -150.64 157.95 5.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.654 179.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.53 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 34.1 m-85 -78.39 113.24 16.21 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 178.068 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 17.3 m -116.45 107.13 47.5 Favored Pre-proline 0 CA--C 1.562 1.41 0 C-N-CA 119.5 -0.88 . . . . 0.0 112.186 -177.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -65.89 176.24 20.9 Favored 'Cis proline' 0 C--N 1.361 1.217 0 C-N-CA 125.198 -0.751 . . . . 0.0 111.414 -0.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.02 -52.05 4.39 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.486 -0.885 . . . . 0.0 110.265 179.264 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 4.5 m -132.03 135.28 46.4 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.413 179.09 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 12.8 p90 -155.71 142.32 18.74 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 118.495 -1.282 . . . . 0.0 111.573 -179.097 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 46.9 p -84.17 151.24 24.99 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.439 179.458 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.0 m -144.59 161.79 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 119.356 -0.938 . . . . 0.0 111.137 179.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.448 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -81.35 146.55 30.28 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.65 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.05 74.52 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 119.673 -0.811 . . . . 0.0 111.23 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.448 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 155.68 18.2 0.04 OUTLIER Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.466 -1.35 . . . . 0.0 109.797 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -98.63 150.95 21.22 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.951 -179.49 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.8 mttt -92.43 117.95 30.45 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.337 -0.945 . . . . 0.0 111.016 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.6 mt -97.94 110.4 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.771 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 75.6 p -110.94 114.48 27.83 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.672 -0.811 . . . . 0.0 112.515 -178.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -87.01 111.55 20.97 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.373 178.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -106.57 141.01 38.54 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 119.68 -0.808 . . . . 0.0 112.045 -178.535 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -82.27 115.99 21.59 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.877 178.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 4.2 p-10 -98.75 -32.76 11.21 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 118.755 -1.178 . . . . 0.0 111.839 -179.398 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.483 ' N ' ' OD1' ' A' ' 32' ' ' ASN . . . 171.91 52.22 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.496 -0.881 . . . . 0.0 110.042 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.506 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -153.45 26.67 0.77 Allowed Glycine 0 N--CA 1.487 2.041 0 C-N-CA 118.992 -1.575 . . . . 0.0 110.734 -179.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.636 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -79.23 160.34 70.9 Favored Pre-proline 0 C--N 1.309 -1.191 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.96 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -77.41 138.66 54.15 Favored 'Cis proline' 0 C--O 1.215 -0.657 0 C-N-CA 123.876 -1.302 . . . . 0.0 111.757 -1.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.506 ' CE1' ' O ' ' A' ' 34' ' ' GLY . 38.2 m-70 -107.66 179.52 4.21 Favored 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 119.631 -0.828 . . . . 0.0 111.49 -179.293 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -156.09 143.25 19.08 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.61 -0.836 . . . . 0.0 110.354 179.781 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.2 mp -130.25 118.31 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.304 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t -145.3 147.65 18.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.656 179.064 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -99.43 139.97 34.29 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.144 -1.022 . . . . 0.0 112.006 -179.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.704 ' C ' ' H ' ' A' ' 44' ' ' ASP . 39.8 p-10 -75.37 108.37 8.11 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 115.142 -0.935 . . . . 0.0 111.296 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 27.4 mm-40 -56.47 10.8 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.156 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.589 179.748 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.704 ' H ' ' C ' ' A' ' 42' ' ' ASP . 70.8 m-20 -82.92 -68.49 0.7 Allowed 'General case' 0 C--N 1.288 -2.081 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.249 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -99.38 -5.23 29.92 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.826 -1.15 . . . . 0.0 114.038 -175.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -54.15 143.88 41.94 Favored Pre-proline 0 C--N 1.282 -2.362 0 C-N-CA 118.206 -1.397 . . . . 0.0 107.784 179.023 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_exo -46.71 146.92 5.0 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 120.713 0.942 . . . . 0.0 112.116 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -85.34 51.13 2.1 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.771 -0.772 . . . . 0.0 111.051 -179.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -165.63 -23.49 0.02 OUTLIER Glycine 0 N--CA 1.488 2.122 0 C-N-CA 119.478 -1.344 . . . . 0.0 109.965 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 53.2 t -97.85 104.26 15.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.683 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -45.56 139.85 3.6 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 119.223 -0.991 . . . . 0.0 110.567 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.433 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -101.29 -8.29 22.25 Favored 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.229 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -83.79 -21.05 32.28 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.164 -1.014 . . . . 0.0 110.966 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 51.6 mmtt -86.41 -32.88 20.66 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.263 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.4 pt -89.14 -19.81 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 C-N-CA 118.876 -1.13 . . . . 0.0 111.438 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.433 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 74.3 m -74.44 -176.6 2.77 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.971 179.354 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.537 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.4 mt-30 -142.51 82.82 12.41 Favored Pre-proline 0 N--CA 1.491 1.617 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.43 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -61.96 -9.59 14.9 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 121.187 1.258 . . . . 0.0 112.067 -179.039 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -99.23 112.55 24.69 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.387 -0.925 . . . . 0.0 110.87 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -58.69 178.04 0.12 Allowed 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.574 -0.851 . . . . 0.0 110.71 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.0 pp -151.21 142.12 22.95 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.551 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.519 ' N ' ' ND2' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -134.58 19.95 3.6 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.883 -179.752 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -86.4 139.26 16.52 Favored Glycine 0 N--CA 1.489 2.213 0 C-N-CA 119.168 -1.491 . . . . 0.0 110.219 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -85.5 111.39 19.95 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.509 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 102.25 -15.21 56.54 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 -179.624 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -64.01 147.02 53.08 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.227 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -142.43 169.92 16.67 Favored 'General case' 0 N--CA 1.486 1.369 0 C-N-CA 119.206 -0.997 . . . . 0.0 111.466 -179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.537 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 26.5 t80 -134.44 135.97 42.9 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.477 179.251 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.48 ' H ' ' CD ' ' A' ' 69' ' ' GLU . 1.6 mp0 -97.36 152.63 18.73 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.25 -0.98 . . . . 0.0 112.371 -178.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.1 t -151.58 133.5 5.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 CA-C-N 115.221 -0.899 . . . . 0.0 109.033 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 8.4 m -127.13 104.3 7.9 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.113 -179.376 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 13.9 mt -90.37 160.06 16.28 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.268 -0.973 . . . . 0.0 109.749 179.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 67.3 p -148.41 48.04 1.04 Allowed 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.558 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.438 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.9 mt-10 -147.08 105.9 3.84 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.972 -1.091 . . . . 0.0 110.453 179.311 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.74 112.03 0.42 Allowed 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.002 -1.079 . . . . 0.0 110.633 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.66 8.61 Favored Glycine 0 N--CA 1.487 2.064 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.282 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -141.44 123.73 15.68 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.399 -179.642 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.547 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -115.49 120.29 39.02 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.339 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 26.1 mttt -97.83 126.95 43.45 Favored 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 119.209 -0.996 . . . . 0.0 112.603 -178.406 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.58 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -127.61 158.58 37.13 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.679 177.928 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -165.0 176.87 8.23 Favored 'General case' 0 C--N 1.283 -2.296 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.131 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.6 t -104.39 123.86 48.19 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.787 -0.765 . . . . 0.0 110.547 -179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.542 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tt0 -66.4 -44.97 58.88 Favored Pre-proline 0 C--N 1.306 -1.303 0 C-N-CA 119.685 -0.806 . . . . 0.0 112.913 -179.673 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.542 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.6 Cg_exo -65.36 -50.29 2.05 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 121.179 1.252 . . . . 0.0 111.801 -178.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -86.77 16.18 5.04 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.727 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.21 -9.35 4.74 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.777 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.36 -20.12 49.87 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.485 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.14 -12.93 39.65 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.478 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 99.02 26.07 9.17 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.505 -1.331 . . . . 0.0 110.719 179.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -76.83 101.63 5.97 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.174 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.53 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 1.5 ptmt -124.98 162.58 24.18 Favored 'General case' 0 N--CA 1.493 1.712 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.946 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.549 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -146.76 149.84 22.04 Favored Glycine 0 N--CA 1.495 2.608 0 C-N-CA 119.296 -1.431 . . . . 0.0 111.419 -178.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -156.39 145.47 20.42 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.005 179.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.47 ' CG1' ' O ' ' A' ' 94' ' ' VAL . 12.6 p -135.94 117.53 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.466 -0.893 . . . . 0.0 110.464 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 46.1 m -93.72 100.4 12.63 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.194 -1.003 . . . . 0.0 110.599 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 22.9 t -79.22 146.5 7.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 C-N-CA 118.46 -1.296 . . . . 0.0 110.333 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.308 -1.233 0 CA-C-O 116.345 -1.788 . . . . 0.0 110.587 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.087 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -118.51 122.06 41.77 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.644 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 57.6 t -114.89 113.81 44.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.866 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 29.5 mtmt -88.63 116.77 27.11 Favored 'General case' 0 C--N 1.298 -1.641 0 C-N-CA 119.193 -1.003 . . . . 0.0 110.854 -179.555 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 7.8 mt -78.6 105.79 10.13 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 118.788 -1.165 . . . . 0.0 110.41 178.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 103.12 121.42 4.93 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.1 p . . . . . 0 C--N 1.304 -1.371 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.672 179.838 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 23.0 mt . . . . . 0 N--CA 1.487 1.381 0 CA-C-O 120.459 0.171 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.7 m -151.0 157.43 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 C-N-CA 118.974 -1.09 . . . . 0.0 111.381 179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' A' ' 16' ' ' PRO . 22.1 m-85 -78.53 110.0 13.22 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 177.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.4 m -115.62 109.19 45.99 Favored Pre-proline 0 N--CA 1.488 1.449 0 C-N-CA 119.28 -0.968 . . . . 0.0 112.564 -177.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.421 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.4 Cg_exo -65.9 178.62 15.26 Favored 'Cis proline' 0 C--N 1.364 1.35 0 C-N-CA 125.191 -0.754 . . . . 0.0 111.526 -1.075 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 41.8 t -95.75 -60.47 1.64 Allowed 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.376 179.474 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.4 t -124.74 140.33 53.03 Favored 'General case' 0 N--CA 1.488 1.438 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.884 179.37 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -165.22 149.62 8.82 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 118.592 -1.243 . . . . 0.0 111.258 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -87.03 160.45 18.61 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.273 -179.876 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.3 m -148.86 165.56 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.941 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.499 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -87.29 142.91 27.54 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.556 179.817 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.71 77.28 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.136 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.499 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 146.56 18.41 0.13 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -98.35 138.58 35.38 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.852 -0.739 . . . . 0.0 110.609 -179.627 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.5 mttm -80.1 118.65 22.0 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.141 -179.634 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.3 mt -100.41 120.21 49.57 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.228 179.345 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 68.3 p -114.93 118.45 33.49 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.523 -0.871 . . . . 0.0 112.988 -177.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -84.71 114.15 21.83 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 177.415 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.4 mttp -103.94 132.33 50.3 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.415 -0.914 . . . . 0.0 111.46 -177.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 50.3 t-20 -84.97 110.82 19.17 Favored 'General case' 0 C--N 1.29 -2.004 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.025 178.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -106.67 -30.22 9.12 Favored 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 119.275 -0.97 . . . . 0.0 112.038 -179.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -178.67 161.11 1.25 Allowed 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 119.26 -0.976 . . . . 0.0 111.194 -179.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . 75.58 58.61 3.79 Favored Glycine 0 N--CA 1.495 2.58 0 C-N-CA 119.536 -1.316 . . . . 0.0 113.062 178.04 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -97.3 165.27 16.02 Favored Pre-proline 0 N--CA 1.496 1.853 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 177.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -78.08 138.46 51.44 Favored 'Cis proline' 0 C--O 1.214 -0.691 0 C-N-CA 124.808 -0.913 . . . . 0.0 113.047 -0.042 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . 0.505 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 36.6 m-70 -102.81 177.34 4.88 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.713 -0.795 . . . . 0.0 110.574 178.566 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -165.69 154.48 11.64 Favored 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.88 179.688 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.412 ' N ' ' CD1' ' A' ' 39' ' ' ILE . 2.5 mp -139.25 114.67 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 119.64 -0.824 . . . . 0.0 111.103 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 t -130.48 152.21 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.603 179.397 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.434 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 9.5 m-85 -102.94 141.07 36.37 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.525 -0.87 . . . . 0.0 111.796 -179.025 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -78.28 109.97 12.88 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.817 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.434 ' OE2' ' O ' ' A' ' 41' ' ' PHE . 35.3 mp0 -73.36 47.27 0.21 Allowed 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.94 -179.188 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -138.74 -5.84 1.51 Allowed 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.804 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -145.11 7.12 1.17 Allowed 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 118.54 -1.264 . . . . 0.0 111.981 179.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.1 t -80.53 150.79 70.83 Favored Pre-proline 0 C--N 1.289 -2.04 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.661 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -52.87 158.17 6.79 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 120.944 1.096 . . . . 0.0 111.794 -179.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.87 48.7 1.67 Allowed 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.751 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -154.6 -32.63 0.03 OUTLIER Glycine 0 N--CA 1.49 2.242 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.134 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 51.6 t -97.29 95.39 4.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 C-N-CA 119.599 -0.84 . . . . 0.0 110.841 179.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -46.05 148.29 0.87 Allowed 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.037 -1.065 . . . . 0.0 110.322 179.701 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -92.87 -33.77 14.09 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.339 -0.945 . . . . 0.0 111.211 -179.591 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -65.81 -17.83 64.91 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.823 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.37 -35.88 54.08 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.284 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.9 pt -95.69 -35.13 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.108 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 39.9 m -43.46 158.88 0.03 OUTLIER 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.995 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.622 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 7.5 mt-30 -137.98 71.19 49.08 Favored Pre-proline 0 N--CA 1.486 1.328 0 C-N-CA 119.947 -0.701 . . . . 0.0 110.699 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -61.28 -5.73 5.65 Favored 'Trans proline' 0 C--N 1.321 -0.871 0 C-N-CA 121.274 1.316 . . . . 0.0 111.07 -179.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.419 ' H ' ' C ' ' A' ' 57' ' ' GLN . 1.3 mm-40 -83.65 113.78 21.09 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.005 179.364 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -69.38 166.4 18.72 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.551 -0.859 . . . . 0.0 111.297 -179.258 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.15 125.65 19.07 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.863 179.537 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.65 ' ND2' ' H ' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -104.87 -74.39 0.65 Allowed 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.309 -179.472 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.528 ' H ' ' CG ' ' A' ' 62' ' ' ASN . . . -35.06 146.12 0.04 OUTLIER Glycine 0 N--CA 1.501 2.975 0 C-N-CA 120.401 -0.904 . . . . 0.0 111.446 -179.448 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -81.42 151.56 27.83 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.744 -0.782 . . . . 0.0 110.888 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.22 -11.25 69.3 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.365 -1.397 . . . . 0.0 111.307 179.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -74.72 119.94 19.6 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.123 -1.031 . . . . 0.0 111.036 -179.767 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 3.9 p -127.5 160.78 30.47 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.949 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.622 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 34.5 t80 -136.48 141.41 43.49 Favored 'General case' 0 N--CA 1.494 1.749 0 C-N-CA 119.784 -0.767 . . . . 0.0 110.171 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -101.42 149.62 23.87 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 119.48 -0.888 . . . . 0.0 112.09 -178.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 t -146.05 138.4 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.105 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.2 m -132.39 99.76 4.78 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.577 -0.849 . . . . 0.0 111.28 -179.46 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 65.3 mt -82.48 162.83 21.93 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.158 179.461 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 97.7 m -150.57 45.07 0.86 Allowed 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.904 -1.118 . . . . 0.0 111.919 -179.105 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -145.02 102.05 3.71 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 118.924 -1.11 . . . . 0.0 110.418 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 22.6 mtmt -45.85 107.94 0.12 Allowed 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.201 -1.0 . . . . 0.0 110.425 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 177.21 -146.57 7.83 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.219 -1.467 . . . . 0.0 110.39 -179.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.99 130.1 22.07 Favored 'General case' 0 N--CA 1.484 1.257 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.646 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.588 ' N ' ' CD1' ' A' ' 78' ' ' TYR . 0.2 OUTLIER -120.95 147.33 45.61 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 178.996 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.586 ' HZ3' ' CB ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -121.91 121.75 37.83 Favored 'General case' 0 N--CA 1.5 2.032 0 C-N-CA 119.069 -1.052 . . . . 0.0 110.957 179.47 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.6 OUTLIER -123.5 161.28 25.19 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.764 -0.774 . . . . 0.0 109.904 178.692 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 36.9 p90 -161.5 177.17 10.31 Favored 'General case' 0 C--N 1.285 -2.231 0 C-N-CA 119.184 -1.006 . . . . 0.0 111.176 -179.082 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -100.07 119.09 37.75 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.714 179.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.573 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 14.8 tt0 -72.03 -36.05 3.91 Favored Pre-proline 0 C--N 1.308 -1.213 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.953 -179.104 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.6 Cg_endo -72.05 -54.57 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.377 0.718 . . . . 0.0 111.049 179.727 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . 0.4 ' C ' ' H ' ' A' ' 87' ' ' GLY . 28.4 m170 -79.82 14.93 1.55 Allowed 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.602 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.56 -11.64 0.94 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.628 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.4 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -78.62 -25.38 60.84 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.162 179.719 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.55 -31.74 26.23 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.414 179.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 110.3 26.72 4.76 Favored Glycine 0 N--CA 1.492 2.4 0 C-N-CA 119.781 -1.2 . . . . 0.0 110.859 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 32.0 mtp -67.82 108.49 3.0 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.081 -1.048 . . . . 0.0 110.79 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -121.03 154.31 36.22 Favored 'General case' 0 N--CA 1.491 1.611 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.917 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.76 146.24 17.19 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.511 -1.328 . . . . 0.0 111.236 -178.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -152.71 145.12 24.05 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.594 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 12.0 p -138.45 125.46 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.794 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 91.0 m -102.77 99.07 8.99 Favored 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.532 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 31.7 t -79.87 148.61 5.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 118.692 -1.203 . . . . 0.0 110.472 -179.054 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 48.7 p30 . . . . . 0 C--N 1.306 -1.297 0 CA-C-O 116.324 -1.798 . . . . 0.0 110.671 -179.843 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 120.839 0.352 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . 0.524 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 10.8 mp0 -105.12 130.97 53.18 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.848 -0.741 . . . . 0.0 110.548 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.1 t -114.08 118.89 59.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.852 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 30.4 mttt -92.77 114.2 26.68 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.78 -179.095 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mp -79.71 105.83 11.29 Favored 'General case' 0 C--N 1.313 -1.016 0 C-N-CA 118.597 -1.241 . . . . 0.0 109.696 177.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.439 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.32 90.66 2.14 Favored Glycine 0 C--N 1.29 -2.018 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -178.755 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.443 ' H ' ' HG ' ' A' ' 7' ' ' SER . 3.1 p . . . . . 0 C--N 1.303 -1.456 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.766 -179.546 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.8 mt . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 120.608 0.242 . . . . 0.0 110.921 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.7 m -149.55 155.29 8.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 C-N-CA 118.898 -1.121 . . . . 0.0 111.058 179.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' A' ' 16' ' ' PRO . 29.7 m-85 -78.29 106.93 10.54 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 177.825 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 46.9 m -112.73 113.03 50.48 Favored Pre-proline 0 CA--C 1.556 1.2 0 C-N-CA 119.423 -0.911 . . . . 0.0 112.3 -177.11 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.5 Cg_endo -66.68 175.6 25.26 Favored 'Cis proline' 0 C--N 1.358 1.039 0 C-N-CA 125.4 -0.667 . . . . 0.0 111.5 -1.052 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -92.83 -61.16 1.64 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.469 -0.893 . . . . 0.0 110.014 179.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -119.92 142.53 48.64 Favored 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.474 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 19.8 p90 -167.78 137.11 2.6 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 118.577 -1.249 . . . . 0.0 111.304 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -84.64 161.21 20.19 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.301 -0.959 . . . . 0.0 111.028 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.1 m -148.49 162.42 5.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.274 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.978 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.475 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -82.76 144.45 30.17 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.278 -0.969 . . . . 0.0 110.435 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.27 76.92 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.369 -0.933 . . . . 0.0 111.07 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.475 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 149.22 19.45 0.08 OUTLIER Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.467 ' CD ' ' N ' ' A' ' 26' ' ' LYS . 5.9 tm-20 -101.51 144.56 30.13 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.654 -179.666 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.467 ' N ' ' CD ' ' A' ' 25' ' ' GLU . 67.6 mttt -88.49 133.44 34.13 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.807 -179.799 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.6 mt -117.38 118.14 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.55 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.8 p -109.95 114.76 28.57 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.825 -0.75 . . . . 0.0 112.392 -178.3 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -84.45 117.96 23.98 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.446 178.356 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.69 127.65 53.08 Favored 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 119.289 -0.965 . . . . 0.0 111.525 -177.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 39.0 t-20 -84.29 130.66 34.79 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.667 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.439 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 12.0 p-10 -134.22 -8.01 2.62 Favored 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 118.893 -1.123 . . . . 0.0 112.444 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -171.74 144.52 1.83 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 118.376 -1.33 . . . . 0.0 112.318 -179.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 72.15 54.57 7.86 Favored Glycine 0 N--CA 1.489 2.199 0 C-N-CA 119.903 -1.141 . . . . 0.0 113.53 177.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.482 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -92.74 167.07 15.26 Favored Pre-proline 0 N--CA 1.497 1.884 0 C-N-CA 118.718 -1.193 . . . . 0.0 108.498 177.22 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -77.05 146.35 83.4 Favored 'Cis proline' 0 N--CA 1.481 0.738 0 C-N-CA 124.958 -0.851 . . . . 0.0 113.047 -0.323 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 30.5 m-70 -104.69 -177.23 3.31 Favored 'General case' 0 N--CA 1.489 1.485 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.499 178.088 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.658 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -164.61 135.3 4.11 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.742 -0.783 . . . . 0.0 110.057 178.747 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.658 ' N ' HD21 ' A' ' 38' ' ' ASN . 2.8 mp -124.0 119.42 56.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 C-N-CA 119.837 -0.745 . . . . 0.0 110.898 -179.716 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.9 t -142.26 145.5 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.61 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -97.37 121.63 39.49 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.586 -0.845 . . . . 0.0 111.221 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.475 ' C ' ' H ' ' A' ' 44' ' ' ASP . 38.1 p-10 -59.91 117.3 4.88 Favored 'General case' 0 C--N 1.309 -1.165 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.781 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -74.96 41.73 0.17 Allowed 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.809 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.475 ' H ' ' C ' ' A' ' 42' ' ' ASP . 7.3 m-20 -135.64 -3.26 2.35 Favored 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.656 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -147.38 19.25 1.2 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.054 -1.058 . . . . 0.0 111.215 179.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -96.71 146.01 30.57 Favored Pre-proline 0 C--N 1.3 -1.544 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.351 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -57.41 147.82 75.55 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.794 0.996 . . . . 0.0 111.82 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.47 158.63 14.43 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 119.14 -1.024 . . . . 0.0 109.945 179.29 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 79.64 -52.26 4.13 Favored Glycine 0 N--CA 1.487 2.075 0 C-N-CA 118.991 -1.576 . . . . 0.0 109.956 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 71.6 t -69.81 73.84 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.165 0 C-N-CA 119.236 -0.986 . . . . 0.0 110.496 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -44.86 142.35 1.81 Allowed 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.698 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -79.3 -29.29 42.38 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.401 -0.919 . . . . 0.0 111.052 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -74.03 3.61 6.66 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.693 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.34 -35.61 10.66 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.948 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt -99.79 -28.37 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.044 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 68.9 m -64.74 154.81 35.68 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.247 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.612 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.1 OUTLIER -135.86 76.82 52.15 Favored Pre-proline 0 N--CA 1.486 1.356 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.96 179.65 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -57.41 -3.32 0.83 Allowed 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 121.193 1.262 . . . . 0.0 111.87 -178.571 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.48 ' H ' ' C ' ' A' ' 57' ' ' GLN . 11.4 tt0 -72.97 91.53 1.56 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.021 -1.072 . . . . 0.0 110.021 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.539 ' CE1' ' OD1' ' A' ' 38' ' ' ASN . 36.4 m-85 -43.61 165.63 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.947 -179.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -142.43 110.47 5.94 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.896 179.55 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.625 ' H ' ' ND2' ' A' ' 62' ' ' ASN . 0.3 OUTLIER -103.28 -6.82 21.65 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.664 179.898 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -71.05 152.04 49.64 Favored Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.456 -1.354 . . . . 0.0 110.44 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -94.83 103.9 15.79 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.764 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.24 -7.3 16.51 Favored Glycine 0 N--CA 1.496 2.677 0 C-N-CA 119.941 -1.123 . . . . 0.0 110.62 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.4 148.08 42.81 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.055 -1.058 . . . . 0.0 110.457 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 4.9 p -147.18 165.24 30.61 Favored 'General case' 0 N--CA 1.491 1.595 0 C-N-CA 118.901 -1.12 . . . . 0.0 111.889 -179.531 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.612 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 42.3 t80 -137.09 150.8 48.25 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.805 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.445 ' O ' ' CE1' ' A' ' 68' ' ' TYR . 2.2 mp0 -108.1 151.4 25.93 Favored 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.423 -179.711 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -150.31 135.77 10.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.303 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.0 m -135.75 92.17 2.79 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.155 -179.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 21.4 mt -79.82 158.7 26.73 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.263 -0.975 . . . . 0.0 109.659 179.412 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 23.4 p -150.53 41.98 0.8 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.143 -179.237 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.438 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 8.8 mt-10 -140.02 105.98 5.2 Favored 'General case' 0 N--CA 1.498 1.957 0 C-N-CA 118.807 -1.157 . . . . 0.0 110.422 179.178 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.5 tttp -40.19 112.37 0.27 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.301 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.43 -149.86 14.21 Favored Glycine 0 N--CA 1.488 2.162 0 C-N-CA 118.854 -1.641 . . . . 0.0 110.675 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -138.09 139.44 39.49 Favored 'General case' 0 N--CA 1.482 1.175 0 C-N-CA 119.761 -0.776 . . . . 0.0 110.984 -179.77 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.563 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.1 m-85 -126.42 128.78 47.53 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.107 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.442 ' O ' ' OD1' ' A' ' 42' ' ' ASP . 3.3 mptp? -105.12 123.94 48.67 Favored 'General case' 0 N--CA 1.493 1.699 0 C-N-CA 119.531 -0.868 . . . . 0.0 112.216 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.449 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 9.0 p90 -134.71 171.8 13.86 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.161 177.693 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 25.9 p90 -171.22 -168.92 0.68 Allowed 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 119.409 -0.916 . . . . 0.0 111.188 -178.009 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -116.65 130.04 56.5 Favored 'General case' 0 N--CA 1.482 1.141 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.206 179.036 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.512 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.0 mt-10 -72.17 -46.42 11.04 Favored Pre-proline 0 N--CA 1.484 1.271 0 C-N-CA 119.505 -0.878 . . . . 0.0 112.929 -179.394 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.512 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.8 Cg_endo -66.8 -46.38 3.53 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 120.806 1.004 . . . . 0.0 112.03 -178.656 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.6 m80 -90.46 21.11 4.08 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.239 -179.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -67.08 -16.73 64.52 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.359 -0.936 . . . . 0.0 110.597 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -77.49 -24.07 66.29 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.457 -1.354 . . . . 0.0 110.298 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.62 -15.6 39.27 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.392 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 98.77 31.88 6.16 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 119.561 -1.304 . . . . 0.0 110.576 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.63 103.91 9.86 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.997 179.765 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -129.34 166.46 19.45 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.801 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -146.49 155.18 26.4 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 119.123 -1.513 . . . . 0.0 111.779 -178.398 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -155.25 143.46 20.2 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.82 179.452 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.12 128.65 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.317 -0.953 . . . . 0.0 110.126 179.079 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 98.9 m -106.86 106.82 17.53 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 119.624 -0.83 . . . . 0.0 110.784 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.436 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 41.3 t -82.26 138.15 19.92 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 118.347 -1.341 . . . . 0.0 110.586 -179.101 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 96' ' ' VAL . 6.7 m-20 . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 116.374 -1.774 . . . . 0.0 110.805 -179.841 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -138.23 142.61 39.93 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.787 -0.765 . . . . 0.0 110.579 179.933 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 t -131.44 118.75 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.563 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.0 mtmp? -90.1 115.3 27.26 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.114 -1.034 . . . . 0.0 111.313 -178.991 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 4.8 mt -76.94 105.71 8.17 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 118.937 -1.105 . . . . 0.0 109.688 178.392 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 111.05 135.58 6.87 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.055 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.0 p . . . . . 0 C--N 1.302 -1.479 0 C-N-CA 119.233 -0.987 . . . . 0.0 110.67 179.941 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.8 mt . . . . . 0 N--CA 1.489 1.492 0 CA-C-O 120.445 0.164 . . . . 0.0 110.913 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.0 m -150.22 157.09 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.362 179.124 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.51 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 37.2 m-85 -77.84 115.09 17.32 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.898 -1.121 . . . . 0.0 108.15 178.809 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.5 m -116.89 106.98 46.83 Favored Pre-proline 0 CA--C 1.561 1.367 0 C-N-CA 119.58 -0.848 . . . . 0.0 111.813 -177.564 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -66.32 175.66 23.85 Favored 'Cis proline' 0 C--N 1.359 1.124 0 C-N-CA 125.166 -0.764 . . . . 0.0 111.429 -0.132 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.96 -37.39 11.7 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 119.426 -0.91 . . . . 0.0 109.709 178.836 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.6 m -145.72 142.63 29.14 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.941 179.18 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.403 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 26.0 p90 -165.91 146.27 6.56 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 118.711 -1.196 . . . . 0.0 111.339 -179.013 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.2 p -90.1 163.54 14.82 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.26 -179.755 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.1 m -150.27 175.61 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.687 179.43 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.452 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -91.07 146.61 23.7 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.859 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.03 74.73 0.05 OUTLIER 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.549 -0.86 . . . . 0.0 110.947 179.742 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 146.18 19.58 0.13 Allowed Glycine 0 N--CA 1.488 2.104 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -96.96 150.03 21.22 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.877 -0.729 . . . . 0.0 111.007 -179.415 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.79 136.13 35.47 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.607 179.592 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.9 mt -118.62 151.03 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 C-N-CA 120.038 -0.665 . . . . 0.0 109.212 179.848 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 9.2 p -142.16 118.46 10.81 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.695 -179.533 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 63.7 m-85 -83.65 125.38 31.78 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.427 -0.909 . . . . 0.0 109.1 178.471 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.0 tptp -110.4 133.69 53.03 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 120.044 -0.662 . . . . 0.0 110.52 -179.142 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.402 ' ND2' ' CD1' ' A' ' 61' ' ' LEU . 2.7 m120 -89.34 103.33 15.97 Favored 'General case' 0 C--N 1.293 -1.875 0 C-N-CA 119.19 -1.004 . . . . 0.0 110.087 179.331 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.459 ' O ' ' CB ' ' A' ' 33' ' ' ALA . 0.3 OUTLIER -89.84 -30.63 17.8 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 119.176 -1.01 . . . . 0.0 111.435 -179.079 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 168.99 146.86 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 118.992 -1.083 . . . . 0.0 111.017 -179.864 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 112.74 -5.71 26.01 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.619 -1.277 . . . . 0.0 111.369 179.368 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -47.45 162.83 0.28 Allowed Pre-proline 0 N--CA 1.484 1.26 0 C-N-CA 118.332 -1.347 . . . . 0.0 109.639 179.878 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -77.1 137.95 51.24 Favored 'Cis proline' 0 C--O 1.214 -0.682 0 C-N-CA 124.143 -1.19 . . . . 0.0 112.285 -0.362 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 32.0 m-70 -103.79 177.69 4.77 Favored 'General case' 0 N--CA 1.489 1.497 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.568 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -153.9 140.35 18.73 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.217 179.557 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.459 ' O ' ' N ' ' A' ' 57' ' ' GLN . 3.9 mp -133.22 99.5 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.136 -179.773 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.6 t -121.61 152.55 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.831 179.29 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -104.9 122.87 46.7 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.6 -0.84 . . . . 0.0 111.724 -178.971 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.529 ' C ' ' H ' ' A' ' 44' ' ' ASP . 26.7 t0 -56.14 118.12 4.39 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.442 179.393 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.442 ' O ' ' CG ' ' A' ' 43' ' ' GLU . 2.2 tt0 -73.19 25.86 0.06 Allowed 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.419 -0.913 . . . . 0.0 111.211 -179.431 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.529 ' H ' ' C ' ' A' ' 42' ' ' ASP . 26.0 m-20 -129.1 1.88 5.23 Favored 'General case' 0 N--CA 1.49 1.551 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.795 179.779 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -147.1 53.02 1.08 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.408 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -135.03 148.1 65.42 Favored Pre-proline 0 N--CA 1.49 1.57 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -179.802 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -47.68 140.14 17.54 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 120.903 1.069 . . . . 0.0 111.986 -179.4 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.65 83.01 1.56 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.887 -179.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.06 -33.81 0.52 Allowed Glycine 0 N--CA 1.488 2.129 0 C-N-CA 119.558 -1.305 . . . . 0.0 110.027 -179.893 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 35.7 t -87.33 109.08 18.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.713 179.807 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -51.49 153.83 2.07 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.799 -179.92 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -110.88 -6.48 14.71 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 120.018 -0.673 . . . . 0.0 110.864 -179.844 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -90.16 -15.37 31.66 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.461 -0.895 . . . . 0.0 111.102 -179.81 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.7 mtmm -91.86 -28.92 17.0 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.905 -179.858 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 11.8 pt -98.57 1.14 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 C-N-CA 119.633 -0.827 . . . . 0.0 110.994 -179.887 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.8 m -94.42 -178.52 4.61 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.079 180.0 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.655 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 52.1 mt-30 -139.64 69.9 37.89 Favored Pre-proline 0 C--N 1.305 -1.34 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.338 -179.972 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -59.74 -21.49 63.58 Favored 'Trans proline' 0 C--N 1.325 -0.696 0 C-N-CA 121.531 1.488 . . . . 0.0 111.829 -178.879 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.411 ' O ' ' O ' ' A' ' 60' ' ' TYR . 1.3 tm-20 -91.86 109.91 21.25 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.236 179.539 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.411 ' O ' ' O ' ' A' ' 59' ' ' GLU . 52.8 m-85 -43.09 166.07 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.541 -0.864 . . . . 0.0 110.948 -179.884 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.433 ' C ' ' CD1' ' A' ' 61' ' ' LEU . 0.5 OUTLIER -140.38 148.43 41.25 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.726 -0.79 . . . . 0.0 109.938 179.68 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -149.05 22.67 0.96 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.111 -179.464 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -83.14 102.47 2.4 Favored Glycine 0 N--CA 1.486 1.978 0 C-N-CA 119.163 -1.494 . . . . 0.0 110.382 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -57.34 113.28 1.69 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.067 -1.053 . . . . 0.0 110.178 179.512 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 97.85 -18.48 57.15 Favored Glycine 0 N--CA 1.487 2.093 0 C-N-CA 119.413 -1.375 . . . . 0.0 110.162 -179.49 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 25.6 tp10 -65.7 128.3 35.42 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.207 -0.997 . . . . 0.0 110.165 179.896 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -110.74 166.65 10.85 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.796 -0.761 . . . . 0.0 111.427 -179.653 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.655 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 43.1 t80 -135.8 139.86 43.8 Favored 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.455 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -108.78 158.24 17.83 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.258 -0.977 . . . . 0.0 112.709 -178.589 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -160.07 137.49 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.122 179.138 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 9.1 m -127.65 97.25 4.79 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.339 -179.242 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 16.8 mt -81.75 159.29 23.89 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.322 -0.951 . . . . 0.0 109.831 179.499 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 18.0 p -150.79 50.85 0.86 Allowed 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 118.882 -1.127 . . . . 0.0 111.946 -178.965 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 75' ' ' LYS . 3.9 tp10 -146.15 99.9 3.31 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.094 -1.043 . . . . 0.0 110.121 178.992 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.417 ' C ' ' O ' ' A' ' 74' ' ' GLU . 8.7 ptmm? -42.27 112.15 0.31 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.051 -179.309 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 168.63 -146.26 10.22 Favored Glycine 0 N--CA 1.485 1.919 0 C-N-CA 119.26 -1.448 . . . . 0.0 110.062 -179.69 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.81 138.33 35.73 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.643 -0.823 . . . . 0.0 110.987 -179.726 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.549 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -121.27 147.78 45.19 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.332 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 18.2 mmtp -112.93 123.56 50.6 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.586 -0.846 . . . . 0.0 111.83 -179.643 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.574 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.5 OUTLIER -136.96 158.66 43.96 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.611 -0.836 . . . . 0.0 109.789 177.523 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 32.3 p90 -169.86 179.96 3.47 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 119.261 -0.976 . . . . 0.0 111.206 -178.197 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -103.91 124.63 49.32 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.83 179.753 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.548 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.5 OUTLIER -70.57 -44.42 17.35 Favored Pre-proline 0 N--CA 1.487 1.387 0 C-N-CA 119.66 -0.816 . . . . 0.0 112.752 -179.77 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.548 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.0 Cg_exo -66.72 -53.54 0.55 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 120.892 1.061 . . . . 0.0 111.921 -178.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . 0.455 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.3 m80 -80.0 8.35 7.23 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.336 -0.945 . . . . 0.0 111.292 -179.521 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.37 -7.72 0.64 Allowed 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.705 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.455 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -76.2 -24.91 67.45 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.393 -1.384 . . . . 0.0 110.381 -179.924 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.65 -35.17 15.12 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.602 -179.994 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 124.77 21.09 2.21 Favored Glycine 0 N--CA 1.495 2.624 0 C-N-CA 119.869 -1.158 . . . . 0.0 110.531 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.79 108.99 1.29 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.416 -0.914 . . . . 0.0 111.256 -179.857 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 17.4 mttm -131.57 162.31 30.61 Favored 'General case' 0 N--CA 1.495 1.817 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.392 -179.871 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.19 147.86 19.49 Favored Glycine 0 N--CA 1.495 2.602 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.098 -179.194 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -149.21 138.05 21.21 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.891 179.842 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.7 p -135.24 127.95 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 C-N-CA 118.723 -1.191 . . . . 0.0 110.883 178.694 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 47.4 m -106.91 100.46 9.96 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.572 179.319 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 45.3 t -80.5 144.66 10.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 C-N-CA 118.632 -1.227 . . . . 0.0 110.496 -179.045 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 116.284 -1.817 . . . . 0.0 110.758 -179.809 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 120.827 0.346 . . . . 0.0 110.163 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.1 mt-10 -100.05 121.68 41.76 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.765 179.88 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -99.15 119.25 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.998 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . 0.485 ' HZ3' ' CB ' ' A' ' 4' ' ' LYS . 2.3 mtmp? -91.3 113.22 25.42 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 119.626 -0.83 . . . . 0.0 111.021 -179.921 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 mp -79.7 110.58 15.17 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 118.88 -1.128 . . . . 0.0 109.547 178.472 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 98.71 103.82 2.41 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -178.864 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.9 p . . . . . 0 C--N 1.303 -1.453 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.937 -179.552 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt . . . . . 0 N--CA 1.486 1.342 0 CA-C-O 120.513 0.197 . . . . 0.0 110.746 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.7 m -145.7 157.9 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 C-N-CA 118.962 -1.095 . . . . 0.0 111.131 179.843 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.403 ' O ' ' C ' ' A' ' 16' ' ' PRO . 47.3 m-85 -79.17 111.37 15.32 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.459 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 47.8 m -114.89 107.96 49.46 Favored Pre-proline 0 C--N 1.307 -1.275 0 C-N-CA 119.536 -0.866 . . . . 0.0 112.406 -177.071 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.403 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.9 Cg_endo -67.01 167.35 58.32 Favored 'Cis proline' 0 C--N 1.359 1.086 0 C-N-CA 125.34 -0.692 . . . . 0.0 111.528 -0.827 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.423 ' OG ' ' N ' ' A' ' 18' ' ' SER . 0.2 OUTLIER -95.29 -67.24 0.86 Allowed 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.496 -0.881 . . . . 0.0 109.716 178.885 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.423 ' N ' ' OG ' ' A' ' 17' ' ' SER . 0.7 OUTLIER -112.2 123.44 50.27 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.437 178.816 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.487 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 11.5 p90 -156.72 144.31 19.14 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 118.782 -1.167 . . . . 0.0 111.141 -179.005 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -88.84 157.26 18.51 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.299 -0.96 . . . . 0.0 111.247 -179.84 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.5 m -148.61 171.44 2.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.493 179.631 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.81 151.92 22.94 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.477 -179.933 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.4 65.95 0.65 Allowed 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.873 179.761 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 171.02 8.58 0.02 OUTLIER Glycine 0 N--CA 1.486 1.983 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -98.65 154.14 18.17 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.752 -0.779 . . . . 0.0 110.549 -179.931 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 49.6 mttm -95.17 144.06 26.1 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.288 -179.718 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 37.1 mm -111.89 98.34 6.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 CA-C-N 115.541 -0.754 . . . . 0.0 108.999 179.033 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.7 p -92.85 115.49 28.17 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.145 -1.022 . . . . 0.0 112.477 -178.217 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -85.18 121.2 27.59 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.021 -0.991 . . . . 0.0 109.136 178.512 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -124.68 134.87 52.72 Favored 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.686 -0.806 . . . . 0.0 111.734 -178.519 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 66' ' ' GLU . 57.5 m-80 -84.67 113.31 21.2 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.505 179.604 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -97.98 -30.23 12.84 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 119.195 -1.002 . . . . 0.0 111.354 -179.23 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 170.7 99.33 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.004 179.724 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 153.11 23.45 0.05 OUTLIER Glycine 0 N--CA 1.489 2.22 0 C-N-CA 118.874 -1.632 . . . . 0.0 111.234 179.487 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.62 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -73.67 162.68 73.06 Favored Pre-proline 0 C--N 1.307 -1.253 0 C-N-CA 118.744 -1.182 . . . . 0.0 109.907 179.756 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -75.8 147.51 88.18 Favored 'Cis proline' 0 N--CA 1.479 0.658 0 C-N-CA 124.396 -1.085 . . . . 0.0 112.366 -1.118 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -112.59 -177.66 3.2 Favored 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.944 -0.702 . . . . 0.0 110.817 179.279 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.777 HD21 ' H ' ' A' ' 83' ' ' GLU . 2.7 t30 -163.75 144.35 8.7 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.771 -0.772 . . . . 0.0 110.005 179.173 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.9 mp -133.78 122.79 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 119.567 -0.853 . . . . 0.0 111.436 -179.48 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.8 t -140.61 146.5 24.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.403 179.101 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -100.51 128.49 46.56 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.214 -0.994 . . . . 0.0 111.888 -179.094 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 25.8 t0 -66.71 119.98 12.71 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.244 179.512 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -68.66 -7.21 31.2 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.026 -178.991 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -97.37 7.15 47.1 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.247 -0.981 . . . . 0.0 111.649 -179.208 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -145.55 27.63 1.22 Allowed 'General case' 0 N--CA 1.488 1.466 0 C-N-CA 119.284 -0.966 . . . . 0.0 110.748 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -118.78 146.77 40.8 Favored Pre-proline 0 N--CA 1.492 1.627 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.088 179.801 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -53.05 144.15 47.48 Favored 'Trans proline' 0 C--O 1.214 -0.706 0 C-N-CA 120.953 1.102 . . . . 0.0 111.907 -179.926 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.04 72.2 1.14 Allowed 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 119.533 -0.867 . . . . 0.0 110.855 179.839 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.09 -46.52 0.1 Allowed Glycine 0 N--CA 1.49 2.282 0 C-N-CA 119.544 -1.312 . . . . 0.0 109.978 179.929 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 96.8 t -79.92 87.8 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 119.435 -0.906 . . . . 0.0 110.474 179.697 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -44.63 140.11 2.59 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.964 -179.615 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.409 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -80.0 -20.88 44.4 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.889 -179.94 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -74.38 -22.37 59.22 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.437 -0.905 . . . . 0.0 111.128 -179.713 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -79.27 -24.86 42.67 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.36 -179.612 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -109.79 -18.47 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.427 -179.774 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.409 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 41.3 m -71.37 171.0 12.01 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.183 179.82 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.633 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 56.5 mt-30 -128.06 78.53 75.19 Favored Pre-proline 0 N--CA 1.488 1.446 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.333 179.914 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -60.86 -11.24 17.08 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.208 1.272 . . . . 0.0 111.615 -178.864 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 20.4 mt-10 -99.47 108.02 20.37 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.749 179.779 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -55.1 176.74 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.531 -0.867 . . . . 0.0 110.85 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.8 pp -154.9 153.1 30.58 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.131 -1.028 . . . . 0.0 111.468 -179.576 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -149.01 14.96 0.92 Allowed 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.987 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -80.95 125.25 6.78 Favored Glycine 0 N--CA 1.491 2.326 0 C-N-CA 119.355 -1.402 . . . . 0.0 110.689 -179.574 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -68.22 126.77 30.61 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.63 179.687 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.56 -12.06 62.17 Favored Glycine 0 N--CA 1.488 2.151 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.713 179.887 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.489 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 2.8 tp10 -65.1 144.3 57.33 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.263 179.749 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -140.79 170.54 15.57 Favored 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.372 -179.387 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.633 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 47.5 t80 -135.57 -179.76 5.84 Favored 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.49 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.56 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 3.3 mt-10 -140.69 146.16 37.46 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.166 -1.014 . . . . 0.0 111.652 -179.818 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.6 t -147.64 126.66 4.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.349 -0.842 . . . . 0.0 109.222 179.377 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.1 m -121.28 99.82 6.7 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.839 -0.744 . . . . 0.0 111.453 -178.841 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 54.9 mt -82.3 159.89 23.03 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.021 179.227 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 57.5 p -150.09 42.99 0.87 Allowed 'General case' 0 C--N 1.296 -1.757 0 C-N-CA 119.214 -0.994 . . . . 0.0 111.083 -179.529 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.429 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 2.9 mm-40 -143.49 101.37 3.77 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.026 -1.07 . . . . 0.0 110.836 179.76 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -44.61 113.43 0.55 Allowed 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.451 -0.899 . . . . 0.0 110.67 -179.953 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.9 -145.0 8.17 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.399 -1.381 . . . . 0.0 110.044 -179.961 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.82 127.14 16.73 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.893 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.564 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.8 m-85 -114.16 161.9 17.21 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.639 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.5 mmtm -130.48 116.81 18.72 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.47 -0.892 . . . . 0.0 111.987 -178.929 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -123.87 159.05 30.48 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.844 -0.742 . . . . 0.0 109.887 178.081 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -168.67 -179.3 3.75 Favored 'General case' 0 C--N 1.289 -2.025 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.982 -178.936 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -108.81 124.27 50.34 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.634 179.825 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.777 ' H ' HD21 ' A' ' 38' ' ' ASN . 2.3 mt-10 -63.18 -45.28 85.52 Favored Pre-proline 0 N--CA 1.485 1.308 0 C-N-CA 119.728 -0.789 . . . . 0.0 112.997 -179.611 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.51 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.8 Cg_endo -66.16 -46.04 4.94 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 120.99 1.127 . . . . 0.0 112.077 -179.202 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . 0.406 ' C ' ' H ' ' A' ' 87' ' ' GLY . 29.1 m80 -92.59 14.62 16.4 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 119.16 -1.016 . . . . 0.0 111.55 -179.262 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -67.97 -1.19 5.26 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 118.946 -1.101 . . . . 0.0 110.455 179.66 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.406 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -95.27 -18.76 32.51 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.439 -1.362 . . . . 0.0 110.095 179.871 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.94 -36.34 15.05 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.44 179.676 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 130.72 26.0 0.81 Allowed Glycine 0 N--CA 1.494 2.539 0 C-N-CA 119.911 -1.137 . . . . 0.0 110.342 179.836 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -82.65 95.37 7.79 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.186 -1.006 . . . . 0.0 110.865 -179.924 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.7 162.51 24.03 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.816 179.926 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -143.62 144.83 14.14 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.294 -1.432 . . . . 0.0 111.874 -178.455 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -148.52 143.69 26.83 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.963 -0.695 . . . . 0.0 110.084 179.282 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.406 ' CG1' ' O ' ' A' ' 94' ' ' VAL . 14.0 p -137.44 118.68 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 119.09 -1.044 . . . . 0.0 110.793 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 90.8 m -95.62 99.17 11.07 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.486 179.528 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 35.5 t -80.11 149.38 5.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 C-N-CA 118.999 -1.08 . . . . 0.0 110.805 -178.804 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 116.332 -1.794 . . . . 0.0 110.797 -179.862 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.066 0 CA-C-O 120.867 0.365 . . . . 0.0 110.052 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -93.77 140.46 29.63 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.701 179.866 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 t -126.95 131.88 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.523 179.477 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 11.7 mtmm -105.17 118.09 35.66 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.844 -179.534 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.408 ' C ' ' OD1' ' A' ' 32' ' ' ASN . 5.7 mt -79.87 103.71 9.95 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 118.754 -1.178 . . . . 0.0 109.639 178.809 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.495 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 118.53 134.3 4.97 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -178.527 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 6' ' ' GLY . 26.0 p . . . . . 0 C--N 1.305 -1.33 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.198 -179.423 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.0 mt . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 120.471 0.177 . . . . 0.0 110.711 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 4.5 m -147.67 154.18 11.34 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 C-N-CA 118.952 -1.099 . . . . 0.0 111.044 179.626 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' A' ' 16' ' ' PRO . 9.9 m-85 -78.22 107.61 10.94 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.431 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.8 m -113.77 109.04 50.67 Favored Pre-proline 0 C--N 1.306 -1.313 0 C-N-CA 119.81 -0.756 . . . . 0.0 111.912 -177.447 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.424 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.6 Cg_endo -67.64 177.05 23.95 Favored 'Cis proline' 0 C--N 1.355 0.916 0 CA-C-N 119.053 0.697 . . . . 0.0 111.671 -0.376 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.4 p -93.92 -47.16 6.85 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.77 178.862 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.8 p -132.82 144.28 50.11 Favored 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.287 178.841 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -164.6 134.58 3.9 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 118.456 -1.297 . . . . 0.0 111.409 -178.962 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.5 p -86.42 159.71 19.27 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.855 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.7 m -148.79 172.49 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.902 179.755 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -87.57 149.61 24.23 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.774 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.29 73.33 0.49 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.348 -0.941 . . . . 0.0 111.072 179.974 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 155.75 14.32 0.05 OUTLIER Glycine 0 N--CA 1.486 2.028 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -104.45 147.24 27.79 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.552 -179.597 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.1 pttm -95.36 149.84 20.93 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.48 -179.616 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.4 mt -119.95 148.9 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.237 179.202 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.3 p -138.6 119.34 14.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.224 -0.991 . . . . 0.0 111.692 -179.153 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -86.61 146.03 26.5 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.338 178.9 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.3 tttm -138.39 132.04 30.84 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.356 -179.231 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.408 ' OD1' ' N ' ' A' ' 31' ' ' ASN . 3.0 m-20 -81.18 113.09 19.1 Favored 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.815 179.576 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 4.0 p-10 -106.2 -23.54 12.56 Favored 'General case' 0 N--CA 1.493 1.689 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.743 -179.775 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.447 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 170.82 101.89 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 118.509 -1.277 . . . . 0.0 111.326 179.837 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 141.65 22.19 0.25 Allowed Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.239 -1.458 . . . . 0.0 111.457 179.574 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.61 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -78.2 161.98 68.44 Favored Pre-proline 0 N--CA 1.485 1.288 0 C-N-CA 118.159 -1.417 . . . . 0.0 110.026 179.502 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -75.9 148.56 90.45 Favored 'Cis proline' 0 C--O 1.214 -0.684 0 C-N-CA 124.21 -1.162 . . . . 0.0 112.291 -0.755 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -115.48 178.56 4.25 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.166 179.585 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.657 HD21 ' H ' ' A' ' 39' ' ' ILE . 1.2 t-20 -151.13 137.98 18.97 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.2 -1.0 . . . . 0.0 110.338 178.875 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.657 ' H ' HD21 ' A' ' 38' ' ' ASN . 5.7 mt -124.06 106.1 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.135 -179.494 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t -128.32 149.0 32.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.001 179.54 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -103.94 126.76 51.3 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.861 -179.305 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.471 ' C ' ' H ' ' A' ' 44' ' ' ASP . 0.4 OUTLIER -70.64 118.07 12.97 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.412 179.636 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -74.76 41.6 0.16 Allowed 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.386 -0.926 . . . . 0.0 110.861 -179.677 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.471 ' H ' ' C ' ' A' ' 42' ' ' ASP . 8.6 m-20 -128.28 -10.53 5.23 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.586 179.815 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -132.81 15.93 4.3 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.74 179.831 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 55.5 t -99.1 143.45 26.41 Favored Pre-proline 0 C--N 1.296 -1.73 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.571 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -55.42 161.75 6.97 Favored 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 120.81 1.006 . . . . 0.0 111.619 -179.947 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -90.22 51.23 1.99 Allowed 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 119.578 -0.849 . . . . 0.0 111.001 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -154.0 -42.86 0.02 OUTLIER Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.46 -1.352 . . . . 0.0 109.998 179.827 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 5.6 p -77.35 152.28 5.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 119.812 -0.755 . . . . 0.0 110.407 179.643 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -88.79 139.47 30.43 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.048 179.173 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -102.76 -4.48 24.91 Favored 'General case' 0 N--CA 1.491 1.611 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.252 -179.782 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -90.69 -33.68 15.7 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.645 -179.531 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 62.8 mttt -78.26 -21.82 49.25 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.434 -0.906 . . . . 0.0 111.972 -179.018 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.3 pt -92.91 -25.03 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.213 -179.547 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 33.3 m -69.19 174.1 5.0 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.133 179.658 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.659 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 66.7 mt-30 -126.88 78.98 73.14 Favored Pre-proline 0 N--CA 1.488 1.456 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.65 -179.888 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.27 -14.44 38.45 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 120.958 1.105 . . . . 0.0 111.187 -179.258 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.423 ' O ' ' O ' ' A' ' 60' ' ' TYR . 10.5 mt-10 -100.53 105.06 16.46 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.78 -0.768 . . . . 0.0 110.646 179.445 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.423 ' O ' ' O ' ' A' ' 59' ' ' GLU . 31.6 m-85 -46.01 172.4 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.941 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.0 pp -138.54 125.79 21.58 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.688 -0.805 . . . . 0.0 110.29 179.548 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -132.61 45.49 2.74 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.409 -178.845 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.28 118.97 3.56 Favored Glycine 0 N--CA 1.499 2.896 0 C-N-CA 119.718 -1.229 . . . . 0.0 110.528 179.822 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -54.64 123.4 13.07 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.398 179.735 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 81.48 3.86 90.54 Favored Glycine 0 N--CA 1.489 2.225 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.648 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -69.47 107.16 3.24 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.921 179.607 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.5 p -98.09 164.59 12.28 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.499 -0.88 . . . . 0.0 111.55 -178.96 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.659 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 45.1 t80 -135.0 176.97 8.17 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 178.844 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.605 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 5.3 mt-10 -144.89 150.86 37.79 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 118.539 -1.265 . . . . 0.0 112.252 -179.316 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -157.85 136.83 3.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 115.066 -0.97 . . . . 0.0 108.727 179.205 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 19.1 m -129.12 92.74 3.44 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.53 -0.868 . . . . 0.0 111.716 -178.907 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 10.0 mt -79.76 155.39 27.94 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 118.995 -1.082 . . . . 0.0 108.709 178.833 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' THR . . . . . 0.434 ' O ' ' OG1' ' A' ' 73' ' ' THR . 3.1 t -150.47 46.57 0.88 Allowed 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.678 -1.209 . . . . 0.0 111.719 -179.29 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 34.1 mm-40 -138.81 103.12 4.74 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.47 -0.892 . . . . 0.0 109.78 178.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -40.11 107.18 0.07 Allowed 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 119.781 -0.768 . . . . 0.0 111.321 -179.448 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 176.74 -150.36 10.32 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.172 -1.489 . . . . 0.0 110.591 -179.778 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.89 133.61 28.81 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.258 -179.521 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.604 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.9 OUTLIER -120.13 155.43 33.07 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.765 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 27.0 mmtt -126.93 127.94 45.65 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.532 -0.867 . . . . 0.0 111.909 -178.876 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.512 ' O ' ' N ' ' A' ' 92' ' ' GLY . 2.0 p90 -139.11 165.85 26.06 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.432 -0.907 . . . . 0.0 110.701 178.377 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 35.2 p90 -169.91 -179.78 3.35 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.144 -177.928 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -104.07 125.53 50.48 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.321 179.404 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.55 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tt0 -68.6 -44.48 33.19 Favored Pre-proline 0 N--CA 1.486 1.358 0 C-N-CA 119.531 -0.868 . . . . 0.0 112.985 -179.436 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -68.44 -50.06 0.76 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 120.931 1.087 . . . . 0.0 111.94 -178.771 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 33.4 m80 -88.9 16.91 6.2 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.342 -0.943 . . . . 0.0 111.572 -179.363 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.64 -10.32 3.48 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.726 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -89.13 -17.09 56.63 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.374 -1.393 . . . . 0.0 110.304 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.34 -22.89 24.82 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.385 179.881 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 112.7 17.48 7.99 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.798 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.1 mtp -70.64 99.87 1.75 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.228 179.806 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.1 pttp -125.1 164.33 20.46 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 120.045 -0.662 . . . . 0.0 110.088 178.723 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.02 147.75 18.49 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 118.538 -1.791 . . . . 0.0 111.862 -178.497 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -153.94 146.9 24.47 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 119.721 -0.792 . . . . 0.0 110.568 179.103 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.8 p -140.68 134.36 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.125 179.252 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.2 m -110.66 101.73 10.35 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.65 -0.82 . . . . 0.0 110.886 179.734 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 49.0 t -80.68 152.1 4.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.902 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.6 p30 . . . . . 0 C--N 1.304 -1.4 0 CA-C-O 116.364 -1.779 . . . . 0.0 110.81 -179.867 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.156 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -110.54 122.86 48.78 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.996 179.965 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.0 t -111.26 126.36 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 119.983 -0.687 . . . . 0.0 110.524 179.728 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 39.4 mttt -98.72 118.45 35.48 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.809 -179.483 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . 0.419 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 12.8 mt -82.05 107.1 14.49 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 118.754 -1.179 . . . . 0.0 110.625 179.135 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.418 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 114.49 138.71 6.83 Favored Glycine 0 N--CA 1.495 2.626 0 C-N-CA 120.218 -0.991 . . . . 0.0 110.669 -179.588 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 24.2 p . . . . . 0 C--N 1.308 -1.201 0 C-N-CA 119.532 -0.867 . . . . 0.0 110.624 179.747 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.8 mt . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 120.465 0.174 . . . . 0.0 110.695 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.4 m -150.72 159.71 4.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.708 179.234 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.508 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 23.3 m-85 -78.46 114.58 17.49 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 177.948 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.4 m -116.24 105.99 49.81 Favored Pre-proline 0 C--N 1.308 -1.238 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.865 -177.45 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -67.55 178.32 20.2 Favored 'Cis proline' 0 C--N 1.359 1.131 0 CA-C-N 118.921 0.65 . . . . 0.0 111.946 -0.395 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.4 ' C ' ' HG ' ' A' ' 18' ' ' SER . 1.1 m -94.14 -48.12 6.35 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.643 -0.823 . . . . 0.0 110.182 179.162 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.4 ' HG ' ' C ' ' A' ' 17' ' ' SER . 44.6 m -137.34 140.98 41.82 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.419 179.144 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.405 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 25.1 p90 -162.93 143.21 9.33 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.626 -179.138 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.27 155.51 18.5 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.146 179.894 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.07 157.13 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 C-N-CA 119.416 -0.914 . . . . 0.0 111.082 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.46 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -75.4 141.06 43.3 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.17 179.456 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.94 75.32 0.04 OUTLIER 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.045 -179.783 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 161.53 13.48 0.03 OUTLIER Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -104.94 151.04 24.37 Favored 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.622 -179.649 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.8 mttp -94.53 141.1 28.99 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.037 -179.919 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 mt -117.89 153.06 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.743 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.5 p -147.77 113.45 5.7 Favored 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 118.811 -1.156 . . . . 0.0 111.954 -179.448 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -84.39 116.18 22.91 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.36 -0.936 . . . . 0.0 108.962 178.485 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.2 tttm -111.56 132.84 54.25 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.778 -178.264 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -76.48 104.23 6.89 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.703 -0.799 . . . . 0.0 109.849 178.904 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.419 ' OD1' ' O ' ' A' ' 5' ' ' LEU . 5.2 p-10 -94.21 -26.23 16.74 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 118.906 -1.118 . . . . 0.0 112.025 -178.642 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 179.12 147.53 0.2 Allowed 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 118.489 -1.284 . . . . 0.0 111.593 -179.783 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 89.63 10.28 65.47 Favored Glycine 0 N--CA 1.481 1.674 0 C-N-CA 119.485 -1.341 . . . . 0.0 111.731 178.661 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -49.66 162.54 0.44 Allowed Pre-proline 0 N--CA 1.48 1.055 0 C-N-CA 117.844 -1.542 . . . . 0.0 108.895 179.431 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -75.93 -173.67 13.0 Favored 'Cis proline' 0 C--O 1.204 -1.189 0 C-N-CA 124.324 -1.115 . . . . 0.0 112.294 -0.213 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.8 m-70 -151.07 171.92 16.56 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 120.142 -0.623 . . . . 0.0 110.522 178.576 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.715 HD21 ' H ' ' A' ' 39' ' ' ILE . 1.3 t-20 -149.61 148.29 29.14 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.488 179.393 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.715 ' H ' HD21 ' A' ' 38' ' ' ASN . 4.1 mp -135.55 112.17 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 C-N-CA 119.676 -0.81 . . . . 0.0 111.322 -179.437 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 t -134.98 149.65 29.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.948 179.224 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.445 ' H ' ' HG ' ' A' ' 56' ' ' SER . 23.5 m-85 -104.77 128.38 52.89 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.512 -0.875 . . . . 0.0 112.04 -179.077 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.46 ' C ' ' H ' ' A' ' 44' ' ' ASP . 49.3 t0 -66.97 126.38 28.94 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.086 179.344 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 63.8 mt-10 -72.1 11.51 0.55 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.229 -0.989 . . . . 0.0 111.221 -179.662 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.46 ' H ' ' C ' ' A' ' 42' ' ' ASP . 28.4 m-20 -105.85 -5.54 19.68 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.667 -0.813 . . . . 0.0 111.068 -179.862 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -142.7 51.97 1.42 Allowed 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 119.719 -0.792 . . . . 0.0 110.229 -179.743 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -139.6 145.97 45.81 Favored Pre-proline 0 N--CA 1.487 1.393 0 CA-C-N 115.286 -0.87 . . . . 0.0 108.825 179.678 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -54.17 163.7 3.18 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 120.798 0.999 . . . . 0.0 112.216 -179.358 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -89.26 61.76 5.85 Favored 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 119.84 -0.744 . . . . 0.0 110.824 -179.968 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.21 -46.38 0.04 OUTLIER Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.529 -1.319 . . . . 0.0 110.014 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.5 t -79.6 84.07 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 C-N-CA 119.554 -0.858 . . . . 0.0 110.39 179.703 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -45.09 139.71 3.12 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.204 -0.999 . . . . 0.0 110.712 -179.636 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.439 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -73.08 -33.06 65.4 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.728 -179.875 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -61.68 -17.91 57.44 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.304 -179.637 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.32 -45.46 11.91 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.422 -179.728 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.0 pt -90.35 -13.8 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 119.233 -0.987 . . . . 0.0 111.327 -179.641 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.445 ' HG ' ' H ' ' A' ' 41' ' ' PHE . 69.2 m -77.65 173.44 12.04 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.582 179.551 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.615 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 69.4 mt-30 -129.24 78.83 75.35 Favored Pre-proline 0 N--CA 1.489 1.481 0 C-N-CA 120.036 -0.665 . . . . 0.0 110.64 -179.868 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.93 -11.47 18.28 Favored 'Trans proline' 0 C--O 1.216 -0.605 0 C-N-CA 121.032 1.155 . . . . 0.0 111.024 -179.539 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -101.35 116.89 33.82 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.535 179.14 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -58.38 159.4 6.27 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.359 -0.936 . . . . 0.0 110.999 -179.672 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.426 ' C ' ' CD1' ' A' ' 61' ' ' LEU . 0.7 OUTLIER -125.41 146.97 49.37 Favored 'General case' 0 N--CA 1.49 1.532 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.666 179.233 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.459 ' ND2' ' O ' ' A' ' 62' ' ' ASN . 9.8 p-10 -155.17 58.6 0.65 Allowed 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.253 -0.979 . . . . 0.0 111.343 -178.744 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.62 130.1 6.23 Favored Glycine 0 N--CA 1.497 2.734 0 C-N-CA 119.737 -1.22 . . . . 0.0 110.784 179.805 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -69.94 103.88 2.36 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.459 -0.896 . . . . 0.0 110.464 179.575 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.45 -7.29 46.53 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.222 -179.709 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -64.7 151.81 44.05 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.141 179.515 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.7 165.15 31.35 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 118.884 -1.126 . . . . 0.0 111.838 -179.679 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.615 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 49.5 t80 -136.07 138.25 41.94 Favored 'General case' 0 N--CA 1.484 1.258 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.323 179.149 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -108.62 153.38 23.49 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.423 -0.911 . . . . 0.0 112.164 -178.765 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -155.41 139.93 9.26 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.439 178.891 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.8 m -126.02 95.95 4.58 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.083 -179.44 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 13.9 mt -79.68 160.9 26.12 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.437 179.434 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.71 25.29 0.76 Allowed 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 118.717 -1.193 . . . . 0.0 112.057 -178.497 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.466 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -116.69 99.9 7.45 Favored 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.357 179.846 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 8.5 mttt -43.44 105.79 0.06 Allowed 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.724 -179.76 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.3 -139.61 5.02 Favored Glycine 0 N--CA 1.483 1.79 0 C-N-CA 119.321 -1.418 . . . . 0.0 109.929 -179.769 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.2 m -146.68 136.02 22.79 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.251 -0.98 . . . . 0.0 111.168 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.576 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -120.52 140.78 50.96 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.829 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 22.9 mmtt -110.17 124.28 51.26 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 119.433 -0.907 . . . . 0.0 111.872 -179.0 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.566 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -134.39 160.89 36.57 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.14 178.395 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . 0.419 ' CD1' ' N ' ' A' ' 81' ' ' TYR . 23.8 p90 -168.29 179.21 4.58 Favored 'General case' 0 C--N 1.293 -1.87 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.889 -178.54 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -102.72 125.4 49.44 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.401 179.663 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.509 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 mt-10 -67.05 -46.25 52.79 Favored Pre-proline 0 C--N 1.306 -1.319 0 C-N-CA 119.499 -0.88 . . . . 0.0 112.819 -179.56 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.509 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.9 Cg_endo -67.01 -48.64 1.74 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 120.97 1.113 . . . . 0.0 112.114 -178.725 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -88.5 20.51 3.33 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.009 -179.515 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.87 -10.4 20.41 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.454 179.449 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.6 -17.31 57.09 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.491 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.15 -15.13 32.18 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.433 -0.907 . . . . 0.0 110.582 179.952 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.64 21.27 11.51 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.722 -1.228 . . . . 0.0 110.573 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.3 mtp -73.05 98.51 2.55 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.174 179.941 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.508 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 16.5 ttmt -121.41 159.6 25.85 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.475 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.38 143.49 12.17 Favored Glycine 0 N--CA 1.496 2.636 0 C-N-CA 119.352 -1.404 . . . . 0.0 111.255 -179.065 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.75 143.67 24.64 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.635 179.514 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.423 ' O ' ' CG1' ' A' ' 94' ' ' VAL . 9.9 p -136.31 122.43 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.318 179.523 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 99.9 m -100.93 100.48 11.12 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.745 -179.951 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 40.3 t -79.84 139.84 17.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 C-N-CA 118.634 -1.226 . . . . 0.0 110.478 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . 0.543 ' ND2' ' N ' ' A' ' 97' ' ' ASN . 0.2 OUTLIER . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 116.441 -1.743 . . . . 0.0 110.965 -179.869 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -106.06 133.39 50.84 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.92 -179.931 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.9 t -123.47 117.48 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 C-N-CA 119.991 -0.684 . . . . 0.0 110.419 179.657 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 29.3 mttp -91.95 114.35 26.87 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.652 -178.81 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.5 mt -76.37 113.28 13.78 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.069 -1.053 . . . . 0.0 109.805 178.007 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.46 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.36 125.35 5.61 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.764 -1.207 . . . . 0.0 110.238 -179.448 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.7 p . . . . . 0 C--N 1.302 -1.481 0 C-N-CA 119.462 -0.895 . . . . 0.0 110.7 179.884 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.1 mt . . . . . 0 N--CA 1.487 1.41 0 CA-C-O 120.487 0.184 . . . . 0.0 110.596 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.0 m -150.99 157.06 5.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.116 0 C-N-CA 118.892 -1.123 . . . . 0.0 110.747 179.297 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.522 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 56.8 m-85 -78.12 113.1 15.74 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 177.887 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.6 m -115.19 109.08 47.01 Favored Pre-proline 0 CA--C 1.559 1.311 0 C-N-CA 119.552 -0.859 . . . . 0.0 112.176 -176.954 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -67.14 172.59 37.29 Favored 'Cis proline' 0 C--N 1.359 1.119 0 C-N-CA 125.216 -0.743 . . . . 0.0 111.331 -0.444 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 38.8 t -94.19 -64.31 1.09 Allowed 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.704 178.934 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 t -113.11 135.19 54.08 Favored 'General case' 0 N--CA 1.485 1.292 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.546 178.748 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.418 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 21.7 p90 -160.97 137.91 8.84 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 118.71 -1.196 . . . . 0.0 111.308 -179.141 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -88.25 154.98 19.99 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.073 179.766 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.7 m -145.95 168.66 7.02 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 119.447 -0.901 . . . . 0.0 110.815 179.771 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.49 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -92.3 146.62 23.56 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.656 179.833 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.17 76.4 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.52 -0.872 . . . . 0.0 111.052 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 154.02 15.14 0.06 OUTLIER Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.888 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -102.43 132.94 48.12 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.898 -179.592 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.8 mtpp -75.75 141.53 42.59 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.0 mt -125.72 112.1 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 C-N-CA 120.088 -0.645 . . . . 0.0 109.261 179.407 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 13.4 p -108.52 121.43 44.96 Favored 'General case' 0 N--CA 1.488 1.462 0 C-N-CA 119.622 -0.831 . . . . 0.0 112.256 -178.561 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -86.36 121.18 28.56 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.449 -0.9 . . . . 0.0 109.182 178.502 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.0 tmtp? -112.71 142.42 45.34 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.871 -0.731 . . . . 0.0 110.655 -178.689 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -94.05 118.41 31.48 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.178 179.87 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.46 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 0.8 OUTLIER -98.9 -30.74 12.21 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.864 -179.989 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 165.02 146.34 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.078 179.896 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 111.51 2.53 27.51 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.91 -1.138 . . . . 0.0 110.861 179.484 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.597 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -52.2 163.91 0.66 Allowed Pre-proline 0 C--N 1.308 -1.219 0 C-N-CA 118.868 -1.133 . . . . 0.0 109.917 179.797 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_endo -78.31 143.69 73.34 Favored 'Cis proline' 0 C--O 1.212 -0.821 0 C-N-CA 124.156 -1.185 . . . . 0.0 112.489 -0.808 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 35.2 m-70 -107.29 178.88 4.41 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.032 179.149 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.718 HD21 ' H ' ' A' ' 39' ' ' ILE . 0.5 OUTLIER -158.03 145.0 17.91 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.635 -0.826 . . . . 0.0 110.061 179.098 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.718 ' H ' HD21 ' A' ' 38' ' ' ASN . 3.9 mp -131.92 117.04 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.758 -0.777 . . . . 0.0 110.948 -179.771 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 40.4 t -136.03 141.79 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.19 179.667 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -93.78 134.02 36.55 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 119.442 -0.903 . . . . 0.0 111.064 -179.584 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.682 ' C ' ' H ' ' A' ' 44' ' ' ASP . 24.7 p-10 -75.23 101.49 4.67 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.279 -0.969 . . . . 0.0 110.975 -179.523 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.493 ' H ' ' CD ' ' A' ' 43' ' ' GLU . 1.6 pm0 -55.63 6.5 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.175 0 C-N-CA 119.969 -0.692 . . . . 0.0 111.38 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.682 ' H ' ' C ' ' A' ' 42' ' ' ASP . 4.2 m-20 -83.08 -67.31 0.8 Allowed 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.837 179.138 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -97.83 27.36 4.49 Favored 'General case' 0 N--CA 1.49 1.539 0 C-N-CA 119.335 -0.946 . . . . 0.0 112.089 -177.049 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 45.3 t -102.48 143.97 27.67 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.598 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.458 ' C ' ' H ' ' A' ' 49' ' ' GLY . 4.6 Cg_exo -46.61 140.9 11.71 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 120.777 0.984 . . . . 0.0 112.178 -179.107 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.53 39.28 0.26 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.863 -179.892 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.458 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -142.55 -41.0 0.07 OUTLIER Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.703 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 71.6 t -87.73 84.63 2.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.894 179.207 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -44.19 139.9 2.38 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.573 -0.851 . . . . 0.0 111.083 -179.185 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.438 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -86.21 0.65 53.21 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.473 -0.891 . . . . 0.0 110.766 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -87.39 -10.76 51.2 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.826 179.914 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.0 mtmt -98.17 -35.47 10.37 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.594 -0.842 . . . . 0.0 111.232 -179.668 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.3 pt -92.86 -13.37 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.245 -0.982 . . . . 0.0 111.373 -179.522 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.438 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 29.0 m -76.3 170.31 16.58 Favored 'General case' 0 C--N 1.307 -1.241 0 C-N-CA 119.186 -1.006 . . . . 0.0 110.893 179.791 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.626 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 4.0 mt-30 -138.37 69.82 46.9 Favored Pre-proline 0 N--CA 1.487 1.379 0 C-N-CA 120.046 -0.662 . . . . 0.0 110.584 -179.854 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -59.56 -10.08 10.56 Favored 'Trans proline' 0 C--N 1.323 -0.798 0 C-N-CA 121.457 1.438 . . . . 0.0 111.554 -179.304 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.418 ' O ' ' O ' ' A' ' 60' ' ' TYR . 0.7 OUTLIER -85.84 103.32 14.48 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.184 179.482 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.418 ' O ' ' O ' ' A' ' 59' ' ' GLU . 90.0 m-85 -44.16 168.26 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.164 -179.593 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.1 pp -151.8 146.4 25.68 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.05 179.913 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -143.69 -7.05 0.77 Allowed 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 119.318 -0.953 . . . . 0.0 111.387 -179.684 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -48.23 125.43 12.89 Favored Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.174 -1.489 . . . . 0.0 110.628 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -71.36 111.78 6.96 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.818 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 91.83 -11.19 72.79 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.252 -1.451 . . . . 0.0 110.84 -179.895 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -57.98 159.35 5.71 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.178 -1.009 . . . . 0.0 110.487 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.58 172.63 12.7 Favored 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.987 -179.442 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.626 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 51.9 t80 -135.34 178.59 6.92 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.36 179.09 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.571 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 8.4 mt-10 -145.99 152.0 38.68 Favored 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 118.747 -1.181 . . . . 0.0 111.986 -179.739 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -162.41 140.42 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 119.876 -0.729 . . . . 0.0 109.713 178.539 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.1 m -129.83 97.9 4.63 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.744 -179.619 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.3 mt -79.75 159.29 26.65 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.012 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 4.1 p -150.41 51.39 0.89 Allowed 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.793 -179.25 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.466 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.3 tt0 -142.95 99.81 3.53 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.406 -0.918 . . . . 0.0 109.839 178.829 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 74' ' ' GLU . 3.9 mttp -42.65 103.37 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.436 -0.906 . . . . 0.0 110.618 -179.568 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.0 -142.27 5.51 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.171 -1.49 . . . . 0.0 110.281 -179.544 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.97 133.4 21.86 Favored 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.476 -179.657 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.59 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -122.18 116.87 24.93 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.4 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.456 ' O ' ' OD1' ' A' ' 42' ' ' ASP . 11.2 mptt -95.88 115.69 27.81 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.172 -1.011 . . . . 0.0 111.787 -178.713 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.569 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -119.5 170.09 9.47 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.825 -0.75 . . . . 0.0 110.1 178.755 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -170.37 179.78 3.29 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.329 -178.631 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -102.94 128.27 49.81 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 119.754 -0.779 . . . . 0.0 110.17 179.258 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.53 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 mt-10 -73.34 -45.58 7.77 Favored Pre-proline 0 C--N 1.304 -1.399 0 C-N-CA 119.552 -0.859 . . . . 0.0 112.788 -179.399 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.53 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.3 Cg_exo -65.95 -51.11 1.33 Allowed 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 120.88 1.053 . . . . 0.0 111.684 -179.087 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . 0.497 ' C ' ' H ' ' A' ' 87' ' ' GLY . 38.2 m80 -83.52 13.96 4.12 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.321 -0.952 . . . . 0.0 111.054 -179.774 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.24 -5.4 0.48 Allowed 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.299 -0.96 . . . . 0.0 110.742 179.806 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.497 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -81.04 -26.54 52.72 Favored Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.515 -179.848 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.96 -13.64 35.74 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.626 179.916 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.44 7.15 49.5 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 119.709 -1.234 . . . . 0.0 110.418 179.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -48.31 109.69 0.26 Allowed 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.734 179.902 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.522 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -134.95 170.78 15.37 Favored 'General case' 0 N--CA 1.494 1.756 0 C-N-CA 119.551 -0.86 . . . . 0.0 111.422 -179.849 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -151.63 149.34 21.07 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.192 -1.48 . . . . 0.0 111.266 -178.67 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -152.89 139.3 18.57 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.397 179.522 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.426 ' CG1' ' O ' ' A' ' 94' ' ' VAL . 10.7 p -132.79 121.5 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 C-N-CA 119.289 -0.965 . . . . 0.0 110.5 179.279 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 39.3 m -98.64 100.77 12.03 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.908 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 25.8 t -82.68 151.04 4.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 118.747 -1.181 . . . . 0.0 110.367 -179.369 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 116.397 -1.763 . . . . 0.0 110.846 -179.744 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.1 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -131.37 136.97 48.5 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 120.017 -0.673 . . . . 0.0 110.521 179.977 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.1 t -131.13 124.23 55.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.587 179.839 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 7.0 mptt -95.85 116.89 29.57 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.165 -179.606 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 37.7 mt -75.69 109.93 9.68 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 118.681 -1.208 . . . . 0.0 109.235 178.151 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.527 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 99.46 134.07 8.35 Favored Glycine 0 N--CA 1.484 1.895 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -178.612 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.9 p . . . . . 0 C--N 1.303 -1.439 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.737 -179.905 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 mt . . . . . 0 N--CA 1.489 1.477 0 CA-C-O 120.551 0.215 . . . . 0.0 110.642 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.2 m -150.01 155.36 7.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.781 179.889 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.425 ' O ' ' O ' ' A' ' 16' ' ' PRO . 75.3 m-85 -78.62 108.97 12.41 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 177.579 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.7 m -111.63 114.43 52.39 Favored Pre-proline 0 C--N 1.303 -1.453 0 C-N-CA 119.389 -0.925 . . . . 0.0 112.07 -177.283 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.6 Cg_endo -66.68 172.47 35.74 Favored 'Cis proline' 0 C--N 1.361 1.201 0 C-N-CA 125.333 -0.695 . . . . 0.0 111.449 -0.685 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.44 -67.06 0.87 Allowed 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.334 179.193 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -108.61 140.4 42.04 Favored 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.556 179.129 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 22.1 p90 -165.69 140.16 4.71 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 118.227 -1.389 . . . . 0.0 111.786 -179.213 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 75.7 p -88.83 157.42 18.47 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.761 179.423 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -149.9 151.48 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 C-N-CA 119.297 -0.961 . . . . 0.0 111.159 179.739 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.46 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -71.95 142.55 49.43 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.316 -0.954 . . . . 0.0 110.462 179.724 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.17 75.98 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 119.414 -0.914 . . . . 0.0 111.188 -179.752 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 161.08 11.1 0.04 OUTLIER Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.857 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -105.13 148.56 26.73 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 120.1 -0.64 . . . . 0.0 110.832 -179.497 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 10.3 pttm -95.16 155.01 16.91 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.493 -0.883 . . . . 0.0 111.09 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 mt -127.22 109.21 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.799 179.56 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.1 p -100.68 117.69 35.31 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.789 -0.764 . . . . 0.0 112.028 -178.757 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -84.66 129.83 34.79 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.238 -0.985 . . . . 0.0 108.723 178.315 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.0 ttmt -120.0 128.12 53.25 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.394 -178.53 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 35.1 m120 -71.81 111.49 7.12 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.536 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.527 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 0.9 OUTLIER -96.09 -31.9 12.79 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.023 -1.071 . . . . 0.0 111.32 -179.856 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.472 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 163.26 130.97 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.894 179.585 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 124.89 2.58 7.86 Favored Glycine 0 N--CA 1.496 2.665 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.142 179.488 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -50.55 162.98 0.49 Allowed Pre-proline 0 C--N 1.307 -1.245 0 C-N-CA 118.518 -1.273 . . . . 0.0 109.739 179.798 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -75.96 144.37 79.57 Favored 'Cis proline' 0 C--O 1.215 -0.655 0 C-N-CA 124.279 -1.134 . . . . 0.0 112.341 -0.482 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 30.6 m-70 -108.05 173.74 6.19 Favored 'General case' 0 N--CA 1.493 1.719 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.637 179.541 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.715 HD21 ' H ' ' A' ' 39' ' ' ILE . 0.6 OUTLIER -152.62 138.35 17.9 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.925 179.534 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.715 ' H ' HD21 ' A' ' 38' ' ' ASN . 3.7 mp -128.13 99.97 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.904 -179.728 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.6 t -123.36 147.35 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.011 179.341 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -101.26 129.63 47.25 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.464 -0.894 . . . . 0.0 111.505 -179.676 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -67.03 113.72 5.24 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.702 -0.799 . . . . 0.0 110.632 179.656 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -62.06 -4.42 1.66 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.678 -0.809 . . . . 0.0 111.718 -179.22 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -95.78 -2.4 47.75 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.089 -179.78 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -140.65 50.47 1.67 Allowed 'General case' 0 C--N 1.312 -1.031 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.704 179.871 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -140.35 145.9 43.23 Favored Pre-proline 0 N--CA 1.489 1.502 0 CA-C-N 115.51 -0.768 . . . . 0.0 108.936 179.879 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -54.81 162.33 5.15 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 120.798 0.998 . . . . 0.0 111.742 -179.739 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -90.16 55.47 3.1 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.835 179.958 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -161.59 -42.27 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.06 179.926 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 88.5 t -86.28 92.62 3.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 C-N-CA 119.565 -0.854 . . . . 0.0 110.421 179.756 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -44.55 139.78 2.68 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.953 -179.785 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.437 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -80.88 -15.6 55.89 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.519 -0.873 . . . . 0.0 110.965 -179.8 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -77.68 -28.0 50.95 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.406 -0.917 . . . . 0.0 111.309 -179.479 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -73.45 -35.63 65.79 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.44 -179.202 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.9 pt -96.54 -13.83 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.533 -179.353 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.437 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 19.3 m -77.27 176.3 8.91 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.025 -1.07 . . . . 0.0 111.35 -179.611 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.651 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 60.6 mt-30 -137.31 71.58 53.36 Favored Pre-proline 0 C--N 1.306 -1.298 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.432 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -59.26 -19.08 48.41 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 121.307 1.338 . . . . 0.0 111.34 -179.217 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -91.83 97.25 10.87 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.294 179.259 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -43.54 163.94 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.725 -179.731 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.7 pp -134.8 139.5 45.15 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.567 -0.853 . . . . 0.0 110.887 179.728 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.412 ' ND2' ' N ' ' A' ' 62' ' ' ASN . 0.1 OUTLIER -131.53 31.52 4.29 Favored 'General case' 0 N--CA 1.484 1.234 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.479 179.942 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -99.76 128.45 9.58 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.475 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -78.17 128.91 34.48 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.413 -0.915 . . . . 0.0 110.799 179.955 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 81.5 -21.84 5.95 Favored Glycine 0 N--CA 1.489 2.227 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.794 179.915 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.422 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 2.2 mm-40 -49.72 162.82 0.15 Allowed 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.178 -1.009 . . . . 0.0 110.267 179.858 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 7.6 p -146.28 163.36 35.76 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.79 -179.38 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.651 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 37.2 t80 -136.05 146.13 46.75 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.421 179.39 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -106.12 148.69 27.53 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 119.466 -0.894 . . . . 0.0 112.318 -178.773 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -149.41 132.88 7.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.498 178.786 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 18.2 m -131.21 105.36 7.62 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.469 -0.892 . . . . 0.0 111.639 -179.012 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 17.9 mt -95.32 152.64 18.21 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 119.422 -0.911 . . . . 0.0 109.693 179.091 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 47.4 p -150.57 47.02 0.88 Allowed 'General case' 0 C--N 1.293 -1.854 0 C-N-CA 119.304 -0.959 . . . . 0.0 110.862 -179.54 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.453 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 3.7 mm-40 -137.81 107.79 6.34 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.728 -179.948 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 8.5 tptt -44.45 112.51 0.42 Allowed 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.333 -179.876 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 167.94 -152.28 20.4 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.086 -1.531 . . . . 0.0 110.391 179.722 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.92 135.46 32.85 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.495 -179.922 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.558 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -121.36 166.3 14.27 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.659 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 17.3 mmtp -138.2 130.14 28.43 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.804 -179.322 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.528 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.5 p90 -137.24 164.18 29.15 Favored 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.214 178.673 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 39.4 p90 -170.32 -173.83 1.56 Allowed 'General case' 0 C--N 1.287 -2.146 0 C-N-CA 119.586 -0.846 . . . . 0.0 110.704 -178.497 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -112.38 129.85 56.17 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.57 179.478 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.502 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.9 mm-40 -69.71 -45.77 24.95 Favored Pre-proline 0 N--CA 1.488 1.454 0 C-N-CA 119.393 -0.923 . . . . 0.0 112.906 -179.446 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.502 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.9 Cg_endo -66.95 -52.22 0.7 Allowed 'Trans proline' 0 C--O 1.216 -0.6 0 C-N-CA 120.756 0.971 . . . . 0.0 112.41 -179.244 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . 0.497 ' C ' ' H ' ' A' ' 87' ' ' GLY . 35.2 m80 -81.54 5.61 17.43 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.449 -0.901 . . . . 0.0 112.224 -178.912 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.59 -2.01 0.69 Allowed 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.712 -1.195 . . . . 0.0 110.525 179.935 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.497 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -81.63 -23.52 57.97 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 119.503 -1.332 . . . . 0.0 110.39 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.5 -45.45 7.76 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.346 -0.941 . . . . 0.0 110.43 -179.996 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.01 29.18 0.15 Allowed Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.531 179.687 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -76.12 102.69 5.83 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.124 -1.03 . . . . 0.0 110.961 179.888 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.6 pttt -131.12 166.49 20.98 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.434 -179.898 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.84 147.31 17.43 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.23 -1.462 . . . . 0.0 111.612 -178.713 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -149.47 147.71 28.55 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.347 179.189 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.3 p -143.39 136.19 24.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 118.911 -1.116 . . . . 0.0 110.363 179.377 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.8 m -114.52 108.19 16.52 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.914 -0.714 . . . . 0.0 110.626 179.815 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.6 t -84.96 143.86 10.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 C-N-CA 118.532 -1.267 . . . . 0.0 110.527 -178.932 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 116.293 -1.813 . . . . 0.0 111.229 -179.664 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.161 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -115.56 121.16 41.81 Favored 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.479 179.589 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 61.5 t -110.5 122.38 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 C-N-CA 119.792 -0.763 . . . . 0.0 111.062 -179.787 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.1 mtmt -91.89 112.11 23.92 Favored 'General case' 0 C--N 1.297 -1.685 0 C-N-CA 119.449 -0.9 . . . . 0.0 110.454 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 7.7 mt -77.33 108.15 10.26 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 118.869 -1.133 . . . . 0.0 110.471 179.083 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.422 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 113.76 147.66 9.79 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.557 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.6 p . . . . . 0 C--N 1.306 -1.314 0 C-N-CA 119.561 -0.855 . . . . 0.0 110.901 179.846 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 120.333 0.111 . . . . 0.0 110.771 . . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.8 m -151.8 156.61 5.83 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 C-N-CA 118.963 -1.095 . . . . 0.0 110.646 178.978 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.406 ' O ' ' C ' ' A' ' 16' ' ' PRO . 43.5 m-85 -78.55 113.31 16.46 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 177.572 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.8 m -115.21 107.58 49.38 Favored Pre-proline 0 N--CA 1.484 1.25 0 C-N-CA 119.434 -0.907 . . . . 0.0 112.089 -177.277 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.406 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -66.79 176.24 23.75 Favored 'Cis proline' 0 C--N 1.359 1.101 0 C-N-CA 125.409 -0.663 . . . . 0.0 111.738 -0.414 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.27 -52.98 4.92 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.611 -0.836 . . . . 0.0 110.088 179.138 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.4 t -131.09 146.68 52.45 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.398 178.985 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.404 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 23.0 p90 -161.55 140.04 9.53 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 118.374 -1.33 . . . . 0.0 111.96 -179.066 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 64.3 p -81.62 155.66 25.53 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.837 -0.745 . . . . 0.0 110.913 179.652 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.9 m -148.76 164.76 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 119.572 -0.851 . . . . 0.0 110.483 179.528 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.507 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -89.93 147.56 23.65 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.288 -0.965 . . . . 0.0 110.998 -179.754 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.15 77.59 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.509 -0.876 . . . . 0.0 110.788 179.756 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.66 23.15 0.09 OUTLIER Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -179.97 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -103.99 140.01 38.33 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.987 -0.685 . . . . 0.0 110.764 -179.578 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.9 mtmt -85.03 125.9 33.11 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.282 -0.967 . . . . 0.0 110.97 -179.851 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.2 mt -102.62 119.77 51.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 C-N-CA 119.803 -0.759 . . . . 0.0 109.578 179.779 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 43.3 p -117.1 114.57 23.91 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.7 -0.8 . . . . 0.0 112.393 -178.513 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -87.46 117.91 26.56 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.003 178.319 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.8 tttt -112.29 138.61 48.76 Favored 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 119.544 -0.862 . . . . 0.0 111.86 -178.338 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -81.13 131.36 35.3 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.2 179.683 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.462 ' O ' ' CB ' ' A' ' 33' ' ' ALA . 1.8 p-10 -125.56 -17.06 5.63 Favored 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.067 179.217 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.462 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 166.04 149.55 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 C-N-CA 119.542 -0.863 . . . . 0.0 111.247 178.992 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.28 -5.74 59.19 Favored Glycine 0 N--CA 1.495 2.581 0 C-N-CA 119.279 -1.439 . . . . 0.0 112.284 178.626 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -48.14 162.23 0.34 Allowed Pre-proline 0 N--CA 1.489 1.488 0 C-N-CA 118.133 -1.427 . . . . 0.0 109.723 -179.923 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -76.23 142.99 75.12 Favored 'Cis proline' 0 C--O 1.212 -0.796 0 C-N-CA 124.304 -1.123 . . . . 0.0 112.538 -0.638 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.2 m-70 -108.66 -179.63 3.92 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 119.856 -0.738 . . . . 0.0 111.498 -179.896 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.55 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -158.63 146.71 18.25 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.841 -0.744 . . . . 0.0 110.241 179.167 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.55 ' N ' HD21 ' A' ' 38' ' ' ASN . 3.9 mp -135.94 117.81 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 119.519 -0.873 . . . . 0.0 111.08 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.55 160.4 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.298 179.089 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.5 m-85 -113.38 125.0 53.78 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.41 -0.916 . . . . 0.0 112.058 -178.973 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.527 ' C ' ' H ' ' A' ' 44' ' ' ASP . 1.1 t70 -65.23 107.18 1.51 Allowed 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.664 178.786 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -67.86 16.38 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 119.505 -0.878 . . . . 0.0 112.207 -178.826 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.527 ' H ' ' C ' ' A' ' 42' ' ' ASP . 1.9 m-20 -106.02 -3.68 21.36 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 119.5 -0.88 . . . . 0.0 111.019 179.89 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -140.89 12.39 2.25 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.917 179.596 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -92.32 147.02 33.68 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.615 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -49.68 154.67 4.45 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 120.966 1.111 . . . . 0.0 112.019 -179.286 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.79 67.79 10.21 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.682 -179.935 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.86 -38.13 0.07 OUTLIER Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.957 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 55.8 t -90.53 81.19 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.371 179.583 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -44.21 139.62 2.51 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.13 -179.359 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.441 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -87.44 10.31 17.94 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.955 -179.724 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -90.55 -22.68 21.17 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.091 -1.044 . . . . 0.0 111.513 -179.476 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -93.81 -32.32 14.01 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 118.912 -1.115 . . . . 0.0 112.046 -179.329 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.1 pt -90.33 -23.74 5.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.513 -179.327 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 18.1 m -61.78 -178.8 0.16 Allowed 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.098 179.869 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.651 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 9.9 tt0 -157.83 67.84 3.81 Favored Pre-proline 0 C--N 1.303 -1.444 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.689 -179.579 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.96 -29.34 87.82 Favored 'Trans proline' 0 C--N 1.323 -0.781 0 C-N-CA 121.308 1.339 . . . . 0.0 111.286 -179.419 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -59.01 112.28 1.62 Allowed 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.554 179.701 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.447 ' CD1' ' OD1' ' A' ' 38' ' ' ASN . 43.9 m-85 -58.55 169.55 0.9 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.998 -179.95 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.2 pp -153.73 149.17 27.2 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.362 179.688 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.512 ' O ' ' C ' ' A' ' 63' ' ' GLY . 0.0 OUTLIER -127.21 -74.31 0.59 Allowed 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.396 -179.288 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . 0.512 ' C ' ' O ' ' A' ' 62' ' ' ASN . . . -9.65 123.41 0.01 OUTLIER Glycine 1 N--CA 1.518 4.113 0 O-C-N 124.202 0.939 . . . . 0.0 112.75 -179.641 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -75.05 131.41 40.56 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.43 -0.908 . . . . 0.0 110.664 179.736 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.63 -14.96 58.92 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.596 -1.288 . . . . 0.0 110.528 -179.975 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' A' ' 66' ' ' GLU . 1.2 mp0 -62.96 148.51 47.33 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.446 179.844 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.38 163.24 34.35 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.246 -0.982 . . . . 0.0 111.396 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.651 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 41.5 t80 -136.54 143.73 43.85 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 119.87 -0.732 . . . . 0.0 109.276 179.269 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -106.15 152.16 23.8 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.219 -0.992 . . . . 0.0 111.995 -179.149 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -151.82 131.58 3.62 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 CA-C-N 115.345 -0.843 . . . . 0.0 108.813 179.555 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.7 m -121.52 112.87 19.04 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.804 -179.067 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 45.7 mt -96.56 158.61 15.35 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.725 -0.79 . . . . 0.0 109.417 178.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.0 m -150.89 41.9 0.77 Allowed 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 118.56 -1.256 . . . . 0.0 112.351 -179.133 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.424 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 62.8 mt-10 -145.92 110.98 5.27 Favored 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.378 178.918 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -44.06 116.51 1.01 Allowed 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.934 -179.569 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 164.5 175.16 35.04 Favored Glycine 0 N--CA 1.483 1.807 0 C-N-CA 119.293 -1.432 . . . . 0.0 110.35 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.76 126.77 53.38 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.992 -0.683 . . . . 0.0 110.977 -179.785 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.554 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -108.35 141.99 39.34 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.352 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 16.5 mmtp -105.12 122.22 45.45 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.953 -179.139 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.423 ' CZ ' ' N ' ' A' ' 93' ' ' GLU . 5.7 p90 -138.48 160.04 40.57 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 119.315 -0.954 . . . . 0.0 110.076 177.508 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -170.24 -175.26 1.91 Allowed 'General case' 0 C--N 1.287 -2.112 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.908 -177.655 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.6 t -103.48 122.72 45.49 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.732 -0.787 . . . . 0.0 109.372 179.245 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.564 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 4.9 tt0 -73.4 -36.04 2.94 Favored Pre-proline 0 CA--C 1.557 1.236 0 C-N-CA 118.84 -1.144 . . . . 0.0 113.267 -178.701 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.564 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.0 OUTLIER -70.25 -47.74 0.73 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 120.376 0.718 . . . . 0.0 111.105 179.66 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . 0.449 ' C ' ' H ' ' A' ' 87' ' ' GLY . 36.7 m80 -87.77 16.45 5.76 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.593 -0.843 . . . . 0.0 110.808 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.53 -2.61 1.69 Allowed 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.364 -0.935 . . . . 0.0 110.821 179.908 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.449 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -88.16 -17.83 56.82 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.354 -1.403 . . . . 0.0 110.29 179.911 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.45 -41.61 10.2 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.644 179.961 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 132.72 13.88 1.56 Allowed Glycine 0 N--CA 1.494 2.555 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.562 179.861 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.49 101.86 0.21 Allowed 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.928 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.5 tptt -124.71 154.1 41.35 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 119.914 -0.715 . . . . 0.0 111.256 -179.854 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.55 153.1 21.88 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.85 -179.055 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.423 ' N ' ' CZ ' ' A' ' 80' ' ' PHE . 2.7 mt-10 -156.4 146.05 20.9 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.363 -0.935 . . . . 0.0 111.289 179.911 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.1 p -138.7 128.54 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.24 178.792 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 98.8 m -106.77 100.09 9.62 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.68 179.831 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.0 t -80.04 150.78 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.237 0 C-N-CA 118.779 -1.169 . . . . 0.0 110.392 -179.714 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 116.339 -1.791 . . . . 0.0 110.828 179.969 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.153 0 CA-C-O 120.855 0.36 . . . . 0.0 110.079 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -105.27 135.69 46.17 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.929 -0.708 . . . . 0.0 110.647 179.887 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.0 t -124.11 126.62 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.817 -0.753 . . . . 0.0 110.445 179.591 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 7.3 mttp -100.84 118.57 37.16 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.792 -0.763 . . . . 0.0 110.591 -179.819 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.2 mt -83.66 109.82 17.77 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.646 178.84 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.543 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 106.25 133.36 7.42 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -178.8 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.2 p . . . . . 0 C--N 1.301 -1.511 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.624 179.64 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.9 mt . . . . . 0 N--CA 1.489 1.498 0 CA-C-O 120.692 0.282 . . . . 0.0 110.645 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.1 m -147.3 154.67 11.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 C-N-CA 119.091 -1.044 . . . . 0.0 111.023 179.899 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.443 ' O ' ' O ' ' A' ' 16' ' ' PRO . 40.4 m-85 -78.39 109.08 12.22 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 177.893 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 20.0 m -115.37 111.32 44.38 Favored Pre-proline 0 C--O 1.205 -1.24 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.51 -177.446 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.443 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -66.16 176.57 20.88 Favored 'Cis proline' 0 C--N 1.355 0.909 0 C-N-CA 125.304 -0.707 . . . . 0.0 111.612 0.102 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -92.86 -56.58 2.94 Favored 'General case' 0 N--CA 1.486 1.371 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.726 178.803 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.8 t -125.75 139.37 53.58 Favored 'General case' 0 N--CA 1.486 1.341 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.073 178.806 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 16.4 p90 -159.03 132.84 7.49 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.448 -178.915 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -83.12 155.07 24.01 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.271 -0.972 . . . . 0.0 110.865 179.762 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 17.8 m -146.57 171.55 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.326 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.998 179.741 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -93.94 151.45 19.55 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.414 -0.914 . . . . 0.0 110.684 179.728 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.2 73.54 0.12 Allowed 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.146 -179.986 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 154.69 13.14 0.06 OUTLIER Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.791 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -99.07 117.04 32.67 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.663 -179.783 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.1 mtmp? -65.96 133.44 50.86 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 119.477 -0.889 . . . . 0.0 111.066 -179.774 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 mt -113.55 131.77 64.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 C-N-CA 119.954 -0.698 . . . . 0.0 109.248 179.454 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.5 p -125.29 123.29 39.16 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.526 -0.87 . . . . 0.0 112.173 -178.54 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -84.4 147.29 27.22 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.414 -0.914 . . . . 0.0 108.851 178.346 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 tttm -136.62 127.9 28.18 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.396 -0.921 . . . . 0.0 111.371 -178.873 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.2 m-80 -79.45 109.45 13.82 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.69 -0.804 . . . . 0.0 110.52 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.543 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 0.6 OUTLIER -95.49 -30.73 13.7 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.76 -179.474 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.453 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 166.4 136.92 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.041 -179.661 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 116.27 -2.23 20.65 Favored Glycine 0 N--CA 1.495 2.599 0 C-N-CA 119.836 -1.174 . . . . 0.0 111.033 179.189 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -47.37 163.83 0.25 Allowed Pre-proline 0 C--N 1.308 -1.224 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.775 179.792 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -76.23 145.34 82.01 Favored 'Cis proline' 0 C--O 1.214 -0.722 0 C-N-CA 124.223 -1.157 . . . . 0.0 112.659 -0.756 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -111.22 172.15 7.05 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.889 179.298 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.663 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.2 OUTLIER -149.8 137.98 20.47 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.111 179.34 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.663 ' N ' HD21 ' A' ' 38' ' ' ASN . 3.5 mp -125.17 110.68 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 C-N-CA 119.893 -0.723 . . . . 0.0 110.888 -179.689 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.5 t -130.93 145.31 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.95 -0.7 . . . . 0.0 110.326 179.528 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -99.53 121.7 41.55 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.586 -0.845 . . . . 0.0 111.322 -179.356 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -60.48 100.87 0.11 Allowed 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.131 -1.028 . . . . 0.0 110.044 179.484 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -57.65 -6.6 0.52 Allowed 'General case' 0 N--CA 1.489 1.488 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.277 -179.012 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -93.36 3.19 56.01 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 118.993 -1.083 . . . . 0.0 112.263 -178.733 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 30.6 mt-10 -144.56 13.52 1.55 Allowed 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 119.116 -1.033 . . . . 0.0 111.741 -179.944 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -90.85 149.96 41.22 Favored Pre-proline 0 C--N 1.292 -1.919 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.287 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -47.91 144.25 12.05 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.917 1.078 . . . . 0.0 111.878 -179.539 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.6 73.98 1.99 Allowed 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.531 -0.868 . . . . 0.0 110.617 179.994 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.47 -32.72 0.12 Allowed Glycine 0 N--CA 1.487 2.053 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.241 -179.94 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 81.4 t -94.83 105.79 17.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.374 -0.93 . . . . 0.0 111.073 -179.855 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -52.17 143.99 13.29 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.715 179.882 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.435 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -93.04 -3.28 54.6 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.328 -0.949 . . . . 0.0 110.908 -179.773 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -90.22 -21.45 22.15 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.255 -0.978 . . . . 0.0 110.94 -179.931 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 23.4 mmtt -78.14 -26.96 48.08 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.304 -0.958 . . . . 0.0 110.936 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.3 pt -105.8 -12.22 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.845 -179.192 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.435 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 18.6 m -78.39 170.07 17.22 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.108 -1.037 . . . . 0.0 111.316 -179.952 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.655 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 55.5 mt-30 -134.19 74.11 68.27 Favored Pre-proline 0 N--CA 1.486 1.335 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.241 179.902 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -59.52 -20.26 56.19 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 121.277 1.318 . . . . 0.0 111.63 -178.69 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.444 ' O ' ' CG ' ' A' ' 59' ' ' GLU . 3.4 pt-20 -89.14 107.0 18.8 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.527 179.513 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.419 ' CD2' ' OD1' ' A' ' 38' ' ' ASN . 27.6 m-85 -51.93 165.61 0.19 Allowed 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 119.411 -0.915 . . . . 0.0 110.849 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.4 pp -139.34 126.38 21.09 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.43 179.466 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.457 ' OD1' ' N ' ' A' ' 62' ' ' ASN . 19.8 p-10 -118.31 34.97 4.94 Favored 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.057 -179.49 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -87.99 -172.08 47.06 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 119.238 -1.458 . . . . 0.0 110.214 179.64 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -133.59 105.94 7.14 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.049 179.579 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 94.24 -11.37 70.58 Favored Glycine 0 N--CA 1.486 2.03 0 C-N-CA 119.308 -1.425 . . . . 0.0 109.713 -179.299 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -50.59 160.94 0.37 Allowed 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.359 179.684 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.7 p -145.8 158.99 43.82 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.393 -179.374 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.655 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 15.6 t80 -136.16 137.01 40.5 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.365 179.068 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -99.97 152.3 20.35 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 119.292 -0.963 . . . . 0.0 112.494 -178.769 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -155.81 134.53 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 115.191 -0.913 . . . . 0.0 108.9 179.509 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.1 m -128.6 96.7 4.47 Favored 'General case' 0 N--CA 1.486 1.327 0 C-N-CA 119.559 -0.856 . . . . 0.0 111.208 -179.482 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.5 mt -79.88 157.63 26.9 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.25 -0.98 . . . . 0.0 109.9 179.433 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 77.6 p -150.06 45.96 0.91 Allowed 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.495 -179.169 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.439 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.7 mm-40 -142.46 113.29 7.45 Favored 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.098 -1.041 . . . . 0.0 110.448 179.557 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.466 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 0.6 OUTLIER -52.45 119.33 4.35 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.268 -0.973 . . . . 0.0 111.058 -179.322 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 163.36 -147.87 13.91 Favored Glycine 0 N--CA 1.483 1.78 0 C-N-CA 119.254 -1.451 . . . . 0.0 110.142 179.86 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.74 130.18 23.9 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.752 -179.938 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.53 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.6 m-85 -114.86 123.8 50.08 Favored 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.923 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . 0.516 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.5 OUTLIER -103.97 121.03 42.29 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.133 -1.027 . . . . 0.0 111.76 -178.949 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 4.2 p90 -129.54 173.19 10.81 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.212 178.295 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -171.11 -174.29 1.46 Allowed 'General case' 0 C--N 1.292 -1.894 0 C-N-CA 119.531 -0.868 . . . . 0.0 110.814 -178.576 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -108.89 132.07 54.41 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 119.898 -0.721 . . . . 0.0 110.49 179.209 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.496 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.2 mt-10 -73.38 -47.18 7.61 Favored Pre-proline 0 N--CA 1.485 1.286 0 C-N-CA 119.432 -0.907 . . . . 0.0 112.472 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.2 Cg_exo -64.54 -47.18 5.94 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 120.89 1.06 . . . . 0.0 111.953 -179.227 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . 0.478 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.6 m80 -90.51 21.42 3.95 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.971 -179.421 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.73 1.66 1.24 Allowed 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.692 179.844 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.478 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -96.5 -20.94 23.41 Favored Glycine 0 N--CA 1.49 2.277 0 C-N-CA 119.471 -1.347 . . . . 0.0 110.412 -179.869 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.41 -9.87 45.95 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.485 179.667 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 96.46 20.28 25.33 Favored Glycine 0 N--CA 1.488 2.102 0 C-N-CA 119.498 -1.334 . . . . 0.0 110.462 179.817 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.31 102.72 0.7 Allowed 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.151 -1.02 . . . . 0.0 110.982 -179.829 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.07 162.1 26.86 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.003 179.826 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -142.96 153.26 24.6 Favored Glycine 0 N--CA 1.491 2.359 0 C-N-CA 119.436 -1.364 . . . . 0.0 111.468 -178.587 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -155.62 144.87 20.85 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.429 -0.908 . . . . 0.0 111.078 179.629 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -141.78 123.32 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.193 178.461 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 92.3 m -101.14 108.2 19.81 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.158 -179.526 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 23.2 t -88.93 148.15 4.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 118.771 -1.172 . . . . 0.0 110.764 -179.329 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 . . . . . 0 N--CA 1.485 1.317 0 CA-C-O 116.341 -1.79 . . . . 0.0 110.868 -179.903 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.14 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -135.26 127.38 29.87 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 120.027 -0.669 . . . . 0.0 110.574 179.741 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.7 t -115.72 131.86 66.85 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 C-N-CA 119.864 -0.735 . . . . 0.0 110.991 -179.745 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.7 mtpp -104.72 118.9 37.71 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.205 -179.749 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.9 mt -81.52 108.22 14.93 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 118.956 -1.098 . . . . 0.0 109.672 178.269 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.531 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 110.41 125.64 4.91 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.649 -1.381 . . . . 0.0 109.649 -179.1 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.2 p . . . . . 0 C--N 1.299 -1.588 0 C-N-CA 119.162 -1.015 . . . . 0.0 110.934 -179.746 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.6 mt . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 120.496 0.189 . . . . 0.0 110.67 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.4 m -150.01 154.25 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.122 0 C-N-CA 118.777 -1.169 . . . . 0.0 111.268 179.749 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.433 ' O ' ' O ' ' A' ' 16' ' ' PRO . 11.1 m-85 -78.6 108.57 12.09 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 177.818 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 53.3 m -114.76 112.31 45.29 Favored Pre-proline 0 CA--C 1.559 1.303 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.248 -177.176 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.433 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -65.56 176.79 18.52 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 125.188 -0.755 . . . . 0.0 111.702 -0.936 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.9 t -93.86 -55.97 3.05 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.453 179.212 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.4 p -128.92 142.65 50.87 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.814 179.212 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -163.9 143.01 7.83 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 118.663 -1.215 . . . . 0.0 111.782 -179.278 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -90.76 153.59 20.15 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.903 179.533 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.7 m -145.95 -176.75 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 119.494 -0.882 . . . . 0.0 110.585 179.617 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.409 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -97.53 147.09 24.62 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.716 179.773 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.3 74.03 0.14 Allowed 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.836 179.741 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 155.54 18.09 0.04 OUTLIER Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.913 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -99.65 156.1 17.25 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.767 -0.773 . . . . 0.0 110.881 -179.783 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.0 mptp? -93.81 119.28 32.56 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.722 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.1 mt -100.06 106.5 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.254 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.2 p -104.26 117.7 34.85 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.582 -0.847 . . . . 0.0 112.888 -177.893 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -84.38 149.0 26.31 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.408 -0.917 . . . . 0.0 108.548 177.893 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 6.4 ttpp -141.19 133.39 27.98 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 118.965 -1.094 . . . . 0.0 111.664 -178.445 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 0.0 OUTLIER -89.48 104.02 16.61 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.735 178.946 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 2.3 p-10 -91.56 -31.72 15.8 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 118.864 -1.134 . . . . 0.0 111.846 -178.584 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -175.21 139.78 0.48 Allowed 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.138 -179.693 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.26 15.35 33.02 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.495 -1.335 . . . . 0.0 111.784 178.784 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.404 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -58.55 163.24 5.26 Favored Pre-proline 0 N--CA 1.481 1.113 0 C-N-CA 117.96 -1.496 . . . . 0.0 109.2 179.557 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -74.53 -174.48 13.85 Favored 'Cis proline' 0 C--O 1.206 -1.091 0 C-N-CA 124.481 -1.05 . . . . 0.0 112.195 -0.382 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.3 m-70 -149.7 -178.71 6.6 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.885 178.544 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.684 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.2 OUTLIER -156.75 137.22 13.05 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.375 179.166 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.684 ' N ' HD21 ' A' ' 38' ' ' ASN . 7.6 mt -122.0 85.27 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 C-N-CA 119.866 -0.734 . . . . 0.0 111.479 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 t -103.34 157.94 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 C-N-CA 119.922 -0.711 . . . . 0.0 109.484 178.755 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -112.29 138.97 48.25 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 119.285 -0.966 . . . . 0.0 111.949 -179.42 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.542 ' C ' ' H ' ' A' ' 44' ' ' ASP . 4.4 t70 -82.36 105.95 13.85 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.003 179.162 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -70.81 32.92 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.378 -179.451 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.542 ' H ' ' C ' ' A' ' 42' ' ' ASP . 82.5 m-20 -108.95 -15.13 14.43 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 120.032 -0.667 . . . . 0.0 110.693 179.518 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -139.79 16.33 2.5 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.718 179.491 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -93.41 143.7 27.09 Favored Pre-proline 0 C--N 1.296 -1.735 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 179.31 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . 0.435 ' C ' ' H ' ' A' ' 49' ' ' GLY . 3.0 Cg_exo -48.45 140.74 20.69 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 120.754 0.97 . . . . 0.0 111.961 -179.392 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.32 43.16 0.37 Allowed 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.67 179.973 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -148.78 -26.51 0.07 OUTLIER Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 46.7 t -101.83 93.95 3.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.458 179.746 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -44.88 139.62 2.97 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.741 -179.919 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -90.81 3.42 54.47 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.502 179.851 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -90.3 -31.63 16.86 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.933 179.909 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 37.0 mttt -69.68 -32.52 71.18 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.421 -0.912 . . . . 0.0 111.32 -179.762 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.0 pt -93.22 -35.07 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.123 -1.031 . . . . 0.0 111.148 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.4 m -56.27 163.88 1.51 Allowed 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.198 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.642 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 63.3 mt-30 -124.97 84.59 58.76 Favored Pre-proline 0 N--CA 1.487 1.42 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.231 179.713 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -60.37 -22.71 72.25 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 120.995 1.13 . . . . 0.0 111.834 -178.761 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -96.35 115.93 28.22 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.349 -0.94 . . . . 0.0 110.858 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . 0.533 ' CE1' ' OD1' ' A' ' 38' ' ' ASN . 55.0 m-85 -56.34 177.37 0.07 Allowed 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.624 179.879 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.7 pp -148.33 132.75 17.6 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.283 -0.967 . . . . 0.0 110.8 179.93 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -128.99 39.03 3.85 Favored 'General case' 0 N--CA 1.493 1.721 0 C-N-CA 119.976 -0.69 . . . . 0.0 110.955 -179.745 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -102.27 125.52 8.55 Favored Glycine 0 N--CA 1.494 2.512 0 C-N-CA 119.632 -1.271 . . . . 0.0 110.388 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -70.52 103.3 2.44 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.532 179.748 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.38 -0.24 55.76 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.614 -1.279 . . . . 0.0 110.458 -179.884 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 17.6 tt0 -72.99 106.99 5.1 Favored 'General case' 0 N--CA 1.49 1.562 0 C-N-CA 119.062 -1.055 . . . . 0.0 110.569 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.1 p -96.43 161.99 13.68 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.702 -179.169 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.642 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 24.2 t80 -135.75 136.04 40.45 Favored 'General case' 0 N--CA 1.491 1.592 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.517 179.185 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -98.13 152.23 19.57 Favored 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.256 -0.978 . . . . 0.0 112.547 -178.428 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -151.85 132.78 4.55 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.633 178.951 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 6.6 m -123.52 107.29 11.39 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.622 -0.831 . . . . 0.0 112.023 -178.683 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 50.5 mt -89.58 160.88 16.45 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.513 -0.875 . . . . 0.0 109.348 178.749 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.21 41.09 0.72 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 118.66 -1.216 . . . . 0.0 111.754 -178.918 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.462 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.6 OUTLIER -141.85 116.76 9.88 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 118.874 -1.13 . . . . 0.0 110.981 179.784 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -55.7 106.18 0.23 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.452 -0.899 . . . . 0.0 111.167 -179.685 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 173.93 -163.06 33.93 Favored Glycine 0 N--CA 1.484 1.843 0 C-N-CA 119.353 -1.403 . . . . 0.0 109.831 -179.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.6 125.7 45.3 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.807 -0.757 . . . . 0.0 111.071 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.547 ' N ' ' CD1' ' A' ' 78' ' ' TYR . 1.6 m-85 -109.3 153.73 23.49 Favored 'General case' 0 N--CA 1.483 1.213 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.018 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 81.1 mttt -115.63 134.49 54.99 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.402 -0.919 . . . . 0.0 112.469 -179.394 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.503 ' O ' ' N ' ' A' ' 92' ' ' GLY . 0.9 OUTLIER -143.57 154.98 44.15 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.492 -0.883 . . . . 0.0 110.058 176.917 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 36.5 p90 -168.45 -174.51 2.24 Favored 'General case' 0 C--N 1.284 -2.259 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.582 -178.666 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.3 t -110.94 122.57 48.21 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 119.842 -0.743 . . . . 0.0 109.832 179.732 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.582 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.5 tm-20 -72.74 -35.58 3.09 Favored Pre-proline 0 N--CA 1.483 1.182 0 C-N-CA 119.056 -1.058 . . . . 0.0 113.292 -178.885 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.1 Cg_endo -71.43 -38.48 4.56 Favored 'Trans proline' 0 C--O 1.213 -0.728 0 C-N-CA 120.52 0.814 . . . . 0.0 111.111 179.855 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 32.8 m80 -102.17 21.05 15.55 Favored 'General case' 0 N--CA 1.488 1.474 0 C-N-CA 119.785 -0.766 . . . . 0.0 111.049 -179.771 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.78 -12.9 8.22 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.612 179.766 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -92.5 -13.47 57.0 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.324 179.821 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.59 -20.44 26.39 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.549 179.933 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 110.21 14.82 12.47 Favored Glycine 0 N--CA 1.496 2.654 0 C-N-CA 119.853 -1.165 . . . . 0.0 110.83 179.673 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.3 mtp -72.27 98.4 2.18 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.689 179.875 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 21.0 mmtt -130.37 150.33 51.65 Favored 'General case' 0 N--CA 1.496 1.843 0 C-N-CA 119.962 -0.695 . . . . 0.0 110.835 179.538 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.503 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -140.3 155.92 24.85 Favored Glycine 0 N--CA 1.501 3.021 0 C-N-CA 119.283 -1.437 . . . . 0.0 112.456 -177.914 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 26.5 tt0 -158.64 146.43 18.04 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.203 179.014 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.9 p -138.29 122.25 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.001 179.974 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.5 m -97.19 97.03 8.84 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.673 179.885 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 24.0 t -81.95 154.17 4.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.907 -179.051 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.2 p30 . . . . . 0 C--N 1.306 -1.318 0 CA-C-O 116.348 -1.787 . . . . 0.0 110.651 179.872 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.197 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -104.77 123.98 48.61 Favored 'General case' 0 N--CA 1.488 1.458 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.986 179.948 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.6 t -117.28 128.54 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 C-N-CA 119.888 -0.725 . . . . 0.0 110.404 179.494 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -103.76 117.92 35.49 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.814 -0.754 . . . . 0.0 111.155 -179.49 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 mt -78.18 109.14 12.03 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.727 -1.189 . . . . 0.0 109.529 177.964 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . 0.406 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 107.47 120.47 4.55 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.061 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 31.9 p . . . . . 0 C--N 1.305 -1.355 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.992 -179.808 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 73.5 mt . . . . . 0 N--CA 1.488 1.451 0 CA-C-O 120.401 0.143 . . . . 0.0 111.041 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.9 m -150.07 157.44 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.73 179.325 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' PHE . . . . . 0.415 ' O ' ' O ' ' A' ' 16' ' ' PRO . 14.2 m-85 -78.44 112.02 15.05 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.135 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 54.6 m -116.03 108.79 45.69 Favored Pre-proline 0 CA--C 1.558 1.26 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.824 -177.861 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . 0.415 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.6 Cg_endo -65.76 177.84 16.68 Favored 'Cis proline' 0 C--N 1.362 1.244 0 C-N-CA 125.353 -0.686 . . . . 0.0 111.75 -0.49 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.439 ' H ' ' HG ' ' A' ' 17' ' ' SER . 0.0 OUTLIER -93.65 -51.64 4.83 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.509 -0.877 . . . . 0.0 110.423 179.437 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 94.5 p -140.02 141.89 36.27 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.782 179.385 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 22.4 p90 -162.71 149.42 12.95 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.743 -1.183 . . . . 0.0 111.183 -179.169 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -91.01 159.26 16.23 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.388 -0.925 . . . . 0.0 111.169 -179.972 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.6 m -149.95 172.01 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.858 179.697 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . 0.487 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -88.83 147.79 24.23 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.459 -0.897 . . . . 0.0 110.662 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.85 76.3 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.943 179.802 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.18 22.28 0.09 OUTLIER Glycine 0 N--CA 1.49 2.268 0 C-N-CA 119.537 -1.315 . . . . 0.0 109.933 179.968 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -96.3 145.97 25.13 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.01 -179.787 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.8 mttm -87.12 128.68 35.11 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.863 -179.971 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.8 mt -118.55 131.97 69.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.432 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 25.1 p -128.7 116.96 20.35 Favored 'General case' 0 N--CA 1.492 1.647 0 C-N-CA 119.354 -0.938 . . . . 0.0 112.384 -178.55 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -84.82 109.72 18.3 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.453 -0.899 . . . . 0.0 108.855 177.905 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.3 tttm -106.05 138.06 42.89 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 119.719 -0.792 . . . . 0.0 111.445 -178.103 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.423 HD22 ' CD1' ' A' ' 61' ' ' LEU . 4.3 m-20 -83.26 106.9 15.42 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.062 179.404 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 32' ' ' ASN . . . . . 0.48 ' O ' ' CB ' ' A' ' 33' ' ' ALA . 1.0 OUTLIER -90.19 -30.75 17.39 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 118.88 -1.128 . . . . 0.0 111.774 -178.865 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 33' ' ' ALA . . . . . 0.48 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 167.81 114.62 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 118.827 -1.149 . . . . 0.0 111.144 179.916 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 139.37 -0.96 2.34 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.587 -1.292 . . . . 0.0 110.559 179.858 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 35' ' ' PHE . . . . . 0.426 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -48.0 161.83 0.35 Allowed Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 118.749 -1.18 . . . . 0.0 110.071 -179.65 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -77.62 144.05 75.89 Favored 'Cis proline' 0 C--O 1.216 -0.587 0 C-N-CA 124.113 -1.203 . . . . 0.0 112.271 -1.022 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.5 m-70 -112.85 175.56 5.39 Favored 'General case' 0 N--CA 1.495 1.782 0 C-N-CA 119.915 -0.714 . . . . 0.0 110.135 179.42 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . 0.656 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -151.64 148.97 28.6 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.529 179.493 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.656 ' N ' HD21 ' A' ' 38' ' ' ASN . 4.0 mp -134.86 103.47 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 C-N-CA 119.616 -0.833 . . . . 0.0 111.351 -179.502 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 t -119.08 144.65 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 C-N-CA 120.075 -0.65 . . . . 0.0 110.123 179.22 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.469 ' H ' ' HG ' ' A' ' 56' ' ' SER . 9.9 m-85 -99.88 114.67 28.05 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.526 -0.87 . . . . 0.0 111.443 -179.338 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 42' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 44' ' ' ASP . 32.8 t0 -55.6 88.41 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 119.441 -0.903 . . . . 0.0 110.48 179.676 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 43' ' ' GLU . . . . . 0.467 ' N ' ' O ' ' A' ' 41' ' ' PHE . 16.0 pt-20 -46.71 -13.25 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.515 -0.874 . . . . 0.0 111.357 -179.688 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . 0.519 ' N ' ' O ' ' A' ' 42' ' ' ASP . 0.9 OUTLIER -87.97 13.11 11.66 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.388 -179.594 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -151.66 15.32 0.67 Allowed 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.114 179.843 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -104.06 154.87 37.85 Favored Pre-proline 0 N--CA 1.491 1.624 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.838 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -52.83 149.79 24.69 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 120.887 1.058 . . . . 0.0 111.236 179.646 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -83.06 40.78 0.72 Allowed 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.293 -0.963 . . . . 0.0 110.716 -179.899 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -142.89 -40.09 0.07 OUTLIER Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 70.3 t -92.48 90.8 3.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.146 179.449 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.2 m-80 -44.8 146.5 0.77 Allowed 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.314 -0.955 . . . . 0.0 110.877 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.433 ' C ' ' H ' ' A' ' 54' ' ' LYS . . . -90.84 -29.58 17.46 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.544 -0.862 . . . . 0.0 111.076 -179.728 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -60.74 -5.43 1.28 Allowed 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.995 -179.719 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.433 ' H ' ' C ' ' A' ' 52' ' ' ALA . 22.2 mtmt -99.55 -38.39 8.78 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.605 -0.838 . . . . 0.0 111.486 -179.828 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.1 pt -90.49 -29.25 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.208 -179.562 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 56' ' ' SER . . . . . 0.469 ' HG ' ' H ' ' A' ' 41' ' ' PHE . 58.8 m -56.23 172.34 0.22 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.107 179.909 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . 0.64 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 60.9 mt-30 -134.45 71.92 70.96 Favored Pre-proline 0 N--CA 1.491 1.601 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.815 179.757 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -59.29 -6.81 4.31 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 121.074 1.183 . . . . 0.0 111.209 -179.664 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 59' ' ' GLU . . . . . 0.413 ' H ' ' C ' ' A' ' 57' ' ' GLN . 26.1 tt0 -100.25 106.48 18.15 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.651 179.577 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 31.1 m-85 -52.34 168.3 0.11 Allowed 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.594 -0.842 . . . . 0.0 110.471 -179.993 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.423 ' CD1' HD22 ' A' ' 31' ' ' ASN . 1.7 pp -148.26 141.73 25.35 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.12 -1.032 . . . . 0.0 110.877 179.85 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -137.85 8.09 2.76 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.088 -179.835 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -65.52 127.47 31.65 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 119.091 -1.528 . . . . 0.0 110.302 179.892 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -72.0 120.81 18.13 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.179 -1.008 . . . . 0.0 110.266 179.659 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.29 -14.69 53.45 Favored Glycine 0 N--CA 1.487 2.047 0 C-N-CA 119.111 -1.519 . . . . 0.0 110.657 -179.664 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.19 152.08 34.22 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.169 -1.012 . . . . 0.0 110.469 179.762 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -142.93 171.97 13.33 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.592 -179.615 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.64 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 34.2 t80 -135.73 128.41 30.86 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.145 179.218 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -99.23 155.79 17.31 Favored 'General case' 0 N--CA 1.49 1.562 0 C-N-CA 119.052 -1.059 . . . . 0.0 112.383 -178.604 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -156.34 142.94 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.023 178.93 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.9 m -130.99 96.13 3.98 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 119.784 -0.766 . . . . 0.0 111.265 -179.287 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . 0.431 ' C ' ' HG1' ' A' ' 73' ' ' THR . 11.7 mt -79.58 161.3 26.02 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.045 -1.062 . . . . 0.0 109.134 179.172 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 73' ' ' THR . . . . . 0.431 ' HG1' ' C ' ' A' ' 72' ' ' LEU . 0.2 OUTLIER -150.46 45.47 0.87 Allowed 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 118.596 -1.242 . . . . 0.0 112.242 -178.688 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 74' ' ' GLU . . . . . 0.43 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 29.2 mm-40 -143.82 105.7 4.34 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 118.876 -1.13 . . . . 0.0 110.269 179.279 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -43.51 109.93 0.17 Allowed 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.816 -179.296 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.98 -147.89 8.95 Favored Glycine 0 N--CA 1.486 1.989 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.417 -179.918 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.55 131.65 21.81 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.598 -0.841 . . . . 0.0 110.807 -179.898 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 78' ' ' TYR . . . . . 0.595 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -119.6 129.61 54.7 Favored 'General case' 0 N--CA 1.486 1.336 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.578 -179.942 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -101.3 121.21 41.48 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 119.424 -0.91 . . . . 0.0 111.827 -179.49 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.7 p90 -131.48 166.34 21.55 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.816 -0.753 . . . . 0.0 110.009 178.161 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 29.6 p90 -170.29 -176.85 2.31 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.105 -1.038 . . . . 0.0 111.409 -178.355 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -102.21 130.75 48.96 Favored 'General case' 0 N--CA 1.482 1.154 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.301 179.16 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.55 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.9 OUTLIER -77.3 -44.64 2.68 Favored Pre-proline 0 N--CA 1.485 1.279 0 C-N-CA 119.328 -0.949 . . . . 0.0 112.713 -179.71 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 84' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 4.1 Cg_exo -65.57 -52.91 0.88 Allowed 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 120.914 1.076 . . . . 0.0 111.535 -179.096 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . 0.509 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.4 m80 -81.94 15.58 2.22 Favored 'General case' 0 C--N 1.302 -1.46 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.804 -179.874 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.65 -0.94 0.32 Allowed 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.107 -179.938 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 87' ' ' GLY . . . . . 0.509 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -95.15 -14.14 49.73 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.324 -1.417 . . . . 0.0 110.361 179.951 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.14 -51.89 4.82 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.596 179.925 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.26 24.75 0.2 Allowed Glycine 0 N--CA 1.488 2.166 0 C-N-CA 119.537 -1.316 . . . . 0.0 110.502 179.901 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.1 mtp -73.16 97.99 2.51 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.148 -1.021 . . . . 0.0 110.962 -179.95 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.3 ptpt -119.7 154.99 33.28 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.507 179.22 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.4 145.66 16.31 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.396 -1.383 . . . . 0.0 111.399 -178.764 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -152.2 143.78 23.49 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.486 -0.886 . . . . 0.0 111.062 179.636 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 12.3 p -137.16 125.2 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.678 179.159 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 46.2 m -102.56 99.18 9.17 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.549 179.408 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 40.3 t -79.69 147.84 6.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 C-N-CA 118.763 -1.175 . . . . 0.0 110.633 -178.843 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 116.285 -1.816 . . . . 0.0 110.75 -179.697 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 109.908 -0.405 . . . . 0.0 109.908 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -131.17 122.15 26.1 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.823 -0.751 . . . . 0.0 110.835 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.6 t -115.15 126.59 72.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 119.966 -0.694 . . . . 0.0 110.33 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 22.1 mtmt -101.72 116.15 32.1 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.918 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.0 mt -79.56 114.64 18.64 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.167 -1.013 . . . . 0.0 109.971 178.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.499 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 96.83 108.02 2.49 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.491 -1.338 . . . . 0.0 109.787 -179.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.546 ' OG ' ' N ' ' A' ' 11' ' ' GLY . 3.0 p -67.52 164.14 19.59 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.934 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.33 -10.79 59.93 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.473 -0.891 . . . . 0.0 110.877 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -170.28 -9.7 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.876 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -74.47 -23.45 75.44 Favored Glycine 0 N--CA 1.491 2.357 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.453 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.546 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . 119.99 -142.06 15.86 Favored Glycine 0 N--CA 1.497 2.717 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.2 mt -103.29 102.52 12.48 Favored 'General case' 0 N--CA 1.49 1.527 0 C-N-CA 119.696 -0.802 . . . . 0.0 110.658 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.7 m -150.48 158.11 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 119.009 -1.076 . . . . 0.0 110.999 179.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.535 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 16.7 m-85 -78.8 111.96 15.45 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 177.628 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.0 m -114.4 107.62 51.06 Favored Pre-proline 0 N--CA 1.484 1.264 0 C-N-CA 119.421 -0.911 . . . . 0.0 112.226 -177.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.413 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.0 OUTLIER -67.64 176.58 25.44 Favored 'Cis proline' 0 C--N 1.362 1.275 0 C-N-CA 125.4 -0.667 . . . . 0.0 111.6 -0.555 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -92.49 -58.8 2.25 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.014 179.118 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.2 t -124.06 138.55 54.43 Favored 'General case' 0 N--CA 1.487 1.4 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.265 178.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.41 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 9.0 p90 -159.72 136.06 8.96 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 118.328 -1.349 . . . . 0.0 111.706 -178.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -85.98 150.67 24.32 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.329 179.436 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.3 m -144.21 177.79 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.179 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -98.05 145.79 26.18 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.68 -0.808 . . . . 0.0 110.365 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.4 88.9 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.122 -1.031 . . . . 0.0 110.934 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 139.16 19.73 0.46 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -96.28 137.67 35.0 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.715 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 54.1 mttm -84.89 120.11 26.1 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.248 -0.981 . . . . 0.0 110.924 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.7 mt -109.27 110.88 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.038 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 30.3 p -106.2 116.92 32.77 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.379 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 94.2 m-85 -85.86 103.59 14.74 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.023 178.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.6 tttm -101.7 135.19 43.66 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.758 -0.777 . . . . 0.0 112.218 -177.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.471 ' N ' ' OD1' ' A' ' 31' ' ' ASN . 1.3 m-20 -76.71 126.24 30.64 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.935 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 0.9 OUTLIER -106.78 -32.62 7.88 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.086 -1.046 . . . . 0.0 113.136 -178.371 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 178.11 11.94 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.387 0 C-N-CA 119.052 -1.059 . . . . 0.0 111.729 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -124.88 49.68 0.9 Allowed Glycine 0 N--CA 1.5 2.931 0 C-N-CA 119.35 -1.405 . . . . 0.0 112.104 -178.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.596 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -91.06 161.31 35.63 Favored Pre-proline 0 N--CA 1.488 1.428 0 C-N-CA 118.35 -1.34 . . . . 0.0 110.291 178.805 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -78.17 142.42 69.6 Favored 'Cis proline' 0 C--O 1.215 -0.658 0 C-N-CA 124.004 -1.248 . . . . 0.0 111.825 -1.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.524 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 36.9 m-70 -107.26 162.38 13.95 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.596 -0.842 . . . . 0.0 111.016 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -144.6 137.76 26.94 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 119.607 -0.837 . . . . 0.0 109.852 179.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.4 mp -127.29 117.46 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.16 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.58 142.84 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.765 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 7.5 m-85 -95.08 117.74 30.7 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.738 -178.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.513 ' C ' ' H ' ' A' ' 44' ' ' ASP . 21.6 t0 -55.4 99.33 0.03 OUTLIER 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.374 179.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -64.01 5.26 0.25 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.446 -0.902 . . . . 0.0 111.392 -179.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.513 ' H ' ' C ' ' A' ' 42' ' ' ASP . 9.6 m-20 -99.78 -8.67 23.91 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.915 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -134.6 16.33 3.65 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.957 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -95.53 147.03 32.36 Favored Pre-proline 0 N--CA 1.49 1.529 0 N-CA-C 108.957 -0.756 . . . . 0.0 108.957 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -47.84 142.73 14.3 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.958 1.105 . . . . 0.0 111.799 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.2 70.64 1.63 Allowed 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.712 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.46 -37.75 0.12 Allowed Glycine 0 N--CA 1.488 2.102 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.077 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 15.4 t -86.22 104.9 14.15 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.789 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -48.28 147.7 2.18 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.738 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -99.46 -5.81 28.73 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.918 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.07 -30.45 17.7 Favored 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.511 -0.876 . . . . 0.0 111.19 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 36.0 mttt -69.25 -29.91 67.92 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.148 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.1 pt -94.16 -37.52 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.748 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 57.7 m -64.01 159.62 19.68 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.537 -0.865 . . . . 0.0 111.253 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.611 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -139.66 75.67 31.15 Favored Pre-proline 0 N--CA 1.486 1.361 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.398 179.635 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -57.63 -21.76 48.62 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 121.262 1.308 . . . . 0.0 111.567 -179.078 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.21 95.67 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.021 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -42.71 163.11 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.799 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -150.09 111.64 4.48 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 118.862 -1.135 . . . . 0.0 111.878 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -106.33 21.66 17.03 Favored 'General case' 0 N--CA 1.488 1.475 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.918 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -83.65 137.66 16.5 Favored Glycine 0 N--CA 1.494 2.53 0 C-N-CA 119.355 -1.403 . . . . 0.0 110.655 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -82.32 114.48 20.82 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.533 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.07 -13.67 66.62 Favored Glycine 0 N--CA 1.488 2.147 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.506 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.25 150.34 26.05 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.209 -0.996 . . . . 0.0 110.31 179.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.57 168.75 19.88 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 118.981 -1.087 . . . . 0.0 111.884 -179.599 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.611 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 29.3 t80 -135.29 129.88 34.24 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.555 179.228 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.96 152.86 21.01 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.306 -178.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.1 t -151.79 130.78 3.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 CA-C-N 115.105 -0.952 . . . . 0.0 108.844 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 20.6 m -129.86 93.93 3.62 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.652 -0.819 . . . . 0.0 111.226 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 13.7 mt -79.39 157.98 27.49 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.213 -0.995 . . . . 0.0 109.507 179.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' THR . . . . . 0.437 ' O ' ' OG1' ' A' ' 73' ' ' THR . 2.2 t -149.94 46.07 0.92 Allowed 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 118.793 -1.163 . . . . 0.0 111.649 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.416 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 5.6 tt0 -144.93 99.98 3.42 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 118.977 -1.089 . . . . 0.0 109.913 179.048 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.404 ' C ' ' O ' ' A' ' 74' ' ' GLU . 0.0 OUTLIER -39.45 112.48 0.26 Allowed 'General case' 0 N--CA 1.484 1.239 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.344 -179.124 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.76 -148.88 10.0 Favored Glycine 0 N--CA 1.484 1.849 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.004 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.96 132.34 25.09 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.922 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.562 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.2 m-85 -120.8 126.01 49.03 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.66 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.442 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -100.4 114.11 27.39 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.78 -179.361 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.594 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -125.02 169.74 11.83 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.09 178.686 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -171.25 -179.76 2.76 Favored 'General case' 0 C--N 1.297 -1.694 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.073 -179.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 2.1 t -106.39 115.31 29.99 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.504 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.563 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 tt0 -66.87 -40.38 29.77 Favored Pre-proline 0 C--N 1.3 -1.576 0 C-N-CA 119.379 -0.928 . . . . 0.0 112.724 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.563 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.4 Cg_endo -68.95 -47.69 1.12 Allowed 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 120.822 1.015 . . . . 0.0 112.03 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -87.87 12.15 13.84 Favored 'General case' 0 N--CA 1.487 1.423 0 C-N-CA 119.238 -0.985 . . . . 0.0 111.296 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.72 -24.4 61.42 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.771 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -62.24 -22.19 62.8 Favored Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.514 -1.327 . . . . 0.0 110.414 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.92 -31.83 14.8 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.621 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 117.21 30.22 1.96 Allowed Glycine 0 N--CA 1.495 2.611 0 C-N-CA 119.991 -1.1 . . . . 0.0 110.495 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.3 mtp -77.88 105.52 9.12 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.862 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.535 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 0.6 OUTLIER -127.61 166.89 17.19 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 119.956 -0.698 . . . . 0.0 110.777 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -147.83 148.44 19.98 Favored Glycine 0 N--CA 1.488 2.104 0 C-N-CA 119.018 -1.563 . . . . 0.0 111.286 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -153.63 141.64 20.28 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.625 179.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.2 p -136.87 125.26 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.624 179.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 95.8 m -103.32 98.71 8.58 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.409 -0.916 . . . . 0.0 110.645 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 41.1 t -80.03 148.3 5.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.255 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 6.7 m-80 . . . . . 0 C--N 1.304 -1.41 0 CA-C-O 116.344 -1.789 . . . . 0.0 111.007 -179.554 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.105 0 CA-C-O 120.792 0.33 . . . . 0.0 110.197 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -130.19 121.46 26.27 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.54 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.8 t -112.87 122.02 66.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.682 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 60.8 mttt -94.53 116.61 28.98 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.761 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.434 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 8.5 mt -76.21 102.4 5.79 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 118.615 -1.234 . . . . 0.0 109.525 178.18 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 121.25 155.7 9.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.031 -1.627 . . . . 0.0 109.031 -178.204 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.2 p -87.44 -81.29 0.24 Allowed 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 119.039 -1.064 . . . . 0.0 111.047 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -161.12 -25.31 0.06 Allowed 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.802 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 9' ' ' ASP . 0.6 OUTLIER 178.5 78.4 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.26 -0.976 . . . . 0.0 111.068 179.837 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.83 39.68 2.29 Favored Glycine 0 N--CA 1.495 2.589 0 C-N-CA 119.775 -1.202 . . . . 0.0 110.713 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -157.47 110.3 0.44 Allowed Glycine 0 N--CA 1.489 2.169 0 C-N-CA 119.332 -1.413 . . . . 0.0 110.357 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 80.1 mt -99.04 100.55 11.71 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 119.527 -0.869 . . . . 0.0 110.382 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 m -149.71 154.78 8.77 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 C-N-CA 118.74 -1.184 . . . . 0.0 111.072 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' A' ' 16' ' ' PRO . 17.2 m-85 -78.2 110.16 12.94 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.7 m -115.0 109.01 47.5 Favored Pre-proline 0 CA--C 1.562 1.41 0 C-N-CA 119.369 -0.933 . . . . 0.0 112.503 -177.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.421 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.9 Cg_endo -66.66 178.35 17.84 Favored 'Cis proline' 0 C--N 1.364 1.348 0 C-N-CA 125.27 -0.721 . . . . 0.0 111.484 -0.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.6 p -94.94 -60.43 1.69 Allowed 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.933 179.177 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.2 p -121.05 135.41 55.2 Favored 'General case' 0 N--CA 1.486 1.34 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.076 178.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.465 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 14.4 p90 -157.88 140.74 14.89 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 118.528 -1.269 . . . . 0.0 111.49 -178.729 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -87.77 153.45 21.33 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.357 -0.937 . . . . 0.0 110.633 179.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.1 m -145.94 158.76 11.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.105 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.421 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -75.04 145.88 42.02 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.211 -0.996 . . . . 0.0 110.427 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.27 73.03 0.12 Allowed 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.459 -0.896 . . . . 0.0 110.9 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 160.98 11.15 0.04 OUTLIER Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -98.81 157.14 16.49 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.913 -179.532 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.4 mmtp -95.48 134.2 38.6 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.33 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.9 mt -107.09 104.36 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 120.076 -0.649 . . . . 0.0 109.358 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 52.3 p -101.41 117.57 35.21 Favored 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 119.553 -0.859 . . . . 0.0 112.612 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -91.16 109.76 21.03 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.12 178.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 31.0 tttt -103.14 135.14 45.37 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.58 -178.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 1.0 OUTLIER -84.67 106.11 15.98 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.258 -0.977 . . . . 0.0 110.108 179.237 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.434 ' OD1' ' O ' ' A' ' 5' ' ' LEU . 4.3 p-10 -93.36 -28.6 16.07 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.208 -0.997 . . . . 0.0 112.016 -178.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 175.44 133.57 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 118.55 -1.26 . . . . 0.0 111.371 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 111.48 5.97 25.73 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.782 -1.199 . . . . 0.0 111.579 179.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.452 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -52.47 162.54 0.89 Allowed Pre-proline 0 N--CA 1.488 1.437 0 C-N-CA 118.188 -1.405 . . . . 0.0 109.744 179.814 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -78.76 161.62 88.95 Favored 'Cis proline' 0 C--O 1.212 -0.798 0 C-N-CA 124.38 -1.091 . . . . 0.0 112.636 -0.689 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -125.75 172.7 9.6 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.952 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.418 HD21 ' CG2' ' A' ' 40' ' ' VAL . 0.7 OUTLIER -153.49 117.53 4.81 Favored 'General case' 0 N--CA 1.492 1.67 0 C-N-CA 118.978 -1.089 . . . . 0.0 110.622 179.185 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.586 ' N ' ' CD1' ' A' ' 39' ' ' ILE . 2.4 mp -96.18 129.71 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.146 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.418 ' CG2' HD21 ' A' ' 38' ' ' ASN . 2.6 t -143.31 138.63 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 C-N-CA 119.679 -0.808 . . . . 0.0 110.427 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 9.1 m-85 -98.33 118.26 34.59 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.206 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.524 ' OD2' ' N ' ' A' ' 45' ' ' GLU . 11.2 t70 -53.1 120.4 5.86 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.348 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -73.57 0.47 12.51 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.433 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.404 ' N ' ' OD2' ' A' ' 42' ' ' ASP . 14.6 m-20 -107.99 4.2 24.92 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.813 -0.755 . . . . 0.0 111.135 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.524 ' N ' ' OD2' ' A' ' 42' ' ' ASP . 34.5 mt-10 -146.18 52.56 1.14 Allowed 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 119.486 -0.886 . . . . 0.0 110.835 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -137.03 148.36 62.52 Favored Pre-proline 0 N--CA 1.493 1.676 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -49.58 145.78 16.31 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 121.061 1.174 . . . . 0.0 111.678 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.89 81.92 2.8 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.709 -0.796 . . . . 0.0 111.025 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 161.54 -41.95 0.4 Allowed Glycine 0 N--CA 1.489 2.174 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.312 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 92.0 t -81.96 95.94 3.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.348 -0.941 . . . . 0.0 110.84 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -44.94 143.76 1.39 Allowed 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.969 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.412 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -95.54 -2.04 49.3 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.625 -0.83 . . . . 0.0 110.898 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -86.55 -35.13 19.7 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.98 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 30.7 mttt -68.75 -34.38 75.5 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.581 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.1 pt -89.94 -29.68 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 C-N-CA 118.938 -1.105 . . . . 0.0 111.062 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.412 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 7.6 m -58.95 -178.63 0.05 Allowed 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.928 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.614 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 61.2 mt-30 -146.38 73.19 13.02 Favored Pre-proline 0 N--CA 1.484 1.274 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.031 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -62.39 -4.52 5.5 Favored 'Trans proline' 0 C--N 1.321 -0.879 0 C-N-CA 121.094 1.196 . . . . 0.0 110.984 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.405 ' H ' ' C ' ' A' ' 57' ' ' GLN . 16.0 mt-10 -100.31 99.98 10.71 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.828 -0.749 . . . . 0.0 110.545 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -47.54 164.49 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.411 -0.916 . . . . 0.0 110.92 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.1 pp -142.32 135.95 29.21 Favored 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.96 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -135.46 42.41 2.7 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.664 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -102.5 128.28 9.49 Favored Glycine 0 N--CA 1.495 2.595 0 C-N-CA 119.584 -1.293 . . . . 0.0 110.532 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -78.06 108.22 11.19 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.628 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.51 -6.37 59.14 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.325 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -71.96 157.69 37.37 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.555 179.835 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 4.9 p -148.64 163.29 37.71 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.051 -1.059 . . . . 0.0 111.229 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.614 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 28.5 t80 -134.7 139.16 45.02 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.651 179.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.411 ' CD ' ' H ' ' A' ' 69' ' ' GLU . 1.7 mp0 -102.76 148.5 25.53 Favored 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 119.434 -0.907 . . . . 0.0 112.252 -178.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -142.82 126.05 14.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 115.124 -0.943 . . . . 0.0 108.748 179.208 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.0 m -117.47 112.82 21.15 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.61 -0.836 . . . . 0.0 112.039 -178.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 58.3 mt -95.88 161.7 13.89 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.47 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 87.9 m -150.57 42.61 0.81 Allowed 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 118.662 -1.215 . . . . 0.0 112.044 -179.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -147.9 102.97 3.45 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 118.658 -1.217 . . . . 0.0 110.33 179.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.472 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 11.5 pttt -43.97 120.2 2.0 Allowed 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.723 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.446 ' C ' ' HG1' ' A' ' 77' ' ' THR . . . 169.45 -147.01 10.58 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.807 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' THR . . . . . 0.446 ' HG1' ' C ' ' A' ' 76' ' ' GLY . 0.1 OUTLIER -143.25 128.85 19.16 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.405 -0.918 . . . . 0.0 111.248 -179.864 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.562 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -115.73 136.87 52.64 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.422 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.412 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -107.86 116.27 31.64 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.634 -0.826 . . . . 0.0 111.541 -179.348 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.489 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 2.4 p90 -130.26 166.8 19.58 Favored 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.082 178.485 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -170.46 -172.74 1.3 Allowed 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.682 -178.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -107.32 126.08 51.99 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.756 179.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.499 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.9 mt-10 -68.78 -47.11 33.18 Favored Pre-proline 0 C--N 1.305 -1.336 0 C-N-CA 119.593 -0.843 . . . . 0.0 112.599 -179.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.499 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.9 Cg_endo -64.72 -47.77 4.89 Favored 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 120.719 0.946 . . . . 0.0 111.746 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -90.84 19.88 5.21 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.808 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.44 -14.23 11.63 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.346 -0.942 . . . . 0.0 110.462 179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -93.76 -12.47 56.75 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.151 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.01 -13.53 38.59 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.597 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 96.96 25.6 11.23 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.605 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.64 99.77 10.42 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.234 -0.987 . . . . 0.0 111.022 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -120.97 159.7 25.06 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.793 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.74 143.03 11.47 Favored Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.337 -1.411 . . . . 0.0 111.071 -179.049 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -150.68 144.74 25.39 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.35 179.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.0 p -135.24 125.73 44.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.689 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 55.0 m -101.67 98.22 8.54 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.274 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 41.2 t -79.75 152.51 4.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 118.587 -1.245 . . . . 0.0 110.734 -178.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 116.283 -1.818 . . . . 0.0 110.826 -179.688 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.118 0 CA-C-O 120.78 0.324 . . . . 0.0 110.142 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.439 ' OE1' ' O ' ' A' ' 28' ' ' THR . 3.1 mm-40 -140.19 121.0 14.43 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.618 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -108.72 120.54 60.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 C-N-CA 119.917 -0.713 . . . . 0.0 110.509 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.7 mttt -91.16 114.55 27.11 Favored 'General case' 0 C--N 1.299 -1.59 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.992 -179.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.0 mt -74.51 113.84 12.22 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.239 178.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.47 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 99.28 124.13 5.12 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.488 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.591 ' HG ' ' N ' ' A' ' 11' ' ' GLY . 16.6 p -66.29 -179.16 0.74 Allowed 'General case' 0 C--N 1.302 -1.46 0 C-N-CA 119.324 -0.951 . . . . 0.0 110.428 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -91.93 -40.59 11.06 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.508 179.624 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.472 ' CG ' ' N ' ' A' ' 10' ' ' GLY . 6.2 p-10 -63.21 -44.88 94.07 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.792 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.472 ' N ' ' CG ' ' A' ' 9' ' ' ASP . . . 147.18 69.47 0.01 OUTLIER Glycine 0 N--CA 1.489 2.223 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.404 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.591 ' N ' ' HG ' ' A' ' 7' ' ' SER . . . -151.01 157.01 26.97 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.39 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.3 mt -107.02 90.31 3.26 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.983 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.4 m -144.25 155.86 15.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 C-N-CA 119.098 -1.041 . . . . 0.0 110.674 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.401 ' O ' ' C ' ' A' ' 16' ' ' PRO . 16.6 m-85 -77.36 112.98 14.67 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 177.895 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.8 m -114.89 108.46 48.66 Favored Pre-proline 0 CA--C 1.558 1.283 0 C-N-CA 119.219 -0.992 . . . . 0.0 112.007 -177.348 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.401 ' C ' ' O ' ' A' ' 14' ' ' PHE . 3.2 Cg_exo -67.5 170.71 46.55 Favored 'Cis proline' 0 C--N 1.362 1.269 0 C-N-CA 125.321 -0.7 . . . . 0.0 111.597 -0.536 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.5 t -90.23 -64.51 1.12 Allowed 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.543 178.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.35 139.58 50.25 Favored 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.199 178.69 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.401 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 9.5 p90 -167.95 139.45 2.91 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 118.468 -1.293 . . . . 0.0 111.424 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -85.06 159.12 20.26 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.623 -0.831 . . . . 0.0 111.411 -179.591 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 25.9 m -146.69 -177.75 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.059 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.87 148.95 21.76 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.438 -0.905 . . . . 0.0 111.015 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.39 68.48 0.54 Allowed 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.042 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 159.21 14.03 0.04 OUTLIER Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -97.36 155.95 16.67 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.907 -0.717 . . . . 0.0 111.038 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 13.7 mttp -95.44 138.53 33.0 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.76 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.9 mt -117.65 127.58 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.443 179.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.439 ' O ' ' OE1' ' A' ' 2' ' ' GLU . 7.6 p -125.51 119.07 27.18 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.544 -0.862 . . . . 0.0 112.17 -178.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -84.91 110.37 18.81 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.489 -0.885 . . . . 0.0 109.024 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 50.0 tttp -101.45 139.13 37.54 Favored 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.158 -178.272 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -86.45 112.57 21.62 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.47 179.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.484 ' O ' ' CB ' ' A' ' 33' ' ' ALA . 1.0 OUTLIER -95.66 -30.8 13.57 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 119.224 -0.991 . . . . 0.0 111.543 -179.227 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.484 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 164.69 118.08 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 119.349 -0.94 . . . . 0.0 111.182 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 138.6 -1.03 2.57 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.957 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.409 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -47.69 164.66 0.24 Allowed Pre-proline 0 C--N 1.307 -1.281 0 C-N-CA 118.839 -1.144 . . . . 0.0 110.137 -179.835 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_endo -75.99 138.9 57.6 Favored 'Cis proline' 0 C--O 1.214 -0.722 0 C-N-CA 124.292 -1.128 . . . . 0.0 112.633 -0.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.5 m-70 -110.3 156.4 20.77 Favored 'General case' 0 N--CA 1.485 1.295 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.205 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.429 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 6.2 t30 -148.42 116.23 6.35 Favored 'General case' 0 C--N 1.3 -1.58 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.136 179.251 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.7 mp -96.64 137.22 25.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.652 -178.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.429 ' CG2' ' ND2' ' A' ' 38' ' ' ASN . 1.5 t -146.54 149.42 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.987 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -107.58 118.28 36.32 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.712 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.516 ' OD2' ' N ' ' A' ' 45' ' ' GLU . 1.6 t70 -55.58 119.32 5.5 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 119.576 -0.849 . . . . 0.0 110.28 179.47 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -75.5 14.21 0.65 Allowed 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 119.393 -0.923 . . . . 0.0 111.55 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.414 ' H ' ' C ' ' A' ' 42' ' ' ASP . 4.0 m-20 -115.39 2.1 13.86 Favored 'General case' 0 N--CA 1.495 1.779 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.049 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.548 ' OE1' ' NZ ' ' A' ' 79' ' ' LYS . 11.8 mm-40 -140.6 19.3 2.36 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 119.657 -0.817 . . . . 0.0 110.446 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -107.69 147.12 34.76 Favored Pre-proline 0 N--CA 1.488 1.471 0 CA-C-N 115.23 -0.895 . . . . 0.0 108.856 179.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -48.6 145.24 12.76 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 120.804 1.003 . . . . 0.0 111.718 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.35 50.56 0.79 Allowed 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.935 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -160.6 -31.11 0.02 OUTLIER Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 86.3 t -96.18 90.69 2.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.745 -0.782 . . . . 0.0 110.638 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -45.95 139.89 4.05 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.888 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.08 -26.35 36.33 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.62 -0.832 . . . . 0.0 111.109 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -67.48 -19.89 65.39 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.456 -0.898 . . . . 0.0 110.93 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -78.03 -38.01 45.62 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.876 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.7 pt -94.26 -26.41 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.306 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.0 m -72.35 155.89 39.67 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.431 -0.908 . . . . 0.0 111.297 -179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.621 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.1 OUTLIER -137.95 75.98 40.8 Favored Pre-proline 0 C--N 1.303 -1.432 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.972 179.484 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.412 ' O ' ' OD1' ' A' ' 38' ' ' ASN . 5.2 Cg_exo -56.5 -29.07 76.82 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 121.234 1.289 . . . . 0.0 111.496 -178.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -52.96 103.67 0.08 Allowed 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 118.813 -1.155 . . . . 0.0 109.844 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 46.8 m-85 -42.63 161.56 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.69 -0.804 . . . . 0.0 111.105 -179.388 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.475 ' C ' ' CD1' ' A' ' 61' ' ' LEU . 0.3 OUTLIER -143.65 148.08 35.27 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.542 -0.863 . . . . 0.0 110.239 -179.644 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.664 HD21 ' N ' ' A' ' 63' ' ' GLY . 0.0 OUTLIER -148.2 -12.56 0.36 Allowed 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.265 -179.83 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.664 ' N ' HD21 ' A' ' 62' ' ' ASN . . . -48.74 115.82 2.84 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.203 -1.475 . . . . 0.0 110.403 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.51 119.92 10.1 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.962 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.85 -21.29 27.62 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.639 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -58.05 153.76 13.98 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.048 -1.061 . . . . 0.0 110.326 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -140.68 170.01 16.56 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 119.329 -0.948 . . . . 0.0 111.67 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.621 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 22.8 t80 -130.96 130.98 44.11 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.284 179.361 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -93.33 150.76 20.23 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 119.081 -1.048 . . . . 0.0 112.716 -178.11 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -151.59 136.52 10.28 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-N 115.127 -0.942 . . . . 0.0 108.933 179.246 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.3 m -127.31 104.65 8.05 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.521 -0.871 . . . . 0.0 111.503 -179.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 49.6 mt -88.17 155.14 19.92 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.001 179.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 4.8 p -150.92 47.32 0.85 Allowed 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.935 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.439 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 1.5 mm-40 -144.18 108.48 4.81 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.099 -1.041 . . . . 0.0 110.722 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.508 ' H ' ' HZ2' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -49.79 114.33 1.05 Allowed 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 119.372 -0.931 . . . . 0.0 110.854 -179.572 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 165.28 -137.74 4.86 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.183 -1.484 . . . . 0.0 110.235 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -149.46 143.0 25.4 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.286 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.563 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -127.34 123.74 37.02 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.37 179.716 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.548 ' NZ ' ' OE1' ' A' ' 45' ' ' GLU . 1.2 mptm? -95.43 119.67 34.34 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.728 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.551 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.2 p90 -130.31 171.91 12.4 Favored 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 119.571 -0.852 . . . . 0.0 109.978 177.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 42.5 p90 -171.83 -175.33 1.5 Allowed 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.922 -178.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -108.82 117.18 33.51 Favored 'General case' 0 C--N 1.31 -1.112 0 C-N-CA 119.856 -0.738 . . . . 0.0 109.713 178.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.561 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.4 tt0 -68.3 -39.59 17.0 Favored Pre-proline 0 C--N 1.303 -1.455 0 C-N-CA 119.431 -0.907 . . . . 0.0 112.89 -178.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.561 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.0 Cg_endo -68.99 -43.78 3.07 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 120.638 0.892 . . . . 0.0 111.699 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . 0.463 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.4 m80 -94.15 14.83 18.83 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.306 -0.958 . . . . 0.0 111.173 -179.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.52 0.27 1.65 Allowed 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.089 -1.044 . . . . 0.0 110.687 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.463 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -86.92 -18.05 58.62 Favored Glycine 0 N--CA 1.49 2.238 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.215 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -97.97 -19.99 17.7 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 119.615 -0.834 . . . . 0.0 110.675 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.73 22.0 6.2 Favored Glycine 0 N--CA 1.497 2.74 0 C-N-CA 119.877 -1.154 . . . . 0.0 110.624 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 9.6 ttt -71.22 108.72 4.85 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.494 -0.882 . . . . 0.0 110.832 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.406 ' CG ' ' N ' ' A' ' 92' ' ' GLY . 30.9 ttpt -137.13 159.91 40.53 Favored 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 119.754 -0.778 . . . . 0.0 111.299 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' A' ' 91' ' ' LYS . . . -140.84 156.97 25.71 Favored Glycine 0 N--CA 1.497 2.757 0 C-N-CA 119.688 -1.244 . . . . 0.0 111.559 -178.484 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -157.15 145.94 19.82 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 120.027 -0.669 . . . . 0.0 110.639 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.8 p -139.94 124.91 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 C-N-CA 119.106 -1.038 . . . . 0.0 110.937 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 34.0 m -102.68 103.17 13.41 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.543 -0.863 . . . . 0.0 110.582 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.497 ' C ' HD21 ' A' ' 97' ' ' ASN . 26.2 t -85.71 146.31 6.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 118.866 -1.133 . . . . 0.0 110.622 -178.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.497 HD21 ' C ' ' A' ' 96' ' ' VAL . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 116.375 -1.774 . . . . 0.0 110.661 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.17 0 CA-C-O 120.821 0.343 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -96.73 119.89 36.05 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.702 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 73.4 t -108.31 122.38 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.07 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 76.9 mttt -88.31 111.46 21.73 Favored 'General case' 0 C--N 1.297 -1.706 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.865 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 11.6 mt -73.91 110.08 7.92 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 118.539 -1.264 . . . . 0.0 109.763 178.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.54 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 98.86 126.51 5.64 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -179.109 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.509 ' HG ' ' N ' ' A' ' 10' ' ' GLY . 24.5 p -76.18 157.15 33.02 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.581 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -76.93 -20.48 56.13 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.87 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -164.04 68.74 0.18 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.711 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.509 ' N ' ' HG ' ' A' ' 7' ' ' SER . . . -165.25 -70.12 0.03 OUTLIER Glycine 0 N--CA 1.489 2.169 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.472 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -176.46 -158.04 19.02 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.387 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.0 mt -100.49 104.43 15.82 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 119.688 -0.805 . . . . 0.0 110.756 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 23.6 m -150.83 157.91 5.33 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.65 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.533 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 35.9 m-85 -78.15 113.63 16.28 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 177.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 18.5 m -115.54 109.77 45.53 Favored Pre-proline 0 CA--C 1.56 1.355 0 C-N-CA 119.515 -0.874 . . . . 0.0 112.187 -177.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -65.98 170.58 39.44 Favored 'Cis proline' 0 C--N 1.361 1.232 0 C-N-CA 125.123 -0.782 . . . . 0.0 111.567 -0.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.03 -68.64 0.79 Allowed 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.836 178.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.6 m -110.12 132.92 53.73 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.652 178.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 36.0 p90 -162.15 141.49 9.59 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 118.681 -1.208 . . . . 0.0 111.323 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -85.23 160.28 19.91 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.545 -0.862 . . . . 0.0 111.3 -179.577 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.4 m -149.29 179.11 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.645 179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -96.0 148.29 22.81 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 119.476 -0.89 . . . . 0.0 110.931 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.38 71.1 0.18 Allowed 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.229 179.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 157.52 16.19 0.04 OUTLIER Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 23.0 tt0 -102.8 154.89 18.74 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.682 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.3 mtpt -95.33 141.18 29.2 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.419 -0.912 . . . . 0.0 111.386 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.5 mt -119.78 114.81 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.435 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.4 p -111.41 120.97 43.96 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.53 -0.868 . . . . 0.0 112.616 -178.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -85.57 111.72 20.29 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.876 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.7 tttp -102.89 138.77 39.32 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 119.575 -0.85 . . . . 0.0 111.455 -178.078 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.466 ' ND2' ' O ' ' A' ' 66' ' ' GLU . 77.3 m-20 -80.53 110.54 16.1 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.805 179.678 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.54 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 2.0 t30 -98.34 -31.23 12.15 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.225 -0.99 . . . . 0.0 111.673 -179.318 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 170.52 128.19 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.383 -0.927 . . . . 0.0 111.214 179.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 119.5 11.08 7.48 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.789 -1.196 . . . . 0.0 111.355 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.431 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -60.62 163.44 9.15 Favored Pre-proline 0 N--CA 1.484 1.265 0 C-N-CA 118.391 -1.324 . . . . 0.0 110.042 179.819 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -76.92 146.33 83.6 Favored 'Cis proline' 0 C--O 1.217 -0.564 0 C-N-CA 124.145 -1.189 . . . . 0.0 112.636 -0.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 35.3 m-70 -110.67 -179.66 3.82 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.119 179.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -155.67 142.6 19.02 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.015 179.153 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 mt -125.2 121.78 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.247 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.0 t -144.8 143.86 22.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.149 179.395 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -96.32 135.99 37.41 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.877 -179.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.546 ' C ' ' H ' ' A' ' 44' ' ' ASP . 7.8 t0 -71.95 111.24 7.04 Favored 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.671 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -71.4 35.22 0.05 Allowed 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 119.526 -0.869 . . . . 0.0 110.858 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.546 ' H ' ' C ' ' A' ' 42' ' ' ASP . 13.6 m-20 -111.34 -15.65 13.55 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 120.092 -0.643 . . . . 0.0 111.364 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -145.81 -5.39 0.63 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 118.261 -1.376 . . . . 0.0 112.464 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -52.51 142.31 31.45 Favored Pre-proline 0 C--N 1.285 -2.216 0 C-N-CA 118.628 -1.229 . . . . 0.0 108.112 179.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -49.09 148.03 10.2 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 120.895 1.063 . . . . 0.0 112.236 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.25 64.55 2.06 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.722 -0.791 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.58 -39.48 0.06 OUTLIER Glycine 0 N--CA 1.488 2.147 0 C-N-CA 119.57 -1.3 . . . . 0.0 109.863 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 98.8 t -92.16 97.1 6.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.336 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -44.61 162.33 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.447 -0.901 . . . . 0.0 111.155 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -102.91 -29.01 11.69 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.919 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -78.97 -14.15 59.38 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.146 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 1.8 mptp? -81.9 -37.69 26.47 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.064 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -90.87 -17.93 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 C-N-CA 119.199 -1.0 . . . . 0.0 111.019 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 73.6 m -76.55 -177.44 4.19 Favored 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.256 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.638 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -159.96 78.55 2.67 Favored Pre-proline 0 C--N 1.304 -1.405 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.788 179.635 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -60.56 0.99 0.59 Allowed 'Trans proline' 0 C--O 1.213 -0.747 0 C-N-CA 121.372 1.381 . . . . 0.0 112.216 -178.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.485 ' H ' ' C ' ' A' ' 57' ' ' GLN . 6.9 tt0 -82.9 100.44 10.39 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 118.878 -1.129 . . . . 0.0 110.249 179.387 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.43 ' O ' ' O ' ' A' ' 59' ' ' GLU . 43.9 m-85 -41.92 164.79 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.932 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.0 pp -147.3 124.47 11.47 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.103 -1.039 . . . . 0.0 111.037 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.585 ' N ' ' ND2' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -120.8 32.55 5.93 Favored 'General case' 0 N--CA 1.496 1.875 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.706 -179.963 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -97.02 120.87 6.86 Favored Glycine 0 N--CA 1.494 2.56 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.8 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -68.67 118.5 11.74 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.544 -0.862 . . . . 0.0 110.774 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.03 -19.75 40.48 Favored Glycine 0 N--CA 1.488 2.159 0 C-N-CA 119.419 -1.372 . . . . 0.0 110.374 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.466 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 34.8 tt0 -56.99 153.7 10.84 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.22 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -144.88 169.37 18.19 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.212 -0.995 . . . . 0.0 111.579 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.638 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 29.2 t80 -134.73 139.06 44.9 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.141 178.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.486 ' H ' ' CD ' ' A' ' 69' ' ' GLU . 1.3 mp0 -100.32 148.24 24.9 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.181 -1.008 . . . . 0.0 112.755 -178.046 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.3 t -145.74 131.31 13.18 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 114.924 -1.035 . . . . 0.0 108.721 179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.1 m -123.2 113.69 19.28 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.905 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 46.2 mt -98.77 159.12 15.17 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.526 178.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.95 34.45 0.59 Allowed 'General case' 0 C--N 1.297 -1.702 0 C-N-CA 118.824 -1.151 . . . . 0.0 111.64 -178.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.446 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 2.3 mm-40 -137.87 102.38 4.7 Favored 'General case' 0 N--CA 1.492 1.654 0 C-N-CA 119.092 -1.043 . . . . 0.0 110.624 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.431 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 11.2 pttm -43.57 114.59 0.66 Allowed 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.884 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.18 -145.33 7.78 Favored Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.487 -1.34 . . . . 0.0 110.129 -179.407 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.06 128.93 20.61 Favored 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 119.303 -0.959 . . . . 0.0 111.557 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.578 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -121.66 138.85 54.17 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 115.242 -0.89 . . . . 0.0 108.922 179.303 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 12.4 mttp -111.19 127.77 55.7 Favored 'General case' 0 N--CA 1.493 1.689 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.767 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.541 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.6 OUTLIER -129.05 159.81 34.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.048 177.753 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -167.93 178.44 5.16 Favored 'General case' 0 C--N 1.286 -2.171 0 C-N-CA 119.621 -0.832 . . . . 0.0 110.593 -178.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -104.4 131.77 51.39 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.27 179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.496 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.6 mt-10 -71.48 -46.22 13.26 Favored Pre-proline 0 C--N 1.306 -1.308 0 C-N-CA 119.364 -0.934 . . . . 0.0 112.843 -179.596 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.0 Cg_endo -67.01 -45.1 4.33 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 120.902 1.068 . . . . 0.0 111.87 -179.402 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -93.52 22.81 5.04 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.886 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -68.5 -13.67 62.48 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.739 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -87.27 -12.3 67.88 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.261 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.54 -12.16 30.21 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.406 -0.918 . . . . 0.0 110.819 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.16 10.79 38.44 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.743 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -66.68 101.6 0.82 Allowed 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.364 -0.935 . . . . 0.0 111.081 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.533 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 18.4 mttp -129.11 173.18 10.7 Favored 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.349 -179.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -155.58 152.09 23.59 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.333 -1.413 . . . . 0.0 111.444 -178.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -155.75 144.95 20.76 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.789 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.4 p -136.46 124.33 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.809 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 68.6 m -100.73 97.92 8.52 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.254 179.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.7 t -79.53 151.9 4.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 119.097 -1.041 . . . . 0.0 110.622 -178.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 10.8 m120 . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 116.319 -1.8 . . . . 0.0 110.783 -179.99 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.087 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -134.31 118.37 17.45 Favored 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.685 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.2 t -102.76 123.51 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 C-N-CA 119.713 -0.795 . . . . 0.0 110.51 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.451 ' CD ' ' HZ1' ' A' ' 30' ' ' LYS . 1.5 mmmm -95.42 117.55 30.56 Favored 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.111 -179.431 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 3.6 mt -86.52 109.85 19.38 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.012 -1.075 . . . . 0.0 110.013 178.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.433 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 101.42 93.56 2.19 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.844 -1.17 . . . . 0.0 110.214 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.6 p -47.41 159.17 0.14 Allowed 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.932 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -74.37 -50.3 19.19 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 119.438 -0.905 . . . . 0.0 110.773 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.449 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 1.4 p-10 -44.21 -45.26 8.35 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.744 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 140.37 68.22 0.04 OUTLIER Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.646 -1.264 . . . . 0.0 110.274 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -153.18 150.0 21.66 Favored Glycine 0 N--CA 1.488 2.145 0 C-N-CA 119.221 -1.466 . . . . 0.0 110.514 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt -99.89 94.81 6.5 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.628 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.7 m -150.4 158.39 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 118.624 -1.23 . . . . 0.0 111.57 179.399 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.447 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 18.2 m-85 -78.84 110.45 14.04 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 177.274 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 38.7 m -116.35 108.48 45.51 Favored Pre-proline 0 C--N 1.304 -1.394 0 C-N-CA 119.54 -0.864 . . . . 0.0 112.08 -177.382 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -66.0 175.0 24.47 Favored 'Cis proline' 0 C--N 1.357 0.98 0 C-N-CA 125.312 -0.703 . . . . 0.0 111.8 -0.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.41 ' HG ' ' N ' ' A' ' 18' ' ' SER . 2.2 t -95.71 -64.96 1.01 Allowed 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.706 178.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.41 ' N ' ' HG ' ' A' ' 17' ' ' SER . 81.4 p -118.63 128.3 54.41 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.958 178.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.476 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 12.6 p90 -156.23 145.68 20.8 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 118.477 -1.289 . . . . 0.0 111.255 -178.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -87.46 158.67 18.91 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 119.376 -0.93 . . . . 0.0 111.278 -179.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.0 m -147.39 169.18 4.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.569 179.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -85.83 147.36 26.33 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.664 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.99 73.02 0.18 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.309 -179.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 154.47 15.83 0.05 OUTLIER Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -98.8 154.82 17.72 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.667 -0.813 . . . . 0.0 110.983 -179.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 12.7 mttm -95.43 136.92 35.19 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.549 -0.86 . . . . 0.0 111.136 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 85.6 mt -115.19 104.92 17.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.611 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 26.7 p -99.98 114.65 28.07 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.532 -0.867 . . . . 0.0 112.215 -178.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -85.07 127.74 34.35 Favored 'General case' 0 C--N 1.309 -1.188 0 C-N-CA 119.277 -0.969 . . . . 0.0 109.241 178.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.451 ' HZ1' ' CD ' ' A' ' 4' ' ' LYS . 23.7 tttm -124.41 131.49 53.5 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 119.892 -0.723 . . . . 0.0 111.341 -179.059 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.625 HD22 ' H ' ' A' ' 66' ' ' GLU . 31.3 p-10 -90.15 127.26 36.06 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.355 -0.938 . . . . 0.0 109.792 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.433 ' OD1' ' O ' ' A' ' 6' ' ' GLY . 2.6 p-10 -127.65 -6.4 5.73 Favored 'General case' 0 N--CA 1.495 1.787 0 C-N-CA 118.939 -1.104 . . . . 0.0 112.871 -178.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 177.7 90.74 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 117.982 -1.487 . . . . 0.0 112.184 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 135.73 28.83 0.38 Allowed Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.455 -1.355 . . . . 0.0 111.114 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.596 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -75.95 162.29 72.35 Favored Pre-proline 0 N--CA 1.483 1.191 0 C-N-CA 118.297 -1.361 . . . . 0.0 109.829 179.627 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -79.88 148.55 79.37 Favored 'Cis proline' 0 C--O 1.211 -0.853 0 C-N-CA 124.185 -1.173 . . . . 0.0 112.531 -0.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -110.64 170.96 7.75 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.914 -0.715 . . . . 0.0 110.162 178.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.432 ' OD1' ' CD2' ' A' ' 60' ' ' TYR . 1.0 OUTLIER -149.46 151.87 34.7 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.193 -1.003 . . . . 0.0 110.646 179.525 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.4 mt -132.74 114.51 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 C-N-CA 119.771 -0.772 . . . . 0.0 111.019 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.0 t -131.14 141.97 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.732 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -100.02 120.12 39.33 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 119.278 -0.969 . . . . 0.0 112.085 -179.109 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.556 ' C ' ' H ' ' A' ' 44' ' ' ASP . 1.6 t0 -65.77 114.42 5.03 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.39 -0.924 . . . . 0.0 109.709 178.992 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.35 15.1 0.06 Allowed 'General case' 0 N--CA 1.491 1.609 0 C-N-CA 119.274 -0.97 . . . . 0.0 111.592 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.556 ' H ' ' C ' ' A' ' 42' ' ' ASP . 3.0 m-20 -101.86 -2.79 29.14 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.224 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -143.1 14.64 1.87 Allowed 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.213 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -96.83 145.51 29.71 Favored Pre-proline 0 C--N 1.299 -1.599 0 C-N-CA 119.868 -0.733 . . . . 0.0 109.107 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -52.9 154.1 13.72 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 120.785 0.99 . . . . 0.0 111.63 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.53 44.08 0.78 Allowed 'General case' 0 C--N 1.307 -1.278 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.584 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -147.68 -38.39 0.04 OUTLIER Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 86.9 t -98.93 94.05 3.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 C-N-CA 119.775 -0.77 . . . . 0.0 110.339 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -44.57 155.36 0.1 Allowed 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.955 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -93.89 -11.66 30.59 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.177 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -89.49 -9.25 50.75 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.92 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 3.0 mmpt? -88.03 -28.62 21.27 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.402 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -105.49 -5.51 9.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.739 -179.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.0 m -74.23 171.53 13.45 Favored 'General case' 0 C--N 1.308 -1.218 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.355 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.617 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 56.3 mt-30 -123.95 80.04 57.38 Favored Pre-proline 0 N--CA 1.49 1.536 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.35 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -61.41 -16.11 45.22 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 120.722 0.948 . . . . 0.0 110.852 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -100.49 119.73 38.94 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.81 -0.756 . . . . 0.0 110.679 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.432 ' CD2' ' OD1' ' A' ' 38' ' ' ASN . 38.4 m-85 -69.04 174.98 4.03 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.839 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.4 pp -144.38 123.31 12.75 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.221 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -116.13 -14.63 11.15 Favored 'General case' 0 N--CA 1.501 2.112 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.184 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.508 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . -52.07 137.5 32.63 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.036 -1.554 . . . . 0.0 110.633 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.64 106.37 5.37 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.661 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 97.61 12.64 46.94 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.519 -1.325 . . . . 0.0 110.004 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.625 ' H ' HD22 ' A' ' 31' ' ' ASN . 1.9 mm-40 -66.02 158.37 28.47 Favored 'General case' 0 N--CA 1.484 1.242 0 C-N-CA 119.229 -0.989 . . . . 0.0 110.244 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.4 p -147.48 160.01 43.08 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 118.805 -1.158 . . . . 0.0 111.979 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.617 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 42.9 t80 -135.8 178.07 7.34 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.371 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.586 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 8.4 mt-10 -140.62 149.74 42.7 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 118.916 -1.113 . . . . 0.0 111.929 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -150.07 132.7 6.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-N 115.322 -0.853 . . . . 0.0 109.218 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.3 m -127.21 106.28 9.14 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.424 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 30.3 mt -91.79 159.72 15.67 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.249 -0.98 . . . . 0.0 110.117 179.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 6.4 p -150.63 46.36 0.87 Allowed 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.098 -1.041 . . . . 0.0 111.544 -179.354 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.433 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 2.0 mm-40 -143.84 101.6 3.77 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 118.995 -1.082 . . . . 0.0 110.565 179.475 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 19.5 tttm -43.96 108.03 0.1 Allowed 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.657 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.71 -143.71 6.76 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.193 -1.479 . . . . 0.0 110.202 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -145.03 133.17 21.5 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.918 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.58 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.3 m-85 -119.62 157.35 28.61 Favored 'General case' 0 N--CA 1.485 1.29 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.134 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.1 mmtm -124.62 123.81 40.86 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.545 -0.862 . . . . 0.0 112.224 -179.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.574 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.0 OUTLIER -135.25 163.89 28.96 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.099 178.408 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -169.49 179.59 3.78 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 119.165 -1.014 . . . . 0.0 111.223 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -102.17 116.87 33.57 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.778 -0.769 . . . . 0.0 109.651 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.58 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 7.0 tt0 -71.99 -36.08 3.96 Favored Pre-proline 0 C--N 1.304 -1.374 0 C-N-CA 118.941 -1.104 . . . . 0.0 112.901 -179.223 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.58 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -70.2 -52.48 0.29 Allowed 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 120.429 0.753 . . . . 0.0 111.144 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . 0.514 ' C ' ' H ' ' A' ' 87' ' ' GLY . 35.1 m170 -82.14 13.91 3.17 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.829 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.25 -6.14 0.14 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.659 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.514 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -80.55 -27.6 50.73 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.575 -1.298 . . . . 0.0 110.327 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.73 -32.56 23.43 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.4 -0.92 . . . . 0.0 110.392 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 114.94 23.23 4.69 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.926 -1.131 . . . . 0.0 110.903 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 28.6 mtp -65.14 107.68 1.63 Allowed 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.869 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.447 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 17.4 pttp -124.97 159.0 32.26 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 119.975 -0.69 . . . . 0.0 110.461 179.501 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.47 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.86 145.6 15.13 Favored Glycine 0 N--CA 1.497 2.729 0 C-N-CA 119.053 -1.546 . . . . 0.0 111.742 -178.701 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 51.3 tt0 -150.8 144.7 25.25 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.317 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.2 p -136.99 124.6 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 C-N-CA 119.121 -1.031 . . . . 0.0 111.179 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 41.4 m -100.61 99.51 10.09 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.672 179.406 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.7 t -79.79 146.23 8.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.374 -179.067 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.486 1.346 0 CA-C-O 116.412 -1.756 . . . . 0.0 110.999 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.893 0.377 . . . . 0.0 110.077 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -97.32 122.06 39.92 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.809 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 43.9 t -107.7 121.56 60.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.149 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 45.6 mtpt -92.05 117.36 29.76 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.157 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 16.8 mt -78.15 111.71 14.36 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.558 179.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.554 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 97.33 120.45 4.02 Favored Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.789 -1.196 . . . . 0.0 110.227 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 18.3 p -67.25 146.18 54.43 Favored 'General case' 0 C--N 1.301 -1.5 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.609 179.669 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -44.49 -45.29 9.13 Favored 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.928 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.31 66.81 0.19 Allowed 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.74 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -146.55 -55.22 0.02 OUTLIER Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.531 -1.319 . . . . 0.0 110.215 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -179.04 -168.12 37.65 Favored Glycine 0 N--CA 1.486 1.983 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.3 mt -99.74 106.73 18.66 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.668 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.4 m -150.89 158.39 4.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 C-N-CA 118.918 -1.113 . . . . 0.0 110.872 179.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.415 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 58.0 m-85 -78.75 112.83 16.28 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 177.093 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 53.8 m -115.0 110.9 45.51 Favored Pre-proline 0 N--CA 1.485 1.316 0 C-N-CA 119.315 -0.954 . . . . 0.0 112.431 -177.089 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -65.82 170.95 37.19 Favored 'Cis proline' 0 C--N 1.362 1.284 0 C-N-CA 125.228 -0.738 . . . . 0.0 111.51 -0.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.424 ' HG ' ' H ' ' A' ' 18' ' ' SER . 6.0 p -94.86 -67.95 0.83 Allowed 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.055 179.082 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.424 ' H ' ' HG ' ' A' ' 17' ' ' SER . 0.3 OUTLIER -109.67 137.32 47.66 Favored 'General case' 0 N--CA 1.486 1.326 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.672 179.198 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -163.57 134.9 4.75 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 118.456 -1.298 . . . . 0.0 111.658 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -85.54 152.88 22.82 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.237 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -144.84 173.78 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.677 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.518 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -94.1 139.22 31.25 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.452 -0.899 . . . . 0.0 110.357 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.19 77.79 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.319 -0.953 . . . . 0.0 110.888 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 158.12 13.83 0.04 OUTLIER Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -104.05 149.69 24.96 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 120.102 -0.639 . . . . 0.0 110.767 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 78.0 mttt -94.91 137.56 33.82 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.105 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mp -115.9 150.47 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 68.5 p -141.75 121.89 13.82 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 118.92 -1.112 . . . . 0.0 112.1 -179.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -87.18 120.93 28.97 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.373 -0.931 . . . . 0.0 108.895 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.5 ttmm -110.99 136.81 49.43 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.669 -0.812 . . . . 0.0 111.742 -178.442 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.631 ' ND2' ' CD1' ' A' ' 35' ' ' PHE . 19.2 t30 -80.42 104.27 10.85 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 115.109 -0.95 . . . . 0.0 109.723 179.146 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.554 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 1.2 t30 -101.27 -32.03 10.7 Favored 'General case' 0 N--CA 1.491 1.575 0 C-N-CA 118.838 -1.145 . . . . 0.0 112.389 -178.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 177.27 143.06 0.09 Allowed 'General case' 0 N--CA 1.502 2.134 0 C-N-CA 119.503 -0.879 . . . . 0.0 111.166 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 100.89 8.54 48.01 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 119.338 -1.411 . . . . 0.0 112.299 178.286 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.631 ' CD1' ' ND2' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -55.45 162.88 2.06 Favored Pre-proline 0 C--N 1.308 -1.229 0 C-N-CA 117.763 -1.575 . . . . 0.0 109.478 179.569 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_endo -76.67 140.76 67.11 Favored 'Cis proline' 0 C--O 1.215 -0.64 0 C-N-CA 124.285 -1.131 . . . . 0.0 112.521 -0.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.3 m-70 -109.91 163.46 13.53 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.801 179.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.61 HD21 ' H ' ' A' ' 39' ' ' ILE . 1.6 t-20 -148.12 139.79 23.77 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.682 179.649 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.61 ' H ' HD21 ' A' ' 38' ' ' ASN . 2.7 mp -116.45 118.01 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 120.046 -0.662 . . . . 0.0 111.045 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 28.3 t -129.8 162.37 37.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.899 179.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.8 m-85 -121.09 122.0 39.1 Favored 'General case' 0 N--CA 1.494 1.755 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.552 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.43 ' C ' ' H ' ' A' ' 44' ' ' ASP . 14.7 t70 -54.13 117.48 3.28 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.346 -179.691 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.451 ' O ' ' OD1' ' A' ' 44' ' ' ASP . 9.2 mt-10 -76.38 39.06 0.19 Allowed 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.297 -179.627 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.451 ' OD1' ' O ' ' A' ' 43' ' ' GLU . 75.4 m-20 -148.91 -3.22 0.45 Allowed 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.157 -1.017 . . . . 0.0 110.975 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -130.71 8.62 4.92 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.821 -0.752 . . . . 0.0 109.885 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -95.8 148.06 33.97 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 115.027 -0.988 . . . . 0.0 108.79 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -49.45 151.1 7.42 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 120.89 1.06 . . . . 0.0 111.827 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.34 54.84 1.47 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.864 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -165.06 -40.93 0.02 OUTLIER Glycine 0 N--CA 1.489 2.197 0 C-N-CA 119.465 -1.35 . . . . 0.0 110.322 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 46.3 t -86.56 93.95 4.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.969 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -47.14 158.25 0.15 Allowed 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.649 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.64 -25.01 16.3 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.786 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 90.7 mt-10 -71.71 -13.22 61.66 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.884 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.9 mmpp? -87.6 -39.75 14.81 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.775 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.0 pt -91.62 -25.86 5.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.242 -0.983 . . . . 0.0 111.258 -179.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.7 m -55.52 -176.98 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 119.124 -1.031 . . . . 0.0 110.686 179.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.617 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 13.9 tt0 -144.95 78.12 12.78 Favored Pre-proline 0 C--N 1.302 -1.464 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.528 -179.556 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -59.51 -24.51 75.24 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 120.971 1.114 . . . . 0.0 111.532 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -77.9 99.57 6.04 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.201 -1.0 . . . . 0.0 110.484 179.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -56.99 167.28 0.84 Allowed 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.045 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -135.61 105.27 6.11 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 119.729 -0.788 . . . . 0.0 110.708 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -107.26 4.93 27.13 Favored 'General case' 0 N--CA 1.488 1.426 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.701 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -90.88 139.38 14.81 Favored Glycine 0 N--CA 1.489 2.216 0 C-N-CA 119.386 -1.388 . . . . 0.0 110.433 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -74.19 123.55 24.69 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.722 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.19 -8.99 59.32 Favored Glycine 0 N--CA 1.498 2.826 0 C-N-CA 119.547 -1.311 . . . . 0.0 110.983 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -55.83 150.65 12.67 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.976 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 3.2 p -150.59 160.11 44.03 Favored 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 118.829 -1.149 . . . . 0.0 111.667 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.617 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 53.5 t80 -135.68 177.39 7.86 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.898 -0.721 . . . . 0.0 109.745 179.092 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.506 ' O ' ' CE2' ' A' ' 68' ' ' TYR . 9.0 mt-10 -144.99 151.94 39.37 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.118 -1.033 . . . . 0.0 111.554 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.444 ' O ' ' CG1' ' A' ' 70' ' ' VAL . 1.8 p -158.76 127.78 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 C-N-CA 119.552 -0.859 . . . . 0.0 109.981 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.6 m -115.03 93.87 4.5 Favored 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.058 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 11.8 mt -79.15 156.07 28.41 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 118.81 -1.156 . . . . 0.0 109.353 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.2 p -150.86 38.37 0.67 Allowed 'General case' 0 C--N 1.293 -1.886 0 C-N-CA 118.902 -1.119 . . . . 0.0 111.559 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.437 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 0.5 OUTLIER -124.2 96.4 4.91 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 119.482 -0.887 . . . . 0.0 109.62 179.202 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.418 ' C ' ' O ' ' A' ' 74' ' ' GLU . 16.3 mtmm -39.52 99.75 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.292 -178.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.34 -135.4 2.64 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 119.257 -1.449 . . . . 0.0 110.359 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.3 m -150.36 142.56 24.15 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.145 -1.022 . . . . 0.0 111.225 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.611 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.7 m-85 -128.47 125.48 38.55 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.606 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 6.2 mptt -99.23 116.33 31.17 Favored 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.23 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.573 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -123.5 168.87 12.01 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.082 178.74 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -170.73 -176.81 2.15 Favored 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.683 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.5 t -105.86 127.1 52.9 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.775 -0.77 . . . . 0.0 109.865 179.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.567 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 tm-20 -74.59 -37.14 2.75 Favored Pre-proline 0 CA--C 1.558 1.259 0 C-N-CA 119.161 -1.016 . . . . 0.0 113.318 -178.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.1 Cg_endo -71.03 -50.04 0.35 Allowed 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 120.716 0.944 . . . . 0.0 111.416 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -83.72 16.29 2.79 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.594 -0.842 . . . . 0.0 110.888 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.89 -6.21 5.63 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.671 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.83 -11.94 64.8 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.146 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -97.16 -42.41 7.85 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.794 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.25 30.61 0.72 Allowed Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -79.43 110.99 15.25 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.212 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.415 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 1.0 OUTLIER -133.96 162.62 31.55 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.237 -179.808 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -144.1 152.12 23.99 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.675 -1.25 . . . . 0.0 110.661 -178.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -154.13 146.74 24.14 Favored 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 119.105 -1.038 . . . . 0.0 111.29 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.4 p -143.74 126.52 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.261 0 C-N-CA 119.016 -1.074 . . . . 0.0 110.334 178.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 99.4 m -105.61 102.49 11.95 Favored 'General case' 0 N--CA 1.494 1.76 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.723 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.9 t -82.67 141.36 15.06 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.226 -179.172 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 . . . . . 0 C--N 1.302 -1.458 0 CA-C-O 116.344 -1.788 . . . . 0.0 110.857 -179.85 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.114 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -107.66 118.99 38.2 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.741 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 t -108.22 120.01 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 C-N-CA 119.866 -0.734 . . . . 0.0 110.642 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -95.01 116.52 28.8 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.414 -0.914 . . . . 0.0 110.861 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.1 mt -77.2 113.36 14.87 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 118.891 -1.123 . . . . 0.0 109.993 178.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.487 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 101.64 131.75 7.49 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.1 p -76.61 -179.0 5.01 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.225 -0.99 . . . . 0.0 110.62 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -72.49 -58.09 3.65 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.878 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -49.99 -53.46 26.4 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.86 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.79 11.54 0.05 OUTLIER Glycine 0 N--CA 1.49 2.3 0 C-N-CA 119.45 -1.357 . . . . 0.0 110.4 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -72.49 162.26 54.56 Favored Glycine 0 N--CA 1.49 2.275 0 C-N-CA 119.425 -1.369 . . . . 0.0 110.238 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.9 mt -116.8 96.18 5.36 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.941 -0.704 . . . . 0.0 110.894 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.7 m -151.01 155.2 7.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.828 179.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.402 ' O ' ' C ' ' A' ' 16' ' ' PRO . 67.2 m-85 -78.31 110.53 13.41 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 177.598 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 59.4 m -113.37 110.06 50.82 Favored Pre-proline 0 CA--C 1.557 1.246 0 C-N-CA 119.377 -0.929 . . . . 0.0 112.504 -177.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.402 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.3 Cg_endo -67.62 170.2 49.26 Favored 'Cis proline' 0 C--N 1.363 1.31 0 C-N-CA 125.344 -0.69 . . . . 0.0 111.414 -0.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.4 m -94.0 -70.64 0.7 Allowed 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.441 -0.904 . . . . 0.0 109.648 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.3 t -107.46 129.65 54.92 Favored 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.311 178.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 13.1 p90 -157.22 144.12 18.39 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 118.237 -1.385 . . . . 0.0 111.898 -179.081 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 19.9 m -84.43 157.02 21.51 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.859 179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.5 m -150.66 168.28 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 C-N-CA 119.737 -0.785 . . . . 0.0 110.941 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -89.38 148.64 23.39 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.559 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.93 73.57 0.19 Allowed 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.079 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 156.38 16.04 0.04 OUTLIER Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -97.85 153.97 17.95 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.795 -0.762 . . . . 0.0 111.055 -179.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.0 mtmm -95.17 127.52 41.29 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.069 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.0 mt -107.25 103.26 15.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 C-N-CA 120.069 -0.653 . . . . 0.0 109.87 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 52.5 p -100.99 115.12 29.73 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 119.656 -0.818 . . . . 0.0 112.382 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -85.5 109.83 18.76 Favored 'General case' 0 N--CA 1.489 1.485 0 C-N-CA 119.668 -0.813 . . . . 0.0 109.228 178.471 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.7 tttp -105.61 137.69 43.05 Favored 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 119.46 -0.896 . . . . 0.0 112.122 -178.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.456 ' ND2' ' N ' ' A' ' 31' ' ' ASN . 0.1 OUTLIER -79.64 114.15 18.34 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.272 179.177 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.487 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 0.7 OUTLIER -97.71 -31.04 12.47 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.181 -1.008 . . . . 0.0 111.634 -179.238 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.483 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 165.47 114.38 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.246 -0.981 . . . . 0.0 111.148 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 139.51 3.61 1.56 Allowed Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.434 -1.365 . . . . 0.0 110.863 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.523 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -53.16 163.08 0.96 Allowed Pre-proline 0 C--N 1.304 -1.372 0 C-N-CA 118.704 -1.199 . . . . 0.0 109.741 -179.874 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -77.1 141.26 68.5 Favored 'Cis proline' 0 C--O 1.214 -0.691 0 C-N-CA 124.194 -1.169 . . . . 0.0 112.509 -0.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -107.2 178.23 4.61 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.967 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.534 HD21 ' H ' ' A' ' 83' ' ' GLU . 15.5 t30 -158.09 139.64 13.67 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.618 -0.833 . . . . 0.0 110.212 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.7 mp -128.07 114.74 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 C-N-CA 119.789 -0.765 . . . . 0.0 111.311 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 66.6 t -130.08 134.48 62.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.921 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.8 m-85 -87.07 129.18 35.02 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.147 -1.021 . . . . 0.0 111.446 -179.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.648 ' C ' ' H ' ' A' ' 44' ' ' ASP . 31.1 t0 -65.75 94.29 0.2 Allowed 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.646 -178.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -55.37 5.35 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.858 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.373 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.648 ' H ' ' C ' ' A' ' 42' ' ' ASP . 73.8 m-20 -82.85 -68.18 0.73 Allowed 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.557 179.272 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -98.51 25.51 6.32 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.471 -0.892 . . . . 0.0 112.131 -177.031 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -89.16 154.41 49.32 Favored Pre-proline 0 N--CA 1.489 1.5 0 C-N-CA 119.204 -0.998 . . . . 0.0 108.374 178.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -51.13 144.01 30.42 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 121.017 1.145 . . . . 0.0 112.061 -179.065 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.47 69.38 5.72 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.791 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.73 -43.24 0.08 OUTLIER Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 46.5 t -84.18 83.39 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.078 179.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . 0.48 ' ND2' ' H ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER -44.74 140.87 2.31 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.525 -179.652 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.39 -26.33 60.94 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.539 -0.865 . . . . 0.0 111.293 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' A' ' 53' ' ' GLU . 3.7 mp0 -65.34 -3.17 3.77 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.938 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.0 mmpp? -97.44 -40.92 8.45 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.022 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.3 pt -99.13 -13.99 7.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.638 -0.825 . . . . 0.0 111.087 -179.587 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 68.9 m -73.06 173.11 9.82 Favored 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.855 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.63 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 70.3 mt-30 -136.65 80.3 38.26 Favored Pre-proline 0 N--CA 1.488 1.469 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.623 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -60.92 -20.83 68.73 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.121 1.214 . . . . 0.0 111.443 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -94.56 108.7 20.64 Favored 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.525 179.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 38.9 m-85 -51.51 177.24 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.887 -0.725 . . . . 0.0 111.035 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.8 pp -143.69 139.19 29.4 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.822 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.415 ' OD1' ' N ' ' A' ' 62' ' ' ASN . 2.9 p-10 -134.97 42.95 2.75 Favored 'General case' 0 N--CA 1.489 1.498 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.399 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -105.31 159.54 15.49 Favored Glycine 0 N--CA 1.493 2.461 0 C-N-CA 119.797 -1.192 . . . . 0.0 110.429 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -110.64 110.89 21.76 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 119.989 -0.685 . . . . 0.0 110.726 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.34 -14.21 64.67 Favored Glycine 0 N--CA 1.49 2.285 0 C-N-CA 119.437 -1.364 . . . . 0.0 110.367 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.414 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 1.2 mm-40 -69.82 160.15 32.29 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.269 -0.973 . . . . 0.0 110.345 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -147.22 172.27 14.09 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.669 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.63 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 43.9 t80 -133.61 129.45 36.95 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.082 179.125 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -91.46 149.75 21.55 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 118.892 -1.123 . . . . 0.0 112.461 -178.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -150.28 131.72 5.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.994 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.0 m -127.04 106.54 9.34 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.836 -0.745 . . . . 0.0 111.504 -178.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 20.5 mt -90.58 157.7 17.37 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.837 179.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 8.7 p -150.67 48.37 0.87 Allowed 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.072 -1.051 . . . . 0.0 111.412 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -146.67 100.74 3.37 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.151 179.36 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.469 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 2.0 ptpt -41.77 118.76 1.15 Allowed 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 119.65 -0.82 . . . . 0.0 111.041 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 164.87 -147.22 12.23 Favored Glycine 0 N--CA 1.484 1.9 0 C-N-CA 119.506 -1.331 . . . . 0.0 109.878 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.71 132.96 24.68 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.462 -0.895 . . . . 0.0 111.2 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.585 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.5 OUTLIER -116.81 127.36 54.25 Favored 'General case' 0 N--CA 1.486 1.333 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.342 179.712 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.476 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 2.5 mptp? -101.2 110.72 22.78 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.538 -0.865 . . . . 0.0 111.388 -179.404 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.2 p90 -123.78 168.0 13.3 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.896 -0.722 . . . . 0.0 109.922 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 46.0 p90 -171.43 -173.92 1.32 Allowed 'General case' 0 C--N 1.296 -1.758 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.033 -178.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -107.97 129.5 55.11 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.001 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.534 ' H ' HD21 ' A' ' 38' ' ' ASN . 1.9 mt-10 -69.91 -45.4 23.35 Favored Pre-proline 0 N--CA 1.486 1.374 0 C-N-CA 119.541 -0.864 . . . . 0.0 113.073 -179.385 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.518 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.7 Cg_endo -67.79 -53.17 0.45 Allowed 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 121.066 1.177 . . . . 0.0 111.771 -179.047 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.3 m80 -82.42 16.36 2.12 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.407 -0.917 . . . . 0.0 111.05 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.28 -18.42 58.37 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.365 -0.934 . . . . 0.0 110.809 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.19 -19.6 78.28 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.405 -1.379 . . . . 0.0 110.573 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.97 -4.69 52.23 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.577 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.64 9.67 62.58 Favored Glycine 0 N--CA 1.489 2.178 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.571 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -55.85 102.31 0.07 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.707 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.8 ptmt -126.64 157.48 38.85 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 119.929 -0.708 . . . . 0.0 111.221 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -140.24 133.86 6.21 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.971 -1.109 . . . . 0.0 110.391 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -139.21 148.79 43.59 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.634 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.4 p -141.84 132.47 25.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 119.065 -1.054 . . . . 0.0 110.219 178.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 99.6 m -110.31 104.99 13.85 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.26 -0.976 . . . . 0.0 110.338 179.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 31.4 t -84.83 152.31 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 118.555 -1.258 . . . . 0.0 110.774 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 60.8 m-20 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 116.324 -1.798 . . . . 0.0 110.816 -179.792 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.199 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -130.51 122.59 27.9 Favored 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 120.053 -0.659 . . . . 0.0 110.642 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -99.11 154.4 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.635 -179.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.2 mttt -120.59 106.95 12.25 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.074 -0.967 . . . . 0.0 110.479 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.9 mt -74.77 111.47 10.01 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 118.625 -1.23 . . . . 0.0 110.207 179.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.536 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 112.03 136.32 6.81 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -178.675 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.458 ' OG ' ' N ' ' A' ' 8' ' ' ASP . 79.7 p -59.01 -110.13 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.806 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.458 ' N ' ' OG ' ' A' ' 7' ' ' SER . 2.5 m-20 -154.39 -0.87 0.19 Allowed 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 118.993 -1.083 . . . . 0.0 111.497 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 9' ' ' ASP . 14.4 p30 -166.54 -16.79 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 118.731 -1.188 . . . . 0.0 111.686 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 175.4 69.12 0.05 OUTLIER Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.002 -1.57 . . . . 0.0 110.856 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -172.8 148.06 10.24 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 119.444 -1.36 . . . . 0.0 109.926 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mt -119.13 99.26 6.61 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.084 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.5 m -150.84 155.47 7.3 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 C-N-CA 118.853 -1.139 . . . . 0.0 111.281 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.49 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 57.2 m-85 -78.7 109.84 13.3 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 177.449 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.9 m -115.3 108.19 48.19 Favored Pre-proline 0 CA--C 1.565 1.552 0 C-N-CA 119.596 -0.841 . . . . 0.0 112.875 -176.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -66.23 175.09 25.08 Favored 'Cis proline' 0 C--N 1.368 1.571 0 C-N-CA 125.128 -0.78 . . . . 0.0 111.142 -1.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.521 ' OG ' ' N ' ' A' ' 18' ' ' SER . 0.1 OUTLIER -102.91 -67.84 0.86 Allowed 'General case' 0 N--CA 1.488 1.442 0 C-N-CA 119.704 -0.799 . . . . 0.0 110.305 179.428 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.521 ' N ' ' OG ' ' A' ' 17' ' ' SER . 34.2 t -105.74 133.45 50.46 Favored 'General case' 0 N--CA 1.488 1.433 0 C-N-CA 120.069 -0.652 . . . . 0.0 109.843 179.323 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 32.6 p90 -160.65 137.13 8.69 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 118.817 -1.153 . . . . 0.0 111.177 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -87.77 159.57 18.4 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 119.271 -0.972 . . . . 0.0 111.183 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 30.6 m -148.93 176.35 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.315 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -97.37 150.41 21.03 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.568 -0.853 . . . . 0.0 110.722 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.03 71.67 0.17 Allowed 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.99 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.405 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 164.4 10.02 0.03 OUTLIER Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.405 ' H ' ' H ' ' A' ' 24' ' ' GLY . 3.9 tp10 -104.37 146.59 28.61 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.105 -0.638 . . . . 0.0 110.543 -179.638 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.6 pttt -94.33 153.29 18.08 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.394 -0.922 . . . . 0.0 111.039 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 mt -122.94 145.51 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.486 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.7 p -137.8 118.13 13.69 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.274 -0.97 . . . . 0.0 112.165 -178.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -84.63 126.59 33.49 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.642 -0.823 . . . . 0.0 109.059 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.16 130.76 54.74 Favored 'General case' 0 N--CA 1.493 1.705 0 C-N-CA 119.604 -0.838 . . . . 0.0 111.853 -178.085 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.601 HD22 ' CD1' ' A' ' 61' ' ' LEU . 6.2 m-20 -70.2 125.41 26.71 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.517 -0.873 . . . . 0.0 109.101 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.536 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 0.2 OUTLIER -103.7 -32.24 9.47 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 118.861 -1.136 . . . . 0.0 112.798 -178.533 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.439 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 170.01 -5.16 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 118.019 -1.472 . . . . 0.0 112.016 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.506 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -107.6 41.81 2.1 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.411 -1.376 . . . . 0.0 112.02 -178.798 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -76.14 160.78 77.37 Favored Pre-proline 0 N--CA 1.483 1.218 0 C-N-CA 117.917 -1.513 . . . . 0.0 109.564 179.019 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -74.38 176.98 40.33 Favored 'Cis proline' 0 C--O 1.207 -1.037 0 C-N-CA 124.163 -1.182 . . . . 0.0 111.784 -0.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.506 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 43.0 m-70 -150.98 168.92 23.09 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.567 -0.853 . . . . 0.0 110.794 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.788 HD22 ' H ' ' A' ' 83' ' ' GLU . 4.8 p-10 -154.54 152.89 30.6 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 119.381 -0.928 . . . . 0.0 110.079 178.244 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.0 mp -129.14 97.78 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.652 -179.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -112.39 143.41 22.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.163 178.579 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -99.04 138.5 36.06 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.097 -1.041 . . . . 0.0 112.354 -178.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -75.83 110.81 10.57 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.241 -0.983 . . . . 0.0 108.981 178.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -72.56 49.68 0.22 Allowed 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.405 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -142.5 3.57 1.5 Allowed 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.968 -0.693 . . . . 0.0 110.2 179.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -142.99 8.13 1.65 Allowed 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.721 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 44.3 t -94.63 143.75 26.76 Favored Pre-proline 0 C--N 1.291 -1.968 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -50.94 148.56 16.53 Favored 'Trans proline' 0 C--O 1.216 -0.593 0 C-N-CA 120.868 1.045 . . . . 0.0 112.251 -179.081 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.11 78.25 2.94 Favored 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.503 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 168.32 -43.13 0.23 Allowed Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 55.5 t -79.35 94.21 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.528 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -44.93 139.85 2.9 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.696 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -96.34 -1.46 47.73 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.561 -0.856 . . . . 0.0 110.937 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.439 ' N ' ' OE1' ' A' ' 53' ' ' GLU . 11.0 mp0 -90.33 -15.82 30.41 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.303 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 59.2 pttt -89.88 -27.47 19.87 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.01 -1.076 . . . . 0.0 111.437 -179.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 15.8 pt -92.74 -27.76 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 C-N-CA 119.106 -1.038 . . . . 0.0 110.918 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 9.0 m -60.75 -168.15 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.655 -0.818 . . . . 0.0 111.43 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.634 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 47.8 mt-30 -150.07 74.27 9.21 Favored Pre-proline 0 C--N 1.305 -1.336 0 C-N-CA 119.867 -0.733 . . . . 0.0 110.626 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -60.18 -12.26 19.01 Favored 'Trans proline' 0 C--N 1.325 -0.695 0 C-N-CA 121.202 1.268 . . . . 0.0 111.256 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' A' ' 60' ' ' TYR . 45.0 mt-10 -100.13 95.48 6.85 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.834 -0.746 . . . . 0.0 110.414 179.425 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.44 ' O ' ' O ' ' A' ' 59' ' ' GLU . 71.3 m-85 -43.97 171.19 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.916 -0.714 . . . . 0.0 111.17 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.601 ' CD1' HD22 ' A' ' 31' ' ' ASN . 1.9 pp -139.74 150.3 44.64 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.833 -0.747 . . . . 0.0 110.644 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -149.06 53.26 0.97 Allowed 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.891 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.27 126.98 6.29 Favored Glycine 0 N--CA 1.498 2.774 0 C-N-CA 119.95 -1.119 . . . . 0.0 110.402 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.67 128.78 37.56 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.833 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.47 -14.99 10.13 Favored Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.371 -1.395 . . . . 0.0 110.859 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 -56.44 154.83 7.88 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.336 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -147.99 164.57 33.4 Favored 'General case' 0 N--CA 1.489 1.522 0 C-N-CA 119.016 -1.074 . . . . 0.0 111.788 -179.069 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.634 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 36.0 t80 -136.14 146.45 46.94 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -108.03 154.74 21.22 Favored 'General case' 0 N--CA 1.498 1.935 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.794 -178.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -155.24 135.91 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 CA-C-N 115.086 -0.961 . . . . 0.0 108.936 179.287 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.2 m -128.07 104.16 7.62 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.667 -0.813 . . . . 0.0 111.769 -179.365 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.4 mt -88.22 157.74 18.7 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.237 -0.985 . . . . 0.0 109.614 179.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.71 48.42 0.87 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 118.865 -1.134 . . . . 0.0 111.351 -179.25 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.447 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -142.58 105.08 4.48 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.272 -0.971 . . . . 0.0 110.011 178.996 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 32.0 mtmt -46.59 110.31 0.27 Allowed 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.162 -179.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 171.08 -141.76 6.67 Favored Glycine 0 N--CA 1.485 1.912 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -146.38 137.5 24.39 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.924 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.573 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.4 m-85 -122.32 152.3 40.27 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.131 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 31.2 mttm -115.5 132.42 56.63 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.625 -0.83 . . . . 0.0 112.335 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.516 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -141.9 153.37 44.36 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.843 176.956 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 30.5 p90 -168.48 177.64 5.19 Favored 'General case' 0 C--N 1.285 -2.221 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.55 -178.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . 0.464 ' SG ' ' OD1' ' A' ' 38' ' ' ASN . 1.3 t -101.62 120.65 40.66 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.246 -0.981 . . . . 0.0 109.233 179.424 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.788 ' H ' HD22 ' A' ' 38' ' ' ASN . 6.6 tt0 -65.15 -40.56 46.1 Favored Pre-proline 0 C--N 1.3 -1.548 0 N-CA-C 113.774 1.027 . . . . 0.0 113.774 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.502 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.7 Cg_endo -68.95 -52.41 0.39 Allowed 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 120.401 0.734 . . . . 0.0 111.694 -179.363 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . 0.449 ' C ' ' H ' ' A' ' 87' ' ' GLY . 30.3 m80 -79.78 13.87 1.97 Allowed 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.906 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.31 -2.26 2.1 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.317 -0.953 . . . . 0.0 110.659 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.449 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -88.01 -18.18 56.44 Favored Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.514 -1.326 . . . . 0.0 110.231 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.32 -41.09 10.05 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.631 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 133.69 15.3 1.24 Allowed Glycine 0 N--CA 1.495 2.628 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.456 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.75 100.79 0.31 Allowed 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.392 -0.923 . . . . 0.0 111.017 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.49 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 32.4 mttm -125.99 164.5 20.68 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.9 -0.72 . . . . 0.0 111.497 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -148.58 143.89 11.57 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.927 -179.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -149.13 146.92 27.91 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.484 -0.886 . . . . 0.0 111.131 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.417 ' CG1' ' O ' ' A' ' 94' ' ' VAL . 12.5 p -140.05 119.63 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.53 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 94.5 m -99.07 101.25 12.56 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.628 179.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.436 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 41.8 t -79.61 142.74 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 C-N-CA 118.963 -1.095 . . . . 0.0 110.444 -179.014 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 96' ' ' VAL . 81.2 m-20 . . . . . 0 C--N 1.304 -1.38 0 CA-C-O 116.335 -1.793 . . . . 0.0 110.728 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.109 0 N-CA-C 110.145 -0.316 . . . . 0.0 110.145 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 20.7 mp0 -121.78 122.0 38.5 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 120.128 -0.629 . . . . 0.0 110.652 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.8 t -106.69 119.06 55.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 C-N-CA 119.768 -0.773 . . . . 0.0 110.853 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -91.82 117.63 29.96 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 119.335 -0.946 . . . . 0.0 110.883 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.429 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 4.8 mt -84.27 106.36 15.82 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 119.264 -0.975 . . . . 0.0 110.702 179.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.519 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 106.75 86.64 1.89 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.612 ' HG ' ' H ' ' A' ' 11' ' ' GLY . 2.9 p -48.09 142.08 5.53 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.389 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.401 ' C ' ' O ' ' A' ' 7' ' ' SER . 3.2 m-20 -39.56 -52.07 2.19 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 119.884 -0.726 . . . . 0.0 111.598 -179.259 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -141.04 7.06 2.01 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.501 -0.879 . . . . 0.0 110.766 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -77.66 -39.18 25.92 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.435 -1.364 . . . . 0.0 110.502 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.612 ' H ' ' HG ' ' A' ' 7' ' ' SER . . . 141.66 -153.83 24.38 Favored Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.515 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.1 mt -99.23 94.75 6.65 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.814 -179.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.0 m -146.73 161.38 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 118.804 -1.159 . . . . 0.0 111.427 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -78.58 113.79 16.93 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 177.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.1 m -116.7 107.45 46.46 Favored Pre-proline 0 CA--C 1.559 1.292 0 C-N-CA 119.39 -0.924 . . . . 0.0 111.881 -177.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -66.11 176.38 21.23 Favored 'Cis proline' 0 C--N 1.36 1.153 0 C-N-CA 125.227 -0.739 . . . . 0.0 111.46 -0.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.7 p -95.76 -48.86 5.59 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.205 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 47.9 t -137.07 137.12 38.99 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.601 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 11.3 p90 -163.3 143.68 9.02 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 118.563 -1.255 . . . . 0.0 111.528 -179.117 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -86.44 157.43 19.82 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.896 -179.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.3 m -146.48 146.89 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.313 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.437 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -61.45 141.58 57.58 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.697 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.75 74.21 0.07 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.184 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 154.25 18.89 0.05 OUTLIER Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.364 -1.398 . . . . 0.0 109.922 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 21.7 tt0 -103.63 157.1 17.29 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.947 -0.701 . . . . 0.0 110.8 -179.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 29.1 mttt -94.38 142.07 27.84 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.714 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mt -124.81 125.52 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 C-N-CA 119.992 -0.683 . . . . 0.0 109.519 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.6 p -119.68 129.33 54.5 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.528 -0.869 . . . . 0.0 112.368 -178.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -91.71 131.48 37.07 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.226 178.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.5 tptm -120.94 131.01 54.09 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 120.017 -0.673 . . . . 0.0 111.249 -178.408 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -90.77 94.68 9.78 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.594 -0.842 . . . . 0.0 109.547 178.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 40.1 p-10 -91.26 -23.17 20.25 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.24 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -177.36 162.23 1.87 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 118.999 -1.08 . . . . 0.0 111.219 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.03 12.49 76.68 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.393 -1.384 . . . . 0.0 112.583 178.035 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -63.05 159.93 43.08 Favored Pre-proline 0 C--N 1.308 -1.199 0 C-N-CA 117.283 -1.767 . . . . 0.0 109.378 179.489 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -79.13 147.05 79.27 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 124.13 -1.196 . . . . 0.0 112.195 -0.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 40.5 m-70 -111.3 -175.43 2.7 Favored 'General case' 0 N--CA 1.495 1.805 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.377 179.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.58 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -160.63 146.06 14.67 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.446 179.262 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.58 ' N ' HD21 ' A' ' 38' ' ' ASN . 3.7 mp -134.17 107.27 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.971 -179.376 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.3 t -133.48 144.17 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.849 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -97.42 118.24 33.45 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.962 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -52.28 118.52 3.59 Favored 'General case' 0 C--N 1.308 -1.202 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.281 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -76.09 47.94 0.47 Allowed 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.121 -1.032 . . . . 0.0 111.047 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -147.75 2.68 0.71 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.652 -0.819 . . . . 0.0 109.94 179.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -144.56 21.39 1.67 Allowed 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 119.69 -0.804 . . . . 0.0 110.614 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -104.88 148.13 35.61 Favored Pre-proline 0 N--CA 1.493 1.693 0 CA-C-N 115.45 -0.795 . . . . 0.0 109.28 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -49.66 143.12 22.97 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 120.951 1.101 . . . . 0.0 111.715 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.85 69.37 2.5 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.942 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.0 -43.27 0.1 Allowed Glycine 0 N--CA 1.49 2.238 0 C-N-CA 119.44 -1.362 . . . . 0.0 110.018 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 77.5 t -78.44 97.32 2.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.372 179.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -44.71 139.68 2.83 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.66 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -94.8 2.66 55.5 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.441 -179.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -87.72 -33.22 18.8 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.932 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.1 mmtm -76.41 -32.2 58.36 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.911 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -90.64 -16.09 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 C-N-CA 118.993 -1.083 . . . . 0.0 111.682 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.8 m -79.97 170.72 16.07 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.264 -0.974 . . . . 0.0 110.782 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.65 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 5.8 mt-30 -134.68 73.44 67.36 Favored Pre-proline 0 N--CA 1.487 1.393 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.523 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -61.36 -4.26 3.99 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 121.402 1.401 . . . . 0.0 111.459 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 60' ' ' TYR . 37.8 mt-10 -99.86 100.67 11.63 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.716 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.473 ' CD2' ' OD1' ' A' ' 38' ' ' ASN . 84.7 m-85 -45.82 171.49 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.623 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.2 pp -149.39 126.54 11.34 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.248 -0.981 . . . . 0.0 110.499 179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -120.86 33.61 5.51 Favored 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 120.175 -0.61 . . . . 0.0 110.663 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -87.91 168.19 37.22 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.308 -1.425 . . . . 0.0 110.876 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -121.62 101.27 7.49 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.363 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.94 -7.94 55.5 Favored Glycine 0 N--CA 1.49 2.248 0 C-N-CA 119.622 -1.275 . . . . 0.0 110.063 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -71.1 157.55 38.0 Favored 'General case' 0 N--CA 1.486 1.359 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.226 179.665 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -141.69 173.27 11.66 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.27 -0.972 . . . . 0.0 112.041 -179.077 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.65 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 56.7 t80 -134.66 178.23 7.17 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-N 115.498 -0.773 . . . . 0.0 109.623 178.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.516 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 5.1 mt-10 -145.92 149.34 34.03 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 118.912 -1.115 . . . . 0.0 112.012 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -159.04 133.87 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.659 178.57 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.1 m -122.53 96.34 4.99 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 119.828 -0.749 . . . . 0.0 111.035 -179.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.3 mt -79.75 158.64 26.84 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.448 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 97.0 m -150.96 47.12 0.85 Allowed 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.552 -1.259 . . . . 0.0 112.362 -178.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.446 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 5.9 tp10 -146.2 107.25 4.16 Favored 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 118.746 -1.182 . . . . 0.0 109.95 178.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.62 ' CD ' ' H ' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -43.36 116.32 0.91 Allowed 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.199 -0.909 . . . . 0.0 111.184 -178.972 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.6 -151.22 16.68 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.359 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.17 131.15 34.29 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.846 -0.741 . . . . 0.0 110.677 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.538 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 3.7 m-85 -118.19 121.58 40.86 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 36.8 mmtt -100.19 127.48 46.45 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.524 -0.87 . . . . 0.0 112.839 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.448 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 5.6 p90 -139.87 171.46 14.18 Favored 'General case' 0 C--N 1.312 -1.025 0 C-N-CA 119.616 -0.833 . . . . 0.0 110.433 177.673 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -170.55 -175.71 1.94 Allowed 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 119.437 -0.905 . . . . 0.0 111.178 -178.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -106.7 123.26 47.86 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.757 179.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.532 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.4 OUTLIER -64.05 -45.16 79.79 Favored Pre-proline 0 C--N 1.307 -1.253 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.466 -179.874 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.532 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.3 Cg_endo -66.93 -48.36 1.97 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.994 1.129 . . . . 0.0 112.47 -178.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . 0.51 ' C ' ' H ' ' A' ' 87' ' ' GLY . 34.4 m80 -91.69 23.19 3.68 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.152 -179.196 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -71.19 12.29 0.33 Allowed 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.893 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.51 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -107.15 -18.35 10.54 Favored Glycine 0 N--CA 1.498 2.79 0 C-N-CA 119.746 -1.216 . . . . 0.0 110.682 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -95.1 -16.11 22.88 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.232 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 108.17 17.76 10.5 Favored Glycine 0 N--CA 1.498 2.78 0 C-N-CA 119.777 -1.202 . . . . 0.0 110.242 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.7 ttt -69.99 90.78 0.65 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.215 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 15.4 ttmt -118.39 162.17 18.75 Favored 'General case' 0 N--CA 1.498 1.944 0 C-N-CA 120.045 -0.662 . . . . 0.0 111.16 -179.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -141.74 150.99 22.42 Favored Glycine 0 N--CA 1.495 2.608 0 C-N-CA 119.349 -1.405 . . . . 0.0 111.6 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -157.57 145.43 18.85 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.75 -0.78 . . . . 0.0 110.919 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.2 p -138.55 123.06 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.346 178.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 97.7 m -99.61 103.23 14.92 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.594 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 22.0 t -80.05 142.86 13.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 C-N-CA 118.423 -1.311 . . . . 0.0 110.46 -179.145 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.3 m120 . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 116.358 -1.782 . . . . 0.0 110.764 -179.76 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.221 0 CA-C-O 120.7 0.286 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 89.2 mt-10 -115.08 121.34 42.77 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.586 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 t -102.49 123.61 55.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.915 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 39.1 mttp -88.92 112.9 23.86 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.902 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 13.1 mt -75.82 107.43 8.0 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 118.229 -1.388 . . . . 0.0 109.4 178.104 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.535 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.64 130.4 6.98 Favored Glycine 0 N--CA 1.486 1.986 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -178.819 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.3 p -71.75 171.27 11.89 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.663 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -66.54 -47.73 71.95 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.042 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -55.86 -71.35 0.09 Allowed 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.339 -0.944 . . . . 0.0 110.836 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.35 24.18 0.03 OUTLIER Glycine 0 N--CA 1.489 2.224 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.363 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.7 153.07 21.42 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.296 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.4 mt -104.81 97.46 7.34 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.825 -0.75 . . . . 0.0 110.827 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.2 m -150.12 153.97 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.868 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.423 ' O ' ' O ' ' A' ' 16' ' ' PRO . 69.7 m-85 -78.45 110.61 13.68 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 177.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.2 m -115.59 110.39 44.75 Favored Pre-proline 0 CA--C 1.562 1.419 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.723 -177.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.423 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.7 Cg_exo -64.79 174.7 21.0 Favored 'Cis proline' 0 C--N 1.365 1.43 0 C-N-CA 125.103 -0.79 . . . . 0.0 111.829 -0.157 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.9 t -102.82 -66.36 0.94 Allowed 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.455 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 61.6 m -119.08 131.88 55.97 Favored 'General case' 0 N--CA 1.492 1.634 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.008 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.436 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 16.7 p90 -161.23 170.94 19.28 Favored 'General case' 0 N--CA 1.487 1.391 0 C-N-CA 118.655 -1.218 . . . . 0.0 111.324 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.4 p -102.88 161.45 13.74 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.992 -0.683 . . . . 0.0 111.193 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.9 m -149.23 151.0 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.946 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.519 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -78.82 142.06 37.21 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.274 -0.971 . . . . 0.0 110.359 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.01 77.35 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.51 -0.876 . . . . 0.0 111.395 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 153.79 15.32 0.06 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.583 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -103.94 145.0 30.78 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.754 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ptpt -95.45 136.34 35.95 Favored 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.383 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.1 mt -109.16 113.79 45.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.631 179.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.3 p -107.3 116.47 31.98 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.775 -0.77 . . . . 0.0 112.336 -178.547 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 69.2 m-85 -85.16 118.81 24.94 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 119.526 -0.87 . . . . 0.0 109.05 178.293 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 25.0 tttp -111.74 138.16 48.7 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.657 -0.817 . . . . 0.0 111.482 -178.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.482 HD22 ' CD1' ' A' ' 61' ' ' LEU . 2.6 m-20 -77.65 109.92 12.03 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.413 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.535 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 1.4 t30 -96.51 -30.96 13.03 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 119.147 -1.021 . . . . 0.0 110.703 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.444 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 165.13 129.12 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.806 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 127.98 -9.01 6.75 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.687 -1.244 . . . . 0.0 110.91 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.478 ' CD1' ' ND2' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -45.92 160.64 0.28 Allowed Pre-proline 0 N--CA 1.482 1.142 0 C-N-CA 118.52 -1.272 . . . . 0.0 109.695 -179.881 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -77.3 141.55 68.84 Favored 'Cis proline' 0 C--O 1.214 -0.68 0 C-N-CA 124.139 -1.192 . . . . 0.0 112.241 0.008 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 40.6 m-70 -108.55 -177.24 3.26 Favored 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.072 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.576 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -161.16 141.54 11.06 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.875 -0.73 . . . . 0.0 109.872 178.829 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.576 ' N ' HD21 ' A' ' 38' ' ' ASN . 3.6 mp -129.63 124.69 59.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.438 -179.542 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -143.53 146.99 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.385 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.161 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -97.23 134.56 40.38 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.248 -0.981 . . . . 0.0 111.04 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.659 ' O ' ' N ' ' A' ' 44' ' ' ASP . 44.5 p-10 -73.1 93.81 1.85 Allowed 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.529 -0.868 . . . . 0.0 111.063 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.445 ' O ' ' CG ' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -50.45 78.84 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 O-C-N 124.063 0.852 . . . . 0.0 109.803 179.385 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.659 ' N ' ' O ' ' A' ' 42' ' ' ASP . 59.4 m-20 -157.01 -67.04 0.1 Allowed 'General case' 0 C--N 1.283 -2.3 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.682 -177.785 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -96.24 17.37 15.94 Favored 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.191 -1.003 . . . . 0.0 112.139 -177.399 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -86.07 143.96 38.12 Favored Pre-proline 0 C--N 1.291 -1.959 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.458 ' C ' ' H ' ' A' ' 49' ' ' GLY . 2.7 Cg_exo -48.81 152.21 4.68 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 120.815 1.01 . . . . 0.0 111.797 -179.252 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.68 31.15 0.36 Allowed 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.645 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.458 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -136.27 -35.34 0.21 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.5 t -96.46 93.2 3.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.986 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -45.26 144.48 1.37 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.671 179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -87.99 -29.85 20.44 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.84 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.03 -1.05 21.02 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.747 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -97.62 -35.03 10.73 Favored 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.753 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -96.2 -16.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 C-N-CA 119.404 -0.918 . . . . 0.0 111.102 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 36.7 m -68.27 170.07 9.38 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.733 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.64 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 5.0 mt-30 -137.09 73.37 51.87 Favored Pre-proline 0 N--CA 1.489 1.489 0 C-N-CA 119.811 -0.756 . . . . 0.0 110.901 -179.862 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -57.28 -27.73 76.51 Favored 'Trans proline' 0 C--N 1.322 -0.836 0 C-N-CA 121.038 1.159 . . . . 0.0 110.933 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -65.65 114.1 4.73 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.088 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 -60.72 173.26 0.77 Allowed 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 119.479 -0.888 . . . . 0.0 111.073 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.482 ' CD1' HD22 ' A' ' 31' ' ' ASN . 2.5 pp -149.15 144.63 26.73 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.682 -0.807 . . . . 0.0 110.158 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.581 ' N ' ' ND2' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -128.28 -73.53 0.59 Allowed 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 119.88 -0.728 . . . . 0.0 111.72 -178.992 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.519 ' H ' ' CG ' ' A' ' 62' ' ' ASN . . . -24.2 127.19 0.02 OUTLIER Glycine 0 N--CA 1.511 3.642 0 O-C-N 123.993 0.808 . . . . 0.0 112.612 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.525 ' C ' ' H ' ' A' ' 66' ' ' GLU . . . -62.33 156.76 21.47 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.207 179.394 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 71.28 -14.62 1.65 Allowed Glycine 0 N--CA 1.492 2.376 0 C-N-CA 119.109 -1.519 . . . . 0.0 110.6 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.525 ' H ' ' C ' ' A' ' 64' ' ' ALA . 12.9 tt0 -61.13 101.8 0.18 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.286 -0.966 . . . . 0.0 109.97 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 37.4 p -106.99 162.19 14.06 Favored 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.575 -0.85 . . . . 0.0 112.225 -178.716 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.64 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 29.7 t80 -136.17 143.57 44.52 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.323 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -104.84 154.6 19.84 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.589 -178.605 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -151.59 130.75 3.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.945 -1.025 . . . . 0.0 108.942 179.272 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.4 m -124.6 112.06 16.37 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.693 -0.803 . . . . 0.0 111.585 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 34.3 mt -98.61 156.85 16.6 Favored 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.772 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 11.1 p -150.93 47.98 0.85 Allowed 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 118.714 -1.194 . . . . 0.0 112.274 -179.122 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.429 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 1.4 tp10 -144.49 106.29 4.3 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.781 -1.168 . . . . 0.0 110.467 178.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -44.96 110.84 0.26 Allowed 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.913 -179.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.93 -148.28 10.35 Favored Glycine 0 N--CA 1.487 2.053 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.077 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.92 135.37 32.75 Favored 'General case' 0 N--CA 1.483 1.176 0 C-N-CA 119.424 -0.91 . . . . 0.0 111.095 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.569 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -124.36 159.04 31.23 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 179.565 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 12.2 mtpt -136.5 125.48 24.31 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 118.612 -1.235 . . . . 0.0 112.871 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.542 ' O ' ' N ' ' A' ' 92' ' ' GLY . 3.9 p90 -129.43 162.34 28.3 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.35 178.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 22.7 p90 -166.94 -179.5 4.72 Favored 'General case' 0 C--N 1.285 -2.232 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.496 -178.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -107.34 112.93 25.99 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.49 -0.884 . . . . 0.0 109.573 178.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.487 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.9 OUTLIER -59.37 -42.99 95.58 Favored Pre-proline 0 C--N 1.298 -1.635 0 C-N-CA 119.471 -0.892 . . . . 0.0 112.581 -179.407 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.487 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.4 Cg_endo -66.3 -47.88 2.92 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 120.283 0.655 . . . . 0.0 111.839 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -92.82 10.1 32.42 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.447 -179.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.07 -15.8 15.71 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.559 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -77.91 -20.47 73.31 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.421 -1.371 . . . . 0.0 110.377 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.63 -9.34 47.32 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.694 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 104.54 10.78 32.57 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.67 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.51 105.05 1.72 Allowed 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 118.989 -1.085 . . . . 0.0 110.952 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.422 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 43.9 pttt -135.54 168.34 19.43 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.29 -179.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.04 153.0 24.93 Favored Glycine 0 N--CA 1.485 1.941 0 C-N-CA 119.372 -1.394 . . . . 0.0 111.053 -179.05 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -155.91 145.9 21.39 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.3 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.8 p -141.62 131.29 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 C-N-CA 118.955 -1.098 . . . . 0.0 110.652 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.0 m -109.46 105.15 14.38 Favored 'General case' 0 N--CA 1.493 1.722 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.825 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 37.2 t -79.68 152.93 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 C-N-CA 118.553 -1.259 . . . . 0.0 110.526 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 60.9 m-20 . . . . . 0 C--N 1.307 -1.277 0 CA-C-O 116.284 -1.817 . . . . 0.0 110.932 179.99 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.127 0 N-CA-C 110.071 -0.344 . . . . 0.0 110.071 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -113.92 122.41 46.9 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 120.076 -0.649 . . . . 0.0 110.856 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.3 t -110.4 150.11 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.393 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 10.9 mtpt -124.6 117.69 24.87 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.865 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.2 mt -76.74 109.1 10.24 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.067 -1.053 . . . . 0.0 109.995 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 117.42 162.01 12.36 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.021 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.442 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 59.4 p -84.61 -111.51 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.813 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -151.5 8.31 0.52 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.078 -1.049 . . . . 0.0 111.155 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -167.75 -42.33 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.124 -1.03 . . . . 0.0 111.117 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.46 61.99 0.19 Allowed Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.098 -1.525 . . . . 0.0 110.631 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.423 ' O ' ' N ' ' A' ' 7' ' ' SER . . . -156.18 125.97 1.72 Allowed Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.342 -1.408 . . . . 0.0 110.229 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.3 mt -99.57 95.5 7.03 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.534 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.9 m -144.82 155.37 14.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 119.111 -1.035 . . . . 0.0 110.415 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.425 ' O ' ' O ' ' A' ' 16' ' ' PRO . 5.4 m-85 -78.71 111.99 15.37 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 178.311 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.3 m -114.44 108.59 49.55 Favored Pre-proline 0 C--N 1.303 -1.415 0 C-N-CA 119.734 -0.786 . . . . 0.0 112.007 -177.44 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -67.26 177.9 20.57 Favored 'Cis proline' 0 C--N 1.36 1.149 0 C-N-CA 125.35 -0.688 . . . . 0.0 111.423 -0.205 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.7 m -92.62 -47.78 6.93 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.414 -0.914 . . . . 0.0 109.996 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.63 135.42 31.69 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.756 179.279 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.479 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 13.5 p90 -153.69 146.61 24.44 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.608 -1.237 . . . . 0.0 111.545 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.43 151.25 20.88 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.042 179.579 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.4 158.82 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.933 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.532 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -73.09 137.28 45.15 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.176 -1.01 . . . . 0.0 110.347 179.515 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -59.91 78.82 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.934 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 150.39 18.38 0.07 OUTLIER Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -96.18 158.42 15.45 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.577 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 40.5 mttm -93.5 120.29 33.59 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.093 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.9 mt -105.52 120.52 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.68 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.1 p -118.42 116.6 27.05 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.64 -0.824 . . . . 0.0 112.283 -178.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -87.87 120.31 29.07 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.508 -0.877 . . . . 0.0 109.022 178.336 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 13.0 ttmt -112.21 136.2 51.93 Favored 'General case' 0 N--CA 1.492 1.658 0 C-N-CA 119.697 -0.801 . . . . 0.0 111.75 -178.475 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.8 m120 -80.31 115.57 19.92 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.157 178.688 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.442 ' ND2' ' O ' ' A' ' 7' ' ' SER . 0.1 OUTLIER -100.22 -31.38 11.4 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.257 -0.977 . . . . 0.0 112.141 -178.995 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.44 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 169.02 120.74 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 C-N-CA 118.882 -1.127 . . . . 0.0 111.359 -179.75 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 131.57 -1.19 5.19 Favored Glycine 0 N--CA 1.496 2.667 0 C-N-CA 119.661 -1.257 . . . . 0.0 111.187 179.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -46.84 163.97 0.23 Allowed Pre-proline 0 N--CA 1.487 1.377 0 C-N-CA 118.942 -1.103 . . . . 0.0 110.028 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -75.74 143.0 75.66 Favored 'Cis proline' 0 C--O 1.212 -0.81 0 C-N-CA 124.306 -1.122 . . . . 0.0 112.45 -0.427 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 31.7 m-70 -113.92 160.72 18.48 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.769 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.56 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 8.9 t30 -145.69 133.28 20.92 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 119.426 -0.909 . . . . 0.0 109.945 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.57 ' N ' ' CD1' ' A' ' 39' ' ' ILE . 1.7 mp -115.19 121.41 67.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 C-N-CA 119.767 -0.773 . . . . 0.0 111.405 -179.562 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.56 ' CG2' ' ND2' ' A' ' 38' ' ' ASN . 1.7 t -139.07 154.8 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.068 179.454 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -106.56 134.34 49.85 Favored 'General case' 0 N--CA 1.49 1.533 0 C-N-CA 119.287 -0.965 . . . . 0.0 112.019 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.54 ' C ' ' H ' ' A' ' 44' ' ' ASP . 4.3 t0 -74.32 107.0 6.21 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.188 -1.005 . . . . 0.0 109.179 178.654 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -69.32 33.83 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.833 -178.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.54 ' H ' ' C ' ' A' ' 42' ' ' ASP . 14.9 m-20 -110.23 -9.98 14.65 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.855 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -142.5 -5.8 0.93 Allowed 'General case' 0 N--CA 1.497 1.889 0 C-N-CA 118.865 -1.134 . . . . 0.0 111.634 179.609 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -69.98 146.17 94.88 Favored Pre-proline 0 C--N 1.286 -2.153 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 178.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -51.48 159.32 3.26 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.712 0.941 . . . . 0.0 112.323 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -89.17 40.4 0.98 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 119.722 -0.791 . . . . 0.0 110.374 179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -143.18 -44.63 0.05 OUTLIER Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 50.9 t -83.14 86.29 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 119.384 -0.926 . . . . 0.0 110.18 179.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -45.0 139.59 3.07 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.634 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.425 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -76.99 -28.48 55.1 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.679 179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -66.33 -15.56 63.35 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.379 -0.928 . . . . 0.0 111.13 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.95 -42.89 17.08 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.838 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -93.32 -41.59 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.212 -179.779 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.425 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 42.9 m -48.53 165.98 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.154 179.901 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.594 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.3 mt-30 -138.23 78.55 33.55 Favored Pre-proline 0 N--CA 1.487 1.412 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.561 -179.593 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -61.67 -22.91 75.51 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 121.405 1.403 . . . . 0.0 112.003 -179.068 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -76.08 119.83 20.56 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.122 -1.031 . . . . 0.0 110.585 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -55.86 168.56 0.44 Allowed 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.126 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.449 ' C ' ' CD1' ' A' ' 61' ' ' LEU . 0.4 OUTLIER -144.61 141.91 29.76 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.189 179.329 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.413 ' ND2' ' O ' ' A' ' 62' ' ' ASN . 4.1 p-10 -146.51 32.7 0.96 Allowed 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.198 -179.263 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -97.26 112.26 4.43 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.482 -1.342 . . . . 0.0 110.539 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.15 111.6 1.58 Allowed 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.22 -0.992 . . . . 0.0 110.571 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.7 -12.5 66.02 Favored Glycine 0 N--CA 1.489 2.23 0 C-N-CA 119.464 -1.351 . . . . 0.0 110.203 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -63.04 151.22 40.49 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.335 -0.946 . . . . 0.0 110.302 179.689 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.73 166.72 23.88 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.214 -0.995 . . . . 0.0 111.511 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.594 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 31.6 t80 -135.83 138.32 42.41 Favored 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.524 179.246 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -98.16 152.94 18.82 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.885 -178.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -149.61 133.69 8.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.34 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.6 m -125.92 100.3 6.32 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.304 -179.23 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 54.2 mt -81.0 165.43 21.72 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.173 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' THR . . . . . 0.478 ' CG2' ' O ' ' A' ' 73' ' ' THR . 81.1 m -150.43 31.01 0.67 Allowed 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 118.608 -1.237 . . . . 0.0 112.589 -178.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.456 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 2.5 mt-10 -143.39 124.28 14.3 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 118.781 -1.168 . . . . 0.0 110.35 178.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 14.4 pttt -58.69 128.14 35.72 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.221 -0.992 . . . . 0.0 111.281 -179.271 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 156.31 174.59 26.28 Favored Glycine 0 N--CA 1.488 2.116 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.223 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.79 105.35 15.34 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.914 -0.715 . . . . 0.0 110.281 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.463 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.8 m-30 -89.58 156.54 18.54 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 118.591 -1.244 . . . . 0.0 107.981 -179.261 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 71.1 mttt -115.19 127.77 55.74 Favored 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.165 -1.014 . . . . 0.0 112.782 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.469 ' O ' ' N ' ' A' ' 92' ' ' GLY . 1.7 p90 -138.14 157.5 46.19 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.834 -0.746 . . . . 0.0 109.526 176.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 33.8 p90 -169.8 -175.23 2.03 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.523 -178.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -110.14 116.31 31.31 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.398 179.265 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.563 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tp10 -69.67 -39.34 11.46 Favored Pre-proline 0 C--N 1.305 -1.358 0 C-N-CA 119.518 -0.873 . . . . 0.0 112.435 -179.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.563 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 4.4 Cg_exo -66.17 -41.92 11.84 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 120.394 0.729 . . . . 0.0 111.268 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . 0.475 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.8 m80 -97.71 18.91 14.57 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.518 -0.873 . . . . 0.0 110.638 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.37 0.21 1.09 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.853 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.475 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -94.31 -13.38 54.3 Favored Glycine 0 N--CA 1.487 2.081 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.449 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.45 -47.55 6.81 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.377 -0.929 . . . . 0.0 110.57 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 141.27 18.22 0.35 Allowed Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.629 -1.272 . . . . 0.0 110.271 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 12.8 mtp -71.55 100.41 2.25 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.16 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.465 ' O ' ' CD ' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -129.17 148.48 51.11 Favored 'General case' 0 N--CA 1.495 1.792 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.221 179.489 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -136.29 153.78 21.7 Favored Glycine 0 N--CA 1.499 2.889 0 C-N-CA 119.508 -1.33 . . . . 0.0 112.211 -178.057 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -154.68 149.37 26.49 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 120.314 -0.555 . . . . 0.0 109.937 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.484 ' CG1' ' O ' ' A' ' 94' ' ' VAL . 12.2 p -139.32 114.88 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 C-N-CA 119.079 -1.048 . . . . 0.0 111.07 -179.327 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 16.0 m -89.84 93.55 9.47 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.096 -1.042 . . . . 0.0 110.616 179.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 14.0 t -78.77 148.31 6.23 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.617 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 17.8 p30 . . . . . 0 C--N 1.307 -1.277 0 CA-C-O 116.309 -1.805 . . . . 0.0 110.818 -179.744 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.103 0 CA-C-O 120.873 0.368 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -107.86 120.63 42.81 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 120.033 -0.667 . . . . 0.0 110.687 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.8 t -98.52 122.35 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.651 179.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.7 mptt -90.0 114.72 26.62 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.983 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.43 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 5.3 mp -80.45 100.03 8.3 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 118.572 -1.251 . . . . 0.0 109.62 178.507 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.425 ' C ' HD22 ' A' ' 32' ' ' ASN . . . 122.6 146.6 7.25 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -178.718 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.55 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 53.5 p -74.48 -173.14 1.67 Allowed 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.439 -0.905 . . . . 0.0 110.709 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -90.95 -6.77 53.61 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.131 -1.028 . . . . 0.0 111.685 -179.183 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -173.38 77.93 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 118.616 -1.233 . . . . 0.0 112.273 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 85.45 70.75 1.32 Allowed Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.269 -1.444 . . . . 0.0 111.235 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.447 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . -176.37 146.81 8.2 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.397 -1.382 . . . . 0.0 110.187 179.215 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.0 mt -124.34 91.8 3.53 Favored 'General case' 0 N--CA 1.491 1.597 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.357 179.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.9 m -145.38 156.27 13.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.022 0 C-N-CA 118.996 -1.082 . . . . 0.0 111.075 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -78.59 111.54 14.77 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 178.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -114.5 108.34 49.8 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 119.566 -0.854 . . . . 0.0 112.232 -177.106 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -68.04 173.48 37.72 Favored 'Cis proline' 0 C--N 1.359 1.085 0 C-N-CA 125.45 -0.646 . . . . 0.0 111.503 -0.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 p -88.9 -45.22 9.87 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 119.307 -0.957 . . . . 0.0 109.76 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.76 140.5 34.81 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.55 179.114 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -162.41 147.3 12.34 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 118.356 -1.338 . . . . 0.0 111.598 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -93.24 151.71 19.64 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.275 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -146.06 169.24 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.809 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.76 146.48 28.14 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.257 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.27 71.26 0.42 Allowed 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.32 -0.952 . . . . 0.0 110.848 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 165.51 11.08 0.03 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -101.92 145.89 28.61 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.841 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.1 mttm -84.97 134.87 34.23 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.288 -0.965 . . . . 0.0 110.671 179.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.5 mp -115.94 118.31 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 36.2 p -110.6 121.51 45.49 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.471 -0.891 . . . . 0.0 113.299 -177.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 70.6 m-85 -84.88 111.12 19.37 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.051 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 45.5 tttt -109.9 131.62 54.89 Favored 'General case' 0 N--CA 1.496 1.83 0 C-N-CA 119.431 -0.907 . . . . 0.0 111.76 -177.2 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.414 ' ND2' ' CD1' ' A' ' 61' ' ' LEU . 7.8 m-20 -90.06 117.39 28.82 Favored 'General case' 0 C--N 1.294 -1.82 0 C-N-CA 119.335 -0.946 . . . . 0.0 111.329 -179.536 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 7' ' ' SER . 25.3 p-10 -101.01 -29.54 12.12 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.968 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 174.09 137.59 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.373 -0.931 . . . . 0.0 110.935 -179.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.403 ' O ' ' C ' ' A' ' 35' ' ' PHE . . . 122.22 -6.99 9.98 Favored Glycine 0 N--CA 1.498 2.774 0 C-N-CA 119.524 -1.322 . . . . 0.0 111.626 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.403 ' C ' ' O ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -45.87 163.1 0.23 Allowed Pre-proline 0 N--CA 1.485 1.312 0 C-N-CA 118.423 -1.311 . . . . 0.0 109.908 -179.834 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -76.76 138.43 54.24 Favored 'Cis proline' 0 C--O 1.213 -0.734 0 C-N-CA 124.122 -1.199 . . . . 0.0 112.443 -0.585 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 32.5 m-70 -102.28 179.79 4.21 Favored 'General case' 0 N--CA 1.488 1.462 0 C-N-CA 119.751 -0.78 . . . . 0.0 111.106 179.576 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -159.56 142.11 13.76 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.782 179.293 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -135.11 117.12 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.045 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.4 t -139.25 150.24 22.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.386 179.043 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -99.3 135.08 41.24 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.856 -178.816 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.573 ' C ' ' H ' ' A' ' 44' ' ' ASP . 59.6 t0 -70.62 104.36 2.79 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.284 -0.966 . . . . 0.0 109.519 178.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.465 ' N ' ' CD ' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -68.42 27.27 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.789 -0.765 . . . . 0.0 111.785 -179.229 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.573 ' H ' ' C ' ' A' ' 42' ' ' ASP . 73.3 m-20 -111.26 -7.02 14.46 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.079 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -143.82 -1.46 0.99 Allowed 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 119.218 -0.993 . . . . 0.0 111.721 -179.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -68.56 144.9 96.76 Favored Pre-proline 0 C--N 1.285 -2.21 0 C-N-CA 119.269 -0.972 . . . . 0.0 108.726 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -59.08 160.5 18.61 Favored 'Trans proline' 0 C--O 1.216 -0.603 0 C-N-CA 121.062 1.175 . . . . 0.0 112.243 -178.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.63 145.16 41.29 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.567 -0.853 . . . . 0.0 109.66 178.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 95.26 -59.13 1.65 Allowed Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.238 -1.458 . . . . 0.0 109.849 -179.439 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.4 t -68.52 87.18 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 119.114 -1.035 . . . . 0.0 110.339 179.509 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -44.86 154.51 0.13 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.001 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.25 -25.66 16.26 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.332 179.385 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -81.4 -15.93 53.69 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.611 -0.836 . . . . 0.0 110.774 179.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.18 -21.61 46.16 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.568 -0.853 . . . . 0.0 111.408 -179.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.5 pt -111.04 -19.22 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 C-N-CA 119.753 -0.779 . . . . 0.0 111.312 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.7 m -79.58 169.47 17.97 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.575 -0.85 . . . . 0.0 111.81 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.634 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.8 OUTLIER -150.03 73.24 9.42 Favored Pre-proline 0 C--N 1.306 -1.32 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.785 179.113 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -56.74 -26.45 65.97 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.501 1.467 . . . . 0.0 111.947 -178.574 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.35 102.82 0.08 Allowed 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 118.94 -1.104 . . . . 0.0 110.145 179.251 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -42.46 161.75 0.02 OUTLIER 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 119.581 -0.848 . . . . 0.0 111.103 -179.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.415 ' CD1' ' C ' ' A' ' 61' ' ' LEU . 0.8 OUTLIER -143.3 147.8 35.32 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.614 -0.835 . . . . 0.0 110.459 -179.977 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -145.01 20.99 1.6 Allowed 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.351 -0.939 . . . . 0.0 110.952 -179.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -77.81 119.51 5.27 Favored Glycine 0 N--CA 1.487 2.034 0 C-N-CA 119.182 -1.485 . . . . 0.0 110.199 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.11 106.15 4.85 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.276 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.72 -10.72 49.35 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -68.11 154.85 40.82 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.256 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.87 170.04 16.64 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 119.133 -1.027 . . . . 0.0 111.335 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.634 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 40.7 t80 -135.24 142.49 45.98 Favored 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.487 179.412 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -113.78 151.19 32.35 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 119.404 -0.918 . . . . 0.0 112.335 -178.708 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.6 p -153.78 132.07 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.34 178.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.7 m -119.06 94.5 4.46 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 119.749 -0.78 . . . . 0.0 111.493 -179.153 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.5 mt -79.72 157.77 27.09 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.224 178.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.5 p -150.63 52.68 0.88 Allowed 'General case' 0 C--N 1.3 -1.587 0 C-N-CA 118.536 -1.266 . . . . 0.0 111.949 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.434 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 2.9 tt0 -150.73 99.41 2.73 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 118.73 -1.188 . . . . 0.0 109.934 178.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 74' ' ' GLU . 0.8 OUTLIER -39.87 108.96 0.1 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.255 -178.908 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.51 -148.46 8.43 Favored Glycine 0 N--CA 1.485 1.921 0 C-N-CA 119.29 -1.433 . . . . 0.0 110.302 -179.82 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -141.49 129.99 22.58 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.472 -0.891 . . . . 0.0 111.218 -179.799 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.61 ' N ' ' CD1' ' A' ' 78' ' ' TYR . 0.6 OUTLIER -119.64 161.6 20.4 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.426 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 32.2 mttt -128.98 131.96 47.5 Favored 'General case' 0 N--CA 1.49 1.567 0 C-N-CA 119.187 -1.005 . . . . 0.0 111.958 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.544 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -139.25 158.75 43.62 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.829 177.712 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -167.78 -175.11 2.64 Favored 'General case' 0 C--N 1.288 -2.079 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.989 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -111.98 119.75 39.54 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.913 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.576 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.3 tt0 -65.41 -42.37 57.35 Favored Pre-proline 0 N--CA 1.486 1.326 0 C-N-CA 119.931 -0.708 . . . . 0.0 112.724 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.576 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.1 Cg_endo -69.45 -48.2 0.84 Allowed 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 121.108 1.205 . . . . 0.0 112.035 -179.381 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -90.03 10.39 24.31 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.647 -179.546 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.08 -35.45 62.09 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 118.906 -1.117 . . . . 0.0 110.475 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -62.23 -21.14 61.53 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.199 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -85.3 -17.29 37.31 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.278 179.805 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.23 23.79 9.42 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 119.716 -1.23 . . . . 0.0 110.731 179.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -75.95 101.01 5.04 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.131 -1.028 . . . . 0.0 110.979 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.32 149.67 46.31 Favored 'General case' 0 N--CA 1.49 1.56 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.751 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -137.76 149.13 20.25 Favored Glycine 0 N--CA 1.496 2.655 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.352 -178.827 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -155.63 148.87 24.7 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 120.004 -0.678 . . . . 0.0 110.395 179.45 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.1 p -139.08 128.99 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.81 179.708 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.9 m -104.91 98.55 8.25 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.159 179.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 42.4 t -79.13 150.63 5.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 118.632 -1.227 . . . . 0.0 110.453 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 89.2 m-20 . . . . . 0 N--CA 1.489 1.489 0 CA-C-O 116.333 -1.794 . . . . 0.0 110.894 -179.761 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.128 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -112.62 118.67 35.71 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 120.029 -0.668 . . . . 0.0 110.535 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 83.9 t -102.34 119.9 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.705 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 8.5 mptt -87.12 110.28 20.01 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.959 -179.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 11.9 mt -76.27 104.37 6.76 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.753 177.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 104.23 107.59 3.21 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.42 ' HG ' ' H ' ' A' ' 10' ' ' GLY . 20.1 p -59.55 139.16 57.39 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.442 179.861 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -43.79 -52.44 6.65 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.926 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -147.44 64.15 1.14 Allowed 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.339 -0.944 . . . . 0.0 110.988 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.42 ' H ' ' HG ' ' A' ' 7' ' ' SER . . . -144.61 -76.46 0.03 OUTLIER Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.479 -1.343 . . . . 0.0 110.039 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -162.03 -165.89 19.8 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.56 -1.305 . . . . 0.0 109.917 179.565 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.0 mt -99.49 101.93 13.33 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.488 -0.885 . . . . 0.0 110.024 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.2 m -149.71 160.41 4.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 C-N-CA 119.064 -1.054 . . . . 0.0 110.955 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.456 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 59.3 m-85 -79.02 113.11 16.88 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 176.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.9 m -114.74 110.87 46.24 Favored Pre-proline 0 N--CA 1.485 1.293 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.935 -177.707 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.44 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.9 Cg_endo -65.56 176.1 20.2 Favored 'Cis proline' 0 C--N 1.363 1.324 0 C-N-CA 125.254 -0.728 . . . . 0.0 111.751 -0.254 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.5 ' HG ' ' H ' ' A' ' 18' ' ' SER . 3.2 p -96.34 -60.86 1.53 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.467 179.617 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.5 ' H ' ' HG ' ' A' ' 17' ' ' SER . 60.7 p -123.74 136.69 54.59 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.752 179.168 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 p90 -163.08 146.45 10.75 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 118.583 -1.247 . . . . 0.0 111.443 -179.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -89.62 153.49 20.71 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.445 -0.902 . . . . 0.0 111.075 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.3 m -145.87 176.46 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.641 179.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.03 150.79 21.29 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.589 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.12 66.85 0.87 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.997 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 166.75 11.73 0.03 OUTLIER Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 25.9 tt0 -97.99 155.2 17.21 Favored 'General case' 0 C--N 1.307 -1.276 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.078 -179.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.52 133.47 39.49 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.033 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.7 mt -115.3 114.53 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 C-N-CA 120.022 -0.671 . . . . 0.0 109.614 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 73.2 p -106.87 117.04 32.99 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.782 -0.767 . . . . 0.0 112.417 -178.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -84.17 107.02 16.26 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.6 ttmt -96.59 142.98 28.0 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.054 -1.058 . . . . 0.0 111.295 -177.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.553 ' OD1' ' CD1' ' A' ' 35' ' ' PHE . 19.9 t-20 -100.12 121.23 41.09 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.509 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -132.83 -8.79 3.12 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.961 -1.095 . . . . 0.0 112.13 -179.571 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -168.61 132.25 1.49 Allowed 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 117.986 -1.485 . . . . 0.0 112.711 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.79 59.99 2.87 Favored Glycine 0 N--CA 1.49 2.296 0 C-N-CA 119.868 -1.158 . . . . 0.0 113.805 177.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.553 ' CD1' ' OD1' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -97.06 165.12 16.42 Favored Pre-proline 0 N--CA 1.493 1.685 0 C-N-CA 118.978 -1.089 . . . . 0.0 108.382 176.86 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.5 Cg_endo -77.97 147.41 83.33 Favored 'Cis proline' 0 C--O 1.214 -0.685 0 C-N-CA 124.615 -0.994 . . . . 0.0 112.938 -0.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -103.0 175.21 5.55 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.299 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.566 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.3 OUTLIER -150.81 124.71 9.21 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 119.205 -0.998 . . . . 0.0 110.764 179.703 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.566 ' N ' HD21 ' A' ' 38' ' ' ASN . 0.1 OUTLIER -107.85 115.68 49.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.71 179.78 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.8 t -140.23 141.7 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.194 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.3 m-85 -99.73 122.24 42.43 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 119.457 -0.897 . . . . 0.0 111.864 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.548 ' C ' ' H ' ' A' ' 44' ' ' ASP . 0.7 OUTLIER -64.96 111.86 3.04 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.029 179.183 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -66.64 11.12 0.1 Allowed 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.134 -1.026 . . . . 0.0 111.108 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.548 ' H ' ' C ' ' A' ' 42' ' ' ASP . 50.2 m-20 -93.35 -15.35 25.82 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 119.318 -0.953 . . . . 0.0 111.185 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -141.05 50.22 1.64 Allowed 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 119.635 -0.826 . . . . 0.0 110.495 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -128.41 144.86 53.54 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.931 179.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -48.28 150.65 5.15 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 120.831 1.02 . . . . 0.0 111.959 -179.384 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.53 47.65 0.85 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.926 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -157.78 -44.28 0.02 OUTLIER Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.456 -1.354 . . . . 0.0 109.975 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.6 t -83.57 84.42 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.313 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -44.48 142.48 1.59 Allowed 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.841 -0.743 . . . . 0.0 111.191 -179.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -86.9 -9.74 54.98 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.872 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -85.78 -11.99 52.09 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.853 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.29 -36.24 12.67 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.014 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -89.91 -21.43 6.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 C-N-CA 119.253 -0.979 . . . . 0.0 111.191 -179.774 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 51.6 m -74.43 178.19 5.42 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.415 -0.914 . . . . 0.0 111.142 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.636 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.3 pm0 -159.17 77.37 3.06 Favored Pre-proline 0 C--N 1.303 -1.424 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.018 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -57.78 -0.41 0.39 Allowed 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 121.09 1.193 . . . . 0.0 111.575 -178.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.537 ' H ' ' C ' ' A' ' 57' ' ' GLN . 2.7 mm-40 -80.8 92.39 6.07 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.17 -1.012 . . . . 0.0 110.046 178.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.401 ' O ' ' O ' ' A' ' 59' ' ' GLU . 38.3 m-85 -41.02 162.19 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.521 -179.388 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -135.07 108.63 7.92 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.488 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -104.72 3.51 31.47 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.907 -0.717 . . . . 0.0 110.956 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -73.64 117.74 5.88 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.378 -1.391 . . . . 0.0 110.558 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -59.38 108.68 0.74 Allowed 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.638 -0.825 . . . . 0.0 111.012 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.48 -6.21 59.11 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 119.516 -1.326 . . . . 0.0 110.817 179.595 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -62.23 149.98 40.28 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 118.996 -1.081 . . . . 0.0 110.674 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -140.8 164.44 30.21 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.421 -0.912 . . . . 0.0 111.625 -179.743 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.636 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 17.5 t80 -136.05 130.16 33.06 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.343 179.482 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -94.82 154.38 17.28 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 119.124 -1.03 . . . . 0.0 112.236 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.2 t -152.62 130.97 2.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 114.952 -1.022 . . . . 0.0 108.735 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.3 m -121.04 103.35 8.97 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.68 -178.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 65.7 mt -86.59 158.41 19.51 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.247 -0.981 . . . . 0.0 109.751 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.03 40.94 0.73 Allowed 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 118.845 -1.142 . . . . 0.0 111.614 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.417 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 14.3 mm-40 -142.97 102.18 3.96 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 118.787 -1.165 . . . . 0.0 110.801 179.453 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -43.24 114.44 0.62 Allowed 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.18 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 173.04 -145.36 8.36 Favored Glycine 0 N--CA 1.486 2.0 0 C-N-CA 119.395 -1.383 . . . . 0.0 110.038 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.7 127.83 17.59 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.444 -0.902 . . . . 0.0 110.893 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.566 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -114.72 167.14 11.02 Favored 'General case' 0 N--CA 1.481 1.12 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.123 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 20.4 mmtp -134.96 123.47 23.4 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.421 -0.912 . . . . 0.0 112.338 -178.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.543 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -132.72 161.73 33.25 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.774 -0.77 . . . . 0.0 110.359 178.033 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 34.3 p90 -170.35 -174.08 1.61 Allowed 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.382 -178.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.6 t -113.27 134.51 54.56 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.527 179.483 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.5 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.3 mt-10 -75.61 -46.16 4.21 Favored Pre-proline 0 C--N 1.308 -1.224 0 C-N-CA 119.571 -0.852 . . . . 0.0 112.927 -179.376 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -67.62 -41.97 7.66 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.901 1.067 . . . . 0.0 112.266 -179.192 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -93.99 20.71 7.49 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.447 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -74.27 -11.74 60.36 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.126 -1.03 . . . . 0.0 110.548 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -74.83 -18.48 80.11 Favored Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.345 -1.407 . . . . 0.0 110.247 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.72 -49.48 5.59 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.54 -0.864 . . . . 0.0 110.539 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 143.91 23.55 0.16 Allowed Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.467 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.7 103.54 3.1 Favored 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.052 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 6.5 mtpp -130.93 168.49 17.23 Favored 'General case' 0 N--CA 1.494 1.748 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.384 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -153.62 147.29 16.5 Favored Glycine 0 N--CA 1.493 2.492 0 C-N-CA 119.258 -1.449 . . . . 0.0 111.614 -179.068 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -152.66 146.3 25.05 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 120.004 -0.678 . . . . 0.0 109.979 179.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.4 p -137.64 127.59 36.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 C-N-CA 119.1 -1.04 . . . . 0.0 111.148 -179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 48.2 m -102.0 98.14 8.39 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.346 179.097 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.48 145.63 9.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 118.726 -1.19 . . . . 0.0 110.489 -178.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 . . . . . 0 C--N 1.306 -1.303 0 CA-C-O 116.337 -1.792 . . . . 0.0 110.649 -179.938 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.206 0 N-CA-C 110.148 -0.315 . . . . 0.0 110.148 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -105.16 136.48 44.59 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.829 -0.749 . . . . 0.0 110.825 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.8 t -117.87 143.7 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.931 179.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 13.3 mttm -113.39 107.57 16.04 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.797 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.8 mp -74.69 110.38 8.94 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 118.527 -1.269 . . . . 0.0 109.701 178.437 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.422 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.01 129.17 6.59 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 -179.217 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.423 ' O ' ' N ' ' A' ' 9' ' ' ASP . 21.3 p -78.12 141.71 38.56 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.716 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 36.0 m-20 -45.31 -21.59 0.09 Allowed 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.117 -179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.423 ' N ' ' O ' ' A' ' 7' ' ' SER . 0.1 OUTLIER 178.46 81.6 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.929 -179.959 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.99 -66.65 0.04 OUTLIER Glycine 0 N--CA 1.49 2.242 0 C-N-CA 119.375 -1.393 . . . . 0.0 110.324 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -167.36 -168.81 30.07 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.384 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 mt -99.34 107.02 19.18 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.653 -0.819 . . . . 0.0 110.58 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.9 m -150.03 155.72 7.61 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 119.139 -1.024 . . . . 0.0 110.996 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.414 ' O ' ' O ' ' A' ' 16' ' ' PRO . 61.2 m-85 -78.54 108.44 11.93 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 29.3 m -113.15 110.6 50.98 Favored Pre-proline 0 C--N 1.305 -1.359 0 C-N-CA 119.719 -0.792 . . . . 0.0 112.173 -177.619 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.414 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.2 Cg_endo -67.02 174.56 29.76 Favored 'Cis proline' 0 C--N 1.36 1.137 0 C-N-CA 125.337 -0.693 . . . . 0.0 111.626 -0.215 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.402 ' HG ' ' H ' ' A' ' 18' ' ' SER . 0.2 OUTLIER -95.13 -66.06 0.94 Allowed 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 119.494 -0.883 . . . . 0.0 109.985 179.079 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.402 ' H ' ' HG ' ' A' ' 17' ' ' SER . 19.6 t -114.92 132.53 56.52 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.42 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.448 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 11.1 p90 -157.25 137.8 13.04 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 118.596 -1.242 . . . . 0.0 111.227 -179.137 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -82.28 161.79 22.52 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.184 -1.006 . . . . 0.0 111.082 -179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.3 m -148.97 162.49 4.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.098 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.457 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -77.05 142.6 39.78 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.872 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.11 76.76 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.066 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.85 19.77 0.1 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -102.74 162.39 12.97 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.793 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -95.59 150.85 19.89 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.529 -0.869 . . . . 0.0 111.371 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.8 mm -124.26 103.4 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.002 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.3 p -100.58 114.08 27.45 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.536 -0.866 . . . . 0.0 112.745 -178.205 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -83.8 122.32 28.52 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 177.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.3 tttp -121.34 121.56 37.91 Favored 'General case' 0 N--CA 1.502 2.129 0 C-N-CA 119.396 -0.922 . . . . 0.0 112.104 -177.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 0.6 OUTLIER -69.94 113.13 6.87 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.737 179.551 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.422 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 1.9 t30 -100.34 -27.87 13.25 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.685 -179.282 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 175.85 141.33 0.06 Allowed 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 119.256 -0.978 . . . . 0.0 111.122 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 103.2 0.12 47.52 Favored Glycine 0 N--CA 1.494 2.505 0 C-N-CA 119.428 -1.368 . . . . 0.0 112.194 178.626 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -48.16 162.66 0.32 Allowed Pre-proline 0 N--CA 1.487 1.386 0 C-N-CA 118.013 -1.475 . . . . 0.0 109.614 179.766 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -78.59 154.06 91.76 Favored 'Cis proline' 0 C--O 1.215 -0.635 0 C-N-CA 124.354 -1.102 . . . . 0.0 112.288 -0.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 43.8 m-70 -115.62 -177.02 3.05 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.016 178.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -159.75 108.54 1.78 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.41 178.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.2 mp -91.65 121.35 42.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.011 -1.076 . . . . 0.0 111.906 -179.103 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.2 t -134.76 142.37 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.716 179.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.55 ' H ' ' HG ' ' A' ' 56' ' ' SER . 8.0 m-85 -99.48 123.82 44.09 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.309 -0.956 . . . . 0.0 111.577 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.547 ' C ' ' H ' ' A' ' 44' ' ' ASP . 10.5 t0 -68.75 112.0 5.2 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.911 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -72.67 25.46 0.06 Allowed 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.546 -0.861 . . . . 0.0 111.132 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.547 ' H ' ' C ' ' A' ' 42' ' ' ASP . 32.0 m-20 -108.56 -7.9 15.61 Favored 'General case' 0 N--CA 1.49 1.557 0 C-N-CA 119.888 -0.725 . . . . 0.0 110.812 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -142.75 13.4 1.91 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.706 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -93.05 144.37 28.27 Favored Pre-proline 0 C--N 1.298 -1.658 0 C-N-CA 119.559 -0.856 . . . . 0.0 109.693 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -49.15 148.52 9.78 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.931 1.087 . . . . 0.0 112.09 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.79 74.91 5.31 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 119.651 -0.82 . . . . 0.0 110.49 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.66 -51.12 0.19 Allowed Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 84.4 t -72.3 87.09 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.006 179.088 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -44.47 139.23 2.86 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.77 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -91.14 -16.05 28.41 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.878 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -81.13 -11.74 59.4 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.699 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.9 mtmt -91.89 -27.3 18.01 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.299 -0.96 . . . . 0.0 111.071 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.2 pt -92.31 -30.44 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 C-N-CA 119.149 -1.02 . . . . 0.0 110.727 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.55 ' HG ' ' H ' ' A' ' 41' ' ' PHE . 19.1 m -71.07 167.58 18.96 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.095 179.643 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.609 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -136.17 81.1 39.14 Favored Pre-proline 0 C--N 1.302 -1.46 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.567 179.285 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_exo -56.05 -16.34 16.34 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 121.317 1.345 . . . . 0.0 112.114 -178.315 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.414 ' O ' ' O ' ' A' ' 60' ' ' TYR . 9.6 mt-10 -73.24 103.32 3.91 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.001 179.157 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.414 ' O ' ' O ' ' A' ' 59' ' ' GLU . 83.6 m-85 -43.71 168.39 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 119.6 -0.84 . . . . 0.0 111.148 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.1 pp -147.53 139.17 23.96 Favored 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.379 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -141.15 28.86 1.86 Allowed 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.843 -179.354 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -92.11 115.24 4.74 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.203 -1.475 . . . . 0.0 110.614 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.37 110.33 1.22 Allowed 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.857 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 98.74 -13.02 62.7 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.521 -1.323 . . . . 0.0 110.414 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 38.9 tt0 -62.65 148.95 44.8 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.246 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.11 164.81 29.16 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.244 -0.982 . . . . 0.0 111.371 -179.643 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.609 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 36.9 t80 -135.53 133.16 38.13 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 120.011 -0.676 . . . . 0.0 109.492 179.566 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -94.83 152.88 18.03 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.184 -178.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 t -150.59 135.38 9.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.267 179.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.5 m -127.65 102.4 6.81 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.417 -0.913 . . . . 0.0 112.254 -178.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 19.9 mt -89.47 155.81 19.06 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.184 -1.006 . . . . 0.0 109.02 178.37 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' THR . . . . . 0.408 ' CG2' ' O ' ' A' ' 73' ' ' THR . 67.2 m -150.94 47.81 0.85 Allowed 'General case' 0 C--N 1.293 -1.854 0 C-N-CA 118.878 -1.129 . . . . 0.0 111.79 -179.05 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.438 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 5.2 tp10 -145.91 103.07 3.72 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 118.95 -1.1 . . . . 0.0 110.017 179.204 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.425 ' N ' ' OE2' ' A' ' 74' ' ' GLU . 0.0 OUTLIER -40.69 114.19 0.44 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.49 -179.25 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 170.93 -148.93 11.72 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.169 -1.491 . . . . 0.0 110.372 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -140.32 133.07 28.99 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.926 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.589 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -119.41 154.3 33.89 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.477 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 15.2 mmtm -126.01 128.41 47.41 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.239 -0.985 . . . . 0.0 112.113 -178.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.556 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -137.23 165.44 26.11 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.063 -0.972 . . . . 0.0 110.357 178.463 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.9 p90 -170.58 -175.72 1.93 Allowed 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 119.724 -0.791 . . . . 0.0 110.277 -178.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.2 t -110.38 126.77 54.63 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.498 -0.881 . . . . 0.0 109.95 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.547 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 3.9 tm-20 -73.17 -36.72 3.39 Favored Pre-proline 0 N--CA 1.486 1.366 0 C-N-CA 119.181 -1.008 . . . . 0.0 113.689 -178.462 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.547 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -70.66 -52.39 0.26 Allowed 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 120.527 0.818 . . . . 0.0 110.998 179.701 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -80.25 12.82 2.67 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.759 -0.776 . . . . 0.0 110.791 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.45 -13.43 8.71 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.53 -0.868 . . . . 0.0 110.862 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.26 -18.19 79.45 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.277 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.28 -32.19 13.75 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.921 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.53 8.35 9.21 Favored Glycine 0 N--CA 1.497 2.711 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -50.27 105.26 0.09 Allowed 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.951 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.6 pttp -129.53 160.69 32.43 Favored 'General case' 0 N--CA 1.497 1.883 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.329 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.22 152.21 24.1 Favored Glycine 0 N--CA 1.497 2.742 0 C-N-CA 119.458 -1.354 . . . . 0.0 111.372 -178.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 72.1 tt0 -154.25 148.69 26.16 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.654 -0.818 . . . . 0.0 110.83 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 10.8 p -140.04 125.63 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 C-N-CA 119.205 -0.998 . . . . 0.0 110.449 179.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 41.4 m -102.89 99.82 9.76 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.459 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 43.3 t -79.22 147.11 6.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 C-N-CA 118.558 -1.257 . . . . 0.0 110.597 -178.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.401 ' OD1' ' N ' ' A' ' 97' ' ' ASN . 12.0 p-10 . . . . . 0 C--N 1.305 -1.338 0 CA-C-O 116.275 -1.822 . . . . 0.0 110.787 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 CA-C-O 120.783 0.325 . . . . 0.0 110.169 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -133.14 130.27 38.98 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 120.021 -0.672 . . . . 0.0 110.575 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.1 t -125.55 126.76 70.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.974 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 21.7 mttm -99.83 119.37 38.08 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.985 -179.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.442 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 77.8 mt -79.35 104.01 9.67 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.142 178.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.437 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 116.31 138.35 6.3 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -178.63 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.405 ' OG ' ' N ' ' A' ' 8' ' ' ASP . 58.2 p -64.02 -69.41 0.28 Allowed 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.073 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.405 ' N ' ' OG ' ' A' ' 7' ' ' SER . 5.5 m-20 -153.19 -41.02 0.1 Allowed 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 119.404 -0.918 . . . . 0.0 110.645 179.775 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 179.87 13.53 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.804 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -159.95 22.59 0.27 Allowed Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.425 -1.369 . . . . 0.0 110.559 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.64 138.35 6.61 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.35 -1.405 . . . . 0.0 110.45 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 28.1 mt -113.02 97.56 6.6 Favored 'General case' 0 N--CA 1.49 1.534 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.426 179.752 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.6 m -150.07 155.85 7.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 C-N-CA 118.807 -1.157 . . . . 0.0 111.109 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 18.6 m-85 -78.37 112.1 15.05 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.45 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.8 m -116.17 107.96 46.74 Favored Pre-proline 0 CA--C 1.56 1.354 0 C-N-CA 119.496 -0.882 . . . . 0.0 111.968 -177.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.405 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.3 Cg_endo -65.91 175.53 22.77 Favored 'Cis proline' 0 C--N 1.362 1.268 0 C-N-CA 125.221 -0.741 . . . . 0.0 111.448 0.119 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.01 -45.82 6.12 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.65 -0.82 . . . . 0.0 110.056 179.415 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -137.66 135.18 36.27 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.525 179.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 18.4 p90 -161.5 143.76 11.91 Favored 'General case' 0 N--CA 1.485 1.285 0 C-N-CA 118.577 -1.249 . . . . 0.0 111.497 -179.093 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.3 p -87.27 156.55 19.59 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.331 -0.948 . . . . 0.0 110.957 179.77 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.8 m -148.61 173.12 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.896 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.416 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -88.8 149.43 23.42 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.415 179.635 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.8 74.32 0.1 Allowed 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.981 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 156.08 16.42 0.04 OUTLIER Glycine 0 N--CA 1.488 2.16 0 C-N-CA 119.562 -1.304 . . . . 0.0 109.983 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -95.52 151.26 19.47 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.914 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ptmt -95.34 123.58 38.94 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.527 -0.869 . . . . 0.0 111.114 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.0 mt -101.86 108.07 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.696 179.6 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 p -104.48 112.42 25.47 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.653 -0.819 . . . . 0.0 112.572 -178.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -84.83 116.74 23.46 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.142 178.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.1 ttpt -113.1 126.31 55.32 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.389 -178.036 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -68.11 113.97 6.22 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.737 178.648 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.453 ' O ' ' CB ' ' A' ' 33' ' ' ALA . 2.4 p-10 -107.31 -22.3 12.64 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 119.171 -1.011 . . . . 0.0 111.15 179.552 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.453 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 169.38 114.46 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 118.926 -1.11 . . . . 0.0 111.113 179.511 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 129.15 7.73 3.93 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.124 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.514 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -57.68 161.63 6.01 Favored Pre-proline 0 C--N 1.306 -1.292 0 C-N-CA 118.521 -1.272 . . . . 0.0 109.95 -179.947 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -80.01 152.68 85.23 Favored 'Cis proline' 0 C--O 1.213 -0.731 0 C-N-CA 124.037 -1.235 . . . . 0.0 112.326 -1.079 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 45.1 m-70 -113.06 165.19 12.6 Favored 'General case' 0 N--CA 1.493 1.722 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.246 178.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.403 ' C ' ' ND2' ' A' ' 38' ' ' ASN . 1.2 t-20 -149.6 99.76 2.91 Favored 'General case' 0 N--CA 1.49 1.549 0 C-N-CA 118.974 -1.09 . . . . 0.0 110.783 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.8 mp -84.95 135.65 24.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 119.279 -0.969 . . . . 0.0 111.472 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -143.55 143.56 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.004 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.5 m-85 -101.56 123.0 44.88 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.539 -0.864 . . . . 0.0 111.702 -179.396 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -66.33 118.06 9.46 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 119.404 -0.918 . . . . 0.0 109.994 179.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.504 ' CD ' ' H ' ' A' ' 43' ' ' GLU . 1.5 pm0 -71.32 -6.65 41.55 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 119.454 -0.898 . . . . 0.0 112.211 -178.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -95.58 5.89 50.35 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.174 -1.01 . . . . 0.0 111.574 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -143.22 16.67 1.89 Allowed 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.702 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -105.19 151.64 39.61 Favored Pre-proline 0 N--CA 1.489 1.481 0 CA-C-N 115.241 -0.89 . . . . 0.0 108.635 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -46.37 151.04 1.9 Allowed 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 121.173 1.249 . . . . 0.0 112.131 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.93 72.12 6.67 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.859 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.58 -35.39 0.14 Allowed Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.548 -1.31 . . . . 0.0 110.054 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 72.8 t -90.34 95.24 5.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.612 179.661 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 66.0 m-20 -50.15 152.9 1.57 Allowed 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.167 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.509 ' C ' ' H ' ' A' ' 54' ' ' LYS . . . -83.09 -38.25 22.74 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.468 179.641 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -63.69 0.52 0.77 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.387 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.509 ' H ' ' C ' ' A' ' 52' ' ' ALA . 0.0 OUTLIER -91.36 -45.68 8.45 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.583 179.973 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -94.46 -25.35 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.875 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 37.3 m -48.74 164.63 0.06 Allowed 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.503 -0.879 . . . . 0.0 110.902 179.695 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.624 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 8.0 mt-30 -138.05 73.96 44.26 Favored Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 120.021 -0.671 . . . . 0.0 110.845 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -61.46 -25.6 80.01 Favored 'Trans proline' 0 C--N 1.324 -0.721 0 C-N-CA 121.301 1.334 . . . . 0.0 111.325 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -68.28 97.76 0.76 Allowed 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.421 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 47.5 m-85 -48.19 162.89 0.07 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.509 -0.877 . . . . 0.0 111.219 -179.7 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -142.22 106.32 4.76 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.751 179.631 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -114.23 21.45 14.69 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.075 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -90.85 118.64 5.42 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.281 -1.438 . . . . 0.0 110.525 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -58.42 111.35 1.2 Allowed 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.63 179.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.82 -13.35 57.76 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.732 -1.223 . . . . 0.0 110.407 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -60.81 148.04 40.58 Favored 'General case' 0 N--CA 1.487 1.402 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.456 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 2.3 p -145.83 165.4 28.99 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.275 -0.97 . . . . 0.0 111.3 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.624 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 38.3 t80 -136.15 146.99 47.51 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.868 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.42 ' CD ' ' N ' ' A' ' 69' ' ' GLU . 2.1 mp0 -106.88 154.1 21.54 Favored 'General case' 0 N--CA 1.496 1.874 0 C-N-CA 119.431 -0.908 . . . . 0.0 112.164 -179.053 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -151.18 134.23 7.02 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.137 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 12.5 m -129.44 114.24 15.9 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.735 -0.786 . . . . 0.0 111.125 -179.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 17.1 mt -97.6 163.44 12.84 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.696 -0.802 . . . . 0.0 110.079 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 62.3 m -150.38 51.95 0.89 Allowed 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 118.939 -1.104 . . . . 0.0 111.468 -179.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.419 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 0.4 OUTLIER -152.72 105.8 3.01 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 118.916 -1.114 . . . . 0.0 110.658 179.533 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -48.85 110.43 0.35 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.958 -1.097 . . . . 0.0 110.609 -179.695 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.39 -142.66 6.29 Favored Glycine 0 N--CA 1.488 2.139 0 C-N-CA 119.218 -1.468 . . . . 0.0 110.078 -179.622 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.58 129.25 19.23 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.357 -0.937 . . . . 0.0 111.114 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.568 ' N ' ' CD1' ' A' ' 78' ' ' TYR . 1.5 m-85 -116.03 122.86 46.45 Favored 'General case' 0 N--CA 1.484 1.236 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.535 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.425 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -95.04 113.99 25.75 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.992 -178.843 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.555 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -122.83 165.39 16.71 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.608 178.307 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 30.9 p90 -170.78 -177.62 2.34 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.971 -178.596 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -110.28 113.27 25.81 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.462 178.483 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.541 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.8 tt0 -65.79 -39.75 33.86 Favored Pre-proline 0 C--N 1.303 -1.427 0 C-N-CA 119.416 -0.914 . . . . 0.0 112.891 -178.735 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.541 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.5 Cg_endo -68.53 -50.39 0.68 Allowed 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 120.499 0.8 . . . . 0.0 111.804 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -83.26 15.8 2.76 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.998 -179.579 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.97 -1.97 4.73 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.636 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -72.4 -27.46 69.68 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.307 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.77 -50.48 5.13 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.561 -0.856 . . . . 0.0 110.456 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.84 30.67 0.12 Allowed Glycine 0 N--CA 1.486 1.987 0 C-N-CA 119.618 -1.277 . . . . 0.0 110.492 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 2.5 mtp -72.17 97.65 1.99 Allowed 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.149 -1.02 . . . . 0.0 111.02 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.481 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -122.76 168.06 12.7 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.66 179.688 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -150.53 146.33 15.25 Favored Glycine 0 N--CA 1.487 2.082 0 C-N-CA 118.883 -1.627 . . . . 0.0 111.563 -178.658 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -149.51 140.87 23.23 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 119.808 -0.757 . . . . 0.0 110.535 179.346 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.4 p -131.96 120.57 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.729 179.484 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 6.6 m -94.92 96.97 9.66 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.23 179.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.6 t -79.98 153.01 4.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.639 -178.681 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.307 -1.251 0 CA-C-O 116.349 -1.786 . . . . 0.0 110.775 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.138 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 -103.74 152.43 21.86 Favored 'General case' 0 N--CA 1.49 1.525 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.856 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.3 t -134.03 145.72 32.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 C-N-CA 119.718 -0.793 . . . . 0.0 110.591 179.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -114.74 109.15 17.76 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 115.118 -0.947 . . . . 0.0 110.609 -179.502 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.438 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 3.9 mt -78.9 106.49 10.96 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.131 -1.027 . . . . 0.0 109.848 179.044 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.427 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 115.29 138.18 6.48 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -178.609 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.65 ' HG ' ' H ' ' A' ' 9' ' ' ASP . 32.1 p -71.93 170.33 13.99 Favored 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.363 -0.935 . . . . 0.0 111.383 -179.411 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 19.4 m-20 -69.33 -12.25 61.5 Favored 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 119.457 -0.897 . . . . 0.0 111.515 -179.347 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.65 ' H ' ' HG ' ' A' ' 7' ' ' SER . 0.4 OUTLIER -177.99 81.88 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 118.301 -1.36 . . . . 0.0 112.735 -179.972 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.93 71.13 1.05 Allowed Glycine 0 N--CA 1.497 2.747 0 C-N-CA 119.266 -1.445 . . . . 0.0 112.342 177.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 172.31 139.48 2.84 Favored Glycine 0 N--CA 1.485 1.94 0 C-N-CA 118.973 -1.584 . . . . 0.0 110.831 178.411 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.7 mt -116.95 83.63 2.01 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.158 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.9 m -139.73 161.45 26.8 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 C-N-CA 119.376 -0.929 . . . . 0.0 111.501 -178.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.422 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 22.4 m-85 -78.41 110.46 13.48 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 177.793 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 5.6 m -115.67 106.32 50.42 Favored Pre-proline 0 N--CA 1.486 1.348 0 C-N-CA 119.775 -0.77 . . . . 0.0 111.315 -178.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.402 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.7 Cg_endo -66.78 174.61 28.67 Favored 'Cis proline' 0 C--N 1.356 0.94 0 C-N-CA 125.326 -0.698 . . . . 0.0 112.075 0.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -93.3 -55.05 3.45 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.885 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 69.8 m -125.15 140.36 52.94 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.541 179.022 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.438 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 10.4 p90 -156.69 132.06 9.28 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 118.649 -1.22 . . . . 0.0 111.397 -179.315 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.5 p -87.86 152.58 21.98 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.081 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.4 m -147.0 176.13 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.865 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -90.14 155.89 18.73 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.506 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.49 61.21 0.68 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.565 -0.854 . . . . 0.0 111.296 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 170.77 11.91 0.02 OUTLIER Glycine 0 N--CA 1.489 2.216 0 C-N-CA 119.569 -1.3 . . . . 0.0 109.91 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.408 ' OE1' ' O ' ' A' ' 26' ' ' LYS . 5.7 tm-20 -104.61 123.37 47.44 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.969 -0.693 . . . . 0.0 110.831 -179.636 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.408 ' O ' ' OE1' ' A' ' 25' ' ' GLU . 1.3 pttp -69.73 150.31 47.07 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.25 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mt -122.86 147.45 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.2 p -139.22 117.56 11.99 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.218 -0.993 . . . . 0.0 111.626 -179.321 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -84.28 150.58 25.32 Favored 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 119.267 -0.973 . . . . 0.0 109.796 179.058 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -144.55 138.72 27.69 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 118.999 -1.08 . . . . 0.0 111.707 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.613 HD22 ' CB ' ' A' ' 66' ' ' GLU . 0.5 OUTLIER -85.31 131.27 34.44 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.423 178.839 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 5' ' ' LEU . 5.6 p-10 -111.56 -32.38 6.7 Favored 'General case' 0 N--CA 1.505 2.281 0 C-N-CA 119.107 -1.037 . . . . 0.0 112.587 -179.631 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 176.42 30.48 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 118.941 -1.104 . . . . 0.0 110.819 -179.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.493 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -138.78 40.3 1.47 Allowed Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.229 -1.462 . . . . 0.0 111.233 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.596 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -86.2 161.58 48.82 Favored Pre-proline 0 C--N 1.309 -1.194 0 C-N-CA 118.442 -1.303 . . . . 0.0 109.999 179.226 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -78.65 135.82 38.54 Favored 'Cis proline' 0 C--O 1.215 -0.649 0 C-N-CA 124.075 -1.219 . . . . 0.0 111.568 -0.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.493 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 40.4 m-70 -100.21 -177.1 3.42 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.749 179.589 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.619 ' ND2' ' N ' ' A' ' 39' ' ' ILE . 1.7 t-20 -161.11 146.86 14.36 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.3 -0.96 . . . . 0.0 110.916 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.619 ' N ' ' ND2' ' A' ' 38' ' ' ASN . 3.5 mt -131.0 114.91 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.779 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.449 ' CG2' HD22 ' A' ' 38' ' ' ASN . 3.0 t -137.15 137.24 46.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.124 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 44.1 m-85 -93.67 127.63 39.46 Favored 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.236 -0.986 . . . . 0.0 111.413 -179.602 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.4 125.77 25.28 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.895 179.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -57.47 -49.94 74.64 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 -177.143 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -85.21 8.23 19.11 Favored 'General case' 0 N--CA 1.498 1.936 0 C-N-CA 118.941 -1.104 . . . . 0.0 113.855 -176.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -126.86 40.35 3.74 Favored 'General case' 0 N--CA 1.495 1.781 0 C-N-CA 119.341 -0.944 . . . . 0.0 110.568 179.347 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -135.59 156.33 77.7 Favored Pre-proline 0 N--CA 1.487 1.399 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 179.279 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -48.04 148.06 7.24 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 120.916 1.077 . . . . 0.0 111.73 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.57 70.37 6.03 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.644 -0.822 . . . . 0.0 111.035 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.37 -22.78 0.09 OUTLIER Glycine 0 N--CA 1.489 2.211 0 C-N-CA 119.342 -1.409 . . . . 0.0 110.435 179.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 44.6 t -97.42 99.78 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.809 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -46.75 149.66 0.81 Allowed 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.256 -0.978 . . . . 0.0 110.715 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.435 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -94.64 -5.69 45.09 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.623 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -86.14 -29.6 23.16 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.107 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 21.4 mmtt -71.87 -27.55 62.94 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.463 -0.895 . . . . 0.0 111.481 -179.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 10.7 pt -105.15 -14.95 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 C-N-CA 119.559 -0.857 . . . . 0.0 111.944 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.435 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 4.7 m -67.32 173.62 3.83 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.241 -0.983 . . . . 0.0 110.827 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.656 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 12.9 tt0 -136.93 76.01 47.14 Favored Pre-proline 0 C--N 1.306 -1.321 0 C-N-CA 120.072 -0.651 . . . . 0.0 110.354 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -60.02 -22.33 68.85 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 121.359 1.373 . . . . 0.0 111.985 -178.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 38.8 mm-40 -89.89 106.83 18.74 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.139 -1.024 . . . . 0.0 110.652 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 30.9 m-85 -56.37 170.5 0.35 Allowed 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.728 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.5 pp -140.26 129.48 23.75 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.098 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -127.68 10.33 6.59 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.521 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.48 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . -77.85 118.78 5.08 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.412 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.9 105.12 0.52 Allowed 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.759 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.24 -2.77 43.66 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.559 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.613 ' CB ' HD22 ' A' ' 31' ' ' ASN . 2.8 tp10 -63.16 161.14 14.05 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 118.916 -1.113 . . . . 0.0 110.229 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 66.8 p -147.45 163.14 37.45 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.556 -179.138 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.656 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 76.0 t80 -135.62 139.14 43.57 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.751 179.05 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -107.59 153.17 23.27 Favored 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 119.513 -0.875 . . . . 0.0 112.577 -178.477 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 p -161.51 132.9 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.391 178.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.8 m -119.81 95.6 4.84 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.733 -178.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 12.2 mt -80.46 158.49 25.88 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.384 -0.926 . . . . 0.0 109.226 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.0 p -151.14 28.44 0.67 Allowed 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 118.65 -1.22 . . . . 0.0 112.253 -179.02 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.506 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -114.5 97.75 6.49 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.024 179.599 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.8 tttt -41.68 98.0 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.958 -179.674 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 74' ' ' GLU . . . 177.56 -134.17 2.4 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.176 -1.488 . . . . 0.0 110.257 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -145.31 142.0 29.05 Favored 'General case' 0 C--N 1.309 -1.165 0 C-N-CA 119.216 -0.994 . . . . 0.0 111.519 -179.683 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.574 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.2 m-85 -128.05 128.31 44.72 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.386 -0.825 . . . . 0.0 108.779 179.359 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -105.77 118.97 37.96 Favored 'General case' 0 N--CA 1.488 1.453 0 C-N-CA 119.243 -0.983 . . . . 0.0 111.318 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -124.31 172.91 8.73 Favored 'General case' 0 C--O 1.206 -1.205 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.56 178.532 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -171.06 175.3 4.39 Favored 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 118.932 -1.107 . . . . 0.0 111.577 -178.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.4 t -99.66 127.06 45.77 Favored 'General case' 0 C--N 1.3 -1.587 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.287 179.494 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.593 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 3.2 tm-20 -73.88 -34.95 2.25 Favored Pre-proline 0 N--CA 1.492 1.661 0 C-N-CA 118.85 -1.14 . . . . 0.0 113.667 -178.498 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.1 Cg_endo -72.68 -52.31 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 120.671 0.914 . . . . 0.0 110.99 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 34.4 m80 -81.39 14.72 2.32 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.879 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -62.89 -6.19 3.56 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.187 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.31 -21.43 62.5 Favored Glycine 0 N--CA 1.49 2.267 0 C-N-CA 119.339 -1.41 . . . . 0.0 110.307 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.73 -22.36 18.15 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.956 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.426 ' O ' ' N ' ' A' ' 91' ' ' LYS . . . 109.27 11.82 21.15 Favored Glycine 0 N--CA 1.497 2.754 0 C-N-CA 119.964 -1.112 . . . . 0.0 110.364 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 6.1 ttt -53.9 92.62 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.474 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.584 ' CB ' ' HZ1' ' A' ' 91' ' ' LYS . 0.1 OUTLIER -117.1 158.73 23.7 Favored 'General case' 0 N--CA 1.5 2.039 0 C-N-CA 119.855 -0.738 . . . . 0.0 111.386 -179.73 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.23 146.53 18.45 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.027 -1.082 . . . . 0.0 111.052 -178.676 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -148.85 147.1 28.32 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.842 179.707 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.4 p -140.05 129.89 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.195 179.131 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 90.4 m -106.09 100.78 10.31 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.656 -0.818 . . . . 0.0 110.964 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 47.1 t -82.48 142.99 12.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.364 -179.071 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 17.3 p30 . . . . . 0 C--N 1.307 -1.253 0 CA-C-O 116.328 -1.796 . . . . 0.0 110.952 -179.688 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.905 0.383 . . . . 0.0 110.036 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -92.7 131.46 37.76 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.404 -0.918 . . . . 0.0 110.562 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 t -122.29 121.72 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.404 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.58 118.83 31.86 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.186 179.46 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.8 mt -78.54 98.83 6.26 Favored 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.9 179.019 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.464 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 113.59 131.6 5.39 Favored Glycine 0 N--CA 1.488 2.151 0 CA-C-N 114.546 -1.206 . . . . 0.0 110.323 -179.135 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.534 ' HG ' ' H ' ' A' ' 11' ' ' GLY . 56.3 p -83.22 167.49 17.64 Favored 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 119.299 -0.96 . . . . 0.0 110.548 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.5 -20.07 66.19 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.476 -0.889 . . . . 0.0 111.422 -179.798 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -172.95 1.09 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.141 -1.023 . . . . 0.0 111.238 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.523 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . -77.31 -32.31 48.29 Favored Glycine 0 N--CA 1.492 2.403 0 C-N-CA 119.438 -1.363 . . . . 0.0 110.745 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.534 ' H ' ' HG ' ' A' ' 7' ' ' SER . . . 140.55 -134.68 6.59 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.519 -1.324 . . . . 0.0 110.5 -179.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.7 mt -117.06 104.27 11.07 Favored 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 120.018 -0.673 . . . . 0.0 110.893 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.0 m -150.39 157.06 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 118.979 -1.088 . . . . 0.0 110.954 179.45 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.419 ' O ' ' O ' ' A' ' 16' ' ' PRO . 62.2 m-85 -78.27 110.83 13.63 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 16.5 m -114.2 111.62 47.28 Favored Pre-proline 0 CA--C 1.56 1.341 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.948 -177.459 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.419 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.3 Cg_exo -65.83 174.18 26.4 Favored 'Cis proline' 0 C--N 1.36 1.158 0 C-N-CA 125.105 -0.79 . . . . 0.0 111.611 -0.343 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.9 m -97.45 -65.87 0.94 Allowed 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.098 179.256 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 m -114.39 137.68 51.51 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.734 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 34.5 p90 -168.2 147.4 4.58 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 118.49 -1.284 . . . . 0.0 111.656 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 44.2 p -83.31 161.55 21.4 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.193 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 31.5 m -149.32 148.72 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.228 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.662 179.541 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.539 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -76.51 140.74 41.29 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.294 -0.962 . . . . 0.0 110.751 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -58.78 78.39 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.242 0 C-N-CA 119.657 -0.817 . . . . 0.0 110.937 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 148.21 21.22 0.09 OUTLIER Glycine 0 N--CA 1.487 2.071 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -102.56 150.34 23.5 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.924 -0.71 . . . . 0.0 110.733 -179.718 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 74.9 mttt -95.2 117.69 30.69 Favored 'General case' 0 C--N 1.303 -1.434 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.055 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.5 mt -93.22 98.35 8.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 119.501 -0.88 . . . . 0.0 108.962 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 55.0 p -94.34 117.43 30.11 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 119.493 -0.883 . . . . 0.0 112.821 -177.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -84.68 143.62 29.08 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.049 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 11.4 ttpt -135.3 125.55 26.33 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.387 -178.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.525 ' OD1' ' CD1' ' A' ' 35' ' ' PHE . 36.5 t-20 -79.39 115.8 19.24 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 119.792 -0.763 . . . . 0.0 110.009 179.354 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.464 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 3.0 p-10 -120.29 -22.23 6.63 Favored 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.307 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -177.45 123.43 0.13 Allowed 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 118.358 -1.337 . . . . 0.0 112.188 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 104.17 48.6 1.13 Allowed Glycine 0 N--CA 1.495 2.618 0 C-N-CA 119.272 -1.442 . . . . 0.0 112.849 177.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.623 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -87.54 164.83 33.39 Favored Pre-proline 0 C--N 1.304 -1.37 0 C-N-CA 118.573 -1.251 . . . . 0.0 108.936 177.91 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -77.2 140.13 62.6 Favored 'Cis proline' 0 C--O 1.215 -0.642 0 C-N-CA 124.555 -1.019 . . . . 0.0 112.917 -0.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 33.6 m-70 -108.15 161.28 15.12 Favored 'General case' 0 N--CA 1.495 1.794 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.952 178.607 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.721 HD22 ' H ' ' A' ' 83' ' ' GLU . 4.0 p-10 -153.52 163.18 40.4 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 119.049 -1.061 . . . . 0.0 110.684 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -133.78 124.35 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.841 -0.743 . . . . 0.0 110.758 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.7 t -137.48 141.31 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.264 179.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -96.39 130.75 43.45 Favored 'General case' 0 C--N 1.303 -1.455 0 C-N-CA 119.574 -0.85 . . . . 0.0 111.706 -178.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -73.9 117.19 15.4 Favored 'General case' 0 N--CA 1.485 1.279 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.789 179.034 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -69.56 0.3 5.57 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.435 -0.906 . . . . 0.0 112.013 -178.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 62.3 m-20 -99.76 -5.79 28.08 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.357 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 31.0 mm-40 -123.37 -2.38 8.52 Favored 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.615 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 42.2 t -95.99 144.93 28.66 Favored Pre-proline 0 C--N 1.285 -2.216 0 N-CA-C 107.256 -1.386 . . . . 0.0 107.256 178.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -61.09 165.2 12.82 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 CA-C-N 119.024 0.687 . . . . 0.0 111.89 -178.367 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.8 38.89 0.72 Allowed 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.381 -0.928 . . . . 0.0 110.239 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.18 -57.83 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . 0.454 ' CG1' ' O ' ' A' ' 50' ' ' VAL . 9.8 p -84.46 101.99 9.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.722 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -48.97 153.81 0.82 Allowed 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.681 -0.808 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -98.29 -10.16 24.35 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.443 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -88.1 -10.46 50.02 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.652 -0.819 . . . . 0.0 110.579 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.4 13.2 16.19 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.465 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.1 pt -147.38 -29.09 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 C-N-CA 119.503 -0.879 . . . . 0.0 110.814 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 2.1 m -48.58 174.25 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.948 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.624 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 36.5 mt-30 -135.5 78.95 49.23 Favored Pre-proline 0 N--CA 1.489 1.491 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.022 -179.833 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -60.58 -7.86 7.97 Favored 'Trans proline' 0 N--CA 1.456 -0.686 0 C-N-CA 120.78 0.987 . . . . 0.0 110.641 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.406 ' H ' ' C ' ' A' ' 57' ' ' GLN . 51.2 mt-10 -98.01 127.61 44.06 Favored 'General case' 0 N--CA 1.483 1.179 0 C-N-CA 119.778 -0.769 . . . . 0.0 110.227 179.309 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.435 ' CD1' ' N ' ' A' ' 60' ' ' TYR . 32.4 m-85 -88.59 173.58 8.56 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.917 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -137.94 106.53 5.87 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.658 179.644 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.617 ' H ' ' ND2' ' A' ' 62' ' ' ASN . 0.3 OUTLIER -101.67 3.65 39.97 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.912 179.993 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -65.83 -140.58 0.04 OUTLIER Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.392 -1.385 . . . . 0.0 110.413 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -159.42 99.61 1.46 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.68 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.44 -1.12 43.01 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 119.815 -1.183 . . . . 0.0 110.44 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -63.03 158.74 18.72 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.56 179.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.2 p -147.26 155.48 42.09 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.828 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.624 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 41.0 t80 -136.97 153.51 50.67 Favored 'General case' 0 N--CA 1.488 1.444 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.443 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.411 ' O ' ' CE1' ' A' ' 68' ' ' TYR . 3.6 mt-10 -113.41 149.18 34.52 Favored 'General case' 0 N--CA 1.501 2.082 0 C-N-CA 119.44 -0.904 . . . . 0.0 112.224 -179.076 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -144.62 126.04 9.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.182 179.033 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.9 m -119.22 100.11 7.12 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.82 -0.752 . . . . 0.0 111.268 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 65.9 mt -79.55 161.28 26.08 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.65 179.171 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.9 p -150.07 48.53 0.91 Allowed 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 118.819 -1.152 . . . . 0.0 111.742 -178.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.4 ' O ' ' C ' ' A' ' 75' ' ' LYS . 3.6 mm-40 -148.17 98.26 2.9 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.567 179.416 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 74' ' ' GLU . 0.0 OUTLIER -43.67 107.8 0.09 Allowed 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.596 -179.784 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 176.48 -141.91 5.7 Favored Glycine 0 C--N 1.294 -1.773 0 C-N-CA 119.066 -1.54 . . . . 0.0 110.094 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.52 136.67 26.22 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.476 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.592 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.2 OUTLIER -128.78 137.64 51.64 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.488 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.37 108.64 16.78 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.932 179.759 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.504 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 2.1 p90 -109.87 170.95 7.74 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.202 179.445 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -171.18 179.84 2.9 Favored 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 119.362 -0.935 . . . . 0.0 112.068 -178.454 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . 0.465 ' SG ' ' OD1' ' A' ' 38' ' ' ASN . 1.5 t -108.96 124.45 50.71 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.205 179.122 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.721 ' H ' HD22 ' A' ' 38' ' ' ASN . 0.3 OUTLIER -68.46 -39.4 15.51 Favored Pre-proline 0 N--CA 1.488 1.442 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -178.283 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.3 Cg_endo -73.35 -51.67 0.16 Allowed 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 121.02 1.147 . . . . 0.0 111.84 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -81.4 8.49 9.17 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.286 -0.966 . . . . 0.0 111.328 -179.327 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.03 -17.28 64.31 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.198 -1.001 . . . . 0.0 110.686 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -65.05 -22.98 69.28 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.493 -1.336 . . . . 0.0 110.248 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.25 -39.82 10.78 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.562 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 135.65 20.89 0.67 Allowed Glycine 0 N--CA 1.493 2.461 0 C-N-CA 119.744 -1.217 . . . . 0.0 110.34 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.98 106.2 2.26 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.312 -0.955 . . . . 0.0 111.19 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.409 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 2.1 pttp -135.15 169.5 17.35 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.938 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.462 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -150.51 150.17 22.14 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 119.013 -1.565 . . . . 0.0 111.417 -178.467 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -150.09 143.52 25.15 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.519 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 6.6 p -141.03 126.34 18.77 Favored 'Isoleucine or valine' 0 C--O 1.205 -1.285 0 C-N-CA 119.244 -0.982 . . . . 0.0 110.746 179.703 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 22.7 m -103.45 103.41 13.38 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.647 -0.821 . . . . 0.0 110.423 179.432 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 21.6 t -79.55 143.15 12.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 118.714 -1.194 . . . . 0.0 110.018 -179.36 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 . . . . . 0 N--CA 1.489 1.488 0 CA-C-O 116.314 -1.803 . . . . 0.0 110.818 -179.602 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.096 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -140.21 122.49 15.92 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.748 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 98.4 t -114.52 132.54 63.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 C-N-CA 119.848 -0.741 . . . . 0.0 111.127 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -100.56 111.75 24.03 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.736 -0.786 . . . . 0.0 110.684 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.433 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 9.5 mt -75.68 105.07 6.52 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.923 178.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 112.39 131.68 5.66 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -178.61 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.742 ' HG ' ' H ' ' A' ' 11' ' ' GLY . 3.4 p -82.8 168.96 16.65 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.256 -0.978 . . . . 0.0 111.092 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -62.17 -38.51 89.35 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.671 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.6 p30 -167.7 20.57 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.778 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -96.05 -25.08 13.37 Favored Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.498 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.742 ' H ' ' HG ' ' A' ' 7' ' ' SER . . . 141.18 -140.62 10.48 Favored Glycine 0 N--CA 1.492 2.367 0 C-N-CA 119.573 -1.299 . . . . 0.0 110.475 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.9 mt -115.2 107.64 15.56 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 120.055 -0.658 . . . . 0.0 110.915 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.6 m -150.64 157.95 5.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.654 179.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.53 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 34.1 m-85 -78.39 113.24 16.21 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 178.068 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 17.3 m -116.45 107.13 47.5 Favored Pre-proline 0 CA--C 1.562 1.41 0 C-N-CA 119.5 -0.88 . . . . 0.0 112.186 -177.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -65.89 176.24 20.9 Favored 'Cis proline' 0 C--N 1.361 1.217 0 C-N-CA 125.198 -0.751 . . . . 0.0 111.414 -0.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.02 -52.05 4.39 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.486 -0.885 . . . . 0.0 110.265 179.264 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 4.5 m -132.03 135.28 46.4 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.413 179.09 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 12.8 p90 -155.71 142.32 18.74 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 118.495 -1.282 . . . . 0.0 111.573 -179.097 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 46.9 p -84.17 151.24 24.99 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.439 179.458 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.0 m -144.59 161.79 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 119.356 -0.938 . . . . 0.0 111.137 179.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.448 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -81.35 146.55 30.28 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.65 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.05 74.52 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 119.673 -0.811 . . . . 0.0 111.23 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.448 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 155.68 18.2 0.04 OUTLIER Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.466 -1.35 . . . . 0.0 109.797 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -98.63 150.95 21.22 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.951 -179.49 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.8 mttt -92.43 117.95 30.45 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.337 -0.945 . . . . 0.0 111.016 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.6 mt -97.94 110.4 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.771 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 75.6 p -110.94 114.48 27.83 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.672 -0.811 . . . . 0.0 112.515 -178.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -87.01 111.55 20.97 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.373 178.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -106.57 141.01 38.54 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 119.68 -0.808 . . . . 0.0 112.045 -178.535 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 1.7 m-80 -82.27 115.99 21.59 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.877 178.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.533 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 4.2 p-10 -98.75 -32.76 11.21 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 118.755 -1.178 . . . . 0.0 111.839 -179.398 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.483 ' N ' ' OD1' ' A' ' 32' ' ' ASN . . . 171.91 52.22 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.496 -0.881 . . . . 0.0 110.042 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.506 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -153.45 26.67 0.77 Allowed Glycine 0 N--CA 1.487 2.041 0 C-N-CA 118.992 -1.575 . . . . 0.0 110.734 -179.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.636 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -79.23 160.34 70.9 Favored Pre-proline 0 C--N 1.309 -1.191 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.96 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -77.41 138.66 54.15 Favored 'Cis proline' 0 C--O 1.215 -0.657 0 C-N-CA 123.876 -1.302 . . . . 0.0 111.757 -1.167 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.506 ' CE1' ' O ' ' A' ' 34' ' ' GLY . 38.2 m-70 -107.66 179.52 4.21 Favored 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 119.631 -0.828 . . . . 0.0 111.49 -179.293 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -156.09 143.25 19.08 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.61 -0.836 . . . . 0.0 110.354 179.781 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.2 mp -130.25 118.31 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.304 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t -145.3 147.65 18.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.656 179.064 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -99.43 139.97 34.29 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.144 -1.022 . . . . 0.0 112.006 -179.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.704 ' C ' ' H ' ' A' ' 44' ' ' ASP . 39.8 p-10 -75.37 108.37 8.11 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 115.142 -0.935 . . . . 0.0 111.296 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 27.4 mm-40 -56.47 10.8 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.156 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.589 179.748 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.704 ' H ' ' C ' ' A' ' 42' ' ' ASP . 70.8 m-20 -82.92 -68.49 0.7 Allowed 'General case' 0 C--N 1.288 -2.081 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.249 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -99.38 -5.23 29.92 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.826 -1.15 . . . . 0.0 114.038 -175.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -54.15 143.88 41.94 Favored Pre-proline 0 C--N 1.282 -2.362 0 C-N-CA 118.206 -1.397 . . . . 0.0 107.784 179.023 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_exo -46.71 146.92 5.0 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 120.713 0.942 . . . . 0.0 112.116 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -85.34 51.13 2.1 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.771 -0.772 . . . . 0.0 111.051 -179.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -165.63 -23.49 0.02 OUTLIER Glycine 0 N--CA 1.488 2.122 0 C-N-CA 119.478 -1.344 . . . . 0.0 109.965 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 53.2 t -97.85 104.26 15.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.683 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -45.56 139.85 3.6 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 119.223 -0.991 . . . . 0.0 110.567 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.433 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -101.29 -8.29 22.25 Favored 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.229 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -83.79 -21.05 32.28 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.164 -1.014 . . . . 0.0 110.966 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 51.6 mmtt -86.41 -32.88 20.66 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.263 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.4 pt -89.14 -19.81 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 C-N-CA 118.876 -1.13 . . . . 0.0 111.438 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.433 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 74.3 m -74.44 -176.6 2.77 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.971 179.354 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.537 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.4 mt-30 -142.51 82.82 12.41 Favored Pre-proline 0 N--CA 1.491 1.617 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.43 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -61.96 -9.59 14.9 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 121.187 1.258 . . . . 0.0 112.067 -179.039 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -99.23 112.55 24.69 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.387 -0.925 . . . . 0.0 110.87 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -58.69 178.04 0.12 Allowed 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.574 -0.851 . . . . 0.0 110.71 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.0 pp -151.21 142.12 22.95 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.551 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.519 ' N ' ' ND2' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -134.58 19.95 3.6 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.883 -179.752 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -86.4 139.26 16.52 Favored Glycine 0 N--CA 1.489 2.213 0 C-N-CA 119.168 -1.491 . . . . 0.0 110.219 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -85.5 111.39 19.95 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.509 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 102.25 -15.21 56.54 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 -179.624 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -64.01 147.02 53.08 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.227 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -142.43 169.92 16.67 Favored 'General case' 0 N--CA 1.486 1.369 0 C-N-CA 119.206 -0.997 . . . . 0.0 111.466 -179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.537 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 26.5 t80 -134.44 135.97 42.9 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.477 179.251 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.48 ' H ' ' CD ' ' A' ' 69' ' ' GLU . 1.6 mp0 -97.36 152.63 18.73 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.25 -0.98 . . . . 0.0 112.371 -178.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.1 t -151.58 133.5 5.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 CA-C-N 115.221 -0.899 . . . . 0.0 109.033 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 8.4 m -127.13 104.3 7.9 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.113 -179.376 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 13.9 mt -90.37 160.06 16.28 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.268 -0.973 . . . . 0.0 109.749 179.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 67.3 p -148.41 48.04 1.04 Allowed 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.558 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.438 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.9 mt-10 -147.08 105.9 3.84 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.972 -1.091 . . . . 0.0 110.453 179.311 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.74 112.03 0.42 Allowed 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.002 -1.079 . . . . 0.0 110.633 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.66 8.61 Favored Glycine 0 N--CA 1.487 2.064 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.282 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -141.44 123.73 15.68 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.399 -179.642 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.547 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -115.49 120.29 39.02 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.339 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 26.1 mttt -97.83 126.95 43.45 Favored 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 119.209 -0.996 . . . . 0.0 112.603 -178.406 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.58 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -127.61 158.58 37.13 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.679 177.928 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -165.0 176.87 8.23 Favored 'General case' 0 C--N 1.283 -2.296 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.131 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.6 t -104.39 123.86 48.19 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.787 -0.765 . . . . 0.0 110.547 -179.946 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.542 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tt0 -66.4 -44.97 58.88 Favored Pre-proline 0 C--N 1.306 -1.303 0 C-N-CA 119.685 -0.806 . . . . 0.0 112.913 -179.673 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.542 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.6 Cg_exo -65.36 -50.29 2.05 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 121.179 1.252 . . . . 0.0 111.801 -178.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -86.77 16.18 5.04 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.727 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.21 -9.35 4.74 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.777 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.36 -20.12 49.87 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.485 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.14 -12.93 39.65 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.478 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 99.02 26.07 9.17 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.505 -1.331 . . . . 0.0 110.719 179.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -76.83 101.63 5.97 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.174 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.53 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 1.5 ptmt -124.98 162.58 24.18 Favored 'General case' 0 N--CA 1.493 1.712 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.946 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.549 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -146.76 149.84 22.04 Favored Glycine 0 N--CA 1.495 2.608 0 C-N-CA 119.296 -1.431 . . . . 0.0 111.419 -178.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -156.39 145.47 20.42 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.005 179.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.47 ' CG1' ' O ' ' A' ' 94' ' ' VAL . 12.6 p -135.94 117.53 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.466 -0.893 . . . . 0.0 110.464 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 46.1 m -93.72 100.4 12.63 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.194 -1.003 . . . . 0.0 110.599 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 22.9 t -79.22 146.5 7.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 C-N-CA 118.46 -1.296 . . . . 0.0 110.333 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.308 -1.233 0 CA-C-O 116.345 -1.788 . . . . 0.0 110.587 -179.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.087 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -118.51 122.06 41.77 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.644 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 57.6 t -114.89 113.81 44.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.866 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 29.5 mtmt -88.63 116.77 27.11 Favored 'General case' 0 C--N 1.298 -1.641 0 C-N-CA 119.193 -1.003 . . . . 0.0 110.854 -179.555 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 7.8 mt -78.6 105.79 10.13 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 118.788 -1.165 . . . . 0.0 110.41 178.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 103.12 121.42 4.93 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.1 p -71.35 167.12 20.2 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.672 179.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -91.17 -6.6 53.28 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.349 -0.941 . . . . 0.0 110.77 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.401 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -93.68 -5.69 47.99 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.924 -179.886 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 105.07 74.78 0.97 Allowed Glycine 0 N--CA 1.495 2.581 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.385 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -170.05 144.88 8.78 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.48 -1.343 . . . . 0.0 110.502 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 23.0 mt -99.79 100.77 11.77 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.698 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.7 m -151.0 157.43 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 C-N-CA 118.974 -1.09 . . . . 0.0 111.381 179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' A' ' 16' ' ' PRO . 22.1 m-85 -78.53 110.0 13.22 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 177.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.4 m -115.62 109.19 45.99 Favored Pre-proline 0 N--CA 1.488 1.449 0 C-N-CA 119.28 -0.968 . . . . 0.0 112.564 -177.092 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.421 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.4 Cg_exo -65.9 178.62 15.26 Favored 'Cis proline' 0 C--N 1.364 1.35 0 C-N-CA 125.191 -0.754 . . . . 0.0 111.526 -1.075 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 41.8 t -95.75 -60.47 1.64 Allowed 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.376 179.474 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.4 t -124.74 140.33 53.03 Favored 'General case' 0 N--CA 1.488 1.438 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.884 179.37 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -165.22 149.62 8.82 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 118.592 -1.243 . . . . 0.0 111.258 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -87.03 160.45 18.61 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.273 -179.876 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.3 m -148.86 165.56 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.941 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.499 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -87.29 142.91 27.54 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.556 179.817 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.71 77.28 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.136 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.499 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 146.56 18.41 0.13 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -98.35 138.58 35.38 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.852 -0.739 . . . . 0.0 110.609 -179.627 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.5 mttm -80.1 118.65 22.0 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.141 -179.634 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.3 mt -100.41 120.21 49.57 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.228 179.345 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 68.3 p -114.93 118.45 33.49 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.523 -0.871 . . . . 0.0 112.988 -177.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -84.71 114.15 21.83 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 177.415 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.4 mttp -103.94 132.33 50.3 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.415 -0.914 . . . . 0.0 111.46 -177.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 50.3 t-20 -84.97 110.82 19.17 Favored 'General case' 0 C--N 1.29 -2.004 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.025 178.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -106.67 -30.22 9.12 Favored 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 119.275 -0.97 . . . . 0.0 112.038 -179.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -178.67 161.11 1.25 Allowed 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 119.26 -0.976 . . . . 0.0 111.194 -179.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . 75.58 58.61 3.79 Favored Glycine 0 N--CA 1.495 2.58 0 C-N-CA 119.536 -1.316 . . . . 0.0 113.062 178.04 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -97.3 165.27 16.02 Favored Pre-proline 0 N--CA 1.496 1.853 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 177.665 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -78.08 138.46 51.44 Favored 'Cis proline' 0 C--O 1.214 -0.691 0 C-N-CA 124.808 -0.913 . . . . 0.0 113.047 -0.042 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . 0.505 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 36.6 m-70 -102.81 177.34 4.88 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.713 -0.795 . . . . 0.0 110.574 178.566 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -165.69 154.48 11.64 Favored 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.88 179.688 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.412 ' N ' ' CD1' ' A' ' 39' ' ' ILE . 2.5 mp -139.25 114.67 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 119.64 -0.824 . . . . 0.0 111.103 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 t -130.48 152.21 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.603 179.397 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.434 ' O ' ' OE2' ' A' ' 43' ' ' GLU . 9.5 m-85 -102.94 141.07 36.37 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.525 -0.87 . . . . 0.0 111.796 -179.025 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -78.28 109.97 12.88 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.817 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.434 ' OE2' ' O ' ' A' ' 41' ' ' PHE . 35.3 mp0 -73.36 47.27 0.21 Allowed 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.94 -179.188 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -138.74 -5.84 1.51 Allowed 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.804 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -145.11 7.12 1.17 Allowed 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 118.54 -1.264 . . . . 0.0 111.981 179.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 2.1 t -80.53 150.79 70.83 Favored Pre-proline 0 C--N 1.289 -2.04 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.661 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -52.87 158.17 6.79 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 120.944 1.096 . . . . 0.0 111.794 -179.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.87 48.7 1.67 Allowed 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.751 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -154.6 -32.63 0.03 OUTLIER Glycine 0 N--CA 1.49 2.242 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.134 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 51.6 t -97.29 95.39 4.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 C-N-CA 119.599 -0.84 . . . . 0.0 110.841 179.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -46.05 148.29 0.87 Allowed 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.037 -1.065 . . . . 0.0 110.322 179.701 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -92.87 -33.77 14.09 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.339 -0.945 . . . . 0.0 111.211 -179.591 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -65.81 -17.83 64.91 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.823 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.37 -35.88 54.08 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.284 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.9 pt -95.69 -35.13 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.108 -179.644 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 39.9 m -43.46 158.88 0.03 OUTLIER 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.995 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.622 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 7.5 mt-30 -137.98 71.19 49.08 Favored Pre-proline 0 N--CA 1.486 1.328 0 C-N-CA 119.947 -0.701 . . . . 0.0 110.699 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -61.28 -5.73 5.65 Favored 'Trans proline' 0 C--N 1.321 -0.871 0 C-N-CA 121.274 1.316 . . . . 0.0 111.07 -179.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.419 ' H ' ' C ' ' A' ' 57' ' ' GLN . 1.3 mm-40 -83.65 113.78 21.09 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.005 179.364 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -69.38 166.4 18.72 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.551 -0.859 . . . . 0.0 111.297 -179.258 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.15 125.65 19.07 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.863 179.537 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.65 ' ND2' ' H ' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -104.87 -74.39 0.65 Allowed 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.309 -179.472 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.528 ' H ' ' CG ' ' A' ' 62' ' ' ASN . . . -35.06 146.12 0.04 OUTLIER Glycine 0 N--CA 1.501 2.975 0 C-N-CA 120.401 -0.904 . . . . 0.0 111.446 -179.448 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -81.42 151.56 27.83 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.744 -0.782 . . . . 0.0 110.888 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.22 -11.25 69.3 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.365 -1.397 . . . . 0.0 111.307 179.355 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -74.72 119.94 19.6 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.123 -1.031 . . . . 0.0 111.036 -179.767 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 3.9 p -127.5 160.78 30.47 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.949 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.622 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 34.5 t80 -136.48 141.41 43.49 Favored 'General case' 0 N--CA 1.494 1.749 0 C-N-CA 119.784 -0.767 . . . . 0.0 110.171 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -101.42 149.62 23.87 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 119.48 -0.888 . . . . 0.0 112.09 -178.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 t -146.05 138.4 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.105 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.2 m -132.39 99.76 4.78 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.577 -0.849 . . . . 0.0 111.28 -179.46 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 65.3 mt -82.48 162.83 21.93 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.158 179.461 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 97.7 m -150.57 45.07 0.86 Allowed 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.904 -1.118 . . . . 0.0 111.919 -179.105 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -145.02 102.05 3.71 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 118.924 -1.11 . . . . 0.0 110.418 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 22.6 mtmt -45.85 107.94 0.12 Allowed 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.201 -1.0 . . . . 0.0 110.425 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 177.21 -146.57 7.83 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.219 -1.467 . . . . 0.0 110.39 -179.601 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.99 130.1 22.07 Favored 'General case' 0 N--CA 1.484 1.257 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.646 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.588 ' N ' ' CD1' ' A' ' 78' ' ' TYR . 0.2 OUTLIER -120.95 147.33 45.61 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 178.996 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.586 ' HZ3' ' CB ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -121.91 121.75 37.83 Favored 'General case' 0 N--CA 1.5 2.032 0 C-N-CA 119.069 -1.052 . . . . 0.0 110.957 179.47 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.6 OUTLIER -123.5 161.28 25.19 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.764 -0.774 . . . . 0.0 109.904 178.692 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 36.9 p90 -161.5 177.17 10.31 Favored 'General case' 0 C--N 1.285 -2.231 0 C-N-CA 119.184 -1.006 . . . . 0.0 111.176 -179.082 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -100.07 119.09 37.75 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.714 179.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.573 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 14.8 tt0 -72.03 -36.05 3.91 Favored Pre-proline 0 C--N 1.308 -1.213 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.953 -179.104 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.6 Cg_endo -72.05 -54.57 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.377 0.718 . . . . 0.0 111.049 179.727 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . 0.4 ' C ' ' H ' ' A' ' 87' ' ' GLY . 28.4 m170 -79.82 14.93 1.55 Allowed 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.602 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.56 -11.64 0.94 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.628 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.4 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -78.62 -25.38 60.84 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.162 179.719 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.55 -31.74 26.23 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.414 179.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 110.3 26.72 4.76 Favored Glycine 0 N--CA 1.492 2.4 0 C-N-CA 119.781 -1.2 . . . . 0.0 110.859 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 32.0 mtp -67.82 108.49 3.0 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.081 -1.048 . . . . 0.0 110.79 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -121.03 154.31 36.22 Favored 'General case' 0 N--CA 1.491 1.611 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.917 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.76 146.24 17.19 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.511 -1.328 . . . . 0.0 111.236 -178.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -152.71 145.12 24.05 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.594 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 12.0 p -138.45 125.46 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.794 179.647 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 91.0 m -102.77 99.07 8.99 Favored 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.532 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 31.7 t -79.87 148.61 5.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 118.692 -1.203 . . . . 0.0 110.472 -179.054 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 48.7 p30 . . . . . 0 C--N 1.306 -1.297 0 CA-C-O 116.324 -1.798 . . . . 0.0 110.671 -179.843 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 120.839 0.352 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.524 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 10.8 mp0 -105.12 130.97 53.18 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.848 -0.741 . . . . 0.0 110.548 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.1 t -114.08 118.89 59.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.852 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 30.4 mttt -92.77 114.2 26.68 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.78 -179.095 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mp -79.71 105.83 11.29 Favored 'General case' 0 C--N 1.313 -1.016 0 C-N-CA 118.597 -1.241 . . . . 0.0 109.696 177.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.439 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.32 90.66 2.14 Favored Glycine 0 C--N 1.29 -2.018 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -178.755 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.541 ' OG ' ' N ' ' A' ' 11' ' ' GLY . 3.1 p -54.41 155.3 3.98 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.766 -179.546 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -59.53 -33.7 71.72 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.426 -0.91 . . . . 0.0 111.039 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -144.71 -0.23 0.94 Allowed 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.459 -0.896 . . . . 0.0 111.009 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -78.19 -36.74 30.36 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.426 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.541 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . 125.61 -141.56 13.06 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.8 mt -99.47 94.88 6.65 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.921 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.7 m -149.55 155.29 8.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 C-N-CA 118.898 -1.121 . . . . 0.0 111.058 179.798 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' A' ' 16' ' ' PRO . 29.7 m-85 -78.29 106.93 10.54 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 177.825 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 46.9 m -112.73 113.03 50.48 Favored Pre-proline 0 CA--C 1.556 1.2 0 C-N-CA 119.423 -0.911 . . . . 0.0 112.3 -177.11 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.5 Cg_endo -66.68 175.6 25.26 Favored 'Cis proline' 0 C--N 1.358 1.039 0 C-N-CA 125.4 -0.667 . . . . 0.0 111.5 -1.052 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -92.83 -61.16 1.64 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.469 -0.893 . . . . 0.0 110.014 179.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -119.92 142.53 48.64 Favored 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.474 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 19.8 p90 -167.78 137.11 2.6 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 118.577 -1.249 . . . . 0.0 111.304 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -84.64 161.21 20.19 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.301 -0.959 . . . . 0.0 111.028 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.1 m -148.49 162.42 5.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.274 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.978 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.475 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -82.76 144.45 30.17 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.278 -0.969 . . . . 0.0 110.435 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.27 76.92 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.369 -0.933 . . . . 0.0 111.07 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.475 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 149.22 19.45 0.08 OUTLIER Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.467 ' CD ' ' N ' ' A' ' 26' ' ' LYS . 5.9 tm-20 -101.51 144.56 30.13 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.654 -179.666 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.467 ' N ' ' CD ' ' A' ' 25' ' ' GLU . 67.6 mttt -88.49 133.44 34.13 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.807 -179.799 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.6 mt -117.38 118.14 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.55 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.8 p -109.95 114.76 28.57 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.825 -0.75 . . . . 0.0 112.392 -178.3 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -84.45 117.96 23.98 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.446 178.356 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.69 127.65 53.08 Favored 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 119.289 -0.965 . . . . 0.0 111.525 -177.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 39.0 t-20 -84.29 130.66 34.79 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.667 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.439 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 12.0 p-10 -134.22 -8.01 2.62 Favored 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 118.893 -1.123 . . . . 0.0 112.444 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -171.74 144.52 1.83 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 118.376 -1.33 . . . . 0.0 112.318 -179.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 72.15 54.57 7.86 Favored Glycine 0 N--CA 1.489 2.199 0 C-N-CA 119.903 -1.141 . . . . 0.0 113.53 177.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.482 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -92.74 167.07 15.26 Favored Pre-proline 0 N--CA 1.497 1.884 0 C-N-CA 118.718 -1.193 . . . . 0.0 108.498 177.22 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -77.05 146.35 83.4 Favored 'Cis proline' 0 N--CA 1.481 0.738 0 C-N-CA 124.958 -0.851 . . . . 0.0 113.047 -0.323 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 30.5 m-70 -104.69 -177.23 3.31 Favored 'General case' 0 N--CA 1.489 1.485 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.499 178.088 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.658 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -164.61 135.3 4.11 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.742 -0.783 . . . . 0.0 110.057 178.747 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.658 ' N ' HD21 ' A' ' 38' ' ' ASN . 2.8 mp -124.0 119.42 56.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 C-N-CA 119.837 -0.745 . . . . 0.0 110.898 -179.716 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.9 t -142.26 145.5 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.61 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -97.37 121.63 39.49 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.586 -0.845 . . . . 0.0 111.221 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.475 ' C ' ' H ' ' A' ' 44' ' ' ASP . 38.1 p-10 -59.91 117.3 4.88 Favored 'General case' 0 C--N 1.309 -1.165 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.781 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -74.96 41.73 0.17 Allowed 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.809 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.475 ' H ' ' C ' ' A' ' 42' ' ' ASP . 7.3 m-20 -135.64 -3.26 2.35 Favored 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.656 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -147.38 19.25 1.2 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.054 -1.058 . . . . 0.0 111.215 179.823 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -96.71 146.01 30.57 Favored Pre-proline 0 C--N 1.3 -1.544 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.351 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -57.41 147.82 75.55 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.794 0.996 . . . . 0.0 111.82 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.47 158.63 14.43 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 119.14 -1.024 . . . . 0.0 109.945 179.29 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 79.64 -52.26 4.13 Favored Glycine 0 N--CA 1.487 2.075 0 C-N-CA 118.991 -1.576 . . . . 0.0 109.956 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 71.6 t -69.81 73.84 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.165 0 C-N-CA 119.236 -0.986 . . . . 0.0 110.496 179.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -44.86 142.35 1.81 Allowed 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.698 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -79.3 -29.29 42.38 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.401 -0.919 . . . . 0.0 111.052 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -74.03 3.61 6.66 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.693 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.34 -35.61 10.66 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.948 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt -99.79 -28.37 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.044 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 68.9 m -64.74 154.81 35.68 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.247 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.612 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.1 OUTLIER -135.86 76.82 52.15 Favored Pre-proline 0 N--CA 1.486 1.356 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.96 179.65 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -57.41 -3.32 0.83 Allowed 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 121.193 1.262 . . . . 0.0 111.87 -178.571 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.48 ' H ' ' C ' ' A' ' 57' ' ' GLN . 11.4 tt0 -72.97 91.53 1.56 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.021 -1.072 . . . . 0.0 110.021 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.539 ' CE1' ' OD1' ' A' ' 38' ' ' ASN . 36.4 m-85 -43.61 165.63 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.947 -179.528 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -142.43 110.47 5.94 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.896 179.55 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.625 ' H ' ' ND2' ' A' ' 62' ' ' ASN . 0.3 OUTLIER -103.28 -6.82 21.65 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.664 179.898 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -71.05 152.04 49.64 Favored Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.456 -1.354 . . . . 0.0 110.44 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -94.83 103.9 15.79 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.764 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.24 -7.3 16.51 Favored Glycine 0 N--CA 1.496 2.677 0 C-N-CA 119.941 -1.123 . . . . 0.0 110.62 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.4 148.08 42.81 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.055 -1.058 . . . . 0.0 110.457 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 4.9 p -147.18 165.24 30.61 Favored 'General case' 0 N--CA 1.491 1.595 0 C-N-CA 118.901 -1.12 . . . . 0.0 111.889 -179.531 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.612 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 42.3 t80 -137.09 150.8 48.25 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.805 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.445 ' O ' ' CE1' ' A' ' 68' ' ' TYR . 2.2 mp0 -108.1 151.4 25.93 Favored 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.423 -179.711 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -150.31 135.77 10.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.303 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.0 m -135.75 92.17 2.79 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.155 -179.558 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 21.4 mt -79.82 158.7 26.73 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.263 -0.975 . . . . 0.0 109.659 179.412 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 23.4 p -150.53 41.98 0.8 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.143 -179.237 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.438 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 8.8 mt-10 -140.02 105.98 5.2 Favored 'General case' 0 N--CA 1.498 1.957 0 C-N-CA 118.807 -1.157 . . . . 0.0 110.422 179.178 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.5 tttp -40.19 112.37 0.27 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.301 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.43 -149.86 14.21 Favored Glycine 0 N--CA 1.488 2.162 0 C-N-CA 118.854 -1.641 . . . . 0.0 110.675 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -138.09 139.44 39.49 Favored 'General case' 0 N--CA 1.482 1.175 0 C-N-CA 119.761 -0.776 . . . . 0.0 110.984 -179.77 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.563 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.1 m-85 -126.42 128.78 47.53 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.107 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.442 ' O ' ' OD1' ' A' ' 42' ' ' ASP . 3.3 mptp? -105.12 123.94 48.67 Favored 'General case' 0 N--CA 1.493 1.699 0 C-N-CA 119.531 -0.868 . . . . 0.0 112.216 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.449 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 9.0 p90 -134.71 171.8 13.86 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.161 177.693 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 25.9 p90 -171.22 -168.92 0.68 Allowed 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 119.409 -0.916 . . . . 0.0 111.188 -178.009 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -116.65 130.04 56.5 Favored 'General case' 0 N--CA 1.482 1.141 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.206 179.036 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.512 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.0 mt-10 -72.17 -46.42 11.04 Favored Pre-proline 0 N--CA 1.484 1.271 0 C-N-CA 119.505 -0.878 . . . . 0.0 112.929 -179.394 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.512 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.8 Cg_endo -66.8 -46.38 3.53 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 120.806 1.004 . . . . 0.0 112.03 -178.656 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.6 m80 -90.46 21.11 4.08 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.239 -179.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -67.08 -16.73 64.52 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.359 -0.936 . . . . 0.0 110.597 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -77.49 -24.07 66.29 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.457 -1.354 . . . . 0.0 110.298 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.62 -15.6 39.27 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.392 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 98.77 31.88 6.16 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 119.561 -1.304 . . . . 0.0 110.576 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.63 103.91 9.86 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.997 179.765 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -129.34 166.46 19.45 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.801 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -146.49 155.18 26.4 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 119.123 -1.513 . . . . 0.0 111.779 -178.398 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -155.25 143.46 20.2 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.82 179.452 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.12 128.65 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.317 -0.953 . . . . 0.0 110.126 179.079 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 98.9 m -106.86 106.82 17.53 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 119.624 -0.83 . . . . 0.0 110.784 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.436 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 41.3 t -82.26 138.15 19.92 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 118.347 -1.341 . . . . 0.0 110.586 -179.101 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 96' ' ' VAL . 6.7 m-20 . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 116.374 -1.774 . . . . 0.0 110.805 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -138.23 142.61 39.93 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.787 -0.765 . . . . 0.0 110.579 179.933 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 t -131.44 118.75 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.563 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.0 mtmp? -90.1 115.3 27.26 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.114 -1.034 . . . . 0.0 111.313 -178.991 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 4.8 mt -76.94 105.71 8.17 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 118.937 -1.105 . . . . 0.0 109.688 178.392 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 111.05 135.58 6.87 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.055 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.428 ' OG ' ' OD1' ' A' ' 9' ' ' ASP . 20.0 p -77.84 169.63 17.96 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.233 -0.987 . . . . 0.0 110.67 179.941 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.431 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 6.3 m-20 -63.63 -48.49 77.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.918 179.907 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.428 ' OD1' ' OG ' ' A' ' 7' ' ' SER . 4.2 p-10 -56.73 -53.12 61.4 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.994 -179.817 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 155.06 11.98 0.06 OUTLIER Glycine 0 N--CA 1.492 2.392 0 C-N-CA 119.379 -1.391 . . . . 0.0 110.282 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.06 164.05 52.62 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.572 -1.299 . . . . 0.0 110.42 179.995 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.8 mt -113.55 95.17 5.21 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.963 -0.695 . . . . 0.0 110.913 -179.992 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.0 m -150.22 157.09 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.362 179.124 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.51 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 37.2 m-85 -77.84 115.09 17.32 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.898 -1.121 . . . . 0.0 108.15 178.809 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.5 m -116.89 106.98 46.83 Favored Pre-proline 0 CA--C 1.561 1.367 0 C-N-CA 119.58 -0.848 . . . . 0.0 111.813 -177.564 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -66.32 175.66 23.85 Favored 'Cis proline' 0 C--N 1.359 1.124 0 C-N-CA 125.166 -0.764 . . . . 0.0 111.429 -0.132 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.96 -37.39 11.7 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 119.426 -0.91 . . . . 0.0 109.709 178.836 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.6 m -145.72 142.63 29.14 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.941 179.18 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.403 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 26.0 p90 -165.91 146.27 6.56 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 118.711 -1.196 . . . . 0.0 111.339 -179.013 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.2 p -90.1 163.54 14.82 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.26 -179.755 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.1 m -150.27 175.61 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.687 179.43 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.452 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -91.07 146.61 23.7 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.859 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.03 74.73 0.05 OUTLIER 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.549 -0.86 . . . . 0.0 110.947 179.742 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 146.18 19.58 0.13 Allowed Glycine 0 N--CA 1.488 2.104 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -96.96 150.03 21.22 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.877 -0.729 . . . . 0.0 111.007 -179.415 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.79 136.13 35.47 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.607 179.592 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.9 mt -118.62 151.03 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 C-N-CA 120.038 -0.665 . . . . 0.0 109.212 179.848 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 9.2 p -142.16 118.46 10.81 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.695 -179.533 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 63.7 m-85 -83.65 125.38 31.78 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.427 -0.909 . . . . 0.0 109.1 178.471 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.0 tptp -110.4 133.69 53.03 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 120.044 -0.662 . . . . 0.0 110.52 -179.142 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.402 ' ND2' ' CD1' ' A' ' 61' ' ' LEU . 2.7 m120 -89.34 103.33 15.97 Favored 'General case' 0 C--N 1.293 -1.875 0 C-N-CA 119.19 -1.004 . . . . 0.0 110.087 179.331 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.459 ' O ' ' CB ' ' A' ' 33' ' ' ALA . 0.3 OUTLIER -89.84 -30.63 17.8 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 119.176 -1.01 . . . . 0.0 111.435 -179.079 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 168.99 146.86 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 118.992 -1.083 . . . . 0.0 111.017 -179.864 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 112.74 -5.71 26.01 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.619 -1.277 . . . . 0.0 111.369 179.368 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -47.45 162.83 0.28 Allowed Pre-proline 0 N--CA 1.484 1.26 0 C-N-CA 118.332 -1.347 . . . . 0.0 109.639 179.878 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -77.1 137.95 51.24 Favored 'Cis proline' 0 C--O 1.214 -0.682 0 C-N-CA 124.143 -1.19 . . . . 0.0 112.285 -0.362 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 32.0 m-70 -103.79 177.69 4.77 Favored 'General case' 0 N--CA 1.489 1.497 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.568 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -153.9 140.35 18.73 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.217 179.557 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.459 ' O ' ' N ' ' A' ' 57' ' ' GLN . 3.9 mp -133.22 99.5 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.136 -179.773 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.6 t -121.61 152.55 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.831 179.29 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -104.9 122.87 46.7 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.6 -0.84 . . . . 0.0 111.724 -178.971 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.529 ' C ' ' H ' ' A' ' 44' ' ' ASP . 26.7 t0 -56.14 118.12 4.39 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.442 179.393 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.442 ' O ' ' CG ' ' A' ' 43' ' ' GLU . 2.2 tt0 -73.19 25.86 0.06 Allowed 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.419 -0.913 . . . . 0.0 111.211 -179.431 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.529 ' H ' ' C ' ' A' ' 42' ' ' ASP . 26.0 m-20 -129.1 1.88 5.23 Favored 'General case' 0 N--CA 1.49 1.551 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.795 179.779 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -147.1 53.02 1.08 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.408 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -135.03 148.1 65.42 Favored Pre-proline 0 N--CA 1.49 1.57 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -179.802 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -47.68 140.14 17.54 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 120.903 1.069 . . . . 0.0 111.986 -179.4 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.65 83.01 1.56 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.887 -179.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.06 -33.81 0.52 Allowed Glycine 0 N--CA 1.488 2.129 0 C-N-CA 119.558 -1.305 . . . . 0.0 110.027 -179.893 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 35.7 t -87.33 109.08 18.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.713 179.807 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -51.49 153.83 2.07 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.799 -179.92 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -110.88 -6.48 14.71 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 120.018 -0.673 . . . . 0.0 110.864 -179.844 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -90.16 -15.37 31.66 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.461 -0.895 . . . . 0.0 111.102 -179.81 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.7 mtmm -91.86 -28.92 17.0 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.905 -179.858 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 11.8 pt -98.57 1.14 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 C-N-CA 119.633 -0.827 . . . . 0.0 110.994 -179.887 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.8 m -94.42 -178.52 4.61 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.079 180.0 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.655 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 52.1 mt-30 -139.64 69.9 37.89 Favored Pre-proline 0 C--N 1.305 -1.34 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.338 -179.972 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -59.74 -21.49 63.58 Favored 'Trans proline' 0 C--N 1.325 -0.696 0 C-N-CA 121.531 1.488 . . . . 0.0 111.829 -178.879 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.411 ' O ' ' O ' ' A' ' 60' ' ' TYR . 1.3 tm-20 -91.86 109.91 21.25 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.236 179.539 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.411 ' O ' ' O ' ' A' ' 59' ' ' GLU . 52.8 m-85 -43.09 166.07 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.541 -0.864 . . . . 0.0 110.948 -179.884 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.433 ' C ' ' CD1' ' A' ' 61' ' ' LEU . 0.5 OUTLIER -140.38 148.43 41.25 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.726 -0.79 . . . . 0.0 109.938 179.68 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -149.05 22.67 0.96 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.111 -179.464 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -83.14 102.47 2.4 Favored Glycine 0 N--CA 1.486 1.978 0 C-N-CA 119.163 -1.494 . . . . 0.0 110.382 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -57.34 113.28 1.69 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.067 -1.053 . . . . 0.0 110.178 179.512 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 97.85 -18.48 57.15 Favored Glycine 0 N--CA 1.487 2.093 0 C-N-CA 119.413 -1.375 . . . . 0.0 110.162 -179.49 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 25.6 tp10 -65.7 128.3 35.42 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.207 -0.997 . . . . 0.0 110.165 179.896 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -110.74 166.65 10.85 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.796 -0.761 . . . . 0.0 111.427 -179.653 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.655 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 43.1 t80 -135.8 139.86 43.8 Favored 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.455 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -108.78 158.24 17.83 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.258 -0.977 . . . . 0.0 112.709 -178.589 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -160.07 137.49 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.122 179.138 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 9.1 m -127.65 97.25 4.79 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.339 -179.242 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 16.8 mt -81.75 159.29 23.89 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.322 -0.951 . . . . 0.0 109.831 179.499 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 18.0 p -150.79 50.85 0.86 Allowed 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 118.882 -1.127 . . . . 0.0 111.946 -178.965 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 75' ' ' LYS . 3.9 tp10 -146.15 99.9 3.31 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.094 -1.043 . . . . 0.0 110.121 178.992 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.417 ' C ' ' O ' ' A' ' 74' ' ' GLU . 8.7 ptmm? -42.27 112.15 0.31 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.051 -179.309 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 168.63 -146.26 10.22 Favored Glycine 0 N--CA 1.485 1.919 0 C-N-CA 119.26 -1.448 . . . . 0.0 110.062 -179.69 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.81 138.33 35.73 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.643 -0.823 . . . . 0.0 110.987 -179.726 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.549 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -121.27 147.78 45.19 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.332 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 18.2 mmtp -112.93 123.56 50.6 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.586 -0.846 . . . . 0.0 111.83 -179.643 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.574 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.5 OUTLIER -136.96 158.66 43.96 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.611 -0.836 . . . . 0.0 109.789 177.523 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 32.3 p90 -169.86 179.96 3.47 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 119.261 -0.976 . . . . 0.0 111.206 -178.197 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -103.91 124.63 49.32 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.83 179.753 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.548 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.5 OUTLIER -70.57 -44.42 17.35 Favored Pre-proline 0 N--CA 1.487 1.387 0 C-N-CA 119.66 -0.816 . . . . 0.0 112.752 -179.77 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.548 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.0 Cg_exo -66.72 -53.54 0.55 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 120.892 1.061 . . . . 0.0 111.921 -178.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . 0.455 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.3 m80 -80.0 8.35 7.23 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.336 -0.945 . . . . 0.0 111.292 -179.521 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.37 -7.72 0.64 Allowed 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.705 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.455 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -76.2 -24.91 67.45 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.393 -1.384 . . . . 0.0 110.381 -179.924 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.65 -35.17 15.12 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.602 -179.994 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 124.77 21.09 2.21 Favored Glycine 0 N--CA 1.495 2.624 0 C-N-CA 119.869 -1.158 . . . . 0.0 110.531 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.79 108.99 1.29 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.416 -0.914 . . . . 0.0 111.256 -179.857 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 17.4 mttm -131.57 162.31 30.61 Favored 'General case' 0 N--CA 1.495 1.817 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.392 -179.871 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.19 147.86 19.49 Favored Glycine 0 N--CA 1.495 2.602 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.098 -179.194 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -149.21 138.05 21.21 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.891 179.842 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 9.7 p -135.24 127.95 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 C-N-CA 118.723 -1.191 . . . . 0.0 110.883 178.694 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 47.4 m -106.91 100.46 9.96 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.572 179.319 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 45.3 t -80.5 144.66 10.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 C-N-CA 118.632 -1.227 . . . . 0.0 110.496 -179.045 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 116.284 -1.817 . . . . 0.0 110.758 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 120.827 0.346 . . . . 0.0 110.163 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.1 mt-10 -100.05 121.68 41.76 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.765 179.88 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -99.15 119.25 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.998 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.485 ' HZ3' ' CB ' ' A' ' 4' ' ' LYS . 2.3 mtmp? -91.3 113.22 25.42 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 119.626 -0.83 . . . . 0.0 111.021 -179.921 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 mp -79.7 110.58 15.17 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 118.88 -1.128 . . . . 0.0 109.547 178.472 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 98.71 103.82 2.41 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -178.864 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.699 ' HG ' ' H ' ' A' ' 10' ' ' GLY . 68.9 p -61.3 172.3 1.15 Allowed 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.937 -179.552 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -56.15 -42.55 77.17 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.867 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -161.14 4.85 0.07 Allowed 'General case' 0 N--CA 1.487 1.402 0 C-N-CA 119.312 -0.955 . . . . 0.0 111.062 179.91 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.699 ' H ' ' HG ' ' A' ' 7' ' ' SER . . . -71.54 -42.74 54.75 Favored Glycine 0 N--CA 1.492 2.413 0 C-N-CA 119.374 -1.393 . . . . 0.0 110.572 -179.997 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 154.17 -154.67 25.67 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.487 -1.339 . . . . 0.0 110.349 -179.959 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt -100.11 100.31 11.14 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.746 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.7 m -145.7 157.9 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 C-N-CA 118.962 -1.095 . . . . 0.0 111.131 179.843 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.403 ' O ' ' C ' ' A' ' 16' ' ' PRO . 47.3 m-85 -79.17 111.37 15.32 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.459 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 47.8 m -114.89 107.96 49.46 Favored Pre-proline 0 C--N 1.307 -1.275 0 C-N-CA 119.536 -0.866 . . . . 0.0 112.406 -177.071 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.403 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.9 Cg_endo -67.01 167.35 58.32 Favored 'Cis proline' 0 C--N 1.359 1.086 0 C-N-CA 125.34 -0.692 . . . . 0.0 111.528 -0.827 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.423 ' OG ' ' N ' ' A' ' 18' ' ' SER . 0.2 OUTLIER -95.29 -67.24 0.86 Allowed 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.496 -0.881 . . . . 0.0 109.716 178.885 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.423 ' N ' ' OG ' ' A' ' 17' ' ' SER . 0.7 OUTLIER -112.2 123.44 50.27 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.437 178.816 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.487 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 11.5 p90 -156.72 144.31 19.14 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 118.782 -1.167 . . . . 0.0 111.141 -179.005 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -88.84 157.26 18.51 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.299 -0.96 . . . . 0.0 111.247 -179.84 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.5 m -148.61 171.44 2.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.493 179.631 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.81 151.92 22.94 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.477 -179.933 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.4 65.95 0.65 Allowed 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.873 179.761 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 171.02 8.58 0.02 OUTLIER Glycine 0 N--CA 1.486 1.983 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -98.65 154.14 18.17 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.752 -0.779 . . . . 0.0 110.549 -179.931 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 49.6 mttm -95.17 144.06 26.1 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.288 -179.718 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 37.1 mm -111.89 98.34 6.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 CA-C-N 115.541 -0.754 . . . . 0.0 108.999 179.033 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.7 p -92.85 115.49 28.17 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.145 -1.022 . . . . 0.0 112.477 -178.217 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -85.18 121.2 27.59 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.021 -0.991 . . . . 0.0 109.136 178.512 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -124.68 134.87 52.72 Favored 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.686 -0.806 . . . . 0.0 111.734 -178.519 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 66' ' ' GLU . 57.5 m-80 -84.67 113.31 21.2 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.505 179.604 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -97.98 -30.23 12.84 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 119.195 -1.002 . . . . 0.0 111.354 -179.23 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 170.7 99.33 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.004 179.724 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 153.11 23.45 0.05 OUTLIER Glycine 0 N--CA 1.489 2.22 0 C-N-CA 118.874 -1.632 . . . . 0.0 111.234 179.487 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.62 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -73.67 162.68 73.06 Favored Pre-proline 0 C--N 1.307 -1.253 0 C-N-CA 118.744 -1.182 . . . . 0.0 109.907 179.756 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -75.8 147.51 88.18 Favored 'Cis proline' 0 N--CA 1.479 0.658 0 C-N-CA 124.396 -1.085 . . . . 0.0 112.366 -1.118 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -112.59 -177.66 3.2 Favored 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.944 -0.702 . . . . 0.0 110.817 179.279 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.777 HD21 ' H ' ' A' ' 83' ' ' GLU . 2.7 t30 -163.75 144.35 8.7 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.771 -0.772 . . . . 0.0 110.005 179.173 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.9 mp -133.78 122.79 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 119.567 -0.853 . . . . 0.0 111.436 -179.48 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.8 t -140.61 146.5 24.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.403 179.101 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -100.51 128.49 46.56 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.214 -0.994 . . . . 0.0 111.888 -179.094 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 25.8 t0 -66.71 119.98 12.71 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.244 179.512 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -68.66 -7.21 31.2 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.026 -178.991 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -97.37 7.15 47.1 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.247 -0.981 . . . . 0.0 111.649 -179.208 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -145.55 27.63 1.22 Allowed 'General case' 0 N--CA 1.488 1.466 0 C-N-CA 119.284 -0.966 . . . . 0.0 110.748 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -118.78 146.77 40.8 Favored Pre-proline 0 N--CA 1.492 1.627 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.088 179.801 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -53.05 144.15 47.48 Favored 'Trans proline' 0 C--O 1.214 -0.706 0 C-N-CA 120.953 1.102 . . . . 0.0 111.907 -179.926 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.04 72.2 1.14 Allowed 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 119.533 -0.867 . . . . 0.0 110.855 179.839 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.09 -46.52 0.1 Allowed Glycine 0 N--CA 1.49 2.282 0 C-N-CA 119.544 -1.312 . . . . 0.0 109.978 179.929 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 96.8 t -79.92 87.8 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 119.435 -0.906 . . . . 0.0 110.474 179.697 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -44.63 140.11 2.59 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.964 -179.615 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.409 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -80.0 -20.88 44.4 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.889 -179.94 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -74.38 -22.37 59.22 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.437 -0.905 . . . . 0.0 111.128 -179.713 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -79.27 -24.86 42.67 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.36 -179.612 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -109.79 -18.47 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.427 -179.774 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.409 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 41.3 m -71.37 171.0 12.01 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.183 179.82 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.633 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 56.5 mt-30 -128.06 78.53 75.19 Favored Pre-proline 0 N--CA 1.488 1.446 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.333 179.914 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -60.86 -11.24 17.08 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.208 1.272 . . . . 0.0 111.615 -178.864 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 20.4 mt-10 -99.47 108.02 20.37 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.749 179.779 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -55.1 176.74 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.531 -0.867 . . . . 0.0 110.85 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.8 pp -154.9 153.1 30.58 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.131 -1.028 . . . . 0.0 111.468 -179.576 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -149.01 14.96 0.92 Allowed 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.987 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -80.95 125.25 6.78 Favored Glycine 0 N--CA 1.491 2.326 0 C-N-CA 119.355 -1.402 . . . . 0.0 110.689 -179.574 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -68.22 126.77 30.61 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.63 179.687 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.56 -12.06 62.17 Favored Glycine 0 N--CA 1.488 2.151 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.713 179.887 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.489 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 2.8 tp10 -65.1 144.3 57.33 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.263 179.749 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -140.79 170.54 15.57 Favored 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.372 -179.387 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.633 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 47.5 t80 -135.57 -179.76 5.84 Favored 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.49 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.56 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 3.3 mt-10 -140.69 146.16 37.46 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.166 -1.014 . . . . 0.0 111.652 -179.818 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.6 t -147.64 126.66 4.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.349 -0.842 . . . . 0.0 109.222 179.377 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.1 m -121.28 99.82 6.7 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.839 -0.744 . . . . 0.0 111.453 -178.841 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 54.9 mt -82.3 159.89 23.03 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.021 179.227 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 57.5 p -150.09 42.99 0.87 Allowed 'General case' 0 C--N 1.296 -1.757 0 C-N-CA 119.214 -0.994 . . . . 0.0 111.083 -179.529 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.429 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 2.9 mm-40 -143.49 101.37 3.77 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.026 -1.07 . . . . 0.0 110.836 179.76 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -44.61 113.43 0.55 Allowed 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.451 -0.899 . . . . 0.0 110.67 -179.953 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.9 -145.0 8.17 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.399 -1.381 . . . . 0.0 110.044 -179.961 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.82 127.14 16.73 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.893 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.564 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.8 m-85 -114.16 161.9 17.21 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.639 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.5 mmtm -130.48 116.81 18.72 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.47 -0.892 . . . . 0.0 111.987 -178.929 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -123.87 159.05 30.48 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.844 -0.742 . . . . 0.0 109.887 178.081 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -168.67 -179.3 3.75 Favored 'General case' 0 C--N 1.289 -2.025 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.982 -178.936 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -108.81 124.27 50.34 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.634 179.825 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.777 ' H ' HD21 ' A' ' 38' ' ' ASN . 2.3 mt-10 -63.18 -45.28 85.52 Favored Pre-proline 0 N--CA 1.485 1.308 0 C-N-CA 119.728 -0.789 . . . . 0.0 112.997 -179.611 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.51 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.8 Cg_endo -66.16 -46.04 4.94 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 120.99 1.127 . . . . 0.0 112.077 -179.202 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . 0.406 ' C ' ' H ' ' A' ' 87' ' ' GLY . 29.1 m80 -92.59 14.62 16.4 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 119.16 -1.016 . . . . 0.0 111.55 -179.262 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -67.97 -1.19 5.26 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 118.946 -1.101 . . . . 0.0 110.455 179.66 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.406 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -95.27 -18.76 32.51 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.439 -1.362 . . . . 0.0 110.095 179.871 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.94 -36.34 15.05 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.44 179.676 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 130.72 26.0 0.81 Allowed Glycine 0 N--CA 1.494 2.539 0 C-N-CA 119.911 -1.137 . . . . 0.0 110.342 179.836 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -82.65 95.37 7.79 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.186 -1.006 . . . . 0.0 110.865 -179.924 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.7 162.51 24.03 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.816 179.926 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -143.62 144.83 14.14 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.294 -1.432 . . . . 0.0 111.874 -178.455 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -148.52 143.69 26.83 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.963 -0.695 . . . . 0.0 110.084 179.282 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.406 ' CG1' ' O ' ' A' ' 94' ' ' VAL . 14.0 p -137.44 118.68 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 119.09 -1.044 . . . . 0.0 110.793 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 90.8 m -95.62 99.17 11.07 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.486 179.528 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 35.5 t -80.11 149.38 5.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 C-N-CA 118.999 -1.08 . . . . 0.0 110.805 -178.804 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 116.332 -1.794 . . . . 0.0 110.797 -179.862 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.066 0 CA-C-O 120.867 0.365 . . . . 0.0 110.052 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -93.77 140.46 29.63 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.701 179.866 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 t -126.95 131.88 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.523 179.477 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 11.7 mtmm -105.17 118.09 35.66 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.844 -179.534 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.408 ' C ' ' OD1' ' A' ' 32' ' ' ASN . 5.7 mt -79.87 103.71 9.95 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 118.754 -1.178 . . . . 0.0 109.639 178.809 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.495 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 118.53 134.3 4.97 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -178.527 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.539 ' HG ' ' CA ' ' A' ' 11' ' ' GLY . 26.0 p -52.79 -103.81 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.198 -179.423 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -156.06 -22.14 0.1 Allowed 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.032 -1.067 . . . . 0.0 111.173 -179.9 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -106.72 -28.43 10.18 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.809 -0.757 . . . . 0.0 110.894 -179.847 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.28 26.4 0.03 OUTLIER Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.409 -1.377 . . . . 0.0 110.469 -179.975 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.539 ' CA ' ' HG ' ' A' ' 7' ' ' SER . . . -96.3 163.67 23.11 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.442 -1.361 . . . . 0.0 110.342 -179.993 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.0 mt -121.13 91.44 3.53 Favored 'General case' 0 N--CA 1.49 1.545 0 C-N-CA 120.101 -0.64 . . . . 0.0 110.711 179.745 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 4.5 m -147.67 154.18 11.34 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 C-N-CA 118.952 -1.099 . . . . 0.0 111.044 179.626 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' A' ' 16' ' ' PRO . 9.9 m-85 -78.22 107.61 10.94 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.431 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.8 m -113.77 109.04 50.67 Favored Pre-proline 0 C--N 1.306 -1.313 0 C-N-CA 119.81 -0.756 . . . . 0.0 111.912 -177.447 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.424 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.6 Cg_endo -67.64 177.05 23.95 Favored 'Cis proline' 0 C--N 1.355 0.916 0 CA-C-N 119.053 0.697 . . . . 0.0 111.671 -0.376 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.4 p -93.92 -47.16 6.85 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.77 178.862 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.8 p -132.82 144.28 50.11 Favored 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.287 178.841 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -164.6 134.58 3.9 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 118.456 -1.297 . . . . 0.0 111.409 -178.962 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.5 p -86.42 159.71 19.27 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.855 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.7 m -148.79 172.49 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.902 179.755 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -87.57 149.61 24.23 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.774 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.29 73.33 0.49 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.348 -0.941 . . . . 0.0 111.072 179.974 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 155.75 14.32 0.05 OUTLIER Glycine 0 N--CA 1.486 2.028 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.5 tt0 -104.45 147.24 27.79 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.552 -179.597 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.1 pttm -95.36 149.84 20.93 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.48 -179.616 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.4 mt -119.95 148.9 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.237 179.202 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.3 p -138.6 119.34 14.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.224 -0.991 . . . . 0.0 111.692 -179.153 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -86.61 146.03 26.5 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.338 178.9 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.3 tttm -138.39 132.04 30.84 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.356 -179.231 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.408 ' OD1' ' N ' ' A' ' 31' ' ' ASN . 3.0 m-20 -81.18 113.09 19.1 Favored 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.815 179.576 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.495 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 4.0 p-10 -106.2 -23.54 12.56 Favored 'General case' 0 N--CA 1.493 1.689 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.743 -179.775 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.447 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 170.82 101.89 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 118.509 -1.277 . . . . 0.0 111.326 179.837 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 141.65 22.19 0.25 Allowed Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.239 -1.458 . . . . 0.0 111.457 179.574 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.61 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -78.2 161.98 68.44 Favored Pre-proline 0 N--CA 1.485 1.288 0 C-N-CA 118.159 -1.417 . . . . 0.0 110.026 179.502 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -75.9 148.56 90.45 Favored 'Cis proline' 0 C--O 1.214 -0.684 0 C-N-CA 124.21 -1.162 . . . . 0.0 112.291 -0.755 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 48.9 m-70 -115.48 178.56 4.25 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.166 179.585 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.657 HD21 ' H ' ' A' ' 39' ' ' ILE . 1.2 t-20 -151.13 137.98 18.97 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.2 -1.0 . . . . 0.0 110.338 178.875 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.657 ' H ' HD21 ' A' ' 38' ' ' ASN . 5.7 mt -124.06 106.1 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.135 -179.494 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t -128.32 149.0 32.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.001 179.54 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -103.94 126.76 51.3 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.861 -179.305 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.471 ' C ' ' H ' ' A' ' 44' ' ' ASP . 0.4 OUTLIER -70.64 118.07 12.97 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.412 179.636 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -74.76 41.6 0.16 Allowed 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.386 -0.926 . . . . 0.0 110.861 -179.677 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.471 ' H ' ' C ' ' A' ' 42' ' ' ASP . 8.6 m-20 -128.28 -10.53 5.23 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.586 179.815 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -132.81 15.93 4.3 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.74 179.831 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 55.5 t -99.1 143.45 26.41 Favored Pre-proline 0 C--N 1.296 -1.73 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.571 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -55.42 161.75 6.97 Favored 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 120.81 1.006 . . . . 0.0 111.619 -179.947 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -90.22 51.23 1.99 Allowed 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 119.578 -0.849 . . . . 0.0 111.001 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -154.0 -42.86 0.02 OUTLIER Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.46 -1.352 . . . . 0.0 109.998 179.827 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 5.6 p -77.35 152.28 5.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 119.812 -0.755 . . . . 0.0 110.407 179.643 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -88.79 139.47 30.43 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.048 179.173 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -102.76 -4.48 24.91 Favored 'General case' 0 N--CA 1.491 1.611 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.252 -179.782 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -90.69 -33.68 15.7 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.645 -179.531 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 62.8 mttt -78.26 -21.82 49.25 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.434 -0.906 . . . . 0.0 111.972 -179.018 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.3 pt -92.91 -25.03 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.213 -179.547 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 33.3 m -69.19 174.1 5.0 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.133 179.658 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.659 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 66.7 mt-30 -126.88 78.98 73.14 Favored Pre-proline 0 N--CA 1.488 1.456 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.65 -179.888 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.27 -14.44 38.45 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 120.958 1.105 . . . . 0.0 111.187 -179.258 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.423 ' O ' ' O ' ' A' ' 60' ' ' TYR . 10.5 mt-10 -100.53 105.06 16.46 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.78 -0.768 . . . . 0.0 110.646 179.445 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.423 ' O ' ' O ' ' A' ' 59' ' ' GLU . 31.6 m-85 -46.01 172.4 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.941 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.0 pp -138.54 125.79 21.58 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.688 -0.805 . . . . 0.0 110.29 179.548 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -132.61 45.49 2.74 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.409 -178.845 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.28 118.97 3.56 Favored Glycine 0 N--CA 1.499 2.896 0 C-N-CA 119.718 -1.229 . . . . 0.0 110.528 179.822 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -54.64 123.4 13.07 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.398 179.735 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 81.48 3.86 90.54 Favored Glycine 0 N--CA 1.489 2.225 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.648 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -69.47 107.16 3.24 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.921 179.607 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.5 p -98.09 164.59 12.28 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.499 -0.88 . . . . 0.0 111.55 -178.96 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.659 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 45.1 t80 -135.0 176.97 8.17 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 178.844 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.605 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 5.3 mt-10 -144.89 150.86 37.79 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 118.539 -1.265 . . . . 0.0 112.252 -179.316 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -157.85 136.83 3.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 115.066 -0.97 . . . . 0.0 108.727 179.205 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 19.1 m -129.12 92.74 3.44 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.53 -0.868 . . . . 0.0 111.716 -178.907 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 10.0 mt -79.76 155.39 27.94 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 118.995 -1.082 . . . . 0.0 108.709 178.833 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' THR . . . . . 0.434 ' O ' ' OG1' ' A' ' 73' ' ' THR . 3.1 t -150.47 46.57 0.88 Allowed 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.678 -1.209 . . . . 0.0 111.719 -179.29 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 34.1 mm-40 -138.81 103.12 4.74 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.47 -0.892 . . . . 0.0 109.78 178.916 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -40.11 107.18 0.07 Allowed 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 119.781 -0.768 . . . . 0.0 111.321 -179.448 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 176.74 -150.36 10.32 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.172 -1.489 . . . . 0.0 110.591 -179.778 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.89 133.61 28.81 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.258 -179.521 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.604 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.9 OUTLIER -120.13 155.43 33.07 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.765 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 27.0 mmtt -126.93 127.94 45.65 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.532 -0.867 . . . . 0.0 111.909 -178.876 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.512 ' O ' ' N ' ' A' ' 92' ' ' GLY . 2.0 p90 -139.11 165.85 26.06 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.432 -0.907 . . . . 0.0 110.701 178.377 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 35.2 p90 -169.91 -179.78 3.35 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.144 -177.928 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -104.07 125.53 50.48 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.321 179.404 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.55 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tt0 -68.6 -44.48 33.19 Favored Pre-proline 0 N--CA 1.486 1.358 0 C-N-CA 119.531 -0.868 . . . . 0.0 112.985 -179.436 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -68.44 -50.06 0.76 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 120.931 1.087 . . . . 0.0 111.94 -178.771 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 33.4 m80 -88.9 16.91 6.2 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.342 -0.943 . . . . 0.0 111.572 -179.363 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.64 -10.32 3.48 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.726 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -89.13 -17.09 56.63 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.374 -1.393 . . . . 0.0 110.304 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.34 -22.89 24.82 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.385 179.881 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 112.7 17.48 7.99 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.798 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.1 mtp -70.64 99.87 1.75 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.228 179.806 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.1 pttp -125.1 164.33 20.46 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 120.045 -0.662 . . . . 0.0 110.088 178.723 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.02 147.75 18.49 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 118.538 -1.791 . . . . 0.0 111.862 -178.497 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -153.94 146.9 24.47 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 119.721 -0.792 . . . . 0.0 110.568 179.103 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.8 p -140.68 134.36 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.125 179.252 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.2 m -110.66 101.73 10.35 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.65 -0.82 . . . . 0.0 110.886 179.734 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 49.0 t -80.68 152.1 4.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.902 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.6 p30 . . . . . 0 C--N 1.304 -1.4 0 CA-C-O 116.364 -1.779 . . . . 0.0 110.81 -179.867 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.156 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -110.54 122.86 48.78 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.996 179.965 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.0 t -111.26 126.36 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 119.983 -0.687 . . . . 0.0 110.524 179.728 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 39.4 mttt -98.72 118.45 35.48 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.809 -179.483 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.419 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 12.8 mt -82.05 107.1 14.49 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 118.754 -1.179 . . . . 0.0 110.625 179.135 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.418 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 114.49 138.71 6.83 Favored Glycine 0 N--CA 1.495 2.626 0 C-N-CA 120.218 -0.991 . . . . 0.0 110.669 -179.588 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 24.2 p -79.5 163.98 24.29 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 119.532 -0.867 . . . . 0.0 110.624 179.747 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -62.25 -35.4 78.85 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.954 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -169.6 17.86 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.289 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.849 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -97.05 -68.37 0.96 Allowed Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.44 -1.362 . . . . 0.0 110.564 179.96 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -164.04 -147.06 4.96 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.43 -179.843 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.8 mt -112.92 111.62 22.51 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.695 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.4 m -150.72 159.71 4.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.708 179.234 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.508 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 23.3 m-85 -78.46 114.58 17.49 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 177.948 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.4 m -116.24 105.99 49.81 Favored Pre-proline 0 C--N 1.308 -1.238 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.865 -177.45 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -67.55 178.32 20.2 Favored 'Cis proline' 0 C--N 1.359 1.131 0 CA-C-N 118.921 0.65 . . . . 0.0 111.946 -0.395 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.4 ' C ' ' HG ' ' A' ' 18' ' ' SER . 1.1 m -94.14 -48.12 6.35 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.643 -0.823 . . . . 0.0 110.182 179.162 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.4 ' HG ' ' C ' ' A' ' 17' ' ' SER . 44.6 m -137.34 140.98 41.82 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.419 179.144 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.405 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 25.1 p90 -162.93 143.21 9.33 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.626 -179.138 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.27 155.51 18.5 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.146 179.894 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.07 157.13 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 C-N-CA 119.416 -0.914 . . . . 0.0 111.082 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.46 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -75.4 141.06 43.3 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.17 179.456 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.94 75.32 0.04 OUTLIER 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.045 -179.783 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 161.53 13.48 0.03 OUTLIER Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -104.94 151.04 24.37 Favored 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.622 -179.649 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.8 mttp -94.53 141.1 28.99 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.037 -179.919 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 mt -117.89 153.06 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.743 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.5 p -147.77 113.45 5.7 Favored 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 118.811 -1.156 . . . . 0.0 111.954 -179.448 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -84.39 116.18 22.91 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.36 -0.936 . . . . 0.0 108.962 178.485 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.2 tttm -111.56 132.84 54.25 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.778 -178.264 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -76.48 104.23 6.89 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.703 -0.799 . . . . 0.0 109.849 178.904 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.419 ' OD1' ' O ' ' A' ' 5' ' ' LEU . 5.2 p-10 -94.21 -26.23 16.74 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 118.906 -1.118 . . . . 0.0 112.025 -178.642 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 179.12 147.53 0.2 Allowed 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 118.489 -1.284 . . . . 0.0 111.593 -179.783 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 89.63 10.28 65.47 Favored Glycine 0 N--CA 1.481 1.674 0 C-N-CA 119.485 -1.341 . . . . 0.0 111.731 178.661 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -49.66 162.54 0.44 Allowed Pre-proline 0 N--CA 1.48 1.055 0 C-N-CA 117.844 -1.542 . . . . 0.0 108.895 179.431 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -75.93 -173.67 13.0 Favored 'Cis proline' 0 C--O 1.204 -1.189 0 C-N-CA 124.324 -1.115 . . . . 0.0 112.294 -0.213 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.8 m-70 -151.07 171.92 16.56 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 120.142 -0.623 . . . . 0.0 110.522 178.576 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.715 HD21 ' H ' ' A' ' 39' ' ' ILE . 1.3 t-20 -149.61 148.29 29.14 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.488 179.393 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.715 ' H ' HD21 ' A' ' 38' ' ' ASN . 4.1 mp -135.55 112.17 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 C-N-CA 119.676 -0.81 . . . . 0.0 111.322 -179.437 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 t -134.98 149.65 29.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.948 179.224 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.445 ' H ' ' HG ' ' A' ' 56' ' ' SER . 23.5 m-85 -104.77 128.38 52.89 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.512 -0.875 . . . . 0.0 112.04 -179.077 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.46 ' C ' ' H ' ' A' ' 44' ' ' ASP . 49.3 t0 -66.97 126.38 28.94 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.086 179.344 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 63.8 mt-10 -72.1 11.51 0.55 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.229 -0.989 . . . . 0.0 111.221 -179.662 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.46 ' H ' ' C ' ' A' ' 42' ' ' ASP . 28.4 m-20 -105.85 -5.54 19.68 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.667 -0.813 . . . . 0.0 111.068 -179.862 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -142.7 51.97 1.42 Allowed 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 119.719 -0.792 . . . . 0.0 110.229 -179.743 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -139.6 145.97 45.81 Favored Pre-proline 0 N--CA 1.487 1.393 0 CA-C-N 115.286 -0.87 . . . . 0.0 108.825 179.678 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -54.17 163.7 3.18 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 120.798 0.999 . . . . 0.0 112.216 -179.358 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -89.26 61.76 5.85 Favored 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 119.84 -0.744 . . . . 0.0 110.824 -179.968 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.21 -46.38 0.04 OUTLIER Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.529 -1.319 . . . . 0.0 110.014 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.5 t -79.6 84.07 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 C-N-CA 119.554 -0.858 . . . . 0.0 110.39 179.703 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -45.09 139.71 3.12 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.204 -0.999 . . . . 0.0 110.712 -179.636 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.439 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -73.08 -33.06 65.4 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.728 -179.875 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -61.68 -17.91 57.44 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.304 -179.637 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.32 -45.46 11.91 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.422 -179.728 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.0 pt -90.35 -13.8 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 119.233 -0.987 . . . . 0.0 111.327 -179.641 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.445 ' HG ' ' H ' ' A' ' 41' ' ' PHE . 69.2 m -77.65 173.44 12.04 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.582 179.551 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.615 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 69.4 mt-30 -129.24 78.83 75.35 Favored Pre-proline 0 N--CA 1.489 1.481 0 C-N-CA 120.036 -0.665 . . . . 0.0 110.64 -179.868 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.93 -11.47 18.28 Favored 'Trans proline' 0 C--O 1.216 -0.605 0 C-N-CA 121.032 1.155 . . . . 0.0 111.024 -179.539 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -101.35 116.89 33.82 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.535 179.14 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -58.38 159.4 6.27 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.359 -0.936 . . . . 0.0 110.999 -179.672 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.426 ' C ' ' CD1' ' A' ' 61' ' ' LEU . 0.7 OUTLIER -125.41 146.97 49.37 Favored 'General case' 0 N--CA 1.49 1.532 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.666 179.233 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.459 ' ND2' ' O ' ' A' ' 62' ' ' ASN . 9.8 p-10 -155.17 58.6 0.65 Allowed 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.253 -0.979 . . . . 0.0 111.343 -178.744 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.62 130.1 6.23 Favored Glycine 0 N--CA 1.497 2.734 0 C-N-CA 119.737 -1.22 . . . . 0.0 110.784 179.805 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -69.94 103.88 2.36 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.459 -0.896 . . . . 0.0 110.464 179.575 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.45 -7.29 46.53 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.222 -179.709 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -64.7 151.81 44.05 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.141 179.515 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.7 165.15 31.35 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 118.884 -1.126 . . . . 0.0 111.838 -179.679 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.615 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 49.5 t80 -136.07 138.25 41.94 Favored 'General case' 0 N--CA 1.484 1.258 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.323 179.149 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -108.62 153.38 23.49 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.423 -0.911 . . . . 0.0 112.164 -178.765 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -155.41 139.93 9.26 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.439 178.891 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.8 m -126.02 95.95 4.58 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.083 -179.44 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 13.9 mt -79.68 160.9 26.12 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.437 179.434 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.71 25.29 0.76 Allowed 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 118.717 -1.193 . . . . 0.0 112.057 -178.497 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.466 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -116.69 99.9 7.45 Favored 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.357 179.846 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 8.5 mttt -43.44 105.79 0.06 Allowed 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.724 -179.76 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.3 -139.61 5.02 Favored Glycine 0 N--CA 1.483 1.79 0 C-N-CA 119.321 -1.418 . . . . 0.0 109.929 -179.769 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.2 m -146.68 136.02 22.79 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.251 -0.98 . . . . 0.0 111.168 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.576 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -120.52 140.78 50.96 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.829 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 22.9 mmtt -110.17 124.28 51.26 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 119.433 -0.907 . . . . 0.0 111.872 -179.0 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.566 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -134.39 160.89 36.57 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.14 178.395 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . 0.419 ' CD1' ' N ' ' A' ' 81' ' ' TYR . 23.8 p90 -168.29 179.21 4.58 Favored 'General case' 0 C--N 1.293 -1.87 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.889 -178.54 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -102.72 125.4 49.44 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.401 179.663 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.509 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 mt-10 -67.05 -46.25 52.79 Favored Pre-proline 0 C--N 1.306 -1.319 0 C-N-CA 119.499 -0.88 . . . . 0.0 112.819 -179.56 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.509 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.9 Cg_endo -67.01 -48.64 1.74 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 120.97 1.113 . . . . 0.0 112.114 -178.725 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -88.5 20.51 3.33 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.009 -179.515 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.87 -10.4 20.41 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.454 179.449 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.6 -17.31 57.09 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.491 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.15 -15.13 32.18 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.433 -0.907 . . . . 0.0 110.582 179.952 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.64 21.27 11.51 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.722 -1.228 . . . . 0.0 110.573 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.3 mtp -73.05 98.51 2.55 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.174 179.941 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.508 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 16.5 ttmt -121.41 159.6 25.85 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.475 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.38 143.49 12.17 Favored Glycine 0 N--CA 1.496 2.636 0 C-N-CA 119.352 -1.404 . . . . 0.0 111.255 -179.065 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.75 143.67 24.64 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.635 179.514 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.423 ' O ' ' CG1' ' A' ' 94' ' ' VAL . 9.9 p -136.31 122.43 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.318 179.523 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 99.9 m -100.93 100.48 11.12 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.745 -179.951 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 40.3 t -79.84 139.84 17.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 C-N-CA 118.634 -1.226 . . . . 0.0 110.478 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . 0.543 ' ND2' ' N ' ' A' ' 97' ' ' ASN . 0.2 OUTLIER . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 116.441 -1.743 . . . . 0.0 110.965 -179.869 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -106.06 133.39 50.84 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.92 -179.931 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.9 t -123.47 117.48 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 C-N-CA 119.991 -0.684 . . . . 0.0 110.419 179.657 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 29.3 mttp -91.95 114.35 26.87 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.652 -178.81 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.5 mt -76.37 113.28 13.78 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.069 -1.053 . . . . 0.0 109.805 178.007 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.46 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.36 125.35 5.61 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.764 -1.207 . . . . 0.0 110.238 -179.448 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.7 p -67.64 169.75 8.89 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 119.462 -0.895 . . . . 0.0 110.7 179.884 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -95.52 43.61 1.09 Allowed 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.524 -0.871 . . . . 0.0 111.27 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.428 ' CG ' ' H ' ' A' ' 10' ' ' GLY . 5.0 p-10 -158.04 -52.99 0.07 Allowed 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.233 -0.987 . . . . 0.0 110.813 179.833 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.428 ' H ' ' CG ' ' A' ' 9' ' ' ASP . . . 168.84 66.26 0.03 OUTLIER Glycine 0 N--CA 1.49 2.266 0 C-N-CA 119.388 -1.386 . . . . 0.0 110.366 179.953 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -161.94 146.29 11.88 Favored Glycine 0 N--CA 1.489 2.211 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.409 -179.917 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.1 mt -107.17 101.13 10.55 Favored 'General case' 0 N--CA 1.487 1.41 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.596 179.867 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.0 m -150.99 157.06 5.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.116 0 C-N-CA 118.892 -1.123 . . . . 0.0 110.747 179.297 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.522 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 56.8 m-85 -78.12 113.1 15.74 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 177.887 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.6 m -115.19 109.08 47.01 Favored Pre-proline 0 CA--C 1.559 1.311 0 C-N-CA 119.552 -0.859 . . . . 0.0 112.176 -176.954 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -67.14 172.59 37.29 Favored 'Cis proline' 0 C--N 1.359 1.119 0 C-N-CA 125.216 -0.743 . . . . 0.0 111.331 -0.444 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 38.8 t -94.19 -64.31 1.09 Allowed 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.704 178.934 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 t -113.11 135.19 54.08 Favored 'General case' 0 N--CA 1.485 1.292 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.546 178.748 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.418 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 21.7 p90 -160.97 137.91 8.84 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 118.71 -1.196 . . . . 0.0 111.308 -179.141 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -88.25 154.98 19.99 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.073 179.766 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.7 m -145.95 168.66 7.02 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 119.447 -0.901 . . . . 0.0 110.815 179.771 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.49 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -92.3 146.62 23.56 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.656 179.833 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.17 76.4 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.52 -0.872 . . . . 0.0 111.052 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 154.02 15.14 0.06 OUTLIER Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.888 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -102.43 132.94 48.12 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.898 -179.592 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.8 mtpp -75.75 141.53 42.59 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.0 mt -125.72 112.1 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 C-N-CA 120.088 -0.645 . . . . 0.0 109.261 179.407 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 13.4 p -108.52 121.43 44.96 Favored 'General case' 0 N--CA 1.488 1.462 0 C-N-CA 119.622 -0.831 . . . . 0.0 112.256 -178.561 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -86.36 121.18 28.56 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.449 -0.9 . . . . 0.0 109.182 178.502 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.0 tmtp? -112.71 142.42 45.34 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.871 -0.731 . . . . 0.0 110.655 -178.689 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -94.05 118.41 31.48 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.178 179.87 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.46 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 0.8 OUTLIER -98.9 -30.74 12.21 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.864 -179.989 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.459 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 165.02 146.34 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.078 179.896 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 111.51 2.53 27.51 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.91 -1.138 . . . . 0.0 110.861 179.484 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.597 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -52.2 163.91 0.66 Allowed Pre-proline 0 C--N 1.308 -1.219 0 C-N-CA 118.868 -1.133 . . . . 0.0 109.917 179.797 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_endo -78.31 143.69 73.34 Favored 'Cis proline' 0 C--O 1.212 -0.821 0 C-N-CA 124.156 -1.185 . . . . 0.0 112.489 -0.808 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 35.2 m-70 -107.29 178.88 4.41 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.032 179.149 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.718 HD21 ' H ' ' A' ' 39' ' ' ILE . 0.5 OUTLIER -158.03 145.0 17.91 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.635 -0.826 . . . . 0.0 110.061 179.098 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.718 ' H ' HD21 ' A' ' 38' ' ' ASN . 3.9 mp -131.92 117.04 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.758 -0.777 . . . . 0.0 110.948 -179.771 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 40.4 t -136.03 141.79 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.19 179.667 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -93.78 134.02 36.55 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 119.442 -0.903 . . . . 0.0 111.064 -179.584 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.682 ' C ' ' H ' ' A' ' 44' ' ' ASP . 24.7 p-10 -75.23 101.49 4.67 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.279 -0.969 . . . . 0.0 110.975 -179.523 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.493 ' H ' ' CD ' ' A' ' 43' ' ' GLU . 1.6 pm0 -55.63 6.5 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.175 0 C-N-CA 119.969 -0.692 . . . . 0.0 111.38 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.682 ' H ' ' C ' ' A' ' 42' ' ' ASP . 4.2 m-20 -83.08 -67.31 0.8 Allowed 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.837 179.138 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -97.83 27.36 4.49 Favored 'General case' 0 N--CA 1.49 1.539 0 C-N-CA 119.335 -0.946 . . . . 0.0 112.089 -177.049 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 45.3 t -102.48 143.97 27.67 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.598 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.458 ' C ' ' H ' ' A' ' 49' ' ' GLY . 4.6 Cg_exo -46.61 140.9 11.71 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 120.777 0.984 . . . . 0.0 112.178 -179.107 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.53 39.28 0.26 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.863 -179.892 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.458 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -142.55 -41.0 0.07 OUTLIER Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.703 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 71.6 t -87.73 84.63 2.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.894 179.207 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -44.19 139.9 2.38 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.573 -0.851 . . . . 0.0 111.083 -179.185 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.438 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -86.21 0.65 53.21 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.473 -0.891 . . . . 0.0 110.766 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -87.39 -10.76 51.2 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.826 179.914 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.0 mtmt -98.17 -35.47 10.37 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.594 -0.842 . . . . 0.0 111.232 -179.668 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 8.3 pt -92.86 -13.37 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.245 -0.982 . . . . 0.0 111.373 -179.522 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.438 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 29.0 m -76.3 170.31 16.58 Favored 'General case' 0 C--N 1.307 -1.241 0 C-N-CA 119.186 -1.006 . . . . 0.0 110.893 179.791 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.626 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 4.0 mt-30 -138.37 69.82 46.9 Favored Pre-proline 0 N--CA 1.487 1.379 0 C-N-CA 120.046 -0.662 . . . . 0.0 110.584 -179.854 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -59.56 -10.08 10.56 Favored 'Trans proline' 0 C--N 1.323 -0.798 0 C-N-CA 121.457 1.438 . . . . 0.0 111.554 -179.304 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.418 ' O ' ' O ' ' A' ' 60' ' ' TYR . 0.7 OUTLIER -85.84 103.32 14.48 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.184 179.482 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.418 ' O ' ' O ' ' A' ' 59' ' ' GLU . 90.0 m-85 -44.16 168.26 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.164 -179.593 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 3.1 pp -151.8 146.4 25.68 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.05 179.913 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -143.69 -7.05 0.77 Allowed 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 119.318 -0.953 . . . . 0.0 111.387 -179.684 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -48.23 125.43 12.89 Favored Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.174 -1.489 . . . . 0.0 110.628 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -71.36 111.78 6.96 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.818 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 91.83 -11.19 72.79 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.252 -1.451 . . . . 0.0 110.84 -179.895 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -57.98 159.35 5.71 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.178 -1.009 . . . . 0.0 110.487 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.58 172.63 12.7 Favored 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.987 -179.442 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.626 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 51.9 t80 -135.34 178.59 6.92 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.36 179.09 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.571 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 8.4 mt-10 -145.99 152.0 38.68 Favored 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 118.747 -1.181 . . . . 0.0 111.986 -179.739 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -162.41 140.42 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 119.876 -0.729 . . . . 0.0 109.713 178.539 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.1 m -129.83 97.9 4.63 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.744 -179.619 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.3 mt -79.75 159.29 26.65 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.012 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 4.1 p -150.41 51.39 0.89 Allowed 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.793 -179.25 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.466 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.3 tt0 -142.95 99.81 3.53 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.406 -0.918 . . . . 0.0 109.839 178.829 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 74' ' ' GLU . 3.9 mttp -42.65 103.37 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.436 -0.906 . . . . 0.0 110.618 -179.568 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.0 -142.27 5.51 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.171 -1.49 . . . . 0.0 110.281 -179.544 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.97 133.4 21.86 Favored 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.476 -179.657 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.59 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -122.18 116.87 24.93 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.4 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.456 ' O ' ' OD1' ' A' ' 42' ' ' ASP . 11.2 mptt -95.88 115.69 27.81 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.172 -1.011 . . . . 0.0 111.787 -178.713 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.569 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -119.5 170.09 9.47 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.825 -0.75 . . . . 0.0 110.1 178.755 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -170.37 179.78 3.29 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.329 -178.631 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -102.94 128.27 49.81 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 119.754 -0.779 . . . . 0.0 110.17 179.258 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.53 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 mt-10 -73.34 -45.58 7.77 Favored Pre-proline 0 C--N 1.304 -1.399 0 C-N-CA 119.552 -0.859 . . . . 0.0 112.788 -179.399 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.53 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.3 Cg_exo -65.95 -51.11 1.33 Allowed 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 120.88 1.053 . . . . 0.0 111.684 -179.087 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . 0.497 ' C ' ' H ' ' A' ' 87' ' ' GLY . 38.2 m80 -83.52 13.96 4.12 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.321 -0.952 . . . . 0.0 111.054 -179.774 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.24 -5.4 0.48 Allowed 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.299 -0.96 . . . . 0.0 110.742 179.806 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.497 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -81.04 -26.54 52.72 Favored Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.515 -179.848 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.96 -13.64 35.74 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.626 179.916 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.44 7.15 49.5 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 119.709 -1.234 . . . . 0.0 110.418 179.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -48.31 109.69 0.26 Allowed 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.734 179.902 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.522 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -134.95 170.78 15.37 Favored 'General case' 0 N--CA 1.494 1.756 0 C-N-CA 119.551 -0.86 . . . . 0.0 111.422 -179.849 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -151.63 149.34 21.07 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.192 -1.48 . . . . 0.0 111.266 -178.67 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -152.89 139.3 18.57 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.397 179.522 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.426 ' CG1' ' O ' ' A' ' 94' ' ' VAL . 10.7 p -132.79 121.5 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 C-N-CA 119.289 -0.965 . . . . 0.0 110.5 179.279 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 39.3 m -98.64 100.77 12.03 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.908 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 25.8 t -82.68 151.04 4.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 118.747 -1.181 . . . . 0.0 110.367 -179.369 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 116.397 -1.763 . . . . 0.0 110.846 -179.744 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.1 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -131.37 136.97 48.5 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 120.017 -0.673 . . . . 0.0 110.521 179.977 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.1 t -131.13 124.23 55.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.587 179.839 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 7.0 mptt -95.85 116.89 29.57 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.165 -179.606 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 37.7 mt -75.69 109.93 9.68 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 118.681 -1.208 . . . . 0.0 109.235 178.151 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.527 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 99.46 134.07 8.35 Favored Glycine 0 N--CA 1.484 1.895 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -178.612 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.463 ' HG ' ' H ' ' A' ' 11' ' ' GLY . 20.9 p -75.96 156.8 33.82 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.737 -179.905 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -51.32 -48.98 62.21 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.014 -179.831 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.414 ' OD2' ' OG ' ' A' ' 7' ' ' SER . 0.2 OUTLIER -58.06 -72.39 0.09 Allowed 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.838 -179.913 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -179.76 7.26 0.02 OUTLIER Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.256 -1.449 . . . . 0.0 110.359 -179.9 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.463 ' H ' ' HG ' ' A' ' 7' ' ' SER . . . -70.38 160.59 53.56 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.405 179.945 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 mt -116.45 91.24 3.53 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.642 -179.921 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.2 m -150.01 155.36 7.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.781 179.889 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.425 ' O ' ' O ' ' A' ' 16' ' ' PRO . 75.3 m-85 -78.62 108.97 12.41 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 177.579 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.7 m -111.63 114.43 52.39 Favored Pre-proline 0 C--N 1.303 -1.453 0 C-N-CA 119.389 -0.925 . . . . 0.0 112.07 -177.283 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.6 Cg_endo -66.68 172.47 35.74 Favored 'Cis proline' 0 C--N 1.361 1.201 0 C-N-CA 125.333 -0.695 . . . . 0.0 111.449 -0.685 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.44 -67.06 0.87 Allowed 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.334 179.193 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -108.61 140.4 42.04 Favored 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.556 179.129 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 22.1 p90 -165.69 140.16 4.71 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 118.227 -1.389 . . . . 0.0 111.786 -179.213 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 75.7 p -88.83 157.42 18.47 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.761 179.423 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -149.9 151.48 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 C-N-CA 119.297 -0.961 . . . . 0.0 111.159 179.739 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.46 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -71.95 142.55 49.43 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.316 -0.954 . . . . 0.0 110.462 179.724 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.17 75.98 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 119.414 -0.914 . . . . 0.0 111.188 -179.752 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 161.08 11.1 0.04 OUTLIER Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.857 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.9 tp10 -105.13 148.56 26.73 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 120.1 -0.64 . . . . 0.0 110.832 -179.497 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 10.3 pttm -95.16 155.01 16.91 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.493 -0.883 . . . . 0.0 111.09 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 mt -127.22 109.21 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.799 179.56 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.1 p -100.68 117.69 35.31 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.789 -0.764 . . . . 0.0 112.028 -178.757 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -84.66 129.83 34.79 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.238 -0.985 . . . . 0.0 108.723 178.315 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.0 ttmt -120.0 128.12 53.25 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.394 -178.53 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 35.1 m120 -71.81 111.49 7.12 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.536 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.527 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 0.9 OUTLIER -96.09 -31.9 12.79 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.023 -1.071 . . . . 0.0 111.32 -179.856 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.472 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 163.26 130.97 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.894 179.585 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 124.89 2.58 7.86 Favored Glycine 0 N--CA 1.496 2.665 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.142 179.488 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -50.55 162.98 0.49 Allowed Pre-proline 0 C--N 1.307 -1.245 0 C-N-CA 118.518 -1.273 . . . . 0.0 109.739 179.798 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -75.96 144.37 79.57 Favored 'Cis proline' 0 C--O 1.215 -0.655 0 C-N-CA 124.279 -1.134 . . . . 0.0 112.341 -0.482 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 30.6 m-70 -108.05 173.74 6.19 Favored 'General case' 0 N--CA 1.493 1.719 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.637 179.541 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.715 HD21 ' H ' ' A' ' 39' ' ' ILE . 0.6 OUTLIER -152.62 138.35 17.9 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.925 179.534 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.715 ' H ' HD21 ' A' ' 38' ' ' ASN . 3.7 mp -128.13 99.97 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.904 -179.728 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.6 t -123.36 147.35 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.011 179.341 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -101.26 129.63 47.25 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.464 -0.894 . . . . 0.0 111.505 -179.676 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -67.03 113.72 5.24 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.702 -0.799 . . . . 0.0 110.632 179.656 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -62.06 -4.42 1.66 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.678 -0.809 . . . . 0.0 111.718 -179.22 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -95.78 -2.4 47.75 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.089 -179.78 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -140.65 50.47 1.67 Allowed 'General case' 0 C--N 1.312 -1.031 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.704 179.871 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -140.35 145.9 43.23 Favored Pre-proline 0 N--CA 1.489 1.502 0 CA-C-N 115.51 -0.768 . . . . 0.0 108.936 179.879 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -54.81 162.33 5.15 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 120.798 0.998 . . . . 0.0 111.742 -179.739 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -90.16 55.47 3.1 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.835 179.958 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -161.59 -42.27 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.06 179.926 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 88.5 t -86.28 92.62 3.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 C-N-CA 119.565 -0.854 . . . . 0.0 110.421 179.756 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -44.55 139.78 2.68 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.953 -179.785 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.437 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -80.88 -15.6 55.89 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.519 -0.873 . . . . 0.0 110.965 -179.8 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -77.68 -28.0 50.95 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.406 -0.917 . . . . 0.0 111.309 -179.479 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -73.45 -35.63 65.79 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.44 -179.202 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.9 pt -96.54 -13.83 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.533 -179.353 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.437 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 19.3 m -77.27 176.3 8.91 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.025 -1.07 . . . . 0.0 111.35 -179.611 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.651 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 60.6 mt-30 -137.31 71.58 53.36 Favored Pre-proline 0 C--N 1.306 -1.298 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.432 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -59.26 -19.08 48.41 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 121.307 1.338 . . . . 0.0 111.34 -179.217 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -91.83 97.25 10.87 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.294 179.259 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -43.54 163.94 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.725 -179.731 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.7 pp -134.8 139.5 45.15 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.567 -0.853 . . . . 0.0 110.887 179.728 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.412 ' ND2' ' N ' ' A' ' 62' ' ' ASN . 0.1 OUTLIER -131.53 31.52 4.29 Favored 'General case' 0 N--CA 1.484 1.234 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.479 179.942 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -99.76 128.45 9.58 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.475 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -78.17 128.91 34.48 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.413 -0.915 . . . . 0.0 110.799 179.955 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 81.5 -21.84 5.95 Favored Glycine 0 N--CA 1.489 2.227 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.794 179.915 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.422 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 2.2 mm-40 -49.72 162.82 0.15 Allowed 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.178 -1.009 . . . . 0.0 110.267 179.858 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 7.6 p -146.28 163.36 35.76 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.79 -179.38 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.651 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 37.2 t80 -136.05 146.13 46.75 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.421 179.39 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -106.12 148.69 27.53 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 119.466 -0.894 . . . . 0.0 112.318 -178.773 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -149.41 132.88 7.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.498 178.786 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 18.2 m -131.21 105.36 7.62 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.469 -0.892 . . . . 0.0 111.639 -179.012 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 17.9 mt -95.32 152.64 18.21 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 119.422 -0.911 . . . . 0.0 109.693 179.091 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 47.4 p -150.57 47.02 0.88 Allowed 'General case' 0 C--N 1.293 -1.854 0 C-N-CA 119.304 -0.959 . . . . 0.0 110.862 -179.54 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.453 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 3.7 mm-40 -137.81 107.79 6.34 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.728 -179.948 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 8.5 tptt -44.45 112.51 0.42 Allowed 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.333 -179.876 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 167.94 -152.28 20.4 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.086 -1.531 . . . . 0.0 110.391 179.722 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.92 135.46 32.85 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.495 -179.922 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.558 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -121.36 166.3 14.27 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.659 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 17.3 mmtp -138.2 130.14 28.43 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.804 -179.322 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.528 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.5 p90 -137.24 164.18 29.15 Favored 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.214 178.673 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 39.4 p90 -170.32 -173.83 1.56 Allowed 'General case' 0 C--N 1.287 -2.146 0 C-N-CA 119.586 -0.846 . . . . 0.0 110.704 -178.497 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -112.38 129.85 56.17 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.57 179.478 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.502 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.9 mm-40 -69.71 -45.77 24.95 Favored Pre-proline 0 N--CA 1.488 1.454 0 C-N-CA 119.393 -0.923 . . . . 0.0 112.906 -179.446 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.502 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.9 Cg_endo -66.95 -52.22 0.7 Allowed 'Trans proline' 0 C--O 1.216 -0.6 0 C-N-CA 120.756 0.971 . . . . 0.0 112.41 -179.244 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . 0.497 ' C ' ' H ' ' A' ' 87' ' ' GLY . 35.2 m80 -81.54 5.61 17.43 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.449 -0.901 . . . . 0.0 112.224 -178.912 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.59 -2.01 0.69 Allowed 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.712 -1.195 . . . . 0.0 110.525 179.935 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.497 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -81.63 -23.52 57.97 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 119.503 -1.332 . . . . 0.0 110.39 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.5 -45.45 7.76 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.346 -0.941 . . . . 0.0 110.43 -179.996 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.01 29.18 0.15 Allowed Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.531 179.687 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -76.12 102.69 5.83 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.124 -1.03 . . . . 0.0 110.961 179.888 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.6 pttt -131.12 166.49 20.98 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.434 -179.898 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.84 147.31 17.43 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.23 -1.462 . . . . 0.0 111.612 -178.713 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -149.47 147.71 28.55 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.347 179.189 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 14.3 p -143.39 136.19 24.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 118.911 -1.116 . . . . 0.0 110.363 179.377 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 4.8 m -114.52 108.19 16.52 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.914 -0.714 . . . . 0.0 110.626 179.815 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.6 t -84.96 143.86 10.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 C-N-CA 118.532 -1.267 . . . . 0.0 110.527 -178.932 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 116.293 -1.813 . . . . 0.0 111.229 -179.664 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.161 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -115.56 121.16 41.81 Favored 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.479 179.589 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 61.5 t -110.5 122.38 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 C-N-CA 119.792 -0.763 . . . . 0.0 111.062 -179.787 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.1 mtmt -91.89 112.11 23.92 Favored 'General case' 0 C--N 1.297 -1.685 0 C-N-CA 119.449 -0.9 . . . . 0.0 110.454 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 7.7 mt -77.33 108.15 10.26 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 118.869 -1.133 . . . . 0.0 110.471 179.083 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.422 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 113.76 147.66 9.79 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.557 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.59 ' HG ' ' N ' ' A' ' 11' ' ' GLY . 21.6 p -88.78 159.68 17.65 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.561 -0.855 . . . . 0.0 110.901 179.846 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -77.38 -20.64 54.41 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.344 -0.943 . . . . 0.0 110.664 179.832 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.477 ' CG ' ' H ' ' A' ' 10' ' ' GLY . 0.8 OUTLIER -87.18 -71.57 0.55 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.473 -0.891 . . . . 0.0 110.796 -179.906 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.477 ' H ' ' CG ' ' A' ' 9' ' ' ASP . . . 179.36 63.62 0.07 OUTLIER Glycine 0 N--CA 1.489 2.22 0 C-N-CA 119.396 -1.383 . . . . 0.0 110.429 179.966 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.59 ' N ' ' HG ' ' A' ' 7' ' ' SER . . . -152.39 166.17 31.09 Favored Glycine 0 N--CA 1.49 2.278 0 C-N-CA 119.528 -1.32 . . . . 0.0 110.278 -179.998 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -115.51 105.77 13.18 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.771 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.8 m -151.8 156.61 5.83 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 C-N-CA 118.963 -1.095 . . . . 0.0 110.646 178.978 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.406 ' O ' ' C ' ' A' ' 16' ' ' PRO . 43.5 m-85 -78.55 113.31 16.46 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 177.572 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.8 m -115.21 107.58 49.38 Favored Pre-proline 0 N--CA 1.484 1.25 0 C-N-CA 119.434 -0.907 . . . . 0.0 112.089 -177.277 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.406 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -66.79 176.24 23.75 Favored 'Cis proline' 0 C--N 1.359 1.101 0 C-N-CA 125.409 -0.663 . . . . 0.0 111.738 -0.414 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.27 -52.98 4.92 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.611 -0.836 . . . . 0.0 110.088 179.138 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.4 t -131.09 146.68 52.45 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.398 178.985 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.404 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 23.0 p90 -161.55 140.04 9.53 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 118.374 -1.33 . . . . 0.0 111.96 -179.066 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 64.3 p -81.62 155.66 25.53 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.837 -0.745 . . . . 0.0 110.913 179.652 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.9 m -148.76 164.76 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 119.572 -0.851 . . . . 0.0 110.483 179.528 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.507 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -89.93 147.56 23.65 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.288 -0.965 . . . . 0.0 110.998 -179.754 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.15 77.59 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.509 -0.876 . . . . 0.0 110.788 179.756 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.66 23.15 0.09 OUTLIER Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -179.97 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -103.99 140.01 38.33 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.987 -0.685 . . . . 0.0 110.764 -179.578 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.9 mtmt -85.03 125.9 33.11 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.282 -0.967 . . . . 0.0 110.97 -179.851 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.2 mt -102.62 119.77 51.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 C-N-CA 119.803 -0.759 . . . . 0.0 109.578 179.779 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 43.3 p -117.1 114.57 23.91 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.7 -0.8 . . . . 0.0 112.393 -178.513 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -87.46 117.91 26.56 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.003 178.319 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.8 tttt -112.29 138.61 48.76 Favored 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 119.544 -0.862 . . . . 0.0 111.86 -178.338 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -81.13 131.36 35.3 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.2 179.683 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.462 ' O ' ' CB ' ' A' ' 33' ' ' ALA . 1.8 p-10 -125.56 -17.06 5.63 Favored 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.067 179.217 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.462 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 166.04 149.55 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 C-N-CA 119.542 -0.863 . . . . 0.0 111.247 178.992 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.28 -5.74 59.19 Favored Glycine 0 N--CA 1.495 2.581 0 C-N-CA 119.279 -1.439 . . . . 0.0 112.284 178.626 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -48.14 162.23 0.34 Allowed Pre-proline 0 N--CA 1.489 1.488 0 C-N-CA 118.133 -1.427 . . . . 0.0 109.723 -179.923 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -76.23 142.99 75.12 Favored 'Cis proline' 0 C--O 1.212 -0.796 0 C-N-CA 124.304 -1.123 . . . . 0.0 112.538 -0.638 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.2 m-70 -108.66 -179.63 3.92 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 119.856 -0.738 . . . . 0.0 111.498 -179.896 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.55 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -158.63 146.71 18.25 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.841 -0.744 . . . . 0.0 110.241 179.167 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.55 ' N ' HD21 ' A' ' 38' ' ' ASN . 3.9 mp -135.94 117.81 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 119.519 -0.873 . . . . 0.0 111.08 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.55 160.4 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.298 179.089 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.5 m-85 -113.38 125.0 53.78 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.41 -0.916 . . . . 0.0 112.058 -178.973 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.527 ' C ' ' H ' ' A' ' 44' ' ' ASP . 1.1 t70 -65.23 107.18 1.51 Allowed 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.664 178.786 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -67.86 16.38 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 119.505 -0.878 . . . . 0.0 112.207 -178.826 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.527 ' H ' ' C ' ' A' ' 42' ' ' ASP . 1.9 m-20 -106.02 -3.68 21.36 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 119.5 -0.88 . . . . 0.0 111.019 179.89 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -140.89 12.39 2.25 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.917 179.596 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -92.32 147.02 33.68 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.615 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -49.68 154.67 4.45 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 120.966 1.111 . . . . 0.0 112.019 -179.286 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.79 67.79 10.21 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.682 -179.935 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.86 -38.13 0.07 OUTLIER Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.957 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 55.8 t -90.53 81.19 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.371 179.583 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -44.21 139.62 2.51 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.13 -179.359 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.441 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -87.44 10.31 17.94 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.955 -179.724 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -90.55 -22.68 21.17 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.091 -1.044 . . . . 0.0 111.513 -179.476 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -93.81 -32.32 14.01 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 118.912 -1.115 . . . . 0.0 112.046 -179.329 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.1 pt -90.33 -23.74 5.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.513 -179.327 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.441 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 18.1 m -61.78 -178.8 0.16 Allowed 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.098 179.869 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.651 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 9.9 tt0 -157.83 67.84 3.81 Favored Pre-proline 0 C--N 1.303 -1.444 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.689 -179.579 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.96 -29.34 87.82 Favored 'Trans proline' 0 C--N 1.323 -0.781 0 C-N-CA 121.308 1.339 . . . . 0.0 111.286 -179.419 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -59.01 112.28 1.62 Allowed 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.554 179.701 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.447 ' CD1' ' OD1' ' A' ' 38' ' ' ASN . 43.9 m-85 -58.55 169.55 0.9 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.998 -179.95 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.2 pp -153.73 149.17 27.2 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.362 179.688 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.512 ' O ' ' C ' ' A' ' 63' ' ' GLY . 0.0 OUTLIER -127.21 -74.31 0.59 Allowed 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.396 -179.288 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . 0.512 ' C ' ' O ' ' A' ' 62' ' ' ASN . . . -9.65 123.41 0.01 OUTLIER Glycine 1 N--CA 1.518 4.113 0 O-C-N 124.202 0.939 . . . . 0.0 112.75 -179.641 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -75.05 131.41 40.56 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.43 -0.908 . . . . 0.0 110.664 179.736 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.63 -14.96 58.92 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.596 -1.288 . . . . 0.0 110.528 -179.975 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' A' ' 66' ' ' GLU . 1.2 mp0 -62.96 148.51 47.33 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.446 179.844 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.38 163.24 34.35 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.246 -0.982 . . . . 0.0 111.396 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.651 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 41.5 t80 -136.54 143.73 43.85 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 119.87 -0.732 . . . . 0.0 109.276 179.269 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -106.15 152.16 23.8 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.219 -0.992 . . . . 0.0 111.995 -179.149 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -151.82 131.58 3.62 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 CA-C-N 115.345 -0.843 . . . . 0.0 108.813 179.555 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.7 m -121.52 112.87 19.04 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.804 -179.067 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 45.7 mt -96.56 158.61 15.35 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.725 -0.79 . . . . 0.0 109.417 178.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.0 m -150.89 41.9 0.77 Allowed 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 118.56 -1.256 . . . . 0.0 112.351 -179.133 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.424 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 62.8 mt-10 -145.92 110.98 5.27 Favored 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.378 178.918 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -44.06 116.51 1.01 Allowed 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.934 -179.569 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 164.5 175.16 35.04 Favored Glycine 0 N--CA 1.483 1.807 0 C-N-CA 119.293 -1.432 . . . . 0.0 110.35 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.76 126.77 53.38 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.992 -0.683 . . . . 0.0 110.977 -179.785 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.554 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -108.35 141.99 39.34 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.352 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 16.5 mmtp -105.12 122.22 45.45 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.953 -179.139 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.423 ' CZ ' ' N ' ' A' ' 93' ' ' GLU . 5.7 p90 -138.48 160.04 40.57 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 119.315 -0.954 . . . . 0.0 110.076 177.508 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -170.24 -175.26 1.91 Allowed 'General case' 0 C--N 1.287 -2.112 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.908 -177.655 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.6 t -103.48 122.72 45.49 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.732 -0.787 . . . . 0.0 109.372 179.245 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.564 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 4.9 tt0 -73.4 -36.04 2.94 Favored Pre-proline 0 CA--C 1.557 1.236 0 C-N-CA 118.84 -1.144 . . . . 0.0 113.267 -178.701 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.564 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.0 OUTLIER -70.25 -47.74 0.73 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 120.376 0.718 . . . . 0.0 111.105 179.66 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . 0.449 ' C ' ' H ' ' A' ' 87' ' ' GLY . 36.7 m80 -87.77 16.45 5.76 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.593 -0.843 . . . . 0.0 110.808 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.53 -2.61 1.69 Allowed 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.364 -0.935 . . . . 0.0 110.821 179.908 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.449 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -88.16 -17.83 56.82 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.354 -1.403 . . . . 0.0 110.29 179.911 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.45 -41.61 10.2 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.644 179.961 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 132.72 13.88 1.56 Allowed Glycine 0 N--CA 1.494 2.555 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.562 179.861 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.49 101.86 0.21 Allowed 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.928 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.5 tptt -124.71 154.1 41.35 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 119.914 -0.715 . . . . 0.0 111.256 -179.854 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.55 153.1 21.88 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.85 -179.055 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.423 ' N ' ' CZ ' ' A' ' 80' ' ' PHE . 2.7 mt-10 -156.4 146.05 20.9 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.363 -0.935 . . . . 0.0 111.289 179.911 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 13.1 p -138.7 128.54 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.24 178.792 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 98.8 m -106.77 100.09 9.62 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.68 179.831 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.0 t -80.04 150.78 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.237 0 C-N-CA 118.779 -1.169 . . . . 0.0 110.392 -179.714 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 116.339 -1.791 . . . . 0.0 110.828 179.969 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.153 0 CA-C-O 120.855 0.36 . . . . 0.0 110.079 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -105.27 135.69 46.17 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.929 -0.708 . . . . 0.0 110.647 179.887 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.0 t -124.11 126.62 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.817 -0.753 . . . . 0.0 110.445 179.591 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 7.3 mttp -100.84 118.57 37.16 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.792 -0.763 . . . . 0.0 110.591 -179.819 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.2 mt -83.66 109.82 17.77 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.646 178.84 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.543 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 106.25 133.36 7.42 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -178.8 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.2 p -73.34 161.46 30.45 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.624 179.64 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -84.47 43.78 0.99 Allowed 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.78 -179.906 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -155.52 -55.68 0.09 Allowed 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.246 -0.982 . . . . 0.0 110.996 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.11 67.19 0.03 OUTLIER Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.295 -1.431 . . . . 0.0 110.648 -179.862 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -161.03 157.53 29.07 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.309 -1.424 . . . . 0.0 110.476 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 49.9 mt -114.82 99.37 7.44 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.645 179.838 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.1 m -147.3 154.67 11.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 C-N-CA 119.091 -1.044 . . . . 0.0 111.023 179.899 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.443 ' O ' ' O ' ' A' ' 16' ' ' PRO . 40.4 m-85 -78.39 109.08 12.22 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 177.893 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 20.0 m -115.37 111.32 44.38 Favored Pre-proline 0 C--O 1.205 -1.24 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.51 -177.446 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.443 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -66.16 176.57 20.88 Favored 'Cis proline' 0 C--N 1.355 0.909 0 C-N-CA 125.304 -0.707 . . . . 0.0 111.612 0.102 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -92.86 -56.58 2.94 Favored 'General case' 0 N--CA 1.486 1.371 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.726 178.803 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.8 t -125.75 139.37 53.58 Favored 'General case' 0 N--CA 1.486 1.341 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.073 178.806 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 16.4 p90 -159.03 132.84 7.49 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.448 -178.915 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -83.12 155.07 24.01 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.271 -0.972 . . . . 0.0 110.865 179.762 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 17.8 m -146.57 171.55 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.326 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.998 179.741 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -93.94 151.45 19.55 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.414 -0.914 . . . . 0.0 110.684 179.728 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.2 73.54 0.12 Allowed 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.146 -179.986 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 154.69 13.14 0.06 OUTLIER Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.791 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -99.07 117.04 32.67 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.663 -179.783 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.1 mtmp? -65.96 133.44 50.86 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 119.477 -0.889 . . . . 0.0 111.066 -179.774 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 mt -113.55 131.77 64.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 C-N-CA 119.954 -0.698 . . . . 0.0 109.248 179.454 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.5 p -125.29 123.29 39.16 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.526 -0.87 . . . . 0.0 112.173 -178.54 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -84.4 147.29 27.22 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.414 -0.914 . . . . 0.0 108.851 178.346 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 tttm -136.62 127.9 28.18 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.396 -0.921 . . . . 0.0 111.371 -178.873 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.2 m-80 -79.45 109.45 13.82 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.69 -0.804 . . . . 0.0 110.52 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.543 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 0.6 OUTLIER -95.49 -30.73 13.7 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.76 -179.474 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.453 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 166.4 136.92 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.041 -179.661 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 116.27 -2.23 20.65 Favored Glycine 0 N--CA 1.495 2.599 0 C-N-CA 119.836 -1.174 . . . . 0.0 111.033 179.189 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -47.37 163.83 0.25 Allowed Pre-proline 0 C--N 1.308 -1.224 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.775 179.792 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -76.23 145.34 82.01 Favored 'Cis proline' 0 C--O 1.214 -0.722 0 C-N-CA 124.223 -1.157 . . . . 0.0 112.659 -0.756 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -111.22 172.15 7.05 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.889 179.298 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.663 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.2 OUTLIER -149.8 137.98 20.47 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.111 179.34 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.663 ' N ' HD21 ' A' ' 38' ' ' ASN . 3.5 mp -125.17 110.68 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 C-N-CA 119.893 -0.723 . . . . 0.0 110.888 -179.689 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.5 t -130.93 145.31 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.95 -0.7 . . . . 0.0 110.326 179.528 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -99.53 121.7 41.55 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.586 -0.845 . . . . 0.0 111.322 -179.356 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -60.48 100.87 0.11 Allowed 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.131 -1.028 . . . . 0.0 110.044 179.484 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -57.65 -6.6 0.52 Allowed 'General case' 0 N--CA 1.489 1.488 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.277 -179.012 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -93.36 3.19 56.01 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 118.993 -1.083 . . . . 0.0 112.263 -178.733 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 30.6 mt-10 -144.56 13.52 1.55 Allowed 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 119.116 -1.033 . . . . 0.0 111.741 -179.944 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -90.85 149.96 41.22 Favored Pre-proline 0 C--N 1.292 -1.919 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.287 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -47.91 144.25 12.05 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.917 1.078 . . . . 0.0 111.878 -179.539 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.6 73.98 1.99 Allowed 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.531 -0.868 . . . . 0.0 110.617 179.994 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.47 -32.72 0.12 Allowed Glycine 0 N--CA 1.487 2.053 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.241 -179.94 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 81.4 t -94.83 105.79 17.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.374 -0.93 . . . . 0.0 111.073 -179.855 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -52.17 143.99 13.29 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.715 179.882 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.435 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -93.04 -3.28 54.6 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.328 -0.949 . . . . 0.0 110.908 -179.773 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -90.22 -21.45 22.15 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.255 -0.978 . . . . 0.0 110.94 -179.931 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 23.4 mmtt -78.14 -26.96 48.08 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.304 -0.958 . . . . 0.0 110.936 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.3 pt -105.8 -12.22 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.845 -179.192 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.435 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 18.6 m -78.39 170.07 17.22 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.108 -1.037 . . . . 0.0 111.316 -179.952 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.655 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 55.5 mt-30 -134.19 74.11 68.27 Favored Pre-proline 0 N--CA 1.486 1.335 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.241 179.902 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -59.52 -20.26 56.19 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 121.277 1.318 . . . . 0.0 111.63 -178.69 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.444 ' O ' ' CG ' ' A' ' 59' ' ' GLU . 3.4 pt-20 -89.14 107.0 18.8 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.527 179.513 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.419 ' CD2' ' OD1' ' A' ' 38' ' ' ASN . 27.6 m-85 -51.93 165.61 0.19 Allowed 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 119.411 -0.915 . . . . 0.0 110.849 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.4 pp -139.34 126.38 21.09 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.43 179.466 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.457 ' OD1' ' N ' ' A' ' 62' ' ' ASN . 19.8 p-10 -118.31 34.97 4.94 Favored 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.057 -179.49 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -87.99 -172.08 47.06 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 119.238 -1.458 . . . . 0.0 110.214 179.64 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -133.59 105.94 7.14 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.049 179.579 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 94.24 -11.37 70.58 Favored Glycine 0 N--CA 1.486 2.03 0 C-N-CA 119.308 -1.425 . . . . 0.0 109.713 -179.299 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -50.59 160.94 0.37 Allowed 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.359 179.684 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.7 p -145.8 158.99 43.82 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.393 -179.374 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.655 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 15.6 t80 -136.16 137.01 40.5 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.365 179.068 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -99.97 152.3 20.35 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 119.292 -0.963 . . . . 0.0 112.494 -178.769 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -155.81 134.53 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 115.191 -0.913 . . . . 0.0 108.9 179.509 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.1 m -128.6 96.7 4.47 Favored 'General case' 0 N--CA 1.486 1.327 0 C-N-CA 119.559 -0.856 . . . . 0.0 111.208 -179.482 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.5 mt -79.88 157.63 26.9 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.25 -0.98 . . . . 0.0 109.9 179.433 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 77.6 p -150.06 45.96 0.91 Allowed 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.495 -179.169 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.439 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.7 mm-40 -142.46 113.29 7.45 Favored 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.098 -1.041 . . . . 0.0 110.448 179.557 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.466 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 0.6 OUTLIER -52.45 119.33 4.35 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.268 -0.973 . . . . 0.0 111.058 -179.322 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 163.36 -147.87 13.91 Favored Glycine 0 N--CA 1.483 1.78 0 C-N-CA 119.254 -1.451 . . . . 0.0 110.142 179.86 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.74 130.18 23.9 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.752 -179.938 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.53 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.6 m-85 -114.86 123.8 50.08 Favored 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.923 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . 0.516 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.5 OUTLIER -103.97 121.03 42.29 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.133 -1.027 . . . . 0.0 111.76 -178.949 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 4.2 p90 -129.54 173.19 10.81 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.212 178.295 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -171.11 -174.29 1.46 Allowed 'General case' 0 C--N 1.292 -1.894 0 C-N-CA 119.531 -0.868 . . . . 0.0 110.814 -178.576 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -108.89 132.07 54.41 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 119.898 -0.721 . . . . 0.0 110.49 179.209 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.496 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.2 mt-10 -73.38 -47.18 7.61 Favored Pre-proline 0 N--CA 1.485 1.286 0 C-N-CA 119.432 -0.907 . . . . 0.0 112.472 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.2 Cg_exo -64.54 -47.18 5.94 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 120.89 1.06 . . . . 0.0 111.953 -179.227 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . 0.478 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.6 m80 -90.51 21.42 3.95 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.971 -179.421 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.73 1.66 1.24 Allowed 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.692 179.844 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.478 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -96.5 -20.94 23.41 Favored Glycine 0 N--CA 1.49 2.277 0 C-N-CA 119.471 -1.347 . . . . 0.0 110.412 -179.869 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.41 -9.87 45.95 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.485 179.667 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 96.46 20.28 25.33 Favored Glycine 0 N--CA 1.488 2.102 0 C-N-CA 119.498 -1.334 . . . . 0.0 110.462 179.817 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.31 102.72 0.7 Allowed 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.151 -1.02 . . . . 0.0 110.982 -179.829 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.07 162.1 26.86 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.003 179.826 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -142.96 153.26 24.6 Favored Glycine 0 N--CA 1.491 2.359 0 C-N-CA 119.436 -1.364 . . . . 0.0 111.468 -178.587 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -155.62 144.87 20.85 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.429 -0.908 . . . . 0.0 111.078 179.629 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -141.78 123.32 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.193 178.461 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 92.3 m -101.14 108.2 19.81 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.158 -179.526 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 23.2 t -88.93 148.15 4.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 118.771 -1.172 . . . . 0.0 110.764 -179.329 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 . . . . . 0 N--CA 1.485 1.317 0 CA-C-O 116.341 -1.79 . . . . 0.0 110.868 -179.903 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.14 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -135.26 127.38 29.87 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 120.027 -0.669 . . . . 0.0 110.574 179.741 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.7 t -115.72 131.86 66.85 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 C-N-CA 119.864 -0.735 . . . . 0.0 110.991 -179.745 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.7 mtpp -104.72 118.9 37.71 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.205 -179.749 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.9 mt -81.52 108.22 14.93 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 118.956 -1.098 . . . . 0.0 109.672 178.269 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.531 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 110.41 125.64 4.91 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.649 -1.381 . . . . 0.0 109.649 -179.1 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' SER . . . . . 0.676 ' HG ' ' N ' ' A' ' 10' ' ' GLY . 3.2 p -78.57 22.72 0.34 Allowed 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.162 -1.015 . . . . 0.0 110.934 -179.746 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . 0.442 ' H ' ' C ' ' A' ' 6' ' ' GLY . 1.3 m-20 57.23 2.64 0.13 Allowed 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 119.829 -0.749 . . . . 0.0 111.395 179.585 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.53 ' H ' ' C ' ' A' ' 7' ' ' SER . 0.3 OUTLIER 175.62 -41.87 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.738 -179.965 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.676 ' N ' ' HG ' ' A' ' 7' ' ' SER . . . -54.44 -32.2 52.25 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.353 -1.403 . . . . 0.0 110.094 179.869 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.567 ' H ' ' HG ' ' A' ' 7' ' ' SER . . . 142.29 -136.1 7.04 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.518 -1.325 . . . . 0.0 110.556 179.978 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.6 mt -117.96 104.56 11.02 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.67 -179.728 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.4 m -150.01 154.25 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.122 0 C-N-CA 118.777 -1.169 . . . . 0.0 111.268 179.749 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.433 ' O ' ' O ' ' A' ' 16' ' ' PRO . 11.1 m-85 -78.6 108.57 12.09 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 177.818 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 53.3 m -114.76 112.31 45.29 Favored Pre-proline 0 CA--C 1.559 1.303 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.248 -177.176 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.433 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -65.56 176.79 18.52 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 125.188 -0.755 . . . . 0.0 111.702 -0.936 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.9 t -93.86 -55.97 3.05 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.453 179.212 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.4 p -128.92 142.65 50.87 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.814 179.212 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -163.9 143.01 7.83 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 118.663 -1.215 . . . . 0.0 111.782 -179.278 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -90.76 153.59 20.15 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.903 179.533 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.7 m -145.95 -176.75 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 119.494 -0.882 . . . . 0.0 110.585 179.617 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.409 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -97.53 147.09 24.62 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.716 179.773 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.3 74.03 0.14 Allowed 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.836 179.741 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 155.54 18.09 0.04 OUTLIER Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.913 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -99.65 156.1 17.25 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.767 -0.773 . . . . 0.0 110.881 -179.783 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.0 mptp? -93.81 119.28 32.56 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.722 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.1 mt -100.06 106.5 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.254 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.2 p -104.26 117.7 34.85 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.582 -0.847 . . . . 0.0 112.888 -177.893 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -84.38 149.0 26.31 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.408 -0.917 . . . . 0.0 108.548 177.893 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 6.4 ttpp -141.19 133.39 27.98 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 118.965 -1.094 . . . . 0.0 111.664 -178.445 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 0.0 OUTLIER -89.48 104.02 16.61 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.735 178.946 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 2.3 p-10 -91.56 -31.72 15.8 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 118.864 -1.134 . . . . 0.0 111.846 -178.584 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -175.21 139.78 0.48 Allowed 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.138 -179.693 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.26 15.35 33.02 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.495 -1.335 . . . . 0.0 111.784 178.784 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.404 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -58.55 163.24 5.26 Favored Pre-proline 0 N--CA 1.481 1.113 0 C-N-CA 117.96 -1.496 . . . . 0.0 109.2 179.557 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -74.53 -174.48 13.85 Favored 'Cis proline' 0 C--O 1.206 -1.091 0 C-N-CA 124.481 -1.05 . . . . 0.0 112.195 -0.382 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.3 m-70 -149.7 -178.71 6.6 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.885 178.544 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.684 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.2 OUTLIER -156.75 137.22 13.05 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.375 179.166 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.684 ' N ' HD21 ' A' ' 38' ' ' ASN . 7.6 mt -122.0 85.27 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 C-N-CA 119.866 -0.734 . . . . 0.0 111.479 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 t -103.34 157.94 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 C-N-CA 119.922 -0.711 . . . . 0.0 109.484 178.755 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -112.29 138.97 48.25 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 119.285 -0.966 . . . . 0.0 111.949 -179.42 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.542 ' C ' ' H ' ' A' ' 44' ' ' ASP . 4.4 t70 -82.36 105.95 13.85 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.003 179.162 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -70.81 32.92 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.378 -179.451 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.542 ' H ' ' C ' ' A' ' 42' ' ' ASP . 82.5 m-20 -108.95 -15.13 14.43 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 120.032 -0.667 . . . . 0.0 110.693 179.518 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -139.79 16.33 2.5 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.718 179.491 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -93.41 143.7 27.09 Favored Pre-proline 0 C--N 1.296 -1.735 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 179.31 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . 0.435 ' C ' ' H ' ' A' ' 49' ' ' GLY . 3.0 Cg_exo -48.45 140.74 20.69 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 120.754 0.97 . . . . 0.0 111.961 -179.392 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.32 43.16 0.37 Allowed 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.67 179.973 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -148.78 -26.51 0.07 OUTLIER Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 46.7 t -101.83 93.95 3.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.458 179.746 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -44.88 139.62 2.97 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.741 -179.919 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -90.81 3.42 54.47 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.502 179.851 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -90.3 -31.63 16.86 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.933 179.909 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 37.0 mttt -69.68 -32.52 71.18 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.421 -0.912 . . . . 0.0 111.32 -179.762 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.0 pt -93.22 -35.07 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.123 -1.031 . . . . 0.0 111.148 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.4 m -56.27 163.88 1.51 Allowed 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.198 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.642 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 63.3 mt-30 -124.97 84.59 58.76 Favored Pre-proline 0 N--CA 1.487 1.42 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.231 179.713 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -60.37 -22.71 72.25 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 120.995 1.13 . . . . 0.0 111.834 -178.761 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -96.35 115.93 28.22 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.349 -0.94 . . . . 0.0 110.858 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . 0.533 ' CE1' ' OD1' ' A' ' 38' ' ' ASN . 55.0 m-85 -56.34 177.37 0.07 Allowed 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.624 179.879 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.7 pp -148.33 132.75 17.6 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.283 -0.967 . . . . 0.0 110.8 179.93 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -128.99 39.03 3.85 Favored 'General case' 0 N--CA 1.493 1.721 0 C-N-CA 119.976 -0.69 . . . . 0.0 110.955 -179.745 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -102.27 125.52 8.55 Favored Glycine 0 N--CA 1.494 2.512 0 C-N-CA 119.632 -1.271 . . . . 0.0 110.388 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -70.52 103.3 2.44 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.532 179.748 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.38 -0.24 55.76 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.614 -1.279 . . . . 0.0 110.458 -179.884 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 17.6 tt0 -72.99 106.99 5.1 Favored 'General case' 0 N--CA 1.49 1.562 0 C-N-CA 119.062 -1.055 . . . . 0.0 110.569 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.1 p -96.43 161.99 13.68 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.702 -179.169 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.642 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 24.2 t80 -135.75 136.04 40.45 Favored 'General case' 0 N--CA 1.491 1.592 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.517 179.185 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -98.13 152.23 19.57 Favored 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.256 -0.978 . . . . 0.0 112.547 -178.428 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -151.85 132.78 4.55 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.633 178.951 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 6.6 m -123.52 107.29 11.39 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.622 -0.831 . . . . 0.0 112.023 -178.683 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 50.5 mt -89.58 160.88 16.45 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.513 -0.875 . . . . 0.0 109.348 178.749 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.21 41.09 0.72 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 118.66 -1.216 . . . . 0.0 111.754 -178.918 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.462 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.6 OUTLIER -141.85 116.76 9.88 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 118.874 -1.13 . . . . 0.0 110.981 179.784 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -55.7 106.18 0.23 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.452 -0.899 . . . . 0.0 111.167 -179.685 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 173.93 -163.06 33.93 Favored Glycine 0 N--CA 1.484 1.843 0 C-N-CA 119.353 -1.403 . . . . 0.0 109.831 -179.987 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.6 125.7 45.3 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.807 -0.757 . . . . 0.0 111.071 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.547 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -109.3 153.73 23.49 Favored 'General case' 0 N--CA 1.483 1.213 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.018 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 81.1 mttt -115.63 134.49 54.99 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.402 -0.919 . . . . 0.0 112.469 -179.394 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.503 ' O ' ' N ' ' A' ' 92' ' ' GLY . 0.9 OUTLIER -143.57 154.98 44.15 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.492 -0.883 . . . . 0.0 110.058 176.917 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 36.5 p90 -168.45 -174.51 2.24 Favored 'General case' 0 C--N 1.284 -2.259 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.582 -178.666 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.3 t -110.94 122.57 48.21 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 119.842 -0.743 . . . . 0.0 109.832 179.732 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.582 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.5 tm-20 -72.74 -35.58 3.09 Favored Pre-proline 0 N--CA 1.483 1.182 0 C-N-CA 119.056 -1.058 . . . . 0.0 113.292 -178.885 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.1 Cg_endo -71.43 -38.48 4.56 Favored 'Trans proline' 0 C--O 1.213 -0.728 0 C-N-CA 120.52 0.814 . . . . 0.0 111.111 179.855 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 32.8 m80 -102.17 21.05 15.55 Favored 'General case' 0 N--CA 1.488 1.474 0 C-N-CA 119.785 -0.766 . . . . 0.0 111.049 -179.771 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.78 -12.9 8.22 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.612 179.766 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -92.5 -13.47 57.0 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.324 179.821 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.59 -20.44 26.39 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.549 179.933 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 110.21 14.82 12.47 Favored Glycine 0 N--CA 1.496 2.654 0 C-N-CA 119.853 -1.165 . . . . 0.0 110.83 179.673 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.3 mtp -72.27 98.4 2.18 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.689 179.875 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 21.0 mmtt -130.37 150.33 51.65 Favored 'General case' 0 N--CA 1.496 1.843 0 C-N-CA 119.962 -0.695 . . . . 0.0 110.835 179.538 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.503 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -140.3 155.92 24.85 Favored Glycine 0 N--CA 1.501 3.021 0 C-N-CA 119.283 -1.437 . . . . 0.0 112.456 -177.914 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 26.5 tt0 -158.64 146.43 18.04 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.203 179.014 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 11.9 p -138.29 122.25 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.001 179.974 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.5 m -97.19 97.03 8.84 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.673 179.885 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 24.0 t -81.95 154.17 4.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.907 -179.051 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.2 p30 . . . . . 0 C--N 1.306 -1.318 0 CA-C-O 116.348 -1.787 . . . . 0.0 110.651 179.872 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.197 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -104.77 123.98 48.61 Favored 'General case' 0 N--CA 1.488 1.458 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.986 179.948 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.6 t -117.28 128.54 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 C-N-CA 119.888 -0.725 . . . . 0.0 110.404 179.494 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -103.76 117.92 35.49 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.814 -0.754 . . . . 0.0 111.155 -179.49 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 mt -78.18 109.14 12.03 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.727 -1.189 . . . . 0.0 109.529 177.964 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.406 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 107.47 120.47 4.55 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.061 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 31.9 p -79.45 166.03 22.43 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.992 -179.808 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -82.93 -29.65 28.98 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.998 179.928 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -65.84 -4.93 7.59 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 119.408 -0.917 . . . . 0.0 111.043 -179.885 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.64 61.07 1.02 Allowed Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.37 -1.395 . . . . 0.0 110.468 179.988 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -154.02 154.2 25.35 Favored Glycine 0 N--CA 1.489 2.213 0 C-N-CA 119.459 -1.353 . . . . 0.0 110.295 -179.995 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 73.5 mt -101.14 99.91 10.4 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.041 -179.885 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.9 m -150.07 157.44 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.73 179.325 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' PHE . . . . . 0.415 ' O ' ' O ' ' A' ' 16' ' ' PRO . 14.2 m-85 -78.44 112.02 15.05 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.135 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 54.6 m -116.03 108.79 45.69 Favored Pre-proline 0 CA--C 1.558 1.26 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.824 -177.861 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . 0.415 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.6 Cg_endo -65.76 177.84 16.68 Favored 'Cis proline' 0 C--N 1.362 1.244 0 C-N-CA 125.353 -0.686 . . . . 0.0 111.75 -0.49 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.439 ' H ' ' HG ' ' A' ' 17' ' ' SER . 0.0 OUTLIER -93.65 -51.64 4.83 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.509 -0.877 . . . . 0.0 110.423 179.437 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 94.5 p -140.02 141.89 36.27 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.782 179.385 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 22.4 p90 -162.71 149.42 12.95 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.743 -1.183 . . . . 0.0 111.183 -179.169 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -91.01 159.26 16.23 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.388 -0.925 . . . . 0.0 111.169 -179.972 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.6 m -149.95 172.01 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.858 179.697 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . 0.487 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -88.83 147.79 24.23 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.459 -0.897 . . . . 0.0 110.662 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.85 76.3 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.943 179.802 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . 0.487 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.18 22.28 0.09 OUTLIER Glycine 0 N--CA 1.49 2.268 0 C-N-CA 119.537 -1.315 . . . . 0.0 109.933 179.968 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -96.3 145.97 25.13 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.01 -179.787 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.8 mttm -87.12 128.68 35.11 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.863 -179.971 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.8 mt -118.55 131.97 69.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.432 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 25.1 p -128.7 116.96 20.35 Favored 'General case' 0 N--CA 1.492 1.647 0 C-N-CA 119.354 -0.938 . . . . 0.0 112.384 -178.55 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -84.82 109.72 18.3 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.453 -0.899 . . . . 0.0 108.855 177.905 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.3 tttm -106.05 138.06 42.89 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 119.719 -0.792 . . . . 0.0 111.445 -178.103 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.423 HD22 ' CD1' ' A' ' 61' ' ' LEU . 4.3 m-20 -83.26 106.9 15.42 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.062 179.404 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 32' ' ' ASN . . . . . 0.48 ' O ' ' CB ' ' A' ' 33' ' ' ALA . 1.0 OUTLIER -90.19 -30.75 17.39 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 118.88 -1.128 . . . . 0.0 111.774 -178.865 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 33' ' ' ALA . . . . . 0.48 ' CB ' ' O ' ' A' ' 32' ' ' ASN . . . 167.81 114.62 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 118.827 -1.149 . . . . 0.0 111.144 179.916 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 139.37 -0.96 2.34 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.587 -1.292 . . . . 0.0 110.559 179.858 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 35' ' ' PHE . . . . . 0.426 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -48.0 161.83 0.35 Allowed Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 118.749 -1.18 . . . . 0.0 110.071 -179.65 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -77.62 144.05 75.89 Favored 'Cis proline' 0 C--O 1.216 -0.587 0 C-N-CA 124.113 -1.203 . . . . 0.0 112.271 -1.022 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.5 m-70 -112.85 175.56 5.39 Favored 'General case' 0 N--CA 1.495 1.782 0 C-N-CA 119.915 -0.714 . . . . 0.0 110.135 179.42 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.656 HD21 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -151.64 148.97 28.6 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.529 179.493 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.656 ' N ' HD21 ' A' ' 38' ' ' ASN . 4.0 mp -134.86 103.47 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 C-N-CA 119.616 -0.833 . . . . 0.0 111.351 -179.502 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 t -119.08 144.65 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 C-N-CA 120.075 -0.65 . . . . 0.0 110.123 179.22 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.469 ' H ' ' HG ' ' A' ' 56' ' ' SER . 9.9 m-85 -99.88 114.67 28.05 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.526 -0.87 . . . . 0.0 111.443 -179.338 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 42' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 44' ' ' ASP . 32.8 t0 -55.6 88.41 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 119.441 -0.903 . . . . 0.0 110.48 179.676 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . 0.467 ' N ' ' O ' ' A' ' 41' ' ' PHE . 16.0 pt-20 -46.71 -13.25 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.515 -0.874 . . . . 0.0 111.357 -179.688 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . 0.519 ' N ' ' O ' ' A' ' 42' ' ' ASP . 0.9 OUTLIER -87.97 13.11 11.66 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.388 -179.594 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -151.66 15.32 0.67 Allowed 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.114 179.843 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -104.06 154.87 37.85 Favored Pre-proline 0 N--CA 1.491 1.624 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.838 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -52.83 149.79 24.69 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 120.887 1.058 . . . . 0.0 111.236 179.646 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -83.06 40.78 0.72 Allowed 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.293 -0.963 . . . . 0.0 110.716 -179.899 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -142.89 -40.09 0.07 OUTLIER Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 70.3 t -92.48 90.8 3.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.146 179.449 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.2 m-80 -44.8 146.5 0.77 Allowed 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.314 -0.955 . . . . 0.0 110.877 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.433 ' C ' ' H ' ' A' ' 54' ' ' LYS . . . -90.84 -29.58 17.46 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.544 -0.862 . . . . 0.0 111.076 -179.728 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -60.74 -5.43 1.28 Allowed 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.995 -179.719 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.433 ' H ' ' C ' ' A' ' 52' ' ' ALA . 22.2 mtmt -99.55 -38.39 8.78 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.605 -0.838 . . . . 0.0 111.486 -179.828 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.1 pt -90.49 -29.25 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.208 -179.562 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 56' ' ' SER . . . . . 0.469 ' HG ' ' H ' ' A' ' 41' ' ' PHE . 58.8 m -56.23 172.34 0.22 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.107 179.909 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . 0.64 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 60.9 mt-30 -134.45 71.92 70.96 Favored Pre-proline 0 N--CA 1.491 1.601 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.815 179.757 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -59.29 -6.81 4.31 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 121.074 1.183 . . . . 0.0 111.209 -179.664 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . 0.413 ' H ' ' C ' ' A' ' 57' ' ' GLN . 26.1 tt0 -100.25 106.48 18.15 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.651 179.577 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 31.1 m-85 -52.34 168.3 0.11 Allowed 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.594 -0.842 . . . . 0.0 110.471 -179.993 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.423 ' CD1' HD22 ' A' ' 31' ' ' ASN . 1.7 pp -148.26 141.73 25.35 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.12 -1.032 . . . . 0.0 110.877 179.85 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -137.85 8.09 2.76 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.088 -179.835 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -65.52 127.47 31.65 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 119.091 -1.528 . . . . 0.0 110.302 179.892 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -72.0 120.81 18.13 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.179 -1.008 . . . . 0.0 110.266 179.659 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.29 -14.69 53.45 Favored Glycine 0 N--CA 1.487 2.047 0 C-N-CA 119.111 -1.519 . . . . 0.0 110.657 -179.664 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.19 152.08 34.22 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.169 -1.012 . . . . 0.0 110.469 179.762 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -142.93 171.97 13.33 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.592 -179.615 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.64 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 34.2 t80 -135.73 128.41 30.86 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.145 179.218 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -99.23 155.79 17.31 Favored 'General case' 0 N--CA 1.49 1.562 0 C-N-CA 119.052 -1.059 . . . . 0.0 112.383 -178.604 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -156.34 142.94 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.023 178.93 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.9 m -130.99 96.13 3.98 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 119.784 -0.766 . . . . 0.0 111.265 -179.287 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . 0.431 ' C ' ' HG1' ' A' ' 73' ' ' THR . 11.7 mt -79.58 161.3 26.02 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.045 -1.062 . . . . 0.0 109.134 179.172 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 73' ' ' THR . . . . . 0.431 ' HG1' ' C ' ' A' ' 72' ' ' LEU . 0.2 OUTLIER -150.46 45.47 0.87 Allowed 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 118.596 -1.242 . . . . 0.0 112.242 -178.688 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 74' ' ' GLU . . . . . 0.43 ' O ' ' OH ' ' A' ' 78' ' ' TYR . 29.2 mm-40 -143.82 105.7 4.34 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 118.876 -1.13 . . . . 0.0 110.269 179.279 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -43.51 109.93 0.17 Allowed 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.816 -179.296 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.98 -147.89 8.95 Favored Glycine 0 N--CA 1.486 1.989 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.417 -179.918 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.55 131.65 21.81 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.598 -0.841 . . . . 0.0 110.807 -179.898 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 78' ' ' TYR . . . . . 0.595 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -119.6 129.61 54.7 Favored 'General case' 0 N--CA 1.486 1.336 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.578 -179.942 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -101.3 121.21 41.48 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 119.424 -0.91 . . . . 0.0 111.827 -179.49 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.7 p90 -131.48 166.34 21.55 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.816 -0.753 . . . . 0.0 110.009 178.161 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 29.6 p90 -170.29 -176.85 2.31 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.105 -1.038 . . . . 0.0 111.409 -178.355 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -102.21 130.75 48.96 Favored 'General case' 0 N--CA 1.482 1.154 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.301 179.16 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.55 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.9 OUTLIER -77.3 -44.64 2.68 Favored Pre-proline 0 N--CA 1.485 1.279 0 C-N-CA 119.328 -0.949 . . . . 0.0 112.713 -179.71 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 84' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 4.1 Cg_exo -65.57 -52.91 0.88 Allowed 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 120.914 1.076 . . . . 0.0 111.535 -179.096 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . 0.509 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.4 m80 -81.94 15.58 2.22 Favored 'General case' 0 C--N 1.302 -1.46 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.804 -179.874 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.65 -0.94 0.32 Allowed 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.107 -179.938 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . 0.509 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -95.15 -14.14 49.73 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.324 -1.417 . . . . 0.0 110.361 179.951 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.14 -51.89 4.82 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.596 179.925 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.26 24.75 0.2 Allowed Glycine 0 N--CA 1.488 2.166 0 C-N-CA 119.537 -1.316 . . . . 0.0 110.502 179.901 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.1 mtp -73.16 97.99 2.51 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.148 -1.021 . . . . 0.0 110.962 -179.95 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.3 ptpt -119.7 154.99 33.28 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.507 179.22 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.4 145.66 16.31 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.396 -1.383 . . . . 0.0 111.399 -178.764 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -152.2 143.78 23.49 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.486 -0.886 . . . . 0.0 111.062 179.636 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 12.3 p -137.16 125.2 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.678 179.159 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 46.2 m -102.56 99.18 9.17 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.549 179.408 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 40.3 t -79.69 147.84 6.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 C-N-CA 118.763 -1.175 . . . . 0.0 110.633 -178.843 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 116.285 -1.816 . . . . 0.0 110.75 -179.697 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 109.908 -0.405 . . . . 0.0 109.908 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -131.17 122.15 26.1 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.823 -0.751 . . . . 0.0 110.835 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.6 t -115.15 126.59 72.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 119.966 -0.694 . . . . 0.0 110.33 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 22.1 mtmt -101.72 116.15 32.1 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.918 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.481 HD11 ' HB3' ' A' ' 29' ' ' PHE . 12.0 mt -79.56 114.64 18.64 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.167 -1.013 . . . . 0.0 109.971 178.736 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 96.83 108.02 2.49 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.491 -1.338 . . . . 0.0 109.787 -179.097 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.0 p . . . . . 0 C--N 1.305 -1.349 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.934 -179.354 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.2 mt . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 120.438 0.161 . . . . 0.0 110.658 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.7 m -150.48 158.11 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 119.009 -1.076 . . . . 0.0 110.999 179.569 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.535 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 16.7 m-85 -78.8 111.96 15.45 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 177.628 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.0 m -114.4 107.62 51.06 Favored Pre-proline 0 N--CA 1.484 1.264 0 C-N-CA 119.421 -0.911 . . . . 0.0 112.226 -177.436 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.413 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.0 OUTLIER -67.64 176.58 25.44 Favored 'Cis proline' 0 C--N 1.362 1.275 0 C-N-CA 125.4 -0.667 . . . . 0.0 111.6 -0.555 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -92.49 -58.8 2.25 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.014 179.118 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.2 t -124.06 138.55 54.43 Favored 'General case' 0 N--CA 1.487 1.4 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.265 178.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.41 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 9.0 p90 -159.72 136.06 8.96 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 118.328 -1.349 . . . . 0.0 111.706 -178.883 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.424 HG23 ' H ' ' A' ' 20' ' ' THR . 0.8 OUTLIER -85.98 150.67 24.32 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.329 179.436 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.3 m -144.21 177.79 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.179 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -98.05 145.79 26.18 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.68 -0.808 . . . . 0.0 110.365 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.4 88.9 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.122 -1.031 . . . . 0.0 110.934 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 139.16 19.73 0.46 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -96.28 137.67 35.0 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.715 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 54.1 mttm -84.89 120.11 26.1 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.248 -0.981 . . . . 0.0 110.924 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.7 mt -109.27 110.88 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.038 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 30.3 p -106.2 116.92 32.77 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.379 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.481 ' HB3' HD11 ' A' ' 5' ' ' LEU . 94.2 m-85 -85.86 103.59 14.74 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.023 178.269 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.6 tttm -101.7 135.19 43.66 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.758 -0.777 . . . . 0.0 112.218 -177.8 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.471 ' N ' ' OD1' ' A' ' 31' ' ' ASN . 1.3 m-20 -76.71 126.24 30.64 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.935 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -106.78 -32.62 7.88 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.086 -1.046 . . . . 0.0 113.136 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 178.11 11.94 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.387 0 C-N-CA 119.052 -1.059 . . . . 0.0 111.729 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -124.88 49.68 0.9 Allowed Glycine 0 N--CA 1.5 2.931 0 C-N-CA 119.35 -1.405 . . . . 0.0 112.104 -178.668 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.596 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -91.06 161.31 35.63 Favored Pre-proline 0 N--CA 1.488 1.428 0 C-N-CA 118.35 -1.34 . . . . 0.0 110.291 178.805 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -78.17 142.42 69.6 Favored 'Cis proline' 0 C--O 1.215 -0.658 0 C-N-CA 124.004 -1.248 . . . . 0.0 111.825 -1.266 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.524 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 36.9 m-70 -107.26 162.38 13.95 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.596 -0.842 . . . . 0.0 111.016 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 25.7 t30 -144.6 137.76 26.94 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 119.607 -0.837 . . . . 0.0 109.852 179.19 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.4 mp -127.29 117.46 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.16 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.58 142.84 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.765 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.753 ' CD2' HD12 ' A' ' 55' ' ' ILE . 7.5 m-85 -95.08 117.74 30.7 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.738 -178.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.485 ' C ' ' H ' ' A' ' 44' ' ' ASP . 21.6 t0 -55.4 99.33 0.03 OUTLIER 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.374 179.645 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -64.01 5.26 0.25 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.446 -0.902 . . . . 0.0 111.392 -179.526 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.485 ' H ' ' C ' ' A' ' 42' ' ' ASP . 9.6 m-20 -99.78 -8.67 23.91 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.915 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -134.6 16.33 3.65 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.957 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -95.53 147.03 32.36 Favored Pre-proline 0 N--CA 1.49 1.529 0 N-CA-C 108.957 -0.756 . . . . 0.0 108.957 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -47.84 142.73 14.3 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.958 1.105 . . . . 0.0 111.799 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.2 70.64 1.63 Allowed 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.712 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.46 -37.75 0.12 Allowed Glycine 0 N--CA 1.488 2.102 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.077 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.418 ' O ' HG12 ' A' ' 50' ' ' VAL . 15.4 t -86.22 104.9 14.15 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.789 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -48.28 147.7 2.18 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.738 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -99.46 -5.81 28.73 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.918 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.07 -30.45 17.7 Favored 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.511 -0.876 . . . . 0.0 111.19 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 36.0 mttt -69.25 -29.91 67.92 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.148 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.753 HD12 ' CD2' ' A' ' 41' ' ' PHE . 1.1 pt -94.16 -37.52 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.748 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 57.7 m -64.01 159.62 19.68 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.537 -0.865 . . . . 0.0 111.253 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.457 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -139.66 75.67 31.15 Favored Pre-proline 0 N--CA 1.486 1.361 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.398 179.635 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -57.63 -21.76 48.62 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 121.262 1.308 . . . . 0.0 111.567 -179.078 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.21 95.67 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.021 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -42.71 163.11 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.799 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -150.09 111.64 4.48 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 118.862 -1.135 . . . . 0.0 111.878 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 8.0 p-10 -106.33 21.66 17.03 Favored 'General case' 0 N--CA 1.488 1.475 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.918 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -83.65 137.66 16.5 Favored Glycine 0 N--CA 1.494 2.53 0 C-N-CA 119.355 -1.403 . . . . 0.0 110.655 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -82.32 114.48 20.82 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.533 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.07 -13.67 66.62 Favored Glycine 0 N--CA 1.488 2.147 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.506 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.25 150.34 26.05 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.209 -0.996 . . . . 0.0 110.31 179.69 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.57 168.75 19.88 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 118.981 -1.087 . . . . 0.0 111.884 -179.599 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.457 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 29.3 t80 -135.29 129.88 34.24 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.555 179.228 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.96 152.86 21.01 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.306 -178.606 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.1 t -151.79 130.78 3.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 CA-C-N 115.105 -0.952 . . . . 0.0 108.844 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 20.6 m -129.86 93.93 3.62 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.652 -0.819 . . . . 0.0 111.226 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.436 ' CD1' HG11 ' A' ' 94' ' ' VAL . 13.7 mt -79.39 157.98 27.49 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.213 -0.995 . . . . 0.0 109.507 179.333 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 2.2 t -149.94 46.07 0.92 Allowed 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 118.793 -1.163 . . . . 0.0 111.649 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.404 ' O ' ' C ' ' A' ' 75' ' ' LYS . 5.6 tt0 -144.93 99.98 3.42 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 118.977 -1.089 . . . . 0.0 109.913 179.048 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.481 ' H ' ' HD2' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -39.45 112.48 0.26 Allowed 'General case' 0 N--CA 1.484 1.239 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.344 -179.124 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.76 -148.88 10.0 Favored Glycine 0 N--CA 1.484 1.849 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.004 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.96 132.34 25.09 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.922 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.562 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.2 m-85 -120.8 126.01 49.03 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.66 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.442 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -100.4 114.11 27.39 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.78 -179.361 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.594 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -125.02 169.74 11.83 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.09 178.686 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -171.25 -179.76 2.76 Favored 'General case' 0 C--N 1.297 -1.694 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.073 -179.206 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 2.1 t -106.39 115.31 29.99 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.504 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.563 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 tt0 -66.87 -40.38 29.77 Favored Pre-proline 0 C--N 1.3 -1.576 0 C-N-CA 119.379 -0.928 . . . . 0.0 112.724 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.563 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.4 Cg_endo -68.95 -47.69 1.12 Allowed 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 120.822 1.015 . . . . 0.0 112.03 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -87.87 12.15 13.84 Favored 'General case' 0 N--CA 1.487 1.423 0 C-N-CA 119.238 -0.985 . . . . 0.0 111.296 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.72 -24.4 61.42 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.771 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -62.24 -22.19 62.8 Favored Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.514 -1.327 . . . . 0.0 110.414 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.92 -31.83 14.8 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.621 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 117.21 30.22 1.96 Allowed Glycine 0 N--CA 1.495 2.611 0 C-N-CA 119.991 -1.1 . . . . 0.0 110.495 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.3 mtp -77.88 105.52 9.12 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.862 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.535 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 0.6 OUTLIER -127.61 166.89 17.19 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 119.956 -0.698 . . . . 0.0 110.777 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -147.83 148.44 19.98 Favored Glycine 0 N--CA 1.488 2.104 0 C-N-CA 119.018 -1.563 . . . . 0.0 111.286 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -153.63 141.64 20.28 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.625 179.583 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 94' ' ' VAL . 7.2 p -136.87 125.26 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.624 179.307 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 95.8 m -103.32 98.71 8.58 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.409 -0.916 . . . . 0.0 110.645 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 41.1 t -80.03 148.3 5.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.255 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 1.9 m120 . . . . . 0 C--N 1.304 -1.41 0 CA-C-O 116.344 -1.789 . . . . 0.0 111.007 -179.554 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.105 0 CA-C-O 120.792 0.33 . . . . 0.0 110.197 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -130.19 121.46 26.27 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.54 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.8 t -112.87 122.02 66.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.682 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 60.8 mttt -94.53 116.61 28.98 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.761 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.434 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 8.5 mt -76.21 102.4 5.79 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 118.615 -1.234 . . . . 0.0 109.525 178.18 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 121.25 155.7 9.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.031 -1.627 . . . . 0.0 109.031 -178.204 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.2 p . . . . . 0 C--N 1.301 -1.528 0 C-N-CA 119.039 -1.064 . . . . 0.0 111.047 -179.395 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 80.1 mt . . . . . 0 N--CA 1.488 1.426 0 N-CA-C 110.382 -0.229 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 m -149.71 154.78 8.77 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 C-N-CA 118.74 -1.184 . . . . 0.0 111.072 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' A' ' 16' ' ' PRO . 17.2 m-85 -78.2 110.16 12.94 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.7 m -115.0 109.01 47.5 Favored Pre-proline 0 CA--C 1.562 1.41 0 C-N-CA 119.369 -0.933 . . . . 0.0 112.503 -177.002 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.421 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.9 Cg_endo -66.66 178.35 17.84 Favored 'Cis proline' 0 C--N 1.364 1.348 0 C-N-CA 125.27 -0.721 . . . . 0.0 111.484 -0.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.6 p -94.94 -60.43 1.69 Allowed 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.933 179.177 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.2 p -121.05 135.41 55.2 Favored 'General case' 0 N--CA 1.486 1.34 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.076 178.702 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.465 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 14.4 p90 -157.88 140.74 14.89 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 118.528 -1.269 . . . . 0.0 111.49 -178.729 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.447 HG23 ' H ' ' A' ' 20' ' ' THR . 0.5 OUTLIER -87.77 153.45 21.33 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.357 -0.937 . . . . 0.0 110.633 179.451 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.1 m -145.94 158.76 11.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.105 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.421 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -75.04 145.88 42.02 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.211 -0.996 . . . . 0.0 110.427 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.27 73.03 0.12 Allowed 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.459 -0.896 . . . . 0.0 110.9 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.438 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 160.98 11.15 0.04 OUTLIER Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.438 ' H ' ' H ' ' A' ' 24' ' ' GLY . 18.5 tt0 -98.81 157.14 16.49 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.913 -179.532 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.4 mmtp -95.48 134.2 38.6 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.33 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.9 mt -107.09 104.36 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 120.076 -0.649 . . . . 0.0 109.358 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 52.3 p -101.41 117.57 35.21 Favored 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 119.553 -0.859 . . . . 0.0 112.612 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -91.16 109.76 21.03 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.12 178.445 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 31.0 tttt -103.14 135.14 45.37 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.58 -178.505 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 1.0 OUTLIER -84.67 106.11 15.98 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.258 -0.977 . . . . 0.0 110.108 179.237 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.547 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 4.3 p-10 -93.36 -28.6 16.07 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.208 -0.997 . . . . 0.0 112.016 -178.758 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.547 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 175.44 133.57 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 118.55 -1.26 . . . . 0.0 111.371 -179.785 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 111.48 5.97 25.73 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.782 -1.199 . . . . 0.0 111.579 179.079 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.452 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -52.47 162.54 0.89 Allowed Pre-proline 0 N--CA 1.488 1.437 0 C-N-CA 118.188 -1.405 . . . . 0.0 109.744 179.814 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -78.76 161.62 88.95 Favored 'Cis proline' 0 C--O 1.212 -0.798 0 C-N-CA 124.38 -1.091 . . . . 0.0 112.636 -0.689 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -125.75 172.7 9.6 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.952 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.508 ' ND2' ' CD1' ' A' ' 60' ' ' TYR . 11.6 t-20 -153.49 117.53 4.81 Favored 'General case' 0 N--CA 1.492 1.67 0 C-N-CA 118.978 -1.089 . . . . 0.0 110.622 179.185 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.842 ' N ' HD12 ' A' ' 39' ' ' ILE . 2.4 mp -96.18 129.71 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.146 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.6 t -143.31 138.63 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 C-N-CA 119.679 -0.808 . . . . 0.0 110.427 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.7 ' CD2' HD12 ' A' ' 55' ' ' ILE . 9.1 m-85 -98.33 118.26 34.59 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.206 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.524 ' OD2' ' N ' ' A' ' 45' ' ' GLU . 11.2 t70 -53.1 120.4 5.86 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.348 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -73.57 0.47 12.51 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.433 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.404 ' N ' ' OD2' ' A' ' 42' ' ' ASP . 14.6 m-20 -107.99 4.2 24.92 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.813 -0.755 . . . . 0.0 111.135 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.524 ' N ' ' OD2' ' A' ' 42' ' ' ASP . 34.5 mt-10 -146.18 52.56 1.14 Allowed 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 119.486 -0.886 . . . . 0.0 110.835 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -137.03 148.36 62.52 Favored Pre-proline 0 N--CA 1.493 1.676 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -49.58 145.78 16.31 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 121.061 1.174 . . . . 0.0 111.678 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.89 81.92 2.8 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.709 -0.796 . . . . 0.0 111.025 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 161.54 -41.95 0.4 Allowed Glycine 0 N--CA 1.489 2.174 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.312 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 92.0 t -81.96 95.94 3.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.348 -0.941 . . . . 0.0 110.84 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -44.94 143.76 1.39 Allowed 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.969 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.54 -2.04 49.3 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.625 -0.83 . . . . 0.0 110.898 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -86.55 -35.13 19.7 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.98 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 30.7 mttt -68.75 -34.38 75.5 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.581 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.7 HD12 ' CD2' ' A' ' 41' ' ' PHE . 1.1 pt -89.94 -29.68 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 C-N-CA 118.938 -1.105 . . . . 0.0 111.062 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 7.6 m -58.95 -178.63 0.05 Allowed 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.928 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.563 ' NE2' HD13 ' A' ' 39' ' ' ILE . 20.0 mt-30 -146.38 73.19 13.02 Favored Pre-proline 0 N--CA 1.484 1.274 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.031 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -62.39 -4.52 5.5 Favored 'Trans proline' 0 C--N 1.321 -0.879 0 C-N-CA 121.094 1.196 . . . . 0.0 110.984 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 16.0 mt-10 -100.31 99.98 10.71 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.828 -0.749 . . . . 0.0 110.545 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.508 ' CD1' ' ND2' ' A' ' 38' ' ' ASN . 44.6 m-85 -47.54 164.49 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.411 -0.916 . . . . 0.0 110.92 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.1 pp -142.32 135.95 29.21 Favored 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.96 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -135.46 42.41 2.7 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.664 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -102.5 128.28 9.49 Favored Glycine 0 N--CA 1.495 2.595 0 C-N-CA 119.584 -1.293 . . . . 0.0 110.532 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -78.06 108.22 11.19 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.628 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.51 -6.37 59.14 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.325 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -71.96 157.69 37.37 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.555 179.835 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 4.9 p -148.64 163.29 37.71 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.051 -1.059 . . . . 0.0 111.229 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.471 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 28.5 t80 -134.7 139.16 45.02 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.651 179.206 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.467 ' H ' ' CD ' ' A' ' 69' ' ' GLU . 1.7 mp0 -102.76 148.5 25.53 Favored 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 119.434 -0.907 . . . . 0.0 112.252 -178.765 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -142.82 126.05 14.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 115.124 -0.943 . . . . 0.0 108.748 179.208 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.0 m -117.47 112.82 21.15 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.61 -0.836 . . . . 0.0 112.039 -178.384 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 58.3 mt -95.88 161.7 13.89 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.47 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.557 ' O ' HG22 ' A' ' 73' ' ' THR . 87.9 m -150.57 42.61 0.81 Allowed 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 118.662 -1.215 . . . . 0.0 112.044 -179.033 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -147.9 102.97 3.45 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 118.658 -1.217 . . . . 0.0 110.33 179.071 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.472 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 11.5 pttt -43.97 120.2 2.0 Allowed 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.723 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.45 -147.01 10.58 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -143.25 128.85 19.16 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.405 -0.918 . . . . 0.0 111.248 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.562 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -115.73 136.87 52.64 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.422 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.412 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -107.86 116.27 31.64 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.634 -0.826 . . . . 0.0 111.541 -179.348 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.489 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 2.4 p90 -130.26 166.8 19.58 Favored 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.082 178.485 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -170.46 -172.74 1.3 Allowed 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.682 -178.685 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -107.32 126.08 51.99 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.756 179.288 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.499 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.9 mt-10 -68.78 -47.11 33.18 Favored Pre-proline 0 C--N 1.305 -1.336 0 C-N-CA 119.593 -0.843 . . . . 0.0 112.599 -179.55 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.499 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.9 Cg_endo -64.72 -47.77 4.89 Favored 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 120.719 0.946 . . . . 0.0 111.746 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -90.84 19.88 5.21 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.808 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.44 -14.23 11.63 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.346 -0.942 . . . . 0.0 110.462 179.696 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -93.76 -12.47 56.75 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.151 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.01 -13.53 38.59 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.597 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 96.96 25.6 11.23 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.605 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.64 99.77 10.42 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.234 -0.987 . . . . 0.0 111.022 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -120.97 159.7 25.06 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.793 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.74 143.03 11.47 Favored Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.337 -1.411 . . . . 0.0 111.071 -179.049 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -150.68 144.74 25.39 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.35 179.514 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.494 ' O ' HG13 ' A' ' 94' ' ' VAL . 8.0 p -135.24 125.73 44.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.689 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 55.0 m -101.67 98.22 8.54 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.274 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 41.2 t -79.75 152.51 4.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 118.587 -1.245 . . . . 0.0 110.734 -178.739 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 116.283 -1.818 . . . . 0.0 110.826 -179.688 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.118 0 CA-C-O 120.78 0.324 . . . . 0.0 110.142 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLU . . . . . 0.439 ' OE1' ' O ' ' A' ' 28' ' ' THR . 3.1 mm-40 -140.19 121.0 14.43 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.618 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -108.72 120.54 60.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 C-N-CA 119.917 -0.713 . . . . 0.0 110.509 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.7 mttt -91.16 114.55 27.11 Favored 'General case' 0 C--N 1.299 -1.59 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.992 -179.253 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.0 mt -74.51 113.84 12.22 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.239 178.855 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.47 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 99.28 124.13 5.12 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.488 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.44 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 16.6 p . . . . . 0 C--N 1.302 -1.46 0 C-N-CA 119.324 -0.951 . . . . 0.0 110.428 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.3 mt . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 120.402 0.144 . . . . 0.0 110.983 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.4 m -144.25 155.86 15.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 C-N-CA 119.098 -1.041 . . . . 0.0 110.674 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.401 ' O ' ' C ' ' A' ' 16' ' ' PRO . 16.6 m-85 -77.36 112.98 14.67 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 177.895 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.8 m -114.89 108.46 48.66 Favored Pre-proline 0 CA--C 1.558 1.283 0 C-N-CA 119.219 -0.992 . . . . 0.0 112.007 -177.348 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.401 ' C ' ' O ' ' A' ' 14' ' ' PHE . 3.2 Cg_exo -67.5 170.71 46.55 Favored 'Cis proline' 0 C--N 1.362 1.269 0 C-N-CA 125.321 -0.7 . . . . 0.0 111.597 -0.536 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.5 t -90.23 -64.51 1.12 Allowed 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.543 178.733 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.35 139.58 50.25 Favored 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.199 178.69 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.401 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 9.5 p90 -167.95 139.45 2.91 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 118.468 -1.293 . . . . 0.0 111.424 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.443 ' H ' HG23 ' A' ' 20' ' ' THR . 0.6 OUTLIER -85.06 159.12 20.26 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.623 -0.831 . . . . 0.0 111.411 -179.591 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 25.9 m -146.69 -177.75 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.059 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.87 148.95 21.76 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.438 -0.905 . . . . 0.0 111.015 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.39 68.48 0.54 Allowed 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.042 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 159.21 14.03 0.04 OUTLIER Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -97.36 155.95 16.67 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.907 -0.717 . . . . 0.0 111.038 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 13.7 mttp -95.44 138.53 33.0 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.76 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.9 mt -117.65 127.58 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.443 179.381 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.439 ' O ' ' OE1' ' A' ' 2' ' ' GLU . 7.6 p -125.51 119.07 27.18 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.544 -0.862 . . . . 0.0 112.17 -178.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -84.91 110.37 18.81 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.489 -0.885 . . . . 0.0 109.024 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 50.0 tttp -101.45 139.13 37.54 Favored 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.158 -178.272 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.944 ' ND2' HD11 ' A' ' 61' ' ' LEU . 2.5 m120 -86.45 112.57 21.62 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.47 179.371 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.677 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.0 OUTLIER -95.66 -30.8 13.57 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 119.224 -0.991 . . . . 0.0 111.543 -179.227 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.677 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 164.69 118.08 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 119.349 -0.94 . . . . 0.0 111.182 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 138.6 -1.03 2.57 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.957 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.409 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -47.69 164.66 0.24 Allowed Pre-proline 0 C--N 1.307 -1.281 0 C-N-CA 118.839 -1.144 . . . . 0.0 110.137 -179.835 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_endo -75.99 138.9 57.6 Favored 'Cis proline' 0 C--O 1.214 -0.722 0 C-N-CA 124.292 -1.128 . . . . 0.0 112.633 -0.481 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.5 m-70 -110.3 156.4 20.77 Favored 'General case' 0 N--CA 1.485 1.295 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.205 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.429 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 6.2 t30 -148.42 116.23 6.35 Favored 'General case' 0 C--N 1.3 -1.58 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.136 179.251 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.442 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.7 mp -96.64 137.22 25.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.652 -178.701 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.429 ' CG2' ' ND2' ' A' ' 38' ' ' ASN . 1.5 t -146.54 149.42 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.987 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -107.58 118.28 36.32 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.712 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.516 ' OD2' ' N ' ' A' ' 45' ' ' GLU . 1.6 t70 -55.58 119.32 5.5 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 119.576 -0.849 . . . . 0.0 110.28 179.47 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -75.5 14.21 0.65 Allowed 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 119.393 -0.923 . . . . 0.0 111.55 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.446 ' H ' ' CG ' ' A' ' 42' ' ' ASP . 4.0 m-20 -115.39 2.1 13.86 Favored 'General case' 0 N--CA 1.495 1.779 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.049 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.548 ' OE1' ' NZ ' ' A' ' 79' ' ' LYS . 11.8 mm-40 -140.6 19.3 2.36 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 119.657 -0.817 . . . . 0.0 110.446 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -107.69 147.12 34.76 Favored Pre-proline 0 N--CA 1.488 1.471 0 CA-C-N 115.23 -0.895 . . . . 0.0 108.856 179.709 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -48.6 145.24 12.76 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 120.804 1.003 . . . . 0.0 111.718 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.35 50.56 0.79 Allowed 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.935 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -160.6 -31.11 0.02 OUTLIER Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 86.3 t -96.18 90.69 2.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.745 -0.782 . . . . 0.0 110.638 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -45.95 139.89 4.05 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.888 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.08 -26.35 36.33 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.62 -0.832 . . . . 0.0 111.109 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -67.48 -19.89 65.39 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.456 -0.898 . . . . 0.0 110.93 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -78.03 -38.01 45.62 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.876 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.7 pt -94.26 -26.41 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.306 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.0 m -72.35 155.89 39.67 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.431 -0.908 . . . . 0.0 111.297 -179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.465 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -137.95 75.98 40.8 Favored Pre-proline 0 C--N 1.303 -1.432 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.972 179.484 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 58' ' ' PRO . . . . . 0.412 ' O ' ' OD1' ' A' ' 38' ' ' ASN . 5.2 Cg_exo -56.5 -29.07 76.82 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 121.234 1.289 . . . . 0.0 111.496 -178.789 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -52.96 103.67 0.08 Allowed 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 118.813 -1.155 . . . . 0.0 109.844 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 46.8 m-85 -42.63 161.56 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.69 -0.804 . . . . 0.0 111.105 -179.388 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.944 HD11 ' ND2' ' A' ' 31' ' ' ASN . 0.3 OUTLIER -143.65 148.08 35.27 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.542 -0.863 . . . . 0.0 110.239 -179.644 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.74 ' N ' HD12 ' A' ' 61' ' ' LEU . 30.1 p-10 -148.2 -12.56 0.36 Allowed 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.265 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -48.74 115.82 2.84 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.203 -1.475 . . . . 0.0 110.403 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.51 119.92 10.1 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.962 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.85 -21.29 27.62 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.639 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -58.05 153.76 13.98 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.048 -1.061 . . . . 0.0 110.326 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -140.68 170.01 16.56 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 119.329 -0.948 . . . . 0.0 111.67 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.465 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 22.8 t80 -130.96 130.98 44.11 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.284 179.361 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -93.33 150.76 20.23 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 119.081 -1.048 . . . . 0.0 112.716 -178.11 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -151.59 136.52 10.28 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-N 115.127 -0.942 . . . . 0.0 108.933 179.246 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.3 m -127.31 104.65 8.05 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.521 -0.871 . . . . 0.0 111.503 -179.13 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.47 ' CD1' HG11 ' A' ' 94' ' ' VAL . 49.6 mt -88.17 155.14 19.92 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.001 179.094 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 4.8 p -150.92 47.32 0.85 Allowed 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.935 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.429 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.5 mm-40 -144.18 108.48 4.81 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.099 -1.041 . . . . 0.0 110.722 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.561 ' H ' ' HZ3' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -49.79 114.33 1.05 Allowed 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 119.372 -0.931 . . . . 0.0 110.854 -179.572 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 165.28 -137.74 4.86 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.183 -1.484 . . . . 0.0 110.235 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -149.46 143.0 25.4 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.286 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.563 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -127.34 123.74 37.02 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.37 179.716 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.548 ' NZ ' ' OE1' ' A' ' 45' ' ' GLU . 1.2 mptm? -95.43 119.67 34.34 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.728 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.551 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.2 p90 -130.31 171.91 12.4 Favored 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 119.571 -0.852 . . . . 0.0 109.978 177.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 42.5 p90 -171.83 -175.33 1.5 Allowed 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.922 -178.806 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' CYS . . . . . 0.41 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.8 t -108.82 117.18 33.51 Favored 'General case' 0 C--N 1.31 -1.112 0 C-N-CA 119.856 -0.738 . . . . 0.0 109.713 178.206 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.561 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.4 tt0 -68.3 -39.59 17.0 Favored Pre-proline 0 C--N 1.303 -1.455 0 C-N-CA 119.431 -0.907 . . . . 0.0 112.89 -178.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.561 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.0 Cg_endo -68.99 -43.78 3.07 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 120.638 0.892 . . . . 0.0 111.699 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' HIS . . . . . 0.425 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.4 m80 -94.15 14.83 18.83 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.306 -0.958 . . . . 0.0 111.173 -179.751 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.41 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -65.52 0.27 1.65 Allowed 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.089 -1.044 . . . . 0.0 110.687 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -86.92 -18.05 58.62 Favored Glycine 0 N--CA 1.49 2.238 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.215 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -97.97 -19.99 17.7 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 119.615 -0.834 . . . . 0.0 110.675 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.73 22.0 6.2 Favored Glycine 0 N--CA 1.497 2.74 0 C-N-CA 119.877 -1.154 . . . . 0.0 110.624 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 9.6 ttt -71.22 108.72 4.85 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.494 -0.882 . . . . 0.0 110.832 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.406 ' CG ' ' N ' ' A' ' 92' ' ' GLY . 30.9 ttpt -137.13 159.91 40.53 Favored 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 119.754 -0.778 . . . . 0.0 111.299 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' A' ' 91' ' ' LYS . . . -140.84 156.97 25.71 Favored Glycine 0 N--CA 1.497 2.757 0 C-N-CA 119.688 -1.244 . . . . 0.0 111.559 -178.484 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -157.15 145.94 19.82 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 120.027 -0.669 . . . . 0.0 110.639 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.494 ' O ' HG13 ' A' ' 94' ' ' VAL . 8.8 p -139.94 124.91 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 C-N-CA 119.106 -1.038 . . . . 0.0 110.937 179.386 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 34.0 m -102.68 103.17 13.41 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.543 -0.863 . . . . 0.0 110.582 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 26.2 t -85.71 146.31 6.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 118.866 -1.133 . . . . 0.0 110.622 -178.84 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 116.375 -1.774 . . . . 0.0 110.661 -179.957 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.17 0 CA-C-O 120.821 0.343 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -96.73 119.89 36.05 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.702 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 73.4 t -108.31 122.38 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.07 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 76.9 mttt -88.31 111.46 21.73 Favored 'General case' 0 C--N 1.297 -1.706 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.865 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 11.6 mt -73.91 110.08 7.92 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 118.539 -1.264 . . . . 0.0 109.763 178.486 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.54 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 98.86 126.51 5.64 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -179.109 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 24.5 p . . . . . 0 C--N 1.305 -1.334 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.581 179.907 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.0 mt . . . . . 0 N--CA 1.487 1.419 0 CA-C-O 120.644 0.259 . . . . 0.0 110.756 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 23.6 m -150.83 157.91 5.33 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.65 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.533 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 35.9 m-85 -78.15 113.63 16.28 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 177.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 18.5 m -115.54 109.77 45.53 Favored Pre-proline 0 CA--C 1.56 1.355 0 C-N-CA 119.515 -0.874 . . . . 0.0 112.187 -177.277 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -65.98 170.58 39.44 Favored 'Cis proline' 0 C--N 1.361 1.232 0 C-N-CA 125.123 -0.782 . . . . 0.0 111.567 -0.466 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.03 -68.64 0.79 Allowed 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.836 178.79 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.6 m -110.12 132.92 53.73 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.652 178.913 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 36.0 p90 -162.15 141.49 9.59 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 118.681 -1.208 . . . . 0.0 111.323 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.439 HG23 ' H ' ' A' ' 20' ' ' THR . 0.2 OUTLIER -85.23 160.28 19.91 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.545 -0.862 . . . . 0.0 111.3 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.4 m -149.29 179.11 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.645 179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -96.0 148.29 22.81 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 119.476 -0.89 . . . . 0.0 110.931 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.51 ' HB2' ' OXT' ' A' ' 97' ' ' ASN . . . -68.38 71.1 0.18 Allowed 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.229 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.418 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 157.52 16.19 0.04 OUTLIER Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.418 ' H ' ' H ' ' A' ' 24' ' ' GLY . 23.0 tt0 -102.8 154.89 18.74 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.682 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.3 mtpt -95.33 141.18 29.2 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.419 -0.912 . . . . 0.0 111.386 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.5 mt -119.78 114.81 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.435 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.4 p -111.41 120.97 43.96 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.53 -0.868 . . . . 0.0 112.616 -178.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -85.57 111.72 20.29 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.876 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.7 tttp -102.89 138.77 39.32 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 119.575 -0.85 . . . . 0.0 111.455 -178.078 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 15.9 m120 -80.53 110.54 16.1 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.805 179.678 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.58 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 2.0 t30 -98.34 -31.23 12.15 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.225 -0.99 . . . . 0.0 111.673 -179.318 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.58 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.52 128.19 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.383 -0.927 . . . . 0.0 111.214 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 119.5 11.08 7.48 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.789 -1.196 . . . . 0.0 111.355 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.429 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -60.62 163.44 9.15 Favored Pre-proline 0 N--CA 1.484 1.265 0 C-N-CA 118.391 -1.324 . . . . 0.0 110.042 179.819 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -76.92 146.33 83.6 Favored 'Cis proline' 0 C--O 1.217 -0.564 0 C-N-CA 124.145 -1.189 . . . . 0.0 112.636 -0.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 35.3 m-70 -110.67 -179.66 3.82 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.119 179.187 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -155.67 142.6 19.02 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.015 179.153 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 mt -125.2 121.78 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.247 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.0 t -144.8 143.86 22.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.149 179.395 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -96.32 135.99 37.41 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.877 -179.226 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.51 ' C ' ' H ' ' A' ' 44' ' ' ASP . 7.8 t0 -71.95 111.24 7.04 Favored 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.671 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -71.4 35.22 0.05 Allowed 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 119.526 -0.869 . . . . 0.0 110.858 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.51 ' H ' ' C ' ' A' ' 42' ' ' ASP . 13.6 m-20 -111.34 -15.65 13.55 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 120.092 -0.643 . . . . 0.0 111.364 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -145.81 -5.39 0.63 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 118.261 -1.376 . . . . 0.0 112.464 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -52.51 142.31 31.45 Favored Pre-proline 0 C--N 1.285 -2.216 0 C-N-CA 118.628 -1.229 . . . . 0.0 108.112 179.248 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -49.09 148.03 10.2 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 120.895 1.063 . . . . 0.0 112.236 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.25 64.55 2.06 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.722 -0.791 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.58 -39.48 0.06 OUTLIER Glycine 0 N--CA 1.488 2.147 0 C-N-CA 119.57 -1.3 . . . . 0.0 109.863 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 98.8 t -92.16 97.1 6.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.336 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -44.61 162.33 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.447 -0.901 . . . . 0.0 111.155 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -102.91 -29.01 11.69 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.919 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -78.97 -14.15 59.38 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.146 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 1.8 mptp? -81.9 -37.69 26.47 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.064 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -90.87 -17.93 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 C-N-CA 119.199 -1.0 . . . . 0.0 111.019 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 73.6 m -76.55 -177.44 4.19 Favored 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.256 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.638 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -159.96 78.55 2.67 Favored Pre-proline 0 C--N 1.304 -1.405 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.788 179.635 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -60.56 0.99 0.59 Allowed 'Trans proline' 0 C--O 1.213 -0.747 0 C-N-CA 121.372 1.381 . . . . 0.0 112.216 -178.354 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.434 ' H ' ' C ' ' A' ' 57' ' ' GLN . 6.9 tt0 -82.9 100.44 10.39 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 118.878 -1.129 . . . . 0.0 110.249 179.387 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.43 ' O ' ' O ' ' A' ' 59' ' ' GLU . 43.9 m-85 -41.92 164.79 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.932 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.569 ' O ' HD12 ' A' ' 61' ' ' LEU . 3.0 pp -147.3 124.47 11.47 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.103 -1.039 . . . . 0.0 111.037 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.442 ' OD1' ' N ' ' A' ' 62' ' ' ASN . 0.9 OUTLIER -120.8 32.55 5.93 Favored 'General case' 0 N--CA 1.496 1.875 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.706 -179.963 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -97.02 120.87 6.86 Favored Glycine 0 N--CA 1.494 2.56 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.8 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -68.67 118.5 11.74 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.544 -0.862 . . . . 0.0 110.774 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.03 -19.75 40.48 Favored Glycine 0 N--CA 1.488 2.159 0 C-N-CA 119.419 -1.372 . . . . 0.0 110.374 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -56.99 153.7 10.84 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.22 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -144.88 169.37 18.19 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.212 -0.995 . . . . 0.0 111.579 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.638 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 29.2 t80 -134.73 139.06 44.9 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.141 178.867 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.542 ' H ' ' CD ' ' A' ' 69' ' ' GLU . 1.3 mp0 -100.32 148.24 24.9 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.181 -1.008 . . . . 0.0 112.755 -178.046 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.3 t -145.74 131.31 13.18 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 114.924 -1.035 . . . . 0.0 108.721 179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.1 m -123.2 113.69 19.28 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.905 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 46.2 mt -98.77 159.12 15.17 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.526 178.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.95 34.45 0.59 Allowed 'General case' 0 C--N 1.297 -1.702 0 C-N-CA 118.824 -1.151 . . . . 0.0 111.64 -178.856 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -137.87 102.38 4.7 Favored 'General case' 0 N--CA 1.492 1.654 0 C-N-CA 119.092 -1.043 . . . . 0.0 110.624 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.431 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 11.2 pttm -43.57 114.59 0.66 Allowed 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.884 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.18 -145.33 7.78 Favored Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.487 -1.34 . . . . 0.0 110.129 -179.407 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.06 128.93 20.61 Favored 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 119.303 -0.959 . . . . 0.0 111.557 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.578 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -121.66 138.85 54.17 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 115.242 -0.89 . . . . 0.0 108.922 179.303 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 12.4 mttp -111.19 127.77 55.7 Favored 'General case' 0 N--CA 1.493 1.689 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.767 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.541 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.6 OUTLIER -129.05 159.81 34.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.048 177.753 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -167.93 178.44 5.16 Favored 'General case' 0 C--N 1.286 -2.171 0 C-N-CA 119.621 -0.832 . . . . 0.0 110.593 -178.655 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' CYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -104.4 131.77 51.39 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.27 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.496 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.6 mt-10 -71.48 -46.22 13.26 Favored Pre-proline 0 C--N 1.306 -1.308 0 C-N-CA 119.364 -0.934 . . . . 0.0 112.843 -179.596 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.0 Cg_endo -67.01 -45.1 4.33 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 120.902 1.068 . . . . 0.0 111.87 -179.402 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -93.52 22.81 5.04 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.886 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.423 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -68.5 -13.67 62.48 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.739 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -87.27 -12.3 67.88 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.261 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.54 -12.16 30.21 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.406 -0.918 . . . . 0.0 110.819 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.16 10.79 38.44 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.743 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -66.68 101.6 0.82 Allowed 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.364 -0.935 . . . . 0.0 111.081 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.533 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 18.4 mttp -129.11 173.18 10.7 Favored 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.349 -179.71 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -155.58 152.09 23.59 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.333 -1.413 . . . . 0.0 111.444 -178.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -155.75 144.95 20.76 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.789 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 94' ' ' VAL . 7.4 p -136.46 124.33 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.809 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 68.6 m -100.73 97.92 8.52 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.254 179.157 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.7 t -79.53 151.9 4.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 119.097 -1.041 . . . . 0.0 110.622 -178.851 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.51 ' OXT' ' HB2' ' A' ' 23' ' ' ALA . 11.7 m-80 . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 116.319 -1.8 . . . . 0.0 110.783 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.087 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -134.31 118.37 17.45 Favored 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.685 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.2 t -102.76 123.51 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 C-N-CA 119.713 -0.795 . . . . 0.0 110.51 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.5 mmmm -95.42 117.55 30.56 Favored 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.111 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 3.6 mt -86.52 109.85 19.38 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.012 -1.075 . . . . 0.0 110.013 178.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.58 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 101.42 93.56 2.19 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.844 -1.17 . . . . 0.0 110.214 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.6 p . . . . . 0 C--N 1.307 -1.256 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.932 -179.755 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt . . . . . 0 N--CA 1.485 1.296 0 N-CA-C 110.628 -0.138 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.7 m -150.4 158.39 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 118.624 -1.23 . . . . 0.0 111.57 179.399 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.447 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 18.2 m-85 -78.84 110.45 14.04 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 177.274 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 38.7 m -116.35 108.48 45.51 Favored Pre-proline 0 C--N 1.304 -1.394 0 C-N-CA 119.54 -0.864 . . . . 0.0 112.08 -177.382 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -66.0 175.0 24.47 Favored 'Cis proline' 0 C--N 1.357 0.98 0 C-N-CA 125.312 -0.703 . . . . 0.0 111.8 -0.206 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 t -95.71 -64.96 1.01 Allowed 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.706 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 81.4 p -118.63 128.3 54.41 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.958 178.644 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.476 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 12.6 p90 -156.23 145.68 20.8 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 118.477 -1.289 . . . . 0.0 111.255 -178.832 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.423 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -87.46 158.67 18.91 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 119.376 -0.93 . . . . 0.0 111.278 -179.856 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.0 m -147.39 169.18 4.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.569 179.476 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -85.83 147.36 26.33 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.664 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.99 73.02 0.18 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.309 -179.736 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.412 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 154.47 15.83 0.05 OUTLIER Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.718 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.412 ' H ' ' H ' ' A' ' 24' ' ' GLY . 24.5 tt0 -98.8 154.82 17.72 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.667 -0.813 . . . . 0.0 110.983 -179.462 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 12.7 mttm -95.43 136.92 35.19 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.549 -0.86 . . . . 0.0 111.136 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 85.6 mt -115.19 104.92 17.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.611 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 26.7 p -99.98 114.65 28.07 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.532 -0.867 . . . . 0.0 112.215 -178.603 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -85.07 127.74 34.35 Favored 'General case' 0 C--N 1.309 -1.188 0 C-N-CA 119.277 -0.969 . . . . 0.0 109.241 178.742 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.7 tttm -124.41 131.49 53.5 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 119.892 -0.723 . . . . 0.0 111.341 -179.059 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.712 HD21 ' H ' ' A' ' 66' ' ' GLU . 31.3 p-10 -90.15 127.26 36.06 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.355 -0.938 . . . . 0.0 109.792 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.58 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 5.1 p30 -127.65 -6.4 5.73 Favored 'General case' 0 N--CA 1.495 1.787 0 C-N-CA 118.939 -1.104 . . . . 0.0 112.871 -178.84 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.523 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 177.7 90.74 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 117.982 -1.487 . . . . 0.0 112.184 179.611 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 135.73 28.83 0.38 Allowed Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.455 -1.355 . . . . 0.0 111.114 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.596 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -75.95 162.29 72.35 Favored Pre-proline 0 N--CA 1.483 1.191 0 C-N-CA 118.297 -1.361 . . . . 0.0 109.829 179.627 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -79.88 148.55 79.37 Favored 'Cis proline' 0 C--O 1.211 -0.853 0 C-N-CA 124.185 -1.173 . . . . 0.0 112.531 -0.664 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -110.64 170.96 7.75 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.914 -0.715 . . . . 0.0 110.162 178.867 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.582 ' ND2' ' CD2' ' A' ' 60' ' ' TYR . 9.3 t-20 -149.46 151.87 34.7 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.193 -1.003 . . . . 0.0 110.646 179.525 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.4 mt -132.74 114.51 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 C-N-CA 119.771 -0.772 . . . . 0.0 111.019 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.0 t -131.14 141.97 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.732 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -100.02 120.12 39.33 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 119.278 -0.969 . . . . 0.0 112.085 -179.109 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.512 ' C ' ' H ' ' A' ' 44' ' ' ASP . 1.6 t0 -65.77 114.42 5.03 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.39 -0.924 . . . . 0.0 109.709 178.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.35 15.1 0.06 Allowed 'General case' 0 N--CA 1.491 1.609 0 C-N-CA 119.274 -0.97 . . . . 0.0 111.592 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.512 ' H ' ' C ' ' A' ' 42' ' ' ASP . 3.0 m-20 -101.86 -2.79 29.14 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.224 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -143.1 14.64 1.87 Allowed 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.213 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -96.83 145.51 29.71 Favored Pre-proline 0 C--N 1.299 -1.599 0 C-N-CA 119.868 -0.733 . . . . 0.0 109.107 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -52.9 154.1 13.72 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 120.785 0.99 . . . . 0.0 111.63 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.53 44.08 0.78 Allowed 'General case' 0 C--N 1.307 -1.278 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.584 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -147.68 -38.39 0.04 OUTLIER Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 86.9 t -98.93 94.05 3.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 C-N-CA 119.775 -0.77 . . . . 0.0 110.339 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -44.57 155.36 0.1 Allowed 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.955 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -93.89 -11.66 30.59 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.177 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -89.49 -9.25 50.75 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.92 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 3.0 mmpt? -88.03 -28.62 21.27 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.402 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -105.49 -5.51 9.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.739 -179.214 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.0 m -74.23 171.53 13.45 Favored 'General case' 0 C--N 1.308 -1.218 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.355 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.617 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 56.3 mt-30 -123.95 80.04 57.38 Favored Pre-proline 0 N--CA 1.49 1.536 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.35 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -61.41 -16.11 45.22 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 120.722 0.948 . . . . 0.0 110.852 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -100.49 119.73 38.94 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.81 -0.756 . . . . 0.0 110.679 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.582 ' CD2' ' ND2' ' A' ' 38' ' ' ASN . 38.4 m-85 -69.04 174.98 4.03 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.839 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.4 pp -144.38 123.31 12.75 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.221 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -116.13 -14.63 11.15 Favored 'General case' 0 N--CA 1.501 2.112 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.184 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.508 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . -52.07 137.5 32.63 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.036 -1.554 . . . . 0.0 110.633 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.64 106.37 5.37 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.661 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 97.61 12.64 46.94 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.519 -1.325 . . . . 0.0 110.004 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.712 ' H ' HD21 ' A' ' 31' ' ' ASN . 1.9 mm-40 -66.02 158.37 28.47 Favored 'General case' 0 N--CA 1.484 1.242 0 C-N-CA 119.229 -0.989 . . . . 0.0 110.244 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.4 p -147.48 160.01 43.08 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 118.805 -1.158 . . . . 0.0 111.979 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.617 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 42.9 t80 -135.8 178.07 7.34 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.371 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.586 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 8.4 mt-10 -140.62 149.74 42.7 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 118.916 -1.113 . . . . 0.0 111.929 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -150.07 132.7 6.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-N 115.322 -0.853 . . . . 0.0 109.218 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.3 m -127.21 106.28 9.14 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.424 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.523 ' CD1' HG11 ' A' ' 94' ' ' VAL . 30.3 mt -91.79 159.72 15.67 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.249 -0.98 . . . . 0.0 110.117 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 6.4 p -150.63 46.36 0.87 Allowed 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.098 -1.041 . . . . 0.0 111.544 -179.354 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.406 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 2.0 mm-40 -143.84 101.6 3.77 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 118.995 -1.082 . . . . 0.0 110.565 179.475 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 19.5 tttm -43.96 108.03 0.1 Allowed 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.657 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.71 -143.71 6.76 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.193 -1.479 . . . . 0.0 110.202 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.458 HG23 HG23 ' A' ' 95' ' ' THR . 0.0 OUTLIER -145.03 133.17 21.5 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.918 179.959 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.58 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.3 m-85 -119.62 157.35 28.61 Favored 'General case' 0 N--CA 1.485 1.29 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.134 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.1 mmtm -124.62 123.81 40.86 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.545 -0.862 . . . . 0.0 112.224 -179.115 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.574 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.0 OUTLIER -135.25 163.89 28.96 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.099 178.408 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -169.49 179.59 3.78 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 119.165 -1.014 . . . . 0.0 111.223 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -102.17 116.87 33.57 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.778 -0.769 . . . . 0.0 109.651 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.58 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 7.0 tt0 -71.99 -36.08 3.96 Favored Pre-proline 0 C--N 1.304 -1.374 0 C-N-CA 118.941 -1.104 . . . . 0.0 112.901 -179.223 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.58 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -70.2 -52.48 0.29 Allowed 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 120.429 0.753 . . . . 0.0 111.144 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' HIS . . . . . 0.493 ' C ' ' H ' ' A' ' 87' ' ' GLY . 35.1 m170 -82.14 13.91 3.17 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.829 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.25 -6.14 0.14 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.659 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.493 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -80.55 -27.6 50.73 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.575 -1.298 . . . . 0.0 110.327 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.73 -32.56 23.43 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.4 -0.92 . . . . 0.0 110.392 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 114.94 23.23 4.69 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.926 -1.131 . . . . 0.0 110.903 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 28.6 mtp -65.14 107.68 1.63 Allowed 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.869 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.447 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 17.4 pttp -124.97 159.0 32.26 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 119.975 -0.69 . . . . 0.0 110.461 179.501 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.86 145.6 15.13 Favored Glycine 0 N--CA 1.497 2.729 0 C-N-CA 119.053 -1.546 . . . . 0.0 111.742 -178.701 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 51.3 tt0 -150.8 144.7 25.25 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.317 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.523 HG11 ' CD1' ' A' ' 72' ' ' LEU . 11.2 p -136.99 124.6 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 C-N-CA 119.121 -1.031 . . . . 0.0 111.179 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.458 HG23 HG23 ' A' ' 77' ' ' THR . 41.4 m -100.61 99.51 10.09 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.672 179.406 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.7 t -79.79 146.23 8.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.374 -179.067 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.486 1.346 0 CA-C-O 116.412 -1.756 . . . . 0.0 110.999 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.43 ' HB3' HG13 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.893 0.377 . . . . 0.0 110.077 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -97.32 122.06 39.92 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.809 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 43.9 t -107.7 121.56 60.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.149 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 45.6 mtpt -92.05 117.36 29.76 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.157 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.404 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 16.8 mt -78.15 111.71 14.36 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.558 179.665 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.404 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 97.33 120.45 4.02 Favored Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.789 -1.196 . . . . 0.0 110.227 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 18.3 p . . . . . 0 C--N 1.301 -1.5 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.609 179.669 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.3 mt . . . . . 0 N--CA 1.483 1.182 0 CA-C-O 120.525 0.202 . . . . 0.0 110.668 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.4 m -150.89 158.39 4.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 C-N-CA 118.918 -1.113 . . . . 0.0 110.872 179.383 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.415 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 58.0 m-85 -78.75 112.83 16.28 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 177.093 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 53.8 m -115.0 110.9 45.51 Favored Pre-proline 0 N--CA 1.485 1.316 0 C-N-CA 119.315 -0.954 . . . . 0.0 112.431 -177.089 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -65.82 170.95 37.19 Favored 'Cis proline' 0 C--N 1.362 1.284 0 C-N-CA 125.228 -0.738 . . . . 0.0 111.51 -0.664 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.0 p -94.86 -67.95 0.83 Allowed 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.055 179.082 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.67 137.32 47.66 Favored 'General case' 0 N--CA 1.486 1.326 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.672 179.198 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -163.57 134.9 4.75 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 118.456 -1.298 . . . . 0.0 111.658 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.445 HG23 ' H ' ' A' ' 20' ' ' THR . 0.3 OUTLIER -85.54 152.88 22.82 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.237 -179.957 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -144.84 173.78 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.677 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.518 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -94.1 139.22 31.25 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.452 -0.899 . . . . 0.0 110.357 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.19 77.79 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.319 -0.953 . . . . 0.0 110.888 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 158.12 13.83 0.04 OUTLIER Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -104.05 149.69 24.96 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 120.102 -0.639 . . . . 0.0 110.767 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.486 ' C ' HD12 ' A' ' 27' ' ' ILE . 78.0 mttt -94.91 137.56 33.82 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.105 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.486 HD12 ' C ' ' A' ' 26' ' ' LYS . 1.5 mp -115.9 150.47 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.08 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 68.5 p -141.75 121.89 13.82 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 118.92 -1.112 . . . . 0.0 112.1 -179.202 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -87.18 120.93 28.97 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.373 -0.931 . . . . 0.0 108.895 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.5 ttmm -110.99 136.81 49.43 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.669 -0.812 . . . . 0.0 111.742 -178.442 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.631 ' ND2' ' CD1' ' A' ' 35' ' ' PHE . 19.2 t30 -80.42 104.27 10.85 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 115.109 -0.95 . . . . 0.0 109.723 179.146 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.404 ' OD1' ' O ' ' A' ' 6' ' ' GLY . 2.0 t-20 -101.27 -32.03 10.7 Favored 'General case' 0 N--CA 1.491 1.575 0 C-N-CA 118.838 -1.145 . . . . 0.0 112.389 -178.787 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 177.27 143.06 0.09 Allowed 'General case' 0 N--CA 1.502 2.134 0 C-N-CA 119.503 -0.879 . . . . 0.0 111.166 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 100.89 8.54 48.01 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 119.338 -1.411 . . . . 0.0 112.299 178.286 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.631 ' CD1' ' ND2' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -55.45 162.88 2.06 Favored Pre-proline 0 C--N 1.308 -1.229 0 C-N-CA 117.763 -1.575 . . . . 0.0 109.478 179.569 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_endo -76.67 140.76 67.11 Favored 'Cis proline' 0 C--O 1.215 -0.64 0 C-N-CA 124.285 -1.131 . . . . 0.0 112.521 -0.54 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.404 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 34.3 m-70 -109.91 163.46 13.53 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.801 179.129 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.405 ' OD1' ' N ' ' A' ' 39' ' ' ILE . 36.0 t30 -148.12 139.79 23.77 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.682 179.649 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.405 ' N ' ' OD1' ' A' ' 38' ' ' ASN . 2.7 mp -116.45 118.01 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 120.046 -0.662 . . . . 0.0 111.045 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.484 HG12 ' N ' ' A' ' 41' ' ' PHE . 28.3 t -129.8 162.37 37.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.899 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.484 ' N ' HG12 ' A' ' 40' ' ' VAL . 27.8 m-85 -121.09 122.0 39.1 Favored 'General case' 0 N--CA 1.494 1.755 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.552 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -54.13 117.48 3.28 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.346 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.451 ' O ' ' OD1' ' A' ' 44' ' ' ASP . 9.2 mt-10 -76.38 39.06 0.19 Allowed 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.297 -179.627 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.451 ' OD1' ' O ' ' A' ' 43' ' ' GLU . 75.4 m-20 -148.91 -3.22 0.45 Allowed 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.157 -1.017 . . . . 0.0 110.975 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -130.71 8.62 4.92 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.821 -0.752 . . . . 0.0 109.885 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -95.8 148.06 33.97 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 115.027 -0.988 . . . . 0.0 108.79 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -49.45 151.1 7.42 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 120.89 1.06 . . . . 0.0 111.827 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.34 54.84 1.47 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.864 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -165.06 -40.93 0.02 OUTLIER Glycine 0 N--CA 1.489 2.197 0 C-N-CA 119.465 -1.35 . . . . 0.0 110.322 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 46.3 t -86.56 93.95 4.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.969 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -47.14 158.25 0.15 Allowed 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.649 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.64 -25.01 16.3 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.786 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 90.7 mt-10 -71.71 -13.22 61.66 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.884 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.9 mmpp? -87.6 -39.75 14.81 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.775 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.409 HD12 ' CD2' ' A' ' 41' ' ' PHE . 3.0 pt -91.62 -25.86 5.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.242 -0.983 . . . . 0.0 111.258 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.7 m -55.52 -176.98 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 119.124 -1.031 . . . . 0.0 110.686 179.384 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.475 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 22.1 tt0 -144.95 78.12 12.78 Favored Pre-proline 0 C--N 1.302 -1.464 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.528 -179.556 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -59.51 -24.51 75.24 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 120.971 1.114 . . . . 0.0 111.532 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -77.9 99.57 6.04 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.201 -1.0 . . . . 0.0 110.484 179.579 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -56.99 167.28 0.84 Allowed 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.045 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.446 HD22 ' NE2' ' A' ' 57' ' ' GLN . 0.2 OUTLIER -135.61 105.27 6.11 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 119.729 -0.788 . . . . 0.0 110.708 179.59 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -107.26 4.93 27.13 Favored 'General case' 0 N--CA 1.488 1.426 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.701 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -90.88 139.38 14.81 Favored Glycine 0 N--CA 1.489 2.216 0 C-N-CA 119.386 -1.388 . . . . 0.0 110.433 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -74.19 123.55 24.69 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.722 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.19 -8.99 59.32 Favored Glycine 0 N--CA 1.498 2.826 0 C-N-CA 119.547 -1.311 . . . . 0.0 110.983 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -55.83 150.65 12.67 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.976 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 3.2 p -150.59 160.11 44.03 Favored 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 118.829 -1.149 . . . . 0.0 111.667 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.506 ' CE2' ' O ' ' A' ' 69' ' ' GLU . 53.5 t80 -135.68 177.39 7.86 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.898 -0.721 . . . . 0.0 109.745 179.092 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.506 ' O ' ' CE2' ' A' ' 68' ' ' TYR . 9.0 mt-10 -144.99 151.94 39.37 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.118 -1.033 . . . . 0.0 111.554 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.444 ' O ' ' CG1' ' A' ' 70' ' ' VAL . 1.8 p -158.76 127.78 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 C-N-CA 119.552 -0.859 . . . . 0.0 109.981 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.6 m -115.03 93.87 4.5 Favored 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.058 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 11.8 mt -79.15 156.07 28.41 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 118.81 -1.156 . . . . 0.0 109.353 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.2 p -150.86 38.37 0.67 Allowed 'General case' 0 C--N 1.293 -1.886 0 C-N-CA 118.902 -1.119 . . . . 0.0 111.559 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.424 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.5 OUTLIER -124.2 96.4 4.91 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 119.482 -0.887 . . . . 0.0 109.62 179.202 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.418 ' C ' ' O ' ' A' ' 74' ' ' GLU . 16.3 mtmm -39.52 99.75 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.292 -178.87 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.34 -135.4 2.64 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 119.257 -1.449 . . . . 0.0 110.359 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.3 m -150.36 142.56 24.15 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.145 -1.022 . . . . 0.0 111.225 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.611 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.7 m-85 -128.47 125.48 38.55 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.606 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 6.2 mptt -99.23 116.33 31.17 Favored 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.23 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.573 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -123.5 168.87 12.01 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.082 178.74 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -170.73 -176.81 2.15 Favored 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.683 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.5 t -105.86 127.1 52.9 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.775 -0.77 . . . . 0.0 109.865 179.532 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.567 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 tm-20 -74.59 -37.14 2.75 Favored Pre-proline 0 CA--C 1.558 1.259 0 C-N-CA 119.161 -1.016 . . . . 0.0 113.318 -178.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.1 Cg_endo -71.03 -50.04 0.35 Allowed 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 120.716 0.944 . . . . 0.0 111.416 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -83.72 16.29 2.79 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.594 -0.842 . . . . 0.0 110.888 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.89 -6.21 5.63 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.671 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.83 -11.94 64.8 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.146 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -97.16 -42.41 7.85 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.794 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.25 30.61 0.72 Allowed Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -79.43 110.99 15.25 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.212 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.415 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 1.0 OUTLIER -133.96 162.62 31.55 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.237 -179.808 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -144.1 152.12 23.99 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.675 -1.25 . . . . 0.0 110.661 -178.799 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -154.13 146.74 24.14 Favored 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 119.105 -1.038 . . . . 0.0 111.29 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.494 ' O ' HG13 ' A' ' 94' ' ' VAL . 8.4 p -143.74 126.52 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.261 0 C-N-CA 119.016 -1.074 . . . . 0.0 110.334 178.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 99.4 m -105.61 102.49 11.95 Favored 'General case' 0 N--CA 1.494 1.76 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.723 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.9 t -82.67 141.36 15.06 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.226 -179.172 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 . . . . . 0 C--N 1.302 -1.458 0 CA-C-O 116.344 -1.788 . . . . 0.0 110.857 -179.85 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.114 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -107.66 118.99 38.2 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.741 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 t -108.22 120.01 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 C-N-CA 119.866 -0.734 . . . . 0.0 110.642 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -95.01 116.52 28.8 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.414 -0.914 . . . . 0.0 110.861 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.1 mt -77.2 113.36 14.87 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 118.891 -1.123 . . . . 0.0 109.993 178.535 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.487 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 101.64 131.75 7.49 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.1 p . . . . . 0 C--N 1.304 -1.388 0 C-N-CA 119.225 -0.99 . . . . 0.0 110.62 179.998 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.9 mt . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 120.634 0.254 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.7 m -151.01 155.2 7.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.828 179.375 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.402 ' O ' ' C ' ' A' ' 16' ' ' PRO . 67.2 m-85 -78.31 110.53 13.41 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 177.598 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 59.4 m -113.37 110.06 50.82 Favored Pre-proline 0 CA--C 1.557 1.246 0 C-N-CA 119.377 -0.929 . . . . 0.0 112.504 -177.176 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.402 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.3 Cg_endo -67.62 170.2 49.26 Favored 'Cis proline' 0 C--N 1.363 1.31 0 C-N-CA 125.344 -0.69 . . . . 0.0 111.414 -0.745 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.4 m -94.0 -70.64 0.7 Allowed 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.441 -0.904 . . . . 0.0 109.648 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.3 t -107.46 129.65 54.92 Favored 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.311 178.783 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 13.1 p90 -157.22 144.12 18.39 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 118.237 -1.385 . . . . 0.0 111.898 -179.081 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.517 HG23 ' O ' ' A' ' 95' ' ' THR . 19.9 m -84.43 157.02 21.51 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.859 179.692 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.5 m -150.66 168.28 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 C-N-CA 119.737 -0.785 . . . . 0.0 110.941 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -89.38 148.64 23.39 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.559 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.93 73.57 0.19 Allowed 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.079 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 156.38 16.04 0.04 OUTLIER Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -97.85 153.97 17.95 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.795 -0.762 . . . . 0.0 111.055 -179.44 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.0 mtmm -95.17 127.52 41.29 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.069 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.0 mt -107.25 103.26 15.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 C-N-CA 120.069 -0.653 . . . . 0.0 109.87 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 52.5 p -100.99 115.12 29.73 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 119.656 -0.818 . . . . 0.0 112.382 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -85.5 109.83 18.76 Favored 'General case' 0 N--CA 1.489 1.485 0 C-N-CA 119.668 -0.813 . . . . 0.0 109.228 178.471 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.7 tttp -105.61 137.69 43.05 Favored 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 119.46 -0.896 . . . . 0.0 112.122 -178.122 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.456 ' ND2' ' N ' ' A' ' 31' ' ' ASN . 0.1 OUTLIER -79.64 114.15 18.34 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.272 179.177 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.67 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.7 OUTLIER -97.71 -31.04 12.47 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.181 -1.008 . . . . 0.0 111.634 -179.238 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.67 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 165.47 114.38 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.246 -0.981 . . . . 0.0 111.148 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 139.51 3.61 1.56 Allowed Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.434 -1.365 . . . . 0.0 110.863 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.445 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -53.16 163.08 0.96 Allowed Pre-proline 0 C--N 1.304 -1.372 0 C-N-CA 118.704 -1.199 . . . . 0.0 109.741 -179.874 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -77.1 141.26 68.5 Favored 'Cis proline' 0 C--O 1.214 -0.691 0 C-N-CA 124.194 -1.169 . . . . 0.0 112.509 -0.483 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -107.2 178.23 4.61 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.967 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.3 t-20 -158.09 139.64 13.67 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.618 -0.833 . . . . 0.0 110.212 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.7 mp -128.07 114.74 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 C-N-CA 119.789 -0.765 . . . . 0.0 111.311 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 66.6 t -130.08 134.48 62.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.921 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.754 ' CD2' HD12 ' A' ' 55' ' ' ILE . 8.8 m-85 -87.07 129.18 35.02 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.147 -1.021 . . . . 0.0 111.446 -179.21 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.659 ' C ' ' H ' ' A' ' 44' ' ' ASP . 31.1 t0 -65.75 94.29 0.2 Allowed 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.646 -178.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -55.37 5.35 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.858 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.373 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.659 ' H ' ' C ' ' A' ' 42' ' ' ASP . 73.8 m-20 -82.85 -68.18 0.73 Allowed 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.557 179.272 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -98.51 25.51 6.32 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.471 -0.892 . . . . 0.0 112.131 -177.031 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.608 HG22 ' HD2' ' A' ' 47' ' ' PRO . 0.5 OUTLIER -89.16 154.41 49.32 Favored Pre-proline 0 N--CA 1.489 1.5 0 C-N-CA 119.204 -0.998 . . . . 0.0 108.374 178.967 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.608 ' HD2' HG22 ' A' ' 46' ' ' VAL . 6.1 Cg_exo -51.13 144.01 30.42 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 121.017 1.145 . . . . 0.0 112.061 -179.065 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.47 69.38 5.72 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.791 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.73 -43.24 0.08 OUTLIER Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 46.5 t -84.18 83.39 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.078 179.283 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.554 ' ND2' ' H ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER -44.74 140.87 2.31 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.525 -179.652 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.39 -26.33 60.94 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.539 -0.865 . . . . 0.0 111.293 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' A' ' 53' ' ' GLU . 3.7 mp0 -65.34 -3.17 3.77 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.938 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.0 mmpp? -97.44 -40.92 8.45 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.022 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.754 HD12 ' CD2' ' A' ' 41' ' ' PHE . 1.3 pt -99.13 -13.99 7.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.638 -0.825 . . . . 0.0 111.087 -179.587 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 68.9 m -73.06 173.11 9.82 Favored 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.855 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.63 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 70.3 mt-30 -136.65 80.3 38.26 Favored Pre-proline 0 N--CA 1.488 1.469 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.623 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -60.92 -20.83 68.73 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.121 1.214 . . . . 0.0 111.443 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -94.56 108.7 20.64 Favored 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.525 179.647 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 38.9 m-85 -51.51 177.24 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.887 -0.725 . . . . 0.0 111.035 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.8 pp -143.69 139.19 29.4 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.822 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.415 ' OD1' ' N ' ' A' ' 62' ' ' ASN . 2.9 p-10 -134.97 42.95 2.75 Favored 'General case' 0 N--CA 1.489 1.498 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.399 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -105.31 159.54 15.49 Favored Glycine 0 N--CA 1.493 2.461 0 C-N-CA 119.797 -1.192 . . . . 0.0 110.429 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -110.64 110.89 21.76 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 119.989 -0.685 . . . . 0.0 110.726 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.34 -14.21 64.67 Favored Glycine 0 N--CA 1.49 2.285 0 C-N-CA 119.437 -1.364 . . . . 0.0 110.367 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.414 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 1.2 mm-40 -69.82 160.15 32.29 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.269 -0.973 . . . . 0.0 110.345 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -147.22 172.27 14.09 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.669 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.63 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 43.9 t80 -133.61 129.45 36.95 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.082 179.125 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -91.46 149.75 21.55 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 118.892 -1.123 . . . . 0.0 112.461 -178.462 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -150.28 131.72 5.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.994 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.0 m -127.04 106.54 9.34 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.836 -0.745 . . . . 0.0 111.504 -178.782 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.48 ' CD1' HG11 ' A' ' 94' ' ' VAL . 20.5 mt -90.58 157.7 17.37 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.837 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 8.7 p -150.67 48.37 0.87 Allowed 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.072 -1.051 . . . . 0.0 111.412 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -146.67 100.74 3.37 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.151 179.36 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.469 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 2.0 ptpt -41.77 118.76 1.15 Allowed 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 119.65 -0.82 . . . . 0.0 111.041 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 164.87 -147.22 12.23 Favored Glycine 0 N--CA 1.484 1.9 0 C-N-CA 119.506 -1.331 . . . . 0.0 109.878 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.71 132.96 24.68 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.462 -0.895 . . . . 0.0 111.2 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.585 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.5 OUTLIER -116.81 127.36 54.25 Favored 'General case' 0 N--CA 1.486 1.333 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.342 179.712 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.476 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 2.5 mptp? -101.2 110.72 22.78 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.538 -0.865 . . . . 0.0 111.388 -179.404 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.2 p90 -123.78 168.0 13.3 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.896 -0.722 . . . . 0.0 109.922 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 46.0 p90 -171.43 -173.92 1.32 Allowed 'General case' 0 C--N 1.296 -1.758 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.033 -178.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -107.97 129.5 55.11 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.001 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.518 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.9 mt-10 -69.91 -45.4 23.35 Favored Pre-proline 0 N--CA 1.486 1.374 0 C-N-CA 119.541 -0.864 . . . . 0.0 113.073 -179.385 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.518 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.7 Cg_endo -67.79 -53.17 0.45 Allowed 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 121.066 1.177 . . . . 0.0 111.771 -179.047 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.3 m80 -82.42 16.36 2.12 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.407 -0.917 . . . . 0.0 111.05 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.28 -18.42 58.37 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.365 -0.934 . . . . 0.0 110.809 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.19 -19.6 78.28 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.405 -1.379 . . . . 0.0 110.573 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.97 -4.69 52.23 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.577 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.64 9.67 62.58 Favored Glycine 0 N--CA 1.489 2.178 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.571 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -55.85 102.31 0.07 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.707 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.8 ptmt -126.64 157.48 38.85 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 119.929 -0.708 . . . . 0.0 111.221 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -140.24 133.86 6.21 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.971 -1.109 . . . . 0.0 110.391 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -139.21 148.79 43.59 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.634 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.48 HG11 ' CD1' ' A' ' 72' ' ' LEU . 11.4 p -141.84 132.47 25.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 119.065 -1.054 . . . . 0.0 110.219 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.517 ' O ' HG23 ' A' ' 20' ' ' THR . 99.6 m -110.31 104.99 13.85 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.26 -0.976 . . . . 0.0 110.338 179.667 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 31.4 t -84.83 152.31 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 118.555 -1.258 . . . . 0.0 110.774 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 60.8 m-20 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 116.324 -1.798 . . . . 0.0 110.816 -179.792 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.199 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -130.51 122.59 27.9 Favored 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 120.053 -0.659 . . . . 0.0 110.642 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -99.11 154.4 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.635 -179.511 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.2 mttt -120.59 106.95 12.25 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.074 -0.967 . . . . 0.0 110.479 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.9 mt -74.77 111.47 10.01 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 118.625 -1.23 . . . . 0.0 110.207 179.374 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 112.03 136.32 6.81 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -178.675 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 79.7 p . . . . . 0 C--N 1.3 -1.556 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.806 -179.909 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mt . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.5 m -150.84 155.47 7.3 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 C-N-CA 118.853 -1.139 . . . . 0.0 111.281 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.49 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 57.2 m-85 -78.7 109.84 13.3 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 177.449 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.9 m -115.3 108.19 48.19 Favored Pre-proline 0 CA--C 1.565 1.552 0 C-N-CA 119.596 -0.841 . . . . 0.0 112.875 -176.878 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -66.23 175.09 25.08 Favored 'Cis proline' 0 C--N 1.368 1.571 0 C-N-CA 125.128 -0.78 . . . . 0.0 111.142 -1.48 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.521 ' OG ' ' N ' ' A' ' 18' ' ' SER . 0.1 OUTLIER -102.91 -67.84 0.86 Allowed 'General case' 0 N--CA 1.488 1.442 0 C-N-CA 119.704 -0.799 . . . . 0.0 110.305 179.428 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.521 ' N ' ' OG ' ' A' ' 17' ' ' SER . 34.2 t -105.74 133.45 50.46 Favored 'General case' 0 N--CA 1.488 1.433 0 C-N-CA 120.069 -0.652 . . . . 0.0 109.843 179.323 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 32.6 p90 -160.65 137.13 8.69 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 118.817 -1.153 . . . . 0.0 111.177 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.419 ' H ' HG23 ' A' ' 20' ' ' THR . 0.4 OUTLIER -87.77 159.57 18.4 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 119.271 -0.972 . . . . 0.0 111.183 -179.891 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 30.6 m -148.93 176.35 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.315 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -97.37 150.41 21.03 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.568 -0.853 . . . . 0.0 110.722 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.03 71.67 0.17 Allowed 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.99 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 164.4 10.02 0.03 OUTLIER Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -104.37 146.59 28.61 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.105 -0.638 . . . . 0.0 110.543 -179.638 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.6 pttt -94.33 153.29 18.08 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.394 -0.922 . . . . 0.0 111.039 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 mt -122.94 145.51 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.486 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.7 p -137.8 118.13 13.69 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.274 -0.97 . . . . 0.0 112.165 -178.843 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -84.63 126.59 33.49 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.642 -0.823 . . . . 0.0 109.059 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.459 ' HB3' ' HZ2' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -120.16 130.76 54.74 Favored 'General case' 0 N--CA 1.493 1.705 0 C-N-CA 119.604 -0.838 . . . . 0.0 111.853 -178.085 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.635 HD21 ' CD1' ' A' ' 61' ' ' LEU . 6.2 m-20 -70.2 125.41 26.71 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.517 -0.873 . . . . 0.0 109.101 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.652 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.1 OUTLIER -103.7 -32.24 9.47 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 118.861 -1.136 . . . . 0.0 112.798 -178.533 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.652 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.01 -5.16 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 118.019 -1.472 . . . . 0.0 112.016 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.506 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -107.6 41.81 2.1 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.411 -1.376 . . . . 0.0 112.02 -178.798 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -76.14 160.78 77.37 Favored Pre-proline 0 N--CA 1.483 1.218 0 C-N-CA 117.917 -1.513 . . . . 0.0 109.564 179.019 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -74.38 176.98 40.33 Favored 'Cis proline' 0 C--O 1.207 -1.037 0 C-N-CA 124.163 -1.182 . . . . 0.0 111.784 -0.843 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.506 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 43.0 m-70 -150.98 168.92 23.09 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.567 -0.853 . . . . 0.0 110.794 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.846 HD21 ' H ' ' A' ' 83' ' ' GLU . 4.8 p-10 -154.54 152.89 30.6 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 119.381 -0.928 . . . . 0.0 110.079 178.244 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.0 mp -129.14 97.78 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.652 -179.379 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -112.39 143.41 22.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.163 178.579 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -99.04 138.5 36.06 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.097 -1.041 . . . . 0.0 112.354 -178.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -75.83 110.81 10.57 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.241 -0.983 . . . . 0.0 108.981 178.461 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -72.56 49.68 0.22 Allowed 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.405 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -142.5 3.57 1.5 Allowed 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.968 -0.693 . . . . 0.0 110.2 179.367 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -142.99 8.13 1.65 Allowed 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.721 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.422 HG13 ' HD2' ' A' ' 47' ' ' PRO . 44.3 t -94.63 143.75 26.76 Favored Pre-proline 0 C--N 1.291 -1.968 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.422 ' HD2' HG13 ' A' ' 46' ' ' VAL . 5.2 Cg_exo -50.94 148.56 16.53 Favored 'Trans proline' 0 C--O 1.216 -0.593 0 C-N-CA 120.868 1.045 . . . . 0.0 112.251 -179.081 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.11 78.25 2.94 Favored 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.503 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 168.32 -43.13 0.23 Allowed Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.402 ' O ' HG12 ' A' ' 50' ' ' VAL . 55.5 t -79.35 94.21 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.528 179.544 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -44.93 139.85 2.9 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.696 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -96.34 -1.46 47.73 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.561 -0.856 . . . . 0.0 110.937 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.439 ' N ' ' OE1' ' A' ' 53' ' ' GLU . 11.0 mp0 -90.33 -15.82 30.41 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.303 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.419 ' HG3' HG23 ' A' ' 55' ' ' ILE . 59.2 pttt -89.88 -27.47 19.87 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.01 -1.076 . . . . 0.0 111.437 -179.54 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.424 HD13 HG21 ' A' ' 55' ' ' ILE . 15.8 pt -92.74 -27.76 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 C-N-CA 119.106 -1.038 . . . . 0.0 110.918 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 9.0 m -60.75 -168.15 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.655 -0.818 . . . . 0.0 111.43 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.479 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 15.0 mt-30 -150.07 74.27 9.21 Favored Pre-proline 0 C--N 1.305 -1.336 0 C-N-CA 119.867 -0.733 . . . . 0.0 110.626 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -60.18 -12.26 19.01 Favored 'Trans proline' 0 C--N 1.325 -0.695 0 C-N-CA 121.202 1.268 . . . . 0.0 111.256 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' A' ' 60' ' ' TYR . 45.0 mt-10 -100.13 95.48 6.85 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.834 -0.746 . . . . 0.0 110.414 179.425 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.44 ' O ' ' O ' ' A' ' 59' ' ' GLU . 71.3 m-85 -43.97 171.19 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.916 -0.714 . . . . 0.0 111.17 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.635 ' CD1' HD21 ' A' ' 31' ' ' ASN . 1.9 pp -139.74 150.3 44.64 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.833 -0.747 . . . . 0.0 110.644 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -149.06 53.26 0.97 Allowed 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.891 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.27 126.98 6.29 Favored Glycine 0 N--CA 1.498 2.774 0 C-N-CA 119.95 -1.119 . . . . 0.0 110.402 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.67 128.78 37.56 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.833 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.47 -14.99 10.13 Favored Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.371 -1.395 . . . . 0.0 110.859 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 -56.44 154.83 7.88 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.336 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -147.99 164.57 33.4 Favored 'General case' 0 N--CA 1.489 1.522 0 C-N-CA 119.016 -1.074 . . . . 0.0 111.788 -179.069 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.479 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 36.0 t80 -136.14 146.45 46.94 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -108.03 154.74 21.22 Favored 'General case' 0 N--CA 1.498 1.935 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.794 -178.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -155.24 135.91 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 CA-C-N 115.086 -0.961 . . . . 0.0 108.936 179.287 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.2 m -128.07 104.16 7.62 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.667 -0.813 . . . . 0.0 111.769 -179.365 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.525 ' CD1' HG11 ' A' ' 94' ' ' VAL . 14.4 mt -88.22 157.74 18.7 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.237 -0.985 . . . . 0.0 109.614 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.71 48.42 0.87 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 118.865 -1.134 . . . . 0.0 111.351 -179.25 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.447 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -142.58 105.08 4.48 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.272 -0.971 . . . . 0.0 110.011 178.996 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 32.0 mtmt -46.59 110.31 0.27 Allowed 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.162 -179.285 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 171.08 -141.76 6.67 Favored Glycine 0 N--CA 1.485 1.912 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -146.38 137.5 24.39 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.924 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.573 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.4 m-85 -122.32 152.3 40.27 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.131 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 31.2 mttm -115.5 132.42 56.63 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.625 -0.83 . . . . 0.0 112.335 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.516 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -141.9 153.37 44.36 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.843 176.956 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 30.5 p90 -168.48 177.64 5.19 Favored 'General case' 0 C--N 1.285 -2.221 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.55 -178.497 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' CYS . . . . . 0.474 ' HG ' ' HD2' ' A' ' 84' ' ' PRO . 1.3 t -101.62 120.65 40.66 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.246 -0.981 . . . . 0.0 109.233 179.424 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.846 ' H ' HD21 ' A' ' 38' ' ' ASN . 6.6 tt0 -65.15 -40.56 46.1 Favored Pre-proline 0 C--N 1.3 -1.548 0 N-CA-C 113.774 1.027 . . . . 0.0 113.774 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.502 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.7 Cg_endo -68.95 -52.41 0.39 Allowed 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 120.401 0.734 . . . . 0.0 111.694 -179.363 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' HIS . . . . . 0.41 ' C ' ' H ' ' A' ' 87' ' ' GLY . 30.3 m80 -79.78 13.87 1.97 Allowed 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.906 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.31 -2.26 2.1 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.317 -0.953 . . . . 0.0 110.659 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.41 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -88.01 -18.18 56.44 Favored Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.514 -1.326 . . . . 0.0 110.231 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.32 -41.09 10.05 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.631 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 133.69 15.3 1.24 Allowed Glycine 0 N--CA 1.495 2.628 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.456 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.75 100.79 0.31 Allowed 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.392 -0.923 . . . . 0.0 111.017 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.49 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 32.4 mttm -125.99 164.5 20.68 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.9 -0.72 . . . . 0.0 111.497 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -148.58 143.89 11.57 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.927 -179.33 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -149.13 146.92 27.91 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.484 -0.886 . . . . 0.0 111.131 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.601 ' O ' HG13 ' A' ' 94' ' ' VAL . 12.5 p -140.05 119.63 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.53 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 94.5 m -99.07 101.25 12.56 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.628 179.608 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.436 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 41.8 t -79.61 142.74 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 C-N-CA 118.963 -1.095 . . . . 0.0 110.444 -179.014 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 96' ' ' VAL . 81.2 m-20 . . . . . 0 C--N 1.304 -1.38 0 CA-C-O 116.335 -1.793 . . . . 0.0 110.728 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.109 0 N-CA-C 110.145 -0.316 . . . . 0.0 110.145 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 20.7 mp0 -121.78 122.0 38.5 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 120.128 -0.629 . . . . 0.0 110.652 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.8 t -106.69 119.06 55.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 C-N-CA 119.768 -0.773 . . . . 0.0 110.853 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -91.82 117.63 29.96 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 119.335 -0.946 . . . . 0.0 110.883 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.429 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 4.8 mt -84.27 106.36 15.82 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 119.264 -0.975 . . . . 0.0 110.702 179.022 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.519 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 106.75 86.64 1.89 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 2.9 p . . . . . 0 C--N 1.304 -1.37 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.389 -179.59 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.1 mt . . . . . 0 N--CA 1.488 1.449 0 CA-C-O 120.326 0.108 . . . . 0.0 110.814 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.0 m -146.73 161.38 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 118.804 -1.159 . . . . 0.0 111.427 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -78.58 113.79 16.93 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 177.377 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.1 m -116.7 107.45 46.46 Favored Pre-proline 0 CA--C 1.559 1.292 0 C-N-CA 119.39 -0.924 . . . . 0.0 111.881 -177.64 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -66.11 176.38 21.23 Favored 'Cis proline' 0 C--N 1.36 1.153 0 C-N-CA 125.227 -0.739 . . . . 0.0 111.46 -0.188 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.7 p -95.76 -48.86 5.59 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.205 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 47.9 t -137.07 137.12 38.99 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.601 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 11.3 p90 -163.3 143.68 9.02 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 118.563 -1.255 . . . . 0.0 111.528 -179.117 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.429 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -86.44 157.43 19.82 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.896 -179.889 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.3 m -146.48 146.89 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.313 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.437 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -61.45 141.58 57.58 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.697 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.75 74.21 0.07 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.184 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 154.25 18.89 0.05 OUTLIER Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.364 -1.398 . . . . 0.0 109.922 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.428 ' O ' HG23 ' A' ' 71' ' ' THR . 21.7 tt0 -103.63 157.1 17.29 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.947 -0.701 . . . . 0.0 110.8 -179.597 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 29.1 mttt -94.38 142.07 27.84 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.714 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mt -124.81 125.52 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 C-N-CA 119.992 -0.683 . . . . 0.0 109.519 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.6 p -119.68 129.33 54.5 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.528 -0.869 . . . . 0.0 112.368 -178.672 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -91.71 131.48 37.07 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.226 178.369 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.5 tptm -120.94 131.01 54.09 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 120.017 -0.673 . . . . 0.0 111.249 -178.408 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.453 ' ND2' HD11 ' A' ' 61' ' ' LEU . 0.5 OUTLIER -90.77 94.68 9.78 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.594 -0.842 . . . . 0.0 109.547 178.981 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 40.1 p-10 -91.26 -23.17 20.25 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.24 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -177.36 162.23 1.87 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 118.999 -1.08 . . . . 0.0 111.219 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.03 12.49 76.68 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.393 -1.384 . . . . 0.0 112.583 178.035 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -63.05 159.93 43.08 Favored Pre-proline 0 C--N 1.308 -1.199 0 C-N-CA 117.283 -1.767 . . . . 0.0 109.378 179.489 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -79.13 147.05 79.27 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 124.13 -1.196 . . . . 0.0 112.195 -0.712 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 40.5 m-70 -111.3 -175.43 2.7 Favored 'General case' 0 N--CA 1.495 1.805 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.377 179.146 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.623 ' ND2' ' CD2' ' A' ' 60' ' ' TYR . 2.8 t-20 -160.63 146.06 14.67 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.446 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.436 ' N ' HD12 ' A' ' 39' ' ' ILE . 3.7 mp -134.17 107.27 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.971 -179.376 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.3 t -133.48 144.17 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.849 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -97.42 118.24 33.45 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.962 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -52.28 118.52 3.59 Favored 'General case' 0 C--N 1.308 -1.202 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.281 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -76.09 47.94 0.47 Allowed 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.121 -1.032 . . . . 0.0 111.047 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -147.75 2.68 0.71 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.652 -0.819 . . . . 0.0 109.94 179.054 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -144.56 21.39 1.67 Allowed 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 119.69 -0.804 . . . . 0.0 110.614 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -104.88 148.13 35.61 Favored Pre-proline 0 N--CA 1.493 1.693 0 CA-C-N 115.45 -0.795 . . . . 0.0 109.28 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -49.66 143.12 22.97 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 120.951 1.101 . . . . 0.0 111.715 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.85 69.37 2.5 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.942 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.0 -43.27 0.1 Allowed Glycine 0 N--CA 1.49 2.238 0 C-N-CA 119.44 -1.362 . . . . 0.0 110.018 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 77.5 t -78.44 97.32 2.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.372 179.588 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -44.71 139.68 2.83 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.66 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -94.8 2.66 55.5 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.441 -179.341 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -87.72 -33.22 18.8 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.932 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.1 mmtm -76.41 -32.2 58.36 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.911 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -90.64 -16.09 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 C-N-CA 118.993 -1.083 . . . . 0.0 111.682 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.8 m -79.97 170.72 16.07 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.264 -0.974 . . . . 0.0 110.782 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.502 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -134.68 73.44 67.36 Favored Pre-proline 0 N--CA 1.487 1.393 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.523 -179.94 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -61.36 -4.26 3.99 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 121.402 1.401 . . . . 0.0 111.459 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 60' ' ' TYR . 37.8 mt-10 -99.86 100.67 11.63 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.716 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.623 ' CD2' ' ND2' ' A' ' 38' ' ' ASN . 84.7 m-85 -45.82 171.49 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.623 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.572 ' O ' HD12 ' A' ' 61' ' ' LEU . 3.2 pp -149.39 126.54 11.34 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.248 -0.981 . . . . 0.0 110.499 179.434 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -120.86 33.61 5.51 Favored 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 120.175 -0.61 . . . . 0.0 110.663 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -87.91 168.19 37.22 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.308 -1.425 . . . . 0.0 110.876 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -121.62 101.27 7.49 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.363 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.94 -7.94 55.5 Favored Glycine 0 N--CA 1.49 2.248 0 C-N-CA 119.622 -1.275 . . . . 0.0 110.063 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -71.1 157.55 38.0 Favored 'General case' 0 N--CA 1.486 1.359 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.226 179.665 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -141.69 173.27 11.66 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.27 -0.972 . . . . 0.0 112.041 -179.077 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.516 ' CD2' ' N ' ' A' ' 69' ' ' GLU . 56.7 t80 -134.66 178.23 7.17 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-N 115.498 -0.773 . . . . 0.0 109.623 178.822 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.516 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 5.1 mt-10 -145.92 149.34 34.03 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 118.912 -1.115 . . . . 0.0 112.012 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -159.04 133.87 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.659 178.57 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.428 HG23 ' O ' ' A' ' 25' ' ' GLU . 4.1 m -122.53 96.34 4.99 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 119.828 -0.749 . . . . 0.0 111.035 -179.272 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.3 mt -79.75 158.64 26.84 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.448 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.577 ' O ' HG22 ' A' ' 73' ' ' THR . 97.0 m -150.96 47.12 0.85 Allowed 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.552 -1.259 . . . . 0.0 112.362 -178.672 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.424 ' OE2' ' O ' ' A' ' 75' ' ' LYS . 5.9 tp10 -146.2 107.25 4.16 Favored 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 118.746 -1.182 . . . . 0.0 109.95 178.787 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.7 ' CD ' ' H ' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -43.36 116.32 0.91 Allowed 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.199 -0.909 . . . . 0.0 111.184 -178.972 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.6 -151.22 16.68 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.359 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.17 131.15 34.29 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.846 -0.741 . . . . 0.0 110.677 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.538 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 3.7 m-85 -118.19 121.58 40.86 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 36.8 mmtt -100.19 127.48 46.45 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.524 -0.87 . . . . 0.0 112.839 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.448 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 5.6 p90 -139.87 171.46 14.18 Favored 'General case' 0 C--N 1.312 -1.025 0 C-N-CA 119.616 -0.833 . . . . 0.0 110.433 177.673 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -170.55 -175.71 1.94 Allowed 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 119.437 -0.905 . . . . 0.0 111.178 -178.359 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' CYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.8 t -106.7 123.26 47.86 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.757 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.532 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.4 OUTLIER -64.05 -45.16 79.79 Favored Pre-proline 0 C--N 1.307 -1.253 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.466 -179.874 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.532 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.3 Cg_endo -66.93 -48.36 1.97 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.994 1.129 . . . . 0.0 112.47 -178.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' HIS . . . . . 0.468 ' C ' ' H ' ' A' ' 87' ' ' GLY . 34.4 m80 -91.69 23.19 3.68 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.152 -179.196 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.404 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -71.19 12.29 0.33 Allowed 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.893 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.468 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -107.15 -18.35 10.54 Favored Glycine 0 N--CA 1.498 2.79 0 C-N-CA 119.746 -1.216 . . . . 0.0 110.682 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -95.1 -16.11 22.88 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.232 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 108.17 17.76 10.5 Favored Glycine 0 N--CA 1.498 2.78 0 C-N-CA 119.777 -1.202 . . . . 0.0 110.242 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.7 ttt -69.99 90.78 0.65 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.215 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 15.4 ttmt -118.39 162.17 18.75 Favored 'General case' 0 N--CA 1.498 1.944 0 C-N-CA 120.045 -0.662 . . . . 0.0 111.16 -179.464 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -141.74 150.99 22.42 Favored Glycine 0 N--CA 1.495 2.608 0 C-N-CA 119.349 -1.405 . . . . 0.0 111.6 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -157.57 145.43 18.85 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.75 -0.78 . . . . 0.0 110.919 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.2 p -138.55 123.06 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.346 178.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 97.7 m -99.61 103.23 14.92 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.594 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 22.0 t -80.05 142.86 13.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 C-N-CA 118.423 -1.311 . . . . 0.0 110.46 -179.145 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.3 m120 . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 116.358 -1.782 . . . . 0.0 110.764 -179.76 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.221 0 CA-C-O 120.7 0.286 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 89.2 mt-10 -115.08 121.34 42.77 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.586 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 t -102.49 123.61 55.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.915 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 39.1 mttp -88.92 112.9 23.86 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.902 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.404 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 13.1 mt -75.82 107.43 8.0 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 118.229 -1.388 . . . . 0.0 109.4 178.104 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 102.64 130.4 6.98 Favored Glycine 0 N--CA 1.486 1.986 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -178.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.3 p . . . . . 0 C--N 1.302 -1.476 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.663 179.619 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.4 mt . . . . . 0 N--CA 1.487 1.422 0 CA-C-O 120.374 0.131 . . . . 0.0 110.827 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.2 m -150.12 153.97 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.868 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.423 ' O ' ' O ' ' A' ' 16' ' ' PRO . 69.7 m-85 -78.45 110.61 13.68 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 177.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.2 m -115.59 110.39 44.75 Favored Pre-proline 0 CA--C 1.562 1.419 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.723 -177.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.423 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.7 Cg_exo -64.79 174.7 21.0 Favored 'Cis proline' 0 C--N 1.365 1.43 0 C-N-CA 125.103 -0.79 . . . . 0.0 111.829 -0.157 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.9 t -102.82 -66.36 0.94 Allowed 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.455 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 61.6 m -119.08 131.88 55.97 Favored 'General case' 0 N--CA 1.492 1.634 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.008 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.436 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 16.7 p90 -161.23 170.94 19.28 Favored 'General case' 0 N--CA 1.487 1.391 0 C-N-CA 118.655 -1.218 . . . . 0.0 111.324 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.4 p -102.88 161.45 13.74 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.992 -0.683 . . . . 0.0 111.193 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.9 m -149.23 151.0 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.946 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.519 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -78.82 142.06 37.21 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.274 -0.971 . . . . 0.0 110.359 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.01 77.35 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.51 -0.876 . . . . 0.0 111.395 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 153.79 15.32 0.06 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.583 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -103.94 145.0 30.78 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.754 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ptpt -95.45 136.34 35.95 Favored 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.383 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.1 mt -109.16 113.79 45.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.631 179.226 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.3 p -107.3 116.47 31.98 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.775 -0.77 . . . . 0.0 112.336 -178.547 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 69.2 m-85 -85.16 118.81 24.94 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 119.526 -0.87 . . . . 0.0 109.05 178.293 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.538 ' HA ' HG22 ' A' ' 67' ' ' THR . 25.0 tttp -111.74 138.16 48.7 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.657 -0.817 . . . . 0.0 111.482 -178.802 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.533 HD22 HD11 ' A' ' 61' ' ' LEU . 0.4 OUTLIER -77.65 109.92 12.03 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.413 179.995 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.661 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.7 t-20 -96.51 -30.96 13.03 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 119.147 -1.021 . . . . 0.0 110.703 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.661 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 165.13 129.12 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.806 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 127.98 -9.01 6.75 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.687 -1.244 . . . . 0.0 110.91 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.414 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -45.92 160.64 0.28 Allowed Pre-proline 0 N--CA 1.482 1.142 0 C-N-CA 118.52 -1.272 . . . . 0.0 109.695 -179.881 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -77.3 141.55 68.84 Favored 'Cis proline' 0 C--O 1.214 -0.68 0 C-N-CA 124.139 -1.192 . . . . 0.0 112.241 0.008 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.404 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 40.6 m-70 -108.55 -177.24 3.26 Favored 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.072 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.415 ' ND2' ' CE2' ' A' ' 60' ' ' TYR . 4.7 t-20 -161.16 141.54 11.06 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.875 -0.73 . . . . 0.0 109.872 178.829 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.6 mp -129.63 124.69 59.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.438 -179.542 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -143.53 146.99 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.385 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.161 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -97.23 134.56 40.38 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.248 -0.981 . . . . 0.0 111.04 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.659 ' O ' ' N ' ' A' ' 44' ' ' ASP . 44.5 p-10 -73.1 93.81 1.85 Allowed 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.529 -0.868 . . . . 0.0 111.063 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.445 ' O ' ' CG ' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -50.45 78.84 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 O-C-N 124.063 0.852 . . . . 0.0 109.803 179.385 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.659 ' N ' ' O ' ' A' ' 42' ' ' ASP . 59.4 m-20 -157.01 -67.04 0.1 Allowed 'General case' 0 C--N 1.283 -2.3 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.682 -177.785 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -96.24 17.37 15.94 Favored 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.191 -1.003 . . . . 0.0 112.139 -177.399 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -86.07 143.96 38.12 Favored Pre-proline 0 C--N 1.291 -1.959 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.431 ' C ' ' H ' ' A' ' 49' ' ' GLY . 2.7 Cg_exo -48.81 152.21 4.68 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 120.815 1.01 . . . . 0.0 111.797 -179.252 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.68 31.15 0.36 Allowed 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.645 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.431 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -136.27 -35.34 0.21 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.5 t -96.46 93.2 3.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.986 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -45.26 144.48 1.37 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.671 179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -87.99 -29.85 20.44 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.84 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.03 -1.05 21.02 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.747 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -97.62 -35.03 10.73 Favored 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.753 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -96.2 -16.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 C-N-CA 119.404 -0.918 . . . . 0.0 111.102 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 36.7 m -68.27 170.07 9.38 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.733 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.489 ' OE1' ' CD1' ' A' ' 68' ' ' TYR . 4.1 mt-30 -137.09 73.37 51.87 Favored Pre-proline 0 N--CA 1.489 1.489 0 C-N-CA 119.811 -0.756 . . . . 0.0 110.901 -179.862 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -57.28 -27.73 76.51 Favored 'Trans proline' 0 C--N 1.322 -0.836 0 C-N-CA 121.038 1.159 . . . . 0.0 110.933 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -65.65 114.1 4.73 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.088 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.415 ' CE2' ' ND2' ' A' ' 38' ' ' ASN . 56.6 m-85 -60.72 173.26 0.77 Allowed 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 119.479 -0.888 . . . . 0.0 111.073 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.533 HD11 HD22 ' A' ' 31' ' ' ASN . 2.5 pp -149.15 144.63 26.73 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.682 -0.807 . . . . 0.0 110.158 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.547 ' ND2' ' H ' ' A' ' 63' ' ' GLY . 2.7 p-10 -128.28 -73.53 0.59 Allowed 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 119.88 -0.728 . . . . 0.0 111.72 -178.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.547 ' H ' ' ND2' ' A' ' 62' ' ' ASN . . . -24.2 127.19 0.02 OUTLIER Glycine 0 N--CA 1.511 3.642 0 O-C-N 123.993 0.808 . . . . 0.0 112.612 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.486 ' C ' ' H ' ' A' ' 66' ' ' GLU . . . -62.33 156.76 21.47 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.207 179.394 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' GLY . . . . . 0.724 ' O ' HG23 ' A' ' 67' ' ' THR . . . 71.28 -14.62 1.65 Allowed Glycine 0 N--CA 1.492 2.376 0 C-N-CA 119.109 -1.519 . . . . 0.0 110.6 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.486 ' H ' ' C ' ' A' ' 64' ' ' ALA . 12.9 tt0 -61.13 101.8 0.18 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.286 -0.966 . . . . 0.0 109.97 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.724 HG23 ' O ' ' A' ' 65' ' ' GLY . 37.4 p -106.99 162.19 14.06 Favored 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.575 -0.85 . . . . 0.0 112.225 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.489 ' CD1' ' OE1' ' A' ' 57' ' ' GLN . 29.7 t80 -136.17 143.57 44.52 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.323 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -104.84 154.6 19.84 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.589 -178.605 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -151.59 130.75 3.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.945 -1.025 . . . . 0.0 108.942 179.272 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.4 m -124.6 112.06 16.37 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.693 -0.803 . . . . 0.0 111.585 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 34.3 mt -98.61 156.85 16.6 Favored 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.772 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 11.1 p -150.93 47.98 0.85 Allowed 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 118.714 -1.194 . . . . 0.0 112.274 -179.122 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -144.49 106.29 4.3 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.781 -1.168 . . . . 0.0 110.467 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.437 ' H ' ' HD2' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -44.96 110.84 0.26 Allowed 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.913 -179.696 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.93 -148.28 10.35 Favored Glycine 0 N--CA 1.487 2.053 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.077 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.92 135.37 32.75 Favored 'General case' 0 N--CA 1.483 1.176 0 C-N-CA 119.424 -0.91 . . . . 0.0 111.095 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.569 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -124.36 159.04 31.23 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 179.565 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 12.2 mtpt -136.5 125.48 24.31 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 118.612 -1.235 . . . . 0.0 112.871 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.542 ' O ' ' N ' ' A' ' 92' ' ' GLY . 3.9 p90 -129.43 162.34 28.3 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.35 178.445 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 22.7 p90 -166.94 -179.5 4.72 Favored 'General case' 0 C--N 1.285 -2.232 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.496 -178.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' CYS . . . . . 0.502 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -107.34 112.93 25.99 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.49 -0.884 . . . . 0.0 109.573 178.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.487 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.9 OUTLIER -59.37 -42.99 95.58 Favored Pre-proline 0 C--N 1.298 -1.635 0 C-N-CA 119.471 -0.892 . . . . 0.0 112.581 -179.407 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.487 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.4 Cg_endo -66.3 -47.88 2.92 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 120.283 0.655 . . . . 0.0 111.839 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -92.82 10.1 32.42 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.447 -179.57 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -59.07 -15.8 15.71 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.559 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -77.91 -20.47 73.31 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.421 -1.371 . . . . 0.0 110.377 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.63 -9.34 47.32 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.694 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 104.54 10.78 32.57 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.67 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.51 105.05 1.72 Allowed 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 118.989 -1.085 . . . . 0.0 110.952 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.422 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 43.9 pttt -135.54 168.34 19.43 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.29 -179.545 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.04 153.0 24.93 Favored Glycine 0 N--CA 1.485 1.941 0 C-N-CA 119.372 -1.394 . . . . 0.0 111.053 -179.05 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -155.91 145.9 21.39 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.3 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.8 p -141.62 131.29 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 C-N-CA 118.955 -1.098 . . . . 0.0 110.652 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.0 m -109.46 105.15 14.38 Favored 'General case' 0 N--CA 1.493 1.722 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.825 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.4 HG12 ' N ' ' A' ' 97' ' ' ASN . 37.2 t -79.68 152.93 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 C-N-CA 118.553 -1.259 . . . . 0.0 110.526 -179.364 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.4 ' N ' HG12 ' A' ' 96' ' ' VAL . 60.9 m-20 . . . . . 0 C--N 1.307 -1.277 0 CA-C-O 116.284 -1.817 . . . . 0.0 110.932 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.127 0 N-CA-C 110.071 -0.344 . . . . 0.0 110.071 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -113.92 122.41 46.9 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 120.076 -0.649 . . . . 0.0 110.856 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.3 t -110.4 150.11 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.393 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 10.9 mtpt -124.6 117.69 24.87 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.865 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.2 mt -76.74 109.1 10.24 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.067 -1.053 . . . . 0.0 109.995 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 117.42 162.01 12.36 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.021 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.442 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 59.4 p . . . . . 0 C--N 1.302 -1.491 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.813 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.3 mt . . . . . 0 N--CA 1.485 1.287 0 CA-C-O 120.59 0.234 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.9 m -144.82 155.37 14.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 119.111 -1.035 . . . . 0.0 110.415 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.425 ' O ' ' O ' ' A' ' 16' ' ' PRO . 5.4 m-85 -78.71 111.99 15.37 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 178.311 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.3 m -114.44 108.59 49.55 Favored Pre-proline 0 C--N 1.303 -1.415 0 C-N-CA 119.734 -0.786 . . . . 0.0 112.007 -177.44 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -67.26 177.9 20.57 Favored 'Cis proline' 0 C--N 1.36 1.149 0 C-N-CA 125.35 -0.688 . . . . 0.0 111.423 -0.205 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.7 m -92.62 -47.78 6.93 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.414 -0.914 . . . . 0.0 109.996 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.63 135.42 31.69 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.756 179.279 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.479 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 13.5 p90 -153.69 146.61 24.44 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.608 -1.237 . . . . 0.0 111.545 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.44 HG23 ' H ' ' A' ' 20' ' ' THR . 0.6 OUTLIER -91.43 151.25 20.88 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.042 179.579 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.4 158.82 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.933 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.532 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -73.09 137.28 45.15 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.176 -1.01 . . . . 0.0 110.347 179.515 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -59.91 78.82 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.934 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 150.39 18.38 0.07 OUTLIER Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -96.18 158.42 15.45 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.577 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 40.5 mttm -93.5 120.29 33.59 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.093 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.9 mt -105.52 120.52 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.68 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.1 p -118.42 116.6 27.05 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.64 -0.824 . . . . 0.0 112.283 -178.563 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -87.87 120.31 29.07 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.508 -0.877 . . . . 0.0 109.022 178.336 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 13.0 ttmt -112.21 136.2 51.93 Favored 'General case' 0 N--CA 1.492 1.658 0 C-N-CA 119.697 -0.801 . . . . 0.0 111.75 -178.475 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.899 ' ND2' HD11 ' A' ' 61' ' ' LEU . 3.8 m120 -80.31 115.57 19.92 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.157 178.688 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.632 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.1 OUTLIER -100.22 -31.38 11.4 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.257 -0.977 . . . . 0.0 112.141 -178.995 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.632 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 169.02 120.74 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 C-N-CA 118.882 -1.127 . . . . 0.0 111.359 -179.75 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 131.57 -1.19 5.19 Favored Glycine 0 N--CA 1.496 2.667 0 C-N-CA 119.661 -1.257 . . . . 0.0 111.187 179.499 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -46.84 163.97 0.23 Allowed Pre-proline 0 N--CA 1.487 1.377 0 C-N-CA 118.942 -1.103 . . . . 0.0 110.028 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -75.74 143.0 75.66 Favored 'Cis proline' 0 C--O 1.212 -0.81 0 C-N-CA 124.306 -1.122 . . . . 0.0 112.45 -0.427 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 31.7 m-70 -113.92 160.72 18.48 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.769 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.535 HD21 ' HA ' ' A' ' 60' ' ' TYR . 12.7 t-20 -145.69 133.28 20.92 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 119.426 -0.909 . . . . 0.0 109.945 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.821 ' N ' HD12 ' A' ' 39' ' ' ILE . 1.7 mp -115.19 121.41 67.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 C-N-CA 119.767 -0.773 . . . . 0.0 111.405 -179.562 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.408 ' CG2' ' OD1' ' A' ' 38' ' ' ASN . 1.7 t -139.07 154.8 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.068 179.454 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -106.56 134.34 49.85 Favored 'General case' 0 N--CA 1.49 1.533 0 C-N-CA 119.287 -0.965 . . . . 0.0 112.019 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.502 ' C ' ' H ' ' A' ' 44' ' ' ASP . 4.3 t0 -74.32 107.0 6.21 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.188 -1.005 . . . . 0.0 109.179 178.654 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -69.32 33.83 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.833 -178.859 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.502 ' H ' ' C ' ' A' ' 42' ' ' ASP . 14.9 m-20 -110.23 -9.98 14.65 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.855 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -142.5 -5.8 0.93 Allowed 'General case' 0 N--CA 1.497 1.889 0 C-N-CA 118.865 -1.134 . . . . 0.0 111.634 179.609 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -69.98 146.17 94.88 Favored Pre-proline 0 C--N 1.286 -2.153 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 178.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -51.48 159.32 3.26 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.712 0.941 . . . . 0.0 112.323 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -89.17 40.4 0.98 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 119.722 -0.791 . . . . 0.0 110.374 179.776 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -143.18 -44.63 0.05 OUTLIER Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.528 ' O ' HG12 ' A' ' 50' ' ' VAL . 50.9 t -83.14 86.29 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 119.384 -0.926 . . . . 0.0 110.18 179.343 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 -45.0 139.59 3.07 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.634 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.99 -28.48 55.1 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.679 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -66.33 -15.56 63.35 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.379 -0.928 . . . . 0.0 111.13 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.95 -42.89 17.08 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.838 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -93.32 -41.59 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.212 -179.779 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 42.9 m -48.53 165.98 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.154 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.594 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.3 mt-30 -138.23 78.55 33.55 Favored Pre-proline 0 N--CA 1.487 1.412 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.561 -179.593 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -61.67 -22.91 75.51 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 121.405 1.403 . . . . 0.0 112.003 -179.068 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -76.08 119.83 20.56 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.122 -1.031 . . . . 0.0 110.585 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.535 ' HA ' HD21 ' A' ' 38' ' ' ASN . 74.2 m-85 -55.86 168.56 0.44 Allowed 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.126 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.899 HD11 ' ND2' ' A' ' 31' ' ' ASN . 0.4 OUTLIER -144.61 141.91 29.76 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.189 179.329 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.587 ' N ' HD12 ' A' ' 61' ' ' LEU . 6.2 p30 -146.51 32.7 0.96 Allowed 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.198 -179.263 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -97.26 112.26 4.43 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.482 -1.342 . . . . 0.0 110.539 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.15 111.6 1.58 Allowed 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.22 -0.992 . . . . 0.0 110.571 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.7 -12.5 66.02 Favored Glycine 0 N--CA 1.489 2.23 0 C-N-CA 119.464 -1.351 . . . . 0.0 110.203 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -63.04 151.22 40.49 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.335 -0.946 . . . . 0.0 110.302 179.689 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.73 166.72 23.88 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.214 -0.995 . . . . 0.0 111.511 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.594 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 31.6 t80 -135.83 138.32 42.41 Favored 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.524 179.246 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.402 ' CD ' ' H ' ' A' ' 69' ' ' GLU . 2.0 mp0 -98.16 152.94 18.82 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.885 -178.651 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -149.61 133.69 8.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.34 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.6 m -125.92 100.3 6.32 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.304 -179.23 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.468 ' CD1' HG11 ' A' ' 94' ' ' VAL . 54.2 mt -81.0 165.43 21.72 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.173 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.715 ' O ' HG22 ' A' ' 73' ' ' THR . 81.1 m -150.43 31.01 0.67 Allowed 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 118.608 -1.237 . . . . 0.0 112.589 -178.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.456 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 2.5 mt-10 -143.39 124.28 14.3 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 118.781 -1.168 . . . . 0.0 110.35 178.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 14.4 pttt -58.69 128.14 35.72 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.221 -0.992 . . . . 0.0 111.281 -179.271 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 156.31 174.59 26.28 Favored Glycine 0 N--CA 1.488 2.116 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.223 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.79 105.35 15.34 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.914 -0.715 . . . . 0.0 110.281 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.463 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.8 m-30 -89.58 156.54 18.54 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 118.591 -1.244 . . . . 0.0 107.981 -179.261 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 71.1 mttt -115.19 127.77 55.74 Favored 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.165 -1.014 . . . . 0.0 112.782 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.469 ' O ' ' N ' ' A' ' 92' ' ' GLY . 1.7 p90 -138.14 157.5 46.19 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.834 -0.746 . . . . 0.0 109.526 176.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 33.8 p90 -169.8 -175.23 2.03 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.523 -178.204 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -110.14 116.31 31.31 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.398 179.265 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.563 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tp10 -69.67 -39.34 11.46 Favored Pre-proline 0 C--N 1.305 -1.358 0 C-N-CA 119.518 -0.873 . . . . 0.0 112.435 -179.52 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.563 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 4.4 Cg_exo -66.17 -41.92 11.84 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 120.394 0.729 . . . . 0.0 111.268 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' HIS . . . . . 0.435 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.8 m80 -97.71 18.91 14.57 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.518 -0.873 . . . . 0.0 110.638 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.37 0.21 1.09 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.853 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -94.31 -13.38 54.3 Favored Glycine 0 N--CA 1.487 2.081 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.449 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.45 -47.55 6.81 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.377 -0.929 . . . . 0.0 110.57 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 141.27 18.22 0.35 Allowed Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.629 -1.272 . . . . 0.0 110.271 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 12.8 mtp -71.55 100.41 2.25 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.16 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.485 ' HD2' ' H ' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -129.17 148.48 51.11 Favored 'General case' 0 N--CA 1.495 1.792 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.221 179.489 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -136.29 153.78 21.7 Favored Glycine 0 N--CA 1.499 2.889 0 C-N-CA 119.508 -1.33 . . . . 0.0 112.211 -178.057 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -154.68 149.37 26.49 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 120.314 -0.555 . . . . 0.0 109.937 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.708 ' O ' HG13 ' A' ' 94' ' ' VAL . 12.2 p -139.32 114.88 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 C-N-CA 119.079 -1.048 . . . . 0.0 111.07 -179.327 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 16.0 m -89.84 93.55 9.47 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.096 -1.042 . . . . 0.0 110.616 179.8 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 14.0 t -78.77 148.31 6.23 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.617 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 17.8 p30 . . . . . 0 C--N 1.307 -1.277 0 CA-C-O 116.309 -1.805 . . . . 0.0 110.818 -179.744 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.103 0 CA-C-O 120.873 0.368 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -107.86 120.63 42.81 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 120.033 -0.667 . . . . 0.0 110.687 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.8 t -98.52 122.35 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.651 179.685 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.7 mptt -90.0 114.72 26.62 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.983 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.448 HD11 ' HB3' ' A' ' 29' ' ' PHE . 5.3 mp -80.45 100.03 8.3 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 118.572 -1.251 . . . . 0.0 109.62 178.507 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.461 ' C ' HD21 ' A' ' 32' ' ' ASN . . . 122.6 146.6 7.25 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -178.718 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.55 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 53.5 p . . . . . 0 C--N 1.302 -1.477 0 C-N-CA 119.439 -0.905 . . . . 0.0 110.709 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.0 mt . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 110.357 -0.238 . . . . 0.0 110.357 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.9 m -145.38 156.27 13.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.022 0 C-N-CA 118.996 -1.082 . . . . 0.0 111.075 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -78.59 111.54 14.77 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 178.177 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -114.5 108.34 49.8 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 119.566 -0.854 . . . . 0.0 112.232 -177.106 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -68.04 173.48 37.72 Favored 'Cis proline' 0 C--N 1.359 1.085 0 C-N-CA 125.45 -0.646 . . . . 0.0 111.503 -0.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 p -88.9 -45.22 9.87 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 119.307 -0.957 . . . . 0.0 109.76 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.76 140.5 34.81 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.55 179.114 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -162.41 147.3 12.34 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 118.356 -1.338 . . . . 0.0 111.598 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.412 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -93.24 151.71 19.64 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.275 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -146.06 169.24 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.809 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.76 146.48 28.14 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.257 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.27 71.26 0.42 Allowed 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.32 -0.952 . . . . 0.0 110.848 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 165.51 11.08 0.03 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -101.92 145.89 28.61 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.841 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.523 ' C ' HD12 ' A' ' 27' ' ' ILE . 19.1 mttm -84.97 134.87 34.23 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.288 -0.965 . . . . 0.0 110.671 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.523 HD12 ' C ' ' A' ' 26' ' ' LYS . 1.5 mp -115.94 118.31 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.679 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 36.2 p -110.6 121.51 45.49 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.471 -0.891 . . . . 0.0 113.299 -177.848 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.448 ' HB3' HD11 ' A' ' 5' ' ' LEU . 70.6 m-85 -84.88 111.12 19.37 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.051 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 45.5 tttt -109.9 131.62 54.89 Favored 'General case' 0 N--CA 1.496 1.83 0 C-N-CA 119.431 -0.907 . . . . 0.0 111.76 -177.2 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.934 ' ND2' HD11 ' A' ' 61' ' ' LEU . 7.8 m-20 -90.06 117.39 28.82 Favored 'General case' 0 C--N 1.294 -1.82 0 C-N-CA 119.335 -0.946 . . . . 0.0 111.329 -179.536 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 7' ' ' SER . 25.3 p-10 -101.01 -29.54 12.12 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.968 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.522 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 174.09 137.59 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.373 -0.931 . . . . 0.0 110.935 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.403 ' O ' ' C ' ' A' ' 35' ' ' PHE . . . 122.22 -6.99 9.98 Favored Glycine 0 N--CA 1.498 2.774 0 C-N-CA 119.524 -1.322 . . . . 0.0 111.626 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.403 ' C ' ' O ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -45.87 163.1 0.23 Allowed Pre-proline 0 N--CA 1.485 1.312 0 C-N-CA 118.423 -1.311 . . . . 0.0 109.908 -179.834 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -76.76 138.43 54.24 Favored 'Cis proline' 0 C--O 1.213 -0.734 0 C-N-CA 124.122 -1.199 . . . . 0.0 112.443 -0.585 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 32.5 m-70 -102.28 179.79 4.21 Favored 'General case' 0 N--CA 1.488 1.462 0 C-N-CA 119.751 -0.78 . . . . 0.0 111.106 179.576 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -159.56 142.11 13.76 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.782 179.293 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -135.11 117.12 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.045 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.4 t -139.25 150.24 22.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.386 179.043 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -99.3 135.08 41.24 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.856 -178.816 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.539 ' C ' ' H ' ' A' ' 44' ' ' ASP . 59.6 t0 -70.62 104.36 2.79 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.284 -0.966 . . . . 0.0 109.519 178.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.465 ' CD ' ' N ' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -68.42 27.27 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.789 -0.765 . . . . 0.0 111.785 -179.229 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.539 ' H ' ' C ' ' A' ' 42' ' ' ASP . 73.3 m-20 -111.26 -7.02 14.46 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.079 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -143.82 -1.46 0.99 Allowed 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 119.218 -0.993 . . . . 0.0 111.721 -179.666 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -68.56 144.9 96.76 Favored Pre-proline 0 C--N 1.285 -2.21 0 C-N-CA 119.269 -0.972 . . . . 0.0 108.726 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -59.08 160.5 18.61 Favored 'Trans proline' 0 C--O 1.216 -0.603 0 C-N-CA 121.062 1.175 . . . . 0.0 112.243 -178.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.63 145.16 41.29 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.567 -0.853 . . . . 0.0 109.66 178.9 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 95.26 -59.13 1.65 Allowed Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.238 -1.458 . . . . 0.0 109.849 -179.439 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.4 t -68.52 87.18 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 119.114 -1.035 . . . . 0.0 110.339 179.509 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -44.86 154.51 0.13 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.001 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.25 -25.66 16.26 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.332 179.385 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -81.4 -15.93 53.69 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.611 -0.836 . . . . 0.0 110.774 179.805 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.18 -21.61 46.16 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.568 -0.853 . . . . 0.0 111.408 -179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.5 pt -111.04 -19.22 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 C-N-CA 119.753 -0.779 . . . . 0.0 111.312 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.7 m -79.58 169.47 17.97 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.575 -0.85 . . . . 0.0 111.81 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.634 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.8 OUTLIER -150.03 73.24 9.42 Favored Pre-proline 0 C--N 1.306 -1.32 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.785 179.113 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -56.74 -26.45 65.97 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.501 1.467 . . . . 0.0 111.947 -178.574 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.35 102.82 0.08 Allowed 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 118.94 -1.104 . . . . 0.0 110.145 179.251 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -42.46 161.75 0.02 OUTLIER 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 119.581 -0.848 . . . . 0.0 111.103 -179.415 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.934 HD11 ' ND2' ' A' ' 31' ' ' ASN . 0.8 OUTLIER -143.3 147.8 35.32 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.614 -0.835 . . . . 0.0 110.459 -179.977 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.504 ' N ' HD12 ' A' ' 61' ' ' LEU . 1.1 p30 -145.01 20.99 1.6 Allowed 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.351 -0.939 . . . . 0.0 110.952 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -77.81 119.51 5.27 Favored Glycine 0 N--CA 1.487 2.034 0 C-N-CA 119.182 -1.485 . . . . 0.0 110.199 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.11 106.15 4.85 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.276 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.72 -10.72 49.35 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -68.11 154.85 40.82 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.256 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.87 170.04 16.64 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 119.133 -1.027 . . . . 0.0 111.335 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.634 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 40.7 t80 -135.24 142.49 45.98 Favored 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.487 179.412 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -113.78 151.19 32.35 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 119.404 -0.918 . . . . 0.0 112.335 -178.708 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.6 p -153.78 132.07 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.34 178.77 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.7 m -119.06 94.5 4.46 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 119.749 -0.78 . . . . 0.0 111.493 -179.153 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.5 mt -79.72 157.77 27.09 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.224 178.865 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.5 p -150.63 52.68 0.88 Allowed 'General case' 0 C--N 1.3 -1.587 0 C-N-CA 118.536 -1.266 . . . . 0.0 111.949 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.4 ' O ' ' C ' ' A' ' 75' ' ' LYS . 2.9 tt0 -150.73 99.41 2.73 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 118.73 -1.188 . . . . 0.0 109.934 178.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 74' ' ' GLU . 0.8 OUTLIER -39.87 108.96 0.1 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.255 -178.908 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.51 -148.46 8.43 Favored Glycine 0 N--CA 1.485 1.921 0 C-N-CA 119.29 -1.433 . . . . 0.0 110.302 -179.82 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -141.49 129.99 22.58 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.472 -0.891 . . . . 0.0 111.218 -179.799 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.61 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.6 OUTLIER -119.64 161.6 20.4 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.426 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 32.2 mttt -128.98 131.96 47.5 Favored 'General case' 0 N--CA 1.49 1.567 0 C-N-CA 119.187 -1.005 . . . . 0.0 111.958 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.544 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -139.25 158.75 43.62 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.829 177.712 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -167.78 -175.11 2.64 Favored 'General case' 0 C--N 1.288 -2.079 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.989 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -111.98 119.75 39.54 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.913 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.576 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.3 tt0 -65.41 -42.37 57.35 Favored Pre-proline 0 N--CA 1.486 1.326 0 C-N-CA 119.931 -0.708 . . . . 0.0 112.724 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.576 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.1 Cg_endo -69.45 -48.2 0.84 Allowed 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 121.108 1.205 . . . . 0.0 112.035 -179.381 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -90.03 10.39 24.31 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.647 -179.546 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.08 -35.45 62.09 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 118.906 -1.117 . . . . 0.0 110.475 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -62.23 -21.14 61.53 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.199 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -85.3 -17.29 37.31 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.278 179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.23 23.79 9.42 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 119.716 -1.23 . . . . 0.0 110.731 179.711 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -75.95 101.01 5.04 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.131 -1.028 . . . . 0.0 110.979 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.32 149.67 46.31 Favored 'General case' 0 N--CA 1.49 1.56 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.751 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -137.76 149.13 20.25 Favored Glycine 0 N--CA 1.496 2.655 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.352 -178.827 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -155.63 148.87 24.7 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 120.004 -0.678 . . . . 0.0 110.395 179.45 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.493 ' O ' HG13 ' A' ' 94' ' ' VAL . 7.1 p -139.08 128.99 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.81 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.9 m -104.91 98.55 8.25 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.159 179.32 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 42.4 t -79.13 150.63 5.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 118.632 -1.227 . . . . 0.0 110.453 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 89.2 m-20 . . . . . 0 N--CA 1.489 1.489 0 CA-C-O 116.333 -1.794 . . . . 0.0 110.894 -179.761 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.128 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -112.62 118.67 35.71 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 120.029 -0.668 . . . . 0.0 110.535 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 83.9 t -102.34 119.9 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.705 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 8.5 mptt -87.12 110.28 20.01 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.959 -179.617 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 11.9 mt -76.27 104.37 6.76 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.753 177.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 104.23 107.59 3.21 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.1 p . . . . . 0 C--N 1.304 -1.38 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.442 179.861 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.0 mt . . . . . 0 N--CA 1.484 1.235 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.2 m -149.71 160.41 4.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 C-N-CA 119.064 -1.054 . . . . 0.0 110.955 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.456 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 59.3 m-85 -79.02 113.11 16.88 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 176.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.9 m -114.74 110.87 46.24 Favored Pre-proline 0 N--CA 1.485 1.293 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.935 -177.707 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.44 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.9 Cg_endo -65.56 176.1 20.2 Favored 'Cis proline' 0 C--N 1.363 1.324 0 C-N-CA 125.254 -0.728 . . . . 0.0 111.751 -0.254 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.2 p -96.34 -60.86 1.53 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.467 179.617 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 60.7 p -123.74 136.69 54.59 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.752 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 p90 -163.08 146.45 10.75 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 118.583 -1.247 . . . . 0.0 111.443 -179.347 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.428 HG23 ' H ' ' A' ' 20' ' ' THR . 0.8 OUTLIER -89.62 153.49 20.71 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.445 -0.902 . . . . 0.0 111.075 179.92 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.3 m -145.87 176.46 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.641 179.79 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.03 150.79 21.29 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.589 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.12 66.85 0.87 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.997 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.45 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 166.75 11.73 0.03 OUTLIER Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.45 ' H ' ' H ' ' A' ' 24' ' ' GLY . 25.9 tt0 -97.99 155.2 17.21 Favored 'General case' 0 C--N 1.307 -1.276 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.078 -179.586 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.52 133.47 39.49 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.033 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.7 mt -115.3 114.53 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 C-N-CA 120.022 -0.671 . . . . 0.0 109.614 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 73.2 p -106.87 117.04 32.99 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.782 -0.767 . . . . 0.0 112.417 -178.501 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -84.17 107.02 16.26 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.916 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.6 ttmt -96.59 142.98 28.0 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.054 -1.058 . . . . 0.0 111.295 -177.512 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.679 ' ND2' ' CD1' ' A' ' 35' ' ' PHE . 0.2 OUTLIER -100.12 121.23 41.09 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.509 179.86 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -132.83 -8.79 3.12 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.961 -1.095 . . . . 0.0 112.13 -179.571 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -168.61 132.25 1.49 Allowed 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 117.986 -1.485 . . . . 0.0 112.711 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.79 59.99 2.87 Favored Glycine 0 N--CA 1.49 2.296 0 C-N-CA 119.868 -1.158 . . . . 0.0 113.805 177.08 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.679 ' CD1' ' ND2' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -97.06 165.12 16.42 Favored Pre-proline 0 N--CA 1.493 1.685 0 C-N-CA 118.978 -1.089 . . . . 0.0 108.382 176.86 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.5 Cg_endo -77.97 147.41 83.33 Favored 'Cis proline' 0 C--O 1.214 -0.685 0 C-N-CA 124.615 -0.994 . . . . 0.0 112.938 -0.731 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -103.0 175.21 5.55 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.299 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.523 ' ND2' ' CE1' ' A' ' 60' ' ' TYR . 22.2 t-20 -150.81 124.71 9.21 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 119.205 -0.998 . . . . 0.0 110.764 179.703 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -107.85 115.68 49.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.71 179.78 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.8 t -140.23 141.7 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.194 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.3 m-85 -99.73 122.24 42.43 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 119.457 -0.897 . . . . 0.0 111.864 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.531 ' C ' ' H ' ' A' ' 44' ' ' ASP . 0.7 OUTLIER -64.96 111.86 3.04 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.029 179.183 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -66.64 11.12 0.1 Allowed 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.134 -1.026 . . . . 0.0 111.108 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.531 ' H ' ' C ' ' A' ' 42' ' ' ASP . 50.2 m-20 -93.35 -15.35 25.82 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 119.318 -0.953 . . . . 0.0 111.185 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -141.05 50.22 1.64 Allowed 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 119.635 -0.826 . . . . 0.0 110.495 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -128.41 144.86 53.54 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.931 179.607 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -48.28 150.65 5.15 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 120.831 1.02 . . . . 0.0 111.959 -179.384 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.53 47.65 0.85 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.926 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -157.78 -44.28 0.02 OUTLIER Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.456 -1.354 . . . . 0.0 109.975 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.6 t -83.57 84.42 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.313 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -44.48 142.48 1.59 Allowed 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.841 -0.743 . . . . 0.0 111.191 -179.567 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -86.9 -9.74 54.98 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.872 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -85.78 -11.99 52.09 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.853 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.29 -36.24 12.67 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.014 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -89.91 -21.43 6.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 C-N-CA 119.253 -0.979 . . . . 0.0 111.191 -179.774 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 51.6 m -74.43 178.19 5.42 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.415 -0.914 . . . . 0.0 111.142 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.636 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.3 pm0 -159.17 77.37 3.06 Favored Pre-proline 0 C--N 1.303 -1.424 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.018 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -57.78 -0.41 0.39 Allowed 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 121.09 1.193 . . . . 0.0 111.575 -178.853 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.489 ' H ' ' C ' ' A' ' 57' ' ' GLN . 2.7 mm-40 -80.8 92.39 6.07 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.17 -1.012 . . . . 0.0 110.046 178.834 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.523 ' CE1' ' ND2' ' A' ' 38' ' ' ASN . 38.3 m-85 -41.02 162.19 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.521 -179.388 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -135.07 108.63 7.92 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.488 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -104.72 3.51 31.47 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.907 -0.717 . . . . 0.0 110.956 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -73.64 117.74 5.88 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.378 -1.391 . . . . 0.0 110.558 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -59.38 108.68 0.74 Allowed 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.638 -0.825 . . . . 0.0 111.012 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.48 -6.21 59.11 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 119.516 -1.326 . . . . 0.0 110.817 179.595 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -62.23 149.98 40.28 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 118.996 -1.081 . . . . 0.0 110.674 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -140.8 164.44 30.21 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.421 -0.912 . . . . 0.0 111.625 -179.743 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.636 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 17.5 t80 -136.05 130.16 33.06 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.343 179.482 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -94.82 154.38 17.28 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 119.124 -1.03 . . . . 0.0 112.236 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.2 t -152.62 130.97 2.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 114.952 -1.022 . . . . 0.0 108.735 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.3 m -121.04 103.35 8.97 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.68 -178.689 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 65.7 mt -86.59 158.41 19.51 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.247 -0.981 . . . . 0.0 109.751 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.03 40.94 0.73 Allowed 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 118.845 -1.142 . . . . 0.0 111.614 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -142.97 102.18 3.96 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 118.787 -1.165 . . . . 0.0 110.801 179.453 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -43.24 114.44 0.62 Allowed 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.18 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 173.04 -145.36 8.36 Favored Glycine 0 N--CA 1.486 2.0 0 C-N-CA 119.395 -1.383 . . . . 0.0 110.038 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.7 127.83 17.59 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.444 -0.902 . . . . 0.0 110.893 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.566 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -114.72 167.14 11.02 Favored 'General case' 0 N--CA 1.481 1.12 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.123 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 20.4 mmtp -134.96 123.47 23.4 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.421 -0.912 . . . . 0.0 112.338 -178.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.543 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -132.72 161.73 33.25 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.774 -0.77 . . . . 0.0 110.359 178.033 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 34.3 p90 -170.35 -174.08 1.61 Allowed 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.382 -178.754 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' CYS . . . . . 0.443 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.6 t -113.27 134.51 54.56 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.527 179.483 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.5 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.3 mt-10 -75.61 -46.16 4.21 Favored Pre-proline 0 C--N 1.308 -1.224 0 C-N-CA 119.571 -0.852 . . . . 0.0 112.927 -179.376 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -67.62 -41.97 7.66 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.901 1.067 . . . . 0.0 112.266 -179.192 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -93.99 20.71 7.49 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.447 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.443 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -74.27 -11.74 60.36 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.126 -1.03 . . . . 0.0 110.548 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -74.83 -18.48 80.11 Favored Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.345 -1.407 . . . . 0.0 110.247 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.72 -49.48 5.59 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.54 -0.864 . . . . 0.0 110.539 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 143.91 23.55 0.16 Allowed Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.467 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.7 103.54 3.1 Favored 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.052 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 6.5 mtpp -130.93 168.49 17.23 Favored 'General case' 0 N--CA 1.494 1.748 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.384 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -153.62 147.29 16.5 Favored Glycine 0 N--CA 1.493 2.492 0 C-N-CA 119.258 -1.449 . . . . 0.0 111.614 -179.068 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -152.66 146.3 25.05 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 120.004 -0.678 . . . . 0.0 109.979 179.157 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 94' ' ' VAL . 8.4 p -137.64 127.59 36.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 C-N-CA 119.1 -1.04 . . . . 0.0 111.148 -179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 48.2 m -102.0 98.14 8.39 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.346 179.097 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.48 145.63 9.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 118.726 -1.19 . . . . 0.0 110.489 -178.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 9.1 m120 . . . . . 0 C--N 1.306 -1.303 0 CA-C-O 116.337 -1.792 . . . . 0.0 110.649 -179.938 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.206 0 N-CA-C 110.148 -0.315 . . . . 0.0 110.148 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -105.16 136.48 44.59 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.829 -0.749 . . . . 0.0 110.825 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.8 t -117.87 143.7 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.931 179.679 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 13.3 mttm -113.39 107.57 16.04 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.797 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.8 mp -74.69 110.38 8.94 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 118.527 -1.269 . . . . 0.0 109.701 178.437 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.422 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.01 129.17 6.59 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 -179.217 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.3 p . . . . . 0 C--N 1.302 -1.463 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.716 -179.988 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 mt . . . . . 0 N--CA 1.486 1.338 0 CA-C-O 120.665 0.269 . . . . 0.0 110.58 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.9 m -150.03 155.72 7.61 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 119.139 -1.024 . . . . 0.0 110.996 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.414 ' O ' ' O ' ' A' ' 16' ' ' PRO . 61.2 m-85 -78.54 108.44 11.93 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 29.3 m -113.15 110.6 50.98 Favored Pre-proline 0 C--N 1.305 -1.359 0 C-N-CA 119.719 -0.792 . . . . 0.0 112.173 -177.619 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.414 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.2 Cg_endo -67.02 174.56 29.76 Favored 'Cis proline' 0 C--N 1.36 1.137 0 C-N-CA 125.337 -0.693 . . . . 0.0 111.626 -0.215 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.13 -66.06 0.94 Allowed 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 119.494 -0.883 . . . . 0.0 109.985 179.079 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.6 t -114.92 132.53 56.52 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.42 178.89 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.448 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 11.1 p90 -157.25 137.8 13.04 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 118.596 -1.242 . . . . 0.0 111.227 -179.137 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.452 HG23 ' H ' ' A' ' 20' ' ' THR . 0.6 OUTLIER -82.28 161.79 22.52 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.184 -1.006 . . . . 0.0 111.082 -179.935 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.3 m -148.97 162.49 4.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.098 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.457 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -77.05 142.6 39.78 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.872 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.11 76.76 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.066 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.85 19.77 0.1 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -102.74 162.39 12.97 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.793 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -95.59 150.85 19.89 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.529 -0.869 . . . . 0.0 111.371 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.8 mm -124.26 103.4 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.002 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.3 p -100.58 114.08 27.45 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.536 -0.866 . . . . 0.0 112.745 -178.205 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -83.8 122.32 28.52 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 177.688 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.3 tttp -121.34 121.56 37.91 Favored 'General case' 0 N--CA 1.502 2.129 0 C-N-CA 119.396 -0.922 . . . . 0.0 112.104 -177.732 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 0.6 OUTLIER -69.94 113.13 6.87 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.737 179.551 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.487 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.9 t30 -100.34 -27.87 13.25 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.685 -179.282 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.487 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 175.85 141.33 0.06 Allowed 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 119.256 -0.978 . . . . 0.0 111.122 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 103.2 0.12 47.52 Favored Glycine 0 N--CA 1.494 2.505 0 C-N-CA 119.428 -1.368 . . . . 0.0 112.194 178.626 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -48.16 162.66 0.32 Allowed Pre-proline 0 N--CA 1.487 1.386 0 C-N-CA 118.013 -1.475 . . . . 0.0 109.614 179.766 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -78.59 154.06 91.76 Favored 'Cis proline' 0 C--O 1.215 -0.635 0 C-N-CA 124.354 -1.102 . . . . 0.0 112.288 -0.548 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 43.8 m-70 -115.62 -177.02 3.05 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.016 178.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -159.75 108.54 1.78 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.41 178.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.2 mp -91.65 121.35 42.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.011 -1.076 . . . . 0.0 111.906 -179.103 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.2 t -134.76 142.37 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.716 179.099 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -99.48 123.82 44.09 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.309 -0.956 . . . . 0.0 111.577 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.513 ' C ' ' H ' ' A' ' 44' ' ' ASP . 10.5 t0 -68.75 112.0 5.2 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.911 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -72.67 25.46 0.06 Allowed 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.546 -0.861 . . . . 0.0 111.132 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.513 ' H ' ' C ' ' A' ' 42' ' ' ASP . 32.0 m-20 -108.56 -7.9 15.61 Favored 'General case' 0 N--CA 1.49 1.557 0 C-N-CA 119.888 -0.725 . . . . 0.0 110.812 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -142.75 13.4 1.91 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.706 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -93.05 144.37 28.27 Favored Pre-proline 0 C--N 1.298 -1.658 0 C-N-CA 119.559 -0.856 . . . . 0.0 109.693 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -49.15 148.52 9.78 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.931 1.087 . . . . 0.0 112.09 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.79 74.91 5.31 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 119.651 -0.82 . . . . 0.0 110.49 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.66 -51.12 0.19 Allowed Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 84.4 t -72.3 87.09 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.006 179.088 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -44.47 139.23 2.86 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.77 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -91.14 -16.05 28.41 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.878 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -81.13 -11.74 59.4 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.699 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.9 mtmt -91.89 -27.3 18.01 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.299 -0.96 . . . . 0.0 111.071 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.2 pt -92.31 -30.44 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 C-N-CA 119.149 -1.02 . . . . 0.0 110.727 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.1 m -71.07 167.58 18.96 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.095 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.609 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -136.17 81.1 39.14 Favored Pre-proline 0 C--N 1.302 -1.46 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.567 179.285 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_exo -56.05 -16.34 16.34 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 121.317 1.345 . . . . 0.0 112.114 -178.315 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.414 ' O ' ' O ' ' A' ' 60' ' ' TYR . 9.6 mt-10 -73.24 103.32 3.91 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.001 179.157 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.414 ' O ' ' O ' ' A' ' 59' ' ' GLU . 83.6 m-85 -43.71 168.39 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 119.6 -0.84 . . . . 0.0 111.148 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.1 pp -147.53 139.17 23.96 Favored 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.379 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -141.15 28.86 1.86 Allowed 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.843 -179.354 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -92.11 115.24 4.74 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.203 -1.475 . . . . 0.0 110.614 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.37 110.33 1.22 Allowed 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.857 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 98.74 -13.02 62.7 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.521 -1.323 . . . . 0.0 110.414 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 38.9 tt0 -62.65 148.95 44.8 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.246 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.11 164.81 29.16 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.244 -0.982 . . . . 0.0 111.371 -179.643 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.609 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 36.9 t80 -135.53 133.16 38.13 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 120.011 -0.676 . . . . 0.0 109.492 179.566 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -94.83 152.88 18.03 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.184 -178.743 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 t -150.59 135.38 9.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.267 179.362 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.5 m -127.65 102.4 6.81 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.417 -0.913 . . . . 0.0 112.254 -178.459 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 19.9 mt -89.47 155.81 19.06 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.184 -1.006 . . . . 0.0 109.02 178.37 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.63 ' O ' HG22 ' A' ' 73' ' ' THR . 67.2 m -150.94 47.81 0.85 Allowed 'General case' 0 C--N 1.293 -1.854 0 C-N-CA 118.878 -1.129 . . . . 0.0 111.79 -179.05 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.425 ' OE2' ' N ' ' A' ' 75' ' ' LYS . 5.2 tp10 -145.91 103.07 3.72 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 118.95 -1.1 . . . . 0.0 110.017 179.204 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.425 ' N ' ' OE2' ' A' ' 74' ' ' GLU . 0.0 OUTLIER -40.69 114.19 0.44 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.49 -179.25 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 170.93 -148.93 11.72 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.169 -1.491 . . . . 0.0 110.372 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -140.32 133.07 28.99 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.926 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.589 ' N ' ' CD1' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -119.41 154.3 33.89 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.477 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 15.2 mmtm -126.01 128.41 47.41 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.239 -0.985 . . . . 0.0 112.113 -178.803 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.556 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -137.23 165.44 26.11 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.063 -0.972 . . . . 0.0 110.357 178.463 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.9 p90 -170.58 -175.72 1.93 Allowed 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 119.724 -0.791 . . . . 0.0 110.277 -178.386 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.2 t -110.38 126.77 54.63 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.498 -0.881 . . . . 0.0 109.95 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.547 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 3.9 tm-20 -73.17 -36.72 3.39 Favored Pre-proline 0 N--CA 1.486 1.366 0 C-N-CA 119.181 -1.008 . . . . 0.0 113.689 -178.462 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.547 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -70.66 -52.39 0.26 Allowed 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 120.527 0.818 . . . . 0.0 110.998 179.701 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -80.25 12.82 2.67 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.759 -0.776 . . . . 0.0 110.791 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.45 -13.43 8.71 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.53 -0.868 . . . . 0.0 110.862 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.26 -18.19 79.45 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.277 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.28 -32.19 13.75 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.921 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.53 8.35 9.21 Favored Glycine 0 N--CA 1.497 2.711 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -50.27 105.26 0.09 Allowed 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.951 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.6 pttp -129.53 160.69 32.43 Favored 'General case' 0 N--CA 1.497 1.883 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.329 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.22 152.21 24.1 Favored Glycine 0 N--CA 1.497 2.742 0 C-N-CA 119.458 -1.354 . . . . 0.0 111.372 -178.652 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 72.1 tt0 -154.25 148.69 26.16 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.654 -0.818 . . . . 0.0 110.83 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.499 HG13 ' O ' ' A' ' 94' ' ' VAL . 10.8 p -140.04 125.63 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 C-N-CA 119.205 -0.998 . . . . 0.0 110.449 179.389 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 41.4 m -102.89 99.82 9.76 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.459 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 43.3 t -79.22 147.11 6.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 C-N-CA 118.558 -1.257 . . . . 0.0 110.597 -178.788 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.401 ' OD1' ' N ' ' A' ' 97' ' ' ASN . 12.0 p-10 . . . . . 0 C--N 1.305 -1.338 0 CA-C-O 116.275 -1.822 . . . . 0.0 110.787 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 CA-C-O 120.783 0.325 . . . . 0.0 110.169 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -133.14 130.27 38.98 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 120.021 -0.672 . . . . 0.0 110.575 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.1 t -125.55 126.76 70.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.974 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 21.7 mttm -99.83 119.37 38.08 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.985 -179.64 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.442 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 77.8 mt -79.35 104.01 9.67 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.142 178.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.437 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 116.31 138.35 6.3 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -178.63 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 58.2 p . . . . . 0 C--N 1.304 -1.403 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.073 -179.627 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 28.1 mt . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 110.426 -0.213 . . . . 0.0 110.426 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.6 m -150.07 155.85 7.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 C-N-CA 118.807 -1.157 . . . . 0.0 111.109 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 18.6 m-85 -78.37 112.1 15.05 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.45 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.8 m -116.17 107.96 46.74 Favored Pre-proline 0 CA--C 1.56 1.354 0 C-N-CA 119.496 -0.882 . . . . 0.0 111.968 -177.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.405 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.3 Cg_endo -65.91 175.53 22.77 Favored 'Cis proline' 0 C--N 1.362 1.268 0 C-N-CA 125.221 -0.741 . . . . 0.0 111.448 0.119 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.01 -45.82 6.12 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.65 -0.82 . . . . 0.0 110.056 179.415 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -137.66 135.18 36.27 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.525 179.29 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 18.4 p90 -161.5 143.76 11.91 Favored 'General case' 0 N--CA 1.485 1.285 0 C-N-CA 118.577 -1.249 . . . . 0.0 111.497 -179.093 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.3 p -87.27 156.55 19.59 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.331 -0.948 . . . . 0.0 110.957 179.77 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.8 m -148.61 173.12 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.896 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.416 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -88.8 149.43 23.42 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.415 179.635 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.8 74.32 0.1 Allowed 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.981 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 156.08 16.42 0.04 OUTLIER Glycine 0 N--CA 1.488 2.16 0 C-N-CA 119.562 -1.304 . . . . 0.0 109.983 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -95.52 151.26 19.47 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.914 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ptmt -95.34 123.58 38.94 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.527 -0.869 . . . . 0.0 111.114 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.0 mt -101.86 108.07 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.696 179.6 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 p -104.48 112.42 25.47 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.653 -0.819 . . . . 0.0 112.572 -178.287 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -84.83 116.74 23.46 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.142 178.413 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.1 ttpt -113.1 126.31 55.32 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.389 -178.036 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -68.11 113.97 6.22 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.737 178.648 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.645 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 2.4 p-10 -107.31 -22.3 12.64 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 119.171 -1.011 . . . . 0.0 111.15 179.552 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.645 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 169.38 114.46 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 118.926 -1.11 . . . . 0.0 111.113 179.511 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 129.15 7.73 3.93 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.124 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.514 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -57.68 161.63 6.01 Favored Pre-proline 0 C--N 1.306 -1.292 0 C-N-CA 118.521 -1.272 . . . . 0.0 109.95 -179.947 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -80.01 152.68 85.23 Favored 'Cis proline' 0 C--O 1.213 -0.731 0 C-N-CA 124.037 -1.235 . . . . 0.0 112.326 -1.079 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 45.1 m-70 -113.06 165.19 12.6 Favored 'General case' 0 N--CA 1.493 1.722 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.246 178.811 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 20.5 t30 -149.6 99.76 2.91 Favored 'General case' 0 N--CA 1.49 1.549 0 C-N-CA 118.974 -1.09 . . . . 0.0 110.783 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.8 mp -84.95 135.65 24.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 119.279 -0.969 . . . . 0.0 111.472 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -143.55 143.56 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.004 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.682 ' CD2' HD12 ' A' ' 55' ' ' ILE . 27.5 m-85 -101.56 123.0 44.88 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.539 -0.864 . . . . 0.0 111.702 -179.396 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -66.33 118.06 9.46 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 119.404 -0.918 . . . . 0.0 109.994 179.319 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.589 ' H ' ' CD ' ' A' ' 43' ' ' GLU . 1.5 pm0 -71.32 -6.65 41.55 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 119.454 -0.898 . . . . 0.0 112.211 -178.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -95.58 5.89 50.35 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.174 -1.01 . . . . 0.0 111.574 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -143.22 16.67 1.89 Allowed 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.702 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -105.19 151.64 39.61 Favored Pre-proline 0 N--CA 1.489 1.481 0 CA-C-N 115.241 -0.89 . . . . 0.0 108.635 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -46.37 151.04 1.9 Allowed 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 121.173 1.249 . . . . 0.0 112.131 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.93 72.12 6.67 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.859 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.58 -35.39 0.14 Allowed Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.548 -1.31 . . . . 0.0 110.054 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 72.8 t -90.34 95.24 5.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.612 179.661 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 66.0 m-20 -50.15 152.9 1.57 Allowed 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.167 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.478 ' C ' ' H ' ' A' ' 54' ' ' LYS . . . -83.09 -38.25 22.74 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.468 179.641 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -63.69 0.52 0.77 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.387 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.478 ' H ' ' C ' ' A' ' 52' ' ' ALA . 0.0 OUTLIER -91.36 -45.68 8.45 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.583 179.973 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.682 HD12 ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -94.46 -25.35 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.875 179.927 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 37.3 m -48.74 164.63 0.06 Allowed 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.503 -0.879 . . . . 0.0 110.902 179.695 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.481 ' OE1' ' CD1' ' A' ' 68' ' ' TYR . 5.5 mt-30 -138.05 73.96 44.26 Favored Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 120.021 -0.671 . . . . 0.0 110.845 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -61.46 -25.6 80.01 Favored 'Trans proline' 0 C--N 1.324 -0.721 0 C-N-CA 121.301 1.334 . . . . 0.0 111.325 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -68.28 97.76 0.76 Allowed 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.421 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 47.5 m-85 -48.19 162.89 0.07 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.509 -0.877 . . . . 0.0 111.219 -179.7 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -142.22 106.32 4.76 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.751 179.631 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -114.23 21.45 14.69 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.075 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -90.85 118.64 5.42 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.281 -1.438 . . . . 0.0 110.525 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -58.42 111.35 1.2 Allowed 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.63 179.671 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.82 -13.35 57.76 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.732 -1.223 . . . . 0.0 110.407 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -60.81 148.04 40.58 Favored 'General case' 0 N--CA 1.487 1.402 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.456 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 2.3 p -145.83 165.4 28.99 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.275 -0.97 . . . . 0.0 111.3 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.481 ' CD1' ' OE1' ' A' ' 57' ' ' GLN . 38.3 t80 -136.15 146.99 47.51 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.868 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.443 ' H ' ' CD ' ' A' ' 69' ' ' GLU . 2.1 mp0 -106.88 154.1 21.54 Favored 'General case' 0 N--CA 1.496 1.874 0 C-N-CA 119.431 -0.908 . . . . 0.0 112.164 -179.053 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -151.18 134.23 7.02 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.137 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 12.5 m -129.44 114.24 15.9 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.735 -0.786 . . . . 0.0 111.125 -179.549 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.49 ' CD1' HG11 ' A' ' 94' ' ' VAL . 17.1 mt -97.6 163.44 12.84 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.696 -0.802 . . . . 0.0 110.079 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.597 ' O ' HG22 ' A' ' 73' ' ' THR . 62.3 m -150.38 51.95 0.89 Allowed 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 118.939 -1.104 . . . . 0.0 111.468 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -152.72 105.8 3.01 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 118.916 -1.114 . . . . 0.0 110.658 179.533 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -48.85 110.43 0.35 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.958 -1.097 . . . . 0.0 110.609 -179.695 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.39 -142.66 6.29 Favored Glycine 0 N--CA 1.488 2.139 0 C-N-CA 119.218 -1.468 . . . . 0.0 110.078 -179.622 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.408 HG23 HG23 ' A' ' 95' ' ' THR . 0.0 OUTLIER -143.58 129.25 19.23 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.357 -0.937 . . . . 0.0 111.114 -179.845 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.568 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -116.03 122.86 46.45 Favored 'General case' 0 N--CA 1.484 1.236 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.535 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.425 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -95.04 113.99 25.75 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.992 -178.843 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.555 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -122.83 165.39 16.71 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.608 178.307 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 30.9 p90 -170.78 -177.62 2.34 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.971 -178.596 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -110.28 113.27 25.81 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.462 178.483 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.541 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.8 tt0 -65.79 -39.75 33.86 Favored Pre-proline 0 C--N 1.303 -1.427 0 C-N-CA 119.416 -0.914 . . . . 0.0 112.891 -178.735 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.541 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.5 Cg_endo -68.53 -50.39 0.68 Allowed 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 120.499 0.8 . . . . 0.0 111.804 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -83.26 15.8 2.76 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.998 -179.579 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.97 -1.97 4.73 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.636 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -72.4 -27.46 69.68 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.307 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.77 -50.48 5.13 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.561 -0.856 . . . . 0.0 110.456 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.84 30.67 0.12 Allowed Glycine 0 N--CA 1.486 1.987 0 C-N-CA 119.618 -1.277 . . . . 0.0 110.492 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 2.5 mtp -72.17 97.65 1.99 Allowed 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.149 -1.02 . . . . 0.0 111.02 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.481 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -122.76 168.06 12.7 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.66 179.688 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -150.53 146.33 15.25 Favored Glycine 0 N--CA 1.487 2.082 0 C-N-CA 118.883 -1.627 . . . . 0.0 111.563 -178.658 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -149.51 140.87 23.23 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 119.808 -0.757 . . . . 0.0 110.535 179.346 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.572 ' O ' HG13 ' A' ' 94' ' ' VAL . 14.4 p -131.96 120.57 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.729 179.484 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.408 HG23 HG23 ' A' ' 77' ' ' THR . 6.6 m -94.92 96.97 9.66 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.23 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.6 t -79.98 153.01 4.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.639 -178.681 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.307 -1.251 0 CA-C-O 116.349 -1.786 . . . . 0.0 110.775 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.138 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 -103.74 152.43 21.86 Favored 'General case' 0 N--CA 1.49 1.525 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.856 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.3 t -134.03 145.72 32.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 C-N-CA 119.718 -0.793 . . . . 0.0 110.591 179.499 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -114.74 109.15 17.76 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 115.118 -0.947 . . . . 0.0 110.609 -179.502 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.438 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 3.9 mt -78.9 106.49 10.96 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.131 -1.027 . . . . 0.0 109.848 179.044 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.427 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 115.29 138.18 6.48 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -178.609 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.437 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 32.1 p . . . . . 0 C--N 1.302 -1.458 0 C-N-CA 119.363 -0.935 . . . . 0.0 111.383 -179.411 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.7 mt . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.9 m -139.73 161.45 26.8 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 C-N-CA 119.376 -0.929 . . . . 0.0 111.501 -178.739 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.422 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 22.4 m-85 -78.41 110.46 13.48 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 177.793 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 5.6 m -115.67 106.32 50.42 Favored Pre-proline 0 N--CA 1.486 1.348 0 C-N-CA 119.775 -0.77 . . . . 0.0 111.315 -178.52 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.402 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.7 Cg_endo -66.78 174.61 28.67 Favored 'Cis proline' 0 C--N 1.356 0.94 0 C-N-CA 125.326 -0.698 . . . . 0.0 112.075 0.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -93.3 -55.05 3.45 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.885 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 69.8 m -125.15 140.36 52.94 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.541 179.022 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.438 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 10.4 p90 -156.69 132.06 9.28 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 118.649 -1.22 . . . . 0.0 111.397 -179.315 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.5 p -87.86 152.58 21.98 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.081 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.4 m -147.0 176.13 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.865 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -90.14 155.89 18.73 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.506 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.49 61.21 0.68 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.565 -0.854 . . . . 0.0 111.296 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 170.77 11.91 0.02 OUTLIER Glycine 0 N--CA 1.489 2.216 0 C-N-CA 119.569 -1.3 . . . . 0.0 109.91 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.408 ' OE1' ' O ' ' A' ' 26' ' ' LYS . 5.7 tm-20 -104.61 123.37 47.44 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.969 -0.693 . . . . 0.0 110.831 -179.636 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.408 ' O ' ' OE1' ' A' ' 25' ' ' GLU . 1.3 pttp -69.73 150.31 47.07 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.25 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mt -122.86 147.45 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.528 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.2 p -139.22 117.56 11.99 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.218 -0.993 . . . . 0.0 111.626 -179.321 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -84.28 150.58 25.32 Favored 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 119.267 -0.973 . . . . 0.0 109.796 179.058 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -144.55 138.72 27.69 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 118.999 -1.08 . . . . 0.0 111.707 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.651 HD21 ' CB ' ' A' ' 66' ' ' GLU . 0.5 OUTLIER -85.31 131.27 34.44 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.423 178.839 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.465 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 5.6 p-10 -111.56 -32.38 6.7 Favored 'General case' 0 N--CA 1.505 2.281 0 C-N-CA 119.107 -1.037 . . . . 0.0 112.587 -179.631 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.465 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 176.42 30.48 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 118.941 -1.104 . . . . 0.0 110.819 -179.433 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.493 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -138.78 40.3 1.47 Allowed Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.229 -1.462 . . . . 0.0 111.233 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.596 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -86.2 161.58 48.82 Favored Pre-proline 0 C--N 1.309 -1.194 0 C-N-CA 118.442 -1.303 . . . . 0.0 109.999 179.226 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -78.65 135.82 38.54 Favored 'Cis proline' 0 C--O 1.215 -0.649 0 C-N-CA 124.075 -1.219 . . . . 0.0 111.568 -0.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.493 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 40.4 m-70 -100.21 -177.1 3.42 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.749 179.589 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.619 ' ND2' ' N ' ' A' ' 39' ' ' ILE . 1.7 t-20 -161.11 146.86 14.36 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.3 -0.96 . . . . 0.0 110.916 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.619 ' N ' ' ND2' ' A' ' 38' ' ' ASN . 3.5 mt -131.0 114.91 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.779 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.478 ' CG2' HD21 ' A' ' 38' ' ' ASN . 3.0 t -137.15 137.24 46.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.124 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 44.1 m-85 -93.67 127.63 39.46 Favored 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.236 -0.986 . . . . 0.0 111.413 -179.602 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.4 125.77 25.28 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.895 179.526 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -57.47 -49.94 74.64 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 -177.143 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -85.21 8.23 19.11 Favored 'General case' 0 N--CA 1.498 1.936 0 C-N-CA 118.941 -1.104 . . . . 0.0 113.855 -176.901 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -126.86 40.35 3.74 Favored 'General case' 0 N--CA 1.495 1.781 0 C-N-CA 119.341 -0.944 . . . . 0.0 110.568 179.347 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.657 HG22 ' HD2' ' A' ' 47' ' ' PRO . 0.5 OUTLIER -135.59 156.33 77.7 Favored Pre-proline 0 N--CA 1.487 1.399 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 179.279 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.657 ' HD2' HG22 ' A' ' 46' ' ' VAL . 3.6 Cg_exo -48.04 148.06 7.24 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 120.916 1.077 . . . . 0.0 111.73 -179.583 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.57 70.37 6.03 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.644 -0.822 . . . . 0.0 111.035 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.37 -22.78 0.09 OUTLIER Glycine 0 N--CA 1.489 2.211 0 C-N-CA 119.342 -1.409 . . . . 0.0 110.435 179.808 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 44.6 t -97.42 99.78 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.809 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -46.75 149.66 0.81 Allowed 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.256 -0.978 . . . . 0.0 110.715 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.409 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -94.64 -5.69 45.09 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.623 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -86.14 -29.6 23.16 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.107 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 21.4 mmtt -71.87 -27.55 62.94 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.463 -0.895 . . . . 0.0 111.481 -179.296 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 10.7 pt -105.15 -14.95 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 C-N-CA 119.559 -0.857 . . . . 0.0 111.944 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.409 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 4.7 m -67.32 173.62 3.83 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.241 -0.983 . . . . 0.0 110.827 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.508 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 28.8 tt0 -136.93 76.01 47.14 Favored Pre-proline 0 C--N 1.306 -1.321 0 C-N-CA 120.072 -0.651 . . . . 0.0 110.354 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -60.02 -22.33 68.85 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 121.359 1.373 . . . . 0.0 111.985 -178.731 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 38.8 mm-40 -89.89 106.83 18.74 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.139 -1.024 . . . . 0.0 110.652 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 30.9 m-85 -56.37 170.5 0.35 Allowed 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.728 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.432 HD23 ' NE2' ' A' ' 57' ' ' GLN . 2.5 pp -140.26 129.48 23.75 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.098 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -127.68 10.33 6.59 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.521 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.48 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . -77.85 118.78 5.08 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.412 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.9 105.12 0.52 Allowed 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.759 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.24 -2.77 43.66 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.559 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.651 ' CB ' HD21 ' A' ' 31' ' ' ASN . 2.8 tp10 -63.16 161.14 14.05 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 118.916 -1.113 . . . . 0.0 110.229 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 66.8 p -147.45 163.14 37.45 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.556 -179.138 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.508 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 76.0 t80 -135.62 139.14 43.57 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.751 179.05 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -107.59 153.17 23.27 Favored 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 119.513 -0.875 . . . . 0.0 112.577 -178.477 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 p -161.51 132.9 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.391 178.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.8 m -119.81 95.6 4.84 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.733 -178.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 12.2 mt -80.46 158.49 25.88 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.384 -0.926 . . . . 0.0 109.226 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.0 p -151.14 28.44 0.67 Allowed 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 118.65 -1.22 . . . . 0.0 112.253 -179.02 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.506 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -114.5 97.75 6.49 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.024 179.599 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.8 tttt -41.68 98.0 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.958 -179.674 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 74' ' ' GLU . . . 177.56 -134.17 2.4 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.176 -1.488 . . . . 0.0 110.257 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -145.31 142.0 29.05 Favored 'General case' 0 C--N 1.309 -1.165 0 C-N-CA 119.216 -0.994 . . . . 0.0 111.519 -179.683 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.574 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.2 m-85 -128.05 128.31 44.72 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.386 -0.825 . . . . 0.0 108.779 179.359 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -105.77 118.97 37.96 Favored 'General case' 0 N--CA 1.488 1.453 0 C-N-CA 119.243 -0.983 . . . . 0.0 111.318 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -124.31 172.91 8.73 Favored 'General case' 0 C--O 1.206 -1.205 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.56 178.532 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -171.06 175.3 4.39 Favored 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 118.932 -1.107 . . . . 0.0 111.577 -178.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.4 t -99.66 127.06 45.77 Favored 'General case' 0 C--N 1.3 -1.587 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.287 179.494 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.593 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 3.2 tm-20 -73.88 -34.95 2.25 Favored Pre-proline 0 N--CA 1.492 1.661 0 C-N-CA 118.85 -1.14 . . . . 0.0 113.667 -178.498 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.1 Cg_endo -72.68 -52.31 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 120.671 0.914 . . . . 0.0 110.99 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 34.4 m80 -81.39 14.72 2.32 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.879 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -62.89 -6.19 3.56 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.187 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.31 -21.43 62.5 Favored Glycine 0 N--CA 1.49 2.267 0 C-N-CA 119.339 -1.41 . . . . 0.0 110.307 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.73 -22.36 18.15 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.956 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.426 ' O ' ' N ' ' A' ' 91' ' ' LYS . . . 109.27 11.82 21.15 Favored Glycine 0 N--CA 1.497 2.754 0 C-N-CA 119.964 -1.112 . . . . 0.0 110.364 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 6.1 ttt -53.9 92.62 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.474 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.53 ' CB ' ' NZ ' ' A' ' 91' ' ' LYS . 0.1 OUTLIER -117.1 158.73 23.7 Favored 'General case' 0 N--CA 1.5 2.039 0 C-N-CA 119.855 -0.738 . . . . 0.0 111.386 -179.73 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.23 146.53 18.45 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.027 -1.082 . . . . 0.0 111.052 -178.676 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -148.85 147.1 28.32 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.842 179.707 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 94' ' ' VAL . 7.4 p -140.05 129.89 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.195 179.131 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 90.4 m -106.09 100.78 10.31 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.656 -0.818 . . . . 0.0 110.964 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 47.1 t -82.48 142.99 12.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.364 -179.071 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.436 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 0.9 OUTLIER . . . . . 0 C--N 1.307 -1.253 0 CA-C-O 116.328 -1.796 . . . . 0.0 110.952 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.905 0.383 . . . . 0.0 110.036 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -92.7 131.46 37.76 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.404 -0.918 . . . . 0.0 110.562 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 t -122.29 121.72 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.404 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.58 118.83 31.86 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.186 179.46 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.8 mt -78.54 98.83 6.26 Favored 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.9 179.019 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.464 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 113.59 131.6 5.39 Favored Glycine 0 N--CA 1.488 2.151 0 CA-C-N 114.546 -1.206 . . . . 0.0 110.323 -179.135 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 56.3 p . . . . . 0 C--N 1.302 -1.48 0 C-N-CA 119.299 -0.96 . . . . 0.0 110.548 179.578 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.7 mt . . . . . 0 N--CA 1.492 1.625 0 CA-C-O 120.471 0.177 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.0 m -150.39 157.06 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 118.979 -1.088 . . . . 0.0 110.954 179.45 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.419 ' O ' ' O ' ' A' ' 16' ' ' PRO . 62.2 m-85 -78.27 110.83 13.63 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 16.5 m -114.2 111.62 47.28 Favored Pre-proline 0 CA--C 1.56 1.341 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.948 -177.459 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.419 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.3 Cg_exo -65.83 174.18 26.4 Favored 'Cis proline' 0 C--N 1.36 1.158 0 C-N-CA 125.105 -0.79 . . . . 0.0 111.611 -0.343 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.9 m -97.45 -65.87 0.94 Allowed 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.098 179.256 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 m -114.39 137.68 51.51 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.734 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 34.5 p90 -168.2 147.4 4.58 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 118.49 -1.284 . . . . 0.0 111.656 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.672 HG22 ' HB ' ' A' ' 95' ' ' THR . 44.2 p -83.31 161.55 21.4 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.193 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 31.5 m -149.32 148.72 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.228 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.662 179.541 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.539 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -76.51 140.74 41.29 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.294 -0.962 . . . . 0.0 110.751 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -58.78 78.39 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.242 0 C-N-CA 119.657 -0.817 . . . . 0.0 110.937 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 148.21 21.22 0.09 OUTLIER Glycine 0 N--CA 1.487 2.071 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -102.56 150.34 23.5 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.924 -0.71 . . . . 0.0 110.733 -179.718 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 74.9 mttt -95.2 117.69 30.69 Favored 'General case' 0 C--N 1.303 -1.434 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.055 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.5 mt -93.22 98.35 8.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 119.501 -0.88 . . . . 0.0 108.962 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 55.0 p -94.34 117.43 30.11 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 119.493 -0.883 . . . . 0.0 112.821 -177.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -84.68 143.62 29.08 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.049 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 11.4 ttpt -135.3 125.55 26.33 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.387 -178.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.525 ' OD1' ' CD1' ' A' ' 35' ' ' PHE . 36.5 t-20 -79.39 115.8 19.24 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 119.792 -0.763 . . . . 0.0 110.009 179.354 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.464 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 3.0 p-10 -120.29 -22.23 6.63 Favored 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.307 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -177.45 123.43 0.13 Allowed 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 118.358 -1.337 . . . . 0.0 112.188 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 104.17 48.6 1.13 Allowed Glycine 0 N--CA 1.495 2.618 0 C-N-CA 119.272 -1.442 . . . . 0.0 112.849 177.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.623 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -87.54 164.83 33.39 Favored Pre-proline 0 C--N 1.304 -1.37 0 C-N-CA 118.573 -1.251 . . . . 0.0 108.936 177.91 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -77.2 140.13 62.6 Favored 'Cis proline' 0 C--O 1.215 -0.642 0 C-N-CA 124.555 -1.019 . . . . 0.0 112.917 -0.5 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 33.6 m-70 -108.15 161.28 15.12 Favored 'General case' 0 N--CA 1.495 1.794 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.952 178.607 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.763 HD21 ' H ' ' A' ' 83' ' ' GLU . 4.0 p-10 -153.52 163.18 40.4 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 119.049 -1.061 . . . . 0.0 110.684 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -133.78 124.35 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.841 -0.743 . . . . 0.0 110.758 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.7 t -137.48 141.31 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.264 179.74 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.485 ' CE2' HD12 ' A' ' 55' ' ' ILE . 5.6 m-85 -96.39 130.75 43.45 Favored 'General case' 0 C--N 1.303 -1.455 0 C-N-CA 119.574 -0.85 . . . . 0.0 111.706 -178.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -73.9 117.19 15.4 Favored 'General case' 0 N--CA 1.485 1.279 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.789 179.034 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -69.56 0.3 5.57 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.435 -0.906 . . . . 0.0 112.013 -178.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 62.3 m-20 -99.76 -5.79 28.08 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.357 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 31.0 mm-40 -123.37 -2.38 8.52 Favored 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.615 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.407 HG13 ' HD2' ' A' ' 47' ' ' PRO . 42.2 t -95.99 144.93 28.66 Favored Pre-proline 0 C--N 1.285 -2.216 0 N-CA-C 107.256 -1.386 . . . . 0.0 107.256 178.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.473 ' HG2' HG12 ' A' ' 50' ' ' VAL . 1.8 Cg_endo -61.09 165.2 12.82 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 CA-C-N 119.024 0.687 . . . . 0.0 111.89 -178.367 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.8 38.89 0.72 Allowed 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.381 -0.928 . . . . 0.0 110.239 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.18 -57.83 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.684 ' O ' HG13 ' A' ' 50' ' ' VAL . 9.8 p -84.46 101.99 9.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.722 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -48.97 153.81 0.82 Allowed 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.681 -0.808 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -98.29 -10.16 24.35 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.443 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -88.1 -10.46 50.02 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.652 -0.819 . . . . 0.0 110.579 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.4 13.2 16.19 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.465 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.485 HD12 ' CE2' ' A' ' 41' ' ' PHE . 1.1 pt -147.38 -29.09 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 C-N-CA 119.503 -0.879 . . . . 0.0 110.814 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 2.1 m -48.58 174.25 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.948 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.624 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 36.5 mt-30 -135.5 78.95 49.23 Favored Pre-proline 0 N--CA 1.489 1.491 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.022 -179.833 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -60.58 -7.86 7.97 Favored 'Trans proline' 0 N--CA 1.456 -0.686 0 C-N-CA 120.78 0.987 . . . . 0.0 110.641 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -98.01 127.61 44.06 Favored 'General case' 0 N--CA 1.483 1.179 0 C-N-CA 119.778 -0.769 . . . . 0.0 110.227 179.309 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.435 ' CD1' ' N ' ' A' ' 60' ' ' TYR . 32.4 m-85 -88.59 173.58 8.56 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.917 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -137.94 106.53 5.87 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.658 179.644 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -101.67 3.65 39.97 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.912 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -65.83 -140.58 0.04 OUTLIER Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.392 -1.385 . . . . 0.0 110.413 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -159.42 99.61 1.46 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.68 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.44 -1.12 43.01 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 119.815 -1.183 . . . . 0.0 110.44 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -63.03 158.74 18.72 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.56 179.801 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.2 p -147.26 155.48 42.09 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.828 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.624 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 41.0 t80 -136.97 153.51 50.67 Favored 'General case' 0 N--CA 1.488 1.444 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.443 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.411 ' O ' ' CE1' ' A' ' 68' ' ' TYR . 3.6 mt-10 -113.41 149.18 34.52 Favored 'General case' 0 N--CA 1.501 2.082 0 C-N-CA 119.44 -0.904 . . . . 0.0 112.224 -179.076 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -144.62 126.04 9.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.182 179.033 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.9 m -119.22 100.11 7.12 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.82 -0.752 . . . . 0.0 111.268 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 65.9 mt -79.55 161.28 26.08 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.65 179.171 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.9 p -150.07 48.53 0.91 Allowed 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 118.819 -1.152 . . . . 0.0 111.742 -178.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.4 ' O ' ' C ' ' A' ' 75' ' ' LYS . 3.6 mm-40 -148.17 98.26 2.9 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.567 179.416 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 74' ' ' GLU . 0.0 OUTLIER -43.67 107.8 0.09 Allowed 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.596 -179.784 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 176.48 -141.91 5.7 Favored Glycine 0 C--N 1.294 -1.773 0 C-N-CA 119.066 -1.54 . . . . 0.0 110.094 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.52 136.67 26.22 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.476 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.592 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.2 OUTLIER -128.78 137.64 51.64 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.488 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.37 108.64 16.78 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.932 179.759 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.504 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 2.1 p90 -109.87 170.95 7.74 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.202 179.445 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -171.18 179.84 2.9 Favored 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 119.362 -0.935 . . . . 0.0 112.068 -178.454 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' CYS . . . . . 0.566 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.5 t -108.96 124.45 50.71 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.205 179.122 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.763 ' H ' HD21 ' A' ' 38' ' ' ASN . 0.3 OUTLIER -68.46 -39.4 15.51 Favored Pre-proline 0 N--CA 1.488 1.442 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -178.283 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.3 Cg_endo -73.35 -51.67 0.16 Allowed 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 121.02 1.147 . . . . 0.0 111.84 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -81.4 8.49 9.17 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.286 -0.966 . . . . 0.0 111.328 -179.327 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.566 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -65.03 -17.28 64.31 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.198 -1.001 . . . . 0.0 110.686 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -65.05 -22.98 69.28 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.493 -1.336 . . . . 0.0 110.248 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.25 -39.82 10.78 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.562 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 135.65 20.89 0.67 Allowed Glycine 0 N--CA 1.493 2.461 0 C-N-CA 119.744 -1.217 . . . . 0.0 110.34 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.98 106.2 2.26 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.312 -0.955 . . . . 0.0 111.19 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.409 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 2.1 pttp -135.15 169.5 17.35 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.938 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.462 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -150.51 150.17 22.14 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 119.013 -1.565 . . . . 0.0 111.417 -178.467 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -150.09 143.52 25.15 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.519 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 94' ' ' VAL . 6.6 p -141.03 126.34 18.77 Favored 'Isoleucine or valine' 0 C--O 1.205 -1.285 0 C-N-CA 119.244 -0.982 . . . . 0.0 110.746 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.672 ' HB ' HG22 ' A' ' 20' ' ' THR . 22.7 m -103.45 103.41 13.38 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.647 -0.821 . . . . 0.0 110.423 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 21.6 t -79.55 143.15 12.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 118.714 -1.194 . . . . 0.0 110.018 -179.36 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 . . . . . 0 N--CA 1.489 1.488 0 CA-C-O 116.314 -1.803 . . . . 0.0 110.818 -179.602 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.096 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -140.21 122.49 15.92 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.748 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 98.4 t -114.52 132.54 63.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 C-N-CA 119.848 -0.741 . . . . 0.0 111.127 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -100.56 111.75 24.03 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.736 -0.786 . . . . 0.0 110.684 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.433 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 9.5 mt -75.68 105.07 6.52 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.923 178.684 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 112.39 131.68 5.66 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -178.61 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.4 p . . . . . 0 C--N 1.306 -1.309 0 C-N-CA 119.256 -0.978 . . . . 0.0 111.092 -179.63 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.9 mt . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 120.629 0.252 . . . . 0.0 110.915 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.6 m -150.64 157.95 5.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.654 179.455 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.53 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 34.1 m-85 -78.39 113.24 16.21 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 178.068 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 17.3 m -116.45 107.13 47.5 Favored Pre-proline 0 CA--C 1.562 1.41 0 C-N-CA 119.5 -0.88 . . . . 0.0 112.186 -177.453 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -65.89 176.24 20.9 Favored 'Cis proline' 0 C--N 1.361 1.217 0 C-N-CA 125.198 -0.751 . . . . 0.0 111.414 -0.757 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.02 -52.05 4.39 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.486 -0.885 . . . . 0.0 110.265 179.264 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 4.5 m -132.03 135.28 46.4 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.413 179.09 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 12.8 p90 -155.71 142.32 18.74 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 118.495 -1.282 . . . . 0.0 111.573 -179.097 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.623 HG22 ' HB ' ' A' ' 95' ' ' THR . 46.9 p -84.17 151.24 24.99 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.439 179.458 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.0 m -144.59 161.79 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 119.356 -0.938 . . . . 0.0 111.137 179.71 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.449 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -81.35 146.55 30.28 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.65 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.05 74.52 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 119.673 -0.811 . . . . 0.0 111.23 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 155.68 18.2 0.04 OUTLIER Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.466 -1.35 . . . . 0.0 109.797 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -98.63 150.95 21.22 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.951 -179.49 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.8 mttt -92.43 117.95 30.45 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.337 -0.945 . . . . 0.0 111.016 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.6 mt -97.94 110.4 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.771 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 75.6 p -110.94 114.48 27.83 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.672 -0.811 . . . . 0.0 112.515 -178.519 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -87.01 111.55 20.97 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.373 178.391 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -106.57 141.01 38.54 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 119.68 -0.808 . . . . 0.0 112.045 -178.535 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.544 HD21 HD11 ' A' ' 61' ' ' LEU . 1.7 m-80 -82.27 115.99 21.59 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.877 178.799 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.537 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 4.2 p-10 -98.75 -32.76 11.21 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 118.755 -1.178 . . . . 0.0 111.839 -179.398 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.537 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 171.91 52.22 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.496 -0.881 . . . . 0.0 110.042 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.506 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -153.45 26.67 0.77 Allowed Glycine 0 N--CA 1.487 2.041 0 C-N-CA 118.992 -1.575 . . . . 0.0 110.734 -179.67 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.636 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -79.23 160.34 70.9 Favored Pre-proline 0 C--N 1.309 -1.191 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.96 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -77.41 138.66 54.15 Favored 'Cis proline' 0 C--O 1.215 -0.657 0 C-N-CA 123.876 -1.302 . . . . 0.0 111.757 -1.167 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.506 ' CE1' ' O ' ' A' ' 34' ' ' GLY . 38.2 m-70 -107.66 179.52 4.21 Favored 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 119.631 -0.828 . . . . 0.0 111.49 -179.293 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -156.09 143.25 19.08 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.61 -0.836 . . . . 0.0 110.354 179.781 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.2 mp -130.25 118.31 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.304 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t -145.3 147.65 18.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.656 179.064 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -99.43 139.97 34.29 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.144 -1.022 . . . . 0.0 112.006 -179.191 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.698 ' C ' ' H ' ' A' ' 44' ' ' ASP . 39.8 p-10 -75.37 108.37 8.11 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 115.142 -0.935 . . . . 0.0 111.296 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.489 ' OE1' ' HB3' ' A' ' 52' ' ' ALA . 27.4 mm-40 -56.47 10.8 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.156 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.589 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.698 ' H ' ' C ' ' A' ' 42' ' ' ASP . 70.8 m-20 -82.92 -68.49 0.7 Allowed 'General case' 0 C--N 1.288 -2.081 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.249 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -99.38 -5.23 29.92 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.826 -1.15 . . . . 0.0 114.038 -175.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -54.15 143.88 41.94 Favored Pre-proline 0 C--N 1.282 -2.362 0 C-N-CA 118.206 -1.397 . . . . 0.0 107.784 179.023 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_exo -46.71 146.92 5.0 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 120.713 0.942 . . . . 0.0 112.116 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -85.34 51.13 2.1 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.771 -0.772 . . . . 0.0 111.051 -179.679 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -165.63 -23.49 0.02 OUTLIER Glycine 0 N--CA 1.488 2.122 0 C-N-CA 119.478 -1.344 . . . . 0.0 109.965 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 53.2 t -97.85 104.26 15.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.683 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -45.56 139.85 3.6 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 119.223 -0.991 . . . . 0.0 110.567 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.489 ' HB3' ' OE1' ' A' ' 43' ' ' GLU . . . -101.29 -8.29 22.25 Favored 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.229 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -83.79 -21.05 32.28 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.164 -1.014 . . . . 0.0 110.966 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 51.6 mmtt -86.41 -32.88 20.66 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.263 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.4 pt -89.14 -19.81 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 C-N-CA 118.876 -1.13 . . . . 0.0 111.438 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 74.3 m -74.44 -176.6 2.77 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.971 179.354 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -142.51 82.82 12.41 Favored Pre-proline 0 N--CA 1.491 1.617 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.43 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -61.96 -9.59 14.9 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 121.187 1.258 . . . . 0.0 112.067 -179.039 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -99.23 112.55 24.69 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.387 -0.925 . . . . 0.0 110.87 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -58.69 178.04 0.12 Allowed 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.574 -0.851 . . . . 0.0 110.71 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.544 HD11 HD21 ' A' ' 31' ' ' ASN . 2.0 pp -151.21 142.12 22.95 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.551 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -134.58 19.95 3.6 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.883 -179.752 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -86.4 139.26 16.52 Favored Glycine 0 N--CA 1.489 2.213 0 C-N-CA 119.168 -1.491 . . . . 0.0 110.219 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -85.5 111.39 19.95 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.509 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 102.25 -15.21 56.54 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 -179.624 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -64.01 147.02 53.08 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.227 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -142.43 169.92 16.67 Favored 'General case' 0 N--CA 1.486 1.369 0 C-N-CA 119.206 -0.997 . . . . 0.0 111.466 -179.65 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 26.5 t80 -134.44 135.97 42.9 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.477 179.251 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.549 ' H ' ' CD ' ' A' ' 69' ' ' GLU . 1.6 mp0 -97.36 152.63 18.73 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.25 -0.98 . . . . 0.0 112.371 -178.573 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.1 t -151.58 133.5 5.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 CA-C-N 115.221 -0.899 . . . . 0.0 109.033 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 8.4 m -127.13 104.3 7.9 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.113 -179.376 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.5 ' CD1' HG11 ' A' ' 94' ' ' VAL . 13.9 mt -90.37 160.06 16.28 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.268 -0.973 . . . . 0.0 109.749 179.489 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 67.3 p -148.41 48.04 1.04 Allowed 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.558 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.438 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.9 mt-10 -147.08 105.9 3.84 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.972 -1.091 . . . . 0.0 110.453 179.311 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.74 112.03 0.42 Allowed 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.002 -1.079 . . . . 0.0 110.633 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.66 8.61 Favored Glycine 0 N--CA 1.487 2.064 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.282 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -141.44 123.73 15.68 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.399 -179.642 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.547 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -115.49 120.29 39.02 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.339 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 26.1 mttt -97.83 126.95 43.45 Favored 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 119.209 -0.996 . . . . 0.0 112.603 -178.406 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.58 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -127.61 158.58 37.13 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.679 177.928 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -165.0 176.87 8.23 Favored 'General case' 0 C--N 1.283 -2.296 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.131 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.6 t -104.39 123.86 48.19 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.787 -0.765 . . . . 0.0 110.547 -179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.542 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tt0 -66.4 -44.97 58.88 Favored Pre-proline 0 C--N 1.306 -1.303 0 C-N-CA 119.685 -0.806 . . . . 0.0 112.913 -179.673 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.542 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.6 Cg_exo -65.36 -50.29 2.05 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 121.179 1.252 . . . . 0.0 111.801 -178.947 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -86.77 16.18 5.04 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.727 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.21 -9.35 4.74 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.777 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.36 -20.12 49.87 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.485 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.14 -12.93 39.65 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.478 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 99.02 26.07 9.17 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.505 -1.331 . . . . 0.0 110.719 179.767 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -76.83 101.63 5.97 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.174 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.53 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 1.5 ptmt -124.98 162.58 24.18 Favored 'General case' 0 N--CA 1.493 1.712 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.946 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.549 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -146.76 149.84 22.04 Favored Glycine 0 N--CA 1.495 2.608 0 C-N-CA 119.296 -1.431 . . . . 0.0 111.419 -178.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -156.39 145.47 20.42 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.005 179.239 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.673 ' O ' HG13 ' A' ' 94' ' ' VAL . 12.6 p -135.94 117.53 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.466 -0.893 . . . . 0.0 110.464 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.623 ' HB ' HG22 ' A' ' 20' ' ' THR . 46.1 m -93.72 100.4 12.63 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.194 -1.003 . . . . 0.0 110.599 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 22.9 t -79.22 146.5 7.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 C-N-CA 118.46 -1.296 . . . . 0.0 110.333 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.308 -1.233 0 CA-C-O 116.345 -1.788 . . . . 0.0 110.587 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.087 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -118.51 122.06 41.77 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.644 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 57.6 t -114.89 113.81 44.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.866 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 29.5 mtmt -88.63 116.77 27.11 Favored 'General case' 0 C--N 1.298 -1.641 0 C-N-CA 119.193 -1.003 . . . . 0.0 110.854 -179.555 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 7.8 mt -78.6 105.79 10.13 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 118.788 -1.165 . . . . 0.0 110.41 178.617 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 103.12 121.42 4.93 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.59 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.1 p . . . . . 0 C--N 1.304 -1.371 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.672 179.838 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 23.0 mt . . . . . 0 N--CA 1.487 1.381 0 CA-C-O 120.459 0.171 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.7 m -151.0 157.43 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 C-N-CA 118.974 -1.09 . . . . 0.0 111.381 179.638 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' A' ' 16' ' ' PRO . 22.1 m-85 -78.53 110.0 13.22 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 177.499 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.4 m -115.62 109.19 45.99 Favored Pre-proline 0 N--CA 1.488 1.449 0 C-N-CA 119.28 -0.968 . . . . 0.0 112.564 -177.092 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.421 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.4 Cg_exo -65.9 178.62 15.26 Favored 'Cis proline' 0 C--N 1.364 1.35 0 C-N-CA 125.191 -0.754 . . . . 0.0 111.526 -1.075 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 41.8 t -95.75 -60.47 1.64 Allowed 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.376 179.474 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.4 t -124.74 140.33 53.03 Favored 'General case' 0 N--CA 1.488 1.438 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.884 179.37 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -165.22 149.62 8.82 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 118.592 -1.243 . . . . 0.0 111.258 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.416 ' H ' HG23 ' A' ' 20' ' ' THR . 0.8 OUTLIER -87.03 160.45 18.61 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.273 -179.876 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.3 m -148.86 165.56 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.941 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.499 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -87.29 142.91 27.54 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.556 179.817 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.71 77.28 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.136 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.499 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 146.56 18.41 0.13 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -98.35 138.58 35.38 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.852 -0.739 . . . . 0.0 110.609 -179.627 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.5 mttm -80.1 118.65 22.0 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.141 -179.634 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.3 mt -100.41 120.21 49.57 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.228 179.345 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 68.3 p -114.93 118.45 33.49 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.523 -0.871 . . . . 0.0 112.988 -177.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -84.71 114.15 21.83 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 177.415 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.4 mttp -103.94 132.33 50.3 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.415 -0.914 . . . . 0.0 111.46 -177.593 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 50.3 t-20 -84.97 110.82 19.17 Favored 'General case' 0 C--N 1.29 -2.004 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.025 178.826 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -106.67 -30.22 9.12 Favored 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 119.275 -0.97 . . . . 0.0 112.038 -179.03 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -178.67 161.11 1.25 Allowed 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 119.26 -0.976 . . . . 0.0 111.194 -179.543 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . 75.58 58.61 3.79 Favored Glycine 0 N--CA 1.495 2.58 0 C-N-CA 119.536 -1.316 . . . . 0.0 113.062 178.04 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -97.3 165.27 16.02 Favored Pre-proline 0 N--CA 1.496 1.853 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 177.665 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -78.08 138.46 51.44 Favored 'Cis proline' 0 C--O 1.214 -0.691 0 C-N-CA 124.808 -0.913 . . . . 0.0 113.047 -0.042 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.505 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 36.6 m-70 -102.81 177.34 4.88 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.713 -0.795 . . . . 0.0 110.574 178.566 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.506 ' ND2' ' CD1' ' A' ' 60' ' ' TYR . 5.0 t-20 -165.69 154.48 11.64 Favored 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.88 179.688 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.623 ' N ' HD12 ' A' ' 39' ' ' ILE . 2.5 mp -139.25 114.67 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 119.64 -0.824 . . . . 0.0 111.103 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 t -130.48 152.21 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.603 179.397 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.45 ' CE2' HD12 ' A' ' 55' ' ' ILE . 9.5 m-85 -102.94 141.07 36.37 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.525 -0.87 . . . . 0.0 111.796 -179.025 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -78.28 109.97 12.88 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.817 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.434 ' OE2' ' O ' ' A' ' 41' ' ' PHE . 35.3 mp0 -73.36 47.27 0.21 Allowed 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.94 -179.188 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -138.74 -5.84 1.51 Allowed 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.804 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -145.11 7.12 1.17 Allowed 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 118.54 -1.264 . . . . 0.0 111.981 179.754 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.592 HG13 ' HD2' ' A' ' 47' ' ' PRO . 2.1 t -80.53 150.79 70.83 Favored Pre-proline 0 C--N 1.289 -2.04 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.661 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.592 ' HD2' HG13 ' A' ' 46' ' ' VAL . 4.0 Cg_exo -52.87 158.17 6.79 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 120.944 1.096 . . . . 0.0 111.794 -179.428 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.87 48.7 1.67 Allowed 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.751 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -154.6 -32.63 0.03 OUTLIER Glycine 0 N--CA 1.49 2.242 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.134 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.413 ' O ' HG12 ' A' ' 50' ' ' VAL . 51.6 t -97.29 95.39 4.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 C-N-CA 119.599 -0.84 . . . . 0.0 110.841 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -46.05 148.29 0.87 Allowed 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.037 -1.065 . . . . 0.0 110.322 179.701 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -92.87 -33.77 14.09 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.339 -0.945 . . . . 0.0 111.211 -179.591 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -65.81 -17.83 64.91 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.823 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.37 -35.88 54.08 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.284 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.45 HD12 ' CE2' ' A' ' 41' ' ' PHE . 1.9 pt -95.69 -35.13 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.108 -179.644 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 39.9 m -43.46 158.88 0.03 OUTLIER 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.995 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.47 ' OE1' ' CD1' ' A' ' 68' ' ' TYR . 3.8 mt-30 -137.98 71.19 49.08 Favored Pre-proline 0 N--CA 1.486 1.328 0 C-N-CA 119.947 -0.701 . . . . 0.0 110.699 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -61.28 -5.73 5.65 Favored 'Trans proline' 0 C--N 1.321 -0.871 0 C-N-CA 121.274 1.316 . . . . 0.0 111.07 -179.571 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -83.65 113.78 21.09 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.005 179.364 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.506 ' CD1' ' ND2' ' A' ' 38' ' ' ASN . 30.4 m-85 -69.38 166.4 18.72 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.551 -0.859 . . . . 0.0 111.297 -179.258 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.15 125.65 19.07 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.863 179.537 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.604 ' ND2' ' H ' ' A' ' 63' ' ' GLY . 2.3 p-10 -104.87 -74.39 0.65 Allowed 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.309 -179.472 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.604 ' H ' ' ND2' ' A' ' 62' ' ' ASN . . . -35.06 146.12 0.04 OUTLIER Glycine 0 N--CA 1.501 2.975 0 C-N-CA 120.401 -0.904 . . . . 0.0 111.446 -179.448 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -81.42 151.56 27.83 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.744 -0.782 . . . . 0.0 110.888 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.22 -11.25 69.3 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.365 -1.397 . . . . 0.0 111.307 179.355 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -74.72 119.94 19.6 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.123 -1.031 . . . . 0.0 111.036 -179.767 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 3.9 p -127.5 160.78 30.47 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.949 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.47 ' CD1' ' OE1' ' A' ' 57' ' ' GLN . 34.5 t80 -136.48 141.41 43.49 Favored 'General case' 0 N--CA 1.494 1.749 0 C-N-CA 119.784 -0.767 . . . . 0.0 110.171 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -101.42 149.62 23.87 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 119.48 -0.888 . . . . 0.0 112.09 -178.897 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 t -146.05 138.4 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.105 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.2 m -132.39 99.76 4.78 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.577 -0.849 . . . . 0.0 111.28 -179.46 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.465 ' CD1' HG11 ' A' ' 94' ' ' VAL . 65.3 mt -82.48 162.83 21.93 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.158 179.461 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.604 ' O ' HG22 ' A' ' 73' ' ' THR . 97.7 m -150.57 45.07 0.86 Allowed 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.904 -1.118 . . . . 0.0 111.919 -179.105 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -145.02 102.05 3.71 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 118.924 -1.11 . . . . 0.0 110.418 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 22.6 mtmt -45.85 107.94 0.12 Allowed 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.201 -1.0 . . . . 0.0 110.425 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 177.21 -146.57 7.83 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.219 -1.467 . . . . 0.0 110.39 -179.601 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.99 130.1 22.07 Favored 'General case' 0 N--CA 1.484 1.257 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.646 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.588 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.2 OUTLIER -120.95 147.33 45.61 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 178.996 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.458 ' CB ' ' NZ ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -121.91 121.75 37.83 Favored 'General case' 0 N--CA 1.5 2.032 0 C-N-CA 119.069 -1.052 . . . . 0.0 110.957 179.47 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.6 OUTLIER -123.5 161.28 25.19 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.764 -0.774 . . . . 0.0 109.904 178.692 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 36.9 p90 -161.5 177.17 10.31 Favored 'General case' 0 C--N 1.285 -2.231 0 C-N-CA 119.184 -1.006 . . . . 0.0 111.176 -179.082 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -100.07 119.09 37.75 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.714 179.374 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.573 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 14.8 tt0 -72.03 -36.05 3.91 Favored Pre-proline 0 C--N 1.308 -1.213 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.953 -179.104 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.6 Cg_endo -72.05 -54.57 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.377 0.718 . . . . 0.0 111.049 179.727 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 61.8 m-70 -79.82 14.93 1.55 Allowed 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.602 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.56 -11.64 0.94 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.628 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -78.62 -25.38 60.84 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.162 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.55 -31.74 26.23 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.414 179.808 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 110.3 26.72 4.76 Favored Glycine 0 N--CA 1.492 2.4 0 C-N-CA 119.781 -1.2 . . . . 0.0 110.859 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 32.0 mtp -67.82 108.49 3.0 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.081 -1.048 . . . . 0.0 110.79 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -121.03 154.31 36.22 Favored 'General case' 0 N--CA 1.491 1.611 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.917 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.492 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.76 146.24 17.19 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.511 -1.328 . . . . 0.0 111.236 -178.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -152.71 145.12 24.05 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.594 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.551 ' O ' HG13 ' A' ' 94' ' ' VAL . 12.0 p -138.45 125.46 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.794 179.647 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 91.0 m -102.77 99.07 8.99 Favored 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.532 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 31.7 t -79.87 148.61 5.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 118.692 -1.203 . . . . 0.0 110.472 -179.054 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 48.7 p30 . . . . . 0 C--N 1.306 -1.297 0 CA-C-O 116.324 -1.798 . . . . 0.0 110.671 -179.843 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 120.839 0.352 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLU . . . . . 0.524 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 10.8 mp0 -105.12 130.97 53.18 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.848 -0.741 . . . . 0.0 110.548 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.1 t -114.08 118.89 59.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.852 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 30.4 mttt -92.77 114.2 26.68 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.78 -179.095 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mp -79.71 105.83 11.29 Favored 'General case' 0 C--N 1.313 -1.016 0 C-N-CA 118.597 -1.241 . . . . 0.0 109.696 177.61 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.439 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.32 90.66 2.14 Favored Glycine 0 C--N 1.29 -2.018 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -178.755 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.1 p . . . . . 0 C--N 1.303 -1.456 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.766 -179.546 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.8 mt . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 120.608 0.242 . . . . 0.0 110.921 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.7 m -149.55 155.29 8.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 C-N-CA 118.898 -1.121 . . . . 0.0 111.058 179.798 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' A' ' 16' ' ' PRO . 29.7 m-85 -78.29 106.93 10.54 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 177.825 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 46.9 m -112.73 113.03 50.48 Favored Pre-proline 0 CA--C 1.556 1.2 0 C-N-CA 119.423 -0.911 . . . . 0.0 112.3 -177.11 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.5 Cg_endo -66.68 175.6 25.26 Favored 'Cis proline' 0 C--N 1.358 1.039 0 C-N-CA 125.4 -0.667 . . . . 0.0 111.5 -1.052 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -92.83 -61.16 1.64 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.469 -0.893 . . . . 0.0 110.014 179.055 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -119.92 142.53 48.64 Favored 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.474 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 19.8 p90 -167.78 137.11 2.6 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 118.577 -1.249 . . . . 0.0 111.304 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.447 ' H ' HG23 ' A' ' 20' ' ' THR . 0.3 OUTLIER -84.64 161.21 20.19 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.301 -0.959 . . . . 0.0 111.028 -179.946 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.1 m -148.49 162.42 5.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.274 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.978 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.475 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -82.76 144.45 30.17 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.278 -0.969 . . . . 0.0 110.435 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.27 76.92 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.369 -0.933 . . . . 0.0 111.07 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.475 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 149.22 19.45 0.08 OUTLIER Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.467 ' CD ' ' N ' ' A' ' 26' ' ' LYS . 5.9 tm-20 -101.51 144.56 30.13 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.654 -179.666 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.467 ' N ' ' CD ' ' A' ' 25' ' ' GLU . 67.6 mttt -88.49 133.44 34.13 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.807 -179.799 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.6 mt -117.38 118.14 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.55 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.8 p -109.95 114.76 28.57 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.825 -0.75 . . . . 0.0 112.392 -178.3 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -84.45 117.96 23.98 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.446 178.356 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.69 127.65 53.08 Favored 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 119.289 -0.965 . . . . 0.0 111.525 -177.851 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 39.0 t-20 -84.29 130.66 34.79 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.667 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.439 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 12.0 p-10 -134.22 -8.01 2.62 Favored 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 118.893 -1.123 . . . . 0.0 112.444 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -171.74 144.52 1.83 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 118.376 -1.33 . . . . 0.0 112.318 -179.775 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 72.15 54.57 7.86 Favored Glycine 0 N--CA 1.489 2.199 0 C-N-CA 119.903 -1.141 . . . . 0.0 113.53 177.277 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.482 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -92.74 167.07 15.26 Favored Pre-proline 0 N--CA 1.497 1.884 0 C-N-CA 118.718 -1.193 . . . . 0.0 108.498 177.22 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -77.05 146.35 83.4 Favored 'Cis proline' 0 N--CA 1.481 0.738 0 C-N-CA 124.958 -0.851 . . . . 0.0 113.047 -0.323 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 30.5 m-70 -104.69 -177.23 3.31 Favored 'General case' 0 N--CA 1.489 1.485 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.499 178.088 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.689 ' ND2' ' CE1' ' A' ' 60' ' ' TYR . 10.3 t-20 -164.61 135.3 4.11 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.742 -0.783 . . . . 0.0 110.057 178.747 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.8 mp -124.0 119.42 56.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 C-N-CA 119.837 -0.745 . . . . 0.0 110.898 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.9 t -142.26 145.5 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.61 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -97.37 121.63 39.49 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.586 -0.845 . . . . 0.0 111.221 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.444 ' OD1' ' O ' ' A' ' 42' ' ' ASP . 38.1 p-10 -59.91 117.3 4.88 Favored 'General case' 0 C--N 1.309 -1.165 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.781 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -74.96 41.73 0.17 Allowed 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.809 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.44 ' H ' ' C ' ' A' ' 42' ' ' ASP . 7.3 m-20 -135.64 -3.26 2.35 Favored 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.656 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -147.38 19.25 1.2 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.054 -1.058 . . . . 0.0 111.215 179.823 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -96.71 146.01 30.57 Favored Pre-proline 0 C--N 1.3 -1.544 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.351 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -57.41 147.82 75.55 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.794 0.996 . . . . 0.0 111.82 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.47 158.63 14.43 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 119.14 -1.024 . . . . 0.0 109.945 179.29 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 79.64 -52.26 4.13 Favored Glycine 0 N--CA 1.487 2.075 0 C-N-CA 118.991 -1.576 . . . . 0.0 109.956 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.608 ' O ' HG12 ' A' ' 50' ' ' VAL . 71.6 t -69.81 73.84 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.165 0 C-N-CA 119.236 -0.986 . . . . 0.0 110.496 179.625 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -44.86 142.35 1.81 Allowed 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.698 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -79.3 -29.29 42.38 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.401 -0.919 . . . . 0.0 111.052 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -74.03 3.61 6.66 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.693 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.34 -35.61 10.66 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.948 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt -99.79 -28.37 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.044 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 68.9 m -64.74 154.81 35.68 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.247 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.473 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -135.86 76.82 52.15 Favored Pre-proline 0 N--CA 1.486 1.356 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.96 179.65 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -57.41 -3.32 0.83 Allowed 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 121.193 1.262 . . . . 0.0 111.87 -178.571 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.432 ' H ' ' C ' ' A' ' 57' ' ' GLN . 11.4 tt0 -72.97 91.53 1.56 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.021 -1.072 . . . . 0.0 110.021 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.689 ' CE1' ' ND2' ' A' ' 38' ' ' ASN . 36.4 m-85 -43.61 165.63 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.947 -179.528 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -142.43 110.47 5.94 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.896 179.55 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 -103.28 -6.82 21.65 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.664 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -71.05 152.04 49.64 Favored Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.456 -1.354 . . . . 0.0 110.44 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -94.83 103.9 15.79 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.764 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.24 -7.3 16.51 Favored Glycine 0 N--CA 1.496 2.677 0 C-N-CA 119.941 -1.123 . . . . 0.0 110.62 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.4 148.08 42.81 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.055 -1.058 . . . . 0.0 110.457 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 4.9 p -147.18 165.24 30.61 Favored 'General case' 0 N--CA 1.491 1.595 0 C-N-CA 118.901 -1.12 . . . . 0.0 111.889 -179.531 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.473 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 42.3 t80 -137.09 150.8 48.25 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.805 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.445 ' O ' ' CE1' ' A' ' 68' ' ' TYR . 2.2 mp0 -108.1 151.4 25.93 Favored 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.423 -179.711 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -150.31 135.77 10.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.303 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.0 m -135.75 92.17 2.79 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.155 -179.558 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 21.4 mt -79.82 158.7 26.73 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.263 -0.975 . . . . 0.0 109.659 179.412 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 23.4 p -150.53 41.98 0.8 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.143 -179.237 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -140.02 105.98 5.2 Favored 'General case' 0 N--CA 1.498 1.957 0 C-N-CA 118.807 -1.157 . . . . 0.0 110.422 179.178 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.5 tttp -40.19 112.37 0.27 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.301 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.43 -149.86 14.21 Favored Glycine 0 N--CA 1.488 2.162 0 C-N-CA 118.854 -1.641 . . . . 0.0 110.675 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -138.09 139.44 39.49 Favored 'General case' 0 N--CA 1.482 1.175 0 C-N-CA 119.761 -0.776 . . . . 0.0 110.984 -179.77 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.563 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.1 m-85 -126.42 128.78 47.53 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.107 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.442 ' O ' ' OD1' ' A' ' 42' ' ' ASP . 3.3 mptp? -105.12 123.94 48.67 Favored 'General case' 0 N--CA 1.493 1.699 0 C-N-CA 119.531 -0.868 . . . . 0.0 112.216 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.449 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 9.0 p90 -134.71 171.8 13.86 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.161 177.693 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 25.9 p90 -171.22 -168.92 0.68 Allowed 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 119.409 -0.916 . . . . 0.0 111.188 -178.009 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -116.65 130.04 56.5 Favored 'General case' 0 N--CA 1.482 1.141 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.206 179.036 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.512 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.0 mt-10 -72.17 -46.42 11.04 Favored Pre-proline 0 N--CA 1.484 1.271 0 C-N-CA 119.505 -0.878 . . . . 0.0 112.929 -179.394 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.512 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.8 Cg_endo -66.8 -46.38 3.53 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 120.806 1.004 . . . . 0.0 112.03 -178.656 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.6 m80 -90.46 21.11 4.08 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.239 -179.379 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -67.08 -16.73 64.52 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.359 -0.936 . . . . 0.0 110.597 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -77.49 -24.07 66.29 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.457 -1.354 . . . . 0.0 110.298 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.62 -15.6 39.27 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.392 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 98.77 31.88 6.16 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 119.561 -1.304 . . . . 0.0 110.576 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.63 103.91 9.86 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.997 179.765 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -129.34 166.46 19.45 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.801 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -146.49 155.18 26.4 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 119.123 -1.513 . . . . 0.0 111.779 -178.398 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -155.25 143.46 20.2 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.82 179.452 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.12 128.65 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.317 -0.953 . . . . 0.0 110.126 179.079 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 98.9 m -106.86 106.82 17.53 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 119.624 -0.83 . . . . 0.0 110.784 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.436 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 41.3 t -82.26 138.15 19.92 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 118.347 -1.341 . . . . 0.0 110.586 -179.101 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 96' ' ' VAL . 6.7 m-20 . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 116.374 -1.774 . . . . 0.0 110.805 -179.841 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -138.23 142.61 39.93 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.787 -0.765 . . . . 0.0 110.579 179.933 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 t -131.44 118.75 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.563 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.0 mtmp? -90.1 115.3 27.26 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.114 -1.034 . . . . 0.0 111.313 -178.991 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 4.8 mt -76.94 105.71 8.17 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 118.937 -1.105 . . . . 0.0 109.688 178.392 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 111.05 135.58 6.87 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.055 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.0 p . . . . . 0 C--N 1.302 -1.479 0 C-N-CA 119.233 -0.987 . . . . 0.0 110.67 179.941 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.8 mt . . . . . 0 N--CA 1.489 1.492 0 CA-C-O 120.445 0.164 . . . . 0.0 110.913 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.0 m -150.22 157.09 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.362 179.124 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.51 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 37.2 m-85 -77.84 115.09 17.32 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.898 -1.121 . . . . 0.0 108.15 178.809 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.5 m -116.89 106.98 46.83 Favored Pre-proline 0 CA--C 1.561 1.367 0 C-N-CA 119.58 -0.848 . . . . 0.0 111.813 -177.564 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -66.32 175.66 23.85 Favored 'Cis proline' 0 C--N 1.359 1.124 0 C-N-CA 125.166 -0.764 . . . . 0.0 111.429 -0.132 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.96 -37.39 11.7 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 119.426 -0.91 . . . . 0.0 109.709 178.836 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.6 m -145.72 142.63 29.14 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.941 179.18 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.403 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 26.0 p90 -165.91 146.27 6.56 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 118.711 -1.196 . . . . 0.0 111.339 -179.013 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.424 HG23 ' H ' ' A' ' 20' ' ' THR . 1.2 p -90.1 163.54 14.82 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.26 -179.755 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.1 m -150.27 175.61 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.687 179.43 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.452 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -91.07 146.61 23.7 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.859 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.03 74.73 0.05 OUTLIER 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.549 -0.86 . . . . 0.0 110.947 179.742 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 146.18 19.58 0.13 Allowed Glycine 0 N--CA 1.488 2.104 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -96.96 150.03 21.22 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.877 -0.729 . . . . 0.0 111.007 -179.415 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.79 136.13 35.47 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.607 179.592 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.9 mt -118.62 151.03 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 C-N-CA 120.038 -0.665 . . . . 0.0 109.212 179.848 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 9.2 p -142.16 118.46 10.81 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.695 -179.533 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 63.7 m-85 -83.65 125.38 31.78 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.427 -0.909 . . . . 0.0 109.1 178.471 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.0 tptp -110.4 133.69 53.03 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 120.044 -0.662 . . . . 0.0 110.52 -179.142 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.764 ' OD1' HD11 ' A' ' 61' ' ' LEU . 1.7 m-80 -89.34 103.33 15.97 Favored 'General case' 0 C--N 1.293 -1.875 0 C-N-CA 119.19 -1.004 . . . . 0.0 110.087 179.331 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.66 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.3 OUTLIER -89.84 -30.63 17.8 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 119.176 -1.01 . . . . 0.0 111.435 -179.079 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 168.99 146.86 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 118.992 -1.083 . . . . 0.0 111.017 -179.864 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 112.74 -5.71 26.01 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.619 -1.277 . . . . 0.0 111.369 179.368 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -47.45 162.83 0.28 Allowed Pre-proline 0 N--CA 1.484 1.26 0 C-N-CA 118.332 -1.347 . . . . 0.0 109.639 179.878 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -77.1 137.95 51.24 Favored 'Cis proline' 0 C--O 1.214 -0.682 0 C-N-CA 124.143 -1.19 . . . . 0.0 112.285 -0.362 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 32.0 m-70 -103.79 177.69 4.77 Favored 'General case' 0 N--CA 1.489 1.497 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.568 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.511 ' ND2' ' CD1' ' A' ' 60' ' ' TYR . 2.0 t-20 -153.9 140.35 18.73 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.217 179.557 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.459 ' O ' ' N ' ' A' ' 57' ' ' GLN . 3.9 mp -133.22 99.5 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.136 -179.773 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.6 t -121.61 152.55 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.831 179.29 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -104.9 122.87 46.7 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.6 -0.84 . . . . 0.0 111.724 -178.971 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.489 ' C ' ' H ' ' A' ' 44' ' ' ASP . 26.7 t0 -56.14 118.12 4.39 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.442 179.393 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.442 ' O ' ' CG ' ' A' ' 43' ' ' GLU . 2.2 tt0 -73.19 25.86 0.06 Allowed 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.419 -0.913 . . . . 0.0 111.211 -179.431 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.489 ' H ' ' C ' ' A' ' 42' ' ' ASP . 26.0 m-20 -129.1 1.88 5.23 Favored 'General case' 0 N--CA 1.49 1.551 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.795 179.779 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -147.1 53.02 1.08 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.408 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -135.03 148.1 65.42 Favored Pre-proline 0 N--CA 1.49 1.57 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -179.802 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -47.68 140.14 17.54 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 120.903 1.069 . . . . 0.0 111.986 -179.4 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.65 83.01 1.56 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.887 -179.953 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.06 -33.81 0.52 Allowed Glycine 0 N--CA 1.488 2.129 0 C-N-CA 119.558 -1.305 . . . . 0.0 110.027 -179.893 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 35.7 t -87.33 109.08 18.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.713 179.807 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -51.49 153.83 2.07 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.799 -179.92 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -110.88 -6.48 14.71 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 120.018 -0.673 . . . . 0.0 110.864 -179.844 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -90.16 -15.37 31.66 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.461 -0.895 . . . . 0.0 111.102 -179.81 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.7 mtmm -91.86 -28.92 17.0 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.905 -179.858 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 11.8 pt -98.57 1.14 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 C-N-CA 119.633 -0.827 . . . . 0.0 110.994 -179.887 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.8 m -94.42 -178.52 4.61 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.079 180.0 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.655 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 52.1 mt-30 -139.64 69.9 37.89 Favored Pre-proline 0 C--N 1.305 -1.34 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.338 -179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -59.74 -21.49 63.58 Favored 'Trans proline' 0 C--N 1.325 -0.696 0 C-N-CA 121.531 1.488 . . . . 0.0 111.829 -178.879 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.411 ' O ' ' O ' ' A' ' 60' ' ' TYR . 1.3 tm-20 -91.86 109.91 21.25 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.236 179.539 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.511 ' CD1' ' ND2' ' A' ' 38' ' ' ASN . 52.8 m-85 -43.09 166.07 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.541 -0.864 . . . . 0.0 110.948 -179.884 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.764 HD11 ' OD1' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -140.38 148.43 41.25 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.726 -0.79 . . . . 0.0 109.938 179.68 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.609 ' N ' HD12 ' A' ' 61' ' ' LEU . 0.0 OUTLIER -149.05 22.67 0.96 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.111 -179.464 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -83.14 102.47 2.4 Favored Glycine 0 N--CA 1.486 1.978 0 C-N-CA 119.163 -1.494 . . . . 0.0 110.382 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -57.34 113.28 1.69 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.067 -1.053 . . . . 0.0 110.178 179.512 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 97.85 -18.48 57.15 Favored Glycine 0 N--CA 1.487 2.093 0 C-N-CA 119.413 -1.375 . . . . 0.0 110.162 -179.49 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 25.6 tp10 -65.7 128.3 35.42 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.207 -0.997 . . . . 0.0 110.165 179.896 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -110.74 166.65 10.85 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.796 -0.761 . . . . 0.0 111.427 -179.653 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.655 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 43.1 t80 -135.8 139.86 43.8 Favored 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.455 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -108.78 158.24 17.83 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.258 -0.977 . . . . 0.0 112.709 -178.589 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -160.07 137.49 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.122 179.138 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 9.1 m -127.65 97.25 4.79 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.339 -179.242 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 16.8 mt -81.75 159.29 23.89 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.322 -0.951 . . . . 0.0 109.831 179.499 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 18.0 p -150.79 50.85 0.86 Allowed 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 118.882 -1.127 . . . . 0.0 111.946 -178.965 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 75' ' ' LYS . 3.9 tp10 -146.15 99.9 3.31 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.094 -1.043 . . . . 0.0 110.121 178.992 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.417 ' C ' ' O ' ' A' ' 74' ' ' GLU . 8.7 ptmm? -42.27 112.15 0.31 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.051 -179.309 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 168.63 -146.26 10.22 Favored Glycine 0 N--CA 1.485 1.919 0 C-N-CA 119.26 -1.448 . . . . 0.0 110.062 -179.69 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.81 138.33 35.73 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.643 -0.823 . . . . 0.0 110.987 -179.726 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.549 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -121.27 147.78 45.19 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.332 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 18.2 mmtp -112.93 123.56 50.6 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.586 -0.846 . . . . 0.0 111.83 -179.643 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.574 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.5 OUTLIER -136.96 158.66 43.96 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.611 -0.836 . . . . 0.0 109.789 177.523 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 32.3 p90 -169.86 179.96 3.47 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 119.261 -0.976 . . . . 0.0 111.206 -178.197 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -103.91 124.63 49.32 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.83 179.753 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.548 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.5 OUTLIER -70.57 -44.42 17.35 Favored Pre-proline 0 N--CA 1.487 1.387 0 C-N-CA 119.66 -0.816 . . . . 0.0 112.752 -179.77 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.548 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.0 Cg_exo -66.72 -53.54 0.55 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 120.892 1.061 . . . . 0.0 111.921 -178.942 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 85' ' ' HIS . . . . . 0.425 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.3 m80 -80.0 8.35 7.23 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.336 -0.945 . . . . 0.0 111.292 -179.521 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.37 -7.72 0.64 Allowed 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.705 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -76.2 -24.91 67.45 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.393 -1.384 . . . . 0.0 110.381 -179.924 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.65 -35.17 15.12 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.602 -179.994 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 124.77 21.09 2.21 Favored Glycine 0 N--CA 1.495 2.624 0 C-N-CA 119.869 -1.158 . . . . 0.0 110.531 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.79 108.99 1.29 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.416 -0.914 . . . . 0.0 111.256 -179.857 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 17.4 mttm -131.57 162.31 30.61 Favored 'General case' 0 N--CA 1.495 1.817 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.392 -179.871 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.454 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.19 147.86 19.49 Favored Glycine 0 N--CA 1.495 2.602 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.098 -179.194 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -149.21 138.05 21.21 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.891 179.842 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 94' ' ' VAL . 9.7 p -135.24 127.95 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 C-N-CA 118.723 -1.191 . . . . 0.0 110.883 178.694 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 47.4 m -106.91 100.46 9.96 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.572 179.319 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 45.3 t -80.5 144.66 10.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 C-N-CA 118.632 -1.227 . . . . 0.0 110.496 -179.045 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 116.284 -1.817 . . . . 0.0 110.758 -179.809 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 120.827 0.346 . . . . 0.0 110.163 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.1 mt-10 -100.05 121.68 41.76 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.765 179.88 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -99.15 119.25 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.998 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -91.3 113.22 25.42 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 119.626 -0.83 . . . . 0.0 111.021 -179.921 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 mp -79.7 110.58 15.17 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 118.88 -1.128 . . . . 0.0 109.547 178.472 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 98.71 103.82 2.41 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -178.864 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.9 p . . . . . 0 C--N 1.303 -1.453 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.937 -179.552 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt . . . . . 0 N--CA 1.486 1.342 0 CA-C-O 120.513 0.197 . . . . 0.0 110.746 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.7 m -145.7 157.9 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 C-N-CA 118.962 -1.095 . . . . 0.0 111.131 179.843 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.403 ' O ' ' C ' ' A' ' 16' ' ' PRO . 47.3 m-85 -79.17 111.37 15.32 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.459 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 47.8 m -114.89 107.96 49.46 Favored Pre-proline 0 C--N 1.307 -1.275 0 C-N-CA 119.536 -0.866 . . . . 0.0 112.406 -177.071 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.403 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.9 Cg_endo -67.01 167.35 58.32 Favored 'Cis proline' 0 C--N 1.359 1.086 0 C-N-CA 125.34 -0.692 . . . . 0.0 111.528 -0.827 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.423 ' OG ' ' N ' ' A' ' 18' ' ' SER . 0.2 OUTLIER -95.29 -67.24 0.86 Allowed 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.496 -0.881 . . . . 0.0 109.716 178.885 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.423 ' N ' ' OG ' ' A' ' 17' ' ' SER . 0.7 OUTLIER -112.2 123.44 50.27 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.437 178.816 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.487 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 11.5 p90 -156.72 144.31 19.14 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 118.782 -1.167 . . . . 0.0 111.141 -179.005 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -88.84 157.26 18.51 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.299 -0.96 . . . . 0.0 111.247 -179.84 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.5 m -148.61 171.44 2.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.493 179.631 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.81 151.92 22.94 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.477 -179.933 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.4 65.95 0.65 Allowed 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.873 179.761 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.444 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 171.02 8.58 0.02 OUTLIER Glycine 0 N--CA 1.486 1.983 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.444 ' H ' ' H ' ' A' ' 24' ' ' GLY . 6.8 tp10 -98.65 154.14 18.17 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.752 -0.779 . . . . 0.0 110.549 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 49.6 mttm -95.17 144.06 26.1 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.288 -179.718 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 37.1 mm -111.89 98.34 6.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 CA-C-N 115.541 -0.754 . . . . 0.0 108.999 179.033 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.7 p -92.85 115.49 28.17 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.145 -1.022 . . . . 0.0 112.477 -178.217 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -85.18 121.2 27.59 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.021 -0.991 . . . . 0.0 109.136 178.512 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -124.68 134.87 52.72 Favored 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.686 -0.806 . . . . 0.0 111.734 -178.519 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 66' ' ' GLU . 57.5 m-80 -84.67 113.31 21.2 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.505 179.604 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.549 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.9 t30 -97.98 -30.23 12.84 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 119.195 -1.002 . . . . 0.0 111.354 -179.23 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.549 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.7 99.33 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.004 179.724 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 153.11 23.45 0.05 OUTLIER Glycine 0 N--CA 1.489 2.22 0 C-N-CA 118.874 -1.632 . . . . 0.0 111.234 179.487 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.62 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -73.67 162.68 73.06 Favored Pre-proline 0 C--N 1.307 -1.253 0 C-N-CA 118.744 -1.182 . . . . 0.0 109.907 179.756 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -75.8 147.51 88.18 Favored 'Cis proline' 0 N--CA 1.479 0.658 0 C-N-CA 124.396 -1.085 . . . . 0.0 112.366 -1.118 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -112.59 -177.66 3.2 Favored 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.944 -0.702 . . . . 0.0 110.817 179.279 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -163.75 144.35 8.7 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.771 -0.772 . . . . 0.0 110.005 179.173 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.52 HD13 ' NE2' ' A' ' 57' ' ' GLN . 3.9 mp -133.78 122.79 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 119.567 -0.853 . . . . 0.0 111.436 -179.48 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.8 t -140.61 146.5 24.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.403 179.101 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -100.51 128.49 46.56 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.214 -0.994 . . . . 0.0 111.888 -179.094 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 25.8 t0 -66.71 119.98 12.71 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.244 179.512 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -68.66 -7.21 31.2 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.026 -178.991 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -97.37 7.15 47.1 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.247 -0.981 . . . . 0.0 111.649 -179.208 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -145.55 27.63 1.22 Allowed 'General case' 0 N--CA 1.488 1.466 0 C-N-CA 119.284 -0.966 . . . . 0.0 110.748 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -118.78 146.77 40.8 Favored Pre-proline 0 N--CA 1.492 1.627 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.088 179.801 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -53.05 144.15 47.48 Favored 'Trans proline' 0 C--O 1.214 -0.706 0 C-N-CA 120.953 1.102 . . . . 0.0 111.907 -179.926 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.04 72.2 1.14 Allowed 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 119.533 -0.867 . . . . 0.0 110.855 179.839 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.09 -46.52 0.1 Allowed Glycine 0 N--CA 1.49 2.282 0 C-N-CA 119.544 -1.312 . . . . 0.0 109.978 179.929 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 96.8 t -79.92 87.8 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 119.435 -0.906 . . . . 0.0 110.474 179.697 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -44.63 140.11 2.59 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.964 -179.615 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.0 -20.88 44.4 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.889 -179.94 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -74.38 -22.37 59.22 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.437 -0.905 . . . . 0.0 111.128 -179.713 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -79.27 -24.86 42.67 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.36 -179.612 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -109.79 -18.47 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.427 -179.774 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.3 m -71.37 171.0 12.01 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.183 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.52 ' NE2' HD13 ' A' ' 39' ' ' ILE . 18.1 mt-30 -128.06 78.53 75.19 Favored Pre-proline 0 N--CA 1.488 1.446 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.333 179.914 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -60.86 -11.24 17.08 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.208 1.272 . . . . 0.0 111.615 -178.864 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 20.4 mt-10 -99.47 108.02 20.37 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.749 179.779 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -55.1 176.74 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.531 -0.867 . . . . 0.0 110.85 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.8 pp -154.9 153.1 30.58 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.131 -1.028 . . . . 0.0 111.468 -179.576 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -149.01 14.96 0.92 Allowed 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.987 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -80.95 125.25 6.78 Favored Glycine 0 N--CA 1.491 2.326 0 C-N-CA 119.355 -1.402 . . . . 0.0 110.689 -179.574 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -68.22 126.77 30.61 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.63 179.687 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.56 -12.06 62.17 Favored Glycine 0 N--CA 1.488 2.151 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.713 179.887 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.489 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 2.8 tp10 -65.1 144.3 57.33 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.263 179.749 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -140.79 170.54 15.57 Favored 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.372 -179.387 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.56 ' CD2' ' N ' ' A' ' 69' ' ' GLU . 47.5 t80 -135.57 -179.76 5.84 Favored 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.49 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.56 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 3.3 mt-10 -140.69 146.16 37.46 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.166 -1.014 . . . . 0.0 111.652 -179.818 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.6 t -147.64 126.66 4.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.349 -0.842 . . . . 0.0 109.222 179.377 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.1 m -121.28 99.82 6.7 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.839 -0.744 . . . . 0.0 111.453 -178.841 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.432 ' CD1' HG11 ' A' ' 94' ' ' VAL . 54.9 mt -82.3 159.89 23.03 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.021 179.227 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 57.5 p -150.09 42.99 0.87 Allowed 'General case' 0 C--N 1.296 -1.757 0 C-N-CA 119.214 -0.994 . . . . 0.0 111.083 -179.529 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -143.49 101.37 3.77 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.026 -1.07 . . . . 0.0 110.836 179.76 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -44.61 113.43 0.55 Allowed 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.451 -0.899 . . . . 0.0 110.67 -179.953 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.9 -145.0 8.17 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.399 -1.381 . . . . 0.0 110.044 -179.961 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.82 127.14 16.73 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.893 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.564 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.8 m-85 -114.16 161.9 17.21 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.639 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.5 mmtm -130.48 116.81 18.72 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.47 -0.892 . . . . 0.0 111.987 -178.929 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -123.87 159.05 30.48 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.844 -0.742 . . . . 0.0 109.887 178.081 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -168.67 -179.3 3.75 Favored 'General case' 0 C--N 1.289 -2.025 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.982 -178.936 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 82' ' ' CYS . . . . . 0.484 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -108.81 124.27 50.34 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.634 179.825 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.51 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.3 mt-10 -63.18 -45.28 85.52 Favored Pre-proline 0 N--CA 1.485 1.308 0 C-N-CA 119.728 -0.789 . . . . 0.0 112.997 -179.611 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.51 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.8 Cg_endo -66.16 -46.04 4.94 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 120.99 1.127 . . . . 0.0 112.077 -179.202 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -92.59 14.62 16.4 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 119.16 -1.016 . . . . 0.0 111.55 -179.262 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.484 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -67.97 -1.19 5.26 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 118.946 -1.101 . . . . 0.0 110.455 179.66 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -95.27 -18.76 32.51 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.439 -1.362 . . . . 0.0 110.095 179.871 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.94 -36.34 15.05 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.44 179.676 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 130.72 26.0 0.81 Allowed Glycine 0 N--CA 1.494 2.539 0 C-N-CA 119.911 -1.137 . . . . 0.0 110.342 179.836 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -82.65 95.37 7.79 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.186 -1.006 . . . . 0.0 110.865 -179.924 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.7 162.51 24.03 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.816 179.926 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -143.62 144.83 14.14 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.294 -1.432 . . . . 0.0 111.874 -178.455 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -148.52 143.69 26.83 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.963 -0.695 . . . . 0.0 110.084 179.282 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.611 ' O ' HG13 ' A' ' 94' ' ' VAL . 14.0 p -137.44 118.68 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 119.09 -1.044 . . . . 0.0 110.793 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 90.8 m -95.62 99.17 11.07 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.486 179.528 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 35.5 t -80.11 149.38 5.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 C-N-CA 118.999 -1.08 . . . . 0.0 110.805 -178.804 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 116.332 -1.794 . . . . 0.0 110.797 -179.862 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.066 0 CA-C-O 120.867 0.365 . . . . 0.0 110.052 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -93.77 140.46 29.63 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.701 179.866 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 t -126.95 131.88 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.523 179.477 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 11.7 mtmm -105.17 118.09 35.66 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.844 -179.534 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.408 ' C ' ' OD1' ' A' ' 32' ' ' ASN . 5.7 mt -79.87 103.71 9.95 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 118.754 -1.178 . . . . 0.0 109.639 178.809 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.521 ' C ' HD21 ' A' ' 32' ' ' ASN . . . 118.53 134.3 4.97 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -178.527 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 7' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 6' ' ' GLY . 26.0 p . . . . . 0 C--N 1.305 -1.33 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.198 -179.423 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.0 mt . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 120.471 0.177 . . . . 0.0 110.711 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 4.5 m -147.67 154.18 11.34 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 C-N-CA 118.952 -1.099 . . . . 0.0 111.044 179.626 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' A' ' 16' ' ' PRO . 9.9 m-85 -78.22 107.61 10.94 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.431 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.8 m -113.77 109.04 50.67 Favored Pre-proline 0 C--N 1.306 -1.313 0 C-N-CA 119.81 -0.756 . . . . 0.0 111.912 -177.447 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.424 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.6 Cg_endo -67.64 177.05 23.95 Favored 'Cis proline' 0 C--N 1.355 0.916 0 CA-C-N 119.053 0.697 . . . . 0.0 111.671 -0.376 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.4 p -93.92 -47.16 6.85 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.77 178.862 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.8 p -132.82 144.28 50.11 Favored 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.287 178.841 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -164.6 134.58 3.9 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 118.456 -1.297 . . . . 0.0 111.409 -178.962 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.5 p -86.42 159.71 19.27 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.855 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.7 m -148.79 172.49 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.902 179.755 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -87.57 149.61 24.23 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.774 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.29 73.33 0.49 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.348 -0.941 . . . . 0.0 111.072 179.974 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.433 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 155.75 14.32 0.05 OUTLIER Glycine 0 N--CA 1.486 2.028 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.433 ' H ' ' H ' ' A' ' 24' ' ' GLY . 24.5 tt0 -104.45 147.24 27.79 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.552 -179.597 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.1 pttm -95.36 149.84 20.93 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.48 -179.616 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.4 mt -119.95 148.9 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.237 179.202 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.3 p -138.6 119.34 14.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.224 -0.991 . . . . 0.0 111.692 -179.153 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -86.61 146.03 26.5 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.338 178.9 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.3 tttm -138.39 132.04 30.84 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.356 -179.231 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.568 HD21 ' N ' ' A' ' 31' ' ' ASN . 1.0 OUTLIER -81.18 113.09 19.1 Favored 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.815 179.576 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.633 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 4.0 p-10 -106.2 -23.54 12.56 Favored 'General case' 0 N--CA 1.493 1.689 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.743 -179.775 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.633 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.82 101.89 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 118.509 -1.277 . . . . 0.0 111.326 179.837 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 141.65 22.19 0.25 Allowed Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.239 -1.458 . . . . 0.0 111.457 179.574 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.61 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -78.2 161.98 68.44 Favored Pre-proline 0 N--CA 1.485 1.288 0 C-N-CA 118.159 -1.417 . . . . 0.0 110.026 179.502 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -75.9 148.56 90.45 Favored 'Cis proline' 0 C--O 1.214 -0.684 0 C-N-CA 124.21 -1.162 . . . . 0.0 112.291 -0.755 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.402 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 48.9 m-70 -115.48 178.56 4.25 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.166 179.585 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 44.2 t30 -151.13 137.98 18.97 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.2 -1.0 . . . . 0.0 110.338 178.875 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.405 HD12 ' OE1' ' A' ' 57' ' ' GLN . 5.7 mt -124.06 106.1 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.135 -179.494 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t -128.32 149.0 32.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.001 179.54 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -103.94 126.76 51.3 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.861 -179.305 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.432 ' C ' ' H ' ' A' ' 44' ' ' ASP . 0.4 OUTLIER -70.64 118.07 12.97 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.412 179.636 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -74.76 41.6 0.16 Allowed 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.386 -0.926 . . . . 0.0 110.861 -179.677 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.432 ' H ' ' C ' ' A' ' 42' ' ' ASP . 8.6 m-20 -128.28 -10.53 5.23 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.586 179.815 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -132.81 15.93 4.3 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.74 179.831 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.402 HG13 ' HD2' ' A' ' 47' ' ' PRO . 55.5 t -99.1 143.45 26.41 Favored Pre-proline 0 C--N 1.296 -1.73 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.571 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.402 ' HD2' HG13 ' A' ' 46' ' ' VAL . 3.6 Cg_exo -55.42 161.75 6.97 Favored 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 120.81 1.006 . . . . 0.0 111.619 -179.947 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -90.22 51.23 1.99 Allowed 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 119.578 -0.849 . . . . 0.0 111.001 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -154.0 -42.86 0.02 OUTLIER Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.46 -1.352 . . . . 0.0 109.998 179.827 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 5.6 p -77.35 152.28 5.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 119.812 -0.755 . . . . 0.0 110.407 179.643 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 -88.79 139.47 30.43 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.048 179.173 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.419 ' HA ' HD11 ' A' ' 55' ' ' ILE . . . -102.76 -4.48 24.91 Favored 'General case' 0 N--CA 1.491 1.611 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.252 -179.782 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -90.69 -33.68 15.7 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.645 -179.531 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 62.8 mttt -78.26 -21.82 49.25 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.434 -0.906 . . . . 0.0 111.972 -179.018 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.419 HD11 ' HA ' ' A' ' 52' ' ' ALA . 6.3 pt -92.91 -25.03 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.213 -179.547 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 33.3 m -69.19 174.1 5.0 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.133 179.658 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.659 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 66.7 mt-30 -126.88 78.98 73.14 Favored Pre-proline 0 N--CA 1.488 1.456 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.65 -179.888 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.27 -14.44 38.45 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 120.958 1.105 . . . . 0.0 111.187 -179.258 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.423 ' O ' ' O ' ' A' ' 60' ' ' TYR . 10.5 mt-10 -100.53 105.06 16.46 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.78 -0.768 . . . . 0.0 110.646 179.445 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.423 ' O ' ' O ' ' A' ' 59' ' ' GLU . 31.6 m-85 -46.01 172.4 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.941 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.544 ' O ' HD12 ' A' ' 61' ' ' LEU . 3.0 pp -138.54 125.79 21.58 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.688 -0.805 . . . . 0.0 110.29 179.548 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -132.61 45.49 2.74 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.409 -178.845 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.28 118.97 3.56 Favored Glycine 0 N--CA 1.499 2.896 0 C-N-CA 119.718 -1.229 . . . . 0.0 110.528 179.822 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -54.64 123.4 13.07 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.398 179.735 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 81.48 3.86 90.54 Favored Glycine 0 N--CA 1.489 2.225 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.648 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -69.47 107.16 3.24 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.921 179.607 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.5 p -98.09 164.59 12.28 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.499 -0.88 . . . . 0.0 111.55 -178.96 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.659 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 45.1 t80 -135.0 176.97 8.17 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 178.844 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.605 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 5.3 mt-10 -144.89 150.86 37.79 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 118.539 -1.265 . . . . 0.0 112.252 -179.316 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -157.85 136.83 3.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 115.066 -0.97 . . . . 0.0 108.727 179.205 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 19.1 m -129.12 92.74 3.44 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.53 -0.868 . . . . 0.0 111.716 -178.907 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 10.0 mt -79.76 155.39 27.94 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 118.995 -1.082 . . . . 0.0 108.709 178.833 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.567 HG23 ' OE2' ' A' ' 74' ' ' GLU . 3.1 t -150.47 46.57 0.88 Allowed 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.678 -1.209 . . . . 0.0 111.719 -179.29 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.567 ' OE2' HG23 ' A' ' 73' ' ' THR . 34.1 mm-40 -138.81 103.12 4.74 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.47 -0.892 . . . . 0.0 109.78 178.916 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -40.11 107.18 0.07 Allowed 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 119.781 -0.768 . . . . 0.0 111.321 -179.448 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 176.74 -150.36 10.32 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.172 -1.489 . . . . 0.0 110.591 -179.778 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.89 133.61 28.81 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.258 -179.521 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.604 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.9 OUTLIER -120.13 155.43 33.07 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.765 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 27.0 mmtt -126.93 127.94 45.65 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.532 -0.867 . . . . 0.0 111.909 -178.876 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.512 ' O ' ' N ' ' A' ' 92' ' ' GLY . 2.0 p90 -139.11 165.85 26.06 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.432 -0.907 . . . . 0.0 110.701 178.377 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 35.2 p90 -169.91 -179.78 3.35 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.144 -177.928 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -104.07 125.53 50.48 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.321 179.404 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.55 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tt0 -68.6 -44.48 33.19 Favored Pre-proline 0 N--CA 1.486 1.358 0 C-N-CA 119.531 -0.868 . . . . 0.0 112.985 -179.436 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -68.44 -50.06 0.76 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 120.931 1.087 . . . . 0.0 111.94 -178.771 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 33.4 m80 -88.9 16.91 6.2 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.342 -0.943 . . . . 0.0 111.572 -179.363 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.64 -10.32 3.48 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.726 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -89.13 -17.09 56.63 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.374 -1.393 . . . . 0.0 110.304 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.34 -22.89 24.82 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.385 179.881 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 112.7 17.48 7.99 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.798 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.1 mtp -70.64 99.87 1.75 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.228 179.806 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.1 pttp -125.1 164.33 20.46 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 120.045 -0.662 . . . . 0.0 110.088 178.723 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.02 147.75 18.49 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 118.538 -1.791 . . . . 0.0 111.862 -178.497 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -153.94 146.9 24.47 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 119.721 -0.792 . . . . 0.0 110.568 179.103 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.8 p -140.68 134.36 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.125 179.252 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.2 m -110.66 101.73 10.35 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.65 -0.82 . . . . 0.0 110.886 179.734 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 49.0 t -80.68 152.1 4.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.902 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.6 p30 . . . . . 0 C--N 1.304 -1.4 0 CA-C-O 116.364 -1.779 . . . . 0.0 110.81 -179.867 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.156 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -110.54 122.86 48.78 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.996 179.965 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.0 t -111.26 126.36 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 119.983 -0.687 . . . . 0.0 110.524 179.728 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 39.4 mttt -98.72 118.45 35.48 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.809 -179.483 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.419 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 12.8 mt -82.05 107.1 14.49 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 118.754 -1.179 . . . . 0.0 110.625 179.135 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.418 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 114.49 138.71 6.83 Favored Glycine 0 N--CA 1.495 2.626 0 C-N-CA 120.218 -0.991 . . . . 0.0 110.669 -179.588 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 24.2 p . . . . . 0 C--N 1.308 -1.201 0 C-N-CA 119.532 -0.867 . . . . 0.0 110.624 179.747 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.8 mt . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 120.465 0.174 . . . . 0.0 110.695 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.4 m -150.72 159.71 4.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.708 179.234 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.508 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 23.3 m-85 -78.46 114.58 17.49 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 177.948 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.4 m -116.24 105.99 49.81 Favored Pre-proline 0 C--N 1.308 -1.238 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.865 -177.45 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -67.55 178.32 20.2 Favored 'Cis proline' 0 C--N 1.359 1.131 0 CA-C-N 118.921 0.65 . . . . 0.0 111.946 -0.395 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.1 m -94.14 -48.12 6.35 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.643 -0.823 . . . . 0.0 110.182 179.162 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 44.6 m -137.34 140.98 41.82 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.419 179.144 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.405 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 25.1 p90 -162.93 143.21 9.33 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.626 -179.138 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.415 HG23 ' H ' ' A' ' 20' ' ' THR . 0.6 OUTLIER -91.27 155.51 18.5 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.146 179.894 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.07 157.13 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 C-N-CA 119.416 -0.914 . . . . 0.0 111.082 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.46 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -75.4 141.06 43.3 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.17 179.456 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.94 75.32 0.04 OUTLIER 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.045 -179.783 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 161.53 13.48 0.03 OUTLIER Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -104.94 151.04 24.37 Favored 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.622 -179.649 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.8 mttp -94.53 141.1 28.99 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.037 -179.919 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 mt -117.89 153.06 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.743 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.5 p -147.77 113.45 5.7 Favored 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 118.811 -1.156 . . . . 0.0 111.954 -179.448 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -84.39 116.18 22.91 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.36 -0.936 . . . . 0.0 108.962 178.485 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.2 tttm -111.56 132.84 54.25 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.778 -178.264 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.579 ' OD1' HD11 ' A' ' 61' ' ' LEU . 0.6 OUTLIER -76.48 104.23 6.89 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.703 -0.799 . . . . 0.0 109.849 178.904 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.466 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 5.2 p-10 -94.21 -26.23 16.74 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 118.906 -1.118 . . . . 0.0 112.025 -178.642 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.466 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 179.12 147.53 0.2 Allowed 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 118.489 -1.284 . . . . 0.0 111.593 -179.783 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 89.63 10.28 65.47 Favored Glycine 0 N--CA 1.481 1.674 0 C-N-CA 119.485 -1.341 . . . . 0.0 111.731 178.661 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -49.66 162.54 0.44 Allowed Pre-proline 0 N--CA 1.48 1.055 0 C-N-CA 117.844 -1.542 . . . . 0.0 108.895 179.431 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -75.93 -173.67 13.0 Favored 'Cis proline' 0 C--O 1.204 -1.189 0 C-N-CA 124.324 -1.115 . . . . 0.0 112.294 -0.213 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.8 m-70 -151.07 171.92 16.56 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 120.142 -0.623 . . . . 0.0 110.522 178.576 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.423 ' OD1' ' N ' ' A' ' 39' ' ' ILE . 45.9 t30 -149.61 148.29 29.14 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.488 179.393 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.423 ' N ' ' OD1' ' A' ' 38' ' ' ASN . 4.1 mp -135.55 112.17 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 C-N-CA 119.676 -0.81 . . . . 0.0 111.322 -179.437 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 t -134.98 149.65 29.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.948 179.224 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -104.77 128.38 52.89 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.512 -0.875 . . . . 0.0 112.04 -179.077 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.42 ' C ' ' H ' ' A' ' 44' ' ' ASP . 49.3 t0 -66.97 126.38 28.94 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.086 179.344 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 63.8 mt-10 -72.1 11.51 0.55 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.229 -0.989 . . . . 0.0 111.221 -179.662 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.42 ' H ' ' C ' ' A' ' 42' ' ' ASP . 28.4 m-20 -105.85 -5.54 19.68 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.667 -0.813 . . . . 0.0 111.068 -179.862 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -142.7 51.97 1.42 Allowed 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 119.719 -0.792 . . . . 0.0 110.229 -179.743 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -139.6 145.97 45.81 Favored Pre-proline 0 N--CA 1.487 1.393 0 CA-C-N 115.286 -0.87 . . . . 0.0 108.825 179.678 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -54.17 163.7 3.18 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 120.798 0.999 . . . . 0.0 112.216 -179.358 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -89.26 61.76 5.85 Favored 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 119.84 -0.744 . . . . 0.0 110.824 -179.968 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.21 -46.38 0.04 OUTLIER Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.529 -1.319 . . . . 0.0 110.014 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.5 t -79.6 84.07 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 C-N-CA 119.554 -0.858 . . . . 0.0 110.39 179.703 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -45.09 139.71 3.12 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.204 -0.999 . . . . 0.0 110.712 -179.636 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.08 -33.06 65.4 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.728 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -61.68 -17.91 57.44 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.304 -179.637 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.32 -45.46 11.91 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.422 -179.728 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.0 pt -90.35 -13.8 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 119.233 -0.987 . . . . 0.0 111.327 -179.641 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 69.2 m -77.65 173.44 12.04 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.582 179.551 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.615 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 69.4 mt-30 -129.24 78.83 75.35 Favored Pre-proline 0 N--CA 1.489 1.481 0 C-N-CA 120.036 -0.665 . . . . 0.0 110.64 -179.868 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.93 -11.47 18.28 Favored 'Trans proline' 0 C--O 1.216 -0.605 0 C-N-CA 121.032 1.155 . . . . 0.0 111.024 -179.539 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -101.35 116.89 33.82 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.535 179.14 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -58.38 159.4 6.27 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.359 -0.936 . . . . 0.0 110.999 -179.672 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.616 ' C ' HD12 ' A' ' 61' ' ' LEU . 0.7 OUTLIER -125.41 146.97 49.37 Favored 'General case' 0 N--CA 1.49 1.532 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.666 179.233 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.551 ' N ' HD12 ' A' ' 61' ' ' LEU . 9.8 p-10 -155.17 58.6 0.65 Allowed 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.253 -0.979 . . . . 0.0 111.343 -178.744 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.62 130.1 6.23 Favored Glycine 0 N--CA 1.497 2.734 0 C-N-CA 119.737 -1.22 . . . . 0.0 110.784 179.805 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -69.94 103.88 2.36 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.459 -0.896 . . . . 0.0 110.464 179.575 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.45 -7.29 46.53 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.222 -179.709 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -64.7 151.81 44.05 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.141 179.515 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.7 165.15 31.35 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 118.884 -1.126 . . . . 0.0 111.838 -179.679 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.615 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 49.5 t80 -136.07 138.25 41.94 Favored 'General case' 0 N--CA 1.484 1.258 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.323 179.149 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -108.62 153.38 23.49 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.423 -0.911 . . . . 0.0 112.164 -178.765 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -155.41 139.93 9.26 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.439 178.891 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.8 m -126.02 95.95 4.58 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.083 -179.44 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.472 ' CD1' HG11 ' A' ' 94' ' ' VAL . 13.9 mt -79.68 160.9 26.12 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.437 179.434 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.71 25.29 0.76 Allowed 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 118.717 -1.193 . . . . 0.0 112.057 -178.497 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.466 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -116.69 99.9 7.45 Favored 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.357 179.846 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 8.5 mttt -43.44 105.79 0.06 Allowed 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.724 -179.76 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.3 -139.61 5.02 Favored Glycine 0 N--CA 1.483 1.79 0 C-N-CA 119.321 -1.418 . . . . 0.0 109.929 -179.769 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.2 m -146.68 136.02 22.79 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.251 -0.98 . . . . 0.0 111.168 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.576 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -120.52 140.78 50.96 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.829 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 22.9 mmtt -110.17 124.28 51.26 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 119.433 -0.907 . . . . 0.0 111.872 -179.0 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.566 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -134.39 160.89 36.57 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.14 178.395 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 81' ' ' TYR . . . . . 0.419 ' CD1' ' N ' ' A' ' 81' ' ' TYR . 23.8 p90 -168.29 179.21 4.58 Favored 'General case' 0 C--N 1.293 -1.87 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.889 -178.54 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -102.72 125.4 49.44 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.401 179.663 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.509 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 mt-10 -67.05 -46.25 52.79 Favored Pre-proline 0 C--N 1.306 -1.319 0 C-N-CA 119.499 -0.88 . . . . 0.0 112.819 -179.56 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.509 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.9 Cg_endo -67.01 -48.64 1.74 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 120.97 1.113 . . . . 0.0 112.114 -178.725 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -88.5 20.51 3.33 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.009 -179.515 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.87 -10.4 20.41 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.454 179.449 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.6 -17.31 57.09 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.491 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.15 -15.13 32.18 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.433 -0.907 . . . . 0.0 110.582 179.952 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.64 21.27 11.51 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.722 -1.228 . . . . 0.0 110.573 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.3 mtp -73.05 98.51 2.55 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.174 179.941 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.508 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 16.5 ttmt -121.41 159.6 25.85 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.38 143.49 12.17 Favored Glycine 0 N--CA 1.496 2.636 0 C-N-CA 119.352 -1.404 . . . . 0.0 111.255 -179.065 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.75 143.67 24.64 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.635 179.514 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.578 ' O ' HG13 ' A' ' 94' ' ' VAL . 9.9 p -136.31 122.43 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.318 179.523 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 99.9 m -100.93 100.48 11.12 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.745 -179.951 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 40.3 t -79.84 139.84 17.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 C-N-CA 118.634 -1.226 . . . . 0.0 110.478 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 116.441 -1.743 . . . . 0.0 110.965 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -106.06 133.39 50.84 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.92 -179.931 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.9 t -123.47 117.48 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 C-N-CA 119.991 -0.684 . . . . 0.0 110.419 179.657 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 29.3 mttp -91.95 114.35 26.87 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.652 -178.81 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 5' ' ' LEU . . . . . 0.441 ' HB3' ' CE1' ' A' ' 37' ' ' HIS . 5.5 mt -76.37 113.28 13.78 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.069 -1.053 . . . . 0.0 109.805 178.007 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.46 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.36 125.35 5.61 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.764 -1.207 . . . . 0.0 110.238 -179.448 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.7 p . . . . . 0 C--N 1.302 -1.481 0 C-N-CA 119.462 -0.895 . . . . 0.0 110.7 179.884 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.1 mt . . . . . 0 N--CA 1.487 1.41 0 CA-C-O 120.487 0.184 . . . . 0.0 110.596 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.0 m -150.99 157.06 5.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.116 0 C-N-CA 118.892 -1.123 . . . . 0.0 110.747 179.297 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.522 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 56.8 m-85 -78.12 113.1 15.74 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 177.887 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.6 m -115.19 109.08 47.01 Favored Pre-proline 0 CA--C 1.559 1.311 0 C-N-CA 119.552 -0.859 . . . . 0.0 112.176 -176.954 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -67.14 172.59 37.29 Favored 'Cis proline' 0 C--N 1.359 1.119 0 C-N-CA 125.216 -0.743 . . . . 0.0 111.331 -0.444 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 38.8 t -94.19 -64.31 1.09 Allowed 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.704 178.934 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 t -113.11 135.19 54.08 Favored 'General case' 0 N--CA 1.485 1.292 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.546 178.748 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.418 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 21.7 p90 -160.97 137.91 8.84 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 118.71 -1.196 . . . . 0.0 111.308 -179.141 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.417 HG23 ' H ' ' A' ' 20' ' ' THR . 0.8 OUTLIER -88.25 154.98 19.99 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.073 179.766 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.7 m -145.95 168.66 7.02 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 119.447 -0.901 . . . . 0.0 110.815 179.771 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.49 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -92.3 146.62 23.56 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.656 179.833 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.17 76.4 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.52 -0.872 . . . . 0.0 111.052 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 154.02 15.14 0.06 OUTLIER Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.888 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -102.43 132.94 48.12 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.898 -179.592 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.8 mtpp -75.75 141.53 42.59 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.42 ' O ' HG22 ' A' ' 27' ' ' ILE . 3.0 mt -125.72 112.1 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 C-N-CA 120.088 -0.645 . . . . 0.0 109.261 179.407 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 13.4 p -108.52 121.43 44.96 Favored 'General case' 0 N--CA 1.488 1.462 0 C-N-CA 119.622 -0.831 . . . . 0.0 112.256 -178.561 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -86.36 121.18 28.56 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.449 -0.9 . . . . 0.0 109.182 178.502 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.0 tmtp? -112.71 142.42 45.34 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.871 -0.731 . . . . 0.0 110.655 -178.689 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.471 ' ND2' ' CD2' ' A' ' 35' ' ' PHE . 0.2 OUTLIER -94.05 118.41 31.48 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.178 179.87 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.679 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.8 OUTLIER -98.9 -30.74 12.21 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.864 -179.989 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.679 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 165.02 146.34 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.078 179.896 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 111.51 2.53 27.51 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.91 -1.138 . . . . 0.0 110.861 179.484 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.597 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -52.2 163.91 0.66 Allowed Pre-proline 0 C--N 1.308 -1.219 0 C-N-CA 118.868 -1.133 . . . . 0.0 109.917 179.797 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_endo -78.31 143.69 73.34 Favored 'Cis proline' 0 C--O 1.212 -0.821 0 C-N-CA 124.156 -1.185 . . . . 0.0 112.489 -0.808 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 37' ' ' HIS . . . . . 0.441 ' CE1' ' HB3' ' A' ' 5' ' ' LEU . 11.7 m80 -107.29 178.88 4.41 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.032 179.149 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 33.5 t-20 -158.03 145.0 17.91 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.635 -0.826 . . . . 0.0 110.061 179.098 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.9 mp -131.92 117.04 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.758 -0.777 . . . . 0.0 110.948 -179.771 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 40.4 t -136.03 141.79 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.19 179.667 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.491 ' HB2' ' HB1' ' A' ' 52' ' ' ALA . 48.7 m-85 -93.78 134.02 36.55 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 119.442 -0.903 . . . . 0.0 111.064 -179.584 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.676 ' C ' ' H ' ' A' ' 44' ' ' ASP . 24.7 p-10 -75.23 101.49 4.67 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.279 -0.969 . . . . 0.0 110.975 -179.523 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.571 ' H ' ' CD ' ' A' ' 43' ' ' GLU . 1.6 pm0 -55.63 6.5 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.175 0 C-N-CA 119.969 -0.692 . . . . 0.0 111.38 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.676 ' H ' ' C ' ' A' ' 42' ' ' ASP . 4.2 m-20 -83.08 -67.31 0.8 Allowed 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.837 179.138 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -97.83 27.36 4.49 Favored 'General case' 0 N--CA 1.49 1.539 0 C-N-CA 119.335 -0.946 . . . . 0.0 112.089 -177.049 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 42' ' ' ASP . 45.3 t -102.48 143.97 27.67 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.598 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.439 ' HD2' HG13 ' A' ' 46' ' ' VAL . 4.6 Cg_exo -46.61 140.9 11.71 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 120.777 0.984 . . . . 0.0 112.178 -179.107 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.53 39.28 0.26 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.863 -179.892 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.433 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -142.55 -41.0 0.07 OUTLIER Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.703 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.487 HG23 ' OE1' ' A' ' 74' ' ' GLU . 71.6 t -87.73 84.63 2.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.894 179.207 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -44.19 139.9 2.38 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.573 -0.851 . . . . 0.0 111.083 -179.185 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.491 ' HB1' ' HB2' ' A' ' 41' ' ' PHE . . . -86.21 0.65 53.21 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.473 -0.891 . . . . 0.0 110.766 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -87.39 -10.76 51.2 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.826 179.914 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.0 mtmt -98.17 -35.47 10.37 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.594 -0.842 . . . . 0.0 111.232 -179.668 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.487 HD12 ' CD2' ' A' ' 41' ' ' PHE . 8.3 pt -92.86 -13.37 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.245 -0.982 . . . . 0.0 111.373 -179.522 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 29.0 m -76.3 170.31 16.58 Favored 'General case' 0 C--N 1.307 -1.241 0 C-N-CA 119.186 -1.006 . . . . 0.0 110.893 179.791 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.483 ' OE1' ' CD2' ' A' ' 68' ' ' TYR . 2.1 mt-30 -138.37 69.82 46.9 Favored Pre-proline 0 N--CA 1.487 1.379 0 C-N-CA 120.046 -0.662 . . . . 0.0 110.584 -179.854 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -59.56 -10.08 10.56 Favored 'Trans proline' 0 C--N 1.323 -0.798 0 C-N-CA 121.457 1.438 . . . . 0.0 111.554 -179.304 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.418 ' O ' ' O ' ' A' ' 60' ' ' TYR . 0.7 OUTLIER -85.84 103.32 14.48 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.184 179.482 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.418 ' O ' ' O ' ' A' ' 59' ' ' GLU . 90.0 m-85 -44.16 168.26 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.164 -179.593 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.43 HD11 ' OD1' ' A' ' 31' ' ' ASN . 3.1 pp -151.8 146.4 25.68 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.05 179.913 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -143.69 -7.05 0.77 Allowed 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 119.318 -0.953 . . . . 0.0 111.387 -179.684 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -48.23 125.43 12.89 Favored Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.174 -1.489 . . . . 0.0 110.628 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -71.36 111.78 6.96 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.818 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 91.83 -11.19 72.79 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.252 -1.451 . . . . 0.0 110.84 -179.895 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -57.98 159.35 5.71 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.178 -1.009 . . . . 0.0 110.487 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.58 172.63 12.7 Favored 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.987 -179.442 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.571 ' CD2' ' N ' ' A' ' 69' ' ' GLU . 51.9 t80 -135.34 178.59 6.92 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.36 179.09 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.571 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 8.4 mt-10 -145.99 152.0 38.68 Favored 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 118.747 -1.181 . . . . 0.0 111.986 -179.739 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -162.41 140.42 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 119.876 -0.729 . . . . 0.0 109.713 178.539 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.1 m -129.83 97.9 4.63 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.744 -179.619 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.498 ' CD1' HG11 ' A' ' 94' ' ' VAL . 9.3 mt -79.75 159.29 26.65 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.012 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 4.1 p -150.41 51.39 0.89 Allowed 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.793 -179.25 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.487 ' OE1' HG23 ' A' ' 50' ' ' VAL . 1.3 tt0 -142.95 99.81 3.53 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.406 -0.918 . . . . 0.0 109.839 178.829 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 74' ' ' GLU . 3.9 mttp -42.65 103.37 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.436 -0.906 . . . . 0.0 110.618 -179.568 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.0 -142.27 5.51 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.171 -1.49 . . . . 0.0 110.281 -179.544 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.97 133.4 21.86 Favored 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.476 -179.657 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.59 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -122.18 116.87 24.93 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.4 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.456 ' O ' ' OD1' ' A' ' 42' ' ' ASP . 11.2 mptt -95.88 115.69 27.81 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.172 -1.011 . . . . 0.0 111.787 -178.713 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.569 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -119.5 170.09 9.47 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.825 -0.75 . . . . 0.0 110.1 178.755 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -170.37 179.78 3.29 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.329 -178.631 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -102.94 128.27 49.81 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 119.754 -0.779 . . . . 0.0 110.17 179.258 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.53 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 mt-10 -73.34 -45.58 7.77 Favored Pre-proline 0 C--N 1.304 -1.399 0 C-N-CA 119.552 -0.859 . . . . 0.0 112.788 -179.399 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.53 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.3 Cg_exo -65.95 -51.11 1.33 Allowed 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 120.88 1.053 . . . . 0.0 111.684 -179.087 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 85' ' ' HIS . . . . . 0.457 ' C ' ' H ' ' A' ' 87' ' ' GLY . 38.2 m80 -83.52 13.96 4.12 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.321 -0.952 . . . . 0.0 111.054 -179.774 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.24 -5.4 0.48 Allowed 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.299 -0.96 . . . . 0.0 110.742 179.806 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.457 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -81.04 -26.54 52.72 Favored Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.515 -179.848 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.96 -13.64 35.74 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.626 179.916 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.44 7.15 49.5 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 119.709 -1.234 . . . . 0.0 110.418 179.932 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -48.31 109.69 0.26 Allowed 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.734 179.902 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.522 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -134.95 170.78 15.37 Favored 'General case' 0 N--CA 1.494 1.756 0 C-N-CA 119.551 -0.86 . . . . 0.0 111.422 -179.849 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -151.63 149.34 21.07 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.192 -1.48 . . . . 0.0 111.266 -178.67 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -152.89 139.3 18.57 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.397 179.522 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.598 ' O ' HG13 ' A' ' 94' ' ' VAL . 10.7 p -132.79 121.5 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 C-N-CA 119.289 -0.965 . . . . 0.0 110.5 179.279 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 39.3 m -98.64 100.77 12.03 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.908 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 25.8 t -82.68 151.04 4.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 118.747 -1.181 . . . . 0.0 110.367 -179.369 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 116.397 -1.763 . . . . 0.0 110.846 -179.744 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.1 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -131.37 136.97 48.5 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 120.017 -0.673 . . . . 0.0 110.521 179.977 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.1 t -131.13 124.23 55.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.587 179.839 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 7.0 mptt -95.85 116.89 29.57 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.165 -179.606 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 37.7 mt -75.69 109.93 9.68 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 118.681 -1.208 . . . . 0.0 109.235 178.151 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 99.46 134.07 8.35 Favored Glycine 0 N--CA 1.484 1.895 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -178.612 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.9 p . . . . . 0 C--N 1.303 -1.439 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.737 -179.905 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 mt . . . . . 0 N--CA 1.489 1.477 0 CA-C-O 120.551 0.215 . . . . 0.0 110.642 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.2 m -150.01 155.36 7.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.781 179.889 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.425 ' O ' ' O ' ' A' ' 16' ' ' PRO . 75.3 m-85 -78.62 108.97 12.41 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 177.579 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.7 m -111.63 114.43 52.39 Favored Pre-proline 0 C--N 1.303 -1.453 0 C-N-CA 119.389 -0.925 . . . . 0.0 112.07 -177.283 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.6 Cg_endo -66.68 172.47 35.74 Favored 'Cis proline' 0 C--N 1.361 1.201 0 C-N-CA 125.333 -0.695 . . . . 0.0 111.449 -0.685 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.44 -67.06 0.87 Allowed 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.334 179.193 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -108.61 140.4 42.04 Favored 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.556 179.129 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 22.1 p90 -165.69 140.16 4.71 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 118.227 -1.389 . . . . 0.0 111.786 -179.213 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.683 HG22 ' HB ' ' A' ' 95' ' ' THR . 75.7 p -88.83 157.42 18.47 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.761 179.423 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -149.9 151.48 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 C-N-CA 119.297 -0.961 . . . . 0.0 111.159 179.739 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.46 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -71.95 142.55 49.43 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.316 -0.954 . . . . 0.0 110.462 179.724 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.17 75.98 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 119.414 -0.914 . . . . 0.0 111.188 -179.752 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 161.08 11.1 0.04 OUTLIER Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.857 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.45 ' H ' ' H ' ' A' ' 24' ' ' GLY . 2.9 tp10 -105.13 148.56 26.73 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 120.1 -0.64 . . . . 0.0 110.832 -179.497 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 10.3 pttm -95.16 155.01 16.91 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.493 -0.883 . . . . 0.0 111.09 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 mt -127.22 109.21 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.799 179.56 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.1 p -100.68 117.69 35.31 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.789 -0.764 . . . . 0.0 112.028 -178.757 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -84.66 129.83 34.79 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.238 -0.985 . . . . 0.0 108.723 178.315 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.0 ttmt -120.0 128.12 53.25 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.394 -178.53 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.571 ' ND2' ' O ' ' A' ' 66' ' ' GLU . 70.4 m-80 -71.81 111.49 7.12 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.536 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.673 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.9 OUTLIER -96.09 -31.9 12.79 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.023 -1.071 . . . . 0.0 111.32 -179.856 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.673 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 163.26 130.97 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.894 179.585 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 124.89 2.58 7.86 Favored Glycine 0 N--CA 1.496 2.665 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.142 179.488 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -50.55 162.98 0.49 Allowed Pre-proline 0 C--N 1.307 -1.245 0 C-N-CA 118.518 -1.273 . . . . 0.0 109.739 179.798 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -75.96 144.37 79.57 Favored 'Cis proline' 0 C--O 1.215 -0.655 0 C-N-CA 124.279 -1.134 . . . . 0.0 112.341 -0.482 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 30.6 m-70 -108.05 173.74 6.19 Favored 'General case' 0 N--CA 1.493 1.719 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.637 179.541 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 51.6 t-20 -152.62 138.35 17.9 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.925 179.534 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.448 ' O ' ' N ' ' A' ' 57' ' ' GLN . 3.7 mp -128.13 99.97 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.904 -179.728 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.6 t -123.36 147.35 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.011 179.341 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -101.26 129.63 47.25 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.464 -0.894 . . . . 0.0 111.505 -179.676 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -67.03 113.72 5.24 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.702 -0.799 . . . . 0.0 110.632 179.656 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -62.06 -4.42 1.66 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.678 -0.809 . . . . 0.0 111.718 -179.22 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -95.78 -2.4 47.75 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.089 -179.78 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -140.65 50.47 1.67 Allowed 'General case' 0 C--N 1.312 -1.031 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.704 179.871 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -140.35 145.9 43.23 Favored Pre-proline 0 N--CA 1.489 1.502 0 CA-C-N 115.51 -0.768 . . . . 0.0 108.936 179.879 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -54.81 162.33 5.15 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 120.798 0.998 . . . . 0.0 111.742 -179.739 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -90.16 55.47 3.1 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.835 179.958 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -161.59 -42.27 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.06 179.926 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 88.5 t -86.28 92.62 3.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 C-N-CA 119.565 -0.854 . . . . 0.0 110.421 179.756 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -44.55 139.78 2.68 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.953 -179.785 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.88 -15.6 55.89 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.519 -0.873 . . . . 0.0 110.965 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -77.68 -28.0 50.95 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.406 -0.917 . . . . 0.0 111.309 -179.479 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -73.45 -35.63 65.79 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.44 -179.202 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.9 pt -96.54 -13.83 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.533 -179.353 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.3 m -77.27 176.3 8.91 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.025 -1.07 . . . . 0.0 111.35 -179.611 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.651 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 60.6 mt-30 -137.31 71.58 53.36 Favored Pre-proline 0 C--N 1.306 -1.298 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.432 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -59.26 -19.08 48.41 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 121.307 1.338 . . . . 0.0 111.34 -179.217 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -91.83 97.25 10.87 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.294 179.259 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -43.54 163.94 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.725 -179.731 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.7 pp -134.8 139.5 45.15 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.567 -0.853 . . . . 0.0 110.887 179.728 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.412 ' ND2' ' N ' ' A' ' 62' ' ' ASN . 0.1 OUTLIER -131.53 31.52 4.29 Favored 'General case' 0 N--CA 1.484 1.234 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.479 179.942 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -99.76 128.45 9.58 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.475 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -78.17 128.91 34.48 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.413 -0.915 . . . . 0.0 110.799 179.955 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 81.5 -21.84 5.95 Favored Glycine 0 N--CA 1.489 2.227 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.794 179.915 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.571 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 2.2 mm-40 -49.72 162.82 0.15 Allowed 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.178 -1.009 . . . . 0.0 110.267 179.858 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 7.6 p -146.28 163.36 35.76 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.79 -179.38 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.651 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 37.2 t80 -136.05 146.13 46.75 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.421 179.39 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -106.12 148.69 27.53 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 119.466 -0.894 . . . . 0.0 112.318 -178.773 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -149.41 132.88 7.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.498 178.786 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 18.2 m -131.21 105.36 7.62 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.469 -0.892 . . . . 0.0 111.639 -179.012 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.452 ' CD1' HG11 ' A' ' 94' ' ' VAL . 17.9 mt -95.32 152.64 18.21 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 119.422 -0.911 . . . . 0.0 109.693 179.091 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 47.4 p -150.57 47.02 0.88 Allowed 'General case' 0 C--N 1.293 -1.854 0 C-N-CA 119.304 -0.959 . . . . 0.0 110.862 -179.54 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -137.81 107.79 6.34 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.728 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 8.5 tptt -44.45 112.51 0.42 Allowed 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.333 -179.876 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 167.94 -152.28 20.4 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.086 -1.531 . . . . 0.0 110.391 179.722 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.92 135.46 32.85 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.495 -179.922 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.558 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -121.36 166.3 14.27 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.659 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 17.3 mmtp -138.2 130.14 28.43 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.804 -179.322 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.528 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.5 p90 -137.24 164.18 29.15 Favored 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.214 178.673 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 39.4 p90 -170.32 -173.83 1.56 Allowed 'General case' 0 C--N 1.287 -2.146 0 C-N-CA 119.586 -0.846 . . . . 0.0 110.704 -178.497 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 82' ' ' CYS . . . . . 0.551 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -112.38 129.85 56.17 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.57 179.478 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.502 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.9 mm-40 -69.71 -45.77 24.95 Favored Pre-proline 0 N--CA 1.488 1.454 0 C-N-CA 119.393 -0.923 . . . . 0.0 112.906 -179.446 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.502 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.9 Cg_endo -66.95 -52.22 0.7 Allowed 'Trans proline' 0 C--O 1.216 -0.6 0 C-N-CA 120.756 0.971 . . . . 0.0 112.41 -179.244 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 85' ' ' HIS . . . . . 0.455 ' C ' ' H ' ' A' ' 87' ' ' GLY . 35.2 m80 -81.54 5.61 17.43 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.449 -0.901 . . . . 0.0 112.224 -178.912 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 86' ' ' ALA . . . . . 0.551 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -61.59 -2.01 0.69 Allowed 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.712 -1.195 . . . . 0.0 110.525 179.935 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.455 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -81.63 -23.52 57.97 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 119.503 -1.332 . . . . 0.0 110.39 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.5 -45.45 7.76 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.346 -0.941 . . . . 0.0 110.43 -179.996 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.01 29.18 0.15 Allowed Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.531 179.687 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -76.12 102.69 5.83 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.124 -1.03 . . . . 0.0 110.961 179.888 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.6 pttt -131.12 166.49 20.98 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.434 -179.898 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.84 147.31 17.43 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.23 -1.462 . . . . 0.0 111.612 -178.713 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -149.47 147.71 28.55 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.347 179.189 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.452 HG11 ' CD1' ' A' ' 72' ' ' LEU . 14.3 p -143.39 136.19 24.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 118.911 -1.116 . . . . 0.0 110.363 179.377 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.683 ' HB ' HG22 ' A' ' 20' ' ' THR . 4.8 m -114.52 108.19 16.52 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.914 -0.714 . . . . 0.0 110.626 179.815 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.6 t -84.96 143.86 10.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 C-N-CA 118.532 -1.267 . . . . 0.0 110.527 -178.932 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 116.293 -1.813 . . . . 0.0 111.229 -179.664 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.161 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -115.56 121.16 41.81 Favored 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.479 179.589 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 61.5 t -110.5 122.38 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 C-N-CA 119.792 -0.763 . . . . 0.0 111.062 -179.787 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.1 mtmt -91.89 112.11 23.92 Favored 'General case' 0 C--N 1.297 -1.685 0 C-N-CA 119.449 -0.9 . . . . 0.0 110.454 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 7.7 mt -77.33 108.15 10.26 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 118.869 -1.133 . . . . 0.0 110.471 179.083 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.422 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 113.76 147.66 9.79 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.557 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.6 p . . . . . 0 C--N 1.306 -1.314 0 C-N-CA 119.561 -0.855 . . . . 0.0 110.901 179.846 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 120.333 0.111 . . . . 0.0 110.771 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.8 m -151.8 156.61 5.83 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 C-N-CA 118.963 -1.095 . . . . 0.0 110.646 178.978 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.406 ' O ' ' C ' ' A' ' 16' ' ' PRO . 43.5 m-85 -78.55 113.31 16.46 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 177.572 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.8 m -115.21 107.58 49.38 Favored Pre-proline 0 N--CA 1.484 1.25 0 C-N-CA 119.434 -0.907 . . . . 0.0 112.089 -177.277 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.406 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -66.79 176.24 23.75 Favored 'Cis proline' 0 C--N 1.359 1.101 0 C-N-CA 125.409 -0.663 . . . . 0.0 111.738 -0.414 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.27 -52.98 4.92 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.611 -0.836 . . . . 0.0 110.088 179.138 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.4 t -131.09 146.68 52.45 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.398 178.985 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.404 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 23.0 p90 -161.55 140.04 9.53 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 118.374 -1.33 . . . . 0.0 111.96 -179.066 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.654 HG22 ' HB ' ' A' ' 95' ' ' THR . 64.3 p -81.62 155.66 25.53 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.837 -0.745 . . . . 0.0 110.913 179.652 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.9 m -148.76 164.76 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 119.572 -0.851 . . . . 0.0 110.483 179.528 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.507 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -89.93 147.56 23.65 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.288 -0.965 . . . . 0.0 110.998 -179.754 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.15 77.59 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.509 -0.876 . . . . 0.0 110.788 179.756 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.66 23.15 0.09 OUTLIER Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -179.97 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -103.99 140.01 38.33 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.987 -0.685 . . . . 0.0 110.764 -179.578 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.9 mtmt -85.03 125.9 33.11 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.282 -0.967 . . . . 0.0 110.97 -179.851 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.2 mt -102.62 119.77 51.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 C-N-CA 119.803 -0.759 . . . . 0.0 109.578 179.779 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 43.3 p -117.1 114.57 23.91 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.7 -0.8 . . . . 0.0 112.393 -178.513 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -87.46 117.91 26.56 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.003 178.319 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.8 tttt -112.29 138.61 48.76 Favored 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 119.544 -0.862 . . . . 0.0 111.86 -178.338 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.417 HD21 HD13 ' A' ' 61' ' ' LEU . 3.9 m-20 -81.13 131.36 35.3 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.2 179.683 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.66 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.8 p-10 -125.56 -17.06 5.63 Favored 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.067 179.217 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 166.04 149.55 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 C-N-CA 119.542 -0.863 . . . . 0.0 111.247 178.992 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.28 -5.74 59.19 Favored Glycine 0 N--CA 1.495 2.581 0 C-N-CA 119.279 -1.439 . . . . 0.0 112.284 178.626 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -48.14 162.23 0.34 Allowed Pre-proline 0 N--CA 1.489 1.488 0 C-N-CA 118.133 -1.427 . . . . 0.0 109.723 -179.923 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -76.23 142.99 75.12 Favored 'Cis proline' 0 C--O 1.212 -0.796 0 C-N-CA 124.304 -1.123 . . . . 0.0 112.538 -0.638 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.2 m-70 -108.66 -179.63 3.92 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 119.856 -0.738 . . . . 0.0 111.498 -179.896 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.595 ' ND2' ' CD1' ' A' ' 60' ' ' TYR . 2.5 t-20 -158.63 146.71 18.25 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.841 -0.744 . . . . 0.0 110.241 179.167 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.9 mp -135.94 117.81 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 119.519 -0.873 . . . . 0.0 111.08 -179.925 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.55 160.4 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.298 179.089 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.552 ' HB2' ' HB1' ' A' ' 52' ' ' ALA . 12.5 m-85 -113.38 125.0 53.78 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.41 -0.916 . . . . 0.0 112.058 -178.973 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.5 ' C ' ' H ' ' A' ' 44' ' ' ASP . 1.1 t70 -65.23 107.18 1.51 Allowed 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.664 178.786 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -67.86 16.38 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 119.505 -0.878 . . . . 0.0 112.207 -178.826 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.5 ' H ' ' C ' ' A' ' 42' ' ' ASP . 1.9 m-20 -106.02 -3.68 21.36 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 119.5 -0.88 . . . . 0.0 111.019 179.89 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -140.89 12.39 2.25 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.917 179.596 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -92.32 147.02 33.68 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.615 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -49.68 154.67 4.45 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 120.966 1.111 . . . . 0.0 112.019 -179.286 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.79 67.79 10.21 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.682 -179.935 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.86 -38.13 0.07 OUTLIER Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.957 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 55.8 t -90.53 81.19 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.371 179.583 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -44.21 139.62 2.51 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.13 -179.359 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.552 ' HB1' ' HB2' ' A' ' 41' ' ' PHE . . . -87.44 10.31 17.94 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.955 -179.724 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -90.55 -22.68 21.17 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.091 -1.044 . . . . 0.0 111.513 -179.476 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -93.81 -32.32 14.01 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 118.912 -1.115 . . . . 0.0 112.046 -179.329 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.1 pt -90.33 -23.74 5.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.513 -179.327 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 56' ' ' SER . . . . . 0.404 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 18.1 m -61.78 -178.8 0.16 Allowed 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.098 179.869 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.501 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 18.0 tt0 -157.83 67.84 3.81 Favored Pre-proline 0 C--N 1.303 -1.444 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.689 -179.579 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.96 -29.34 87.82 Favored 'Trans proline' 0 C--N 1.323 -0.781 0 C-N-CA 121.308 1.339 . . . . 0.0 111.286 -179.419 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -59.01 112.28 1.62 Allowed 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.554 179.701 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.595 ' CD1' ' ND2' ' A' ' 38' ' ' ASN . 43.9 m-85 -58.55 169.55 0.9 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.998 -179.95 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.417 HD13 HD21 ' A' ' 31' ' ' ASN . 1.2 pp -153.73 149.17 27.2 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.362 179.688 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.512 ' O ' ' C ' ' A' ' 63' ' ' GLY . 0.0 OUTLIER -127.21 -74.31 0.59 Allowed 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.396 -179.288 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 63' ' ' GLY . . . . . 0.512 ' C ' ' O ' ' A' ' 62' ' ' ASN . . . -9.65 123.41 0.01 OUTLIER Glycine 1 N--CA 1.518 4.113 0 O-C-N 124.202 0.939 . . . . 0.0 112.75 -179.641 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -75.05 131.41 40.56 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.43 -0.908 . . . . 0.0 110.664 179.736 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.63 -14.96 58.92 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.596 -1.288 . . . . 0.0 110.528 -179.975 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' A' ' 66' ' ' GLU . 1.2 mp0 -62.96 148.51 47.33 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.446 179.844 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.38 163.24 34.35 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.246 -0.982 . . . . 0.0 111.396 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.501 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 41.5 t80 -136.54 143.73 43.85 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 119.87 -0.732 . . . . 0.0 109.276 179.269 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -106.15 152.16 23.8 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.219 -0.992 . . . . 0.0 111.995 -179.149 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -151.82 131.58 3.62 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 CA-C-N 115.345 -0.843 . . . . 0.0 108.813 179.555 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.7 m -121.52 112.87 19.04 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.804 -179.067 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.47 ' CD1' HG11 ' A' ' 94' ' ' VAL . 45.7 mt -96.56 158.61 15.35 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.725 -0.79 . . . . 0.0 109.417 178.924 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.0 m -150.89 41.9 0.77 Allowed 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 118.56 -1.256 . . . . 0.0 112.351 -179.133 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 62.8 mt-10 -145.92 110.98 5.27 Favored 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.378 178.918 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -44.06 116.51 1.01 Allowed 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.934 -179.569 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 164.5 175.16 35.04 Favored Glycine 0 N--CA 1.483 1.807 0 C-N-CA 119.293 -1.432 . . . . 0.0 110.35 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.76 126.77 53.38 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.992 -0.683 . . . . 0.0 110.977 -179.785 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.554 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -108.35 141.99 39.34 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.352 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 16.5 mmtp -105.12 122.22 45.45 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.953 -179.139 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.423 ' CZ ' ' N ' ' A' ' 93' ' ' GLU . 5.7 p90 -138.48 160.04 40.57 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 119.315 -0.954 . . . . 0.0 110.076 177.508 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -170.24 -175.26 1.91 Allowed 'General case' 0 C--N 1.287 -2.112 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.908 -177.655 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.6 t -103.48 122.72 45.49 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.732 -0.787 . . . . 0.0 109.372 179.245 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.564 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 4.9 tt0 -73.4 -36.04 2.94 Favored Pre-proline 0 CA--C 1.557 1.236 0 C-N-CA 118.84 -1.144 . . . . 0.0 113.267 -178.701 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.564 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.0 OUTLIER -70.25 -47.74 0.73 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 120.376 0.718 . . . . 0.0 111.105 179.66 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 85' ' ' HIS . . . . . 0.407 ' C ' ' H ' ' A' ' 87' ' ' GLY . 36.7 m80 -87.77 16.45 5.76 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.593 -0.843 . . . . 0.0 110.808 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.53 -2.61 1.69 Allowed 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.364 -0.935 . . . . 0.0 110.821 179.908 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.407 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -88.16 -17.83 56.82 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.354 -1.403 . . . . 0.0 110.29 179.911 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.45 -41.61 10.2 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.644 179.961 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 132.72 13.88 1.56 Allowed Glycine 0 N--CA 1.494 2.555 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.562 179.861 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.49 101.86 0.21 Allowed 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.928 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.5 tptt -124.71 154.1 41.35 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 119.914 -0.715 . . . . 0.0 111.256 -179.854 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.55 153.1 21.88 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.85 -179.055 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.423 ' N ' ' CZ ' ' A' ' 80' ' ' PHE . 2.7 mt-10 -156.4 146.05 20.9 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.363 -0.935 . . . . 0.0 111.289 179.911 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.501 ' O ' HG13 ' A' ' 94' ' ' VAL . 13.1 p -138.7 128.54 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.24 178.792 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.654 ' HB ' HG22 ' A' ' 20' ' ' THR . 98.8 m -106.77 100.09 9.62 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.68 179.831 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.0 t -80.04 150.78 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.237 0 C-N-CA 118.779 -1.169 . . . . 0.0 110.392 -179.714 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 116.339 -1.791 . . . . 0.0 110.828 179.969 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.153 0 CA-C-O 120.855 0.36 . . . . 0.0 110.079 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -105.27 135.69 46.17 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.929 -0.708 . . . . 0.0 110.647 179.887 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.0 t -124.11 126.62 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.817 -0.753 . . . . 0.0 110.445 179.591 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 7.3 mttp -100.84 118.57 37.16 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.792 -0.763 . . . . 0.0 110.591 -179.819 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.2 mt -83.66 109.82 17.77 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.646 178.84 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 106.25 133.36 7.42 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -178.8 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.2 p . . . . . 0 C--N 1.301 -1.511 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.624 179.64 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.619 HD13 ' CD2' ' A' ' 85' ' ' HIS . 49.9 mt . . . . . 0 N--CA 1.489 1.498 0 CA-C-O 120.692 0.282 . . . . 0.0 110.645 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.1 m -147.3 154.67 11.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 C-N-CA 119.091 -1.044 . . . . 0.0 111.023 179.899 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.443 ' O ' ' O ' ' A' ' 16' ' ' PRO . 40.4 m-85 -78.39 109.08 12.22 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 177.893 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 20.0 m -115.37 111.32 44.38 Favored Pre-proline 0 C--O 1.205 -1.24 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.51 -177.446 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.443 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -66.16 176.57 20.88 Favored 'Cis proline' 0 C--N 1.355 0.909 0 C-N-CA 125.304 -0.707 . . . . 0.0 111.612 0.102 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -92.86 -56.58 2.94 Favored 'General case' 0 N--CA 1.486 1.371 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.726 178.803 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.8 t -125.75 139.37 53.58 Favored 'General case' 0 N--CA 1.486 1.341 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.073 178.806 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 16.4 p90 -159.03 132.84 7.49 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.448 -178.915 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.454 ' H ' HG23 ' A' ' 20' ' ' THR . 0.8 OUTLIER -83.12 155.07 24.01 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.271 -0.972 . . . . 0.0 110.865 179.762 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 17.8 m -146.57 171.55 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.326 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.998 179.741 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -93.94 151.45 19.55 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.414 -0.914 . . . . 0.0 110.684 179.728 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.2 73.54 0.12 Allowed 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.146 -179.986 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 154.69 13.14 0.06 OUTLIER Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.791 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -99.07 117.04 32.67 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.663 -179.783 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.1 mtmp? -65.96 133.44 50.86 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 119.477 -0.889 . . . . 0.0 111.066 -179.774 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 mt -113.55 131.77 64.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 C-N-CA 119.954 -0.698 . . . . 0.0 109.248 179.454 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.5 p -125.29 123.29 39.16 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.526 -0.87 . . . . 0.0 112.173 -178.54 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -84.4 147.29 27.22 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.414 -0.914 . . . . 0.0 108.851 178.346 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 tttm -136.62 127.9 28.18 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.396 -0.921 . . . . 0.0 111.371 -178.873 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.2 m-80 -79.45 109.45 13.82 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.69 -0.804 . . . . 0.0 110.52 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.654 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.3 OUTLIER -95.49 -30.73 13.7 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.76 -179.474 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.654 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 166.4 136.92 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.041 -179.661 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 116.27 -2.23 20.65 Favored Glycine 0 N--CA 1.495 2.599 0 C-N-CA 119.836 -1.174 . . . . 0.0 111.033 179.189 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -47.37 163.83 0.25 Allowed Pre-proline 0 C--N 1.308 -1.224 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.775 179.792 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -76.23 145.34 82.01 Favored 'Cis proline' 0 C--O 1.214 -0.722 0 C-N-CA 124.223 -1.157 . . . . 0.0 112.659 -0.756 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -111.22 172.15 7.05 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.889 179.298 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.566 ' ND2' ' CD2' ' A' ' 60' ' ' TYR . 7.0 t-20 -149.8 137.98 20.47 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.111 179.34 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.412 HD13 ' NE2' ' A' ' 57' ' ' GLN . 3.5 mp -125.17 110.68 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 C-N-CA 119.893 -0.723 . . . . 0.0 110.888 -179.689 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.5 t -130.93 145.31 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.95 -0.7 . . . . 0.0 110.326 179.528 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -99.53 121.7 41.55 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.586 -0.845 . . . . 0.0 111.322 -179.356 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -60.48 100.87 0.11 Allowed 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.131 -1.028 . . . . 0.0 110.044 179.484 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -57.65 -6.6 0.52 Allowed 'General case' 0 N--CA 1.489 1.488 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.277 -179.012 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -93.36 3.19 56.01 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 118.993 -1.083 . . . . 0.0 112.263 -178.733 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 30.6 mt-10 -144.56 13.52 1.55 Allowed 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 119.116 -1.033 . . . . 0.0 111.741 -179.944 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -90.85 149.96 41.22 Favored Pre-proline 0 C--N 1.292 -1.919 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.287 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -47.91 144.25 12.05 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.917 1.078 . . . . 0.0 111.878 -179.539 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.6 73.98 1.99 Allowed 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.531 -0.868 . . . . 0.0 110.617 179.994 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.47 -32.72 0.12 Allowed Glycine 0 N--CA 1.487 2.053 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.241 -179.94 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 81.4 t -94.83 105.79 17.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.374 -0.93 . . . . 0.0 111.073 -179.855 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -52.17 143.99 13.29 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.715 179.882 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -93.04 -3.28 54.6 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.328 -0.949 . . . . 0.0 110.908 -179.773 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -90.22 -21.45 22.15 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.255 -0.978 . . . . 0.0 110.94 -179.931 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 23.4 mmtt -78.14 -26.96 48.08 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.304 -0.958 . . . . 0.0 110.936 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.3 pt -105.8 -12.22 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.845 -179.192 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 18.6 m -78.39 170.07 17.22 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.108 -1.037 . . . . 0.0 111.316 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.501 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 16.0 mt-30 -134.19 74.11 68.27 Favored Pre-proline 0 N--CA 1.486 1.335 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.241 179.902 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -59.52 -20.26 56.19 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 121.277 1.318 . . . . 0.0 111.63 -178.69 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 59' ' ' GLU . . . . . 0.444 ' O ' ' CG ' ' A' ' 59' ' ' GLU . 3.4 pt-20 -89.14 107.0 18.8 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.527 179.513 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.566 ' CD2' ' ND2' ' A' ' 38' ' ' ASN . 27.6 m-85 -51.93 165.61 0.19 Allowed 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 119.411 -0.915 . . . . 0.0 110.849 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.4 pp -139.34 126.38 21.09 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.43 179.466 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.457 ' OD1' ' N ' ' A' ' 62' ' ' ASN . 19.8 p-10 -118.31 34.97 4.94 Favored 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.057 -179.49 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -87.99 -172.08 47.06 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 119.238 -1.458 . . . . 0.0 110.214 179.64 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -133.59 105.94 7.14 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.049 179.579 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 94.24 -11.37 70.58 Favored Glycine 0 N--CA 1.486 2.03 0 C-N-CA 119.308 -1.425 . . . . 0.0 109.713 -179.299 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -50.59 160.94 0.37 Allowed 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.359 179.684 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.7 p -145.8 158.99 43.82 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.393 -179.374 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.501 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 15.6 t80 -136.16 137.01 40.5 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.365 179.068 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -99.97 152.3 20.35 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 119.292 -0.963 . . . . 0.0 112.494 -178.769 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -155.81 134.53 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 115.191 -0.913 . . . . 0.0 108.9 179.509 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.1 m -128.6 96.7 4.47 Favored 'General case' 0 N--CA 1.486 1.327 0 C-N-CA 119.559 -0.856 . . . . 0.0 111.208 -179.482 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.5 mt -79.88 157.63 26.9 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.25 -0.98 . . . . 0.0 109.9 179.433 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 77.6 p -150.06 45.96 0.91 Allowed 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.495 -179.169 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.439 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.7 mm-40 -142.46 113.29 7.45 Favored 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.098 -1.041 . . . . 0.0 110.448 179.557 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.466 ' CG ' ' O ' ' A' ' 75' ' ' LYS . 0.6 OUTLIER -52.45 119.33 4.35 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.268 -0.973 . . . . 0.0 111.058 -179.322 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 163.36 -147.87 13.91 Favored Glycine 0 N--CA 1.483 1.78 0 C-N-CA 119.254 -1.451 . . . . 0.0 110.142 179.86 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.74 130.18 23.9 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.752 -179.938 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.53 ' N ' ' CD1' ' A' ' 78' ' ' TYR . 2.6 m-85 -114.86 123.8 50.08 Favored 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.923 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 79' ' ' LYS . . . . . 0.516 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.5 OUTLIER -103.97 121.03 42.29 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.133 -1.027 . . . . 0.0 111.76 -178.949 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 4.2 p90 -129.54 173.19 10.81 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.212 178.295 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -171.11 -174.29 1.46 Allowed 'General case' 0 C--N 1.292 -1.894 0 C-N-CA 119.531 -0.868 . . . . 0.0 110.814 -178.576 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -108.89 132.07 54.41 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 119.898 -0.721 . . . . 0.0 110.49 179.209 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.496 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.2 mt-10 -73.38 -47.18 7.61 Favored Pre-proline 0 N--CA 1.485 1.286 0 C-N-CA 119.432 -0.907 . . . . 0.0 112.472 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.2 Cg_exo -64.54 -47.18 5.94 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 120.89 1.06 . . . . 0.0 111.953 -179.227 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 85' ' ' HIS . . . . . 0.619 ' CD2' HD13 ' A' ' 12' ' ' LEU . 37.6 m80 -90.51 21.42 3.95 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.971 -179.421 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.73 1.66 1.24 Allowed 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.692 179.844 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.446 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -96.5 -20.94 23.41 Favored Glycine 0 N--CA 1.49 2.277 0 C-N-CA 119.471 -1.347 . . . . 0.0 110.412 -179.869 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.41 -9.87 45.95 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.485 179.667 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 96.46 20.28 25.33 Favored Glycine 0 N--CA 1.488 2.102 0 C-N-CA 119.498 -1.334 . . . . 0.0 110.462 179.817 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.31 102.72 0.7 Allowed 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.151 -1.02 . . . . 0.0 110.982 -179.829 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.07 162.1 26.86 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.003 179.826 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -142.96 153.26 24.6 Favored Glycine 0 N--CA 1.491 2.359 0 C-N-CA 119.436 -1.364 . . . . 0.0 111.468 -178.587 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -155.62 144.87 20.85 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.429 -0.908 . . . . 0.0 111.078 179.629 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -141.78 123.32 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.193 178.461 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 92.3 m -101.14 108.2 19.81 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.158 -179.526 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 23.2 t -88.93 148.15 4.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 118.771 -1.172 . . . . 0.0 110.764 -179.329 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 . . . . . 0 N--CA 1.485 1.317 0 CA-C-O 116.341 -1.79 . . . . 0.0 110.868 -179.903 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.14 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -135.26 127.38 29.87 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 120.027 -0.669 . . . . 0.0 110.574 179.741 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.7 t -115.72 131.86 66.85 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 C-N-CA 119.864 -0.735 . . . . 0.0 110.991 -179.745 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.7 mtpp -104.72 118.9 37.71 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.205 -179.749 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.9 mt -81.52 108.22 14.93 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 118.956 -1.098 . . . . 0.0 109.672 178.269 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.531 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 110.41 125.64 4.91 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.649 -1.381 . . . . 0.0 109.649 -179.1 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.2 p . . . . . 0 C--N 1.299 -1.588 0 C-N-CA 119.162 -1.015 . . . . 0.0 110.934 -179.746 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.6 mt . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 120.496 0.189 . . . . 0.0 110.67 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.4 m -150.01 154.25 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.122 0 C-N-CA 118.777 -1.169 . . . . 0.0 111.268 179.749 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.433 ' O ' ' O ' ' A' ' 16' ' ' PRO . 11.1 m-85 -78.6 108.57 12.09 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 177.818 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 53.3 m -114.76 112.31 45.29 Favored Pre-proline 0 CA--C 1.559 1.303 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.248 -177.176 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.433 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -65.56 176.79 18.52 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 125.188 -0.755 . . . . 0.0 111.702 -0.936 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.9 t -93.86 -55.97 3.05 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.453 179.212 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.4 p -128.92 142.65 50.87 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.814 179.212 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -163.9 143.01 7.83 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 118.663 -1.215 . . . . 0.0 111.782 -179.278 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.431 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -90.76 153.59 20.15 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.903 179.533 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.7 m -145.95 -176.75 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 119.494 -0.882 . . . . 0.0 110.585 179.617 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.409 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -97.53 147.09 24.62 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.716 179.773 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.3 74.03 0.14 Allowed 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.836 179.741 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.411 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 155.54 18.09 0.04 OUTLIER Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.913 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.411 ' H ' ' H ' ' A' ' 24' ' ' GLY . 14.7 tt0 -99.65 156.1 17.25 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.767 -0.773 . . . . 0.0 110.881 -179.783 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.0 mptp? -93.81 119.28 32.56 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.722 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.1 mt -100.06 106.5 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.254 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.2 p -104.26 117.7 34.85 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.582 -0.847 . . . . 0.0 112.888 -177.893 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -84.38 149.0 26.31 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.408 -0.917 . . . . 0.0 108.548 177.893 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 6.4 ttpp -141.19 133.39 27.98 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 118.965 -1.094 . . . . 0.0 111.664 -178.445 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.588 ' ND2' ' O ' ' A' ' 66' ' ' GLU . 0.1 OUTLIER -89.48 104.02 16.61 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.735 178.946 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 2.3 p-10 -91.56 -31.72 15.8 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 118.864 -1.134 . . . . 0.0 111.846 -178.584 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -175.21 139.78 0.48 Allowed 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.138 -179.693 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.26 15.35 33.02 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.495 -1.335 . . . . 0.0 111.784 178.784 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.404 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -58.55 163.24 5.26 Favored Pre-proline 0 N--CA 1.481 1.113 0 C-N-CA 117.96 -1.496 . . . . 0.0 109.2 179.557 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -74.53 -174.48 13.85 Favored 'Cis proline' 0 C--O 1.206 -1.091 0 C-N-CA 124.481 -1.05 . . . . 0.0 112.195 -0.382 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.3 m-70 -149.7 -178.71 6.6 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.885 178.544 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.672 ' ND2' ' CE1' ' A' ' 60' ' ' TYR . 9.1 t-20 -156.75 137.22 13.05 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.375 179.166 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.552 HD12 ' NE2' ' A' ' 57' ' ' GLN . 7.6 mt -122.0 85.27 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 C-N-CA 119.866 -0.734 . . . . 0.0 111.479 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 t -103.34 157.94 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 C-N-CA 119.922 -0.711 . . . . 0.0 109.484 178.755 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -112.29 138.97 48.25 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 119.285 -0.966 . . . . 0.0 111.949 -179.42 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.512 ' C ' ' H ' ' A' ' 44' ' ' ASP . 4.4 t70 -82.36 105.95 13.85 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.003 179.162 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -70.81 32.92 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.378 -179.451 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.512 ' H ' ' C ' ' A' ' 42' ' ' ASP . 82.5 m-20 -108.95 -15.13 14.43 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 120.032 -0.667 . . . . 0.0 110.693 179.518 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -139.79 16.33 2.5 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.718 179.491 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -93.41 143.7 27.09 Favored Pre-proline 0 C--N 1.296 -1.735 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 179.31 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.403 ' C ' ' H ' ' A' ' 49' ' ' GLY . 3.0 Cg_exo -48.45 140.74 20.69 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 120.754 0.97 . . . . 0.0 111.961 -179.392 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.32 43.16 0.37 Allowed 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.67 179.973 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.403 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -148.78 -26.51 0.07 OUTLIER Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 50' ' ' VAL . . . . . 0.441 ' O ' HG12 ' A' ' 50' ' ' VAL . 46.7 t -101.83 93.95 3.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.458 179.746 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -44.88 139.62 2.97 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.741 -179.919 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -90.81 3.42 54.47 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.502 179.851 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -90.3 -31.63 16.86 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.933 179.909 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 37.0 mttt -69.68 -32.52 71.18 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.421 -0.912 . . . . 0.0 111.32 -179.762 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.0 pt -93.22 -35.07 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.123 -1.031 . . . . 0.0 111.148 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.4 m -56.27 163.88 1.51 Allowed 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.198 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.552 ' NE2' HD12 ' A' ' 39' ' ' ILE . 20.6 mt-30 -124.97 84.59 58.76 Favored Pre-proline 0 N--CA 1.487 1.42 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.231 179.713 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -60.37 -22.71 72.25 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 120.995 1.13 . . . . 0.0 111.834 -178.761 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -96.35 115.93 28.22 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.349 -0.94 . . . . 0.0 110.858 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.672 ' CE1' ' ND2' ' A' ' 38' ' ' ASN . 55.0 m-85 -56.34 177.37 0.07 Allowed 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.624 179.879 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.7 pp -148.33 132.75 17.6 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.283 -0.967 . . . . 0.0 110.8 179.93 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -128.99 39.03 3.85 Favored 'General case' 0 N--CA 1.493 1.721 0 C-N-CA 119.976 -0.69 . . . . 0.0 110.955 -179.745 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -102.27 125.52 8.55 Favored Glycine 0 N--CA 1.494 2.512 0 C-N-CA 119.632 -1.271 . . . . 0.0 110.388 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -70.52 103.3 2.44 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.532 179.748 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.38 -0.24 55.76 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.614 -1.279 . . . . 0.0 110.458 -179.884 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.588 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 17.6 tt0 -72.99 106.99 5.1 Favored 'General case' 0 N--CA 1.49 1.562 0 C-N-CA 119.062 -1.055 . . . . 0.0 110.569 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.1 p -96.43 161.99 13.68 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.702 -179.169 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.492 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 24.2 t80 -135.75 136.04 40.45 Favored 'General case' 0 N--CA 1.491 1.592 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.517 179.185 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -98.13 152.23 19.57 Favored 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.256 -0.978 . . . . 0.0 112.547 -178.428 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -151.85 132.78 4.55 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.633 178.951 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 6.6 m -123.52 107.29 11.39 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.622 -0.831 . . . . 0.0 112.023 -178.683 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 72' ' ' LEU . . . . . 0.424 ' CD1' HG11 ' A' ' 94' ' ' VAL . 50.5 mt -89.58 160.88 16.45 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.513 -0.875 . . . . 0.0 109.348 178.749 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.21 41.09 0.72 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 118.66 -1.216 . . . . 0.0 111.754 -178.918 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 74' ' ' GLU . . . . . 0.462 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.6 OUTLIER -141.85 116.76 9.88 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 118.874 -1.13 . . . . 0.0 110.981 179.784 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -55.7 106.18 0.23 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.452 -0.899 . . . . 0.0 111.167 -179.685 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 173.93 -163.06 33.93 Favored Glycine 0 N--CA 1.484 1.843 0 C-N-CA 119.353 -1.403 . . . . 0.0 109.831 -179.987 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.6 125.7 45.3 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.807 -0.757 . . . . 0.0 111.071 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.547 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -109.3 153.73 23.49 Favored 'General case' 0 N--CA 1.483 1.213 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.018 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 81.1 mttt -115.63 134.49 54.99 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.402 -0.919 . . . . 0.0 112.469 -179.394 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.503 ' O ' ' N ' ' A' ' 92' ' ' GLY . 0.9 OUTLIER -143.57 154.98 44.15 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.492 -0.883 . . . . 0.0 110.058 176.917 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 36.5 p90 -168.45 -174.51 2.24 Favored 'General case' 0 C--N 1.284 -2.259 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.582 -178.666 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.3 t -110.94 122.57 48.21 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 119.842 -0.743 . . . . 0.0 109.832 179.732 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.582 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.5 tm-20 -72.74 -35.58 3.09 Favored Pre-proline 0 N--CA 1.483 1.182 0 C-N-CA 119.056 -1.058 . . . . 0.0 113.292 -178.885 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.1 Cg_endo -71.43 -38.48 4.56 Favored 'Trans proline' 0 C--O 1.213 -0.728 0 C-N-CA 120.52 0.814 . . . . 0.0 111.111 179.855 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 32.8 m80 -102.17 21.05 15.55 Favored 'General case' 0 N--CA 1.488 1.474 0 C-N-CA 119.785 -0.766 . . . . 0.0 111.049 -179.771 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.78 -12.9 8.22 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.612 179.766 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -92.5 -13.47 57.0 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.324 179.821 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.59 -20.44 26.39 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.549 179.933 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 110.21 14.82 12.47 Favored Glycine 0 N--CA 1.496 2.654 0 C-N-CA 119.853 -1.165 . . . . 0.0 110.83 179.673 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.3 mtp -72.27 98.4 2.18 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.689 179.875 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 21.0 mmtt -130.37 150.33 51.65 Favored 'General case' 0 N--CA 1.496 1.843 0 C-N-CA 119.962 -0.695 . . . . 0.0 110.835 179.538 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.503 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -140.3 155.92 24.85 Favored Glycine 0 N--CA 1.501 3.021 0 C-N-CA 119.283 -1.437 . . . . 0.0 112.456 -177.914 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 26.5 tt0 -158.64 146.43 18.04 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.203 179.014 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.542 ' O ' HG13 ' A' ' 94' ' ' VAL . 11.9 p -138.29 122.25 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.001 179.974 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.5 m -97.19 97.03 8.84 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.673 179.885 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 24.0 t -81.95 154.17 4.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.907 -179.051 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.2 p30 . . . . . 0 C--N 1.306 -1.318 0 CA-C-O 116.348 -1.787 . . . . 0.0 110.651 179.872 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.197 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -104.77 123.98 48.61 Favored 'General case' 0 N--CA 1.488 1.458 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.986 179.948 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.6 t -117.28 128.54 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 C-N-CA 119.888 -0.725 . . . . 0.0 110.404 179.494 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -103.76 117.92 35.49 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.814 -0.754 . . . . 0.0 111.155 -179.49 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 mt -78.18 109.14 12.03 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.727 -1.189 . . . . 0.0 109.529 177.964 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 6' ' ' GLY . . . . . 0.406 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 107.47 120.47 4.55 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.061 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 31.9 p . . . . . 0 C--N 1.305 -1.355 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.992 -179.808 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 73.5 mt . . . . . 0 N--CA 1.488 1.451 0 CA-C-O 120.401 0.143 . . . . 0.0 111.041 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.9 m -150.07 157.44 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.73 179.325 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 14' ' ' PHE . . . . . 0.415 ' O ' ' O ' ' A' ' 16' ' ' PRO . 14.2 m-85 -78.44 112.02 15.05 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.135 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 54.6 m -116.03 108.79 45.69 Favored Pre-proline 0 CA--C 1.558 1.26 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.824 -177.861 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 16' ' ' PRO . . . . . 0.415 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.6 Cg_endo -65.76 177.84 16.68 Favored 'Cis proline' 0 C--N 1.362 1.244 0 C-N-CA 125.353 -0.686 . . . . 0.0 111.75 -0.49 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.65 -51.64 4.83 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.509 -0.877 . . . . 0.0 110.423 179.437 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 94.5 p -140.02 141.89 36.27 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.782 179.385 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 22.4 p90 -162.71 149.42 12.95 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.743 -1.183 . . . . 0.0 111.183 -179.169 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 20' ' ' THR . . . . . 0.422 HG23 ' H ' ' A' ' 20' ' ' THR . 0.7 OUTLIER -91.01 159.26 16.23 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.388 -0.925 . . . . 0.0 111.169 -179.972 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.6 m -149.95 172.01 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.858 179.697 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.503 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -88.83 147.79 24.23 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.459 -0.897 . . . . 0.0 110.662 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.85 76.3 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.943 179.802 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 24' ' ' GLY . . . . . 0.503 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.18 22.28 0.09 OUTLIER Glycine 0 N--CA 1.49 2.268 0 C-N-CA 119.537 -1.315 . . . . 0.0 109.933 179.968 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -96.3 145.97 25.13 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.01 -179.787 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.8 mttm -87.12 128.68 35.11 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.863 -179.971 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.8 mt -118.55 131.97 69.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.432 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 25.1 p -128.7 116.96 20.35 Favored 'General case' 0 N--CA 1.492 1.647 0 C-N-CA 119.354 -0.938 . . . . 0.0 112.384 -178.55 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -84.82 109.72 18.3 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.453 -0.899 . . . . 0.0 108.855 177.905 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.3 tttm -106.05 138.06 42.89 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 119.719 -0.792 . . . . 0.0 111.445 -178.103 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -83.26 106.9 15.42 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.062 179.404 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 32' ' ' ASN . . . . . 0.663 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.0 OUTLIER -90.19 -30.75 17.39 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 118.88 -1.128 . . . . 0.0 111.774 -178.865 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 33' ' ' ALA . . . . . 0.663 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 167.81 114.62 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 118.827 -1.149 . . . . 0.0 111.144 179.916 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 139.37 -0.96 2.34 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.587 -1.292 . . . . 0.0 110.559 179.858 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 35' ' ' PHE . . . . . 0.426 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -48.0 161.83 0.35 Allowed Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 118.749 -1.18 . . . . 0.0 110.071 -179.65 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -77.62 144.05 75.89 Favored 'Cis proline' 0 C--O 1.216 -0.587 0 C-N-CA 124.113 -1.203 . . . . 0.0 112.271 -1.022 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.5 m-70 -112.85 175.56 5.39 Favored 'General case' 0 N--CA 1.495 1.782 0 C-N-CA 119.915 -0.714 . . . . 0.0 110.135 179.42 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 38' ' ' ASN . . . . . 0.541 ' ND2' ' CD1' ' A' ' 60' ' ' TYR . 3.2 t-20 -151.64 148.97 28.6 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.529 179.493 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.438 HD13 ' NE2' ' A' ' 57' ' ' GLN . 4.0 mp -134.86 103.47 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 C-N-CA 119.616 -0.833 . . . . 0.0 111.351 -179.502 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 t -119.08 144.65 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 C-N-CA 120.075 -0.65 . . . . 0.0 110.123 179.22 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.689 ' CD2' HD12 ' A' ' 55' ' ' ILE . 9.9 m-85 -99.88 114.67 28.05 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.526 -0.87 . . . . 0.0 111.443 -179.338 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 42' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 44' ' ' ASP . 32.8 t0 -55.6 88.41 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 119.441 -0.903 . . . . 0.0 110.48 179.676 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 43' ' ' GLU . . . . . 0.467 ' N ' ' O ' ' A' ' 41' ' ' PHE . 16.0 pt-20 -46.71 -13.25 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.515 -0.874 . . . . 0.0 111.357 -179.688 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 44' ' ' ASP . . . . . 0.519 ' N ' ' O ' ' A' ' 42' ' ' ASP . 0.9 OUTLIER -87.97 13.11 11.66 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.388 -179.594 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -151.66 15.32 0.67 Allowed 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.114 179.843 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.588 HG22 ' HD2' ' A' ' 47' ' ' PRO . 0.5 OUTLIER -104.06 154.87 37.85 Favored Pre-proline 0 N--CA 1.491 1.624 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.838 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 47' ' ' PRO . . . . . 0.588 ' HD2' HG22 ' A' ' 46' ' ' VAL . 6.1 Cg_exo -52.83 149.79 24.69 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 120.887 1.058 . . . . 0.0 111.236 179.646 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -83.06 40.78 0.72 Allowed 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.293 -0.963 . . . . 0.0 110.716 -179.899 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -142.89 -40.09 0.07 OUTLIER Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 70.3 t -92.48 90.8 3.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.146 179.449 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.3 m120 -44.8 146.5 0.77 Allowed 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.314 -0.955 . . . . 0.0 110.877 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -90.84 -29.58 17.46 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.544 -0.862 . . . . 0.0 111.076 -179.728 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -60.74 -5.43 1.28 Allowed 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.995 -179.719 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 22.2 mtmt -99.55 -38.39 8.78 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.605 -0.838 . . . . 0.0 111.486 -179.828 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 55' ' ' ILE . . . . . 0.689 HD12 ' CD2' ' A' ' 41' ' ' PHE . 2.1 pt -90.49 -29.25 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.208 -179.562 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 58.8 m -56.23 172.34 0.22 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.107 179.909 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.49 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 17.6 mt-30 -134.45 71.92 70.96 Favored Pre-proline 0 N--CA 1.491 1.601 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.815 179.757 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -59.29 -6.81 4.31 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 121.074 1.183 . . . . 0.0 111.209 -179.664 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -100.25 106.48 18.15 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.651 179.577 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 60' ' ' TYR . . . . . 0.541 ' CD1' ' ND2' ' A' ' 38' ' ' ASN . 31.1 m-85 -52.34 168.3 0.11 Allowed 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.594 -0.842 . . . . 0.0 110.471 -179.993 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.7 pp -148.26 141.73 25.35 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.12 -1.032 . . . . 0.0 110.877 179.85 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -137.85 8.09 2.76 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.088 -179.835 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -65.52 127.47 31.65 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 119.091 -1.528 . . . . 0.0 110.302 179.892 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -72.0 120.81 18.13 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.179 -1.008 . . . . 0.0 110.266 179.659 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.29 -14.69 53.45 Favored Glycine 0 N--CA 1.487 2.047 0 C-N-CA 119.111 -1.519 . . . . 0.0 110.657 -179.664 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.19 152.08 34.22 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.169 -1.012 . . . . 0.0 110.469 179.762 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -142.93 171.97 13.33 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.592 -179.615 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.49 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 34.2 t80 -135.73 128.41 30.86 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.145 179.218 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -99.23 155.79 17.31 Favored 'General case' 0 N--CA 1.49 1.562 0 C-N-CA 119.052 -1.059 . . . . 0.0 112.383 -178.604 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -156.34 142.94 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.023 178.93 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.9 m -130.99 96.13 3.98 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 119.784 -0.766 . . . . 0.0 111.265 -179.287 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 11.7 mt -79.58 161.3 26.02 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.045 -1.062 . . . . 0.0 109.134 179.172 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.46 45.47 0.87 Allowed 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 118.596 -1.242 . . . . 0.0 112.242 -178.688 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 29.2 mm-40 -143.82 105.7 4.34 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 118.876 -1.13 . . . . 0.0 110.269 179.279 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -43.51 109.93 0.17 Allowed 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.816 -179.296 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.98 -147.89 8.95 Favored Glycine 0 N--CA 1.486 1.989 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.417 -179.918 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 77' ' ' THR . . . . . 0.461 HG23 HG23 ' A' ' 95' ' ' THR . 0.0 OUTLIER -143.55 131.65 21.81 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.598 -0.841 . . . . 0.0 110.807 -179.898 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 78' ' ' TYR . . . . . 0.595 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -119.6 129.61 54.7 Favored 'General case' 0 N--CA 1.486 1.336 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.578 -179.942 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -101.3 121.21 41.48 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 119.424 -0.91 . . . . 0.0 111.827 -179.49 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 80' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.7 p90 -131.48 166.34 21.55 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.816 -0.753 . . . . 0.0 110.009 178.161 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 29.6 p90 -170.29 -176.85 2.31 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.105 -1.038 . . . . 0.0 111.409 -178.355 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -102.21 130.75 48.96 Favored 'General case' 0 N--CA 1.482 1.154 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.301 179.16 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.55 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.9 OUTLIER -77.3 -44.64 2.68 Favored Pre-proline 0 N--CA 1.485 1.279 0 C-N-CA 119.328 -0.949 . . . . 0.0 112.713 -179.71 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 84' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 4.1 Cg_exo -65.57 -52.91 0.88 Allowed 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 120.914 1.076 . . . . 0.0 111.535 -179.096 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 85' ' ' HIS . . . . . 0.466 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.4 m80 -81.94 15.58 2.22 Favored 'General case' 0 C--N 1.302 -1.46 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.804 -179.874 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.65 -0.94 0.32 Allowed 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.107 -179.938 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 87' ' ' GLY . . . . . 0.466 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -95.15 -14.14 49.73 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.324 -1.417 . . . . 0.0 110.361 179.951 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.14 -51.89 4.82 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.596 179.925 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.26 24.75 0.2 Allowed Glycine 0 N--CA 1.488 2.166 0 C-N-CA 119.537 -1.316 . . . . 0.0 110.502 179.901 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.1 mtp -73.16 97.99 2.51 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.148 -1.021 . . . . 0.0 110.962 -179.95 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.3 ptpt -119.7 154.99 33.28 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.507 179.22 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 92' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.4 145.66 16.31 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.396 -1.383 . . . . 0.0 111.399 -178.764 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -152.2 143.78 23.49 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.486 -0.886 . . . . 0.0 111.062 179.636 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 94' ' ' VAL . 12.3 p -137.16 125.2 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.678 179.159 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.461 HG23 HG23 ' A' ' 77' ' ' THR . 46.2 m -102.56 99.18 9.17 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.549 179.408 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 40.3 t -79.69 147.84 6.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 C-N-CA 118.763 -1.175 . . . . 0.0 110.633 -178.843 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 116.285 -1.816 . . . . 0.0 110.75 -179.697 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 109.908 -0.405 . . . . 0.0 109.908 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -131.17 122.15 26.1 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.823 -0.751 . . . . 0.0 110.835 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.6 t -115.15 126.59 72.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 119.966 -0.694 . . . . 0.0 110.33 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 22.1 mtmt -101.72 116.15 32.1 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.918 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.481 HD11 ' HB3' ' A' ' 29' ' ' PHE . 12.0 mt -79.56 114.64 18.64 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.167 -1.013 . . . . 0.0 109.971 178.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 96.83 108.02 2.49 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.491 -1.338 . . . . 0.0 109.787 -179.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.546 ' OG ' ' N ' ' A' ' 11' ' ' GLY . 3.0 p -67.52 164.14 19.59 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.934 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.33 -10.79 59.93 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.473 -0.891 . . . . 0.0 110.877 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.427 ' H ' ' H ' ' A' ' 10' ' ' GLY . 3.2 p30 -170.28 -9.7 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.876 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.427 ' H ' ' H ' ' A' ' 9' ' ' ASP . . . -74.47 -23.45 75.44 Favored Glycine 0 N--CA 1.491 2.357 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.453 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.546 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . 119.99 -142.06 15.86 Favored Glycine 0 N--CA 1.497 2.717 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.2 mt -103.29 102.52 12.48 Favored 'General case' 0 N--CA 1.49 1.527 0 C-N-CA 119.696 -0.802 . . . . 0.0 110.658 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.7 m -150.48 158.11 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 119.009 -1.076 . . . . 0.0 110.999 179.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.535 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 16.7 m-85 -78.8 111.96 15.45 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 177.628 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.0 m -114.4 107.62 51.06 Favored Pre-proline 0 N--CA 1.484 1.264 0 C-N-CA 119.421 -0.911 . . . . 0.0 112.226 -177.436 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.413 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.0 OUTLIER -67.64 176.58 25.44 Favored 'Cis proline' 0 C--N 1.362 1.275 0 C-N-CA 125.4 -0.667 . . . . 0.0 111.6 -0.555 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -92.49 -58.8 2.25 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.014 179.118 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.2 t -124.06 138.55 54.43 Favored 'General case' 0 N--CA 1.487 1.4 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.265 178.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.41 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 9.0 p90 -159.72 136.06 8.96 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 118.328 -1.349 . . . . 0.0 111.706 -178.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.424 HG23 ' H ' ' A' ' 20' ' ' THR . 0.8 OUTLIER -85.98 150.67 24.32 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.329 179.436 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.3 m -144.21 177.79 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.179 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -98.05 145.79 26.18 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.68 -0.808 . . . . 0.0 110.365 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.4 88.9 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.122 -1.031 . . . . 0.0 110.934 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 139.16 19.73 0.46 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -96.28 137.67 35.0 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.715 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 54.1 mttm -84.89 120.11 26.1 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.248 -0.981 . . . . 0.0 110.924 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.7 mt -109.27 110.88 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.038 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 30.3 p -106.2 116.92 32.77 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.379 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.481 ' HB3' HD11 ' A' ' 5' ' ' LEU . 94.2 m-85 -85.86 103.59 14.74 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.023 178.269 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.6 tttm -101.7 135.19 43.66 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.758 -0.777 . . . . 0.0 112.218 -177.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.471 ' N ' ' OD1' ' A' ' 31' ' ' ASN . 1.3 m-20 -76.71 126.24 30.64 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.935 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -106.78 -32.62 7.88 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.086 -1.046 . . . . 0.0 113.136 -178.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 178.11 11.94 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.387 0 C-N-CA 119.052 -1.059 . . . . 0.0 111.729 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -124.88 49.68 0.9 Allowed Glycine 0 N--CA 1.5 2.931 0 C-N-CA 119.35 -1.405 . . . . 0.0 112.104 -178.668 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.596 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -91.06 161.31 35.63 Favored Pre-proline 0 N--CA 1.488 1.428 0 C-N-CA 118.35 -1.34 . . . . 0.0 110.291 178.805 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -78.17 142.42 69.6 Favored 'Cis proline' 0 C--O 1.215 -0.658 0 C-N-CA 124.004 -1.248 . . . . 0.0 111.825 -1.266 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.524 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 36.9 m-70 -107.26 162.38 13.95 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.596 -0.842 . . . . 0.0 111.016 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 25.7 t30 -144.6 137.76 26.94 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 119.607 -0.837 . . . . 0.0 109.852 179.19 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.4 mp -127.29 117.46 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.16 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.58 142.84 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.765 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.753 ' CD2' HD12 ' A' ' 55' ' ' ILE . 7.5 m-85 -95.08 117.74 30.7 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.738 -178.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.485 ' C ' ' H ' ' A' ' 44' ' ' ASP . 21.6 t0 -55.4 99.33 0.03 OUTLIER 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.374 179.645 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -64.01 5.26 0.25 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.446 -0.902 . . . . 0.0 111.392 -179.526 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.485 ' H ' ' C ' ' A' ' 42' ' ' ASP . 9.6 m-20 -99.78 -8.67 23.91 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.915 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -134.6 16.33 3.65 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.957 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -95.53 147.03 32.36 Favored Pre-proline 0 N--CA 1.49 1.529 0 N-CA-C 108.957 -0.756 . . . . 0.0 108.957 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -47.84 142.73 14.3 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.958 1.105 . . . . 0.0 111.799 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.2 70.64 1.63 Allowed 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.712 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.46 -37.75 0.12 Allowed Glycine 0 N--CA 1.488 2.102 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.077 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.418 ' O ' HG12 ' A' ' 50' ' ' VAL . 15.4 t -86.22 104.9 14.15 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.789 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -48.28 147.7 2.18 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.738 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -99.46 -5.81 28.73 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.918 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.07 -30.45 17.7 Favored 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.511 -0.876 . . . . 0.0 111.19 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 36.0 mttt -69.25 -29.91 67.92 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.148 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.753 HD12 ' CD2' ' A' ' 41' ' ' PHE . 1.1 pt -94.16 -37.52 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.748 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 57.7 m -64.01 159.62 19.68 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.537 -0.865 . . . . 0.0 111.253 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.457 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -139.66 75.67 31.15 Favored Pre-proline 0 N--CA 1.486 1.361 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.398 179.635 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -57.63 -21.76 48.62 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 121.262 1.308 . . . . 0.0 111.567 -179.078 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.21 95.67 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.021 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -42.71 163.11 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.799 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -150.09 111.64 4.48 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 118.862 -1.135 . . . . 0.0 111.878 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 8.0 p-10 -106.33 21.66 17.03 Favored 'General case' 0 N--CA 1.488 1.475 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.918 179.84 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -83.65 137.66 16.5 Favored Glycine 0 N--CA 1.494 2.53 0 C-N-CA 119.355 -1.403 . . . . 0.0 110.655 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -82.32 114.48 20.82 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.533 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.07 -13.67 66.62 Favored Glycine 0 N--CA 1.488 2.147 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.506 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.25 150.34 26.05 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.209 -0.996 . . . . 0.0 110.31 179.69 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.57 168.75 19.88 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 118.981 -1.087 . . . . 0.0 111.884 -179.599 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.457 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 29.3 t80 -135.29 129.88 34.24 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.555 179.228 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.96 152.86 21.01 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.306 -178.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.1 t -151.79 130.78 3.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 CA-C-N 115.105 -0.952 . . . . 0.0 108.844 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 20.6 m -129.86 93.93 3.62 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.652 -0.819 . . . . 0.0 111.226 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.436 ' CD1' HG11 ' A' ' 94' ' ' VAL . 13.7 mt -79.39 157.98 27.49 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.213 -0.995 . . . . 0.0 109.507 179.333 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 2.2 t -149.94 46.07 0.92 Allowed 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 118.793 -1.163 . . . . 0.0 111.649 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.404 ' O ' ' C ' ' A' ' 75' ' ' LYS . 5.6 tt0 -144.93 99.98 3.42 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 118.977 -1.089 . . . . 0.0 109.913 179.048 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.481 ' H ' ' HD2' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -39.45 112.48 0.26 Allowed 'General case' 0 N--CA 1.484 1.239 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.344 -179.124 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.76 -148.88 10.0 Favored Glycine 0 N--CA 1.484 1.849 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.004 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.96 132.34 25.09 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.922 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.562 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.2 m-85 -120.8 126.01 49.03 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.66 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.442 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -100.4 114.11 27.39 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.78 -179.361 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.594 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -125.02 169.74 11.83 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.09 178.686 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -171.25 -179.76 2.76 Favored 'General case' 0 C--N 1.297 -1.694 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.073 -179.206 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 2.1 t -106.39 115.31 29.99 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.504 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.563 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 tt0 -66.87 -40.38 29.77 Favored Pre-proline 0 C--N 1.3 -1.576 0 C-N-CA 119.379 -0.928 . . . . 0.0 112.724 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.563 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.4 Cg_endo -68.95 -47.69 1.12 Allowed 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 120.822 1.015 . . . . 0.0 112.03 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -87.87 12.15 13.84 Favored 'General case' 0 N--CA 1.487 1.423 0 C-N-CA 119.238 -0.985 . . . . 0.0 111.296 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.72 -24.4 61.42 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.771 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -62.24 -22.19 62.8 Favored Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.514 -1.327 . . . . 0.0 110.414 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.92 -31.83 14.8 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.621 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 117.21 30.22 1.96 Allowed Glycine 0 N--CA 1.495 2.611 0 C-N-CA 119.991 -1.1 . . . . 0.0 110.495 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.3 mtp -77.88 105.52 9.12 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.862 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.535 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 0.6 OUTLIER -127.61 166.89 17.19 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 119.956 -0.698 . . . . 0.0 110.777 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -147.83 148.44 19.98 Favored Glycine 0 N--CA 1.488 2.104 0 C-N-CA 119.018 -1.563 . . . . 0.0 111.286 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -153.63 141.64 20.28 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.625 179.583 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 94' ' ' VAL . 7.2 p -136.87 125.26 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.624 179.307 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 95.8 m -103.32 98.71 8.58 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.409 -0.916 . . . . 0.0 110.645 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 41.1 t -80.03 148.3 5.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.255 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 1.9 m120 . . . . . 0 C--N 1.304 -1.41 0 CA-C-O 116.344 -1.789 . . . . 0.0 111.007 -179.554 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.105 0 CA-C-O 120.792 0.33 . . . . 0.0 110.197 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -130.19 121.46 26.27 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.54 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.8 t -112.87 122.02 66.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.682 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 60.8 mttt -94.53 116.61 28.98 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.761 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.434 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 8.5 mt -76.21 102.4 5.79 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 118.615 -1.234 . . . . 0.0 109.525 178.18 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 121.25 155.7 9.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.031 -1.627 . . . . 0.0 109.031 -178.204 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.2 p -87.44 -81.29 0.24 Allowed 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 119.039 -1.064 . . . . 0.0 111.047 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -161.12 -25.31 0.06 Allowed 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.802 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 9' ' ' ASP . 0.6 OUTLIER 178.5 78.4 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.26 -0.976 . . . . 0.0 111.068 179.837 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.83 39.68 2.29 Favored Glycine 0 N--CA 1.495 2.589 0 C-N-CA 119.775 -1.202 . . . . 0.0 110.713 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -157.47 110.3 0.44 Allowed Glycine 0 N--CA 1.489 2.169 0 C-N-CA 119.332 -1.413 . . . . 0.0 110.357 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 80.1 mt -99.04 100.55 11.71 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 119.527 -0.869 . . . . 0.0 110.382 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 m -149.71 154.78 8.77 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 C-N-CA 118.74 -1.184 . . . . 0.0 111.072 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' A' ' 16' ' ' PRO . 17.2 m-85 -78.2 110.16 12.94 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.7 m -115.0 109.01 47.5 Favored Pre-proline 0 CA--C 1.562 1.41 0 C-N-CA 119.369 -0.933 . . . . 0.0 112.503 -177.002 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.421 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.9 Cg_endo -66.66 178.35 17.84 Favored 'Cis proline' 0 C--N 1.364 1.348 0 C-N-CA 125.27 -0.721 . . . . 0.0 111.484 -0.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.6 p -94.94 -60.43 1.69 Allowed 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.933 179.177 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.2 p -121.05 135.41 55.2 Favored 'General case' 0 N--CA 1.486 1.34 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.076 178.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.465 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 14.4 p90 -157.88 140.74 14.89 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 118.528 -1.269 . . . . 0.0 111.49 -178.729 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.447 HG23 ' H ' ' A' ' 20' ' ' THR . 0.5 OUTLIER -87.77 153.45 21.33 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.357 -0.937 . . . . 0.0 110.633 179.451 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.1 m -145.94 158.76 11.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.105 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.421 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -75.04 145.88 42.02 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.211 -0.996 . . . . 0.0 110.427 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.27 73.03 0.12 Allowed 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.459 -0.896 . . . . 0.0 110.9 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.438 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 160.98 11.15 0.04 OUTLIER Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.438 ' H ' ' H ' ' A' ' 24' ' ' GLY . 18.5 tt0 -98.81 157.14 16.49 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.913 -179.532 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.4 mmtp -95.48 134.2 38.6 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.33 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.9 mt -107.09 104.36 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 120.076 -0.649 . . . . 0.0 109.358 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 52.3 p -101.41 117.57 35.21 Favored 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 119.553 -0.859 . . . . 0.0 112.612 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -91.16 109.76 21.03 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.12 178.445 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 31.0 tttt -103.14 135.14 45.37 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.58 -178.505 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 1.0 OUTLIER -84.67 106.11 15.98 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.258 -0.977 . . . . 0.0 110.108 179.237 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.547 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 4.3 p-10 -93.36 -28.6 16.07 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.208 -0.997 . . . . 0.0 112.016 -178.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.547 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 175.44 133.57 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 118.55 -1.26 . . . . 0.0 111.371 -179.785 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 111.48 5.97 25.73 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.782 -1.199 . . . . 0.0 111.579 179.079 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.452 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -52.47 162.54 0.89 Allowed Pre-proline 0 N--CA 1.488 1.437 0 C-N-CA 118.188 -1.405 . . . . 0.0 109.744 179.814 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -78.76 161.62 88.95 Favored 'Cis proline' 0 C--O 1.212 -0.798 0 C-N-CA 124.38 -1.091 . . . . 0.0 112.636 -0.689 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -125.75 172.7 9.6 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.952 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.508 ' ND2' ' CD1' ' A' ' 60' ' ' TYR . 11.6 t-20 -153.49 117.53 4.81 Favored 'General case' 0 N--CA 1.492 1.67 0 C-N-CA 118.978 -1.089 . . . . 0.0 110.622 179.185 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.842 ' N ' HD12 ' A' ' 39' ' ' ILE . 2.4 mp -96.18 129.71 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.146 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.6 t -143.31 138.63 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 C-N-CA 119.679 -0.808 . . . . 0.0 110.427 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.7 ' CD2' HD12 ' A' ' 55' ' ' ILE . 9.1 m-85 -98.33 118.26 34.59 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.206 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.524 ' OD2' ' N ' ' A' ' 45' ' ' GLU . 11.2 t70 -53.1 120.4 5.86 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.348 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -73.57 0.47 12.51 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.433 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.404 ' N ' ' OD2' ' A' ' 42' ' ' ASP . 14.6 m-20 -107.99 4.2 24.92 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.813 -0.755 . . . . 0.0 111.135 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.524 ' N ' ' OD2' ' A' ' 42' ' ' ASP . 34.5 mt-10 -146.18 52.56 1.14 Allowed 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 119.486 -0.886 . . . . 0.0 110.835 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -137.03 148.36 62.52 Favored Pre-proline 0 N--CA 1.493 1.676 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -49.58 145.78 16.31 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 121.061 1.174 . . . . 0.0 111.678 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.89 81.92 2.8 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.709 -0.796 . . . . 0.0 111.025 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 161.54 -41.95 0.4 Allowed Glycine 0 N--CA 1.489 2.174 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.312 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 92.0 t -81.96 95.94 3.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.348 -0.941 . . . . 0.0 110.84 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -44.94 143.76 1.39 Allowed 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.969 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.54 -2.04 49.3 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.625 -0.83 . . . . 0.0 110.898 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -86.55 -35.13 19.7 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.98 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 30.7 mttt -68.75 -34.38 75.5 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.581 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.7 HD12 ' CD2' ' A' ' 41' ' ' PHE . 1.1 pt -89.94 -29.68 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 C-N-CA 118.938 -1.105 . . . . 0.0 111.062 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 7.6 m -58.95 -178.63 0.05 Allowed 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.928 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.563 ' NE2' HD13 ' A' ' 39' ' ' ILE . 20.0 mt-30 -146.38 73.19 13.02 Favored Pre-proline 0 N--CA 1.484 1.274 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.031 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -62.39 -4.52 5.5 Favored 'Trans proline' 0 C--N 1.321 -0.879 0 C-N-CA 121.094 1.196 . . . . 0.0 110.984 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 16.0 mt-10 -100.31 99.98 10.71 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.828 -0.749 . . . . 0.0 110.545 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.508 ' CD1' ' ND2' ' A' ' 38' ' ' ASN . 44.6 m-85 -47.54 164.49 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.411 -0.916 . . . . 0.0 110.92 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.1 pp -142.32 135.95 29.21 Favored 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.96 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -135.46 42.41 2.7 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.664 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -102.5 128.28 9.49 Favored Glycine 0 N--CA 1.495 2.595 0 C-N-CA 119.584 -1.293 . . . . 0.0 110.532 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -78.06 108.22 11.19 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.628 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.51 -6.37 59.14 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.325 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -71.96 157.69 37.37 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.555 179.835 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 4.9 p -148.64 163.29 37.71 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.051 -1.059 . . . . 0.0 111.229 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.471 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 28.5 t80 -134.7 139.16 45.02 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.651 179.206 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.467 ' H ' ' CD ' ' A' ' 69' ' ' GLU . 1.7 mp0 -102.76 148.5 25.53 Favored 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 119.434 -0.907 . . . . 0.0 112.252 -178.765 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -142.82 126.05 14.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 115.124 -0.943 . . . . 0.0 108.748 179.208 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.0 m -117.47 112.82 21.15 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.61 -0.836 . . . . 0.0 112.039 -178.384 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 58.3 mt -95.88 161.7 13.89 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.47 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.557 ' O ' HG22 ' A' ' 73' ' ' THR . 87.9 m -150.57 42.61 0.81 Allowed 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 118.662 -1.215 . . . . 0.0 112.044 -179.033 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -147.9 102.97 3.45 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 118.658 -1.217 . . . . 0.0 110.33 179.071 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.472 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 11.5 pttt -43.97 120.2 2.0 Allowed 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.723 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.45 -147.01 10.58 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -143.25 128.85 19.16 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.405 -0.918 . . . . 0.0 111.248 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.562 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -115.73 136.87 52.64 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.422 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.412 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -107.86 116.27 31.64 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.634 -0.826 . . . . 0.0 111.541 -179.348 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.489 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 2.4 p90 -130.26 166.8 19.58 Favored 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.082 178.485 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -170.46 -172.74 1.3 Allowed 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.682 -178.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -107.32 126.08 51.99 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.756 179.288 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.499 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.9 mt-10 -68.78 -47.11 33.18 Favored Pre-proline 0 C--N 1.305 -1.336 0 C-N-CA 119.593 -0.843 . . . . 0.0 112.599 -179.55 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.499 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.9 Cg_endo -64.72 -47.77 4.89 Favored 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 120.719 0.946 . . . . 0.0 111.746 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -90.84 19.88 5.21 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.808 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.44 -14.23 11.63 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.346 -0.942 . . . . 0.0 110.462 179.696 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -93.76 -12.47 56.75 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.151 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.01 -13.53 38.59 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.597 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 96.96 25.6 11.23 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.605 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.64 99.77 10.42 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.234 -0.987 . . . . 0.0 111.022 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -120.97 159.7 25.06 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.793 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.74 143.03 11.47 Favored Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.337 -1.411 . . . . 0.0 111.071 -179.049 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -150.68 144.74 25.39 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.35 179.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.494 ' O ' HG13 ' A' ' 94' ' ' VAL . 8.0 p -135.24 125.73 44.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.689 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 55.0 m -101.67 98.22 8.54 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.274 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 41.2 t -79.75 152.51 4.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 118.587 -1.245 . . . . 0.0 110.734 -178.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 116.283 -1.818 . . . . 0.0 110.826 -179.688 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.118 0 CA-C-O 120.78 0.324 . . . . 0.0 110.142 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.439 ' OE1' ' O ' ' A' ' 28' ' ' THR . 3.1 mm-40 -140.19 121.0 14.43 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.618 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -108.72 120.54 60.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 C-N-CA 119.917 -0.713 . . . . 0.0 110.509 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.7 mttt -91.16 114.55 27.11 Favored 'General case' 0 C--N 1.299 -1.59 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.992 -179.253 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.0 mt -74.51 113.84 12.22 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.239 178.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.47 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 99.28 124.13 5.12 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.488 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.44 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 16.6 p -66.29 -179.16 0.74 Allowed 'General case' 0 C--N 1.302 -1.46 0 C-N-CA 119.324 -0.951 . . . . 0.0 110.428 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -91.93 -40.59 11.06 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.508 179.624 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.472 ' CG ' ' N ' ' A' ' 10' ' ' GLY . 6.2 p-10 -63.21 -44.88 94.07 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.792 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.472 ' N ' ' CG ' ' A' ' 9' ' ' ASP . . . 147.18 69.47 0.01 OUTLIER Glycine 0 N--CA 1.489 2.223 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.404 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -151.01 157.01 26.97 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.39 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.3 mt -107.02 90.31 3.26 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.983 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.4 m -144.25 155.86 15.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 C-N-CA 119.098 -1.041 . . . . 0.0 110.674 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.401 ' O ' ' C ' ' A' ' 16' ' ' PRO . 16.6 m-85 -77.36 112.98 14.67 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 177.895 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.8 m -114.89 108.46 48.66 Favored Pre-proline 0 CA--C 1.558 1.283 0 C-N-CA 119.219 -0.992 . . . . 0.0 112.007 -177.348 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.401 ' C ' ' O ' ' A' ' 14' ' ' PHE . 3.2 Cg_exo -67.5 170.71 46.55 Favored 'Cis proline' 0 C--N 1.362 1.269 0 C-N-CA 125.321 -0.7 . . . . 0.0 111.597 -0.536 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.5 t -90.23 -64.51 1.12 Allowed 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.543 178.733 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.35 139.58 50.25 Favored 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.199 178.69 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.401 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 9.5 p90 -167.95 139.45 2.91 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 118.468 -1.293 . . . . 0.0 111.424 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.443 ' H ' HG23 ' A' ' 20' ' ' THR . 0.6 OUTLIER -85.06 159.12 20.26 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.623 -0.831 . . . . 0.0 111.411 -179.591 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 25.9 m -146.69 -177.75 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.059 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.87 148.95 21.76 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.438 -0.905 . . . . 0.0 111.015 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.39 68.48 0.54 Allowed 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.042 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 159.21 14.03 0.04 OUTLIER Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -97.36 155.95 16.67 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.907 -0.717 . . . . 0.0 111.038 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 13.7 mttp -95.44 138.53 33.0 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.76 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.9 mt -117.65 127.58 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.443 179.381 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.439 ' O ' ' OE1' ' A' ' 2' ' ' GLU . 7.6 p -125.51 119.07 27.18 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.544 -0.862 . . . . 0.0 112.17 -178.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -84.91 110.37 18.81 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.489 -0.885 . . . . 0.0 109.024 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 50.0 tttp -101.45 139.13 37.54 Favored 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.158 -178.272 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.944 ' ND2' HD11 ' A' ' 61' ' ' LEU . 2.5 m120 -86.45 112.57 21.62 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.47 179.371 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.677 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.0 OUTLIER -95.66 -30.8 13.57 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 119.224 -0.991 . . . . 0.0 111.543 -179.227 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.677 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 164.69 118.08 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 119.349 -0.94 . . . . 0.0 111.182 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 138.6 -1.03 2.57 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.957 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.409 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -47.69 164.66 0.24 Allowed Pre-proline 0 C--N 1.307 -1.281 0 C-N-CA 118.839 -1.144 . . . . 0.0 110.137 -179.835 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_endo -75.99 138.9 57.6 Favored 'Cis proline' 0 C--O 1.214 -0.722 0 C-N-CA 124.292 -1.128 . . . . 0.0 112.633 -0.481 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.5 m-70 -110.3 156.4 20.77 Favored 'General case' 0 N--CA 1.485 1.295 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.205 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.429 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 6.2 t30 -148.42 116.23 6.35 Favored 'General case' 0 C--N 1.3 -1.58 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.136 179.251 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.442 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.7 mp -96.64 137.22 25.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.652 -178.701 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.429 ' CG2' ' ND2' ' A' ' 38' ' ' ASN . 1.5 t -146.54 149.42 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.987 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -107.58 118.28 36.32 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.712 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.516 ' OD2' ' N ' ' A' ' 45' ' ' GLU . 1.6 t70 -55.58 119.32 5.5 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 119.576 -0.849 . . . . 0.0 110.28 179.47 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -75.5 14.21 0.65 Allowed 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 119.393 -0.923 . . . . 0.0 111.55 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.446 ' H ' ' CG ' ' A' ' 42' ' ' ASP . 4.0 m-20 -115.39 2.1 13.86 Favored 'General case' 0 N--CA 1.495 1.779 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.049 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.548 ' OE1' ' NZ ' ' A' ' 79' ' ' LYS . 11.8 mm-40 -140.6 19.3 2.36 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 119.657 -0.817 . . . . 0.0 110.446 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -107.69 147.12 34.76 Favored Pre-proline 0 N--CA 1.488 1.471 0 CA-C-N 115.23 -0.895 . . . . 0.0 108.856 179.709 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -48.6 145.24 12.76 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 120.804 1.003 . . . . 0.0 111.718 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.35 50.56 0.79 Allowed 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.935 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -160.6 -31.11 0.02 OUTLIER Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 86.3 t -96.18 90.69 2.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.745 -0.782 . . . . 0.0 110.638 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -45.95 139.89 4.05 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.888 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.08 -26.35 36.33 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.62 -0.832 . . . . 0.0 111.109 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -67.48 -19.89 65.39 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.456 -0.898 . . . . 0.0 110.93 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -78.03 -38.01 45.62 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.876 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.7 pt -94.26 -26.41 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.306 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.0 m -72.35 155.89 39.67 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.431 -0.908 . . . . 0.0 111.297 -179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.465 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -137.95 75.98 40.8 Favored Pre-proline 0 C--N 1.303 -1.432 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.972 179.484 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.412 ' O ' ' OD1' ' A' ' 38' ' ' ASN . 5.2 Cg_exo -56.5 -29.07 76.82 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 121.234 1.289 . . . . 0.0 111.496 -178.789 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -52.96 103.67 0.08 Allowed 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 118.813 -1.155 . . . . 0.0 109.844 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 46.8 m-85 -42.63 161.56 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.69 -0.804 . . . . 0.0 111.105 -179.388 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.944 HD11 ' ND2' ' A' ' 31' ' ' ASN . 0.3 OUTLIER -143.65 148.08 35.27 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.542 -0.863 . . . . 0.0 110.239 -179.644 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.74 ' N ' HD12 ' A' ' 61' ' ' LEU . 30.1 p-10 -148.2 -12.56 0.36 Allowed 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.265 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -48.74 115.82 2.84 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.203 -1.475 . . . . 0.0 110.403 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.51 119.92 10.1 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.962 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.85 -21.29 27.62 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.639 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -58.05 153.76 13.98 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.048 -1.061 . . . . 0.0 110.326 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -140.68 170.01 16.56 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 119.329 -0.948 . . . . 0.0 111.67 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.465 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 22.8 t80 -130.96 130.98 44.11 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.284 179.361 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -93.33 150.76 20.23 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 119.081 -1.048 . . . . 0.0 112.716 -178.11 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -151.59 136.52 10.28 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-N 115.127 -0.942 . . . . 0.0 108.933 179.246 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.3 m -127.31 104.65 8.05 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.521 -0.871 . . . . 0.0 111.503 -179.13 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.47 ' CD1' HG11 ' A' ' 94' ' ' VAL . 49.6 mt -88.17 155.14 19.92 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.001 179.094 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 4.8 p -150.92 47.32 0.85 Allowed 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.935 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.429 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.5 mm-40 -144.18 108.48 4.81 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.099 -1.041 . . . . 0.0 110.722 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.561 ' H ' ' HZ3' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -49.79 114.33 1.05 Allowed 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 119.372 -0.931 . . . . 0.0 110.854 -179.572 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 165.28 -137.74 4.86 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.183 -1.484 . . . . 0.0 110.235 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -149.46 143.0 25.4 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.286 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.563 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -127.34 123.74 37.02 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.37 179.716 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.548 ' NZ ' ' OE1' ' A' ' 45' ' ' GLU . 1.2 mptm? -95.43 119.67 34.34 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.728 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.551 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.2 p90 -130.31 171.91 12.4 Favored 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 119.571 -0.852 . . . . 0.0 109.978 177.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 42.5 p90 -171.83 -175.33 1.5 Allowed 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.922 -178.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' CYS . . . . . 0.41 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.8 t -108.82 117.18 33.51 Favored 'General case' 0 C--N 1.31 -1.112 0 C-N-CA 119.856 -0.738 . . . . 0.0 109.713 178.206 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.561 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.4 tt0 -68.3 -39.59 17.0 Favored Pre-proline 0 C--N 1.303 -1.455 0 C-N-CA 119.431 -0.907 . . . . 0.0 112.89 -178.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.561 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.0 Cg_endo -68.99 -43.78 3.07 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 120.638 0.892 . . . . 0.0 111.699 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' HIS . . . . . 0.425 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.4 m80 -94.15 14.83 18.83 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.306 -0.958 . . . . 0.0 111.173 -179.751 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.41 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -65.52 0.27 1.65 Allowed 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.089 -1.044 . . . . 0.0 110.687 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -86.92 -18.05 58.62 Favored Glycine 0 N--CA 1.49 2.238 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.215 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -97.97 -19.99 17.7 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 119.615 -0.834 . . . . 0.0 110.675 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.73 22.0 6.2 Favored Glycine 0 N--CA 1.497 2.74 0 C-N-CA 119.877 -1.154 . . . . 0.0 110.624 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 9.6 ttt -71.22 108.72 4.85 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.494 -0.882 . . . . 0.0 110.832 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.406 ' CG ' ' N ' ' A' ' 92' ' ' GLY . 30.9 ttpt -137.13 159.91 40.53 Favored 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 119.754 -0.778 . . . . 0.0 111.299 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' A' ' 91' ' ' LYS . . . -140.84 156.97 25.71 Favored Glycine 0 N--CA 1.497 2.757 0 C-N-CA 119.688 -1.244 . . . . 0.0 111.559 -178.484 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -157.15 145.94 19.82 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 120.027 -0.669 . . . . 0.0 110.639 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.494 ' O ' HG13 ' A' ' 94' ' ' VAL . 8.8 p -139.94 124.91 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 C-N-CA 119.106 -1.038 . . . . 0.0 110.937 179.386 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 34.0 m -102.68 103.17 13.41 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.543 -0.863 . . . . 0.0 110.582 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 26.2 t -85.71 146.31 6.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 118.866 -1.133 . . . . 0.0 110.622 -178.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 116.375 -1.774 . . . . 0.0 110.661 -179.957 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.17 0 CA-C-O 120.821 0.343 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -96.73 119.89 36.05 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.702 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 73.4 t -108.31 122.38 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.07 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 76.9 mttt -88.31 111.46 21.73 Favored 'General case' 0 C--N 1.297 -1.706 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.865 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 11.6 mt -73.91 110.08 7.92 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 118.539 -1.264 . . . . 0.0 109.763 178.486 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 98.86 126.51 5.64 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -179.109 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 24.5 p -76.18 157.15 33.02 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.581 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -76.93 -20.48 56.13 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.87 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -164.04 68.74 0.18 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.711 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -165.25 -70.12 0.03 OUTLIER Glycine 0 N--CA 1.489 2.169 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.472 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -176.46 -158.04 19.02 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.387 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.0 mt -100.49 104.43 15.82 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 119.688 -0.805 . . . . 0.0 110.756 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 23.6 m -150.83 157.91 5.33 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.65 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.533 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 35.9 m-85 -78.15 113.63 16.28 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 177.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 18.5 m -115.54 109.77 45.53 Favored Pre-proline 0 CA--C 1.56 1.355 0 C-N-CA 119.515 -0.874 . . . . 0.0 112.187 -177.277 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -65.98 170.58 39.44 Favored 'Cis proline' 0 C--N 1.361 1.232 0 C-N-CA 125.123 -0.782 . . . . 0.0 111.567 -0.466 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.03 -68.64 0.79 Allowed 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.836 178.79 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.6 m -110.12 132.92 53.73 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.652 178.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 36.0 p90 -162.15 141.49 9.59 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 118.681 -1.208 . . . . 0.0 111.323 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.439 HG23 ' H ' ' A' ' 20' ' ' THR . 0.2 OUTLIER -85.23 160.28 19.91 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.545 -0.862 . . . . 0.0 111.3 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.4 m -149.29 179.11 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.645 179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -96.0 148.29 22.81 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 119.476 -0.89 . . . . 0.0 110.931 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.51 ' HB2' ' OXT' ' A' ' 97' ' ' ASN . . . -68.38 71.1 0.18 Allowed 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.229 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.418 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 157.52 16.19 0.04 OUTLIER Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.418 ' H ' ' H ' ' A' ' 24' ' ' GLY . 23.0 tt0 -102.8 154.89 18.74 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.682 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.3 mtpt -95.33 141.18 29.2 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.419 -0.912 . . . . 0.0 111.386 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.5 mt -119.78 114.81 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.435 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.4 p -111.41 120.97 43.96 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.53 -0.868 . . . . 0.0 112.616 -178.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -85.57 111.72 20.29 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.876 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.7 tttp -102.89 138.77 39.32 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 119.575 -0.85 . . . . 0.0 111.455 -178.078 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 15.9 m120 -80.53 110.54 16.1 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.805 179.678 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.58 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 3.1 t-20 -98.34 -31.23 12.15 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.225 -0.99 . . . . 0.0 111.673 -179.318 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.58 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.52 128.19 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.383 -0.927 . . . . 0.0 111.214 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 119.5 11.08 7.48 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.789 -1.196 . . . . 0.0 111.355 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.429 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -60.62 163.44 9.15 Favored Pre-proline 0 N--CA 1.484 1.265 0 C-N-CA 118.391 -1.324 . . . . 0.0 110.042 179.819 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -76.92 146.33 83.6 Favored 'Cis proline' 0 C--O 1.217 -0.564 0 C-N-CA 124.145 -1.189 . . . . 0.0 112.636 -0.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 35.3 m-70 -110.67 -179.66 3.82 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.119 179.187 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -155.67 142.6 19.02 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.015 179.153 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 mt -125.2 121.78 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.247 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.0 t -144.8 143.86 22.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.149 179.395 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -96.32 135.99 37.41 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.877 -179.226 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.51 ' C ' ' H ' ' A' ' 44' ' ' ASP . 7.8 t0 -71.95 111.24 7.04 Favored 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.671 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -71.4 35.22 0.05 Allowed 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 119.526 -0.869 . . . . 0.0 110.858 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.51 ' H ' ' C ' ' A' ' 42' ' ' ASP . 13.6 m-20 -111.34 -15.65 13.55 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 120.092 -0.643 . . . . 0.0 111.364 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -145.81 -5.39 0.63 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 118.261 -1.376 . . . . 0.0 112.464 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -52.51 142.31 31.45 Favored Pre-proline 0 C--N 1.285 -2.216 0 C-N-CA 118.628 -1.229 . . . . 0.0 108.112 179.248 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -49.09 148.03 10.2 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 120.895 1.063 . . . . 0.0 112.236 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.25 64.55 2.06 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.722 -0.791 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.58 -39.48 0.06 OUTLIER Glycine 0 N--CA 1.488 2.147 0 C-N-CA 119.57 -1.3 . . . . 0.0 109.863 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 98.8 t -92.16 97.1 6.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.336 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -44.61 162.33 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.447 -0.901 . . . . 0.0 111.155 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -102.91 -29.01 11.69 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.919 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -78.97 -14.15 59.38 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.146 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 1.8 mptp? -81.9 -37.69 26.47 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.064 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -90.87 -17.93 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 C-N-CA 119.199 -1.0 . . . . 0.0 111.019 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 73.6 m -76.55 -177.44 4.19 Favored 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.256 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.638 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -159.96 78.55 2.67 Favored Pre-proline 0 C--N 1.304 -1.405 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.788 179.635 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -60.56 0.99 0.59 Allowed 'Trans proline' 0 C--O 1.213 -0.747 0 C-N-CA 121.372 1.381 . . . . 0.0 112.216 -178.354 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.434 ' H ' ' C ' ' A' ' 57' ' ' GLN . 6.9 tt0 -82.9 100.44 10.39 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 118.878 -1.129 . . . . 0.0 110.249 179.387 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.43 ' O ' ' O ' ' A' ' 59' ' ' GLU . 43.9 m-85 -41.92 164.79 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.932 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.569 ' O ' HD12 ' A' ' 61' ' ' LEU . 3.0 pp -147.3 124.47 11.47 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.103 -1.039 . . . . 0.0 111.037 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.442 ' OD1' ' N ' ' A' ' 62' ' ' ASN . 0.9 OUTLIER -120.8 32.55 5.93 Favored 'General case' 0 N--CA 1.496 1.875 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.706 -179.963 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -97.02 120.87 6.86 Favored Glycine 0 N--CA 1.494 2.56 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.8 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -68.67 118.5 11.74 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.544 -0.862 . . . . 0.0 110.774 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.03 -19.75 40.48 Favored Glycine 0 N--CA 1.488 2.159 0 C-N-CA 119.419 -1.372 . . . . 0.0 110.374 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 34.8 tt0 -56.99 153.7 10.84 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.22 179.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -144.88 169.37 18.19 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.212 -0.995 . . . . 0.0 111.579 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.638 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 29.2 t80 -134.73 139.06 44.9 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.141 178.867 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.542 ' H ' ' CD ' ' A' ' 69' ' ' GLU . 1.3 mp0 -100.32 148.24 24.9 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.181 -1.008 . . . . 0.0 112.755 -178.046 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.3 t -145.74 131.31 13.18 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 114.924 -1.035 . . . . 0.0 108.721 179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.1 m -123.2 113.69 19.28 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.905 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 46.2 mt -98.77 159.12 15.17 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.526 178.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.95 34.45 0.59 Allowed 'General case' 0 C--N 1.297 -1.702 0 C-N-CA 118.824 -1.151 . . . . 0.0 111.64 -178.856 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -137.87 102.38 4.7 Favored 'General case' 0 N--CA 1.492 1.654 0 C-N-CA 119.092 -1.043 . . . . 0.0 110.624 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.431 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 11.2 pttm -43.57 114.59 0.66 Allowed 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.884 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.18 -145.33 7.78 Favored Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.487 -1.34 . . . . 0.0 110.129 -179.407 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.06 128.93 20.61 Favored 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 119.303 -0.959 . . . . 0.0 111.557 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.578 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -121.66 138.85 54.17 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 115.242 -0.89 . . . . 0.0 108.922 179.303 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 12.4 mttp -111.19 127.77 55.7 Favored 'General case' 0 N--CA 1.493 1.689 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.767 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.541 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.6 OUTLIER -129.05 159.81 34.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.048 177.753 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -167.93 178.44 5.16 Favored 'General case' 0 C--N 1.286 -2.171 0 C-N-CA 119.621 -0.832 . . . . 0.0 110.593 -178.655 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' CYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -104.4 131.77 51.39 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.27 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.496 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.6 mt-10 -71.48 -46.22 13.26 Favored Pre-proline 0 C--N 1.306 -1.308 0 C-N-CA 119.364 -0.934 . . . . 0.0 112.843 -179.596 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.0 Cg_endo -67.01 -45.1 4.33 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 120.902 1.068 . . . . 0.0 111.87 -179.402 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -93.52 22.81 5.04 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.886 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.423 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -68.5 -13.67 62.48 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.739 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -87.27 -12.3 67.88 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.261 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.54 -12.16 30.21 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.406 -0.918 . . . . 0.0 110.819 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.16 10.79 38.44 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.743 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -66.68 101.6 0.82 Allowed 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.364 -0.935 . . . . 0.0 111.081 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.533 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 18.4 mttp -129.11 173.18 10.7 Favored 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.349 -179.71 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -155.58 152.09 23.59 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.333 -1.413 . . . . 0.0 111.444 -178.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -155.75 144.95 20.76 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.789 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 94' ' ' VAL . 7.4 p -136.46 124.33 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.809 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 68.6 m -100.73 97.92 8.52 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.254 179.157 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.7 t -79.53 151.9 4.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 119.097 -1.041 . . . . 0.0 110.622 -178.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.51 ' OXT' ' HB2' ' A' ' 23' ' ' ALA . 11.7 m-80 . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 116.319 -1.8 . . . . 0.0 110.783 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.087 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -134.31 118.37 17.45 Favored 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.685 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.2 t -102.76 123.51 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 C-N-CA 119.713 -0.795 . . . . 0.0 110.51 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.5 mmmm -95.42 117.55 30.56 Favored 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.111 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 3.6 mt -86.52 109.85 19.38 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.012 -1.075 . . . . 0.0 110.013 178.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.58 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 101.42 93.56 2.19 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.844 -1.17 . . . . 0.0 110.214 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.6 p -47.41 159.17 0.14 Allowed 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.932 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -74.37 -50.3 19.19 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 119.438 -0.905 . . . . 0.0 110.773 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.449 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 1.4 p-10 -44.21 -45.26 8.35 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.744 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 140.37 68.22 0.04 OUTLIER Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.646 -1.264 . . . . 0.0 110.274 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -153.18 150.0 21.66 Favored Glycine 0 N--CA 1.488 2.145 0 C-N-CA 119.221 -1.466 . . . . 0.0 110.514 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt -99.89 94.81 6.5 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.628 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.7 m -150.4 158.39 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 118.624 -1.23 . . . . 0.0 111.57 179.399 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.447 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 18.2 m-85 -78.84 110.45 14.04 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 177.274 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 38.7 m -116.35 108.48 45.51 Favored Pre-proline 0 C--N 1.304 -1.394 0 C-N-CA 119.54 -0.864 . . . . 0.0 112.08 -177.382 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -66.0 175.0 24.47 Favored 'Cis proline' 0 C--N 1.357 0.98 0 C-N-CA 125.312 -0.703 . . . . 0.0 111.8 -0.206 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 t -95.71 -64.96 1.01 Allowed 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.706 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 81.4 p -118.63 128.3 54.41 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.958 178.644 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.476 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 12.6 p90 -156.23 145.68 20.8 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 118.477 -1.289 . . . . 0.0 111.255 -178.832 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.423 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -87.46 158.67 18.91 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 119.376 -0.93 . . . . 0.0 111.278 -179.856 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.0 m -147.39 169.18 4.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.569 179.476 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -85.83 147.36 26.33 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.664 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.99 73.02 0.18 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.309 -179.736 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.412 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 154.47 15.83 0.05 OUTLIER Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.718 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.412 ' H ' ' H ' ' A' ' 24' ' ' GLY . 24.5 tt0 -98.8 154.82 17.72 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.667 -0.813 . . . . 0.0 110.983 -179.462 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 12.7 mttm -95.43 136.92 35.19 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.549 -0.86 . . . . 0.0 111.136 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 85.6 mt -115.19 104.92 17.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.611 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 26.7 p -99.98 114.65 28.07 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.532 -0.867 . . . . 0.0 112.215 -178.603 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -85.07 127.74 34.35 Favored 'General case' 0 C--N 1.309 -1.188 0 C-N-CA 119.277 -0.969 . . . . 0.0 109.241 178.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.7 tttm -124.41 131.49 53.5 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 119.892 -0.723 . . . . 0.0 111.341 -179.059 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.712 HD21 ' H ' ' A' ' 66' ' ' GLU . 31.3 p-10 -90.15 127.26 36.06 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.355 -0.938 . . . . 0.0 109.792 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.58 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 5.1 p30 -127.65 -6.4 5.73 Favored 'General case' 0 N--CA 1.495 1.787 0 C-N-CA 118.939 -1.104 . . . . 0.0 112.871 -178.84 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.523 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 177.7 90.74 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 117.982 -1.487 . . . . 0.0 112.184 179.611 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 135.73 28.83 0.38 Allowed Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.455 -1.355 . . . . 0.0 111.114 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.596 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -75.95 162.29 72.35 Favored Pre-proline 0 N--CA 1.483 1.191 0 C-N-CA 118.297 -1.361 . . . . 0.0 109.829 179.627 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -79.88 148.55 79.37 Favored 'Cis proline' 0 C--O 1.211 -0.853 0 C-N-CA 124.185 -1.173 . . . . 0.0 112.531 -0.664 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -110.64 170.96 7.75 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.914 -0.715 . . . . 0.0 110.162 178.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.582 ' ND2' ' CD2' ' A' ' 60' ' ' TYR . 9.3 t-20 -149.46 151.87 34.7 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.193 -1.003 . . . . 0.0 110.646 179.525 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.4 mt -132.74 114.51 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 C-N-CA 119.771 -0.772 . . . . 0.0 111.019 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.0 t -131.14 141.97 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.732 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -100.02 120.12 39.33 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 119.278 -0.969 . . . . 0.0 112.085 -179.109 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.512 ' C ' ' H ' ' A' ' 44' ' ' ASP . 1.6 t0 -65.77 114.42 5.03 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.39 -0.924 . . . . 0.0 109.709 178.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.35 15.1 0.06 Allowed 'General case' 0 N--CA 1.491 1.609 0 C-N-CA 119.274 -0.97 . . . . 0.0 111.592 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.512 ' H ' ' C ' ' A' ' 42' ' ' ASP . 3.0 m-20 -101.86 -2.79 29.14 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.224 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -143.1 14.64 1.87 Allowed 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.213 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -96.83 145.51 29.71 Favored Pre-proline 0 C--N 1.299 -1.599 0 C-N-CA 119.868 -0.733 . . . . 0.0 109.107 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -52.9 154.1 13.72 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 120.785 0.99 . . . . 0.0 111.63 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.53 44.08 0.78 Allowed 'General case' 0 C--N 1.307 -1.278 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.584 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -147.68 -38.39 0.04 OUTLIER Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 86.9 t -98.93 94.05 3.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 C-N-CA 119.775 -0.77 . . . . 0.0 110.339 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -44.57 155.36 0.1 Allowed 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.955 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -93.89 -11.66 30.59 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.177 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -89.49 -9.25 50.75 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.92 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 3.0 mmpt? -88.03 -28.62 21.27 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.402 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -105.49 -5.51 9.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.739 -179.214 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.0 m -74.23 171.53 13.45 Favored 'General case' 0 C--N 1.308 -1.218 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.355 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.617 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 56.3 mt-30 -123.95 80.04 57.38 Favored Pre-proline 0 N--CA 1.49 1.536 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.35 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -61.41 -16.11 45.22 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 120.722 0.948 . . . . 0.0 110.852 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -100.49 119.73 38.94 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.81 -0.756 . . . . 0.0 110.679 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.582 ' CD2' ' ND2' ' A' ' 38' ' ' ASN . 38.4 m-85 -69.04 174.98 4.03 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.839 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.4 pp -144.38 123.31 12.75 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.221 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -116.13 -14.63 11.15 Favored 'General case' 0 N--CA 1.501 2.112 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.184 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.508 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . -52.07 137.5 32.63 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.036 -1.554 . . . . 0.0 110.633 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.64 106.37 5.37 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.661 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 97.61 12.64 46.94 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.519 -1.325 . . . . 0.0 110.004 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.712 ' H ' HD21 ' A' ' 31' ' ' ASN . 1.9 mm-40 -66.02 158.37 28.47 Favored 'General case' 0 N--CA 1.484 1.242 0 C-N-CA 119.229 -0.989 . . . . 0.0 110.244 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.4 p -147.48 160.01 43.08 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 118.805 -1.158 . . . . 0.0 111.979 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.617 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 42.9 t80 -135.8 178.07 7.34 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.371 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.586 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 8.4 mt-10 -140.62 149.74 42.7 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 118.916 -1.113 . . . . 0.0 111.929 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -150.07 132.7 6.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-N 115.322 -0.853 . . . . 0.0 109.218 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.3 m -127.21 106.28 9.14 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.424 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.523 ' CD1' HG11 ' A' ' 94' ' ' VAL . 30.3 mt -91.79 159.72 15.67 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.249 -0.98 . . . . 0.0 110.117 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 6.4 p -150.63 46.36 0.87 Allowed 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.098 -1.041 . . . . 0.0 111.544 -179.354 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.406 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 2.0 mm-40 -143.84 101.6 3.77 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 118.995 -1.082 . . . . 0.0 110.565 179.475 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 19.5 tttm -43.96 108.03 0.1 Allowed 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.657 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.71 -143.71 6.76 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.193 -1.479 . . . . 0.0 110.202 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.458 HG23 HG23 ' A' ' 95' ' ' THR . 0.0 OUTLIER -145.03 133.17 21.5 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.918 179.959 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.58 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.3 m-85 -119.62 157.35 28.61 Favored 'General case' 0 N--CA 1.485 1.29 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.134 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.1 mmtm -124.62 123.81 40.86 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.545 -0.862 . . . . 0.0 112.224 -179.115 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.574 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.0 OUTLIER -135.25 163.89 28.96 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.099 178.408 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -169.49 179.59 3.78 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 119.165 -1.014 . . . . 0.0 111.223 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -102.17 116.87 33.57 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.778 -0.769 . . . . 0.0 109.651 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.58 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 7.0 tt0 -71.99 -36.08 3.96 Favored Pre-proline 0 C--N 1.304 -1.374 0 C-N-CA 118.941 -1.104 . . . . 0.0 112.901 -179.223 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.58 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -70.2 -52.48 0.29 Allowed 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 120.429 0.753 . . . . 0.0 111.144 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' HIS . . . . . 0.493 ' C ' ' H ' ' A' ' 87' ' ' GLY . 35.1 m170 -82.14 13.91 3.17 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.829 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.25 -6.14 0.14 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.659 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.493 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -80.55 -27.6 50.73 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.575 -1.298 . . . . 0.0 110.327 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.73 -32.56 23.43 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.4 -0.92 . . . . 0.0 110.392 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 114.94 23.23 4.69 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.926 -1.131 . . . . 0.0 110.903 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 28.6 mtp -65.14 107.68 1.63 Allowed 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.869 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.447 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 17.4 pttp -124.97 159.0 32.26 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 119.975 -0.69 . . . . 0.0 110.461 179.501 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.86 145.6 15.13 Favored Glycine 0 N--CA 1.497 2.729 0 C-N-CA 119.053 -1.546 . . . . 0.0 111.742 -178.701 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 51.3 tt0 -150.8 144.7 25.25 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.317 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.523 HG11 ' CD1' ' A' ' 72' ' ' LEU . 11.2 p -136.99 124.6 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 C-N-CA 119.121 -1.031 . . . . 0.0 111.179 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.458 HG23 HG23 ' A' ' 77' ' ' THR . 41.4 m -100.61 99.51 10.09 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.672 179.406 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.7 t -79.79 146.23 8.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.374 -179.067 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.486 1.346 0 CA-C-O 116.412 -1.756 . . . . 0.0 110.999 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.43 ' HB3' HG13 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.893 0.377 . . . . 0.0 110.077 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -97.32 122.06 39.92 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.809 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 43.9 t -107.7 121.56 60.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.149 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 45.6 mtpt -92.05 117.36 29.76 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.157 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.404 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 16.8 mt -78.15 111.71 14.36 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.558 179.665 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.404 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 97.33 120.45 4.02 Favored Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.789 -1.196 . . . . 0.0 110.227 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 18.3 p -67.25 146.18 54.43 Favored 'General case' 0 C--N 1.301 -1.5 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.609 179.669 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -44.49 -45.29 9.13 Favored 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.928 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.31 66.81 0.19 Allowed 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.74 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -146.55 -55.22 0.02 OUTLIER Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.531 -1.319 . . . . 0.0 110.215 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -179.04 -168.12 37.65 Favored Glycine 0 N--CA 1.486 1.983 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.3 mt -99.74 106.73 18.66 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.668 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.4 m -150.89 158.39 4.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 C-N-CA 118.918 -1.113 . . . . 0.0 110.872 179.383 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.415 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 58.0 m-85 -78.75 112.83 16.28 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 177.093 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 53.8 m -115.0 110.9 45.51 Favored Pre-proline 0 N--CA 1.485 1.316 0 C-N-CA 119.315 -0.954 . . . . 0.0 112.431 -177.089 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -65.82 170.95 37.19 Favored 'Cis proline' 0 C--N 1.362 1.284 0 C-N-CA 125.228 -0.738 . . . . 0.0 111.51 -0.664 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.0 p -94.86 -67.95 0.83 Allowed 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.055 179.082 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.67 137.32 47.66 Favored 'General case' 0 N--CA 1.486 1.326 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.672 179.198 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -163.57 134.9 4.75 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 118.456 -1.298 . . . . 0.0 111.658 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.445 HG23 ' H ' ' A' ' 20' ' ' THR . 0.3 OUTLIER -85.54 152.88 22.82 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.237 -179.957 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -144.84 173.78 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.677 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.518 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -94.1 139.22 31.25 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.452 -0.899 . . . . 0.0 110.357 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.19 77.79 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.319 -0.953 . . . . 0.0 110.888 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 158.12 13.83 0.04 OUTLIER Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -104.05 149.69 24.96 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 120.102 -0.639 . . . . 0.0 110.767 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.486 ' C ' HD12 ' A' ' 27' ' ' ILE . 78.0 mttt -94.91 137.56 33.82 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.105 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.486 HD12 ' C ' ' A' ' 26' ' ' LYS . 1.5 mp -115.9 150.47 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.08 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 68.5 p -141.75 121.89 13.82 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 118.92 -1.112 . . . . 0.0 112.1 -179.202 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -87.18 120.93 28.97 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.373 -0.931 . . . . 0.0 108.895 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.5 ttmm -110.99 136.81 49.43 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.669 -0.812 . . . . 0.0 111.742 -178.442 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.631 ' ND2' ' CD1' ' A' ' 35' ' ' PHE . 19.2 t30 -80.42 104.27 10.85 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 115.109 -0.95 . . . . 0.0 109.723 179.146 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.404 ' OD1' ' O ' ' A' ' 6' ' ' GLY . 2.0 t-20 -101.27 -32.03 10.7 Favored 'General case' 0 N--CA 1.491 1.575 0 C-N-CA 118.838 -1.145 . . . . 0.0 112.389 -178.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 177.27 143.06 0.09 Allowed 'General case' 0 N--CA 1.502 2.134 0 C-N-CA 119.503 -0.879 . . . . 0.0 111.166 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 100.89 8.54 48.01 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 119.338 -1.411 . . . . 0.0 112.299 178.286 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.631 ' CD1' ' ND2' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -55.45 162.88 2.06 Favored Pre-proline 0 C--N 1.308 -1.229 0 C-N-CA 117.763 -1.575 . . . . 0.0 109.478 179.569 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_endo -76.67 140.76 67.11 Favored 'Cis proline' 0 C--O 1.215 -0.64 0 C-N-CA 124.285 -1.131 . . . . 0.0 112.521 -0.54 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.404 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 34.3 m-70 -109.91 163.46 13.53 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.801 179.129 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.405 ' OD1' ' N ' ' A' ' 39' ' ' ILE . 36.0 t30 -148.12 139.79 23.77 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.682 179.649 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.405 ' N ' ' OD1' ' A' ' 38' ' ' ASN . 2.7 mp -116.45 118.01 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 120.046 -0.662 . . . . 0.0 111.045 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.484 HG12 ' N ' ' A' ' 41' ' ' PHE . 28.3 t -129.8 162.37 37.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.899 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.484 ' N ' HG12 ' A' ' 40' ' ' VAL . 27.8 m-85 -121.09 122.0 39.1 Favored 'General case' 0 N--CA 1.494 1.755 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.552 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -54.13 117.48 3.28 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.346 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.451 ' O ' ' OD1' ' A' ' 44' ' ' ASP . 9.2 mt-10 -76.38 39.06 0.19 Allowed 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.297 -179.627 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.451 ' OD1' ' O ' ' A' ' 43' ' ' GLU . 75.4 m-20 -148.91 -3.22 0.45 Allowed 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.157 -1.017 . . . . 0.0 110.975 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -130.71 8.62 4.92 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.821 -0.752 . . . . 0.0 109.885 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -95.8 148.06 33.97 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 115.027 -0.988 . . . . 0.0 108.79 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -49.45 151.1 7.42 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 120.89 1.06 . . . . 0.0 111.827 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.34 54.84 1.47 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.864 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -165.06 -40.93 0.02 OUTLIER Glycine 0 N--CA 1.489 2.197 0 C-N-CA 119.465 -1.35 . . . . 0.0 110.322 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 46.3 t -86.56 93.95 4.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.969 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -47.14 158.25 0.15 Allowed 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.649 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.64 -25.01 16.3 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.786 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 90.7 mt-10 -71.71 -13.22 61.66 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.884 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.9 mmpp? -87.6 -39.75 14.81 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.775 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.409 HD12 ' CD2' ' A' ' 41' ' ' PHE . 3.0 pt -91.62 -25.86 5.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.242 -0.983 . . . . 0.0 111.258 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.7 m -55.52 -176.98 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 119.124 -1.031 . . . . 0.0 110.686 179.384 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.475 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 22.1 tt0 -144.95 78.12 12.78 Favored Pre-proline 0 C--N 1.302 -1.464 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.528 -179.556 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -59.51 -24.51 75.24 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 120.971 1.114 . . . . 0.0 111.532 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -77.9 99.57 6.04 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.201 -1.0 . . . . 0.0 110.484 179.579 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -56.99 167.28 0.84 Allowed 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.045 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.446 HD22 ' NE2' ' A' ' 57' ' ' GLN . 0.2 OUTLIER -135.61 105.27 6.11 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 119.729 -0.788 . . . . 0.0 110.708 179.59 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -107.26 4.93 27.13 Favored 'General case' 0 N--CA 1.488 1.426 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.701 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -90.88 139.38 14.81 Favored Glycine 0 N--CA 1.489 2.216 0 C-N-CA 119.386 -1.388 . . . . 0.0 110.433 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -74.19 123.55 24.69 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.722 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.19 -8.99 59.32 Favored Glycine 0 N--CA 1.498 2.826 0 C-N-CA 119.547 -1.311 . . . . 0.0 110.983 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -55.83 150.65 12.67 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.976 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 3.2 p -150.59 160.11 44.03 Favored 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 118.829 -1.149 . . . . 0.0 111.667 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.506 ' CE2' ' O ' ' A' ' 69' ' ' GLU . 53.5 t80 -135.68 177.39 7.86 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.898 -0.721 . . . . 0.0 109.745 179.092 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.506 ' O ' ' CE2' ' A' ' 68' ' ' TYR . 9.0 mt-10 -144.99 151.94 39.37 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.118 -1.033 . . . . 0.0 111.554 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.444 ' O ' ' CG1' ' A' ' 70' ' ' VAL . 1.8 p -158.76 127.78 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 C-N-CA 119.552 -0.859 . . . . 0.0 109.981 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.6 m -115.03 93.87 4.5 Favored 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.058 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 11.8 mt -79.15 156.07 28.41 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 118.81 -1.156 . . . . 0.0 109.353 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.2 p -150.86 38.37 0.67 Allowed 'General case' 0 C--N 1.293 -1.886 0 C-N-CA 118.902 -1.119 . . . . 0.0 111.559 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.424 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.5 OUTLIER -124.2 96.4 4.91 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 119.482 -0.887 . . . . 0.0 109.62 179.202 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.418 ' C ' ' O ' ' A' ' 74' ' ' GLU . 16.3 mtmm -39.52 99.75 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.292 -178.87 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.34 -135.4 2.64 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 119.257 -1.449 . . . . 0.0 110.359 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.3 m -150.36 142.56 24.15 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.145 -1.022 . . . . 0.0 111.225 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.611 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.7 m-85 -128.47 125.48 38.55 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.606 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 6.2 mptt -99.23 116.33 31.17 Favored 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.23 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.573 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -123.5 168.87 12.01 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.082 178.74 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -170.73 -176.81 2.15 Favored 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.683 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.5 t -105.86 127.1 52.9 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.775 -0.77 . . . . 0.0 109.865 179.532 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.567 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 tm-20 -74.59 -37.14 2.75 Favored Pre-proline 0 CA--C 1.558 1.259 0 C-N-CA 119.161 -1.016 . . . . 0.0 113.318 -178.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.1 Cg_endo -71.03 -50.04 0.35 Allowed 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 120.716 0.944 . . . . 0.0 111.416 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -83.72 16.29 2.79 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.594 -0.842 . . . . 0.0 110.888 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.89 -6.21 5.63 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.671 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.83 -11.94 64.8 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.146 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -97.16 -42.41 7.85 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.794 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.25 30.61 0.72 Allowed Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -79.43 110.99 15.25 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.212 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.415 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 1.0 OUTLIER -133.96 162.62 31.55 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.237 -179.808 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -144.1 152.12 23.99 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.675 -1.25 . . . . 0.0 110.661 -178.799 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -154.13 146.74 24.14 Favored 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 119.105 -1.038 . . . . 0.0 111.29 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.494 ' O ' HG13 ' A' ' 94' ' ' VAL . 8.4 p -143.74 126.52 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.261 0 C-N-CA 119.016 -1.074 . . . . 0.0 110.334 178.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 99.4 m -105.61 102.49 11.95 Favored 'General case' 0 N--CA 1.494 1.76 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.723 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.9 t -82.67 141.36 15.06 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.226 -179.172 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 . . . . . 0 C--N 1.302 -1.458 0 CA-C-O 116.344 -1.788 . . . . 0.0 110.857 -179.85 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.114 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -107.66 118.99 38.2 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.741 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 t -108.22 120.01 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 C-N-CA 119.866 -0.734 . . . . 0.0 110.642 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -95.01 116.52 28.8 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.414 -0.914 . . . . 0.0 110.861 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.1 mt -77.2 113.36 14.87 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 118.891 -1.123 . . . . 0.0 109.993 178.535 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.487 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 101.64 131.75 7.49 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.1 p -76.61 -179.0 5.01 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.225 -0.99 . . . . 0.0 110.62 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -72.49 -58.09 3.65 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.878 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -49.99 -53.46 26.4 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.86 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.79 11.54 0.05 OUTLIER Glycine 0 N--CA 1.49 2.3 0 C-N-CA 119.45 -1.357 . . . . 0.0 110.4 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -72.49 162.26 54.56 Favored Glycine 0 N--CA 1.49 2.275 0 C-N-CA 119.425 -1.369 . . . . 0.0 110.238 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.9 mt -116.8 96.18 5.36 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.941 -0.704 . . . . 0.0 110.894 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.7 m -151.01 155.2 7.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.828 179.375 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.402 ' O ' ' C ' ' A' ' 16' ' ' PRO . 67.2 m-85 -78.31 110.53 13.41 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 177.598 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 59.4 m -113.37 110.06 50.82 Favored Pre-proline 0 CA--C 1.557 1.246 0 C-N-CA 119.377 -0.929 . . . . 0.0 112.504 -177.176 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.402 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.3 Cg_endo -67.62 170.2 49.26 Favored 'Cis proline' 0 C--N 1.363 1.31 0 C-N-CA 125.344 -0.69 . . . . 0.0 111.414 -0.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.4 m -94.0 -70.64 0.7 Allowed 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.441 -0.904 . . . . 0.0 109.648 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.3 t -107.46 129.65 54.92 Favored 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.311 178.783 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 13.1 p90 -157.22 144.12 18.39 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 118.237 -1.385 . . . . 0.0 111.898 -179.081 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.517 HG23 ' O ' ' A' ' 95' ' ' THR . 19.9 m -84.43 157.02 21.51 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.859 179.692 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.5 m -150.66 168.28 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 C-N-CA 119.737 -0.785 . . . . 0.0 110.941 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -89.38 148.64 23.39 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.559 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.93 73.57 0.19 Allowed 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.079 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 156.38 16.04 0.04 OUTLIER Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -97.85 153.97 17.95 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.795 -0.762 . . . . 0.0 111.055 -179.44 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.0 mtmm -95.17 127.52 41.29 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.069 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.0 mt -107.25 103.26 15.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 C-N-CA 120.069 -0.653 . . . . 0.0 109.87 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 52.5 p -100.99 115.12 29.73 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 119.656 -0.818 . . . . 0.0 112.382 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -85.5 109.83 18.76 Favored 'General case' 0 N--CA 1.489 1.485 0 C-N-CA 119.668 -0.813 . . . . 0.0 109.228 178.471 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.7 tttp -105.61 137.69 43.05 Favored 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 119.46 -0.896 . . . . 0.0 112.122 -178.122 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.456 ' ND2' ' N ' ' A' ' 31' ' ' ASN . 0.1 OUTLIER -79.64 114.15 18.34 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.272 179.177 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.67 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.7 OUTLIER -97.71 -31.04 12.47 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.181 -1.008 . . . . 0.0 111.634 -179.238 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.67 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 165.47 114.38 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.246 -0.981 . . . . 0.0 111.148 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 139.51 3.61 1.56 Allowed Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.434 -1.365 . . . . 0.0 110.863 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.445 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -53.16 163.08 0.96 Allowed Pre-proline 0 C--N 1.304 -1.372 0 C-N-CA 118.704 -1.199 . . . . 0.0 109.741 -179.874 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -77.1 141.26 68.5 Favored 'Cis proline' 0 C--O 1.214 -0.691 0 C-N-CA 124.194 -1.169 . . . . 0.0 112.509 -0.483 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -107.2 178.23 4.61 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.967 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 12.3 t-20 -158.09 139.64 13.67 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.618 -0.833 . . . . 0.0 110.212 179.088 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.7 mp -128.07 114.74 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 C-N-CA 119.789 -0.765 . . . . 0.0 111.311 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 66.6 t -130.08 134.48 62.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.921 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.754 ' CD2' HD12 ' A' ' 55' ' ' ILE . 8.8 m-85 -87.07 129.18 35.02 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.147 -1.021 . . . . 0.0 111.446 -179.21 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.659 ' C ' ' H ' ' A' ' 44' ' ' ASP . 31.1 t0 -65.75 94.29 0.2 Allowed 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.646 -178.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -55.37 5.35 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.858 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.373 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.659 ' H ' ' C ' ' A' ' 42' ' ' ASP . 73.8 m-20 -82.85 -68.18 0.73 Allowed 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.557 179.272 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -98.51 25.51 6.32 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.471 -0.892 . . . . 0.0 112.131 -177.031 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.608 HG22 ' HD2' ' A' ' 47' ' ' PRO . 0.5 OUTLIER -89.16 154.41 49.32 Favored Pre-proline 0 N--CA 1.489 1.5 0 C-N-CA 119.204 -0.998 . . . . 0.0 108.374 178.967 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.608 ' HD2' HG22 ' A' ' 46' ' ' VAL . 6.1 Cg_exo -51.13 144.01 30.42 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 121.017 1.145 . . . . 0.0 112.061 -179.065 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.47 69.38 5.72 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.791 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.73 -43.24 0.08 OUTLIER Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 46.5 t -84.18 83.39 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.078 179.283 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.554 ' ND2' ' H ' ' A' ' 51' ' ' ASN . 0.0 OUTLIER -44.74 140.87 2.31 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.525 -179.652 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.39 -26.33 60.94 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.539 -0.865 . . . . 0.0 111.293 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' A' ' 53' ' ' GLU . 3.7 mp0 -65.34 -3.17 3.77 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.938 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.0 mmpp? -97.44 -40.92 8.45 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.022 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.754 HD12 ' CD2' ' A' ' 41' ' ' PHE . 1.3 pt -99.13 -13.99 7.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.638 -0.825 . . . . 0.0 111.087 -179.587 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 68.9 m -73.06 173.11 9.82 Favored 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.855 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.63 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 70.3 mt-30 -136.65 80.3 38.26 Favored Pre-proline 0 N--CA 1.488 1.469 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.623 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -60.92 -20.83 68.73 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.121 1.214 . . . . 0.0 111.443 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -94.56 108.7 20.64 Favored 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.525 179.647 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 38.9 m-85 -51.51 177.24 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.887 -0.725 . . . . 0.0 111.035 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.8 pp -143.69 139.19 29.4 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.822 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.415 ' OD1' ' N ' ' A' ' 62' ' ' ASN . 2.9 p-10 -134.97 42.95 2.75 Favored 'General case' 0 N--CA 1.489 1.498 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.399 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -105.31 159.54 15.49 Favored Glycine 0 N--CA 1.493 2.461 0 C-N-CA 119.797 -1.192 . . . . 0.0 110.429 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -110.64 110.89 21.76 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 119.989 -0.685 . . . . 0.0 110.726 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.34 -14.21 64.67 Favored Glycine 0 N--CA 1.49 2.285 0 C-N-CA 119.437 -1.364 . . . . 0.0 110.367 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.414 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 1.2 mm-40 -69.82 160.15 32.29 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.269 -0.973 . . . . 0.0 110.345 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -147.22 172.27 14.09 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.669 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.63 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 43.9 t80 -133.61 129.45 36.95 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.082 179.125 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -91.46 149.75 21.55 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 118.892 -1.123 . . . . 0.0 112.461 -178.462 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -150.28 131.72 5.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.994 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.0 m -127.04 106.54 9.34 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.836 -0.745 . . . . 0.0 111.504 -178.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.48 ' CD1' HG11 ' A' ' 94' ' ' VAL . 20.5 mt -90.58 157.7 17.37 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.837 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 8.7 p -150.67 48.37 0.87 Allowed 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.072 -1.051 . . . . 0.0 111.412 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -146.67 100.74 3.37 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.151 179.36 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.469 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 2.0 ptpt -41.77 118.76 1.15 Allowed 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 119.65 -0.82 . . . . 0.0 111.041 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 164.87 -147.22 12.23 Favored Glycine 0 N--CA 1.484 1.9 0 C-N-CA 119.506 -1.331 . . . . 0.0 109.878 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.71 132.96 24.68 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.462 -0.895 . . . . 0.0 111.2 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.585 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.5 OUTLIER -116.81 127.36 54.25 Favored 'General case' 0 N--CA 1.486 1.333 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.342 179.712 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.476 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 2.5 mptp? -101.2 110.72 22.78 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.538 -0.865 . . . . 0.0 111.388 -179.404 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.2 p90 -123.78 168.0 13.3 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.896 -0.722 . . . . 0.0 109.922 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 46.0 p90 -171.43 -173.92 1.32 Allowed 'General case' 0 C--N 1.296 -1.758 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.033 -178.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -107.97 129.5 55.11 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.001 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.518 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.9 mt-10 -69.91 -45.4 23.35 Favored Pre-proline 0 N--CA 1.486 1.374 0 C-N-CA 119.541 -0.864 . . . . 0.0 113.073 -179.385 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.518 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.7 Cg_endo -67.79 -53.17 0.45 Allowed 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 121.066 1.177 . . . . 0.0 111.771 -179.047 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.3 m80 -82.42 16.36 2.12 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.407 -0.917 . . . . 0.0 111.05 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.28 -18.42 58.37 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.365 -0.934 . . . . 0.0 110.809 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.19 -19.6 78.28 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.405 -1.379 . . . . 0.0 110.573 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.97 -4.69 52.23 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.577 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.64 9.67 62.58 Favored Glycine 0 N--CA 1.489 2.178 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.571 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -55.85 102.31 0.07 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.707 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.8 ptmt -126.64 157.48 38.85 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 119.929 -0.708 . . . . 0.0 111.221 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -140.24 133.86 6.21 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.971 -1.109 . . . . 0.0 110.391 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -139.21 148.79 43.59 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.634 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.48 HG11 ' CD1' ' A' ' 72' ' ' LEU . 11.4 p -141.84 132.47 25.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 119.065 -1.054 . . . . 0.0 110.219 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.517 ' O ' HG23 ' A' ' 20' ' ' THR . 99.6 m -110.31 104.99 13.85 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.26 -0.976 . . . . 0.0 110.338 179.667 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 31.4 t -84.83 152.31 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 118.555 -1.258 . . . . 0.0 110.774 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 60.8 m-20 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 116.324 -1.798 . . . . 0.0 110.816 -179.792 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.199 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -130.51 122.59 27.9 Favored 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 120.053 -0.659 . . . . 0.0 110.642 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -99.11 154.4 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.635 -179.511 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.2 mttt -120.59 106.95 12.25 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.074 -0.967 . . . . 0.0 110.479 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.9 mt -74.77 111.47 10.01 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 118.625 -1.23 . . . . 0.0 110.207 179.374 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 112.03 136.32 6.81 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -178.675 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.458 ' OG ' ' N ' ' A' ' 8' ' ' ASP . 79.7 p -59.01 -110.13 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.806 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.458 ' N ' ' OG ' ' A' ' 7' ' ' SER . 2.5 m-20 -154.39 -0.87 0.19 Allowed 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 118.993 -1.083 . . . . 0.0 111.497 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 9' ' ' ASP . 14.4 p30 -166.54 -16.79 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 118.731 -1.188 . . . . 0.0 111.686 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 175.4 69.12 0.05 OUTLIER Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.002 -1.57 . . . . 0.0 110.856 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -172.8 148.06 10.24 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 119.444 -1.36 . . . . 0.0 109.926 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mt -119.13 99.26 6.61 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.084 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.5 m -150.84 155.47 7.3 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 C-N-CA 118.853 -1.139 . . . . 0.0 111.281 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.49 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 57.2 m-85 -78.7 109.84 13.3 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 177.449 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.9 m -115.3 108.19 48.19 Favored Pre-proline 0 CA--C 1.565 1.552 0 C-N-CA 119.596 -0.841 . . . . 0.0 112.875 -176.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -66.23 175.09 25.08 Favored 'Cis proline' 0 C--N 1.368 1.571 0 C-N-CA 125.128 -0.78 . . . . 0.0 111.142 -1.48 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.521 ' OG ' ' N ' ' A' ' 18' ' ' SER . 0.1 OUTLIER -102.91 -67.84 0.86 Allowed 'General case' 0 N--CA 1.488 1.442 0 C-N-CA 119.704 -0.799 . . . . 0.0 110.305 179.428 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.521 ' N ' ' OG ' ' A' ' 17' ' ' SER . 34.2 t -105.74 133.45 50.46 Favored 'General case' 0 N--CA 1.488 1.433 0 C-N-CA 120.069 -0.652 . . . . 0.0 109.843 179.323 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 32.6 p90 -160.65 137.13 8.69 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 118.817 -1.153 . . . . 0.0 111.177 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.419 ' H ' HG23 ' A' ' 20' ' ' THR . 0.4 OUTLIER -87.77 159.57 18.4 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 119.271 -0.972 . . . . 0.0 111.183 -179.891 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 30.6 m -148.93 176.35 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.315 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -97.37 150.41 21.03 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.568 -0.853 . . . . 0.0 110.722 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.03 71.67 0.17 Allowed 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.99 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 164.4 10.02 0.03 OUTLIER Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -104.37 146.59 28.61 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.105 -0.638 . . . . 0.0 110.543 -179.638 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.6 pttt -94.33 153.29 18.08 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.394 -0.922 . . . . 0.0 111.039 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 mt -122.94 145.51 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.486 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.7 p -137.8 118.13 13.69 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.274 -0.97 . . . . 0.0 112.165 -178.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -84.63 126.59 33.49 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.642 -0.823 . . . . 0.0 109.059 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.459 ' HB3' ' HZ2' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -120.16 130.76 54.74 Favored 'General case' 0 N--CA 1.493 1.705 0 C-N-CA 119.604 -0.838 . . . . 0.0 111.853 -178.085 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.635 HD21 ' CD1' ' A' ' 61' ' ' LEU . 6.2 m-20 -70.2 125.41 26.71 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.517 -0.873 . . . . 0.0 109.101 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.652 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.1 OUTLIER -103.7 -32.24 9.47 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 118.861 -1.136 . . . . 0.0 112.798 -178.533 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.652 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.01 -5.16 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 118.019 -1.472 . . . . 0.0 112.016 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.506 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -107.6 41.81 2.1 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.411 -1.376 . . . . 0.0 112.02 -178.798 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -76.14 160.78 77.37 Favored Pre-proline 0 N--CA 1.483 1.218 0 C-N-CA 117.917 -1.513 . . . . 0.0 109.564 179.019 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -74.38 176.98 40.33 Favored 'Cis proline' 0 C--O 1.207 -1.037 0 C-N-CA 124.163 -1.182 . . . . 0.0 111.784 -0.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.506 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 43.0 m-70 -150.98 168.92 23.09 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.567 -0.853 . . . . 0.0 110.794 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.846 HD21 ' H ' ' A' ' 83' ' ' GLU . 4.8 p-10 -154.54 152.89 30.6 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 119.381 -0.928 . . . . 0.0 110.079 178.244 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.0 mp -129.14 97.78 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.652 -179.379 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -112.39 143.41 22.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.163 178.579 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -99.04 138.5 36.06 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.097 -1.041 . . . . 0.0 112.354 -178.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -75.83 110.81 10.57 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.241 -0.983 . . . . 0.0 108.981 178.461 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -72.56 49.68 0.22 Allowed 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.405 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -142.5 3.57 1.5 Allowed 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.968 -0.693 . . . . 0.0 110.2 179.367 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -142.99 8.13 1.65 Allowed 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.721 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.422 HG13 ' HD2' ' A' ' 47' ' ' PRO . 44.3 t -94.63 143.75 26.76 Favored Pre-proline 0 C--N 1.291 -1.968 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.422 ' HD2' HG13 ' A' ' 46' ' ' VAL . 5.2 Cg_exo -50.94 148.56 16.53 Favored 'Trans proline' 0 C--O 1.216 -0.593 0 C-N-CA 120.868 1.045 . . . . 0.0 112.251 -179.081 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.11 78.25 2.94 Favored 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.503 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 168.32 -43.13 0.23 Allowed Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.402 ' O ' HG12 ' A' ' 50' ' ' VAL . 55.5 t -79.35 94.21 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.528 179.544 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -44.93 139.85 2.9 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.696 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -96.34 -1.46 47.73 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.561 -0.856 . . . . 0.0 110.937 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.439 ' N ' ' OE1' ' A' ' 53' ' ' GLU . 11.0 mp0 -90.33 -15.82 30.41 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.303 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.419 ' HG3' HG23 ' A' ' 55' ' ' ILE . 59.2 pttt -89.88 -27.47 19.87 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.01 -1.076 . . . . 0.0 111.437 -179.54 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.424 HD13 HG21 ' A' ' 55' ' ' ILE . 15.8 pt -92.74 -27.76 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 C-N-CA 119.106 -1.038 . . . . 0.0 110.918 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 9.0 m -60.75 -168.15 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.655 -0.818 . . . . 0.0 111.43 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.479 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 15.0 mt-30 -150.07 74.27 9.21 Favored Pre-proline 0 C--N 1.305 -1.336 0 C-N-CA 119.867 -0.733 . . . . 0.0 110.626 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -60.18 -12.26 19.01 Favored 'Trans proline' 0 C--N 1.325 -0.695 0 C-N-CA 121.202 1.268 . . . . 0.0 111.256 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' A' ' 60' ' ' TYR . 45.0 mt-10 -100.13 95.48 6.85 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.834 -0.746 . . . . 0.0 110.414 179.425 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.44 ' O ' ' O ' ' A' ' 59' ' ' GLU . 71.3 m-85 -43.97 171.19 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.916 -0.714 . . . . 0.0 111.17 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.635 ' CD1' HD21 ' A' ' 31' ' ' ASN . 1.9 pp -139.74 150.3 44.64 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.833 -0.747 . . . . 0.0 110.644 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -149.06 53.26 0.97 Allowed 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.891 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.27 126.98 6.29 Favored Glycine 0 N--CA 1.498 2.774 0 C-N-CA 119.95 -1.119 . . . . 0.0 110.402 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.67 128.78 37.56 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.833 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.47 -14.99 10.13 Favored Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.371 -1.395 . . . . 0.0 110.859 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 -56.44 154.83 7.88 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.336 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -147.99 164.57 33.4 Favored 'General case' 0 N--CA 1.489 1.522 0 C-N-CA 119.016 -1.074 . . . . 0.0 111.788 -179.069 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.479 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 36.0 t80 -136.14 146.45 46.94 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -108.03 154.74 21.22 Favored 'General case' 0 N--CA 1.498 1.935 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.794 -178.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -155.24 135.91 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 CA-C-N 115.086 -0.961 . . . . 0.0 108.936 179.287 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.2 m -128.07 104.16 7.62 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.667 -0.813 . . . . 0.0 111.769 -179.365 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.525 ' CD1' HG11 ' A' ' 94' ' ' VAL . 14.4 mt -88.22 157.74 18.7 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.237 -0.985 . . . . 0.0 109.614 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.71 48.42 0.87 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 118.865 -1.134 . . . . 0.0 111.351 -179.25 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.447 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -142.58 105.08 4.48 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.272 -0.971 . . . . 0.0 110.011 178.996 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 32.0 mtmt -46.59 110.31 0.27 Allowed 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.162 -179.285 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 171.08 -141.76 6.67 Favored Glycine 0 N--CA 1.485 1.912 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -146.38 137.5 24.39 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.924 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.573 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.4 m-85 -122.32 152.3 40.27 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.131 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 31.2 mttm -115.5 132.42 56.63 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.625 -0.83 . . . . 0.0 112.335 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.516 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -141.9 153.37 44.36 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.843 176.956 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 30.5 p90 -168.48 177.64 5.19 Favored 'General case' 0 C--N 1.285 -2.221 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.55 -178.497 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' CYS . . . . . 0.464 ' SG ' ' OD1' ' A' ' 38' ' ' ASN . 1.3 t -101.62 120.65 40.66 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.246 -0.981 . . . . 0.0 109.233 179.424 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.846 ' H ' HD21 ' A' ' 38' ' ' ASN . 6.6 tt0 -65.15 -40.56 46.1 Favored Pre-proline 0 C--N 1.3 -1.548 0 N-CA-C 113.774 1.027 . . . . 0.0 113.774 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.502 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.7 Cg_endo -68.95 -52.41 0.39 Allowed 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 120.401 0.734 . . . . 0.0 111.694 -179.363 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' HIS . . . . . 0.41 ' C ' ' H ' ' A' ' 87' ' ' GLY . 30.3 m80 -79.78 13.87 1.97 Allowed 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.906 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.31 -2.26 2.1 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.317 -0.953 . . . . 0.0 110.659 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.41 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -88.01 -18.18 56.44 Favored Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.514 -1.326 . . . . 0.0 110.231 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.32 -41.09 10.05 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.631 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 133.69 15.3 1.24 Allowed Glycine 0 N--CA 1.495 2.628 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.456 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.75 100.79 0.31 Allowed 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.392 -0.923 . . . . 0.0 111.017 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.49 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 32.4 mttm -125.99 164.5 20.68 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.9 -0.72 . . . . 0.0 111.497 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -148.58 143.89 11.57 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.927 -179.33 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -149.13 146.92 27.91 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.484 -0.886 . . . . 0.0 111.131 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.601 ' O ' HG13 ' A' ' 94' ' ' VAL . 12.5 p -140.05 119.63 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.53 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 94.5 m -99.07 101.25 12.56 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.628 179.608 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.436 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 41.8 t -79.61 142.74 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 C-N-CA 118.963 -1.095 . . . . 0.0 110.444 -179.014 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 96' ' ' VAL . 81.2 m-20 . . . . . 0 C--N 1.304 -1.38 0 CA-C-O 116.335 -1.793 . . . . 0.0 110.728 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.109 0 N-CA-C 110.145 -0.316 . . . . 0.0 110.145 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 20.7 mp0 -121.78 122.0 38.5 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 120.128 -0.629 . . . . 0.0 110.652 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.8 t -106.69 119.06 55.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 C-N-CA 119.768 -0.773 . . . . 0.0 110.853 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -91.82 117.63 29.96 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 119.335 -0.946 . . . . 0.0 110.883 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.429 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 4.8 mt -84.27 106.36 15.82 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 119.264 -0.975 . . . . 0.0 110.702 179.022 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.519 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 106.75 86.64 1.89 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.549 ' OG ' ' N ' ' A' ' 11' ' ' GLY . 2.9 p -48.09 142.08 5.53 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.389 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.401 ' C ' ' O ' ' A' ' 7' ' ' SER . 3.2 m-20 -39.56 -52.07 2.19 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 119.884 -0.726 . . . . 0.0 111.598 -179.259 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -141.04 7.06 2.01 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.501 -0.879 . . . . 0.0 110.766 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -77.66 -39.18 25.92 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.435 -1.364 . . . . 0.0 110.502 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.549 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . 141.66 -153.83 24.38 Favored Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.515 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.1 mt -99.23 94.75 6.65 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.814 -179.689 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.0 m -146.73 161.38 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 118.804 -1.159 . . . . 0.0 111.427 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -78.58 113.79 16.93 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 177.377 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.1 m -116.7 107.45 46.46 Favored Pre-proline 0 CA--C 1.559 1.292 0 C-N-CA 119.39 -0.924 . . . . 0.0 111.881 -177.64 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -66.11 176.38 21.23 Favored 'Cis proline' 0 C--N 1.36 1.153 0 C-N-CA 125.227 -0.739 . . . . 0.0 111.46 -0.188 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.7 p -95.76 -48.86 5.59 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.205 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 47.9 t -137.07 137.12 38.99 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.601 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 11.3 p90 -163.3 143.68 9.02 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 118.563 -1.255 . . . . 0.0 111.528 -179.117 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.429 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -86.44 157.43 19.82 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.896 -179.889 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.3 m -146.48 146.89 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.313 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.437 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -61.45 141.58 57.58 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.697 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.75 74.21 0.07 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.184 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 154.25 18.89 0.05 OUTLIER Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.364 -1.398 . . . . 0.0 109.922 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.428 ' O ' HG23 ' A' ' 71' ' ' THR . 21.7 tt0 -103.63 157.1 17.29 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.947 -0.701 . . . . 0.0 110.8 -179.597 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 29.1 mttt -94.38 142.07 27.84 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.714 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mt -124.81 125.52 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 C-N-CA 119.992 -0.683 . . . . 0.0 109.519 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.6 p -119.68 129.33 54.5 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.528 -0.869 . . . . 0.0 112.368 -178.672 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -91.71 131.48 37.07 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.226 178.369 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.5 tptm -120.94 131.01 54.09 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 120.017 -0.673 . . . . 0.0 111.249 -178.408 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.453 ' ND2' HD11 ' A' ' 61' ' ' LEU . 0.5 OUTLIER -90.77 94.68 9.78 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.594 -0.842 . . . . 0.0 109.547 178.981 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 40.1 p-10 -91.26 -23.17 20.25 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.24 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -177.36 162.23 1.87 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 118.999 -1.08 . . . . 0.0 111.219 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.03 12.49 76.68 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.393 -1.384 . . . . 0.0 112.583 178.035 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -63.05 159.93 43.08 Favored Pre-proline 0 C--N 1.308 -1.199 0 C-N-CA 117.283 -1.767 . . . . 0.0 109.378 179.489 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -79.13 147.05 79.27 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 124.13 -1.196 . . . . 0.0 112.195 -0.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 40.5 m-70 -111.3 -175.43 2.7 Favored 'General case' 0 N--CA 1.495 1.805 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.377 179.146 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.623 ' ND2' ' CD2' ' A' ' 60' ' ' TYR . 2.8 t-20 -160.63 146.06 14.67 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.446 179.262 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.436 ' N ' HD12 ' A' ' 39' ' ' ILE . 3.7 mp -134.17 107.27 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.971 -179.376 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.3 t -133.48 144.17 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.849 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -97.42 118.24 33.45 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.962 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -52.28 118.52 3.59 Favored 'General case' 0 C--N 1.308 -1.202 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.281 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -76.09 47.94 0.47 Allowed 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.121 -1.032 . . . . 0.0 111.047 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -147.75 2.68 0.71 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.652 -0.819 . . . . 0.0 109.94 179.054 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -144.56 21.39 1.67 Allowed 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 119.69 -0.804 . . . . 0.0 110.614 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -104.88 148.13 35.61 Favored Pre-proline 0 N--CA 1.493 1.693 0 CA-C-N 115.45 -0.795 . . . . 0.0 109.28 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -49.66 143.12 22.97 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 120.951 1.101 . . . . 0.0 111.715 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.85 69.37 2.5 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.942 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.0 -43.27 0.1 Allowed Glycine 0 N--CA 1.49 2.238 0 C-N-CA 119.44 -1.362 . . . . 0.0 110.018 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 77.5 t -78.44 97.32 2.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.372 179.588 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -44.71 139.68 2.83 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.66 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -94.8 2.66 55.5 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.441 -179.341 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -87.72 -33.22 18.8 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.932 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.1 mmtm -76.41 -32.2 58.36 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.911 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -90.64 -16.09 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 C-N-CA 118.993 -1.083 . . . . 0.0 111.682 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.8 m -79.97 170.72 16.07 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.264 -0.974 . . . . 0.0 110.782 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.502 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -134.68 73.44 67.36 Favored Pre-proline 0 N--CA 1.487 1.393 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.523 -179.94 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -61.36 -4.26 3.99 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 121.402 1.401 . . . . 0.0 111.459 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 60' ' ' TYR . 37.8 mt-10 -99.86 100.67 11.63 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.716 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.623 ' CD2' ' ND2' ' A' ' 38' ' ' ASN . 84.7 m-85 -45.82 171.49 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.623 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.572 ' O ' HD12 ' A' ' 61' ' ' LEU . 3.2 pp -149.39 126.54 11.34 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.248 -0.981 . . . . 0.0 110.499 179.434 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -120.86 33.61 5.51 Favored 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 120.175 -0.61 . . . . 0.0 110.663 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -87.91 168.19 37.22 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.308 -1.425 . . . . 0.0 110.876 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -121.62 101.27 7.49 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.363 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.94 -7.94 55.5 Favored Glycine 0 N--CA 1.49 2.248 0 C-N-CA 119.622 -1.275 . . . . 0.0 110.063 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -71.1 157.55 38.0 Favored 'General case' 0 N--CA 1.486 1.359 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.226 179.665 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -141.69 173.27 11.66 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.27 -0.972 . . . . 0.0 112.041 -179.077 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.516 ' CD2' ' N ' ' A' ' 69' ' ' GLU . 56.7 t80 -134.66 178.23 7.17 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-N 115.498 -0.773 . . . . 0.0 109.623 178.822 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.516 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 5.1 mt-10 -145.92 149.34 34.03 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 118.912 -1.115 . . . . 0.0 112.012 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -159.04 133.87 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.659 178.57 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.428 HG23 ' O ' ' A' ' 25' ' ' GLU . 4.1 m -122.53 96.34 4.99 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 119.828 -0.749 . . . . 0.0 111.035 -179.272 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.3 mt -79.75 158.64 26.84 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.448 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.577 ' O ' HG22 ' A' ' 73' ' ' THR . 97.0 m -150.96 47.12 0.85 Allowed 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.552 -1.259 . . . . 0.0 112.362 -178.672 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.424 ' OE2' ' O ' ' A' ' 75' ' ' LYS . 5.9 tp10 -146.2 107.25 4.16 Favored 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 118.746 -1.182 . . . . 0.0 109.95 178.787 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.7 ' CD ' ' H ' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -43.36 116.32 0.91 Allowed 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.199 -0.909 . . . . 0.0 111.184 -178.972 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.6 -151.22 16.68 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.359 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.17 131.15 34.29 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.846 -0.741 . . . . 0.0 110.677 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.538 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 3.7 m-85 -118.19 121.58 40.86 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 36.8 mmtt -100.19 127.48 46.45 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.524 -0.87 . . . . 0.0 112.839 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.448 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 5.6 p90 -139.87 171.46 14.18 Favored 'General case' 0 C--N 1.312 -1.025 0 C-N-CA 119.616 -0.833 . . . . 0.0 110.433 177.673 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -170.55 -175.71 1.94 Allowed 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 119.437 -0.905 . . . . 0.0 111.178 -178.359 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' CYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.8 t -106.7 123.26 47.86 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.757 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.532 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.4 OUTLIER -64.05 -45.16 79.79 Favored Pre-proline 0 C--N 1.307 -1.253 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.466 -179.874 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.532 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.3 Cg_endo -66.93 -48.36 1.97 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.994 1.129 . . . . 0.0 112.47 -178.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' HIS . . . . . 0.468 ' C ' ' H ' ' A' ' 87' ' ' GLY . 34.4 m80 -91.69 23.19 3.68 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.152 -179.196 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.404 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -71.19 12.29 0.33 Allowed 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.893 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.468 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -107.15 -18.35 10.54 Favored Glycine 0 N--CA 1.498 2.79 0 C-N-CA 119.746 -1.216 . . . . 0.0 110.682 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -95.1 -16.11 22.88 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.232 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 108.17 17.76 10.5 Favored Glycine 0 N--CA 1.498 2.78 0 C-N-CA 119.777 -1.202 . . . . 0.0 110.242 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.7 ttt -69.99 90.78 0.65 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.215 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 15.4 ttmt -118.39 162.17 18.75 Favored 'General case' 0 N--CA 1.498 1.944 0 C-N-CA 120.045 -0.662 . . . . 0.0 111.16 -179.464 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -141.74 150.99 22.42 Favored Glycine 0 N--CA 1.495 2.608 0 C-N-CA 119.349 -1.405 . . . . 0.0 111.6 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -157.57 145.43 18.85 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.75 -0.78 . . . . 0.0 110.919 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.2 p -138.55 123.06 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.346 178.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 97.7 m -99.61 103.23 14.92 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.594 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 22.0 t -80.05 142.86 13.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 C-N-CA 118.423 -1.311 . . . . 0.0 110.46 -179.145 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.3 m120 . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 116.358 -1.782 . . . . 0.0 110.764 -179.76 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.221 0 CA-C-O 120.7 0.286 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 89.2 mt-10 -115.08 121.34 42.77 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.586 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 t -102.49 123.61 55.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.915 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 39.1 mttp -88.92 112.9 23.86 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.902 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.404 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 13.1 mt -75.82 107.43 8.0 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 118.229 -1.388 . . . . 0.0 109.4 178.104 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 102.64 130.4 6.98 Favored Glycine 0 N--CA 1.486 1.986 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -178.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.3 p -71.75 171.27 11.89 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.663 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -66.54 -47.73 71.95 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.042 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -55.86 -71.35 0.09 Allowed 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.339 -0.944 . . . . 0.0 110.836 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.35 24.18 0.03 OUTLIER Glycine 0 N--CA 1.489 2.224 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.363 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.7 153.07 21.42 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.296 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.4 mt -104.81 97.46 7.34 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.825 -0.75 . . . . 0.0 110.827 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.2 m -150.12 153.97 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.868 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.423 ' O ' ' O ' ' A' ' 16' ' ' PRO . 69.7 m-85 -78.45 110.61 13.68 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 177.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.2 m -115.59 110.39 44.75 Favored Pre-proline 0 CA--C 1.562 1.419 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.723 -177.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.423 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.7 Cg_exo -64.79 174.7 21.0 Favored 'Cis proline' 0 C--N 1.365 1.43 0 C-N-CA 125.103 -0.79 . . . . 0.0 111.829 -0.157 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.9 t -102.82 -66.36 0.94 Allowed 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.455 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 61.6 m -119.08 131.88 55.97 Favored 'General case' 0 N--CA 1.492 1.634 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.008 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.436 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 16.7 p90 -161.23 170.94 19.28 Favored 'General case' 0 N--CA 1.487 1.391 0 C-N-CA 118.655 -1.218 . . . . 0.0 111.324 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.4 p -102.88 161.45 13.74 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.992 -0.683 . . . . 0.0 111.193 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.9 m -149.23 151.0 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.946 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.519 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -78.82 142.06 37.21 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.274 -0.971 . . . . 0.0 110.359 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.01 77.35 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.51 -0.876 . . . . 0.0 111.395 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 153.79 15.32 0.06 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.583 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -103.94 145.0 30.78 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.754 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ptpt -95.45 136.34 35.95 Favored 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.383 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.1 mt -109.16 113.79 45.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.631 179.226 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.3 p -107.3 116.47 31.98 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.775 -0.77 . . . . 0.0 112.336 -178.547 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 69.2 m-85 -85.16 118.81 24.94 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 119.526 -0.87 . . . . 0.0 109.05 178.293 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.538 ' HA ' HG22 ' A' ' 67' ' ' THR . 25.0 tttp -111.74 138.16 48.7 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.657 -0.817 . . . . 0.0 111.482 -178.802 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.533 HD22 HD11 ' A' ' 61' ' ' LEU . 0.4 OUTLIER -77.65 109.92 12.03 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.413 179.995 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.661 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.7 t-20 -96.51 -30.96 13.03 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 119.147 -1.021 . . . . 0.0 110.703 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.661 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 165.13 129.12 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.806 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 127.98 -9.01 6.75 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.687 -1.244 . . . . 0.0 110.91 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.414 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -45.92 160.64 0.28 Allowed Pre-proline 0 N--CA 1.482 1.142 0 C-N-CA 118.52 -1.272 . . . . 0.0 109.695 -179.881 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -77.3 141.55 68.84 Favored 'Cis proline' 0 C--O 1.214 -0.68 0 C-N-CA 124.139 -1.192 . . . . 0.0 112.241 0.008 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.404 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 40.6 m-70 -108.55 -177.24 3.26 Favored 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.072 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.415 ' ND2' ' CE2' ' A' ' 60' ' ' TYR . 4.7 t-20 -161.16 141.54 11.06 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.875 -0.73 . . . . 0.0 109.872 178.829 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.6 mp -129.63 124.69 59.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.438 -179.542 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -143.53 146.99 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.385 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.161 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -97.23 134.56 40.38 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.248 -0.981 . . . . 0.0 111.04 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.659 ' O ' ' N ' ' A' ' 44' ' ' ASP . 44.5 p-10 -73.1 93.81 1.85 Allowed 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.529 -0.868 . . . . 0.0 111.063 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.445 ' O ' ' CG ' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -50.45 78.84 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 O-C-N 124.063 0.852 . . . . 0.0 109.803 179.385 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.659 ' N ' ' O ' ' A' ' 42' ' ' ASP . 59.4 m-20 -157.01 -67.04 0.1 Allowed 'General case' 0 C--N 1.283 -2.3 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.682 -177.785 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -96.24 17.37 15.94 Favored 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.191 -1.003 . . . . 0.0 112.139 -177.399 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -86.07 143.96 38.12 Favored Pre-proline 0 C--N 1.291 -1.959 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.431 ' C ' ' H ' ' A' ' 49' ' ' GLY . 2.7 Cg_exo -48.81 152.21 4.68 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 120.815 1.01 . . . . 0.0 111.797 -179.252 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.68 31.15 0.36 Allowed 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.645 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.431 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -136.27 -35.34 0.21 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.5 t -96.46 93.2 3.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.986 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -45.26 144.48 1.37 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.671 179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -87.99 -29.85 20.44 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.84 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.03 -1.05 21.02 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.747 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -97.62 -35.03 10.73 Favored 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.753 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -96.2 -16.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 C-N-CA 119.404 -0.918 . . . . 0.0 111.102 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 36.7 m -68.27 170.07 9.38 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.733 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.489 ' OE1' ' CD1' ' A' ' 68' ' ' TYR . 4.1 mt-30 -137.09 73.37 51.87 Favored Pre-proline 0 N--CA 1.489 1.489 0 C-N-CA 119.811 -0.756 . . . . 0.0 110.901 -179.862 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -57.28 -27.73 76.51 Favored 'Trans proline' 0 C--N 1.322 -0.836 0 C-N-CA 121.038 1.159 . . . . 0.0 110.933 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -65.65 114.1 4.73 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.088 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.415 ' CE2' ' ND2' ' A' ' 38' ' ' ASN . 56.6 m-85 -60.72 173.26 0.77 Allowed 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 119.479 -0.888 . . . . 0.0 111.073 -179.578 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.533 HD11 HD22 ' A' ' 31' ' ' ASN . 2.5 pp -149.15 144.63 26.73 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.682 -0.807 . . . . 0.0 110.158 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.547 ' ND2' ' H ' ' A' ' 63' ' ' GLY . 2.7 p-10 -128.28 -73.53 0.59 Allowed 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 119.88 -0.728 . . . . 0.0 111.72 -178.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.547 ' H ' ' ND2' ' A' ' 62' ' ' ASN . . . -24.2 127.19 0.02 OUTLIER Glycine 0 N--CA 1.511 3.642 0 O-C-N 123.993 0.808 . . . . 0.0 112.612 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.486 ' C ' ' H ' ' A' ' 66' ' ' GLU . . . -62.33 156.76 21.47 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.207 179.394 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' GLY . . . . . 0.724 ' O ' HG23 ' A' ' 67' ' ' THR . . . 71.28 -14.62 1.65 Allowed Glycine 0 N--CA 1.492 2.376 0 C-N-CA 119.109 -1.519 . . . . 0.0 110.6 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.486 ' H ' ' C ' ' A' ' 64' ' ' ALA . 12.9 tt0 -61.13 101.8 0.18 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.286 -0.966 . . . . 0.0 109.97 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.724 HG23 ' O ' ' A' ' 65' ' ' GLY . 37.4 p -106.99 162.19 14.06 Favored 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.575 -0.85 . . . . 0.0 112.225 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.489 ' CD1' ' OE1' ' A' ' 57' ' ' GLN . 29.7 t80 -136.17 143.57 44.52 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.323 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -104.84 154.6 19.84 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.589 -178.605 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -151.59 130.75 3.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.945 -1.025 . . . . 0.0 108.942 179.272 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.4 m -124.6 112.06 16.37 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.693 -0.803 . . . . 0.0 111.585 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 34.3 mt -98.61 156.85 16.6 Favored 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.772 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 11.1 p -150.93 47.98 0.85 Allowed 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 118.714 -1.194 . . . . 0.0 112.274 -179.122 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -144.49 106.29 4.3 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.781 -1.168 . . . . 0.0 110.467 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.437 ' H ' ' HD2' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -44.96 110.84 0.26 Allowed 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.913 -179.696 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.93 -148.28 10.35 Favored Glycine 0 N--CA 1.487 2.053 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.077 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.92 135.37 32.75 Favored 'General case' 0 N--CA 1.483 1.176 0 C-N-CA 119.424 -0.91 . . . . 0.0 111.095 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.569 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -124.36 159.04 31.23 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 179.565 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 12.2 mtpt -136.5 125.48 24.31 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 118.612 -1.235 . . . . 0.0 112.871 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.542 ' O ' ' N ' ' A' ' 92' ' ' GLY . 3.9 p90 -129.43 162.34 28.3 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.35 178.445 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 22.7 p90 -166.94 -179.5 4.72 Favored 'General case' 0 C--N 1.285 -2.232 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.496 -178.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' CYS . . . . . 0.502 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -107.34 112.93 25.99 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.49 -0.884 . . . . 0.0 109.573 178.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.487 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.9 OUTLIER -59.37 -42.99 95.58 Favored Pre-proline 0 C--N 1.298 -1.635 0 C-N-CA 119.471 -0.892 . . . . 0.0 112.581 -179.407 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.487 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.4 Cg_endo -66.3 -47.88 2.92 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 120.283 0.655 . . . . 0.0 111.839 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -92.82 10.1 32.42 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.447 -179.57 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -59.07 -15.8 15.71 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.559 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -77.91 -20.47 73.31 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.421 -1.371 . . . . 0.0 110.377 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.63 -9.34 47.32 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.694 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 104.54 10.78 32.57 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.67 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.51 105.05 1.72 Allowed 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 118.989 -1.085 . . . . 0.0 110.952 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.422 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 43.9 pttt -135.54 168.34 19.43 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.29 -179.545 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.04 153.0 24.93 Favored Glycine 0 N--CA 1.485 1.941 0 C-N-CA 119.372 -1.394 . . . . 0.0 111.053 -179.05 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -155.91 145.9 21.39 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.3 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.8 p -141.62 131.29 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 C-N-CA 118.955 -1.098 . . . . 0.0 110.652 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.0 m -109.46 105.15 14.38 Favored 'General case' 0 N--CA 1.493 1.722 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.825 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.4 HG12 ' N ' ' A' ' 97' ' ' ASN . 37.2 t -79.68 152.93 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 C-N-CA 118.553 -1.259 . . . . 0.0 110.526 -179.364 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.4 ' N ' HG12 ' A' ' 96' ' ' VAL . 60.9 m-20 . . . . . 0 C--N 1.307 -1.277 0 CA-C-O 116.284 -1.817 . . . . 0.0 110.932 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.127 0 N-CA-C 110.071 -0.344 . . . . 0.0 110.071 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -113.92 122.41 46.9 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 120.076 -0.649 . . . . 0.0 110.856 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.3 t -110.4 150.11 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.393 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 10.9 mtpt -124.6 117.69 24.87 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.865 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.2 mt -76.74 109.1 10.24 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.067 -1.053 . . . . 0.0 109.995 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 117.42 162.01 12.36 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.021 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.442 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 59.4 p -84.61 -111.51 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.813 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -151.5 8.31 0.52 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.078 -1.049 . . . . 0.0 111.155 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -167.75 -42.33 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.124 -1.03 . . . . 0.0 111.117 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.46 61.99 0.19 Allowed Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.098 -1.525 . . . . 0.0 110.631 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' A' ' 7' ' ' SER . . . -156.18 125.97 1.72 Allowed Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.342 -1.408 . . . . 0.0 110.229 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.3 mt -99.57 95.5 7.03 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.534 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.9 m -144.82 155.37 14.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 119.111 -1.035 . . . . 0.0 110.415 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.425 ' O ' ' O ' ' A' ' 16' ' ' PRO . 5.4 m-85 -78.71 111.99 15.37 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 178.311 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.3 m -114.44 108.59 49.55 Favored Pre-proline 0 C--N 1.303 -1.415 0 C-N-CA 119.734 -0.786 . . . . 0.0 112.007 -177.44 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -67.26 177.9 20.57 Favored 'Cis proline' 0 C--N 1.36 1.149 0 C-N-CA 125.35 -0.688 . . . . 0.0 111.423 -0.205 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.7 m -92.62 -47.78 6.93 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.414 -0.914 . . . . 0.0 109.996 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.63 135.42 31.69 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.756 179.279 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.479 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 13.5 p90 -153.69 146.61 24.44 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.608 -1.237 . . . . 0.0 111.545 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.44 HG23 ' H ' ' A' ' 20' ' ' THR . 0.6 OUTLIER -91.43 151.25 20.88 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.042 179.579 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.4 158.82 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.933 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.532 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -73.09 137.28 45.15 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.176 -1.01 . . . . 0.0 110.347 179.515 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -59.91 78.82 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.934 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 150.39 18.38 0.07 OUTLIER Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -96.18 158.42 15.45 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.577 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 40.5 mttm -93.5 120.29 33.59 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.093 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.9 mt -105.52 120.52 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.68 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.1 p -118.42 116.6 27.05 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.64 -0.824 . . . . 0.0 112.283 -178.563 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -87.87 120.31 29.07 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.508 -0.877 . . . . 0.0 109.022 178.336 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 13.0 ttmt -112.21 136.2 51.93 Favored 'General case' 0 N--CA 1.492 1.658 0 C-N-CA 119.697 -0.801 . . . . 0.0 111.75 -178.475 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.899 ' ND2' HD11 ' A' ' 61' ' ' LEU . 3.8 m120 -80.31 115.57 19.92 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.157 178.688 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.632 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.1 OUTLIER -100.22 -31.38 11.4 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.257 -0.977 . . . . 0.0 112.141 -178.995 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.632 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 169.02 120.74 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 C-N-CA 118.882 -1.127 . . . . 0.0 111.359 -179.75 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 131.57 -1.19 5.19 Favored Glycine 0 N--CA 1.496 2.667 0 C-N-CA 119.661 -1.257 . . . . 0.0 111.187 179.499 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -46.84 163.97 0.23 Allowed Pre-proline 0 N--CA 1.487 1.377 0 C-N-CA 118.942 -1.103 . . . . 0.0 110.028 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -75.74 143.0 75.66 Favored 'Cis proline' 0 C--O 1.212 -0.81 0 C-N-CA 124.306 -1.122 . . . . 0.0 112.45 -0.427 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 31.7 m-70 -113.92 160.72 18.48 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.769 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.535 HD21 ' HA ' ' A' ' 60' ' ' TYR . 12.7 t-20 -145.69 133.28 20.92 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 119.426 -0.909 . . . . 0.0 109.945 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.821 ' N ' HD12 ' A' ' 39' ' ' ILE . 1.7 mp -115.19 121.41 67.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 C-N-CA 119.767 -0.773 . . . . 0.0 111.405 -179.562 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.408 ' CG2' ' OD1' ' A' ' 38' ' ' ASN . 1.7 t -139.07 154.8 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.068 179.454 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -106.56 134.34 49.85 Favored 'General case' 0 N--CA 1.49 1.533 0 C-N-CA 119.287 -0.965 . . . . 0.0 112.019 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.502 ' C ' ' H ' ' A' ' 44' ' ' ASP . 4.3 t0 -74.32 107.0 6.21 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.188 -1.005 . . . . 0.0 109.179 178.654 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -69.32 33.83 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.833 -178.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.502 ' H ' ' C ' ' A' ' 42' ' ' ASP . 14.9 m-20 -110.23 -9.98 14.65 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.855 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -142.5 -5.8 0.93 Allowed 'General case' 0 N--CA 1.497 1.889 0 C-N-CA 118.865 -1.134 . . . . 0.0 111.634 179.609 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -69.98 146.17 94.88 Favored Pre-proline 0 C--N 1.286 -2.153 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 178.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -51.48 159.32 3.26 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.712 0.941 . . . . 0.0 112.323 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -89.17 40.4 0.98 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 119.722 -0.791 . . . . 0.0 110.374 179.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -143.18 -44.63 0.05 OUTLIER Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.528 ' O ' HG12 ' A' ' 50' ' ' VAL . 50.9 t -83.14 86.29 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 119.384 -0.926 . . . . 0.0 110.18 179.343 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 68.5 m-20 -45.0 139.59 3.07 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.634 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.99 -28.48 55.1 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.679 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -66.33 -15.56 63.35 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.379 -0.928 . . . . 0.0 111.13 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.95 -42.89 17.08 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.838 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -93.32 -41.59 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.212 -179.779 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 42.9 m -48.53 165.98 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.154 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.594 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.3 mt-30 -138.23 78.55 33.55 Favored Pre-proline 0 N--CA 1.487 1.412 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.561 -179.593 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -61.67 -22.91 75.51 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 121.405 1.403 . . . . 0.0 112.003 -179.068 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -76.08 119.83 20.56 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.122 -1.031 . . . . 0.0 110.585 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.535 ' HA ' HD21 ' A' ' 38' ' ' ASN . 74.2 m-85 -55.86 168.56 0.44 Allowed 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.126 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.899 HD11 ' ND2' ' A' ' 31' ' ' ASN . 0.4 OUTLIER -144.61 141.91 29.76 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.189 179.329 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.587 ' N ' HD12 ' A' ' 61' ' ' LEU . 6.2 p30 -146.51 32.7 0.96 Allowed 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.198 -179.263 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -97.26 112.26 4.43 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.482 -1.342 . . . . 0.0 110.539 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.15 111.6 1.58 Allowed 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.22 -0.992 . . . . 0.0 110.571 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.7 -12.5 66.02 Favored Glycine 0 N--CA 1.489 2.23 0 C-N-CA 119.464 -1.351 . . . . 0.0 110.203 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -63.04 151.22 40.49 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.335 -0.946 . . . . 0.0 110.302 179.689 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.73 166.72 23.88 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.214 -0.995 . . . . 0.0 111.511 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.594 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 31.6 t80 -135.83 138.32 42.41 Favored 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.524 179.246 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.402 ' CD ' ' H ' ' A' ' 69' ' ' GLU . 2.0 mp0 -98.16 152.94 18.82 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.885 -178.651 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -149.61 133.69 8.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.34 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.6 m -125.92 100.3 6.32 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.304 -179.23 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.468 ' CD1' HG11 ' A' ' 94' ' ' VAL . 54.2 mt -81.0 165.43 21.72 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.173 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.715 ' O ' HG22 ' A' ' 73' ' ' THR . 81.1 m -150.43 31.01 0.67 Allowed 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 118.608 -1.237 . . . . 0.0 112.589 -178.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.456 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 2.5 mt-10 -143.39 124.28 14.3 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 118.781 -1.168 . . . . 0.0 110.35 178.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 14.4 pttt -58.69 128.14 35.72 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.221 -0.992 . . . . 0.0 111.281 -179.271 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 156.31 174.59 26.28 Favored Glycine 0 N--CA 1.488 2.116 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.223 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.79 105.35 15.34 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.914 -0.715 . . . . 0.0 110.281 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.463 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.8 m-30 -89.58 156.54 18.54 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 118.591 -1.244 . . . . 0.0 107.981 -179.261 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 71.1 mttt -115.19 127.77 55.74 Favored 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.165 -1.014 . . . . 0.0 112.782 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.469 ' O ' ' N ' ' A' ' 92' ' ' GLY . 1.7 p90 -138.14 157.5 46.19 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.834 -0.746 . . . . 0.0 109.526 176.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 33.8 p90 -169.8 -175.23 2.03 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.523 -178.204 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -110.14 116.31 31.31 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.398 179.265 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.563 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tp10 -69.67 -39.34 11.46 Favored Pre-proline 0 C--N 1.305 -1.358 0 C-N-CA 119.518 -0.873 . . . . 0.0 112.435 -179.52 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.563 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 4.4 Cg_exo -66.17 -41.92 11.84 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 120.394 0.729 . . . . 0.0 111.268 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' HIS . . . . . 0.435 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.8 m80 -97.71 18.91 14.57 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.518 -0.873 . . . . 0.0 110.638 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.37 0.21 1.09 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.853 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -94.31 -13.38 54.3 Favored Glycine 0 N--CA 1.487 2.081 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.449 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.45 -47.55 6.81 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.377 -0.929 . . . . 0.0 110.57 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 141.27 18.22 0.35 Allowed Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.629 -1.272 . . . . 0.0 110.271 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 12.8 mtp -71.55 100.41 2.25 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.16 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.485 ' HD2' ' H ' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -129.17 148.48 51.11 Favored 'General case' 0 N--CA 1.495 1.792 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.221 179.489 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -136.29 153.78 21.7 Favored Glycine 0 N--CA 1.499 2.889 0 C-N-CA 119.508 -1.33 . . . . 0.0 112.211 -178.057 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -154.68 149.37 26.49 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 120.314 -0.555 . . . . 0.0 109.937 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.708 ' O ' HG13 ' A' ' 94' ' ' VAL . 12.2 p -139.32 114.88 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 C-N-CA 119.079 -1.048 . . . . 0.0 111.07 -179.327 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 16.0 m -89.84 93.55 9.47 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.096 -1.042 . . . . 0.0 110.616 179.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 14.0 t -78.77 148.31 6.23 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.617 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 17.8 p30 . . . . . 0 C--N 1.307 -1.277 0 CA-C-O 116.309 -1.805 . . . . 0.0 110.818 -179.744 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.103 0 CA-C-O 120.873 0.368 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -107.86 120.63 42.81 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 120.033 -0.667 . . . . 0.0 110.687 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.8 t -98.52 122.35 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.651 179.685 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.7 mptt -90.0 114.72 26.62 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.983 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.448 HD11 ' HB3' ' A' ' 29' ' ' PHE . 5.3 mp -80.45 100.03 8.3 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 118.572 -1.251 . . . . 0.0 109.62 178.507 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.461 ' C ' HD21 ' A' ' 32' ' ' ASN . . . 122.6 146.6 7.25 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -178.718 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.55 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 53.5 p -74.48 -173.14 1.67 Allowed 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.439 -0.905 . . . . 0.0 110.709 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -90.95 -6.77 53.61 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.131 -1.028 . . . . 0.0 111.685 -179.183 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -173.38 77.93 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 118.616 -1.233 . . . . 0.0 112.273 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 85.45 70.75 1.32 Allowed Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.269 -1.444 . . . . 0.0 111.235 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.447 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . -176.37 146.81 8.2 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.397 -1.382 . . . . 0.0 110.187 179.215 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.0 mt -124.34 91.8 3.53 Favored 'General case' 0 N--CA 1.491 1.597 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.357 179.731 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.9 m -145.38 156.27 13.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.022 0 C-N-CA 118.996 -1.082 . . . . 0.0 111.075 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -78.59 111.54 14.77 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 178.177 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -114.5 108.34 49.8 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 119.566 -0.854 . . . . 0.0 112.232 -177.106 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -68.04 173.48 37.72 Favored 'Cis proline' 0 C--N 1.359 1.085 0 C-N-CA 125.45 -0.646 . . . . 0.0 111.503 -0.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 p -88.9 -45.22 9.87 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 119.307 -0.957 . . . . 0.0 109.76 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.76 140.5 34.81 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.55 179.114 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -162.41 147.3 12.34 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 118.356 -1.338 . . . . 0.0 111.598 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.412 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -93.24 151.71 19.64 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.275 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -146.06 169.24 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.809 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.76 146.48 28.14 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.257 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.27 71.26 0.42 Allowed 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.32 -0.952 . . . . 0.0 110.848 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 165.51 11.08 0.03 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -101.92 145.89 28.61 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.841 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.523 ' C ' HD12 ' A' ' 27' ' ' ILE . 19.1 mttm -84.97 134.87 34.23 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.288 -0.965 . . . . 0.0 110.671 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.523 HD12 ' C ' ' A' ' 26' ' ' LYS . 1.5 mp -115.94 118.31 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.679 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 36.2 p -110.6 121.51 45.49 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.471 -0.891 . . . . 0.0 113.299 -177.848 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.448 ' HB3' HD11 ' A' ' 5' ' ' LEU . 70.6 m-85 -84.88 111.12 19.37 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.051 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 45.5 tttt -109.9 131.62 54.89 Favored 'General case' 0 N--CA 1.496 1.83 0 C-N-CA 119.431 -0.907 . . . . 0.0 111.76 -177.2 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.934 ' ND2' HD11 ' A' ' 61' ' ' LEU . 7.8 m-20 -90.06 117.39 28.82 Favored 'General case' 0 C--N 1.294 -1.82 0 C-N-CA 119.335 -0.946 . . . . 0.0 111.329 -179.536 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 7' ' ' SER . 25.3 p-10 -101.01 -29.54 12.12 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.968 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.522 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 174.09 137.59 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.373 -0.931 . . . . 0.0 110.935 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.403 ' O ' ' C ' ' A' ' 35' ' ' PHE . . . 122.22 -6.99 9.98 Favored Glycine 0 N--CA 1.498 2.774 0 C-N-CA 119.524 -1.322 . . . . 0.0 111.626 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.403 ' C ' ' O ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -45.87 163.1 0.23 Allowed Pre-proline 0 N--CA 1.485 1.312 0 C-N-CA 118.423 -1.311 . . . . 0.0 109.908 -179.834 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -76.76 138.43 54.24 Favored 'Cis proline' 0 C--O 1.213 -0.734 0 C-N-CA 124.122 -1.199 . . . . 0.0 112.443 -0.585 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 32.5 m-70 -102.28 179.79 4.21 Favored 'General case' 0 N--CA 1.488 1.462 0 C-N-CA 119.751 -0.78 . . . . 0.0 111.106 179.576 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -159.56 142.11 13.76 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.782 179.293 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -135.11 117.12 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.045 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.4 t -139.25 150.24 22.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.386 179.043 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -99.3 135.08 41.24 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.856 -178.816 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.539 ' C ' ' H ' ' A' ' 44' ' ' ASP . 59.6 t0 -70.62 104.36 2.79 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.284 -0.966 . . . . 0.0 109.519 178.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.465 ' CD ' ' N ' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -68.42 27.27 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.789 -0.765 . . . . 0.0 111.785 -179.229 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.539 ' H ' ' C ' ' A' ' 42' ' ' ASP . 73.3 m-20 -111.26 -7.02 14.46 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.079 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -143.82 -1.46 0.99 Allowed 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 119.218 -0.993 . . . . 0.0 111.721 -179.666 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -68.56 144.9 96.76 Favored Pre-proline 0 C--N 1.285 -2.21 0 C-N-CA 119.269 -0.972 . . . . 0.0 108.726 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -59.08 160.5 18.61 Favored 'Trans proline' 0 C--O 1.216 -0.603 0 C-N-CA 121.062 1.175 . . . . 0.0 112.243 -178.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.63 145.16 41.29 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.567 -0.853 . . . . 0.0 109.66 178.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 95.26 -59.13 1.65 Allowed Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.238 -1.458 . . . . 0.0 109.849 -179.439 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.4 t -68.52 87.18 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 119.114 -1.035 . . . . 0.0 110.339 179.509 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -44.86 154.51 0.13 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.001 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.25 -25.66 16.26 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.332 179.385 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -81.4 -15.93 53.69 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.611 -0.836 . . . . 0.0 110.774 179.805 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.18 -21.61 46.16 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.568 -0.853 . . . . 0.0 111.408 -179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.5 pt -111.04 -19.22 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 C-N-CA 119.753 -0.779 . . . . 0.0 111.312 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.7 m -79.58 169.47 17.97 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.575 -0.85 . . . . 0.0 111.81 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.634 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.8 OUTLIER -150.03 73.24 9.42 Favored Pre-proline 0 C--N 1.306 -1.32 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.785 179.113 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -56.74 -26.45 65.97 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.501 1.467 . . . . 0.0 111.947 -178.574 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.35 102.82 0.08 Allowed 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 118.94 -1.104 . . . . 0.0 110.145 179.251 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -42.46 161.75 0.02 OUTLIER 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 119.581 -0.848 . . . . 0.0 111.103 -179.415 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.934 HD11 ' ND2' ' A' ' 31' ' ' ASN . 0.8 OUTLIER -143.3 147.8 35.32 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.614 -0.835 . . . . 0.0 110.459 -179.977 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.504 ' N ' HD12 ' A' ' 61' ' ' LEU . 1.1 p30 -145.01 20.99 1.6 Allowed 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.351 -0.939 . . . . 0.0 110.952 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -77.81 119.51 5.27 Favored Glycine 0 N--CA 1.487 2.034 0 C-N-CA 119.182 -1.485 . . . . 0.0 110.199 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.11 106.15 4.85 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.276 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.72 -10.72 49.35 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -68.11 154.85 40.82 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.256 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.87 170.04 16.64 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 119.133 -1.027 . . . . 0.0 111.335 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.634 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 40.7 t80 -135.24 142.49 45.98 Favored 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.487 179.412 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -113.78 151.19 32.35 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 119.404 -0.918 . . . . 0.0 112.335 -178.708 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.6 p -153.78 132.07 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.34 178.77 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.7 m -119.06 94.5 4.46 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 119.749 -0.78 . . . . 0.0 111.493 -179.153 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.5 mt -79.72 157.77 27.09 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.224 178.865 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.5 p -150.63 52.68 0.88 Allowed 'General case' 0 C--N 1.3 -1.587 0 C-N-CA 118.536 -1.266 . . . . 0.0 111.949 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.4 ' O ' ' C ' ' A' ' 75' ' ' LYS . 2.9 tt0 -150.73 99.41 2.73 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 118.73 -1.188 . . . . 0.0 109.934 178.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 74' ' ' GLU . 0.8 OUTLIER -39.87 108.96 0.1 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.255 -178.908 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.51 -148.46 8.43 Favored Glycine 0 N--CA 1.485 1.921 0 C-N-CA 119.29 -1.433 . . . . 0.0 110.302 -179.82 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -141.49 129.99 22.58 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.472 -0.891 . . . . 0.0 111.218 -179.799 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.61 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.6 OUTLIER -119.64 161.6 20.4 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.426 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 32.2 mttt -128.98 131.96 47.5 Favored 'General case' 0 N--CA 1.49 1.567 0 C-N-CA 119.187 -1.005 . . . . 0.0 111.958 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.544 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -139.25 158.75 43.62 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.829 177.712 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -167.78 -175.11 2.64 Favored 'General case' 0 C--N 1.288 -2.079 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.989 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -111.98 119.75 39.54 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.913 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.576 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.3 tt0 -65.41 -42.37 57.35 Favored Pre-proline 0 N--CA 1.486 1.326 0 C-N-CA 119.931 -0.708 . . . . 0.0 112.724 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.576 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.1 Cg_endo -69.45 -48.2 0.84 Allowed 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 121.108 1.205 . . . . 0.0 112.035 -179.381 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -90.03 10.39 24.31 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.647 -179.546 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.08 -35.45 62.09 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 118.906 -1.117 . . . . 0.0 110.475 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -62.23 -21.14 61.53 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.199 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -85.3 -17.29 37.31 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.278 179.805 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.23 23.79 9.42 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 119.716 -1.23 . . . . 0.0 110.731 179.711 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -75.95 101.01 5.04 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.131 -1.028 . . . . 0.0 110.979 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.32 149.67 46.31 Favored 'General case' 0 N--CA 1.49 1.56 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.751 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -137.76 149.13 20.25 Favored Glycine 0 N--CA 1.496 2.655 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.352 -178.827 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -155.63 148.87 24.7 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 120.004 -0.678 . . . . 0.0 110.395 179.45 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.493 ' O ' HG13 ' A' ' 94' ' ' VAL . 7.1 p -139.08 128.99 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.81 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.9 m -104.91 98.55 8.25 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.159 179.32 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 42.4 t -79.13 150.63 5.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 118.632 -1.227 . . . . 0.0 110.453 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 89.2 m-20 . . . . . 0 N--CA 1.489 1.489 0 CA-C-O 116.333 -1.794 . . . . 0.0 110.894 -179.761 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.128 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -112.62 118.67 35.71 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 120.029 -0.668 . . . . 0.0 110.535 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 83.9 t -102.34 119.9 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.705 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 8.5 mptt -87.12 110.28 20.01 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.959 -179.617 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 11.9 mt -76.27 104.37 6.76 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.753 177.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 104.23 107.59 3.21 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.1 p -59.55 139.16 57.39 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.442 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -43.79 -52.44 6.65 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.926 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -147.44 64.15 1.14 Allowed 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.339 -0.944 . . . . 0.0 110.988 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -144.61 -76.46 0.03 OUTLIER Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.479 -1.343 . . . . 0.0 110.039 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -162.03 -165.89 19.8 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.56 -1.305 . . . . 0.0 109.917 179.565 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.0 mt -99.49 101.93 13.33 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.488 -0.885 . . . . 0.0 110.024 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.2 m -149.71 160.41 4.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 C-N-CA 119.064 -1.054 . . . . 0.0 110.955 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.456 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 59.3 m-85 -79.02 113.11 16.88 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 176.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.9 m -114.74 110.87 46.24 Favored Pre-proline 0 N--CA 1.485 1.293 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.935 -177.707 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.44 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.9 Cg_endo -65.56 176.1 20.2 Favored 'Cis proline' 0 C--N 1.363 1.324 0 C-N-CA 125.254 -0.728 . . . . 0.0 111.751 -0.254 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.2 p -96.34 -60.86 1.53 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.467 179.617 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 60.7 p -123.74 136.69 54.59 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.752 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 p90 -163.08 146.45 10.75 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 118.583 -1.247 . . . . 0.0 111.443 -179.347 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.428 HG23 ' H ' ' A' ' 20' ' ' THR . 0.8 OUTLIER -89.62 153.49 20.71 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.445 -0.902 . . . . 0.0 111.075 179.92 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.3 m -145.87 176.46 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.641 179.79 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.03 150.79 21.29 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.589 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.12 66.85 0.87 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.997 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.45 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 166.75 11.73 0.03 OUTLIER Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.45 ' H ' ' H ' ' A' ' 24' ' ' GLY . 25.9 tt0 -97.99 155.2 17.21 Favored 'General case' 0 C--N 1.307 -1.276 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.078 -179.586 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.52 133.47 39.49 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.033 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.7 mt -115.3 114.53 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 C-N-CA 120.022 -0.671 . . . . 0.0 109.614 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 73.2 p -106.87 117.04 32.99 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.782 -0.767 . . . . 0.0 112.417 -178.501 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -84.17 107.02 16.26 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.6 ttmt -96.59 142.98 28.0 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.054 -1.058 . . . . 0.0 111.295 -177.512 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.679 ' ND2' ' CD1' ' A' ' 35' ' ' PHE . 0.2 OUTLIER -100.12 121.23 41.09 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.509 179.86 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -132.83 -8.79 3.12 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.961 -1.095 . . . . 0.0 112.13 -179.571 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -168.61 132.25 1.49 Allowed 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 117.986 -1.485 . . . . 0.0 112.711 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.79 59.99 2.87 Favored Glycine 0 N--CA 1.49 2.296 0 C-N-CA 119.868 -1.158 . . . . 0.0 113.805 177.08 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.679 ' CD1' ' ND2' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -97.06 165.12 16.42 Favored Pre-proline 0 N--CA 1.493 1.685 0 C-N-CA 118.978 -1.089 . . . . 0.0 108.382 176.86 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.5 Cg_endo -77.97 147.41 83.33 Favored 'Cis proline' 0 C--O 1.214 -0.685 0 C-N-CA 124.615 -0.994 . . . . 0.0 112.938 -0.731 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -103.0 175.21 5.55 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.299 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.523 ' ND2' ' CE1' ' A' ' 60' ' ' TYR . 22.2 t-20 -150.81 124.71 9.21 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 119.205 -0.998 . . . . 0.0 110.764 179.703 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -107.85 115.68 49.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.71 179.78 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.8 t -140.23 141.7 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.194 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.3 m-85 -99.73 122.24 42.43 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 119.457 -0.897 . . . . 0.0 111.864 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.531 ' C ' ' H ' ' A' ' 44' ' ' ASP . 0.7 OUTLIER -64.96 111.86 3.04 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.029 179.183 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -66.64 11.12 0.1 Allowed 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.134 -1.026 . . . . 0.0 111.108 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.531 ' H ' ' C ' ' A' ' 42' ' ' ASP . 50.2 m-20 -93.35 -15.35 25.82 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 119.318 -0.953 . . . . 0.0 111.185 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -141.05 50.22 1.64 Allowed 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 119.635 -0.826 . . . . 0.0 110.495 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -128.41 144.86 53.54 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.931 179.607 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -48.28 150.65 5.15 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 120.831 1.02 . . . . 0.0 111.959 -179.384 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.53 47.65 0.85 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.926 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -157.78 -44.28 0.02 OUTLIER Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.456 -1.354 . . . . 0.0 109.975 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.6 t -83.57 84.42 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.313 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -44.48 142.48 1.59 Allowed 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.841 -0.743 . . . . 0.0 111.191 -179.567 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -86.9 -9.74 54.98 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.872 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -85.78 -11.99 52.09 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.853 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.29 -36.24 12.67 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.014 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -89.91 -21.43 6.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 C-N-CA 119.253 -0.979 . . . . 0.0 111.191 -179.774 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 51.6 m -74.43 178.19 5.42 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.415 -0.914 . . . . 0.0 111.142 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.636 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.3 pm0 -159.17 77.37 3.06 Favored Pre-proline 0 C--N 1.303 -1.424 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.018 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -57.78 -0.41 0.39 Allowed 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 121.09 1.193 . . . . 0.0 111.575 -178.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.489 ' H ' ' C ' ' A' ' 57' ' ' GLN . 2.7 mm-40 -80.8 92.39 6.07 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.17 -1.012 . . . . 0.0 110.046 178.834 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.523 ' CE1' ' ND2' ' A' ' 38' ' ' ASN . 38.3 m-85 -41.02 162.19 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.521 -179.388 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -135.07 108.63 7.92 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.488 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -104.72 3.51 31.47 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.907 -0.717 . . . . 0.0 110.956 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -73.64 117.74 5.88 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.378 -1.391 . . . . 0.0 110.558 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -59.38 108.68 0.74 Allowed 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.638 -0.825 . . . . 0.0 111.012 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.48 -6.21 59.11 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 119.516 -1.326 . . . . 0.0 110.817 179.595 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -62.23 149.98 40.28 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 118.996 -1.081 . . . . 0.0 110.674 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -140.8 164.44 30.21 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.421 -0.912 . . . . 0.0 111.625 -179.743 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.636 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 17.5 t80 -136.05 130.16 33.06 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.343 179.482 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -94.82 154.38 17.28 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 119.124 -1.03 . . . . 0.0 112.236 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.2 t -152.62 130.97 2.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 114.952 -1.022 . . . . 0.0 108.735 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.3 m -121.04 103.35 8.97 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.68 -178.689 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 65.7 mt -86.59 158.41 19.51 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.247 -0.981 . . . . 0.0 109.751 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.03 40.94 0.73 Allowed 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 118.845 -1.142 . . . . 0.0 111.614 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -142.97 102.18 3.96 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 118.787 -1.165 . . . . 0.0 110.801 179.453 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -43.24 114.44 0.62 Allowed 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.18 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 173.04 -145.36 8.36 Favored Glycine 0 N--CA 1.486 2.0 0 C-N-CA 119.395 -1.383 . . . . 0.0 110.038 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.7 127.83 17.59 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.444 -0.902 . . . . 0.0 110.893 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.566 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -114.72 167.14 11.02 Favored 'General case' 0 N--CA 1.481 1.12 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.123 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 20.4 mmtp -134.96 123.47 23.4 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.421 -0.912 . . . . 0.0 112.338 -178.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.543 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -132.72 161.73 33.25 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.774 -0.77 . . . . 0.0 110.359 178.033 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 34.3 p90 -170.35 -174.08 1.61 Allowed 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.382 -178.754 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' CYS . . . . . 0.443 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.6 t -113.27 134.51 54.56 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.527 179.483 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.5 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.3 mt-10 -75.61 -46.16 4.21 Favored Pre-proline 0 C--N 1.308 -1.224 0 C-N-CA 119.571 -0.852 . . . . 0.0 112.927 -179.376 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -67.62 -41.97 7.66 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.901 1.067 . . . . 0.0 112.266 -179.192 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -93.99 20.71 7.49 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.447 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.443 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -74.27 -11.74 60.36 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.126 -1.03 . . . . 0.0 110.548 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -74.83 -18.48 80.11 Favored Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.345 -1.407 . . . . 0.0 110.247 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.72 -49.48 5.59 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.54 -0.864 . . . . 0.0 110.539 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 143.91 23.55 0.16 Allowed Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.467 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.7 103.54 3.1 Favored 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.052 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 6.5 mtpp -130.93 168.49 17.23 Favored 'General case' 0 N--CA 1.494 1.748 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.384 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -153.62 147.29 16.5 Favored Glycine 0 N--CA 1.493 2.492 0 C-N-CA 119.258 -1.449 . . . . 0.0 111.614 -179.068 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -152.66 146.3 25.05 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 120.004 -0.678 . . . . 0.0 109.979 179.157 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.463 ' O ' HG13 ' A' ' 94' ' ' VAL . 8.4 p -137.64 127.59 36.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 C-N-CA 119.1 -1.04 . . . . 0.0 111.148 -179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 48.2 m -102.0 98.14 8.39 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.346 179.097 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.48 145.63 9.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 118.726 -1.19 . . . . 0.0 110.489 -178.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 9.1 m120 . . . . . 0 C--N 1.306 -1.303 0 CA-C-O 116.337 -1.792 . . . . 0.0 110.649 -179.938 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.206 0 N-CA-C 110.148 -0.315 . . . . 0.0 110.148 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -105.16 136.48 44.59 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.829 -0.749 . . . . 0.0 110.825 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.8 t -117.87 143.7 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.931 179.679 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 13.3 mttm -113.39 107.57 16.04 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.797 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.8 mp -74.69 110.38 8.94 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 118.527 -1.269 . . . . 0.0 109.701 178.437 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.422 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.01 129.17 6.59 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 -179.217 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.423 ' O ' ' N ' ' A' ' 9' ' ' ASP . 21.3 p -78.12 141.71 38.56 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.716 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 36.0 m-20 -45.31 -21.59 0.09 Allowed 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.117 -179.795 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.423 ' N ' ' O ' ' A' ' 7' ' ' SER . 0.1 OUTLIER 178.46 81.6 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.929 -179.959 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.99 -66.65 0.04 OUTLIER Glycine 0 N--CA 1.49 2.242 0 C-N-CA 119.375 -1.393 . . . . 0.0 110.324 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -167.36 -168.81 30.07 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.384 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 mt -99.34 107.02 19.18 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.653 -0.819 . . . . 0.0 110.58 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.9 m -150.03 155.72 7.61 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 119.139 -1.024 . . . . 0.0 110.996 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.414 ' O ' ' O ' ' A' ' 16' ' ' PRO . 61.2 m-85 -78.54 108.44 11.93 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 29.3 m -113.15 110.6 50.98 Favored Pre-proline 0 C--N 1.305 -1.359 0 C-N-CA 119.719 -0.792 . . . . 0.0 112.173 -177.619 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.414 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.2 Cg_endo -67.02 174.56 29.76 Favored 'Cis proline' 0 C--N 1.36 1.137 0 C-N-CA 125.337 -0.693 . . . . 0.0 111.626 -0.215 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.13 -66.06 0.94 Allowed 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 119.494 -0.883 . . . . 0.0 109.985 179.079 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.6 t -114.92 132.53 56.52 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.42 178.89 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.448 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 11.1 p90 -157.25 137.8 13.04 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 118.596 -1.242 . . . . 0.0 111.227 -179.137 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.452 HG23 ' H ' ' A' ' 20' ' ' THR . 0.6 OUTLIER -82.28 161.79 22.52 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.184 -1.006 . . . . 0.0 111.082 -179.935 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.3 m -148.97 162.49 4.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.098 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.457 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -77.05 142.6 39.78 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.872 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.11 76.76 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.066 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.85 19.77 0.1 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -102.74 162.39 12.97 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.793 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -95.59 150.85 19.89 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.529 -0.869 . . . . 0.0 111.371 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.8 mm -124.26 103.4 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.002 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.3 p -100.58 114.08 27.45 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.536 -0.866 . . . . 0.0 112.745 -178.205 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -83.8 122.32 28.52 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 177.688 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.3 tttp -121.34 121.56 37.91 Favored 'General case' 0 N--CA 1.502 2.129 0 C-N-CA 119.396 -0.922 . . . . 0.0 112.104 -177.732 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 0.6 OUTLIER -69.94 113.13 6.87 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.737 179.551 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.487 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.9 t30 -100.34 -27.87 13.25 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.685 -179.282 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.487 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 175.85 141.33 0.06 Allowed 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 119.256 -0.978 . . . . 0.0 111.122 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 103.2 0.12 47.52 Favored Glycine 0 N--CA 1.494 2.505 0 C-N-CA 119.428 -1.368 . . . . 0.0 112.194 178.626 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -48.16 162.66 0.32 Allowed Pre-proline 0 N--CA 1.487 1.386 0 C-N-CA 118.013 -1.475 . . . . 0.0 109.614 179.766 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -78.59 154.06 91.76 Favored 'Cis proline' 0 C--O 1.215 -0.635 0 C-N-CA 124.354 -1.102 . . . . 0.0 112.288 -0.548 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 43.8 m-70 -115.62 -177.02 3.05 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.016 178.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 -159.75 108.54 1.78 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.41 178.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.2 mp -91.65 121.35 42.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.011 -1.076 . . . . 0.0 111.906 -179.103 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.2 t -134.76 142.37 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.716 179.099 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -99.48 123.82 44.09 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.309 -0.956 . . . . 0.0 111.577 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.513 ' C ' ' H ' ' A' ' 44' ' ' ASP . 10.5 t0 -68.75 112.0 5.2 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.911 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -72.67 25.46 0.06 Allowed 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.546 -0.861 . . . . 0.0 111.132 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.513 ' H ' ' C ' ' A' ' 42' ' ' ASP . 32.0 m-20 -108.56 -7.9 15.61 Favored 'General case' 0 N--CA 1.49 1.557 0 C-N-CA 119.888 -0.725 . . . . 0.0 110.812 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -142.75 13.4 1.91 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.706 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -93.05 144.37 28.27 Favored Pre-proline 0 C--N 1.298 -1.658 0 C-N-CA 119.559 -0.856 . . . . 0.0 109.693 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -49.15 148.52 9.78 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.931 1.087 . . . . 0.0 112.09 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.79 74.91 5.31 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 119.651 -0.82 . . . . 0.0 110.49 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.66 -51.12 0.19 Allowed Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 84.4 t -72.3 87.09 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.006 179.088 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -44.47 139.23 2.86 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.77 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -91.14 -16.05 28.41 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.878 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -81.13 -11.74 59.4 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.699 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.9 mtmt -91.89 -27.3 18.01 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.299 -0.96 . . . . 0.0 111.071 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.2 pt -92.31 -30.44 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 C-N-CA 119.149 -1.02 . . . . 0.0 110.727 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.1 m -71.07 167.58 18.96 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.095 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.609 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -136.17 81.1 39.14 Favored Pre-proline 0 C--N 1.302 -1.46 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.567 179.285 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_exo -56.05 -16.34 16.34 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 121.317 1.345 . . . . 0.0 112.114 -178.315 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.414 ' O ' ' O ' ' A' ' 60' ' ' TYR . 9.6 mt-10 -73.24 103.32 3.91 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.001 179.157 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.414 ' O ' ' O ' ' A' ' 59' ' ' GLU . 83.6 m-85 -43.71 168.39 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 119.6 -0.84 . . . . 0.0 111.148 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.1 pp -147.53 139.17 23.96 Favored 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.379 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -141.15 28.86 1.86 Allowed 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.843 -179.354 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -92.11 115.24 4.74 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.203 -1.475 . . . . 0.0 110.614 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.37 110.33 1.22 Allowed 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.857 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 98.74 -13.02 62.7 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.521 -1.323 . . . . 0.0 110.414 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 38.9 tt0 -62.65 148.95 44.8 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.246 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.11 164.81 29.16 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.244 -0.982 . . . . 0.0 111.371 -179.643 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.609 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 36.9 t80 -135.53 133.16 38.13 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 120.011 -0.676 . . . . 0.0 109.492 179.566 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -94.83 152.88 18.03 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.184 -178.743 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 t -150.59 135.38 9.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.267 179.362 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.5 m -127.65 102.4 6.81 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.417 -0.913 . . . . 0.0 112.254 -178.459 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 19.9 mt -89.47 155.81 19.06 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.184 -1.006 . . . . 0.0 109.02 178.37 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.63 ' O ' HG22 ' A' ' 73' ' ' THR . 67.2 m -150.94 47.81 0.85 Allowed 'General case' 0 C--N 1.293 -1.854 0 C-N-CA 118.878 -1.129 . . . . 0.0 111.79 -179.05 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.425 ' OE2' ' N ' ' A' ' 75' ' ' LYS . 5.2 tp10 -145.91 103.07 3.72 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 118.95 -1.1 . . . . 0.0 110.017 179.204 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.425 ' N ' ' OE2' ' A' ' 74' ' ' GLU . 0.0 OUTLIER -40.69 114.19 0.44 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.49 -179.25 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 170.93 -148.93 11.72 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.169 -1.491 . . . . 0.0 110.372 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -140.32 133.07 28.99 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.926 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.589 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -119.41 154.3 33.89 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.477 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 15.2 mmtm -126.01 128.41 47.41 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.239 -0.985 . . . . 0.0 112.113 -178.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.556 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -137.23 165.44 26.11 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.063 -0.972 . . . . 0.0 110.357 178.463 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.9 p90 -170.58 -175.72 1.93 Allowed 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 119.724 -0.791 . . . . 0.0 110.277 -178.386 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.2 t -110.38 126.77 54.63 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.498 -0.881 . . . . 0.0 109.95 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.547 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 3.9 tm-20 -73.17 -36.72 3.39 Favored Pre-proline 0 N--CA 1.486 1.366 0 C-N-CA 119.181 -1.008 . . . . 0.0 113.689 -178.462 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.547 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -70.66 -52.39 0.26 Allowed 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 120.527 0.818 . . . . 0.0 110.998 179.701 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -80.25 12.82 2.67 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.759 -0.776 . . . . 0.0 110.791 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.45 -13.43 8.71 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.53 -0.868 . . . . 0.0 110.862 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.26 -18.19 79.45 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.277 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.28 -32.19 13.75 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.921 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.53 8.35 9.21 Favored Glycine 0 N--CA 1.497 2.711 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -50.27 105.26 0.09 Allowed 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.951 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.6 pttp -129.53 160.69 32.43 Favored 'General case' 0 N--CA 1.497 1.883 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.329 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.22 152.21 24.1 Favored Glycine 0 N--CA 1.497 2.742 0 C-N-CA 119.458 -1.354 . . . . 0.0 111.372 -178.652 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 72.1 tt0 -154.25 148.69 26.16 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.654 -0.818 . . . . 0.0 110.83 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 94' ' ' VAL . 10.8 p -140.04 125.63 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 C-N-CA 119.205 -0.998 . . . . 0.0 110.449 179.389 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 41.4 m -102.89 99.82 9.76 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.459 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 43.3 t -79.22 147.11 6.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 C-N-CA 118.558 -1.257 . . . . 0.0 110.597 -178.788 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.401 ' OD1' ' N ' ' A' ' 97' ' ' ASN . 12.0 p-10 . . . . . 0 C--N 1.305 -1.338 0 CA-C-O 116.275 -1.822 . . . . 0.0 110.787 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 CA-C-O 120.783 0.325 . . . . 0.0 110.169 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -133.14 130.27 38.98 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 120.021 -0.672 . . . . 0.0 110.575 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.1 t -125.55 126.76 70.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.974 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 21.7 mttm -99.83 119.37 38.08 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.985 -179.64 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.442 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 77.8 mt -79.35 104.01 9.67 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.142 178.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.437 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 116.31 138.35 6.3 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -178.63 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.411 ' OG ' ' N ' ' A' ' 8' ' ' ASP . 58.2 p -64.02 -69.41 0.28 Allowed 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.073 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.411 ' N ' ' OG ' ' A' ' 7' ' ' SER . 5.5 m-20 -153.19 -41.02 0.1 Allowed 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 119.404 -0.918 . . . . 0.0 110.645 179.775 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.404 ' H ' ' H ' ' A' ' 10' ' ' GLY . 0.1 OUTLIER 179.87 13.53 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.804 -179.963 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.404 ' H ' ' H ' ' A' ' 9' ' ' ASP . . . -159.95 22.59 0.27 Allowed Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.425 -1.369 . . . . 0.0 110.559 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.64 138.35 6.61 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.35 -1.405 . . . . 0.0 110.45 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 28.1 mt -113.02 97.56 6.6 Favored 'General case' 0 N--CA 1.49 1.534 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.426 179.752 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.6 m -150.07 155.85 7.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 C-N-CA 118.807 -1.157 . . . . 0.0 111.109 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 18.6 m-85 -78.37 112.1 15.05 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.45 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.8 m -116.17 107.96 46.74 Favored Pre-proline 0 CA--C 1.56 1.354 0 C-N-CA 119.496 -0.882 . . . . 0.0 111.968 -177.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.405 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.3 Cg_endo -65.91 175.53 22.77 Favored 'Cis proline' 0 C--N 1.362 1.268 0 C-N-CA 125.221 -0.741 . . . . 0.0 111.448 0.119 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.01 -45.82 6.12 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.65 -0.82 . . . . 0.0 110.056 179.415 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -137.66 135.18 36.27 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.525 179.29 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 18.4 p90 -161.5 143.76 11.91 Favored 'General case' 0 N--CA 1.485 1.285 0 C-N-CA 118.577 -1.249 . . . . 0.0 111.497 -179.093 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.3 p -87.27 156.55 19.59 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.331 -0.948 . . . . 0.0 110.957 179.77 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.8 m -148.61 173.12 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.896 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.416 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -88.8 149.43 23.42 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.415 179.635 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.8 74.32 0.1 Allowed 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.981 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 156.08 16.42 0.04 OUTLIER Glycine 0 N--CA 1.488 2.16 0 C-N-CA 119.562 -1.304 . . . . 0.0 109.983 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -95.52 151.26 19.47 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.914 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ptmt -95.34 123.58 38.94 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.527 -0.869 . . . . 0.0 111.114 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.0 mt -101.86 108.07 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.696 179.6 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 p -104.48 112.42 25.47 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.653 -0.819 . . . . 0.0 112.572 -178.287 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -84.83 116.74 23.46 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.142 178.413 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.1 ttpt -113.1 126.31 55.32 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.389 -178.036 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -68.11 113.97 6.22 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.737 178.648 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.645 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 2.4 p-10 -107.31 -22.3 12.64 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 119.171 -1.011 . . . . 0.0 111.15 179.552 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.645 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 169.38 114.46 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 118.926 -1.11 . . . . 0.0 111.113 179.511 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 129.15 7.73 3.93 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.124 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.514 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -57.68 161.63 6.01 Favored Pre-proline 0 C--N 1.306 -1.292 0 C-N-CA 118.521 -1.272 . . . . 0.0 109.95 -179.947 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -80.01 152.68 85.23 Favored 'Cis proline' 0 C--O 1.213 -0.731 0 C-N-CA 124.037 -1.235 . . . . 0.0 112.326 -1.079 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 45.1 m-70 -113.06 165.19 12.6 Favored 'General case' 0 N--CA 1.493 1.722 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.246 178.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 20.5 t30 -149.6 99.76 2.91 Favored 'General case' 0 N--CA 1.49 1.549 0 C-N-CA 118.974 -1.09 . . . . 0.0 110.783 179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.8 mp -84.95 135.65 24.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 119.279 -0.969 . . . . 0.0 111.472 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -143.55 143.56 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.004 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.682 ' CD2' HD12 ' A' ' 55' ' ' ILE . 27.5 m-85 -101.56 123.0 44.88 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.539 -0.864 . . . . 0.0 111.702 -179.396 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -66.33 118.06 9.46 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 119.404 -0.918 . . . . 0.0 109.994 179.319 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.589 ' H ' ' CD ' ' A' ' 43' ' ' GLU . 1.5 pm0 -71.32 -6.65 41.55 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 119.454 -0.898 . . . . 0.0 112.211 -178.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -95.58 5.89 50.35 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.174 -1.01 . . . . 0.0 111.574 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -143.22 16.67 1.89 Allowed 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.702 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -105.19 151.64 39.61 Favored Pre-proline 0 N--CA 1.489 1.481 0 CA-C-N 115.241 -0.89 . . . . 0.0 108.635 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -46.37 151.04 1.9 Allowed 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 121.173 1.249 . . . . 0.0 112.131 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.93 72.12 6.67 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.859 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.58 -35.39 0.14 Allowed Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.548 -1.31 . . . . 0.0 110.054 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 72.8 t -90.34 95.24 5.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.612 179.661 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 66.0 m-20 -50.15 152.9 1.57 Allowed 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.167 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.478 ' C ' ' H ' ' A' ' 54' ' ' LYS . . . -83.09 -38.25 22.74 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.468 179.641 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -63.69 0.52 0.77 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.387 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.478 ' H ' ' C ' ' A' ' 52' ' ' ALA . 0.0 OUTLIER -91.36 -45.68 8.45 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.583 179.973 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.682 HD12 ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -94.46 -25.35 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.875 179.927 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 37.3 m -48.74 164.63 0.06 Allowed 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.503 -0.879 . . . . 0.0 110.902 179.695 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.481 ' OE1' ' CD1' ' A' ' 68' ' ' TYR . 5.5 mt-30 -138.05 73.96 44.26 Favored Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 120.021 -0.671 . . . . 0.0 110.845 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -61.46 -25.6 80.01 Favored 'Trans proline' 0 C--N 1.324 -0.721 0 C-N-CA 121.301 1.334 . . . . 0.0 111.325 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -68.28 97.76 0.76 Allowed 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.421 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 47.5 m-85 -48.19 162.89 0.07 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.509 -0.877 . . . . 0.0 111.219 -179.7 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -142.22 106.32 4.76 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.751 179.631 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -114.23 21.45 14.69 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.075 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -90.85 118.64 5.42 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.281 -1.438 . . . . 0.0 110.525 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -58.42 111.35 1.2 Allowed 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.63 179.671 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.82 -13.35 57.76 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.732 -1.223 . . . . 0.0 110.407 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -60.81 148.04 40.58 Favored 'General case' 0 N--CA 1.487 1.402 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.456 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 2.3 p -145.83 165.4 28.99 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.275 -0.97 . . . . 0.0 111.3 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.481 ' CD1' ' OE1' ' A' ' 57' ' ' GLN . 38.3 t80 -136.15 146.99 47.51 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.868 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.443 ' H ' ' CD ' ' A' ' 69' ' ' GLU . 2.1 mp0 -106.88 154.1 21.54 Favored 'General case' 0 N--CA 1.496 1.874 0 C-N-CA 119.431 -0.908 . . . . 0.0 112.164 -179.053 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -151.18 134.23 7.02 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.137 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 12.5 m -129.44 114.24 15.9 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.735 -0.786 . . . . 0.0 111.125 -179.549 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.49 ' CD1' HG11 ' A' ' 94' ' ' VAL . 17.1 mt -97.6 163.44 12.84 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.696 -0.802 . . . . 0.0 110.079 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.597 ' O ' HG22 ' A' ' 73' ' ' THR . 62.3 m -150.38 51.95 0.89 Allowed 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 118.939 -1.104 . . . . 0.0 111.468 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -152.72 105.8 3.01 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 118.916 -1.114 . . . . 0.0 110.658 179.533 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -48.85 110.43 0.35 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.958 -1.097 . . . . 0.0 110.609 -179.695 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.39 -142.66 6.29 Favored Glycine 0 N--CA 1.488 2.139 0 C-N-CA 119.218 -1.468 . . . . 0.0 110.078 -179.622 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.408 HG23 HG23 ' A' ' 95' ' ' THR . 0.0 OUTLIER -143.58 129.25 19.23 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.357 -0.937 . . . . 0.0 111.114 -179.845 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.568 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -116.03 122.86 46.45 Favored 'General case' 0 N--CA 1.484 1.236 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.535 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.425 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -95.04 113.99 25.75 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.992 -178.843 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.555 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -122.83 165.39 16.71 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.608 178.307 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 30.9 p90 -170.78 -177.62 2.34 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.971 -178.596 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -110.28 113.27 25.81 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.462 178.483 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.541 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.8 tt0 -65.79 -39.75 33.86 Favored Pre-proline 0 C--N 1.303 -1.427 0 C-N-CA 119.416 -0.914 . . . . 0.0 112.891 -178.735 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.541 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.5 Cg_endo -68.53 -50.39 0.68 Allowed 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 120.499 0.8 . . . . 0.0 111.804 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -83.26 15.8 2.76 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.998 -179.579 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.97 -1.97 4.73 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.636 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -72.4 -27.46 69.68 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.307 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.77 -50.48 5.13 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.561 -0.856 . . . . 0.0 110.456 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.84 30.67 0.12 Allowed Glycine 0 N--CA 1.486 1.987 0 C-N-CA 119.618 -1.277 . . . . 0.0 110.492 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 2.5 mtp -72.17 97.65 1.99 Allowed 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.149 -1.02 . . . . 0.0 111.02 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.481 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -122.76 168.06 12.7 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.66 179.688 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -150.53 146.33 15.25 Favored Glycine 0 N--CA 1.487 2.082 0 C-N-CA 118.883 -1.627 . . . . 0.0 111.563 -178.658 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -149.51 140.87 23.23 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 119.808 -0.757 . . . . 0.0 110.535 179.346 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.572 ' O ' HG13 ' A' ' 94' ' ' VAL . 14.4 p -131.96 120.57 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.729 179.484 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.408 HG23 HG23 ' A' ' 77' ' ' THR . 6.6 m -94.92 96.97 9.66 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.23 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.6 t -79.98 153.01 4.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.639 -178.681 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.307 -1.251 0 CA-C-O 116.349 -1.786 . . . . 0.0 110.775 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.138 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 -103.74 152.43 21.86 Favored 'General case' 0 N--CA 1.49 1.525 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.856 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.3 t -134.03 145.72 32.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 C-N-CA 119.718 -0.793 . . . . 0.0 110.591 179.499 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -114.74 109.15 17.76 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 115.118 -0.947 . . . . 0.0 110.609 -179.502 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.438 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 3.9 mt -78.9 106.49 10.96 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.131 -1.027 . . . . 0.0 109.848 179.044 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.427 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 115.29 138.18 6.48 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -178.609 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.437 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 32.1 p -71.93 170.33 13.99 Favored 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.363 -0.935 . . . . 0.0 111.383 -179.411 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 19.4 m-20 -69.33 -12.25 61.5 Favored 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 119.457 -0.897 . . . . 0.0 111.515 -179.347 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -177.99 81.88 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 118.301 -1.36 . . . . 0.0 112.735 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.93 71.13 1.05 Allowed Glycine 0 N--CA 1.497 2.747 0 C-N-CA 119.266 -1.445 . . . . 0.0 112.342 177.851 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 172.31 139.48 2.84 Favored Glycine 0 N--CA 1.485 1.94 0 C-N-CA 118.973 -1.584 . . . . 0.0 110.831 178.411 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.7 mt -116.95 83.63 2.01 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.158 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.9 m -139.73 161.45 26.8 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 C-N-CA 119.376 -0.929 . . . . 0.0 111.501 -178.739 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.422 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 22.4 m-85 -78.41 110.46 13.48 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 177.793 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 5.6 m -115.67 106.32 50.42 Favored Pre-proline 0 N--CA 1.486 1.348 0 C-N-CA 119.775 -0.77 . . . . 0.0 111.315 -178.52 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.402 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.7 Cg_endo -66.78 174.61 28.67 Favored 'Cis proline' 0 C--N 1.356 0.94 0 C-N-CA 125.326 -0.698 . . . . 0.0 112.075 0.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -93.3 -55.05 3.45 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.885 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 69.8 m -125.15 140.36 52.94 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.541 179.022 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.438 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 10.4 p90 -156.69 132.06 9.28 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 118.649 -1.22 . . . . 0.0 111.397 -179.315 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.5 p -87.86 152.58 21.98 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.081 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.4 m -147.0 176.13 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.865 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -90.14 155.89 18.73 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.506 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.49 61.21 0.68 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.565 -0.854 . . . . 0.0 111.296 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 170.77 11.91 0.02 OUTLIER Glycine 0 N--CA 1.489 2.216 0 C-N-CA 119.569 -1.3 . . . . 0.0 109.91 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.408 ' OE1' ' O ' ' A' ' 26' ' ' LYS . 5.7 tm-20 -104.61 123.37 47.44 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.969 -0.693 . . . . 0.0 110.831 -179.636 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.408 ' O ' ' OE1' ' A' ' 25' ' ' GLU . 1.3 pttp -69.73 150.31 47.07 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.25 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mt -122.86 147.45 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.528 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.2 p -139.22 117.56 11.99 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.218 -0.993 . . . . 0.0 111.626 -179.321 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -84.28 150.58 25.32 Favored 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 119.267 -0.973 . . . . 0.0 109.796 179.058 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -144.55 138.72 27.69 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 118.999 -1.08 . . . . 0.0 111.707 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.651 HD21 ' CB ' ' A' ' 66' ' ' GLU . 0.5 OUTLIER -85.31 131.27 34.44 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.423 178.839 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.465 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 5.6 p-10 -111.56 -32.38 6.7 Favored 'General case' 0 N--CA 1.505 2.281 0 C-N-CA 119.107 -1.037 . . . . 0.0 112.587 -179.631 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.465 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 176.42 30.48 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 118.941 -1.104 . . . . 0.0 110.819 -179.433 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.493 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -138.78 40.3 1.47 Allowed Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.229 -1.462 . . . . 0.0 111.233 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.596 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -86.2 161.58 48.82 Favored Pre-proline 0 C--N 1.309 -1.194 0 C-N-CA 118.442 -1.303 . . . . 0.0 109.999 179.226 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -78.65 135.82 38.54 Favored 'Cis proline' 0 C--O 1.215 -0.649 0 C-N-CA 124.075 -1.219 . . . . 0.0 111.568 -0.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.493 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 40.4 m-70 -100.21 -177.1 3.42 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.749 179.589 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.619 ' ND2' ' N ' ' A' ' 39' ' ' ILE . 1.7 t-20 -161.11 146.86 14.36 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.3 -0.96 . . . . 0.0 110.916 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.619 ' N ' ' ND2' ' A' ' 38' ' ' ASN . 3.5 mt -131.0 114.91 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.779 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.478 ' CG2' HD21 ' A' ' 38' ' ' ASN . 3.0 t -137.15 137.24 46.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.124 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 44.1 m-85 -93.67 127.63 39.46 Favored 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.236 -0.986 . . . . 0.0 111.413 -179.602 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.4 125.77 25.28 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.895 179.526 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -57.47 -49.94 74.64 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 -177.143 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -85.21 8.23 19.11 Favored 'General case' 0 N--CA 1.498 1.936 0 C-N-CA 118.941 -1.104 . . . . 0.0 113.855 -176.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -126.86 40.35 3.74 Favored 'General case' 0 N--CA 1.495 1.781 0 C-N-CA 119.341 -0.944 . . . . 0.0 110.568 179.347 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.657 HG22 ' HD2' ' A' ' 47' ' ' PRO . 0.5 OUTLIER -135.59 156.33 77.7 Favored Pre-proline 0 N--CA 1.487 1.399 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 179.279 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.657 ' HD2' HG22 ' A' ' 46' ' ' VAL . 3.6 Cg_exo -48.04 148.06 7.24 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 120.916 1.077 . . . . 0.0 111.73 -179.583 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.57 70.37 6.03 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.644 -0.822 . . . . 0.0 111.035 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.37 -22.78 0.09 OUTLIER Glycine 0 N--CA 1.489 2.211 0 C-N-CA 119.342 -1.409 . . . . 0.0 110.435 179.808 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 44.6 t -97.42 99.78 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.809 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -46.75 149.66 0.81 Allowed 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.256 -0.978 . . . . 0.0 110.715 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.409 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -94.64 -5.69 45.09 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.623 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -86.14 -29.6 23.16 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.107 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 21.4 mmtt -71.87 -27.55 62.94 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.463 -0.895 . . . . 0.0 111.481 -179.296 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 10.7 pt -105.15 -14.95 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 C-N-CA 119.559 -0.857 . . . . 0.0 111.944 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.409 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 4.7 m -67.32 173.62 3.83 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.241 -0.983 . . . . 0.0 110.827 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.508 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 28.8 tt0 -136.93 76.01 47.14 Favored Pre-proline 0 C--N 1.306 -1.321 0 C-N-CA 120.072 -0.651 . . . . 0.0 110.354 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -60.02 -22.33 68.85 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 121.359 1.373 . . . . 0.0 111.985 -178.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 38.8 mm-40 -89.89 106.83 18.74 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.139 -1.024 . . . . 0.0 110.652 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 30.9 m-85 -56.37 170.5 0.35 Allowed 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.728 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.432 HD23 ' NE2' ' A' ' 57' ' ' GLN . 2.5 pp -140.26 129.48 23.75 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.098 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -127.68 10.33 6.59 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.521 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.48 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . -77.85 118.78 5.08 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.412 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.9 105.12 0.52 Allowed 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.759 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.24 -2.77 43.66 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.559 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.651 ' CB ' HD21 ' A' ' 31' ' ' ASN . 2.8 tp10 -63.16 161.14 14.05 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 118.916 -1.113 . . . . 0.0 110.229 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 66.8 p -147.45 163.14 37.45 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.556 -179.138 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.508 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 76.0 t80 -135.62 139.14 43.57 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.751 179.05 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -107.59 153.17 23.27 Favored 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 119.513 -0.875 . . . . 0.0 112.577 -178.477 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 p -161.51 132.9 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.391 178.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.8 m -119.81 95.6 4.84 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.733 -178.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 12.2 mt -80.46 158.49 25.88 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.384 -0.926 . . . . 0.0 109.226 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.0 p -151.14 28.44 0.67 Allowed 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 118.65 -1.22 . . . . 0.0 112.253 -179.02 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.506 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -114.5 97.75 6.49 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.024 179.599 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.8 tttt -41.68 98.0 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.958 -179.674 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 74' ' ' GLU . . . 177.56 -134.17 2.4 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.176 -1.488 . . . . 0.0 110.257 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -145.31 142.0 29.05 Favored 'General case' 0 C--N 1.309 -1.165 0 C-N-CA 119.216 -0.994 . . . . 0.0 111.519 -179.683 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.574 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.2 m-85 -128.05 128.31 44.72 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.386 -0.825 . . . . 0.0 108.779 179.359 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -105.77 118.97 37.96 Favored 'General case' 0 N--CA 1.488 1.453 0 C-N-CA 119.243 -0.983 . . . . 0.0 111.318 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -124.31 172.91 8.73 Favored 'General case' 0 C--O 1.206 -1.205 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.56 178.532 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -171.06 175.3 4.39 Favored 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 118.932 -1.107 . . . . 0.0 111.577 -178.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.4 t -99.66 127.06 45.77 Favored 'General case' 0 C--N 1.3 -1.587 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.287 179.494 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.593 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 3.2 tm-20 -73.88 -34.95 2.25 Favored Pre-proline 0 N--CA 1.492 1.661 0 C-N-CA 118.85 -1.14 . . . . 0.0 113.667 -178.498 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.1 Cg_endo -72.68 -52.31 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 120.671 0.914 . . . . 0.0 110.99 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 34.4 m80 -81.39 14.72 2.32 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.879 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -62.89 -6.19 3.56 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.187 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.31 -21.43 62.5 Favored Glycine 0 N--CA 1.49 2.267 0 C-N-CA 119.339 -1.41 . . . . 0.0 110.307 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.73 -22.36 18.15 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.956 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.426 ' O ' ' N ' ' A' ' 91' ' ' LYS . . . 109.27 11.82 21.15 Favored Glycine 0 N--CA 1.497 2.754 0 C-N-CA 119.964 -1.112 . . . . 0.0 110.364 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 6.1 ttt -53.9 92.62 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.474 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.53 ' CB ' ' NZ ' ' A' ' 91' ' ' LYS . 0.1 OUTLIER -117.1 158.73 23.7 Favored 'General case' 0 N--CA 1.5 2.039 0 C-N-CA 119.855 -0.738 . . . . 0.0 111.386 -179.73 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.23 146.53 18.45 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.027 -1.082 . . . . 0.0 111.052 -178.676 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -148.85 147.1 28.32 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.842 179.707 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 94' ' ' VAL . 7.4 p -140.05 129.89 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.195 179.131 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 90.4 m -106.09 100.78 10.31 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.656 -0.818 . . . . 0.0 110.964 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 47.1 t -82.48 142.99 12.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.364 -179.071 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.436 ' O ' ' ND2' ' A' ' 97' ' ' ASN . 0.9 OUTLIER . . . . . 0 C--N 1.307 -1.253 0 CA-C-O 116.328 -1.796 . . . . 0.0 110.952 -179.688 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.905 0.383 . . . . 0.0 110.036 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -92.7 131.46 37.76 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.404 -0.918 . . . . 0.0 110.562 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 t -122.29 121.72 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.404 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.58 118.83 31.86 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.186 179.46 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.8 mt -78.54 98.83 6.26 Favored 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.9 179.019 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.464 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 113.59 131.6 5.39 Favored Glycine 0 N--CA 1.488 2.151 0 CA-C-N 114.546 -1.206 . . . . 0.0 110.323 -179.135 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.523 ' OG ' ' N ' ' A' ' 10' ' ' GLY . 56.3 p -83.22 167.49 17.64 Favored 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 119.299 -0.96 . . . . 0.0 110.548 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.5 -20.07 66.19 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.476 -0.889 . . . . 0.0 111.422 -179.798 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -172.95 1.09 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.141 -1.023 . . . . 0.0 111.238 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.523 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . -77.31 -32.31 48.29 Favored Glycine 0 N--CA 1.492 2.403 0 C-N-CA 119.438 -1.363 . . . . 0.0 110.745 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 140.55 -134.68 6.59 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.519 -1.324 . . . . 0.0 110.5 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.7 mt -117.06 104.27 11.07 Favored 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 120.018 -0.673 . . . . 0.0 110.893 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.0 m -150.39 157.06 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 118.979 -1.088 . . . . 0.0 110.954 179.45 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.419 ' O ' ' O ' ' A' ' 16' ' ' PRO . 62.2 m-85 -78.27 110.83 13.63 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 16.5 m -114.2 111.62 47.28 Favored Pre-proline 0 CA--C 1.56 1.341 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.948 -177.459 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.419 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.3 Cg_exo -65.83 174.18 26.4 Favored 'Cis proline' 0 C--N 1.36 1.158 0 C-N-CA 125.105 -0.79 . . . . 0.0 111.611 -0.343 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.9 m -97.45 -65.87 0.94 Allowed 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.098 179.256 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 m -114.39 137.68 51.51 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.734 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 34.5 p90 -168.2 147.4 4.58 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 118.49 -1.284 . . . . 0.0 111.656 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.672 HG22 ' HB ' ' A' ' 95' ' ' THR . 44.2 p -83.31 161.55 21.4 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.193 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 31.5 m -149.32 148.72 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.228 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.662 179.541 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.539 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -76.51 140.74 41.29 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.294 -0.962 . . . . 0.0 110.751 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -58.78 78.39 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.242 0 C-N-CA 119.657 -0.817 . . . . 0.0 110.937 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 148.21 21.22 0.09 OUTLIER Glycine 0 N--CA 1.487 2.071 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -102.56 150.34 23.5 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.924 -0.71 . . . . 0.0 110.733 -179.718 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 74.9 mttt -95.2 117.69 30.69 Favored 'General case' 0 C--N 1.303 -1.434 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.055 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.5 mt -93.22 98.35 8.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 119.501 -0.88 . . . . 0.0 108.962 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 55.0 p -94.34 117.43 30.11 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 119.493 -0.883 . . . . 0.0 112.821 -177.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -84.68 143.62 29.08 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.049 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 11.4 ttpt -135.3 125.55 26.33 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.387 -178.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.525 ' OD1' ' CD1' ' A' ' 35' ' ' PHE . 36.5 t-20 -79.39 115.8 19.24 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 119.792 -0.763 . . . . 0.0 110.009 179.354 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.464 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 3.0 p-10 -120.29 -22.23 6.63 Favored 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.307 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -177.45 123.43 0.13 Allowed 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 118.358 -1.337 . . . . 0.0 112.188 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 104.17 48.6 1.13 Allowed Glycine 0 N--CA 1.495 2.618 0 C-N-CA 119.272 -1.442 . . . . 0.0 112.849 177.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.623 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -87.54 164.83 33.39 Favored Pre-proline 0 C--N 1.304 -1.37 0 C-N-CA 118.573 -1.251 . . . . 0.0 108.936 177.91 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -77.2 140.13 62.6 Favored 'Cis proline' 0 C--O 1.215 -0.642 0 C-N-CA 124.555 -1.019 . . . . 0.0 112.917 -0.5 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 33.6 m-70 -108.15 161.28 15.12 Favored 'General case' 0 N--CA 1.495 1.794 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.952 178.607 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.763 HD21 ' H ' ' A' ' 83' ' ' GLU . 4.0 p-10 -153.52 163.18 40.4 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 119.049 -1.061 . . . . 0.0 110.684 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -133.78 124.35 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.841 -0.743 . . . . 0.0 110.758 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.7 t -137.48 141.31 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.264 179.74 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.485 ' CE2' HD12 ' A' ' 55' ' ' ILE . 5.6 m-85 -96.39 130.75 43.45 Favored 'General case' 0 C--N 1.303 -1.455 0 C-N-CA 119.574 -0.85 . . . . 0.0 111.706 -178.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -73.9 117.19 15.4 Favored 'General case' 0 N--CA 1.485 1.279 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.789 179.034 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -69.56 0.3 5.57 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.435 -0.906 . . . . 0.0 112.013 -178.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 62.3 m-20 -99.76 -5.79 28.08 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.357 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 31.0 mm-40 -123.37 -2.38 8.52 Favored 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.615 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.407 HG13 ' HD2' ' A' ' 47' ' ' PRO . 42.2 t -95.99 144.93 28.66 Favored Pre-proline 0 C--N 1.285 -2.216 0 N-CA-C 107.256 -1.386 . . . . 0.0 107.256 178.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.473 ' HG2' HG12 ' A' ' 50' ' ' VAL . 1.8 Cg_endo -61.09 165.2 12.82 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 CA-C-N 119.024 0.687 . . . . 0.0 111.89 -178.367 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.8 38.89 0.72 Allowed 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.381 -0.928 . . . . 0.0 110.239 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.18 -57.83 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.684 ' O ' HG13 ' A' ' 50' ' ' VAL . 9.8 p -84.46 101.99 9.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.722 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -48.97 153.81 0.82 Allowed 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.681 -0.808 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -98.29 -10.16 24.35 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.443 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -88.1 -10.46 50.02 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.652 -0.819 . . . . 0.0 110.579 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.4 13.2 16.19 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.465 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.485 HD12 ' CE2' ' A' ' 41' ' ' PHE . 1.1 pt -147.38 -29.09 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 C-N-CA 119.503 -0.879 . . . . 0.0 110.814 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 2.1 m -48.58 174.25 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.948 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.624 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 36.5 mt-30 -135.5 78.95 49.23 Favored Pre-proline 0 N--CA 1.489 1.491 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.022 -179.833 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -60.58 -7.86 7.97 Favored 'Trans proline' 0 N--CA 1.456 -0.686 0 C-N-CA 120.78 0.987 . . . . 0.0 110.641 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -98.01 127.61 44.06 Favored 'General case' 0 N--CA 1.483 1.179 0 C-N-CA 119.778 -0.769 . . . . 0.0 110.227 179.309 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.435 ' CD1' ' N ' ' A' ' 60' ' ' TYR . 32.4 m-85 -88.59 173.58 8.56 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.917 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -137.94 106.53 5.87 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.658 179.644 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.5 p-10 -101.67 3.65 39.97 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.912 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -65.83 -140.58 0.04 OUTLIER Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.392 -1.385 . . . . 0.0 110.413 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -159.42 99.61 1.46 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.68 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.44 -1.12 43.01 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 119.815 -1.183 . . . . 0.0 110.44 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -63.03 158.74 18.72 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.56 179.801 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.2 p -147.26 155.48 42.09 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.828 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.624 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 41.0 t80 -136.97 153.51 50.67 Favored 'General case' 0 N--CA 1.488 1.444 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.443 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.411 ' O ' ' CE1' ' A' ' 68' ' ' TYR . 3.6 mt-10 -113.41 149.18 34.52 Favored 'General case' 0 N--CA 1.501 2.082 0 C-N-CA 119.44 -0.904 . . . . 0.0 112.224 -179.076 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -144.62 126.04 9.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.182 179.033 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.9 m -119.22 100.11 7.12 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.82 -0.752 . . . . 0.0 111.268 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 65.9 mt -79.55 161.28 26.08 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.65 179.171 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.9 p -150.07 48.53 0.91 Allowed 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 118.819 -1.152 . . . . 0.0 111.742 -178.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.4 ' O ' ' C ' ' A' ' 75' ' ' LYS . 3.6 mm-40 -148.17 98.26 2.9 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.567 179.416 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 74' ' ' GLU . 0.0 OUTLIER -43.67 107.8 0.09 Allowed 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.596 -179.784 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 176.48 -141.91 5.7 Favored Glycine 0 C--N 1.294 -1.773 0 C-N-CA 119.066 -1.54 . . . . 0.0 110.094 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.52 136.67 26.22 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.476 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.592 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.2 OUTLIER -128.78 137.64 51.64 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.488 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.37 108.64 16.78 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.932 179.759 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.504 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 2.1 p90 -109.87 170.95 7.74 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.202 179.445 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -171.18 179.84 2.9 Favored 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 119.362 -0.935 . . . . 0.0 112.068 -178.454 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' CYS . . . . . 0.566 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.5 t -108.96 124.45 50.71 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.205 179.122 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.763 ' H ' HD21 ' A' ' 38' ' ' ASN . 0.3 OUTLIER -68.46 -39.4 15.51 Favored Pre-proline 0 N--CA 1.488 1.442 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -178.283 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.3 Cg_endo -73.35 -51.67 0.16 Allowed 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 121.02 1.147 . . . . 0.0 111.84 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -81.4 8.49 9.17 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.286 -0.966 . . . . 0.0 111.328 -179.327 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.566 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -65.03 -17.28 64.31 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.198 -1.001 . . . . 0.0 110.686 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -65.05 -22.98 69.28 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.493 -1.336 . . . . 0.0 110.248 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.25 -39.82 10.78 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.562 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 135.65 20.89 0.67 Allowed Glycine 0 N--CA 1.493 2.461 0 C-N-CA 119.744 -1.217 . . . . 0.0 110.34 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.98 106.2 2.26 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.312 -0.955 . . . . 0.0 111.19 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.409 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 2.1 pttp -135.15 169.5 17.35 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.938 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.462 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -150.51 150.17 22.14 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 119.013 -1.565 . . . . 0.0 111.417 -178.467 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -150.09 143.52 25.15 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.519 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.435 ' O ' HG13 ' A' ' 94' ' ' VAL . 6.6 p -141.03 126.34 18.77 Favored 'Isoleucine or valine' 0 C--O 1.205 -1.285 0 C-N-CA 119.244 -0.982 . . . . 0.0 110.746 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.672 ' HB ' HG22 ' A' ' 20' ' ' THR . 22.7 m -103.45 103.41 13.38 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.647 -0.821 . . . . 0.0 110.423 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 21.6 t -79.55 143.15 12.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 118.714 -1.194 . . . . 0.0 110.018 -179.36 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 . . . . . 0 N--CA 1.489 1.488 0 CA-C-O 116.314 -1.803 . . . . 0.0 110.818 -179.602 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.096 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -140.21 122.49 15.92 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.748 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 98.4 t -114.52 132.54 63.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 C-N-CA 119.848 -0.741 . . . . 0.0 111.127 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -100.56 111.75 24.03 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.736 -0.786 . . . . 0.0 110.684 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.433 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 9.5 mt -75.68 105.07 6.52 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.923 178.684 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 112.39 131.68 5.66 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -178.61 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.421 ' OG ' ' N ' ' A' ' 11' ' ' GLY . 3.4 p -82.8 168.96 16.65 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.256 -0.978 . . . . 0.0 111.092 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -62.17 -38.51 89.35 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.671 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.6 p30 -167.7 20.57 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.778 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -96.05 -25.08 13.37 Favored Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.498 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.421 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . 141.18 -140.62 10.48 Favored Glycine 0 N--CA 1.492 2.367 0 C-N-CA 119.573 -1.299 . . . . 0.0 110.475 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.9 mt -115.2 107.64 15.56 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 120.055 -0.658 . . . . 0.0 110.915 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.6 m -150.64 157.95 5.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.654 179.455 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.53 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 34.1 m-85 -78.39 113.24 16.21 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 178.068 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 17.3 m -116.45 107.13 47.5 Favored Pre-proline 0 CA--C 1.562 1.41 0 C-N-CA 119.5 -0.88 . . . . 0.0 112.186 -177.453 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -65.89 176.24 20.9 Favored 'Cis proline' 0 C--N 1.361 1.217 0 C-N-CA 125.198 -0.751 . . . . 0.0 111.414 -0.757 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.02 -52.05 4.39 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.486 -0.885 . . . . 0.0 110.265 179.264 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 4.5 m -132.03 135.28 46.4 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.413 179.09 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 12.8 p90 -155.71 142.32 18.74 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 118.495 -1.282 . . . . 0.0 111.573 -179.097 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.623 HG22 ' HB ' ' A' ' 95' ' ' THR . 46.9 p -84.17 151.24 24.99 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.439 179.458 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.0 m -144.59 161.79 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 119.356 -0.938 . . . . 0.0 111.137 179.71 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.449 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -81.35 146.55 30.28 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.65 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.05 74.52 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 119.673 -0.811 . . . . 0.0 111.23 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 155.68 18.2 0.04 OUTLIER Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.466 -1.35 . . . . 0.0 109.797 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -98.63 150.95 21.22 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.951 -179.49 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.8 mttt -92.43 117.95 30.45 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.337 -0.945 . . . . 0.0 111.016 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.6 mt -97.94 110.4 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.771 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 75.6 p -110.94 114.48 27.83 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.672 -0.811 . . . . 0.0 112.515 -178.519 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -87.01 111.55 20.97 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.373 178.391 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -106.57 141.01 38.54 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 119.68 -0.808 . . . . 0.0 112.045 -178.535 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.544 HD21 HD11 ' A' ' 61' ' ' LEU . 1.7 m-80 -82.27 115.99 21.59 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.877 178.799 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.537 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 4.2 p-10 -98.75 -32.76 11.21 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 118.755 -1.178 . . . . 0.0 111.839 -179.398 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.537 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 171.91 52.22 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.496 -0.881 . . . . 0.0 110.042 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.506 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -153.45 26.67 0.77 Allowed Glycine 0 N--CA 1.487 2.041 0 C-N-CA 118.992 -1.575 . . . . 0.0 110.734 -179.67 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.636 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -79.23 160.34 70.9 Favored Pre-proline 0 C--N 1.309 -1.191 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.96 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -77.41 138.66 54.15 Favored 'Cis proline' 0 C--O 1.215 -0.657 0 C-N-CA 123.876 -1.302 . . . . 0.0 111.757 -1.167 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.506 ' CE1' ' O ' ' A' ' 34' ' ' GLY . 38.2 m-70 -107.66 179.52 4.21 Favored 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 119.631 -0.828 . . . . 0.0 111.49 -179.293 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -156.09 143.25 19.08 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.61 -0.836 . . . . 0.0 110.354 179.781 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.2 mp -130.25 118.31 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.304 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t -145.3 147.65 18.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.656 179.064 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -99.43 139.97 34.29 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.144 -1.022 . . . . 0.0 112.006 -179.191 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.698 ' C ' ' H ' ' A' ' 44' ' ' ASP . 39.8 p-10 -75.37 108.37 8.11 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 115.142 -0.935 . . . . 0.0 111.296 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.489 ' OE1' ' HB3' ' A' ' 52' ' ' ALA . 27.4 mm-40 -56.47 10.8 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.156 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.589 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.698 ' H ' ' C ' ' A' ' 42' ' ' ASP . 70.8 m-20 -82.92 -68.49 0.7 Allowed 'General case' 0 C--N 1.288 -2.081 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.249 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -99.38 -5.23 29.92 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.826 -1.15 . . . . 0.0 114.038 -175.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -54.15 143.88 41.94 Favored Pre-proline 0 C--N 1.282 -2.362 0 C-N-CA 118.206 -1.397 . . . . 0.0 107.784 179.023 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_exo -46.71 146.92 5.0 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 120.713 0.942 . . . . 0.0 112.116 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -85.34 51.13 2.1 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.771 -0.772 . . . . 0.0 111.051 -179.679 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -165.63 -23.49 0.02 OUTLIER Glycine 0 N--CA 1.488 2.122 0 C-N-CA 119.478 -1.344 . . . . 0.0 109.965 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 53.2 t -97.85 104.26 15.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.683 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -45.56 139.85 3.6 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 119.223 -0.991 . . . . 0.0 110.567 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.489 ' HB3' ' OE1' ' A' ' 43' ' ' GLU . . . -101.29 -8.29 22.25 Favored 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.229 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -83.79 -21.05 32.28 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.164 -1.014 . . . . 0.0 110.966 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 51.6 mmtt -86.41 -32.88 20.66 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.263 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.4 pt -89.14 -19.81 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 C-N-CA 118.876 -1.13 . . . . 0.0 111.438 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 74.3 m -74.44 -176.6 2.77 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.971 179.354 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -142.51 82.82 12.41 Favored Pre-proline 0 N--CA 1.491 1.617 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.43 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -61.96 -9.59 14.9 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 121.187 1.258 . . . . 0.0 112.067 -179.039 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -99.23 112.55 24.69 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.387 -0.925 . . . . 0.0 110.87 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -58.69 178.04 0.12 Allowed 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.574 -0.851 . . . . 0.0 110.71 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.544 HD11 HD21 ' A' ' 31' ' ' ASN . 2.0 pp -151.21 142.12 22.95 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.551 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -134.58 19.95 3.6 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.883 -179.752 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -86.4 139.26 16.52 Favored Glycine 0 N--CA 1.489 2.213 0 C-N-CA 119.168 -1.491 . . . . 0.0 110.219 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -85.5 111.39 19.95 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.509 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 102.25 -15.21 56.54 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 -179.624 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -64.01 147.02 53.08 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.227 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -142.43 169.92 16.67 Favored 'General case' 0 N--CA 1.486 1.369 0 C-N-CA 119.206 -0.997 . . . . 0.0 111.466 -179.65 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 26.5 t80 -134.44 135.97 42.9 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.477 179.251 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.549 ' H ' ' CD ' ' A' ' 69' ' ' GLU . 1.6 mp0 -97.36 152.63 18.73 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.25 -0.98 . . . . 0.0 112.371 -178.573 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.1 t -151.58 133.5 5.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 CA-C-N 115.221 -0.899 . . . . 0.0 109.033 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 8.4 m -127.13 104.3 7.9 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.113 -179.376 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.5 ' CD1' HG11 ' A' ' 94' ' ' VAL . 13.9 mt -90.37 160.06 16.28 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.268 -0.973 . . . . 0.0 109.749 179.489 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 67.3 p -148.41 48.04 1.04 Allowed 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.558 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.438 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.9 mt-10 -147.08 105.9 3.84 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.972 -1.091 . . . . 0.0 110.453 179.311 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.74 112.03 0.42 Allowed 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.002 -1.079 . . . . 0.0 110.633 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.66 8.61 Favored Glycine 0 N--CA 1.487 2.064 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.282 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -141.44 123.73 15.68 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.399 -179.642 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.547 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -115.49 120.29 39.02 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.339 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 26.1 mttt -97.83 126.95 43.45 Favored 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 119.209 -0.996 . . . . 0.0 112.603 -178.406 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.58 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -127.61 158.58 37.13 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.679 177.928 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -165.0 176.87 8.23 Favored 'General case' 0 C--N 1.283 -2.296 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.131 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.6 t -104.39 123.86 48.19 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.787 -0.765 . . . . 0.0 110.547 -179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.542 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tt0 -66.4 -44.97 58.88 Favored Pre-proline 0 C--N 1.306 -1.303 0 C-N-CA 119.685 -0.806 . . . . 0.0 112.913 -179.673 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.542 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.6 Cg_exo -65.36 -50.29 2.05 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 121.179 1.252 . . . . 0.0 111.801 -178.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -86.77 16.18 5.04 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.727 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.21 -9.35 4.74 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.777 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.36 -20.12 49.87 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.485 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.14 -12.93 39.65 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.478 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 99.02 26.07 9.17 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.505 -1.331 . . . . 0.0 110.719 179.767 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -76.83 101.63 5.97 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.174 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.53 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 1.5 ptmt -124.98 162.58 24.18 Favored 'General case' 0 N--CA 1.493 1.712 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.946 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.549 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -146.76 149.84 22.04 Favored Glycine 0 N--CA 1.495 2.608 0 C-N-CA 119.296 -1.431 . . . . 0.0 111.419 -178.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -156.39 145.47 20.42 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.005 179.239 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.673 ' O ' HG13 ' A' ' 94' ' ' VAL . 12.6 p -135.94 117.53 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.466 -0.893 . . . . 0.0 110.464 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.623 ' HB ' HG22 ' A' ' 20' ' ' THR . 46.1 m -93.72 100.4 12.63 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.194 -1.003 . . . . 0.0 110.599 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 22.9 t -79.22 146.5 7.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 C-N-CA 118.46 -1.296 . . . . 0.0 110.333 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.308 -1.233 0 CA-C-O 116.345 -1.788 . . . . 0.0 110.587 -179.647 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.087 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -118.51 122.06 41.77 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.644 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 57.6 t -114.89 113.81 44.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.866 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 29.5 mtmt -88.63 116.77 27.11 Favored 'General case' 0 C--N 1.298 -1.641 0 C-N-CA 119.193 -1.003 . . . . 0.0 110.854 -179.555 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 7.8 mt -78.6 105.79 10.13 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 118.788 -1.165 . . . . 0.0 110.41 178.617 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 103.12 121.42 4.93 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.59 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.1 p -71.35 167.12 20.2 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.672 179.838 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -91.17 -6.6 53.28 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.349 -0.941 . . . . 0.0 110.77 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.401 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -93.68 -5.69 47.99 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.924 -179.886 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 105.07 74.78 0.97 Allowed Glycine 0 N--CA 1.495 2.581 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.385 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -170.05 144.88 8.78 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.48 -1.343 . . . . 0.0 110.502 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 23.0 mt -99.79 100.77 11.77 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.698 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.7 m -151.0 157.43 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 C-N-CA 118.974 -1.09 . . . . 0.0 111.381 179.638 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' A' ' 16' ' ' PRO . 22.1 m-85 -78.53 110.0 13.22 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 177.499 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.4 m -115.62 109.19 45.99 Favored Pre-proline 0 N--CA 1.488 1.449 0 C-N-CA 119.28 -0.968 . . . . 0.0 112.564 -177.092 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.421 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.4 Cg_exo -65.9 178.62 15.26 Favored 'Cis proline' 0 C--N 1.364 1.35 0 C-N-CA 125.191 -0.754 . . . . 0.0 111.526 -1.075 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 41.8 t -95.75 -60.47 1.64 Allowed 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.376 179.474 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.4 t -124.74 140.33 53.03 Favored 'General case' 0 N--CA 1.488 1.438 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.884 179.37 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -165.22 149.62 8.82 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 118.592 -1.243 . . . . 0.0 111.258 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.416 ' H ' HG23 ' A' ' 20' ' ' THR . 0.8 OUTLIER -87.03 160.45 18.61 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.273 -179.876 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.3 m -148.86 165.56 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.941 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.499 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -87.29 142.91 27.54 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.556 179.817 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.71 77.28 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.136 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.499 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 146.56 18.41 0.13 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -98.35 138.58 35.38 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.852 -0.739 . . . . 0.0 110.609 -179.627 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.5 mttm -80.1 118.65 22.0 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.141 -179.634 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.3 mt -100.41 120.21 49.57 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.228 179.345 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 68.3 p -114.93 118.45 33.49 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.523 -0.871 . . . . 0.0 112.988 -177.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -84.71 114.15 21.83 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 177.415 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.4 mttp -103.94 132.33 50.3 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.415 -0.914 . . . . 0.0 111.46 -177.593 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 50.3 t-20 -84.97 110.82 19.17 Favored 'General case' 0 C--N 1.29 -2.004 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.025 178.826 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -106.67 -30.22 9.12 Favored 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 119.275 -0.97 . . . . 0.0 112.038 -179.03 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -178.67 161.11 1.25 Allowed 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 119.26 -0.976 . . . . 0.0 111.194 -179.543 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . 75.58 58.61 3.79 Favored Glycine 0 N--CA 1.495 2.58 0 C-N-CA 119.536 -1.316 . . . . 0.0 113.062 178.04 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -97.3 165.27 16.02 Favored Pre-proline 0 N--CA 1.496 1.853 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 177.665 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -78.08 138.46 51.44 Favored 'Cis proline' 0 C--O 1.214 -0.691 0 C-N-CA 124.808 -0.913 . . . . 0.0 113.047 -0.042 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.505 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 36.6 m-70 -102.81 177.34 4.88 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.713 -0.795 . . . . 0.0 110.574 178.566 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.506 ' ND2' ' CD1' ' A' ' 60' ' ' TYR . 5.0 t-20 -165.69 154.48 11.64 Favored 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.88 179.688 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.623 ' N ' HD12 ' A' ' 39' ' ' ILE . 2.5 mp -139.25 114.67 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 119.64 -0.824 . . . . 0.0 111.103 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 t -130.48 152.21 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.603 179.397 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.45 ' CE2' HD12 ' A' ' 55' ' ' ILE . 9.5 m-85 -102.94 141.07 36.37 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.525 -0.87 . . . . 0.0 111.796 -179.025 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -78.28 109.97 12.88 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.817 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.434 ' OE2' ' O ' ' A' ' 41' ' ' PHE . 35.3 mp0 -73.36 47.27 0.21 Allowed 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.94 -179.188 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -138.74 -5.84 1.51 Allowed 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.804 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -145.11 7.12 1.17 Allowed 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 118.54 -1.264 . . . . 0.0 111.981 179.754 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.592 HG13 ' HD2' ' A' ' 47' ' ' PRO . 2.1 t -80.53 150.79 70.83 Favored Pre-proline 0 C--N 1.289 -2.04 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.661 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.592 ' HD2' HG13 ' A' ' 46' ' ' VAL . 4.0 Cg_exo -52.87 158.17 6.79 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 120.944 1.096 . . . . 0.0 111.794 -179.428 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.87 48.7 1.67 Allowed 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.751 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -154.6 -32.63 0.03 OUTLIER Glycine 0 N--CA 1.49 2.242 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.134 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.413 ' O ' HG12 ' A' ' 50' ' ' VAL . 51.6 t -97.29 95.39 4.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 C-N-CA 119.599 -0.84 . . . . 0.0 110.841 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -46.05 148.29 0.87 Allowed 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.037 -1.065 . . . . 0.0 110.322 179.701 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -92.87 -33.77 14.09 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.339 -0.945 . . . . 0.0 111.211 -179.591 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -65.81 -17.83 64.91 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.823 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.37 -35.88 54.08 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.284 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.45 HD12 ' CE2' ' A' ' 41' ' ' PHE . 1.9 pt -95.69 -35.13 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.108 -179.644 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 39.9 m -43.46 158.88 0.03 OUTLIER 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.995 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.47 ' OE1' ' CD1' ' A' ' 68' ' ' TYR . 3.8 mt-30 -137.98 71.19 49.08 Favored Pre-proline 0 N--CA 1.486 1.328 0 C-N-CA 119.947 -0.701 . . . . 0.0 110.699 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -61.28 -5.73 5.65 Favored 'Trans proline' 0 C--N 1.321 -0.871 0 C-N-CA 121.274 1.316 . . . . 0.0 111.07 -179.571 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -83.65 113.78 21.09 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.005 179.364 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.506 ' CD1' ' ND2' ' A' ' 38' ' ' ASN . 30.4 m-85 -69.38 166.4 18.72 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.551 -0.859 . . . . 0.0 111.297 -179.258 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.15 125.65 19.07 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.863 179.537 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.604 ' ND2' ' H ' ' A' ' 63' ' ' GLY . 2.3 p-10 -104.87 -74.39 0.65 Allowed 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.309 -179.472 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.604 ' H ' ' ND2' ' A' ' 62' ' ' ASN . . . -35.06 146.12 0.04 OUTLIER Glycine 0 N--CA 1.501 2.975 0 C-N-CA 120.401 -0.904 . . . . 0.0 111.446 -179.448 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -81.42 151.56 27.83 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.744 -0.782 . . . . 0.0 110.888 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.22 -11.25 69.3 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.365 -1.397 . . . . 0.0 111.307 179.355 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -74.72 119.94 19.6 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.123 -1.031 . . . . 0.0 111.036 -179.767 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 3.9 p -127.5 160.78 30.47 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.949 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.47 ' CD1' ' OE1' ' A' ' 57' ' ' GLN . 34.5 t80 -136.48 141.41 43.49 Favored 'General case' 0 N--CA 1.494 1.749 0 C-N-CA 119.784 -0.767 . . . . 0.0 110.171 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -101.42 149.62 23.87 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 119.48 -0.888 . . . . 0.0 112.09 -178.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 t -146.05 138.4 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.105 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.2 m -132.39 99.76 4.78 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.577 -0.849 . . . . 0.0 111.28 -179.46 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.465 ' CD1' HG11 ' A' ' 94' ' ' VAL . 65.3 mt -82.48 162.83 21.93 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.158 179.461 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.604 ' O ' HG22 ' A' ' 73' ' ' THR . 97.7 m -150.57 45.07 0.86 Allowed 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.904 -1.118 . . . . 0.0 111.919 -179.105 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -145.02 102.05 3.71 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 118.924 -1.11 . . . . 0.0 110.418 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 22.6 mtmt -45.85 107.94 0.12 Allowed 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.201 -1.0 . . . . 0.0 110.425 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 177.21 -146.57 7.83 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.219 -1.467 . . . . 0.0 110.39 -179.601 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.99 130.1 22.07 Favored 'General case' 0 N--CA 1.484 1.257 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.646 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.588 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.2 OUTLIER -120.95 147.33 45.61 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 178.996 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.458 ' CB ' ' NZ ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -121.91 121.75 37.83 Favored 'General case' 0 N--CA 1.5 2.032 0 C-N-CA 119.069 -1.052 . . . . 0.0 110.957 179.47 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.612 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.6 OUTLIER -123.5 161.28 25.19 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.764 -0.774 . . . . 0.0 109.904 178.692 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 36.9 p90 -161.5 177.17 10.31 Favored 'General case' 0 C--N 1.285 -2.231 0 C-N-CA 119.184 -1.006 . . . . 0.0 111.176 -179.082 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -100.07 119.09 37.75 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.714 179.374 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.573 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 14.8 tt0 -72.03 -36.05 3.91 Favored Pre-proline 0 C--N 1.308 -1.213 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.953 -179.104 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.6 Cg_endo -72.05 -54.57 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.377 0.718 . . . . 0.0 111.049 179.727 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -79.82 14.93 1.55 Allowed 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.602 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.56 -11.64 0.94 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.628 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -78.62 -25.38 60.84 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.162 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.55 -31.74 26.23 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.414 179.808 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 110.3 26.72 4.76 Favored Glycine 0 N--CA 1.492 2.4 0 C-N-CA 119.781 -1.2 . . . . 0.0 110.859 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 32.0 mtp -67.82 108.49 3.0 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.081 -1.048 . . . . 0.0 110.79 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -121.03 154.31 36.22 Favored 'General case' 0 N--CA 1.491 1.611 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.917 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.492 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.76 146.24 17.19 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.511 -1.328 . . . . 0.0 111.236 -178.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -152.71 145.12 24.05 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.594 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.551 ' O ' HG13 ' A' ' 94' ' ' VAL . 12.0 p -138.45 125.46 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.794 179.647 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 91.0 m -102.77 99.07 8.99 Favored 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.532 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 31.7 t -79.87 148.61 5.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 118.692 -1.203 . . . . 0.0 110.472 -179.054 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 48.7 p30 . . . . . 0 C--N 1.306 -1.297 0 CA-C-O 116.324 -1.798 . . . . 0.0 110.671 -179.843 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 120.839 0.352 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.524 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 10.8 mp0 -105.12 130.97 53.18 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.848 -0.741 . . . . 0.0 110.548 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.1 t -114.08 118.89 59.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.852 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 30.4 mttt -92.77 114.2 26.68 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.78 -179.095 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mp -79.71 105.83 11.29 Favored 'General case' 0 C--N 1.313 -1.016 0 C-N-CA 118.597 -1.241 . . . . 0.0 109.696 177.61 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.439 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.32 90.66 2.14 Favored Glycine 0 C--N 1.29 -2.018 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -178.755 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.541 ' OG ' ' N ' ' A' ' 11' ' ' GLY . 3.1 p -54.41 155.3 3.98 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.766 -179.546 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -59.53 -33.7 71.72 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.426 -0.91 . . . . 0.0 111.039 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -144.71 -0.23 0.94 Allowed 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.459 -0.896 . . . . 0.0 111.009 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -78.19 -36.74 30.36 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.426 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.541 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . 125.61 -141.56 13.06 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.8 mt -99.47 94.88 6.65 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.921 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.7 m -149.55 155.29 8.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 C-N-CA 118.898 -1.121 . . . . 0.0 111.058 179.798 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' A' ' 16' ' ' PRO . 29.7 m-85 -78.29 106.93 10.54 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 177.825 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 46.9 m -112.73 113.03 50.48 Favored Pre-proline 0 CA--C 1.556 1.2 0 C-N-CA 119.423 -0.911 . . . . 0.0 112.3 -177.11 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.5 Cg_endo -66.68 175.6 25.26 Favored 'Cis proline' 0 C--N 1.358 1.039 0 C-N-CA 125.4 -0.667 . . . . 0.0 111.5 -1.052 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -92.83 -61.16 1.64 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.469 -0.893 . . . . 0.0 110.014 179.055 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -119.92 142.53 48.64 Favored 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.474 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 19.8 p90 -167.78 137.11 2.6 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 118.577 -1.249 . . . . 0.0 111.304 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.447 ' H ' HG23 ' A' ' 20' ' ' THR . 0.3 OUTLIER -84.64 161.21 20.19 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.301 -0.959 . . . . 0.0 111.028 -179.946 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.1 m -148.49 162.42 5.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.274 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.978 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.475 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -82.76 144.45 30.17 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.278 -0.969 . . . . 0.0 110.435 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.27 76.92 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.369 -0.933 . . . . 0.0 111.07 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.475 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 149.22 19.45 0.08 OUTLIER Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.467 ' CD ' ' N ' ' A' ' 26' ' ' LYS . 5.9 tm-20 -101.51 144.56 30.13 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.654 -179.666 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.467 ' N ' ' CD ' ' A' ' 25' ' ' GLU . 67.6 mttt -88.49 133.44 34.13 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.807 -179.799 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.6 mt -117.38 118.14 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.55 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.8 p -109.95 114.76 28.57 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.825 -0.75 . . . . 0.0 112.392 -178.3 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -84.45 117.96 23.98 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.446 178.356 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.69 127.65 53.08 Favored 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 119.289 -0.965 . . . . 0.0 111.525 -177.851 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 39.0 t-20 -84.29 130.66 34.79 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.667 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.439 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 12.0 p-10 -134.22 -8.01 2.62 Favored 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 118.893 -1.123 . . . . 0.0 112.444 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -171.74 144.52 1.83 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 118.376 -1.33 . . . . 0.0 112.318 -179.775 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 72.15 54.57 7.86 Favored Glycine 0 N--CA 1.489 2.199 0 C-N-CA 119.903 -1.141 . . . . 0.0 113.53 177.277 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.482 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -92.74 167.07 15.26 Favored Pre-proline 0 N--CA 1.497 1.884 0 C-N-CA 118.718 -1.193 . . . . 0.0 108.498 177.22 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -77.05 146.35 83.4 Favored 'Cis proline' 0 N--CA 1.481 0.738 0 C-N-CA 124.958 -0.851 . . . . 0.0 113.047 -0.323 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 30.5 m-70 -104.69 -177.23 3.31 Favored 'General case' 0 N--CA 1.489 1.485 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.499 178.088 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.689 ' ND2' ' CE1' ' A' ' 60' ' ' TYR . 10.3 t-20 -164.61 135.3 4.11 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.742 -0.783 . . . . 0.0 110.057 178.747 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.8 mp -124.0 119.42 56.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 C-N-CA 119.837 -0.745 . . . . 0.0 110.898 -179.716 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.9 t -142.26 145.5 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.61 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -97.37 121.63 39.49 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.586 -0.845 . . . . 0.0 111.221 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.444 ' OD1' ' O ' ' A' ' 42' ' ' ASP . 38.1 p-10 -59.91 117.3 4.88 Favored 'General case' 0 C--N 1.309 -1.165 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.781 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -74.96 41.73 0.17 Allowed 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.809 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.44 ' H ' ' C ' ' A' ' 42' ' ' ASP . 7.3 m-20 -135.64 -3.26 2.35 Favored 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.656 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -147.38 19.25 1.2 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.054 -1.058 . . . . 0.0 111.215 179.823 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -96.71 146.01 30.57 Favored Pre-proline 0 C--N 1.3 -1.544 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.351 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -57.41 147.82 75.55 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.794 0.996 . . . . 0.0 111.82 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.47 158.63 14.43 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 119.14 -1.024 . . . . 0.0 109.945 179.29 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 79.64 -52.26 4.13 Favored Glycine 0 N--CA 1.487 2.075 0 C-N-CA 118.991 -1.576 . . . . 0.0 109.956 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.608 ' O ' HG12 ' A' ' 50' ' ' VAL . 71.6 t -69.81 73.84 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.165 0 C-N-CA 119.236 -0.986 . . . . 0.0 110.496 179.625 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -44.86 142.35 1.81 Allowed 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.698 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -79.3 -29.29 42.38 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.401 -0.919 . . . . 0.0 111.052 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -74.03 3.61 6.66 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.693 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.34 -35.61 10.66 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.948 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt -99.79 -28.37 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.044 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 68.9 m -64.74 154.81 35.68 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.247 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.473 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -135.86 76.82 52.15 Favored Pre-proline 0 N--CA 1.486 1.356 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.96 179.65 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -57.41 -3.32 0.83 Allowed 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 121.193 1.262 . . . . 0.0 111.87 -178.571 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.432 ' H ' ' C ' ' A' ' 57' ' ' GLN . 11.4 tt0 -72.97 91.53 1.56 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.021 -1.072 . . . . 0.0 110.021 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.689 ' CE1' ' ND2' ' A' ' 38' ' ' ASN . 36.4 m-85 -43.61 165.63 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.947 -179.528 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -142.43 110.47 5.94 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.896 179.55 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 6.6 p-10 -103.28 -6.82 21.65 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.664 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -71.05 152.04 49.64 Favored Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.456 -1.354 . . . . 0.0 110.44 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -94.83 103.9 15.79 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.764 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.24 -7.3 16.51 Favored Glycine 0 N--CA 1.496 2.677 0 C-N-CA 119.941 -1.123 . . . . 0.0 110.62 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.4 148.08 42.81 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.055 -1.058 . . . . 0.0 110.457 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 4.9 p -147.18 165.24 30.61 Favored 'General case' 0 N--CA 1.491 1.595 0 C-N-CA 118.901 -1.12 . . . . 0.0 111.889 -179.531 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.473 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 42.3 t80 -137.09 150.8 48.25 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.805 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.445 ' O ' ' CE1' ' A' ' 68' ' ' TYR . 2.2 mp0 -108.1 151.4 25.93 Favored 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.423 -179.711 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -150.31 135.77 10.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.303 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.0 m -135.75 92.17 2.79 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.155 -179.558 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 21.4 mt -79.82 158.7 26.73 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.263 -0.975 . . . . 0.0 109.659 179.412 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 23.4 p -150.53 41.98 0.8 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.143 -179.237 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -140.02 105.98 5.2 Favored 'General case' 0 N--CA 1.498 1.957 0 C-N-CA 118.807 -1.157 . . . . 0.0 110.422 179.178 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.5 tttp -40.19 112.37 0.27 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.301 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.43 -149.86 14.21 Favored Glycine 0 N--CA 1.488 2.162 0 C-N-CA 118.854 -1.641 . . . . 0.0 110.675 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -138.09 139.44 39.49 Favored 'General case' 0 N--CA 1.482 1.175 0 C-N-CA 119.761 -0.776 . . . . 0.0 110.984 -179.77 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.563 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.1 m-85 -126.42 128.78 47.53 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.107 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.442 ' O ' ' OD1' ' A' ' 42' ' ' ASP . 3.3 mptp? -105.12 123.94 48.67 Favored 'General case' 0 N--CA 1.493 1.699 0 C-N-CA 119.531 -0.868 . . . . 0.0 112.216 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.449 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 9.0 p90 -134.71 171.8 13.86 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.161 177.693 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 25.9 p90 -171.22 -168.92 0.68 Allowed 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 119.409 -0.916 . . . . 0.0 111.188 -178.009 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -116.65 130.04 56.5 Favored 'General case' 0 N--CA 1.482 1.141 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.206 179.036 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.512 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.0 mt-10 -72.17 -46.42 11.04 Favored Pre-proline 0 N--CA 1.484 1.271 0 C-N-CA 119.505 -0.878 . . . . 0.0 112.929 -179.394 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.512 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.8 Cg_endo -66.8 -46.38 3.53 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 120.806 1.004 . . . . 0.0 112.03 -178.656 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.6 m80 -90.46 21.11 4.08 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.239 -179.379 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -67.08 -16.73 64.52 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.359 -0.936 . . . . 0.0 110.597 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -77.49 -24.07 66.29 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.457 -1.354 . . . . 0.0 110.298 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.62 -15.6 39.27 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.392 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 98.77 31.88 6.16 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 119.561 -1.304 . . . . 0.0 110.576 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.63 103.91 9.86 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.997 179.765 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -129.34 166.46 19.45 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.801 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -146.49 155.18 26.4 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 119.123 -1.513 . . . . 0.0 111.779 -178.398 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -155.25 143.46 20.2 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.82 179.452 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.12 128.65 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.317 -0.953 . . . . 0.0 110.126 179.079 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 98.9 m -106.86 106.82 17.53 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 119.624 -0.83 . . . . 0.0 110.784 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.436 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 41.3 t -82.26 138.15 19.92 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 118.347 -1.341 . . . . 0.0 110.586 -179.101 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 96' ' ' VAL . 6.7 m-20 . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 116.374 -1.774 . . . . 0.0 110.805 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -138.23 142.61 39.93 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.787 -0.765 . . . . 0.0 110.579 179.933 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 t -131.44 118.75 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.563 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.0 mtmp? -90.1 115.3 27.26 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.114 -1.034 . . . . 0.0 111.313 -178.991 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 4.8 mt -76.94 105.71 8.17 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 118.937 -1.105 . . . . 0.0 109.688 178.392 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 111.05 135.58 6.87 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.055 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.413 ' OG ' ' OD1' ' A' ' 9' ' ' ASP . 20.0 p -77.84 169.63 17.96 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.233 -0.987 . . . . 0.0 110.67 179.941 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.431 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 6.3 m-20 -63.63 -48.49 77.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.918 179.907 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.413 ' OD1' ' OG ' ' A' ' 7' ' ' SER . 4.2 p-10 -56.73 -53.12 61.4 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.994 -179.817 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 155.06 11.98 0.06 OUTLIER Glycine 0 N--CA 1.492 2.392 0 C-N-CA 119.379 -1.391 . . . . 0.0 110.282 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.06 164.05 52.62 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.572 -1.299 . . . . 0.0 110.42 179.995 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.8 mt -113.55 95.17 5.21 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.963 -0.695 . . . . 0.0 110.913 -179.992 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.0 m -150.22 157.09 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.362 179.124 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.51 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 37.2 m-85 -77.84 115.09 17.32 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.898 -1.121 . . . . 0.0 108.15 178.809 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.5 m -116.89 106.98 46.83 Favored Pre-proline 0 CA--C 1.561 1.367 0 C-N-CA 119.58 -0.848 . . . . 0.0 111.813 -177.564 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -66.32 175.66 23.85 Favored 'Cis proline' 0 C--N 1.359 1.124 0 C-N-CA 125.166 -0.764 . . . . 0.0 111.429 -0.132 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.96 -37.39 11.7 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 119.426 -0.91 . . . . 0.0 109.709 178.836 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.6 m -145.72 142.63 29.14 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.941 179.18 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.403 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 26.0 p90 -165.91 146.27 6.56 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 118.711 -1.196 . . . . 0.0 111.339 -179.013 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.424 HG23 ' H ' ' A' ' 20' ' ' THR . 1.2 p -90.1 163.54 14.82 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.26 -179.755 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.1 m -150.27 175.61 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.687 179.43 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.452 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -91.07 146.61 23.7 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.859 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.03 74.73 0.05 OUTLIER 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.549 -0.86 . . . . 0.0 110.947 179.742 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 146.18 19.58 0.13 Allowed Glycine 0 N--CA 1.488 2.104 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -96.96 150.03 21.22 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.877 -0.729 . . . . 0.0 111.007 -179.415 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.79 136.13 35.47 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.607 179.592 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.9 mt -118.62 151.03 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 C-N-CA 120.038 -0.665 . . . . 0.0 109.212 179.848 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 9.2 p -142.16 118.46 10.81 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.695 -179.533 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 63.7 m-85 -83.65 125.38 31.78 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.427 -0.909 . . . . 0.0 109.1 178.471 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.0 tptp -110.4 133.69 53.03 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 120.044 -0.662 . . . . 0.0 110.52 -179.142 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.764 ' OD1' HD11 ' A' ' 61' ' ' LEU . 1.7 m-80 -89.34 103.33 15.97 Favored 'General case' 0 C--N 1.293 -1.875 0 C-N-CA 119.19 -1.004 . . . . 0.0 110.087 179.331 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.66 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.3 OUTLIER -89.84 -30.63 17.8 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 119.176 -1.01 . . . . 0.0 111.435 -179.079 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 168.99 146.86 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 118.992 -1.083 . . . . 0.0 111.017 -179.864 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 112.74 -5.71 26.01 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.619 -1.277 . . . . 0.0 111.369 179.368 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -47.45 162.83 0.28 Allowed Pre-proline 0 N--CA 1.484 1.26 0 C-N-CA 118.332 -1.347 . . . . 0.0 109.639 179.878 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -77.1 137.95 51.24 Favored 'Cis proline' 0 C--O 1.214 -0.682 0 C-N-CA 124.143 -1.19 . . . . 0.0 112.285 -0.362 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 32.0 m-70 -103.79 177.69 4.77 Favored 'General case' 0 N--CA 1.489 1.497 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.568 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.511 ' ND2' ' CD1' ' A' ' 60' ' ' TYR . 2.0 t-20 -153.9 140.35 18.73 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.217 179.557 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.459 ' O ' ' N ' ' A' ' 57' ' ' GLN . 3.9 mp -133.22 99.5 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.136 -179.773 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.6 t -121.61 152.55 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.831 179.29 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -104.9 122.87 46.7 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.6 -0.84 . . . . 0.0 111.724 -178.971 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.489 ' C ' ' H ' ' A' ' 44' ' ' ASP . 26.7 t0 -56.14 118.12 4.39 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.442 179.393 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.442 ' O ' ' CG ' ' A' ' 43' ' ' GLU . 2.2 tt0 -73.19 25.86 0.06 Allowed 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.419 -0.913 . . . . 0.0 111.211 -179.431 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.489 ' H ' ' C ' ' A' ' 42' ' ' ASP . 26.0 m-20 -129.1 1.88 5.23 Favored 'General case' 0 N--CA 1.49 1.551 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.795 179.779 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -147.1 53.02 1.08 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.408 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -135.03 148.1 65.42 Favored Pre-proline 0 N--CA 1.49 1.57 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -179.802 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -47.68 140.14 17.54 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 120.903 1.069 . . . . 0.0 111.986 -179.4 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.65 83.01 1.56 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.887 -179.953 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.06 -33.81 0.52 Allowed Glycine 0 N--CA 1.488 2.129 0 C-N-CA 119.558 -1.305 . . . . 0.0 110.027 -179.893 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 35.7 t -87.33 109.08 18.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.713 179.807 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -51.49 153.83 2.07 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.799 -179.92 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -110.88 -6.48 14.71 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 120.018 -0.673 . . . . 0.0 110.864 -179.844 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -90.16 -15.37 31.66 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.461 -0.895 . . . . 0.0 111.102 -179.81 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.7 mtmm -91.86 -28.92 17.0 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.905 -179.858 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 11.8 pt -98.57 1.14 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 C-N-CA 119.633 -0.827 . . . . 0.0 110.994 -179.887 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.8 m -94.42 -178.52 4.61 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.079 180.0 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.655 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 52.1 mt-30 -139.64 69.9 37.89 Favored Pre-proline 0 C--N 1.305 -1.34 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.338 -179.972 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -59.74 -21.49 63.58 Favored 'Trans proline' 0 C--N 1.325 -0.696 0 C-N-CA 121.531 1.488 . . . . 0.0 111.829 -178.879 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.411 ' O ' ' O ' ' A' ' 60' ' ' TYR . 1.3 tm-20 -91.86 109.91 21.25 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.236 179.539 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.511 ' CD1' ' ND2' ' A' ' 38' ' ' ASN . 52.8 m-85 -43.09 166.07 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.541 -0.864 . . . . 0.0 110.948 -179.884 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.764 HD11 ' OD1' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -140.38 148.43 41.25 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.726 -0.79 . . . . 0.0 109.938 179.68 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.609 ' N ' HD12 ' A' ' 61' ' ' LEU . 0.0 OUTLIER -149.05 22.67 0.96 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.111 -179.464 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -83.14 102.47 2.4 Favored Glycine 0 N--CA 1.486 1.978 0 C-N-CA 119.163 -1.494 . . . . 0.0 110.382 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -57.34 113.28 1.69 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.067 -1.053 . . . . 0.0 110.178 179.512 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 97.85 -18.48 57.15 Favored Glycine 0 N--CA 1.487 2.093 0 C-N-CA 119.413 -1.375 . . . . 0.0 110.162 -179.49 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 25.6 tp10 -65.7 128.3 35.42 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.207 -0.997 . . . . 0.0 110.165 179.896 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -110.74 166.65 10.85 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.796 -0.761 . . . . 0.0 111.427 -179.653 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.655 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 43.1 t80 -135.8 139.86 43.8 Favored 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.455 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -108.78 158.24 17.83 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.258 -0.977 . . . . 0.0 112.709 -178.589 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -160.07 137.49 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.122 179.138 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 9.1 m -127.65 97.25 4.79 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.339 -179.242 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 16.8 mt -81.75 159.29 23.89 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.322 -0.951 . . . . 0.0 109.831 179.499 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 18.0 p -150.79 50.85 0.86 Allowed 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 118.882 -1.127 . . . . 0.0 111.946 -178.965 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 75' ' ' LYS . 3.9 tp10 -146.15 99.9 3.31 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.094 -1.043 . . . . 0.0 110.121 178.992 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.417 ' C ' ' O ' ' A' ' 74' ' ' GLU . 8.7 ptmm? -42.27 112.15 0.31 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.051 -179.309 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 168.63 -146.26 10.22 Favored Glycine 0 N--CA 1.485 1.919 0 C-N-CA 119.26 -1.448 . . . . 0.0 110.062 -179.69 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.81 138.33 35.73 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.643 -0.823 . . . . 0.0 110.987 -179.726 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.549 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -121.27 147.78 45.19 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.332 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 18.2 mmtp -112.93 123.56 50.6 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.586 -0.846 . . . . 0.0 111.83 -179.643 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.574 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.5 OUTLIER -136.96 158.66 43.96 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.611 -0.836 . . . . 0.0 109.789 177.523 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 32.3 p90 -169.86 179.96 3.47 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 119.261 -0.976 . . . . 0.0 111.206 -178.197 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -103.91 124.63 49.32 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.83 179.753 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.548 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.5 OUTLIER -70.57 -44.42 17.35 Favored Pre-proline 0 N--CA 1.487 1.387 0 C-N-CA 119.66 -0.816 . . . . 0.0 112.752 -179.77 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.548 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.0 Cg_exo -66.72 -53.54 0.55 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 120.892 1.061 . . . . 0.0 111.921 -178.942 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 85' ' ' HIS . . . . . 0.425 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.3 m80 -80.0 8.35 7.23 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.336 -0.945 . . . . 0.0 111.292 -179.521 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.37 -7.72 0.64 Allowed 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.705 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -76.2 -24.91 67.45 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.393 -1.384 . . . . 0.0 110.381 -179.924 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.65 -35.17 15.12 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.602 -179.994 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 124.77 21.09 2.21 Favored Glycine 0 N--CA 1.495 2.624 0 C-N-CA 119.869 -1.158 . . . . 0.0 110.531 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.79 108.99 1.29 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.416 -0.914 . . . . 0.0 111.256 -179.857 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 17.4 mttm -131.57 162.31 30.61 Favored 'General case' 0 N--CA 1.495 1.817 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.392 -179.871 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.454 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.19 147.86 19.49 Favored Glycine 0 N--CA 1.495 2.602 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.098 -179.194 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -149.21 138.05 21.21 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.891 179.842 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.452 ' O ' HG13 ' A' ' 94' ' ' VAL . 9.7 p -135.24 127.95 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 C-N-CA 118.723 -1.191 . . . . 0.0 110.883 178.694 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 47.4 m -106.91 100.46 9.96 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.572 179.319 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 45.3 t -80.5 144.66 10.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 C-N-CA 118.632 -1.227 . . . . 0.0 110.496 -179.045 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 116.284 -1.817 . . . . 0.0 110.758 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 120.827 0.346 . . . . 0.0 110.163 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.1 mt-10 -100.05 121.68 41.76 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.765 179.88 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -99.15 119.25 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.998 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -91.3 113.22 25.42 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 119.626 -0.83 . . . . 0.0 111.021 -179.921 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 mp -79.7 110.58 15.17 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 118.88 -1.128 . . . . 0.0 109.547 178.472 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 98.71 103.82 2.41 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -178.864 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.9 p -61.3 172.3 1.15 Allowed 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.937 -179.552 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -56.15 -42.55 77.17 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.867 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -161.14 4.85 0.07 Allowed 'General case' 0 N--CA 1.487 1.402 0 C-N-CA 119.312 -0.955 . . . . 0.0 111.062 179.91 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -71.54 -42.74 54.75 Favored Glycine 0 N--CA 1.492 2.413 0 C-N-CA 119.374 -1.393 . . . . 0.0 110.572 -179.997 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 154.17 -154.67 25.67 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.487 -1.339 . . . . 0.0 110.349 -179.959 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt -100.11 100.31 11.14 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.746 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.7 m -145.7 157.9 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 C-N-CA 118.962 -1.095 . . . . 0.0 111.131 179.843 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.403 ' O ' ' C ' ' A' ' 16' ' ' PRO . 47.3 m-85 -79.17 111.37 15.32 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.459 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 47.8 m -114.89 107.96 49.46 Favored Pre-proline 0 C--N 1.307 -1.275 0 C-N-CA 119.536 -0.866 . . . . 0.0 112.406 -177.071 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.403 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.9 Cg_endo -67.01 167.35 58.32 Favored 'Cis proline' 0 C--N 1.359 1.086 0 C-N-CA 125.34 -0.692 . . . . 0.0 111.528 -0.827 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.423 ' OG ' ' N ' ' A' ' 18' ' ' SER . 0.2 OUTLIER -95.29 -67.24 0.86 Allowed 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.496 -0.881 . . . . 0.0 109.716 178.885 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.423 ' N ' ' OG ' ' A' ' 17' ' ' SER . 0.7 OUTLIER -112.2 123.44 50.27 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.437 178.816 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.487 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 11.5 p90 -156.72 144.31 19.14 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 118.782 -1.167 . . . . 0.0 111.141 -179.005 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -88.84 157.26 18.51 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.299 -0.96 . . . . 0.0 111.247 -179.84 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.5 m -148.61 171.44 2.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.493 179.631 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.81 151.92 22.94 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.477 -179.933 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.4 65.95 0.65 Allowed 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.873 179.761 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.444 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 171.02 8.58 0.02 OUTLIER Glycine 0 N--CA 1.486 1.983 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.444 ' H ' ' H ' ' A' ' 24' ' ' GLY . 6.8 tp10 -98.65 154.14 18.17 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.752 -0.779 . . . . 0.0 110.549 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 49.6 mttm -95.17 144.06 26.1 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.288 -179.718 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 37.1 mm -111.89 98.34 6.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 CA-C-N 115.541 -0.754 . . . . 0.0 108.999 179.033 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.7 p -92.85 115.49 28.17 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.145 -1.022 . . . . 0.0 112.477 -178.217 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -85.18 121.2 27.59 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.021 -0.991 . . . . 0.0 109.136 178.512 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -124.68 134.87 52.72 Favored 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.686 -0.806 . . . . 0.0 111.734 -178.519 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 66' ' ' GLU . 57.5 m-80 -84.67 113.31 21.2 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.505 179.604 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.549 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.9 t30 -97.98 -30.23 12.84 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 119.195 -1.002 . . . . 0.0 111.354 -179.23 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.549 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.7 99.33 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.004 179.724 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 153.11 23.45 0.05 OUTLIER Glycine 0 N--CA 1.489 2.22 0 C-N-CA 118.874 -1.632 . . . . 0.0 111.234 179.487 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.62 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -73.67 162.68 73.06 Favored Pre-proline 0 C--N 1.307 -1.253 0 C-N-CA 118.744 -1.182 . . . . 0.0 109.907 179.756 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -75.8 147.51 88.18 Favored 'Cis proline' 0 N--CA 1.479 0.658 0 C-N-CA 124.396 -1.085 . . . . 0.0 112.366 -1.118 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -112.59 -177.66 3.2 Favored 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.944 -0.702 . . . . 0.0 110.817 179.279 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 4.2 t-20 -163.75 144.35 8.7 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.771 -0.772 . . . . 0.0 110.005 179.173 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.52 HD13 ' NE2' ' A' ' 57' ' ' GLN . 3.9 mp -133.78 122.79 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 119.567 -0.853 . . . . 0.0 111.436 -179.48 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.8 t -140.61 146.5 24.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.403 179.101 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -100.51 128.49 46.56 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.214 -0.994 . . . . 0.0 111.888 -179.094 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 25.8 t0 -66.71 119.98 12.71 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.244 179.512 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -68.66 -7.21 31.2 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.026 -178.991 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -97.37 7.15 47.1 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.247 -0.981 . . . . 0.0 111.649 -179.208 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -145.55 27.63 1.22 Allowed 'General case' 0 N--CA 1.488 1.466 0 C-N-CA 119.284 -0.966 . . . . 0.0 110.748 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -118.78 146.77 40.8 Favored Pre-proline 0 N--CA 1.492 1.627 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.088 179.801 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -53.05 144.15 47.48 Favored 'Trans proline' 0 C--O 1.214 -0.706 0 C-N-CA 120.953 1.102 . . . . 0.0 111.907 -179.926 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.04 72.2 1.14 Allowed 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 119.533 -0.867 . . . . 0.0 110.855 179.839 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.09 -46.52 0.1 Allowed Glycine 0 N--CA 1.49 2.282 0 C-N-CA 119.544 -1.312 . . . . 0.0 109.978 179.929 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 96.8 t -79.92 87.8 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 119.435 -0.906 . . . . 0.0 110.474 179.697 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -44.63 140.11 2.59 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.964 -179.615 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.0 -20.88 44.4 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.889 -179.94 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -74.38 -22.37 59.22 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.437 -0.905 . . . . 0.0 111.128 -179.713 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -79.27 -24.86 42.67 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.36 -179.612 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -109.79 -18.47 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.427 -179.774 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.3 m -71.37 171.0 12.01 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.183 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.52 ' NE2' HD13 ' A' ' 39' ' ' ILE . 18.1 mt-30 -128.06 78.53 75.19 Favored Pre-proline 0 N--CA 1.488 1.446 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.333 179.914 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -60.86 -11.24 17.08 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.208 1.272 . . . . 0.0 111.615 -178.864 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 20.4 mt-10 -99.47 108.02 20.37 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.749 179.779 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -55.1 176.74 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.531 -0.867 . . . . 0.0 110.85 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.8 pp -154.9 153.1 30.58 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.131 -1.028 . . . . 0.0 111.468 -179.576 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -149.01 14.96 0.92 Allowed 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.987 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -80.95 125.25 6.78 Favored Glycine 0 N--CA 1.491 2.326 0 C-N-CA 119.355 -1.402 . . . . 0.0 110.689 -179.574 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -68.22 126.77 30.61 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.63 179.687 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.56 -12.06 62.17 Favored Glycine 0 N--CA 1.488 2.151 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.713 179.887 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.489 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 2.8 tp10 -65.1 144.3 57.33 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.263 179.749 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -140.79 170.54 15.57 Favored 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.372 -179.387 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.56 ' CD2' ' N ' ' A' ' 69' ' ' GLU . 47.5 t80 -135.57 -179.76 5.84 Favored 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.49 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.56 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 3.3 mt-10 -140.69 146.16 37.46 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.166 -1.014 . . . . 0.0 111.652 -179.818 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.6 t -147.64 126.66 4.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.349 -0.842 . . . . 0.0 109.222 179.377 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.1 m -121.28 99.82 6.7 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.839 -0.744 . . . . 0.0 111.453 -178.841 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.432 ' CD1' HG11 ' A' ' 94' ' ' VAL . 54.9 mt -82.3 159.89 23.03 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.021 179.227 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 57.5 p -150.09 42.99 0.87 Allowed 'General case' 0 C--N 1.296 -1.757 0 C-N-CA 119.214 -0.994 . . . . 0.0 111.083 -179.529 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -143.49 101.37 3.77 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.026 -1.07 . . . . 0.0 110.836 179.76 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -44.61 113.43 0.55 Allowed 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.451 -0.899 . . . . 0.0 110.67 -179.953 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.9 -145.0 8.17 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.399 -1.381 . . . . 0.0 110.044 -179.961 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.82 127.14 16.73 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.893 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.564 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.8 m-85 -114.16 161.9 17.21 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.639 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.5 mmtm -130.48 116.81 18.72 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.47 -0.892 . . . . 0.0 111.987 -178.929 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.554 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -123.87 159.05 30.48 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.844 -0.742 . . . . 0.0 109.887 178.081 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -168.67 -179.3 3.75 Favored 'General case' 0 C--N 1.289 -2.025 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.982 -178.936 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 82' ' ' CYS . . . . . 0.484 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -108.81 124.27 50.34 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.634 179.825 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.51 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.3 mt-10 -63.18 -45.28 85.52 Favored Pre-proline 0 N--CA 1.485 1.308 0 C-N-CA 119.728 -0.789 . . . . 0.0 112.997 -179.611 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.51 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.8 Cg_endo -66.16 -46.04 4.94 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 120.99 1.127 . . . . 0.0 112.077 -179.202 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -92.59 14.62 16.4 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 119.16 -1.016 . . . . 0.0 111.55 -179.262 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.484 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -67.97 -1.19 5.26 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 118.946 -1.101 . . . . 0.0 110.455 179.66 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -95.27 -18.76 32.51 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.439 -1.362 . . . . 0.0 110.095 179.871 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.94 -36.34 15.05 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.44 179.676 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 130.72 26.0 0.81 Allowed Glycine 0 N--CA 1.494 2.539 0 C-N-CA 119.911 -1.137 . . . . 0.0 110.342 179.836 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -82.65 95.37 7.79 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.186 -1.006 . . . . 0.0 110.865 -179.924 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.7 162.51 24.03 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.816 179.926 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -143.62 144.83 14.14 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.294 -1.432 . . . . 0.0 111.874 -178.455 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -148.52 143.69 26.83 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.963 -0.695 . . . . 0.0 110.084 179.282 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.611 ' O ' HG13 ' A' ' 94' ' ' VAL . 14.0 p -137.44 118.68 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 119.09 -1.044 . . . . 0.0 110.793 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 90.8 m -95.62 99.17 11.07 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.486 179.528 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 35.5 t -80.11 149.38 5.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 C-N-CA 118.999 -1.08 . . . . 0.0 110.805 -178.804 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 116.332 -1.794 . . . . 0.0 110.797 -179.862 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.066 0 CA-C-O 120.867 0.365 . . . . 0.0 110.052 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -93.77 140.46 29.63 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.701 179.866 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 t -126.95 131.88 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.523 179.477 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 11.7 mtmm -105.17 118.09 35.66 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.844 -179.534 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.408 ' C ' ' OD1' ' A' ' 32' ' ' ASN . 5.7 mt -79.87 103.71 9.95 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 118.754 -1.178 . . . . 0.0 109.639 178.809 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.521 ' C ' HD21 ' A' ' 32' ' ' ASN . . . 118.53 134.3 4.97 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -178.527 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 6' ' ' GLY . 26.0 p -52.79 -103.81 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.198 -179.423 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -156.06 -22.14 0.1 Allowed 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.032 -1.067 . . . . 0.0 111.173 -179.9 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -106.72 -28.43 10.18 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.809 -0.757 . . . . 0.0 110.894 -179.847 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.28 26.4 0.03 OUTLIER Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.409 -1.377 . . . . 0.0 110.469 -179.975 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.3 163.67 23.11 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.442 -1.361 . . . . 0.0 110.342 -179.993 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.0 mt -121.13 91.44 3.53 Favored 'General case' 0 N--CA 1.49 1.545 0 C-N-CA 120.101 -0.64 . . . . 0.0 110.711 179.745 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 4.5 m -147.67 154.18 11.34 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 C-N-CA 118.952 -1.099 . . . . 0.0 111.044 179.626 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' A' ' 16' ' ' PRO . 9.9 m-85 -78.22 107.61 10.94 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.431 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.8 m -113.77 109.04 50.67 Favored Pre-proline 0 C--N 1.306 -1.313 0 C-N-CA 119.81 -0.756 . . . . 0.0 111.912 -177.447 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.424 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.6 Cg_endo -67.64 177.05 23.95 Favored 'Cis proline' 0 C--N 1.355 0.916 0 CA-C-N 119.053 0.697 . . . . 0.0 111.671 -0.376 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.4 p -93.92 -47.16 6.85 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.77 178.862 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.8 p -132.82 144.28 50.11 Favored 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.287 178.841 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -164.6 134.58 3.9 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 118.456 -1.297 . . . . 0.0 111.409 -178.962 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.5 p -86.42 159.71 19.27 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.855 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.7 m -148.79 172.49 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.902 179.755 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -87.57 149.61 24.23 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.774 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.29 73.33 0.49 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.348 -0.941 . . . . 0.0 111.072 179.974 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.433 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 155.75 14.32 0.05 OUTLIER Glycine 0 N--CA 1.486 2.028 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.433 ' H ' ' H ' ' A' ' 24' ' ' GLY . 24.5 tt0 -104.45 147.24 27.79 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.552 -179.597 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.1 pttm -95.36 149.84 20.93 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.48 -179.616 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.4 mt -119.95 148.9 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.237 179.202 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.3 p -138.6 119.34 14.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.224 -0.991 . . . . 0.0 111.692 -179.153 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -86.61 146.03 26.5 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.338 178.9 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.3 tttm -138.39 132.04 30.84 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.356 -179.231 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.568 HD21 ' N ' ' A' ' 31' ' ' ASN . 1.0 OUTLIER -81.18 113.09 19.1 Favored 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.815 179.576 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.633 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 4.0 p-10 -106.2 -23.54 12.56 Favored 'General case' 0 N--CA 1.493 1.689 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.743 -179.775 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.633 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.82 101.89 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 118.509 -1.277 . . . . 0.0 111.326 179.837 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 141.65 22.19 0.25 Allowed Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.239 -1.458 . . . . 0.0 111.457 179.574 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.61 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -78.2 161.98 68.44 Favored Pre-proline 0 N--CA 1.485 1.288 0 C-N-CA 118.159 -1.417 . . . . 0.0 110.026 179.502 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -75.9 148.56 90.45 Favored 'Cis proline' 0 C--O 1.214 -0.684 0 C-N-CA 124.21 -1.162 . . . . 0.0 112.291 -0.755 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 37' ' ' HIS . . . . . 0.402 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 48.9 m-70 -115.48 178.56 4.25 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.166 179.585 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 44.2 t30 -151.13 137.98 18.97 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.2 -1.0 . . . . 0.0 110.338 178.875 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.405 HD12 ' OE1' ' A' ' 57' ' ' GLN . 5.7 mt -124.06 106.1 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.135 -179.494 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t -128.32 149.0 32.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.001 179.54 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -103.94 126.76 51.3 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.861 -179.305 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.432 ' C ' ' H ' ' A' ' 44' ' ' ASP . 0.4 OUTLIER -70.64 118.07 12.97 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.412 179.636 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -74.76 41.6 0.16 Allowed 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.386 -0.926 . . . . 0.0 110.861 -179.677 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.432 ' H ' ' C ' ' A' ' 42' ' ' ASP . 8.6 m-20 -128.28 -10.53 5.23 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.586 179.815 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -132.81 15.93 4.3 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.74 179.831 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.402 HG13 ' HD2' ' A' ' 47' ' ' PRO . 55.5 t -99.1 143.45 26.41 Favored Pre-proline 0 C--N 1.296 -1.73 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.571 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.402 ' HD2' HG13 ' A' ' 46' ' ' VAL . 3.6 Cg_exo -55.42 161.75 6.97 Favored 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 120.81 1.006 . . . . 0.0 111.619 -179.947 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -90.22 51.23 1.99 Allowed 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 119.578 -0.849 . . . . 0.0 111.001 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -154.0 -42.86 0.02 OUTLIER Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.46 -1.352 . . . . 0.0 109.998 179.827 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 5.6 p -77.35 152.28 5.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 119.812 -0.755 . . . . 0.0 110.407 179.643 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 81.0 m-20 -88.79 139.47 30.43 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.048 179.173 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.419 ' HA ' HD11 ' A' ' 55' ' ' ILE . . . -102.76 -4.48 24.91 Favored 'General case' 0 N--CA 1.491 1.611 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.252 -179.782 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -90.69 -33.68 15.7 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.645 -179.531 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 62.8 mttt -78.26 -21.82 49.25 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.434 -0.906 . . . . 0.0 111.972 -179.018 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.419 HD11 ' HA ' ' A' ' 52' ' ' ALA . 6.3 pt -92.91 -25.03 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.213 -179.547 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 33.3 m -69.19 174.1 5.0 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.133 179.658 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.659 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 66.7 mt-30 -126.88 78.98 73.14 Favored Pre-proline 0 N--CA 1.488 1.456 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.65 -179.888 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.27 -14.44 38.45 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 120.958 1.105 . . . . 0.0 111.187 -179.258 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.423 ' O ' ' O ' ' A' ' 60' ' ' TYR . 10.5 mt-10 -100.53 105.06 16.46 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.78 -0.768 . . . . 0.0 110.646 179.445 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.423 ' O ' ' O ' ' A' ' 59' ' ' GLU . 31.6 m-85 -46.01 172.4 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.941 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.544 ' O ' HD12 ' A' ' 61' ' ' LEU . 3.0 pp -138.54 125.79 21.58 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.688 -0.805 . . . . 0.0 110.29 179.548 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -132.61 45.49 2.74 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.409 -178.845 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.28 118.97 3.56 Favored Glycine 0 N--CA 1.499 2.896 0 C-N-CA 119.718 -1.229 . . . . 0.0 110.528 179.822 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -54.64 123.4 13.07 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.398 179.735 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 81.48 3.86 90.54 Favored Glycine 0 N--CA 1.489 2.225 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.648 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -69.47 107.16 3.24 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.921 179.607 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.5 p -98.09 164.59 12.28 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.499 -0.88 . . . . 0.0 111.55 -178.96 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.659 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 45.1 t80 -135.0 176.97 8.17 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 178.844 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.605 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 5.3 mt-10 -144.89 150.86 37.79 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 118.539 -1.265 . . . . 0.0 112.252 -179.316 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -157.85 136.83 3.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 115.066 -0.97 . . . . 0.0 108.727 179.205 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 19.1 m -129.12 92.74 3.44 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.53 -0.868 . . . . 0.0 111.716 -178.907 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 10.0 mt -79.76 155.39 27.94 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 118.995 -1.082 . . . . 0.0 108.709 178.833 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.567 HG23 ' OE2' ' A' ' 74' ' ' GLU . 3.1 t -150.47 46.57 0.88 Allowed 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.678 -1.209 . . . . 0.0 111.719 -179.29 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.567 ' OE2' HG23 ' A' ' 73' ' ' THR . 34.1 mm-40 -138.81 103.12 4.74 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.47 -0.892 . . . . 0.0 109.78 178.916 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -40.11 107.18 0.07 Allowed 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 119.781 -0.768 . . . . 0.0 111.321 -179.448 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 176.74 -150.36 10.32 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.172 -1.489 . . . . 0.0 110.591 -179.778 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.89 133.61 28.81 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.258 -179.521 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.604 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.9 OUTLIER -120.13 155.43 33.07 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.765 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 27.0 mmtt -126.93 127.94 45.65 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.532 -0.867 . . . . 0.0 111.909 -178.876 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.512 ' O ' ' N ' ' A' ' 92' ' ' GLY . 2.0 p90 -139.11 165.85 26.06 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.432 -0.907 . . . . 0.0 110.701 178.377 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 35.2 p90 -169.91 -179.78 3.35 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.144 -177.928 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -104.07 125.53 50.48 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.321 179.404 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.55 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tt0 -68.6 -44.48 33.19 Favored Pre-proline 0 N--CA 1.486 1.358 0 C-N-CA 119.531 -0.868 . . . . 0.0 112.985 -179.436 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -68.44 -50.06 0.76 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 120.931 1.087 . . . . 0.0 111.94 -178.771 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 33.4 m80 -88.9 16.91 6.2 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.342 -0.943 . . . . 0.0 111.572 -179.363 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.64 -10.32 3.48 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.726 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -89.13 -17.09 56.63 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.374 -1.393 . . . . 0.0 110.304 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.34 -22.89 24.82 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.385 179.881 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 112.7 17.48 7.99 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.798 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.1 mtp -70.64 99.87 1.75 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.228 179.806 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.1 pttp -125.1 164.33 20.46 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 120.045 -0.662 . . . . 0.0 110.088 178.723 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.02 147.75 18.49 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 118.538 -1.791 . . . . 0.0 111.862 -178.497 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -153.94 146.9 24.47 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 119.721 -0.792 . . . . 0.0 110.568 179.103 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.8 p -140.68 134.36 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.125 179.252 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.2 m -110.66 101.73 10.35 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.65 -0.82 . . . . 0.0 110.886 179.734 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 49.0 t -80.68 152.1 4.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.902 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.6 p30 . . . . . 0 C--N 1.304 -1.4 0 CA-C-O 116.364 -1.779 . . . . 0.0 110.81 -179.867 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.156 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -110.54 122.86 48.78 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.996 179.965 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.0 t -111.26 126.36 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 119.983 -0.687 . . . . 0.0 110.524 179.728 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 39.4 mttt -98.72 118.45 35.48 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.809 -179.483 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.419 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 12.8 mt -82.05 107.1 14.49 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 118.754 -1.179 . . . . 0.0 110.625 179.135 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.418 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 114.49 138.71 6.83 Favored Glycine 0 N--CA 1.495 2.626 0 C-N-CA 120.218 -0.991 . . . . 0.0 110.669 -179.588 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 24.2 p -79.5 163.98 24.29 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 119.532 -0.867 . . . . 0.0 110.624 179.747 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -62.25 -35.4 78.85 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.954 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -169.6 17.86 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.289 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.849 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -97.05 -68.37 0.96 Allowed Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.44 -1.362 . . . . 0.0 110.564 179.96 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -164.04 -147.06 4.96 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.43 -179.843 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.8 mt -112.92 111.62 22.51 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.695 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.4 m -150.72 159.71 4.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.708 179.234 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.508 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 23.3 m-85 -78.46 114.58 17.49 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 177.948 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.4 m -116.24 105.99 49.81 Favored Pre-proline 0 C--N 1.308 -1.238 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.865 -177.45 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -67.55 178.32 20.2 Favored 'Cis proline' 0 C--N 1.359 1.131 0 CA-C-N 118.921 0.65 . . . . 0.0 111.946 -0.395 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.1 m -94.14 -48.12 6.35 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.643 -0.823 . . . . 0.0 110.182 179.162 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 44.6 m -137.34 140.98 41.82 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.419 179.144 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.405 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 25.1 p90 -162.93 143.21 9.33 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.626 -179.138 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.415 HG23 ' H ' ' A' ' 20' ' ' THR . 0.6 OUTLIER -91.27 155.51 18.5 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.146 179.894 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.07 157.13 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 C-N-CA 119.416 -0.914 . . . . 0.0 111.082 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.46 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -75.4 141.06 43.3 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.17 179.456 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.94 75.32 0.04 OUTLIER 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.045 -179.783 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 161.53 13.48 0.03 OUTLIER Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -104.94 151.04 24.37 Favored 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.622 -179.649 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.8 mttp -94.53 141.1 28.99 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.037 -179.919 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 mt -117.89 153.06 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.743 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.5 p -147.77 113.45 5.7 Favored 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 118.811 -1.156 . . . . 0.0 111.954 -179.448 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -84.39 116.18 22.91 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.36 -0.936 . . . . 0.0 108.962 178.485 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.2 tttm -111.56 132.84 54.25 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.778 -178.264 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.579 ' OD1' HD11 ' A' ' 61' ' ' LEU . 0.6 OUTLIER -76.48 104.23 6.89 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.703 -0.799 . . . . 0.0 109.849 178.904 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.466 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 5.2 p-10 -94.21 -26.23 16.74 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 118.906 -1.118 . . . . 0.0 112.025 -178.642 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.466 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 179.12 147.53 0.2 Allowed 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 118.489 -1.284 . . . . 0.0 111.593 -179.783 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 89.63 10.28 65.47 Favored Glycine 0 N--CA 1.481 1.674 0 C-N-CA 119.485 -1.341 . . . . 0.0 111.731 178.661 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -49.66 162.54 0.44 Allowed Pre-proline 0 N--CA 1.48 1.055 0 C-N-CA 117.844 -1.542 . . . . 0.0 108.895 179.431 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -75.93 -173.67 13.0 Favored 'Cis proline' 0 C--O 1.204 -1.189 0 C-N-CA 124.324 -1.115 . . . . 0.0 112.294 -0.213 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.8 m-70 -151.07 171.92 16.56 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 120.142 -0.623 . . . . 0.0 110.522 178.576 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.423 ' OD1' ' N ' ' A' ' 39' ' ' ILE . 45.9 t30 -149.61 148.29 29.14 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.488 179.393 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.423 ' N ' ' OD1' ' A' ' 38' ' ' ASN . 4.1 mp -135.55 112.17 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 C-N-CA 119.676 -0.81 . . . . 0.0 111.322 -179.437 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 t -134.98 149.65 29.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.948 179.224 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -104.77 128.38 52.89 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.512 -0.875 . . . . 0.0 112.04 -179.077 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.42 ' C ' ' H ' ' A' ' 44' ' ' ASP . 49.3 t0 -66.97 126.38 28.94 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.086 179.344 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 63.8 mt-10 -72.1 11.51 0.55 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.229 -0.989 . . . . 0.0 111.221 -179.662 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.42 ' H ' ' C ' ' A' ' 42' ' ' ASP . 28.4 m-20 -105.85 -5.54 19.68 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.667 -0.813 . . . . 0.0 111.068 -179.862 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -142.7 51.97 1.42 Allowed 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 119.719 -0.792 . . . . 0.0 110.229 -179.743 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -139.6 145.97 45.81 Favored Pre-proline 0 N--CA 1.487 1.393 0 CA-C-N 115.286 -0.87 . . . . 0.0 108.825 179.678 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -54.17 163.7 3.18 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 120.798 0.999 . . . . 0.0 112.216 -179.358 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -89.26 61.76 5.85 Favored 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 119.84 -0.744 . . . . 0.0 110.824 -179.968 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.21 -46.38 0.04 OUTLIER Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.529 -1.319 . . . . 0.0 110.014 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.5 t -79.6 84.07 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 C-N-CA 119.554 -0.858 . . . . 0.0 110.39 179.703 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -45.09 139.71 3.12 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.204 -0.999 . . . . 0.0 110.712 -179.636 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.08 -33.06 65.4 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.728 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -61.68 -17.91 57.44 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.304 -179.637 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.32 -45.46 11.91 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.422 -179.728 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.0 pt -90.35 -13.8 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 119.233 -0.987 . . . . 0.0 111.327 -179.641 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 69.2 m -77.65 173.44 12.04 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.582 179.551 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.615 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 69.4 mt-30 -129.24 78.83 75.35 Favored Pre-proline 0 N--CA 1.489 1.481 0 C-N-CA 120.036 -0.665 . . . . 0.0 110.64 -179.868 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.93 -11.47 18.28 Favored 'Trans proline' 0 C--O 1.216 -0.605 0 C-N-CA 121.032 1.155 . . . . 0.0 111.024 -179.539 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -101.35 116.89 33.82 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.535 179.14 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -58.38 159.4 6.27 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.359 -0.936 . . . . 0.0 110.999 -179.672 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.616 ' C ' HD12 ' A' ' 61' ' ' LEU . 0.7 OUTLIER -125.41 146.97 49.37 Favored 'General case' 0 N--CA 1.49 1.532 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.666 179.233 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.551 ' N ' HD12 ' A' ' 61' ' ' LEU . 9.8 p-10 -155.17 58.6 0.65 Allowed 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.253 -0.979 . . . . 0.0 111.343 -178.744 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.62 130.1 6.23 Favored Glycine 0 N--CA 1.497 2.734 0 C-N-CA 119.737 -1.22 . . . . 0.0 110.784 179.805 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -69.94 103.88 2.36 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.459 -0.896 . . . . 0.0 110.464 179.575 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.45 -7.29 46.53 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.222 -179.709 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -64.7 151.81 44.05 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.141 179.515 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.7 165.15 31.35 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 118.884 -1.126 . . . . 0.0 111.838 -179.679 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.615 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 49.5 t80 -136.07 138.25 41.94 Favored 'General case' 0 N--CA 1.484 1.258 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.323 179.149 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -108.62 153.38 23.49 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.423 -0.911 . . . . 0.0 112.164 -178.765 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -155.41 139.93 9.26 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.439 178.891 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.8 m -126.02 95.95 4.58 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.083 -179.44 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.472 ' CD1' HG11 ' A' ' 94' ' ' VAL . 13.9 mt -79.68 160.9 26.12 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.437 179.434 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.71 25.29 0.76 Allowed 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 118.717 -1.193 . . . . 0.0 112.057 -178.497 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.466 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -116.69 99.9 7.45 Favored 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.357 179.846 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 8.5 mttt -43.44 105.79 0.06 Allowed 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.724 -179.76 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.3 -139.61 5.02 Favored Glycine 0 N--CA 1.483 1.79 0 C-N-CA 119.321 -1.418 . . . . 0.0 109.929 -179.769 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.2 m -146.68 136.02 22.79 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.251 -0.98 . . . . 0.0 111.168 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.576 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -120.52 140.78 50.96 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.829 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 22.9 mmtt -110.17 124.28 51.26 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 119.433 -0.907 . . . . 0.0 111.872 -179.0 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.566 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -134.39 160.89 36.57 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.14 178.395 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 81' ' ' TYR . . . . . 0.419 ' CD1' ' N ' ' A' ' 81' ' ' TYR . 23.8 p90 -168.29 179.21 4.58 Favored 'General case' 0 C--N 1.293 -1.87 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.889 -178.54 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -102.72 125.4 49.44 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.401 179.663 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.509 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 mt-10 -67.05 -46.25 52.79 Favored Pre-proline 0 C--N 1.306 -1.319 0 C-N-CA 119.499 -0.88 . . . . 0.0 112.819 -179.56 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.509 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.9 Cg_endo -67.01 -48.64 1.74 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 120.97 1.113 . . . . 0.0 112.114 -178.725 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -88.5 20.51 3.33 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.009 -179.515 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.87 -10.4 20.41 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.454 179.449 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.6 -17.31 57.09 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.491 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.15 -15.13 32.18 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.433 -0.907 . . . . 0.0 110.582 179.952 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.64 21.27 11.51 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.722 -1.228 . . . . 0.0 110.573 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.3 mtp -73.05 98.51 2.55 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.174 179.941 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.508 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 16.5 ttmt -121.41 159.6 25.85 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.38 143.49 12.17 Favored Glycine 0 N--CA 1.496 2.636 0 C-N-CA 119.352 -1.404 . . . . 0.0 111.255 -179.065 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.75 143.67 24.64 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.635 179.514 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.578 ' O ' HG13 ' A' ' 94' ' ' VAL . 9.9 p -136.31 122.43 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.318 179.523 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 99.9 m -100.93 100.48 11.12 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.745 -179.951 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 40.3 t -79.84 139.84 17.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 C-N-CA 118.634 -1.226 . . . . 0.0 110.478 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 116.441 -1.743 . . . . 0.0 110.965 -179.869 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -106.06 133.39 50.84 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.92 -179.931 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.9 t -123.47 117.48 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 C-N-CA 119.991 -0.684 . . . . 0.0 110.419 179.657 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 29.3 mttp -91.95 114.35 26.87 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.652 -178.81 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.5 mt -76.37 113.28 13.78 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.069 -1.053 . . . . 0.0 109.805 178.007 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.46 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.36 125.35 5.61 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.764 -1.207 . . . . 0.0 110.238 -179.448 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.7 p -67.64 169.75 8.89 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 119.462 -0.895 . . . . 0.0 110.7 179.884 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -95.52 43.61 1.09 Allowed 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.524 -0.871 . . . . 0.0 111.27 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -158.04 -52.99 0.07 Allowed 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.233 -0.987 . . . . 0.0 110.813 179.833 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 168.84 66.26 0.03 OUTLIER Glycine 0 N--CA 1.49 2.266 0 C-N-CA 119.388 -1.386 . . . . 0.0 110.366 179.953 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -161.94 146.29 11.88 Favored Glycine 0 N--CA 1.489 2.211 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.409 -179.917 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.1 mt -107.17 101.13 10.55 Favored 'General case' 0 N--CA 1.487 1.41 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.596 179.867 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.0 m -150.99 157.06 5.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.116 0 C-N-CA 118.892 -1.123 . . . . 0.0 110.747 179.297 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.522 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 56.8 m-85 -78.12 113.1 15.74 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 177.887 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.6 m -115.19 109.08 47.01 Favored Pre-proline 0 CA--C 1.559 1.311 0 C-N-CA 119.552 -0.859 . . . . 0.0 112.176 -176.954 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -67.14 172.59 37.29 Favored 'Cis proline' 0 C--N 1.359 1.119 0 C-N-CA 125.216 -0.743 . . . . 0.0 111.331 -0.444 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 38.8 t -94.19 -64.31 1.09 Allowed 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.704 178.934 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 t -113.11 135.19 54.08 Favored 'General case' 0 N--CA 1.485 1.292 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.546 178.748 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.418 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 21.7 p90 -160.97 137.91 8.84 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 118.71 -1.196 . . . . 0.0 111.308 -179.141 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.417 HG23 ' H ' ' A' ' 20' ' ' THR . 0.8 OUTLIER -88.25 154.98 19.99 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.073 179.766 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.7 m -145.95 168.66 7.02 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 119.447 -0.901 . . . . 0.0 110.815 179.771 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.49 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -92.3 146.62 23.56 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.656 179.833 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.17 76.4 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.52 -0.872 . . . . 0.0 111.052 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 154.02 15.14 0.06 OUTLIER Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.888 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -102.43 132.94 48.12 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.898 -179.592 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.8 mtpp -75.75 141.53 42.59 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.42 ' O ' HG22 ' A' ' 27' ' ' ILE . 3.0 mt -125.72 112.1 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 C-N-CA 120.088 -0.645 . . . . 0.0 109.261 179.407 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 13.4 p -108.52 121.43 44.96 Favored 'General case' 0 N--CA 1.488 1.462 0 C-N-CA 119.622 -0.831 . . . . 0.0 112.256 -178.561 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -86.36 121.18 28.56 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.449 -0.9 . . . . 0.0 109.182 178.502 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.0 tmtp? -112.71 142.42 45.34 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.871 -0.731 . . . . 0.0 110.655 -178.689 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.581 ' ND2' HD11 ' A' ' 61' ' ' LEU . 0.9 OUTLIER -94.05 118.41 31.48 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.178 179.87 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.679 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.8 OUTLIER -98.9 -30.74 12.21 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.864 -179.989 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.679 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 165.02 146.34 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.078 179.896 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 111.51 2.53 27.51 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.91 -1.138 . . . . 0.0 110.861 179.484 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.597 ' N ' ' CD1' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -52.2 163.91 0.66 Allowed Pre-proline 0 C--N 1.308 -1.219 0 C-N-CA 118.868 -1.133 . . . . 0.0 109.917 179.797 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_endo -78.31 143.69 73.34 Favored 'Cis proline' 0 C--O 1.212 -0.821 0 C-N-CA 124.156 -1.185 . . . . 0.0 112.489 -0.808 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 35.2 m-70 -107.29 178.88 4.41 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.032 179.149 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 33.5 t-20 -158.03 145.0 17.91 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.635 -0.826 . . . . 0.0 110.061 179.098 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.9 mp -131.92 117.04 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.758 -0.777 . . . . 0.0 110.948 -179.771 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 40.4 t -136.03 141.79 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.19 179.667 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.491 ' HB2' ' HB1' ' A' ' 52' ' ' ALA . 48.7 m-85 -93.78 134.02 36.55 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 119.442 -0.903 . . . . 0.0 111.064 -179.584 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.676 ' C ' ' H ' ' A' ' 44' ' ' ASP . 24.7 p-10 -75.23 101.49 4.67 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.279 -0.969 . . . . 0.0 110.975 -179.523 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.571 ' H ' ' CD ' ' A' ' 43' ' ' GLU . 1.6 pm0 -55.63 6.5 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.175 0 C-N-CA 119.969 -0.692 . . . . 0.0 111.38 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.676 ' H ' ' C ' ' A' ' 42' ' ' ASP . 4.2 m-20 -83.08 -67.31 0.8 Allowed 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.837 179.138 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -97.83 27.36 4.49 Favored 'General case' 0 N--CA 1.49 1.539 0 C-N-CA 119.335 -0.946 . . . . 0.0 112.089 -177.049 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 42' ' ' ASP . 45.3 t -102.48 143.97 27.67 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.598 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.439 ' HD2' HG13 ' A' ' 46' ' ' VAL . 4.6 Cg_exo -46.61 140.9 11.71 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 120.777 0.984 . . . . 0.0 112.178 -179.107 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.53 39.28 0.26 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.863 -179.892 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.433 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -142.55 -41.0 0.07 OUTLIER Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.703 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.487 HG23 ' OE1' ' A' ' 74' ' ' GLU . 71.6 t -87.73 84.63 2.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.894 179.207 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -44.19 139.9 2.38 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.573 -0.851 . . . . 0.0 111.083 -179.185 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.491 ' HB1' ' HB2' ' A' ' 41' ' ' PHE . . . -86.21 0.65 53.21 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.473 -0.891 . . . . 0.0 110.766 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -87.39 -10.76 51.2 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.826 179.914 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.0 mtmt -98.17 -35.47 10.37 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.594 -0.842 . . . . 0.0 111.232 -179.668 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.487 HD12 ' CD2' ' A' ' 41' ' ' PHE . 8.3 pt -92.86 -13.37 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.245 -0.982 . . . . 0.0 111.373 -179.522 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 29.0 m -76.3 170.31 16.58 Favored 'General case' 0 C--N 1.307 -1.241 0 C-N-CA 119.186 -1.006 . . . . 0.0 110.893 179.791 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.483 ' OE1' ' CD2' ' A' ' 68' ' ' TYR . 2.1 mt-30 -138.37 69.82 46.9 Favored Pre-proline 0 N--CA 1.487 1.379 0 C-N-CA 120.046 -0.662 . . . . 0.0 110.584 -179.854 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -59.56 -10.08 10.56 Favored 'Trans proline' 0 C--N 1.323 -0.798 0 C-N-CA 121.457 1.438 . . . . 0.0 111.554 -179.304 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.418 ' O ' ' O ' ' A' ' 60' ' ' TYR . 0.7 OUTLIER -85.84 103.32 14.48 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.184 179.482 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.418 ' O ' ' O ' ' A' ' 59' ' ' GLU . 90.0 m-85 -44.16 168.26 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.164 -179.593 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.581 HD11 ' ND2' ' A' ' 31' ' ' ASN . 3.1 pp -151.8 146.4 25.68 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.05 179.913 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -143.69 -7.05 0.77 Allowed 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 119.318 -0.953 . . . . 0.0 111.387 -179.684 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -48.23 125.43 12.89 Favored Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.174 -1.489 . . . . 0.0 110.628 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -71.36 111.78 6.96 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.818 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 91.83 -11.19 72.79 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.252 -1.451 . . . . 0.0 110.84 -179.895 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -57.98 159.35 5.71 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.178 -1.009 . . . . 0.0 110.487 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.58 172.63 12.7 Favored 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.987 -179.442 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.571 ' CD2' ' N ' ' A' ' 69' ' ' GLU . 51.9 t80 -135.34 178.59 6.92 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.36 179.09 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.571 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 8.4 mt-10 -145.99 152.0 38.68 Favored 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 118.747 -1.181 . . . . 0.0 111.986 -179.739 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -162.41 140.42 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 119.876 -0.729 . . . . 0.0 109.713 178.539 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.1 m -129.83 97.9 4.63 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.744 -179.619 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.498 ' CD1' HG11 ' A' ' 94' ' ' VAL . 9.3 mt -79.75 159.29 26.65 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.012 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 4.1 p -150.41 51.39 0.89 Allowed 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.793 -179.25 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.487 ' OE1' HG23 ' A' ' 50' ' ' VAL . 1.3 tt0 -142.95 99.81 3.53 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.406 -0.918 . . . . 0.0 109.839 178.829 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 74' ' ' GLU . 3.9 mttp -42.65 103.37 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.436 -0.906 . . . . 0.0 110.618 -179.568 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.0 -142.27 5.51 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.171 -1.49 . . . . 0.0 110.281 -179.544 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.97 133.4 21.86 Favored 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.476 -179.657 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.59 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -122.18 116.87 24.93 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.4 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.456 ' O ' ' OD1' ' A' ' 42' ' ' ASP . 11.2 mptt -95.88 115.69 27.81 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.172 -1.011 . . . . 0.0 111.787 -178.713 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.569 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.1 p90 -119.5 170.09 9.47 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.825 -0.75 . . . . 0.0 110.1 178.755 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -170.37 179.78 3.29 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.329 -178.631 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -102.94 128.27 49.81 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 119.754 -0.779 . . . . 0.0 110.17 179.258 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.53 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 mt-10 -73.34 -45.58 7.77 Favored Pre-proline 0 C--N 1.304 -1.399 0 C-N-CA 119.552 -0.859 . . . . 0.0 112.788 -179.399 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.53 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.3 Cg_exo -65.95 -51.11 1.33 Allowed 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 120.88 1.053 . . . . 0.0 111.684 -179.087 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 85' ' ' HIS . . . . . 0.457 ' C ' ' H ' ' A' ' 87' ' ' GLY . 38.2 m80 -83.52 13.96 4.12 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.321 -0.952 . . . . 0.0 111.054 -179.774 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.24 -5.4 0.48 Allowed 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.299 -0.96 . . . . 0.0 110.742 179.806 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.457 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -81.04 -26.54 52.72 Favored Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.515 -179.848 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.96 -13.64 35.74 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.626 179.916 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.44 7.15 49.5 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 119.709 -1.234 . . . . 0.0 110.418 179.932 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -48.31 109.69 0.26 Allowed 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.734 179.902 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.522 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -134.95 170.78 15.37 Favored 'General case' 0 N--CA 1.494 1.756 0 C-N-CA 119.551 -0.86 . . . . 0.0 111.422 -179.849 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -151.63 149.34 21.07 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.192 -1.48 . . . . 0.0 111.266 -178.67 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -152.89 139.3 18.57 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.397 179.522 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.598 ' O ' HG13 ' A' ' 94' ' ' VAL . 10.7 p -132.79 121.5 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 C-N-CA 119.289 -0.965 . . . . 0.0 110.5 179.279 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 39.3 m -98.64 100.77 12.03 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.908 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 25.8 t -82.68 151.04 4.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 118.747 -1.181 . . . . 0.0 110.367 -179.369 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 116.397 -1.763 . . . . 0.0 110.846 -179.744 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.1 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -131.37 136.97 48.5 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 120.017 -0.673 . . . . 0.0 110.521 179.977 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.1 t -131.13 124.23 55.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.587 179.839 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 7.0 mptt -95.85 116.89 29.57 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.165 -179.606 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 37.7 mt -75.69 109.93 9.68 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 118.681 -1.208 . . . . 0.0 109.235 178.151 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 99.46 134.07 8.35 Favored Glycine 0 N--CA 1.484 1.895 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -178.612 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.417 ' HG ' ' H ' ' A' ' 11' ' ' GLY . 20.9 p -75.96 156.8 33.82 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.737 -179.905 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -51.32 -48.98 62.21 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.014 -179.831 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -58.06 -72.39 0.09 Allowed 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.838 -179.913 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.401 ' H ' ' H ' ' A' ' 11' ' ' GLY . . . -179.76 7.26 0.02 OUTLIER Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.256 -1.449 . . . . 0.0 110.359 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.417 ' H ' ' HG ' ' A' ' 7' ' ' SER . . . -70.38 160.59 53.56 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.405 179.945 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 mt -116.45 91.24 3.53 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.642 -179.921 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.2 m -150.01 155.36 7.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.781 179.889 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.425 ' O ' ' O ' ' A' ' 16' ' ' PRO . 75.3 m-85 -78.62 108.97 12.41 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 177.579 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.7 m -111.63 114.43 52.39 Favored Pre-proline 0 C--N 1.303 -1.453 0 C-N-CA 119.389 -0.925 . . . . 0.0 112.07 -177.283 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.6 Cg_endo -66.68 172.47 35.74 Favored 'Cis proline' 0 C--N 1.361 1.201 0 C-N-CA 125.333 -0.695 . . . . 0.0 111.449 -0.685 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.44 -67.06 0.87 Allowed 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.334 179.193 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -108.61 140.4 42.04 Favored 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.556 179.129 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 22.1 p90 -165.69 140.16 4.71 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 118.227 -1.389 . . . . 0.0 111.786 -179.213 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.683 HG22 ' HB ' ' A' ' 95' ' ' THR . 75.7 p -88.83 157.42 18.47 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.761 179.423 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -149.9 151.48 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 C-N-CA 119.297 -0.961 . . . . 0.0 111.159 179.739 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.46 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -71.95 142.55 49.43 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.316 -0.954 . . . . 0.0 110.462 179.724 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.17 75.98 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 119.414 -0.914 . . . . 0.0 111.188 -179.752 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 161.08 11.1 0.04 OUTLIER Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.857 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.45 ' H ' ' H ' ' A' ' 24' ' ' GLY . 2.9 tp10 -105.13 148.56 26.73 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 120.1 -0.64 . . . . 0.0 110.832 -179.497 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 10.3 pttm -95.16 155.01 16.91 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.493 -0.883 . . . . 0.0 111.09 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 mt -127.22 109.21 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.799 179.56 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.1 p -100.68 117.69 35.31 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.789 -0.764 . . . . 0.0 112.028 -178.757 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -84.66 129.83 34.79 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.238 -0.985 . . . . 0.0 108.723 178.315 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.0 ttmt -120.0 128.12 53.25 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.394 -178.53 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.571 ' ND2' ' O ' ' A' ' 66' ' ' GLU . 70.4 m-80 -71.81 111.49 7.12 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.536 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.673 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.9 OUTLIER -96.09 -31.9 12.79 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.023 -1.071 . . . . 0.0 111.32 -179.856 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.673 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 163.26 130.97 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.894 179.585 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 124.89 2.58 7.86 Favored Glycine 0 N--CA 1.496 2.665 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.142 179.488 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -50.55 162.98 0.49 Allowed Pre-proline 0 C--N 1.307 -1.245 0 C-N-CA 118.518 -1.273 . . . . 0.0 109.739 179.798 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -75.96 144.37 79.57 Favored 'Cis proline' 0 C--O 1.215 -0.655 0 C-N-CA 124.279 -1.134 . . . . 0.0 112.341 -0.482 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 30.6 m-70 -108.05 173.74 6.19 Favored 'General case' 0 N--CA 1.493 1.719 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.637 179.541 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 51.6 t-20 -152.62 138.35 17.9 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.925 179.534 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.448 ' O ' ' N ' ' A' ' 57' ' ' GLN . 3.7 mp -128.13 99.97 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.904 -179.728 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.6 t -123.36 147.35 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.011 179.341 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -101.26 129.63 47.25 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.464 -0.894 . . . . 0.0 111.505 -179.676 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -67.03 113.72 5.24 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.702 -0.799 . . . . 0.0 110.632 179.656 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -62.06 -4.42 1.66 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.678 -0.809 . . . . 0.0 111.718 -179.22 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -95.78 -2.4 47.75 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.089 -179.78 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -140.65 50.47 1.67 Allowed 'General case' 0 C--N 1.312 -1.031 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.704 179.871 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -140.35 145.9 43.23 Favored Pre-proline 0 N--CA 1.489 1.502 0 CA-C-N 115.51 -0.768 . . . . 0.0 108.936 179.879 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -54.81 162.33 5.15 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 120.798 0.998 . . . . 0.0 111.742 -179.739 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -90.16 55.47 3.1 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.835 179.958 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -161.59 -42.27 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.06 179.926 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 88.5 t -86.28 92.62 3.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 C-N-CA 119.565 -0.854 . . . . 0.0 110.421 179.756 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -44.55 139.78 2.68 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.953 -179.785 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.88 -15.6 55.89 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.519 -0.873 . . . . 0.0 110.965 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -77.68 -28.0 50.95 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.406 -0.917 . . . . 0.0 111.309 -179.479 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -73.45 -35.63 65.79 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.44 -179.202 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.9 pt -96.54 -13.83 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.533 -179.353 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.3 m -77.27 176.3 8.91 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.025 -1.07 . . . . 0.0 111.35 -179.611 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.651 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 60.6 mt-30 -137.31 71.58 53.36 Favored Pre-proline 0 C--N 1.306 -1.298 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.432 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -59.26 -19.08 48.41 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 121.307 1.338 . . . . 0.0 111.34 -179.217 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -91.83 97.25 10.87 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.294 179.259 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -43.54 163.94 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.725 -179.731 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.7 pp -134.8 139.5 45.15 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.567 -0.853 . . . . 0.0 110.887 179.728 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.412 ' ND2' ' N ' ' A' ' 62' ' ' ASN . 0.1 OUTLIER -131.53 31.52 4.29 Favored 'General case' 0 N--CA 1.484 1.234 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.479 179.942 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -99.76 128.45 9.58 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.475 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -78.17 128.91 34.48 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.413 -0.915 . . . . 0.0 110.799 179.955 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 81.5 -21.84 5.95 Favored Glycine 0 N--CA 1.489 2.227 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.794 179.915 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.571 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 2.2 mm-40 -49.72 162.82 0.15 Allowed 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.178 -1.009 . . . . 0.0 110.267 179.858 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 7.6 p -146.28 163.36 35.76 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.79 -179.38 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.651 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 37.2 t80 -136.05 146.13 46.75 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.421 179.39 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -106.12 148.69 27.53 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 119.466 -0.894 . . . . 0.0 112.318 -178.773 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -149.41 132.88 7.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.498 178.786 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 18.2 m -131.21 105.36 7.62 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.469 -0.892 . . . . 0.0 111.639 -179.012 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.452 ' CD1' HG11 ' A' ' 94' ' ' VAL . 17.9 mt -95.32 152.64 18.21 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 119.422 -0.911 . . . . 0.0 109.693 179.091 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 47.4 p -150.57 47.02 0.88 Allowed 'General case' 0 C--N 1.293 -1.854 0 C-N-CA 119.304 -0.959 . . . . 0.0 110.862 -179.54 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -137.81 107.79 6.34 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.728 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 8.5 tptt -44.45 112.51 0.42 Allowed 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.333 -179.876 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 167.94 -152.28 20.4 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.086 -1.531 . . . . 0.0 110.391 179.722 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.92 135.46 32.85 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.495 -179.922 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.558 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -121.36 166.3 14.27 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.659 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 17.3 mmtp -138.2 130.14 28.43 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.804 -179.322 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.528 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.5 p90 -137.24 164.18 29.15 Favored 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.214 178.673 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 39.4 p90 -170.32 -173.83 1.56 Allowed 'General case' 0 C--N 1.287 -2.146 0 C-N-CA 119.586 -0.846 . . . . 0.0 110.704 -178.497 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 82' ' ' CYS . . . . . 0.551 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -112.38 129.85 56.17 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.57 179.478 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.502 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.9 mm-40 -69.71 -45.77 24.95 Favored Pre-proline 0 N--CA 1.488 1.454 0 C-N-CA 119.393 -0.923 . . . . 0.0 112.906 -179.446 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.502 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.9 Cg_endo -66.95 -52.22 0.7 Allowed 'Trans proline' 0 C--O 1.216 -0.6 0 C-N-CA 120.756 0.971 . . . . 0.0 112.41 -179.244 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 85' ' ' HIS . . . . . 0.455 ' C ' ' H ' ' A' ' 87' ' ' GLY . 35.2 m80 -81.54 5.61 17.43 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.449 -0.901 . . . . 0.0 112.224 -178.912 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.551 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -61.59 -2.01 0.69 Allowed 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.712 -1.195 . . . . 0.0 110.525 179.935 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.455 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -81.63 -23.52 57.97 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 119.503 -1.332 . . . . 0.0 110.39 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.5 -45.45 7.76 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.346 -0.941 . . . . 0.0 110.43 -179.996 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.01 29.18 0.15 Allowed Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.531 179.687 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -76.12 102.69 5.83 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.124 -1.03 . . . . 0.0 110.961 179.888 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.6 pttt -131.12 166.49 20.98 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.434 -179.898 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.84 147.31 17.43 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.23 -1.462 . . . . 0.0 111.612 -178.713 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -149.47 147.71 28.55 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.347 179.189 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.452 HG11 ' CD1' ' A' ' 72' ' ' LEU . 14.3 p -143.39 136.19 24.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 118.911 -1.116 . . . . 0.0 110.363 179.377 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.683 ' HB ' HG22 ' A' ' 20' ' ' THR . 4.8 m -114.52 108.19 16.52 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.914 -0.714 . . . . 0.0 110.626 179.815 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.6 t -84.96 143.86 10.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 C-N-CA 118.532 -1.267 . . . . 0.0 110.527 -178.932 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 116.293 -1.813 . . . . 0.0 111.229 -179.664 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.161 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -115.56 121.16 41.81 Favored 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.479 179.589 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 61.5 t -110.5 122.38 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 C-N-CA 119.792 -0.763 . . . . 0.0 111.062 -179.787 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.1 mtmt -91.89 112.11 23.92 Favored 'General case' 0 C--N 1.297 -1.685 0 C-N-CA 119.449 -0.9 . . . . 0.0 110.454 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 7.7 mt -77.33 108.15 10.26 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 118.869 -1.133 . . . . 0.0 110.471 179.083 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.422 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 113.76 147.66 9.79 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.557 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.6 p -88.78 159.68 17.65 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.561 -0.855 . . . . 0.0 110.901 179.846 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -77.38 -20.64 54.41 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.344 -0.943 . . . . 0.0 110.664 179.832 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.433 ' CG ' ' H ' ' A' ' 10' ' ' GLY . 0.8 OUTLIER -87.18 -71.57 0.55 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.473 -0.891 . . . . 0.0 110.796 -179.906 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.433 ' H ' ' CG ' ' A' ' 9' ' ' ASP . . . 179.36 63.62 0.07 OUTLIER Glycine 0 N--CA 1.489 2.22 0 C-N-CA 119.396 -1.383 . . . . 0.0 110.429 179.966 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -152.39 166.17 31.09 Favored Glycine 0 N--CA 1.49 2.278 0 C-N-CA 119.528 -1.32 . . . . 0.0 110.278 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -115.51 105.77 13.18 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.771 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.8 m -151.8 156.61 5.83 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 C-N-CA 118.963 -1.095 . . . . 0.0 110.646 178.978 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.406 ' O ' ' C ' ' A' ' 16' ' ' PRO . 43.5 m-85 -78.55 113.31 16.46 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 177.572 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.8 m -115.21 107.58 49.38 Favored Pre-proline 0 N--CA 1.484 1.25 0 C-N-CA 119.434 -0.907 . . . . 0.0 112.089 -177.277 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.406 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -66.79 176.24 23.75 Favored 'Cis proline' 0 C--N 1.359 1.101 0 C-N-CA 125.409 -0.663 . . . . 0.0 111.738 -0.414 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.27 -52.98 4.92 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.611 -0.836 . . . . 0.0 110.088 179.138 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.4 t -131.09 146.68 52.45 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.398 178.985 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.404 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 23.0 p90 -161.55 140.04 9.53 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 118.374 -1.33 . . . . 0.0 111.96 -179.066 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.654 HG22 ' HB ' ' A' ' 95' ' ' THR . 64.3 p -81.62 155.66 25.53 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.837 -0.745 . . . . 0.0 110.913 179.652 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.9 m -148.76 164.76 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 119.572 -0.851 . . . . 0.0 110.483 179.528 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.507 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -89.93 147.56 23.65 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.288 -0.965 . . . . 0.0 110.998 -179.754 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.15 77.59 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.509 -0.876 . . . . 0.0 110.788 179.756 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.66 23.15 0.09 OUTLIER Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -179.97 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -103.99 140.01 38.33 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.987 -0.685 . . . . 0.0 110.764 -179.578 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.9 mtmt -85.03 125.9 33.11 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.282 -0.967 . . . . 0.0 110.97 -179.851 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.2 mt -102.62 119.77 51.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 C-N-CA 119.803 -0.759 . . . . 0.0 109.578 179.779 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 43.3 p -117.1 114.57 23.91 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.7 -0.8 . . . . 0.0 112.393 -178.513 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -87.46 117.91 26.56 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.003 178.319 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.8 tttt -112.29 138.61 48.76 Favored 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 119.544 -0.862 . . . . 0.0 111.86 -178.338 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.417 HD21 HD13 ' A' ' 61' ' ' LEU . 3.9 m-20 -81.13 131.36 35.3 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.2 179.683 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.66 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.8 p-10 -125.56 -17.06 5.63 Favored 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.067 179.217 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 166.04 149.55 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 C-N-CA 119.542 -0.863 . . . . 0.0 111.247 178.992 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.28 -5.74 59.19 Favored Glycine 0 N--CA 1.495 2.581 0 C-N-CA 119.279 -1.439 . . . . 0.0 112.284 178.626 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -48.14 162.23 0.34 Allowed Pre-proline 0 N--CA 1.489 1.488 0 C-N-CA 118.133 -1.427 . . . . 0.0 109.723 -179.923 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -76.23 142.99 75.12 Favored 'Cis proline' 0 C--O 1.212 -0.796 0 C-N-CA 124.304 -1.123 . . . . 0.0 112.538 -0.638 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.2 m-70 -108.66 -179.63 3.92 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 119.856 -0.738 . . . . 0.0 111.498 -179.896 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.595 ' ND2' ' CD1' ' A' ' 60' ' ' TYR . 2.5 t-20 -158.63 146.71 18.25 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.841 -0.744 . . . . 0.0 110.241 179.167 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.9 mp -135.94 117.81 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 119.519 -0.873 . . . . 0.0 111.08 -179.925 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.55 160.4 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.298 179.089 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.552 ' HB2' ' HB1' ' A' ' 52' ' ' ALA . 12.5 m-85 -113.38 125.0 53.78 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.41 -0.916 . . . . 0.0 112.058 -178.973 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.5 ' C ' ' H ' ' A' ' 44' ' ' ASP . 1.1 t70 -65.23 107.18 1.51 Allowed 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.664 178.786 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -67.86 16.38 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 119.505 -0.878 . . . . 0.0 112.207 -178.826 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.5 ' H ' ' C ' ' A' ' 42' ' ' ASP . 1.9 m-20 -106.02 -3.68 21.36 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 119.5 -0.88 . . . . 0.0 111.019 179.89 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -140.89 12.39 2.25 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.917 179.596 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -92.32 147.02 33.68 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.615 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -49.68 154.67 4.45 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 120.966 1.111 . . . . 0.0 112.019 -179.286 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.79 67.79 10.21 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.682 -179.935 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.86 -38.13 0.07 OUTLIER Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.957 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 55.8 t -90.53 81.19 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.371 179.583 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -44.21 139.62 2.51 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.13 -179.359 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.552 ' HB1' ' HB2' ' A' ' 41' ' ' PHE . . . -87.44 10.31 17.94 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.955 -179.724 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -90.55 -22.68 21.17 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.091 -1.044 . . . . 0.0 111.513 -179.476 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -93.81 -32.32 14.01 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 118.912 -1.115 . . . . 0.0 112.046 -179.329 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.1 pt -90.33 -23.74 5.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.513 -179.327 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 56' ' ' SER . . . . . 0.404 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 18.1 m -61.78 -178.8 0.16 Allowed 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.098 179.869 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.501 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 18.0 tt0 -157.83 67.84 3.81 Favored Pre-proline 0 C--N 1.303 -1.444 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.689 -179.579 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.96 -29.34 87.82 Favored 'Trans proline' 0 C--N 1.323 -0.781 0 C-N-CA 121.308 1.339 . . . . 0.0 111.286 -179.419 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -59.01 112.28 1.62 Allowed 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.554 179.701 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.595 ' CD1' ' ND2' ' A' ' 38' ' ' ASN . 43.9 m-85 -58.55 169.55 0.9 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.998 -179.95 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.417 HD13 HD21 ' A' ' 31' ' ' ASN . 1.2 pp -153.73 149.17 27.2 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.362 179.688 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.512 ' O ' ' C ' ' A' ' 63' ' ' GLY . 0.0 OUTLIER -127.21 -74.31 0.59 Allowed 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.396 -179.288 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 63' ' ' GLY . . . . . 0.512 ' C ' ' O ' ' A' ' 62' ' ' ASN . . . -9.65 123.41 0.01 OUTLIER Glycine 1 N--CA 1.518 4.113 0 O-C-N 124.202 0.939 . . . . 0.0 112.75 -179.641 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -75.05 131.41 40.56 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.43 -0.908 . . . . 0.0 110.664 179.736 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.63 -14.96 58.92 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.596 -1.288 . . . . 0.0 110.528 -179.975 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' A' ' 66' ' ' GLU . 1.2 mp0 -62.96 148.51 47.33 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.446 179.844 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.38 163.24 34.35 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.246 -0.982 . . . . 0.0 111.396 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.501 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 41.5 t80 -136.54 143.73 43.85 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 119.87 -0.732 . . . . 0.0 109.276 179.269 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -106.15 152.16 23.8 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.219 -0.992 . . . . 0.0 111.995 -179.149 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -151.82 131.58 3.62 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 CA-C-N 115.345 -0.843 . . . . 0.0 108.813 179.555 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.7 m -121.52 112.87 19.04 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.804 -179.067 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.47 ' CD1' HG11 ' A' ' 94' ' ' VAL . 45.7 mt -96.56 158.61 15.35 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.725 -0.79 . . . . 0.0 109.417 178.924 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.0 m -150.89 41.9 0.77 Allowed 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 118.56 -1.256 . . . . 0.0 112.351 -179.133 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 62.8 mt-10 -145.92 110.98 5.27 Favored 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.378 178.918 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -44.06 116.51 1.01 Allowed 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.934 -179.569 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 164.5 175.16 35.04 Favored Glycine 0 N--CA 1.483 1.807 0 C-N-CA 119.293 -1.432 . . . . 0.0 110.35 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.76 126.77 53.38 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.992 -0.683 . . . . 0.0 110.977 -179.785 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.554 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -108.35 141.99 39.34 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.352 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 16.5 mmtp -105.12 122.22 45.45 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.953 -179.139 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.423 ' CZ ' ' N ' ' A' ' 93' ' ' GLU . 5.7 p90 -138.48 160.04 40.57 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 119.315 -0.954 . . . . 0.0 110.076 177.508 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -170.24 -175.26 1.91 Allowed 'General case' 0 C--N 1.287 -2.112 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.908 -177.655 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.6 t -103.48 122.72 45.49 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.732 -0.787 . . . . 0.0 109.372 179.245 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.564 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 4.9 tt0 -73.4 -36.04 2.94 Favored Pre-proline 0 CA--C 1.557 1.236 0 C-N-CA 118.84 -1.144 . . . . 0.0 113.267 -178.701 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.564 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.0 OUTLIER -70.25 -47.74 0.73 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 120.376 0.718 . . . . 0.0 111.105 179.66 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 85' ' ' HIS . . . . . 0.407 ' C ' ' H ' ' A' ' 87' ' ' GLY . 36.7 m80 -87.77 16.45 5.76 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.593 -0.843 . . . . 0.0 110.808 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.53 -2.61 1.69 Allowed 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.364 -0.935 . . . . 0.0 110.821 179.908 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.407 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -88.16 -17.83 56.82 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.354 -1.403 . . . . 0.0 110.29 179.911 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.45 -41.61 10.2 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.644 179.961 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 132.72 13.88 1.56 Allowed Glycine 0 N--CA 1.494 2.555 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.562 179.861 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.49 101.86 0.21 Allowed 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.928 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.5 tptt -124.71 154.1 41.35 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 119.914 -0.715 . . . . 0.0 111.256 -179.854 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.55 153.1 21.88 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.85 -179.055 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.423 ' N ' ' CZ ' ' A' ' 80' ' ' PHE . 2.7 mt-10 -156.4 146.05 20.9 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.363 -0.935 . . . . 0.0 111.289 179.911 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.501 ' O ' HG13 ' A' ' 94' ' ' VAL . 13.1 p -138.7 128.54 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.24 178.792 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.654 ' HB ' HG22 ' A' ' 20' ' ' THR . 98.8 m -106.77 100.09 9.62 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.68 179.831 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.0 t -80.04 150.78 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.237 0 C-N-CA 118.779 -1.169 . . . . 0.0 110.392 -179.714 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 116.339 -1.791 . . . . 0.0 110.828 179.969 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.153 0 CA-C-O 120.855 0.36 . . . . 0.0 110.079 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -105.27 135.69 46.17 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.929 -0.708 . . . . 0.0 110.647 179.887 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.0 t -124.11 126.62 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.817 -0.753 . . . . 0.0 110.445 179.591 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 7.3 mttp -100.84 118.57 37.16 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.792 -0.763 . . . . 0.0 110.591 -179.819 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.2 mt -83.66 109.82 17.77 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.646 178.84 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 106.25 133.36 7.42 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -178.8 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.2 p -73.34 161.46 30.45 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.624 179.64 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -84.47 43.78 0.99 Allowed 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.78 -179.906 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -155.52 -55.68 0.09 Allowed 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.246 -0.982 . . . . 0.0 110.996 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.11 67.19 0.03 OUTLIER Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.295 -1.431 . . . . 0.0 110.648 -179.862 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -161.03 157.53 29.07 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.309 -1.424 . . . . 0.0 110.476 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.619 HD13 ' CD2' ' A' ' 85' ' ' HIS . 49.9 mt -114.82 99.37 7.44 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.645 179.838 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.1 m -147.3 154.67 11.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 C-N-CA 119.091 -1.044 . . . . 0.0 111.023 179.899 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.443 ' O ' ' O ' ' A' ' 16' ' ' PRO . 40.4 m-85 -78.39 109.08 12.22 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 177.893 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 20.0 m -115.37 111.32 44.38 Favored Pre-proline 0 C--O 1.205 -1.24 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.51 -177.446 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.443 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -66.16 176.57 20.88 Favored 'Cis proline' 0 C--N 1.355 0.909 0 C-N-CA 125.304 -0.707 . . . . 0.0 111.612 0.102 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -92.86 -56.58 2.94 Favored 'General case' 0 N--CA 1.486 1.371 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.726 178.803 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.8 t -125.75 139.37 53.58 Favored 'General case' 0 N--CA 1.486 1.341 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.073 178.806 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 16.4 p90 -159.03 132.84 7.49 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.448 -178.915 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.454 ' H ' HG23 ' A' ' 20' ' ' THR . 0.8 OUTLIER -83.12 155.07 24.01 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.271 -0.972 . . . . 0.0 110.865 179.762 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 17.8 m -146.57 171.55 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.326 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.998 179.741 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -93.94 151.45 19.55 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.414 -0.914 . . . . 0.0 110.684 179.728 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.2 73.54 0.12 Allowed 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.146 -179.986 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 154.69 13.14 0.06 OUTLIER Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.791 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -99.07 117.04 32.67 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.663 -179.783 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.1 mtmp? -65.96 133.44 50.86 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 119.477 -0.889 . . . . 0.0 111.066 -179.774 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 mt -113.55 131.77 64.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 C-N-CA 119.954 -0.698 . . . . 0.0 109.248 179.454 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.5 p -125.29 123.29 39.16 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.526 -0.87 . . . . 0.0 112.173 -178.54 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -84.4 147.29 27.22 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.414 -0.914 . . . . 0.0 108.851 178.346 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 tttm -136.62 127.9 28.18 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.396 -0.921 . . . . 0.0 111.371 -178.873 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.2 m-80 -79.45 109.45 13.82 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.69 -0.804 . . . . 0.0 110.52 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.654 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.3 OUTLIER -95.49 -30.73 13.7 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.76 -179.474 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.654 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 166.4 136.92 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.041 -179.661 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 116.27 -2.23 20.65 Favored Glycine 0 N--CA 1.495 2.599 0 C-N-CA 119.836 -1.174 . . . . 0.0 111.033 179.189 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -47.37 163.83 0.25 Allowed Pre-proline 0 C--N 1.308 -1.224 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.775 179.792 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -76.23 145.34 82.01 Favored 'Cis proline' 0 C--O 1.214 -0.722 0 C-N-CA 124.223 -1.157 . . . . 0.0 112.659 -0.756 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -111.22 172.15 7.05 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.889 179.298 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.566 ' ND2' ' CD2' ' A' ' 60' ' ' TYR . 7.0 t-20 -149.8 137.98 20.47 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.111 179.34 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.412 HD13 ' NE2' ' A' ' 57' ' ' GLN . 3.5 mp -125.17 110.68 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 C-N-CA 119.893 -0.723 . . . . 0.0 110.888 -179.689 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.5 t -130.93 145.31 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.95 -0.7 . . . . 0.0 110.326 179.528 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -99.53 121.7 41.55 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.586 -0.845 . . . . 0.0 111.322 -179.356 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -60.48 100.87 0.11 Allowed 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.131 -1.028 . . . . 0.0 110.044 179.484 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -57.65 -6.6 0.52 Allowed 'General case' 0 N--CA 1.489 1.488 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.277 -179.012 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -93.36 3.19 56.01 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 118.993 -1.083 . . . . 0.0 112.263 -178.733 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 30.6 mt-10 -144.56 13.52 1.55 Allowed 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 119.116 -1.033 . . . . 0.0 111.741 -179.944 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -90.85 149.96 41.22 Favored Pre-proline 0 C--N 1.292 -1.919 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.287 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -47.91 144.25 12.05 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.917 1.078 . . . . 0.0 111.878 -179.539 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.6 73.98 1.99 Allowed 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.531 -0.868 . . . . 0.0 110.617 179.994 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.47 -32.72 0.12 Allowed Glycine 0 N--CA 1.487 2.053 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.241 -179.94 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 81.4 t -94.83 105.79 17.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.374 -0.93 . . . . 0.0 111.073 -179.855 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -52.17 143.99 13.29 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.715 179.882 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -93.04 -3.28 54.6 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.328 -0.949 . . . . 0.0 110.908 -179.773 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -90.22 -21.45 22.15 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.255 -0.978 . . . . 0.0 110.94 -179.931 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 23.4 mmtt -78.14 -26.96 48.08 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.304 -0.958 . . . . 0.0 110.936 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.3 pt -105.8 -12.22 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.845 -179.192 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 18.6 m -78.39 170.07 17.22 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.108 -1.037 . . . . 0.0 111.316 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.501 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 16.0 mt-30 -134.19 74.11 68.27 Favored Pre-proline 0 N--CA 1.486 1.335 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.241 179.902 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -59.52 -20.26 56.19 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 121.277 1.318 . . . . 0.0 111.63 -178.69 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 59' ' ' GLU . . . . . 0.444 ' O ' ' CG ' ' A' ' 59' ' ' GLU . 3.4 pt-20 -89.14 107.0 18.8 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.527 179.513 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.566 ' CD2' ' ND2' ' A' ' 38' ' ' ASN . 27.6 m-85 -51.93 165.61 0.19 Allowed 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 119.411 -0.915 . . . . 0.0 110.849 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.4 pp -139.34 126.38 21.09 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.43 179.466 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.457 ' OD1' ' N ' ' A' ' 62' ' ' ASN . 19.8 p-10 -118.31 34.97 4.94 Favored 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.057 -179.49 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -87.99 -172.08 47.06 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 119.238 -1.458 . . . . 0.0 110.214 179.64 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -133.59 105.94 7.14 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.049 179.579 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 94.24 -11.37 70.58 Favored Glycine 0 N--CA 1.486 2.03 0 C-N-CA 119.308 -1.425 . . . . 0.0 109.713 -179.299 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -50.59 160.94 0.37 Allowed 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.359 179.684 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.7 p -145.8 158.99 43.82 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.393 -179.374 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.501 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 15.6 t80 -136.16 137.01 40.5 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.365 179.068 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -99.97 152.3 20.35 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 119.292 -0.963 . . . . 0.0 112.494 -178.769 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -155.81 134.53 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 115.191 -0.913 . . . . 0.0 108.9 179.509 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.1 m -128.6 96.7 4.47 Favored 'General case' 0 N--CA 1.486 1.327 0 C-N-CA 119.559 -0.856 . . . . 0.0 111.208 -179.482 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.5 mt -79.88 157.63 26.9 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.25 -0.98 . . . . 0.0 109.9 179.433 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 77.6 p -150.06 45.96 0.91 Allowed 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.495 -179.169 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.439 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.7 mm-40 -142.46 113.29 7.45 Favored 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.098 -1.041 . . . . 0.0 110.448 179.557 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.466 ' CG ' ' O ' ' A' ' 75' ' ' LYS . 0.6 OUTLIER -52.45 119.33 4.35 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.268 -0.973 . . . . 0.0 111.058 -179.322 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 163.36 -147.87 13.91 Favored Glycine 0 N--CA 1.483 1.78 0 C-N-CA 119.254 -1.451 . . . . 0.0 110.142 179.86 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.74 130.18 23.9 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.752 -179.938 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.53 ' N ' ' CD1' ' A' ' 78' ' ' TYR . 2.6 m-85 -114.86 123.8 50.08 Favored 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.923 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 79' ' ' LYS . . . . . 0.516 ' CD ' ' N ' ' A' ' 79' ' ' LYS . 0.5 OUTLIER -103.97 121.03 42.29 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.133 -1.027 . . . . 0.0 111.76 -178.949 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.478 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 4.2 p90 -129.54 173.19 10.81 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.212 178.295 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -171.11 -174.29 1.46 Allowed 'General case' 0 C--N 1.292 -1.894 0 C-N-CA 119.531 -0.868 . . . . 0.0 110.814 -178.576 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -108.89 132.07 54.41 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 119.898 -0.721 . . . . 0.0 110.49 179.209 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.496 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.2 mt-10 -73.38 -47.18 7.61 Favored Pre-proline 0 N--CA 1.485 1.286 0 C-N-CA 119.432 -0.907 . . . . 0.0 112.472 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.2 Cg_exo -64.54 -47.18 5.94 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 120.89 1.06 . . . . 0.0 111.953 -179.227 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 85' ' ' HIS . . . . . 0.619 ' CD2' HD13 ' A' ' 12' ' ' LEU . 37.6 m80 -90.51 21.42 3.95 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.971 -179.421 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.73 1.66 1.24 Allowed 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.692 179.844 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.446 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -96.5 -20.94 23.41 Favored Glycine 0 N--CA 1.49 2.277 0 C-N-CA 119.471 -1.347 . . . . 0.0 110.412 -179.869 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.41 -9.87 45.95 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.485 179.667 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 96.46 20.28 25.33 Favored Glycine 0 N--CA 1.488 2.102 0 C-N-CA 119.498 -1.334 . . . . 0.0 110.462 179.817 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.31 102.72 0.7 Allowed 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.151 -1.02 . . . . 0.0 110.982 -179.829 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.07 162.1 26.86 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.003 179.826 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -142.96 153.26 24.6 Favored Glycine 0 N--CA 1.491 2.359 0 C-N-CA 119.436 -1.364 . . . . 0.0 111.468 -178.587 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -155.62 144.87 20.85 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.429 -0.908 . . . . 0.0 111.078 179.629 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -141.78 123.32 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.193 178.461 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 92.3 m -101.14 108.2 19.81 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.158 -179.526 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 23.2 t -88.93 148.15 4.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 118.771 -1.172 . . . . 0.0 110.764 -179.329 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 . . . . . 0 N--CA 1.485 1.317 0 CA-C-O 116.341 -1.79 . . . . 0.0 110.868 -179.903 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.14 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -135.26 127.38 29.87 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 120.027 -0.669 . . . . 0.0 110.574 179.741 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.7 t -115.72 131.86 66.85 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 C-N-CA 119.864 -0.735 . . . . 0.0 110.991 -179.745 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.7 mtpp -104.72 118.9 37.71 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.205 -179.749 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.9 mt -81.52 108.22 14.93 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 118.956 -1.098 . . . . 0.0 109.672 178.269 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.531 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 110.41 125.64 4.91 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.649 -1.381 . . . . 0.0 109.649 -179.1 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 7' ' ' SER . . . . . 0.525 ' OG ' ' N ' ' A' ' 11' ' ' GLY . 3.2 p -78.57 22.72 0.34 Allowed 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.162 -1.015 . . . . 0.0 110.934 -179.746 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.422 ' H ' ' C ' ' A' ' 6' ' ' GLY . 1.3 m-20 57.23 2.64 0.13 Allowed 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 119.829 -0.749 . . . . 0.0 111.395 179.585 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.485 ' H ' ' C ' ' A' ' 7' ' ' SER . 0.3 OUTLIER 175.62 -41.87 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.738 -179.965 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -54.44 -32.2 52.25 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.353 -1.403 . . . . 0.0 110.094 179.869 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.525 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . 142.29 -136.1 7.04 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.518 -1.325 . . . . 0.0 110.556 179.978 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.6 mt -117.96 104.56 11.02 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.67 -179.728 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.4 m -150.01 154.25 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.122 0 C-N-CA 118.777 -1.169 . . . . 0.0 111.268 179.749 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.433 ' O ' ' O ' ' A' ' 16' ' ' PRO . 11.1 m-85 -78.6 108.57 12.09 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 177.818 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 53.3 m -114.76 112.31 45.29 Favored Pre-proline 0 CA--C 1.559 1.303 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.248 -177.176 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.433 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -65.56 176.79 18.52 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 125.188 -0.755 . . . . 0.0 111.702 -0.936 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.9 t -93.86 -55.97 3.05 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.453 179.212 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.4 p -128.92 142.65 50.87 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.814 179.212 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -163.9 143.01 7.83 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 118.663 -1.215 . . . . 0.0 111.782 -179.278 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.431 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -90.76 153.59 20.15 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.903 179.533 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.7 m -145.95 -176.75 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 119.494 -0.882 . . . . 0.0 110.585 179.617 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.409 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -97.53 147.09 24.62 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.716 179.773 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.3 74.03 0.14 Allowed 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.836 179.741 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.411 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 155.54 18.09 0.04 OUTLIER Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.913 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.411 ' H ' ' H ' ' A' ' 24' ' ' GLY . 14.7 tt0 -99.65 156.1 17.25 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.767 -0.773 . . . . 0.0 110.881 -179.783 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.0 mptp? -93.81 119.28 32.56 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.722 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.1 mt -100.06 106.5 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.254 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.2 p -104.26 117.7 34.85 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.582 -0.847 . . . . 0.0 112.888 -177.893 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -84.38 149.0 26.31 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.408 -0.917 . . . . 0.0 108.548 177.893 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 6.4 ttpp -141.19 133.39 27.98 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 118.965 -1.094 . . . . 0.0 111.664 -178.445 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.588 ' ND2' ' O ' ' A' ' 66' ' ' GLU . 0.1 OUTLIER -89.48 104.02 16.61 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.735 178.946 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 2.3 p-10 -91.56 -31.72 15.8 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 118.864 -1.134 . . . . 0.0 111.846 -178.584 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -175.21 139.78 0.48 Allowed 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.138 -179.693 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.26 15.35 33.02 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.495 -1.335 . . . . 0.0 111.784 178.784 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.404 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -58.55 163.24 5.26 Favored Pre-proline 0 N--CA 1.481 1.113 0 C-N-CA 117.96 -1.496 . . . . 0.0 109.2 179.557 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -74.53 -174.48 13.85 Favored 'Cis proline' 0 C--O 1.206 -1.091 0 C-N-CA 124.481 -1.05 . . . . 0.0 112.195 -0.382 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.3 m-70 -149.7 -178.71 6.6 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.885 178.544 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.672 ' ND2' ' CE1' ' A' ' 60' ' ' TYR . 9.1 t-20 -156.75 137.22 13.05 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.375 179.166 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.552 HD12 ' NE2' ' A' ' 57' ' ' GLN . 7.6 mt -122.0 85.27 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 C-N-CA 119.866 -0.734 . . . . 0.0 111.479 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 t -103.34 157.94 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 C-N-CA 119.922 -0.711 . . . . 0.0 109.484 178.755 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -112.29 138.97 48.25 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 119.285 -0.966 . . . . 0.0 111.949 -179.42 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.512 ' C ' ' H ' ' A' ' 44' ' ' ASP . 4.4 t70 -82.36 105.95 13.85 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.003 179.162 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -70.81 32.92 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.378 -179.451 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.512 ' H ' ' C ' ' A' ' 42' ' ' ASP . 82.5 m-20 -108.95 -15.13 14.43 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 120.032 -0.667 . . . . 0.0 110.693 179.518 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -139.79 16.33 2.5 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.718 179.491 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -93.41 143.7 27.09 Favored Pre-proline 0 C--N 1.296 -1.735 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 179.31 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.403 ' C ' ' H ' ' A' ' 49' ' ' GLY . 3.0 Cg_exo -48.45 140.74 20.69 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 120.754 0.97 . . . . 0.0 111.961 -179.392 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.32 43.16 0.37 Allowed 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.67 179.973 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.403 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -148.78 -26.51 0.07 OUTLIER Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 50' ' ' VAL . . . . . 0.441 ' O ' HG12 ' A' ' 50' ' ' VAL . 46.7 t -101.83 93.95 3.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.458 179.746 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -44.88 139.62 2.97 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.741 -179.919 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -90.81 3.42 54.47 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.502 179.851 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -90.3 -31.63 16.86 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.933 179.909 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 37.0 mttt -69.68 -32.52 71.18 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.421 -0.912 . . . . 0.0 111.32 -179.762 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.0 pt -93.22 -35.07 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.123 -1.031 . . . . 0.0 111.148 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.4 m -56.27 163.88 1.51 Allowed 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.198 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.552 ' NE2' HD12 ' A' ' 39' ' ' ILE . 20.6 mt-30 -124.97 84.59 58.76 Favored Pre-proline 0 N--CA 1.487 1.42 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.231 179.713 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -60.37 -22.71 72.25 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 120.995 1.13 . . . . 0.0 111.834 -178.761 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -96.35 115.93 28.22 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.349 -0.94 . . . . 0.0 110.858 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.672 ' CE1' ' ND2' ' A' ' 38' ' ' ASN . 55.0 m-85 -56.34 177.37 0.07 Allowed 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.624 179.879 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.7 pp -148.33 132.75 17.6 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.283 -0.967 . . . . 0.0 110.8 179.93 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -128.99 39.03 3.85 Favored 'General case' 0 N--CA 1.493 1.721 0 C-N-CA 119.976 -0.69 . . . . 0.0 110.955 -179.745 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -102.27 125.52 8.55 Favored Glycine 0 N--CA 1.494 2.512 0 C-N-CA 119.632 -1.271 . . . . 0.0 110.388 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -70.52 103.3 2.44 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.532 179.748 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.38 -0.24 55.76 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.614 -1.279 . . . . 0.0 110.458 -179.884 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.588 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 17.6 tt0 -72.99 106.99 5.1 Favored 'General case' 0 N--CA 1.49 1.562 0 C-N-CA 119.062 -1.055 . . . . 0.0 110.569 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.1 p -96.43 161.99 13.68 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.702 -179.169 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.492 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 24.2 t80 -135.75 136.04 40.45 Favored 'General case' 0 N--CA 1.491 1.592 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.517 179.185 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -98.13 152.23 19.57 Favored 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.256 -0.978 . . . . 0.0 112.547 -178.428 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -151.85 132.78 4.55 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.633 178.951 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 6.6 m -123.52 107.29 11.39 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.622 -0.831 . . . . 0.0 112.023 -178.683 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 72' ' ' LEU . . . . . 0.424 ' CD1' HG11 ' A' ' 94' ' ' VAL . 50.5 mt -89.58 160.88 16.45 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.513 -0.875 . . . . 0.0 109.348 178.749 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.21 41.09 0.72 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 118.66 -1.216 . . . . 0.0 111.754 -178.918 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 74' ' ' GLU . . . . . 0.462 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.6 OUTLIER -141.85 116.76 9.88 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 118.874 -1.13 . . . . 0.0 110.981 179.784 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -55.7 106.18 0.23 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.452 -0.899 . . . . 0.0 111.167 -179.685 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 173.93 -163.06 33.93 Favored Glycine 0 N--CA 1.484 1.843 0 C-N-CA 119.353 -1.403 . . . . 0.0 109.831 -179.987 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.6 125.7 45.3 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.807 -0.757 . . . . 0.0 111.071 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.547 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -109.3 153.73 23.49 Favored 'General case' 0 N--CA 1.483 1.213 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.018 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 81.1 mttt -115.63 134.49 54.99 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.402 -0.919 . . . . 0.0 112.469 -179.394 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.503 ' O ' ' N ' ' A' ' 92' ' ' GLY . 0.9 OUTLIER -143.57 154.98 44.15 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.492 -0.883 . . . . 0.0 110.058 176.917 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 36.5 p90 -168.45 -174.51 2.24 Favored 'General case' 0 C--N 1.284 -2.259 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.582 -178.666 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.3 t -110.94 122.57 48.21 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 119.842 -0.743 . . . . 0.0 109.832 179.732 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.582 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.5 tm-20 -72.74 -35.58 3.09 Favored Pre-proline 0 N--CA 1.483 1.182 0 C-N-CA 119.056 -1.058 . . . . 0.0 113.292 -178.885 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.1 Cg_endo -71.43 -38.48 4.56 Favored 'Trans proline' 0 C--O 1.213 -0.728 0 C-N-CA 120.52 0.814 . . . . 0.0 111.111 179.855 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 32.8 m80 -102.17 21.05 15.55 Favored 'General case' 0 N--CA 1.488 1.474 0 C-N-CA 119.785 -0.766 . . . . 0.0 111.049 -179.771 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.78 -12.9 8.22 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.612 179.766 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -92.5 -13.47 57.0 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.324 179.821 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.59 -20.44 26.39 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.549 179.933 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 110.21 14.82 12.47 Favored Glycine 0 N--CA 1.496 2.654 0 C-N-CA 119.853 -1.165 . . . . 0.0 110.83 179.673 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.3 mtp -72.27 98.4 2.18 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.689 179.875 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 21.0 mmtt -130.37 150.33 51.65 Favored 'General case' 0 N--CA 1.496 1.843 0 C-N-CA 119.962 -0.695 . . . . 0.0 110.835 179.538 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.503 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -140.3 155.92 24.85 Favored Glycine 0 N--CA 1.501 3.021 0 C-N-CA 119.283 -1.437 . . . . 0.0 112.456 -177.914 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 26.5 tt0 -158.64 146.43 18.04 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.203 179.014 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.542 ' O ' HG13 ' A' ' 94' ' ' VAL . 11.9 p -138.29 122.25 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.001 179.974 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.5 m -97.19 97.03 8.84 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.673 179.885 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 24.0 t -81.95 154.17 4.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.907 -179.051 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.2 p30 . . . . . 0 C--N 1.306 -1.318 0 CA-C-O 116.348 -1.787 . . . . 0.0 110.651 179.872 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.197 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -104.77 123.98 48.61 Favored 'General case' 0 N--CA 1.488 1.458 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.986 179.948 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.6 t -117.28 128.54 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 C-N-CA 119.888 -0.725 . . . . 0.0 110.404 179.494 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -103.76 117.92 35.49 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.814 -0.754 . . . . 0.0 111.155 -179.49 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 mt -78.18 109.14 12.03 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.727 -1.189 . . . . 0.0 109.529 177.964 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.406 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 107.47 120.47 4.55 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.061 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 31.9 p -79.45 166.03 22.43 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.992 -179.808 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -82.93 -29.65 28.98 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.998 179.928 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -65.84 -4.93 7.59 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 119.408 -0.917 . . . . 0.0 111.043 -179.885 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.64 61.07 1.02 Allowed Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.37 -1.395 . . . . 0.0 110.468 179.988 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -154.02 154.2 25.35 Favored Glycine 0 N--CA 1.489 2.213 0 C-N-CA 119.459 -1.353 . . . . 0.0 110.295 -179.995 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 73.5 mt -101.14 99.91 10.4 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.041 -179.885 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.9 m -150.07 157.44 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.73 179.325 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 14' ' ' PHE . . . . . 0.415 ' O ' ' O ' ' A' ' 16' ' ' PRO . 14.2 m-85 -78.44 112.02 15.05 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.135 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 54.6 m -116.03 108.79 45.69 Favored Pre-proline 0 CA--C 1.558 1.26 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.824 -177.861 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 16' ' ' PRO . . . . . 0.415 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.6 Cg_endo -65.76 177.84 16.68 Favored 'Cis proline' 0 C--N 1.362 1.244 0 C-N-CA 125.353 -0.686 . . . . 0.0 111.75 -0.49 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.65 -51.64 4.83 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.509 -0.877 . . . . 0.0 110.423 179.437 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 94.5 p -140.02 141.89 36.27 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.782 179.385 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 22.4 p90 -162.71 149.42 12.95 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.743 -1.183 . . . . 0.0 111.183 -179.169 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 20' ' ' THR . . . . . 0.422 HG23 ' H ' ' A' ' 20' ' ' THR . 0.7 OUTLIER -91.01 159.26 16.23 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.388 -0.925 . . . . 0.0 111.169 -179.972 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.6 m -149.95 172.01 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.858 179.697 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.503 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -88.83 147.79 24.23 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.459 -0.897 . . . . 0.0 110.662 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.85 76.3 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.943 179.802 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 24' ' ' GLY . . . . . 0.503 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.18 22.28 0.09 OUTLIER Glycine 0 N--CA 1.49 2.268 0 C-N-CA 119.537 -1.315 . . . . 0.0 109.933 179.968 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -96.3 145.97 25.13 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.01 -179.787 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.8 mttm -87.12 128.68 35.11 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.863 -179.971 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.8 mt -118.55 131.97 69.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.432 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 25.1 p -128.7 116.96 20.35 Favored 'General case' 0 N--CA 1.492 1.647 0 C-N-CA 119.354 -0.938 . . . . 0.0 112.384 -178.55 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -84.82 109.72 18.3 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.453 -0.899 . . . . 0.0 108.855 177.905 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.3 tttm -106.05 138.06 42.89 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 119.719 -0.792 . . . . 0.0 111.445 -178.103 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -83.26 106.9 15.42 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.062 179.404 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 32' ' ' ASN . . . . . 0.663 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.0 OUTLIER -90.19 -30.75 17.39 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 118.88 -1.128 . . . . 0.0 111.774 -178.865 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 33' ' ' ALA . . . . . 0.663 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 167.81 114.62 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 118.827 -1.149 . . . . 0.0 111.144 179.916 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 139.37 -0.96 2.34 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.587 -1.292 . . . . 0.0 110.559 179.858 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 35' ' ' PHE . . . . . 0.426 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -48.0 161.83 0.35 Allowed Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 118.749 -1.18 . . . . 0.0 110.071 -179.65 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -77.62 144.05 75.89 Favored 'Cis proline' 0 C--O 1.216 -0.587 0 C-N-CA 124.113 -1.203 . . . . 0.0 112.271 -1.022 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.5 m-70 -112.85 175.56 5.39 Favored 'General case' 0 N--CA 1.495 1.782 0 C-N-CA 119.915 -0.714 . . . . 0.0 110.135 179.42 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.541 ' ND2' ' CD1' ' A' ' 60' ' ' TYR . 3.2 t-20 -151.64 148.97 28.6 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.529 179.493 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.438 HD13 ' NE2' ' A' ' 57' ' ' GLN . 4.0 mp -134.86 103.47 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 C-N-CA 119.616 -0.833 . . . . 0.0 111.351 -179.502 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 t -119.08 144.65 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 C-N-CA 120.075 -0.65 . . . . 0.0 110.123 179.22 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.689 ' CD2' HD12 ' A' ' 55' ' ' ILE . 9.9 m-85 -99.88 114.67 28.05 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.526 -0.87 . . . . 0.0 111.443 -179.338 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 42' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 44' ' ' ASP . 32.8 t0 -55.6 88.41 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 119.441 -0.903 . . . . 0.0 110.48 179.676 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 43' ' ' GLU . . . . . 0.467 ' N ' ' O ' ' A' ' 41' ' ' PHE . 16.0 pt-20 -46.71 -13.25 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.515 -0.874 . . . . 0.0 111.357 -179.688 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 44' ' ' ASP . . . . . 0.519 ' N ' ' O ' ' A' ' 42' ' ' ASP . 0.9 OUTLIER -87.97 13.11 11.66 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.388 -179.594 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -151.66 15.32 0.67 Allowed 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.114 179.843 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.588 HG22 ' HD2' ' A' ' 47' ' ' PRO . 0.5 OUTLIER -104.06 154.87 37.85 Favored Pre-proline 0 N--CA 1.491 1.624 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.838 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 47' ' ' PRO . . . . . 0.588 ' HD2' HG22 ' A' ' 46' ' ' VAL . 6.1 Cg_exo -52.83 149.79 24.69 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 120.887 1.058 . . . . 0.0 111.236 179.646 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -83.06 40.78 0.72 Allowed 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.293 -0.963 . . . . 0.0 110.716 -179.899 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -142.89 -40.09 0.07 OUTLIER Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 70.3 t -92.48 90.8 3.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.146 179.449 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.3 m120 -44.8 146.5 0.77 Allowed 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.314 -0.955 . . . . 0.0 110.877 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -90.84 -29.58 17.46 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.544 -0.862 . . . . 0.0 111.076 -179.728 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -60.74 -5.43 1.28 Allowed 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.995 -179.719 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 22.2 mtmt -99.55 -38.39 8.78 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.605 -0.838 . . . . 0.0 111.486 -179.828 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 55' ' ' ILE . . . . . 0.689 HD12 ' CD2' ' A' ' 41' ' ' PHE . 2.1 pt -90.49 -29.25 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.208 -179.562 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 58.8 m -56.23 172.34 0.22 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.107 179.909 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.49 ' OE1' ' CG ' ' A' ' 68' ' ' TYR . 17.6 mt-30 -134.45 71.92 70.96 Favored Pre-proline 0 N--CA 1.491 1.601 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.815 179.757 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -59.29 -6.81 4.31 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 121.074 1.183 . . . . 0.0 111.209 -179.664 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -100.25 106.48 18.15 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.651 179.577 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 60' ' ' TYR . . . . . 0.541 ' CD1' ' ND2' ' A' ' 38' ' ' ASN . 31.1 m-85 -52.34 168.3 0.11 Allowed 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.594 -0.842 . . . . 0.0 110.471 -179.993 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.7 pp -148.26 141.73 25.35 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.12 -1.032 . . . . 0.0 110.877 179.85 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -137.85 8.09 2.76 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.088 -179.835 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -65.52 127.47 31.65 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 119.091 -1.528 . . . . 0.0 110.302 179.892 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -72.0 120.81 18.13 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.179 -1.008 . . . . 0.0 110.266 179.659 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.29 -14.69 53.45 Favored Glycine 0 N--CA 1.487 2.047 0 C-N-CA 119.111 -1.519 . . . . 0.0 110.657 -179.664 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.19 152.08 34.22 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.169 -1.012 . . . . 0.0 110.469 179.762 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -142.93 171.97 13.33 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.592 -179.615 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.49 ' CG ' ' OE1' ' A' ' 57' ' ' GLN . 34.2 t80 -135.73 128.41 30.86 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.145 179.218 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -99.23 155.79 17.31 Favored 'General case' 0 N--CA 1.49 1.562 0 C-N-CA 119.052 -1.059 . . . . 0.0 112.383 -178.604 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -156.34 142.94 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.023 178.93 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.9 m -130.99 96.13 3.98 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 119.784 -0.766 . . . . 0.0 111.265 -179.287 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 11.7 mt -79.58 161.3 26.02 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.045 -1.062 . . . . 0.0 109.134 179.172 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.46 45.47 0.87 Allowed 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 118.596 -1.242 . . . . 0.0 112.242 -178.688 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 29.2 mm-40 -143.82 105.7 4.34 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 118.876 -1.13 . . . . 0.0 110.269 179.279 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -43.51 109.93 0.17 Allowed 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.816 -179.296 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.98 -147.89 8.95 Favored Glycine 0 N--CA 1.486 1.989 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.417 -179.918 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 77' ' ' THR . . . . . 0.461 HG23 HG23 ' A' ' 95' ' ' THR . 0.0 OUTLIER -143.55 131.65 21.81 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.598 -0.841 . . . . 0.0 110.807 -179.898 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 78' ' ' TYR . . . . . 0.595 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -119.6 129.61 54.7 Favored 'General case' 0 N--CA 1.486 1.336 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.578 -179.942 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -101.3 121.21 41.48 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 119.424 -0.91 . . . . 0.0 111.827 -179.49 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 80' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 80' ' ' PHE . 1.7 p90 -131.48 166.34 21.55 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.816 -0.753 . . . . 0.0 110.009 178.161 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 29.6 p90 -170.29 -176.85 2.31 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.105 -1.038 . . . . 0.0 111.409 -178.355 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -102.21 130.75 48.96 Favored 'General case' 0 N--CA 1.482 1.154 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.301 179.16 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.55 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.9 OUTLIER -77.3 -44.64 2.68 Favored Pre-proline 0 N--CA 1.485 1.279 0 C-N-CA 119.328 -0.949 . . . . 0.0 112.713 -179.71 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 84' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 4.1 Cg_exo -65.57 -52.91 0.88 Allowed 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 120.914 1.076 . . . . 0.0 111.535 -179.096 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 85' ' ' HIS . . . . . 0.466 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.4 m80 -81.94 15.58 2.22 Favored 'General case' 0 C--N 1.302 -1.46 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.804 -179.874 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.65 -0.94 0.32 Allowed 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.107 -179.938 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 87' ' ' GLY . . . . . 0.466 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -95.15 -14.14 49.73 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.324 -1.417 . . . . 0.0 110.361 179.951 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.14 -51.89 4.82 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.596 179.925 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.26 24.75 0.2 Allowed Glycine 0 N--CA 1.488 2.166 0 C-N-CA 119.537 -1.316 . . . . 0.0 110.502 179.901 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.1 mtp -73.16 97.99 2.51 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.148 -1.021 . . . . 0.0 110.962 -179.95 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.3 ptpt -119.7 154.99 33.28 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.507 179.22 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 92' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.4 145.66 16.31 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.396 -1.383 . . . . 0.0 111.399 -178.764 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -152.2 143.78 23.49 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.486 -0.886 . . . . 0.0 111.062 179.636 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.499 ' O ' HG13 ' A' ' 94' ' ' VAL . 12.3 p -137.16 125.2 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.678 179.159 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.461 HG23 HG23 ' A' ' 77' ' ' THR . 46.2 m -102.56 99.18 9.17 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.549 179.408 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 40.3 t -79.69 147.84 6.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 C-N-CA 118.763 -1.175 . . . . 0.0 110.633 -178.843 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 116.285 -1.816 . . . . 0.0 110.75 -179.697 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 109.908 -0.405 . . . . 0.0 109.908 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -131.17 122.15 26.1 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.823 -0.751 . . . . 0.0 110.835 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.6 t -115.15 126.59 72.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 119.966 -0.694 . . . . 0.0 110.33 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 22.1 mtmt -101.72 116.15 32.1 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.918 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.481 HD11 ' HB3' ' A' ' 29' ' ' PHE . 12.0 mt -79.56 114.64 18.64 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.167 -1.013 . . . . 0.0 109.971 178.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.499 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 96.83 108.02 2.49 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.491 -1.338 . . . . 0.0 109.787 -179.097 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.0 p . . . . . 0 C--N 1.305 -1.349 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.934 -179.354 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.2 mt . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 120.438 0.161 . . . . 0.0 110.658 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.7 m -150.48 158.11 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 119.009 -1.076 . . . . 0.0 110.999 179.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.535 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 16.7 m-85 -78.8 111.96 15.45 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 177.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.0 m -114.4 107.62 51.06 Favored Pre-proline 0 N--CA 1.484 1.264 0 C-N-CA 119.421 -0.911 . . . . 0.0 112.226 -177.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.413 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.0 OUTLIER -67.64 176.58 25.44 Favored 'Cis proline' 0 C--N 1.362 1.275 0 C-N-CA 125.4 -0.667 . . . . 0.0 111.6 -0.555 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -92.49 -58.8 2.25 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.014 179.118 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.2 t -124.06 138.55 54.43 Favored 'General case' 0 N--CA 1.487 1.4 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.265 178.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.41 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 9.0 p90 -159.72 136.06 8.96 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 118.328 -1.349 . . . . 0.0 111.706 -178.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.424 HG23 ' H ' ' A' ' 20' ' ' THR . 0.8 OUTLIER -85.98 150.67 24.32 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.329 179.436 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.3 m -144.21 177.79 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.179 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -98.05 145.79 26.18 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.68 -0.808 . . . . 0.0 110.365 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.4 88.9 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.122 -1.031 . . . . 0.0 110.934 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 139.16 19.73 0.46 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -96.28 137.67 35.0 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.715 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 54.1 mttm -84.89 120.11 26.1 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.248 -0.981 . . . . 0.0 110.924 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.7 mt -109.27 110.88 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.038 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 30.3 p -106.2 116.92 32.77 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.379 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.481 ' HB3' HD11 ' A' ' 5' ' ' LEU . 94.2 m-85 -85.86 103.59 14.74 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.023 178.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.6 tttm -101.7 135.19 43.66 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.758 -0.777 . . . . 0.0 112.218 -177.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.471 ' N ' ' OD1' ' A' ' 31' ' ' ASN . 1.3 m-20 -76.71 126.24 30.64 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.935 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 0.9 OUTLIER -106.78 -32.62 7.88 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.086 -1.046 . . . . 0.0 113.136 -178.371 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 178.11 11.94 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.387 0 C-N-CA 119.052 -1.059 . . . . 0.0 111.729 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -124.88 49.68 0.9 Allowed Glycine 0 N--CA 1.5 2.931 0 C-N-CA 119.35 -1.405 . . . . 0.0 112.104 -178.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.596 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -91.06 161.31 35.63 Favored Pre-proline 0 N--CA 1.488 1.428 0 C-N-CA 118.35 -1.34 . . . . 0.0 110.291 178.805 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -78.17 142.42 69.6 Favored 'Cis proline' 0 C--O 1.215 -0.658 0 C-N-CA 124.004 -1.248 . . . . 0.0 111.825 -1.266 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.524 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 36.9 m-70 -107.26 162.38 13.95 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.596 -0.842 . . . . 0.0 111.016 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -144.6 137.76 26.94 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 119.607 -0.837 . . . . 0.0 109.852 179.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.4 mp -127.29 117.46 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.16 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.58 142.84 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.765 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.753 ' CD2' HD12 ' A' ' 55' ' ' ILE . 7.5 m-85 -95.08 117.74 30.7 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.738 -178.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.485 ' C ' ' H ' ' A' ' 44' ' ' ASP . 21.6 t0 -55.4 99.33 0.03 OUTLIER 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.374 179.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -64.01 5.26 0.25 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.446 -0.902 . . . . 0.0 111.392 -179.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.485 ' H ' ' C ' ' A' ' 42' ' ' ASP . 9.6 m-20 -99.78 -8.67 23.91 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.915 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -134.6 16.33 3.65 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.957 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -95.53 147.03 32.36 Favored Pre-proline 0 N--CA 1.49 1.529 0 N-CA-C 108.957 -0.756 . . . . 0.0 108.957 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -47.84 142.73 14.3 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.958 1.105 . . . . 0.0 111.799 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.2 70.64 1.63 Allowed 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.712 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.46 -37.75 0.12 Allowed Glycine 0 N--CA 1.488 2.102 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.077 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.418 ' O ' HG12 ' A' ' 50' ' ' VAL . 15.4 t -86.22 104.9 14.15 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.789 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -48.28 147.7 2.18 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.738 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -99.46 -5.81 28.73 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.918 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.07 -30.45 17.7 Favored 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.511 -0.876 . . . . 0.0 111.19 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 36.0 mttt -69.25 -29.91 67.92 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.148 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.753 HD12 ' CD2' ' A' ' 41' ' ' PHE . 1.1 pt -94.16 -37.52 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.748 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 57.7 m -64.01 159.62 19.68 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.537 -0.865 . . . . 0.0 111.253 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.611 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -139.66 75.67 31.15 Favored Pre-proline 0 N--CA 1.486 1.361 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.398 179.635 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -57.63 -21.76 48.62 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 121.262 1.308 . . . . 0.0 111.567 -179.078 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.21 95.67 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.021 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -42.71 163.11 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.799 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -150.09 111.64 4.48 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 118.862 -1.135 . . . . 0.0 111.878 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.463 ' H ' ' ND2' ' A' ' 62' ' ' ASN . 2.8 p30 -106.33 21.66 17.03 Favored 'General case' 0 N--CA 1.488 1.475 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.918 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -83.65 137.66 16.5 Favored Glycine 0 N--CA 1.494 2.53 0 C-N-CA 119.355 -1.403 . . . . 0.0 110.655 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -82.32 114.48 20.82 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.533 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.07 -13.67 66.62 Favored Glycine 0 N--CA 1.488 2.147 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.506 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.25 150.34 26.05 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.209 -0.996 . . . . 0.0 110.31 179.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.57 168.75 19.88 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 118.981 -1.087 . . . . 0.0 111.884 -179.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.611 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 29.3 t80 -135.29 129.88 34.24 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.555 179.228 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.96 152.86 21.01 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.306 -178.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.1 t -151.79 130.78 3.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 CA-C-N 115.105 -0.952 . . . . 0.0 108.844 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 20.6 m -129.86 93.93 3.62 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.652 -0.819 . . . . 0.0 111.226 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.436 ' CD1' HG11 ' A' ' 94' ' ' VAL . 13.7 mt -79.39 157.98 27.49 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.213 -0.995 . . . . 0.0 109.507 179.333 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 2.2 t -149.94 46.07 0.92 Allowed 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 118.793 -1.163 . . . . 0.0 111.649 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.404 ' O ' ' C ' ' A' ' 75' ' ' LYS . 5.6 tt0 -144.93 99.98 3.42 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 118.977 -1.089 . . . . 0.0 109.913 179.048 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.481 ' HD2' ' H ' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -39.45 112.48 0.26 Allowed 'General case' 0 N--CA 1.484 1.239 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.344 -179.124 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.76 -148.88 10.0 Favored Glycine 0 N--CA 1.484 1.849 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.004 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.96 132.34 25.09 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.922 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.562 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.2 m-85 -120.8 126.01 49.03 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.66 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.442 ' N ' ' CD ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -100.4 114.11 27.39 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.78 -179.361 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.594 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -125.02 169.74 11.83 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.09 178.686 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -171.25 -179.76 2.76 Favored 'General case' 0 C--N 1.297 -1.694 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.073 -179.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 2.1 t -106.39 115.31 29.99 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.504 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.563 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 tt0 -66.87 -40.38 29.77 Favored Pre-proline 0 C--N 1.3 -1.576 0 C-N-CA 119.379 -0.928 . . . . 0.0 112.724 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.563 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.4 Cg_endo -68.95 -47.69 1.12 Allowed 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 120.822 1.015 . . . . 0.0 112.03 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -87.87 12.15 13.84 Favored 'General case' 0 N--CA 1.487 1.423 0 C-N-CA 119.238 -0.985 . . . . 0.0 111.296 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.72 -24.4 61.42 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.771 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -62.24 -22.19 62.8 Favored Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.514 -1.327 . . . . 0.0 110.414 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.92 -31.83 14.8 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.621 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 117.21 30.22 1.96 Allowed Glycine 0 N--CA 1.495 2.611 0 C-N-CA 119.991 -1.1 . . . . 0.0 110.495 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.3 mtp -77.88 105.52 9.12 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.862 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.535 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 0.6 OUTLIER -127.61 166.89 17.19 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 119.956 -0.698 . . . . 0.0 110.777 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -147.83 148.44 19.98 Favored Glycine 0 N--CA 1.488 2.104 0 C-N-CA 119.018 -1.563 . . . . 0.0 111.286 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -153.63 141.64 20.28 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.625 179.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.463 HG13 ' O ' ' A' ' 94' ' ' VAL . 7.2 p -136.87 125.26 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.624 179.307 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 95.8 m -103.32 98.71 8.58 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.409 -0.916 . . . . 0.0 110.645 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 41.1 t -80.03 148.3 5.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.255 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 6.7 m-80 . . . . . 0 C--N 1.304 -1.41 0 CA-C-O 116.344 -1.789 . . . . 0.0 111.007 -179.554 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.105 0 CA-C-O 120.792 0.33 . . . . 0.0 110.197 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -130.19 121.46 26.27 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.54 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.8 t -112.87 122.02 66.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.682 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 60.8 mttt -94.53 116.61 28.98 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.761 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.434 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 8.5 mt -76.21 102.4 5.79 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 118.615 -1.234 . . . . 0.0 109.525 178.18 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 121.25 155.7 9.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.031 -1.627 . . . . 0.0 109.031 -178.204 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.2 p . . . . . 0 C--N 1.301 -1.528 0 C-N-CA 119.039 -1.064 . . . . 0.0 111.047 -179.395 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 80.1 mt . . . . . 0 N--CA 1.488 1.426 0 N-CA-C 110.382 -0.229 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 m -149.71 154.78 8.77 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 C-N-CA 118.74 -1.184 . . . . 0.0 111.072 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' A' ' 16' ' ' PRO . 17.2 m-85 -78.2 110.16 12.94 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.7 m -115.0 109.01 47.5 Favored Pre-proline 0 CA--C 1.562 1.41 0 C-N-CA 119.369 -0.933 . . . . 0.0 112.503 -177.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.421 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.9 Cg_endo -66.66 178.35 17.84 Favored 'Cis proline' 0 C--N 1.364 1.348 0 C-N-CA 125.27 -0.721 . . . . 0.0 111.484 -0.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.6 p -94.94 -60.43 1.69 Allowed 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.933 179.177 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.2 p -121.05 135.41 55.2 Favored 'General case' 0 N--CA 1.486 1.34 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.076 178.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.465 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 14.4 p90 -157.88 140.74 14.89 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 118.528 -1.269 . . . . 0.0 111.49 -178.729 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.447 HG23 ' H ' ' A' ' 20' ' ' THR . 0.5 OUTLIER -87.77 153.45 21.33 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.357 -0.937 . . . . 0.0 110.633 179.451 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.1 m -145.94 158.76 11.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.105 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.421 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -75.04 145.88 42.02 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.211 -0.996 . . . . 0.0 110.427 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.27 73.03 0.12 Allowed 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.459 -0.896 . . . . 0.0 110.9 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.438 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 160.98 11.15 0.04 OUTLIER Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.438 ' H ' ' H ' ' A' ' 24' ' ' GLY . 18.5 tt0 -98.81 157.14 16.49 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.913 -179.532 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.4 mmtp -95.48 134.2 38.6 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.33 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.9 mt -107.09 104.36 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 120.076 -0.649 . . . . 0.0 109.358 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 52.3 p -101.41 117.57 35.21 Favored 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 119.553 -0.859 . . . . 0.0 112.612 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -91.16 109.76 21.03 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.12 178.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 31.0 tttt -103.14 135.14 45.37 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.58 -178.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 1.0 OUTLIER -84.67 106.11 15.98 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.258 -0.977 . . . . 0.0 110.108 179.237 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.547 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 4.3 p-10 -93.36 -28.6 16.07 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.208 -0.997 . . . . 0.0 112.016 -178.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.547 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 175.44 133.57 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 118.55 -1.26 . . . . 0.0 111.371 -179.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 111.48 5.97 25.73 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.782 -1.199 . . . . 0.0 111.579 179.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.452 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -52.47 162.54 0.89 Allowed Pre-proline 0 N--CA 1.488 1.437 0 C-N-CA 118.188 -1.405 . . . . 0.0 109.744 179.814 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -78.76 161.62 88.95 Favored 'Cis proline' 0 C--O 1.212 -0.798 0 C-N-CA 124.38 -1.091 . . . . 0.0 112.636 -0.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -125.75 172.7 9.6 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.952 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.439 HD22 ' CG2' ' A' ' 40' ' ' VAL . 0.7 OUTLIER -153.49 117.53 4.81 Favored 'General case' 0 N--CA 1.492 1.67 0 C-N-CA 118.978 -1.089 . . . . 0.0 110.622 179.185 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.842 ' N ' HD12 ' A' ' 39' ' ' ILE . 2.4 mp -96.18 129.71 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.146 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.439 ' CG2' HD22 ' A' ' 38' ' ' ASN . 2.6 t -143.31 138.63 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 C-N-CA 119.679 -0.808 . . . . 0.0 110.427 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.7 ' CD2' HD12 ' A' ' 55' ' ' ILE . 9.1 m-85 -98.33 118.26 34.59 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.206 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.524 ' OD2' ' N ' ' A' ' 45' ' ' GLU . 11.2 t70 -53.1 120.4 5.86 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.348 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -73.57 0.47 12.51 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.433 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.404 ' N ' ' OD2' ' A' ' 42' ' ' ASP . 14.6 m-20 -107.99 4.2 24.92 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.813 -0.755 . . . . 0.0 111.135 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.524 ' N ' ' OD2' ' A' ' 42' ' ' ASP . 34.5 mt-10 -146.18 52.56 1.14 Allowed 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 119.486 -0.886 . . . . 0.0 110.835 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -137.03 148.36 62.52 Favored Pre-proline 0 N--CA 1.493 1.676 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -49.58 145.78 16.31 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 121.061 1.174 . . . . 0.0 111.678 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.89 81.92 2.8 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.709 -0.796 . . . . 0.0 111.025 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 161.54 -41.95 0.4 Allowed Glycine 0 N--CA 1.489 2.174 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.312 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 92.0 t -81.96 95.94 3.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.348 -0.941 . . . . 0.0 110.84 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -44.94 143.76 1.39 Allowed 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.969 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.54 -2.04 49.3 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.625 -0.83 . . . . 0.0 110.898 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -86.55 -35.13 19.7 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.98 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 30.7 mttt -68.75 -34.38 75.5 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.581 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.7 HD12 ' CD2' ' A' ' 41' ' ' PHE . 1.1 pt -89.94 -29.68 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 C-N-CA 118.938 -1.105 . . . . 0.0 111.062 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 7.6 m -58.95 -178.63 0.05 Allowed 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.928 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.614 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 61.2 mt-30 -146.38 73.19 13.02 Favored Pre-proline 0 N--CA 1.484 1.274 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.031 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -62.39 -4.52 5.5 Favored 'Trans proline' 0 C--N 1.321 -0.879 0 C-N-CA 121.094 1.196 . . . . 0.0 110.984 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 16.0 mt-10 -100.31 99.98 10.71 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.828 -0.749 . . . . 0.0 110.545 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -47.54 164.49 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.411 -0.916 . . . . 0.0 110.92 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.1 pp -142.32 135.95 29.21 Favored 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.96 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -135.46 42.41 2.7 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.664 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -102.5 128.28 9.49 Favored Glycine 0 N--CA 1.495 2.595 0 C-N-CA 119.584 -1.293 . . . . 0.0 110.532 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -78.06 108.22 11.19 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.628 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.51 -6.37 59.14 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.325 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -71.96 157.69 37.37 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.555 179.835 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 4.9 p -148.64 163.29 37.71 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.051 -1.059 . . . . 0.0 111.229 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.614 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 28.5 t80 -134.7 139.16 45.02 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.651 179.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.467 ' CD ' ' H ' ' A' ' 69' ' ' GLU . 1.7 mp0 -102.76 148.5 25.53 Favored 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 119.434 -0.907 . . . . 0.0 112.252 -178.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -142.82 126.05 14.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 115.124 -0.943 . . . . 0.0 108.748 179.208 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.0 m -117.47 112.82 21.15 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.61 -0.836 . . . . 0.0 112.039 -178.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 58.3 mt -95.88 161.7 13.89 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.47 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.557 ' O ' HG22 ' A' ' 73' ' ' THR . 87.9 m -150.57 42.61 0.81 Allowed 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 118.662 -1.215 . . . . 0.0 112.044 -179.033 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -147.9 102.97 3.45 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 118.658 -1.217 . . . . 0.0 110.33 179.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.472 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 11.5 pttt -43.97 120.2 2.0 Allowed 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.723 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.45 -147.01 10.58 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -143.25 128.85 19.16 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.405 -0.918 . . . . 0.0 111.248 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.562 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -115.73 136.87 52.64 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.422 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.412 ' N ' ' CD ' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -107.86 116.27 31.64 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.634 -0.826 . . . . 0.0 111.541 -179.348 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.489 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 2.4 p90 -130.26 166.8 19.58 Favored 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.082 178.485 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -170.46 -172.74 1.3 Allowed 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.682 -178.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -107.32 126.08 51.99 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.756 179.288 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.499 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.9 mt-10 -68.78 -47.11 33.18 Favored Pre-proline 0 C--N 1.305 -1.336 0 C-N-CA 119.593 -0.843 . . . . 0.0 112.599 -179.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.499 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.9 Cg_endo -64.72 -47.77 4.89 Favored 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 120.719 0.946 . . . . 0.0 111.746 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -90.84 19.88 5.21 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.808 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.44 -14.23 11.63 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.346 -0.942 . . . . 0.0 110.462 179.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -93.76 -12.47 56.75 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.151 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.01 -13.53 38.59 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.597 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 96.96 25.6 11.23 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.605 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.64 99.77 10.42 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.234 -0.987 . . . . 0.0 111.022 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -120.97 159.7 25.06 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.793 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.74 143.03 11.47 Favored Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.337 -1.411 . . . . 0.0 111.071 -179.049 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -150.68 144.74 25.39 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.35 179.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.494 HG13 ' O ' ' A' ' 94' ' ' VAL . 8.0 p -135.24 125.73 44.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.689 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 55.0 m -101.67 98.22 8.54 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.274 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 41.2 t -79.75 152.51 4.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 118.587 -1.245 . . . . 0.0 110.734 -178.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 116.283 -1.818 . . . . 0.0 110.826 -179.688 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.118 0 CA-C-O 120.78 0.324 . . . . 0.0 110.142 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . 0.439 ' OE1' ' O ' ' A' ' 28' ' ' THR . 3.1 mm-40 -140.19 121.0 14.43 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.618 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -108.72 120.54 60.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 C-N-CA 119.917 -0.713 . . . . 0.0 110.509 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.7 mttt -91.16 114.55 27.11 Favored 'General case' 0 C--N 1.299 -1.59 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.992 -179.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.0 mt -74.51 113.84 12.22 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.239 178.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.47 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 99.28 124.13 5.12 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.44 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 16.6 p . . . . . 0 C--N 1.302 -1.46 0 C-N-CA 119.324 -0.951 . . . . 0.0 110.428 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.3 mt . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 120.402 0.144 . . . . 0.0 110.983 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.4 m -144.25 155.86 15.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 C-N-CA 119.098 -1.041 . . . . 0.0 110.674 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.401 ' O ' ' C ' ' A' ' 16' ' ' PRO . 16.6 m-85 -77.36 112.98 14.67 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 177.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.8 m -114.89 108.46 48.66 Favored Pre-proline 0 CA--C 1.558 1.283 0 C-N-CA 119.219 -0.992 . . . . 0.0 112.007 -177.348 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.401 ' C ' ' O ' ' A' ' 14' ' ' PHE . 3.2 Cg_exo -67.5 170.71 46.55 Favored 'Cis proline' 0 C--N 1.362 1.269 0 C-N-CA 125.321 -0.7 . . . . 0.0 111.597 -0.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.5 t -90.23 -64.51 1.12 Allowed 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.543 178.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.35 139.58 50.25 Favored 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.199 178.69 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.401 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 9.5 p90 -167.95 139.45 2.91 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 118.468 -1.293 . . . . 0.0 111.424 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.443 ' H ' HG23 ' A' ' 20' ' ' THR . 0.6 OUTLIER -85.06 159.12 20.26 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.623 -0.831 . . . . 0.0 111.411 -179.591 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 25.9 m -146.69 -177.75 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.059 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.87 148.95 21.76 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.438 -0.905 . . . . 0.0 111.015 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.39 68.48 0.54 Allowed 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.042 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 159.21 14.03 0.04 OUTLIER Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -97.36 155.95 16.67 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.907 -0.717 . . . . 0.0 111.038 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 13.7 mttp -95.44 138.53 33.0 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.76 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.9 mt -117.65 127.58 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.443 179.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.439 ' O ' ' OE1' ' A' ' 2' ' ' GLU . 7.6 p -125.51 119.07 27.18 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.544 -0.862 . . . . 0.0 112.17 -178.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -84.91 110.37 18.81 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.489 -0.885 . . . . 0.0 109.024 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 50.0 tttp -101.45 139.13 37.54 Favored 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.158 -178.272 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.944 ' ND2' HD11 ' A' ' 61' ' ' LEU . 2.5 m120 -86.45 112.57 21.62 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.47 179.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.677 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.0 OUTLIER -95.66 -30.8 13.57 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 119.224 -0.991 . . . . 0.0 111.543 -179.227 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.677 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 164.69 118.08 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 119.349 -0.94 . . . . 0.0 111.182 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 138.6 -1.03 2.57 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.957 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.409 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -47.69 164.66 0.24 Allowed Pre-proline 0 C--N 1.307 -1.281 0 C-N-CA 118.839 -1.144 . . . . 0.0 110.137 -179.835 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_endo -75.99 138.9 57.6 Favored 'Cis proline' 0 C--O 1.214 -0.722 0 C-N-CA 124.292 -1.128 . . . . 0.0 112.633 -0.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.5 m-70 -110.3 156.4 20.77 Favored 'General case' 0 N--CA 1.485 1.295 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.205 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.429 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 6.2 t30 -148.42 116.23 6.35 Favored 'General case' 0 C--N 1.3 -1.58 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.136 179.251 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.442 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.7 mp -96.64 137.22 25.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.652 -178.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.429 ' CG2' ' ND2' ' A' ' 38' ' ' ASN . 1.5 t -146.54 149.42 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.987 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -107.58 118.28 36.32 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.712 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.516 ' OD2' ' N ' ' A' ' 45' ' ' GLU . 1.6 t70 -55.58 119.32 5.5 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 119.576 -0.849 . . . . 0.0 110.28 179.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -75.5 14.21 0.65 Allowed 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 119.393 -0.923 . . . . 0.0 111.55 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.446 ' H ' ' CG ' ' A' ' 42' ' ' ASP . 4.0 m-20 -115.39 2.1 13.86 Favored 'General case' 0 N--CA 1.495 1.779 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.049 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.548 ' OE1' ' NZ ' ' A' ' 79' ' ' LYS . 11.8 mm-40 -140.6 19.3 2.36 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 119.657 -0.817 . . . . 0.0 110.446 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -107.69 147.12 34.76 Favored Pre-proline 0 N--CA 1.488 1.471 0 CA-C-N 115.23 -0.895 . . . . 0.0 108.856 179.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -48.6 145.24 12.76 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 120.804 1.003 . . . . 0.0 111.718 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.35 50.56 0.79 Allowed 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.935 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -160.6 -31.11 0.02 OUTLIER Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 86.3 t -96.18 90.69 2.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.745 -0.782 . . . . 0.0 110.638 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -45.95 139.89 4.05 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.888 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.08 -26.35 36.33 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.62 -0.832 . . . . 0.0 111.109 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -67.48 -19.89 65.39 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.456 -0.898 . . . . 0.0 110.93 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -78.03 -38.01 45.62 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.876 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.7 pt -94.26 -26.41 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.306 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.0 m -72.35 155.89 39.67 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.431 -0.908 . . . . 0.0 111.297 -179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.621 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.1 OUTLIER -137.95 75.98 40.8 Favored Pre-proline 0 C--N 1.303 -1.432 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.972 179.484 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.412 ' O ' ' OD1' ' A' ' 38' ' ' ASN . 5.2 Cg_exo -56.5 -29.07 76.82 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 121.234 1.289 . . . . 0.0 111.496 -178.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -52.96 103.67 0.08 Allowed 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 118.813 -1.155 . . . . 0.0 109.844 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 46.8 m-85 -42.63 161.56 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.69 -0.804 . . . . 0.0 111.105 -179.388 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.944 HD11 ' ND2' ' A' ' 31' ' ' ASN . 0.3 OUTLIER -143.65 148.08 35.27 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.542 -0.863 . . . . 0.0 110.239 -179.644 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.768 ' H ' HD22 ' A' ' 62' ' ' ASN . 0.0 OUTLIER -148.2 -12.56 0.36 Allowed 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.265 -179.83 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.695 ' N ' HD22 ' A' ' 62' ' ' ASN . . . -48.74 115.82 2.84 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.203 -1.475 . . . . 0.0 110.403 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.51 119.92 10.1 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.962 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.85 -21.29 27.62 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.639 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -58.05 153.76 13.98 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.048 -1.061 . . . . 0.0 110.326 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -140.68 170.01 16.56 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 119.329 -0.948 . . . . 0.0 111.67 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.621 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 22.8 t80 -130.96 130.98 44.11 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.284 179.361 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -93.33 150.76 20.23 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 119.081 -1.048 . . . . 0.0 112.716 -178.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -151.59 136.52 10.28 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-N 115.127 -0.942 . . . . 0.0 108.933 179.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.3 m -127.31 104.65 8.05 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.521 -0.871 . . . . 0.0 111.503 -179.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.47 ' CD1' HG11 ' A' ' 94' ' ' VAL . 49.6 mt -88.17 155.14 19.92 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.001 179.094 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 4.8 p -150.92 47.32 0.85 Allowed 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.935 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.429 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.5 mm-40 -144.18 108.48 4.81 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.099 -1.041 . . . . 0.0 110.722 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.561 ' H ' ' HZ3' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -49.79 114.33 1.05 Allowed 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 119.372 -0.931 . . . . 0.0 110.854 -179.572 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 165.28 -137.74 4.86 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.183 -1.484 . . . . 0.0 110.235 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -149.46 143.0 25.4 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.286 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.563 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -127.34 123.74 37.02 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.37 179.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.548 ' NZ ' ' OE1' ' A' ' 45' ' ' GLU . 1.2 mptm? -95.43 119.67 34.34 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.728 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.551 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.2 p90 -130.31 171.91 12.4 Favored 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 119.571 -0.852 . . . . 0.0 109.978 177.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 42.5 p90 -171.83 -175.33 1.5 Allowed 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.922 -178.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . 0.41 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.8 t -108.82 117.18 33.51 Favored 'General case' 0 C--N 1.31 -1.112 0 C-N-CA 119.856 -0.738 . . . . 0.0 109.713 178.206 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.561 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.4 tt0 -68.3 -39.59 17.0 Favored Pre-proline 0 C--N 1.303 -1.455 0 C-N-CA 119.431 -0.907 . . . . 0.0 112.89 -178.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.561 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.0 Cg_endo -68.99 -43.78 3.07 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 120.638 0.892 . . . . 0.0 111.699 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . 0.425 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.4 m80 -94.15 14.83 18.83 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.306 -0.958 . . . . 0.0 111.173 -179.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.41 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -65.52 0.27 1.65 Allowed 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.089 -1.044 . . . . 0.0 110.687 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -86.92 -18.05 58.62 Favored Glycine 0 N--CA 1.49 2.238 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.215 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -97.97 -19.99 17.7 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 119.615 -0.834 . . . . 0.0 110.675 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.73 22.0 6.2 Favored Glycine 0 N--CA 1.497 2.74 0 C-N-CA 119.877 -1.154 . . . . 0.0 110.624 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 9.6 ttt -71.22 108.72 4.85 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.494 -0.882 . . . . 0.0 110.832 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.406 ' CG ' ' N ' ' A' ' 92' ' ' GLY . 30.9 ttpt -137.13 159.91 40.53 Favored 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 119.754 -0.778 . . . . 0.0 111.299 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' A' ' 91' ' ' LYS . . . -140.84 156.97 25.71 Favored Glycine 0 N--CA 1.497 2.757 0 C-N-CA 119.688 -1.244 . . . . 0.0 111.559 -178.484 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -157.15 145.94 19.82 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 120.027 -0.669 . . . . 0.0 110.639 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.494 HG13 ' O ' ' A' ' 94' ' ' VAL . 8.8 p -139.94 124.91 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 C-N-CA 119.106 -1.038 . . . . 0.0 110.937 179.386 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 34.0 m -102.68 103.17 13.41 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.543 -0.863 . . . . 0.0 110.582 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.534 ' C ' HD22 ' A' ' 97' ' ' ASN . 26.2 t -85.71 146.31 6.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 118.866 -1.133 . . . . 0.0 110.622 -178.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.534 HD22 ' C ' ' A' ' 96' ' ' VAL . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 116.375 -1.774 . . . . 0.0 110.661 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.17 0 CA-C-O 120.821 0.343 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -96.73 119.89 36.05 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.702 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 73.4 t -108.31 122.38 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.07 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 76.9 mttt -88.31 111.46 21.73 Favored 'General case' 0 C--N 1.297 -1.706 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.865 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 11.6 mt -73.91 110.08 7.92 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 118.539 -1.264 . . . . 0.0 109.763 178.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.54 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 98.86 126.51 5.64 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -179.109 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 24.5 p . . . . . 0 C--N 1.305 -1.334 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.581 179.907 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.0 mt . . . . . 0 N--CA 1.487 1.419 0 CA-C-O 120.644 0.259 . . . . 0.0 110.756 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 23.6 m -150.83 157.91 5.33 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.65 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.533 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 35.9 m-85 -78.15 113.63 16.28 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 177.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 18.5 m -115.54 109.77 45.53 Favored Pre-proline 0 CA--C 1.56 1.355 0 C-N-CA 119.515 -0.874 . . . . 0.0 112.187 -177.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -65.98 170.58 39.44 Favored 'Cis proline' 0 C--N 1.361 1.232 0 C-N-CA 125.123 -0.782 . . . . 0.0 111.567 -0.466 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.03 -68.64 0.79 Allowed 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.836 178.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.6 m -110.12 132.92 53.73 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.652 178.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 36.0 p90 -162.15 141.49 9.59 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 118.681 -1.208 . . . . 0.0 111.323 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.439 HG23 ' H ' ' A' ' 20' ' ' THR . 0.2 OUTLIER -85.23 160.28 19.91 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.545 -0.862 . . . . 0.0 111.3 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.4 m -149.29 179.11 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.645 179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -96.0 148.29 22.81 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 119.476 -0.89 . . . . 0.0 110.931 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.51 ' HB2' ' OXT' ' A' ' 97' ' ' ASN . . . -68.38 71.1 0.18 Allowed 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.229 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.418 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 157.52 16.19 0.04 OUTLIER Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.418 ' H ' ' H ' ' A' ' 24' ' ' GLY . 23.0 tt0 -102.8 154.89 18.74 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.682 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.3 mtpt -95.33 141.18 29.2 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.419 -0.912 . . . . 0.0 111.386 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.5 mt -119.78 114.81 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.435 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.4 p -111.41 120.97 43.96 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.53 -0.868 . . . . 0.0 112.616 -178.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -85.57 111.72 20.29 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.876 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.7 tttp -102.89 138.77 39.32 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 119.575 -0.85 . . . . 0.0 111.455 -178.078 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.544 HD21 HD13 ' A' ' 61' ' ' LEU . 77.3 m-20 -80.53 110.54 16.1 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.805 179.678 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.58 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 2.0 t30 -98.34 -31.23 12.15 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.225 -0.99 . . . . 0.0 111.673 -179.318 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.58 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.52 128.19 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.383 -0.927 . . . . 0.0 111.214 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 119.5 11.08 7.48 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.789 -1.196 . . . . 0.0 111.355 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.429 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -60.62 163.44 9.15 Favored Pre-proline 0 N--CA 1.484 1.265 0 C-N-CA 118.391 -1.324 . . . . 0.0 110.042 179.819 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -76.92 146.33 83.6 Favored 'Cis proline' 0 C--O 1.217 -0.564 0 C-N-CA 124.145 -1.189 . . . . 0.0 112.636 -0.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 35.3 m-70 -110.67 -179.66 3.82 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.119 179.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -155.67 142.6 19.02 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.015 179.153 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 mt -125.2 121.78 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.247 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.0 t -144.8 143.86 22.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.149 179.395 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -96.32 135.99 37.41 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.877 -179.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.51 ' C ' ' H ' ' A' ' 44' ' ' ASP . 7.8 t0 -71.95 111.24 7.04 Favored 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.671 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -71.4 35.22 0.05 Allowed 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 119.526 -0.869 . . . . 0.0 110.858 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.51 ' H ' ' C ' ' A' ' 42' ' ' ASP . 13.6 m-20 -111.34 -15.65 13.55 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 120.092 -0.643 . . . . 0.0 111.364 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -145.81 -5.39 0.63 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 118.261 -1.376 . . . . 0.0 112.464 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -52.51 142.31 31.45 Favored Pre-proline 0 C--N 1.285 -2.216 0 C-N-CA 118.628 -1.229 . . . . 0.0 108.112 179.248 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -49.09 148.03 10.2 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 120.895 1.063 . . . . 0.0 112.236 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.25 64.55 2.06 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.722 -0.791 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.58 -39.48 0.06 OUTLIER Glycine 0 N--CA 1.488 2.147 0 C-N-CA 119.57 -1.3 . . . . 0.0 109.863 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 98.8 t -92.16 97.1 6.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.336 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -44.61 162.33 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.447 -0.901 . . . . 0.0 111.155 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -102.91 -29.01 11.69 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.919 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -78.97 -14.15 59.38 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.146 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 1.8 mptp? -81.9 -37.69 26.47 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.064 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -90.87 -17.93 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 C-N-CA 119.199 -1.0 . . . . 0.0 111.019 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 73.6 m -76.55 -177.44 4.19 Favored 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.256 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.638 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -159.96 78.55 2.67 Favored Pre-proline 0 C--N 1.304 -1.405 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.788 179.635 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -60.56 0.99 0.59 Allowed 'Trans proline' 0 C--O 1.213 -0.747 0 C-N-CA 121.372 1.381 . . . . 0.0 112.216 -178.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.434 ' H ' ' C ' ' A' ' 57' ' ' GLN . 6.9 tt0 -82.9 100.44 10.39 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 118.878 -1.129 . . . . 0.0 110.249 179.387 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.43 ' O ' ' O ' ' A' ' 59' ' ' GLU . 43.9 m-85 -41.92 164.79 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.932 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.569 ' O ' HD12 ' A' ' 61' ' ' LEU . 3.0 pp -147.3 124.47 11.47 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.103 -1.039 . . . . 0.0 111.037 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.585 ' ND2' ' N ' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -120.8 32.55 5.93 Favored 'General case' 0 N--CA 1.496 1.875 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.706 -179.963 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -97.02 120.87 6.86 Favored Glycine 0 N--CA 1.494 2.56 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.8 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -68.67 118.5 11.74 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.544 -0.862 . . . . 0.0 110.774 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.03 -19.75 40.48 Favored Glycine 0 N--CA 1.488 2.159 0 C-N-CA 119.419 -1.372 . . . . 0.0 110.374 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.466 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 34.8 tt0 -56.99 153.7 10.84 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.22 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -144.88 169.37 18.19 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.212 -0.995 . . . . 0.0 111.579 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.638 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 29.2 t80 -134.73 139.06 44.9 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.141 178.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.542 ' CD ' ' H ' ' A' ' 69' ' ' GLU . 1.3 mp0 -100.32 148.24 24.9 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.181 -1.008 . . . . 0.0 112.755 -178.046 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.3 t -145.74 131.31 13.18 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 114.924 -1.035 . . . . 0.0 108.721 179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.1 m -123.2 113.69 19.28 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.905 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 46.2 mt -98.77 159.12 15.17 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.526 178.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.95 34.45 0.59 Allowed 'General case' 0 C--N 1.297 -1.702 0 C-N-CA 118.824 -1.151 . . . . 0.0 111.64 -178.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -137.87 102.38 4.7 Favored 'General case' 0 N--CA 1.492 1.654 0 C-N-CA 119.092 -1.043 . . . . 0.0 110.624 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.431 ' CG ' ' O ' ' A' ' 75' ' ' LYS . 11.2 pttm -43.57 114.59 0.66 Allowed 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.884 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.18 -145.33 7.78 Favored Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.487 -1.34 . . . . 0.0 110.129 -179.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.06 128.93 20.61 Favored 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 119.303 -0.959 . . . . 0.0 111.557 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.578 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -121.66 138.85 54.17 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 115.242 -0.89 . . . . 0.0 108.922 179.303 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 12.4 mttp -111.19 127.77 55.7 Favored 'General case' 0 N--CA 1.493 1.689 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.767 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.541 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.6 OUTLIER -129.05 159.81 34.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.048 177.753 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -167.93 178.44 5.16 Favored 'General case' 0 C--N 1.286 -2.171 0 C-N-CA 119.621 -0.832 . . . . 0.0 110.593 -178.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -104.4 131.77 51.39 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.27 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.496 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.6 mt-10 -71.48 -46.22 13.26 Favored Pre-proline 0 C--N 1.306 -1.308 0 C-N-CA 119.364 -0.934 . . . . 0.0 112.843 -179.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.0 Cg_endo -67.01 -45.1 4.33 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 120.902 1.068 . . . . 0.0 111.87 -179.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -93.52 22.81 5.04 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.886 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.423 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -68.5 -13.67 62.48 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.739 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -87.27 -12.3 67.88 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.261 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.54 -12.16 30.21 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.406 -0.918 . . . . 0.0 110.819 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.16 10.79 38.44 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.743 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -66.68 101.6 0.82 Allowed 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.364 -0.935 . . . . 0.0 111.081 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.533 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 18.4 mttp -129.11 173.18 10.7 Favored 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.349 -179.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -155.58 152.09 23.59 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.333 -1.413 . . . . 0.0 111.444 -178.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -155.75 144.95 20.76 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.789 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.499 HG13 ' O ' ' A' ' 94' ' ' VAL . 7.4 p -136.46 124.33 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.809 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 68.6 m -100.73 97.92 8.52 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.254 179.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.7 t -79.53 151.9 4.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 119.097 -1.041 . . . . 0.0 110.622 -178.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.51 ' OXT' ' HB2' ' A' ' 23' ' ' ALA . 10.8 m120 . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 116.319 -1.8 . . . . 0.0 110.783 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.087 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -134.31 118.37 17.45 Favored 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.685 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.2 t -102.76 123.51 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 C-N-CA 119.713 -0.795 . . . . 0.0 110.51 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.5 mmmm -95.42 117.55 30.56 Favored 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.111 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 3.6 mt -86.52 109.85 19.38 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.012 -1.075 . . . . 0.0 110.013 178.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.433 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 101.42 93.56 2.19 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.844 -1.17 . . . . 0.0 110.214 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.6 p . . . . . 0 C--N 1.307 -1.256 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.932 -179.755 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt . . . . . 0 N--CA 1.485 1.296 0 N-CA-C 110.628 -0.138 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.7 m -150.4 158.39 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 118.624 -1.23 . . . . 0.0 111.57 179.399 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.447 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 18.2 m-85 -78.84 110.45 14.04 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 177.274 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 38.7 m -116.35 108.48 45.51 Favored Pre-proline 0 C--N 1.304 -1.394 0 C-N-CA 119.54 -0.864 . . . . 0.0 112.08 -177.382 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -66.0 175.0 24.47 Favored 'Cis proline' 0 C--N 1.357 0.98 0 C-N-CA 125.312 -0.703 . . . . 0.0 111.8 -0.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 t -95.71 -64.96 1.01 Allowed 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.706 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 81.4 p -118.63 128.3 54.41 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.958 178.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.476 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 12.6 p90 -156.23 145.68 20.8 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 118.477 -1.289 . . . . 0.0 111.255 -178.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.423 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -87.46 158.67 18.91 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 119.376 -0.93 . . . . 0.0 111.278 -179.856 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.0 m -147.39 169.18 4.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.569 179.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -85.83 147.36 26.33 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.664 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.99 73.02 0.18 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.309 -179.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.412 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 154.47 15.83 0.05 OUTLIER Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.718 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.412 ' H ' ' H ' ' A' ' 24' ' ' GLY . 24.5 tt0 -98.8 154.82 17.72 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.667 -0.813 . . . . 0.0 110.983 -179.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 12.7 mttm -95.43 136.92 35.19 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.549 -0.86 . . . . 0.0 111.136 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 85.6 mt -115.19 104.92 17.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.611 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 26.7 p -99.98 114.65 28.07 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.532 -0.867 . . . . 0.0 112.215 -178.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -85.07 127.74 34.35 Favored 'General case' 0 C--N 1.309 -1.188 0 C-N-CA 119.277 -0.969 . . . . 0.0 109.241 178.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.7 tttm -124.41 131.49 53.5 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 119.892 -0.723 . . . . 0.0 111.341 -179.059 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.712 HD21 ' H ' ' A' ' 66' ' ' GLU . 31.3 p-10 -90.15 127.26 36.06 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.355 -0.938 . . . . 0.0 109.792 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.523 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 2.6 p-10 -127.65 -6.4 5.73 Favored 'General case' 0 N--CA 1.495 1.787 0 C-N-CA 118.939 -1.104 . . . . 0.0 112.871 -178.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.523 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 177.7 90.74 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 117.982 -1.487 . . . . 0.0 112.184 179.611 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 135.73 28.83 0.38 Allowed Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.455 -1.355 . . . . 0.0 111.114 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.596 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -75.95 162.29 72.35 Favored Pre-proline 0 N--CA 1.483 1.191 0 C-N-CA 118.297 -1.361 . . . . 0.0 109.829 179.627 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -79.88 148.55 79.37 Favored 'Cis proline' 0 C--O 1.211 -0.853 0 C-N-CA 124.185 -1.173 . . . . 0.0 112.531 -0.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -110.64 170.96 7.75 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.914 -0.715 . . . . 0.0 110.162 178.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.432 ' OD1' ' CD2' ' A' ' 60' ' ' TYR . 1.0 OUTLIER -149.46 151.87 34.7 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.193 -1.003 . . . . 0.0 110.646 179.525 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.4 mt -132.74 114.51 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 C-N-CA 119.771 -0.772 . . . . 0.0 111.019 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.0 t -131.14 141.97 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.732 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -100.02 120.12 39.33 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 119.278 -0.969 . . . . 0.0 112.085 -179.109 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.512 ' C ' ' H ' ' A' ' 44' ' ' ASP . 1.6 t0 -65.77 114.42 5.03 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.39 -0.924 . . . . 0.0 109.709 178.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.35 15.1 0.06 Allowed 'General case' 0 N--CA 1.491 1.609 0 C-N-CA 119.274 -0.97 . . . . 0.0 111.592 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.512 ' H ' ' C ' ' A' ' 42' ' ' ASP . 3.0 m-20 -101.86 -2.79 29.14 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.224 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -143.1 14.64 1.87 Allowed 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.213 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -96.83 145.51 29.71 Favored Pre-proline 0 C--N 1.299 -1.599 0 C-N-CA 119.868 -0.733 . . . . 0.0 109.107 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -52.9 154.1 13.72 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 120.785 0.99 . . . . 0.0 111.63 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.53 44.08 0.78 Allowed 'General case' 0 C--N 1.307 -1.278 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.584 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -147.68 -38.39 0.04 OUTLIER Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 86.9 t -98.93 94.05 3.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 C-N-CA 119.775 -0.77 . . . . 0.0 110.339 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -44.57 155.36 0.1 Allowed 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.955 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -93.89 -11.66 30.59 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.177 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -89.49 -9.25 50.75 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.92 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 3.0 mmpt? -88.03 -28.62 21.27 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.402 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -105.49 -5.51 9.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.739 -179.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.0 m -74.23 171.53 13.45 Favored 'General case' 0 C--N 1.308 -1.218 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.355 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.617 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 56.3 mt-30 -123.95 80.04 57.38 Favored Pre-proline 0 N--CA 1.49 1.536 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.35 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -61.41 -16.11 45.22 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 120.722 0.948 . . . . 0.0 110.852 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -100.49 119.73 38.94 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.81 -0.756 . . . . 0.0 110.679 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.432 ' CD2' ' OD1' ' A' ' 38' ' ' ASN . 38.4 m-85 -69.04 174.98 4.03 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.839 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.4 pp -144.38 123.31 12.75 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.221 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -116.13 -14.63 11.15 Favored 'General case' 0 N--CA 1.501 2.112 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.184 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.508 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . -52.07 137.5 32.63 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.036 -1.554 . . . . 0.0 110.633 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.64 106.37 5.37 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.661 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 97.61 12.64 46.94 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.519 -1.325 . . . . 0.0 110.004 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.712 ' H ' HD21 ' A' ' 31' ' ' ASN . 1.9 mm-40 -66.02 158.37 28.47 Favored 'General case' 0 N--CA 1.484 1.242 0 C-N-CA 119.229 -0.989 . . . . 0.0 110.244 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.4 p -147.48 160.01 43.08 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 118.805 -1.158 . . . . 0.0 111.979 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.617 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 42.9 t80 -135.8 178.07 7.34 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.371 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.586 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 8.4 mt-10 -140.62 149.74 42.7 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 118.916 -1.113 . . . . 0.0 111.929 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -150.07 132.7 6.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-N 115.322 -0.853 . . . . 0.0 109.218 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.3 m -127.21 106.28 9.14 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.424 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.523 ' CD1' HG11 ' A' ' 94' ' ' VAL . 30.3 mt -91.79 159.72 15.67 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.249 -0.98 . . . . 0.0 110.117 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 6.4 p -150.63 46.36 0.87 Allowed 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.098 -1.041 . . . . 0.0 111.544 -179.354 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.406 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 2.0 mm-40 -143.84 101.6 3.77 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 118.995 -1.082 . . . . 0.0 110.565 179.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 19.5 tttm -43.96 108.03 0.1 Allowed 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.657 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.71 -143.71 6.76 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.193 -1.479 . . . . 0.0 110.202 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.458 HG23 HG23 ' A' ' 95' ' ' THR . 0.0 OUTLIER -145.03 133.17 21.5 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.918 179.959 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.58 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.3 m-85 -119.62 157.35 28.61 Favored 'General case' 0 N--CA 1.485 1.29 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.134 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.1 mmtm -124.62 123.81 40.86 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.545 -0.862 . . . . 0.0 112.224 -179.115 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.0 OUTLIER -135.25 163.89 28.96 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.099 178.408 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -169.49 179.59 3.78 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 119.165 -1.014 . . . . 0.0 111.223 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -102.17 116.87 33.57 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.778 -0.769 . . . . 0.0 109.651 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.58 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 7.0 tt0 -71.99 -36.08 3.96 Favored Pre-proline 0 C--N 1.304 -1.374 0 C-N-CA 118.941 -1.104 . . . . 0.0 112.901 -179.223 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.58 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -70.2 -52.48 0.29 Allowed 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 120.429 0.753 . . . . 0.0 111.144 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . 0.493 ' C ' ' H ' ' A' ' 87' ' ' GLY . 35.1 m170 -82.14 13.91 3.17 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.829 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.25 -6.14 0.14 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.659 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.493 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -80.55 -27.6 50.73 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.575 -1.298 . . . . 0.0 110.327 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.73 -32.56 23.43 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.4 -0.92 . . . . 0.0 110.392 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 114.94 23.23 4.69 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.926 -1.131 . . . . 0.0 110.903 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 28.6 mtp -65.14 107.68 1.63 Allowed 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.869 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.447 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 17.4 pttp -124.97 159.0 32.26 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 119.975 -0.69 . . . . 0.0 110.461 179.501 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.86 145.6 15.13 Favored Glycine 0 N--CA 1.497 2.729 0 C-N-CA 119.053 -1.546 . . . . 0.0 111.742 -178.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 51.3 tt0 -150.8 144.7 25.25 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.317 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.523 HG11 ' CD1' ' A' ' 72' ' ' LEU . 11.2 p -136.99 124.6 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 C-N-CA 119.121 -1.031 . . . . 0.0 111.179 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.458 HG23 HG23 ' A' ' 77' ' ' THR . 41.4 m -100.61 99.51 10.09 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.672 179.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.7 t -79.79 146.23 8.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.374 -179.067 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.486 1.346 0 CA-C-O 116.412 -1.756 . . . . 0.0 110.999 -179.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.43 ' HB3' HG13 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.893 0.377 . . . . 0.0 110.077 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -97.32 122.06 39.92 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.809 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 43.9 t -107.7 121.56 60.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.149 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 45.6 mtpt -92.05 117.36 29.76 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.157 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.404 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 16.8 mt -78.15 111.71 14.36 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.558 179.665 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.554 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 97.33 120.45 4.02 Favored Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.789 -1.196 . . . . 0.0 110.227 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 18.3 p . . . . . 0 C--N 1.301 -1.5 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.609 179.669 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.3 mt . . . . . 0 N--CA 1.483 1.182 0 CA-C-O 120.525 0.202 . . . . 0.0 110.668 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.4 m -150.89 158.39 4.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 C-N-CA 118.918 -1.113 . . . . 0.0 110.872 179.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.415 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 58.0 m-85 -78.75 112.83 16.28 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 177.093 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 53.8 m -115.0 110.9 45.51 Favored Pre-proline 0 N--CA 1.485 1.316 0 C-N-CA 119.315 -0.954 . . . . 0.0 112.431 -177.089 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -65.82 170.95 37.19 Favored 'Cis proline' 0 C--N 1.362 1.284 0 C-N-CA 125.228 -0.738 . . . . 0.0 111.51 -0.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.0 p -94.86 -67.95 0.83 Allowed 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.055 179.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.67 137.32 47.66 Favored 'General case' 0 N--CA 1.486 1.326 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.672 179.198 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -163.57 134.9 4.75 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 118.456 -1.298 . . . . 0.0 111.658 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.445 HG23 ' H ' ' A' ' 20' ' ' THR . 0.3 OUTLIER -85.54 152.88 22.82 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.237 -179.957 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -144.84 173.78 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.677 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.518 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -94.1 139.22 31.25 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.452 -0.899 . . . . 0.0 110.357 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.19 77.79 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.319 -0.953 . . . . 0.0 110.888 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 158.12 13.83 0.04 OUTLIER Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -104.05 149.69 24.96 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 120.102 -0.639 . . . . 0.0 110.767 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.486 ' C ' HD12 ' A' ' 27' ' ' ILE . 78.0 mttt -94.91 137.56 33.82 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.105 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.486 HD12 ' C ' ' A' ' 26' ' ' LYS . 1.5 mp -115.9 150.47 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.08 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 68.5 p -141.75 121.89 13.82 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 118.92 -1.112 . . . . 0.0 112.1 -179.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -87.18 120.93 28.97 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.373 -0.931 . . . . 0.0 108.895 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.5 ttmm -110.99 136.81 49.43 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.669 -0.812 . . . . 0.0 111.742 -178.442 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.631 ' ND2' ' CD1' ' A' ' 35' ' ' PHE . 19.2 t30 -80.42 104.27 10.85 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 115.109 -0.95 . . . . 0.0 109.723 179.146 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.554 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 1.2 t30 -101.27 -32.03 10.7 Favored 'General case' 0 N--CA 1.491 1.575 0 C-N-CA 118.838 -1.145 . . . . 0.0 112.389 -178.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 177.27 143.06 0.09 Allowed 'General case' 0 N--CA 1.502 2.134 0 C-N-CA 119.503 -0.879 . . . . 0.0 111.166 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 100.89 8.54 48.01 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 119.338 -1.411 . . . . 0.0 112.299 178.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.631 ' CD1' ' ND2' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -55.45 162.88 2.06 Favored Pre-proline 0 C--N 1.308 -1.229 0 C-N-CA 117.763 -1.575 . . . . 0.0 109.478 179.569 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_endo -76.67 140.76 67.11 Favored 'Cis proline' 0 C--O 1.215 -0.64 0 C-N-CA 124.285 -1.131 . . . . 0.0 112.521 -0.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.404 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 34.3 m-70 -109.91 163.46 13.53 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.801 179.129 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.586 HD22 ' H ' ' A' ' 39' ' ' ILE . 1.6 t-20 -148.12 139.79 23.77 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.682 179.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.586 ' H ' HD22 ' A' ' 38' ' ' ASN . 2.7 mp -116.45 118.01 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 120.046 -0.662 . . . . 0.0 111.045 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.484 HG12 ' N ' ' A' ' 41' ' ' PHE . 28.3 t -129.8 162.37 37.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.899 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.484 ' N ' HG12 ' A' ' 40' ' ' VAL . 27.8 m-85 -121.09 122.0 39.1 Favored 'General case' 0 N--CA 1.494 1.755 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.552 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -54.13 117.48 3.28 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.346 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.451 ' O ' ' OD1' ' A' ' 44' ' ' ASP . 9.2 mt-10 -76.38 39.06 0.19 Allowed 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.297 -179.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.451 ' OD1' ' O ' ' A' ' 43' ' ' GLU . 75.4 m-20 -148.91 -3.22 0.45 Allowed 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.157 -1.017 . . . . 0.0 110.975 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -130.71 8.62 4.92 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.821 -0.752 . . . . 0.0 109.885 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -95.8 148.06 33.97 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 115.027 -0.988 . . . . 0.0 108.79 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -49.45 151.1 7.42 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 120.89 1.06 . . . . 0.0 111.827 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.34 54.84 1.47 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.864 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -165.06 -40.93 0.02 OUTLIER Glycine 0 N--CA 1.489 2.197 0 C-N-CA 119.465 -1.35 . . . . 0.0 110.322 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 46.3 t -86.56 93.95 4.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.969 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -47.14 158.25 0.15 Allowed 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.649 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.64 -25.01 16.3 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.786 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 90.7 mt-10 -71.71 -13.22 61.66 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.884 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.9 mmpp? -87.6 -39.75 14.81 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.775 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.409 HD12 ' CD2' ' A' ' 41' ' ' PHE . 3.0 pt -91.62 -25.86 5.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.242 -0.983 . . . . 0.0 111.258 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.7 m -55.52 -176.98 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 119.124 -1.031 . . . . 0.0 110.686 179.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.617 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 13.9 tt0 -144.95 78.12 12.78 Favored Pre-proline 0 C--N 1.302 -1.464 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.528 -179.556 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -59.51 -24.51 75.24 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 120.971 1.114 . . . . 0.0 111.532 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -77.9 99.57 6.04 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.201 -1.0 . . . . 0.0 110.484 179.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -56.99 167.28 0.84 Allowed 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.045 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -135.61 105.27 6.11 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 119.729 -0.788 . . . . 0.0 110.708 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -107.26 4.93 27.13 Favored 'General case' 0 N--CA 1.488 1.426 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.701 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -90.88 139.38 14.81 Favored Glycine 0 N--CA 1.489 2.216 0 C-N-CA 119.386 -1.388 . . . . 0.0 110.433 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -74.19 123.55 24.69 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.722 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.19 -8.99 59.32 Favored Glycine 0 N--CA 1.498 2.826 0 C-N-CA 119.547 -1.311 . . . . 0.0 110.983 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -55.83 150.65 12.67 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.976 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 3.2 p -150.59 160.11 44.03 Favored 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 118.829 -1.149 . . . . 0.0 111.667 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.617 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 53.5 t80 -135.68 177.39 7.86 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.898 -0.721 . . . . 0.0 109.745 179.092 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.506 ' O ' ' CE2' ' A' ' 68' ' ' TYR . 9.0 mt-10 -144.99 151.94 39.37 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.118 -1.033 . . . . 0.0 111.554 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.444 ' O ' ' CG1' ' A' ' 70' ' ' VAL . 1.8 p -158.76 127.78 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 C-N-CA 119.552 -0.859 . . . . 0.0 109.981 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.6 m -115.03 93.87 4.5 Favored 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.058 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 11.8 mt -79.15 156.07 28.41 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 118.81 -1.156 . . . . 0.0 109.353 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.2 p -150.86 38.37 0.67 Allowed 'General case' 0 C--N 1.293 -1.886 0 C-N-CA 118.902 -1.119 . . . . 0.0 111.559 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.424 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.5 OUTLIER -124.2 96.4 4.91 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 119.482 -0.887 . . . . 0.0 109.62 179.202 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.418 ' C ' ' O ' ' A' ' 74' ' ' GLU . 16.3 mtmm -39.52 99.75 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.292 -178.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.34 -135.4 2.64 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 119.257 -1.449 . . . . 0.0 110.359 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.3 m -150.36 142.56 24.15 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.145 -1.022 . . . . 0.0 111.225 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.611 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.7 m-85 -128.47 125.48 38.55 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.606 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 6.2 mptt -99.23 116.33 31.17 Favored 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.23 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.573 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -123.5 168.87 12.01 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.082 178.74 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -170.73 -176.81 2.15 Favored 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.683 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.5 t -105.86 127.1 52.9 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.775 -0.77 . . . . 0.0 109.865 179.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.567 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 tm-20 -74.59 -37.14 2.75 Favored Pre-proline 0 CA--C 1.558 1.259 0 C-N-CA 119.161 -1.016 . . . . 0.0 113.318 -178.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.1 Cg_endo -71.03 -50.04 0.35 Allowed 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 120.716 0.944 . . . . 0.0 111.416 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -83.72 16.29 2.79 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.594 -0.842 . . . . 0.0 110.888 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.89 -6.21 5.63 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.671 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.83 -11.94 64.8 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.146 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -97.16 -42.41 7.85 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.794 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.25 30.61 0.72 Allowed Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -79.43 110.99 15.25 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.212 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.415 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 1.0 OUTLIER -133.96 162.62 31.55 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.237 -179.808 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -144.1 152.12 23.99 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.675 -1.25 . . . . 0.0 110.661 -178.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -154.13 146.74 24.14 Favored 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 119.105 -1.038 . . . . 0.0 111.29 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.494 HG13 ' O ' ' A' ' 94' ' ' VAL . 8.4 p -143.74 126.52 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.261 0 C-N-CA 119.016 -1.074 . . . . 0.0 110.334 178.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 99.4 m -105.61 102.49 11.95 Favored 'General case' 0 N--CA 1.494 1.76 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.723 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.9 t -82.67 141.36 15.06 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.226 -179.172 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 . . . . . 0 C--N 1.302 -1.458 0 CA-C-O 116.344 -1.788 . . . . 0.0 110.857 -179.85 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.114 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -107.66 118.99 38.2 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.741 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 t -108.22 120.01 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 C-N-CA 119.866 -0.734 . . . . 0.0 110.642 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -95.01 116.52 28.8 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.414 -0.914 . . . . 0.0 110.861 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.1 mt -77.2 113.36 14.87 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 118.891 -1.123 . . . . 0.0 109.993 178.535 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.487 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 101.64 131.75 7.49 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.1 p . . . . . 0 C--N 1.304 -1.388 0 C-N-CA 119.225 -0.99 . . . . 0.0 110.62 179.998 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.9 mt . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 120.634 0.254 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.7 m -151.01 155.2 7.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.828 179.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.402 ' O ' ' C ' ' A' ' 16' ' ' PRO . 67.2 m-85 -78.31 110.53 13.41 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 177.598 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 59.4 m -113.37 110.06 50.82 Favored Pre-proline 0 CA--C 1.557 1.246 0 C-N-CA 119.377 -0.929 . . . . 0.0 112.504 -177.176 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.402 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.3 Cg_endo -67.62 170.2 49.26 Favored 'Cis proline' 0 C--N 1.363 1.31 0 C-N-CA 125.344 -0.69 . . . . 0.0 111.414 -0.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.4 m -94.0 -70.64 0.7 Allowed 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.441 -0.904 . . . . 0.0 109.648 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.3 t -107.46 129.65 54.92 Favored 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.311 178.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.478 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 13.1 p90 -157.22 144.12 18.39 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 118.237 -1.385 . . . . 0.0 111.898 -179.081 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.517 HG23 ' O ' ' A' ' 95' ' ' THR . 19.9 m -84.43 157.02 21.51 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.859 179.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.5 m -150.66 168.28 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 C-N-CA 119.737 -0.785 . . . . 0.0 110.941 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -89.38 148.64 23.39 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.559 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.93 73.57 0.19 Allowed 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.079 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 156.38 16.04 0.04 OUTLIER Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -97.85 153.97 17.95 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.795 -0.762 . . . . 0.0 111.055 -179.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.0 mtmm -95.17 127.52 41.29 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.069 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.0 mt -107.25 103.26 15.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 C-N-CA 120.069 -0.653 . . . . 0.0 109.87 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 52.5 p -100.99 115.12 29.73 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 119.656 -0.818 . . . . 0.0 112.382 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -85.5 109.83 18.76 Favored 'General case' 0 N--CA 1.489 1.485 0 C-N-CA 119.668 -0.813 . . . . 0.0 109.228 178.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.7 tttp -105.61 137.69 43.05 Favored 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 119.46 -0.896 . . . . 0.0 112.122 -178.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.456 ' N ' ' ND2' ' A' ' 31' ' ' ASN . 0.1 OUTLIER -79.64 114.15 18.34 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.272 179.177 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.67 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.7 OUTLIER -97.71 -31.04 12.47 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.181 -1.008 . . . . 0.0 111.634 -179.238 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.67 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 165.47 114.38 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.246 -0.981 . . . . 0.0 111.148 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 139.51 3.61 1.56 Allowed Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.434 -1.365 . . . . 0.0 110.863 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.445 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -53.16 163.08 0.96 Allowed Pre-proline 0 C--N 1.304 -1.372 0 C-N-CA 118.704 -1.199 . . . . 0.0 109.741 -179.874 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -77.1 141.26 68.5 Favored 'Cis proline' 0 C--O 1.214 -0.691 0 C-N-CA 124.194 -1.169 . . . . 0.0 112.509 -0.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -107.2 178.23 4.61 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.967 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.623 HD22 ' H ' ' A' ' 83' ' ' GLU . 15.5 t30 -158.09 139.64 13.67 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.618 -0.833 . . . . 0.0 110.212 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.7 mp -128.07 114.74 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 C-N-CA 119.789 -0.765 . . . . 0.0 111.311 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.511 HG23 HD21 ' A' ' 38' ' ' ASN . 66.6 t -130.08 134.48 62.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.921 179.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.754 ' CD2' HD12 ' A' ' 55' ' ' ILE . 8.8 m-85 -87.07 129.18 35.02 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.147 -1.021 . . . . 0.0 111.446 -179.21 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.659 ' C ' ' H ' ' A' ' 44' ' ' ASP . 31.1 t0 -65.75 94.29 0.2 Allowed 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.646 -178.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -55.37 5.35 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.858 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.373 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.659 ' H ' ' C ' ' A' ' 42' ' ' ASP . 73.8 m-20 -82.85 -68.18 0.73 Allowed 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.557 179.272 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -98.51 25.51 6.32 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.471 -0.892 . . . . 0.0 112.131 -177.031 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.608 HG22 ' HD2' ' A' ' 47' ' ' PRO . 0.5 OUTLIER -89.16 154.41 49.32 Favored Pre-proline 0 N--CA 1.489 1.5 0 C-N-CA 119.204 -0.998 . . . . 0.0 108.374 178.967 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.608 ' HD2' HG22 ' A' ' 46' ' ' VAL . 6.1 Cg_exo -51.13 144.01 30.42 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 121.017 1.145 . . . . 0.0 112.061 -179.065 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.47 69.38 5.72 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.791 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.73 -43.24 0.08 OUTLIER Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 46.5 t -84.18 83.39 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.078 179.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.554 ' H ' ' ND2' ' A' ' 51' ' ' ASN . 0.0 OUTLIER -44.74 140.87 2.31 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.525 -179.652 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.39 -26.33 60.94 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.539 -0.865 . . . . 0.0 111.293 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' A' ' 53' ' ' GLU . 3.7 mp0 -65.34 -3.17 3.77 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.938 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.0 mmpp? -97.44 -40.92 8.45 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.022 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.754 HD12 ' CD2' ' A' ' 41' ' ' PHE . 1.3 pt -99.13 -13.99 7.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.638 -0.825 . . . . 0.0 111.087 -179.587 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 68.9 m -73.06 173.11 9.82 Favored 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.855 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.63 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 70.3 mt-30 -136.65 80.3 38.26 Favored Pre-proline 0 N--CA 1.488 1.469 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.623 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -60.92 -20.83 68.73 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.121 1.214 . . . . 0.0 111.443 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -94.56 108.7 20.64 Favored 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.525 179.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 38.9 m-85 -51.51 177.24 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.887 -0.725 . . . . 0.0 111.035 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.8 pp -143.69 139.19 29.4 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.822 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.415 ' OD1' ' N ' ' A' ' 62' ' ' ASN . 2.9 p-10 -134.97 42.95 2.75 Favored 'General case' 0 N--CA 1.489 1.498 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.399 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -105.31 159.54 15.49 Favored Glycine 0 N--CA 1.493 2.461 0 C-N-CA 119.797 -1.192 . . . . 0.0 110.429 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -110.64 110.89 21.76 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 119.989 -0.685 . . . . 0.0 110.726 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.34 -14.21 64.67 Favored Glycine 0 N--CA 1.49 2.285 0 C-N-CA 119.437 -1.364 . . . . 0.0 110.367 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.414 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 1.2 mm-40 -69.82 160.15 32.29 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.269 -0.973 . . . . 0.0 110.345 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -147.22 172.27 14.09 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.669 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.63 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 43.9 t80 -133.61 129.45 36.95 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.082 179.125 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -91.46 149.75 21.55 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 118.892 -1.123 . . . . 0.0 112.461 -178.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -150.28 131.72 5.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.994 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.0 m -127.04 106.54 9.34 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.836 -0.745 . . . . 0.0 111.504 -178.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.48 ' CD1' HG11 ' A' ' 94' ' ' VAL . 20.5 mt -90.58 157.7 17.37 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.837 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 8.7 p -150.67 48.37 0.87 Allowed 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.072 -1.051 . . . . 0.0 111.412 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -146.67 100.74 3.37 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.151 179.36 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.469 ' CG ' ' O ' ' A' ' 75' ' ' LYS . 2.0 ptpt -41.77 118.76 1.15 Allowed 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 119.65 -0.82 . . . . 0.0 111.041 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 164.87 -147.22 12.23 Favored Glycine 0 N--CA 1.484 1.9 0 C-N-CA 119.506 -1.331 . . . . 0.0 109.878 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.71 132.96 24.68 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.462 -0.895 . . . . 0.0 111.2 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.585 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.5 OUTLIER -116.81 127.36 54.25 Favored 'General case' 0 N--CA 1.486 1.333 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.342 179.712 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.476 ' N ' ' CD ' ' A' ' 79' ' ' LYS . 2.5 mptp? -101.2 110.72 22.78 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.538 -0.865 . . . . 0.0 111.388 -179.404 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.2 p90 -123.78 168.0 13.3 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.896 -0.722 . . . . 0.0 109.922 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 46.0 p90 -171.43 -173.92 1.32 Allowed 'General case' 0 C--N 1.296 -1.758 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.033 -178.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -107.97 129.5 55.11 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.001 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.623 ' H ' HD22 ' A' ' 38' ' ' ASN . 1.9 mt-10 -69.91 -45.4 23.35 Favored Pre-proline 0 N--CA 1.486 1.374 0 C-N-CA 119.541 -0.864 . . . . 0.0 113.073 -179.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.518 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.7 Cg_endo -67.79 -53.17 0.45 Allowed 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 121.066 1.177 . . . . 0.0 111.771 -179.047 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.3 m80 -82.42 16.36 2.12 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.407 -0.917 . . . . 0.0 111.05 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.28 -18.42 58.37 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.365 -0.934 . . . . 0.0 110.809 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.19 -19.6 78.28 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.405 -1.379 . . . . 0.0 110.573 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.97 -4.69 52.23 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.577 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.64 9.67 62.58 Favored Glycine 0 N--CA 1.489 2.178 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.571 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -55.85 102.31 0.07 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.707 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.8 ptmt -126.64 157.48 38.85 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 119.929 -0.708 . . . . 0.0 111.221 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -140.24 133.86 6.21 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.971 -1.109 . . . . 0.0 110.391 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -139.21 148.79 43.59 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.634 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.48 HG11 ' CD1' ' A' ' 72' ' ' LEU . 11.4 p -141.84 132.47 25.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 119.065 -1.054 . . . . 0.0 110.219 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.517 ' O ' HG23 ' A' ' 20' ' ' THR . 99.6 m -110.31 104.99 13.85 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.26 -0.976 . . . . 0.0 110.338 179.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 31.4 t -84.83 152.31 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 118.555 -1.258 . . . . 0.0 110.774 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 60.8 m-20 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 116.324 -1.798 . . . . 0.0 110.816 -179.792 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.199 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -130.51 122.59 27.9 Favored 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 120.053 -0.659 . . . . 0.0 110.642 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -99.11 154.4 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.635 -179.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.2 mttt -120.59 106.95 12.25 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.074 -0.967 . . . . 0.0 110.479 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.9 mt -74.77 111.47 10.01 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 118.625 -1.23 . . . . 0.0 110.207 179.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.536 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 112.03 136.32 6.81 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -178.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 79.7 p . . . . . 0 C--N 1.3 -1.556 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.806 -179.909 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mt . . . . . 0 N--CA 1.49 1.556 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.5 m -150.84 155.47 7.3 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 C-N-CA 118.853 -1.139 . . . . 0.0 111.281 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.49 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 57.2 m-85 -78.7 109.84 13.3 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 177.449 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.9 m -115.3 108.19 48.19 Favored Pre-proline 0 CA--C 1.565 1.552 0 C-N-CA 119.596 -0.841 . . . . 0.0 112.875 -176.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -66.23 175.09 25.08 Favored 'Cis proline' 0 C--N 1.368 1.571 0 C-N-CA 125.128 -0.78 . . . . 0.0 111.142 -1.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.521 ' OG ' ' N ' ' A' ' 18' ' ' SER . 0.1 OUTLIER -102.91 -67.84 0.86 Allowed 'General case' 0 N--CA 1.488 1.442 0 C-N-CA 119.704 -0.799 . . . . 0.0 110.305 179.428 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.521 ' N ' ' OG ' ' A' ' 17' ' ' SER . 34.2 t -105.74 133.45 50.46 Favored 'General case' 0 N--CA 1.488 1.433 0 C-N-CA 120.069 -0.652 . . . . 0.0 109.843 179.323 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 32.6 p90 -160.65 137.13 8.69 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 118.817 -1.153 . . . . 0.0 111.177 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.419 ' H ' HG23 ' A' ' 20' ' ' THR . 0.4 OUTLIER -87.77 159.57 18.4 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 119.271 -0.972 . . . . 0.0 111.183 -179.891 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 30.6 m -148.93 176.35 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.315 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -97.37 150.41 21.03 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.568 -0.853 . . . . 0.0 110.722 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.03 71.67 0.17 Allowed 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.99 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 164.4 10.02 0.03 OUTLIER Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -104.37 146.59 28.61 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.105 -0.638 . . . . 0.0 110.543 -179.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.6 pttt -94.33 153.29 18.08 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.394 -0.922 . . . . 0.0 111.039 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 mt -122.94 145.51 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.486 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.7 p -137.8 118.13 13.69 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.274 -0.97 . . . . 0.0 112.165 -178.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -84.63 126.59 33.49 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.642 -0.823 . . . . 0.0 109.059 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.459 ' HB3' ' HZ2' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -120.16 130.76 54.74 Favored 'General case' 0 N--CA 1.493 1.705 0 C-N-CA 119.604 -0.838 . . . . 0.0 111.853 -178.085 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.635 HD21 ' CD1' ' A' ' 61' ' ' LEU . 6.2 m-20 -70.2 125.41 26.71 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.517 -0.873 . . . . 0.0 109.101 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.652 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.2 OUTLIER -103.7 -32.24 9.47 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 118.861 -1.136 . . . . 0.0 112.798 -178.533 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.652 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.01 -5.16 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 118.019 -1.472 . . . . 0.0 112.016 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.506 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -107.6 41.81 2.1 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.411 -1.376 . . . . 0.0 112.02 -178.798 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -76.14 160.78 77.37 Favored Pre-proline 0 N--CA 1.483 1.218 0 C-N-CA 117.917 -1.513 . . . . 0.0 109.564 179.019 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -74.38 176.98 40.33 Favored 'Cis proline' 0 C--O 1.207 -1.037 0 C-N-CA 124.163 -1.182 . . . . 0.0 111.784 -0.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.506 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 43.0 m-70 -150.98 168.92 23.09 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.567 -0.853 . . . . 0.0 110.794 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.846 HD21 ' H ' ' A' ' 83' ' ' GLU . 4.8 p-10 -154.54 152.89 30.6 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 119.381 -0.928 . . . . 0.0 110.079 178.244 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.0 mp -129.14 97.78 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.652 -179.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -112.39 143.41 22.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.163 178.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -99.04 138.5 36.06 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.097 -1.041 . . . . 0.0 112.354 -178.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -75.83 110.81 10.57 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.241 -0.983 . . . . 0.0 108.981 178.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -72.56 49.68 0.22 Allowed 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.405 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -142.5 3.57 1.5 Allowed 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.968 -0.693 . . . . 0.0 110.2 179.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -142.99 8.13 1.65 Allowed 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.721 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.422 HG13 ' HD2' ' A' ' 47' ' ' PRO . 44.3 t -94.63 143.75 26.76 Favored Pre-proline 0 C--N 1.291 -1.968 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.422 ' HD2' HG13 ' A' ' 46' ' ' VAL . 5.2 Cg_exo -50.94 148.56 16.53 Favored 'Trans proline' 0 C--O 1.216 -0.593 0 C-N-CA 120.868 1.045 . . . . 0.0 112.251 -179.081 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.11 78.25 2.94 Favored 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.503 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 168.32 -43.13 0.23 Allowed Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.402 ' O ' HG12 ' A' ' 50' ' ' VAL . 55.5 t -79.35 94.21 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.528 179.544 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -44.93 139.85 2.9 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.696 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -96.34 -1.46 47.73 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.561 -0.856 . . . . 0.0 110.937 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.439 ' N ' ' OE1' ' A' ' 53' ' ' GLU . 11.0 mp0 -90.33 -15.82 30.41 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.303 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.419 ' HG3' HG23 ' A' ' 55' ' ' ILE . 59.2 pttt -89.88 -27.47 19.87 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.01 -1.076 . . . . 0.0 111.437 -179.54 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.424 HD13 HG21 ' A' ' 55' ' ' ILE . 15.8 pt -92.74 -27.76 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 C-N-CA 119.106 -1.038 . . . . 0.0 110.918 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 9.0 m -60.75 -168.15 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.655 -0.818 . . . . 0.0 111.43 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.634 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 47.8 mt-30 -150.07 74.27 9.21 Favored Pre-proline 0 C--N 1.305 -1.336 0 C-N-CA 119.867 -0.733 . . . . 0.0 110.626 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -60.18 -12.26 19.01 Favored 'Trans proline' 0 C--N 1.325 -0.695 0 C-N-CA 121.202 1.268 . . . . 0.0 111.256 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' A' ' 60' ' ' TYR . 45.0 mt-10 -100.13 95.48 6.85 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.834 -0.746 . . . . 0.0 110.414 179.425 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.44 ' O ' ' O ' ' A' ' 59' ' ' GLU . 71.3 m-85 -43.97 171.19 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.916 -0.714 . . . . 0.0 111.17 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.635 ' CD1' HD21 ' A' ' 31' ' ' ASN . 1.9 pp -139.74 150.3 44.64 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.833 -0.747 . . . . 0.0 110.644 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -149.06 53.26 0.97 Allowed 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.891 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.27 126.98 6.29 Favored Glycine 0 N--CA 1.498 2.774 0 C-N-CA 119.95 -1.119 . . . . 0.0 110.402 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.67 128.78 37.56 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.833 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.47 -14.99 10.13 Favored Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.371 -1.395 . . . . 0.0 110.859 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 -56.44 154.83 7.88 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.336 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -147.99 164.57 33.4 Favored 'General case' 0 N--CA 1.489 1.522 0 C-N-CA 119.016 -1.074 . . . . 0.0 111.788 -179.069 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.634 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 36.0 t80 -136.14 146.45 46.94 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -108.03 154.74 21.22 Favored 'General case' 0 N--CA 1.498 1.935 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.794 -178.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -155.24 135.91 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 CA-C-N 115.086 -0.961 . . . . 0.0 108.936 179.287 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.2 m -128.07 104.16 7.62 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.667 -0.813 . . . . 0.0 111.769 -179.365 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.525 ' CD1' HG11 ' A' ' 94' ' ' VAL . 14.4 mt -88.22 157.74 18.7 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.237 -0.985 . . . . 0.0 109.614 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.71 48.42 0.87 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 118.865 -1.134 . . . . 0.0 111.351 -179.25 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.447 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -142.58 105.08 4.48 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.272 -0.971 . . . . 0.0 110.011 178.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 32.0 mtmt -46.59 110.31 0.27 Allowed 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.162 -179.285 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 171.08 -141.76 6.67 Favored Glycine 0 N--CA 1.485 1.912 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -146.38 137.5 24.39 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.924 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.573 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.4 m-85 -122.32 152.3 40.27 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.131 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 31.2 mttm -115.5 132.42 56.63 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.625 -0.83 . . . . 0.0 112.335 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.516 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -141.9 153.37 44.36 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.843 176.956 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 30.5 p90 -168.48 177.64 5.19 Favored 'General case' 0 C--N 1.285 -2.221 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.55 -178.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . 0.474 ' HG ' ' HD2' ' A' ' 84' ' ' PRO . 1.3 t -101.62 120.65 40.66 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.246 -0.981 . . . . 0.0 109.233 179.424 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.846 ' H ' HD21 ' A' ' 38' ' ' ASN . 6.6 tt0 -65.15 -40.56 46.1 Favored Pre-proline 0 C--N 1.3 -1.548 0 N-CA-C 113.774 1.027 . . . . 0.0 113.774 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.502 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.7 Cg_endo -68.95 -52.41 0.39 Allowed 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 120.401 0.734 . . . . 0.0 111.694 -179.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . 0.41 ' C ' ' H ' ' A' ' 87' ' ' GLY . 30.3 m80 -79.78 13.87 1.97 Allowed 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.906 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.31 -2.26 2.1 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.317 -0.953 . . . . 0.0 110.659 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.41 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -88.01 -18.18 56.44 Favored Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.514 -1.326 . . . . 0.0 110.231 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.32 -41.09 10.05 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.631 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 133.69 15.3 1.24 Allowed Glycine 0 N--CA 1.495 2.628 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.456 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.75 100.79 0.31 Allowed 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.392 -0.923 . . . . 0.0 111.017 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.49 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 32.4 mttm -125.99 164.5 20.68 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.9 -0.72 . . . . 0.0 111.497 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -148.58 143.89 11.57 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.927 -179.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -149.13 146.92 27.91 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.484 -0.886 . . . . 0.0 111.131 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.601 HG13 ' O ' ' A' ' 94' ' ' VAL . 12.5 p -140.05 119.63 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.53 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 94.5 m -99.07 101.25 12.56 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.628 179.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.436 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 41.8 t -79.61 142.74 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 C-N-CA 118.963 -1.095 . . . . 0.0 110.444 -179.014 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 96' ' ' VAL . 81.2 m-20 . . . . . 0 C--N 1.304 -1.38 0 CA-C-O 116.335 -1.793 . . . . 0.0 110.728 -179.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.109 0 N-CA-C 110.145 -0.316 . . . . 0.0 110.145 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 20.7 mp0 -121.78 122.0 38.5 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 120.128 -0.629 . . . . 0.0 110.652 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.8 t -106.69 119.06 55.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 C-N-CA 119.768 -0.773 . . . . 0.0 110.853 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -91.82 117.63 29.96 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 119.335 -0.946 . . . . 0.0 110.883 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.429 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 4.8 mt -84.27 106.36 15.82 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 119.264 -0.975 . . . . 0.0 110.702 179.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.519 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 106.75 86.64 1.89 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 2.9 p . . . . . 0 C--N 1.304 -1.37 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.389 -179.59 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.1 mt . . . . . 0 N--CA 1.488 1.449 0 CA-C-O 120.326 0.108 . . . . 0.0 110.814 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.0 m -146.73 161.38 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 118.804 -1.159 . . . . 0.0 111.427 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -78.58 113.79 16.93 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 177.377 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.1 m -116.7 107.45 46.46 Favored Pre-proline 0 CA--C 1.559 1.292 0 C-N-CA 119.39 -0.924 . . . . 0.0 111.881 -177.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -66.11 176.38 21.23 Favored 'Cis proline' 0 C--N 1.36 1.153 0 C-N-CA 125.227 -0.739 . . . . 0.0 111.46 -0.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.7 p -95.76 -48.86 5.59 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.205 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 47.9 t -137.07 137.12 38.99 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.601 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 11.3 p90 -163.3 143.68 9.02 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 118.563 -1.255 . . . . 0.0 111.528 -179.117 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.429 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -86.44 157.43 19.82 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.896 -179.889 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.3 m -146.48 146.89 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.313 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.437 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -61.45 141.58 57.58 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.697 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.75 74.21 0.07 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.184 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 154.25 18.89 0.05 OUTLIER Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.364 -1.398 . . . . 0.0 109.922 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.428 ' O ' HG23 ' A' ' 71' ' ' THR . 21.7 tt0 -103.63 157.1 17.29 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.947 -0.701 . . . . 0.0 110.8 -179.597 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 29.1 mttt -94.38 142.07 27.84 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.714 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mt -124.81 125.52 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 C-N-CA 119.992 -0.683 . . . . 0.0 109.519 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.6 p -119.68 129.33 54.5 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.528 -0.869 . . . . 0.0 112.368 -178.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -91.71 131.48 37.07 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.226 178.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.5 tptm -120.94 131.01 54.09 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 120.017 -0.673 . . . . 0.0 111.249 -178.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.453 ' ND2' HD11 ' A' ' 61' ' ' LEU . 0.5 OUTLIER -90.77 94.68 9.78 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.594 -0.842 . . . . 0.0 109.547 178.981 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 40.1 p-10 -91.26 -23.17 20.25 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.24 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -177.36 162.23 1.87 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 118.999 -1.08 . . . . 0.0 111.219 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.03 12.49 76.68 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.393 -1.384 . . . . 0.0 112.583 178.035 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -63.05 159.93 43.08 Favored Pre-proline 0 C--N 1.308 -1.199 0 C-N-CA 117.283 -1.767 . . . . 0.0 109.378 179.489 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -79.13 147.05 79.27 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 124.13 -1.196 . . . . 0.0 112.195 -0.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 40.5 m-70 -111.3 -175.43 2.7 Favored 'General case' 0 N--CA 1.495 1.805 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.377 179.146 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.617 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -160.63 146.06 14.67 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.446 179.262 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.617 ' N ' HD22 ' A' ' 38' ' ' ASN . 3.7 mp -134.17 107.27 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.971 -179.376 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.3 t -133.48 144.17 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.849 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -97.42 118.24 33.45 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.962 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -52.28 118.52 3.59 Favored 'General case' 0 C--N 1.308 -1.202 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.281 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -76.09 47.94 0.47 Allowed 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.121 -1.032 . . . . 0.0 111.047 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -147.75 2.68 0.71 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.652 -0.819 . . . . 0.0 109.94 179.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -144.56 21.39 1.67 Allowed 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 119.69 -0.804 . . . . 0.0 110.614 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -104.88 148.13 35.61 Favored Pre-proline 0 N--CA 1.493 1.693 0 CA-C-N 115.45 -0.795 . . . . 0.0 109.28 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -49.66 143.12 22.97 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 120.951 1.101 . . . . 0.0 111.715 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.85 69.37 2.5 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.942 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.0 -43.27 0.1 Allowed Glycine 0 N--CA 1.49 2.238 0 C-N-CA 119.44 -1.362 . . . . 0.0 110.018 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 77.5 t -78.44 97.32 2.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.372 179.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -44.71 139.68 2.83 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.66 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -94.8 2.66 55.5 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.441 -179.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -87.72 -33.22 18.8 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.932 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.1 mmtm -76.41 -32.2 58.36 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.911 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -90.64 -16.09 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 C-N-CA 118.993 -1.083 . . . . 0.0 111.682 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.8 m -79.97 170.72 16.07 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.264 -0.974 . . . . 0.0 110.782 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.65 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 5.8 mt-30 -134.68 73.44 67.36 Favored Pre-proline 0 N--CA 1.487 1.393 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.523 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -61.36 -4.26 3.99 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 121.402 1.401 . . . . 0.0 111.459 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 60' ' ' TYR . 37.8 mt-10 -99.86 100.67 11.63 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.716 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.473 ' CD2' ' OD1' ' A' ' 38' ' ' ASN . 84.7 m-85 -45.82 171.49 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.623 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.572 ' O ' HD12 ' A' ' 61' ' ' LEU . 3.2 pp -149.39 126.54 11.34 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.248 -0.981 . . . . 0.0 110.499 179.434 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -120.86 33.61 5.51 Favored 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 120.175 -0.61 . . . . 0.0 110.663 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -87.91 168.19 37.22 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.308 -1.425 . . . . 0.0 110.876 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -121.62 101.27 7.49 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.363 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.94 -7.94 55.5 Favored Glycine 0 N--CA 1.49 2.248 0 C-N-CA 119.622 -1.275 . . . . 0.0 110.063 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -71.1 157.55 38.0 Favored 'General case' 0 N--CA 1.486 1.359 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.226 179.665 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -141.69 173.27 11.66 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.27 -0.972 . . . . 0.0 112.041 -179.077 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.65 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 56.7 t80 -134.66 178.23 7.17 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-N 115.498 -0.773 . . . . 0.0 109.623 178.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.516 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 5.1 mt-10 -145.92 149.34 34.03 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 118.912 -1.115 . . . . 0.0 112.012 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -159.04 133.87 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.659 178.57 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.428 HG23 ' O ' ' A' ' 25' ' ' GLU . 4.1 m -122.53 96.34 4.99 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 119.828 -0.749 . . . . 0.0 111.035 -179.272 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.3 mt -79.75 158.64 26.84 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.448 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.577 ' O ' HG22 ' A' ' 73' ' ' THR . 97.0 m -150.96 47.12 0.85 Allowed 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.552 -1.259 . . . . 0.0 112.362 -178.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.424 ' OE2' ' O ' ' A' ' 75' ' ' LYS . 5.9 tp10 -146.2 107.25 4.16 Favored 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 118.746 -1.182 . . . . 0.0 109.95 178.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.7 ' H ' ' CD ' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -43.36 116.32 0.91 Allowed 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.199 -0.909 . . . . 0.0 111.184 -178.972 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.6 -151.22 16.68 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.359 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.17 131.15 34.29 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.846 -0.741 . . . . 0.0 110.677 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.538 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 3.7 m-85 -118.19 121.58 40.86 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 36.8 mmtt -100.19 127.48 46.45 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.524 -0.87 . . . . 0.0 112.839 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.448 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 5.6 p90 -139.87 171.46 14.18 Favored 'General case' 0 C--N 1.312 -1.025 0 C-N-CA 119.616 -0.833 . . . . 0.0 110.433 177.673 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -170.55 -175.71 1.94 Allowed 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 119.437 -0.905 . . . . 0.0 111.178 -178.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.8 t -106.7 123.26 47.86 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.757 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.532 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.4 OUTLIER -64.05 -45.16 79.79 Favored Pre-proline 0 C--N 1.307 -1.253 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.466 -179.874 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.532 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.3 Cg_endo -66.93 -48.36 1.97 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.994 1.129 . . . . 0.0 112.47 -178.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . 0.468 ' C ' ' H ' ' A' ' 87' ' ' GLY . 34.4 m80 -91.69 23.19 3.68 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.152 -179.196 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.404 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -71.19 12.29 0.33 Allowed 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.893 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.468 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -107.15 -18.35 10.54 Favored Glycine 0 N--CA 1.498 2.79 0 C-N-CA 119.746 -1.216 . . . . 0.0 110.682 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -95.1 -16.11 22.88 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.232 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 108.17 17.76 10.5 Favored Glycine 0 N--CA 1.498 2.78 0 C-N-CA 119.777 -1.202 . . . . 0.0 110.242 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.7 ttt -69.99 90.78 0.65 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.215 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 15.4 ttmt -118.39 162.17 18.75 Favored 'General case' 0 N--CA 1.498 1.944 0 C-N-CA 120.045 -0.662 . . . . 0.0 111.16 -179.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -141.74 150.99 22.42 Favored Glycine 0 N--CA 1.495 2.608 0 C-N-CA 119.349 -1.405 . . . . 0.0 111.6 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -157.57 145.43 18.85 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.75 -0.78 . . . . 0.0 110.919 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.2 p -138.55 123.06 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.346 178.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 97.7 m -99.61 103.23 14.92 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.594 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 22.0 t -80.05 142.86 13.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 C-N-CA 118.423 -1.311 . . . . 0.0 110.46 -179.145 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.3 m120 . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 116.358 -1.782 . . . . 0.0 110.764 -179.76 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.221 0 CA-C-O 120.7 0.286 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 89.2 mt-10 -115.08 121.34 42.77 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.586 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 t -102.49 123.61 55.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.915 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 39.1 mttp -88.92 112.9 23.86 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.902 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.404 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 13.1 mt -75.82 107.43 8.0 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 118.229 -1.388 . . . . 0.0 109.4 178.104 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.535 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.64 130.4 6.98 Favored Glycine 0 N--CA 1.486 1.986 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -178.819 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.3 p . . . . . 0 C--N 1.302 -1.476 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.663 179.619 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.4 mt . . . . . 0 N--CA 1.487 1.422 0 CA-C-O 120.374 0.131 . . . . 0.0 110.827 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.2 m -150.12 153.97 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.868 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.423 ' O ' ' O ' ' A' ' 16' ' ' PRO . 69.7 m-85 -78.45 110.61 13.68 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 177.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.2 m -115.59 110.39 44.75 Favored Pre-proline 0 CA--C 1.562 1.419 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.723 -177.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.423 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.7 Cg_exo -64.79 174.7 21.0 Favored 'Cis proline' 0 C--N 1.365 1.43 0 C-N-CA 125.103 -0.79 . . . . 0.0 111.829 -0.157 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.9 t -102.82 -66.36 0.94 Allowed 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.455 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 61.6 m -119.08 131.88 55.97 Favored 'General case' 0 N--CA 1.492 1.634 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.008 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.436 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 16.7 p90 -161.23 170.94 19.28 Favored 'General case' 0 N--CA 1.487 1.391 0 C-N-CA 118.655 -1.218 . . . . 0.0 111.324 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.4 p -102.88 161.45 13.74 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.992 -0.683 . . . . 0.0 111.193 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.9 m -149.23 151.0 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.946 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.519 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -78.82 142.06 37.21 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.274 -0.971 . . . . 0.0 110.359 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.01 77.35 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.51 -0.876 . . . . 0.0 111.395 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 153.79 15.32 0.06 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.583 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -103.94 145.0 30.78 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.754 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ptpt -95.45 136.34 35.95 Favored 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.383 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.1 mt -109.16 113.79 45.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.631 179.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.3 p -107.3 116.47 31.98 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.775 -0.77 . . . . 0.0 112.336 -178.547 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 69.2 m-85 -85.16 118.81 24.94 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 119.526 -0.87 . . . . 0.0 109.05 178.293 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.538 ' HA ' HG22 ' A' ' 67' ' ' THR . 25.0 tttp -111.74 138.16 48.7 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.657 -0.817 . . . . 0.0 111.482 -178.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.51 HD21 ' CD1' ' A' ' 61' ' ' LEU . 2.6 m-20 -77.65 109.92 12.03 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.413 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.661 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.4 t30 -96.51 -30.96 13.03 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 119.147 -1.021 . . . . 0.0 110.703 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.661 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 165.13 129.12 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.806 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 127.98 -9.01 6.75 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.687 -1.244 . . . . 0.0 110.91 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.478 ' CD1' ' ND2' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -45.92 160.64 0.28 Allowed Pre-proline 0 N--CA 1.482 1.142 0 C-N-CA 118.52 -1.272 . . . . 0.0 109.695 -179.881 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -77.3 141.55 68.84 Favored 'Cis proline' 0 C--O 1.214 -0.68 0 C-N-CA 124.139 -1.192 . . . . 0.0 112.241 0.008 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.404 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 40.6 m-70 -108.55 -177.24 3.26 Favored 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.072 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.611 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -161.16 141.54 11.06 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.875 -0.73 . . . . 0.0 109.872 178.829 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.611 ' N ' HD22 ' A' ' 38' ' ' ASN . 3.6 mp -129.63 124.69 59.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.438 -179.542 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -143.53 146.99 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.385 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.161 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -97.23 134.56 40.38 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.248 -0.981 . . . . 0.0 111.04 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.659 ' O ' ' N ' ' A' ' 44' ' ' ASP . 44.5 p-10 -73.1 93.81 1.85 Allowed 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.529 -0.868 . . . . 0.0 111.063 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.445 ' CG ' ' O ' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -50.45 78.84 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 O-C-N 124.063 0.852 . . . . 0.0 109.803 179.385 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.659 ' N ' ' O ' ' A' ' 42' ' ' ASP . 59.4 m-20 -157.01 -67.04 0.1 Allowed 'General case' 0 C--N 1.283 -2.3 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.682 -177.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -96.24 17.37 15.94 Favored 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.191 -1.003 . . . . 0.0 112.139 -177.399 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -86.07 143.96 38.12 Favored Pre-proline 0 C--N 1.291 -1.959 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.431 ' C ' ' H ' ' A' ' 49' ' ' GLY . 2.7 Cg_exo -48.81 152.21 4.68 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 120.815 1.01 . . . . 0.0 111.797 -179.252 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.68 31.15 0.36 Allowed 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.645 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.431 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -136.27 -35.34 0.21 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.5 t -96.46 93.2 3.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.986 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -45.26 144.48 1.37 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.671 179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -87.99 -29.85 20.44 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.84 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.03 -1.05 21.02 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.747 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -97.62 -35.03 10.73 Favored 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.753 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -96.2 -16.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 C-N-CA 119.404 -0.918 . . . . 0.0 111.102 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 36.7 m -68.27 170.07 9.38 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.733 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.64 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 5.0 mt-30 -137.09 73.37 51.87 Favored Pre-proline 0 N--CA 1.489 1.489 0 C-N-CA 119.811 -0.756 . . . . 0.0 110.901 -179.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -57.28 -27.73 76.51 Favored 'Trans proline' 0 C--N 1.322 -0.836 0 C-N-CA 121.038 1.159 . . . . 0.0 110.933 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -65.65 114.1 4.73 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.088 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 -60.72 173.26 0.77 Allowed 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 119.479 -0.888 . . . . 0.0 111.073 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.51 ' CD1' HD21 ' A' ' 31' ' ' ASN . 2.5 pp -149.15 144.63 26.73 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.682 -0.807 . . . . 0.0 110.158 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.581 ' ND2' ' N ' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -128.28 -73.53 0.59 Allowed 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 119.88 -0.728 . . . . 0.0 111.72 -178.992 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.488 ' H ' ' CG ' ' A' ' 62' ' ' ASN . . . -24.2 127.19 0.02 OUTLIER Glycine 0 N--CA 1.511 3.642 0 O-C-N 123.993 0.808 . . . . 0.0 112.612 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.486 ' C ' ' H ' ' A' ' 66' ' ' GLU . . . -62.33 156.76 21.47 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.207 179.394 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . 0.724 ' O ' HG23 ' A' ' 67' ' ' THR . . . 71.28 -14.62 1.65 Allowed Glycine 0 N--CA 1.492 2.376 0 C-N-CA 119.109 -1.519 . . . . 0.0 110.6 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.486 ' H ' ' C ' ' A' ' 64' ' ' ALA . 12.9 tt0 -61.13 101.8 0.18 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.286 -0.966 . . . . 0.0 109.97 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.724 HG23 ' O ' ' A' ' 65' ' ' GLY . 37.4 p -106.99 162.19 14.06 Favored 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.575 -0.85 . . . . 0.0 112.225 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.64 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 29.7 t80 -136.17 143.57 44.52 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.323 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -104.84 154.6 19.84 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.589 -178.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -151.59 130.75 3.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.945 -1.025 . . . . 0.0 108.942 179.272 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.4 m -124.6 112.06 16.37 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.693 -0.803 . . . . 0.0 111.585 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 34.3 mt -98.61 156.85 16.6 Favored 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.772 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 11.1 p -150.93 47.98 0.85 Allowed 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 118.714 -1.194 . . . . 0.0 112.274 -179.122 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -144.49 106.29 4.3 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.781 -1.168 . . . . 0.0 110.467 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.437 ' HD2' ' H ' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -44.96 110.84 0.26 Allowed 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.913 -179.696 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.93 -148.28 10.35 Favored Glycine 0 N--CA 1.487 2.053 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.077 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.92 135.37 32.75 Favored 'General case' 0 N--CA 1.483 1.176 0 C-N-CA 119.424 -0.91 . . . . 0.0 111.095 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.569 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -124.36 159.04 31.23 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 179.565 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 12.2 mtpt -136.5 125.48 24.31 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 118.612 -1.235 . . . . 0.0 112.871 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.542 ' O ' ' N ' ' A' ' 92' ' ' GLY . 3.9 p90 -129.43 162.34 28.3 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.35 178.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 22.7 p90 -166.94 -179.5 4.72 Favored 'General case' 0 C--N 1.285 -2.232 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.496 -178.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . 0.502 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -107.34 112.93 25.99 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.49 -0.884 . . . . 0.0 109.573 178.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.487 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.9 OUTLIER -59.37 -42.99 95.58 Favored Pre-proline 0 C--N 1.298 -1.635 0 C-N-CA 119.471 -0.892 . . . . 0.0 112.581 -179.407 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.487 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.4 Cg_endo -66.3 -47.88 2.92 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 120.283 0.655 . . . . 0.0 111.839 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -92.82 10.1 32.42 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.447 -179.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -59.07 -15.8 15.71 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.559 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -77.91 -20.47 73.31 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.421 -1.371 . . . . 0.0 110.377 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.63 -9.34 47.32 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.694 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 104.54 10.78 32.57 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.67 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.51 105.05 1.72 Allowed 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 118.989 -1.085 . . . . 0.0 110.952 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.422 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 43.9 pttt -135.54 168.34 19.43 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.29 -179.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.04 153.0 24.93 Favored Glycine 0 N--CA 1.485 1.941 0 C-N-CA 119.372 -1.394 . . . . 0.0 111.053 -179.05 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -155.91 145.9 21.39 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.3 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.8 p -141.62 131.29 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 C-N-CA 118.955 -1.098 . . . . 0.0 110.652 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.0 m -109.46 105.15 14.38 Favored 'General case' 0 N--CA 1.493 1.722 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.825 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.4 HG12 ' N ' ' A' ' 97' ' ' ASN . 37.2 t -79.68 152.93 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 C-N-CA 118.553 -1.259 . . . . 0.0 110.526 -179.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.4 ' N ' HG12 ' A' ' 96' ' ' VAL . 60.9 m-20 . . . . . 0 C--N 1.307 -1.277 0 CA-C-O 116.284 -1.817 . . . . 0.0 110.932 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.127 0 N-CA-C 110.071 -0.344 . . . . 0.0 110.071 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -113.92 122.41 46.9 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 120.076 -0.649 . . . . 0.0 110.856 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.3 t -110.4 150.11 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.393 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 10.9 mtpt -124.6 117.69 24.87 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.865 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.2 mt -76.74 109.1 10.24 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.067 -1.053 . . . . 0.0 109.995 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 117.42 162.01 12.36 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.021 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.442 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 59.4 p . . . . . 0 C--N 1.302 -1.491 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.813 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.3 mt . . . . . 0 N--CA 1.485 1.287 0 CA-C-O 120.59 0.234 . . . . 0.0 110.534 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.9 m -144.82 155.37 14.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 119.111 -1.035 . . . . 0.0 110.415 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.425 ' O ' ' O ' ' A' ' 16' ' ' PRO . 5.4 m-85 -78.71 111.99 15.37 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 178.311 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.3 m -114.44 108.59 49.55 Favored Pre-proline 0 C--N 1.303 -1.415 0 C-N-CA 119.734 -0.786 . . . . 0.0 112.007 -177.44 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -67.26 177.9 20.57 Favored 'Cis proline' 0 C--N 1.36 1.149 0 C-N-CA 125.35 -0.688 . . . . 0.0 111.423 -0.205 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.7 m -92.62 -47.78 6.93 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.414 -0.914 . . . . 0.0 109.996 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.63 135.42 31.69 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.756 179.279 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.479 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 13.5 p90 -153.69 146.61 24.44 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.608 -1.237 . . . . 0.0 111.545 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.44 HG23 ' H ' ' A' ' 20' ' ' THR . 0.6 OUTLIER -91.43 151.25 20.88 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.042 179.579 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.4 158.82 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.933 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.532 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -73.09 137.28 45.15 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.176 -1.01 . . . . 0.0 110.347 179.515 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -59.91 78.82 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.934 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 150.39 18.38 0.07 OUTLIER Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -96.18 158.42 15.45 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.577 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 40.5 mttm -93.5 120.29 33.59 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.093 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.9 mt -105.52 120.52 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.68 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.1 p -118.42 116.6 27.05 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.64 -0.824 . . . . 0.0 112.283 -178.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -87.87 120.31 29.07 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.508 -0.877 . . . . 0.0 109.022 178.336 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 13.0 ttmt -112.21 136.2 51.93 Favored 'General case' 0 N--CA 1.492 1.658 0 C-N-CA 119.697 -0.801 . . . . 0.0 111.75 -178.475 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.899 ' ND2' HD11 ' A' ' 61' ' ' LEU . 3.8 m120 -80.31 115.57 19.92 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.157 178.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.632 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.1 OUTLIER -100.22 -31.38 11.4 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.257 -0.977 . . . . 0.0 112.141 -178.995 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.632 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 169.02 120.74 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 C-N-CA 118.882 -1.127 . . . . 0.0 111.359 -179.75 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 131.57 -1.19 5.19 Favored Glycine 0 N--CA 1.496 2.667 0 C-N-CA 119.661 -1.257 . . . . 0.0 111.187 179.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -46.84 163.97 0.23 Allowed Pre-proline 0 N--CA 1.487 1.377 0 C-N-CA 118.942 -1.103 . . . . 0.0 110.028 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -75.74 143.0 75.66 Favored 'Cis proline' 0 C--O 1.212 -0.81 0 C-N-CA 124.306 -1.122 . . . . 0.0 112.45 -0.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 31.7 m-70 -113.92 160.72 18.48 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.769 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.56 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 8.9 t30 -145.69 133.28 20.92 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 119.426 -0.909 . . . . 0.0 109.945 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.821 ' N ' HD12 ' A' ' 39' ' ' ILE . 1.7 mp -115.19 121.41 67.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 C-N-CA 119.767 -0.773 . . . . 0.0 111.405 -179.562 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.56 ' CG2' ' ND2' ' A' ' 38' ' ' ASN . 1.7 t -139.07 154.8 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.068 179.454 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -106.56 134.34 49.85 Favored 'General case' 0 N--CA 1.49 1.533 0 C-N-CA 119.287 -0.965 . . . . 0.0 112.019 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.502 ' C ' ' H ' ' A' ' 44' ' ' ASP . 4.3 t0 -74.32 107.0 6.21 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.188 -1.005 . . . . 0.0 109.179 178.654 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -69.32 33.83 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.833 -178.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.502 ' H ' ' C ' ' A' ' 42' ' ' ASP . 14.9 m-20 -110.23 -9.98 14.65 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.855 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -142.5 -5.8 0.93 Allowed 'General case' 0 N--CA 1.497 1.889 0 C-N-CA 118.865 -1.134 . . . . 0.0 111.634 179.609 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -69.98 146.17 94.88 Favored Pre-proline 0 C--N 1.286 -2.153 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 178.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -51.48 159.32 3.26 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.712 0.941 . . . . 0.0 112.323 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -89.17 40.4 0.98 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 119.722 -0.791 . . . . 0.0 110.374 179.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -143.18 -44.63 0.05 OUTLIER Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.528 ' O ' HG12 ' A' ' 50' ' ' VAL . 50.9 t -83.14 86.29 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 119.384 -0.926 . . . . 0.0 110.18 179.343 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -45.0 139.59 3.07 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.634 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.99 -28.48 55.1 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.679 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -66.33 -15.56 63.35 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.379 -0.928 . . . . 0.0 111.13 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.95 -42.89 17.08 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.838 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -93.32 -41.59 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.212 -179.779 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 42.9 m -48.53 165.98 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.154 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.594 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.3 mt-30 -138.23 78.55 33.55 Favored Pre-proline 0 N--CA 1.487 1.412 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.561 -179.593 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -61.67 -22.91 75.51 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 121.405 1.403 . . . . 0.0 112.003 -179.068 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -76.08 119.83 20.56 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.122 -1.031 . . . . 0.0 110.585 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -55.86 168.56 0.44 Allowed 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.126 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.899 HD11 ' ND2' ' A' ' 31' ' ' ASN . 0.4 OUTLIER -144.61 141.91 29.76 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.189 179.329 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.587 ' N ' HD12 ' A' ' 61' ' ' LEU . 4.1 p-10 -146.51 32.7 0.96 Allowed 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.198 -179.263 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -97.26 112.26 4.43 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.482 -1.342 . . . . 0.0 110.539 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.15 111.6 1.58 Allowed 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.22 -0.992 . . . . 0.0 110.571 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.7 -12.5 66.02 Favored Glycine 0 N--CA 1.489 2.23 0 C-N-CA 119.464 -1.351 . . . . 0.0 110.203 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -63.04 151.22 40.49 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.335 -0.946 . . . . 0.0 110.302 179.689 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.73 166.72 23.88 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.214 -0.995 . . . . 0.0 111.511 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.594 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 31.6 t80 -135.83 138.32 42.41 Favored 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.524 179.246 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.402 ' CD ' ' H ' ' A' ' 69' ' ' GLU . 2.0 mp0 -98.16 152.94 18.82 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.885 -178.651 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -149.61 133.69 8.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.34 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.6 m -125.92 100.3 6.32 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.304 -179.23 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.468 ' CD1' HG11 ' A' ' 94' ' ' VAL . 54.2 mt -81.0 165.43 21.72 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.173 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.715 ' O ' HG22 ' A' ' 73' ' ' THR . 81.1 m -150.43 31.01 0.67 Allowed 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 118.608 -1.237 . . . . 0.0 112.589 -178.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.456 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 2.5 mt-10 -143.39 124.28 14.3 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 118.781 -1.168 . . . . 0.0 110.35 178.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 14.4 pttt -58.69 128.14 35.72 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.221 -0.992 . . . . 0.0 111.281 -179.271 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 156.31 174.59 26.28 Favored Glycine 0 N--CA 1.488 2.116 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.223 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.79 105.35 15.34 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.914 -0.715 . . . . 0.0 110.281 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.463 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.8 m-30 -89.58 156.54 18.54 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 118.591 -1.244 . . . . 0.0 107.981 -179.261 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 71.1 mttt -115.19 127.77 55.74 Favored 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.165 -1.014 . . . . 0.0 112.782 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.469 ' O ' ' N ' ' A' ' 92' ' ' GLY . 1.7 p90 -138.14 157.5 46.19 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.834 -0.746 . . . . 0.0 109.526 176.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 33.8 p90 -169.8 -175.23 2.03 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.523 -178.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -110.14 116.31 31.31 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.398 179.265 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.563 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tp10 -69.67 -39.34 11.46 Favored Pre-proline 0 C--N 1.305 -1.358 0 C-N-CA 119.518 -0.873 . . . . 0.0 112.435 -179.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.563 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 4.4 Cg_exo -66.17 -41.92 11.84 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 120.394 0.729 . . . . 0.0 111.268 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . 0.435 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.8 m80 -97.71 18.91 14.57 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.518 -0.873 . . . . 0.0 110.638 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.37 0.21 1.09 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.853 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -94.31 -13.38 54.3 Favored Glycine 0 N--CA 1.487 2.081 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.449 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.45 -47.55 6.81 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.377 -0.929 . . . . 0.0 110.57 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 141.27 18.22 0.35 Allowed Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.629 -1.272 . . . . 0.0 110.271 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 12.8 mtp -71.55 100.41 2.25 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.16 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.485 ' HD2' ' H ' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -129.17 148.48 51.11 Favored 'General case' 0 N--CA 1.495 1.792 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.221 179.489 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -136.29 153.78 21.7 Favored Glycine 0 N--CA 1.499 2.889 0 C-N-CA 119.508 -1.33 . . . . 0.0 112.211 -178.057 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -154.68 149.37 26.49 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 120.314 -0.555 . . . . 0.0 109.937 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.708 HG13 ' O ' ' A' ' 94' ' ' VAL . 12.2 p -139.32 114.88 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 C-N-CA 119.079 -1.048 . . . . 0.0 111.07 -179.327 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 16.0 m -89.84 93.55 9.47 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.096 -1.042 . . . . 0.0 110.616 179.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 14.0 t -78.77 148.31 6.23 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.617 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 17.8 p30 . . . . . 0 C--N 1.307 -1.277 0 CA-C-O 116.309 -1.805 . . . . 0.0 110.818 -179.744 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.103 0 CA-C-O 120.873 0.368 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -107.86 120.63 42.81 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 120.033 -0.667 . . . . 0.0 110.687 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.8 t -98.52 122.35 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.651 179.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.7 mptt -90.0 114.72 26.62 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.983 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.448 HD11 ' HB3' ' A' ' 29' ' ' PHE . 5.3 mp -80.45 100.03 8.3 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 118.572 -1.251 . . . . 0.0 109.62 178.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.461 ' C ' HD21 ' A' ' 32' ' ' ASN . . . 122.6 146.6 7.25 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -178.718 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.55 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 53.5 p . . . . . 0 C--N 1.302 -1.477 0 C-N-CA 119.439 -0.905 . . . . 0.0 110.709 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.0 mt . . . . . 0 N--CA 1.491 1.597 0 N-CA-C 110.357 -0.238 . . . . 0.0 110.357 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.9 m -145.38 156.27 13.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.022 0 C-N-CA 118.996 -1.082 . . . . 0.0 111.075 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -78.59 111.54 14.77 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 178.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -114.5 108.34 49.8 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 119.566 -0.854 . . . . 0.0 112.232 -177.106 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -68.04 173.48 37.72 Favored 'Cis proline' 0 C--N 1.359 1.085 0 C-N-CA 125.45 -0.646 . . . . 0.0 111.503 -0.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 p -88.9 -45.22 9.87 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 119.307 -0.957 . . . . 0.0 109.76 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.76 140.5 34.81 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.55 179.114 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -162.41 147.3 12.34 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 118.356 -1.338 . . . . 0.0 111.598 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.412 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -93.24 151.71 19.64 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.275 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -146.06 169.24 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.809 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.76 146.48 28.14 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.257 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.27 71.26 0.42 Allowed 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.32 -0.952 . . . . 0.0 110.848 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 165.51 11.08 0.03 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -101.92 145.89 28.61 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.841 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.523 ' C ' HD12 ' A' ' 27' ' ' ILE . 19.1 mttm -84.97 134.87 34.23 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.288 -0.965 . . . . 0.0 110.671 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.523 HD12 ' C ' ' A' ' 26' ' ' LYS . 1.5 mp -115.94 118.31 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.679 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 36.2 p -110.6 121.51 45.49 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.471 -0.891 . . . . 0.0 113.299 -177.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.448 ' HB3' HD11 ' A' ' 5' ' ' LEU . 70.6 m-85 -84.88 111.12 19.37 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.051 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 45.5 tttt -109.9 131.62 54.89 Favored 'General case' 0 N--CA 1.496 1.83 0 C-N-CA 119.431 -0.907 . . . . 0.0 111.76 -177.2 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.934 ' ND2' HD11 ' A' ' 61' ' ' LEU . 7.8 m-20 -90.06 117.39 28.82 Favored 'General case' 0 C--N 1.294 -1.82 0 C-N-CA 119.335 -0.946 . . . . 0.0 111.329 -179.536 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 7' ' ' SER . 25.3 p-10 -101.01 -29.54 12.12 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.968 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.522 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 174.09 137.59 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.373 -0.931 . . . . 0.0 110.935 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.403 ' O ' ' C ' ' A' ' 35' ' ' PHE . . . 122.22 -6.99 9.98 Favored Glycine 0 N--CA 1.498 2.774 0 C-N-CA 119.524 -1.322 . . . . 0.0 111.626 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.403 ' C ' ' O ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -45.87 163.1 0.23 Allowed Pre-proline 0 N--CA 1.485 1.312 0 C-N-CA 118.423 -1.311 . . . . 0.0 109.908 -179.834 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -76.76 138.43 54.24 Favored 'Cis proline' 0 C--O 1.213 -0.734 0 C-N-CA 124.122 -1.199 . . . . 0.0 112.443 -0.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 32.5 m-70 -102.28 179.79 4.21 Favored 'General case' 0 N--CA 1.488 1.462 0 C-N-CA 119.751 -0.78 . . . . 0.0 111.106 179.576 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -159.56 142.11 13.76 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.782 179.293 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -135.11 117.12 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.045 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.4 t -139.25 150.24 22.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.386 179.043 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -99.3 135.08 41.24 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.856 -178.816 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.539 ' C ' ' H ' ' A' ' 44' ' ' ASP . 59.6 t0 -70.62 104.36 2.79 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.284 -0.966 . . . . 0.0 109.519 178.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.465 ' CD ' ' N ' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -68.42 27.27 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.789 -0.765 . . . . 0.0 111.785 -179.229 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.539 ' H ' ' C ' ' A' ' 42' ' ' ASP . 73.3 m-20 -111.26 -7.02 14.46 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.079 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -143.82 -1.46 0.99 Allowed 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 119.218 -0.993 . . . . 0.0 111.721 -179.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -68.56 144.9 96.76 Favored Pre-proline 0 C--N 1.285 -2.21 0 C-N-CA 119.269 -0.972 . . . . 0.0 108.726 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -59.08 160.5 18.61 Favored 'Trans proline' 0 C--O 1.216 -0.603 0 C-N-CA 121.062 1.175 . . . . 0.0 112.243 -178.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.63 145.16 41.29 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.567 -0.853 . . . . 0.0 109.66 178.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 95.26 -59.13 1.65 Allowed Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.238 -1.458 . . . . 0.0 109.849 -179.439 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.4 t -68.52 87.18 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 119.114 -1.035 . . . . 0.0 110.339 179.509 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -44.86 154.51 0.13 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.001 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.25 -25.66 16.26 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.332 179.385 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -81.4 -15.93 53.69 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.611 -0.836 . . . . 0.0 110.774 179.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.18 -21.61 46.16 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.568 -0.853 . . . . 0.0 111.408 -179.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.5 pt -111.04 -19.22 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 C-N-CA 119.753 -0.779 . . . . 0.0 111.312 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.7 m -79.58 169.47 17.97 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.575 -0.85 . . . . 0.0 111.81 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.634 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.8 OUTLIER -150.03 73.24 9.42 Favored Pre-proline 0 C--N 1.306 -1.32 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.785 179.113 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -56.74 -26.45 65.97 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.501 1.467 . . . . 0.0 111.947 -178.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.35 102.82 0.08 Allowed 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 118.94 -1.104 . . . . 0.0 110.145 179.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -42.46 161.75 0.02 OUTLIER 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 119.581 -0.848 . . . . 0.0 111.103 -179.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.934 HD11 ' ND2' ' A' ' 31' ' ' ASN . 0.8 OUTLIER -143.3 147.8 35.32 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.614 -0.835 . . . . 0.0 110.459 -179.977 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.504 ' N ' HD12 ' A' ' 61' ' ' LEU . 1.1 p30 -145.01 20.99 1.6 Allowed 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.351 -0.939 . . . . 0.0 110.952 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -77.81 119.51 5.27 Favored Glycine 0 N--CA 1.487 2.034 0 C-N-CA 119.182 -1.485 . . . . 0.0 110.199 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.11 106.15 4.85 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.276 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.72 -10.72 49.35 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -68.11 154.85 40.82 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.256 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.87 170.04 16.64 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 119.133 -1.027 . . . . 0.0 111.335 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.634 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 40.7 t80 -135.24 142.49 45.98 Favored 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.487 179.412 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -113.78 151.19 32.35 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 119.404 -0.918 . . . . 0.0 112.335 -178.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.6 p -153.78 132.07 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.34 178.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.7 m -119.06 94.5 4.46 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 119.749 -0.78 . . . . 0.0 111.493 -179.153 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.5 mt -79.72 157.77 27.09 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.224 178.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.5 p -150.63 52.68 0.88 Allowed 'General case' 0 C--N 1.3 -1.587 0 C-N-CA 118.536 -1.266 . . . . 0.0 111.949 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.4 ' O ' ' C ' ' A' ' 75' ' ' LYS . 2.9 tt0 -150.73 99.41 2.73 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 118.73 -1.188 . . . . 0.0 109.934 178.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 74' ' ' GLU . 0.8 OUTLIER -39.87 108.96 0.1 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.255 -178.908 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.51 -148.46 8.43 Favored Glycine 0 N--CA 1.485 1.921 0 C-N-CA 119.29 -1.433 . . . . 0.0 110.302 -179.82 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -141.49 129.99 22.58 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.472 -0.891 . . . . 0.0 111.218 -179.799 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.61 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.6 OUTLIER -119.64 161.6 20.4 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.426 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 32.2 mttt -128.98 131.96 47.5 Favored 'General case' 0 N--CA 1.49 1.567 0 C-N-CA 119.187 -1.005 . . . . 0.0 111.958 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.544 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -139.25 158.75 43.62 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.829 177.712 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -167.78 -175.11 2.64 Favored 'General case' 0 C--N 1.288 -2.079 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.989 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -111.98 119.75 39.54 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.913 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.576 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.3 tt0 -65.41 -42.37 57.35 Favored Pre-proline 0 N--CA 1.486 1.326 0 C-N-CA 119.931 -0.708 . . . . 0.0 112.724 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.576 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.1 Cg_endo -69.45 -48.2 0.84 Allowed 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 121.108 1.205 . . . . 0.0 112.035 -179.381 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -90.03 10.39 24.31 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.647 -179.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.08 -35.45 62.09 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 118.906 -1.117 . . . . 0.0 110.475 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -62.23 -21.14 61.53 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.199 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -85.3 -17.29 37.31 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.278 179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.23 23.79 9.42 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 119.716 -1.23 . . . . 0.0 110.731 179.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -75.95 101.01 5.04 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.131 -1.028 . . . . 0.0 110.979 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.32 149.67 46.31 Favored 'General case' 0 N--CA 1.49 1.56 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.751 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -137.76 149.13 20.25 Favored Glycine 0 N--CA 1.496 2.655 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.352 -178.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -155.63 148.87 24.7 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 120.004 -0.678 . . . . 0.0 110.395 179.45 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.493 HG13 ' O ' ' A' ' 94' ' ' VAL . 7.1 p -139.08 128.99 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.81 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.9 m -104.91 98.55 8.25 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.159 179.32 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 42.4 t -79.13 150.63 5.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 118.632 -1.227 . . . . 0.0 110.453 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 89.2 m-20 . . . . . 0 N--CA 1.489 1.489 0 CA-C-O 116.333 -1.794 . . . . 0.0 110.894 -179.761 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.128 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -112.62 118.67 35.71 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 120.029 -0.668 . . . . 0.0 110.535 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 83.9 t -102.34 119.9 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.705 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 8.5 mptt -87.12 110.28 20.01 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.959 -179.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 11.9 mt -76.27 104.37 6.76 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.753 177.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 104.23 107.59 3.21 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.1 p . . . . . 0 C--N 1.304 -1.38 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.442 179.861 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.0 mt . . . . . 0 N--CA 1.484 1.235 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.2 m -149.71 160.41 4.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 C-N-CA 119.064 -1.054 . . . . 0.0 110.955 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.456 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 59.3 m-85 -79.02 113.11 16.88 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 176.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.9 m -114.74 110.87 46.24 Favored Pre-proline 0 N--CA 1.485 1.293 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.935 -177.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.44 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.9 Cg_endo -65.56 176.1 20.2 Favored 'Cis proline' 0 C--N 1.363 1.324 0 C-N-CA 125.254 -0.728 . . . . 0.0 111.751 -0.254 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.2 p -96.34 -60.86 1.53 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.467 179.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 60.7 p -123.74 136.69 54.59 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.752 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 p90 -163.08 146.45 10.75 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 118.583 -1.247 . . . . 0.0 111.443 -179.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.428 HG23 ' H ' ' A' ' 20' ' ' THR . 0.8 OUTLIER -89.62 153.49 20.71 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.445 -0.902 . . . . 0.0 111.075 179.92 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.3 m -145.87 176.46 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.641 179.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.03 150.79 21.29 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.589 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.12 66.85 0.87 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.997 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.45 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 166.75 11.73 0.03 OUTLIER Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.45 ' H ' ' H ' ' A' ' 24' ' ' GLY . 25.9 tt0 -97.99 155.2 17.21 Favored 'General case' 0 C--N 1.307 -1.276 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.078 -179.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.52 133.47 39.49 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.033 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.7 mt -115.3 114.53 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 C-N-CA 120.022 -0.671 . . . . 0.0 109.614 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 73.2 p -106.87 117.04 32.99 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.782 -0.767 . . . . 0.0 112.417 -178.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -84.17 107.02 16.26 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.6 ttmt -96.59 142.98 28.0 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.054 -1.058 . . . . 0.0 111.295 -177.512 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.553 ' OD1' ' CD1' ' A' ' 35' ' ' PHE . 19.9 t-20 -100.12 121.23 41.09 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.509 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -132.83 -8.79 3.12 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.961 -1.095 . . . . 0.0 112.13 -179.571 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -168.61 132.25 1.49 Allowed 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 117.986 -1.485 . . . . 0.0 112.711 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.79 59.99 2.87 Favored Glycine 0 N--CA 1.49 2.296 0 C-N-CA 119.868 -1.158 . . . . 0.0 113.805 177.08 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.553 ' CD1' ' OD1' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -97.06 165.12 16.42 Favored Pre-proline 0 N--CA 1.493 1.685 0 C-N-CA 118.978 -1.089 . . . . 0.0 108.382 176.86 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.5 Cg_endo -77.97 147.41 83.33 Favored 'Cis proline' 0 C--O 1.214 -0.685 0 C-N-CA 124.615 -0.994 . . . . 0.0 112.938 -0.731 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -103.0 175.21 5.55 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.299 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.603 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.3 OUTLIER -150.81 124.71 9.21 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 119.205 -0.998 . . . . 0.0 110.764 179.703 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.603 ' N ' HD22 ' A' ' 38' ' ' ASN . 0.1 OUTLIER -107.85 115.68 49.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.71 179.78 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.8 t -140.23 141.7 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.194 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.3 m-85 -99.73 122.24 42.43 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 119.457 -0.897 . . . . 0.0 111.864 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.531 ' C ' ' H ' ' A' ' 44' ' ' ASP . 0.7 OUTLIER -64.96 111.86 3.04 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.029 179.183 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -66.64 11.12 0.1 Allowed 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.134 -1.026 . . . . 0.0 111.108 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.531 ' H ' ' C ' ' A' ' 42' ' ' ASP . 50.2 m-20 -93.35 -15.35 25.82 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 119.318 -0.953 . . . . 0.0 111.185 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -141.05 50.22 1.64 Allowed 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 119.635 -0.826 . . . . 0.0 110.495 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -128.41 144.86 53.54 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.931 179.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -48.28 150.65 5.15 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 120.831 1.02 . . . . 0.0 111.959 -179.384 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.53 47.65 0.85 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.926 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -157.78 -44.28 0.02 OUTLIER Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.456 -1.354 . . . . 0.0 109.975 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.6 t -83.57 84.42 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.313 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -44.48 142.48 1.59 Allowed 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.841 -0.743 . . . . 0.0 111.191 -179.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -86.9 -9.74 54.98 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.872 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -85.78 -11.99 52.09 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.853 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.29 -36.24 12.67 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.014 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -89.91 -21.43 6.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 C-N-CA 119.253 -0.979 . . . . 0.0 111.191 -179.774 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 51.6 m -74.43 178.19 5.42 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.415 -0.914 . . . . 0.0 111.142 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.636 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.3 pm0 -159.17 77.37 3.06 Favored Pre-proline 0 C--N 1.303 -1.424 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.018 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . 0.442 ' HA ' HD21 ' A' ' 38' ' ' ASN . 2.8 Cg_exo -57.78 -0.41 0.39 Allowed 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 121.09 1.193 . . . . 0.0 111.575 -178.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.489 ' H ' ' C ' ' A' ' 57' ' ' GLN . 2.7 mm-40 -80.8 92.39 6.07 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.17 -1.012 . . . . 0.0 110.046 178.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.401 ' O ' ' O ' ' A' ' 59' ' ' GLU . 38.3 m-85 -41.02 162.19 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.521 -179.388 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -135.07 108.63 7.92 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.488 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -104.72 3.51 31.47 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.907 -0.717 . . . . 0.0 110.956 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -73.64 117.74 5.88 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.378 -1.391 . . . . 0.0 110.558 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -59.38 108.68 0.74 Allowed 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.638 -0.825 . . . . 0.0 111.012 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.48 -6.21 59.11 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 119.516 -1.326 . . . . 0.0 110.817 179.595 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -62.23 149.98 40.28 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 118.996 -1.081 . . . . 0.0 110.674 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -140.8 164.44 30.21 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.421 -0.912 . . . . 0.0 111.625 -179.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.636 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 17.5 t80 -136.05 130.16 33.06 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.343 179.482 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -94.82 154.38 17.28 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 119.124 -1.03 . . . . 0.0 112.236 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.2 t -152.62 130.97 2.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 114.952 -1.022 . . . . 0.0 108.735 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.3 m -121.04 103.35 8.97 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.68 -178.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 65.7 mt -86.59 158.41 19.51 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.247 -0.981 . . . . 0.0 109.751 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.03 40.94 0.73 Allowed 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 118.845 -1.142 . . . . 0.0 111.614 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -142.97 102.18 3.96 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 118.787 -1.165 . . . . 0.0 110.801 179.453 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -43.24 114.44 0.62 Allowed 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.18 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 173.04 -145.36 8.36 Favored Glycine 0 N--CA 1.486 2.0 0 C-N-CA 119.395 -1.383 . . . . 0.0 110.038 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.7 127.83 17.59 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.444 -0.902 . . . . 0.0 110.893 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.566 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -114.72 167.14 11.02 Favored 'General case' 0 N--CA 1.481 1.12 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.123 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 20.4 mmtp -134.96 123.47 23.4 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.421 -0.912 . . . . 0.0 112.338 -178.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.543 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.1 p90 -132.72 161.73 33.25 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.774 -0.77 . . . . 0.0 110.359 178.033 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 34.3 p90 -170.35 -174.08 1.61 Allowed 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.382 -178.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . 0.443 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.6 t -113.27 134.51 54.56 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.527 179.483 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.5 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.3 mt-10 -75.61 -46.16 4.21 Favored Pre-proline 0 C--N 1.308 -1.224 0 C-N-CA 119.571 -0.852 . . . . 0.0 112.927 -179.376 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -67.62 -41.97 7.66 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.901 1.067 . . . . 0.0 112.266 -179.192 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -93.99 20.71 7.49 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.447 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.443 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -74.27 -11.74 60.36 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.126 -1.03 . . . . 0.0 110.548 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -74.83 -18.48 80.11 Favored Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.345 -1.407 . . . . 0.0 110.247 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.72 -49.48 5.59 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.54 -0.864 . . . . 0.0 110.539 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 143.91 23.55 0.16 Allowed Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.467 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.7 103.54 3.1 Favored 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.052 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 6.5 mtpp -130.93 168.49 17.23 Favored 'General case' 0 N--CA 1.494 1.748 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.384 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -153.62 147.29 16.5 Favored Glycine 0 N--CA 1.493 2.492 0 C-N-CA 119.258 -1.449 . . . . 0.0 111.614 -179.068 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -152.66 146.3 25.05 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 120.004 -0.678 . . . . 0.0 109.979 179.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.463 HG13 ' O ' ' A' ' 94' ' ' VAL . 8.4 p -137.64 127.59 36.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 C-N-CA 119.1 -1.04 . . . . 0.0 111.148 -179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.409 HG22 ' ND2' ' A' ' 97' ' ' ASN . 48.2 m -102.0 98.14 8.39 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.346 179.097 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.48 145.63 9.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 118.726 -1.19 . . . . 0.0 110.489 -178.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.409 ' ND2' HG22 ' A' ' 95' ' ' THR . 30.8 m-80 . . . . . 0 C--N 1.306 -1.303 0 CA-C-O 116.337 -1.792 . . . . 0.0 110.649 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.206 0 N-CA-C 110.148 -0.315 . . . . 0.0 110.148 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -105.16 136.48 44.59 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.829 -0.749 . . . . 0.0 110.825 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.8 t -117.87 143.7 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.931 179.679 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 13.3 mttm -113.39 107.57 16.04 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.797 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.8 mp -74.69 110.38 8.94 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 118.527 -1.269 . . . . 0.0 109.701 178.437 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.422 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.01 129.17 6.59 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 -179.217 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.3 p . . . . . 0 C--N 1.302 -1.463 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.716 -179.988 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 mt . . . . . 0 N--CA 1.486 1.338 0 CA-C-O 120.665 0.269 . . . . 0.0 110.58 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.9 m -150.03 155.72 7.61 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 119.139 -1.024 . . . . 0.0 110.996 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.414 ' O ' ' O ' ' A' ' 16' ' ' PRO . 61.2 m-85 -78.54 108.44 11.93 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 29.3 m -113.15 110.6 50.98 Favored Pre-proline 0 C--N 1.305 -1.359 0 C-N-CA 119.719 -0.792 . . . . 0.0 112.173 -177.619 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.414 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.2 Cg_endo -67.02 174.56 29.76 Favored 'Cis proline' 0 C--N 1.36 1.137 0 C-N-CA 125.337 -0.693 . . . . 0.0 111.626 -0.215 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.13 -66.06 0.94 Allowed 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 119.494 -0.883 . . . . 0.0 109.985 179.079 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.6 t -114.92 132.53 56.52 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.42 178.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.448 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 11.1 p90 -157.25 137.8 13.04 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 118.596 -1.242 . . . . 0.0 111.227 -179.137 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.452 HG23 ' H ' ' A' ' 20' ' ' THR . 0.6 OUTLIER -82.28 161.79 22.52 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.184 -1.006 . . . . 0.0 111.082 -179.935 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.3 m -148.97 162.49 4.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.098 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.457 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -77.05 142.6 39.78 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.872 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.11 76.76 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.066 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.85 19.77 0.1 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -102.74 162.39 12.97 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.793 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -95.59 150.85 19.89 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.529 -0.869 . . . . 0.0 111.371 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.8 mm -124.26 103.4 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.002 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.3 p -100.58 114.08 27.45 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.536 -0.866 . . . . 0.0 112.745 -178.205 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -83.8 122.32 28.52 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 177.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.3 tttp -121.34 121.56 37.91 Favored 'General case' 0 N--CA 1.502 2.129 0 C-N-CA 119.396 -0.922 . . . . 0.0 112.104 -177.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 0.6 OUTLIER -69.94 113.13 6.87 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.737 179.551 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.487 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.9 t30 -100.34 -27.87 13.25 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.685 -179.282 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.487 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 175.85 141.33 0.06 Allowed 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 119.256 -0.978 . . . . 0.0 111.122 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 103.2 0.12 47.52 Favored Glycine 0 N--CA 1.494 2.505 0 C-N-CA 119.428 -1.368 . . . . 0.0 112.194 178.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -48.16 162.66 0.32 Allowed Pre-proline 0 N--CA 1.487 1.386 0 C-N-CA 118.013 -1.475 . . . . 0.0 109.614 179.766 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -78.59 154.06 91.76 Favored 'Cis proline' 0 C--O 1.215 -0.635 0 C-N-CA 124.354 -1.102 . . . . 0.0 112.288 -0.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 43.8 m-70 -115.62 -177.02 3.05 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.016 178.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.414 HD22 ' C ' ' A' ' 38' ' ' ASN . 0.2 OUTLIER -159.75 108.54 1.78 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.41 178.979 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.2 mp -91.65 121.35 42.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.011 -1.076 . . . . 0.0 111.906 -179.103 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.2 t -134.76 142.37 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.716 179.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -99.48 123.82 44.09 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.309 -0.956 . . . . 0.0 111.577 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.513 ' C ' ' H ' ' A' ' 44' ' ' ASP . 10.5 t0 -68.75 112.0 5.2 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.911 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -72.67 25.46 0.06 Allowed 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.546 -0.861 . . . . 0.0 111.132 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.513 ' H ' ' C ' ' A' ' 42' ' ' ASP . 32.0 m-20 -108.56 -7.9 15.61 Favored 'General case' 0 N--CA 1.49 1.557 0 C-N-CA 119.888 -0.725 . . . . 0.0 110.812 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -142.75 13.4 1.91 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.706 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -93.05 144.37 28.27 Favored Pre-proline 0 C--N 1.298 -1.658 0 C-N-CA 119.559 -0.856 . . . . 0.0 109.693 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -49.15 148.52 9.78 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.931 1.087 . . . . 0.0 112.09 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.79 74.91 5.31 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 119.651 -0.82 . . . . 0.0 110.49 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.66 -51.12 0.19 Allowed Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 84.4 t -72.3 87.09 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.006 179.088 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -44.47 139.23 2.86 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.77 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -91.14 -16.05 28.41 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.878 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -81.13 -11.74 59.4 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.699 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.9 mtmt -91.89 -27.3 18.01 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.299 -0.96 . . . . 0.0 111.071 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.2 pt -92.31 -30.44 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 C-N-CA 119.149 -1.02 . . . . 0.0 110.727 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.1 m -71.07 167.58 18.96 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.095 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.609 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -136.17 81.1 39.14 Favored Pre-proline 0 C--N 1.302 -1.46 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.567 179.285 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_exo -56.05 -16.34 16.34 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 121.317 1.345 . . . . 0.0 112.114 -178.315 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.414 ' O ' ' O ' ' A' ' 60' ' ' TYR . 9.6 mt-10 -73.24 103.32 3.91 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.001 179.157 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.414 ' O ' ' O ' ' A' ' 59' ' ' GLU . 83.6 m-85 -43.71 168.39 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 119.6 -0.84 . . . . 0.0 111.148 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.1 pp -147.53 139.17 23.96 Favored 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.379 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -141.15 28.86 1.86 Allowed 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.843 -179.354 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -92.11 115.24 4.74 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.203 -1.475 . . . . 0.0 110.614 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.37 110.33 1.22 Allowed 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.857 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 98.74 -13.02 62.7 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.521 -1.323 . . . . 0.0 110.414 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 38.9 tt0 -62.65 148.95 44.8 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.246 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.11 164.81 29.16 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.244 -0.982 . . . . 0.0 111.371 -179.643 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.609 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 36.9 t80 -135.53 133.16 38.13 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 120.011 -0.676 . . . . 0.0 109.492 179.566 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -94.83 152.88 18.03 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.184 -178.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 t -150.59 135.38 9.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.267 179.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.5 m -127.65 102.4 6.81 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.417 -0.913 . . . . 0.0 112.254 -178.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 19.9 mt -89.47 155.81 19.06 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.184 -1.006 . . . . 0.0 109.02 178.37 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.63 ' O ' HG22 ' A' ' 73' ' ' THR . 67.2 m -150.94 47.81 0.85 Allowed 'General case' 0 C--N 1.293 -1.854 0 C-N-CA 118.878 -1.129 . . . . 0.0 111.79 -179.05 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.425 ' OE2' ' N ' ' A' ' 75' ' ' LYS . 5.2 tp10 -145.91 103.07 3.72 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 118.95 -1.1 . . . . 0.0 110.017 179.204 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.425 ' N ' ' OE2' ' A' ' 74' ' ' GLU . 0.0 OUTLIER -40.69 114.19 0.44 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.49 -179.25 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 170.93 -148.93 11.72 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.169 -1.491 . . . . 0.0 110.372 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -140.32 133.07 28.99 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.926 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.589 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -119.41 154.3 33.89 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.477 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 15.2 mmtm -126.01 128.41 47.41 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.239 -0.985 . . . . 0.0 112.113 -178.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.556 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.1 p90 -137.23 165.44 26.11 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.063 -0.972 . . . . 0.0 110.357 178.463 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.9 p90 -170.58 -175.72 1.93 Allowed 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 119.724 -0.791 . . . . 0.0 110.277 -178.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.2 t -110.38 126.77 54.63 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.498 -0.881 . . . . 0.0 109.95 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.547 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 3.9 tm-20 -73.17 -36.72 3.39 Favored Pre-proline 0 N--CA 1.486 1.366 0 C-N-CA 119.181 -1.008 . . . . 0.0 113.689 -178.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.547 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -70.66 -52.39 0.26 Allowed 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 120.527 0.818 . . . . 0.0 110.998 179.701 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -80.25 12.82 2.67 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.759 -0.776 . . . . 0.0 110.791 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.45 -13.43 8.71 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.53 -0.868 . . . . 0.0 110.862 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.26 -18.19 79.45 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.277 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.28 -32.19 13.75 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.921 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.53 8.35 9.21 Favored Glycine 0 N--CA 1.497 2.711 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -50.27 105.26 0.09 Allowed 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.951 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.6 pttp -129.53 160.69 32.43 Favored 'General case' 0 N--CA 1.497 1.883 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.329 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.22 152.21 24.1 Favored Glycine 0 N--CA 1.497 2.742 0 C-N-CA 119.458 -1.354 . . . . 0.0 111.372 -178.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 72.1 tt0 -154.25 148.69 26.16 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.654 -0.818 . . . . 0.0 110.83 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.499 HG13 ' O ' ' A' ' 94' ' ' VAL . 10.8 p -140.04 125.63 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 C-N-CA 119.205 -0.998 . . . . 0.0 110.449 179.389 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 41.4 m -102.89 99.82 9.76 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.459 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 43.3 t -79.22 147.11 6.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 C-N-CA 118.558 -1.257 . . . . 0.0 110.597 -178.788 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.401 ' OD1' ' N ' ' A' ' 97' ' ' ASN . 12.0 p-10 . . . . . 0 C--N 1.305 -1.338 0 CA-C-O 116.275 -1.822 . . . . 0.0 110.787 -179.782 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 CA-C-O 120.783 0.325 . . . . 0.0 110.169 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -133.14 130.27 38.98 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 120.021 -0.672 . . . . 0.0 110.575 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.1 t -125.55 126.76 70.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.974 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 21.7 mttm -99.83 119.37 38.08 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.985 -179.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.442 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 77.8 mt -79.35 104.01 9.67 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.142 178.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.437 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 116.31 138.35 6.3 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -178.63 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 58.2 p . . . . . 0 C--N 1.304 -1.403 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.073 -179.627 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 28.1 mt . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 110.426 -0.213 . . . . 0.0 110.426 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.6 m -150.07 155.85 7.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 C-N-CA 118.807 -1.157 . . . . 0.0 111.109 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 18.6 m-85 -78.37 112.1 15.05 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.45 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.8 m -116.17 107.96 46.74 Favored Pre-proline 0 CA--C 1.56 1.354 0 C-N-CA 119.496 -0.882 . . . . 0.0 111.968 -177.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.405 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.3 Cg_endo -65.91 175.53 22.77 Favored 'Cis proline' 0 C--N 1.362 1.268 0 C-N-CA 125.221 -0.741 . . . . 0.0 111.448 0.119 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.01 -45.82 6.12 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.65 -0.82 . . . . 0.0 110.056 179.415 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -137.66 135.18 36.27 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.525 179.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 18.4 p90 -161.5 143.76 11.91 Favored 'General case' 0 N--CA 1.485 1.285 0 C-N-CA 118.577 -1.249 . . . . 0.0 111.497 -179.093 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.3 p -87.27 156.55 19.59 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.331 -0.948 . . . . 0.0 110.957 179.77 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.8 m -148.61 173.12 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.896 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.416 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -88.8 149.43 23.42 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.415 179.635 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.8 74.32 0.1 Allowed 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.981 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 156.08 16.42 0.04 OUTLIER Glycine 0 N--CA 1.488 2.16 0 C-N-CA 119.562 -1.304 . . . . 0.0 109.983 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -95.52 151.26 19.47 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.914 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ptmt -95.34 123.58 38.94 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.527 -0.869 . . . . 0.0 111.114 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.0 mt -101.86 108.07 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.696 179.6 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 p -104.48 112.42 25.47 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.653 -0.819 . . . . 0.0 112.572 -178.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -84.83 116.74 23.46 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.142 178.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.1 ttpt -113.1 126.31 55.32 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.389 -178.036 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -68.11 113.97 6.22 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.737 178.648 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.645 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 2.4 p-10 -107.31 -22.3 12.64 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 119.171 -1.011 . . . . 0.0 111.15 179.552 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.645 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 169.38 114.46 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 118.926 -1.11 . . . . 0.0 111.113 179.511 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 129.15 7.73 3.93 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.124 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.514 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -57.68 161.63 6.01 Favored Pre-proline 0 C--N 1.306 -1.292 0 C-N-CA 118.521 -1.272 . . . . 0.0 109.95 -179.947 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -80.01 152.68 85.23 Favored 'Cis proline' 0 C--O 1.213 -0.731 0 C-N-CA 124.037 -1.235 . . . . 0.0 112.326 -1.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 45.1 m-70 -113.06 165.19 12.6 Favored 'General case' 0 N--CA 1.493 1.722 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.246 178.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.403 ' C ' ' ND2' ' A' ' 38' ' ' ASN . 1.2 t-20 -149.6 99.76 2.91 Favored 'General case' 0 N--CA 1.49 1.549 0 C-N-CA 118.974 -1.09 . . . . 0.0 110.783 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.8 mp -84.95 135.65 24.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 119.279 -0.969 . . . . 0.0 111.472 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -143.55 143.56 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.004 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.682 ' CD2' HD12 ' A' ' 55' ' ' ILE . 27.5 m-85 -101.56 123.0 44.88 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.539 -0.864 . . . . 0.0 111.702 -179.396 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -66.33 118.06 9.46 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 119.404 -0.918 . . . . 0.0 109.994 179.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.589 ' H ' ' CD ' ' A' ' 43' ' ' GLU . 1.5 pm0 -71.32 -6.65 41.55 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 119.454 -0.898 . . . . 0.0 112.211 -178.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -95.58 5.89 50.35 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.174 -1.01 . . . . 0.0 111.574 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -143.22 16.67 1.89 Allowed 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.702 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -105.19 151.64 39.61 Favored Pre-proline 0 N--CA 1.489 1.481 0 CA-C-N 115.241 -0.89 . . . . 0.0 108.635 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -46.37 151.04 1.9 Allowed 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 121.173 1.249 . . . . 0.0 112.131 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.93 72.12 6.67 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.859 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.58 -35.39 0.14 Allowed Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.548 -1.31 . . . . 0.0 110.054 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 72.8 t -90.34 95.24 5.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.612 179.661 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 66.0 m-20 -50.15 152.9 1.57 Allowed 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.167 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.478 ' C ' ' H ' ' A' ' 54' ' ' LYS . . . -83.09 -38.25 22.74 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.468 179.641 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -63.69 0.52 0.77 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.387 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.478 ' H ' ' C ' ' A' ' 52' ' ' ALA . 0.0 OUTLIER -91.36 -45.68 8.45 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.583 179.973 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.682 HD12 ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -94.46 -25.35 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.875 179.927 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 37.3 m -48.74 164.63 0.06 Allowed 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.503 -0.879 . . . . 0.0 110.902 179.695 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.624 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 8.0 mt-30 -138.05 73.96 44.26 Favored Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 120.021 -0.671 . . . . 0.0 110.845 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -61.46 -25.6 80.01 Favored 'Trans proline' 0 C--N 1.324 -0.721 0 C-N-CA 121.301 1.334 . . . . 0.0 111.325 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -68.28 97.76 0.76 Allowed 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.421 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 47.5 m-85 -48.19 162.89 0.07 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.509 -0.877 . . . . 0.0 111.219 -179.7 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -142.22 106.32 4.76 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.751 179.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -114.23 21.45 14.69 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.075 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -90.85 118.64 5.42 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.281 -1.438 . . . . 0.0 110.525 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -58.42 111.35 1.2 Allowed 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.63 179.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.82 -13.35 57.76 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.732 -1.223 . . . . 0.0 110.407 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -60.81 148.04 40.58 Favored 'General case' 0 N--CA 1.487 1.402 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.456 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 2.3 p -145.83 165.4 28.99 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.275 -0.97 . . . . 0.0 111.3 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.624 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 38.3 t80 -136.15 146.99 47.51 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.868 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.443 ' CD ' ' H ' ' A' ' 69' ' ' GLU . 2.1 mp0 -106.88 154.1 21.54 Favored 'General case' 0 N--CA 1.496 1.874 0 C-N-CA 119.431 -0.908 . . . . 0.0 112.164 -179.053 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -151.18 134.23 7.02 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.137 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 12.5 m -129.44 114.24 15.9 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.735 -0.786 . . . . 0.0 111.125 -179.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.49 ' CD1' HG11 ' A' ' 94' ' ' VAL . 17.1 mt -97.6 163.44 12.84 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.696 -0.802 . . . . 0.0 110.079 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.597 ' O ' HG22 ' A' ' 73' ' ' THR . 62.3 m -150.38 51.95 0.89 Allowed 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 118.939 -1.104 . . . . 0.0 111.468 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -152.72 105.8 3.01 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 118.916 -1.114 . . . . 0.0 110.658 179.533 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -48.85 110.43 0.35 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.958 -1.097 . . . . 0.0 110.609 -179.695 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.39 -142.66 6.29 Favored Glycine 0 N--CA 1.488 2.139 0 C-N-CA 119.218 -1.468 . . . . 0.0 110.078 -179.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.408 HG23 HG23 ' A' ' 95' ' ' THR . 0.0 OUTLIER -143.58 129.25 19.23 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.357 -0.937 . . . . 0.0 111.114 -179.845 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.568 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -116.03 122.86 46.45 Favored 'General case' 0 N--CA 1.484 1.236 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.535 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.425 ' N ' ' CD ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -95.04 113.99 25.75 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.992 -178.843 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.555 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -122.83 165.39 16.71 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.608 178.307 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 30.9 p90 -170.78 -177.62 2.34 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.971 -178.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -110.28 113.27 25.81 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.462 178.483 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.541 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.8 tt0 -65.79 -39.75 33.86 Favored Pre-proline 0 C--N 1.303 -1.427 0 C-N-CA 119.416 -0.914 . . . . 0.0 112.891 -178.735 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.541 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.5 Cg_endo -68.53 -50.39 0.68 Allowed 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 120.499 0.8 . . . . 0.0 111.804 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -83.26 15.8 2.76 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.998 -179.579 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.97 -1.97 4.73 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.636 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -72.4 -27.46 69.68 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.307 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.77 -50.48 5.13 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.561 -0.856 . . . . 0.0 110.456 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.84 30.67 0.12 Allowed Glycine 0 N--CA 1.486 1.987 0 C-N-CA 119.618 -1.277 . . . . 0.0 110.492 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 2.5 mtp -72.17 97.65 1.99 Allowed 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.149 -1.02 . . . . 0.0 111.02 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.481 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -122.76 168.06 12.7 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.66 179.688 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -150.53 146.33 15.25 Favored Glycine 0 N--CA 1.487 2.082 0 C-N-CA 118.883 -1.627 . . . . 0.0 111.563 -178.658 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -149.51 140.87 23.23 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 119.808 -0.757 . . . . 0.0 110.535 179.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.572 HG13 ' O ' ' A' ' 94' ' ' VAL . 14.4 p -131.96 120.57 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.729 179.484 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.408 HG23 HG23 ' A' ' 77' ' ' THR . 6.6 m -94.92 96.97 9.66 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.23 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.6 t -79.98 153.01 4.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.639 -178.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.307 -1.251 0 CA-C-O 116.349 -1.786 . . . . 0.0 110.775 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.138 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 -103.74 152.43 21.86 Favored 'General case' 0 N--CA 1.49 1.525 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.856 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.3 t -134.03 145.72 32.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 C-N-CA 119.718 -0.793 . . . . 0.0 110.591 179.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -114.74 109.15 17.76 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 115.118 -0.947 . . . . 0.0 110.609 -179.502 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.438 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 3.9 mt -78.9 106.49 10.96 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.131 -1.027 . . . . 0.0 109.848 179.044 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.427 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 115.29 138.18 6.48 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -178.609 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.437 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 32.1 p . . . . . 0 C--N 1.302 -1.458 0 C-N-CA 119.363 -0.935 . . . . 0.0 111.383 -179.411 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.7 mt . . . . . 0 N--CA 1.489 1.485 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.9 m -139.73 161.45 26.8 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 C-N-CA 119.376 -0.929 . . . . 0.0 111.501 -178.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.422 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 22.4 m-85 -78.41 110.46 13.48 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 177.793 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 5.6 m -115.67 106.32 50.42 Favored Pre-proline 0 N--CA 1.486 1.348 0 C-N-CA 119.775 -0.77 . . . . 0.0 111.315 -178.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.402 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.7 Cg_endo -66.78 174.61 28.67 Favored 'Cis proline' 0 C--N 1.356 0.94 0 C-N-CA 125.326 -0.698 . . . . 0.0 112.075 0.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -93.3 -55.05 3.45 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.885 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 69.8 m -125.15 140.36 52.94 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.541 179.022 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.438 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 10.4 p90 -156.69 132.06 9.28 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 118.649 -1.22 . . . . 0.0 111.397 -179.315 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.5 p -87.86 152.58 21.98 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.081 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.4 m -147.0 176.13 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.865 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -90.14 155.89 18.73 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.506 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.49 61.21 0.68 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.565 -0.854 . . . . 0.0 111.296 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 170.77 11.91 0.02 OUTLIER Glycine 0 N--CA 1.489 2.216 0 C-N-CA 119.569 -1.3 . . . . 0.0 109.91 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.408 ' OE1' ' O ' ' A' ' 26' ' ' LYS . 5.7 tm-20 -104.61 123.37 47.44 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.969 -0.693 . . . . 0.0 110.831 -179.636 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.408 ' O ' ' OE1' ' A' ' 25' ' ' GLU . 1.3 pttp -69.73 150.31 47.07 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.25 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mt -122.86 147.45 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.2 p -139.22 117.56 11.99 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.218 -0.993 . . . . 0.0 111.626 -179.321 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -84.28 150.58 25.32 Favored 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 119.267 -0.973 . . . . 0.0 109.796 179.058 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -144.55 138.72 27.69 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 118.999 -1.08 . . . . 0.0 111.707 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.651 HD21 ' CB ' ' A' ' 66' ' ' GLU . 0.5 OUTLIER -85.31 131.27 34.44 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.423 178.839 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.465 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 5.6 p-10 -111.56 -32.38 6.7 Favored 'General case' 0 N--CA 1.505 2.281 0 C-N-CA 119.107 -1.037 . . . . 0.0 112.587 -179.631 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.465 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 176.42 30.48 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 118.941 -1.104 . . . . 0.0 110.819 -179.433 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.493 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -138.78 40.3 1.47 Allowed Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.229 -1.462 . . . . 0.0 111.233 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.596 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -86.2 161.58 48.82 Favored Pre-proline 0 C--N 1.309 -1.194 0 C-N-CA 118.442 -1.303 . . . . 0.0 109.999 179.226 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -78.65 135.82 38.54 Favored 'Cis proline' 0 C--O 1.215 -0.649 0 C-N-CA 124.075 -1.219 . . . . 0.0 111.568 -0.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.493 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 40.4 m-70 -100.21 -177.1 3.42 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.749 179.589 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.619 ' ND2' ' N ' ' A' ' 39' ' ' ILE . 1.7 t-20 -161.11 146.86 14.36 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.3 -0.96 . . . . 0.0 110.916 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.619 ' N ' ' ND2' ' A' ' 38' ' ' ASN . 3.5 mt -131.0 114.91 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.779 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.478 ' CG2' HD21 ' A' ' 38' ' ' ASN . 3.0 t -137.15 137.24 46.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.124 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 44.1 m-85 -93.67 127.63 39.46 Favored 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.236 -0.986 . . . . 0.0 111.413 -179.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.4 125.77 25.28 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.895 179.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -57.47 -49.94 74.64 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 -177.143 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -85.21 8.23 19.11 Favored 'General case' 0 N--CA 1.498 1.936 0 C-N-CA 118.941 -1.104 . . . . 0.0 113.855 -176.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -126.86 40.35 3.74 Favored 'General case' 0 N--CA 1.495 1.781 0 C-N-CA 119.341 -0.944 . . . . 0.0 110.568 179.347 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.657 HG22 ' HD2' ' A' ' 47' ' ' PRO . 0.5 OUTLIER -135.59 156.33 77.7 Favored Pre-proline 0 N--CA 1.487 1.399 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 179.279 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.657 ' HD2' HG22 ' A' ' 46' ' ' VAL . 3.6 Cg_exo -48.04 148.06 7.24 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 120.916 1.077 . . . . 0.0 111.73 -179.583 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.57 70.37 6.03 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.644 -0.822 . . . . 0.0 111.035 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.37 -22.78 0.09 OUTLIER Glycine 0 N--CA 1.489 2.211 0 C-N-CA 119.342 -1.409 . . . . 0.0 110.435 179.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 44.6 t -97.42 99.78 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.809 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -46.75 149.66 0.81 Allowed 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.256 -0.978 . . . . 0.0 110.715 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.409 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -94.64 -5.69 45.09 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.623 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -86.14 -29.6 23.16 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.107 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 21.4 mmtt -71.87 -27.55 62.94 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.463 -0.895 . . . . 0.0 111.481 -179.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 10.7 pt -105.15 -14.95 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 C-N-CA 119.559 -0.857 . . . . 0.0 111.944 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.409 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 4.7 m -67.32 173.62 3.83 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.241 -0.983 . . . . 0.0 110.827 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.656 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 12.9 tt0 -136.93 76.01 47.14 Favored Pre-proline 0 C--N 1.306 -1.321 0 C-N-CA 120.072 -0.651 . . . . 0.0 110.354 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -60.02 -22.33 68.85 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 121.359 1.373 . . . . 0.0 111.985 -178.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 38.8 mm-40 -89.89 106.83 18.74 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.139 -1.024 . . . . 0.0 110.652 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 30.9 m-85 -56.37 170.5 0.35 Allowed 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.728 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.5 pp -140.26 129.48 23.75 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.098 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -127.68 10.33 6.59 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.521 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.48 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . -77.85 118.78 5.08 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.412 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.9 105.12 0.52 Allowed 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.759 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.24 -2.77 43.66 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.559 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.651 ' CB ' HD21 ' A' ' 31' ' ' ASN . 2.8 tp10 -63.16 161.14 14.05 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 118.916 -1.113 . . . . 0.0 110.229 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 66.8 p -147.45 163.14 37.45 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.556 -179.138 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.656 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 76.0 t80 -135.62 139.14 43.57 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.751 179.05 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -107.59 153.17 23.27 Favored 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 119.513 -0.875 . . . . 0.0 112.577 -178.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 p -161.51 132.9 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.391 178.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.8 m -119.81 95.6 4.84 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.733 -178.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 12.2 mt -80.46 158.49 25.88 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.384 -0.926 . . . . 0.0 109.226 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.0 p -151.14 28.44 0.67 Allowed 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 118.65 -1.22 . . . . 0.0 112.253 -179.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.506 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -114.5 97.75 6.49 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.024 179.599 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.8 tttt -41.68 98.0 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.958 -179.674 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 74' ' ' GLU . . . 177.56 -134.17 2.4 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.176 -1.488 . . . . 0.0 110.257 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -145.31 142.0 29.05 Favored 'General case' 0 C--N 1.309 -1.165 0 C-N-CA 119.216 -0.994 . . . . 0.0 111.519 -179.683 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.574 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.2 m-85 -128.05 128.31 44.72 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.386 -0.825 . . . . 0.0 108.779 179.359 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -105.77 118.97 37.96 Favored 'General case' 0 N--CA 1.488 1.453 0 C-N-CA 119.243 -0.983 . . . . 0.0 111.318 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.1 p90 -124.31 172.91 8.73 Favored 'General case' 0 C--O 1.206 -1.205 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.56 178.532 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -171.06 175.3 4.39 Favored 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 118.932 -1.107 . . . . 0.0 111.577 -178.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.4 t -99.66 127.06 45.77 Favored 'General case' 0 C--N 1.3 -1.587 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.287 179.494 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.593 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 3.2 tm-20 -73.88 -34.95 2.25 Favored Pre-proline 0 N--CA 1.492 1.661 0 C-N-CA 118.85 -1.14 . . . . 0.0 113.667 -178.498 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.1 Cg_endo -72.68 -52.31 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 120.671 0.914 . . . . 0.0 110.99 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 34.4 m80 -81.39 14.72 2.32 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.879 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -62.89 -6.19 3.56 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.187 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.31 -21.43 62.5 Favored Glycine 0 N--CA 1.49 2.267 0 C-N-CA 119.339 -1.41 . . . . 0.0 110.307 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.73 -22.36 18.15 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.956 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.426 ' O ' ' N ' ' A' ' 91' ' ' LYS . . . 109.27 11.82 21.15 Favored Glycine 0 N--CA 1.497 2.754 0 C-N-CA 119.964 -1.112 . . . . 0.0 110.364 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 6.1 ttt -53.9 92.62 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.474 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.53 ' NZ ' ' CB ' ' A' ' 91' ' ' LYS . 0.1 OUTLIER -117.1 158.73 23.7 Favored 'General case' 0 N--CA 1.5 2.039 0 C-N-CA 119.855 -0.738 . . . . 0.0 111.386 -179.73 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.23 146.53 18.45 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.027 -1.082 . . . . 0.0 111.052 -178.676 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -148.85 147.1 28.32 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.842 179.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.435 HG13 ' O ' ' A' ' 94' ' ' VAL . 7.4 p -140.05 129.89 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.195 179.131 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 90.4 m -106.09 100.78 10.31 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.656 -0.818 . . . . 0.0 110.964 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 47.1 t -82.48 142.99 12.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.364 -179.071 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 17.3 p30 . . . . . 0 C--N 1.307 -1.253 0 CA-C-O 116.328 -1.796 . . . . 0.0 110.952 -179.688 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.905 0.383 . . . . 0.0 110.036 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -92.7 131.46 37.76 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.404 -0.918 . . . . 0.0 110.562 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 t -122.29 121.72 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.404 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.58 118.83 31.86 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.186 179.46 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.8 mt -78.54 98.83 6.26 Favored 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.9 179.019 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.464 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 113.59 131.6 5.39 Favored Glycine 0 N--CA 1.488 2.151 0 CA-C-N 114.546 -1.206 . . . . 0.0 110.323 -179.135 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 56.3 p . . . . . 0 C--N 1.302 -1.48 0 C-N-CA 119.299 -0.96 . . . . 0.0 110.548 179.578 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.7 mt . . . . . 0 N--CA 1.492 1.625 0 CA-C-O 120.471 0.177 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.0 m -150.39 157.06 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 118.979 -1.088 . . . . 0.0 110.954 179.45 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.419 ' O ' ' O ' ' A' ' 16' ' ' PRO . 62.2 m-85 -78.27 110.83 13.63 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 16.5 m -114.2 111.62 47.28 Favored Pre-proline 0 CA--C 1.56 1.341 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.948 -177.459 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.419 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.3 Cg_exo -65.83 174.18 26.4 Favored 'Cis proline' 0 C--N 1.36 1.158 0 C-N-CA 125.105 -0.79 . . . . 0.0 111.611 -0.343 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.9 m -97.45 -65.87 0.94 Allowed 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.098 179.256 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 m -114.39 137.68 51.51 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.734 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 34.5 p90 -168.2 147.4 4.58 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 118.49 -1.284 . . . . 0.0 111.656 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.672 HG22 ' HB ' ' A' ' 95' ' ' THR . 44.2 p -83.31 161.55 21.4 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.193 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 31.5 m -149.32 148.72 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.228 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.662 179.541 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.539 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -76.51 140.74 41.29 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.294 -0.962 . . . . 0.0 110.751 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -58.78 78.39 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.242 0 C-N-CA 119.657 -0.817 . . . . 0.0 110.937 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 148.21 21.22 0.09 OUTLIER Glycine 0 N--CA 1.487 2.071 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -102.56 150.34 23.5 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.924 -0.71 . . . . 0.0 110.733 -179.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 74.9 mttt -95.2 117.69 30.69 Favored 'General case' 0 C--N 1.303 -1.434 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.055 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.5 mt -93.22 98.35 8.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 119.501 -0.88 . . . . 0.0 108.962 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 55.0 p -94.34 117.43 30.11 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 119.493 -0.883 . . . . 0.0 112.821 -177.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -84.68 143.62 29.08 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.049 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 11.4 ttpt -135.3 125.55 26.33 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.387 -178.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.525 ' OD1' ' CD1' ' A' ' 35' ' ' PHE . 36.5 t-20 -79.39 115.8 19.24 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 119.792 -0.763 . . . . 0.0 110.009 179.354 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.464 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 3.0 p-10 -120.29 -22.23 6.63 Favored 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.307 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -177.45 123.43 0.13 Allowed 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 118.358 -1.337 . . . . 0.0 112.188 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 104.17 48.6 1.13 Allowed Glycine 0 N--CA 1.495 2.618 0 C-N-CA 119.272 -1.442 . . . . 0.0 112.849 177.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.623 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -87.54 164.83 33.39 Favored Pre-proline 0 C--N 1.304 -1.37 0 C-N-CA 118.573 -1.251 . . . . 0.0 108.936 177.91 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -77.2 140.13 62.6 Favored 'Cis proline' 0 C--O 1.215 -0.642 0 C-N-CA 124.555 -1.019 . . . . 0.0 112.917 -0.5 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 33.6 m-70 -108.15 161.28 15.12 Favored 'General case' 0 N--CA 1.495 1.794 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.952 178.607 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.763 HD21 ' H ' ' A' ' 83' ' ' GLU . 4.0 p-10 -153.52 163.18 40.4 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 119.049 -1.061 . . . . 0.0 110.684 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -133.78 124.35 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.841 -0.743 . . . . 0.0 110.758 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.7 t -137.48 141.31 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.264 179.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.485 ' CE2' HD12 ' A' ' 55' ' ' ILE . 5.6 m-85 -96.39 130.75 43.45 Favored 'General case' 0 C--N 1.303 -1.455 0 C-N-CA 119.574 -0.85 . . . . 0.0 111.706 -178.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -73.9 117.19 15.4 Favored 'General case' 0 N--CA 1.485 1.279 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.789 179.034 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -69.56 0.3 5.57 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.435 -0.906 . . . . 0.0 112.013 -178.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 62.3 m-20 -99.76 -5.79 28.08 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.357 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 31.0 mm-40 -123.37 -2.38 8.52 Favored 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.615 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.407 HG13 ' HD2' ' A' ' 47' ' ' PRO . 42.2 t -95.99 144.93 28.66 Favored Pre-proline 0 C--N 1.285 -2.216 0 N-CA-C 107.256 -1.386 . . . . 0.0 107.256 178.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.473 ' HG2' HG12 ' A' ' 50' ' ' VAL . 1.8 Cg_endo -61.09 165.2 12.82 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 CA-C-N 119.024 0.687 . . . . 0.0 111.89 -178.367 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.8 38.89 0.72 Allowed 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.381 -0.928 . . . . 0.0 110.239 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.18 -57.83 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.684 ' O ' HG13 ' A' ' 50' ' ' VAL . 9.8 p -84.46 101.99 9.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.722 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -48.97 153.81 0.82 Allowed 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.681 -0.808 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -98.29 -10.16 24.35 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.443 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -88.1 -10.46 50.02 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.652 -0.819 . . . . 0.0 110.579 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.4 13.2 16.19 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.465 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.485 HD12 ' CE2' ' A' ' 41' ' ' PHE . 1.1 pt -147.38 -29.09 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 C-N-CA 119.503 -0.879 . . . . 0.0 110.814 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 2.1 m -48.58 174.25 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.948 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.624 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 36.5 mt-30 -135.5 78.95 49.23 Favored Pre-proline 0 N--CA 1.489 1.491 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.022 -179.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -60.58 -7.86 7.97 Favored 'Trans proline' 0 N--CA 1.456 -0.686 0 C-N-CA 120.78 0.987 . . . . 0.0 110.641 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -98.01 127.61 44.06 Favored 'General case' 0 N--CA 1.483 1.179 0 C-N-CA 119.778 -0.769 . . . . 0.0 110.227 179.309 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.435 ' CD1' ' N ' ' A' ' 60' ' ' TYR . 32.4 m-85 -88.59 173.58 8.56 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.917 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -137.94 106.53 5.87 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.658 179.644 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.668 ' H ' ' ND2' ' A' ' 62' ' ' ASN . 0.3 OUTLIER -101.67 3.65 39.97 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.912 179.993 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -65.83 -140.58 0.04 OUTLIER Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.392 -1.385 . . . . 0.0 110.413 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -159.42 99.61 1.46 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.68 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.44 -1.12 43.01 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 119.815 -1.183 . . . . 0.0 110.44 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -63.03 158.74 18.72 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.56 179.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.2 p -147.26 155.48 42.09 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.828 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.624 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 41.0 t80 -136.97 153.51 50.67 Favored 'General case' 0 N--CA 1.488 1.444 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.443 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.411 ' O ' ' CE1' ' A' ' 68' ' ' TYR . 3.6 mt-10 -113.41 149.18 34.52 Favored 'General case' 0 N--CA 1.501 2.082 0 C-N-CA 119.44 -0.904 . . . . 0.0 112.224 -179.076 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -144.62 126.04 9.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.182 179.033 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.9 m -119.22 100.11 7.12 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.82 -0.752 . . . . 0.0 111.268 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 65.9 mt -79.55 161.28 26.08 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.65 179.171 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.9 p -150.07 48.53 0.91 Allowed 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 118.819 -1.152 . . . . 0.0 111.742 -178.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.4 ' O ' ' C ' ' A' ' 75' ' ' LYS . 3.6 mm-40 -148.17 98.26 2.9 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.567 179.416 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 74' ' ' GLU . 0.0 OUTLIER -43.67 107.8 0.09 Allowed 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.596 -179.784 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 176.48 -141.91 5.7 Favored Glycine 0 C--N 1.294 -1.773 0 C-N-CA 119.066 -1.54 . . . . 0.0 110.094 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.52 136.67 26.22 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.476 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.592 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.2 OUTLIER -128.78 137.64 51.64 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.488 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.37 108.64 16.78 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.932 179.759 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.504 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 2.1 p90 -109.87 170.95 7.74 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.202 179.445 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -171.18 179.84 2.9 Favored 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 119.362 -0.935 . . . . 0.0 112.068 -178.454 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . 0.566 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.5 t -108.96 124.45 50.71 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.205 179.122 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.763 ' H ' HD21 ' A' ' 38' ' ' ASN . 0.3 OUTLIER -68.46 -39.4 15.51 Favored Pre-proline 0 N--CA 1.488 1.442 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -178.283 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.3 Cg_endo -73.35 -51.67 0.16 Allowed 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 121.02 1.147 . . . . 0.0 111.84 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -81.4 8.49 9.17 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.286 -0.966 . . . . 0.0 111.328 -179.327 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.566 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -65.03 -17.28 64.31 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.198 -1.001 . . . . 0.0 110.686 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -65.05 -22.98 69.28 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.493 -1.336 . . . . 0.0 110.248 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.25 -39.82 10.78 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.562 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 135.65 20.89 0.67 Allowed Glycine 0 N--CA 1.493 2.461 0 C-N-CA 119.744 -1.217 . . . . 0.0 110.34 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.98 106.2 2.26 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.312 -0.955 . . . . 0.0 111.19 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.409 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 2.1 pttp -135.15 169.5 17.35 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.938 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.462 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -150.51 150.17 22.14 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 119.013 -1.565 . . . . 0.0 111.417 -178.467 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -150.09 143.52 25.15 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.519 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.435 HG13 ' O ' ' A' ' 94' ' ' VAL . 6.6 p -141.03 126.34 18.77 Favored 'Isoleucine or valine' 0 C--O 1.205 -1.285 0 C-N-CA 119.244 -0.982 . . . . 0.0 110.746 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.672 ' HB ' HG22 ' A' ' 20' ' ' THR . 22.7 m -103.45 103.41 13.38 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.647 -0.821 . . . . 0.0 110.423 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 21.6 t -79.55 143.15 12.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 118.714 -1.194 . . . . 0.0 110.018 -179.36 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 . . . . . 0 N--CA 1.489 1.488 0 CA-C-O 116.314 -1.803 . . . . 0.0 110.818 -179.602 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.096 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -140.21 122.49 15.92 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.748 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 98.4 t -114.52 132.54 63.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 C-N-CA 119.848 -0.741 . . . . 0.0 111.127 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -100.56 111.75 24.03 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.736 -0.786 . . . . 0.0 110.684 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.433 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 9.5 mt -75.68 105.07 6.52 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.923 178.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 112.39 131.68 5.66 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -178.61 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.4 p . . . . . 0 C--N 1.306 -1.309 0 C-N-CA 119.256 -0.978 . . . . 0.0 111.092 -179.63 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.9 mt . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 120.629 0.252 . . . . 0.0 110.915 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.6 m -150.64 157.95 5.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.654 179.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.53 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 34.1 m-85 -78.39 113.24 16.21 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 178.068 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 17.3 m -116.45 107.13 47.5 Favored Pre-proline 0 CA--C 1.562 1.41 0 C-N-CA 119.5 -0.88 . . . . 0.0 112.186 -177.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -65.89 176.24 20.9 Favored 'Cis proline' 0 C--N 1.361 1.217 0 C-N-CA 125.198 -0.751 . . . . 0.0 111.414 -0.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.02 -52.05 4.39 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.486 -0.885 . . . . 0.0 110.265 179.264 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 4.5 m -132.03 135.28 46.4 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.413 179.09 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.478 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 12.8 p90 -155.71 142.32 18.74 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 118.495 -1.282 . . . . 0.0 111.573 -179.097 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.623 HG22 ' HB ' ' A' ' 95' ' ' THR . 46.9 p -84.17 151.24 24.99 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.439 179.458 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.0 m -144.59 161.79 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 119.356 -0.938 . . . . 0.0 111.137 179.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.449 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -81.35 146.55 30.28 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.65 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.05 74.52 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 119.673 -0.811 . . . . 0.0 111.23 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 155.68 18.2 0.04 OUTLIER Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.466 -1.35 . . . . 0.0 109.797 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -98.63 150.95 21.22 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.951 -179.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.8 mttt -92.43 117.95 30.45 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.337 -0.945 . . . . 0.0 111.016 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.6 mt -97.94 110.4 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.771 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 75.6 p -110.94 114.48 27.83 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.672 -0.811 . . . . 0.0 112.515 -178.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -87.01 111.55 20.97 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.373 178.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -106.57 141.01 38.54 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 119.68 -0.808 . . . . 0.0 112.045 -178.535 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.544 HD21 HD11 ' A' ' 61' ' ' LEU . 1.7 m-80 -82.27 115.99 21.59 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.877 178.799 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.537 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 4.2 p-10 -98.75 -32.76 11.21 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 118.755 -1.178 . . . . 0.0 111.839 -179.398 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.537 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 171.91 52.22 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.496 -0.881 . . . . 0.0 110.042 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.506 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -153.45 26.67 0.77 Allowed Glycine 0 N--CA 1.487 2.041 0 C-N-CA 118.992 -1.575 . . . . 0.0 110.734 -179.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.636 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -79.23 160.34 70.9 Favored Pre-proline 0 C--N 1.309 -1.191 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.96 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -77.41 138.66 54.15 Favored 'Cis proline' 0 C--O 1.215 -0.657 0 C-N-CA 123.876 -1.302 . . . . 0.0 111.757 -1.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.506 ' CE1' ' O ' ' A' ' 34' ' ' GLY . 38.2 m-70 -107.66 179.52 4.21 Favored 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 119.631 -0.828 . . . . 0.0 111.49 -179.293 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -156.09 143.25 19.08 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.61 -0.836 . . . . 0.0 110.354 179.781 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.2 mp -130.25 118.31 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.304 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t -145.3 147.65 18.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.656 179.064 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -99.43 139.97 34.29 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.144 -1.022 . . . . 0.0 112.006 -179.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.698 ' C ' ' H ' ' A' ' 44' ' ' ASP . 39.8 p-10 -75.37 108.37 8.11 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 115.142 -0.935 . . . . 0.0 111.296 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.489 ' OE1' ' HB3' ' A' ' 52' ' ' ALA . 27.4 mm-40 -56.47 10.8 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.156 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.589 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.698 ' H ' ' C ' ' A' ' 42' ' ' ASP . 70.8 m-20 -82.92 -68.49 0.7 Allowed 'General case' 0 C--N 1.288 -2.081 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.249 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -99.38 -5.23 29.92 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.826 -1.15 . . . . 0.0 114.038 -175.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -54.15 143.88 41.94 Favored Pre-proline 0 C--N 1.282 -2.362 0 C-N-CA 118.206 -1.397 . . . . 0.0 107.784 179.023 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_exo -46.71 146.92 5.0 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 120.713 0.942 . . . . 0.0 112.116 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -85.34 51.13 2.1 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.771 -0.772 . . . . 0.0 111.051 -179.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -165.63 -23.49 0.02 OUTLIER Glycine 0 N--CA 1.488 2.122 0 C-N-CA 119.478 -1.344 . . . . 0.0 109.965 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 53.2 t -97.85 104.26 15.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.683 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -45.56 139.85 3.6 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 119.223 -0.991 . . . . 0.0 110.567 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.489 ' HB3' ' OE1' ' A' ' 43' ' ' GLU . . . -101.29 -8.29 22.25 Favored 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.229 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -83.79 -21.05 32.28 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.164 -1.014 . . . . 0.0 110.966 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 51.6 mmtt -86.41 -32.88 20.66 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.263 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.4 pt -89.14 -19.81 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 C-N-CA 118.876 -1.13 . . . . 0.0 111.438 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 74.3 m -74.44 -176.6 2.77 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.971 179.354 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.537 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.4 mt-30 -142.51 82.82 12.41 Favored Pre-proline 0 N--CA 1.491 1.617 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.43 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -61.96 -9.59 14.9 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 121.187 1.258 . . . . 0.0 112.067 -179.039 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -99.23 112.55 24.69 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.387 -0.925 . . . . 0.0 110.87 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -58.69 178.04 0.12 Allowed 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.574 -0.851 . . . . 0.0 110.71 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.544 HD11 HD21 ' A' ' 31' ' ' ASN . 2.0 pp -151.21 142.12 22.95 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.551 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.519 ' ND2' ' N ' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -134.58 19.95 3.6 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.883 -179.752 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -86.4 139.26 16.52 Favored Glycine 0 N--CA 1.489 2.213 0 C-N-CA 119.168 -1.491 . . . . 0.0 110.219 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -85.5 111.39 19.95 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.509 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 102.25 -15.21 56.54 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 -179.624 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -64.01 147.02 53.08 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.227 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -142.43 169.92 16.67 Favored 'General case' 0 N--CA 1.486 1.369 0 C-N-CA 119.206 -0.997 . . . . 0.0 111.466 -179.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.537 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 26.5 t80 -134.44 135.97 42.9 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.477 179.251 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.549 ' CD ' ' H ' ' A' ' 69' ' ' GLU . 1.6 mp0 -97.36 152.63 18.73 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.25 -0.98 . . . . 0.0 112.371 -178.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.1 t -151.58 133.5 5.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 CA-C-N 115.221 -0.899 . . . . 0.0 109.033 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 8.4 m -127.13 104.3 7.9 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.113 -179.376 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.5 ' CD1' HG11 ' A' ' 94' ' ' VAL . 13.9 mt -90.37 160.06 16.28 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.268 -0.973 . . . . 0.0 109.749 179.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 67.3 p -148.41 48.04 1.04 Allowed 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.558 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.438 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.9 mt-10 -147.08 105.9 3.84 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.972 -1.091 . . . . 0.0 110.453 179.311 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.74 112.03 0.42 Allowed 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.002 -1.079 . . . . 0.0 110.633 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.66 8.61 Favored Glycine 0 N--CA 1.487 2.064 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.282 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -141.44 123.73 15.68 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.399 -179.642 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.547 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -115.49 120.29 39.02 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.339 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 26.1 mttt -97.83 126.95 43.45 Favored 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 119.209 -0.996 . . . . 0.0 112.603 -178.406 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.58 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -127.61 158.58 37.13 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.679 177.928 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -165.0 176.87 8.23 Favored 'General case' 0 C--N 1.283 -2.296 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.131 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.6 t -104.39 123.86 48.19 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.787 -0.765 . . . . 0.0 110.547 -179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.542 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tt0 -66.4 -44.97 58.88 Favored Pre-proline 0 C--N 1.306 -1.303 0 C-N-CA 119.685 -0.806 . . . . 0.0 112.913 -179.673 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.542 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.6 Cg_exo -65.36 -50.29 2.05 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 121.179 1.252 . . . . 0.0 111.801 -178.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -86.77 16.18 5.04 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.727 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.21 -9.35 4.74 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.777 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.36 -20.12 49.87 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.485 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.14 -12.93 39.65 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.478 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 99.02 26.07 9.17 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.505 -1.331 . . . . 0.0 110.719 179.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -76.83 101.63 5.97 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.174 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.53 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 1.5 ptmt -124.98 162.58 24.18 Favored 'General case' 0 N--CA 1.493 1.712 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.946 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.549 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -146.76 149.84 22.04 Favored Glycine 0 N--CA 1.495 2.608 0 C-N-CA 119.296 -1.431 . . . . 0.0 111.419 -178.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -156.39 145.47 20.42 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.005 179.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.673 HG13 ' O ' ' A' ' 94' ' ' VAL . 12.6 p -135.94 117.53 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.466 -0.893 . . . . 0.0 110.464 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.623 ' HB ' HG22 ' A' ' 20' ' ' THR . 46.1 m -93.72 100.4 12.63 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.194 -1.003 . . . . 0.0 110.599 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 22.9 t -79.22 146.5 7.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 C-N-CA 118.46 -1.296 . . . . 0.0 110.333 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.308 -1.233 0 CA-C-O 116.345 -1.788 . . . . 0.0 110.587 -179.647 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.087 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -118.51 122.06 41.77 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.644 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 57.6 t -114.89 113.81 44.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.866 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 29.5 mtmt -88.63 116.77 27.11 Favored 'General case' 0 C--N 1.298 -1.641 0 C-N-CA 119.193 -1.003 . . . . 0.0 110.854 -179.555 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 7.8 mt -78.6 105.79 10.13 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 118.788 -1.165 . . . . 0.0 110.41 178.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 103.12 121.42 4.93 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.1 p . . . . . 0 C--N 1.304 -1.371 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.672 179.838 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 23.0 mt . . . . . 0 N--CA 1.487 1.381 0 CA-C-O 120.459 0.171 . . . . 0.0 110.698 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.7 m -151.0 157.43 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 C-N-CA 118.974 -1.09 . . . . 0.0 111.381 179.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' A' ' 16' ' ' PRO . 22.1 m-85 -78.53 110.0 13.22 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 177.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.4 m -115.62 109.19 45.99 Favored Pre-proline 0 N--CA 1.488 1.449 0 C-N-CA 119.28 -0.968 . . . . 0.0 112.564 -177.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.421 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.4 Cg_exo -65.9 178.62 15.26 Favored 'Cis proline' 0 C--N 1.364 1.35 0 C-N-CA 125.191 -0.754 . . . . 0.0 111.526 -1.075 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 41.8 t -95.75 -60.47 1.64 Allowed 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.376 179.474 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.4 t -124.74 140.33 53.03 Favored 'General case' 0 N--CA 1.488 1.438 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.884 179.37 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -165.22 149.62 8.82 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 118.592 -1.243 . . . . 0.0 111.258 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.416 ' H ' HG23 ' A' ' 20' ' ' THR . 0.8 OUTLIER -87.03 160.45 18.61 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.273 -179.876 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.3 m -148.86 165.56 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.941 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.499 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -87.29 142.91 27.54 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.556 179.817 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.71 77.28 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.136 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.499 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 146.56 18.41 0.13 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -98.35 138.58 35.38 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.852 -0.739 . . . . 0.0 110.609 -179.627 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.5 mttm -80.1 118.65 22.0 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.141 -179.634 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.3 mt -100.41 120.21 49.57 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.228 179.345 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 68.3 p -114.93 118.45 33.49 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.523 -0.871 . . . . 0.0 112.988 -177.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -84.71 114.15 21.83 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 177.415 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.4 mttp -103.94 132.33 50.3 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.415 -0.914 . . . . 0.0 111.46 -177.593 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 50.3 t-20 -84.97 110.82 19.17 Favored 'General case' 0 C--N 1.29 -2.004 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.025 178.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -106.67 -30.22 9.12 Favored 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 119.275 -0.97 . . . . 0.0 112.038 -179.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -178.67 161.11 1.25 Allowed 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 119.26 -0.976 . . . . 0.0 111.194 -179.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . 75.58 58.61 3.79 Favored Glycine 0 N--CA 1.495 2.58 0 C-N-CA 119.536 -1.316 . . . . 0.0 113.062 178.04 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -97.3 165.27 16.02 Favored Pre-proline 0 N--CA 1.496 1.853 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 177.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -78.08 138.46 51.44 Favored 'Cis proline' 0 C--O 1.214 -0.691 0 C-N-CA 124.808 -0.913 . . . . 0.0 113.047 -0.042 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.505 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 36.6 m-70 -102.81 177.34 4.88 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.713 -0.795 . . . . 0.0 110.574 178.566 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.409 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.6 OUTLIER -165.69 154.48 11.64 Favored 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.88 179.688 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.623 ' N ' HD12 ' A' ' 39' ' ' ILE . 2.5 mp -139.25 114.67 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 119.64 -0.824 . . . . 0.0 111.103 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 t -130.48 152.21 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.603 179.397 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.45 ' CE2' HD12 ' A' ' 55' ' ' ILE . 9.5 m-85 -102.94 141.07 36.37 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.525 -0.87 . . . . 0.0 111.796 -179.025 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -78.28 109.97 12.88 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.817 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.434 ' OE2' ' O ' ' A' ' 41' ' ' PHE . 35.3 mp0 -73.36 47.27 0.21 Allowed 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.94 -179.188 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -138.74 -5.84 1.51 Allowed 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.804 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -145.11 7.12 1.17 Allowed 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 118.54 -1.264 . . . . 0.0 111.981 179.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.592 HG13 ' HD2' ' A' ' 47' ' ' PRO . 2.1 t -80.53 150.79 70.83 Favored Pre-proline 0 C--N 1.289 -2.04 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.661 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.592 ' HD2' HG13 ' A' ' 46' ' ' VAL . 4.0 Cg_exo -52.87 158.17 6.79 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 120.944 1.096 . . . . 0.0 111.794 -179.428 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.87 48.7 1.67 Allowed 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.751 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -154.6 -32.63 0.03 OUTLIER Glycine 0 N--CA 1.49 2.242 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.134 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.413 ' O ' HG12 ' A' ' 50' ' ' VAL . 51.6 t -97.29 95.39 4.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 C-N-CA 119.599 -0.84 . . . . 0.0 110.841 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -46.05 148.29 0.87 Allowed 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.037 -1.065 . . . . 0.0 110.322 179.701 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -92.87 -33.77 14.09 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.339 -0.945 . . . . 0.0 111.211 -179.591 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -65.81 -17.83 64.91 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.823 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.37 -35.88 54.08 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.284 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.45 HD12 ' CE2' ' A' ' 41' ' ' PHE . 1.9 pt -95.69 -35.13 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.108 -179.644 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 39.9 m -43.46 158.88 0.03 OUTLIER 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.995 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.622 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 7.5 mt-30 -137.98 71.19 49.08 Favored Pre-proline 0 N--CA 1.486 1.328 0 C-N-CA 119.947 -0.701 . . . . 0.0 110.699 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -61.28 -5.73 5.65 Favored 'Trans proline' 0 C--N 1.321 -0.871 0 C-N-CA 121.274 1.316 . . . . 0.0 111.07 -179.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -83.65 113.78 21.09 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.005 179.364 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -69.38 166.4 18.72 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.551 -0.859 . . . . 0.0 111.297 -179.258 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.15 125.65 19.07 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.863 179.537 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.713 ' H ' ' ND2' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -104.87 -74.39 0.65 Allowed 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.309 -179.472 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.488 ' H ' ' CG ' ' A' ' 62' ' ' ASN . . . -35.06 146.12 0.04 OUTLIER Glycine 0 N--CA 1.501 2.975 0 C-N-CA 120.401 -0.904 . . . . 0.0 111.446 -179.448 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -81.42 151.56 27.83 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.744 -0.782 . . . . 0.0 110.888 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.22 -11.25 69.3 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.365 -1.397 . . . . 0.0 111.307 179.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -74.72 119.94 19.6 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.123 -1.031 . . . . 0.0 111.036 -179.767 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 3.9 p -127.5 160.78 30.47 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.949 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.622 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 34.5 t80 -136.48 141.41 43.49 Favored 'General case' 0 N--CA 1.494 1.749 0 C-N-CA 119.784 -0.767 . . . . 0.0 110.171 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -101.42 149.62 23.87 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 119.48 -0.888 . . . . 0.0 112.09 -178.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 t -146.05 138.4 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.105 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.2 m -132.39 99.76 4.78 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.577 -0.849 . . . . 0.0 111.28 -179.46 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.465 ' CD1' HG11 ' A' ' 94' ' ' VAL . 65.3 mt -82.48 162.83 21.93 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.158 179.461 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.604 ' O ' HG22 ' A' ' 73' ' ' THR . 97.7 m -150.57 45.07 0.86 Allowed 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.904 -1.118 . . . . 0.0 111.919 -179.105 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -145.02 102.05 3.71 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 118.924 -1.11 . . . . 0.0 110.418 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 22.6 mtmt -45.85 107.94 0.12 Allowed 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.201 -1.0 . . . . 0.0 110.425 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 177.21 -146.57 7.83 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.219 -1.467 . . . . 0.0 110.39 -179.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.99 130.1 22.07 Favored 'General case' 0 N--CA 1.484 1.257 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.646 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.588 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.2 OUTLIER -120.95 147.33 45.61 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 178.996 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.458 ' CB ' ' NZ ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -121.91 121.75 37.83 Favored 'General case' 0 N--CA 1.5 2.032 0 C-N-CA 119.069 -1.052 . . . . 0.0 110.957 179.47 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.612 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.6 OUTLIER -123.5 161.28 25.19 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.764 -0.774 . . . . 0.0 109.904 178.692 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 36.9 p90 -161.5 177.17 10.31 Favored 'General case' 0 C--N 1.285 -2.231 0 C-N-CA 119.184 -1.006 . . . . 0.0 111.176 -179.082 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -100.07 119.09 37.75 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.714 179.374 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.573 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 14.8 tt0 -72.03 -36.05 3.91 Favored Pre-proline 0 C--N 1.308 -1.213 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.953 -179.104 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.6 Cg_endo -72.05 -54.57 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.377 0.718 . . . . 0.0 111.049 179.727 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -79.82 14.93 1.55 Allowed 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.602 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.56 -11.64 0.94 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.628 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -78.62 -25.38 60.84 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.162 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.55 -31.74 26.23 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.414 179.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 110.3 26.72 4.76 Favored Glycine 0 N--CA 1.492 2.4 0 C-N-CA 119.781 -1.2 . . . . 0.0 110.859 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 32.0 mtp -67.82 108.49 3.0 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.081 -1.048 . . . . 0.0 110.79 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -121.03 154.31 36.22 Favored 'General case' 0 N--CA 1.491 1.611 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.917 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.492 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.76 146.24 17.19 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.511 -1.328 . . . . 0.0 111.236 -178.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -152.71 145.12 24.05 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.594 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.551 HG13 ' O ' ' A' ' 94' ' ' VAL . 12.0 p -138.45 125.46 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.794 179.647 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 91.0 m -102.77 99.07 8.99 Favored 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.532 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 31.7 t -79.87 148.61 5.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 118.692 -1.203 . . . . 0.0 110.472 -179.054 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 48.7 p30 . . . . . 0 C--N 1.306 -1.297 0 CA-C-O 116.324 -1.798 . . . . 0.0 110.671 -179.843 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 120.839 0.352 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . 0.524 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 10.8 mp0 -105.12 130.97 53.18 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.848 -0.741 . . . . 0.0 110.548 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.1 t -114.08 118.89 59.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.852 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 30.4 mttt -92.77 114.2 26.68 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.78 -179.095 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mp -79.71 105.83 11.29 Favored 'General case' 0 C--N 1.313 -1.016 0 C-N-CA 118.597 -1.241 . . . . 0.0 109.696 177.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.439 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.32 90.66 2.14 Favored Glycine 0 C--N 1.29 -2.018 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -178.755 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.1 p . . . . . 0 C--N 1.303 -1.456 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.766 -179.546 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.8 mt . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 120.608 0.242 . . . . 0.0 110.921 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.7 m -149.55 155.29 8.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 C-N-CA 118.898 -1.121 . . . . 0.0 111.058 179.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' A' ' 16' ' ' PRO . 29.7 m-85 -78.29 106.93 10.54 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 177.825 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 46.9 m -112.73 113.03 50.48 Favored Pre-proline 0 CA--C 1.556 1.2 0 C-N-CA 119.423 -0.911 . . . . 0.0 112.3 -177.11 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.5 Cg_endo -66.68 175.6 25.26 Favored 'Cis proline' 0 C--N 1.358 1.039 0 C-N-CA 125.4 -0.667 . . . . 0.0 111.5 -1.052 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -92.83 -61.16 1.64 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.469 -0.893 . . . . 0.0 110.014 179.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -119.92 142.53 48.64 Favored 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.474 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 19.8 p90 -167.78 137.11 2.6 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 118.577 -1.249 . . . . 0.0 111.304 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.447 ' H ' HG23 ' A' ' 20' ' ' THR . 0.3 OUTLIER -84.64 161.21 20.19 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.301 -0.959 . . . . 0.0 111.028 -179.946 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.1 m -148.49 162.42 5.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.274 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.978 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.475 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -82.76 144.45 30.17 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.278 -0.969 . . . . 0.0 110.435 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.27 76.92 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.369 -0.933 . . . . 0.0 111.07 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.475 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 149.22 19.45 0.08 OUTLIER Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.467 ' CD ' ' N ' ' A' ' 26' ' ' LYS . 5.9 tm-20 -101.51 144.56 30.13 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.654 -179.666 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.467 ' N ' ' CD ' ' A' ' 25' ' ' GLU . 67.6 mttt -88.49 133.44 34.13 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.807 -179.799 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.6 mt -117.38 118.14 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.55 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.8 p -109.95 114.76 28.57 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.825 -0.75 . . . . 0.0 112.392 -178.3 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -84.45 117.96 23.98 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.446 178.356 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.69 127.65 53.08 Favored 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 119.289 -0.965 . . . . 0.0 111.525 -177.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 39.0 t-20 -84.29 130.66 34.79 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.667 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.439 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 12.0 p-10 -134.22 -8.01 2.62 Favored 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 118.893 -1.123 . . . . 0.0 112.444 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -171.74 144.52 1.83 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 118.376 -1.33 . . . . 0.0 112.318 -179.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 72.15 54.57 7.86 Favored Glycine 0 N--CA 1.489 2.199 0 C-N-CA 119.903 -1.141 . . . . 0.0 113.53 177.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.482 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -92.74 167.07 15.26 Favored Pre-proline 0 N--CA 1.497 1.884 0 C-N-CA 118.718 -1.193 . . . . 0.0 108.498 177.22 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -77.05 146.35 83.4 Favored 'Cis proline' 0 N--CA 1.481 0.738 0 C-N-CA 124.958 -0.851 . . . . 0.0 113.047 -0.323 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 30.5 m-70 -104.69 -177.23 3.31 Favored 'General case' 0 N--CA 1.489 1.485 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.499 178.088 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.696 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -164.61 135.3 4.11 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.742 -0.783 . . . . 0.0 110.057 178.747 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.696 ' N ' HD22 ' A' ' 38' ' ' ASN . 2.8 mp -124.0 119.42 56.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 C-N-CA 119.837 -0.745 . . . . 0.0 110.898 -179.716 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.9 t -142.26 145.5 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.61 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -97.37 121.63 39.49 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.586 -0.845 . . . . 0.0 111.221 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.444 ' O ' ' OD1' ' A' ' 42' ' ' ASP . 38.1 p-10 -59.91 117.3 4.88 Favored 'General case' 0 C--N 1.309 -1.165 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.781 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -74.96 41.73 0.17 Allowed 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.809 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.44 ' H ' ' C ' ' A' ' 42' ' ' ASP . 7.3 m-20 -135.64 -3.26 2.35 Favored 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.656 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -147.38 19.25 1.2 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.054 -1.058 . . . . 0.0 111.215 179.823 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -96.71 146.01 30.57 Favored Pre-proline 0 C--N 1.3 -1.544 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.351 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -57.41 147.82 75.55 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.794 0.996 . . . . 0.0 111.82 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.47 158.63 14.43 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 119.14 -1.024 . . . . 0.0 109.945 179.29 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 79.64 -52.26 4.13 Favored Glycine 0 N--CA 1.487 2.075 0 C-N-CA 118.991 -1.576 . . . . 0.0 109.956 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.608 ' O ' HG12 ' A' ' 50' ' ' VAL . 71.6 t -69.81 73.84 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.165 0 C-N-CA 119.236 -0.986 . . . . 0.0 110.496 179.625 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -44.86 142.35 1.81 Allowed 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.698 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -79.3 -29.29 42.38 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.401 -0.919 . . . . 0.0 111.052 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -74.03 3.61 6.66 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.693 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.34 -35.61 10.66 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.948 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt -99.79 -28.37 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.044 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 68.9 m -64.74 154.81 35.68 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.247 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.612 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.1 OUTLIER -135.86 76.82 52.15 Favored Pre-proline 0 N--CA 1.486 1.356 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.96 179.65 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -57.41 -3.32 0.83 Allowed 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 121.193 1.262 . . . . 0.0 111.87 -178.571 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.432 ' H ' ' C ' ' A' ' 57' ' ' GLN . 11.4 tt0 -72.97 91.53 1.56 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.021 -1.072 . . . . 0.0 110.021 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.539 ' CE1' ' OD1' ' A' ' 38' ' ' ASN . 36.4 m-85 -43.61 165.63 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.947 -179.528 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -142.43 110.47 5.94 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.896 179.55 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.706 ' H ' ' ND2' ' A' ' 62' ' ' ASN . 0.3 OUTLIER -103.28 -6.82 21.65 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.664 179.898 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -71.05 152.04 49.64 Favored Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.456 -1.354 . . . . 0.0 110.44 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -94.83 103.9 15.79 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.764 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.24 -7.3 16.51 Favored Glycine 0 N--CA 1.496 2.677 0 C-N-CA 119.941 -1.123 . . . . 0.0 110.62 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.4 148.08 42.81 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.055 -1.058 . . . . 0.0 110.457 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 4.9 p -147.18 165.24 30.61 Favored 'General case' 0 N--CA 1.491 1.595 0 C-N-CA 118.901 -1.12 . . . . 0.0 111.889 -179.531 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.612 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 42.3 t80 -137.09 150.8 48.25 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.805 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.445 ' O ' ' CE1' ' A' ' 68' ' ' TYR . 2.2 mp0 -108.1 151.4 25.93 Favored 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.423 -179.711 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -150.31 135.77 10.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.303 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.0 m -135.75 92.17 2.79 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.155 -179.558 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 21.4 mt -79.82 158.7 26.73 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.263 -0.975 . . . . 0.0 109.659 179.412 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 23.4 p -150.53 41.98 0.8 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.143 -179.237 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -140.02 105.98 5.2 Favored 'General case' 0 N--CA 1.498 1.957 0 C-N-CA 118.807 -1.157 . . . . 0.0 110.422 179.178 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.5 tttp -40.19 112.37 0.27 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.301 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.43 -149.86 14.21 Favored Glycine 0 N--CA 1.488 2.162 0 C-N-CA 118.854 -1.641 . . . . 0.0 110.675 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -138.09 139.44 39.49 Favored 'General case' 0 N--CA 1.482 1.175 0 C-N-CA 119.761 -0.776 . . . . 0.0 110.984 -179.77 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.563 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.1 m-85 -126.42 128.78 47.53 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.107 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.442 ' O ' ' OD1' ' A' ' 42' ' ' ASP . 3.3 mptp? -105.12 123.94 48.67 Favored 'General case' 0 N--CA 1.493 1.699 0 C-N-CA 119.531 -0.868 . . . . 0.0 112.216 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.449 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 9.0 p90 -134.71 171.8 13.86 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.161 177.693 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 25.9 p90 -171.22 -168.92 0.68 Allowed 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 119.409 -0.916 . . . . 0.0 111.188 -178.009 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -116.65 130.04 56.5 Favored 'General case' 0 N--CA 1.482 1.141 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.206 179.036 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.512 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.0 mt-10 -72.17 -46.42 11.04 Favored Pre-proline 0 N--CA 1.484 1.271 0 C-N-CA 119.505 -0.878 . . . . 0.0 112.929 -179.394 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.512 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.8 Cg_endo -66.8 -46.38 3.53 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 120.806 1.004 . . . . 0.0 112.03 -178.656 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.6 m80 -90.46 21.11 4.08 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.239 -179.379 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -67.08 -16.73 64.52 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.359 -0.936 . . . . 0.0 110.597 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -77.49 -24.07 66.29 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.457 -1.354 . . . . 0.0 110.298 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.62 -15.6 39.27 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.392 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 98.77 31.88 6.16 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 119.561 -1.304 . . . . 0.0 110.576 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.63 103.91 9.86 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.997 179.765 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -129.34 166.46 19.45 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.801 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -146.49 155.18 26.4 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 119.123 -1.513 . . . . 0.0 111.779 -178.398 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -155.25 143.46 20.2 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.82 179.452 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.12 128.65 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.317 -0.953 . . . . 0.0 110.126 179.079 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 98.9 m -106.86 106.82 17.53 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 119.624 -0.83 . . . . 0.0 110.784 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.436 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 41.3 t -82.26 138.15 19.92 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 118.347 -1.341 . . . . 0.0 110.586 -179.101 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 96' ' ' VAL . 6.7 m-20 . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 116.374 -1.774 . . . . 0.0 110.805 -179.841 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -138.23 142.61 39.93 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.787 -0.765 . . . . 0.0 110.579 179.933 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 t -131.44 118.75 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.563 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.0 mtmp? -90.1 115.3 27.26 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.114 -1.034 . . . . 0.0 111.313 -178.991 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 4.8 mt -76.94 105.71 8.17 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 118.937 -1.105 . . . . 0.0 109.688 178.392 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 111.05 135.58 6.87 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.055 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.0 p . . . . . 0 C--N 1.302 -1.479 0 C-N-CA 119.233 -0.987 . . . . 0.0 110.67 179.941 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.8 mt . . . . . 0 N--CA 1.489 1.492 0 CA-C-O 120.445 0.164 . . . . 0.0 110.913 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.0 m -150.22 157.09 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.362 179.124 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.51 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 37.2 m-85 -77.84 115.09 17.32 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.898 -1.121 . . . . 0.0 108.15 178.809 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.5 m -116.89 106.98 46.83 Favored Pre-proline 0 CA--C 1.561 1.367 0 C-N-CA 119.58 -0.848 . . . . 0.0 111.813 -177.564 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -66.32 175.66 23.85 Favored 'Cis proline' 0 C--N 1.359 1.124 0 C-N-CA 125.166 -0.764 . . . . 0.0 111.429 -0.132 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.96 -37.39 11.7 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 119.426 -0.91 . . . . 0.0 109.709 178.836 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.6 m -145.72 142.63 29.14 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.941 179.18 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.403 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 26.0 p90 -165.91 146.27 6.56 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 118.711 -1.196 . . . . 0.0 111.339 -179.013 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.424 HG23 ' H ' ' A' ' 20' ' ' THR . 1.2 p -90.1 163.54 14.82 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.26 -179.755 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.1 m -150.27 175.61 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.687 179.43 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.452 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -91.07 146.61 23.7 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.859 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.03 74.73 0.05 OUTLIER 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.549 -0.86 . . . . 0.0 110.947 179.742 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 146.18 19.58 0.13 Allowed Glycine 0 N--CA 1.488 2.104 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -96.96 150.03 21.22 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.877 -0.729 . . . . 0.0 111.007 -179.415 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.79 136.13 35.47 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.607 179.592 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.9 mt -118.62 151.03 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 C-N-CA 120.038 -0.665 . . . . 0.0 109.212 179.848 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 9.2 p -142.16 118.46 10.81 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.695 -179.533 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 63.7 m-85 -83.65 125.38 31.78 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.427 -0.909 . . . . 0.0 109.1 178.471 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.0 tptp -110.4 133.69 53.03 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 120.044 -0.662 . . . . 0.0 110.52 -179.142 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.917 ' ND2' HD11 ' A' ' 61' ' ' LEU . 2.7 m120 -89.34 103.33 15.97 Favored 'General case' 0 C--N 1.293 -1.875 0 C-N-CA 119.19 -1.004 . . . . 0.0 110.087 179.331 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.66 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.3 OUTLIER -89.84 -30.63 17.8 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 119.176 -1.01 . . . . 0.0 111.435 -179.079 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 168.99 146.86 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 118.992 -1.083 . . . . 0.0 111.017 -179.864 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 112.74 -5.71 26.01 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.619 -1.277 . . . . 0.0 111.369 179.368 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -47.45 162.83 0.28 Allowed Pre-proline 0 N--CA 1.484 1.26 0 C-N-CA 118.332 -1.347 . . . . 0.0 109.639 179.878 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -77.1 137.95 51.24 Favored 'Cis proline' 0 C--O 1.214 -0.682 0 C-N-CA 124.143 -1.19 . . . . 0.0 112.285 -0.362 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 32.0 m-70 -103.79 177.69 4.77 Favored 'General case' 0 N--CA 1.489 1.497 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.568 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -153.9 140.35 18.73 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.217 179.557 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.459 ' O ' ' N ' ' A' ' 57' ' ' GLN . 3.9 mp -133.22 99.5 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.136 -179.773 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.6 t -121.61 152.55 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.831 179.29 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -104.9 122.87 46.7 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.6 -0.84 . . . . 0.0 111.724 -178.971 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.489 ' C ' ' H ' ' A' ' 44' ' ' ASP . 26.7 t0 -56.14 118.12 4.39 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.442 179.393 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.442 ' CG ' ' O ' ' A' ' 43' ' ' GLU . 2.2 tt0 -73.19 25.86 0.06 Allowed 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.419 -0.913 . . . . 0.0 111.211 -179.431 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.489 ' H ' ' C ' ' A' ' 42' ' ' ASP . 26.0 m-20 -129.1 1.88 5.23 Favored 'General case' 0 N--CA 1.49 1.551 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.795 179.779 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -147.1 53.02 1.08 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.408 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -135.03 148.1 65.42 Favored Pre-proline 0 N--CA 1.49 1.57 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -179.802 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -47.68 140.14 17.54 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 120.903 1.069 . . . . 0.0 111.986 -179.4 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.65 83.01 1.56 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.887 -179.953 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.06 -33.81 0.52 Allowed Glycine 0 N--CA 1.488 2.129 0 C-N-CA 119.558 -1.305 . . . . 0.0 110.027 -179.893 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 35.7 t -87.33 109.08 18.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.713 179.807 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -51.49 153.83 2.07 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.799 -179.92 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -110.88 -6.48 14.71 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 120.018 -0.673 . . . . 0.0 110.864 -179.844 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -90.16 -15.37 31.66 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.461 -0.895 . . . . 0.0 111.102 -179.81 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.7 mtmm -91.86 -28.92 17.0 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.905 -179.858 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 11.8 pt -98.57 1.14 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 C-N-CA 119.633 -0.827 . . . . 0.0 110.994 -179.887 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.8 m -94.42 -178.52 4.61 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.079 180.0 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.655 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 52.1 mt-30 -139.64 69.9 37.89 Favored Pre-proline 0 C--N 1.305 -1.34 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.338 -179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -59.74 -21.49 63.58 Favored 'Trans proline' 0 C--N 1.325 -0.696 0 C-N-CA 121.531 1.488 . . . . 0.0 111.829 -178.879 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.411 ' O ' ' O ' ' A' ' 60' ' ' TYR . 1.3 tm-20 -91.86 109.91 21.25 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.236 179.539 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.411 ' O ' ' O ' ' A' ' 59' ' ' GLU . 52.8 m-85 -43.09 166.07 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.541 -0.864 . . . . 0.0 110.948 -179.884 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.917 HD11 ' ND2' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -140.38 148.43 41.25 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.726 -0.79 . . . . 0.0 109.938 179.68 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.609 ' N ' HD12 ' A' ' 61' ' ' LEU . 0.0 OUTLIER -149.05 22.67 0.96 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.111 -179.464 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -83.14 102.47 2.4 Favored Glycine 0 N--CA 1.486 1.978 0 C-N-CA 119.163 -1.494 . . . . 0.0 110.382 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -57.34 113.28 1.69 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.067 -1.053 . . . . 0.0 110.178 179.512 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 97.85 -18.48 57.15 Favored Glycine 0 N--CA 1.487 2.093 0 C-N-CA 119.413 -1.375 . . . . 0.0 110.162 -179.49 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 25.6 tp10 -65.7 128.3 35.42 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.207 -0.997 . . . . 0.0 110.165 179.896 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -110.74 166.65 10.85 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.796 -0.761 . . . . 0.0 111.427 -179.653 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.655 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 43.1 t80 -135.8 139.86 43.8 Favored 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.455 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -108.78 158.24 17.83 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.258 -0.977 . . . . 0.0 112.709 -178.589 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -160.07 137.49 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.122 179.138 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 9.1 m -127.65 97.25 4.79 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.339 -179.242 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 16.8 mt -81.75 159.29 23.89 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.322 -0.951 . . . . 0.0 109.831 179.499 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 18.0 p -150.79 50.85 0.86 Allowed 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 118.882 -1.127 . . . . 0.0 111.946 -178.965 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 75' ' ' LYS . 3.9 tp10 -146.15 99.9 3.31 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.094 -1.043 . . . . 0.0 110.121 178.992 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.417 ' C ' ' O ' ' A' ' 74' ' ' GLU . 8.7 ptmm? -42.27 112.15 0.31 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.051 -179.309 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 168.63 -146.26 10.22 Favored Glycine 0 N--CA 1.485 1.919 0 C-N-CA 119.26 -1.448 . . . . 0.0 110.062 -179.69 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.81 138.33 35.73 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.643 -0.823 . . . . 0.0 110.987 -179.726 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.549 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -121.27 147.78 45.19 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.332 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 18.2 mmtp -112.93 123.56 50.6 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.586 -0.846 . . . . 0.0 111.83 -179.643 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.5 OUTLIER -136.96 158.66 43.96 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.611 -0.836 . . . . 0.0 109.789 177.523 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 32.3 p90 -169.86 179.96 3.47 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 119.261 -0.976 . . . . 0.0 111.206 -178.197 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -103.91 124.63 49.32 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.83 179.753 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.548 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.5 OUTLIER -70.57 -44.42 17.35 Favored Pre-proline 0 N--CA 1.487 1.387 0 C-N-CA 119.66 -0.816 . . . . 0.0 112.752 -179.77 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.548 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.0 Cg_exo -66.72 -53.54 0.55 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 120.892 1.061 . . . . 0.0 111.921 -178.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . 0.425 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.3 m80 -80.0 8.35 7.23 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.336 -0.945 . . . . 0.0 111.292 -179.521 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.37 -7.72 0.64 Allowed 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.705 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -76.2 -24.91 67.45 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.393 -1.384 . . . . 0.0 110.381 -179.924 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.65 -35.17 15.12 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.602 -179.994 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 124.77 21.09 2.21 Favored Glycine 0 N--CA 1.495 2.624 0 C-N-CA 119.869 -1.158 . . . . 0.0 110.531 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.79 108.99 1.29 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.416 -0.914 . . . . 0.0 111.256 -179.857 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 17.4 mttm -131.57 162.31 30.61 Favored 'General case' 0 N--CA 1.495 1.817 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.392 -179.871 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.454 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.19 147.86 19.49 Favored Glycine 0 N--CA 1.495 2.602 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.098 -179.194 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -149.21 138.05 21.21 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.891 179.842 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.452 HG13 ' O ' ' A' ' 94' ' ' VAL . 9.7 p -135.24 127.95 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 C-N-CA 118.723 -1.191 . . . . 0.0 110.883 178.694 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 47.4 m -106.91 100.46 9.96 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.572 179.319 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 45.3 t -80.5 144.66 10.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 C-N-CA 118.632 -1.227 . . . . 0.0 110.496 -179.045 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 116.284 -1.817 . . . . 0.0 110.758 -179.809 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 120.827 0.346 . . . . 0.0 110.163 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.1 mt-10 -100.05 121.68 41.76 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.765 179.88 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -99.15 119.25 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.998 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -91.3 113.22 25.42 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 119.626 -0.83 . . . . 0.0 111.021 -179.921 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 mp -79.7 110.58 15.17 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 118.88 -1.128 . . . . 0.0 109.547 178.472 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 98.71 103.82 2.41 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -178.864 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.9 p . . . . . 0 C--N 1.303 -1.453 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.937 -179.552 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt . . . . . 0 N--CA 1.486 1.342 0 CA-C-O 120.513 0.197 . . . . 0.0 110.746 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.7 m -145.7 157.9 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 C-N-CA 118.962 -1.095 . . . . 0.0 111.131 179.843 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.403 ' O ' ' C ' ' A' ' 16' ' ' PRO . 47.3 m-85 -79.17 111.37 15.32 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.459 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 47.8 m -114.89 107.96 49.46 Favored Pre-proline 0 C--N 1.307 -1.275 0 C-N-CA 119.536 -0.866 . . . . 0.0 112.406 -177.071 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.403 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.9 Cg_endo -67.01 167.35 58.32 Favored 'Cis proline' 0 C--N 1.359 1.086 0 C-N-CA 125.34 -0.692 . . . . 0.0 111.528 -0.827 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.423 ' OG ' ' N ' ' A' ' 18' ' ' SER . 0.2 OUTLIER -95.29 -67.24 0.86 Allowed 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.496 -0.881 . . . . 0.0 109.716 178.885 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.423 ' N ' ' OG ' ' A' ' 17' ' ' SER . 0.7 OUTLIER -112.2 123.44 50.27 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.437 178.816 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.487 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 11.5 p90 -156.72 144.31 19.14 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 118.782 -1.167 . . . . 0.0 111.141 -179.005 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -88.84 157.26 18.51 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.299 -0.96 . . . . 0.0 111.247 -179.84 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.5 m -148.61 171.44 2.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.493 179.631 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.81 151.92 22.94 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.477 -179.933 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.4 65.95 0.65 Allowed 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.873 179.761 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.444 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 171.02 8.58 0.02 OUTLIER Glycine 0 N--CA 1.486 1.983 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.444 ' H ' ' H ' ' A' ' 24' ' ' GLY . 6.8 tp10 -98.65 154.14 18.17 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.752 -0.779 . . . . 0.0 110.549 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 49.6 mttm -95.17 144.06 26.1 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.288 -179.718 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 37.1 mm -111.89 98.34 6.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 CA-C-N 115.541 -0.754 . . . . 0.0 108.999 179.033 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.7 p -92.85 115.49 28.17 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.145 -1.022 . . . . 0.0 112.477 -178.217 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -85.18 121.2 27.59 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.021 -0.991 . . . . 0.0 109.136 178.512 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -124.68 134.87 52.72 Favored 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.686 -0.806 . . . . 0.0 111.734 -178.519 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 66' ' ' GLU . 57.5 m-80 -84.67 113.31 21.2 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.505 179.604 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.549 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.9 t30 -97.98 -30.23 12.84 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 119.195 -1.002 . . . . 0.0 111.354 -179.23 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.549 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.7 99.33 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.004 179.724 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 153.11 23.45 0.05 OUTLIER Glycine 0 N--CA 1.489 2.22 0 C-N-CA 118.874 -1.632 . . . . 0.0 111.234 179.487 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.62 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -73.67 162.68 73.06 Favored Pre-proline 0 C--N 1.307 -1.253 0 C-N-CA 118.744 -1.182 . . . . 0.0 109.907 179.756 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -75.8 147.51 88.18 Favored 'Cis proline' 0 N--CA 1.479 0.658 0 C-N-CA 124.396 -1.085 . . . . 0.0 112.366 -1.118 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -112.59 -177.66 3.2 Favored 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.944 -0.702 . . . . 0.0 110.817 179.279 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.796 HD22 ' H ' ' A' ' 83' ' ' GLU . 2.7 t30 -163.75 144.35 8.7 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.771 -0.772 . . . . 0.0 110.005 179.173 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.9 mp -133.78 122.79 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 119.567 -0.853 . . . . 0.0 111.436 -179.48 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.8 t -140.61 146.5 24.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.403 179.101 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -100.51 128.49 46.56 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.214 -0.994 . . . . 0.0 111.888 -179.094 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 25.8 t0 -66.71 119.98 12.71 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.244 179.512 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -68.66 -7.21 31.2 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.026 -178.991 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -97.37 7.15 47.1 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.247 -0.981 . . . . 0.0 111.649 -179.208 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -145.55 27.63 1.22 Allowed 'General case' 0 N--CA 1.488 1.466 0 C-N-CA 119.284 -0.966 . . . . 0.0 110.748 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -118.78 146.77 40.8 Favored Pre-proline 0 N--CA 1.492 1.627 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.088 179.801 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -53.05 144.15 47.48 Favored 'Trans proline' 0 C--O 1.214 -0.706 0 C-N-CA 120.953 1.102 . . . . 0.0 111.907 -179.926 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.04 72.2 1.14 Allowed 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 119.533 -0.867 . . . . 0.0 110.855 179.839 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.09 -46.52 0.1 Allowed Glycine 0 N--CA 1.49 2.282 0 C-N-CA 119.544 -1.312 . . . . 0.0 109.978 179.929 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 96.8 t -79.92 87.8 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 119.435 -0.906 . . . . 0.0 110.474 179.697 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -44.63 140.11 2.59 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.964 -179.615 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.0 -20.88 44.4 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.889 -179.94 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -74.38 -22.37 59.22 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.437 -0.905 . . . . 0.0 111.128 -179.713 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -79.27 -24.86 42.67 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.36 -179.612 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -109.79 -18.47 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.427 -179.774 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.3 m -71.37 171.0 12.01 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.183 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.633 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 56.5 mt-30 -128.06 78.53 75.19 Favored Pre-proline 0 N--CA 1.488 1.446 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.333 179.914 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -60.86 -11.24 17.08 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.208 1.272 . . . . 0.0 111.615 -178.864 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 20.4 mt-10 -99.47 108.02 20.37 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.749 179.779 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -55.1 176.74 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.531 -0.867 . . . . 0.0 110.85 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.8 pp -154.9 153.1 30.58 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.131 -1.028 . . . . 0.0 111.468 -179.576 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -149.01 14.96 0.92 Allowed 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.987 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -80.95 125.25 6.78 Favored Glycine 0 N--CA 1.491 2.326 0 C-N-CA 119.355 -1.402 . . . . 0.0 110.689 -179.574 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -68.22 126.77 30.61 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.63 179.687 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.56 -12.06 62.17 Favored Glycine 0 N--CA 1.488 2.151 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.713 179.887 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.489 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 2.8 tp10 -65.1 144.3 57.33 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.263 179.749 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -140.79 170.54 15.57 Favored 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.372 -179.387 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.633 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 47.5 t80 -135.57 -179.76 5.84 Favored 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.49 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.56 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 3.3 mt-10 -140.69 146.16 37.46 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.166 -1.014 . . . . 0.0 111.652 -179.818 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.6 t -147.64 126.66 4.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.349 -0.842 . . . . 0.0 109.222 179.377 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.1 m -121.28 99.82 6.7 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.839 -0.744 . . . . 0.0 111.453 -178.841 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.432 ' CD1' HG11 ' A' ' 94' ' ' VAL . 54.9 mt -82.3 159.89 23.03 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.021 179.227 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 57.5 p -150.09 42.99 0.87 Allowed 'General case' 0 C--N 1.296 -1.757 0 C-N-CA 119.214 -0.994 . . . . 0.0 111.083 -179.529 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -143.49 101.37 3.77 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.026 -1.07 . . . . 0.0 110.836 179.76 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -44.61 113.43 0.55 Allowed 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.451 -0.899 . . . . 0.0 110.67 -179.953 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.9 -145.0 8.17 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.399 -1.381 . . . . 0.0 110.044 -179.961 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.82 127.14 16.73 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.893 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.564 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.8 m-85 -114.16 161.9 17.21 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.639 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.5 mmtm -130.48 116.81 18.72 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.47 -0.892 . . . . 0.0 111.987 -178.929 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -123.87 159.05 30.48 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.844 -0.742 . . . . 0.0 109.887 178.081 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -168.67 -179.3 3.75 Favored 'General case' 0 C--N 1.289 -2.025 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.982 -178.936 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . 0.484 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -108.81 124.27 50.34 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.634 179.825 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.796 ' H ' HD22 ' A' ' 38' ' ' ASN . 2.3 mt-10 -63.18 -45.28 85.52 Favored Pre-proline 0 N--CA 1.485 1.308 0 C-N-CA 119.728 -0.789 . . . . 0.0 112.997 -179.611 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.51 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.8 Cg_endo -66.16 -46.04 4.94 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 120.99 1.127 . . . . 0.0 112.077 -179.202 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -92.59 14.62 16.4 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 119.16 -1.016 . . . . 0.0 111.55 -179.262 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.484 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -67.97 -1.19 5.26 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 118.946 -1.101 . . . . 0.0 110.455 179.66 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -95.27 -18.76 32.51 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.439 -1.362 . . . . 0.0 110.095 179.871 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.94 -36.34 15.05 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.44 179.676 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 130.72 26.0 0.81 Allowed Glycine 0 N--CA 1.494 2.539 0 C-N-CA 119.911 -1.137 . . . . 0.0 110.342 179.836 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -82.65 95.37 7.79 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.186 -1.006 . . . . 0.0 110.865 -179.924 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.7 162.51 24.03 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.816 179.926 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -143.62 144.83 14.14 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.294 -1.432 . . . . 0.0 111.874 -178.455 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -148.52 143.69 26.83 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.963 -0.695 . . . . 0.0 110.084 179.282 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.611 HG13 ' O ' ' A' ' 94' ' ' VAL . 14.0 p -137.44 118.68 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 119.09 -1.044 . . . . 0.0 110.793 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 90.8 m -95.62 99.17 11.07 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.486 179.528 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 35.5 t -80.11 149.38 5.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 C-N-CA 118.999 -1.08 . . . . 0.0 110.805 -178.804 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 116.332 -1.794 . . . . 0.0 110.797 -179.862 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.066 0 CA-C-O 120.867 0.365 . . . . 0.0 110.052 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -93.77 140.46 29.63 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.701 179.866 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 t -126.95 131.88 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.523 179.477 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 11.7 mtmm -105.17 118.09 35.66 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.844 -179.534 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.408 ' C ' ' OD1' ' A' ' 32' ' ' ASN . 5.7 mt -79.87 103.71 9.95 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 118.754 -1.178 . . . . 0.0 109.639 178.809 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.521 ' C ' HD21 ' A' ' 32' ' ' ASN . . . 118.53 134.3 4.97 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -178.527 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 6' ' ' GLY . 26.0 p . . . . . 0 C--N 1.305 -1.33 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.198 -179.423 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.0 mt . . . . . 0 N--CA 1.49 1.545 0 CA-C-O 120.471 0.177 . . . . 0.0 110.711 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 4.5 m -147.67 154.18 11.34 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 C-N-CA 118.952 -1.099 . . . . 0.0 111.044 179.626 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' A' ' 16' ' ' PRO . 9.9 m-85 -78.22 107.61 10.94 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.431 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.8 m -113.77 109.04 50.67 Favored Pre-proline 0 C--N 1.306 -1.313 0 C-N-CA 119.81 -0.756 . . . . 0.0 111.912 -177.447 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.424 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.6 Cg_endo -67.64 177.05 23.95 Favored 'Cis proline' 0 C--N 1.355 0.916 0 CA-C-N 119.053 0.697 . . . . 0.0 111.671 -0.376 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.4 p -93.92 -47.16 6.85 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.77 178.862 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.8 p -132.82 144.28 50.11 Favored 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.287 178.841 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -164.6 134.58 3.9 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 118.456 -1.297 . . . . 0.0 111.409 -178.962 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.5 p -86.42 159.71 19.27 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.855 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.7 m -148.79 172.49 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.902 179.755 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -87.57 149.61 24.23 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.774 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.29 73.33 0.49 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.348 -0.941 . . . . 0.0 111.072 179.974 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.433 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 155.75 14.32 0.05 OUTLIER Glycine 0 N--CA 1.486 2.028 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.433 ' H ' ' H ' ' A' ' 24' ' ' GLY . 24.5 tt0 -104.45 147.24 27.79 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.552 -179.597 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.1 pttm -95.36 149.84 20.93 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.48 -179.616 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.4 mt -119.95 148.9 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.237 179.202 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.3 p -138.6 119.34 14.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.224 -0.991 . . . . 0.0 111.692 -179.153 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -86.61 146.03 26.5 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.338 178.9 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.3 tttm -138.39 132.04 30.84 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.356 -179.231 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.607 HD21 HD13 ' A' ' 61' ' ' LEU . 3.0 m-20 -81.18 113.09 19.1 Favored 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.815 179.576 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.633 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 4.0 p-10 -106.2 -23.54 12.56 Favored 'General case' 0 N--CA 1.493 1.689 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.743 -179.775 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.633 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.82 101.89 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 118.509 -1.277 . . . . 0.0 111.326 179.837 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 141.65 22.19 0.25 Allowed Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.239 -1.458 . . . . 0.0 111.457 179.574 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.61 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -78.2 161.98 68.44 Favored Pre-proline 0 N--CA 1.485 1.288 0 C-N-CA 118.159 -1.417 . . . . 0.0 110.026 179.502 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -75.9 148.56 90.45 Favored 'Cis proline' 0 C--O 1.214 -0.684 0 C-N-CA 124.21 -1.162 . . . . 0.0 112.291 -0.755 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . 0.402 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 48.9 m-70 -115.48 178.56 4.25 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.166 179.585 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.629 HD22 ' H ' ' A' ' 39' ' ' ILE . 1.2 t-20 -151.13 137.98 18.97 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.2 -1.0 . . . . 0.0 110.338 178.875 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.629 ' H ' HD22 ' A' ' 38' ' ' ASN . 5.7 mt -124.06 106.1 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.135 -179.494 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t -128.32 149.0 32.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.001 179.54 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -103.94 126.76 51.3 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.861 -179.305 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.432 ' C ' ' H ' ' A' ' 44' ' ' ASP . 0.4 OUTLIER -70.64 118.07 12.97 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.412 179.636 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -74.76 41.6 0.16 Allowed 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.386 -0.926 . . . . 0.0 110.861 -179.677 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.432 ' H ' ' C ' ' A' ' 42' ' ' ASP . 8.6 m-20 -128.28 -10.53 5.23 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.586 179.815 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -132.81 15.93 4.3 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.74 179.831 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.402 HG13 ' HD2' ' A' ' 47' ' ' PRO . 55.5 t -99.1 143.45 26.41 Favored Pre-proline 0 C--N 1.296 -1.73 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.571 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.402 ' HD2' HG13 ' A' ' 46' ' ' VAL . 3.6 Cg_exo -55.42 161.75 6.97 Favored 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 120.81 1.006 . . . . 0.0 111.619 -179.947 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -90.22 51.23 1.99 Allowed 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 119.578 -0.849 . . . . 0.0 111.001 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -154.0 -42.86 0.02 OUTLIER Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.46 -1.352 . . . . 0.0 109.998 179.827 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 5.6 p -77.35 152.28 5.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 119.812 -0.755 . . . . 0.0 110.407 179.643 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -88.79 139.47 30.43 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.048 179.173 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.419 ' HA ' HD11 ' A' ' 55' ' ' ILE . . . -102.76 -4.48 24.91 Favored 'General case' 0 N--CA 1.491 1.611 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.252 -179.782 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -90.69 -33.68 15.7 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.645 -179.531 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 62.8 mttt -78.26 -21.82 49.25 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.434 -0.906 . . . . 0.0 111.972 -179.018 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.419 HD11 ' HA ' ' A' ' 52' ' ' ALA . 6.3 pt -92.91 -25.03 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.213 -179.547 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 33.3 m -69.19 174.1 5.0 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.133 179.658 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.659 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 66.7 mt-30 -126.88 78.98 73.14 Favored Pre-proline 0 N--CA 1.488 1.456 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.65 -179.888 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.27 -14.44 38.45 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 120.958 1.105 . . . . 0.0 111.187 -179.258 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.423 ' O ' ' O ' ' A' ' 60' ' ' TYR . 10.5 mt-10 -100.53 105.06 16.46 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.78 -0.768 . . . . 0.0 110.646 179.445 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.423 ' O ' ' O ' ' A' ' 59' ' ' GLU . 31.6 m-85 -46.01 172.4 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.941 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.607 HD13 HD21 ' A' ' 31' ' ' ASN . 3.0 pp -138.54 125.79 21.58 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.688 -0.805 . . . . 0.0 110.29 179.548 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -132.61 45.49 2.74 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.409 -178.845 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.28 118.97 3.56 Favored Glycine 0 N--CA 1.499 2.896 0 C-N-CA 119.718 -1.229 . . . . 0.0 110.528 179.822 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -54.64 123.4 13.07 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.398 179.735 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 81.48 3.86 90.54 Favored Glycine 0 N--CA 1.489 2.225 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.648 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -69.47 107.16 3.24 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.921 179.607 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.5 p -98.09 164.59 12.28 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.499 -0.88 . . . . 0.0 111.55 -178.96 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.659 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 45.1 t80 -135.0 176.97 8.17 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 178.844 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.605 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 5.3 mt-10 -144.89 150.86 37.79 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 118.539 -1.265 . . . . 0.0 112.252 -179.316 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -157.85 136.83 3.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 115.066 -0.97 . . . . 0.0 108.727 179.205 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 19.1 m -129.12 92.74 3.44 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.53 -0.868 . . . . 0.0 111.716 -178.907 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 10.0 mt -79.76 155.39 27.94 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 118.995 -1.082 . . . . 0.0 108.709 178.833 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.567 HG23 ' OE2' ' A' ' 74' ' ' GLU . 3.1 t -150.47 46.57 0.88 Allowed 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.678 -1.209 . . . . 0.0 111.719 -179.29 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.567 ' OE2' HG23 ' A' ' 73' ' ' THR . 34.1 mm-40 -138.81 103.12 4.74 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.47 -0.892 . . . . 0.0 109.78 178.916 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -40.11 107.18 0.07 Allowed 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 119.781 -0.768 . . . . 0.0 111.321 -179.448 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 176.74 -150.36 10.32 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.172 -1.489 . . . . 0.0 110.591 -179.778 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.89 133.61 28.81 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.258 -179.521 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.604 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.9 OUTLIER -120.13 155.43 33.07 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.765 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 27.0 mmtt -126.93 127.94 45.65 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.532 -0.867 . . . . 0.0 111.909 -178.876 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.512 ' O ' ' N ' ' A' ' 92' ' ' GLY . 2.0 p90 -139.11 165.85 26.06 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.432 -0.907 . . . . 0.0 110.701 178.377 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 35.2 p90 -169.91 -179.78 3.35 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.144 -177.928 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -104.07 125.53 50.48 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.321 179.404 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.55 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tt0 -68.6 -44.48 33.19 Favored Pre-proline 0 N--CA 1.486 1.358 0 C-N-CA 119.531 -0.868 . . . . 0.0 112.985 -179.436 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -68.44 -50.06 0.76 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 120.931 1.087 . . . . 0.0 111.94 -178.771 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 33.4 m80 -88.9 16.91 6.2 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.342 -0.943 . . . . 0.0 111.572 -179.363 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.64 -10.32 3.48 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.726 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -89.13 -17.09 56.63 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.374 -1.393 . . . . 0.0 110.304 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.34 -22.89 24.82 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.385 179.881 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 112.7 17.48 7.99 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.798 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.1 mtp -70.64 99.87 1.75 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.228 179.806 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.1 pttp -125.1 164.33 20.46 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 120.045 -0.662 . . . . 0.0 110.088 178.723 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.02 147.75 18.49 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 118.538 -1.791 . . . . 0.0 111.862 -178.497 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -153.94 146.9 24.47 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 119.721 -0.792 . . . . 0.0 110.568 179.103 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.8 p -140.68 134.36 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.125 179.252 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.2 m -110.66 101.73 10.35 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.65 -0.82 . . . . 0.0 110.886 179.734 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 49.0 t -80.68 152.1 4.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.902 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.6 p30 . . . . . 0 C--N 1.304 -1.4 0 CA-C-O 116.364 -1.779 . . . . 0.0 110.81 -179.867 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.156 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -110.54 122.86 48.78 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.996 179.965 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.0 t -111.26 126.36 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 119.983 -0.687 . . . . 0.0 110.524 179.728 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 39.4 mttt -98.72 118.45 35.48 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.809 -179.483 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.419 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 12.8 mt -82.05 107.1 14.49 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 118.754 -1.179 . . . . 0.0 110.625 179.135 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.418 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 114.49 138.71 6.83 Favored Glycine 0 N--CA 1.495 2.626 0 C-N-CA 120.218 -0.991 . . . . 0.0 110.669 -179.588 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 24.2 p . . . . . 0 C--N 1.308 -1.201 0 C-N-CA 119.532 -0.867 . . . . 0.0 110.624 179.747 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.8 mt . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 120.465 0.174 . . . . 0.0 110.695 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.4 m -150.72 159.71 4.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.708 179.234 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.508 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 23.3 m-85 -78.46 114.58 17.49 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 177.948 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.4 m -116.24 105.99 49.81 Favored Pre-proline 0 C--N 1.308 -1.238 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.865 -177.45 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -67.55 178.32 20.2 Favored 'Cis proline' 0 C--N 1.359 1.131 0 CA-C-N 118.921 0.65 . . . . 0.0 111.946 -0.395 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.1 m -94.14 -48.12 6.35 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.643 -0.823 . . . . 0.0 110.182 179.162 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 44.6 m -137.34 140.98 41.82 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.419 179.144 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.405 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 25.1 p90 -162.93 143.21 9.33 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.626 -179.138 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.415 HG23 ' H ' ' A' ' 20' ' ' THR . 0.6 OUTLIER -91.27 155.51 18.5 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.146 179.894 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.07 157.13 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 C-N-CA 119.416 -0.914 . . . . 0.0 111.082 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.46 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -75.4 141.06 43.3 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.17 179.456 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.94 75.32 0.04 OUTLIER 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.045 -179.783 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 161.53 13.48 0.03 OUTLIER Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -104.94 151.04 24.37 Favored 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.622 -179.649 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.8 mttp -94.53 141.1 28.99 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.037 -179.919 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 mt -117.89 153.06 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.743 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.5 p -147.77 113.45 5.7 Favored 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 118.811 -1.156 . . . . 0.0 111.954 -179.448 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -84.39 116.18 22.91 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.36 -0.936 . . . . 0.0 108.962 178.485 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.2 tttm -111.56 132.84 54.25 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.778 -178.264 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.579 ' OD1' HD11 ' A' ' 61' ' ' LEU . 0.6 OUTLIER -76.48 104.23 6.89 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.703 -0.799 . . . . 0.0 109.849 178.904 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.466 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 5.2 p-10 -94.21 -26.23 16.74 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 118.906 -1.118 . . . . 0.0 112.025 -178.642 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.466 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 179.12 147.53 0.2 Allowed 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 118.489 -1.284 . . . . 0.0 111.593 -179.783 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 89.63 10.28 65.47 Favored Glycine 0 N--CA 1.481 1.674 0 C-N-CA 119.485 -1.341 . . . . 0.0 111.731 178.661 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -49.66 162.54 0.44 Allowed Pre-proline 0 N--CA 1.48 1.055 0 C-N-CA 117.844 -1.542 . . . . 0.0 108.895 179.431 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -75.93 -173.67 13.0 Favored 'Cis proline' 0 C--O 1.204 -1.189 0 C-N-CA 124.324 -1.115 . . . . 0.0 112.294 -0.213 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.8 m-70 -151.07 171.92 16.56 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 120.142 -0.623 . . . . 0.0 110.522 178.576 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.697 HD22 ' H ' ' A' ' 39' ' ' ILE . 1.3 t-20 -149.61 148.29 29.14 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.488 179.393 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.697 ' H ' HD22 ' A' ' 38' ' ' ASN . 4.1 mp -135.55 112.17 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 C-N-CA 119.676 -0.81 . . . . 0.0 111.322 -179.437 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 t -134.98 149.65 29.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.948 179.224 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -104.77 128.38 52.89 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.512 -0.875 . . . . 0.0 112.04 -179.077 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.42 ' C ' ' H ' ' A' ' 44' ' ' ASP . 49.3 t0 -66.97 126.38 28.94 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.086 179.344 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 63.8 mt-10 -72.1 11.51 0.55 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.229 -0.989 . . . . 0.0 111.221 -179.662 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.42 ' H ' ' C ' ' A' ' 42' ' ' ASP . 28.4 m-20 -105.85 -5.54 19.68 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.667 -0.813 . . . . 0.0 111.068 -179.862 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -142.7 51.97 1.42 Allowed 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 119.719 -0.792 . . . . 0.0 110.229 -179.743 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -139.6 145.97 45.81 Favored Pre-proline 0 N--CA 1.487 1.393 0 CA-C-N 115.286 -0.87 . . . . 0.0 108.825 179.678 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -54.17 163.7 3.18 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 120.798 0.999 . . . . 0.0 112.216 -179.358 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -89.26 61.76 5.85 Favored 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 119.84 -0.744 . . . . 0.0 110.824 -179.968 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.21 -46.38 0.04 OUTLIER Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.529 -1.319 . . . . 0.0 110.014 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.5 t -79.6 84.07 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 C-N-CA 119.554 -0.858 . . . . 0.0 110.39 179.703 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -45.09 139.71 3.12 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.204 -0.999 . . . . 0.0 110.712 -179.636 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.08 -33.06 65.4 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.728 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -61.68 -17.91 57.44 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.304 -179.637 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.32 -45.46 11.91 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.422 -179.728 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.0 pt -90.35 -13.8 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 119.233 -0.987 . . . . 0.0 111.327 -179.641 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 69.2 m -77.65 173.44 12.04 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.582 179.551 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.615 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 69.4 mt-30 -129.24 78.83 75.35 Favored Pre-proline 0 N--CA 1.489 1.481 0 C-N-CA 120.036 -0.665 . . . . 0.0 110.64 -179.868 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.93 -11.47 18.28 Favored 'Trans proline' 0 C--O 1.216 -0.605 0 C-N-CA 121.032 1.155 . . . . 0.0 111.024 -179.539 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -101.35 116.89 33.82 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.535 179.14 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -58.38 159.4 6.27 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.359 -0.936 . . . . 0.0 110.999 -179.672 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.616 HD12 ' C ' ' A' ' 61' ' ' LEU . 0.7 OUTLIER -125.41 146.97 49.37 Favored 'General case' 0 N--CA 1.49 1.532 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.666 179.233 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.551 ' N ' HD12 ' A' ' 61' ' ' LEU . 9.8 p-10 -155.17 58.6 0.65 Allowed 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.253 -0.979 . . . . 0.0 111.343 -178.744 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.62 130.1 6.23 Favored Glycine 0 N--CA 1.497 2.734 0 C-N-CA 119.737 -1.22 . . . . 0.0 110.784 179.805 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -69.94 103.88 2.36 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.459 -0.896 . . . . 0.0 110.464 179.575 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.45 -7.29 46.53 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.222 -179.709 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -64.7 151.81 44.05 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.141 179.515 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.7 165.15 31.35 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 118.884 -1.126 . . . . 0.0 111.838 -179.679 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.615 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 49.5 t80 -136.07 138.25 41.94 Favored 'General case' 0 N--CA 1.484 1.258 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.323 179.149 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -108.62 153.38 23.49 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.423 -0.911 . . . . 0.0 112.164 -178.765 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -155.41 139.93 9.26 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.439 178.891 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.8 m -126.02 95.95 4.58 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.083 -179.44 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.472 ' CD1' HG11 ' A' ' 94' ' ' VAL . 13.9 mt -79.68 160.9 26.12 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.437 179.434 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.71 25.29 0.76 Allowed 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 118.717 -1.193 . . . . 0.0 112.057 -178.497 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.466 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -116.69 99.9 7.45 Favored 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.357 179.846 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 8.5 mttt -43.44 105.79 0.06 Allowed 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.724 -179.76 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.3 -139.61 5.02 Favored Glycine 0 N--CA 1.483 1.79 0 C-N-CA 119.321 -1.418 . . . . 0.0 109.929 -179.769 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.2 m -146.68 136.02 22.79 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.251 -0.98 . . . . 0.0 111.168 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.576 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -120.52 140.78 50.96 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.829 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 22.9 mmtt -110.17 124.28 51.26 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 119.433 -0.907 . . . . 0.0 111.872 -179.0 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.566 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -134.39 160.89 36.57 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.14 178.395 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . 0.419 ' CD1' ' N ' ' A' ' 81' ' ' TYR . 23.8 p90 -168.29 179.21 4.58 Favored 'General case' 0 C--N 1.293 -1.87 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.889 -178.54 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -102.72 125.4 49.44 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.401 179.663 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.509 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 mt-10 -67.05 -46.25 52.79 Favored Pre-proline 0 C--N 1.306 -1.319 0 C-N-CA 119.499 -0.88 . . . . 0.0 112.819 -179.56 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.509 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.9 Cg_endo -67.01 -48.64 1.74 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 120.97 1.113 . . . . 0.0 112.114 -178.725 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -88.5 20.51 3.33 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.009 -179.515 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.87 -10.4 20.41 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.454 179.449 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.6 -17.31 57.09 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.491 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.15 -15.13 32.18 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.433 -0.907 . . . . 0.0 110.582 179.952 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.64 21.27 11.51 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.722 -1.228 . . . . 0.0 110.573 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.3 mtp -73.05 98.51 2.55 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.174 179.941 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.508 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 16.5 ttmt -121.41 159.6 25.85 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.38 143.49 12.17 Favored Glycine 0 N--CA 1.496 2.636 0 C-N-CA 119.352 -1.404 . . . . 0.0 111.255 -179.065 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.75 143.67 24.64 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.635 179.514 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.578 HG13 ' O ' ' A' ' 94' ' ' VAL . 9.9 p -136.31 122.43 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.318 179.523 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 99.9 m -100.93 100.48 11.12 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.745 -179.951 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 40.3 t -79.84 139.84 17.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 C-N-CA 118.634 -1.226 . . . . 0.0 110.478 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . 0.543 ' ND2' ' N ' ' A' ' 97' ' ' ASN . 0.2 OUTLIER . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 116.441 -1.743 . . . . 0.0 110.965 -179.869 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -106.06 133.39 50.84 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.92 -179.931 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.9 t -123.47 117.48 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 C-N-CA 119.991 -0.684 . . . . 0.0 110.419 179.657 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 29.3 mttp -91.95 114.35 26.87 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.652 -178.81 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.5 mt -76.37 113.28 13.78 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.069 -1.053 . . . . 0.0 109.805 178.007 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.46 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.36 125.35 5.61 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.764 -1.207 . . . . 0.0 110.238 -179.448 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.7 p . . . . . 0 C--N 1.302 -1.481 0 C-N-CA 119.462 -0.895 . . . . 0.0 110.7 179.884 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.1 mt . . . . . 0 N--CA 1.487 1.41 0 CA-C-O 120.487 0.184 . . . . 0.0 110.596 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.0 m -150.99 157.06 5.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.116 0 C-N-CA 118.892 -1.123 . . . . 0.0 110.747 179.297 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.522 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 56.8 m-85 -78.12 113.1 15.74 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 177.887 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.6 m -115.19 109.08 47.01 Favored Pre-proline 0 CA--C 1.559 1.311 0 C-N-CA 119.552 -0.859 . . . . 0.0 112.176 -176.954 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -67.14 172.59 37.29 Favored 'Cis proline' 0 C--N 1.359 1.119 0 C-N-CA 125.216 -0.743 . . . . 0.0 111.331 -0.444 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 38.8 t -94.19 -64.31 1.09 Allowed 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.704 178.934 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 t -113.11 135.19 54.08 Favored 'General case' 0 N--CA 1.485 1.292 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.546 178.748 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.418 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 21.7 p90 -160.97 137.91 8.84 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 118.71 -1.196 . . . . 0.0 111.308 -179.141 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.417 HG23 ' H ' ' A' ' 20' ' ' THR . 0.8 OUTLIER -88.25 154.98 19.99 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.073 179.766 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.7 m -145.95 168.66 7.02 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 119.447 -0.901 . . . . 0.0 110.815 179.771 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.49 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -92.3 146.62 23.56 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.656 179.833 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.17 76.4 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.52 -0.872 . . . . 0.0 111.052 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 154.02 15.14 0.06 OUTLIER Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.888 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -102.43 132.94 48.12 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.898 -179.592 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.8 mtpp -75.75 141.53 42.59 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.42 ' O ' HG22 ' A' ' 27' ' ' ILE . 3.0 mt -125.72 112.1 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 C-N-CA 120.088 -0.645 . . . . 0.0 109.261 179.407 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 13.4 p -108.52 121.43 44.96 Favored 'General case' 0 N--CA 1.488 1.462 0 C-N-CA 119.622 -0.831 . . . . 0.0 112.256 -178.561 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -86.36 121.18 28.56 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.449 -0.9 . . . . 0.0 109.182 178.502 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.0 tmtp? -112.71 142.42 45.34 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.871 -0.731 . . . . 0.0 110.655 -178.689 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.581 ' ND2' HD11 ' A' ' 61' ' ' LEU . 0.9 OUTLIER -94.05 118.41 31.48 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.178 179.87 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.679 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.8 OUTLIER -98.9 -30.74 12.21 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.864 -179.989 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.679 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 165.02 146.34 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.078 179.896 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 111.51 2.53 27.51 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.91 -1.138 . . . . 0.0 110.861 179.484 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.597 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -52.2 163.91 0.66 Allowed Pre-proline 0 C--N 1.308 -1.219 0 C-N-CA 118.868 -1.133 . . . . 0.0 109.917 179.797 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_endo -78.31 143.69 73.34 Favored 'Cis proline' 0 C--O 1.212 -0.821 0 C-N-CA 124.156 -1.185 . . . . 0.0 112.489 -0.808 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 35.2 m-70 -107.29 178.88 4.41 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.032 179.149 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.725 HD22 ' H ' ' A' ' 39' ' ' ILE . 0.5 OUTLIER -158.03 145.0 17.91 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.635 -0.826 . . . . 0.0 110.061 179.098 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.725 ' H ' HD22 ' A' ' 38' ' ' ASN . 3.9 mp -131.92 117.04 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.758 -0.777 . . . . 0.0 110.948 -179.771 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 40.4 t -136.03 141.79 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.19 179.667 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.491 ' HB2' ' HB1' ' A' ' 52' ' ' ALA . 48.7 m-85 -93.78 134.02 36.55 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 119.442 -0.903 . . . . 0.0 111.064 -179.584 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.676 ' C ' ' H ' ' A' ' 44' ' ' ASP . 24.7 p-10 -75.23 101.49 4.67 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.279 -0.969 . . . . 0.0 110.975 -179.523 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.571 ' H ' ' CD ' ' A' ' 43' ' ' GLU . 1.6 pm0 -55.63 6.5 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.175 0 C-N-CA 119.969 -0.692 . . . . 0.0 111.38 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.676 ' H ' ' C ' ' A' ' 42' ' ' ASP . 4.2 m-20 -83.08 -67.31 0.8 Allowed 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.837 179.138 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -97.83 27.36 4.49 Favored 'General case' 0 N--CA 1.49 1.539 0 C-N-CA 119.335 -0.946 . . . . 0.0 112.089 -177.049 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 42' ' ' ASP . 45.3 t -102.48 143.97 27.67 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.598 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.439 ' HD2' HG13 ' A' ' 46' ' ' VAL . 4.6 Cg_exo -46.61 140.9 11.71 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 120.777 0.984 . . . . 0.0 112.178 -179.107 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.53 39.28 0.26 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.863 -179.892 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.433 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -142.55 -41.0 0.07 OUTLIER Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.703 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.487 HG23 ' OE1' ' A' ' 74' ' ' GLU . 71.6 t -87.73 84.63 2.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.894 179.207 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -44.19 139.9 2.38 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.573 -0.851 . . . . 0.0 111.083 -179.185 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.491 ' HB1' ' HB2' ' A' ' 41' ' ' PHE . . . -86.21 0.65 53.21 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.473 -0.891 . . . . 0.0 110.766 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -87.39 -10.76 51.2 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.826 179.914 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.0 mtmt -98.17 -35.47 10.37 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.594 -0.842 . . . . 0.0 111.232 -179.668 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.487 HD12 ' CD2' ' A' ' 41' ' ' PHE . 8.3 pt -92.86 -13.37 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.245 -0.982 . . . . 0.0 111.373 -179.522 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 29.0 m -76.3 170.31 16.58 Favored 'General case' 0 C--N 1.307 -1.241 0 C-N-CA 119.186 -1.006 . . . . 0.0 110.893 179.791 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.626 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 4.0 mt-30 -138.37 69.82 46.9 Favored Pre-proline 0 N--CA 1.487 1.379 0 C-N-CA 120.046 -0.662 . . . . 0.0 110.584 -179.854 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -59.56 -10.08 10.56 Favored 'Trans proline' 0 C--N 1.323 -0.798 0 C-N-CA 121.457 1.438 . . . . 0.0 111.554 -179.304 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.418 ' O ' ' O ' ' A' ' 60' ' ' TYR . 0.7 OUTLIER -85.84 103.32 14.48 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.184 179.482 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.418 ' O ' ' O ' ' A' ' 59' ' ' GLU . 90.0 m-85 -44.16 168.26 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.164 -179.593 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.581 HD11 ' ND2' ' A' ' 31' ' ' ASN . 3.1 pp -151.8 146.4 25.68 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.05 179.913 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -143.69 -7.05 0.77 Allowed 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 119.318 -0.953 . . . . 0.0 111.387 -179.684 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -48.23 125.43 12.89 Favored Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.174 -1.489 . . . . 0.0 110.628 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -71.36 111.78 6.96 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.818 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 91.83 -11.19 72.79 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.252 -1.451 . . . . 0.0 110.84 -179.895 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -57.98 159.35 5.71 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.178 -1.009 . . . . 0.0 110.487 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.58 172.63 12.7 Favored 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.987 -179.442 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.626 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 51.9 t80 -135.34 178.59 6.92 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.36 179.09 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.571 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 8.4 mt-10 -145.99 152.0 38.68 Favored 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 118.747 -1.181 . . . . 0.0 111.986 -179.739 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -162.41 140.42 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 119.876 -0.729 . . . . 0.0 109.713 178.539 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.1 m -129.83 97.9 4.63 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.744 -179.619 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.498 ' CD1' HG11 ' A' ' 94' ' ' VAL . 9.3 mt -79.75 159.29 26.65 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.012 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 4.1 p -150.41 51.39 0.89 Allowed 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.793 -179.25 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.487 ' OE1' HG23 ' A' ' 50' ' ' VAL . 1.3 tt0 -142.95 99.81 3.53 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.406 -0.918 . . . . 0.0 109.839 178.829 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 74' ' ' GLU . 3.9 mttp -42.65 103.37 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.436 -0.906 . . . . 0.0 110.618 -179.568 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.0 -142.27 5.51 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.171 -1.49 . . . . 0.0 110.281 -179.544 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.97 133.4 21.86 Favored 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.476 -179.657 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.59 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -122.18 116.87 24.93 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.4 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.456 ' O ' ' OD1' ' A' ' 42' ' ' ASP . 11.2 mptt -95.88 115.69 27.81 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.172 -1.011 . . . . 0.0 111.787 -178.713 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.569 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.1 p90 -119.5 170.09 9.47 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.825 -0.75 . . . . 0.0 110.1 178.755 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -170.37 179.78 3.29 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.329 -178.631 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -102.94 128.27 49.81 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 119.754 -0.779 . . . . 0.0 110.17 179.258 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.53 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 mt-10 -73.34 -45.58 7.77 Favored Pre-proline 0 C--N 1.304 -1.399 0 C-N-CA 119.552 -0.859 . . . . 0.0 112.788 -179.399 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.53 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.3 Cg_exo -65.95 -51.11 1.33 Allowed 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 120.88 1.053 . . . . 0.0 111.684 -179.087 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . 0.457 ' C ' ' H ' ' A' ' 87' ' ' GLY . 38.2 m80 -83.52 13.96 4.12 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.321 -0.952 . . . . 0.0 111.054 -179.774 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.24 -5.4 0.48 Allowed 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.299 -0.96 . . . . 0.0 110.742 179.806 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.457 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -81.04 -26.54 52.72 Favored Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.515 -179.848 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.96 -13.64 35.74 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.626 179.916 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.44 7.15 49.5 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 119.709 -1.234 . . . . 0.0 110.418 179.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -48.31 109.69 0.26 Allowed 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.734 179.902 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.522 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -134.95 170.78 15.37 Favored 'General case' 0 N--CA 1.494 1.756 0 C-N-CA 119.551 -0.86 . . . . 0.0 111.422 -179.849 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -151.63 149.34 21.07 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.192 -1.48 . . . . 0.0 111.266 -178.67 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -152.89 139.3 18.57 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.397 179.522 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.598 HG13 ' O ' ' A' ' 94' ' ' VAL . 10.7 p -132.79 121.5 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 C-N-CA 119.289 -0.965 . . . . 0.0 110.5 179.279 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 39.3 m -98.64 100.77 12.03 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.908 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 25.8 t -82.68 151.04 4.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 118.747 -1.181 . . . . 0.0 110.367 -179.369 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 116.397 -1.763 . . . . 0.0 110.846 -179.744 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.1 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -131.37 136.97 48.5 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 120.017 -0.673 . . . . 0.0 110.521 179.977 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.1 t -131.13 124.23 55.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.587 179.839 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 7.0 mptt -95.85 116.89 29.57 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.165 -179.606 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 37.7 mt -75.69 109.93 9.68 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 118.681 -1.208 . . . . 0.0 109.235 178.151 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.527 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 99.46 134.07 8.35 Favored Glycine 0 N--CA 1.484 1.895 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -178.612 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.9 p . . . . . 0 C--N 1.303 -1.439 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.737 -179.905 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 mt . . . . . 0 N--CA 1.489 1.477 0 CA-C-O 120.551 0.215 . . . . 0.0 110.642 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.2 m -150.01 155.36 7.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.781 179.889 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.425 ' O ' ' O ' ' A' ' 16' ' ' PRO . 75.3 m-85 -78.62 108.97 12.41 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 177.579 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.7 m -111.63 114.43 52.39 Favored Pre-proline 0 C--N 1.303 -1.453 0 C-N-CA 119.389 -0.925 . . . . 0.0 112.07 -177.283 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.6 Cg_endo -66.68 172.47 35.74 Favored 'Cis proline' 0 C--N 1.361 1.201 0 C-N-CA 125.333 -0.695 . . . . 0.0 111.449 -0.685 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.44 -67.06 0.87 Allowed 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.334 179.193 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -108.61 140.4 42.04 Favored 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.556 179.129 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 22.1 p90 -165.69 140.16 4.71 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 118.227 -1.389 . . . . 0.0 111.786 -179.213 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.683 HG22 ' HB ' ' A' ' 95' ' ' THR . 75.7 p -88.83 157.42 18.47 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.761 179.423 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -149.9 151.48 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 C-N-CA 119.297 -0.961 . . . . 0.0 111.159 179.739 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.46 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -71.95 142.55 49.43 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.316 -0.954 . . . . 0.0 110.462 179.724 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.17 75.98 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 119.414 -0.914 . . . . 0.0 111.188 -179.752 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 161.08 11.1 0.04 OUTLIER Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.857 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.45 ' H ' ' H ' ' A' ' 24' ' ' GLY . 2.9 tp10 -105.13 148.56 26.73 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 120.1 -0.64 . . . . 0.0 110.832 -179.497 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 10.3 pttm -95.16 155.01 16.91 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.493 -0.883 . . . . 0.0 111.09 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 mt -127.22 109.21 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.799 179.56 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.1 p -100.68 117.69 35.31 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.789 -0.764 . . . . 0.0 112.028 -178.757 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -84.66 129.83 34.79 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.238 -0.985 . . . . 0.0 108.723 178.315 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.0 ttmt -120.0 128.12 53.25 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.394 -178.53 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 35.1 m120 -71.81 111.49 7.12 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.536 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.673 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.9 OUTLIER -96.09 -31.9 12.79 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.023 -1.071 . . . . 0.0 111.32 -179.856 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.673 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 163.26 130.97 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.894 179.585 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 124.89 2.58 7.86 Favored Glycine 0 N--CA 1.496 2.665 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.142 179.488 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -50.55 162.98 0.49 Allowed Pre-proline 0 C--N 1.307 -1.245 0 C-N-CA 118.518 -1.273 . . . . 0.0 109.739 179.798 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -75.96 144.37 79.57 Favored 'Cis proline' 0 C--O 1.215 -0.655 0 C-N-CA 124.279 -1.134 . . . . 0.0 112.341 -0.482 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 30.6 m-70 -108.05 173.74 6.19 Favored 'General case' 0 N--CA 1.493 1.719 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.637 179.541 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.686 HD22 ' H ' ' A' ' 39' ' ' ILE . 0.6 OUTLIER -152.62 138.35 17.9 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.925 179.534 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.686 ' H ' HD22 ' A' ' 38' ' ' ASN . 3.7 mp -128.13 99.97 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.904 -179.728 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.6 t -123.36 147.35 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.011 179.341 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -101.26 129.63 47.25 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.464 -0.894 . . . . 0.0 111.505 -179.676 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -67.03 113.72 5.24 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.702 -0.799 . . . . 0.0 110.632 179.656 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -62.06 -4.42 1.66 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.678 -0.809 . . . . 0.0 111.718 -179.22 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -95.78 -2.4 47.75 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.089 -179.78 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -140.65 50.47 1.67 Allowed 'General case' 0 C--N 1.312 -1.031 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.704 179.871 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -140.35 145.9 43.23 Favored Pre-proline 0 N--CA 1.489 1.502 0 CA-C-N 115.51 -0.768 . . . . 0.0 108.936 179.879 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -54.81 162.33 5.15 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 120.798 0.998 . . . . 0.0 111.742 -179.739 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -90.16 55.47 3.1 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.835 179.958 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -161.59 -42.27 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.06 179.926 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 88.5 t -86.28 92.62 3.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 C-N-CA 119.565 -0.854 . . . . 0.0 110.421 179.756 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -44.55 139.78 2.68 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.953 -179.785 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.88 -15.6 55.89 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.519 -0.873 . . . . 0.0 110.965 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -77.68 -28.0 50.95 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.406 -0.917 . . . . 0.0 111.309 -179.479 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -73.45 -35.63 65.79 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.44 -179.202 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.9 pt -96.54 -13.83 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.533 -179.353 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.3 m -77.27 176.3 8.91 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.025 -1.07 . . . . 0.0 111.35 -179.611 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.651 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 60.6 mt-30 -137.31 71.58 53.36 Favored Pre-proline 0 C--N 1.306 -1.298 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.432 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -59.26 -19.08 48.41 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 121.307 1.338 . . . . 0.0 111.34 -179.217 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -91.83 97.25 10.87 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.294 179.259 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -43.54 163.94 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.725 -179.731 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.405 HD11 HD21 ' A' ' 31' ' ' ASN . 2.7 pp -134.8 139.5 45.15 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.567 -0.853 . . . . 0.0 110.887 179.728 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.412 ' ND2' ' N ' ' A' ' 62' ' ' ASN . 0.1 OUTLIER -131.53 31.52 4.29 Favored 'General case' 0 N--CA 1.484 1.234 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.479 179.942 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -99.76 128.45 9.58 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.475 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -78.17 128.91 34.48 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.413 -0.915 . . . . 0.0 110.799 179.955 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 81.5 -21.84 5.95 Favored Glycine 0 N--CA 1.489 2.227 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.794 179.915 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.422 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 2.2 mm-40 -49.72 162.82 0.15 Allowed 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.178 -1.009 . . . . 0.0 110.267 179.858 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 7.6 p -146.28 163.36 35.76 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.79 -179.38 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.651 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 37.2 t80 -136.05 146.13 46.75 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.421 179.39 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -106.12 148.69 27.53 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 119.466 -0.894 . . . . 0.0 112.318 -178.773 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -149.41 132.88 7.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.498 178.786 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 18.2 m -131.21 105.36 7.62 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.469 -0.892 . . . . 0.0 111.639 -179.012 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.452 ' CD1' HG11 ' A' ' 94' ' ' VAL . 17.9 mt -95.32 152.64 18.21 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 119.422 -0.911 . . . . 0.0 109.693 179.091 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 47.4 p -150.57 47.02 0.88 Allowed 'General case' 0 C--N 1.293 -1.854 0 C-N-CA 119.304 -0.959 . . . . 0.0 110.862 -179.54 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -137.81 107.79 6.34 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.728 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 8.5 tptt -44.45 112.51 0.42 Allowed 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.333 -179.876 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 167.94 -152.28 20.4 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.086 -1.531 . . . . 0.0 110.391 179.722 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.92 135.46 32.85 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.495 -179.922 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.558 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -121.36 166.3 14.27 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.659 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 17.3 mmtp -138.2 130.14 28.43 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.804 -179.322 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.528 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.5 p90 -137.24 164.18 29.15 Favored 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.214 178.673 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 39.4 p90 -170.32 -173.83 1.56 Allowed 'General case' 0 C--N 1.287 -2.146 0 C-N-CA 119.586 -0.846 . . . . 0.0 110.704 -178.497 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . 0.551 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -112.38 129.85 56.17 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.57 179.478 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.502 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.9 mm-40 -69.71 -45.77 24.95 Favored Pre-proline 0 N--CA 1.488 1.454 0 C-N-CA 119.393 -0.923 . . . . 0.0 112.906 -179.446 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.502 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.9 Cg_endo -66.95 -52.22 0.7 Allowed 'Trans proline' 0 C--O 1.216 -0.6 0 C-N-CA 120.756 0.971 . . . . 0.0 112.41 -179.244 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . 0.455 ' C ' ' H ' ' A' ' 87' ' ' GLY . 35.2 m80 -81.54 5.61 17.43 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.449 -0.901 . . . . 0.0 112.224 -178.912 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . 0.551 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -61.59 -2.01 0.69 Allowed 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.712 -1.195 . . . . 0.0 110.525 179.935 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.455 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -81.63 -23.52 57.97 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 119.503 -1.332 . . . . 0.0 110.39 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.5 -45.45 7.76 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.346 -0.941 . . . . 0.0 110.43 -179.996 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.01 29.18 0.15 Allowed Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.531 179.687 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -76.12 102.69 5.83 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.124 -1.03 . . . . 0.0 110.961 179.888 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.6 pttt -131.12 166.49 20.98 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.434 -179.898 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.84 147.31 17.43 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.23 -1.462 . . . . 0.0 111.612 -178.713 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -149.47 147.71 28.55 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.347 179.189 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.452 HG11 ' CD1' ' A' ' 72' ' ' LEU . 14.3 p -143.39 136.19 24.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 118.911 -1.116 . . . . 0.0 110.363 179.377 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.683 ' HB ' HG22 ' A' ' 20' ' ' THR . 4.8 m -114.52 108.19 16.52 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.914 -0.714 . . . . 0.0 110.626 179.815 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.6 t -84.96 143.86 10.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 C-N-CA 118.532 -1.267 . . . . 0.0 110.527 -178.932 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 116.293 -1.813 . . . . 0.0 111.229 -179.664 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.161 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -115.56 121.16 41.81 Favored 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.479 179.589 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 61.5 t -110.5 122.38 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 C-N-CA 119.792 -0.763 . . . . 0.0 111.062 -179.787 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.1 mtmt -91.89 112.11 23.92 Favored 'General case' 0 C--N 1.297 -1.685 0 C-N-CA 119.449 -0.9 . . . . 0.0 110.454 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 7.7 mt -77.33 108.15 10.26 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 118.869 -1.133 . . . . 0.0 110.471 179.083 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.422 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 113.76 147.66 9.79 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.557 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.6 p . . . . . 0 C--N 1.306 -1.314 0 C-N-CA 119.561 -0.855 . . . . 0.0 110.901 179.846 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 120.333 0.111 . . . . 0.0 110.771 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.8 m -151.8 156.61 5.83 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 C-N-CA 118.963 -1.095 . . . . 0.0 110.646 178.978 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.406 ' O ' ' C ' ' A' ' 16' ' ' PRO . 43.5 m-85 -78.55 113.31 16.46 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 177.572 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.8 m -115.21 107.58 49.38 Favored Pre-proline 0 N--CA 1.484 1.25 0 C-N-CA 119.434 -0.907 . . . . 0.0 112.089 -177.277 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.406 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -66.79 176.24 23.75 Favored 'Cis proline' 0 C--N 1.359 1.101 0 C-N-CA 125.409 -0.663 . . . . 0.0 111.738 -0.414 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.27 -52.98 4.92 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.611 -0.836 . . . . 0.0 110.088 179.138 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.4 t -131.09 146.68 52.45 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.398 178.985 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.404 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 23.0 p90 -161.55 140.04 9.53 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 118.374 -1.33 . . . . 0.0 111.96 -179.066 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.654 HG22 ' HB ' ' A' ' 95' ' ' THR . 64.3 p -81.62 155.66 25.53 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.837 -0.745 . . . . 0.0 110.913 179.652 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.9 m -148.76 164.76 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 119.572 -0.851 . . . . 0.0 110.483 179.528 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.507 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -89.93 147.56 23.65 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.288 -0.965 . . . . 0.0 110.998 -179.754 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.15 77.59 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.509 -0.876 . . . . 0.0 110.788 179.756 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.66 23.15 0.09 OUTLIER Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -179.97 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -103.99 140.01 38.33 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.987 -0.685 . . . . 0.0 110.764 -179.578 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.9 mtmt -85.03 125.9 33.11 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.282 -0.967 . . . . 0.0 110.97 -179.851 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.2 mt -102.62 119.77 51.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 C-N-CA 119.803 -0.759 . . . . 0.0 109.578 179.779 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 43.3 p -117.1 114.57 23.91 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.7 -0.8 . . . . 0.0 112.393 -178.513 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -87.46 117.91 26.56 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.003 178.319 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.8 tttt -112.29 138.61 48.76 Favored 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 119.544 -0.862 . . . . 0.0 111.86 -178.338 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.417 HD21 HD13 ' A' ' 61' ' ' LEU . 3.9 m-20 -81.13 131.36 35.3 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.2 179.683 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.66 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.8 p-10 -125.56 -17.06 5.63 Favored 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.067 179.217 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 166.04 149.55 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 C-N-CA 119.542 -0.863 . . . . 0.0 111.247 178.992 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.28 -5.74 59.19 Favored Glycine 0 N--CA 1.495 2.581 0 C-N-CA 119.279 -1.439 . . . . 0.0 112.284 178.626 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -48.14 162.23 0.34 Allowed Pre-proline 0 N--CA 1.489 1.488 0 C-N-CA 118.133 -1.427 . . . . 0.0 109.723 -179.923 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -76.23 142.99 75.12 Favored 'Cis proline' 0 C--O 1.212 -0.796 0 C-N-CA 124.304 -1.123 . . . . 0.0 112.538 -0.638 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.2 m-70 -108.66 -179.63 3.92 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 119.856 -0.738 . . . . 0.0 111.498 -179.896 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.584 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -158.63 146.71 18.25 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.841 -0.744 . . . . 0.0 110.241 179.167 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.584 ' N ' HD22 ' A' ' 38' ' ' ASN . 3.9 mp -135.94 117.81 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 119.519 -0.873 . . . . 0.0 111.08 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.55 160.4 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.298 179.089 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.552 ' HB2' ' HB1' ' A' ' 52' ' ' ALA . 12.5 m-85 -113.38 125.0 53.78 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.41 -0.916 . . . . 0.0 112.058 -178.973 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.5 ' C ' ' H ' ' A' ' 44' ' ' ASP . 1.1 t70 -65.23 107.18 1.51 Allowed 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.664 178.786 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -67.86 16.38 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 119.505 -0.878 . . . . 0.0 112.207 -178.826 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.5 ' H ' ' C ' ' A' ' 42' ' ' ASP . 1.9 m-20 -106.02 -3.68 21.36 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 119.5 -0.88 . . . . 0.0 111.019 179.89 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -140.89 12.39 2.25 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.917 179.596 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -92.32 147.02 33.68 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.615 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -49.68 154.67 4.45 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 120.966 1.111 . . . . 0.0 112.019 -179.286 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.79 67.79 10.21 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.682 -179.935 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.86 -38.13 0.07 OUTLIER Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.957 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 55.8 t -90.53 81.19 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.371 179.583 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -44.21 139.62 2.51 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.13 -179.359 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.552 ' HB1' ' HB2' ' A' ' 41' ' ' PHE . . . -87.44 10.31 17.94 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.955 -179.724 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -90.55 -22.68 21.17 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.091 -1.044 . . . . 0.0 111.513 -179.476 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -93.81 -32.32 14.01 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 118.912 -1.115 . . . . 0.0 112.046 -179.329 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.1 pt -90.33 -23.74 5.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.513 -179.327 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . 0.404 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 18.1 m -61.78 -178.8 0.16 Allowed 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.098 179.869 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.651 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 9.9 tt0 -157.83 67.84 3.81 Favored Pre-proline 0 C--N 1.303 -1.444 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.689 -179.579 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.96 -29.34 87.82 Favored 'Trans proline' 0 C--N 1.323 -0.781 0 C-N-CA 121.308 1.339 . . . . 0.0 111.286 -179.419 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -59.01 112.28 1.62 Allowed 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.554 179.701 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.447 ' CD1' ' OD1' ' A' ' 38' ' ' ASN . 43.9 m-85 -58.55 169.55 0.9 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.998 -179.95 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.417 HD13 HD21 ' A' ' 31' ' ' ASN . 1.2 pp -153.73 149.17 27.2 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.362 179.688 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.512 ' O ' ' C ' ' A' ' 63' ' ' GLY . 0.0 OUTLIER -127.21 -74.31 0.59 Allowed 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.396 -179.288 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . 0.512 ' C ' ' O ' ' A' ' 62' ' ' ASN . . . -9.65 123.41 0.01 OUTLIER Glycine 1 N--CA 1.518 4.113 0 O-C-N 124.202 0.939 . . . . 0.0 112.75 -179.641 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -75.05 131.41 40.56 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.43 -0.908 . . . . 0.0 110.664 179.736 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.63 -14.96 58.92 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.596 -1.288 . . . . 0.0 110.528 -179.975 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' A' ' 66' ' ' GLU . 1.2 mp0 -62.96 148.51 47.33 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.446 179.844 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.38 163.24 34.35 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.246 -0.982 . . . . 0.0 111.396 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.651 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 41.5 t80 -136.54 143.73 43.85 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 119.87 -0.732 . . . . 0.0 109.276 179.269 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -106.15 152.16 23.8 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.219 -0.992 . . . . 0.0 111.995 -179.149 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -151.82 131.58 3.62 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 CA-C-N 115.345 -0.843 . . . . 0.0 108.813 179.555 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.7 m -121.52 112.87 19.04 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.804 -179.067 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.47 ' CD1' HG11 ' A' ' 94' ' ' VAL . 45.7 mt -96.56 158.61 15.35 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.725 -0.79 . . . . 0.0 109.417 178.924 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.0 m -150.89 41.9 0.77 Allowed 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 118.56 -1.256 . . . . 0.0 112.351 -179.133 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 62.8 mt-10 -145.92 110.98 5.27 Favored 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.378 178.918 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -44.06 116.51 1.01 Allowed 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.934 -179.569 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 164.5 175.16 35.04 Favored Glycine 0 N--CA 1.483 1.807 0 C-N-CA 119.293 -1.432 . . . . 0.0 110.35 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.76 126.77 53.38 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.992 -0.683 . . . . 0.0 110.977 -179.785 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.554 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -108.35 141.99 39.34 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.352 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 16.5 mmtp -105.12 122.22 45.45 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.953 -179.139 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.423 ' CZ ' ' N ' ' A' ' 93' ' ' GLU . 5.7 p90 -138.48 160.04 40.57 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 119.315 -0.954 . . . . 0.0 110.076 177.508 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -170.24 -175.26 1.91 Allowed 'General case' 0 C--N 1.287 -2.112 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.908 -177.655 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.6 t -103.48 122.72 45.49 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.732 -0.787 . . . . 0.0 109.372 179.245 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.564 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 4.9 tt0 -73.4 -36.04 2.94 Favored Pre-proline 0 CA--C 1.557 1.236 0 C-N-CA 118.84 -1.144 . . . . 0.0 113.267 -178.701 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.564 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.0 OUTLIER -70.25 -47.74 0.73 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 120.376 0.718 . . . . 0.0 111.105 179.66 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . 0.407 ' C ' ' H ' ' A' ' 87' ' ' GLY . 36.7 m80 -87.77 16.45 5.76 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.593 -0.843 . . . . 0.0 110.808 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.53 -2.61 1.69 Allowed 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.364 -0.935 . . . . 0.0 110.821 179.908 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.407 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -88.16 -17.83 56.82 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.354 -1.403 . . . . 0.0 110.29 179.911 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.45 -41.61 10.2 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.644 179.961 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 132.72 13.88 1.56 Allowed Glycine 0 N--CA 1.494 2.555 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.562 179.861 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.49 101.86 0.21 Allowed 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.928 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.5 tptt -124.71 154.1 41.35 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 119.914 -0.715 . . . . 0.0 111.256 -179.854 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.55 153.1 21.88 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.85 -179.055 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.423 ' N ' ' CZ ' ' A' ' 80' ' ' PHE . 2.7 mt-10 -156.4 146.05 20.9 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.363 -0.935 . . . . 0.0 111.289 179.911 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.501 HG13 ' O ' ' A' ' 94' ' ' VAL . 13.1 p -138.7 128.54 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.24 178.792 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.654 ' HB ' HG22 ' A' ' 20' ' ' THR . 98.8 m -106.77 100.09 9.62 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.68 179.831 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.0 t -80.04 150.78 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.237 0 C-N-CA 118.779 -1.169 . . . . 0.0 110.392 -179.714 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 116.339 -1.791 . . . . 0.0 110.828 179.969 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.153 0 CA-C-O 120.855 0.36 . . . . 0.0 110.079 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -105.27 135.69 46.17 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.929 -0.708 . . . . 0.0 110.647 179.887 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.0 t -124.11 126.62 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.817 -0.753 . . . . 0.0 110.445 179.591 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 7.3 mttp -100.84 118.57 37.16 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.792 -0.763 . . . . 0.0 110.591 -179.819 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.2 mt -83.66 109.82 17.77 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.646 178.84 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.543 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 106.25 133.36 7.42 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -178.8 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.2 p . . . . . 0 C--N 1.301 -1.511 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.624 179.64 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.619 HD13 ' CD2' ' A' ' 85' ' ' HIS . 49.9 mt . . . . . 0 N--CA 1.489 1.498 0 CA-C-O 120.692 0.282 . . . . 0.0 110.645 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.1 m -147.3 154.67 11.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 C-N-CA 119.091 -1.044 . . . . 0.0 111.023 179.899 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.443 ' O ' ' O ' ' A' ' 16' ' ' PRO . 40.4 m-85 -78.39 109.08 12.22 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 177.893 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 20.0 m -115.37 111.32 44.38 Favored Pre-proline 0 C--O 1.205 -1.24 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.51 -177.446 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.443 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -66.16 176.57 20.88 Favored 'Cis proline' 0 C--N 1.355 0.909 0 C-N-CA 125.304 -0.707 . . . . 0.0 111.612 0.102 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -92.86 -56.58 2.94 Favored 'General case' 0 N--CA 1.486 1.371 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.726 178.803 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.8 t -125.75 139.37 53.58 Favored 'General case' 0 N--CA 1.486 1.341 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.073 178.806 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 16.4 p90 -159.03 132.84 7.49 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.448 -178.915 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.454 ' H ' HG23 ' A' ' 20' ' ' THR . 0.8 OUTLIER -83.12 155.07 24.01 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.271 -0.972 . . . . 0.0 110.865 179.762 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 17.8 m -146.57 171.55 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.326 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.998 179.741 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -93.94 151.45 19.55 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.414 -0.914 . . . . 0.0 110.684 179.728 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.2 73.54 0.12 Allowed 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.146 -179.986 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 154.69 13.14 0.06 OUTLIER Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.791 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -99.07 117.04 32.67 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.663 -179.783 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.1 mtmp? -65.96 133.44 50.86 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 119.477 -0.889 . . . . 0.0 111.066 -179.774 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 mt -113.55 131.77 64.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 C-N-CA 119.954 -0.698 . . . . 0.0 109.248 179.454 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.5 p -125.29 123.29 39.16 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.526 -0.87 . . . . 0.0 112.173 -178.54 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -84.4 147.29 27.22 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.414 -0.914 . . . . 0.0 108.851 178.346 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 tttm -136.62 127.9 28.18 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.396 -0.921 . . . . 0.0 111.371 -178.873 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.2 m-80 -79.45 109.45 13.82 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.69 -0.804 . . . . 0.0 110.52 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.654 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.6 OUTLIER -95.49 -30.73 13.7 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.76 -179.474 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.654 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 166.4 136.92 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.041 -179.661 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 116.27 -2.23 20.65 Favored Glycine 0 N--CA 1.495 2.599 0 C-N-CA 119.836 -1.174 . . . . 0.0 111.033 179.189 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -47.37 163.83 0.25 Allowed Pre-proline 0 C--N 1.308 -1.224 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.775 179.792 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -76.23 145.34 82.01 Favored 'Cis proline' 0 C--O 1.214 -0.722 0 C-N-CA 124.223 -1.157 . . . . 0.0 112.659 -0.756 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -111.22 172.15 7.05 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.889 179.298 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.701 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.2 OUTLIER -149.8 137.98 20.47 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.111 179.34 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.701 ' N ' HD22 ' A' ' 38' ' ' ASN . 3.5 mp -125.17 110.68 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 C-N-CA 119.893 -0.723 . . . . 0.0 110.888 -179.689 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.5 t -130.93 145.31 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.95 -0.7 . . . . 0.0 110.326 179.528 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -99.53 121.7 41.55 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.586 -0.845 . . . . 0.0 111.322 -179.356 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -60.48 100.87 0.11 Allowed 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.131 -1.028 . . . . 0.0 110.044 179.484 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -57.65 -6.6 0.52 Allowed 'General case' 0 N--CA 1.489 1.488 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.277 -179.012 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -93.36 3.19 56.01 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 118.993 -1.083 . . . . 0.0 112.263 -178.733 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 30.6 mt-10 -144.56 13.52 1.55 Allowed 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 119.116 -1.033 . . . . 0.0 111.741 -179.944 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -90.85 149.96 41.22 Favored Pre-proline 0 C--N 1.292 -1.919 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.287 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -47.91 144.25 12.05 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.917 1.078 . . . . 0.0 111.878 -179.539 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.6 73.98 1.99 Allowed 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.531 -0.868 . . . . 0.0 110.617 179.994 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.47 -32.72 0.12 Allowed Glycine 0 N--CA 1.487 2.053 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.241 -179.94 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 81.4 t -94.83 105.79 17.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.374 -0.93 . . . . 0.0 111.073 -179.855 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -52.17 143.99 13.29 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.715 179.882 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -93.04 -3.28 54.6 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.328 -0.949 . . . . 0.0 110.908 -179.773 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -90.22 -21.45 22.15 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.255 -0.978 . . . . 0.0 110.94 -179.931 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 23.4 mmtt -78.14 -26.96 48.08 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.304 -0.958 . . . . 0.0 110.936 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.3 pt -105.8 -12.22 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.845 -179.192 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 18.6 m -78.39 170.07 17.22 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.108 -1.037 . . . . 0.0 111.316 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.655 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 55.5 mt-30 -134.19 74.11 68.27 Favored Pre-proline 0 N--CA 1.486 1.335 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.241 179.902 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -59.52 -20.26 56.19 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 121.277 1.318 . . . . 0.0 111.63 -178.69 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . 0.444 ' CG ' ' O ' ' A' ' 59' ' ' GLU . 3.4 pt-20 -89.14 107.0 18.8 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.527 179.513 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.419 ' CD2' ' OD1' ' A' ' 38' ' ' ASN . 27.6 m-85 -51.93 165.61 0.19 Allowed 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 119.411 -0.915 . . . . 0.0 110.849 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.4 pp -139.34 126.38 21.09 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.43 179.466 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.457 ' OD1' ' N ' ' A' ' 62' ' ' ASN . 19.8 p-10 -118.31 34.97 4.94 Favored 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.057 -179.49 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -87.99 -172.08 47.06 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 119.238 -1.458 . . . . 0.0 110.214 179.64 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -133.59 105.94 7.14 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.049 179.579 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 94.24 -11.37 70.58 Favored Glycine 0 N--CA 1.486 2.03 0 C-N-CA 119.308 -1.425 . . . . 0.0 109.713 -179.299 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -50.59 160.94 0.37 Allowed 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.359 179.684 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.7 p -145.8 158.99 43.82 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.393 -179.374 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.655 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 15.6 t80 -136.16 137.01 40.5 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.365 179.068 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -99.97 152.3 20.35 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 119.292 -0.963 . . . . 0.0 112.494 -178.769 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -155.81 134.53 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 115.191 -0.913 . . . . 0.0 108.9 179.509 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.1 m -128.6 96.7 4.47 Favored 'General case' 0 N--CA 1.486 1.327 0 C-N-CA 119.559 -0.856 . . . . 0.0 111.208 -179.482 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.5 mt -79.88 157.63 26.9 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.25 -0.98 . . . . 0.0 109.9 179.433 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 77.6 p -150.06 45.96 0.91 Allowed 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.495 -179.169 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.439 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.7 mm-40 -142.46 113.29 7.45 Favored 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.098 -1.041 . . . . 0.0 110.448 179.557 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.466 ' CG ' ' O ' ' A' ' 75' ' ' LYS . 0.6 OUTLIER -52.45 119.33 4.35 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.268 -0.973 . . . . 0.0 111.058 -179.322 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 163.36 -147.87 13.91 Favored Glycine 0 N--CA 1.483 1.78 0 C-N-CA 119.254 -1.451 . . . . 0.0 110.142 179.86 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.74 130.18 23.9 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.752 -179.938 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.53 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.6 m-85 -114.86 123.8 50.08 Favored 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.923 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . 0.516 ' N ' ' CD ' ' A' ' 79' ' ' LYS . 0.5 OUTLIER -103.97 121.03 42.29 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.133 -1.027 . . . . 0.0 111.76 -178.949 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.478 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 4.2 p90 -129.54 173.19 10.81 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.212 178.295 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -171.11 -174.29 1.46 Allowed 'General case' 0 C--N 1.292 -1.894 0 C-N-CA 119.531 -0.868 . . . . 0.0 110.814 -178.576 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -108.89 132.07 54.41 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 119.898 -0.721 . . . . 0.0 110.49 179.209 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.496 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.2 mt-10 -73.38 -47.18 7.61 Favored Pre-proline 0 N--CA 1.485 1.286 0 C-N-CA 119.432 -0.907 . . . . 0.0 112.472 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.2 Cg_exo -64.54 -47.18 5.94 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 120.89 1.06 . . . . 0.0 111.953 -179.227 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . 0.619 ' CD2' HD13 ' A' ' 12' ' ' LEU . 37.6 m80 -90.51 21.42 3.95 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.971 -179.421 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.73 1.66 1.24 Allowed 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.692 179.844 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.446 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -96.5 -20.94 23.41 Favored Glycine 0 N--CA 1.49 2.277 0 C-N-CA 119.471 -1.347 . . . . 0.0 110.412 -179.869 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.41 -9.87 45.95 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.485 179.667 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 96.46 20.28 25.33 Favored Glycine 0 N--CA 1.488 2.102 0 C-N-CA 119.498 -1.334 . . . . 0.0 110.462 179.817 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.31 102.72 0.7 Allowed 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.151 -1.02 . . . . 0.0 110.982 -179.829 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.07 162.1 26.86 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.003 179.826 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -142.96 153.26 24.6 Favored Glycine 0 N--CA 1.491 2.359 0 C-N-CA 119.436 -1.364 . . . . 0.0 111.468 -178.587 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -155.62 144.87 20.85 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.429 -0.908 . . . . 0.0 111.078 179.629 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -141.78 123.32 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.193 178.461 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 92.3 m -101.14 108.2 19.81 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.158 -179.526 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 23.2 t -88.93 148.15 4.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 118.771 -1.172 . . . . 0.0 110.764 -179.329 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 . . . . . 0 N--CA 1.485 1.317 0 CA-C-O 116.341 -1.79 . . . . 0.0 110.868 -179.903 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.14 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -135.26 127.38 29.87 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 120.027 -0.669 . . . . 0.0 110.574 179.741 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.7 t -115.72 131.86 66.85 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 C-N-CA 119.864 -0.735 . . . . 0.0 110.991 -179.745 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.7 mtpp -104.72 118.9 37.71 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.205 -179.749 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . 0.429 HD12 HD22 ' A' ' 31' ' ' ASN . 2.9 mt -81.52 108.22 14.93 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 118.956 -1.098 . . . . 0.0 109.672 178.269 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.531 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 110.41 125.64 4.91 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.649 -1.381 . . . . 0.0 109.649 -179.1 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 3.2 p . . . . . 0 C--N 1.299 -1.588 0 C-N-CA 119.162 -1.015 . . . . 0.0 110.934 -179.746 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.6 mt . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 120.496 0.189 . . . . 0.0 110.67 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.4 m -150.01 154.25 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.122 0 C-N-CA 118.777 -1.169 . . . . 0.0 111.268 179.749 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.433 ' O ' ' O ' ' A' ' 16' ' ' PRO . 11.1 m-85 -78.6 108.57 12.09 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 177.818 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 53.3 m -114.76 112.31 45.29 Favored Pre-proline 0 CA--C 1.559 1.303 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.248 -177.176 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.433 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -65.56 176.79 18.52 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 125.188 -0.755 . . . . 0.0 111.702 -0.936 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.9 t -93.86 -55.97 3.05 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.453 179.212 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.4 p -128.92 142.65 50.87 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.814 179.212 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -163.9 143.01 7.83 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 118.663 -1.215 . . . . 0.0 111.782 -179.278 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.431 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -90.76 153.59 20.15 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.903 179.533 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.7 m -145.95 -176.75 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 119.494 -0.882 . . . . 0.0 110.585 179.617 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.409 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -97.53 147.09 24.62 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.716 179.773 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.3 74.03 0.14 Allowed 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.836 179.741 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.411 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 155.54 18.09 0.04 OUTLIER Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.913 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.411 ' H ' ' H ' ' A' ' 24' ' ' GLY . 14.7 tt0 -99.65 156.1 17.25 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.767 -0.773 . . . . 0.0 110.881 -179.783 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.0 mptp? -93.81 119.28 32.56 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.722 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.1 mt -100.06 106.5 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.254 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.2 p -104.26 117.7 34.85 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.582 -0.847 . . . . 0.0 112.888 -177.893 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -84.38 149.0 26.31 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.408 -0.917 . . . . 0.0 108.548 177.893 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 6.4 ttpp -141.19 133.39 27.98 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 118.965 -1.094 . . . . 0.0 111.664 -178.445 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 0.0 OUTLIER -89.48 104.02 16.61 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.735 178.946 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 2.3 p-10 -91.56 -31.72 15.8 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 118.864 -1.134 . . . . 0.0 111.846 -178.584 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -175.21 139.78 0.48 Allowed 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.138 -179.693 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.26 15.35 33.02 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.495 -1.335 . . . . 0.0 111.784 178.784 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.404 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -58.55 163.24 5.26 Favored Pre-proline 0 N--CA 1.481 1.113 0 C-N-CA 117.96 -1.496 . . . . 0.0 109.2 179.557 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -74.53 -174.48 13.85 Favored 'Cis proline' 0 C--O 1.206 -1.091 0 C-N-CA 124.481 -1.05 . . . . 0.0 112.195 -0.382 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.3 m-70 -149.7 -178.71 6.6 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.885 178.544 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.726 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.2 OUTLIER -156.75 137.22 13.05 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.375 179.166 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.726 ' N ' HD22 ' A' ' 38' ' ' ASN . 7.6 mt -122.0 85.27 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 C-N-CA 119.866 -0.734 . . . . 0.0 111.479 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 t -103.34 157.94 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 C-N-CA 119.922 -0.711 . . . . 0.0 109.484 178.755 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -112.29 138.97 48.25 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 119.285 -0.966 . . . . 0.0 111.949 -179.42 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.512 ' C ' ' H ' ' A' ' 44' ' ' ASP . 4.4 t70 -82.36 105.95 13.85 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.003 179.162 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -70.81 32.92 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.378 -179.451 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.512 ' H ' ' C ' ' A' ' 42' ' ' ASP . 82.5 m-20 -108.95 -15.13 14.43 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 120.032 -0.667 . . . . 0.0 110.693 179.518 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -139.79 16.33 2.5 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.718 179.491 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -93.41 143.7 27.09 Favored Pre-proline 0 C--N 1.296 -1.735 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 179.31 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.403 ' C ' ' H ' ' A' ' 49' ' ' GLY . 3.0 Cg_exo -48.45 140.74 20.69 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 120.754 0.97 . . . . 0.0 111.961 -179.392 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.32 43.16 0.37 Allowed 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.67 179.973 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.403 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -148.78 -26.51 0.07 OUTLIER Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . 0.441 ' O ' HG12 ' A' ' 50' ' ' VAL . 46.7 t -101.83 93.95 3.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.458 179.746 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -44.88 139.62 2.97 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.741 -179.919 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -90.81 3.42 54.47 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.502 179.851 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -90.3 -31.63 16.86 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.933 179.909 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 37.0 mttt -69.68 -32.52 71.18 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.421 -0.912 . . . . 0.0 111.32 -179.762 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.0 pt -93.22 -35.07 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.123 -1.031 . . . . 0.0 111.148 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.4 m -56.27 163.88 1.51 Allowed 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.198 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.642 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 63.3 mt-30 -124.97 84.59 58.76 Favored Pre-proline 0 N--CA 1.487 1.42 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.231 179.713 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -60.37 -22.71 72.25 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 120.995 1.13 . . . . 0.0 111.834 -178.761 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -96.35 115.93 28.22 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.349 -0.94 . . . . 0.0 110.858 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . 0.533 ' CE1' ' OD1' ' A' ' 38' ' ' ASN . 55.0 m-85 -56.34 177.37 0.07 Allowed 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.624 179.879 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.7 pp -148.33 132.75 17.6 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.283 -0.967 . . . . 0.0 110.8 179.93 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -128.99 39.03 3.85 Favored 'General case' 0 N--CA 1.493 1.721 0 C-N-CA 119.976 -0.69 . . . . 0.0 110.955 -179.745 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -102.27 125.52 8.55 Favored Glycine 0 N--CA 1.494 2.512 0 C-N-CA 119.632 -1.271 . . . . 0.0 110.388 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -70.52 103.3 2.44 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.532 179.748 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.38 -0.24 55.76 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.614 -1.279 . . . . 0.0 110.458 -179.884 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 17.6 tt0 -72.99 106.99 5.1 Favored 'General case' 0 N--CA 1.49 1.562 0 C-N-CA 119.062 -1.055 . . . . 0.0 110.569 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.1 p -96.43 161.99 13.68 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.702 -179.169 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.642 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 24.2 t80 -135.75 136.04 40.45 Favored 'General case' 0 N--CA 1.491 1.592 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.517 179.185 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -98.13 152.23 19.57 Favored 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.256 -0.978 . . . . 0.0 112.547 -178.428 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -151.85 132.78 4.55 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.633 178.951 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 6.6 m -123.52 107.29 11.39 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.622 -0.831 . . . . 0.0 112.023 -178.683 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . 0.424 ' CD1' HG11 ' A' ' 94' ' ' VAL . 50.5 mt -89.58 160.88 16.45 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.513 -0.875 . . . . 0.0 109.348 178.749 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.21 41.09 0.72 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 118.66 -1.216 . . . . 0.0 111.754 -178.918 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . 0.462 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.6 OUTLIER -141.85 116.76 9.88 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 118.874 -1.13 . . . . 0.0 110.981 179.784 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -55.7 106.18 0.23 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.452 -0.899 . . . . 0.0 111.167 -179.685 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 173.93 -163.06 33.93 Favored Glycine 0 N--CA 1.484 1.843 0 C-N-CA 119.353 -1.403 . . . . 0.0 109.831 -179.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.6 125.7 45.3 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.807 -0.757 . . . . 0.0 111.071 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.547 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -109.3 153.73 23.49 Favored 'General case' 0 N--CA 1.483 1.213 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.018 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 81.1 mttt -115.63 134.49 54.99 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.402 -0.919 . . . . 0.0 112.469 -179.394 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.503 ' O ' ' N ' ' A' ' 92' ' ' GLY . 0.9 OUTLIER -143.57 154.98 44.15 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.492 -0.883 . . . . 0.0 110.058 176.917 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 36.5 p90 -168.45 -174.51 2.24 Favored 'General case' 0 C--N 1.284 -2.259 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.582 -178.666 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.3 t -110.94 122.57 48.21 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 119.842 -0.743 . . . . 0.0 109.832 179.732 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.582 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.5 tm-20 -72.74 -35.58 3.09 Favored Pre-proline 0 N--CA 1.483 1.182 0 C-N-CA 119.056 -1.058 . . . . 0.0 113.292 -178.885 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.1 Cg_endo -71.43 -38.48 4.56 Favored 'Trans proline' 0 C--O 1.213 -0.728 0 C-N-CA 120.52 0.814 . . . . 0.0 111.111 179.855 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 32.8 m80 -102.17 21.05 15.55 Favored 'General case' 0 N--CA 1.488 1.474 0 C-N-CA 119.785 -0.766 . . . . 0.0 111.049 -179.771 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.78 -12.9 8.22 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.612 179.766 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -92.5 -13.47 57.0 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.324 179.821 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.59 -20.44 26.39 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.549 179.933 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 110.21 14.82 12.47 Favored Glycine 0 N--CA 1.496 2.654 0 C-N-CA 119.853 -1.165 . . . . 0.0 110.83 179.673 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.3 mtp -72.27 98.4 2.18 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.689 179.875 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 21.0 mmtt -130.37 150.33 51.65 Favored 'General case' 0 N--CA 1.496 1.843 0 C-N-CA 119.962 -0.695 . . . . 0.0 110.835 179.538 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.503 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -140.3 155.92 24.85 Favored Glycine 0 N--CA 1.501 3.021 0 C-N-CA 119.283 -1.437 . . . . 0.0 112.456 -177.914 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 26.5 tt0 -158.64 146.43 18.04 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.203 179.014 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.542 HG13 ' O ' ' A' ' 94' ' ' VAL . 11.9 p -138.29 122.25 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.001 179.974 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.5 m -97.19 97.03 8.84 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.673 179.885 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 24.0 t -81.95 154.17 4.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.907 -179.051 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.2 p30 . . . . . 0 C--N 1.306 -1.318 0 CA-C-O 116.348 -1.787 . . . . 0.0 110.651 179.872 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.197 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -104.77 123.98 48.61 Favored 'General case' 0 N--CA 1.488 1.458 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.986 179.948 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.6 t -117.28 128.54 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 C-N-CA 119.888 -0.725 . . . . 0.0 110.404 179.494 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -103.76 117.92 35.49 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.814 -0.754 . . . . 0.0 111.155 -179.49 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 mt -78.18 109.14 12.03 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.727 -1.189 . . . . 0.0 109.529 177.964 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . 0.406 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 107.47 120.47 4.55 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.061 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 31.9 p . . . . . 0 C--N 1.305 -1.355 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.992 -179.808 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 73.5 mt . . . . . 0 N--CA 1.488 1.451 0 CA-C-O 120.401 0.143 . . . . 0.0 111.041 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.9 m -150.07 157.44 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.73 179.325 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' PHE . . . . . 0.415 ' O ' ' O ' ' A' ' 16' ' ' PRO . 14.2 m-85 -78.44 112.02 15.05 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.135 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 54.6 m -116.03 108.79 45.69 Favored Pre-proline 0 CA--C 1.558 1.26 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.824 -177.861 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . 0.415 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.6 Cg_endo -65.76 177.84 16.68 Favored 'Cis proline' 0 C--N 1.362 1.244 0 C-N-CA 125.353 -0.686 . . . . 0.0 111.75 -0.49 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.65 -51.64 4.83 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.509 -0.877 . . . . 0.0 110.423 179.437 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 94.5 p -140.02 141.89 36.27 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.782 179.385 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 22.4 p90 -162.71 149.42 12.95 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.743 -1.183 . . . . 0.0 111.183 -179.169 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . 0.422 HG23 ' H ' ' A' ' 20' ' ' THR . 0.7 OUTLIER -91.01 159.26 16.23 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.388 -0.925 . . . . 0.0 111.169 -179.972 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.6 m -149.95 172.01 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.858 179.697 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.503 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -88.83 147.79 24.23 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.459 -0.897 . . . . 0.0 110.662 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.85 76.3 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.943 179.802 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . 0.503 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.18 22.28 0.09 OUTLIER Glycine 0 N--CA 1.49 2.268 0 C-N-CA 119.537 -1.315 . . . . 0.0 109.933 179.968 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -96.3 145.97 25.13 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.01 -179.787 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.8 mttm -87.12 128.68 35.11 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.863 -179.971 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.8 mt -118.55 131.97 69.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.432 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 25.1 p -128.7 116.96 20.35 Favored 'General case' 0 N--CA 1.492 1.647 0 C-N-CA 119.354 -0.938 . . . . 0.0 112.384 -178.55 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -84.82 109.72 18.3 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.453 -0.899 . . . . 0.0 108.855 177.905 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.3 tttm -106.05 138.06 42.89 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 119.719 -0.792 . . . . 0.0 111.445 -178.103 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.446 HD21 ' CD1' ' A' ' 61' ' ' LEU . 4.3 m-20 -83.26 106.9 15.42 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.062 179.404 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 32' ' ' ASN . . . . . 0.663 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.0 OUTLIER -90.19 -30.75 17.39 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 118.88 -1.128 . . . . 0.0 111.774 -178.865 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 33' ' ' ALA . . . . . 0.663 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 167.81 114.62 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 118.827 -1.149 . . . . 0.0 111.144 179.916 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 139.37 -0.96 2.34 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.587 -1.292 . . . . 0.0 110.559 179.858 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 35' ' ' PHE . . . . . 0.426 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -48.0 161.83 0.35 Allowed Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 118.749 -1.18 . . . . 0.0 110.071 -179.65 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -77.62 144.05 75.89 Favored 'Cis proline' 0 C--O 1.216 -0.587 0 C-N-CA 124.113 -1.203 . . . . 0.0 112.271 -1.022 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.5 m-70 -112.85 175.56 5.39 Favored 'General case' 0 N--CA 1.495 1.782 0 C-N-CA 119.915 -0.714 . . . . 0.0 110.135 179.42 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . 0.691 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -151.64 148.97 28.6 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.529 179.493 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.691 ' N ' HD22 ' A' ' 38' ' ' ASN . 4.0 mp -134.86 103.47 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 C-N-CA 119.616 -0.833 . . . . 0.0 111.351 -179.502 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 t -119.08 144.65 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 C-N-CA 120.075 -0.65 . . . . 0.0 110.123 179.22 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.689 ' CD2' HD12 ' A' ' 55' ' ' ILE . 9.9 m-85 -99.88 114.67 28.05 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.526 -0.87 . . . . 0.0 111.443 -179.338 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 42' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 44' ' ' ASP . 32.8 t0 -55.6 88.41 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 119.441 -0.903 . . . . 0.0 110.48 179.676 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 43' ' ' GLU . . . . . 0.467 ' N ' ' O ' ' A' ' 41' ' ' PHE . 16.0 pt-20 -46.71 -13.25 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.515 -0.874 . . . . 0.0 111.357 -179.688 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . 0.519 ' N ' ' O ' ' A' ' 42' ' ' ASP . 0.9 OUTLIER -87.97 13.11 11.66 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.388 -179.594 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -151.66 15.32 0.67 Allowed 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.114 179.843 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.588 HG22 ' HD2' ' A' ' 47' ' ' PRO . 0.5 OUTLIER -104.06 154.87 37.85 Favored Pre-proline 0 N--CA 1.491 1.624 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.838 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . 0.588 ' HD2' HG22 ' A' ' 46' ' ' VAL . 6.1 Cg_exo -52.83 149.79 24.69 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 120.887 1.058 . . . . 0.0 111.236 179.646 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -83.06 40.78 0.72 Allowed 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.293 -0.963 . . . . 0.0 110.716 -179.899 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -142.89 -40.09 0.07 OUTLIER Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 70.3 t -92.48 90.8 3.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.146 179.449 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.2 m-80 -44.8 146.5 0.77 Allowed 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.314 -0.955 . . . . 0.0 110.877 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -90.84 -29.58 17.46 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.544 -0.862 . . . . 0.0 111.076 -179.728 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -60.74 -5.43 1.28 Allowed 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.995 -179.719 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 22.2 mtmt -99.55 -38.39 8.78 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.605 -0.838 . . . . 0.0 111.486 -179.828 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 55' ' ' ILE . . . . . 0.689 HD12 ' CD2' ' A' ' 41' ' ' PHE . 2.1 pt -90.49 -29.25 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.208 -179.562 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 58.8 m -56.23 172.34 0.22 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.107 179.909 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.64 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 60.9 mt-30 -134.45 71.92 70.96 Favored Pre-proline 0 N--CA 1.491 1.601 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.815 179.757 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -59.29 -6.81 4.31 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 121.074 1.183 . . . . 0.0 111.209 -179.664 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -100.25 106.48 18.15 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.651 179.577 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 31.1 m-85 -52.34 168.3 0.11 Allowed 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.594 -0.842 . . . . 0.0 110.471 -179.993 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.446 ' CD1' HD21 ' A' ' 31' ' ' ASN . 1.7 pp -148.26 141.73 25.35 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.12 -1.032 . . . . 0.0 110.877 179.85 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -137.85 8.09 2.76 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.088 -179.835 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -65.52 127.47 31.65 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 119.091 -1.528 . . . . 0.0 110.302 179.892 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -72.0 120.81 18.13 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.179 -1.008 . . . . 0.0 110.266 179.659 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.29 -14.69 53.45 Favored Glycine 0 N--CA 1.487 2.047 0 C-N-CA 119.111 -1.519 . . . . 0.0 110.657 -179.664 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.19 152.08 34.22 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.169 -1.012 . . . . 0.0 110.469 179.762 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -142.93 171.97 13.33 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.592 -179.615 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.64 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 34.2 t80 -135.73 128.41 30.86 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.145 179.218 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -99.23 155.79 17.31 Favored 'General case' 0 N--CA 1.49 1.562 0 C-N-CA 119.052 -1.059 . . . . 0.0 112.383 -178.604 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -156.34 142.94 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.023 178.93 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.9 m -130.99 96.13 3.98 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 119.784 -0.766 . . . . 0.0 111.265 -179.287 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 11.7 mt -79.58 161.3 26.02 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.045 -1.062 . . . . 0.0 109.134 179.172 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.46 45.47 0.87 Allowed 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 118.596 -1.242 . . . . 0.0 112.242 -178.688 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 29.2 mm-40 -143.82 105.7 4.34 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 118.876 -1.13 . . . . 0.0 110.269 179.279 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -43.51 109.93 0.17 Allowed 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.816 -179.296 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.98 -147.89 8.95 Favored Glycine 0 N--CA 1.486 1.989 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.417 -179.918 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 77' ' ' THR . . . . . 0.461 HG23 HG23 ' A' ' 95' ' ' THR . 0.0 OUTLIER -143.55 131.65 21.81 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.598 -0.841 . . . . 0.0 110.807 -179.898 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 78' ' ' TYR . . . . . 0.595 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -119.6 129.61 54.7 Favored 'General case' 0 N--CA 1.486 1.336 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.578 -179.942 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -101.3 121.21 41.48 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 119.424 -0.91 . . . . 0.0 111.827 -179.49 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . 0.54 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.7 p90 -131.48 166.34 21.55 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.816 -0.753 . . . . 0.0 110.009 178.161 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 29.6 p90 -170.29 -176.85 2.31 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.105 -1.038 . . . . 0.0 111.409 -178.355 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -102.21 130.75 48.96 Favored 'General case' 0 N--CA 1.482 1.154 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.301 179.16 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.55 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.9 OUTLIER -77.3 -44.64 2.68 Favored Pre-proline 0 N--CA 1.485 1.279 0 C-N-CA 119.328 -0.949 . . . . 0.0 112.713 -179.71 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 84' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 4.1 Cg_exo -65.57 -52.91 0.88 Allowed 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 120.914 1.076 . . . . 0.0 111.535 -179.096 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . 0.466 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.4 m80 -81.94 15.58 2.22 Favored 'General case' 0 C--N 1.302 -1.46 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.804 -179.874 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.65 -0.94 0.32 Allowed 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.107 -179.938 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 87' ' ' GLY . . . . . 0.466 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -95.15 -14.14 49.73 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.324 -1.417 . . . . 0.0 110.361 179.951 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.14 -51.89 4.82 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.596 179.925 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.26 24.75 0.2 Allowed Glycine 0 N--CA 1.488 2.166 0 C-N-CA 119.537 -1.316 . . . . 0.0 110.502 179.901 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.1 mtp -73.16 97.99 2.51 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.148 -1.021 . . . . 0.0 110.962 -179.95 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.3 ptpt -119.7 154.99 33.28 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.507 179.22 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.4 145.66 16.31 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.396 -1.383 . . . . 0.0 111.399 -178.764 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -152.2 143.78 23.49 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.486 -0.886 . . . . 0.0 111.062 179.636 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.499 HG13 ' O ' ' A' ' 94' ' ' VAL . 12.3 p -137.16 125.2 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.678 179.159 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.461 HG23 HG23 ' A' ' 77' ' ' THR . 46.2 m -102.56 99.18 9.17 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.549 179.408 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 40.3 t -79.69 147.84 6.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 C-N-CA 118.763 -1.175 . . . . 0.0 110.633 -178.843 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 116.285 -1.816 . . . . 0.0 110.75 -179.697 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 109.908 -0.405 . . . . 0.0 109.908 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 5.4 mp0 -131.17 122.15 26.1 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.823 -0.751 . . . . 0.0 110.835 -179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.6 t -115.15 126.59 72.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 119.966 -0.694 . . . . 0.0 110.33 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 22.1 mtmt -101.72 116.15 32.1 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.918 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.481 HD11 ' HB3' ' A' ' 29' ' ' PHE . 12.0 mt -79.56 114.64 18.64 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.167 -1.013 . . . . 0.0 109.971 178.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.499 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 96.83 108.02 2.49 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.491 -1.338 . . . . 0.0 109.787 -179.097 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.546 ' OG ' ' N ' ' A' ' 11' ' ' GLY . 3.0 p -67.52 164.14 19.59 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.314 -0.954 . . . . 0.0 110.934 -179.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -74.33 -10.79 59.93 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.473 -0.891 . . . . 0.0 110.877 -179.91 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.427 ' H ' ' H ' ' A' ' 10' ' ' GLY . 3.2 p30 -170.28 -9.7 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 119.33 -0.948 . . . . 0.0 110.876 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.427 ' H ' ' H ' ' A' ' 9' ' ' ASP . . . -74.47 -23.45 75.44 Favored Glycine 0 N--CA 1.491 2.357 0 C-N-CA 119.385 -1.388 . . . . 0.0 110.453 179.929 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.546 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . 119.99 -142.06 15.86 Favored Glycine 0 N--CA 1.497 2.717 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.2 mt -103.29 102.52 12.48 Favored 'General case' 0 N--CA 1.49 1.527 0 C-N-CA 119.696 -0.802 . . . . 0.0 110.658 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 34.7 m -150.48 158.11 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 119.009 -1.076 . . . . 0.0 110.999 179.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.535 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 16.7 m-85 -78.8 111.96 15.45 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 177.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 60.0 m -114.4 107.62 51.06 Favored Pre-proline 0 N--CA 1.484 1.264 0 C-N-CA 119.421 -0.911 . . . . 0.0 112.226 -177.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.413 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.0 OUTLIER -67.64 176.58 25.44 Favored 'Cis proline' 0 C--N 1.362 1.275 0 C-N-CA 125.4 -0.667 . . . . 0.0 111.6 -0.555 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -92.49 -58.8 2.25 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.014 179.118 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.2 t -124.06 138.55 54.43 Favored 'General case' 0 N--CA 1.487 1.4 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.265 178.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.41 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 9.0 p90 -159.72 136.06 8.96 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 118.328 -1.349 . . . . 0.0 111.706 -178.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.424 HG23 ' H ' ' A' ' 20' ' ' THR . 0.8 OUTLIER -85.98 150.67 24.32 Favored 'General case' 0 C--N 1.3 -1.558 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.329 179.436 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 11.3 m -144.21 177.79 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.179 -179.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -98.05 145.79 26.18 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.68 -0.808 . . . . 0.0 110.365 179.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.4 88.9 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.122 -1.031 . . . . 0.0 110.934 -179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 139.16 19.73 0.46 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.6 tp10 -96.28 137.67 35.0 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.861 -0.735 . . . . 0.0 110.715 -179.508 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 54.1 mttm -84.89 120.11 26.1 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.248 -0.981 . . . . 0.0 110.924 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.7 mt -109.27 110.88 33.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.038 179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 30.3 p -106.2 116.92 32.77 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.71 -0.796 . . . . 0.0 112.379 -178.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.481 ' HB3' HD11 ' A' ' 5' ' ' LEU . 94.2 m-85 -85.86 103.59 14.74 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.023 178.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.6 tttm -101.7 135.19 43.66 Favored 'General case' 0 N--CA 1.491 1.592 0 C-N-CA 119.758 -0.777 . . . . 0.0 112.218 -177.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.471 ' N ' ' OD1' ' A' ' 31' ' ' ASN . 1.3 m-20 -76.71 126.24 30.64 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.935 178.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.499 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 0.9 OUTLIER -106.78 -32.62 7.88 Favored 'General case' 0 N--CA 1.495 1.819 0 C-N-CA 119.086 -1.046 . . . . 0.0 113.136 -178.371 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 178.11 11.94 0.0 OUTLIER 'General case' 0 N--CA 1.507 2.387 0 C-N-CA 119.052 -1.059 . . . . 0.0 111.729 -179.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.524 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -124.88 49.68 0.9 Allowed Glycine 0 N--CA 1.5 2.931 0 C-N-CA 119.35 -1.405 . . . . 0.0 112.104 -178.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.596 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -91.06 161.31 35.63 Favored Pre-proline 0 N--CA 1.488 1.428 0 C-N-CA 118.35 -1.34 . . . . 0.0 110.291 178.805 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -78.17 142.42 69.6 Favored 'Cis proline' 0 C--O 1.215 -0.658 0 C-N-CA 124.004 -1.248 . . . . 0.0 111.825 -1.266 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.524 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 36.9 m-70 -107.26 162.38 13.95 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.596 -0.842 . . . . 0.0 111.016 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.9 t-20 -144.6 137.76 26.94 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 119.607 -0.837 . . . . 0.0 109.852 179.19 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.4 mp -127.29 117.46 47.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.16 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -128.58 142.84 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.765 179.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.753 ' CD2' HD12 ' A' ' 55' ' ' ILE . 7.5 m-85 -95.08 117.74 30.7 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.738 -178.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.485 ' C ' ' H ' ' A' ' 44' ' ' ASP . 21.6 t0 -55.4 99.33 0.03 OUTLIER 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.374 179.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -64.01 5.26 0.25 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.446 -0.902 . . . . 0.0 111.392 -179.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.485 ' H ' ' C ' ' A' ' 42' ' ' ASP . 9.6 m-20 -99.78 -8.67 23.91 Favored 'General case' 0 N--CA 1.487 1.379 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.915 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -134.6 16.33 3.65 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.957 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -95.53 147.03 32.36 Favored Pre-proline 0 N--CA 1.49 1.529 0 N-CA-C 108.957 -0.756 . . . . 0.0 108.957 179.578 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -47.84 142.73 14.3 Favored 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.958 1.105 . . . . 0.0 111.799 -179.65 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.2 70.64 1.63 Allowed 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.712 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 174.46 -37.75 0.12 Allowed Glycine 0 N--CA 1.488 2.102 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.077 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.418 ' O ' HG12 ' A' ' 50' ' ' VAL . 15.4 t -86.22 104.9 14.15 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.311 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.789 179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -48.28 147.7 2.18 Favored 'General case' 0 C--N 1.302 -1.497 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.738 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -99.46 -5.81 28.73 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 119.673 -0.811 . . . . 0.0 110.918 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.07 -30.45 17.7 Favored 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.511 -0.876 . . . . 0.0 111.19 -179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 36.0 mttt -69.25 -29.91 67.92 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.148 -179.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.753 HD12 ' CD2' ' A' ' 41' ' ' PHE . 1.1 pt -94.16 -37.52 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.748 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 57.7 m -64.01 159.62 19.68 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 119.537 -0.865 . . . . 0.0 111.253 179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.611 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -139.66 75.67 31.15 Favored Pre-proline 0 N--CA 1.486 1.361 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.398 179.635 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -57.63 -21.76 48.62 Favored 'Trans proline' 0 C--O 1.214 -0.69 0 C-N-CA 121.262 1.308 . . . . 0.0 111.567 -179.078 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -59.21 95.67 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.021 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 46.2 m-85 -42.71 163.11 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.669 -0.812 . . . . 0.0 110.799 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -150.09 111.64 4.48 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 118.862 -1.135 . . . . 0.0 111.878 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.463 ' H ' ' ND2' ' A' ' 62' ' ' ASN . 2.8 p30 -106.33 21.66 17.03 Favored 'General case' 0 N--CA 1.488 1.475 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.918 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -83.65 137.66 16.5 Favored Glycine 0 N--CA 1.494 2.53 0 C-N-CA 119.355 -1.403 . . . . 0.0 110.655 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -82.32 114.48 20.82 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.533 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.07 -13.67 66.62 Favored Glycine 0 N--CA 1.488 2.147 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.506 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -59.25 150.34 26.05 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.209 -0.996 . . . . 0.0 110.31 179.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -145.57 168.75 19.88 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 118.981 -1.087 . . . . 0.0 111.884 -179.599 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.611 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 29.3 t80 -135.29 129.88 34.24 Favored 'General case' 0 N--CA 1.487 1.418 0 CA-C-N 115.381 -0.827 . . . . 0.0 109.555 179.228 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.96 152.86 21.01 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.306 -178.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.1 t -151.79 130.78 3.07 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 CA-C-N 115.105 -0.952 . . . . 0.0 108.844 179.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 20.6 m -129.86 93.93 3.62 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.652 -0.819 . . . . 0.0 111.226 -179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.436 ' CD1' HG11 ' A' ' 94' ' ' VAL . 13.7 mt -79.39 157.98 27.49 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.213 -0.995 . . . . 0.0 109.507 179.333 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 2.2 t -149.94 46.07 0.92 Allowed 'General case' 0 C--N 1.299 -1.61 0 C-N-CA 118.793 -1.163 . . . . 0.0 111.649 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.404 ' O ' ' C ' ' A' ' 75' ' ' LYS . 5.6 tt0 -144.93 99.98 3.42 Favored 'General case' 0 C--N 1.307 -1.257 0 C-N-CA 118.977 -1.089 . . . . 0.0 109.913 179.048 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.481 ' HD2' ' H ' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -39.45 112.48 0.26 Allowed 'General case' 0 N--CA 1.484 1.239 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.344 -179.124 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.76 -148.88 10.0 Favored Glycine 0 N--CA 1.484 1.849 0 C-N-CA 119.453 -1.356 . . . . 0.0 110.004 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.96 132.34 25.09 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.922 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.562 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.2 m-85 -120.8 126.01 49.03 Favored 'General case' 0 N--CA 1.49 1.552 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.66 179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.442 ' N ' ' CD ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -100.4 114.11 27.39 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.633 -0.827 . . . . 0.0 111.78 -179.361 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.594 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -125.02 169.74 11.83 Favored 'General case' 0 N--CA 1.488 1.471 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.09 178.686 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 32.2 p90 -171.25 -179.76 2.76 Favored 'General case' 0 C--N 1.297 -1.694 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.073 -179.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 2.1 t -106.39 115.31 29.99 Favored 'General case' 0 C--N 1.305 -1.359 0 CA-C-N 115.422 -0.808 . . . . 0.0 109.504 178.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.563 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 tt0 -66.87 -40.38 29.77 Favored Pre-proline 0 C--N 1.3 -1.576 0 C-N-CA 119.379 -0.928 . . . . 0.0 112.724 -179.027 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.563 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.4 Cg_endo -68.95 -47.69 1.12 Allowed 'Trans proline' 0 C--O 1.214 -0.705 0 C-N-CA 120.822 1.015 . . . . 0.0 112.03 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -87.87 12.15 13.84 Favored 'General case' 0 N--CA 1.487 1.423 0 C-N-CA 119.238 -0.985 . . . . 0.0 111.296 -179.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.72 -24.4 61.42 Favored 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.771 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -62.24 -22.19 62.8 Favored Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.514 -1.327 . . . . 0.0 110.414 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.92 -31.83 14.8 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.621 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 117.21 30.22 1.96 Allowed Glycine 0 N--CA 1.495 2.611 0 C-N-CA 119.991 -1.1 . . . . 0.0 110.495 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.3 mtp -77.88 105.52 9.12 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.862 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.535 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 0.6 OUTLIER -127.61 166.89 17.19 Favored 'General case' 0 N--CA 1.494 1.774 0 C-N-CA 119.956 -0.698 . . . . 0.0 110.777 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -147.83 148.44 19.98 Favored Glycine 0 N--CA 1.488 2.104 0 C-N-CA 119.018 -1.563 . . . . 0.0 111.286 -178.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -153.63 141.64 20.28 Favored 'General case' 0 N--CA 1.482 1.156 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.625 179.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.463 HG13 ' O ' ' A' ' 94' ' ' VAL . 7.2 p -136.87 125.26 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.624 179.307 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 95.8 m -103.32 98.71 8.58 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.409 -0.916 . . . . 0.0 110.645 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 41.1 t -80.03 148.3 5.9 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.255 -179.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 6.7 m-80 . . . . . 0 C--N 1.304 -1.41 0 CA-C-O 116.344 -1.789 . . . . 0.0 111.007 -179.554 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.105 0 CA-C-O 120.792 0.33 . . . . 0.0 110.197 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -130.19 121.46 26.27 Favored 'General case' 0 N--CA 1.489 1.522 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.54 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 51.8 t -112.87 122.02 66.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.682 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 60.8 mttt -94.53 116.61 28.98 Favored 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.761 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.434 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 8.5 mt -76.21 102.4 5.79 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 118.615 -1.234 . . . . 0.0 109.525 178.18 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 121.25 155.7 9.58 Favored Glycine 0 N--CA 1.49 2.268 0 N-CA-C 109.031 -1.627 . . . . 0.0 109.031 -178.204 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 16.2 p -87.44 -81.29 0.24 Allowed 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 119.039 -1.064 . . . . 0.0 111.047 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -161.12 -25.31 0.06 Allowed 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.802 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 9' ' ' ASP . 0.6 OUTLIER 178.5 78.4 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.26 -0.976 . . . . 0.0 111.068 179.837 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 104.83 39.68 2.29 Favored Glycine 0 N--CA 1.495 2.589 0 C-N-CA 119.775 -1.202 . . . . 0.0 110.713 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -157.47 110.3 0.44 Allowed Glycine 0 N--CA 1.489 2.169 0 C-N-CA 119.332 -1.413 . . . . 0.0 110.357 179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 80.1 mt -99.04 100.55 11.71 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 119.527 -0.869 . . . . 0.0 110.382 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.3 m -149.71 154.78 8.77 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.207 0 C-N-CA 118.74 -1.184 . . . . 0.0 111.072 179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' A' ' 16' ' ' PRO . 17.2 m-85 -78.2 110.16 12.94 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.053 -1.462 . . . . 0.0 107.053 177.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.7 m -115.0 109.01 47.5 Favored Pre-proline 0 CA--C 1.562 1.41 0 C-N-CA 119.369 -0.933 . . . . 0.0 112.503 -177.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.421 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.9 Cg_endo -66.66 178.35 17.84 Favored 'Cis proline' 0 C--N 1.364 1.348 0 C-N-CA 125.27 -0.721 . . . . 0.0 111.484 -0.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.6 p -94.94 -60.43 1.69 Allowed 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.572 -0.851 . . . . 0.0 109.933 179.177 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.2 p -121.05 135.41 55.2 Favored 'General case' 0 N--CA 1.486 1.34 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.076 178.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.465 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 14.4 p90 -157.88 140.74 14.89 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 118.528 -1.269 . . . . 0.0 111.49 -178.729 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.447 HG23 ' H ' ' A' ' 20' ' ' THR . 0.5 OUTLIER -87.77 153.45 21.33 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.357 -0.937 . . . . 0.0 110.633 179.451 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 15.1 m -145.94 158.76 11.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.33 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.105 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.421 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -75.04 145.88 42.02 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.211 -0.996 . . . . 0.0 110.427 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.27 73.03 0.12 Allowed 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.459 -0.896 . . . . 0.0 110.9 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.438 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 160.98 11.15 0.04 OUTLIER Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.438 ' H ' ' H ' ' A' ' 24' ' ' GLY . 18.5 tt0 -98.81 157.14 16.49 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.913 -179.532 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.4 mmtp -95.48 134.2 38.6 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.33 -179.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.9 mt -107.09 104.36 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 120.076 -0.649 . . . . 0.0 109.358 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 52.3 p -101.41 117.57 35.21 Favored 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 119.553 -0.859 . . . . 0.0 112.612 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 93.2 m-85 -91.16 109.76 21.03 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.12 178.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 31.0 tttt -103.14 135.14 45.37 Favored 'General case' 0 N--CA 1.486 1.329 0 C-N-CA 119.54 -0.864 . . . . 0.0 111.58 -178.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 1.0 OUTLIER -84.67 106.11 15.98 Favored 'General case' 0 C--N 1.298 -1.658 0 C-N-CA 119.258 -0.977 . . . . 0.0 110.108 179.237 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.547 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 4.3 p-10 -93.36 -28.6 16.07 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.208 -0.997 . . . . 0.0 112.016 -178.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.547 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 175.44 133.57 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 118.55 -1.26 . . . . 0.0 111.371 -179.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 111.48 5.97 25.73 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.782 -1.199 . . . . 0.0 111.579 179.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.452 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -52.47 162.54 0.89 Allowed Pre-proline 0 N--CA 1.488 1.437 0 C-N-CA 118.188 -1.405 . . . . 0.0 109.744 179.814 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -78.76 161.62 88.95 Favored 'Cis proline' 0 C--O 1.212 -0.798 0 C-N-CA 124.38 -1.091 . . . . 0.0 112.636 -0.689 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -125.75 172.7 9.6 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-N 115.536 -0.757 . . . . 0.0 109.952 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.439 HD22 ' CG2' ' A' ' 40' ' ' VAL . 0.7 OUTLIER -153.49 117.53 4.81 Favored 'General case' 0 N--CA 1.492 1.67 0 C-N-CA 118.978 -1.089 . . . . 0.0 110.622 179.185 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.842 ' N ' HD12 ' A' ' 39' ' ' ILE . 2.4 mp -96.18 129.71 45.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.146 -179.401 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.439 ' CG2' HD22 ' A' ' 38' ' ' ASN . 2.6 t -143.31 138.63 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 C-N-CA 119.679 -0.808 . . . . 0.0 110.427 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.7 ' CD2' HD12 ' A' ' 55' ' ' ILE . 9.1 m-85 -98.33 118.26 34.59 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.206 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.524 ' OD2' ' N ' ' A' ' 45' ' ' GLU . 11.2 t70 -53.1 120.4 5.86 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.348 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 15.6 tt0 -73.57 0.47 12.51 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.433 -179.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.404 ' N ' ' OD2' ' A' ' 42' ' ' ASP . 14.6 m-20 -107.99 4.2 24.92 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.813 -0.755 . . . . 0.0 111.135 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.524 ' N ' ' OD2' ' A' ' 42' ' ' ASP . 34.5 mt-10 -146.18 52.56 1.14 Allowed 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 119.486 -0.886 . . . . 0.0 110.835 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -137.03 148.36 62.52 Favored Pre-proline 0 N--CA 1.493 1.676 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -49.58 145.78 16.31 Favored 'Trans proline' 0 C--O 1.215 -0.658 0 C-N-CA 121.061 1.174 . . . . 0.0 111.678 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.89 81.92 2.8 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.709 -0.796 . . . . 0.0 111.025 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 161.54 -41.95 0.4 Allowed Glycine 0 N--CA 1.489 2.174 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.312 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 92.0 t -81.96 95.94 3.24 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 C-N-CA 119.348 -0.941 . . . . 0.0 110.84 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.0 m120 -44.94 143.76 1.39 Allowed 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.969 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.54 -2.04 49.3 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.625 -0.83 . . . . 0.0 110.898 179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -86.55 -35.13 19.7 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.98 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 30.7 mttt -68.75 -34.38 75.5 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.581 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.7 HD12 ' CD2' ' A' ' 41' ' ' PHE . 1.1 pt -89.94 -29.68 5.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 C-N-CA 118.938 -1.105 . . . . 0.0 111.062 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 7.6 m -58.95 -178.63 0.05 Allowed 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.928 179.835 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.614 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 61.2 mt-30 -146.38 73.19 13.02 Favored Pre-proline 0 N--CA 1.484 1.274 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.031 -179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -62.39 -4.52 5.5 Favored 'Trans proline' 0 C--N 1.321 -0.879 0 C-N-CA 121.094 1.196 . . . . 0.0 110.984 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 16.0 mt-10 -100.31 99.98 10.71 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.828 -0.749 . . . . 0.0 110.545 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 44.6 m-85 -47.54 164.49 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.411 -0.916 . . . . 0.0 110.92 -179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.1 pp -142.32 135.95 29.21 Favored 'General case' 0 N--CA 1.484 1.233 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.96 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -135.46 42.41 2.7 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.664 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -102.5 128.28 9.49 Favored Glycine 0 N--CA 1.495 2.595 0 C-N-CA 119.584 -1.293 . . . . 0.0 110.532 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -78.06 108.22 11.19 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.628 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.51 -6.37 59.14 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.325 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.436 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -71.96 157.69 37.37 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.555 179.835 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 4.9 p -148.64 163.29 37.71 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.051 -1.059 . . . . 0.0 111.229 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.614 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 28.5 t80 -134.7 139.16 45.02 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 120.034 -0.666 . . . . 0.0 109.651 179.206 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.467 ' CD ' ' H ' ' A' ' 69' ' ' GLU . 1.7 mp0 -102.76 148.5 25.53 Favored 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 119.434 -0.907 . . . . 0.0 112.252 -178.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -142.82 126.05 14.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 CA-C-N 115.124 -0.943 . . . . 0.0 108.748 179.208 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.0 m -117.47 112.82 21.15 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.61 -0.836 . . . . 0.0 112.039 -178.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 58.3 mt -95.88 161.7 13.89 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.47 178.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.557 ' O ' HG22 ' A' ' 73' ' ' THR . 87.9 m -150.57 42.61 0.81 Allowed 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 118.662 -1.215 . . . . 0.0 112.044 -179.033 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -147.9 102.97 3.45 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 118.658 -1.217 . . . . 0.0 110.33 179.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.472 ' O ' ' CG ' ' A' ' 75' ' ' LYS . 11.5 pttt -43.97 120.2 2.0 Allowed 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.723 -179.619 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.45 -147.01 10.58 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -143.25 128.85 19.16 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.405 -0.918 . . . . 0.0 111.248 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.562 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -115.73 136.87 52.64 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.422 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.412 ' N ' ' CD ' ' A' ' 79' ' ' LYS . 0.4 OUTLIER -107.86 116.27 31.64 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.634 -0.826 . . . . 0.0 111.541 -179.348 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.489 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 2.4 p90 -130.26 166.8 19.58 Favored 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.082 178.485 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -170.46 -172.74 1.3 Allowed 'General case' 0 C--N 1.294 -1.833 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.682 -178.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -107.32 126.08 51.99 Favored 'General case' 0 N--CA 1.479 0.992 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.756 179.288 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.499 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.9 mt-10 -68.78 -47.11 33.18 Favored Pre-proline 0 C--N 1.305 -1.336 0 C-N-CA 119.593 -0.843 . . . . 0.0 112.599 -179.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.499 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.9 Cg_endo -64.72 -47.77 4.89 Favored 'Trans proline' 0 C--O 1.214 -0.697 0 C-N-CA 120.719 0.946 . . . . 0.0 111.746 -179.122 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -90.84 19.88 5.21 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.808 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.44 -14.23 11.63 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.346 -0.942 . . . . 0.0 110.462 179.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -93.76 -12.47 56.75 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.151 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.01 -13.53 38.59 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.597 179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 96.96 25.6 11.23 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.605 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.64 99.77 10.42 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.234 -0.987 . . . . 0.0 111.022 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -120.97 159.7 25.06 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.793 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.74 143.03 11.47 Favored Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.337 -1.411 . . . . 0.0 111.071 -179.049 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -150.68 144.74 25.39 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.35 179.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.494 HG13 ' O ' ' A' ' 94' ' ' VAL . 8.0 p -135.24 125.73 44.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.689 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 55.0 m -101.67 98.22 8.54 Favored 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.274 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 41.2 t -79.75 152.51 4.68 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 C-N-CA 118.587 -1.245 . . . . 0.0 110.734 -178.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 116.283 -1.818 . . . . 0.0 110.826 -179.688 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.118 0 CA-C-O 120.78 0.324 . . . . 0.0 110.142 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.439 ' OE1' ' O ' ' A' ' 28' ' ' THR . 3.1 mm-40 -140.19 121.0 14.43 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.618 179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -108.72 120.54 60.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 C-N-CA 119.917 -0.713 . . . . 0.0 110.509 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.7 mttt -91.16 114.55 27.11 Favored 'General case' 0 C--N 1.299 -1.59 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.992 -179.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.0 mt -74.51 113.84 12.22 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.239 178.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.47 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 99.28 124.13 5.12 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.44 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 16.6 p -66.29 -179.16 0.74 Allowed 'General case' 0 C--N 1.302 -1.46 0 C-N-CA 119.324 -0.951 . . . . 0.0 110.428 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -91.93 -40.59 11.06 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.508 179.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.472 ' CG ' ' N ' ' A' ' 10' ' ' GLY . 6.2 p-10 -63.21 -44.88 94.07 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.792 -180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.472 ' N ' ' CG ' ' A' ' 9' ' ' ASP . . . 147.18 69.47 0.01 OUTLIER Glycine 0 N--CA 1.489 2.223 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.404 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -151.01 157.01 26.97 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.377 -1.392 . . . . 0.0 110.39 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.3 mt -107.02 90.31 3.26 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.983 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.4 m -144.25 155.86 15.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 C-N-CA 119.098 -1.041 . . . . 0.0 110.674 179.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.401 ' O ' ' C ' ' A' ' 16' ' ' PRO . 16.6 m-85 -77.36 112.98 14.67 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 177.895 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 15.8 m -114.89 108.46 48.66 Favored Pre-proline 0 CA--C 1.558 1.283 0 C-N-CA 119.219 -0.992 . . . . 0.0 112.007 -177.348 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.401 ' C ' ' O ' ' A' ' 14' ' ' PHE . 3.2 Cg_exo -67.5 170.71 46.55 Favored 'Cis proline' 0 C--N 1.362 1.269 0 C-N-CA 125.321 -0.7 . . . . 0.0 111.597 -0.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.5 t -90.23 -64.51 1.12 Allowed 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.543 -0.863 . . . . 0.0 109.543 178.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -116.35 139.58 50.25 Favored 'General case' 0 N--CA 1.485 1.277 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.199 178.69 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.401 ' N ' ' CD1' ' A' ' 19' ' ' PHE . 9.5 p90 -167.95 139.45 2.91 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 118.468 -1.293 . . . . 0.0 111.424 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.443 ' H ' HG23 ' A' ' 20' ' ' THR . 0.6 OUTLIER -85.06 159.12 20.26 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.623 -0.831 . . . . 0.0 111.411 -179.591 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 25.9 m -146.69 -177.75 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.059 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -94.87 148.95 21.76 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.438 -0.905 . . . . 0.0 111.015 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.39 68.48 0.54 Allowed 'General case' 0 N--CA 1.487 1.401 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.042 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 159.21 14.03 0.04 OUTLIER Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -97.36 155.95 16.67 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.907 -0.717 . . . . 0.0 111.038 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 13.7 mttp -95.44 138.53 33.0 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.76 179.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.9 mt -117.65 127.58 75.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 CA-C-N 115.763 -0.653 . . . . 0.0 109.443 179.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.439 ' O ' ' OE1' ' A' ' 2' ' ' GLU . 7.6 p -125.51 119.07 27.18 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.544 -0.862 . . . . 0.0 112.17 -178.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 77.3 m-85 -84.91 110.37 18.81 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.489 -0.885 . . . . 0.0 109.024 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 50.0 tttp -101.45 139.13 37.54 Favored 'General case' 0 N--CA 1.488 1.439 0 C-N-CA 119.444 -0.902 . . . . 0.0 111.158 -178.272 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.944 ' ND2' HD11 ' A' ' 61' ' ' LEU . 2.5 m120 -86.45 112.57 21.62 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.47 179.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.677 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.0 OUTLIER -95.66 -30.8 13.57 Favored 'General case' 0 N--CA 1.481 1.107 0 C-N-CA 119.224 -0.991 . . . . 0.0 111.543 -179.227 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.677 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 164.69 118.08 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 119.349 -0.94 . . . . 0.0 111.182 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 138.6 -1.03 2.57 Favored Glycine 0 N--CA 1.492 2.38 0 C-N-CA 119.428 -1.368 . . . . 0.0 110.957 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.409 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -47.69 164.66 0.24 Allowed Pre-proline 0 C--N 1.307 -1.281 0 C-N-CA 118.839 -1.144 . . . . 0.0 110.137 -179.835 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_endo -75.99 138.9 57.6 Favored 'Cis proline' 0 C--O 1.214 -0.722 0 C-N-CA 124.292 -1.128 . . . . 0.0 112.633 -0.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.5 m-70 -110.3 156.4 20.77 Favored 'General case' 0 N--CA 1.485 1.295 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.205 179.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.429 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 6.2 t30 -148.42 116.23 6.35 Favored 'General case' 0 C--N 1.3 -1.58 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.136 179.251 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.442 ' H ' HD12 ' A' ' 39' ' ' ILE . 3.7 mp -96.64 137.22 25.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.652 -178.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.429 ' CG2' ' ND2' ' A' ' 38' ' ' ASN . 1.5 t -146.54 149.42 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.987 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 36.8 m-85 -107.58 118.28 36.32 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.712 -179.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.516 ' OD2' ' N ' ' A' ' 45' ' ' GLU . 1.6 t70 -55.58 119.32 5.5 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 119.576 -0.849 . . . . 0.0 110.28 179.47 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -75.5 14.21 0.65 Allowed 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 119.393 -0.923 . . . . 0.0 111.55 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.446 ' H ' ' CG ' ' A' ' 42' ' ' ASP . 4.0 m-20 -115.39 2.1 13.86 Favored 'General case' 0 N--CA 1.495 1.779 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.049 179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.548 ' OE1' ' NZ ' ' A' ' 79' ' ' LYS . 11.8 mm-40 -140.6 19.3 2.36 Favored 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 119.657 -0.817 . . . . 0.0 110.446 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -107.69 147.12 34.76 Favored Pre-proline 0 N--CA 1.488 1.471 0 CA-C-N 115.23 -0.895 . . . . 0.0 108.856 179.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -48.6 145.24 12.76 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 120.804 1.003 . . . . 0.0 111.718 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.35 50.56 0.79 Allowed 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.935 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -160.6 -31.11 0.02 OUTLIER Glycine 0 N--CA 1.487 2.08 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 86.3 t -96.18 90.69 2.53 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 C-N-CA 119.745 -0.782 . . . . 0.0 110.638 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -45.95 139.89 4.05 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.888 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -81.08 -26.35 36.33 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.62 -0.832 . . . . 0.0 111.109 -179.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -67.48 -19.89 65.39 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.456 -0.898 . . . . 0.0 110.93 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -78.03 -38.01 45.62 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.367 -0.933 . . . . 0.0 110.876 -179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.7 pt -94.26 -26.41 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.306 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 75.0 m -72.35 155.89 39.67 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.431 -0.908 . . . . 0.0 111.297 -179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.621 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.1 OUTLIER -137.95 75.98 40.8 Favored Pre-proline 0 C--N 1.303 -1.432 0 CA-C-N 115.421 -0.809 . . . . 0.0 109.972 179.484 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.412 ' O ' ' OD1' ' A' ' 38' ' ' ASN . 5.2 Cg_exo -56.5 -29.07 76.82 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 121.234 1.289 . . . . 0.0 111.496 -178.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -52.96 103.67 0.08 Allowed 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 118.813 -1.155 . . . . 0.0 109.844 179.252 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 46.8 m-85 -42.63 161.56 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.69 -0.804 . . . . 0.0 111.105 -179.388 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.944 HD11 ' ND2' ' A' ' 31' ' ' ASN . 0.3 OUTLIER -143.65 148.08 35.27 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.542 -0.863 . . . . 0.0 110.239 -179.644 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.768 ' H ' HD22 ' A' ' 62' ' ' ASN . 0.0 OUTLIER -148.2 -12.56 0.36 Allowed 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.059 -1.056 . . . . 0.0 111.265 -179.83 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.695 ' N ' HD22 ' A' ' 62' ' ' ASN . . . -48.74 115.82 2.84 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.203 -1.475 . . . . 0.0 110.403 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.51 119.92 10.1 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.962 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 88.85 -21.29 27.62 Favored Glycine 0 N--CA 1.489 2.177 0 C-N-CA 119.387 -1.387 . . . . 0.0 110.639 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -58.05 153.76 13.98 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.048 -1.061 . . . . 0.0 110.326 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -140.68 170.01 16.56 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 119.329 -0.948 . . . . 0.0 111.67 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.621 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 22.8 t80 -130.96 130.98 44.11 Favored 'General case' 0 N--CA 1.489 1.525 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.284 179.361 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -93.33 150.76 20.23 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 119.081 -1.048 . . . . 0.0 112.716 -178.11 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -151.59 136.52 10.28 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.925 0 CA-C-N 115.127 -0.942 . . . . 0.0 108.933 179.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.3 m -127.31 104.65 8.05 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.521 -0.871 . . . . 0.0 111.503 -179.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.47 ' CD1' HG11 ' A' ' 94' ' ' VAL . 49.6 mt -88.17 155.14 19.92 Favored 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.001 179.094 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 4.8 p -150.92 47.32 0.85 Allowed 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.935 -179.657 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.429 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.5 mm-40 -144.18 108.48 4.81 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.099 -1.041 . . . . 0.0 110.722 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.561 ' H ' ' HZ3' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -49.79 114.33 1.05 Allowed 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 119.372 -0.931 . . . . 0.0 110.854 -179.572 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 165.28 -137.74 4.86 Favored Glycine 0 N--CA 1.484 1.857 0 C-N-CA 119.183 -1.484 . . . . 0.0 110.235 179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -149.46 143.0 25.4 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.286 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.563 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -127.34 123.74 37.02 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.46 -0.791 . . . . 0.0 109.37 179.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.548 ' NZ ' ' OE1' ' A' ' 45' ' ' GLU . 1.2 mptm? -95.43 119.67 34.34 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.728 -179.707 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.551 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.2 p90 -130.31 171.91 12.4 Favored 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 119.571 -0.852 . . . . 0.0 109.978 177.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 42.5 p90 -171.83 -175.33 1.5 Allowed 'General case' 0 C--N 1.293 -1.859 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.922 -178.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . 0.41 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.8 t -108.82 117.18 33.51 Favored 'General case' 0 C--N 1.31 -1.112 0 C-N-CA 119.856 -0.738 . . . . 0.0 109.713 178.206 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.561 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.4 tt0 -68.3 -39.59 17.0 Favored Pre-proline 0 C--N 1.303 -1.455 0 C-N-CA 119.431 -0.907 . . . . 0.0 112.89 -178.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.561 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.0 Cg_endo -68.99 -43.78 3.07 Favored 'Trans proline' 0 C--O 1.215 -0.639 0 C-N-CA 120.638 0.892 . . . . 0.0 111.699 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . 0.425 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.4 m80 -94.15 14.83 18.83 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.306 -0.958 . . . . 0.0 111.173 -179.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.41 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -65.52 0.27 1.65 Allowed 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.089 -1.044 . . . . 0.0 110.687 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -86.92 -18.05 58.62 Favored Glycine 0 N--CA 1.49 2.238 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.215 179.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -97.97 -19.99 17.7 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 119.615 -0.834 . . . . 0.0 110.675 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 111.73 22.0 6.2 Favored Glycine 0 N--CA 1.497 2.74 0 C-N-CA 119.877 -1.154 . . . . 0.0 110.624 179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 9.6 ttt -71.22 108.72 4.85 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.494 -0.882 . . . . 0.0 110.832 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.406 ' CG ' ' N ' ' A' ' 92' ' ' GLY . 30.9 ttpt -137.13 159.91 40.53 Favored 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 119.754 -0.778 . . . . 0.0 111.299 -179.809 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.406 ' N ' ' CG ' ' A' ' 91' ' ' LYS . . . -140.84 156.97 25.71 Favored Glycine 0 N--CA 1.497 2.757 0 C-N-CA 119.688 -1.244 . . . . 0.0 111.559 -178.484 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.8 tt0 -157.15 145.94 19.82 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 120.027 -0.669 . . . . 0.0 110.639 179.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.494 HG13 ' O ' ' A' ' 94' ' ' VAL . 8.8 p -139.94 124.91 20.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 C-N-CA 119.106 -1.038 . . . . 0.0 110.937 179.386 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 34.0 m -102.68 103.17 13.41 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.543 -0.863 . . . . 0.0 110.582 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.534 ' C ' HD22 ' A' ' 97' ' ' ASN . 26.2 t -85.71 146.31 6.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 C-N-CA 118.866 -1.133 . . . . 0.0 110.622 -178.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.534 HD22 ' C ' ' A' ' 96' ' ' VAL . 1.0 OUTLIER . . . . . 0 N--CA 1.489 1.505 0 CA-C-O 116.375 -1.774 . . . . 0.0 110.661 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.17 0 CA-C-O 120.821 0.343 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -96.73 119.89 36.05 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.702 179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 73.4 t -108.31 122.38 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.07 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 76.9 mttt -88.31 111.46 21.73 Favored 'General case' 0 C--N 1.297 -1.706 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.865 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 11.6 mt -73.91 110.08 7.92 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 118.539 -1.264 . . . . 0.0 109.763 178.486 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.54 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 98.86 126.51 5.64 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -179.109 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 24.5 p -76.18 157.15 33.02 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.581 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 -76.93 -20.48 56.13 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.87 -179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -164.04 68.74 0.18 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.711 -179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -165.25 -70.12 0.03 OUTLIER Glycine 0 N--CA 1.489 2.169 0 C-N-CA 119.415 -1.374 . . . . 0.0 110.472 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -176.46 -158.04 19.02 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.387 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.0 mt -100.49 104.43 15.82 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 119.688 -0.805 . . . . 0.0 110.756 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 23.6 m -150.83 157.91 5.33 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 C-N-CA 119.123 -1.031 . . . . 0.0 110.65 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.533 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 35.9 m-85 -78.15 113.63 16.28 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 177.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 18.5 m -115.54 109.77 45.53 Favored Pre-proline 0 CA--C 1.56 1.355 0 C-N-CA 119.515 -0.874 . . . . 0.0 112.187 -177.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -65.98 170.58 39.44 Favored 'Cis proline' 0 C--N 1.361 1.232 0 C-N-CA 125.123 -0.782 . . . . 0.0 111.567 -0.466 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -96.03 -68.64 0.79 Allowed 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.836 178.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.6 m -110.12 132.92 53.73 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.652 178.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 36.0 p90 -162.15 141.49 9.59 Favored 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 118.681 -1.208 . . . . 0.0 111.323 -179.17 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.439 HG23 ' H ' ' A' ' 20' ' ' THR . 0.2 OUTLIER -85.23 160.28 19.91 Favored 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.545 -0.862 . . . . 0.0 111.3 -179.577 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.4 m -149.29 179.11 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.645 179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -96.0 148.29 22.81 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 119.476 -0.89 . . . . 0.0 110.931 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.51 ' HB2' ' OXT' ' A' ' 97' ' ' ASN . . . -68.38 71.1 0.18 Allowed 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.592 -0.843 . . . . 0.0 111.229 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.418 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 157.52 16.19 0.04 OUTLIER Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 179.73 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.418 ' H ' ' H ' ' A' ' 24' ' ' GLY . 23.0 tt0 -102.8 154.89 18.74 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.927 -0.709 . . . . 0.0 110.682 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.3 mtpt -95.33 141.18 29.2 Favored 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 119.419 -0.912 . . . . 0.0 111.386 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.5 mt -119.78 114.81 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 CA-C-N 115.713 -0.676 . . . . 0.0 109.435 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.4 p -111.41 120.97 43.96 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.53 -0.868 . . . . 0.0 112.616 -178.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -85.57 111.72 20.29 Favored 'General case' 0 C--N 1.303 -1.421 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.876 178.266 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.7 tttp -102.89 138.77 39.32 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 119.575 -0.85 . . . . 0.0 111.455 -178.078 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.544 HD21 HD13 ' A' ' 61' ' ' LEU . 77.3 m-20 -80.53 110.54 16.1 Favored 'General case' 0 C--N 1.299 -1.607 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.805 179.678 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.58 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 2.0 t30 -98.34 -31.23 12.15 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.225 -0.99 . . . . 0.0 111.673 -179.318 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.58 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.52 128.19 0.02 OUTLIER 'General case' 0 N--CA 1.496 1.844 0 C-N-CA 119.383 -0.927 . . . . 0.0 111.214 179.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 119.5 11.08 7.48 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.789 -1.196 . . . . 0.0 111.355 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.429 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -60.62 163.44 9.15 Favored Pre-proline 0 N--CA 1.484 1.265 0 C-N-CA 118.391 -1.324 . . . . 0.0 110.042 179.819 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -76.92 146.33 83.6 Favored 'Cis proline' 0 C--O 1.217 -0.564 0 C-N-CA 124.145 -1.189 . . . . 0.0 112.636 -0.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 35.3 m-70 -110.67 -179.66 3.82 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-N 115.565 -0.743 . . . . 0.0 111.119 179.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -155.67 142.6 19.02 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.015 179.153 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 6.3 mt -125.2 121.78 61.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.247 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.0 t -144.8 143.86 22.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.149 179.395 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -96.32 135.99 37.41 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.412 -0.915 . . . . 0.0 111.877 -179.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.51 ' C ' ' H ' ' A' ' 44' ' ' ASP . 7.8 t0 -71.95 111.24 7.04 Favored 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.678 -0.809 . . . . 0.0 110.671 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -71.4 35.22 0.05 Allowed 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 119.526 -0.869 . . . . 0.0 110.858 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.51 ' H ' ' C ' ' A' ' 42' ' ' ASP . 13.6 m-20 -111.34 -15.65 13.55 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 120.092 -0.643 . . . . 0.0 111.364 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -145.81 -5.39 0.63 Allowed 'General case' 0 N--CA 1.492 1.637 0 C-N-CA 118.261 -1.376 . . . . 0.0 112.464 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -52.51 142.31 31.45 Favored Pre-proline 0 C--N 1.285 -2.216 0 C-N-CA 118.628 -1.229 . . . . 0.0 108.112 179.248 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -49.09 148.03 10.2 Favored 'Trans proline' 0 C--O 1.216 -0.614 0 C-N-CA 120.895 1.063 . . . . 0.0 112.236 -178.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.25 64.55 2.06 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.722 -0.791 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -177.58 -39.48 0.06 OUTLIER Glycine 0 N--CA 1.488 2.147 0 C-N-CA 119.57 -1.3 . . . . 0.0 109.863 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 98.8 t -92.16 97.1 6.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.336 179.621 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -44.61 162.33 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.447 -0.901 . . . . 0.0 111.155 -179.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -102.91 -29.01 11.69 Favored 'General case' 0 C--N 1.304 -1.41 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.919 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.5 tt0 -78.97 -14.15 59.38 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.146 -179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 1.8 mptp? -81.9 -37.69 26.47 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.298 -0.961 . . . . 0.0 111.064 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -90.87 -17.93 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.351 0 C-N-CA 119.199 -1.0 . . . . 0.0 111.019 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 73.6 m -76.55 -177.44 4.19 Favored 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.599 -0.841 . . . . 0.0 111.256 179.71 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.638 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -159.96 78.55 2.67 Favored Pre-proline 0 C--N 1.304 -1.405 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.788 179.635 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -60.56 0.99 0.59 Allowed 'Trans proline' 0 C--O 1.213 -0.747 0 C-N-CA 121.372 1.381 . . . . 0.0 112.216 -178.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.434 ' H ' ' C ' ' A' ' 57' ' ' GLN . 6.9 tt0 -82.9 100.44 10.39 Favored 'General case' 0 C--N 1.299 -1.601 0 C-N-CA 118.878 -1.129 . . . . 0.0 110.249 179.387 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.43 ' O ' ' O ' ' A' ' 59' ' ' GLU . 43.9 m-85 -41.92 164.79 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.178 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.932 -179.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.569 ' O ' HD12 ' A' ' 61' ' ' LEU . 3.0 pp -147.3 124.47 11.47 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.103 -1.039 . . . . 0.0 111.037 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.585 ' ND2' ' N ' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -120.8 32.55 5.93 Favored 'General case' 0 N--CA 1.496 1.875 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.706 -179.963 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -97.02 120.87 6.86 Favored Glycine 0 N--CA 1.494 2.56 0 C-N-CA 119.461 -1.352 . . . . 0.0 110.8 -179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -68.67 118.5 11.74 Favored 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.544 -0.862 . . . . 0.0 110.774 179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 90.03 -19.75 40.48 Favored Glycine 0 N--CA 1.488 2.159 0 C-N-CA 119.419 -1.372 . . . . 0.0 110.374 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.466 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 34.8 tt0 -56.99 153.7 10.84 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.22 179.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -144.88 169.37 18.19 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.212 -0.995 . . . . 0.0 111.579 -179.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.638 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 29.2 t80 -134.73 139.06 44.9 Favored 'General case' 0 N--CA 1.487 1.378 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.141 178.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.542 ' CD ' ' H ' ' A' ' 69' ' ' GLU . 1.3 mp0 -100.32 148.24 24.9 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.181 -1.008 . . . . 0.0 112.755 -178.046 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.3 t -145.74 131.31 13.18 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 114.924 -1.035 . . . . 0.0 108.721 179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.1 m -123.2 113.69 19.28 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.639 -0.824 . . . . 0.0 111.905 -178.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 46.2 mt -98.77 159.12 15.17 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.526 178.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -150.95 34.45 0.59 Allowed 'General case' 0 C--N 1.297 -1.702 0 C-N-CA 118.824 -1.151 . . . . 0.0 111.64 -178.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -137.87 102.38 4.7 Favored 'General case' 0 N--CA 1.492 1.654 0 C-N-CA 119.092 -1.043 . . . . 0.0 110.624 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.431 ' CG ' ' O ' ' A' ' 75' ' ' LYS . 11.2 pttm -43.57 114.59 0.66 Allowed 'General case' 0 C--N 1.31 -1.146 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.884 -179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.18 -145.33 7.78 Favored Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.487 -1.34 . . . . 0.0 110.129 -179.407 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -142.06 128.93 20.61 Favored 'General case' 0 N--CA 1.487 1.397 0 C-N-CA 119.303 -0.959 . . . . 0.0 111.557 -179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.578 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -121.66 138.85 54.17 Favored 'General case' 0 N--CA 1.49 1.556 0 CA-C-N 115.242 -0.89 . . . . 0.0 108.922 179.303 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 12.4 mttp -111.19 127.77 55.7 Favored 'General case' 0 N--CA 1.493 1.689 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.767 -179.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.541 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.6 OUTLIER -129.05 159.81 34.76 Favored 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.048 177.753 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -167.93 178.44 5.16 Favored 'General case' 0 C--N 1.286 -2.171 0 C-N-CA 119.621 -0.832 . . . . 0.0 110.593 -178.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -104.4 131.77 51.39 Favored 'General case' 0 C--N 1.303 -1.454 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.27 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.496 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.6 mt-10 -71.48 -46.22 13.26 Favored Pre-proline 0 C--N 1.306 -1.308 0 C-N-CA 119.364 -0.934 . . . . 0.0 112.843 -179.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.0 Cg_endo -67.01 -45.1 4.33 Favored 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 120.902 1.068 . . . . 0.0 111.87 -179.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 30.3 m80 -93.52 22.81 5.04 Favored 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.886 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.423 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -68.5 -13.67 62.48 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.739 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -87.27 -12.3 67.88 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.261 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.54 -12.16 30.21 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.406 -0.918 . . . . 0.0 110.819 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 102.16 10.79 38.44 Favored Glycine 0 N--CA 1.493 2.499 0 C-N-CA 119.723 -1.227 . . . . 0.0 110.743 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -66.68 101.6 0.82 Allowed 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.364 -0.935 . . . . 0.0 111.081 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.533 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 18.4 mttp -129.11 173.18 10.7 Favored 'General case' 0 N--CA 1.496 1.841 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.349 -179.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.529 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -155.58 152.09 23.59 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.333 -1.413 . . . . 0.0 111.444 -178.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -155.75 144.95 20.76 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.789 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.499 HG13 ' O ' ' A' ' 94' ' ' VAL . 7.4 p -136.46 124.33 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 C-N-CA 119.511 -0.876 . . . . 0.0 110.809 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 68.6 m -100.73 97.92 8.52 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.254 179.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.7 t -79.53 151.9 4.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 119.097 -1.041 . . . . 0.0 110.622 -178.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.51 ' OXT' ' HB2' ' A' ' 23' ' ' ALA . 10.8 m120 . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 116.319 -1.8 . . . . 0.0 110.783 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.087 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -134.31 118.37 17.45 Favored 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.685 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.2 t -102.76 123.51 56.17 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 C-N-CA 119.713 -0.795 . . . . 0.0 110.51 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 1.5 mmmm -95.42 117.55 30.56 Favored 'General case' 0 C--N 1.299 -1.6 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.111 -179.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 3.6 mt -86.52 109.85 19.38 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.012 -1.075 . . . . 0.0 110.013 178.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.433 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 101.42 93.56 2.19 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.844 -1.17 . . . . 0.0 110.214 -179.413 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 19.6 p -47.41 159.17 0.14 Allowed 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.932 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -74.37 -50.3 19.19 Favored 'General case' 0 C--N 1.306 -1.284 0 C-N-CA 119.438 -0.905 . . . . 0.0 110.773 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.449 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 1.4 p-10 -44.21 -45.26 8.35 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.744 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 140.37 68.22 0.04 OUTLIER Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.646 -1.264 . . . . 0.0 110.274 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -153.18 150.0 21.66 Favored Glycine 0 N--CA 1.488 2.145 0 C-N-CA 119.221 -1.466 . . . . 0.0 110.514 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt -99.89 94.81 6.5 Favored 'General case' 0 N--CA 1.485 1.296 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.628 -179.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.7 m -150.4 158.39 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.17 0 C-N-CA 118.624 -1.23 . . . . 0.0 111.57 179.399 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.447 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 18.2 m-85 -78.84 110.45 14.04 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 177.274 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 38.7 m -116.35 108.48 45.51 Favored Pre-proline 0 C--N 1.304 -1.394 0 C-N-CA 119.54 -0.864 . . . . 0.0 112.08 -177.382 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.6 Cg_endo -66.0 175.0 24.47 Favored 'Cis proline' 0 C--N 1.357 0.98 0 C-N-CA 125.312 -0.703 . . . . 0.0 111.8 -0.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.2 t -95.71 -64.96 1.01 Allowed 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.706 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 81.4 p -118.63 128.3 54.41 Favored 'General case' 0 N--CA 1.486 1.337 0 CA-C-N 115.224 -0.898 . . . . 0.0 108.958 178.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.476 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 12.6 p90 -156.23 145.68 20.8 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 118.477 -1.289 . . . . 0.0 111.255 -178.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.423 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -87.46 158.67 18.91 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 119.376 -0.93 . . . . 0.0 111.278 -179.856 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.0 m -147.39 169.18 4.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.301 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.569 179.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -85.83 147.36 26.33 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.664 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.99 73.02 0.18 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.461 -0.896 . . . . 0.0 111.309 -179.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.412 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 154.47 15.83 0.05 OUTLIER Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 179.718 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.412 ' H ' ' H ' ' A' ' 24' ' ' GLY . 24.5 tt0 -98.8 154.82 17.72 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.667 -0.813 . . . . 0.0 110.983 -179.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 12.7 mttm -95.43 136.92 35.19 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.549 -0.86 . . . . 0.0 111.136 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 85.6 mt -115.19 104.92 17.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.611 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 26.7 p -99.98 114.65 28.07 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.532 -0.867 . . . . 0.0 112.215 -178.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -85.07 127.74 34.35 Favored 'General case' 0 C--N 1.309 -1.188 0 C-N-CA 119.277 -0.969 . . . . 0.0 109.241 178.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 23.7 tttm -124.41 131.49 53.5 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 119.892 -0.723 . . . . 0.0 111.341 -179.059 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.712 HD21 ' H ' ' A' ' 66' ' ' GLU . 31.3 p-10 -90.15 127.26 36.06 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.355 -0.938 . . . . 0.0 109.792 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.523 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 2.6 p-10 -127.65 -6.4 5.73 Favored 'General case' 0 N--CA 1.495 1.787 0 C-N-CA 118.939 -1.104 . . . . 0.0 112.871 -178.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.523 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 177.7 90.74 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 117.982 -1.487 . . . . 0.0 112.184 179.611 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 135.73 28.83 0.38 Allowed Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.455 -1.355 . . . . 0.0 111.114 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.596 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -75.95 162.29 72.35 Favored Pre-proline 0 N--CA 1.483 1.191 0 C-N-CA 118.297 -1.361 . . . . 0.0 109.829 179.627 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -79.88 148.55 79.37 Favored 'Cis proline' 0 C--O 1.211 -0.853 0 C-N-CA 124.185 -1.173 . . . . 0.0 112.531 -0.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 43.9 m-70 -110.64 170.96 7.75 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.914 -0.715 . . . . 0.0 110.162 178.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.432 ' OD1' ' CD2' ' A' ' 60' ' ' TYR . 1.0 OUTLIER -149.46 151.87 34.7 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.193 -1.003 . . . . 0.0 110.646 179.525 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.4 mt -132.74 114.51 22.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 C-N-CA 119.771 -0.772 . . . . 0.0 111.019 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.0 t -131.14 141.97 44.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.732 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -100.02 120.12 39.33 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 119.278 -0.969 . . . . 0.0 112.085 -179.109 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.512 ' C ' ' H ' ' A' ' 44' ' ' ASP . 1.6 t0 -65.77 114.42 5.03 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.39 -0.924 . . . . 0.0 109.709 178.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.35 15.1 0.06 Allowed 'General case' 0 N--CA 1.491 1.609 0 C-N-CA 119.274 -0.97 . . . . 0.0 111.592 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.512 ' H ' ' C ' ' A' ' 42' ' ' ASP . 3.0 m-20 -101.86 -2.79 29.14 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.224 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -143.1 14.64 1.87 Allowed 'General case' 0 N--CA 1.485 1.302 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.213 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -96.83 145.51 29.71 Favored Pre-proline 0 C--N 1.299 -1.599 0 C-N-CA 119.868 -0.733 . . . . 0.0 109.107 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -52.9 154.1 13.72 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 120.785 0.99 . . . . 0.0 111.63 -179.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.53 44.08 0.78 Allowed 'General case' 0 C--N 1.307 -1.278 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.584 -179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -147.68 -38.39 0.04 OUTLIER Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 86.9 t -98.93 94.05 3.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 C-N-CA 119.775 -0.77 . . . . 0.0 110.339 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -44.57 155.36 0.1 Allowed 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.955 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -93.89 -11.66 30.59 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.476 -0.89 . . . . 0.0 111.177 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.2 tt0 -89.49 -9.25 50.75 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.92 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 3.0 mmpt? -88.03 -28.62 21.27 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.455 -0.898 . . . . 0.0 111.402 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -105.49 -5.51 9.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.739 -179.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 5.0 m -74.23 171.53 13.45 Favored 'General case' 0 C--N 1.308 -1.218 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.355 179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.617 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 56.3 mt-30 -123.95 80.04 57.38 Favored Pre-proline 0 N--CA 1.49 1.536 0 CA-C-N 115.483 -0.78 . . . . 0.0 110.35 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_exo -61.41 -16.11 45.22 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 120.722 0.948 . . . . 0.0 110.852 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -100.49 119.73 38.94 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.81 -0.756 . . . . 0.0 110.679 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.432 ' CD2' ' OD1' ' A' ' 38' ' ' ASN . 38.4 m-85 -69.04 174.98 4.03 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.506 -0.878 . . . . 0.0 110.839 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.4 pp -144.38 123.31 12.75 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.221 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -116.13 -14.63 11.15 Favored 'General case' 0 N--CA 1.501 2.112 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.184 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.508 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . -52.07 137.5 32.63 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.036 -1.554 . . . . 0.0 110.633 -179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.64 106.37 5.37 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.661 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 97.61 12.64 46.94 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.519 -1.325 . . . . 0.0 110.004 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.712 ' H ' HD21 ' A' ' 31' ' ' ASN . 1.9 mm-40 -66.02 158.37 28.47 Favored 'General case' 0 N--CA 1.484 1.242 0 C-N-CA 119.229 -0.989 . . . . 0.0 110.244 179.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.4 p -147.48 160.01 43.08 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 118.805 -1.158 . . . . 0.0 111.979 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.617 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 42.9 t80 -135.8 178.07 7.34 Favored 'General case' 0 N--CA 1.484 1.268 0 N-CA-C 108.658 -0.867 . . . . 0.0 108.658 179.371 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.586 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 8.4 mt-10 -140.62 149.74 42.7 Favored 'General case' 0 N--CA 1.494 1.741 0 C-N-CA 118.916 -1.113 . . . . 0.0 111.929 -179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -150.07 132.7 6.49 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 CA-C-N 115.322 -0.853 . . . . 0.0 109.218 179.514 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.3 m -127.21 106.28 9.14 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.75 -0.78 . . . . 0.0 111.424 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.523 ' CD1' HG11 ' A' ' 94' ' ' VAL . 30.3 mt -91.79 159.72 15.67 Favored 'General case' 0 C--N 1.306 -1.307 0 C-N-CA 119.249 -0.98 . . . . 0.0 110.117 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 6.4 p -150.63 46.36 0.87 Allowed 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.098 -1.041 . . . . 0.0 111.544 -179.354 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.406 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 2.0 mm-40 -143.84 101.6 3.77 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 118.995 -1.082 . . . . 0.0 110.565 179.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 19.5 tttm -43.96 108.03 0.1 Allowed 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.657 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.71 -143.71 6.76 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.193 -1.479 . . . . 0.0 110.202 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.458 HG23 HG23 ' A' ' 95' ' ' THR . 0.0 OUTLIER -145.03 133.17 21.5 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.918 179.959 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.58 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.3 m-85 -119.62 157.35 28.61 Favored 'General case' 0 N--CA 1.485 1.29 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.134 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.1 mmtm -124.62 123.81 40.86 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.545 -0.862 . . . . 0.0 112.224 -179.115 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.0 OUTLIER -135.25 163.89 28.96 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.099 178.408 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.8 p90 -169.49 179.59 3.78 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 119.165 -1.014 . . . . 0.0 111.223 -178.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -102.17 116.87 33.57 Favored 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.778 -0.769 . . . . 0.0 109.651 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.58 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 7.0 tt0 -71.99 -36.08 3.96 Favored Pre-proline 0 C--N 1.304 -1.374 0 C-N-CA 118.941 -1.104 . . . . 0.0 112.901 -179.223 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.58 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -70.2 -52.48 0.29 Allowed 'Trans proline' 0 C--O 1.214 -0.684 0 C-N-CA 120.429 0.753 . . . . 0.0 111.144 179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . 0.493 ' C ' ' H ' ' A' ' 87' ' ' GLY . 35.1 m170 -82.14 13.91 3.17 Favored 'General case' 0 N--CA 1.487 1.398 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.829 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.25 -6.14 0.14 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.659 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.493 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -80.55 -27.6 50.73 Favored Glycine 0 N--CA 1.491 2.347 0 C-N-CA 119.575 -1.298 . . . . 0.0 110.327 179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -84.73 -32.56 23.43 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.4 -0.92 . . . . 0.0 110.392 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 114.94 23.23 4.69 Favored Glycine 0 N--CA 1.493 2.452 0 C-N-CA 119.926 -1.131 . . . . 0.0 110.903 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 28.6 mtp -65.14 107.68 1.63 Allowed 'General case' 0 N--CA 1.489 1.491 0 C-N-CA 119.071 -1.052 . . . . 0.0 110.869 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.447 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 17.4 pttp -124.97 159.0 32.26 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 119.975 -0.69 . . . . 0.0 110.461 179.501 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.86 145.6 15.13 Favored Glycine 0 N--CA 1.497 2.729 0 C-N-CA 119.053 -1.546 . . . . 0.0 111.742 -178.701 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 51.3 tt0 -150.8 144.7 25.25 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.317 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.523 HG11 ' CD1' ' A' ' 72' ' ' LEU . 11.2 p -136.99 124.6 31.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.969 0 C-N-CA 119.121 -1.031 . . . . 0.0 111.179 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.458 HG23 HG23 ' A' ' 77' ' ' THR . 41.4 m -100.61 99.51 10.09 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.672 179.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.7 t -79.79 146.23 8.06 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.374 -179.067 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.486 1.346 0 CA-C-O 116.412 -1.756 . . . . 0.0 110.999 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.43 ' HB3' HG13 ' A' ' 27' ' ' ILE . . . . . . . . 0 N--CA 1.482 1.126 0 CA-C-O 120.893 0.377 . . . . 0.0 110.077 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -97.32 122.06 39.92 Favored 'General case' 0 N--CA 1.488 1.457 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.809 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 43.9 t -107.7 121.56 60.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 119.77 -0.772 . . . . 0.0 111.149 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 45.6 mtpt -92.05 117.36 29.76 Favored 'General case' 0 C--N 1.298 -1.653 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.157 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.404 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 16.8 mt -78.15 111.71 14.36 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 118.88 -1.128 . . . . 0.0 110.558 179.665 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.554 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 97.33 120.45 4.02 Favored Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.789 -1.196 . . . . 0.0 110.227 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 18.3 p -67.25 146.18 54.43 Favored 'General case' 0 C--N 1.301 -1.5 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.609 179.669 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 39.2 m-20 -44.49 -45.29 9.13 Favored 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.928 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -163.31 66.81 0.19 Allowed 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.358 -0.937 . . . . 0.0 110.74 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -146.55 -55.22 0.02 OUTLIER Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.531 -1.319 . . . . 0.0 110.215 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -179.04 -168.12 37.65 Favored Glycine 0 N--CA 1.486 1.983 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.3 mt -99.74 106.73 18.66 Favored 'General case' 0 C--N 1.304 -1.382 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.668 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 20.4 m -150.89 158.39 4.99 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.152 0 C-N-CA 118.918 -1.113 . . . . 0.0 110.872 179.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.415 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 58.0 m-85 -78.75 112.83 16.28 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 106.772 -1.566 . . . . 0.0 106.772 177.093 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 53.8 m -115.0 110.9 45.51 Favored Pre-proline 0 N--CA 1.485 1.316 0 C-N-CA 119.315 -0.954 . . . . 0.0 112.431 -177.089 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -65.82 170.95 37.19 Favored 'Cis proline' 0 C--N 1.362 1.284 0 C-N-CA 125.228 -0.738 . . . . 0.0 111.51 -0.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 6.0 p -94.86 -67.95 0.83 Allowed 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.055 179.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.67 137.32 47.66 Favored 'General case' 0 N--CA 1.486 1.326 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.672 179.198 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -163.57 134.9 4.75 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 118.456 -1.298 . . . . 0.0 111.658 -179.45 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.445 HG23 ' H ' ' A' ' 20' ' ' THR . 0.3 OUTLIER -85.54 152.88 22.82 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.237 -179.957 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -144.84 173.78 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.677 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.518 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -94.1 139.22 31.25 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 119.452 -0.899 . . . . 0.0 110.357 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.19 77.79 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.319 -0.953 . . . . 0.0 110.888 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 158.12 13.83 0.04 OUTLIER Glycine 0 N--CA 1.489 2.179 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.7 tp10 -104.05 149.69 24.96 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 120.102 -0.639 . . . . 0.0 110.767 -179.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.486 ' C ' HD12 ' A' ' 27' ' ' ILE . 78.0 mttt -94.91 137.56 33.82 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.435 -0.906 . . . . 0.0 111.105 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.486 HD12 ' C ' ' A' ' 26' ' ' LYS . 1.5 mp -115.9 150.47 17.85 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 179.08 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 68.5 p -141.75 121.89 13.82 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 118.92 -1.112 . . . . 0.0 112.1 -179.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.5 m-85 -87.18 120.93 28.97 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.373 -0.931 . . . . 0.0 108.895 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 1.5 ttmm -110.99 136.81 49.43 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 119.669 -0.812 . . . . 0.0 111.742 -178.442 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.631 ' ND2' ' CD1' ' A' ' 35' ' ' PHE . 19.2 t30 -80.42 104.27 10.85 Favored 'General case' 0 C--N 1.297 -1.714 0 CA-C-N 115.109 -0.95 . . . . 0.0 109.723 179.146 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.554 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 1.2 t30 -101.27 -32.03 10.7 Favored 'General case' 0 N--CA 1.491 1.575 0 C-N-CA 118.838 -1.145 . . . . 0.0 112.389 -178.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . 177.27 143.06 0.09 Allowed 'General case' 0 N--CA 1.502 2.134 0 C-N-CA 119.503 -0.879 . . . . 0.0 111.166 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 100.89 8.54 48.01 Favored Glycine 0 N--CA 1.492 2.432 0 C-N-CA 119.338 -1.411 . . . . 0.0 112.299 178.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.631 ' CD1' ' ND2' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -55.45 162.88 2.06 Favored Pre-proline 0 C--N 1.308 -1.229 0 C-N-CA 117.763 -1.575 . . . . 0.0 109.478 179.569 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.4 Cg_endo -76.67 140.76 67.11 Favored 'Cis proline' 0 C--O 1.215 -0.64 0 C-N-CA 124.285 -1.131 . . . . 0.0 112.521 -0.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.404 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 34.3 m-70 -109.91 163.46 13.53 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.801 179.129 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.586 HD22 ' H ' ' A' ' 39' ' ' ILE . 1.6 t-20 -148.12 139.79 23.77 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.682 179.649 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.586 ' H ' HD22 ' A' ' 38' ' ' ASN . 2.7 mp -116.45 118.01 57.35 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 120.046 -0.662 . . . . 0.0 111.045 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.484 HG12 ' N ' ' A' ' 41' ' ' PHE . 28.3 t -129.8 162.37 37.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.899 179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.484 ' N ' HG12 ' A' ' 40' ' ' VAL . 27.8 m-85 -121.09 122.0 39.1 Favored 'General case' 0 N--CA 1.494 1.755 0 C-N-CA 119.591 -0.844 . . . . 0.0 111.552 179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -54.13 117.48 3.28 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.346 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.451 ' O ' ' OD1' ' A' ' 44' ' ' ASP . 9.2 mt-10 -76.38 39.06 0.19 Allowed 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.738 -0.785 . . . . 0.0 111.297 -179.627 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.451 ' OD1' ' O ' ' A' ' 43' ' ' GLU . 75.4 m-20 -148.91 -3.22 0.45 Allowed 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.157 -1.017 . . . . 0.0 110.975 179.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -130.71 8.62 4.92 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 119.821 -0.752 . . . . 0.0 109.885 179.181 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -95.8 148.06 33.97 Favored Pre-proline 0 C--N 1.293 -1.878 0 CA-C-N 115.027 -0.988 . . . . 0.0 108.79 179.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -49.45 151.1 7.42 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 120.89 1.06 . . . . 0.0 111.827 -179.755 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.34 54.84 1.47 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.864 -179.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -165.06 -40.93 0.02 OUTLIER Glycine 0 N--CA 1.489 2.197 0 C-N-CA 119.465 -1.35 . . . . 0.0 110.322 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 46.3 t -86.56 93.95 4.16 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.969 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -47.14 158.25 0.15 Allowed 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.649 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.64 -25.01 16.3 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.786 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 90.7 mt-10 -71.71 -13.22 61.66 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.884 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.9 mmpp? -87.6 -39.75 14.81 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.775 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.409 HD12 ' CD2' ' A' ' 41' ' ' PHE . 3.0 pt -91.62 -25.86 5.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.242 -0.983 . . . . 0.0 111.258 -179.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.7 m -55.52 -176.98 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.217 0 C-N-CA 119.124 -1.031 . . . . 0.0 110.686 179.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.617 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 13.9 tt0 -144.95 78.12 12.78 Favored Pre-proline 0 C--N 1.302 -1.464 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.528 -179.556 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -59.51 -24.51 75.24 Favored 'Trans proline' 0 C--O 1.214 -0.716 0 C-N-CA 120.971 1.114 . . . . 0.0 111.532 -178.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -77.9 99.57 6.04 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.201 -1.0 . . . . 0.0 110.484 179.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -56.99 167.28 0.84 Allowed 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.045 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -135.61 105.27 6.11 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 119.729 -0.788 . . . . 0.0 110.708 179.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -107.26 4.93 27.13 Favored 'General case' 0 N--CA 1.488 1.426 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.701 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -90.88 139.38 14.81 Favored Glycine 0 N--CA 1.489 2.216 0 C-N-CA 119.386 -1.388 . . . . 0.0 110.433 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -74.19 123.55 24.69 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.722 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.19 -8.99 59.32 Favored Glycine 0 N--CA 1.498 2.826 0 C-N-CA 119.547 -1.311 . . . . 0.0 110.983 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -55.83 150.65 12.67 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.976 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 3.2 p -150.59 160.11 44.03 Favored 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 118.829 -1.149 . . . . 0.0 111.667 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.617 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 53.5 t80 -135.68 177.39 7.86 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.898 -0.721 . . . . 0.0 109.745 179.092 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.506 ' O ' ' CE2' ' A' ' 68' ' ' TYR . 9.0 mt-10 -144.99 151.94 39.37 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.118 -1.033 . . . . 0.0 111.554 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.444 ' O ' ' CG1' ' A' ' 70' ' ' VAL . 1.8 p -158.76 127.78 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.243 0 C-N-CA 119.552 -0.859 . . . . 0.0 109.981 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.6 m -115.03 93.87 4.5 Favored 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.943 -0.703 . . . . 0.0 111.058 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 11.8 mt -79.15 156.07 28.41 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 118.81 -1.156 . . . . 0.0 109.353 179.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.2 p -150.86 38.37 0.67 Allowed 'General case' 0 C--N 1.293 -1.886 0 C-N-CA 118.902 -1.119 . . . . 0.0 111.559 -179.251 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.424 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.5 OUTLIER -124.2 96.4 4.91 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 119.482 -0.887 . . . . 0.0 109.62 179.202 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.418 ' C ' ' O ' ' A' ' 74' ' ' GLU . 16.3 mtmm -39.52 99.75 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.325 -0.852 . . . . 0.0 111.292 -178.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.34 -135.4 2.64 Favored Glycine 0 N--CA 1.486 2.026 0 C-N-CA 119.257 -1.449 . . . . 0.0 110.359 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.3 m -150.36 142.56 24.15 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.145 -1.022 . . . . 0.0 111.225 -179.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.611 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.7 m-85 -128.47 125.48 38.55 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.606 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 6.2 mptt -99.23 116.33 31.17 Favored 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.23 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.573 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.7 OUTLIER -123.5 168.87 12.01 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.082 178.74 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 48.9 p90 -170.73 -176.81 2.15 Favored 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.683 -179.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.5 t -105.86 127.1 52.9 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.775 -0.77 . . . . 0.0 109.865 179.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.567 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 tm-20 -74.59 -37.14 2.75 Favored Pre-proline 0 CA--C 1.558 1.259 0 C-N-CA 119.161 -1.016 . . . . 0.0 113.318 -178.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.567 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.1 Cg_endo -71.03 -50.04 0.35 Allowed 'Trans proline' 0 C--O 1.216 -0.618 0 C-N-CA 120.716 0.944 . . . . 0.0 111.416 179.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.0 m80 -83.72 16.29 2.79 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.594 -0.842 . . . . 0.0 110.888 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.89 -6.21 5.63 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.498 -0.881 . . . . 0.0 110.671 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.83 -11.94 64.8 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.146 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -97.16 -42.41 7.85 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.634 -0.826 . . . . 0.0 110.794 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 128.25 30.61 0.72 Allowed Glycine 0 N--CA 1.493 2.443 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.577 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -79.43 110.99 15.25 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.647 -0.821 . . . . 0.0 111.212 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.415 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 1.0 OUTLIER -133.96 162.62 31.55 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.237 -179.808 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -144.1 152.12 23.99 Favored Glycine 0 N--CA 1.492 2.379 0 C-N-CA 119.675 -1.25 . . . . 0.0 110.661 -178.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -154.13 146.74 24.14 Favored 'General case' 0 N--CA 1.487 1.424 0 C-N-CA 119.105 -1.038 . . . . 0.0 111.29 179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.494 HG13 ' O ' ' A' ' 94' ' ' VAL . 8.4 p -143.74 126.52 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.261 0 C-N-CA 119.016 -1.074 . . . . 0.0 110.334 178.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 99.4 m -105.61 102.49 11.95 Favored 'General case' 0 N--CA 1.494 1.76 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.723 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.9 t -82.67 141.36 15.06 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.131 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.226 -179.172 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 4.3 p-10 . . . . . 0 C--N 1.302 -1.458 0 CA-C-O 116.344 -1.788 . . . . 0.0 110.857 -179.85 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.114 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 15.0 mt-10 -107.66 118.99 38.2 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.741 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.6 t -108.22 120.01 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 C-N-CA 119.866 -0.734 . . . . 0.0 110.642 179.805 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -95.01 116.52 28.8 Favored 'General case' 0 C--N 1.298 -1.642 0 C-N-CA 119.414 -0.914 . . . . 0.0 110.861 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.1 mt -77.2 113.36 14.87 Favored 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 118.891 -1.123 . . . . 0.0 109.993 178.535 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.487 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 101.64 131.75 7.49 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.1 p -76.61 -179.0 5.01 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.225 -0.99 . . . . 0.0 110.62 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -72.49 -58.09 3.65 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.878 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -49.99 -53.46 26.4 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.86 -179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.79 11.54 0.05 OUTLIER Glycine 0 N--CA 1.49 2.3 0 C-N-CA 119.45 -1.357 . . . . 0.0 110.4 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -72.49 162.26 54.56 Favored Glycine 0 N--CA 1.49 2.275 0 C-N-CA 119.425 -1.369 . . . . 0.0 110.238 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.9 mt -116.8 96.18 5.36 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.941 -0.704 . . . . 0.0 110.894 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 28.7 m -151.01 155.2 7.45 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.105 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.828 179.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.402 ' O ' ' C ' ' A' ' 16' ' ' PRO . 67.2 m-85 -78.31 110.53 13.41 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 177.598 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 59.4 m -113.37 110.06 50.82 Favored Pre-proline 0 CA--C 1.557 1.246 0 C-N-CA 119.377 -0.929 . . . . 0.0 112.504 -177.176 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.402 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.3 Cg_endo -67.62 170.2 49.26 Favored 'Cis proline' 0 C--N 1.363 1.31 0 C-N-CA 125.344 -0.69 . . . . 0.0 111.414 -0.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.4 m -94.0 -70.64 0.7 Allowed 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.441 -0.904 . . . . 0.0 109.648 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.3 t -107.46 129.65 54.92 Favored 'General case' 0 N--CA 1.485 1.284 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.311 178.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.478 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 13.1 p90 -157.22 144.12 18.39 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 118.237 -1.385 . . . . 0.0 111.898 -179.081 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.517 HG23 ' O ' ' A' ' 95' ' ' THR . 19.9 m -84.43 157.02 21.51 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.859 179.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.5 m -150.66 168.28 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 C-N-CA 119.737 -0.785 . . . . 0.0 110.941 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -89.38 148.64 23.39 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.559 179.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.93 73.57 0.19 Allowed 'General case' 0 C--N 1.303 -1.424 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.079 -179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 156.38 16.04 0.04 OUTLIER Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -97.85 153.97 17.95 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.795 -0.762 . . . . 0.0 111.055 -179.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.0 mtmm -95.17 127.52 41.29 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.069 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.0 mt -107.25 103.26 15.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 C-N-CA 120.069 -0.653 . . . . 0.0 109.87 179.602 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 52.5 p -100.99 115.12 29.73 Favored 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 119.656 -0.818 . . . . 0.0 112.382 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -85.5 109.83 18.76 Favored 'General case' 0 N--CA 1.489 1.485 0 C-N-CA 119.668 -0.813 . . . . 0.0 109.228 178.471 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.7 tttp -105.61 137.69 43.05 Favored 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 119.46 -0.896 . . . . 0.0 112.122 -178.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.456 ' N ' ' ND2' ' A' ' 31' ' ' ASN . 0.1 OUTLIER -79.64 114.15 18.34 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.272 179.177 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.67 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.7 OUTLIER -97.71 -31.04 12.47 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 119.181 -1.008 . . . . 0.0 111.634 -179.238 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.67 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 165.47 114.38 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.246 -0.981 . . . . 0.0 111.148 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 139.51 3.61 1.56 Allowed Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.434 -1.365 . . . . 0.0 110.863 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.445 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -53.16 163.08 0.96 Allowed Pre-proline 0 C--N 1.304 -1.372 0 C-N-CA 118.704 -1.199 . . . . 0.0 109.741 -179.874 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -77.1 141.26 68.5 Favored 'Cis proline' 0 C--O 1.214 -0.691 0 C-N-CA 124.194 -1.169 . . . . 0.0 112.509 -0.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -107.2 178.23 4.61 Favored 'General case' 0 N--CA 1.495 1.8 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.967 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.623 HD22 ' H ' ' A' ' 83' ' ' GLU . 15.5 t30 -158.09 139.64 13.67 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.618 -0.833 . . . . 0.0 110.212 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.7 mp -128.07 114.74 35.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 C-N-CA 119.789 -0.765 . . . . 0.0 111.311 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.511 HG23 HD21 ' A' ' 38' ' ' ASN . 66.6 t -130.08 134.48 62.72 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.325 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.921 179.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.754 ' CD2' HD12 ' A' ' 55' ' ' ILE . 8.8 m-85 -87.07 129.18 35.02 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.147 -1.021 . . . . 0.0 111.446 -179.21 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.659 ' C ' ' H ' ' A' ' 44' ' ' ASP . 31.1 t0 -65.75 94.29 0.2 Allowed 'General case' 0 N--CA 1.487 1.386 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.646 -178.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -55.37 5.35 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.858 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.373 179.699 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.659 ' H ' ' C ' ' A' ' 42' ' ' ASP . 73.8 m-20 -82.85 -68.18 0.73 Allowed 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.557 179.272 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -98.51 25.51 6.32 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.471 -0.892 . . . . 0.0 112.131 -177.031 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.608 HG22 ' HD2' ' A' ' 47' ' ' PRO . 0.5 OUTLIER -89.16 154.41 49.32 Favored Pre-proline 0 N--CA 1.489 1.5 0 C-N-CA 119.204 -0.998 . . . . 0.0 108.374 178.967 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.608 ' HD2' HG22 ' A' ' 46' ' ' VAL . 6.1 Cg_exo -51.13 144.01 30.42 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 121.017 1.145 . . . . 0.0 112.061 -179.065 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.47 69.38 5.72 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.791 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 178.73 -43.24 0.08 OUTLIER Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.645 -1.382 . . . . 0.0 109.645 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 46.5 t -84.18 83.39 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.078 179.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.554 ' H ' ' ND2' ' A' ' 51' ' ' ASN . 0.0 OUTLIER -44.74 140.87 2.31 Favored 'General case' 0 C--N 1.306 -1.291 0 C-N-CA 119.252 -0.979 . . . . 0.0 110.525 -179.652 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.39 -26.33 60.94 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.539 -0.865 . . . . 0.0 111.293 -179.38 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.47 ' N ' ' CD ' ' A' ' 53' ' ' GLU . 3.7 mp0 -65.34 -3.17 3.77 Favored 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.938 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.0 mmpp? -97.44 -40.92 8.45 Favored 'General case' 0 N--CA 1.488 1.461 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.022 -179.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.754 HD12 ' CD2' ' A' ' 41' ' ' PHE . 1.3 pt -99.13 -13.99 7.91 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 119.638 -0.825 . . . . 0.0 111.087 -179.587 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 68.9 m -73.06 173.11 9.82 Favored 'General case' 0 N--CA 1.484 1.245 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.855 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.63 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 70.3 mt-30 -136.65 80.3 38.26 Favored Pre-proline 0 N--CA 1.488 1.469 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.623 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -60.92 -20.83 68.73 Favored 'Trans proline' 0 C--O 1.215 -0.649 0 C-N-CA 121.121 1.214 . . . . 0.0 111.443 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -94.56 108.7 20.64 Favored 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.525 179.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 38.9 m-85 -51.51 177.24 0.02 OUTLIER 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.887 -0.725 . . . . 0.0 111.035 -179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.8 pp -143.69 139.19 29.4 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.822 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.415 ' OD1' ' N ' ' A' ' 62' ' ' ASN . 2.9 p-10 -134.97 42.95 2.75 Favored 'General case' 0 N--CA 1.489 1.498 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.399 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -105.31 159.54 15.49 Favored Glycine 0 N--CA 1.493 2.461 0 C-N-CA 119.797 -1.192 . . . . 0.0 110.429 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -110.64 110.89 21.76 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 119.989 -0.685 . . . . 0.0 110.726 179.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.34 -14.21 64.67 Favored Glycine 0 N--CA 1.49 2.285 0 C-N-CA 119.437 -1.364 . . . . 0.0 110.367 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.414 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 1.2 mm-40 -69.82 160.15 32.29 Favored 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.269 -0.973 . . . . 0.0 110.345 179.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -147.22 172.27 14.09 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.048 -1.061 . . . . 0.0 111.669 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.63 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 43.9 t80 -133.61 129.45 36.95 Favored 'General case' 0 N--CA 1.482 1.169 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.082 179.125 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -91.46 149.75 21.55 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 118.892 -1.123 . . . . 0.0 112.461 -178.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -150.28 131.72 5.15 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 CA-C-N 115.06 -0.973 . . . . 0.0 108.994 179.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.0 m -127.04 106.54 9.34 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.836 -0.745 . . . . 0.0 111.504 -178.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.48 ' CD1' HG11 ' A' ' 94' ' ' VAL . 20.5 mt -90.58 157.7 17.37 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.495 -0.882 . . . . 0.0 109.837 179.211 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 8.7 p -150.67 48.37 0.87 Allowed 'General case' 0 C--N 1.297 -1.691 0 C-N-CA 119.072 -1.051 . . . . 0.0 111.412 -179.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -146.67 100.74 3.37 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.14 -1.024 . . . . 0.0 110.151 179.36 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.469 ' CG ' ' O ' ' A' ' 75' ' ' LYS . 2.0 ptpt -41.77 118.76 1.15 Allowed 'General case' 0 N--CA 1.482 1.158 0 C-N-CA 119.65 -0.82 . . . . 0.0 111.041 -179.322 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 164.87 -147.22 12.23 Favored Glycine 0 N--CA 1.484 1.9 0 C-N-CA 119.506 -1.331 . . . . 0.0 109.878 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -142.71 132.96 24.68 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.462 -0.895 . . . . 0.0 111.2 -179.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.585 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.5 OUTLIER -116.81 127.36 54.25 Favored 'General case' 0 N--CA 1.486 1.333 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.342 179.712 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.476 ' N ' ' CD ' ' A' ' 79' ' ' LYS . 2.5 mptp? -101.2 110.72 22.78 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.538 -0.865 . . . . 0.0 111.388 -179.404 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.2 p90 -123.78 168.0 13.3 Favored 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 119.896 -0.722 . . . . 0.0 109.922 178.738 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 46.0 p90 -171.43 -173.92 1.32 Allowed 'General case' 0 C--N 1.296 -1.758 0 C-N-CA 119.3 -0.96 . . . . 0.0 111.033 -178.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -107.97 129.5 55.11 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.001 179.199 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.623 ' H ' HD22 ' A' ' 38' ' ' ASN . 1.9 mt-10 -69.91 -45.4 23.35 Favored Pre-proline 0 N--CA 1.486 1.374 0 C-N-CA 119.541 -0.864 . . . . 0.0 113.073 -179.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.518 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.7 Cg_endo -67.79 -53.17 0.45 Allowed 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 121.066 1.177 . . . . 0.0 111.771 -179.047 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.3 m80 -82.42 16.36 2.12 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.407 -0.917 . . . . 0.0 111.05 -179.461 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.28 -18.42 58.37 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.365 -0.934 . . . . 0.0 110.809 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.19 -19.6 78.28 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.405 -1.379 . . . . 0.0 110.573 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.97 -4.69 52.23 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.577 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 91.64 9.67 62.58 Favored Glycine 0 N--CA 1.489 2.178 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.571 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -55.85 102.31 0.07 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.707 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.8 ptmt -126.64 157.48 38.85 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 119.929 -0.708 . . . . 0.0 111.221 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -140.24 133.86 6.21 Favored Glycine 0 N--CA 1.49 2.236 0 C-N-CA 119.971 -1.109 . . . . 0.0 110.391 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -139.21 148.79 43.59 Favored 'General case' 0 N--CA 1.492 1.641 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.634 179.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.48 HG11 ' CD1' ' A' ' 72' ' ' LEU . 11.4 p -141.84 132.47 25.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 119.065 -1.054 . . . . 0.0 110.219 178.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.517 ' O ' HG23 ' A' ' 20' ' ' THR . 99.6 m -110.31 104.99 13.85 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.26 -0.976 . . . . 0.0 110.338 179.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 31.4 t -84.83 152.31 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 C-N-CA 118.555 -1.258 . . . . 0.0 110.774 -178.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 60.8 m-20 . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 116.324 -1.798 . . . . 0.0 110.816 -179.792 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.199 0 N-CA-C 110.115 -0.328 . . . . 0.0 110.115 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 -130.51 122.59 27.9 Favored 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 120.053 -0.659 . . . . 0.0 110.642 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -99.11 154.4 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 C-N-CA 119.425 -0.91 . . . . 0.0 111.635 -179.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 40.2 mttt -120.59 106.95 12.25 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.074 -0.967 . . . . 0.0 110.479 179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.9 mt -74.77 111.47 10.01 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 118.625 -1.23 . . . . 0.0 110.207 179.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.536 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 112.03 136.32 6.81 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 -178.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.458 ' OG ' ' N ' ' A' ' 8' ' ' ASP . 79.7 p -59.01 -110.13 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.806 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.458 ' N ' ' OG ' ' A' ' 7' ' ' SER . 2.5 m-20 -154.39 -0.87 0.19 Allowed 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 118.993 -1.083 . . . . 0.0 111.497 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.494 ' N ' ' OD1' ' A' ' 9' ' ' ASP . 14.4 p30 -166.54 -16.79 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 118.731 -1.188 . . . . 0.0 111.686 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 175.4 69.12 0.05 OUTLIER Glycine 0 N--CA 1.492 2.371 0 C-N-CA 119.002 -1.57 . . . . 0.0 110.856 -179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -172.8 148.06 10.24 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 119.444 -1.36 . . . . 0.0 109.926 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mt -119.13 99.26 6.61 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.977 -0.689 . . . . 0.0 110.084 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 6.5 m -150.84 155.47 7.3 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 C-N-CA 118.853 -1.139 . . . . 0.0 111.281 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.49 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 57.2 m-85 -78.7 109.84 13.3 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 177.449 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.9 m -115.3 108.19 48.19 Favored Pre-proline 0 CA--C 1.565 1.552 0 C-N-CA 119.596 -0.841 . . . . 0.0 112.875 -176.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -66.23 175.09 25.08 Favored 'Cis proline' 0 C--N 1.368 1.571 0 C-N-CA 125.128 -0.78 . . . . 0.0 111.142 -1.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.521 ' OG ' ' N ' ' A' ' 18' ' ' SER . 0.1 OUTLIER -102.91 -67.84 0.86 Allowed 'General case' 0 N--CA 1.488 1.442 0 C-N-CA 119.704 -0.799 . . . . 0.0 110.305 179.428 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.521 ' N ' ' OG ' ' A' ' 17' ' ' SER . 34.2 t -105.74 133.45 50.46 Favored 'General case' 0 N--CA 1.488 1.433 0 C-N-CA 120.069 -0.652 . . . . 0.0 109.843 179.323 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 32.6 p90 -160.65 137.13 8.69 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 118.817 -1.153 . . . . 0.0 111.177 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.419 ' H ' HG23 ' A' ' 20' ' ' THR . 0.4 OUTLIER -87.77 159.57 18.4 Favored 'General case' 0 C--N 1.301 -1.542 0 C-N-CA 119.271 -0.972 . . . . 0.0 111.183 -179.891 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 30.6 m -148.93 176.35 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.315 179.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -97.37 150.41 21.03 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.568 -0.853 . . . . 0.0 110.722 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.03 71.67 0.17 Allowed 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.99 179.643 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 164.4 10.02 0.03 OUTLIER Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.539 -1.425 . . . . 0.0 109.539 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -104.37 146.59 28.61 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 120.105 -0.638 . . . . 0.0 110.543 -179.638 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 15.6 pttt -94.33 153.29 18.08 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.394 -0.922 . . . . 0.0 111.039 -179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.3 mt -122.94 145.51 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.486 179.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.7 p -137.8 118.13 13.69 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.274 -0.97 . . . . 0.0 112.165 -178.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -84.63 126.59 33.49 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.642 -0.823 . . . . 0.0 109.059 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.459 ' HB3' ' HZ2' ' A' ' 30' ' ' LYS . 0.0 OUTLIER -120.16 130.76 54.74 Favored 'General case' 0 N--CA 1.493 1.705 0 C-N-CA 119.604 -0.838 . . . . 0.0 111.853 -178.085 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.635 HD21 ' CD1' ' A' ' 61' ' ' LEU . 6.2 m-20 -70.2 125.41 26.71 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.517 -0.873 . . . . 0.0 109.101 178.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.652 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.2 OUTLIER -103.7 -32.24 9.47 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 118.861 -1.136 . . . . 0.0 112.798 -178.533 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.652 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.01 -5.16 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 118.019 -1.472 . . . . 0.0 112.016 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.506 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -107.6 41.81 2.1 Favored Glycine 0 N--CA 1.492 2.383 0 C-N-CA 119.411 -1.376 . . . . 0.0 112.02 -178.798 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -76.14 160.78 77.37 Favored Pre-proline 0 N--CA 1.483 1.218 0 C-N-CA 117.917 -1.513 . . . . 0.0 109.564 179.019 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_endo -74.38 176.98 40.33 Favored 'Cis proline' 0 C--O 1.207 -1.037 0 C-N-CA 124.163 -1.182 . . . . 0.0 111.784 -0.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.506 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 43.0 m-70 -150.98 168.92 23.09 Favored 'General case' 0 C--N 1.298 -1.633 0 C-N-CA 119.567 -0.853 . . . . 0.0 110.794 179.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.846 HD21 ' H ' ' A' ' 83' ' ' GLU . 4.8 p-10 -154.54 152.89 30.6 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 119.381 -0.928 . . . . 0.0 110.079 178.244 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.0 mp -129.14 97.78 3.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.652 -179.379 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -112.39 143.41 22.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 CA-C-N 115.694 -0.684 . . . . 0.0 109.163 178.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -99.04 138.5 36.06 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.097 -1.041 . . . . 0.0 112.354 -178.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -75.83 110.81 10.57 Favored 'General case' 0 C--N 1.301 -1.518 0 C-N-CA 119.241 -0.983 . . . . 0.0 108.981 178.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -72.56 49.68 0.22 Allowed 'General case' 0 N--CA 1.485 1.321 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.405 -179.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 27.8 m-20 -142.5 3.57 1.5 Allowed 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.968 -0.693 . . . . 0.0 110.2 179.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.6 mm-40 -142.99 8.13 1.65 Allowed 'General case' 0 N--CA 1.483 1.175 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.721 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.422 HG13 ' HD2' ' A' ' 47' ' ' PRO . 44.3 t -94.63 143.75 26.76 Favored Pre-proline 0 C--N 1.291 -1.968 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.422 ' HD2' HG13 ' A' ' 46' ' ' VAL . 5.2 Cg_exo -50.94 148.56 16.53 Favored 'Trans proline' 0 C--O 1.216 -0.593 0 C-N-CA 120.868 1.045 . . . . 0.0 112.251 -179.081 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -76.11 78.25 2.94 Favored 'General case' 0 C--N 1.308 -1.196 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.503 179.609 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 168.32 -43.13 0.23 Allowed Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.838 -1.305 . . . . 0.0 109.838 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.402 ' O ' HG12 ' A' ' 50' ' ' VAL . 55.5 t -79.35 94.21 1.82 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 C-N-CA 119.461 -0.896 . . . . 0.0 110.528 179.544 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.9 m120 -44.93 139.85 2.9 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.696 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -96.34 -1.46 47.73 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.561 -0.856 . . . . 0.0 110.937 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.439 ' N ' ' OE1' ' A' ' 53' ' ' GLU . 11.0 mp0 -90.33 -15.82 30.41 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.303 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.419 ' HG3' HG23 ' A' ' 55' ' ' ILE . 59.2 pttt -89.88 -27.47 19.87 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.01 -1.076 . . . . 0.0 111.437 -179.54 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.424 HD13 HG21 ' A' ' 55' ' ' ILE . 15.8 pt -92.74 -27.76 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 C-N-CA 119.106 -1.038 . . . . 0.0 110.918 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 9.0 m -60.75 -168.15 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.322 0 C-N-CA 119.655 -0.818 . . . . 0.0 111.43 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.634 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 47.8 mt-30 -150.07 74.27 9.21 Favored Pre-proline 0 C--N 1.305 -1.336 0 C-N-CA 119.867 -0.733 . . . . 0.0 110.626 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -60.18 -12.26 19.01 Favored 'Trans proline' 0 C--N 1.325 -0.695 0 C-N-CA 121.202 1.268 . . . . 0.0 111.256 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' A' ' 60' ' ' TYR . 45.0 mt-10 -100.13 95.48 6.85 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.834 -0.746 . . . . 0.0 110.414 179.425 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.44 ' O ' ' O ' ' A' ' 59' ' ' GLU . 71.3 m-85 -43.97 171.19 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.916 -0.714 . . . . 0.0 111.17 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.635 ' CD1' HD21 ' A' ' 31' ' ' ASN . 1.9 pp -139.74 150.3 44.64 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.833 -0.747 . . . . 0.0 110.644 179.834 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -149.06 53.26 0.97 Allowed 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.891 -179.771 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.27 126.98 6.29 Favored Glycine 0 N--CA 1.498 2.774 0 C-N-CA 119.95 -1.119 . . . . 0.0 110.402 179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.67 128.78 37.56 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.833 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 78.47 -14.99 10.13 Favored Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.371 -1.395 . . . . 0.0 110.859 179.813 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 3.1 tp10 -56.44 154.83 7.88 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 119.204 -0.998 . . . . 0.0 110.336 179.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -147.99 164.57 33.4 Favored 'General case' 0 N--CA 1.489 1.522 0 C-N-CA 119.016 -1.074 . . . . 0.0 111.788 -179.069 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.634 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 36.0 t80 -136.14 146.45 46.94 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 178.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -108.03 154.74 21.22 Favored 'General case' 0 N--CA 1.498 1.935 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.794 -178.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -155.24 135.91 4.71 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 CA-C-N 115.086 -0.961 . . . . 0.0 108.936 179.287 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.2 m -128.07 104.16 7.62 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.667 -0.813 . . . . 0.0 111.769 -179.365 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.525 ' CD1' HG11 ' A' ' 94' ' ' VAL . 14.4 mt -88.22 157.74 18.7 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.237 -0.985 . . . . 0.0 109.614 179.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.71 48.42 0.87 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 118.865 -1.134 . . . . 0.0 111.351 -179.25 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.447 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -142.58 105.08 4.48 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.272 -0.971 . . . . 0.0 110.011 178.996 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 32.0 mtmt -46.59 110.31 0.27 Allowed 'General case' 0 C--N 1.299 -1.611 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.162 -179.285 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 171.08 -141.76 6.67 Favored Glycine 0 N--CA 1.485 1.912 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -146.38 137.5 24.39 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.924 179.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.573 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.4 m-85 -122.32 152.3 40.27 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 115.442 -0.799 . . . . 0.0 109.131 179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 31.2 mttm -115.5 132.42 56.63 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.625 -0.83 . . . . 0.0 112.335 -179.423 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.516 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -141.9 153.37 44.36 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.843 176.956 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 30.5 p90 -168.48 177.64 5.19 Favored 'General case' 0 C--N 1.285 -2.221 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.55 -178.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . 0.464 ' SG ' ' OD1' ' A' ' 38' ' ' ASN . 1.3 t -101.62 120.65 40.66 Favored 'General case' 0 C--N 1.305 -1.332 0 C-N-CA 119.246 -0.981 . . . . 0.0 109.233 179.424 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.846 ' H ' HD21 ' A' ' 38' ' ' ASN . 6.6 tt0 -65.15 -40.56 46.1 Favored Pre-proline 0 C--N 1.3 -1.548 0 N-CA-C 113.774 1.027 . . . . 0.0 113.774 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.502 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.7 Cg_endo -68.95 -52.41 0.39 Allowed 'Trans proline' 0 C--O 1.215 -0.646 0 C-N-CA 120.401 0.734 . . . . 0.0 111.694 -179.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . 0.41 ' C ' ' H ' ' A' ' 87' ' ' GLY . 30.3 m80 -79.78 13.87 1.97 Allowed 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.906 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.31 -2.26 2.1 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.317 -0.953 . . . . 0.0 110.659 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.41 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -88.01 -18.18 56.44 Favored Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.514 -1.326 . . . . 0.0 110.231 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.32 -41.09 10.05 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.522 -0.871 . . . . 0.0 110.631 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 133.69 15.3 1.24 Allowed Glycine 0 N--CA 1.495 2.628 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.456 179.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.75 100.79 0.31 Allowed 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.392 -0.923 . . . . 0.0 111.017 179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.49 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 32.4 mttm -125.99 164.5 20.68 Favored 'General case' 0 N--CA 1.494 1.766 0 C-N-CA 119.9 -0.72 . . . . 0.0 111.497 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.498 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -148.58 143.89 11.57 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.486 -1.34 . . . . 0.0 110.927 -179.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.7 tt0 -149.13 146.92 27.91 Favored 'General case' 0 N--CA 1.492 1.657 0 C-N-CA 119.484 -0.886 . . . . 0.0 111.131 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.601 HG13 ' O ' ' A' ' 94' ' ' VAL . 12.5 p -140.05 119.63 12.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 C-N-CA 119.224 -0.99 . . . . 0.0 110.53 179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 94.5 m -99.07 101.25 12.56 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.628 179.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.436 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 41.8 t -79.61 142.74 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.231 0 C-N-CA 118.963 -1.095 . . . . 0.0 110.444 -179.014 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 96' ' ' VAL . 81.2 m-20 . . . . . 0 C--N 1.304 -1.38 0 CA-C-O 116.335 -1.793 . . . . 0.0 110.728 -179.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.109 0 N-CA-C 110.145 -0.316 . . . . 0.0 110.145 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 20.7 mp0 -121.78 122.0 38.5 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 120.128 -0.629 . . . . 0.0 110.652 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.8 t -106.69 119.06 55.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 C-N-CA 119.768 -0.773 . . . . 0.0 110.853 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -91.82 117.63 29.96 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 119.335 -0.946 . . . . 0.0 110.883 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.429 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 4.8 mt -84.27 106.36 15.82 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 119.264 -0.975 . . . . 0.0 110.702 179.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.519 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 106.75 86.64 1.89 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.473 -1.051 . . . . 0.0 110.473 -179.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.549 ' OG ' ' N ' ' A' ' 11' ' ' GLY . 2.9 p -48.09 142.08 5.53 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.108 -1.037 . . . . 0.0 110.389 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.401 ' C ' ' O ' ' A' ' 7' ' ' SER . 3.2 m-20 -39.56 -52.07 2.19 Favored 'General case' 0 N--CA 1.489 1.476 0 C-N-CA 119.884 -0.726 . . . . 0.0 111.598 -179.259 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -141.04 7.06 2.01 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.501 -0.879 . . . . 0.0 110.766 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -77.66 -39.18 25.92 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 119.435 -1.364 . . . . 0.0 110.502 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.549 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . 141.66 -153.83 24.38 Favored Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.577 -1.297 . . . . 0.0 110.515 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.1 mt -99.23 94.75 6.65 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.814 -179.689 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.0 m -146.73 161.38 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 C-N-CA 118.804 -1.159 . . . . 0.0 111.427 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -78.58 113.79 16.93 Favored 'General case' 0 C--N 1.306 -1.29 0 N-CA-C 107.405 -1.332 . . . . 0.0 107.405 177.377 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.1 m -116.7 107.45 46.46 Favored Pre-proline 0 CA--C 1.559 1.292 0 C-N-CA 119.39 -0.924 . . . . 0.0 111.881 -177.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -66.11 176.38 21.23 Favored 'Cis proline' 0 C--N 1.36 1.153 0 C-N-CA 125.227 -0.739 . . . . 0.0 111.46 -0.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.7 p -95.76 -48.86 5.59 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 119.501 -0.88 . . . . 0.0 110.205 179.528 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 47.9 t -137.07 137.12 38.99 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.601 179.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 11.3 p90 -163.3 143.68 9.02 Favored 'General case' 0 N--CA 1.483 1.183 0 C-N-CA 118.563 -1.255 . . . . 0.0 111.528 -179.117 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.429 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -86.44 157.43 19.82 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.896 -179.889 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.3 m -146.48 146.89 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.238 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.313 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.437 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -61.45 141.58 57.58 Favored 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.697 179.847 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.75 74.21 0.07 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.606 -0.838 . . . . 0.0 111.184 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 154.25 18.89 0.05 OUTLIER Glycine 0 N--CA 1.488 2.141 0 C-N-CA 119.364 -1.398 . . . . 0.0 109.922 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.428 ' O ' HG23 ' A' ' 71' ' ' THR . 21.7 tt0 -103.63 157.1 17.29 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 119.947 -0.701 . . . . 0.0 110.8 -179.597 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 29.1 mttt -94.38 142.07 27.84 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.495 -0.882 . . . . 0.0 110.714 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.6 mt -124.81 125.52 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 C-N-CA 119.992 -0.683 . . . . 0.0 109.519 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 37.6 p -119.68 129.33 54.5 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 119.528 -0.869 . . . . 0.0 112.368 -178.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 92.3 m-85 -91.71 131.48 37.07 Favored 'General case' 0 C--N 1.306 -1.319 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.226 178.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 17.5 tptm -120.94 131.01 54.09 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 120.017 -0.673 . . . . 0.0 111.249 -178.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.453 ' ND2' HD11 ' A' ' 61' ' ' LEU . 0.5 OUTLIER -90.77 94.68 9.78 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.594 -0.842 . . . . 0.0 109.547 178.981 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.519 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 40.1 p-10 -91.26 -23.17 20.25 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.24 -179.008 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -177.36 162.23 1.87 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 118.999 -1.08 . . . . 0.0 111.219 179.31 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.03 12.49 76.68 Favored Glycine 0 N--CA 1.487 2.059 0 C-N-CA 119.393 -1.384 . . . . 0.0 112.583 178.035 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -63.05 159.93 43.08 Favored Pre-proline 0 C--N 1.308 -1.199 0 C-N-CA 117.283 -1.767 . . . . 0.0 109.378 179.489 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -79.13 147.05 79.27 Favored 'Cis proline' 0 C--O 1.215 -0.637 0 C-N-CA 124.13 -1.196 . . . . 0.0 112.195 -0.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 40.5 m-70 -111.3 -175.43 2.7 Favored 'General case' 0 N--CA 1.495 1.805 0 CA-C-N 115.802 -0.635 . . . . 0.0 110.377 179.146 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.617 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -160.63 146.06 14.67 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.485 -0.886 . . . . 0.0 110.446 179.262 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.617 ' N ' HD22 ' A' ' 38' ' ' ASN . 3.7 mp -134.17 107.27 9.43 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.971 -179.376 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.3 t -133.48 144.17 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 120.007 -0.677 . . . . 0.0 109.849 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 56.3 m-85 -97.42 118.24 33.45 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.962 -179.387 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -52.28 118.52 3.59 Favored 'General case' 0 C--N 1.308 -1.202 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.281 179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.4 pt-20 -76.09 47.94 0.47 Allowed 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.121 -1.032 . . . . 0.0 111.047 -179.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.0 m-20 -147.75 2.68 0.71 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.652 -0.819 . . . . 0.0 109.94 179.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -144.56 21.39 1.67 Allowed 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 119.69 -0.804 . . . . 0.0 110.614 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -104.88 148.13 35.61 Favored Pre-proline 0 N--CA 1.493 1.693 0 CA-C-N 115.45 -0.795 . . . . 0.0 109.28 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -49.66 143.12 22.97 Favored 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 120.951 1.101 . . . . 0.0 111.715 179.639 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.85 69.37 2.5 Favored 'General case' 0 C--N 1.307 -1.242 0 C-N-CA 119.588 -0.845 . . . . 0.0 110.942 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.0 -43.27 0.1 Allowed Glycine 0 N--CA 1.49 2.238 0 C-N-CA 119.44 -1.362 . . . . 0.0 110.018 179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 77.5 t -78.44 97.32 2.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.372 179.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.2 m120 -44.71 139.68 2.83 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.66 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -94.8 2.66 55.5 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.441 -179.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -87.72 -33.22 18.8 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.932 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 33.1 mmtm -76.41 -32.2 58.36 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.911 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 6.6 pt -90.64 -16.09 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 C-N-CA 118.993 -1.083 . . . . 0.0 111.682 -179.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 4.8 m -79.97 170.72 16.07 Favored 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.264 -0.974 . . . . 0.0 110.782 179.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.65 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 5.8 mt-30 -134.68 73.44 67.36 Favored Pre-proline 0 N--CA 1.487 1.393 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.523 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -61.36 -4.26 3.99 Favored 'Trans proline' 0 C--O 1.214 -0.699 0 C-N-CA 121.402 1.401 . . . . 0.0 111.459 -179.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.431 ' O ' ' O ' ' A' ' 60' ' ' TYR . 37.8 mt-10 -99.86 100.67 11.63 Favored 'General case' 0 N--CA 1.485 1.283 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.716 179.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.473 ' CD2' ' OD1' ' A' ' 38' ' ' ASN . 84.7 m-85 -45.82 171.49 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.177 0 C-N-CA 119.46 -0.896 . . . . 0.0 110.623 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.572 ' O ' HD12 ' A' ' 61' ' ' LEU . 3.2 pp -149.39 126.54 11.34 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.248 -0.981 . . . . 0.0 110.499 179.434 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -120.86 33.61 5.51 Favored 'General case' 0 N--CA 1.491 1.577 0 C-N-CA 120.175 -0.61 . . . . 0.0 110.663 -179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -87.91 168.19 37.22 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.308 -1.425 . . . . 0.0 110.876 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -121.62 101.27 7.49 Favored 'General case' 0 N--CA 1.49 1.547 0 C-N-CA 120.324 -0.55 . . . . 0.0 110.363 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.94 -7.94 55.5 Favored Glycine 0 N--CA 1.49 2.248 0 C-N-CA 119.622 -1.275 . . . . 0.0 110.063 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -71.1 157.55 38.0 Favored 'General case' 0 N--CA 1.486 1.359 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.226 179.665 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -141.69 173.27 11.66 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.27 -0.972 . . . . 0.0 112.041 -179.077 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.65 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 56.7 t80 -134.66 178.23 7.17 Favored 'General case' 0 N--CA 1.488 1.429 0 CA-C-N 115.498 -0.773 . . . . 0.0 109.623 178.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.516 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 5.1 mt-10 -145.92 149.34 34.03 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 118.912 -1.115 . . . . 0.0 112.012 -179.648 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -159.04 133.87 1.55 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 CA-C-N 115.569 -0.742 . . . . 0.0 109.659 178.57 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.428 HG23 ' O ' ' A' ' 25' ' ' GLU . 4.1 m -122.53 96.34 4.99 Favored 'General case' 0 N--CA 1.484 1.237 0 C-N-CA 119.828 -0.749 . . . . 0.0 111.035 -179.272 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.3 mt -79.75 158.64 26.84 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.02 -1.072 . . . . 0.0 109.448 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.577 ' O ' HG22 ' A' ' 73' ' ' THR . 97.0 m -150.96 47.12 0.85 Allowed 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.552 -1.259 . . . . 0.0 112.362 -178.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.424 ' OE2' ' O ' ' A' ' 75' ' ' LYS . 5.9 tp10 -146.2 107.25 4.16 Favored 'General case' 0 N--CA 1.488 1.425 0 C-N-CA 118.746 -1.182 . . . . 0.0 109.95 178.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.7 ' H ' ' CD ' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -43.36 116.32 0.91 Allowed 'General case' 0 C--N 1.304 -1.394 0 CA-C-N 115.199 -0.909 . . . . 0.0 111.184 -178.972 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.6 -151.22 16.68 Favored Glycine 0 N--CA 1.485 1.943 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.359 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -136.17 131.15 34.29 Favored 'General case' 0 C--N 1.307 -1.253 0 C-N-CA 119.846 -0.741 . . . . 0.0 110.677 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.538 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 3.7 m-85 -118.19 121.58 40.86 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 36.8 mmtt -100.19 127.48 46.45 Favored 'General case' 0 C--N 1.3 -1.563 0 C-N-CA 119.524 -0.87 . . . . 0.0 112.839 -178.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.448 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 5.6 p90 -139.87 171.46 14.18 Favored 'General case' 0 C--N 1.312 -1.025 0 C-N-CA 119.616 -0.833 . . . . 0.0 110.433 177.673 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 48.3 p90 -170.55 -175.71 1.94 Allowed 'General case' 0 C--N 1.288 -2.089 0 C-N-CA 119.437 -0.905 . . . . 0.0 111.178 -178.359 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.8 t -106.7 123.26 47.86 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.757 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.532 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.4 OUTLIER -64.05 -45.16 79.79 Favored Pre-proline 0 C--N 1.307 -1.253 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.466 -179.874 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.532 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.3 Cg_endo -66.93 -48.36 1.97 Allowed 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.994 1.129 . . . . 0.0 112.47 -178.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . 0.468 ' C ' ' H ' ' A' ' 87' ' ' GLY . 34.4 m80 -91.69 23.19 3.68 Favored 'General case' 0 N--CA 1.49 1.556 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.152 -179.196 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.404 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -71.19 12.29 0.33 Allowed 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.893 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.468 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -107.15 -18.35 10.54 Favored Glycine 0 N--CA 1.498 2.79 0 C-N-CA 119.746 -1.216 . . . . 0.0 110.682 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -95.1 -16.11 22.88 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.232 -179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 108.17 17.76 10.5 Favored Glycine 0 N--CA 1.498 2.78 0 C-N-CA 119.777 -1.202 . . . . 0.0 110.242 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 5.7 ttt -69.99 90.78 0.65 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.363 -0.935 . . . . 0.0 110.215 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 15.4 ttmt -118.39 162.17 18.75 Favored 'General case' 0 N--CA 1.498 1.944 0 C-N-CA 120.045 -0.662 . . . . 0.0 111.16 -179.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -141.74 150.99 22.42 Favored Glycine 0 N--CA 1.495 2.608 0 C-N-CA 119.349 -1.405 . . . . 0.0 111.6 -178.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 54.1 tt0 -157.57 145.43 18.85 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 119.75 -0.78 . . . . 0.0 110.919 179.408 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.2 p -138.55 123.06 21.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.346 178.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 97.7 m -99.61 103.23 14.92 Favored 'General case' 0 N--CA 1.491 1.58 0 C-N-CA 119.392 -0.923 . . . . 0.0 110.594 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 22.0 t -80.05 142.86 13.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 C-N-CA 118.423 -1.311 . . . . 0.0 110.46 -179.145 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 29.3 m120 . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 116.358 -1.782 . . . . 0.0 110.764 -179.76 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.221 0 CA-C-O 120.7 0.286 . . . . 0.0 110.249 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 89.2 mt-10 -115.08 121.34 42.77 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.586 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.4 t -102.49 123.61 55.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.915 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 39.1 mttp -88.92 112.9 23.86 Favored 'General case' 0 C--N 1.294 -1.808 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.902 -179.728 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.404 ' HB3' ' CD2' ' A' ' 37' ' ' HIS . 13.1 mt -75.82 107.43 8.0 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 118.229 -1.388 . . . . 0.0 109.4 178.104 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.535 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.64 130.4 6.98 Favored Glycine 0 N--CA 1.486 1.986 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -178.819 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 22.3 p -71.75 171.27 11.89 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.663 179.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -66.54 -47.73 71.95 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.042 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -55.86 -71.35 0.09 Allowed 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.339 -0.944 . . . . 0.0 110.836 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 174.35 24.18 0.03 OUTLIER Glycine 0 N--CA 1.489 2.224 0 C-N-CA 119.491 -1.338 . . . . 0.0 110.363 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -92.7 153.07 21.42 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.412 -1.375 . . . . 0.0 110.296 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.4 mt -104.81 97.46 7.34 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.825 -0.75 . . . . 0.0 110.827 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.2 m -150.12 153.97 9.7 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.868 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.423 ' O ' ' O ' ' A' ' 16' ' ' PRO . 69.7 m-85 -78.45 110.61 13.68 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.666 -1.235 . . . . 0.0 107.666 177.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.2 m -115.59 110.39 44.75 Favored Pre-proline 0 CA--C 1.562 1.419 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.723 -177.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.423 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.7 Cg_exo -64.79 174.7 21.0 Favored 'Cis proline' 0 C--N 1.365 1.43 0 C-N-CA 125.103 -0.79 . . . . 0.0 111.829 -0.157 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.9 t -102.82 -66.36 0.94 Allowed 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.455 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 61.6 m -119.08 131.88 55.97 Favored 'General case' 0 N--CA 1.492 1.634 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.008 179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.436 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 16.7 p90 -161.23 170.94 19.28 Favored 'General case' 0 N--CA 1.487 1.391 0 C-N-CA 118.655 -1.218 . . . . 0.0 111.324 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 22.4 p -102.88 161.45 13.74 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.992 -0.683 . . . . 0.0 111.193 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 29.9 m -149.23 151.0 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 119.441 -0.904 . . . . 0.0 110.946 179.772 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.519 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -78.82 142.06 37.21 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.274 -0.971 . . . . 0.0 110.359 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -60.01 77.35 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.51 -0.876 . . . . 0.0 111.395 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.519 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 153.79 15.32 0.06 OUTLIER Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.729 -1.349 . . . . 0.0 109.729 179.583 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -103.94 145.0 30.78 Favored 'General case' 0 C--N 1.306 -1.294 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.754 -179.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ptpt -95.45 136.34 35.95 Favored 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 119.473 -0.891 . . . . 0.0 111.383 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 4.1 mt -109.16 113.79 45.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 CA-C-N 115.671 -0.695 . . . . 0.0 109.631 179.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.3 p -107.3 116.47 31.98 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.775 -0.77 . . . . 0.0 112.336 -178.547 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 69.2 m-85 -85.16 118.81 24.94 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 119.526 -0.87 . . . . 0.0 109.05 178.293 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.538 ' HA ' HG22 ' A' ' 67' ' ' THR . 25.0 tttp -111.74 138.16 48.7 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.657 -0.817 . . . . 0.0 111.482 -178.802 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.51 HD21 ' CD1' ' A' ' 61' ' ' LEU . 2.6 m-20 -77.65 109.92 12.03 Favored 'General case' 0 C--N 1.3 -1.557 0 CA-C-N 115.423 -0.808 . . . . 0.0 111.413 179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.661 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.4 t30 -96.51 -30.96 13.03 Favored 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 119.147 -1.021 . . . . 0.0 110.703 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.661 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 165.13 129.12 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.806 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 127.98 -9.01 6.75 Favored Glycine 0 N--CA 1.493 2.482 0 C-N-CA 119.687 -1.244 . . . . 0.0 110.91 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.478 ' CD1' ' ND2' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -45.92 160.64 0.28 Allowed Pre-proline 0 N--CA 1.482 1.142 0 C-N-CA 118.52 -1.272 . . . . 0.0 109.695 -179.881 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -77.3 141.55 68.84 Favored 'Cis proline' 0 C--O 1.214 -0.68 0 C-N-CA 124.139 -1.192 . . . . 0.0 112.241 0.008 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.404 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 40.6 m-70 -108.55 -177.24 3.26 Favored 'General case' 0 N--CA 1.495 1.799 0 C-N-CA 119.94 -0.704 . . . . 0.0 111.072 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.611 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -161.16 141.54 11.06 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.875 -0.73 . . . . 0.0 109.872 178.829 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.611 ' N ' HD22 ' A' ' 38' ' ' ASN . 3.6 mp -129.63 124.69 59.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.438 -179.542 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -143.53 146.99 20.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.385 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.161 179.776 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.4 m-85 -97.23 134.56 40.38 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.248 -0.981 . . . . 0.0 111.04 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.659 ' O ' ' N ' ' A' ' 44' ' ' ASP . 44.5 p-10 -73.1 93.81 1.85 Allowed 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.529 -0.868 . . . . 0.0 111.063 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.445 ' CG ' ' O ' ' A' ' 43' ' ' GLU . 0.1 OUTLIER -50.45 78.84 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.778 0 O-C-N 124.063 0.852 . . . . 0.0 109.803 179.385 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.659 ' N ' ' O ' ' A' ' 42' ' ' ASP . 59.4 m-20 -157.01 -67.04 0.1 Allowed 'General case' 0 C--N 1.283 -2.3 0 CA-C-N 114.494 -1.23 . . . . 0.0 109.682 -177.785 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -96.24 17.37 15.94 Favored 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.191 -1.003 . . . . 0.0 112.139 -177.399 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -86.07 143.96 38.12 Favored Pre-proline 0 C--N 1.291 -1.959 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.431 ' C ' ' H ' ' A' ' 49' ' ' GLY . 2.7 Cg_exo -48.81 152.21 4.68 Favored 'Trans proline' 0 C--O 1.215 -0.651 0 C-N-CA 120.815 1.01 . . . . 0.0 111.797 -179.252 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -81.68 31.15 0.36 Allowed 'General case' 0 N--CA 1.483 1.191 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.645 -179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.431 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -136.27 -35.34 0.21 Allowed Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 16.5 t -96.46 93.2 3.45 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.986 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 96.5 m-20 -45.26 144.48 1.37 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.671 179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -87.99 -29.85 20.44 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.84 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -75.03 -1.05 21.02 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.747 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -97.62 -35.03 10.73 Favored 'General case' 0 N--CA 1.483 1.202 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.753 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -96.2 -16.14 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 C-N-CA 119.404 -0.918 . . . . 0.0 111.102 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 36.7 m -68.27 170.07 9.38 Favored 'General case' 0 C--N 1.309 -1.187 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.733 179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.64 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 5.0 mt-30 -137.09 73.37 51.87 Favored Pre-proline 0 N--CA 1.489 1.489 0 C-N-CA 119.811 -0.756 . . . . 0.0 110.901 -179.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -57.28 -27.73 76.51 Favored 'Trans proline' 0 C--N 1.322 -0.836 0 C-N-CA 121.038 1.159 . . . . 0.0 110.933 -179.792 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -65.65 114.1 4.73 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.088 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 -60.72 173.26 0.77 Allowed 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 119.479 -0.888 . . . . 0.0 111.073 -179.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.51 ' CD1' HD21 ' A' ' 31' ' ' ASN . 2.5 pp -149.15 144.63 26.73 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.682 -0.807 . . . . 0.0 110.158 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.581 ' ND2' ' N ' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -128.28 -73.53 0.59 Allowed 'General case' 0 N--CA 1.495 1.821 0 C-N-CA 119.88 -0.728 . . . . 0.0 111.72 -178.992 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.488 ' H ' ' CG ' ' A' ' 62' ' ' ASN . . . -24.2 127.19 0.02 OUTLIER Glycine 0 N--CA 1.511 3.642 0 O-C-N 123.993 0.808 . . . . 0.0 112.612 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.486 ' C ' ' H ' ' A' ' 66' ' ' GLU . . . -62.33 156.76 21.47 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.207 179.394 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . 0.724 ' O ' HG23 ' A' ' 67' ' ' THR . . . 71.28 -14.62 1.65 Allowed Glycine 0 N--CA 1.492 2.376 0 C-N-CA 119.109 -1.519 . . . . 0.0 110.6 179.791 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.486 ' H ' ' C ' ' A' ' 64' ' ' ALA . 12.9 tt0 -61.13 101.8 0.18 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.286 -0.966 . . . . 0.0 109.97 179.276 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.724 HG23 ' O ' ' A' ' 65' ' ' GLY . 37.4 p -106.99 162.19 14.06 Favored 'General case' 0 N--CA 1.495 1.795 0 C-N-CA 119.575 -0.85 . . . . 0.0 112.225 -178.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.64 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 29.7 t80 -136.17 143.57 44.52 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.323 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -104.84 154.6 19.84 Favored 'General case' 0 N--CA 1.497 1.908 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.589 -178.605 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -151.59 130.75 3.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.945 -1.025 . . . . 0.0 108.942 179.272 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.4 m -124.6 112.06 16.37 Favored 'General case' 0 N--CA 1.487 1.378 0 C-N-CA 119.693 -0.803 . . . . 0.0 111.585 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 34.3 mt -98.61 156.85 16.6 Favored 'General case' 0 N--CA 1.485 1.294 0 CA-C-N 115.659 -0.7 . . . . 0.0 109.772 179.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 11.1 p -150.93 47.98 0.85 Allowed 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 118.714 -1.194 . . . . 0.0 112.274 -179.122 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.4 tp10 -144.49 106.29 4.3 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.781 -1.168 . . . . 0.0 110.467 178.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.437 ' HD2' ' H ' ' A' ' 75' ' ' LYS . 0.0 OUTLIER -44.96 110.84 0.26 Allowed 'General case' 0 C--N 1.3 -1.574 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.913 -179.696 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.93 -148.28 10.35 Favored Glycine 0 N--CA 1.487 2.053 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.077 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -139.92 135.37 32.75 Favored 'General case' 0 N--CA 1.483 1.176 0 C-N-CA 119.424 -0.91 . . . . 0.0 111.095 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.569 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -124.36 159.04 31.23 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 179.565 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 12.2 mtpt -136.5 125.48 24.31 Favored 'General case' 0 N--CA 1.495 1.784 0 C-N-CA 118.612 -1.235 . . . . 0.0 112.871 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.542 ' O ' ' N ' ' A' ' 92' ' ' GLY . 3.9 p90 -129.43 162.34 28.3 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-N 115.471 -0.786 . . . . 0.0 110.35 178.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 22.7 p90 -166.94 -179.5 4.72 Favored 'General case' 0 C--N 1.285 -2.232 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.496 -178.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . 0.502 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -107.34 112.93 25.99 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.49 -0.884 . . . . 0.0 109.573 178.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.487 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.9 OUTLIER -59.37 -42.99 95.58 Favored Pre-proline 0 C--N 1.298 -1.635 0 C-N-CA 119.471 -0.892 . . . . 0.0 112.581 -179.407 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.487 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.4 Cg_endo -66.3 -47.88 2.92 Favored 'Trans proline' 0 C--O 1.215 -0.672 0 C-N-CA 120.283 0.655 . . . . 0.0 111.839 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -92.82 10.1 32.42 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.447 -179.57 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.502 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -59.07 -15.8 15.71 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.559 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -77.91 -20.47 73.31 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.421 -1.371 . . . . 0.0 110.377 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.63 -9.34 47.32 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.397 -0.921 . . . . 0.0 110.694 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 104.54 10.78 32.57 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.688 -1.244 . . . . 0.0 110.67 179.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.51 105.05 1.72 Allowed 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 118.989 -1.085 . . . . 0.0 110.952 179.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.422 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 43.9 pttt -135.54 168.34 19.43 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.7 -0.8 . . . . 0.0 111.29 -179.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.04 153.0 24.93 Favored Glycine 0 N--CA 1.485 1.941 0 C-N-CA 119.372 -1.394 . . . . 0.0 111.053 -179.05 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -155.91 145.9 21.39 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 119.646 -0.822 . . . . 0.0 110.3 179.26 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.8 p -141.62 131.29 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.247 0 C-N-CA 118.955 -1.098 . . . . 0.0 110.652 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 3.0 m -109.46 105.15 14.38 Favored 'General case' 0 N--CA 1.493 1.722 0 C-N-CA 119.677 -0.809 . . . . 0.0 110.825 179.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.4 HG12 ' N ' ' A' ' 97' ' ' ASN . 37.2 t -79.68 152.93 4.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 C-N-CA 118.553 -1.259 . . . . 0.0 110.526 -179.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.4 ' N ' HG12 ' A' ' 96' ' ' VAL . 60.9 m-20 . . . . . 0 C--N 1.307 -1.277 0 CA-C-O 116.284 -1.817 . . . . 0.0 110.932 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.127 0 N-CA-C 110.071 -0.344 . . . . 0.0 110.071 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -113.92 122.41 46.9 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 120.076 -0.649 . . . . 0.0 110.856 179.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.3 t -110.4 150.11 13.06 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 119.959 -0.696 . . . . 0.0 110.393 179.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 10.9 mtpt -124.6 117.69 24.87 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.865 -179.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 8.2 mt -76.74 109.1 10.24 Favored 'General case' 0 C--N 1.31 -1.141 0 C-N-CA 119.067 -1.053 . . . . 0.0 109.995 178.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 117.42 162.01 12.36 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 -179.021 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.442 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 59.4 p -84.61 -111.51 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.813 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -151.5 8.31 0.52 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.078 -1.049 . . . . 0.0 111.155 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 p-10 -167.75 -42.33 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.124 -1.03 . . . . 0.0 111.117 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.46 61.99 0.19 Allowed Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.098 -1.525 . . . . 0.0 110.631 -179.911 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' A' ' 7' ' ' SER . . . -156.18 125.97 1.72 Allowed Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.342 -1.408 . . . . 0.0 110.229 179.788 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.3 mt -99.57 95.5 7.03 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.534 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.9 m -144.82 155.37 14.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 119.111 -1.035 . . . . 0.0 110.415 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.425 ' O ' ' O ' ' A' ' 16' ' ' PRO . 5.4 m-85 -78.71 111.99 15.37 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 178.311 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.3 m -114.44 108.59 49.55 Favored Pre-proline 0 C--N 1.303 -1.415 0 C-N-CA 119.734 -0.786 . . . . 0.0 112.007 -177.44 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -67.26 177.9 20.57 Favored 'Cis proline' 0 C--N 1.36 1.149 0 C-N-CA 125.35 -0.688 . . . . 0.0 111.423 -0.205 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 15.7 m -92.62 -47.78 6.93 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.414 -0.914 . . . . 0.0 109.996 179.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -140.63 135.42 31.69 Favored 'General case' 0 C--N 1.305 -1.354 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.756 179.279 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.479 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 13.5 p90 -153.69 146.61 24.44 Favored 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.608 -1.237 . . . . 0.0 111.545 -179.208 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.44 HG23 ' H ' ' A' ' 20' ' ' THR . 0.6 OUTLIER -91.43 151.25 20.88 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.531 -0.868 . . . . 0.0 111.042 179.579 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.4 158.82 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 C-N-CA 119.559 -0.856 . . . . 0.0 110.933 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.532 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -73.09 137.28 45.15 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.176 -1.01 . . . . 0.0 110.347 179.515 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -59.91 78.82 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.41 0 C-N-CA 119.353 -0.939 . . . . 0.0 110.934 -179.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.532 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 150.39 18.38 0.07 OUTLIER Glycine 0 N--CA 1.489 2.17 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -96.18 158.42 15.45 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.577 -179.855 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 40.5 mttm -93.5 120.29 33.59 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.093 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.9 mt -105.52 120.52 56.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.68 179.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 50.1 p -118.42 116.6 27.05 Favored 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.64 -0.824 . . . . 0.0 112.283 -178.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -87.87 120.31 29.07 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.508 -0.877 . . . . 0.0 109.022 178.336 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 13.0 ttmt -112.21 136.2 51.93 Favored 'General case' 0 N--CA 1.492 1.658 0 C-N-CA 119.697 -0.801 . . . . 0.0 111.75 -178.475 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.899 ' ND2' HD11 ' A' ' 61' ' ' LEU . 3.8 m120 -80.31 115.57 19.92 Favored 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.157 178.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.632 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.1 OUTLIER -100.22 -31.38 11.4 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.257 -0.977 . . . . 0.0 112.141 -178.995 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.632 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 169.02 120.74 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 C-N-CA 118.882 -1.127 . . . . 0.0 111.359 -179.75 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 131.57 -1.19 5.19 Favored Glycine 0 N--CA 1.496 2.667 0 C-N-CA 119.661 -1.257 . . . . 0.0 111.187 179.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -46.84 163.97 0.23 Allowed Pre-proline 0 N--CA 1.487 1.377 0 C-N-CA 118.942 -1.103 . . . . 0.0 110.028 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_endo -75.74 143.0 75.66 Favored 'Cis proline' 0 C--O 1.212 -0.81 0 C-N-CA 124.306 -1.122 . . . . 0.0 112.45 -0.427 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 31.7 m-70 -113.92 160.72 18.48 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.769 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.56 ' ND2' ' CG2' ' A' ' 40' ' ' VAL . 8.9 t30 -145.69 133.28 20.92 Favored 'General case' 0 C--N 1.302 -1.489 0 C-N-CA 119.426 -0.909 . . . . 0.0 109.945 179.077 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.821 ' N ' HD12 ' A' ' 39' ' ' ILE . 1.7 mp -115.19 121.41 67.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 C-N-CA 119.767 -0.773 . . . . 0.0 111.405 -179.562 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.56 ' CG2' ' ND2' ' A' ' 38' ' ' ASN . 1.7 t -139.07 154.8 26.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.068 179.454 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -106.56 134.34 49.85 Favored 'General case' 0 N--CA 1.49 1.533 0 C-N-CA 119.287 -0.965 . . . . 0.0 112.019 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.502 ' C ' ' H ' ' A' ' 44' ' ' ASP . 4.3 t0 -74.32 107.0 6.21 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.188 -1.005 . . . . 0.0 109.179 178.654 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -69.32 33.83 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.677 -0.809 . . . . 0.0 111.833 -178.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.502 ' H ' ' C ' ' A' ' 42' ' ' ASP . 14.9 m-20 -110.23 -9.98 14.65 Favored 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 119.98 -0.688 . . . . 0.0 110.855 179.422 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -142.5 -5.8 0.93 Allowed 'General case' 0 N--CA 1.497 1.889 0 C-N-CA 118.865 -1.134 . . . . 0.0 111.634 179.609 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -69.98 146.17 94.88 Favored Pre-proline 0 C--N 1.286 -2.153 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 178.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -51.48 159.32 3.26 Favored 'Trans proline' 0 C--O 1.215 -0.637 0 C-N-CA 120.712 0.941 . . . . 0.0 112.323 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -89.17 40.4 0.98 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 119.722 -0.791 . . . . 0.0 110.374 179.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -143.18 -44.63 0.05 OUTLIER Glycine 0 N--CA 1.487 2.092 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 179.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.528 ' O ' HG12 ' A' ' 50' ' ' VAL . 50.9 t -83.14 86.29 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 119.384 -0.926 . . . . 0.0 110.18 179.343 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -45.0 139.59 3.07 Favored 'General case' 0 C--N 1.307 -1.271 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.634 -179.82 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.99 -28.48 55.1 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.679 179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -66.33 -15.56 63.35 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.379 -0.928 . . . . 0.0 111.13 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.95 -42.89 17.08 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.838 179.81 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -93.32 -41.59 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.212 -179.779 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 42.9 m -48.53 165.98 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.154 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.594 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.3 mt-30 -138.23 78.55 33.55 Favored Pre-proline 0 N--CA 1.487 1.412 0 CA-C-N 115.727 -0.669 . . . . 0.0 110.561 -179.593 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -61.67 -22.91 75.51 Favored 'Trans proline' 0 C--O 1.215 -0.629 0 C-N-CA 121.405 1.403 . . . . 0.0 112.003 -179.068 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -76.08 119.83 20.56 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.122 -1.031 . . . . 0.0 110.585 179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 74.2 m-85 -55.86 168.56 0.44 Allowed 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.126 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.899 HD11 ' ND2' ' A' ' 31' ' ' ASN . 0.4 OUTLIER -144.61 141.91 29.76 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.189 179.329 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.587 ' N ' HD12 ' A' ' 61' ' ' LEU . 4.1 p-10 -146.51 32.7 0.96 Allowed 'General case' 0 N--CA 1.485 1.314 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.198 -179.263 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -97.26 112.26 4.43 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.482 -1.342 . . . . 0.0 110.539 -179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.15 111.6 1.58 Allowed 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.22 -0.992 . . . . 0.0 110.571 179.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 96.7 -12.5 66.02 Favored Glycine 0 N--CA 1.489 2.23 0 C-N-CA 119.464 -1.351 . . . . 0.0 110.203 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -63.04 151.22 40.49 Favored 'General case' 0 N--CA 1.486 1.366 0 C-N-CA 119.335 -0.946 . . . . 0.0 110.302 179.689 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.73 166.72 23.88 Favored 'General case' 0 N--CA 1.485 1.299 0 C-N-CA 119.214 -0.995 . . . . 0.0 111.511 -179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.594 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 31.6 t80 -135.83 138.32 42.41 Favored 'General case' 0 N--CA 1.484 1.242 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.524 179.246 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.402 ' CD ' ' H ' ' A' ' 69' ' ' GLU . 2.0 mp0 -98.16 152.94 18.82 Favored 'General case' 0 N--CA 1.491 1.579 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.885 -178.651 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -149.61 133.69 8.68 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.227 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.34 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.6 m -125.92 100.3 6.32 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.304 -179.23 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.468 ' CD1' HG11 ' A' ' 94' ' ' VAL . 54.2 mt -81.0 165.43 21.72 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.173 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.715 ' O ' HG22 ' A' ' 73' ' ' THR . 81.1 m -150.43 31.01 0.67 Allowed 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 118.608 -1.237 . . . . 0.0 112.589 -178.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.456 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 2.5 mt-10 -143.39 124.28 14.3 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 118.781 -1.168 . . . . 0.0 110.35 178.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 14.4 pttt -58.69 128.14 35.72 Favored 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.221 -0.992 . . . . 0.0 111.281 -179.271 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 156.31 174.59 26.28 Favored Glycine 0 N--CA 1.488 2.116 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.223 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -106.79 105.35 15.34 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.914 -0.715 . . . . 0.0 110.281 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.463 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.8 m-30 -89.58 156.54 18.54 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 118.591 -1.244 . . . . 0.0 107.981 -179.261 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 71.1 mttt -115.19 127.77 55.74 Favored 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.165 -1.014 . . . . 0.0 112.782 -178.68 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.469 ' O ' ' N ' ' A' ' 92' ' ' GLY . 1.7 p90 -138.14 157.5 46.19 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.834 -0.746 . . . . 0.0 109.526 176.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 33.8 p90 -169.8 -175.23 2.03 Favored 'General case' 0 C--N 1.283 -2.322 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.523 -178.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -110.14 116.31 31.31 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.398 179.265 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.563 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tp10 -69.67 -39.34 11.46 Favored Pre-proline 0 C--N 1.305 -1.358 0 C-N-CA 119.518 -0.873 . . . . 0.0 112.435 -179.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.563 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 4.4 Cg_exo -66.17 -41.92 11.84 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 120.394 0.729 . . . . 0.0 111.268 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . 0.435 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.8 m80 -97.71 18.91 14.57 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.518 -0.873 . . . . 0.0 110.638 179.71 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -64.37 0.21 1.09 Allowed 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.853 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -94.31 -13.38 54.3 Favored Glycine 0 N--CA 1.487 2.081 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.449 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.45 -47.55 6.81 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.377 -0.929 . . . . 0.0 110.57 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 141.27 18.22 0.35 Allowed Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.629 -1.272 . . . . 0.0 110.271 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 12.8 mtp -71.55 100.41 2.25 Favored 'General case' 0 N--CA 1.484 1.239 0 C-N-CA 119.259 -0.977 . . . . 0.0 111.16 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.485 ' HD2' ' H ' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -129.17 148.48 51.11 Favored 'General case' 0 N--CA 1.495 1.792 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.221 179.489 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.469 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -136.29 153.78 21.7 Favored Glycine 0 N--CA 1.499 2.889 0 C-N-CA 119.508 -1.33 . . . . 0.0 112.211 -178.057 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -154.68 149.37 26.49 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 120.314 -0.555 . . . . 0.0 109.937 179.122 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.708 HG13 ' O ' ' A' ' 94' ' ' VAL . 12.2 p -139.32 114.88 8.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 C-N-CA 119.079 -1.048 . . . . 0.0 111.07 -179.327 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 16.0 m -89.84 93.55 9.47 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.096 -1.042 . . . . 0.0 110.616 179.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 14.0 t -78.77 148.31 6.23 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 C-N-CA 119.049 -1.06 . . . . 0.0 110.617 -179.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 17.8 p30 . . . . . 0 C--N 1.307 -1.277 0 CA-C-O 116.309 -1.805 . . . . 0.0 110.818 -179.744 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.103 0 CA-C-O 120.873 0.368 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -107.86 120.63 42.81 Favored 'General case' 0 N--CA 1.486 1.365 0 C-N-CA 120.033 -0.667 . . . . 0.0 110.687 179.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.8 t -98.52 122.35 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.651 179.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.7 mptt -90.0 114.72 26.62 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.983 -179.762 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.448 HD11 ' HB3' ' A' ' 29' ' ' PHE . 5.3 mp -80.45 100.03 8.3 Favored 'General case' 0 C--N 1.314 -0.96 0 C-N-CA 118.572 -1.251 . . . . 0.0 109.62 178.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.461 ' C ' HD21 ' A' ' 32' ' ' ASN . . . 122.6 146.6 7.25 Favored Glycine 0 N--CA 1.486 2.006 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 -178.718 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.55 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 53.5 p -74.48 -173.14 1.67 Allowed 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.439 -0.905 . . . . 0.0 110.709 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -90.95 -6.77 53.61 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.131 -1.028 . . . . 0.0 111.685 -179.183 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -173.38 77.93 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.408 0 C-N-CA 118.616 -1.233 . . . . 0.0 112.273 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 85.45 70.75 1.32 Allowed Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.269 -1.444 . . . . 0.0 111.235 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.447 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . -176.37 146.81 8.2 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.397 -1.382 . . . . 0.0 110.187 179.215 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.0 mt -124.34 91.8 3.53 Favored 'General case' 0 N--CA 1.491 1.597 0 C-N-CA 119.995 -0.682 . . . . 0.0 110.357 179.731 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 1.9 m -145.38 156.27 13.36 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.022 0 C-N-CA 118.996 -1.082 . . . . 0.0 111.075 -179.607 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -78.59 111.54 14.77 Favored 'General case' 0 C--N 1.303 -1.43 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 178.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -114.5 108.34 49.8 Favored Pre-proline 0 C--N 1.304 -1.4 0 C-N-CA 119.566 -0.854 . . . . 0.0 112.232 -177.106 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -68.04 173.48 37.72 Favored 'Cis proline' 0 C--N 1.359 1.085 0 C-N-CA 125.45 -0.646 . . . . 0.0 111.503 -0.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 p -88.9 -45.22 9.87 Favored 'General case' 0 C--N 1.306 -1.295 0 C-N-CA 119.307 -0.957 . . . . 0.0 109.76 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -140.76 140.5 34.81 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.55 179.114 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 30.0 p90 -162.41 147.3 12.34 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 118.356 -1.338 . . . . 0.0 111.598 -179.154 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.412 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -93.24 151.71 19.64 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.561 -0.856 . . . . 0.0 111.275 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -146.06 169.24 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.365 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.809 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -83.76 146.48 28.14 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.327 -0.949 . . . . 0.0 110.257 179.596 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.27 71.26 0.42 Allowed 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.32 -0.952 . . . . 0.0 110.848 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 165.51 11.08 0.03 OUTLIER Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -101.92 145.89 28.61 Favored 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.969 -0.692 . . . . 0.0 110.841 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.523 ' C ' HD12 ' A' ' 27' ' ' ILE . 19.1 mttm -84.97 134.87 34.23 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.288 -0.965 . . . . 0.0 110.671 179.79 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.523 HD12 ' C ' ' A' ' 26' ' ' LYS . 1.5 mp -115.94 118.31 58.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 179.679 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 36.2 p -110.6 121.51 45.49 Favored 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 119.471 -0.891 . . . . 0.0 113.299 -177.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.448 ' HB3' HD11 ' A' ' 5' ' ' LEU . 70.6 m-85 -84.88 111.12 19.37 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.051 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 45.5 tttt -109.9 131.62 54.89 Favored 'General case' 0 N--CA 1.496 1.83 0 C-N-CA 119.431 -0.907 . . . . 0.0 111.76 -177.2 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.934 ' ND2' HD11 ' A' ' 61' ' ' LEU . 7.8 m-20 -90.06 117.39 28.82 Favored 'General case' 0 C--N 1.294 -1.82 0 C-N-CA 119.335 -0.946 . . . . 0.0 111.329 -179.536 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.55 ' ND2' ' O ' ' A' ' 7' ' ' SER . 25.3 p-10 -101.01 -29.54 12.12 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.968 179.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.522 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 174.09 137.59 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.373 -0.931 . . . . 0.0 110.935 -179.699 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.403 ' O ' ' C ' ' A' ' 35' ' ' PHE . . . 122.22 -6.99 9.98 Favored Glycine 0 N--CA 1.498 2.774 0 C-N-CA 119.524 -1.322 . . . . 0.0 111.626 178.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.403 ' C ' ' O ' ' A' ' 34' ' ' GLY . 0.0 OUTLIER -45.87 163.1 0.23 Allowed Pre-proline 0 N--CA 1.485 1.312 0 C-N-CA 118.423 -1.311 . . . . 0.0 109.908 -179.834 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -76.76 138.43 54.24 Favored 'Cis proline' 0 C--O 1.213 -0.734 0 C-N-CA 124.122 -1.199 . . . . 0.0 112.443 -0.585 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 32.5 m-70 -102.28 179.79 4.21 Favored 'General case' 0 N--CA 1.488 1.462 0 C-N-CA 119.751 -0.78 . . . . 0.0 111.106 179.576 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.8 t30 -159.56 142.11 13.76 Favored 'General case' 0 C--N 1.301 -1.522 0 CA-C-N 115.54 -0.754 . . . . 0.0 109.782 179.293 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -135.11 117.12 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.045 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.4 t -139.25 150.24 22.96 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 C-N-CA 119.824 -0.75 . . . . 0.0 109.386 179.043 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -99.3 135.08 41.24 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.856 -178.816 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.539 ' C ' ' H ' ' A' ' 44' ' ' ASP . 59.6 t0 -70.62 104.36 2.79 Favored 'General case' 0 C--N 1.304 -1.386 0 C-N-CA 119.284 -0.966 . . . . 0.0 109.519 178.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.465 ' CD ' ' N ' ' A' ' 43' ' ' GLU . 0.0 OUTLIER -68.42 27.27 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 119.789 -0.765 . . . . 0.0 111.785 -179.229 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.539 ' H ' ' C ' ' A' ' 42' ' ' ASP . 73.3 m-20 -111.26 -7.02 14.46 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.913 -0.715 . . . . 0.0 111.079 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 9.6 mm-40 -143.82 -1.46 0.99 Allowed 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 119.218 -0.993 . . . . 0.0 111.721 -179.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -68.56 144.9 96.76 Favored Pre-proline 0 C--N 1.285 -2.21 0 C-N-CA 119.269 -0.972 . . . . 0.0 108.726 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -59.08 160.5 18.61 Favored 'Trans proline' 0 C--O 1.216 -0.603 0 C-N-CA 121.062 1.175 . . . . 0.0 112.243 -178.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -75.63 145.16 41.29 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.567 -0.853 . . . . 0.0 109.66 178.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 95.26 -59.13 1.65 Allowed Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.238 -1.458 . . . . 0.0 109.849 -179.439 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 11.4 t -68.52 87.18 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.137 0 C-N-CA 119.114 -1.035 . . . . 0.0 110.339 179.509 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -44.86 154.51 0.13 Allowed 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.449 -0.9 . . . . 0.0 111.001 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -95.25 -25.66 16.26 Favored 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.332 179.385 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -81.4 -15.93 53.69 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.611 -0.836 . . . . 0.0 110.774 179.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.18 -21.61 46.16 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.568 -0.853 . . . . 0.0 111.408 -179.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.5 pt -111.04 -19.22 7.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 C-N-CA 119.753 -0.779 . . . . 0.0 111.312 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.7 m -79.58 169.47 17.97 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.575 -0.85 . . . . 0.0 111.81 -179.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.634 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.8 OUTLIER -150.03 73.24 9.42 Favored Pre-proline 0 C--N 1.306 -1.32 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.785 179.113 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_exo -56.74 -26.45 65.97 Favored 'Trans proline' 0 C--O 1.215 -0.644 0 C-N-CA 121.501 1.467 . . . . 0.0 111.947 -178.574 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -55.35 102.82 0.08 Allowed 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 118.94 -1.104 . . . . 0.0 110.145 179.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 38.1 m-85 -42.46 161.75 0.02 OUTLIER 'General case' 0 C--N 1.309 -1.17 0 C-N-CA 119.581 -0.848 . . . . 0.0 111.103 -179.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.934 HD11 ' ND2' ' A' ' 31' ' ' ASN . 0.8 OUTLIER -143.3 147.8 35.32 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.614 -0.835 . . . . 0.0 110.459 -179.977 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.504 ' N ' HD12 ' A' ' 61' ' ' LEU . 1.1 p30 -145.01 20.99 1.6 Allowed 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.351 -0.939 . . . . 0.0 110.952 -179.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -77.81 119.51 5.27 Favored Glycine 0 N--CA 1.487 2.034 0 C-N-CA 119.182 -1.485 . . . . 0.0 110.199 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -73.11 106.15 4.85 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.217 -0.993 . . . . 0.0 110.276 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.72 -10.72 49.35 Favored Glycine 0 N--CA 1.489 2.229 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -68.11 154.85 40.82 Favored 'General case' 0 C--N 1.307 -1.254 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.256 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.87 170.04 16.64 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 119.133 -1.027 . . . . 0.0 111.335 -179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.634 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 40.7 t80 -135.24 142.49 45.98 Favored 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.487 179.412 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -113.78 151.19 32.35 Favored 'General case' 0 N--CA 1.497 1.9 0 C-N-CA 119.404 -0.918 . . . . 0.0 112.335 -178.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.6 p -153.78 132.07 2.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 CA-C-N 115.324 -0.853 . . . . 0.0 109.34 178.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.7 m -119.06 94.5 4.46 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 119.749 -0.78 . . . . 0.0 111.493 -179.153 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.5 mt -79.72 157.77 27.09 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 118.98 -1.088 . . . . 0.0 109.224 178.865 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.5 p -150.63 52.68 0.88 Allowed 'General case' 0 C--N 1.3 -1.587 0 C-N-CA 118.536 -1.266 . . . . 0.0 111.949 -178.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.4 ' O ' ' C ' ' A' ' 75' ' ' LYS . 2.9 tt0 -150.73 99.41 2.73 Favored 'General case' 0 C--N 1.3 -1.566 0 C-N-CA 118.73 -1.188 . . . . 0.0 109.934 178.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 74' ' ' GLU . 0.8 OUTLIER -39.87 108.96 0.1 Allowed 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.255 -178.908 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.51 -148.46 8.43 Favored Glycine 0 N--CA 1.485 1.921 0 C-N-CA 119.29 -1.433 . . . . 0.0 110.302 -179.82 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -141.49 129.99 22.58 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.472 -0.891 . . . . 0.0 111.218 -179.799 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.61 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.6 OUTLIER -119.64 161.6 20.4 Favored 'General case' 0 C--N 1.305 -1.344 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 179.426 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 32.2 mttt -128.98 131.96 47.5 Favored 'General case' 0 N--CA 1.49 1.567 0 C-N-CA 119.187 -1.005 . . . . 0.0 111.958 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.544 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -139.25 158.75 43.62 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.829 177.712 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -167.78 -175.11 2.64 Favored 'General case' 0 C--N 1.288 -2.079 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.989 -179.542 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -111.98 119.75 39.54 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.913 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.576 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.3 tt0 -65.41 -42.37 57.35 Favored Pre-proline 0 N--CA 1.486 1.326 0 C-N-CA 119.931 -0.708 . . . . 0.0 112.724 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.576 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.1 Cg_endo -69.45 -48.2 0.84 Allowed 'Trans proline' 0 C--O 1.216 -0.615 0 C-N-CA 121.108 1.205 . . . . 0.0 112.035 -179.381 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -90.03 10.39 24.31 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.144 -1.022 . . . . 0.0 111.647 -179.546 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.08 -35.45 62.09 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 118.906 -1.117 . . . . 0.0 110.475 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -62.23 -21.14 61.53 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.199 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -85.3 -17.29 37.31 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.278 179.805 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.23 23.79 9.42 Favored Glycine 0 N--CA 1.489 2.18 0 C-N-CA 119.716 -1.23 . . . . 0.0 110.731 179.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -75.95 101.01 5.04 Favored 'General case' 0 C--N 1.308 -1.203 0 C-N-CA 119.131 -1.028 . . . . 0.0 110.979 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -124.32 149.67 46.31 Favored 'General case' 0 N--CA 1.49 1.56 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.751 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.463 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -137.76 149.13 20.25 Favored Glycine 0 N--CA 1.496 2.655 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.352 -178.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 -155.63 148.87 24.7 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 120.004 -0.678 . . . . 0.0 110.395 179.45 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.493 HG13 ' O ' ' A' ' 94' ' ' VAL . 7.1 p -139.08 128.99 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 C-N-CA 118.823 -1.151 . . . . 0.0 110.81 179.708 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.9 m -104.91 98.55 8.25 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.159 179.32 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 42.4 t -79.13 150.63 5.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 C-N-CA 118.632 -1.227 . . . . 0.0 110.453 -178.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 89.2 m-20 . . . . . 0 N--CA 1.489 1.489 0 CA-C-O 116.333 -1.794 . . . . 0.0 110.894 -179.761 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.128 0 N-CA-C 110.103 -0.332 . . . . 0.0 110.103 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -112.62 118.67 35.71 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 120.029 -0.668 . . . . 0.0 110.535 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 83.9 t -102.34 119.9 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.373 0 C-N-CA 119.628 -0.829 . . . . 0.0 110.705 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 8.5 mptt -87.12 110.28 20.01 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 119.587 -0.845 . . . . 0.0 110.959 -179.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 11.9 mt -76.27 104.37 6.76 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 118.785 -1.166 . . . . 0.0 109.753 177.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 104.23 107.59 3.21 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 110.237 -1.145 . . . . 0.0 110.237 -179.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.1 p -59.55 139.16 57.39 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.442 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -43.79 -52.44 6.65 Favored 'General case' 0 N--CA 1.486 1.34 0 C-N-CA 119.318 -0.953 . . . . 0.0 110.926 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -147.44 64.15 1.14 Allowed 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.339 -0.944 . . . . 0.0 110.988 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -144.61 -76.46 0.03 OUTLIER Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.479 -1.343 . . . . 0.0 110.039 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -162.03 -165.89 19.8 Favored Glycine 0 N--CA 1.486 2.02 0 C-N-CA 119.56 -1.305 . . . . 0.0 109.917 179.565 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.0 mt -99.49 101.93 13.33 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.488 -0.885 . . . . 0.0 110.024 179.569 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.2 m -149.71 160.41 4.99 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 C-N-CA 119.064 -1.054 . . . . 0.0 110.955 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.456 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 59.3 m-85 -79.02 113.11 16.88 Favored 'General case' 0 C--N 1.298 -1.646 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 176.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 14.9 m -114.74 110.87 46.24 Favored Pre-proline 0 N--CA 1.485 1.293 0 C-N-CA 119.315 -0.954 . . . . 0.0 111.935 -177.707 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.44 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.9 Cg_endo -65.56 176.1 20.2 Favored 'Cis proline' 0 C--N 1.363 1.324 0 C-N-CA 125.254 -0.728 . . . . 0.0 111.751 -0.254 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.2 p -96.34 -60.86 1.53 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.467 179.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 60.7 p -123.74 136.69 54.59 Favored 'General case' 0 N--CA 1.489 1.518 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.752 179.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.5 p90 -163.08 146.45 10.75 Favored 'General case' 0 N--CA 1.483 1.197 0 C-N-CA 118.583 -1.247 . . . . 0.0 111.443 -179.347 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.428 HG23 ' H ' ' A' ' 20' ' ' THR . 0.8 OUTLIER -89.62 153.49 20.71 Favored 'General case' 0 C--N 1.305 -1.364 0 C-N-CA 119.445 -0.902 . . . . 0.0 111.075 179.92 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 12.3 m -145.87 176.46 1.83 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 C-N-CA 119.481 -0.888 . . . . 0.0 110.641 179.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -91.03 150.79 21.29 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.589 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.12 66.85 0.87 Allowed 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.483 -0.887 . . . . 0.0 110.997 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.45 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 166.75 11.73 0.03 OUTLIER Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.45 ' H ' ' H ' ' A' ' 24' ' ' GLY . 25.9 tt0 -97.99 155.2 17.21 Favored 'General case' 0 C--N 1.307 -1.276 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.078 -179.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -95.52 133.47 39.49 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.597 -0.841 . . . . 0.0 111.033 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.7 mt -115.3 114.53 46.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 C-N-CA 120.022 -0.671 . . . . 0.0 109.614 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 73.2 p -106.87 117.04 32.99 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.782 -0.767 . . . . 0.0 112.417 -178.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 68.2 m-85 -84.17 107.02 16.26 Favored 'General case' 0 C--N 1.305 -1.333 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 9.6 ttmt -96.59 142.98 28.0 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.054 -1.058 . . . . 0.0 111.295 -177.512 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.553 ' OD1' ' CD1' ' A' ' 35' ' ' PHE . 19.9 t-20 -100.12 121.23 41.09 Favored 'General case' 0 C--N 1.295 -1.785 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.509 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 2.9 p-10 -132.83 -8.79 3.12 Favored 'General case' 0 N--CA 1.49 1.569 0 C-N-CA 118.961 -1.095 . . . . 0.0 112.13 -179.571 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -168.61 132.25 1.49 Allowed 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 117.986 -1.485 . . . . 0.0 112.711 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 77.79 59.99 2.87 Favored Glycine 0 N--CA 1.49 2.296 0 C-N-CA 119.868 -1.158 . . . . 0.0 113.805 177.08 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.553 ' CD1' ' OD1' ' A' ' 31' ' ' ASN . 0.0 OUTLIER -97.06 165.12 16.42 Favored Pre-proline 0 N--CA 1.493 1.685 0 C-N-CA 118.978 -1.089 . . . . 0.0 108.382 176.86 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.5 Cg_endo -77.97 147.41 83.33 Favored 'Cis proline' 0 C--O 1.214 -0.685 0 C-N-CA 124.615 -0.994 . . . . 0.0 112.938 -0.731 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.0 m-70 -103.0 175.21 5.55 Favored 'General case' 0 N--CA 1.488 1.474 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.299 177.809 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.603 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.3 OUTLIER -150.81 124.71 9.21 Favored 'General case' 0 C--N 1.301 -1.504 0 C-N-CA 119.205 -0.998 . . . . 0.0 110.764 179.703 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.603 ' N ' HD22 ' A' ' 38' ' ' ASN . 0.1 OUTLIER -107.85 115.68 49.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 C-N-CA 119.731 -0.788 . . . . 0.0 110.71 179.78 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.8 t -140.23 141.7 32.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.194 179.309 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 28.3 m-85 -99.73 122.24 42.43 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 119.457 -0.897 . . . . 0.0 111.864 -179.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.531 ' C ' ' H ' ' A' ' 44' ' ' ASP . 0.7 OUTLIER -64.96 111.86 3.04 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.399 -0.92 . . . . 0.0 110.029 179.183 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -66.64 11.12 0.1 Allowed 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.134 -1.026 . . . . 0.0 111.108 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.531 ' H ' ' C ' ' A' ' 42' ' ' ASP . 50.2 m-20 -93.35 -15.35 25.82 Favored 'General case' 0 N--CA 1.483 1.216 0 C-N-CA 119.318 -0.953 . . . . 0.0 111.185 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 25.8 mt-10 -141.05 50.22 1.64 Allowed 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 119.635 -0.826 . . . . 0.0 110.495 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -128.41 144.86 53.54 Favored Pre-proline 0 N--CA 1.488 1.463 0 CA-C-N 115.248 -0.887 . . . . 0.0 108.931 179.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.3 Cg_exo -48.28 150.65 5.15 Favored 'Trans proline' 0 C--O 1.215 -0.633 0 C-N-CA 120.831 1.02 . . . . 0.0 111.959 -179.384 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.53 47.65 0.85 Allowed 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.926 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -157.78 -44.28 0.02 OUTLIER Glycine 0 N--CA 1.489 2.182 0 C-N-CA 119.456 -1.354 . . . . 0.0 109.975 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 60.6 t -83.57 84.42 1.89 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.313 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -44.48 142.48 1.59 Allowed 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 119.841 -0.743 . . . . 0.0 111.191 -179.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -86.9 -9.74 54.98 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.872 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -85.78 -11.99 52.09 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.382 -0.927 . . . . 0.0 110.853 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.29 -36.24 12.67 Favored 'General case' 0 C--N 1.304 -1.38 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.014 -179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -89.91 -21.43 6.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 C-N-CA 119.253 -0.979 . . . . 0.0 111.191 -179.774 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 51.6 m -74.43 178.19 5.42 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.415 -0.914 . . . . 0.0 111.142 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.636 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.3 pm0 -159.17 77.37 3.06 Favored Pre-proline 0 C--N 1.303 -1.424 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.018 179.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.442 ' HA ' HD21 ' A' ' 38' ' ' ASN . 2.8 Cg_exo -57.78 -0.41 0.39 Allowed 'Trans proline' 0 C--O 1.215 -0.67 0 C-N-CA 121.09 1.193 . . . . 0.0 111.575 -178.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.489 ' H ' ' C ' ' A' ' 57' ' ' GLN . 2.7 mm-40 -80.8 92.39 6.07 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.17 -1.012 . . . . 0.0 110.046 178.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.401 ' O ' ' O ' ' A' ' 59' ' ' GLU . 38.3 m-85 -41.02 162.19 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.521 -179.388 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -135.07 108.63 7.92 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.488 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -104.72 3.51 31.47 Favored 'General case' 0 N--CA 1.487 1.39 0 C-N-CA 119.907 -0.717 . . . . 0.0 110.956 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -73.64 117.74 5.88 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.378 -1.391 . . . . 0.0 110.558 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -59.38 108.68 0.74 Allowed 'General case' 0 C--N 1.305 -1.34 0 C-N-CA 119.638 -0.825 . . . . 0.0 111.012 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 99.48 -6.21 59.11 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 119.516 -1.326 . . . . 0.0 110.817 179.595 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -62.23 149.98 40.28 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 118.996 -1.081 . . . . 0.0 110.674 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -140.8 164.44 30.21 Favored 'General case' 0 N--CA 1.488 1.445 0 C-N-CA 119.421 -0.912 . . . . 0.0 111.625 -179.743 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.636 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 17.5 t80 -136.05 130.16 33.06 Favored 'General case' 0 N--CA 1.49 1.538 0 CA-C-N 115.62 -0.718 . . . . 0.0 109.343 179.482 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -94.82 154.38 17.28 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 119.124 -1.03 . . . . 0.0 112.236 -178.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.2 t -152.62 130.97 2.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 114.952 -1.022 . . . . 0.0 108.735 179.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.3 m -121.04 103.35 8.97 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.68 -178.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 65.7 mt -86.59 158.41 19.51 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.247 -0.981 . . . . 0.0 109.751 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -151.03 40.94 0.73 Allowed 'General case' 0 C--N 1.296 -1.727 0 C-N-CA 118.845 -1.142 . . . . 0.0 111.614 -179.417 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 14.3 mm-40 -142.97 102.18 3.96 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 118.787 -1.165 . . . . 0.0 110.801 179.453 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 7.5 mttm -43.24 114.44 0.62 Allowed 'General case' 0 C--N 1.303 -1.422 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.18 -179.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 173.04 -145.36 8.36 Favored Glycine 0 N--CA 1.486 2.0 0 C-N-CA 119.395 -1.383 . . . . 0.0 110.038 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.7 127.83 17.59 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.444 -0.902 . . . . 0.0 110.893 -179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.566 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -114.72 167.14 11.02 Favored 'General case' 0 N--CA 1.481 1.12 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.123 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 20.4 mmtp -134.96 123.47 23.4 Favored 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.421 -0.912 . . . . 0.0 112.338 -178.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.543 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.1 p90 -132.72 161.73 33.25 Favored 'General case' 0 N--CA 1.483 1.201 0 C-N-CA 119.774 -0.77 . . . . 0.0 110.359 178.033 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 34.3 p90 -170.35 -174.08 1.61 Allowed 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.382 -178.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . 0.443 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.6 t -113.27 134.51 54.56 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 119.803 -0.759 . . . . 0.0 110.527 179.483 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.5 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.3 mt-10 -75.61 -46.16 4.21 Favored Pre-proline 0 C--N 1.308 -1.224 0 C-N-CA 119.571 -0.852 . . . . 0.0 112.927 -179.376 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.5 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -67.62 -41.97 7.66 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 120.901 1.067 . . . . 0.0 112.266 -179.192 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -93.99 20.71 7.49 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.447 -179.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.443 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -74.27 -11.74 60.36 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.126 -1.03 . . . . 0.0 110.548 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -74.83 -18.48 80.11 Favored Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.345 -1.407 . . . . 0.0 110.247 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.72 -49.48 5.59 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.54 -0.864 . . . . 0.0 110.539 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 143.91 23.55 0.16 Allowed Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.554 -1.308 . . . . 0.0 110.467 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.7 103.54 3.1 Favored 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.052 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.456 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 6.5 mtpp -130.93 168.49 17.23 Favored 'General case' 0 N--CA 1.494 1.748 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.384 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.525 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -153.62 147.29 16.5 Favored Glycine 0 N--CA 1.493 2.492 0 C-N-CA 119.258 -1.449 . . . . 0.0 111.614 -179.068 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 12.2 tt0 -152.66 146.3 25.05 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 120.004 -0.678 . . . . 0.0 109.979 179.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.463 HG13 ' O ' ' A' ' 94' ' ' VAL . 8.4 p -137.64 127.59 36.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 C-N-CA 119.1 -1.04 . . . . 0.0 111.148 -179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.409 HG22 ' ND2' ' A' ' 97' ' ' ASN . 48.2 m -102.0 98.14 8.39 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.592 -0.843 . . . . 0.0 110.346 179.097 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 43.6 t -79.48 145.63 9.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 118.726 -1.19 . . . . 0.0 110.489 -178.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.409 ' ND2' HG22 ' A' ' 95' ' ' THR . 30.8 m-80 . . . . . 0 C--N 1.306 -1.303 0 CA-C-O 116.337 -1.792 . . . . 0.0 110.649 -179.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.206 0 N-CA-C 110.148 -0.315 . . . . 0.0 110.148 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -105.16 136.48 44.59 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.829 -0.749 . . . . 0.0 110.825 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.8 t -117.87 143.7 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 C-N-CA 119.782 -0.767 . . . . 0.0 110.931 179.679 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 13.3 mttm -113.39 107.57 16.04 Favored 'General case' 0 C--N 1.304 -1.408 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.797 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 2.8 mp -74.69 110.38 8.94 Favored 'General case' 0 C--N 1.307 -1.249 0 C-N-CA 118.527 -1.269 . . . . 0.0 109.701 178.437 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.422 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.01 129.17 6.59 Favored Glycine 0 N--CA 1.487 2.048 0 N-CA-C 110.047 -1.221 . . . . 0.0 110.047 -179.217 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.423 ' O ' ' N ' ' A' ' 9' ' ' ASP . 21.3 p -78.12 141.71 38.56 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.502 -0.879 . . . . 0.0 110.716 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 36.0 m-20 -45.31 -21.59 0.09 Allowed 'General case' 0 N--CA 1.486 1.361 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.117 -179.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.423 ' N ' ' O ' ' A' ' 7' ' ' SER . 0.1 OUTLIER 178.46 81.6 0.01 OUTLIER 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.31 -0.956 . . . . 0.0 110.929 -179.959 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -169.99 -66.65 0.04 OUTLIER Glycine 0 N--CA 1.49 2.242 0 C-N-CA 119.375 -1.393 . . . . 0.0 110.324 179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -167.36 -168.81 30.07 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.406 -1.378 . . . . 0.0 110.384 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 mt -99.34 107.02 19.18 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 119.653 -0.819 . . . . 0.0 110.58 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.9 m -150.03 155.72 7.61 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 C-N-CA 119.139 -1.024 . . . . 0.0 110.996 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.414 ' O ' ' O ' ' A' ' 16' ' ' PRO . 61.2 m-85 -78.54 108.44 11.93 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 178.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 29.3 m -113.15 110.6 50.98 Favored Pre-proline 0 C--N 1.305 -1.359 0 C-N-CA 119.719 -0.792 . . . . 0.0 112.173 -177.619 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.414 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.2 Cg_endo -67.02 174.56 29.76 Favored 'Cis proline' 0 C--N 1.36 1.137 0 C-N-CA 125.337 -0.693 . . . . 0.0 111.626 -0.215 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -95.13 -66.06 0.94 Allowed 'General case' 0 N--CA 1.489 1.493 0 C-N-CA 119.494 -0.883 . . . . 0.0 109.985 179.079 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 19.6 t -114.92 132.53 56.52 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.42 178.89 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.448 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 11.1 p90 -157.25 137.8 13.04 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 118.596 -1.242 . . . . 0.0 111.227 -179.137 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.452 HG23 ' H ' ' A' ' 20' ' ' THR . 0.6 OUTLIER -82.28 161.79 22.52 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.184 -1.006 . . . . 0.0 111.082 -179.935 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 35.3 m -148.97 162.49 4.91 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.296 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.098 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.457 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -77.05 142.6 39.78 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.872 -179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.11 76.76 0.04 OUTLIER 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.587 -0.845 . . . . 0.0 111.066 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.457 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.85 19.77 0.1 OUTLIER Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 23.1 tt0 -102.74 162.39 12.97 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.793 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.1 mtmp? -95.59 150.85 19.89 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.529 -0.869 . . . . 0.0 111.371 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.8 mm -124.26 103.4 12.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.002 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 4.3 p -100.58 114.08 27.45 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.536 -0.866 . . . . 0.0 112.745 -178.205 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -83.8 122.32 28.52 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 177.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 16.3 tttp -121.34 121.56 37.91 Favored 'General case' 0 N--CA 1.502 2.129 0 C-N-CA 119.396 -0.922 . . . . 0.0 112.104 -177.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 0.6 OUTLIER -69.94 113.13 6.87 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.645 -0.822 . . . . 0.0 110.737 179.551 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.487 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.9 t30 -100.34 -27.87 13.25 Favored 'General case' 0 N--CA 1.487 1.409 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.685 -179.282 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.487 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 175.85 141.33 0.06 Allowed 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 119.256 -0.978 . . . . 0.0 111.122 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 103.2 0.12 47.52 Favored Glycine 0 N--CA 1.494 2.505 0 C-N-CA 119.428 -1.368 . . . . 0.0 112.194 178.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.435 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -48.16 162.66 0.32 Allowed Pre-proline 0 N--CA 1.487 1.386 0 C-N-CA 118.013 -1.475 . . . . 0.0 109.614 179.766 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -78.59 154.06 91.76 Favored 'Cis proline' 0 C--O 1.215 -0.635 0 C-N-CA 124.354 -1.102 . . . . 0.0 112.288 -0.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 43.8 m-70 -115.62 -177.02 3.05 Favored 'General case' 0 N--CA 1.493 1.724 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.016 178.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.414 HD22 ' C ' ' A' ' 38' ' ' ASN . 0.2 OUTLIER -159.75 108.54 1.78 Allowed 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.277 -0.969 . . . . 0.0 110.41 178.979 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.2 mp -91.65 121.35 42.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.011 -1.076 . . . . 0.0 111.906 -179.103 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.2 t -134.76 142.37 40.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.716 179.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -99.48 123.82 44.09 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.309 -0.956 . . . . 0.0 111.577 -179.629 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.513 ' C ' ' H ' ' A' ' 44' ' ' ASP . 10.5 t0 -68.75 112.0 5.2 Favored 'General case' 0 C--N 1.307 -1.252 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.911 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -72.67 25.46 0.06 Allowed 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.546 -0.861 . . . . 0.0 111.132 -179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.513 ' H ' ' C ' ' A' ' 42' ' ' ASP . 32.0 m-20 -108.56 -7.9 15.61 Favored 'General case' 0 N--CA 1.49 1.557 0 C-N-CA 119.888 -0.725 . . . . 0.0 110.812 179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -142.75 13.4 1.91 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.525 -0.87 . . . . 0.0 110.706 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -93.05 144.37 28.27 Favored Pre-proline 0 C--N 1.298 -1.658 0 C-N-CA 119.559 -0.856 . . . . 0.0 109.693 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -49.15 148.52 9.78 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.931 1.087 . . . . 0.0 112.09 -179.46 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -78.79 74.91 5.31 Favored 'General case' 0 N--CA 1.483 1.214 0 C-N-CA 119.651 -0.82 . . . . 0.0 110.49 179.844 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.66 -51.12 0.19 Allowed Glycine 0 N--CA 1.487 2.076 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 84.4 t -72.3 87.09 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.006 179.088 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -44.47 139.23 2.86 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.77 -179.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -91.14 -16.05 28.41 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.878 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -81.13 -11.74 59.4 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.238 -0.985 . . . . 0.0 110.699 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.9 mtmt -91.89 -27.3 18.01 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.299 -0.96 . . . . 0.0 111.071 -179.97 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.2 pt -92.31 -30.44 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 C-N-CA 119.149 -1.02 . . . . 0.0 110.727 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.1 m -71.07 167.58 18.96 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.095 179.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.609 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 0.0 OUTLIER -136.17 81.1 39.14 Favored Pre-proline 0 C--N 1.302 -1.46 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.567 179.285 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.6 Cg_exo -56.05 -16.34 16.34 Favored 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 121.317 1.345 . . . . 0.0 112.114 -178.315 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.414 ' O ' ' O ' ' A' ' 60' ' ' TYR . 9.6 mt-10 -73.24 103.32 3.91 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 118.923 -1.111 . . . . 0.0 110.001 179.157 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.414 ' O ' ' O ' ' A' ' 59' ' ' GLU . 83.6 m-85 -43.71 168.39 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 119.6 -0.84 . . . . 0.0 111.148 -179.477 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.1 pp -147.53 139.17 23.96 Favored 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.379 179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -141.15 28.86 1.86 Allowed 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.843 -179.354 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -92.11 115.24 4.74 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.203 -1.475 . . . . 0.0 110.614 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.37 110.33 1.22 Allowed 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.857 179.806 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 98.74 -13.02 62.7 Favored Glycine 0 N--CA 1.491 2.34 0 C-N-CA 119.521 -1.323 . . . . 0.0 110.414 179.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 38.9 tt0 -62.65 148.95 44.8 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.15 -1.02 . . . . 0.0 110.246 179.902 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -142.11 164.81 29.16 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.244 -0.982 . . . . 0.0 111.371 -179.643 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.609 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 36.9 t80 -135.53 133.16 38.13 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 120.011 -0.676 . . . . 0.0 109.492 179.566 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -94.83 152.88 18.03 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.023 -1.071 . . . . 0.0 112.184 -178.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 t -150.59 135.38 9.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 114.656 -1.156 . . . . 0.0 108.267 179.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.5 m -127.65 102.4 6.81 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.417 -0.913 . . . . 0.0 112.254 -178.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 19.9 mt -89.47 155.81 19.06 Favored 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.184 -1.006 . . . . 0.0 109.02 178.37 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.63 ' O ' HG22 ' A' ' 73' ' ' THR . 67.2 m -150.94 47.81 0.85 Allowed 'General case' 0 C--N 1.293 -1.854 0 C-N-CA 118.878 -1.129 . . . . 0.0 111.79 -179.05 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.425 ' OE2' ' N ' ' A' ' 75' ' ' LYS . 5.2 tp10 -145.91 103.07 3.72 Favored 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 118.95 -1.1 . . . . 0.0 110.017 179.204 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.425 ' N ' ' OE2' ' A' ' 74' ' ' GLU . 0.0 OUTLIER -40.69 114.19 0.44 Allowed 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.367 -0.833 . . . . 0.0 111.49 -179.25 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 170.93 -148.93 11.72 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.169 -1.491 . . . . 0.0 110.372 179.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -140.32 133.07 28.99 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.926 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.589 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -119.41 154.3 33.89 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.477 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 15.2 mmtm -126.01 128.41 47.41 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.239 -0.985 . . . . 0.0 112.113 -178.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.556 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.1 p90 -137.23 165.44 26.11 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.063 -0.972 . . . . 0.0 110.357 178.463 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.9 p90 -170.58 -175.72 1.93 Allowed 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 119.724 -0.791 . . . . 0.0 110.277 -178.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.2 t -110.38 126.77 54.63 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.498 -0.881 . . . . 0.0 109.95 179.339 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.547 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 3.9 tm-20 -73.17 -36.72 3.39 Favored Pre-proline 0 N--CA 1.486 1.366 0 C-N-CA 119.181 -1.008 . . . . 0.0 113.689 -178.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.547 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -70.66 -52.39 0.26 Allowed 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 120.527 0.818 . . . . 0.0 110.998 179.701 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.5 m80 -80.25 12.82 2.67 Favored 'General case' 0 N--CA 1.485 1.292 0 C-N-CA 119.759 -0.776 . . . . 0.0 110.791 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.45 -13.43 8.71 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.53 -0.868 . . . . 0.0 110.862 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -76.26 -18.19 79.45 Favored Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.427 -1.368 . . . . 0.0 110.277 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.28 -32.19 13.75 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.921 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 119.53 8.35 9.21 Favored Glycine 0 N--CA 1.497 2.711 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -50.27 105.26 0.09 Allowed 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.951 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.6 pttp -129.53 160.69 32.43 Favored 'General case' 0 N--CA 1.497 1.883 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.329 -179.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.22 152.21 24.1 Favored Glycine 0 N--CA 1.497 2.742 0 C-N-CA 119.458 -1.354 . . . . 0.0 111.372 -178.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 72.1 tt0 -154.25 148.69 26.16 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.654 -0.818 . . . . 0.0 110.83 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.499 HG13 ' O ' ' A' ' 94' ' ' VAL . 10.8 p -140.04 125.63 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 C-N-CA 119.205 -0.998 . . . . 0.0 110.449 179.389 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 41.4 m -102.89 99.82 9.76 Favored 'General case' 0 N--CA 1.494 1.751 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.459 179.538 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 43.3 t -79.22 147.11 6.96 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.26 0 C-N-CA 118.558 -1.257 . . . . 0.0 110.597 -178.788 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.401 ' OD1' ' N ' ' A' ' 97' ' ' ASN . 12.0 p-10 . . . . . 0 C--N 1.305 -1.338 0 CA-C-O 116.275 -1.822 . . . . 0.0 110.787 -179.782 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 CA-C-O 120.783 0.325 . . . . 0.0 110.169 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -133.14 130.27 38.98 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 120.021 -0.672 . . . . 0.0 110.575 179.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.1 t -125.55 126.76 70.92 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.974 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 21.7 mttm -99.83 119.37 38.08 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.985 -179.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.442 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 77.8 mt -79.35 104.01 9.67 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 119.175 -1.01 . . . . 0.0 110.142 178.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.437 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 116.31 138.35 6.3 Favored Glycine 0 N--CA 1.494 2.564 0 N-CA-C 109.313 -1.515 . . . . 0.0 109.313 -178.63 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.411 ' OG ' ' N ' ' A' ' 8' ' ' ASP . 58.2 p -64.02 -69.41 0.28 Allowed 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.073 -179.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.411 ' N ' ' OG ' ' A' ' 7' ' ' SER . 5.5 m-20 -153.19 -41.02 0.1 Allowed 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 119.404 -0.918 . . . . 0.0 110.645 179.775 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.404 ' H ' ' H ' ' A' ' 10' ' ' GLY . 0.1 OUTLIER 179.87 13.53 0.0 OUTLIER 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.439 -0.904 . . . . 0.0 110.804 -179.963 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.404 ' H ' ' H ' ' A' ' 9' ' ' ASP . . . -159.95 22.59 0.27 Allowed Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.425 -1.369 . . . . 0.0 110.559 179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -150.64 138.35 6.61 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.35 -1.405 . . . . 0.0 110.45 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 28.1 mt -113.02 97.56 6.6 Favored 'General case' 0 N--CA 1.49 1.534 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.426 179.752 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 13.6 m -150.07 155.85 7.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.179 0 C-N-CA 118.807 -1.157 . . . . 0.0 111.109 179.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.481 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 18.6 m-85 -78.37 112.1 15.05 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 107.223 -1.399 . . . . 0.0 107.223 177.45 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 23.8 m -116.17 107.96 46.74 Favored Pre-proline 0 CA--C 1.56 1.354 0 C-N-CA 119.496 -0.882 . . . . 0.0 111.968 -177.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.405 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.3 Cg_endo -65.91 175.53 22.77 Favored 'Cis proline' 0 C--N 1.362 1.268 0 C-N-CA 125.221 -0.741 . . . . 0.0 111.448 0.119 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -98.01 -45.82 6.12 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.65 -0.82 . . . . 0.0 110.056 179.415 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -137.66 135.18 36.27 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.525 179.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 18.4 p90 -161.5 143.76 11.91 Favored 'General case' 0 N--CA 1.485 1.285 0 C-N-CA 118.577 -1.249 . . . . 0.0 111.497 -179.093 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.3 p -87.27 156.55 19.59 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.331 -0.948 . . . . 0.0 110.957 179.77 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.8 m -148.61 173.12 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 C-N-CA 119.448 -0.901 . . . . 0.0 110.896 179.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.416 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -88.8 149.43 23.42 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.415 179.635 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.8 74.32 0.1 Allowed 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.981 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 156.08 16.42 0.04 OUTLIER Glycine 0 N--CA 1.488 2.16 0 C-N-CA 119.562 -1.304 . . . . 0.0 109.983 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.2 tp10 -95.52 151.26 19.47 Favored 'General case' 0 C--N 1.304 -1.376 0 C-N-CA 119.607 -0.837 . . . . 0.0 110.914 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 1.9 ptmt -95.34 123.58 38.94 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.527 -0.869 . . . . 0.0 111.114 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.0 mt -101.86 108.07 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.388 0 C-N-CA 120.002 -0.679 . . . . 0.0 109.696 179.6 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 76.3 p -104.48 112.42 25.47 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.653 -0.819 . . . . 0.0 112.572 -178.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -84.83 116.74 23.46 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.142 178.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.1 ttpt -113.1 126.31 55.32 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.389 -178.036 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 12.7 m-20 -68.11 113.97 6.22 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.737 178.648 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.645 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 2.4 p-10 -107.31 -22.3 12.64 Favored 'General case' 0 N--CA 1.497 1.904 0 C-N-CA 119.171 -1.011 . . . . 0.0 111.15 179.552 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.645 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 169.38 114.46 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 118.926 -1.11 . . . . 0.0 111.113 179.511 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 129.15 7.73 3.93 Favored Glycine 0 N--CA 1.493 2.44 0 C-N-CA 119.652 -1.261 . . . . 0.0 111.124 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.514 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -57.68 161.63 6.01 Favored Pre-proline 0 C--N 1.306 -1.292 0 C-N-CA 118.521 -1.272 . . . . 0.0 109.95 -179.947 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -80.01 152.68 85.23 Favored 'Cis proline' 0 C--O 1.213 -0.731 0 C-N-CA 124.037 -1.235 . . . . 0.0 112.326 -1.079 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 45.1 m-70 -113.06 165.19 12.6 Favored 'General case' 0 N--CA 1.493 1.722 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.246 178.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.403 ' C ' ' ND2' ' A' ' 38' ' ' ASN . 1.2 t-20 -149.6 99.76 2.91 Favored 'General case' 0 N--CA 1.49 1.549 0 C-N-CA 118.974 -1.09 . . . . 0.0 110.783 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 2.8 mp -84.95 135.65 24.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 C-N-CA 119.279 -0.969 . . . . 0.0 111.472 -179.378 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -143.55 143.56 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 CA-C-N 115.6 -0.727 . . . . 0.0 110.004 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.682 ' CD2' HD12 ' A' ' 55' ' ' ILE . 27.5 m-85 -101.56 123.0 44.88 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.539 -0.864 . . . . 0.0 111.702 -179.396 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -66.33 118.06 9.46 Favored 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 119.404 -0.918 . . . . 0.0 109.994 179.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.589 ' H ' ' CD ' ' A' ' 43' ' ' GLU . 1.5 pm0 -71.32 -6.65 41.55 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 119.454 -0.898 . . . . 0.0 112.211 -178.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 28.9 m-20 -95.58 5.89 50.35 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.174 -1.01 . . . . 0.0 111.574 -179.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -143.22 16.67 1.89 Allowed 'General case' 0 N--CA 1.482 1.174 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.702 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -105.19 151.64 39.61 Favored Pre-proline 0 N--CA 1.489 1.481 0 CA-C-N 115.241 -0.89 . . . . 0.0 108.635 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -46.37 151.04 1.9 Allowed 'Trans proline' 0 C--O 1.215 -0.645 0 C-N-CA 121.173 1.249 . . . . 0.0 112.131 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.93 72.12 6.67 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.859 -179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.58 -35.39 0.14 Allowed Glycine 0 N--CA 1.489 2.186 0 C-N-CA 119.548 -1.31 . . . . 0.0 110.054 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 72.8 t -90.34 95.24 5.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.612 179.661 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 66.0 m-20 -50.15 152.9 1.57 Allowed 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.167 -179.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.478 ' C ' ' H ' ' A' ' 54' ' ' LYS . . . -83.09 -38.25 22.74 Favored 'General case' 0 C--N 1.306 -1.3 0 C-N-CA 119.429 -0.908 . . . . 0.0 110.468 179.641 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -63.69 0.52 0.77 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.387 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.478 ' H ' ' C ' ' A' ' 52' ' ' ALA . 0.0 OUTLIER -91.36 -45.68 8.45 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.583 179.973 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.682 HD12 ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -94.46 -25.35 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 C-N-CA 119.289 -0.964 . . . . 0.0 110.875 179.927 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 37.3 m -48.74 164.63 0.06 Allowed 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.503 -0.879 . . . . 0.0 110.902 179.695 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.624 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 8.0 mt-30 -138.05 73.96 44.26 Favored Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 120.021 -0.671 . . . . 0.0 110.845 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -61.46 -25.6 80.01 Favored 'Trans proline' 0 C--N 1.324 -0.721 0 C-N-CA 121.301 1.334 . . . . 0.0 111.325 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -68.28 97.76 0.76 Allowed 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.421 179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 47.5 m-85 -48.19 162.89 0.07 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.509 -0.877 . . . . 0.0 111.219 -179.7 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -142.22 106.32 4.76 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.801 -0.76 . . . . 0.0 110.751 179.631 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -114.23 21.45 14.69 Favored 'General case' 0 N--CA 1.494 1.759 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.075 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -90.85 118.64 5.42 Favored Glycine 0 N--CA 1.489 2.206 0 C-N-CA 119.281 -1.438 . . . . 0.0 110.525 -179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -58.42 111.35 1.2 Allowed 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.313 -0.955 . . . . 0.0 110.63 179.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 101.82 -13.35 57.76 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.732 -1.223 . . . . 0.0 110.407 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -60.81 148.04 40.58 Favored 'General case' 0 N--CA 1.487 1.402 0 C-N-CA 119.257 -0.977 . . . . 0.0 110.456 179.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 2.3 p -145.83 165.4 28.99 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.275 -0.97 . . . . 0.0 111.3 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.624 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 38.3 t80 -136.15 146.99 47.51 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.868 -179.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.443 ' CD ' ' H ' ' A' ' 69' ' ' GLU . 2.1 mp0 -106.88 154.1 21.54 Favored 'General case' 0 N--CA 1.496 1.874 0 C-N-CA 119.431 -0.908 . . . . 0.0 112.164 -179.053 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -151.18 134.23 7.02 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.096 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.137 179.326 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 12.5 m -129.44 114.24 15.9 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.735 -0.786 . . . . 0.0 111.125 -179.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.49 ' CD1' HG11 ' A' ' 94' ' ' VAL . 17.1 mt -97.6 163.44 12.84 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.696 -0.802 . . . . 0.0 110.079 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.597 ' O ' HG22 ' A' ' 73' ' ' THR . 62.3 m -150.38 51.95 0.89 Allowed 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 118.939 -1.104 . . . . 0.0 111.468 -179.47 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -152.72 105.8 3.01 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 118.916 -1.114 . . . . 0.0 110.658 179.533 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -48.85 110.43 0.35 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.958 -1.097 . . . . 0.0 110.609 -179.695 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.39 -142.66 6.29 Favored Glycine 0 N--CA 1.488 2.139 0 C-N-CA 119.218 -1.468 . . . . 0.0 110.078 -179.622 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.408 HG23 HG23 ' A' ' 95' ' ' THR . 0.0 OUTLIER -143.58 129.25 19.23 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.357 -0.937 . . . . 0.0 111.114 -179.845 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.568 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -116.03 122.86 46.45 Favored 'General case' 0 N--CA 1.484 1.236 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.535 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.425 ' N ' ' CD ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -95.04 113.99 25.75 Favored 'General case' 0 C--N 1.302 -1.467 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.992 -178.843 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.555 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -122.83 165.39 16.71 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.826 -0.75 . . . . 0.0 109.608 178.307 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 30.9 p90 -170.78 -177.62 2.34 Favored 'General case' 0 C--N 1.292 -1.906 0 C-N-CA 119.137 -1.025 . . . . 0.0 110.971 -178.596 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -110.28 113.27 25.81 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.462 178.483 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.541 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.8 tt0 -65.79 -39.75 33.86 Favored Pre-proline 0 C--N 1.303 -1.427 0 C-N-CA 119.416 -0.914 . . . . 0.0 112.891 -178.735 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.541 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.5 Cg_endo -68.53 -50.39 0.68 Allowed 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 120.499 0.8 . . . . 0.0 111.804 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -83.26 15.8 2.76 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.191 -1.004 . . . . 0.0 110.998 -179.579 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.97 -1.97 4.73 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.636 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -72.4 -27.46 69.68 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.446 -1.359 . . . . 0.0 110.307 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.77 -50.48 5.13 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.561 -0.856 . . . . 0.0 110.456 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.84 30.67 0.12 Allowed Glycine 0 N--CA 1.486 1.987 0 C-N-CA 119.618 -1.277 . . . . 0.0 110.492 179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 2.5 mtp -72.17 97.65 1.99 Allowed 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.149 -1.02 . . . . 0.0 111.02 179.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.481 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -122.76 168.06 12.7 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.66 179.688 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -150.53 146.33 15.25 Favored Glycine 0 N--CA 1.487 2.082 0 C-N-CA 118.883 -1.627 . . . . 0.0 111.563 -178.658 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -149.51 140.87 23.23 Favored 'General case' 0 N--CA 1.481 1.092 0 C-N-CA 119.808 -0.757 . . . . 0.0 110.535 179.346 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.572 HG13 ' O ' ' A' ' 94' ' ' VAL . 14.4 p -131.96 120.57 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 C-N-CA 119.467 -0.893 . . . . 0.0 110.729 179.484 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.408 HG23 HG23 ' A' ' 77' ' ' THR . 6.6 m -94.92 96.97 9.66 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 119.274 -0.97 . . . . 0.0 110.23 179.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.6 t -79.98 153.01 4.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 C-N-CA 118.873 -1.131 . . . . 0.0 110.639 -178.681 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.307 -1.251 0 CA-C-O 116.349 -1.786 . . . . 0.0 110.775 -179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.138 0 N-CA-C 110.159 -0.311 . . . . 0.0 110.159 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.0 mt-10 -103.74 152.43 21.86 Favored 'General case' 0 N--CA 1.49 1.525 0 C-N-CA 119.743 -0.783 . . . . 0.0 110.856 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.3 t -134.03 145.72 32.7 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.327 0 C-N-CA 119.718 -0.793 . . . . 0.0 110.591 179.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 33.1 mtmm -114.74 109.15 17.76 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 115.118 -0.947 . . . . 0.0 110.609 -179.502 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.438 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 3.9 mt -78.9 106.49 10.96 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.131 -1.027 . . . . 0.0 109.848 179.044 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.427 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 115.29 138.18 6.48 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -178.609 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.437 ' O ' ' ND2' ' A' ' 32' ' ' ASN . 32.1 p -71.93 170.33 13.99 Favored 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 119.363 -0.935 . . . . 0.0 111.383 -179.411 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 19.4 m-20 -69.33 -12.25 61.5 Favored 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 119.457 -0.897 . . . . 0.0 111.515 -179.347 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -177.99 81.88 0.02 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 118.301 -1.36 . . . . 0.0 112.735 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.93 71.13 1.05 Allowed Glycine 0 N--CA 1.497 2.747 0 C-N-CA 119.266 -1.445 . . . . 0.0 112.342 177.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 172.31 139.48 2.84 Favored Glycine 0 N--CA 1.485 1.94 0 C-N-CA 118.973 -1.584 . . . . 0.0 110.831 178.411 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.7 mt -116.95 83.63 2.01 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 179.158 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 11.9 m -139.73 161.45 26.8 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 C-N-CA 119.376 -0.929 . . . . 0.0 111.501 -178.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.422 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 22.4 m-85 -78.41 110.46 13.48 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 177.793 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 5.6 m -115.67 106.32 50.42 Favored Pre-proline 0 N--CA 1.486 1.348 0 C-N-CA 119.775 -0.77 . . . . 0.0 111.315 -178.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.402 ' C ' ' O ' ' A' ' 14' ' ' PHE . 2.7 Cg_endo -66.78 174.61 28.67 Favored 'Cis proline' 0 C--N 1.356 0.94 0 C-N-CA 125.326 -0.698 . . . . 0.0 112.075 0.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 5.0 t -93.3 -55.05 3.45 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.885 179.125 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 69.8 m -125.15 140.36 52.94 Favored 'General case' 0 N--CA 1.484 1.243 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.541 179.022 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.438 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 10.4 p90 -156.69 132.06 9.28 Favored 'General case' 0 C--N 1.306 -1.319 0 C-N-CA 118.649 -1.22 . . . . 0.0 111.397 -179.315 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.5 p -87.86 152.58 21.98 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.081 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.4 m -147.0 176.13 1.5 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 C-N-CA 119.482 -0.887 . . . . 0.0 110.865 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -90.14 155.89 18.73 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 119.209 -0.997 . . . . 0.0 110.506 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -73.49 61.21 0.68 Allowed 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 119.565 -0.854 . . . . 0.0 111.296 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 170.77 11.91 0.02 OUTLIER Glycine 0 N--CA 1.489 2.216 0 C-N-CA 119.569 -1.3 . . . . 0.0 109.91 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.408 ' OE1' ' O ' ' A' ' 26' ' ' LYS . 5.7 tm-20 -104.61 123.37 47.44 Favored 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.969 -0.693 . . . . 0.0 110.831 -179.636 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.408 ' O ' ' OE1' ' A' ' 25' ' ' GLU . 1.3 pttp -69.73 150.31 47.07 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.521 -0.872 . . . . 0.0 111.25 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 1.2 mt -122.86 147.45 27.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.376 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 1.2 p -139.22 117.56 11.99 Favored 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.218 -0.993 . . . . 0.0 111.626 -179.321 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 89.1 m-85 -84.28 150.58 25.32 Favored 'General case' 0 N--CA 1.484 1.265 0 C-N-CA 119.267 -0.973 . . . . 0.0 109.796 179.058 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 10.8 tttm -144.55 138.72 27.69 Favored 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 118.999 -1.08 . . . . 0.0 111.707 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.651 HD21 ' CB ' ' A' ' 66' ' ' GLU . 0.5 OUTLIER -85.31 131.27 34.44 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.423 178.839 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.465 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 5.6 p-10 -111.56 -32.38 6.7 Favored 'General case' 0 N--CA 1.505 2.281 0 C-N-CA 119.107 -1.037 . . . . 0.0 112.587 -179.631 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.465 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 176.42 30.48 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 118.941 -1.104 . . . . 0.0 110.819 -179.433 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.493 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . -138.78 40.3 1.47 Allowed Glycine 0 N--CA 1.49 2.293 0 C-N-CA 119.229 -1.462 . . . . 0.0 111.233 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.596 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -86.2 161.58 48.82 Favored Pre-proline 0 C--N 1.309 -1.194 0 C-N-CA 118.442 -1.303 . . . . 0.0 109.999 179.226 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -78.65 135.82 38.54 Favored 'Cis proline' 0 C--O 1.215 -0.649 0 C-N-CA 124.075 -1.219 . . . . 0.0 111.568 -0.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.493 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 40.4 m-70 -100.21 -177.1 3.42 Favored 'General case' 0 N--CA 1.491 1.601 0 C-N-CA 119.361 -0.936 . . . . 0.0 110.749 179.589 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.619 ' ND2' ' N ' ' A' ' 39' ' ' ILE . 1.7 t-20 -161.11 146.86 14.36 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.3 -0.96 . . . . 0.0 110.916 -179.722 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.619 ' N ' ' ND2' ' A' ' 38' ' ' ASN . 3.5 mt -131.0 114.91 28.18 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.779 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.478 ' CG2' HD21 ' A' ' 38' ' ' ASN . 3.0 t -137.15 137.24 46.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.124 179.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 44.1 m-85 -93.67 127.63 39.46 Favored 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.236 -0.986 . . . . 0.0 111.413 -179.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -63.4 125.77 25.28 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 119.568 -0.853 . . . . 0.0 109.895 179.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -57.47 -49.94 74.64 Favored 'General case' 0 N--CA 1.495 1.799 0 N-CA-C 114.415 1.265 . . . . 0.0 114.415 -177.143 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.2 m-20 -85.21 8.23 19.11 Favored 'General case' 0 N--CA 1.498 1.936 0 C-N-CA 118.941 -1.104 . . . . 0.0 113.855 -176.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 11.6 mt-10 -126.86 40.35 3.74 Favored 'General case' 0 N--CA 1.495 1.781 0 C-N-CA 119.341 -0.944 . . . . 0.0 110.568 179.347 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.657 HG22 ' HD2' ' A' ' 47' ' ' PRO . 0.5 OUTLIER -135.59 156.33 77.7 Favored Pre-proline 0 N--CA 1.487 1.399 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 179.279 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.657 ' HD2' HG22 ' A' ' 46' ' ' VAL . 3.6 Cg_exo -48.04 148.06 7.24 Favored 'Trans proline' 0 C--O 1.215 -0.647 0 C-N-CA 120.916 1.077 . . . . 0.0 111.73 -179.583 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -79.57 70.37 6.03 Favored 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.644 -0.822 . . . . 0.0 111.035 -179.705 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 170.37 -22.78 0.09 OUTLIER Glycine 0 N--CA 1.489 2.211 0 C-N-CA 119.342 -1.409 . . . . 0.0 110.435 179.808 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 44.6 t -97.42 99.78 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.289 0 C-N-CA 119.595 -0.842 . . . . 0.0 110.809 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 88.4 m-20 -46.75 149.66 0.81 Allowed 'General case' 0 C--N 1.303 -1.415 0 C-N-CA 119.256 -0.978 . . . . 0.0 110.715 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.409 ' O ' ' OG ' ' A' ' 56' ' ' SER . . . -94.64 -5.69 45.09 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.623 179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 9.9 mm-40 -86.14 -29.6 23.16 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.45 -0.9 . . . . 0.0 111.107 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 21.4 mmtt -71.87 -27.55 62.94 Favored 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.463 -0.895 . . . . 0.0 111.481 -179.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 10.7 pt -105.15 -14.95 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 C-N-CA 119.559 -0.857 . . . . 0.0 111.944 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.409 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 4.7 m -67.32 173.62 3.83 Favored 'General case' 0 N--CA 1.488 1.448 0 C-N-CA 119.241 -0.983 . . . . 0.0 110.827 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.656 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 12.9 tt0 -136.93 76.01 47.14 Favored Pre-proline 0 C--N 1.306 -1.321 0 C-N-CA 120.072 -0.651 . . . . 0.0 110.354 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -60.02 -22.33 68.85 Favored 'Trans proline' 0 C--O 1.214 -0.68 0 C-N-CA 121.359 1.373 . . . . 0.0 111.985 -178.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 38.8 mm-40 -89.89 106.83 18.74 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.139 -1.024 . . . . 0.0 110.652 179.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 30.9 m-85 -56.37 170.5 0.35 Allowed 'General case' 0 C--N 1.305 -1.341 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.728 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.5 pp -140.26 129.48 23.75 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.502 -0.879 . . . . 0.0 111.098 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -127.68 10.33 6.59 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 120.007 -0.677 . . . . 0.0 110.521 179.813 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.48 ' O ' ' ND2' ' A' ' 31' ' ' ASN . . . -77.85 118.78 5.08 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.412 -179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.9 105.12 0.52 Allowed 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.759 179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.24 -2.77 43.66 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.559 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.651 ' CB ' HD21 ' A' ' 31' ' ' ASN . 2.8 tp10 -63.16 161.14 14.05 Favored 'General case' 0 N--CA 1.489 1.514 0 C-N-CA 118.916 -1.113 . . . . 0.0 110.229 179.629 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 66.8 p -147.45 163.14 37.45 Favored 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.556 -179.138 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.656 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 76.0 t80 -135.62 139.14 43.57 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 120.054 -0.658 . . . . 0.0 109.751 179.05 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -107.59 153.17 23.27 Favored 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 119.513 -0.875 . . . . 0.0 112.577 -178.477 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 p -161.51 132.9 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.264 0 CA-C-N 115.433 -0.803 . . . . 0.0 109.391 178.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 13.8 m -119.81 95.6 4.84 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.733 -178.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 12.2 mt -80.46 158.49 25.88 Favored 'General case' 0 C--N 1.304 -1.412 0 C-N-CA 119.384 -0.926 . . . . 0.0 109.226 178.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 9.0 p -151.14 28.44 0.67 Allowed 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 118.65 -1.22 . . . . 0.0 112.253 -179.02 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.506 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.8 OUTLIER -114.5 97.75 6.49 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.024 179.599 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 36.8 tttt -41.68 98.0 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.733 -0.787 . . . . 0.0 110.958 -179.674 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 74' ' ' GLU . . . 177.56 -134.17 2.4 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.176 -1.488 . . . . 0.0 110.257 -179.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -145.31 142.0 29.05 Favored 'General case' 0 C--N 1.309 -1.165 0 C-N-CA 119.216 -0.994 . . . . 0.0 111.519 -179.683 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.574 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.2 m-85 -128.05 128.31 44.72 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.386 -0.825 . . . . 0.0 108.779 179.359 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -105.77 118.97 37.96 Favored 'General case' 0 N--CA 1.488 1.453 0 C-N-CA 119.243 -0.983 . . . . 0.0 111.318 -179.164 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.1 p90 -124.31 172.91 8.73 Favored 'General case' 0 C--O 1.206 -1.205 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.56 178.532 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -171.06 175.3 4.39 Favored 'General case' 0 C--N 1.292 -1.916 0 C-N-CA 118.932 -1.107 . . . . 0.0 111.577 -178.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.4 t -99.66 127.06 45.77 Favored 'General case' 0 C--N 1.3 -1.587 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.287 179.494 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.593 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 3.2 tm-20 -73.88 -34.95 2.25 Favored Pre-proline 0 N--CA 1.492 1.661 0 C-N-CA 118.85 -1.14 . . . . 0.0 113.667 -178.498 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.593 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.1 Cg_endo -72.68 -52.31 0.17 Allowed 'Trans proline' 0 C--O 1.214 -0.685 0 C-N-CA 120.671 0.914 . . . . 0.0 110.99 -179.831 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 34.4 m80 -81.39 14.72 2.32 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 119.732 -0.787 . . . . 0.0 110.879 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -62.89 -6.19 3.56 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.187 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -81.31 -21.43 62.5 Favored Glycine 0 N--CA 1.49 2.267 0 C-N-CA 119.339 -1.41 . . . . 0.0 110.307 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -94.73 -22.36 18.15 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.956 -179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.426 ' O ' ' N ' ' A' ' 91' ' ' LYS . . . 109.27 11.82 21.15 Favored Glycine 0 N--CA 1.497 2.754 0 C-N-CA 119.964 -1.112 . . . . 0.0 110.364 -179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 6.1 ttt -53.9 92.62 0.01 OUTLIER 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.489 -0.885 . . . . 0.0 110.474 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.53 ' NZ ' ' CB ' ' A' ' 91' ' ' LYS . 0.1 OUTLIER -117.1 158.73 23.7 Favored 'General case' 0 N--CA 1.5 2.039 0 C-N-CA 119.855 -0.738 . . . . 0.0 111.386 -179.73 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.23 146.53 18.45 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 120.027 -1.082 . . . . 0.0 111.052 -178.676 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -148.85 147.1 28.32 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 119.443 -0.903 . . . . 0.0 110.842 179.707 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.435 HG13 ' O ' ' A' ' 94' ' ' VAL . 7.4 p -140.05 129.89 28.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.195 179.131 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 90.4 m -106.09 100.78 10.31 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.656 -0.818 . . . . 0.0 110.964 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 47.1 t -82.48 142.99 12.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 119.045 -1.062 . . . . 0.0 110.364 -179.071 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 17.3 p30 . . . . . 0 C--N 1.307 -1.253 0 CA-C-O 116.328 -1.796 . . . . 0.0 110.952 -179.688 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.099 0 CA-C-O 120.905 0.383 . . . . 0.0 110.036 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.0 mt-10 -92.7 131.46 37.76 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.404 -0.918 . . . . 0.0 110.562 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 t -122.29 121.72 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 C-N-CA 119.786 -0.766 . . . . 0.0 111.404 -179.658 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.58 118.83 31.86 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.519 -0.872 . . . . 0.0 110.186 179.46 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 12.8 mt -78.54 98.83 6.26 Favored 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 118.672 -1.211 . . . . 0.0 109.9 179.019 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.464 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 113.59 131.6 5.39 Favored Glycine 0 N--CA 1.488 2.151 0 CA-C-N 114.546 -1.206 . . . . 0.0 110.323 -179.135 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.523 ' OG ' ' N ' ' A' ' 10' ' ' GLY . 56.3 p -83.22 167.49 17.64 Favored 'General case' 0 C--N 1.302 -1.48 0 C-N-CA 119.299 -0.96 . . . . 0.0 110.548 179.578 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -65.5 -20.07 66.19 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.476 -0.889 . . . . 0.0 111.422 -179.798 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -172.95 1.09 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 119.141 -1.023 . . . . 0.0 111.238 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.523 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . -77.31 -32.31 48.29 Favored Glycine 0 N--CA 1.492 2.403 0 C-N-CA 119.438 -1.363 . . . . 0.0 110.745 -179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 140.55 -134.68 6.59 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.519 -1.324 . . . . 0.0 110.5 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.7 mt -117.06 104.27 11.07 Favored 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 120.018 -0.673 . . . . 0.0 110.893 -179.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.0 m -150.39 157.06 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.136 0 C-N-CA 118.979 -1.088 . . . . 0.0 110.954 179.45 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.419 ' O ' ' O ' ' A' ' 16' ' ' PRO . 62.2 m-85 -78.27 110.83 13.63 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 177.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 16.5 m -114.2 111.62 47.28 Favored Pre-proline 0 CA--C 1.56 1.341 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.948 -177.459 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.419 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.3 Cg_exo -65.83 174.18 26.4 Favored 'Cis proline' 0 C--N 1.36 1.158 0 C-N-CA 125.105 -0.79 . . . . 0.0 111.611 -0.343 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 3.9 m -97.45 -65.87 0.94 Allowed 'General case' 0 N--CA 1.488 1.45 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.098 179.256 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 m -114.39 137.68 51.51 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.734 179.177 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 34.5 p90 -168.2 147.4 4.58 Favored 'General case' 0 N--CA 1.487 1.399 0 C-N-CA 118.49 -1.284 . . . . 0.0 111.656 -179.534 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.672 HG22 ' HB ' ' A' ' 95' ' ' THR . 44.2 p -83.31 161.55 21.4 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.193 179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 31.5 m -149.32 148.72 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.228 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.662 179.541 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.539 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -76.51 140.74 41.29 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.294 -0.962 . . . . 0.0 110.751 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -58.78 78.39 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.242 0 C-N-CA 119.657 -0.817 . . . . 0.0 110.937 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.539 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 148.21 21.22 0.09 OUTLIER Glycine 0 N--CA 1.487 2.071 0 N-CA-C 109.604 -1.398 . . . . 0.0 109.604 -179.968 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -102.56 150.34 23.5 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.924 -0.71 . . . . 0.0 110.733 -179.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 74.9 mttt -95.2 117.69 30.69 Favored 'General case' 0 C--N 1.303 -1.434 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.055 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 10.5 mt -93.22 98.35 8.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 C-N-CA 119.501 -0.88 . . . . 0.0 108.962 179.3 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 55.0 p -94.34 117.43 30.11 Favored 'General case' 0 C--N 1.299 -1.618 0 C-N-CA 119.493 -0.883 . . . . 0.0 112.821 -177.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -84.68 143.62 29.08 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.049 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 11.4 ttpt -135.3 125.55 26.33 Favored 'General case' 0 N--CA 1.49 1.564 0 C-N-CA 119.295 -0.962 . . . . 0.0 111.387 -178.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.525 ' OD1' ' CD1' ' A' ' 35' ' ' PHE . 36.5 t-20 -79.39 115.8 19.24 Favored 'General case' 0 C--N 1.295 -1.782 0 C-N-CA 119.792 -0.763 . . . . 0.0 110.009 179.354 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.464 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 3.0 p-10 -120.29 -22.23 6.63 Favored 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.317 -0.953 . . . . 0.0 112.307 -179.367 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -177.45 123.43 0.13 Allowed 'General case' 0 N--CA 1.492 1.648 0 C-N-CA 118.358 -1.337 . . . . 0.0 112.188 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 104.17 48.6 1.13 Allowed Glycine 0 N--CA 1.495 2.618 0 C-N-CA 119.272 -1.442 . . . . 0.0 112.849 177.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.623 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -87.54 164.83 33.39 Favored Pre-proline 0 C--N 1.304 -1.37 0 C-N-CA 118.573 -1.251 . . . . 0.0 108.936 177.91 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -77.2 140.13 62.6 Favored 'Cis proline' 0 C--O 1.215 -0.642 0 C-N-CA 124.555 -1.019 . . . . 0.0 112.917 -0.5 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 33.6 m-70 -108.15 161.28 15.12 Favored 'General case' 0 N--CA 1.495 1.794 0 CA-C-N 115.703 -0.68 . . . . 0.0 110.952 178.607 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.763 HD21 ' H ' ' A' ' 83' ' ' GLU . 4.0 p-10 -153.52 163.18 40.4 Favored 'General case' 0 N--CA 1.487 1.413 0 C-N-CA 119.049 -1.061 . . . . 0.0 110.684 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mp -133.78 124.35 47.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 C-N-CA 119.841 -0.743 . . . . 0.0 110.758 -179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 21.7 t -137.48 141.31 39.88 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.264 179.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.485 ' CE2' HD12 ' A' ' 55' ' ' ILE . 5.6 m-85 -96.39 130.75 43.45 Favored 'General case' 0 C--N 1.303 -1.455 0 C-N-CA 119.574 -0.85 . . . . 0.0 111.706 -178.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -73.9 117.19 15.4 Favored 'General case' 0 N--CA 1.485 1.279 0 C-N-CA 119.376 -0.93 . . . . 0.0 109.789 179.034 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -69.56 0.3 5.57 Favored 'General case' 0 N--CA 1.491 1.603 0 C-N-CA 119.435 -0.906 . . . . 0.0 112.013 -178.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 62.3 m-20 -99.76 -5.79 28.08 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.357 -179.615 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 31.0 mm-40 -123.37 -2.38 8.52 Favored 'General case' 0 N--CA 1.485 1.294 0 C-N-CA 119.986 -0.686 . . . . 0.0 110.615 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.407 HG13 ' HD2' ' A' ' 47' ' ' PRO . 42.2 t -95.99 144.93 28.66 Favored Pre-proline 0 C--N 1.285 -2.216 0 N-CA-C 107.256 -1.386 . . . . 0.0 107.256 178.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.473 ' HG2' HG12 ' A' ' 50' ' ' VAL . 1.8 Cg_endo -61.09 165.2 12.82 Favored 'Trans proline' 0 C--O 1.215 -0.673 0 CA-C-N 119.024 0.687 . . . . 0.0 111.89 -178.367 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.8 38.89 0.72 Allowed 'General case' 0 C--N 1.308 -1.238 0 C-N-CA 119.381 -0.928 . . . . 0.0 110.239 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -133.18 -57.83 0.08 OUTLIER Glycine 0 N--CA 1.491 2.313 0 N-CA-C 110.115 -1.194 . . . . 0.0 110.115 -179.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.684 ' O ' HG13 ' A' ' 50' ' ' VAL . 9.8 p -84.46 101.99 9.78 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.283 0 C-N-CA 118.989 -1.084 . . . . 0.0 110.722 179.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -48.97 153.81 0.82 Allowed 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.681 -0.808 . . . . 0.0 111.119 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -98.29 -10.16 24.35 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.443 179.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -88.1 -10.46 50.02 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.652 -0.819 . . . . 0.0 110.579 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.4 13.2 16.19 Favored 'General case' 0 C--N 1.303 -1.429 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.465 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.485 HD12 ' CE2' ' A' ' 41' ' ' PHE . 1.1 pt -147.38 -29.09 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 C-N-CA 119.503 -0.879 . . . . 0.0 110.814 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 2.1 m -48.58 174.25 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.466 -0.894 . . . . 0.0 110.948 179.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.624 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 36.5 mt-30 -135.5 78.95 49.23 Favored Pre-proline 0 N--CA 1.489 1.491 0 C-N-CA 119.941 -0.704 . . . . 0.0 111.022 -179.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -60.58 -7.86 7.97 Favored 'Trans proline' 0 N--CA 1.456 -0.686 0 C-N-CA 120.78 0.987 . . . . 0.0 110.641 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 51.2 mt-10 -98.01 127.61 44.06 Favored 'General case' 0 N--CA 1.483 1.179 0 C-N-CA 119.778 -0.769 . . . . 0.0 110.227 179.309 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.435 ' CD1' ' N ' ' A' ' 60' ' ' TYR . 32.4 m-85 -88.59 173.58 8.56 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.917 -179.685 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -137.94 106.53 5.87 Favored 'General case' 0 N--CA 1.487 1.419 0 C-N-CA 119.703 -0.799 . . . . 0.0 110.658 179.644 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.668 ' H ' ' ND2' ' A' ' 62' ' ' ASN . 0.3 OUTLIER -101.67 3.65 39.97 Favored 'General case' 0 N--CA 1.486 1.332 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.912 179.993 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -65.83 -140.58 0.04 OUTLIER Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.392 -1.385 . . . . 0.0 110.413 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -159.42 99.61 1.46 Allowed 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.68 -179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.44 -1.12 43.01 Favored Glycine 0 N--CA 1.492 2.395 0 C-N-CA 119.815 -1.183 . . . . 0.0 110.44 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -63.03 158.74 18.72 Favored 'General case' 0 N--CA 1.487 1.418 0 C-N-CA 119.06 -1.056 . . . . 0.0 110.56 179.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 18.2 p -147.26 155.48 42.09 Favored 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.828 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.624 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 41.0 t80 -136.97 153.51 50.67 Favored 'General case' 0 N--CA 1.488 1.444 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.443 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.411 ' O ' ' CE1' ' A' ' 68' ' ' TYR . 3.6 mt-10 -113.41 149.18 34.52 Favored 'General case' 0 N--CA 1.501 2.082 0 C-N-CA 119.44 -0.904 . . . . 0.0 112.224 -179.076 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -144.62 126.04 9.14 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.12 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.182 179.033 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 2.9 m -119.22 100.11 7.12 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.82 -0.752 . . . . 0.0 111.268 -179.363 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 65.9 mt -79.55 161.28 26.08 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.347 -0.941 . . . . 0.0 109.65 179.171 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 25.9 p -150.07 48.53 0.91 Allowed 'General case' 0 C--N 1.299 -1.605 0 C-N-CA 118.819 -1.152 . . . . 0.0 111.742 -178.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.4 ' O ' ' C ' ' A' ' 75' ' ' LYS . 3.6 mm-40 -148.17 98.26 2.9 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.567 179.416 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 74' ' ' GLU . 0.0 OUTLIER -43.67 107.8 0.09 Allowed 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.596 -179.784 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 176.48 -141.91 5.7 Favored Glycine 0 C--N 1.294 -1.773 0 C-N-CA 119.066 -1.54 . . . . 0.0 110.094 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -144.52 136.67 26.22 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.476 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.592 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.2 OUTLIER -128.78 137.64 51.64 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.488 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -115.37 108.64 16.78 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.932 179.759 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.504 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 2.1 p90 -109.87 170.95 7.74 Favored 'General case' 0 N--CA 1.485 1.277 0 C-N-CA 119.52 -0.872 . . . . 0.0 110.202 179.445 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 0.0 OUTLIER -171.18 179.84 2.9 Favored 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 119.362 -0.935 . . . . 0.0 112.068 -178.454 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . 0.566 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.5 t -108.96 124.45 50.71 Favored 'General case' 0 C--N 1.311 -1.074 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.205 179.122 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.763 ' H ' HD21 ' A' ' 38' ' ' ASN . 0.3 OUTLIER -68.46 -39.4 15.51 Favored Pre-proline 0 N--CA 1.488 1.442 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -178.283 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.586 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.3 Cg_endo -73.35 -51.67 0.16 Allowed 'Trans proline' 0 C--O 1.215 -0.674 0 C-N-CA 121.02 1.147 . . . . 0.0 111.84 -178.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.1 m80 -81.4 8.49 9.17 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.286 -0.966 . . . . 0.0 111.328 -179.327 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.566 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -65.03 -17.28 64.31 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.198 -1.001 . . . . 0.0 110.686 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -65.05 -22.98 69.28 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.493 -1.336 . . . . 0.0 110.248 179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.25 -39.82 10.78 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.562 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 135.65 20.89 0.67 Allowed Glycine 0 N--CA 1.493 2.461 0 C-N-CA 119.744 -1.217 . . . . 0.0 110.34 179.936 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -67.98 106.2 2.26 Favored 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.312 -0.955 . . . . 0.0 111.19 -179.939 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.409 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 2.1 pttp -135.15 169.5 17.35 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.938 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.462 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -150.51 150.17 22.14 Favored Glycine 0 N--CA 1.483 1.822 0 C-N-CA 119.013 -1.565 . . . . 0.0 111.417 -178.467 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 16.2 tt0 -150.09 143.52 25.15 Favored 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.519 179.507 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.435 HG13 ' O ' ' A' ' 94' ' ' VAL . 6.6 p -141.03 126.34 18.77 Favored 'Isoleucine or valine' 0 C--O 1.205 -1.285 0 C-N-CA 119.244 -0.982 . . . . 0.0 110.746 179.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.672 ' HB ' HG22 ' A' ' 20' ' ' THR . 22.7 m -103.45 103.41 13.38 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.647 -0.821 . . . . 0.0 110.423 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 21.6 t -79.55 143.15 12.97 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 C-N-CA 118.714 -1.194 . . . . 0.0 110.018 -179.36 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 7.1 t-20 . . . . . 0 N--CA 1.489 1.488 0 CA-C-O 116.314 -1.803 . . . . 0.0 110.818 -179.602 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.096 0 N-CA-C 110.143 -0.317 . . . . 0.0 110.143 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -140.21 122.49 15.92 Favored 'General case' 0 N--CA 1.486 1.335 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.748 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 98.4 t -114.52 132.54 63.36 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 C-N-CA 119.848 -0.741 . . . . 0.0 111.127 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -100.56 111.75 24.03 Favored 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.736 -0.786 . . . . 0.0 110.684 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.433 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 9.5 mt -75.68 105.07 6.52 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.923 178.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.533 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 112.39 131.68 5.66 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 -178.61 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.421 ' OG ' ' N ' ' A' ' 11' ' ' GLY . 3.4 p -82.8 168.96 16.65 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.256 -0.978 . . . . 0.0 111.092 -179.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -62.17 -38.51 89.35 Favored 'General case' 0 C--N 1.306 -1.317 0 C-N-CA 119.458 -0.897 . . . . 0.0 110.671 179.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.6 p30 -167.7 20.57 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.327 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.778 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -96.05 -25.08 13.37 Favored Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.498 179.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.421 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . 141.18 -140.62 10.48 Favored Glycine 0 N--CA 1.492 2.367 0 C-N-CA 119.573 -1.299 . . . . 0.0 110.475 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.9 mt -115.2 107.64 15.56 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 120.055 -0.658 . . . . 0.0 110.915 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 26.6 m -150.64 157.95 5.45 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.368 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.654 179.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.53 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 34.1 m-85 -78.39 113.24 16.21 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 178.068 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 17.3 m -116.45 107.13 47.5 Favored Pre-proline 0 CA--C 1.562 1.41 0 C-N-CA 119.5 -0.88 . . . . 0.0 112.186 -177.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -65.89 176.24 20.9 Favored 'Cis proline' 0 C--N 1.361 1.217 0 C-N-CA 125.198 -0.751 . . . . 0.0 111.414 -0.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.02 -52.05 4.39 Favored 'General case' 0 C--N 1.305 -1.334 0 C-N-CA 119.486 -0.885 . . . . 0.0 110.265 179.264 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 4.5 m -132.03 135.28 46.4 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.413 179.09 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.478 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 12.8 p90 -155.71 142.32 18.74 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 118.495 -1.282 . . . . 0.0 111.573 -179.097 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.623 HG22 ' HB ' ' A' ' 95' ' ' THR . 46.9 p -84.17 151.24 24.99 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.439 179.458 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 23.0 m -144.59 161.79 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 C-N-CA 119.356 -0.938 . . . . 0.0 111.137 179.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.449 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -81.35 146.55 30.28 Favored 'General case' 0 C--N 1.305 -1.365 0 C-N-CA 119.394 -0.922 . . . . 0.0 110.65 179.894 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.05 74.52 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 119.673 -0.811 . . . . 0.0 111.23 179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.449 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 155.68 18.2 0.04 OUTLIER Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.466 -1.35 . . . . 0.0 109.797 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -98.63 150.95 21.22 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.951 -179.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 56.8 mttt -92.43 117.95 30.45 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.337 -0.945 . . . . 0.0 111.016 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.6 mt -97.94 110.4 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 C-N-CA 119.688 -0.805 . . . . 0.0 109.771 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 75.6 p -110.94 114.48 27.83 Favored 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 119.672 -0.811 . . . . 0.0 112.515 -178.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 50.4 m-85 -87.01 111.55 20.97 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.488 -0.885 . . . . 0.0 109.373 178.391 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 15.7 tttm -106.57 141.01 38.54 Favored 'General case' 0 N--CA 1.49 1.548 0 C-N-CA 119.68 -0.808 . . . . 0.0 112.045 -178.535 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.544 HD21 HD11 ' A' ' 61' ' ' LEU . 1.7 m-80 -82.27 115.99 21.59 Favored 'General case' 0 C--N 1.304 -1.409 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.877 178.799 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.537 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 4.2 p-10 -98.75 -32.76 11.21 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 118.755 -1.178 . . . . 0.0 111.839 -179.398 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.537 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 171.91 52.22 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.496 -0.881 . . . . 0.0 110.042 -179.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.506 ' O ' ' CE1' ' A' ' 37' ' ' HIS . . . -153.45 26.67 0.77 Allowed Glycine 0 N--CA 1.487 2.041 0 C-N-CA 118.992 -1.575 . . . . 0.0 110.734 -179.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.636 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -79.23 160.34 70.9 Favored Pre-proline 0 C--N 1.309 -1.191 0 C-N-CA 118.682 -1.207 . . . . 0.0 109.96 179.856 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -77.41 138.66 54.15 Favored 'Cis proline' 0 C--O 1.215 -0.657 0 C-N-CA 123.876 -1.302 . . . . 0.0 111.757 -1.167 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.506 ' CE1' ' O ' ' A' ' 34' ' ' GLY . 38.2 m-70 -107.66 179.52 4.21 Favored 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 119.631 -0.828 . . . . 0.0 111.49 -179.293 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 4.1 t-20 -156.09 143.25 19.08 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.61 -0.836 . . . . 0.0 110.354 179.781 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.2 mp -130.25 118.31 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 C-N-CA 119.675 -0.81 . . . . 0.0 111.304 -179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t -145.3 147.65 18.49 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.656 179.064 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -99.43 139.97 34.29 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.144 -1.022 . . . . 0.0 112.006 -179.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.698 ' C ' ' H ' ' A' ' 44' ' ' ASP . 39.8 p-10 -75.37 108.37 8.11 Favored 'General case' 0 C--N 1.302 -1.499 0 CA-C-N 115.142 -0.935 . . . . 0.0 111.296 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.489 ' OE1' ' HB3' ' A' ' 52' ' ' ALA . 27.4 mm-40 -56.47 10.8 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.156 0 CA-C-N 115.628 -0.714 . . . . 0.0 111.589 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.698 ' H ' ' C ' ' A' ' 42' ' ' ASP . 70.8 m-20 -82.92 -68.49 0.7 Allowed 'General case' 0 C--N 1.288 -2.081 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.249 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -99.38 -5.23 29.92 Favored 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 118.826 -1.15 . . . . 0.0 114.038 -175.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -54.15 143.88 41.94 Favored Pre-proline 0 C--N 1.282 -2.362 0 C-N-CA 118.206 -1.397 . . . . 0.0 107.784 179.023 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_exo -46.71 146.92 5.0 Favored 'Trans proline' 0 C--O 1.215 -0.634 0 C-N-CA 120.713 0.942 . . . . 0.0 112.116 -179.03 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -85.34 51.13 2.1 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.771 -0.772 . . . . 0.0 111.051 -179.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -165.63 -23.49 0.02 OUTLIER Glycine 0 N--CA 1.488 2.122 0 C-N-CA 119.478 -1.344 . . . . 0.0 109.965 179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 53.2 t -97.85 104.26 15.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.683 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 10.7 m-20 -45.56 139.85 3.6 Favored 'General case' 0 C--N 1.308 -1.234 0 C-N-CA 119.223 -0.991 . . . . 0.0 110.567 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.489 ' HB3' ' OE1' ' A' ' 43' ' ' GLU . . . -101.29 -8.29 22.25 Favored 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.229 -179.736 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -83.79 -21.05 32.28 Favored 'General case' 0 C--N 1.305 -1.335 0 C-N-CA 119.164 -1.014 . . . . 0.0 110.966 -179.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 51.6 mmtt -86.41 -32.88 20.66 Favored 'General case' 0 C--N 1.303 -1.432 0 C-N-CA 119.413 -0.915 . . . . 0.0 111.263 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.4 pt -89.14 -19.81 7.38 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 C-N-CA 118.876 -1.13 . . . . 0.0 111.438 -179.616 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 74.3 m -74.44 -176.6 2.77 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 119.371 -0.932 . . . . 0.0 110.971 179.354 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.537 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 2.4 mt-30 -142.51 82.82 12.41 Favored Pre-proline 0 N--CA 1.491 1.617 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.43 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -61.96 -9.59 14.9 Favored 'Trans proline' 0 C--O 1.214 -0.678 0 C-N-CA 121.187 1.258 . . . . 0.0 112.067 -179.039 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -99.23 112.55 24.69 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.387 -0.925 . . . . 0.0 110.87 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -58.69 178.04 0.12 Allowed 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 119.574 -0.851 . . . . 0.0 110.71 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.544 HD11 HD21 ' A' ' 31' ' ' ASN . 2.0 pp -151.21 142.12 22.95 Favored 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.551 179.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.519 ' ND2' ' N ' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -134.58 19.95 3.6 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.965 -0.694 . . . . 0.0 110.883 -179.752 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -86.4 139.26 16.52 Favored Glycine 0 N--CA 1.489 2.213 0 C-N-CA 119.168 -1.491 . . . . 0.0 110.219 -179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -85.5 111.39 19.95 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.215 -0.994 . . . . 0.0 110.509 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 102.25 -15.21 56.54 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 -179.624 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -64.01 147.02 53.08 Favored 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.298 -0.961 . . . . 0.0 110.227 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.2 p -142.43 169.92 16.67 Favored 'General case' 0 N--CA 1.486 1.369 0 C-N-CA 119.206 -0.997 . . . . 0.0 111.466 -179.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.537 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 26.5 t80 -134.44 135.97 42.9 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-N 115.589 -0.732 . . . . 0.0 109.477 179.251 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.549 ' CD ' ' H ' ' A' ' 69' ' ' GLU . 1.6 mp0 -97.36 152.63 18.73 Favored 'General case' 0 N--CA 1.489 1.512 0 C-N-CA 119.25 -0.98 . . . . 0.0 112.371 -178.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.1 t -151.58 133.5 5.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.043 0 CA-C-N 115.221 -0.899 . . . . 0.0 109.033 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 8.4 m -127.13 104.3 7.9 Favored 'General case' 0 C--N 1.304 -1.398 0 C-N-CA 119.793 -0.763 . . . . 0.0 111.113 -179.376 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.5 ' CD1' HG11 ' A' ' 94' ' ' VAL . 13.9 mt -90.37 160.06 16.28 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.268 -0.973 . . . . 0.0 109.749 179.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 67.3 p -148.41 48.04 1.04 Allowed 'General case' 0 C--N 1.302 -1.457 0 C-N-CA 118.99 -1.084 . . . . 0.0 111.558 -179.211 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.438 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.9 mt-10 -147.08 105.9 3.84 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 118.972 -1.091 . . . . 0.0 110.453 179.311 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -45.74 112.03 0.42 Allowed 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.002 -1.079 . . . . 0.0 110.633 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.77 -146.66 8.61 Favored Glycine 0 N--CA 1.487 2.064 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.282 -179.467 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -141.44 123.73 15.68 Favored 'General case' 0 N--CA 1.486 1.343 0 C-N-CA 119.488 -0.885 . . . . 0.0 111.399 -179.642 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.547 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -115.49 120.29 39.02 Favored 'General case' 0 N--CA 1.493 1.679 0 N-CA-C 108.671 -0.863 . . . . 0.0 108.671 179.339 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 26.1 mttt -97.83 126.95 43.45 Favored 'General case' 0 C--N 1.3 -1.575 0 C-N-CA 119.209 -0.996 . . . . 0.0 112.603 -178.406 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.58 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -127.61 158.58 37.13 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.679 177.928 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -165.0 176.87 8.23 Favored 'General case' 0 C--N 1.283 -2.296 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.131 -179.361 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.6 t -104.39 123.86 48.19 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 119.787 -0.765 . . . . 0.0 110.547 -179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.542 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tt0 -66.4 -44.97 58.88 Favored Pre-proline 0 C--N 1.306 -1.303 0 C-N-CA 119.685 -0.806 . . . . 0.0 112.913 -179.673 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.542 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.6 Cg_exo -65.36 -50.29 2.05 Favored 'Trans proline' 0 C--O 1.215 -0.64 0 C-N-CA 121.179 1.252 . . . . 0.0 111.801 -178.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.6 m80 -86.77 16.18 5.04 Favored 'General case' 0 C--N 1.304 -1.381 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.727 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -61.21 -9.35 4.74 Favored 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.777 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.36 -20.12 49.87 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.473 -1.346 . . . . 0.0 110.485 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.14 -12.93 39.65 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.35 -0.94 . . . . 0.0 110.478 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 99.02 26.07 9.17 Favored Glycine 0 N--CA 1.492 2.372 0 C-N-CA 119.505 -1.331 . . . . 0.0 110.719 179.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -76.83 101.63 5.97 Favored 'General case' 0 C--N 1.307 -1.264 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.174 179.866 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.53 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 1.5 ptmt -124.98 162.58 24.18 Favored 'General case' 0 N--CA 1.493 1.712 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.946 -179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.549 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -146.76 149.84 22.04 Favored Glycine 0 N--CA 1.495 2.608 0 C-N-CA 119.296 -1.431 . . . . 0.0 111.419 -178.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 8.5 tt0 -156.39 145.47 20.42 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.492 -0.883 . . . . 0.0 111.005 179.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.673 HG13 ' O ' ' A' ' 94' ' ' VAL . 12.6 p -135.94 117.53 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.466 -0.893 . . . . 0.0 110.464 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.623 ' HB ' HG22 ' A' ' 20' ' ' THR . 46.1 m -93.72 100.4 12.63 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.194 -1.003 . . . . 0.0 110.599 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 22.9 t -79.22 146.5 7.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 C-N-CA 118.46 -1.296 . . . . 0.0 110.333 -179.077 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.308 -1.233 0 CA-C-O 116.345 -1.788 . . . . 0.0 110.587 -179.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.087 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.1 mt-10 -118.51 122.06 41.77 Favored 'General case' 0 N--CA 1.489 1.519 0 C-N-CA 120.066 -0.654 . . . . 0.0 110.644 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 57.6 t -114.89 113.81 44.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.866 179.829 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 29.5 mtmt -88.63 116.77 27.11 Favored 'General case' 0 C--N 1.298 -1.641 0 C-N-CA 119.193 -1.003 . . . . 0.0 110.854 -179.555 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 7.8 mt -78.6 105.79 10.13 Favored 'General case' 0 C--N 1.31 -1.13 0 C-N-CA 118.788 -1.165 . . . . 0.0 110.41 178.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 103.12 121.42 4.93 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 110.479 -1.048 . . . . 0.0 110.479 -179.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.1 p -71.35 167.12 20.2 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.672 179.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 11.5 m-20 -91.17 -6.6 53.28 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.349 -0.941 . . . . 0.0 110.77 179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.401 ' OD1' ' N ' ' A' ' 9' ' ' ASP . 0.3 OUTLIER -93.68 -5.69 47.99 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.924 -179.886 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 105.07 74.78 0.97 Allowed Glycine 0 N--CA 1.495 2.581 0 C-N-CA 119.727 -1.225 . . . . 0.0 110.385 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -170.05 144.88 8.78 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 119.48 -1.343 . . . . 0.0 110.502 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 23.0 mt -99.79 100.77 11.77 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.698 179.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.7 m -151.0 157.43 5.5 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.211 0 C-N-CA 118.974 -1.09 . . . . 0.0 111.381 179.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.421 ' O ' ' O ' ' A' ' 16' ' ' PRO . 22.1 m-85 -78.53 110.0 13.22 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 177.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.4 m -115.62 109.19 45.99 Favored Pre-proline 0 N--CA 1.488 1.449 0 C-N-CA 119.28 -0.968 . . . . 0.0 112.564 -177.092 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.421 ' O ' ' O ' ' A' ' 14' ' ' PHE . 3.4 Cg_exo -65.9 178.62 15.26 Favored 'Cis proline' 0 C--N 1.364 1.35 0 C-N-CA 125.191 -0.754 . . . . 0.0 111.526 -1.075 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 41.8 t -95.75 -60.47 1.64 Allowed 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 119.562 -0.855 . . . . 0.0 110.376 179.474 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 12.4 t -124.74 140.33 53.03 Favored 'General case' 0 N--CA 1.488 1.438 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.884 179.37 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 28.3 p90 -165.22 149.62 8.82 Favored 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 118.592 -1.243 . . . . 0.0 111.258 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.416 ' H ' HG23 ' A' ' 20' ' ' THR . 0.8 OUTLIER -87.03 160.45 18.61 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.44 -0.904 . . . . 0.0 111.273 -179.876 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 33.3 m -148.86 165.56 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.345 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.941 179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.499 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -87.29 142.91 27.54 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.556 179.817 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.71 77.28 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.305 0 C-N-CA 119.555 -0.858 . . . . 0.0 111.136 -179.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.499 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 146.56 18.41 0.13 Allowed Glycine 0 N--CA 1.488 2.16 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 23.6 tt0 -98.35 138.58 35.38 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.852 -0.739 . . . . 0.0 110.609 -179.627 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.5 mttm -80.1 118.65 22.0 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.141 -179.634 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 7.3 mt -100.41 120.21 49.57 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.228 179.345 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 68.3 p -114.93 118.45 33.49 Favored 'General case' 0 N--CA 1.486 1.363 0 C-N-CA 119.523 -0.871 . . . . 0.0 112.988 -177.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -84.71 114.15 21.83 Favored 'General case' 0 C--N 1.305 -1.327 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 177.415 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 3.4 mttp -103.94 132.33 50.3 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.415 -0.914 . . . . 0.0 111.46 -177.593 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 50.3 t-20 -84.97 110.82 19.17 Favored 'General case' 0 C--N 1.29 -2.004 0 C-N-CA 119.451 -0.9 . . . . 0.0 110.025 178.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -106.67 -30.22 9.12 Favored 'General case' 0 N--CA 1.492 1.638 0 C-N-CA 119.275 -0.97 . . . . 0.0 112.038 -179.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -178.67 161.11 1.25 Allowed 'General case' 0 N--CA 1.494 1.75 0 C-N-CA 119.26 -0.976 . . . . 0.0 111.194 -179.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.505 ' O ' ' NE2' ' A' ' 37' ' ' HIS . . . 75.58 58.61 3.79 Favored Glycine 0 N--CA 1.495 2.58 0 C-N-CA 119.536 -1.316 . . . . 0.0 113.062 178.04 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -97.3 165.27 16.02 Favored Pre-proline 0 N--CA 1.496 1.853 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 177.665 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -78.08 138.46 51.44 Favored 'Cis proline' 0 C--O 1.214 -0.691 0 C-N-CA 124.808 -0.913 . . . . 0.0 113.047 -0.042 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.505 ' NE2' ' O ' ' A' ' 34' ' ' GLY . 36.6 m-70 -102.81 177.34 4.88 Favored 'General case' 0 N--CA 1.493 1.701 0 C-N-CA 119.713 -0.795 . . . . 0.0 110.574 178.566 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.409 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.6 OUTLIER -165.69 154.48 11.64 Favored 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 119.23 -0.988 . . . . 0.0 110.88 179.688 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.623 ' N ' HD12 ' A' ' 39' ' ' ILE . 2.5 mp -139.25 114.67 8.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 C-N-CA 119.64 -0.824 . . . . 0.0 111.103 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 t -130.48 152.21 37.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.603 179.397 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.45 ' CE2' HD12 ' A' ' 55' ' ' ILE . 9.5 m-85 -102.94 141.07 36.37 Favored 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.525 -0.87 . . . . 0.0 111.796 -179.025 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -78.28 109.97 12.88 Favored 'General case' 0 N--CA 1.483 1.184 0 C-N-CA 119.585 -0.846 . . . . 0.0 110.817 179.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.434 ' OE2' ' O ' ' A' ' 41' ' ' PHE . 35.3 mp0 -73.36 47.27 0.21 Allowed 'General case' 0 N--CA 1.491 1.621 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.94 -179.188 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -138.74 -5.84 1.51 Allowed 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.804 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -145.11 7.12 1.17 Allowed 'General case' 0 N--CA 1.487 1.375 0 C-N-CA 118.54 -1.264 . . . . 0.0 111.981 179.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.592 HG13 ' HD2' ' A' ' 47' ' ' PRO . 2.1 t -80.53 150.79 70.83 Favored Pre-proline 0 C--N 1.289 -2.04 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.661 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.592 ' HD2' HG13 ' A' ' 46' ' ' VAL . 4.0 Cg_exo -52.87 158.17 6.79 Favored 'Trans proline' 0 C--O 1.214 -0.681 0 C-N-CA 120.944 1.096 . . . . 0.0 111.794 -179.428 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -88.87 48.7 1.67 Allowed 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.751 -179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -154.6 -32.63 0.03 OUTLIER Glycine 0 N--CA 1.49 2.242 0 C-N-CA 119.515 -1.326 . . . . 0.0 110.134 179.832 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.413 ' O ' HG12 ' A' ' 50' ' ' VAL . 51.6 t -97.29 95.39 4.55 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 C-N-CA 119.599 -0.84 . . . . 0.0 110.841 179.782 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -46.05 148.29 0.87 Allowed 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.037 -1.065 . . . . 0.0 110.322 179.701 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -92.87 -33.77 14.09 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 119.339 -0.945 . . . . 0.0 111.211 -179.591 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -65.81 -17.83 64.91 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.24 -0.984 . . . . 0.0 110.823 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -77.37 -35.88 54.08 Favored 'General case' 0 C--N 1.307 -1.277 0 C-N-CA 119.603 -0.839 . . . . 0.0 111.284 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.45 HD12 ' CE2' ' A' ' 41' ' ' PHE . 1.9 pt -95.69 -35.13 5.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.108 -179.644 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 39.9 m -43.46 158.88 0.03 OUTLIER 'General case' 0 C--N 1.307 -1.26 0 C-N-CA 119.609 -0.836 . . . . 0.0 110.995 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.622 ' NE2' ' CD1' ' A' ' 68' ' ' TYR . 7.5 mt-30 -137.98 71.19 49.08 Favored Pre-proline 0 N--CA 1.486 1.328 0 C-N-CA 119.947 -0.701 . . . . 0.0 110.699 -179.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -61.28 -5.73 5.65 Favored 'Trans proline' 0 C--N 1.321 -0.871 0 C-N-CA 121.274 1.316 . . . . 0.0 111.07 -179.571 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.3 mm-40 -83.65 113.78 21.09 Favored 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.005 179.364 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 30.4 m-85 -69.38 166.4 18.72 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.551 -0.859 . . . . 0.0 111.297 -179.258 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.15 125.65 19.07 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.863 179.537 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.713 ' H ' ' ND2' ' A' ' 62' ' ' ASN . 0.0 OUTLIER -104.87 -74.39 0.65 Allowed 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 119.91 -0.716 . . . . 0.0 111.309 -179.472 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.488 ' H ' ' CG ' ' A' ' 62' ' ' ASN . . . -35.06 146.12 0.04 OUTLIER Glycine 0 N--CA 1.501 2.975 0 C-N-CA 120.401 -0.904 . . . . 0.0 111.446 -179.448 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -81.42 151.56 27.83 Favored 'General case' 0 N--CA 1.484 1.253 0 C-N-CA 119.744 -0.782 . . . . 0.0 110.888 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 95.22 -11.25 69.3 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.365 -1.397 . . . . 0.0 111.307 179.355 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 14.2 mt-10 -74.72 119.94 19.6 Favored 'General case' 0 N--CA 1.487 1.412 0 C-N-CA 119.123 -1.031 . . . . 0.0 111.036 -179.767 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 3.9 p -127.5 160.78 30.47 Favored 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.949 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.622 ' CD1' ' NE2' ' A' ' 57' ' ' GLN . 34.5 t80 -136.48 141.41 43.49 Favored 'General case' 0 N--CA 1.494 1.749 0 C-N-CA 119.784 -0.767 . . . . 0.0 110.171 179.953 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -101.42 149.62 23.87 Favored 'General case' 0 N--CA 1.495 1.804 0 C-N-CA 119.48 -0.888 . . . . 0.0 112.09 -178.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.5 t -146.05 138.4 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.105 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.2 m -132.39 99.76 4.78 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 119.577 -0.849 . . . . 0.0 111.28 -179.46 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.465 ' CD1' HG11 ' A' ' 94' ' ' VAL . 65.3 mt -82.48 162.83 21.93 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.158 179.461 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.604 ' O ' HG22 ' A' ' 73' ' ' THR . 97.7 m -150.57 45.07 0.86 Allowed 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 118.904 -1.118 . . . . 0.0 111.919 -179.105 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -145.02 102.05 3.71 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 118.924 -1.11 . . . . 0.0 110.418 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 22.6 mtmt -45.85 107.94 0.12 Allowed 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.201 -1.0 . . . . 0.0 110.425 -179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 177.21 -146.57 7.83 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.219 -1.467 . . . . 0.0 110.39 -179.601 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.99 130.1 22.07 Favored 'General case' 0 N--CA 1.484 1.257 0 C-N-CA 119.402 -0.919 . . . . 0.0 111.646 -179.589 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.588 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.2 OUTLIER -120.95 147.33 45.61 Favored 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 108.064 -1.088 . . . . 0.0 108.064 178.996 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.458 ' CB ' ' NZ ' ' A' ' 79' ' ' LYS . 0.0 OUTLIER -121.91 121.75 37.83 Favored 'General case' 0 N--CA 1.5 2.032 0 C-N-CA 119.069 -1.052 . . . . 0.0 110.957 179.47 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.612 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.6 OUTLIER -123.5 161.28 25.19 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.764 -0.774 . . . . 0.0 109.904 178.692 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 36.9 p90 -161.5 177.17 10.31 Favored 'General case' 0 C--N 1.285 -2.231 0 C-N-CA 119.184 -1.006 . . . . 0.0 111.176 -179.082 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -100.07 119.09 37.75 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.484 -0.78 . . . . 0.0 109.714 179.374 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.573 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 14.8 tt0 -72.03 -36.05 3.91 Favored Pre-proline 0 C--N 1.308 -1.213 0 C-N-CA 118.998 -1.081 . . . . 0.0 112.953 -179.104 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.573 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.6 Cg_endo -72.05 -54.57 0.14 Allowed 'Trans proline' 0 C--O 1.215 -0.657 0 C-N-CA 120.377 0.718 . . . . 0.0 111.049 179.727 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -79.82 14.93 1.55 Allowed 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.602 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -55.56 -11.64 0.94 Allowed 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.628 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -78.62 -25.38 60.84 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.162 179.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -83.55 -31.74 26.23 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.414 179.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 110.3 26.72 4.76 Favored Glycine 0 N--CA 1.492 2.4 0 C-N-CA 119.781 -1.2 . . . . 0.0 110.859 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 32.0 mtp -67.82 108.49 3.0 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.081 -1.048 . . . . 0.0 110.79 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 mmmm -121.03 154.31 36.22 Favored 'General case' 0 N--CA 1.491 1.611 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.917 179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.492 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.76 146.24 17.19 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.511 -1.328 . . . . 0.0 111.236 -178.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 mt-10 -152.71 145.12 24.05 Favored 'General case' 0 N--CA 1.487 1.393 0 C-N-CA 119.642 -0.823 . . . . 0.0 110.594 179.542 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.551 HG13 ' O ' ' A' ' 94' ' ' VAL . 12.0 p -138.45 125.46 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.794 179.647 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 91.0 m -102.77 99.07 8.99 Favored 'General case' 0 N--CA 1.489 1.49 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.532 179.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 31.7 t -79.87 148.61 5.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.29 0 C-N-CA 118.692 -1.203 . . . . 0.0 110.472 -179.054 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 48.7 p30 . . . . . 0 C--N 1.306 -1.297 0 CA-C-O 116.324 -1.798 . . . . 0.0 110.671 -179.843 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.002 0 CA-C-O 120.839 0.352 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.524 ' OE1' ' N ' ' A' ' 2' ' ' GLU . 10.8 mp0 -105.12 130.97 53.18 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.848 -0.741 . . . . 0.0 110.548 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.1 t -114.08 118.89 59.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 C-N-CA 119.806 -0.758 . . . . 0.0 110.852 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 30.4 mttt -92.77 114.2 26.68 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.78 -179.095 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 1.9 mp -79.71 105.83 11.29 Favored 'General case' 0 C--N 1.313 -1.016 0 C-N-CA 118.597 -1.241 . . . . 0.0 109.696 177.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.439 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.32 90.66 2.14 Favored Glycine 0 C--N 1.29 -2.018 0 N-CA-C 109.741 -1.344 . . . . 0.0 109.741 -178.755 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.541 ' OG ' ' N ' ' A' ' 11' ' ' GLY . 3.1 p -54.41 155.3 3.98 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.766 -179.546 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -59.53 -33.7 71.72 Favored 'General case' 0 C--N 1.304 -1.387 0 C-N-CA 119.426 -0.91 . . . . 0.0 111.039 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -144.71 -0.23 0.94 Allowed 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.459 -0.896 . . . . 0.0 111.009 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -78.19 -36.74 30.36 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.349 -1.405 . . . . 0.0 110.426 -179.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.541 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . 125.61 -141.56 13.06 Favored Glycine 0 N--CA 1.494 2.533 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 -179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.8 mt -99.47 94.88 6.65 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.921 -179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 14.7 m -149.55 155.29 8.31 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 C-N-CA 118.898 -1.121 . . . . 0.0 111.058 179.798 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.439 ' O ' ' O ' ' A' ' 16' ' ' PRO . 29.7 m-85 -78.29 106.93 10.54 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 177.825 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 46.9 m -112.73 113.03 50.48 Favored Pre-proline 0 CA--C 1.556 1.2 0 C-N-CA 119.423 -0.911 . . . . 0.0 112.3 -177.11 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.439 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.5 Cg_endo -66.68 175.6 25.26 Favored 'Cis proline' 0 C--N 1.358 1.039 0 C-N-CA 125.4 -0.667 . . . . 0.0 111.5 -1.052 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -92.83 -61.16 1.64 Allowed 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.469 -0.893 . . . . 0.0 110.014 179.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -119.92 142.53 48.64 Favored 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.474 179.045 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 19.8 p90 -167.78 137.11 2.6 Favored 'General case' 0 C--N 1.308 -1.197 0 C-N-CA 118.577 -1.249 . . . . 0.0 111.304 -179.287 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.447 ' H ' HG23 ' A' ' 20' ' ' THR . 0.3 OUTLIER -84.64 161.21 20.19 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.301 -0.959 . . . . 0.0 111.028 -179.946 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 32.1 m -148.49 162.42 5.75 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.274 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.978 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.475 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -82.76 144.45 30.17 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.278 -0.969 . . . . 0.0 110.435 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.27 76.92 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.369 -0.933 . . . . 0.0 111.07 -179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.475 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 149.22 19.45 0.08 OUTLIER Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.467 ' CD ' ' N ' ' A' ' 26' ' ' LYS . 5.9 tm-20 -101.51 144.56 30.13 Favored 'General case' 0 C--N 1.306 -1.299 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.654 -179.666 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.467 ' N ' ' CD ' ' A' ' 25' ' ' GLU . 67.6 mttt -88.49 133.44 34.13 Favored 'General case' 0 C--N 1.303 -1.435 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.807 -179.799 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.6 mt -117.38 118.14 57.55 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.55 179.727 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 20.8 p -109.95 114.76 28.57 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.825 -0.75 . . . . 0.0 112.392 -178.3 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 45.1 m-85 -84.45 117.96 23.98 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 115.095 -0.957 . . . . 0.0 108.446 178.356 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.69 127.65 53.08 Favored 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 119.289 -0.965 . . . . 0.0 111.525 -177.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 39.0 t-20 -84.29 130.66 34.79 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.667 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.439 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 12.0 p-10 -134.22 -8.01 2.62 Favored 'General case' 0 N--CA 1.493 1.715 0 C-N-CA 118.893 -1.123 . . . . 0.0 112.444 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -171.74 144.52 1.83 Allowed 'General case' 0 N--CA 1.488 1.459 0 C-N-CA 118.376 -1.33 . . . . 0.0 112.318 -179.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 72.15 54.57 7.86 Favored Glycine 0 N--CA 1.489 2.199 0 C-N-CA 119.903 -1.141 . . . . 0.0 113.53 177.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.482 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -92.74 167.07 15.26 Favored Pre-proline 0 N--CA 1.497 1.884 0 C-N-CA 118.718 -1.193 . . . . 0.0 108.498 177.22 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -77.05 146.35 83.4 Favored 'Cis proline' 0 N--CA 1.481 0.738 0 C-N-CA 124.958 -0.851 . . . . 0.0 113.047 -0.323 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 30.5 m-70 -104.69 -177.23 3.31 Favored 'General case' 0 N--CA 1.489 1.485 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.499 178.088 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.696 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -164.61 135.3 4.11 Favored 'General case' 0 C--N 1.303 -1.426 0 C-N-CA 119.742 -0.783 . . . . 0.0 110.057 178.747 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.696 ' N ' HD22 ' A' ' 38' ' ' ASN . 2.8 mp -124.0 119.42 56.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 C-N-CA 119.837 -0.745 . . . . 0.0 110.898 -179.716 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.9 t -142.26 145.5 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.293 0 C-N-CA 119.661 -0.816 . . . . 0.0 110.61 179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 37.2 m-85 -97.37 121.63 39.49 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 119.586 -0.845 . . . . 0.0 111.221 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.444 ' O ' ' OD1' ' A' ' 42' ' ' ASP . 38.1 p-10 -59.91 117.3 4.88 Favored 'General case' 0 C--N 1.309 -1.165 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.781 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -74.96 41.73 0.17 Allowed 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.809 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.44 ' H ' ' C ' ' A' ' 42' ' ' ASP . 7.3 m-20 -135.64 -3.26 2.35 Favored 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.656 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -147.38 19.25 1.2 Allowed 'General case' 0 N--CA 1.485 1.323 0 C-N-CA 119.054 -1.058 . . . . 0.0 111.215 179.823 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -96.71 146.01 30.57 Favored Pre-proline 0 C--N 1.3 -1.544 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.351 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -57.41 147.82 75.55 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.794 0.996 . . . . 0.0 111.82 -179.4 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -61.47 158.63 14.43 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 119.14 -1.024 . . . . 0.0 109.945 179.29 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 79.64 -52.26 4.13 Favored Glycine 0 N--CA 1.487 2.075 0 C-N-CA 118.991 -1.576 . . . . 0.0 109.956 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.608 ' O ' HG12 ' A' ' 50' ' ' VAL . 71.6 t -69.81 73.84 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.165 0 C-N-CA 119.236 -0.986 . . . . 0.0 110.496 179.625 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 60.7 m-20 -44.86 142.35 1.81 Allowed 'General case' 0 C--N 1.306 -1.301 0 C-N-CA 119.362 -0.935 . . . . 0.0 110.698 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -79.3 -29.29 42.38 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.401 -0.919 . . . . 0.0 111.052 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 16.6 mt-10 -74.03 3.61 6.66 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.693 -179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.34 -35.61 10.66 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.948 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.9 pt -99.79 -28.37 3.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 C-N-CA 119.595 -0.842 . . . . 0.0 111.044 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 68.9 m -64.74 154.81 35.68 Favored 'General case' 0 C--N 1.304 -1.385 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.247 -179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.612 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 0.1 OUTLIER -135.86 76.82 52.15 Favored Pre-proline 0 N--CA 1.486 1.356 0 CA-C-N 115.428 -0.805 . . . . 0.0 109.96 179.65 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -57.41 -3.32 0.83 Allowed 'Trans proline' 0 C--O 1.215 -0.63 0 C-N-CA 121.193 1.262 . . . . 0.0 111.87 -178.571 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.432 ' H ' ' C ' ' A' ' 57' ' ' GLN . 11.4 tt0 -72.97 91.53 1.56 Allowed 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 119.021 -1.072 . . . . 0.0 110.021 179.227 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.539 ' CE1' ' OD1' ' A' ' 38' ' ' ASN . 36.4 m-85 -43.61 165.63 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.326 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.947 -179.528 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -142.43 110.47 5.94 Favored 'General case' 0 N--CA 1.487 1.387 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.896 179.55 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.706 ' H ' ' ND2' ' A' ' 62' ' ' ASN . 0.3 OUTLIER -103.28 -6.82 21.65 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.664 179.898 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -71.05 152.04 49.64 Favored Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.456 -1.354 . . . . 0.0 110.44 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -94.83 103.9 15.79 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.764 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 117.24 -7.3 16.51 Favored Glycine 0 N--CA 1.496 2.677 0 C-N-CA 119.941 -1.123 . . . . 0.0 110.62 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -61.4 148.08 42.81 Favored 'General case' 0 N--CA 1.49 1.559 0 C-N-CA 119.055 -1.058 . . . . 0.0 110.457 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 4.9 p -147.18 165.24 30.61 Favored 'General case' 0 N--CA 1.491 1.595 0 C-N-CA 118.901 -1.12 . . . . 0.0 111.889 -179.531 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.612 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 42.3 t80 -137.09 150.8 48.25 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.805 179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.445 ' O ' ' CE1' ' A' ' 68' ' ' TYR . 2.2 mp0 -108.1 151.4 25.93 Favored 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.423 -179.711 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -150.31 135.77 10.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.246 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.303 179.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 15.0 m -135.75 92.17 2.79 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.579 -0.848 . . . . 0.0 111.155 -179.558 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 21.4 mt -79.82 158.7 26.73 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 119.263 -0.975 . . . . 0.0 109.659 179.412 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 23.4 p -150.53 41.98 0.8 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 118.661 -1.216 . . . . 0.0 112.143 -179.237 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 8.8 mt-10 -140.02 105.98 5.2 Favored 'General case' 0 N--CA 1.498 1.957 0 C-N-CA 118.807 -1.157 . . . . 0.0 110.422 179.178 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.5 tttp -40.19 112.37 0.27 Allowed 'General case' 0 N--CA 1.487 1.403 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.301 -179.577 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 169.43 -149.86 14.21 Favored Glycine 0 N--CA 1.488 2.162 0 C-N-CA 118.854 -1.641 . . . . 0.0 110.675 179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -138.09 139.44 39.49 Favored 'General case' 0 N--CA 1.482 1.175 0 C-N-CA 119.761 -0.776 . . . . 0.0 110.984 -179.77 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.563 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.1 m-85 -126.42 128.78 47.53 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.107 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.442 ' O ' ' OD1' ' A' ' 42' ' ' ASP . 3.3 mptp? -105.12 123.94 48.67 Favored 'General case' 0 N--CA 1.493 1.699 0 C-N-CA 119.531 -0.868 . . . . 0.0 112.216 -179.36 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.449 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 9.0 p90 -134.71 171.8 13.86 Favored 'General case' 0 N--CA 1.485 1.315 0 C-N-CA 119.564 -0.854 . . . . 0.0 110.161 177.693 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 25.9 p90 -171.22 -168.92 0.68 Allowed 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 119.409 -0.916 . . . . 0.0 111.188 -178.009 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -116.65 130.04 56.5 Favored 'General case' 0 N--CA 1.482 1.141 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.206 179.036 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.512 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.0 mt-10 -72.17 -46.42 11.04 Favored Pre-proline 0 N--CA 1.484 1.271 0 C-N-CA 119.505 -0.878 . . . . 0.0 112.929 -179.394 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.512 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.8 Cg_endo -66.8 -46.38 3.53 Favored 'Trans proline' 0 C--O 1.215 -0.667 0 C-N-CA 120.806 1.004 . . . . 0.0 112.03 -178.656 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 37.6 m80 -90.46 21.11 4.08 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.28 -0.968 . . . . 0.0 111.239 -179.379 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -67.08 -16.73 64.52 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.359 -0.936 . . . . 0.0 110.597 179.6 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -77.49 -24.07 66.29 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.457 -1.354 . . . . 0.0 110.298 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -86.62 -15.6 39.27 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.475 -0.89 . . . . 0.0 110.392 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 98.77 31.88 6.16 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 119.561 -1.304 . . . . 0.0 110.576 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.63 103.91 9.86 Favored 'General case' 0 C--N 1.306 -1.311 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.997 179.765 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -129.34 166.46 19.45 Favored 'General case' 0 N--CA 1.495 1.794 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.801 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -146.49 155.18 26.4 Favored Glycine 0 N--CA 1.489 2.201 0 C-N-CA 119.123 -1.513 . . . . 0.0 111.779 -178.398 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.9 mt-10 -155.25 143.46 20.2 Favored 'General case' 0 N--CA 1.488 1.455 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.82 179.452 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.12 128.65 30.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 C-N-CA 119.317 -0.953 . . . . 0.0 110.126 179.079 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 98.9 m -106.86 106.82 17.53 Favored 'General case' 0 N--CA 1.497 1.906 0 C-N-CA 119.624 -0.83 . . . . 0.0 110.784 179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.436 ' O ' ' OD1' ' A' ' 97' ' ' ASN . 41.3 t -82.26 138.15 19.92 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 118.347 -1.341 . . . . 0.0 110.586 -179.101 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.436 ' OD1' ' O ' ' A' ' 96' ' ' VAL . 6.7 m-20 . . . . . 0 N--CA 1.486 1.368 0 CA-C-O 116.374 -1.774 . . . . 0.0 110.805 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.134 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -138.23 142.61 39.93 Favored 'General case' 0 N--CA 1.487 1.417 0 C-N-CA 119.787 -0.765 . . . . 0.0 110.579 179.933 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.4 t -131.44 118.75 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 C-N-CA 119.957 -0.697 . . . . 0.0 110.563 -179.938 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.0 mtmp? -90.1 115.3 27.26 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.114 -1.034 . . . . 0.0 111.313 -178.991 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 4.8 mt -76.94 105.71 8.17 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 118.937 -1.105 . . . . 0.0 109.688 178.392 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 111.05 135.58 6.87 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.055 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.413 ' OG ' ' OD1' ' A' ' 9' ' ' ASP . 20.0 p -77.84 169.63 17.96 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.233 -0.987 . . . . 0.0 110.67 179.941 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.431 ' N ' ' OD1' ' A' ' 8' ' ' ASP . 6.3 m-20 -63.63 -48.49 77.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.918 179.907 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.413 ' OD1' ' OG ' ' A' ' 7' ' ' SER . 4.2 p-10 -56.73 -53.12 61.4 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.454 -0.898 . . . . 0.0 110.994 -179.817 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 155.06 11.98 0.06 OUTLIER Glycine 0 N--CA 1.492 2.392 0 C-N-CA 119.379 -1.391 . . . . 0.0 110.282 -179.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.06 164.05 52.62 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 119.572 -1.299 . . . . 0.0 110.42 179.995 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.8 mt -113.55 95.17 5.21 Favored 'General case' 0 N--CA 1.489 1.492 0 C-N-CA 119.963 -0.695 . . . . 0.0 110.913 -179.992 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 19.0 m -150.22 157.09 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.015 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.362 179.124 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.51 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 37.2 m-85 -77.84 115.09 17.32 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 118.898 -1.121 . . . . 0.0 108.15 178.809 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.5 m -116.89 106.98 46.83 Favored Pre-proline 0 CA--C 1.561 1.367 0 C-N-CA 119.58 -0.848 . . . . 0.0 111.813 -177.564 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -66.32 175.66 23.85 Favored 'Cis proline' 0 C--N 1.359 1.124 0 C-N-CA 125.166 -0.764 . . . . 0.0 111.429 -0.132 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -93.96 -37.39 11.7 Favored 'General case' 0 C--N 1.306 -1.318 0 C-N-CA 119.426 -0.91 . . . . 0.0 109.709 178.836 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.6 m -145.72 142.63 29.14 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 115.423 -0.808 . . . . 0.0 109.941 179.18 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.403 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 26.0 p90 -165.91 146.27 6.56 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 118.711 -1.196 . . . . 0.0 111.339 -179.013 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.424 HG23 ' H ' ' A' ' 20' ' ' THR . 1.2 p -90.1 163.54 14.82 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.508 -0.877 . . . . 0.0 111.26 -179.755 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.1 m -150.27 175.61 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.286 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.687 179.43 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.452 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -91.07 146.61 23.7 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.859 -179.988 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.03 74.73 0.05 OUTLIER 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.549 -0.86 . . . . 0.0 110.947 179.742 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 146.18 19.58 0.13 Allowed Glycine 0 N--CA 1.488 2.104 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -96.96 150.03 21.22 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.877 -0.729 . . . . 0.0 111.007 -179.415 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.79 136.13 35.47 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.408 -0.917 . . . . 0.0 110.607 179.592 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 3.9 mt -118.62 151.03 20.77 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 C-N-CA 120.038 -0.665 . . . . 0.0 109.212 179.848 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 9.2 p -142.16 118.46 10.81 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.695 -179.533 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 63.7 m-85 -83.65 125.38 31.78 Favored 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.427 -0.909 . . . . 0.0 109.1 178.471 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 24.0 tptp -110.4 133.69 53.03 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 120.044 -0.662 . . . . 0.0 110.52 -179.142 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.917 ' ND2' HD11 ' A' ' 61' ' ' LEU . 2.7 m120 -89.34 103.33 15.97 Favored 'General case' 0 C--N 1.293 -1.875 0 C-N-CA 119.19 -1.004 . . . . 0.0 110.087 179.331 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.66 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.3 OUTLIER -89.84 -30.63 17.8 Favored 'General case' 0 N--CA 1.482 1.16 0 C-N-CA 119.176 -1.01 . . . . 0.0 111.435 -179.079 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 168.99 146.86 0.03 OUTLIER 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 118.992 -1.083 . . . . 0.0 111.017 -179.864 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 112.74 -5.71 26.01 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.619 -1.277 . . . . 0.0 111.369 179.368 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -47.45 162.83 0.28 Allowed Pre-proline 0 N--CA 1.484 1.26 0 C-N-CA 118.332 -1.347 . . . . 0.0 109.639 179.878 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -77.1 137.95 51.24 Favored 'Cis proline' 0 C--O 1.214 -0.682 0 C-N-CA 124.143 -1.19 . . . . 0.0 112.285 -0.362 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 32.0 m-70 -103.79 177.69 4.77 Favored 'General case' 0 N--CA 1.489 1.497 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.568 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -153.9 140.35 18.73 Favored 'General case' 0 C--N 1.306 -1.303 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.217 179.557 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.459 ' O ' ' N ' ' A' ' 57' ' ' GLN . 3.9 mp -133.22 99.5 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 C-N-CA 119.498 -0.881 . . . . 0.0 111.136 -179.773 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.6 t -121.61 152.55 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.831 179.29 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 13.5 m-85 -104.9 122.87 46.7 Favored 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 119.6 -0.84 . . . . 0.0 111.724 -178.971 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.489 ' C ' ' H ' ' A' ' 44' ' ' ASP . 26.7 t0 -56.14 118.12 4.39 Favored 'General case' 0 N--CA 1.483 1.196 0 C-N-CA 119.705 -0.798 . . . . 0.0 110.442 179.393 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.442 ' CG ' ' O ' ' A' ' 43' ' ' GLU . 2.2 tt0 -73.19 25.86 0.06 Allowed 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.419 -0.913 . . . . 0.0 111.211 -179.431 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.489 ' H ' ' C ' ' A' ' 42' ' ' ASP . 26.0 m-20 -129.1 1.88 5.23 Favored 'General case' 0 N--CA 1.49 1.551 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.795 179.779 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -147.1 53.02 1.08 Allowed 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.674 -0.81 . . . . 0.0 110.408 179.554 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.1 t -135.03 148.1 65.42 Favored Pre-proline 0 N--CA 1.49 1.57 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -179.802 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_exo -47.68 140.14 17.54 Favored 'Trans proline' 0 C--O 1.215 -0.669 0 C-N-CA 120.903 1.069 . . . . 0.0 111.986 -179.4 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.65 83.01 1.56 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.887 -179.953 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 158.06 -33.81 0.52 Allowed Glycine 0 N--CA 1.488 2.129 0 C-N-CA 119.558 -1.305 . . . . 0.0 110.027 -179.893 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 35.7 t -87.33 109.08 18.91 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.713 179.807 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -51.49 153.83 2.07 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.799 -179.92 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -110.88 -6.48 14.71 Favored 'General case' 0 N--CA 1.488 1.446 0 C-N-CA 120.018 -0.673 . . . . 0.0 110.864 -179.844 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -90.16 -15.37 31.66 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.461 -0.895 . . . . 0.0 111.102 -179.81 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.7 mtmm -91.86 -28.92 17.0 Favored 'General case' 0 C--N 1.305 -1.363 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.905 -179.858 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 11.8 pt -98.57 1.14 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.353 0 C-N-CA 119.633 -0.827 . . . . 0.0 110.994 -179.887 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 3.8 m -94.42 -178.52 4.61 Favored 'General case' 0 C--N 1.307 -1.273 0 C-N-CA 119.576 -0.85 . . . . 0.0 111.079 180.0 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.655 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 52.1 mt-30 -139.64 69.9 37.89 Favored Pre-proline 0 C--N 1.305 -1.34 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.338 -179.972 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -59.74 -21.49 63.58 Favored 'Trans proline' 0 C--N 1.325 -0.696 0 C-N-CA 121.531 1.488 . . . . 0.0 111.829 -178.879 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.411 ' O ' ' O ' ' A' ' 60' ' ' TYR . 1.3 tm-20 -91.86 109.91 21.25 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.236 179.539 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.411 ' O ' ' O ' ' A' ' 59' ' ' GLU . 52.8 m-85 -43.09 166.07 0.01 OUTLIER 'General case' 0 C--N 1.309 -1.189 0 C-N-CA 119.541 -0.864 . . . . 0.0 110.948 -179.884 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.917 HD11 ' ND2' ' A' ' 31' ' ' ASN . 0.5 OUTLIER -140.38 148.43 41.25 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.726 -0.79 . . . . 0.0 109.938 179.68 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.609 ' N ' HD12 ' A' ' 61' ' ' LEU . 0.0 OUTLIER -149.05 22.67 0.96 Allowed 'General case' 0 C--N 1.303 -1.447 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.111 -179.464 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -83.14 102.47 2.4 Favored Glycine 0 N--CA 1.486 1.978 0 C-N-CA 119.163 -1.494 . . . . 0.0 110.382 -179.964 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -57.34 113.28 1.69 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.067 -1.053 . . . . 0.0 110.178 179.512 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 97.85 -18.48 57.15 Favored Glycine 0 N--CA 1.487 2.093 0 C-N-CA 119.413 -1.375 . . . . 0.0 110.162 -179.49 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 25.6 tp10 -65.7 128.3 35.42 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.207 -0.997 . . . . 0.0 110.165 179.896 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -110.74 166.65 10.85 Favored 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.796 -0.761 . . . . 0.0 111.427 -179.653 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.655 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 43.1 t80 -135.8 139.86 43.8 Favored 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.455 179.297 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -108.78 158.24 17.83 Favored 'General case' 0 N--CA 1.492 1.65 0 C-N-CA 119.258 -0.977 . . . . 0.0 112.709 -178.589 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -160.07 137.49 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.239 0 CA-C-N 114.982 -1.008 . . . . 0.0 109.122 179.138 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 9.1 m -127.65 97.25 4.79 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.717 -0.793 . . . . 0.0 111.339 -179.242 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 16.8 mt -81.75 159.29 23.89 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.322 -0.951 . . . . 0.0 109.831 179.499 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 18.0 p -150.79 50.85 0.86 Allowed 'General case' 0 C--N 1.3 -1.554 0 C-N-CA 118.882 -1.127 . . . . 0.0 111.946 -178.965 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.417 ' O ' ' C ' ' A' ' 75' ' ' LYS . 3.9 tp10 -146.15 99.9 3.31 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.094 -1.043 . . . . 0.0 110.121 178.992 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.417 ' C ' ' O ' ' A' ' 74' ' ' GLU . 8.7 ptmm? -42.27 112.15 0.31 Allowed 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.292 -0.963 . . . . 0.0 111.051 -179.309 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 168.63 -146.26 10.22 Favored Glycine 0 N--CA 1.485 1.919 0 C-N-CA 119.26 -1.448 . . . . 0.0 110.062 -179.69 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.81 138.33 35.73 Favored 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 119.643 -0.823 . . . . 0.0 110.987 -179.726 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.549 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -121.27 147.78 45.19 Favored 'General case' 0 N--CA 1.482 1.157 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.332 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 18.2 mmtp -112.93 123.56 50.6 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.586 -0.846 . . . . 0.0 111.83 -179.643 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.574 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.5 OUTLIER -136.96 158.66 43.96 Favored 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.611 -0.836 . . . . 0.0 109.789 177.523 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 32.3 p90 -169.86 179.96 3.47 Favored 'General case' 0 C--N 1.292 -1.911 0 C-N-CA 119.261 -0.976 . . . . 0.0 111.206 -178.197 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -103.91 124.63 49.32 Favored 'General case' 0 N--CA 1.484 1.243 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.83 179.753 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.548 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.5 OUTLIER -70.57 -44.42 17.35 Favored Pre-proline 0 N--CA 1.487 1.387 0 C-N-CA 119.66 -0.816 . . . . 0.0 112.752 -179.77 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.548 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.0 Cg_exo -66.72 -53.54 0.55 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 120.892 1.061 . . . . 0.0 111.921 -178.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . 0.425 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.3 m80 -80.0 8.35 7.23 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.336 -0.945 . . . . 0.0 111.292 -179.521 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.37 -7.72 0.64 Allowed 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.266 -0.974 . . . . 0.0 110.705 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.425 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -76.2 -24.91 67.45 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.393 -1.384 . . . . 0.0 110.381 -179.924 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.65 -35.17 15.12 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.602 -179.994 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 124.77 21.09 2.21 Favored Glycine 0 N--CA 1.495 2.624 0 C-N-CA 119.869 -1.158 . . . . 0.0 110.531 179.987 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.79 108.99 1.29 Allowed 'General case' 0 C--N 1.305 -1.328 0 C-N-CA 119.416 -0.914 . . . . 0.0 111.256 -179.857 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.51 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 17.4 mttm -131.57 162.31 30.61 Favored 'General case' 0 N--CA 1.495 1.817 0 C-N-CA 119.685 -0.806 . . . . 0.0 111.392 -179.871 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.454 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.19 147.86 19.49 Favored Glycine 0 N--CA 1.495 2.602 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.098 -179.194 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -149.21 138.05 21.21 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.891 179.842 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.452 HG13 ' O ' ' A' ' 94' ' ' VAL . 9.7 p -135.24 127.95 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.033 0 C-N-CA 118.723 -1.191 . . . . 0.0 110.883 178.694 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 47.4 m -106.91 100.46 9.96 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.572 179.319 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 45.3 t -80.5 144.66 10.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 C-N-CA 118.632 -1.227 . . . . 0.0 110.496 -179.045 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.581 0 CA-C-O 116.284 -1.817 . . . . 0.0 110.758 -179.809 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.184 0 CA-C-O 120.827 0.346 . . . . 0.0 110.163 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.1 mt-10 -100.05 121.68 41.76 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.67 -0.812 . . . . 0.0 110.765 179.88 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.5 t -99.15 119.25 46.89 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 C-N-CA 119.427 -0.909 . . . . 0.0 110.998 179.967 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 2.3 mtmp? -91.3 113.22 25.42 Favored 'General case' 0 C--N 1.297 -1.714 0 C-N-CA 119.626 -0.83 . . . . 0.0 111.021 -179.921 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 mp -79.7 110.58 15.17 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 118.88 -1.128 . . . . 0.0 109.547 178.472 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 98.71 103.82 2.41 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -178.864 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 68.9 p -61.3 172.3 1.15 Allowed 'General case' 0 C--N 1.303 -1.453 0 C-N-CA 119.417 -0.913 . . . . 0.0 110.937 -179.552 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -56.15 -42.55 77.17 Favored 'General case' 0 C--N 1.302 -1.463 0 C-N-CA 119.396 -0.922 . . . . 0.0 110.867 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.0 p-10 -161.14 4.85 0.07 Allowed 'General case' 0 N--CA 1.487 1.402 0 C-N-CA 119.312 -0.955 . . . . 0.0 111.062 179.91 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -71.54 -42.74 54.75 Favored Glycine 0 N--CA 1.492 2.413 0 C-N-CA 119.374 -1.393 . . . . 0.0 110.572 -179.997 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 154.17 -154.67 25.67 Favored Glycine 0 N--CA 1.491 2.315 0 C-N-CA 119.487 -1.339 . . . . 0.0 110.349 -179.959 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.4 mt -100.11 100.31 11.14 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.712 -0.795 . . . . 0.0 110.746 179.996 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 18.7 m -145.7 157.9 12.59 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 C-N-CA 118.962 -1.095 . . . . 0.0 111.131 179.843 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.403 ' O ' ' C ' ' A' ' 16' ' ' PRO . 47.3 m-85 -79.17 111.37 15.32 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 177.459 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 47.8 m -114.89 107.96 49.46 Favored Pre-proline 0 C--N 1.307 -1.275 0 C-N-CA 119.536 -0.866 . . . . 0.0 112.406 -177.071 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.403 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.9 Cg_endo -67.01 167.35 58.32 Favored 'Cis proline' 0 C--N 1.359 1.086 0 C-N-CA 125.34 -0.692 . . . . 0.0 111.528 -0.827 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.423 ' OG ' ' N ' ' A' ' 18' ' ' SER . 0.2 OUTLIER -95.29 -67.24 0.86 Allowed 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.496 -0.881 . . . . 0.0 109.716 178.885 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.423 ' N ' ' OG ' ' A' ' 17' ' ' SER . 0.7 OUTLIER -112.2 123.44 50.27 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 115.573 -0.74 . . . . 0.0 109.437 178.816 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.487 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 11.5 p90 -156.72 144.31 19.14 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 118.782 -1.167 . . . . 0.0 111.141 -179.005 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -88.84 157.26 18.51 Favored 'General case' 0 C--N 1.3 -1.586 0 C-N-CA 119.299 -0.96 . . . . 0.0 111.247 -179.84 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 34.5 m -148.61 171.44 2.26 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.493 179.631 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -86.81 151.92 22.94 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.477 -179.933 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.4 65.95 0.65 Allowed 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.566 -0.854 . . . . 0.0 110.873 179.761 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.444 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 171.02 8.58 0.02 OUTLIER Glycine 0 N--CA 1.486 1.983 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.444 ' H ' ' H ' ' A' ' 24' ' ' GLY . 6.8 tp10 -98.65 154.14 18.17 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.752 -0.779 . . . . 0.0 110.549 -179.931 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 49.6 mttm -95.17 144.06 26.1 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.288 -179.718 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 37.1 mm -111.89 98.34 6.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 CA-C-N 115.541 -0.754 . . . . 0.0 108.999 179.033 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 31.7 p -92.85 115.49 28.17 Favored 'General case' 0 C--N 1.301 -1.517 0 C-N-CA 119.145 -1.022 . . . . 0.0 112.477 -178.217 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 53.6 m-85 -85.18 121.2 27.59 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-N 115.021 -0.991 . . . . 0.0 109.136 178.512 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -124.68 134.87 52.72 Favored 'General case' 0 N--CA 1.491 1.616 0 C-N-CA 119.686 -0.806 . . . . 0.0 111.734 -178.519 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.489 ' ND2' ' O ' ' A' ' 66' ' ' GLU . 57.5 m-80 -84.67 113.31 21.2 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-N 115.483 -0.781 . . . . 0.0 110.505 179.604 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.549 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.9 t30 -97.98 -30.23 12.84 Favored 'General case' 0 N--CA 1.482 1.137 0 C-N-CA 119.195 -1.002 . . . . 0.0 111.354 -179.23 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.549 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.7 99.33 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.865 0 C-N-CA 119.491 -0.884 . . . . 0.0 111.004 179.724 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 153.11 23.45 0.05 OUTLIER Glycine 0 N--CA 1.489 2.22 0 C-N-CA 118.874 -1.632 . . . . 0.0 111.234 179.487 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.62 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -73.67 162.68 73.06 Favored Pre-proline 0 C--N 1.307 -1.253 0 C-N-CA 118.744 -1.182 . . . . 0.0 109.907 179.756 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -75.8 147.51 88.18 Favored 'Cis proline' 0 N--CA 1.479 0.658 0 C-N-CA 124.396 -1.085 . . . . 0.0 112.366 -1.118 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 37.1 m-70 -112.59 -177.66 3.2 Favored 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.944 -0.702 . . . . 0.0 110.817 179.279 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.796 HD22 ' H ' ' A' ' 83' ' ' GLU . 2.7 t30 -163.75 144.35 8.7 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.771 -0.772 . . . . 0.0 110.005 179.173 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.9 mp -133.78 122.79 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 119.567 -0.853 . . . . 0.0 111.436 -179.48 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 61.8 t -140.61 146.5 24.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 CA-C-N 115.354 -0.839 . . . . 0.0 109.403 179.101 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 29.5 m-85 -100.51 128.49 46.56 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.214 -0.994 . . . . 0.0 111.888 -179.094 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 25.8 t0 -66.71 119.98 12.71 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 119.506 -0.877 . . . . 0.0 110.244 179.512 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 42.3 mt-10 -68.66 -7.21 31.2 Favored 'General case' 0 N--CA 1.488 1.456 0 C-N-CA 119.768 -0.773 . . . . 0.0 112.026 -178.991 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 15.3 m-20 -97.37 7.15 47.1 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.247 -0.981 . . . . 0.0 111.649 -179.208 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -145.55 27.63 1.22 Allowed 'General case' 0 N--CA 1.488 1.466 0 C-N-CA 119.284 -0.966 . . . . 0.0 110.748 -179.982 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -118.78 146.77 40.8 Favored Pre-proline 0 N--CA 1.492 1.627 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.088 179.801 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -53.05 144.15 47.48 Favored 'Trans proline' 0 C--O 1.214 -0.706 0 C-N-CA 120.953 1.102 . . . . 0.0 111.907 -179.926 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -73.04 72.2 1.14 Allowed 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 119.533 -0.867 . . . . 0.0 110.855 179.839 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 177.09 -46.52 0.1 Allowed Glycine 0 N--CA 1.49 2.282 0 C-N-CA 119.544 -1.312 . . . . 0.0 109.978 179.929 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 96.8 t -79.92 87.8 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 C-N-CA 119.435 -0.906 . . . . 0.0 110.474 179.697 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m-80 -44.63 140.11 2.59 Favored 'General case' 0 C--N 1.307 -1.268 0 C-N-CA 119.419 -0.913 . . . . 0.0 110.964 -179.615 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.0 -20.88 44.4 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.889 -179.94 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -74.38 -22.37 59.22 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.437 -0.905 . . . . 0.0 111.128 -179.713 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -79.27 -24.86 42.67 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.36 -179.612 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -109.79 -18.47 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.427 -179.774 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 41.3 m -71.37 171.0 12.01 Favored 'General case' 0 C--N 1.307 -1.247 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.183 179.82 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.633 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 56.5 mt-30 -128.06 78.53 75.19 Favored Pre-proline 0 N--CA 1.488 1.446 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.333 179.914 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -60.86 -11.24 17.08 Favored 'Trans proline' 0 C--O 1.216 -0.608 0 C-N-CA 121.208 1.272 . . . . 0.0 111.615 -178.864 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 20.4 mt-10 -99.47 108.02 20.37 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.608 -0.837 . . . . 0.0 110.749 179.779 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -55.1 176.74 0.04 OUTLIER 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.531 -0.867 . . . . 0.0 110.85 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.8 pp -154.9 153.1 30.58 Favored 'General case' 0 N--CA 1.486 1.353 0 C-N-CA 119.131 -1.028 . . . . 0.0 111.468 -179.576 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -149.01 14.96 0.92 Allowed 'General case' 0 N--CA 1.485 1.316 0 C-N-CA 119.555 -0.858 . . . . 0.0 110.987 -179.988 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -80.95 125.25 6.78 Favored Glycine 0 N--CA 1.491 2.326 0 C-N-CA 119.355 -1.402 . . . . 0.0 110.689 -179.574 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -68.22 126.77 30.61 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.415 -0.914 . . . . 0.0 110.63 179.687 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.56 -12.06 62.17 Favored Glycine 0 N--CA 1.488 2.151 0 C-N-CA 119.326 -1.416 . . . . 0.0 110.713 179.887 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.489 ' O ' ' ND2' ' A' ' 31' ' ' ASN . 2.8 tp10 -65.1 144.3 57.33 Favored 'General case' 0 N--CA 1.485 1.275 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.263 179.749 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -140.79 170.54 15.57 Favored 'General case' 0 N--CA 1.489 1.494 0 C-N-CA 119.32 -0.952 . . . . 0.0 111.372 -179.387 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.633 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 47.5 t80 -135.57 -179.76 5.84 Favored 'General case' 0 N--CA 1.485 1.295 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 179.49 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.56 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 3.3 mt-10 -140.69 146.16 37.46 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.166 -1.014 . . . . 0.0 111.652 -179.818 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.6 t -147.64 126.66 4.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.349 -0.842 . . . . 0.0 109.222 179.377 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 5.1 m -121.28 99.82 6.7 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.839 -0.744 . . . . 0.0 111.453 -178.841 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.432 ' CD1' HG11 ' A' ' 94' ' ' VAL . 54.9 mt -82.3 159.89 23.03 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.021 179.227 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 57.5 p -150.09 42.99 0.87 Allowed 'General case' 0 C--N 1.296 -1.757 0 C-N-CA 119.214 -0.994 . . . . 0.0 111.083 -179.529 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -143.49 101.37 3.77 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.026 -1.07 . . . . 0.0 110.836 179.76 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -44.61 113.43 0.55 Allowed 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.451 -0.899 . . . . 0.0 110.67 -179.953 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 172.9 -145.0 8.17 Favored Glycine 0 N--CA 1.487 2.065 0 C-N-CA 119.399 -1.381 . . . . 0.0 110.044 -179.961 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -143.82 127.14 16.73 Favored 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 119.431 -0.908 . . . . 0.0 110.893 179.955 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.564 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.8 m-85 -114.16 161.9 17.21 Favored 'General case' 0 N--CA 1.488 1.43 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.639 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 11.5 mmtm -130.48 116.81 18.72 Favored 'General case' 0 N--CA 1.49 1.537 0 C-N-CA 119.47 -0.892 . . . . 0.0 111.987 -178.929 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.554 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -123.87 159.05 30.48 Favored 'General case' 0 N--CA 1.484 1.241 0 C-N-CA 119.844 -0.742 . . . . 0.0 109.887 178.081 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 47.1 p90 -168.67 -179.3 3.75 Favored 'General case' 0 C--N 1.289 -2.025 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.982 -178.936 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . 0.484 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -108.81 124.27 50.34 Favored 'General case' 0 N--CA 1.485 1.305 0 C-N-CA 119.659 -0.816 . . . . 0.0 110.634 179.825 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.796 ' H ' HD22 ' A' ' 38' ' ' ASN . 2.3 mt-10 -63.18 -45.28 85.52 Favored Pre-proline 0 N--CA 1.485 1.308 0 C-N-CA 119.728 -0.789 . . . . 0.0 112.997 -179.611 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.51 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 2.8 Cg_endo -66.16 -46.04 4.94 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 120.99 1.127 . . . . 0.0 112.077 -179.202 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 29.1 m80 -92.59 14.62 16.4 Favored 'General case' 0 N--CA 1.485 1.29 0 C-N-CA 119.16 -1.016 . . . . 0.0 111.55 -179.262 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.484 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -67.97 -1.19 5.26 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 118.946 -1.101 . . . . 0.0 110.455 179.66 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -95.27 -18.76 32.51 Favored Glycine 0 N--CA 1.489 2.176 0 C-N-CA 119.439 -1.362 . . . . 0.0 110.095 179.871 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.94 -36.34 15.05 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.455 -0.898 . . . . 0.0 110.44 179.676 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 130.72 26.0 0.81 Allowed Glycine 0 N--CA 1.494 2.539 0 C-N-CA 119.911 -1.137 . . . . 0.0 110.342 179.836 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -82.65 95.37 7.79 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.186 -1.006 . . . . 0.0 110.865 -179.924 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -124.7 162.51 24.03 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.946 -0.702 . . . . 0.0 110.816 179.926 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -143.62 144.83 14.14 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.294 -1.432 . . . . 0.0 111.874 -178.455 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 31.2 tt0 -148.52 143.69 26.83 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.963 -0.695 . . . . 0.0 110.084 179.282 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.611 HG13 ' O ' ' A' ' 94' ' ' VAL . 14.0 p -137.44 118.68 17.74 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 C-N-CA 119.09 -1.044 . . . . 0.0 110.793 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 90.8 m -95.62 99.17 11.07 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.222 -0.991 . . . . 0.0 110.486 179.528 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 35.5 t -80.11 149.38 5.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 C-N-CA 118.999 -1.08 . . . . 0.0 110.805 -178.804 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 87.7 m-20 . . . . . 0 N--CA 1.486 1.345 0 CA-C-O 116.332 -1.794 . . . . 0.0 110.797 -179.862 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.066 0 CA-C-O 120.867 0.365 . . . . 0.0 110.052 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -93.77 140.46 29.63 Favored 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.701 179.866 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 3.7 t -126.95 131.88 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 C-N-CA 119.932 -0.707 . . . . 0.0 110.523 179.477 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 11.7 mtmm -105.17 118.09 35.66 Favored 'General case' 0 C--N 1.303 -1.416 0 CA-C-N 115.66 -0.7 . . . . 0.0 110.844 -179.534 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.408 ' C ' ' OD1' ' A' ' 32' ' ' ASN . 5.7 mt -79.87 103.71 9.95 Favored 'General case' 0 C--N 1.307 -1.255 0 C-N-CA 118.754 -1.178 . . . . 0.0 109.639 178.809 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.521 ' C ' HD21 ' A' ' 32' ' ' ASN . . . 118.53 134.3 4.97 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -178.527 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.434 ' O ' ' O ' ' A' ' 6' ' ' GLY . 26.0 p -52.79 -103.81 0.0 OUTLIER 'General case' 0 C--N 1.305 -1.33 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.198 -179.423 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -156.06 -22.14 0.1 Allowed 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.032 -1.067 . . . . 0.0 111.173 -179.9 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -106.72 -28.43 10.18 Favored 'General case' 0 N--CA 1.49 1.538 0 C-N-CA 119.809 -0.757 . . . . 0.0 110.894 -179.847 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 158.28 26.4 0.03 OUTLIER Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.409 -1.377 . . . . 0.0 110.469 -179.975 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -96.3 163.67 23.11 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.442 -1.361 . . . . 0.0 110.342 -179.993 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.0 mt -121.13 91.44 3.53 Favored 'General case' 0 N--CA 1.49 1.545 0 C-N-CA 120.101 -0.64 . . . . 0.0 110.711 179.745 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 4.5 m -147.67 154.18 11.34 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 C-N-CA 118.952 -1.099 . . . . 0.0 111.044 179.626 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.424 ' O ' ' O ' ' A' ' 16' ' ' PRO . 9.9 m-85 -78.22 107.61 10.94 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.431 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.8 m -113.77 109.04 50.67 Favored Pre-proline 0 C--N 1.306 -1.313 0 C-N-CA 119.81 -0.756 . . . . 0.0 111.912 -177.447 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.424 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.6 Cg_endo -67.64 177.05 23.95 Favored 'Cis proline' 0 C--N 1.355 0.916 0 CA-C-N 119.053 0.697 . . . . 0.0 111.671 -0.376 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 2.4 p -93.92 -47.16 6.85 Favored 'General case' 0 N--CA 1.485 1.289 0 C-N-CA 119.56 -0.856 . . . . 0.0 109.77 178.862 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.8 p -132.82 144.28 50.11 Favored 'General case' 0 N--CA 1.486 1.33 0 CA-C-N 115.156 -0.929 . . . . 0.0 109.287 178.841 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 17.6 p90 -164.6 134.58 3.9 Favored 'General case' 0 N--CA 1.484 1.232 0 C-N-CA 118.456 -1.297 . . . . 0.0 111.409 -178.962 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 1.5 p -86.42 159.71 19.27 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.479 -0.888 . . . . 0.0 110.855 -179.983 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.7 m -148.79 172.49 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 C-N-CA 119.37 -0.932 . . . . 0.0 110.902 179.755 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -87.57 149.61 24.23 Favored 'General case' 0 C--N 1.303 -1.428 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.774 -179.999 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.29 73.33 0.49 Allowed 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 119.348 -0.941 . . . . 0.0 111.072 179.974 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.433 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 155.75 14.32 0.05 OUTLIER Glycine 0 N--CA 1.486 2.028 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.433 ' H ' ' H ' ' A' ' 24' ' ' GLY . 24.5 tt0 -104.45 147.24 27.79 Favored 'General case' 0 C--N 1.307 -1.27 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.552 -179.597 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.1 pttm -95.36 149.84 20.93 Favored 'General case' 0 C--N 1.305 -1.344 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.48 -179.616 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.4 mt -119.95 148.9 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.237 179.202 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.3 p -138.6 119.34 14.12 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 119.224 -0.991 . . . . 0.0 111.692 -179.153 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -86.61 146.03 26.5 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.338 178.9 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 12.3 tttm -138.39 132.04 30.84 Favored 'General case' 0 N--CA 1.489 1.481 0 C-N-CA 119.327 -0.949 . . . . 0.0 111.356 -179.231 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.607 HD21 HD13 ' A' ' 61' ' ' LEU . 3.0 m-20 -81.18 113.09 19.1 Favored 'General case' 0 C--N 1.299 -1.589 0 C-N-CA 119.62 -0.832 . . . . 0.0 110.815 179.576 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.633 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 4.0 p-10 -106.2 -23.54 12.56 Favored 'General case' 0 N--CA 1.493 1.689 0 C-N-CA 119.38 -0.928 . . . . 0.0 111.743 -179.775 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.633 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 170.82 101.89 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.251 0 C-N-CA 118.509 -1.277 . . . . 0.0 111.326 179.837 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 141.65 22.19 0.25 Allowed Glycine 0 N--CA 1.489 2.207 0 C-N-CA 119.239 -1.458 . . . . 0.0 111.457 179.574 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.61 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -78.2 161.98 68.44 Favored Pre-proline 0 N--CA 1.485 1.288 0 C-N-CA 118.159 -1.417 . . . . 0.0 110.026 179.502 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -75.9 148.56 90.45 Favored 'Cis proline' 0 C--O 1.214 -0.684 0 C-N-CA 124.21 -1.162 . . . . 0.0 112.291 -0.755 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . 0.402 ' CD2' ' HB3' ' A' ' 5' ' ' LEU . 48.9 m-70 -115.48 178.56 4.25 Favored 'General case' 0 N--CA 1.497 1.916 0 C-N-CA 119.878 -0.729 . . . . 0.0 110.166 179.585 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.629 HD22 ' H ' ' A' ' 39' ' ' ILE . 1.2 t-20 -151.13 137.98 18.97 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.2 -1.0 . . . . 0.0 110.338 178.875 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.629 ' H ' HD22 ' A' ' 38' ' ' ASN . 5.7 mt -124.06 106.1 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 C-N-CA 119.925 -0.71 . . . . 0.0 111.135 -179.494 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 t -128.32 149.0 32.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.001 179.54 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 32.0 m-85 -103.94 126.76 51.3 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.861 -179.305 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.432 ' C ' ' H ' ' A' ' 44' ' ' ASP . 0.4 OUTLIER -70.64 118.07 12.97 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.412 179.636 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -74.76 41.6 0.16 Allowed 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 119.386 -0.926 . . . . 0.0 110.861 -179.677 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.432 ' H ' ' C ' ' A' ' 42' ' ' ASP . 8.6 m-20 -128.28 -10.53 5.23 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.586 179.815 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -132.81 15.93 4.3 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.74 179.831 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.402 HG13 ' HD2' ' A' ' 47' ' ' PRO . 55.5 t -99.1 143.45 26.41 Favored Pre-proline 0 C--N 1.296 -1.73 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 179.571 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.402 ' HD2' HG13 ' A' ' 46' ' ' VAL . 3.6 Cg_exo -55.42 161.75 6.97 Favored 'Trans proline' 0 C--O 1.214 -0.71 0 C-N-CA 120.81 1.006 . . . . 0.0 111.619 -179.947 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -90.22 51.23 1.99 Allowed 'General case' 0 C--N 1.308 -1.236 0 C-N-CA 119.578 -0.849 . . . . 0.0 111.001 -179.964 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -154.0 -42.86 0.02 OUTLIER Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.46 -1.352 . . . . 0.0 109.998 179.827 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 5.6 p -77.35 152.28 5.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 119.812 -0.755 . . . . 0.0 110.407 179.643 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 14.7 m120 -88.79 139.47 30.43 Favored 'General case' 0 C--N 1.305 -1.366 0 C-N-CA 119.077 -1.049 . . . . 0.0 110.048 179.173 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.419 ' HA ' HD11 ' A' ' 55' ' ' ILE . . . -102.76 -4.48 24.91 Favored 'General case' 0 N--CA 1.491 1.611 0 C-N-CA 119.666 -0.814 . . . . 0.0 111.252 -179.782 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.5 mm-40 -90.69 -33.68 15.7 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.645 -179.531 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 62.8 mttt -78.26 -21.82 49.25 Favored 'General case' 0 N--CA 1.488 1.43 0 C-N-CA 119.434 -0.906 . . . . 0.0 111.972 -179.018 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.419 HD11 ' HA ' ' A' ' 52' ' ' ALA . 6.3 pt -92.91 -25.03 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.213 -179.547 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 33.3 m -69.19 174.1 5.0 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.133 179.658 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.659 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 66.7 mt-30 -126.88 78.98 73.14 Favored Pre-proline 0 N--CA 1.488 1.456 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.65 -179.888 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -62.27 -14.44 38.45 Favored 'Trans proline' 0 C--O 1.215 -0.628 0 C-N-CA 120.958 1.105 . . . . 0.0 111.187 -179.258 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.423 ' O ' ' O ' ' A' ' 60' ' ' TYR . 10.5 mt-10 -100.53 105.06 16.46 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.78 -0.768 . . . . 0.0 110.646 179.445 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.423 ' O ' ' O ' ' A' ' 59' ' ' GLU . 31.6 m-85 -46.01 172.4 0.01 OUTLIER 'General case' 0 C--N 1.307 -1.282 0 C-N-CA 119.627 -0.829 . . . . 0.0 110.941 -179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.607 HD13 HD21 ' A' ' 31' ' ' ASN . 3.0 pp -138.54 125.79 21.58 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.688 -0.805 . . . . 0.0 110.29 179.548 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -132.61 45.49 2.74 Favored 'General case' 0 N--CA 1.492 1.636 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.409 -178.845 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -124.28 118.97 3.56 Favored Glycine 0 N--CA 1.499 2.896 0 C-N-CA 119.718 -1.229 . . . . 0.0 110.528 179.822 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -54.64 123.4 13.07 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.378 -0.929 . . . . 0.0 110.398 179.735 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 81.48 3.86 90.54 Favored Glycine 0 N--CA 1.489 2.225 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.648 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -69.47 107.16 3.24 Favored 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 119.232 -0.987 . . . . 0.0 109.921 179.607 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.5 p -98.09 164.59 12.28 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 119.499 -0.88 . . . . 0.0 111.55 -178.96 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.659 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 45.1 t80 -135.0 176.97 8.17 Favored 'General case' 0 C--N 1.308 -1.217 0 N-CA-C 108.39 -0.967 . . . . 0.0 108.39 178.844 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.605 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 5.3 mt-10 -144.89 150.86 37.79 Favored 'General case' 0 N--CA 1.489 1.51 0 C-N-CA 118.539 -1.265 . . . . 0.0 112.252 -179.316 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -157.85 136.83 3.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 CA-C-N 115.066 -0.97 . . . . 0.0 108.727 179.205 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 19.1 m -129.12 92.74 3.44 Favored 'General case' 0 C--N 1.307 -1.274 0 C-N-CA 119.53 -0.868 . . . . 0.0 111.716 -178.907 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 10.0 mt -79.76 155.39 27.94 Favored 'General case' 0 C--N 1.304 -1.389 0 C-N-CA 118.995 -1.082 . . . . 0.0 108.709 178.833 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.567 HG23 ' OE2' ' A' ' 74' ' ' GLU . 3.1 t -150.47 46.57 0.88 Allowed 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 118.678 -1.209 . . . . 0.0 111.719 -179.29 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.567 ' OE2' HG23 ' A' ' 73' ' ' THR . 34.1 mm-40 -138.81 103.12 4.74 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.47 -0.892 . . . . 0.0 109.78 178.916 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -40.11 107.18 0.07 Allowed 'General case' 0 N--CA 1.486 1.349 0 C-N-CA 119.781 -0.768 . . . . 0.0 111.321 -179.448 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 176.74 -150.36 10.32 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.172 -1.489 . . . . 0.0 110.591 -179.778 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -140.89 133.61 28.81 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.258 -179.521 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.604 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 0.9 OUTLIER -120.13 155.43 33.07 Favored 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.765 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 27.0 mmtt -126.93 127.94 45.65 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.532 -0.867 . . . . 0.0 111.909 -178.876 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.512 ' O ' ' N ' ' A' ' 92' ' ' GLY . 2.0 p90 -139.11 165.85 26.06 Favored 'General case' 0 N--CA 1.483 1.215 0 C-N-CA 119.432 -0.907 . . . . 0.0 110.701 178.377 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 35.2 p90 -169.91 -179.78 3.35 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.474 -0.89 . . . . 0.0 111.144 -177.928 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -104.07 125.53 50.48 Favored 'General case' 0 C--N 1.309 -1.192 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.321 179.404 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.55 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.4 tt0 -68.6 -44.48 33.19 Favored Pre-proline 0 N--CA 1.486 1.358 0 C-N-CA 119.531 -0.868 . . . . 0.0 112.985 -179.436 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.6 Cg_endo -68.44 -50.06 0.76 Allowed 'Trans proline' 0 C--O 1.215 -0.652 0 C-N-CA 120.931 1.087 . . . . 0.0 111.94 -178.771 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 33.4 m80 -88.9 16.91 6.2 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 119.342 -0.943 . . . . 0.0 111.572 -179.363 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.64 -10.32 3.48 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 119.202 -0.999 . . . . 0.0 110.726 179.92 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -89.13 -17.09 56.63 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.374 -1.393 . . . . 0.0 110.304 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.34 -22.89 24.82 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.385 179.881 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 112.7 17.48 7.99 Favored Glycine 0 N--CA 1.494 2.523 0 C-N-CA 119.881 -1.152 . . . . 0.0 110.798 179.629 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.1 mtp -70.64 99.87 1.75 Allowed 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.228 179.806 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 8.1 pttp -125.1 164.33 20.46 Favored 'General case' 0 N--CA 1.492 1.63 0 C-N-CA 120.045 -0.662 . . . . 0.0 110.088 178.723 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.02 147.75 18.49 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 118.538 -1.791 . . . . 0.0 111.862 -178.497 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -153.94 146.9 24.47 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 119.721 -0.792 . . . . 0.0 110.568 179.103 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.8 p -140.68 134.36 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 C-N-CA 119.235 -0.986 . . . . 0.0 110.125 179.252 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.2 m -110.66 101.73 10.35 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 119.65 -0.82 . . . . 0.0 110.886 179.734 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 49.0 t -80.68 152.1 4.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.902 -179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.6 p30 . . . . . 0 C--N 1.304 -1.4 0 CA-C-O 116.364 -1.779 . . . . 0.0 110.81 -179.867 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.156 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 16.9 mt-10 -110.54 122.86 48.78 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.996 179.965 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.0 t -111.26 126.36 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 119.983 -0.687 . . . . 0.0 110.524 179.728 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 39.4 mttt -98.72 118.45 35.48 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.591 -0.844 . . . . 0.0 110.809 -179.483 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.419 ' O ' ' OD1' ' A' ' 32' ' ' ASN . 12.8 mt -82.05 107.1 14.49 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 118.754 -1.179 . . . . 0.0 110.625 179.135 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.418 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 114.49 138.71 6.83 Favored Glycine 0 N--CA 1.495 2.626 0 C-N-CA 120.218 -0.991 . . . . 0.0 110.669 -179.588 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 24.2 p -79.5 163.98 24.29 Favored 'General case' 0 C--N 1.308 -1.201 0 C-N-CA 119.532 -0.867 . . . . 0.0 110.624 179.747 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -62.25 -35.4 78.85 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.343 -0.943 . . . . 0.0 110.954 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -169.6 17.86 0.02 OUTLIER 'General case' 0 C--N 1.306 -1.289 0 C-N-CA 119.34 -0.944 . . . . 0.0 110.849 -179.99 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -97.05 -68.37 0.96 Allowed Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.44 -1.362 . . . . 0.0 110.564 179.96 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -164.04 -147.06 4.96 Favored Glycine 0 N--CA 1.491 2.354 0 C-N-CA 119.383 -1.389 . . . . 0.0 110.43 -179.843 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.8 mt -112.92 111.62 22.51 Favored 'General case' 0 N--CA 1.491 1.586 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.695 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 7.4 m -150.72 159.71 4.44 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.185 0 C-N-CA 118.993 -1.083 . . . . 0.0 110.708 179.234 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.508 ' CD2' ' O ' ' A' ' 91' ' ' LYS . 23.3 m-85 -78.46 114.58 17.49 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 107.548 -1.279 . . . . 0.0 107.548 177.948 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 1.4 m -116.24 105.99 49.81 Favored Pre-proline 0 C--N 1.308 -1.238 0 C-N-CA 119.423 -0.911 . . . . 0.0 111.865 -177.45 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -67.55 178.32 20.2 Favored 'Cis proline' 0 C--N 1.359 1.131 0 CA-C-N 118.921 0.65 . . . . 0.0 111.946 -0.395 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 1.1 m -94.14 -48.12 6.35 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.643 -0.823 . . . . 0.0 110.182 179.162 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 44.6 m -137.34 140.98 41.82 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.413 -0.812 . . . . 0.0 109.419 179.144 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.405 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 25.1 p90 -162.93 143.21 9.33 Favored 'General case' 0 C--N 1.305 -1.356 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.626 -179.138 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.415 HG23 ' H ' ' A' ' 20' ' ' THR . 0.6 OUTLIER -91.27 155.51 18.5 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.713 -0.795 . . . . 0.0 111.146 179.894 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.07 157.13 10.4 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 C-N-CA 119.416 -0.914 . . . . 0.0 111.082 -179.95 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.46 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -75.4 141.06 43.3 Favored 'General case' 0 C--N 1.305 -1.362 0 C-N-CA 119.442 -0.903 . . . . 0.0 110.17 179.456 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.94 75.32 0.04 OUTLIER 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.045 -179.783 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 161.53 13.48 0.03 OUTLIER Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 179.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 tt0 -104.94 151.04 24.37 Favored 'General case' 0 C--N 1.308 -1.231 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.622 -179.649 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 21.8 mttp -94.53 141.1 28.99 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.485 -0.886 . . . . 0.0 111.037 -179.919 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 2.5 mt -117.89 153.06 19.88 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.26 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 179.743 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 39.5 p -147.77 113.45 5.7 Favored 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 118.811 -1.156 . . . . 0.0 111.954 -179.448 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -84.39 116.18 22.91 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.36 -0.936 . . . . 0.0 108.962 178.485 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.2 tttm -111.56 132.84 54.25 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.73 -0.788 . . . . 0.0 111.778 -178.264 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.579 ' OD1' HD11 ' A' ' 61' ' ' LEU . 0.6 OUTLIER -76.48 104.23 6.89 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.703 -0.799 . . . . 0.0 109.849 178.904 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.466 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 5.2 p-10 -94.21 -26.23 16.74 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 118.906 -1.118 . . . . 0.0 112.025 -178.642 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.466 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 179.12 147.53 0.2 Allowed 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 118.489 -1.284 . . . . 0.0 111.593 -179.783 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 89.63 10.28 65.47 Favored Glycine 0 N--CA 1.481 1.674 0 C-N-CA 119.485 -1.341 . . . . 0.0 111.731 178.661 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -49.66 162.54 0.44 Allowed Pre-proline 0 N--CA 1.48 1.055 0 C-N-CA 117.844 -1.542 . . . . 0.0 108.895 179.431 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -75.93 -173.67 13.0 Favored 'Cis proline' 0 C--O 1.204 -1.189 0 C-N-CA 124.324 -1.115 . . . . 0.0 112.294 -0.213 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.8 m-70 -151.07 171.92 16.56 Favored 'General case' 0 N--CA 1.493 1.677 0 C-N-CA 120.142 -0.623 . . . . 0.0 110.522 178.576 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.697 HD22 ' H ' ' A' ' 39' ' ' ILE . 1.3 t-20 -149.61 148.29 29.14 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.488 179.393 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.697 ' H ' HD22 ' A' ' 38' ' ' ASN . 4.1 mp -135.55 112.17 13.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 C-N-CA 119.676 -0.81 . . . . 0.0 111.322 -179.437 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 t -134.98 149.65 29.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 C-N-CA 119.902 -0.719 . . . . 0.0 109.948 179.224 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -104.77 128.38 52.89 Favored 'General case' 0 N--CA 1.485 1.3 0 C-N-CA 119.512 -0.875 . . . . 0.0 112.04 -179.077 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.42 ' C ' ' H ' ' A' ' 44' ' ' ASP . 49.3 t0 -66.97 126.38 28.94 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.086 179.344 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 63.8 mt-10 -72.1 11.51 0.55 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.229 -0.989 . . . . 0.0 111.221 -179.662 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.42 ' H ' ' C ' ' A' ' 42' ' ' ASP . 28.4 m-20 -105.85 -5.54 19.68 Favored 'General case' 0 N--CA 1.49 1.546 0 C-N-CA 119.667 -0.813 . . . . 0.0 111.068 -179.862 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -142.7 51.97 1.42 Allowed 'General case' 0 C--N 1.308 -1.224 0 C-N-CA 119.719 -0.792 . . . . 0.0 110.229 -179.743 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -139.6 145.97 45.81 Favored Pre-proline 0 N--CA 1.487 1.393 0 CA-C-N 115.286 -0.87 . . . . 0.0 108.825 179.678 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_exo -54.17 163.7 3.18 Favored 'Trans proline' 0 C--O 1.215 -0.665 0 C-N-CA 120.798 0.999 . . . . 0.0 112.216 -179.358 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -89.26 61.76 5.85 Favored 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 119.84 -0.744 . . . . 0.0 110.824 -179.968 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -172.21 -46.38 0.04 OUTLIER Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.529 -1.319 . . . . 0.0 110.014 -179.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 10.5 t -79.6 84.07 1.19 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 C-N-CA 119.554 -0.858 . . . . 0.0 110.39 179.703 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -45.09 139.71 3.12 Favored 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 119.204 -0.999 . . . . 0.0 110.712 -179.636 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.08 -33.06 65.4 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.39 -0.924 . . . . 0.0 110.728 -179.875 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -61.68 -17.91 57.44 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.304 -179.637 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.32 -45.46 11.91 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 119.372 -0.931 . . . . 0.0 111.422 -179.728 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.0 pt -90.35 -13.8 9.13 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 C-N-CA 119.233 -0.987 . . . . 0.0 111.327 -179.641 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 69.2 m -77.65 173.44 12.04 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.41 -0.916 . . . . 0.0 110.582 179.551 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.615 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 69.4 mt-30 -129.24 78.83 75.35 Favored Pre-proline 0 N--CA 1.489 1.481 0 C-N-CA 120.036 -0.665 . . . . 0.0 110.64 -179.868 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.93 -11.47 18.28 Favored 'Trans proline' 0 C--O 1.216 -0.605 0 C-N-CA 121.032 1.155 . . . . 0.0 111.024 -179.539 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -101.35 116.89 33.82 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.807 -0.757 . . . . 0.0 110.535 179.14 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -58.38 159.4 6.27 Favored 'General case' 0 C--N 1.302 -1.465 0 C-N-CA 119.359 -0.936 . . . . 0.0 110.999 -179.672 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.616 HD12 ' C ' ' A' ' 61' ' ' LEU . 0.7 OUTLIER -125.41 146.97 49.37 Favored 'General case' 0 N--CA 1.49 1.532 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.666 179.233 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.551 ' N ' HD12 ' A' ' 61' ' ' LEU . 9.8 p-10 -155.17 58.6 0.65 Allowed 'General case' 0 N--CA 1.486 1.347 0 C-N-CA 119.253 -0.979 . . . . 0.0 111.343 -178.744 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -129.62 130.1 6.23 Favored Glycine 0 N--CA 1.497 2.734 0 C-N-CA 119.737 -1.22 . . . . 0.0 110.784 179.805 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -69.94 103.88 2.36 Favored 'General case' 0 N--CA 1.484 1.268 0 C-N-CA 119.459 -0.896 . . . . 0.0 110.464 179.575 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 104.45 -7.29 46.53 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.222 -179.709 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -64.7 151.81 44.05 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.177 -1.009 . . . . 0.0 110.141 179.515 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -147.7 165.15 31.35 Favored 'General case' 0 C--N 1.307 -1.261 0 C-N-CA 118.884 -1.126 . . . . 0.0 111.838 -179.679 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.615 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 49.5 t80 -136.07 138.25 41.94 Favored 'General case' 0 N--CA 1.484 1.258 0 CA-C-N 115.283 -0.872 . . . . 0.0 109.323 179.149 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -108.62 153.38 23.49 Favored 'General case' 0 N--CA 1.489 1.501 0 C-N-CA 119.423 -0.911 . . . . 0.0 112.164 -178.765 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -155.41 139.93 9.26 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 CA-C-N 115.443 -0.799 . . . . 0.0 109.439 178.891 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.8 m -126.02 95.95 4.58 Favored 'General case' 0 C--N 1.307 -1.272 0 C-N-CA 119.817 -0.753 . . . . 0.0 111.083 -179.44 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.472 ' CD1' HG11 ' A' ' 94' ' ' VAL . 13.9 mt -79.68 160.9 26.12 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.437 179.434 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -150.71 25.29 0.76 Allowed 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 118.717 -1.193 . . . . 0.0 112.057 -178.497 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.466 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.7 OUTLIER -116.69 99.9 7.45 Favored 'General case' 0 N--CA 1.495 1.815 0 C-N-CA 119.325 -0.95 . . . . 0.0 110.357 179.846 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 8.5 mttt -43.44 105.79 0.06 Allowed 'General case' 0 C--N 1.309 -1.191 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.724 -179.76 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 174.3 -139.61 5.02 Favored Glycine 0 N--CA 1.483 1.79 0 C-N-CA 119.321 -1.418 . . . . 0.0 109.929 -179.769 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 1.2 m -146.68 136.02 22.79 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.251 -0.98 . . . . 0.0 111.168 179.983 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.576 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -120.52 140.78 50.96 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 179.829 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 22.9 mmtt -110.17 124.28 51.26 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 119.433 -0.907 . . . . 0.0 111.872 -179.0 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.566 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 0.8 OUTLIER -134.39 160.89 36.57 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 119.922 -0.711 . . . . 0.0 110.14 178.395 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . 0.419 ' CD1' ' N ' ' A' ' 81' ' ' TYR . 23.8 p90 -168.29 179.21 4.58 Favored 'General case' 0 C--N 1.293 -1.87 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.889 -178.54 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.7 t -102.72 125.4 49.44 Favored 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.773 -0.771 . . . . 0.0 110.401 179.663 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.509 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 mt-10 -67.05 -46.25 52.79 Favored Pre-proline 0 C--N 1.306 -1.319 0 C-N-CA 119.499 -0.88 . . . . 0.0 112.819 -179.56 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.509 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.9 Cg_endo -67.01 -48.64 1.74 Allowed 'Trans proline' 0 C--O 1.215 -0.631 0 C-N-CA 120.97 1.113 . . . . 0.0 112.114 -178.725 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 35.0 m80 -88.5 20.51 3.33 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.009 -179.515 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.87 -10.4 20.41 Favored 'General case' 0 C--N 1.302 -1.491 0 C-N-CA 119.389 -0.924 . . . . 0.0 110.454 179.449 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -88.6 -17.31 57.09 Favored Glycine 0 N--CA 1.491 2.343 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.491 179.948 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.15 -15.13 32.18 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.433 -0.907 . . . . 0.0 110.582 179.952 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.64 21.27 11.51 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.722 -1.228 . . . . 0.0 110.573 179.874 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 3.3 mtp -73.05 98.51 2.55 Favored 'General case' 0 N--CA 1.484 1.231 0 C-N-CA 119.035 -1.066 . . . . 0.0 111.174 179.941 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.508 ' O ' ' CD2' ' A' ' 14' ' ' PHE . 16.5 ttmt -121.41 159.6 25.85 Favored 'General case' 0 N--CA 1.493 1.718 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.906 179.935 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.472 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -144.38 143.49 12.17 Favored Glycine 0 N--CA 1.496 2.636 0 C-N-CA 119.352 -1.404 . . . . 0.0 111.255 -179.065 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.75 143.67 24.64 Favored 'General case' 0 C--N 1.312 -1.057 0 C-N-CA 119.648 -0.821 . . . . 0.0 110.635 179.514 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.578 HG13 ' O ' ' A' ' 94' ' ' VAL . 9.9 p -136.31 122.43 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.318 179.523 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 99.9 m -100.93 100.48 11.12 Favored 'General case' 0 C--N 1.302 -1.459 0 C-N-CA 119.336 -0.946 . . . . 0.0 110.745 -179.951 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 40.3 t -79.84 139.84 17.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 C-N-CA 118.634 -1.226 . . . . 0.0 110.478 -179.02 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . 0.543 ' ND2' ' N ' ' A' ' 97' ' ' ASN . 0.2 OUTLIER . . . . . 0 N--CA 1.485 1.311 0 CA-C-O 116.441 -1.743 . . . . 0.0 110.965 -179.869 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.147 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 24.5 mt-10 -106.06 133.39 50.84 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 119.865 -0.734 . . . . 0.0 110.92 -179.931 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.9 t -123.47 117.48 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 C-N-CA 119.991 -0.684 . . . . 0.0 110.419 179.657 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 29.3 mttp -91.95 114.35 26.87 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.652 -178.81 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.5 mt -76.37 113.28 13.78 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 119.069 -1.053 . . . . 0.0 109.805 178.007 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.46 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 102.36 125.35 5.61 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 119.764 -1.207 . . . . 0.0 110.238 -179.448 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 20.7 p -67.64 169.75 8.89 Favored 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 119.462 -0.895 . . . . 0.0 110.7 179.884 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -95.52 43.61 1.09 Allowed 'General case' 0 C--N 1.305 -1.351 0 C-N-CA 119.524 -0.871 . . . . 0.0 111.27 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.0 p-10 -158.04 -52.99 0.07 Allowed 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.233 -0.987 . . . . 0.0 110.813 179.833 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 168.84 66.26 0.03 OUTLIER Glycine 0 N--CA 1.49 2.266 0 C-N-CA 119.388 -1.386 . . . . 0.0 110.366 179.953 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -161.94 146.29 11.88 Favored Glycine 0 N--CA 1.489 2.211 0 C-N-CA 119.307 -1.425 . . . . 0.0 110.409 -179.917 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 57.1 mt -107.17 101.13 10.55 Favored 'General case' 0 N--CA 1.487 1.41 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.596 179.867 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 9.0 m -150.99 157.06 5.75 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.116 0 C-N-CA 118.892 -1.123 . . . . 0.0 110.747 179.297 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.522 ' CD1' ' O ' ' A' ' 91' ' ' LYS . 56.8 m-85 -78.12 113.1 15.74 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 177.887 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 3.6 m -115.19 109.08 47.01 Favored Pre-proline 0 CA--C 1.559 1.311 0 C-N-CA 119.552 -0.859 . . . . 0.0 112.176 -176.954 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -67.14 172.59 37.29 Favored 'Cis proline' 0 C--N 1.359 1.119 0 C-N-CA 125.216 -0.743 . . . . 0.0 111.331 -0.444 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 38.8 t -94.19 -64.31 1.09 Allowed 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.704 178.934 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 3.1 t -113.11 135.19 54.08 Favored 'General case' 0 N--CA 1.485 1.292 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.546 178.748 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.418 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 21.7 p90 -160.97 137.91 8.84 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 118.71 -1.196 . . . . 0.0 111.308 -179.141 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.417 HG23 ' H ' ' A' ' 20' ' ' THR . 0.8 OUTLIER -88.25 154.98 19.99 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.422 -0.911 . . . . 0.0 111.073 179.766 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 22.7 m -145.95 168.66 7.02 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.275 0 C-N-CA 119.447 -0.901 . . . . 0.0 110.815 179.771 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.49 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -92.3 146.62 23.56 Favored 'General case' 0 C--N 1.302 -1.466 0 C-N-CA 119.405 -0.918 . . . . 0.0 110.656 179.833 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.17 76.4 0.02 OUTLIER 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.52 -0.872 . . . . 0.0 111.052 179.934 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 154.02 15.14 0.06 OUTLIER Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 179.888 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -102.43 132.94 48.12 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.898 -179.592 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.8 mtpp -75.75 141.53 42.59 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.919 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.42 ' O ' HG22 ' A' ' 27' ' ' ILE . 3.0 mt -125.72 112.1 29.47 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 C-N-CA 120.088 -0.645 . . . . 0.0 109.261 179.407 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 13.4 p -108.52 121.43 44.96 Favored 'General case' 0 N--CA 1.488 1.462 0 C-N-CA 119.622 -0.831 . . . . 0.0 112.256 -178.561 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -86.36 121.18 28.56 Favored 'General case' 0 C--N 1.305 -1.367 0 C-N-CA 119.449 -0.9 . . . . 0.0 109.182 178.502 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 4.0 tmtp? -112.71 142.42 45.34 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.871 -0.731 . . . . 0.0 110.655 -178.689 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.581 ' ND2' HD11 ' A' ' 61' ' ' LEU . 0.9 OUTLIER -94.05 118.41 31.48 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.178 179.87 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.679 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.8 OUTLIER -98.9 -30.74 12.21 Favored 'General case' 0 N--CA 1.481 1.094 0 C-N-CA 119.332 -0.947 . . . . 0.0 110.864 -179.989 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.679 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 165.02 146.34 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.443 0 C-N-CA 119.377 -0.929 . . . . 0.0 111.078 179.896 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 111.51 2.53 27.51 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 119.91 -1.138 . . . . 0.0 110.861 179.484 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.597 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -52.2 163.91 0.66 Allowed Pre-proline 0 C--N 1.308 -1.219 0 C-N-CA 118.868 -1.133 . . . . 0.0 109.917 179.797 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_endo -78.31 143.69 73.34 Favored 'Cis proline' 0 C--O 1.212 -0.821 0 C-N-CA 124.156 -1.185 . . . . 0.0 112.489 -0.808 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 35.2 m-70 -107.29 178.88 4.41 Favored 'General case' 0 N--CA 1.49 1.567 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.032 179.149 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.725 HD22 ' H ' ' A' ' 39' ' ' ILE . 0.5 OUTLIER -158.03 145.0 17.91 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.635 -0.826 . . . . 0.0 110.061 179.098 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.725 ' H ' HD22 ' A' ' 38' ' ' ASN . 3.9 mp -131.92 117.04 32.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.758 -0.777 . . . . 0.0 110.948 -179.771 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 40.4 t -136.03 141.79 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 C-N-CA 120.009 -0.676 . . . . 0.0 110.19 179.667 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.491 ' HB2' ' HB1' ' A' ' 52' ' ' ALA . 48.7 m-85 -93.78 134.02 36.55 Favored 'General case' 0 C--N 1.305 -1.331 0 C-N-CA 119.442 -0.903 . . . . 0.0 111.064 -179.584 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.676 ' C ' ' H ' ' A' ' 44' ' ' ASP . 24.7 p-10 -75.23 101.49 4.67 Favored 'General case' 0 C--N 1.307 -1.246 0 C-N-CA 119.279 -0.969 . . . . 0.0 110.975 -179.523 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.571 ' H ' ' CD ' ' A' ' 43' ' ' GLU . 1.6 pm0 -55.63 6.5 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.175 0 C-N-CA 119.969 -0.692 . . . . 0.0 111.38 -179.832 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.676 ' H ' ' C ' ' A' ' 42' ' ' ASP . 4.2 m-20 -83.08 -67.31 0.8 Allowed 'General case' 0 C--N 1.295 -1.777 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.837 179.138 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -97.83 27.36 4.49 Favored 'General case' 0 N--CA 1.49 1.539 0 C-N-CA 119.335 -0.946 . . . . 0.0 112.089 -177.049 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.483 HG23 ' O ' ' A' ' 42' ' ' ASP . 45.3 t -102.48 143.97 27.67 Favored Pre-proline 0 C--N 1.3 -1.578 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 178.598 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.439 ' HD2' HG13 ' A' ' 46' ' ' VAL . 4.6 Cg_exo -46.61 140.9 11.71 Favored 'Trans proline' 0 C--O 1.216 -0.617 0 C-N-CA 120.777 0.984 . . . . 0.0 112.178 -179.107 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.53 39.28 0.26 Allowed 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.863 -179.892 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.433 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -142.55 -41.0 0.07 OUTLIER Glycine 0 N--CA 1.489 2.176 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 179.703 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.487 HG23 ' OE1' ' A' ' 74' ' ' GLU . 71.6 t -87.73 84.63 2.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 C-N-CA 119.645 -0.822 . . . . 0.0 109.894 179.207 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -44.19 139.9 2.38 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 119.573 -0.851 . . . . 0.0 111.083 -179.185 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.491 ' HB1' ' HB2' ' A' ' 41' ' ' PHE . . . -86.21 0.65 53.21 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.473 -0.891 . . . . 0.0 110.766 -179.958 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 24.8 tt0 -87.39 -10.76 51.2 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.826 179.914 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 5.0 mtmt -98.17 -35.47 10.37 Favored 'General case' 0 N--CA 1.486 1.375 0 C-N-CA 119.594 -0.842 . . . . 0.0 111.232 -179.668 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.487 HD12 ' CD2' ' A' ' 41' ' ' PHE . 8.3 pt -92.86 -13.37 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 C-N-CA 119.245 -0.982 . . . . 0.0 111.373 -179.522 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 29.0 m -76.3 170.31 16.58 Favored 'General case' 0 C--N 1.307 -1.241 0 C-N-CA 119.186 -1.006 . . . . 0.0 110.893 179.791 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.626 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 4.0 mt-30 -138.37 69.82 46.9 Favored Pre-proline 0 N--CA 1.487 1.379 0 C-N-CA 120.046 -0.662 . . . . 0.0 110.584 -179.854 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_exo -59.56 -10.08 10.56 Favored 'Trans proline' 0 C--N 1.323 -0.798 0 C-N-CA 121.457 1.438 . . . . 0.0 111.554 -179.304 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.418 ' O ' ' O ' ' A' ' 60' ' ' TYR . 0.7 OUTLIER -85.84 103.32 14.48 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.184 179.482 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.418 ' O ' ' O ' ' A' ' 59' ' ' GLU . 90.0 m-85 -44.16 168.26 0.01 OUTLIER 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.164 -179.593 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.581 HD11 ' ND2' ' A' ' 31' ' ' ASN . 3.1 pp -151.8 146.4 25.68 Favored 'General case' 0 C--N 1.302 -1.5 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.05 179.913 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -143.69 -7.05 0.77 Allowed 'General case' 0 N--CA 1.488 1.463 0 C-N-CA 119.318 -0.953 . . . . 0.0 111.387 -179.684 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -48.23 125.43 12.89 Favored Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.174 -1.489 . . . . 0.0 110.628 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -71.36 111.78 6.96 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.818 -179.966 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 91.83 -11.19 72.79 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 119.252 -1.451 . . . . 0.0 110.84 -179.895 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -57.98 159.35 5.71 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.178 -1.009 . . . . 0.0 110.487 179.973 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.58 172.63 12.7 Favored 'General case' 0 N--CA 1.489 1.484 0 C-N-CA 119.055 -1.058 . . . . 0.0 111.987 -179.442 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.626 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 51.9 t80 -135.34 178.59 6.92 Favored 'General case' 0 N--CA 1.489 1.524 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.36 179.09 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.571 ' N ' ' CD2' ' A' ' 68' ' ' TYR . 8.4 mt-10 -145.99 152.0 38.68 Favored 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 118.747 -1.181 . . . . 0.0 111.986 -179.739 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -162.41 140.42 2.15 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 C-N-CA 119.876 -0.729 . . . . 0.0 109.713 178.539 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 7.1 m -129.83 97.9 4.63 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 119.933 -0.707 . . . . 0.0 110.744 -179.619 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.498 ' CD1' HG11 ' A' ' 94' ' ' VAL . 9.3 mt -79.75 159.29 26.65 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.366 -0.934 . . . . 0.0 110.012 179.973 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 4.1 p -150.41 51.39 0.89 Allowed 'General case' 0 C--N 1.301 -1.512 0 C-N-CA 118.937 -1.105 . . . . 0.0 111.793 -179.25 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.487 ' OE1' HG23 ' A' ' 50' ' ' VAL . 1.3 tt0 -142.95 99.81 3.53 Favored 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 119.406 -0.918 . . . . 0.0 109.839 178.829 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.408 ' C ' ' O ' ' A' ' 74' ' ' GLU . 3.9 mttp -42.65 103.37 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.225 0 C-N-CA 119.436 -0.906 . . . . 0.0 110.618 -179.568 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 178.0 -142.27 5.51 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.171 -1.49 . . . . 0.0 110.281 -179.544 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.97 133.4 21.86 Favored 'General case' 0 C--N 1.309 -1.193 0 C-N-CA 119.336 -0.946 . . . . 0.0 111.476 -179.657 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.59 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -122.18 116.87 24.93 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.4 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.456 ' O ' ' OD1' ' A' ' 42' ' ' ASP . 11.2 mptt -95.88 115.69 27.81 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.172 -1.011 . . . . 0.0 111.787 -178.713 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.569 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.1 p90 -119.5 170.09 9.47 Favored 'General case' 0 N--CA 1.486 1.37 0 C-N-CA 119.825 -0.75 . . . . 0.0 110.1 178.755 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -170.37 179.78 3.29 Favored 'General case' 0 C--N 1.298 -1.668 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.329 -178.631 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -102.94 128.27 49.81 Favored 'General case' 0 N--CA 1.481 1.111 0 C-N-CA 119.754 -0.779 . . . . 0.0 110.17 179.258 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.53 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.7 mt-10 -73.34 -45.58 7.77 Favored Pre-proline 0 C--N 1.304 -1.399 0 C-N-CA 119.552 -0.859 . . . . 0.0 112.788 -179.399 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.53 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.3 Cg_exo -65.95 -51.11 1.33 Allowed 'Trans proline' 0 C--O 1.214 -0.675 0 C-N-CA 120.88 1.053 . . . . 0.0 111.684 -179.087 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . 0.457 ' C ' ' H ' ' A' ' 87' ' ' GLY . 38.2 m80 -83.52 13.96 4.12 Favored 'General case' 0 C--N 1.306 -1.324 0 C-N-CA 119.321 -0.952 . . . . 0.0 111.054 -179.774 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -58.24 -5.4 0.48 Allowed 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 119.299 -0.96 . . . . 0.0 110.742 179.806 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.457 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -81.04 -26.54 52.72 Favored Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.515 -179.848 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -89.96 -13.64 35.74 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.626 179.916 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 101.44 7.15 49.5 Favored Glycine 0 N--CA 1.49 2.241 0 C-N-CA 119.709 -1.234 . . . . 0.0 110.418 179.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -48.31 109.69 0.26 Allowed 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.388 -0.925 . . . . 0.0 110.734 179.902 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.522 ' O ' ' CD1' ' A' ' 14' ' ' PHE . 0.0 OUTLIER -134.95 170.78 15.37 Favored 'General case' 0 N--CA 1.494 1.756 0 C-N-CA 119.551 -0.86 . . . . 0.0 111.422 -179.849 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -151.63 149.34 21.07 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.192 -1.48 . . . . 0.0 111.266 -178.67 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -152.89 139.3 18.57 Favored 'General case' 0 N--CA 1.485 1.297 0 C-N-CA 119.507 -0.877 . . . . 0.0 110.397 179.522 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.598 HG13 ' O ' ' A' ' 94' ' ' VAL . 10.7 p -132.79 121.5 44.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 C-N-CA 119.289 -0.965 . . . . 0.0 110.5 179.279 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 39.3 m -98.64 100.77 12.03 Favored 'General case' 0 C--N 1.303 -1.423 0 C-N-CA 119.575 -0.85 . . . . 0.0 110.908 -179.88 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 25.8 t -82.68 151.04 4.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 118.747 -1.181 . . . . 0.0 110.367 -179.369 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 116.397 -1.763 . . . . 0.0 110.846 -179.744 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.1 0 N-CA-C 110.001 -0.37 . . . . 0.0 110.001 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -131.37 136.97 48.5 Favored 'General case' 0 N--CA 1.489 1.488 0 C-N-CA 120.017 -0.673 . . . . 0.0 110.521 179.977 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.1 t -131.13 124.23 55.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 C-N-CA 119.877 -0.729 . . . . 0.0 110.587 179.839 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 7.0 mptt -95.85 116.89 29.57 Favored 'General case' 0 C--N 1.3 -1.581 0 C-N-CA 119.305 -0.958 . . . . 0.0 111.165 -179.606 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 37.7 mt -75.69 109.93 9.68 Favored 'General case' 0 C--N 1.311 -1.073 0 C-N-CA 118.681 -1.208 . . . . 0.0 109.235 178.151 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.527 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 99.46 134.07 8.35 Favored Glycine 0 N--CA 1.484 1.895 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 -178.612 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.417 ' HG ' ' H ' ' A' ' 11' ' ' GLY . 20.9 p -75.96 156.8 33.82 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.297 -0.961 . . . . 0.0 110.737 -179.905 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -51.32 -48.98 62.21 Favored 'General case' 0 N--CA 1.486 1.331 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.014 -179.831 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -58.06 -72.39 0.09 Allowed 'General case' 0 C--N 1.304 -1.39 0 C-N-CA 119.368 -0.933 . . . . 0.0 110.838 -179.913 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.401 ' H ' ' H ' ' A' ' 11' ' ' GLY . . . -179.76 7.26 0.02 OUTLIER Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.256 -1.449 . . . . 0.0 110.359 -179.9 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.417 ' H ' ' HG ' ' A' ' 7' ' ' SER . . . -70.38 160.59 53.56 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.398 -1.382 . . . . 0.0 110.405 179.945 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.7 mt -116.45 91.24 3.53 Favored 'General case' 0 N--CA 1.489 1.477 0 C-N-CA 120.09 -0.644 . . . . 0.0 110.642 -179.921 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.2 m -150.01 155.36 7.95 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.316 0 C-N-CA 119.038 -1.065 . . . . 0.0 110.781 179.889 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.425 ' O ' ' O ' ' A' ' 16' ' ' PRO . 75.3 m-85 -78.62 108.97 12.41 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 177.579 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 50.7 m -111.63 114.43 52.39 Favored Pre-proline 0 C--N 1.303 -1.453 0 C-N-CA 119.389 -0.925 . . . . 0.0 112.07 -177.283 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.425 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.6 Cg_endo -66.68 172.47 35.74 Favored 'Cis proline' 0 C--N 1.361 1.201 0 C-N-CA 125.333 -0.695 . . . . 0.0 111.449 -0.685 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.44 -67.06 0.87 Allowed 'General case' 0 N--CA 1.491 1.591 0 C-N-CA 119.535 -0.866 . . . . 0.0 110.334 179.193 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -108.61 140.4 42.04 Favored 'General case' 0 N--CA 1.486 1.371 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.556 179.129 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 22.1 p90 -165.69 140.16 4.71 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 118.227 -1.389 . . . . 0.0 111.786 -179.213 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.683 HG22 ' HB ' ' A' ' 95' ' ' THR . 75.7 p -88.83 157.42 18.47 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.761 179.423 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -149.9 151.48 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 C-N-CA 119.297 -0.961 . . . . 0.0 111.159 179.739 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.46 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -71.95 142.55 49.43 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.316 -0.954 . . . . 0.0 110.462 179.724 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.17 75.98 0.04 OUTLIER 'General case' 0 N--CA 1.487 1.415 0 C-N-CA 119.414 -0.914 . . . . 0.0 111.188 -179.752 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.46 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 161.08 11.1 0.04 OUTLIER Glycine 0 N--CA 1.489 2.206 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.857 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.45 ' H ' ' H ' ' A' ' 24' ' ' GLY . 2.9 tp10 -105.13 148.56 26.73 Favored 'General case' 0 C--N 1.306 -1.304 0 C-N-CA 120.1 -0.64 . . . . 0.0 110.832 -179.497 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 10.3 pttm -95.16 155.01 16.91 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 119.493 -0.883 . . . . 0.0 111.09 -179.994 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 mt -127.22 109.21 19.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 CA-C-N 115.646 -0.706 . . . . 0.0 109.799 179.56 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.1 p -100.68 117.69 35.31 Favored 'General case' 0 C--N 1.304 -1.373 0 C-N-CA 119.789 -0.764 . . . . 0.0 112.028 -178.757 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 77.0 m-85 -84.66 129.83 34.79 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.238 -0.985 . . . . 0.0 108.723 178.315 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 14.0 ttmt -120.0 128.12 53.25 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.394 -178.53 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 35.1 m120 -71.81 111.49 7.12 Favored 'General case' 0 C--N 1.298 -1.635 0 C-N-CA 119.662 -0.815 . . . . 0.0 110.536 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.673 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.9 OUTLIER -96.09 -31.9 12.79 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.023 -1.071 . . . . 0.0 111.32 -179.856 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.673 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 163.26 130.97 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 119.605 -0.838 . . . . 0.0 110.894 179.585 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 124.89 2.58 7.86 Favored Glycine 0 N--CA 1.496 2.665 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.142 179.488 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -50.55 162.98 0.49 Allowed Pre-proline 0 C--N 1.307 -1.245 0 C-N-CA 118.518 -1.273 . . . . 0.0 109.739 179.798 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -75.96 144.37 79.57 Favored 'Cis proline' 0 C--O 1.215 -0.655 0 C-N-CA 124.279 -1.134 . . . . 0.0 112.341 -0.482 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 30.6 m-70 -108.05 173.74 6.19 Favored 'General case' 0 N--CA 1.493 1.719 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.637 179.541 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.686 HD22 ' H ' ' A' ' 39' ' ' ILE . 0.6 OUTLIER -152.62 138.35 17.9 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-N 115.257 -0.883 . . . . 0.0 109.925 179.534 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.686 ' H ' HD22 ' A' ' 38' ' ' ASN . 3.7 mp -128.13 99.97 5.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 C-N-CA 119.756 -0.778 . . . . 0.0 110.904 -179.728 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 3.6 t -123.36 147.35 27.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.011 179.341 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -101.26 129.63 47.25 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 119.464 -0.894 . . . . 0.0 111.505 -179.676 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -67.03 113.72 5.24 Favored 'General case' 0 C--N 1.303 -1.425 0 C-N-CA 119.702 -0.799 . . . . 0.0 110.632 179.656 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -62.06 -4.42 1.66 Allowed 'General case' 0 N--CA 1.49 1.554 0 C-N-CA 119.678 -0.809 . . . . 0.0 111.718 -179.22 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -95.78 -2.4 47.75 Favored 'General case' 0 N--CA 1.488 1.428 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.089 -179.78 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -140.65 50.47 1.67 Allowed 'General case' 0 C--N 1.312 -1.031 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.704 179.871 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -140.35 145.9 43.23 Favored Pre-proline 0 N--CA 1.489 1.502 0 CA-C-N 115.51 -0.768 . . . . 0.0 108.936 179.879 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -54.81 162.33 5.15 Favored 'Trans proline' 0 C--O 1.215 -0.626 0 C-N-CA 120.798 0.998 . . . . 0.0 111.742 -179.739 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -90.16 55.47 3.1 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 119.639 -0.824 . . . . 0.0 110.835 179.958 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -161.59 -42.27 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.06 179.926 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 88.5 t -86.28 92.62 3.64 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 C-N-CA 119.565 -0.854 . . . . 0.0 110.421 179.756 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -44.55 139.78 2.68 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.953 -179.785 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -80.88 -15.6 55.89 Favored 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.519 -0.873 . . . . 0.0 110.965 -179.8 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -77.68 -28.0 50.95 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.406 -0.917 . . . . 0.0 111.309 -179.479 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.7 mmtt -73.45 -35.63 65.79 Favored 'General case' 0 N--CA 1.487 1.385 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.44 -179.202 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 4.9 pt -96.54 -13.83 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 C-N-CA 119.291 -0.964 . . . . 0.0 111.533 -179.353 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 19.3 m -77.27 176.3 8.91 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.025 -1.07 . . . . 0.0 111.35 -179.611 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.651 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 60.6 mt-30 -137.31 71.58 53.36 Favored Pre-proline 0 C--N 1.306 -1.298 0 CA-C-N 115.428 -0.805 . . . . 0.0 110.432 -179.98 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -59.26 -19.08 48.41 Favored 'Trans proline' 0 C--O 1.215 -0.648 0 C-N-CA 121.307 1.338 . . . . 0.0 111.34 -179.217 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -91.83 97.25 10.87 Favored 'General case' 0 C--N 1.304 -1.374 0 C-N-CA 119.253 -0.979 . . . . 0.0 110.294 179.259 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 40.8 m-85 -43.54 163.94 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.235 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.725 -179.731 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.405 HD11 HD21 ' A' ' 31' ' ' ASN . 2.7 pp -134.8 139.5 45.15 Favored 'General case' 0 N--CA 1.486 1.356 0 C-N-CA 119.567 -0.853 . . . . 0.0 110.887 179.728 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.412 ' ND2' ' N ' ' A' ' 62' ' ' ASN . 0.1 OUTLIER -131.53 31.52 4.29 Favored 'General case' 0 N--CA 1.484 1.234 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.479 179.942 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -99.76 128.45 9.58 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.728 -1.225 . . . . 0.0 110.475 -179.888 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -78.17 128.91 34.48 Favored 'General case' 0 N--CA 1.486 1.345 0 C-N-CA 119.413 -0.915 . . . . 0.0 110.799 179.955 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 81.5 -21.84 5.95 Favored Glycine 0 N--CA 1.489 2.227 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.794 179.915 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.422 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 2.2 mm-40 -49.72 162.82 0.15 Allowed 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.178 -1.009 . . . . 0.0 110.267 179.858 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 7.6 p -146.28 163.36 35.76 Favored 'General case' 0 N--CA 1.486 1.355 0 C-N-CA 119.028 -1.069 . . . . 0.0 111.79 -179.38 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.651 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 37.2 t80 -136.05 146.13 46.75 Favored 'General case' 0 N--CA 1.487 1.422 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.421 179.39 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mt-10 -106.12 148.69 27.53 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 119.466 -0.894 . . . . 0.0 112.318 -178.773 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -149.41 132.88 7.64 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.264 0 CA-C-N 115.091 -0.959 . . . . 0.0 108.498 178.786 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 18.2 m -131.21 105.36 7.62 Favored 'General case' 0 N--CA 1.487 1.394 0 C-N-CA 119.469 -0.892 . . . . 0.0 111.639 -179.012 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.452 ' CD1' HG11 ' A' ' 94' ' ' VAL . 17.9 mt -95.32 152.64 18.21 Favored 'General case' 0 C--N 1.307 -1.245 0 C-N-CA 119.422 -0.911 . . . . 0.0 109.693 179.091 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 47.4 p -150.57 47.02 0.88 Allowed 'General case' 0 C--N 1.293 -1.854 0 C-N-CA 119.304 -0.959 . . . . 0.0 110.862 -179.54 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 -137.81 107.79 6.34 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.728 -179.948 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 8.5 tptt -44.45 112.51 0.42 Allowed 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 119.407 -0.917 . . . . 0.0 110.333 -179.876 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 167.94 -152.28 20.4 Favored Glycine 0 N--CA 1.482 1.761 0 C-N-CA 119.086 -1.531 . . . . 0.0 110.391 179.722 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -139.92 135.46 32.85 Favored 'General case' 0 C--N 1.302 -1.471 0 C-N-CA 119.781 -0.768 . . . . 0.0 110.495 -179.922 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.558 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.5 m-85 -121.36 166.3 14.27 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.659 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 17.3 mmtp -138.2 130.14 28.43 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.156 -1.018 . . . . 0.0 111.804 -179.322 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.528 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.5 p90 -137.24 164.18 29.15 Favored 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 119.777 -0.769 . . . . 0.0 110.214 178.673 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 39.4 p90 -170.32 -173.83 1.56 Allowed 'General case' 0 C--N 1.287 -2.146 0 C-N-CA 119.586 -0.846 . . . . 0.0 110.704 -178.497 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . 0.551 ' O ' ' HB2' ' A' ' 86' ' ' ALA . 1.7 t -112.38 129.85 56.17 Favored 'General case' 0 N--CA 1.484 1.235 0 C-N-CA 119.86 -0.736 . . . . 0.0 110.57 179.478 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.502 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.9 mm-40 -69.71 -45.77 24.95 Favored Pre-proline 0 N--CA 1.488 1.454 0 C-N-CA 119.393 -0.923 . . . . 0.0 112.906 -179.446 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.502 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.9 Cg_endo -66.95 -52.22 0.7 Allowed 'Trans proline' 0 C--O 1.216 -0.6 0 C-N-CA 120.756 0.971 . . . . 0.0 112.41 -179.244 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . 0.455 ' C ' ' H ' ' A' ' 87' ' ' GLY . 35.2 m80 -81.54 5.61 17.43 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.449 -0.901 . . . . 0.0 112.224 -178.912 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.551 ' HB2' ' O ' ' A' ' 82' ' ' CYS . . . -61.59 -2.01 0.69 Allowed 'General case' 0 N--CA 1.488 1.449 0 C-N-CA 118.712 -1.195 . . . . 0.0 110.525 179.935 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.455 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -81.63 -23.52 57.97 Favored Glycine 0 N--CA 1.489 2.193 0 C-N-CA 119.503 -1.332 . . . . 0.0 110.39 -179.951 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.5 -45.45 7.76 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 119.346 -0.941 . . . . 0.0 110.43 -179.996 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.01 29.18 0.15 Allowed Glycine 0 N--CA 1.489 2.217 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.531 179.687 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -76.12 102.69 5.83 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 119.124 -1.03 . . . . 0.0 110.961 179.888 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.6 pttt -131.12 166.49 20.98 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 119.722 -0.791 . . . . 0.0 111.434 -179.898 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.494 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -149.84 147.31 17.43 Favored Glycine 0 N--CA 1.49 2.246 0 C-N-CA 119.23 -1.462 . . . . 0.0 111.612 -178.713 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -149.47 147.71 28.55 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 119.873 -0.731 . . . . 0.0 110.347 179.189 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.452 HG11 ' CD1' ' A' ' 72' ' ' LEU . 14.3 p -143.39 136.19 24.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 C-N-CA 118.911 -1.116 . . . . 0.0 110.363 179.377 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.683 ' HB ' HG22 ' A' ' 20' ' ' THR . 4.8 m -114.52 108.19 16.52 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.914 -0.714 . . . . 0.0 110.626 179.815 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 39.6 t -84.96 143.86 10.83 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 C-N-CA 118.532 -1.267 . . . . 0.0 110.527 -178.932 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.484 1.245 0 CA-C-O 116.293 -1.813 . . . . 0.0 111.229 -179.664 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.161 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -115.56 121.16 41.81 Favored 'General case' 0 N--CA 1.488 1.472 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.479 179.589 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 61.5 t -110.5 122.38 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 C-N-CA 119.792 -0.763 . . . . 0.0 111.062 -179.787 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.1 mtmt -91.89 112.11 23.92 Favored 'General case' 0 C--N 1.297 -1.685 0 C-N-CA 119.449 -0.9 . . . . 0.0 110.454 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 7.7 mt -77.33 108.15 10.26 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 118.869 -1.133 . . . . 0.0 110.471 179.083 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.422 ' O ' ' OD1' ' A' ' 32' ' ' ASN . . . 113.76 147.66 9.79 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 110.557 -1.017 . . . . 0.0 110.557 -179.557 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.6 p -88.78 159.68 17.65 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 119.561 -0.855 . . . . 0.0 110.901 179.846 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -77.38 -20.64 54.41 Favored 'General case' 0 C--N 1.304 -1.395 0 C-N-CA 119.344 -0.943 . . . . 0.0 110.664 179.832 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.433 ' CG ' ' H ' ' A' ' 10' ' ' GLY . 0.8 OUTLIER -87.18 -71.57 0.55 Allowed 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.473 -0.891 . . . . 0.0 110.796 -179.906 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.433 ' H ' ' CG ' ' A' ' 9' ' ' ASP . . . 179.36 63.62 0.07 OUTLIER Glycine 0 N--CA 1.489 2.22 0 C-N-CA 119.396 -1.383 . . . . 0.0 110.429 179.966 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -152.39 166.17 31.09 Favored Glycine 0 N--CA 1.49 2.278 0 C-N-CA 119.528 -1.32 . . . . 0.0 110.278 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -115.51 105.77 13.18 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.771 -179.885 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 25.8 m -151.8 156.61 5.83 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.263 0 C-N-CA 118.963 -1.095 . . . . 0.0 110.646 178.978 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.406 ' O ' ' C ' ' A' ' 16' ' ' PRO . 43.5 m-85 -78.55 113.31 16.46 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 177.572 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.8 m -115.21 107.58 49.38 Favored Pre-proline 0 N--CA 1.484 1.25 0 C-N-CA 119.434 -0.907 . . . . 0.0 112.089 -177.277 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.406 ' C ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -66.79 176.24 23.75 Favored 'Cis proline' 0 C--N 1.359 1.101 0 C-N-CA 125.409 -0.663 . . . . 0.0 111.738 -0.414 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -88.27 -52.98 4.92 Favored 'General case' 0 N--CA 1.489 1.516 0 C-N-CA 119.611 -0.836 . . . . 0.0 110.088 179.138 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.4 t -131.09 146.68 52.45 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.398 178.985 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.404 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 23.0 p90 -161.55 140.04 9.53 Favored 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 118.374 -1.33 . . . . 0.0 111.96 -179.066 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.654 HG22 ' HB ' ' A' ' 95' ' ' THR . 64.3 p -81.62 155.66 25.53 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 119.837 -0.745 . . . . 0.0 110.913 179.652 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 28.9 m -148.76 164.76 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 C-N-CA 119.572 -0.851 . . . . 0.0 110.483 179.528 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.507 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -89.93 147.56 23.65 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 119.288 -0.965 . . . . 0.0 110.998 -179.754 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.15 77.59 0.01 OUTLIER 'General case' 0 N--CA 1.485 1.293 0 C-N-CA 119.509 -0.876 . . . . 0.0 110.788 179.756 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.66 23.15 0.09 OUTLIER Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -179.97 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 -103.99 140.01 38.33 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.987 -0.685 . . . . 0.0 110.764 -179.578 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.9 mtmt -85.03 125.9 33.11 Favored 'General case' 0 C--N 1.302 -1.472 0 C-N-CA 119.282 -0.967 . . . . 0.0 110.97 -179.851 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 6.2 mt -102.62 119.77 51.45 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 C-N-CA 119.803 -0.759 . . . . 0.0 109.578 179.779 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 43.3 p -117.1 114.57 23.91 Favored 'General case' 0 N--CA 1.487 1.392 0 C-N-CA 119.7 -0.8 . . . . 0.0 112.393 -178.513 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.3 m-85 -87.46 117.91 26.56 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.003 178.319 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.8 tttt -112.29 138.61 48.76 Favored 'General case' 0 N--CA 1.49 1.56 0 C-N-CA 119.544 -0.862 . . . . 0.0 111.86 -178.338 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.417 HD21 HD13 ' A' ' 61' ' ' LEU . 3.9 m-20 -81.13 131.36 35.3 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.2 179.683 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.66 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.8 p-10 -125.56 -17.06 5.63 Favored 'General case' 0 N--CA 1.497 1.892 0 C-N-CA 119.558 -0.857 . . . . 0.0 111.067 179.217 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.66 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 166.04 149.55 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 C-N-CA 119.542 -0.863 . . . . 0.0 111.247 178.992 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.28 -5.74 59.19 Favored Glycine 0 N--CA 1.495 2.581 0 C-N-CA 119.279 -1.439 . . . . 0.0 112.284 178.626 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -48.14 162.23 0.34 Allowed Pre-proline 0 N--CA 1.489 1.488 0 C-N-CA 118.133 -1.427 . . . . 0.0 109.723 -179.923 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -76.23 142.99 75.12 Favored 'Cis proline' 0 C--O 1.212 -0.796 0 C-N-CA 124.304 -1.123 . . . . 0.0 112.538 -0.638 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.2 m-70 -108.66 -179.63 3.92 Favored 'General case' 0 N--CA 1.494 1.77 0 C-N-CA 119.856 -0.738 . . . . 0.0 111.498 -179.896 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.584 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -158.63 146.71 18.25 Favored 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.841 -0.744 . . . . 0.0 110.241 179.167 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.584 ' N ' HD22 ' A' ' 38' ' ' ASN . 3.9 mp -135.94 117.81 20.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 C-N-CA 119.519 -0.873 . . . . 0.0 111.08 -179.925 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -135.55 160.4 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.372 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.298 179.089 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.552 ' HB2' ' HB1' ' A' ' 52' ' ' ALA . 12.5 m-85 -113.38 125.0 53.78 Favored 'General case' 0 N--CA 1.491 1.624 0 C-N-CA 119.41 -0.916 . . . . 0.0 112.058 -178.973 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.5 ' C ' ' H ' ' A' ' 44' ' ' ASP . 1.1 t70 -65.23 107.18 1.51 Allowed 'General case' 0 C--N 1.307 -1.251 0 C-N-CA 119.221 -0.992 . . . . 0.0 109.664 178.786 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -67.86 16.38 0.04 OUTLIER 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 119.505 -0.878 . . . . 0.0 112.207 -178.826 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.5 ' H ' ' C ' ' A' ' 42' ' ' ASP . 1.9 m-20 -106.02 -3.68 21.36 Favored 'General case' 0 N--CA 1.492 1.631 0 C-N-CA 119.5 -0.88 . . . . 0.0 111.019 179.89 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -140.89 12.39 2.25 Favored 'General case' 0 N--CA 1.482 1.134 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.917 179.596 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.2 t -92.32 147.02 33.68 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.615 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -49.68 154.67 4.45 Favored 'Trans proline' 0 C--O 1.215 -0.636 0 C-N-CA 120.966 1.111 . . . . 0.0 112.019 -179.286 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -84.79 67.79 10.21 Favored 'General case' 0 C--N 1.306 -1.288 0 C-N-CA 119.697 -0.801 . . . . 0.0 110.682 -179.935 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -179.86 -38.13 0.07 OUTLIER Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.957 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 55.8 t -90.53 81.19 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 C-N-CA 119.508 -0.877 . . . . 0.0 110.371 179.583 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.0 m-80 -44.21 139.62 2.51 Favored 'General case' 0 C--N 1.306 -1.292 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.13 -179.359 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.552 ' HB1' ' HB2' ' A' ' 41' ' ' PHE . . . -87.44 10.31 17.94 Favored 'General case' 0 C--N 1.305 -1.352 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.955 -179.724 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -90.55 -22.68 21.17 Favored 'General case' 0 C--N 1.302 -1.484 0 C-N-CA 119.091 -1.044 . . . . 0.0 111.513 -179.476 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 6.5 ptpt -93.81 -32.32 14.01 Favored 'General case' 0 N--CA 1.494 1.747 0 C-N-CA 118.912 -1.115 . . . . 0.0 112.046 -179.329 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 1.1 pt -90.33 -23.74 5.96 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.513 -179.327 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . 0.404 ' OG ' ' O ' ' A' ' 52' ' ' ALA . 18.1 m -61.78 -178.8 0.16 Allowed 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.13 -1.028 . . . . 0.0 111.098 179.869 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.651 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 9.9 tt0 -157.83 67.84 3.81 Favored Pre-proline 0 C--N 1.303 -1.444 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.689 -179.579 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -60.96 -29.34 87.82 Favored 'Trans proline' 0 C--N 1.323 -0.781 0 C-N-CA 121.308 1.339 . . . . 0.0 111.286 -179.419 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 19.7 mt-10 -59.01 112.28 1.62 Allowed 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 119.355 -0.938 . . . . 0.0 110.554 179.701 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.447 ' CD1' ' OD1' ' A' ' 38' ' ' ASN . 43.9 m-85 -58.55 169.55 0.9 Allowed 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 119.534 -0.866 . . . . 0.0 110.998 -179.95 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.417 HD13 HD21 ' A' ' 31' ' ' ASN . 1.2 pp -153.73 149.17 27.2 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.604 -0.838 . . . . 0.0 110.362 179.688 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.512 ' O ' ' C ' ' A' ' 63' ' ' GLY . 0.0 OUTLIER -127.21 -74.31 0.59 Allowed 'General case' 0 N--CA 1.493 1.72 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.396 -179.288 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . 0.512 ' C ' ' O ' ' A' ' 62' ' ' ASN . . . -9.65 123.41 0.01 OUTLIER Glycine 1 N--CA 1.518 4.113 0 O-C-N 124.202 0.939 . . . . 0.0 112.75 -179.641 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -75.05 131.41 40.56 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 119.43 -0.908 . . . . 0.0 110.664 179.736 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.63 -14.96 58.92 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.596 -1.288 . . . . 0.0 110.528 -179.975 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' A' ' 66' ' ' GLU . 1.2 mp0 -62.96 148.51 47.33 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.446 179.844 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -144.38 163.24 34.35 Favored 'General case' 0 N--CA 1.487 1.411 0 C-N-CA 119.246 -0.982 . . . . 0.0 111.396 -179.781 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.651 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 41.5 t80 -136.54 143.73 43.85 Favored 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 119.87 -0.732 . . . . 0.0 109.276 179.269 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -106.15 152.16 23.8 Favored 'General case' 0 N--CA 1.494 1.759 0 C-N-CA 119.219 -0.992 . . . . 0.0 111.995 -179.149 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -151.82 131.58 3.62 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.11 0 CA-C-N 115.345 -0.843 . . . . 0.0 108.813 179.555 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 4.7 m -121.52 112.87 19.04 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.804 -179.067 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.47 ' CD1' HG11 ' A' ' 94' ' ' VAL . 45.7 mt -96.56 158.61 15.35 Favored 'General case' 0 C--N 1.306 -1.303 0 C-N-CA 119.725 -0.79 . . . . 0.0 109.417 178.924 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 12.0 m -150.89 41.9 0.77 Allowed 'General case' 0 C--N 1.302 -1.481 0 C-N-CA 118.56 -1.256 . . . . 0.0 112.351 -179.133 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 62.8 mt-10 -145.92 110.98 5.27 Favored 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.378 178.918 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -44.06 116.51 1.01 Allowed 'General case' 0 C--N 1.306 -1.308 0 C-N-CA 119.356 -0.938 . . . . 0.0 110.934 -179.569 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 164.5 175.16 35.04 Favored Glycine 0 N--CA 1.483 1.807 0 C-N-CA 119.293 -1.432 . . . . 0.0 110.35 -179.947 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.76 126.77 53.38 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.992 -0.683 . . . . 0.0 110.977 -179.785 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.554 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -108.35 141.99 39.34 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 179.352 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 16.5 mmtp -105.12 122.22 45.45 Favored 'General case' 0 N--CA 1.486 1.351 0 C-N-CA 119.506 -0.877 . . . . 0.0 111.953 -179.139 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.423 ' CZ ' ' N ' ' A' ' 93' ' ' GLU . 5.7 p90 -138.48 160.04 40.57 Favored 'General case' 0 C--N 1.309 -1.185 0 C-N-CA 119.315 -0.954 . . . . 0.0 110.076 177.508 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 40.6 p90 -170.24 -175.26 1.91 Allowed 'General case' 0 C--N 1.287 -2.112 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.908 -177.655 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.6 t -103.48 122.72 45.49 Favored 'General case' 0 C--N 1.307 -1.28 0 C-N-CA 119.732 -0.787 . . . . 0.0 109.372 179.245 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.564 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 4.9 tt0 -73.4 -36.04 2.94 Favored Pre-proline 0 CA--C 1.557 1.236 0 C-N-CA 118.84 -1.144 . . . . 0.0 113.267 -178.701 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.564 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.0 OUTLIER -70.25 -47.74 0.73 Allowed 'Trans proline' 0 C--O 1.215 -0.666 0 C-N-CA 120.376 0.718 . . . . 0.0 111.105 179.66 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . 0.407 ' C ' ' H ' ' A' ' 87' ' ' GLY . 36.7 m80 -87.77 16.45 5.76 Favored 'General case' 0 N--CA 1.485 1.313 0 C-N-CA 119.593 -0.843 . . . . 0.0 110.808 -179.938 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -63.53 -2.61 1.69 Allowed 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.364 -0.935 . . . . 0.0 110.821 179.908 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.407 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -88.16 -17.83 56.82 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 119.354 -1.403 . . . . 0.0 110.29 179.911 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -92.45 -41.61 10.2 Favored 'General case' 0 C--N 1.305 -1.329 0 C-N-CA 119.391 -0.924 . . . . 0.0 110.644 179.961 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 132.72 13.88 1.56 Allowed Glycine 0 N--CA 1.494 2.555 0 C-N-CA 119.804 -1.189 . . . . 0.0 110.562 179.861 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.49 101.86 0.21 Allowed 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.928 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.5 tptt -124.71 154.1 41.35 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 119.914 -0.715 . . . . 0.0 111.256 -179.854 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -137.55 153.1 21.88 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.85 -179.055 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.423 ' N ' ' CZ ' ' A' ' 80' ' ' PHE . 2.7 mt-10 -156.4 146.05 20.9 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 119.363 -0.935 . . . . 0.0 111.289 179.911 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.501 HG13 ' O ' ' A' ' 94' ' ' VAL . 13.1 p -138.7 128.54 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 C-N-CA 119.046 -1.062 . . . . 0.0 110.24 178.792 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.654 ' HB ' HG22 ' A' ' 20' ' ' THR . 98.8 m -106.77 100.09 9.62 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.68 179.831 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 38.0 t -80.04 150.78 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.237 0 C-N-CA 118.779 -1.169 . . . . 0.0 110.392 -179.714 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 116.339 -1.791 . . . . 0.0 110.828 179.969 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.153 0 CA-C-O 120.855 0.36 . . . . 0.0 110.079 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -105.27 135.69 46.17 Favored 'General case' 0 N--CA 1.488 1.454 0 C-N-CA 119.929 -0.708 . . . . 0.0 110.647 179.887 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 5.0 t -124.11 126.62 72.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 C-N-CA 119.817 -0.753 . . . . 0.0 110.445 179.591 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 7.3 mttp -100.84 118.57 37.16 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.792 -0.763 . . . . 0.0 110.591 -179.819 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 10.2 mt -83.66 109.82 17.77 Favored 'General case' 0 C--N 1.304 -1.403 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.646 178.84 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.543 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 106.25 133.36 7.42 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -178.8 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 21.2 p -73.34 161.46 30.45 Favored 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.374 -0.93 . . . . 0.0 110.624 179.64 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 61.0 m-20 -84.47 43.78 0.99 Allowed 'General case' 0 C--N 1.305 -1.359 0 C-N-CA 119.292 -0.963 . . . . 0.0 110.78 -179.906 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -155.52 -55.68 0.09 Allowed 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 119.246 -0.982 . . . . 0.0 110.996 -179.913 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.11 67.19 0.03 OUTLIER Glycine 0 N--CA 1.491 2.365 0 C-N-CA 119.295 -1.431 . . . . 0.0 110.648 -179.862 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -161.03 157.53 29.07 Favored Glycine 0 N--CA 1.489 2.172 0 C-N-CA 119.309 -1.424 . . . . 0.0 110.476 179.915 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.619 HD13 ' CD2' ' A' ' 85' ' ' HIS . 49.9 mt -114.82 99.37 7.44 Favored 'General case' 0 N--CA 1.489 1.498 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.645 179.838 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.1 m -147.3 154.67 11.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.009 0 C-N-CA 119.091 -1.044 . . . . 0.0 111.023 179.899 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.443 ' O ' ' O ' ' A' ' 16' ' ' PRO . 40.4 m-85 -78.39 109.08 12.22 Favored 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 177.893 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 20.0 m -115.37 111.32 44.38 Favored Pre-proline 0 C--O 1.205 -1.24 0 C-N-CA 119.533 -0.867 . . . . 0.0 111.51 -177.446 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.443 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -66.16 176.57 20.88 Favored 'Cis proline' 0 C--N 1.355 0.909 0 C-N-CA 125.304 -0.707 . . . . 0.0 111.612 0.102 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -92.86 -56.58 2.94 Favored 'General case' 0 N--CA 1.486 1.371 0 C-N-CA 119.537 -0.865 . . . . 0.0 109.726 178.803 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 1.8 t -125.75 139.37 53.58 Favored 'General case' 0 N--CA 1.486 1.341 0 CA-C-N 115.298 -0.864 . . . . 0.0 109.073 178.806 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.443 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 16.4 p90 -159.03 132.84 7.49 Favored 'General case' 0 C--N 1.306 -1.322 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.448 -178.915 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.454 ' H ' HG23 ' A' ' 20' ' ' THR . 0.8 OUTLIER -83.12 155.07 24.01 Favored 'General case' 0 C--N 1.301 -1.52 0 C-N-CA 119.271 -0.972 . . . . 0.0 110.865 179.762 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 17.8 m -146.57 171.55 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.326 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.998 179.741 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -93.94 151.45 19.55 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.414 -0.914 . . . . 0.0 110.684 179.728 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.2 73.54 0.12 Allowed 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 119.509 -0.876 . . . . 0.0 111.146 -179.986 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 154.69 13.14 0.06 OUTLIER Glycine 0 N--CA 1.488 2.143 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.791 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -99.07 117.04 32.67 Favored 'General case' 0 C--N 1.306 -1.321 0 C-N-CA 119.912 -0.715 . . . . 0.0 110.663 -179.783 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 4.1 mtmp? -65.96 133.44 50.86 Favored 'General case' 0 C--N 1.301 -1.525 0 C-N-CA 119.477 -0.889 . . . . 0.0 111.066 -179.774 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 9.8 mt -113.55 131.77 64.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 C-N-CA 119.954 -0.698 . . . . 0.0 109.248 179.454 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.5 p -125.29 123.29 39.16 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 119.526 -0.87 . . . . 0.0 112.173 -178.54 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -84.4 147.29 27.22 Favored 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 119.414 -0.914 . . . . 0.0 108.851 178.346 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.4 tttm -136.62 127.9 28.18 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.396 -0.921 . . . . 0.0 111.371 -178.873 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.2 m-80 -79.45 109.45 13.82 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 119.69 -0.804 . . . . 0.0 110.52 179.625 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.654 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 0.6 OUTLIER -95.49 -30.73 13.7 Favored 'General case' 0 N--CA 1.488 1.429 0 C-N-CA 119.287 -0.965 . . . . 0.0 111.76 -179.474 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.654 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 166.4 136.92 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.378 -0.929 . . . . 0.0 111.041 -179.661 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 116.27 -2.23 20.65 Favored Glycine 0 N--CA 1.495 2.599 0 C-N-CA 119.836 -1.174 . . . . 0.0 111.033 179.189 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -47.37 163.83 0.25 Allowed Pre-proline 0 C--N 1.308 -1.224 0 C-N-CA 118.686 -1.206 . . . . 0.0 109.775 179.792 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -76.23 145.34 82.01 Favored 'Cis proline' 0 C--O 1.214 -0.722 0 C-N-CA 124.223 -1.157 . . . . 0.0 112.659 -0.756 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 34.1 m-70 -111.22 172.15 7.05 Favored 'General case' 0 N--CA 1.491 1.624 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.889 179.298 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.701 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.2 OUTLIER -149.8 137.98 20.47 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.55 -0.86 . . . . 0.0 110.111 179.34 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.701 ' N ' HD22 ' A' ' 38' ' ' ASN . 3.5 mp -125.17 110.68 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 C-N-CA 119.893 -0.723 . . . . 0.0 110.888 -179.689 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.5 t -130.93 145.31 35.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 C-N-CA 119.95 -0.7 . . . . 0.0 110.326 179.528 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 31.3 m-85 -99.53 121.7 41.55 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.586 -0.845 . . . . 0.0 111.322 -179.356 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -60.48 100.87 0.11 Allowed 'General case' 0 C--N 1.307 -1.244 0 C-N-CA 119.131 -1.028 . . . . 0.0 110.044 179.484 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -57.65 -6.6 0.52 Allowed 'General case' 0 N--CA 1.489 1.488 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.277 -179.012 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -93.36 3.19 56.01 Favored 'General case' 0 N--CA 1.488 1.426 0 C-N-CA 118.993 -1.083 . . . . 0.0 112.263 -178.733 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 30.6 mt-10 -144.56 13.52 1.55 Allowed 'General case' 0 N--CA 1.48 1.038 0 C-N-CA 119.116 -1.033 . . . . 0.0 111.741 -179.944 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -90.85 149.96 41.22 Favored Pre-proline 0 C--N 1.292 -1.919 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.287 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_exo -47.91 144.25 12.05 Favored 'Trans proline' 0 C--O 1.216 -0.611 0 C-N-CA 120.917 1.078 . . . . 0.0 111.878 -179.539 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -74.6 73.98 1.99 Allowed 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 119.531 -0.868 . . . . 0.0 110.617 179.994 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 172.47 -32.72 0.12 Allowed Glycine 0 N--CA 1.487 2.053 0 C-N-CA 119.34 -1.41 . . . . 0.0 110.241 -179.94 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 81.4 t -94.83 105.79 17.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 C-N-CA 119.374 -0.93 . . . . 0.0 111.073 -179.855 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -52.17 143.99 13.29 Favored 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.334 -0.946 . . . . 0.0 110.715 179.882 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -93.04 -3.28 54.6 Favored 'General case' 0 C--N 1.304 -1.413 0 C-N-CA 119.328 -0.949 . . . . 0.0 110.908 -179.773 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.5 tt0 -90.22 -21.45 22.15 Favored 'General case' 0 C--N 1.304 -1.409 0 C-N-CA 119.255 -0.978 . . . . 0.0 110.94 -179.931 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 23.4 mmtt -78.14 -26.96 48.08 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.304 -0.958 . . . . 0.0 110.936 -179.997 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 3.3 pt -105.8 -12.22 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 C-N-CA 119.732 -0.787 . . . . 0.0 111.845 -179.192 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 18.6 m -78.39 170.07 17.22 Favored 'General case' 0 C--N 1.305 -1.358 0 C-N-CA 119.108 -1.037 . . . . 0.0 111.316 -179.952 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.655 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 55.5 mt-30 -134.19 74.11 68.27 Favored Pre-proline 0 N--CA 1.486 1.335 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.241 179.902 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -59.52 -20.26 56.19 Favored 'Trans proline' 0 C--O 1.215 -0.641 0 C-N-CA 121.277 1.318 . . . . 0.0 111.63 -178.69 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . 0.444 ' CG ' ' O ' ' A' ' 59' ' ' GLU . 3.4 pt-20 -89.14 107.0 18.8 Favored 'General case' 0 C--N 1.302 -1.495 0 C-N-CA 119.247 -0.981 . . . . 0.0 110.527 179.513 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.419 ' CD2' ' OD1' ' A' ' 38' ' ' ASN . 27.6 m-85 -51.93 165.61 0.19 Allowed 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 119.411 -0.915 . . . . 0.0 110.849 179.954 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.4 pp -139.34 126.38 21.09 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.711 -0.796 . . . . 0.0 110.43 179.466 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.457 ' OD1' ' N ' ' A' ' 62' ' ' ASN . 19.8 p-10 -118.31 34.97 4.94 Favored 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.057 -179.49 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -87.99 -172.08 47.06 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 119.238 -1.458 . . . . 0.0 110.214 179.64 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -133.59 105.94 7.14 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.87 -0.732 . . . . 0.0 110.049 179.579 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 94.24 -11.37 70.58 Favored Glycine 0 N--CA 1.486 2.03 0 C-N-CA 119.308 -1.425 . . . . 0.0 109.713 -179.299 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -50.59 160.94 0.37 Allowed 'General case' 0 C--N 1.307 -1.262 0 C-N-CA 119.446 -0.902 . . . . 0.0 110.359 179.684 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 34.7 p -145.8 158.99 43.82 Favored 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 119.207 -0.997 . . . . 0.0 111.393 -179.374 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.655 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 15.6 t80 -136.16 137.01 40.5 Favored 'General case' 0 N--CA 1.493 1.709 0 C-N-CA 119.738 -0.785 . . . . 0.0 109.365 179.068 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -99.97 152.3 20.35 Favored 'General case' 0 N--CA 1.496 1.856 0 C-N-CA 119.292 -0.963 . . . . 0.0 112.494 -178.769 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -155.81 134.53 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 115.191 -0.913 . . . . 0.0 108.9 179.509 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 10.1 m -128.6 96.7 4.47 Favored 'General case' 0 N--CA 1.486 1.327 0 C-N-CA 119.559 -0.856 . . . . 0.0 111.208 -179.482 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.5 mt -79.88 157.63 26.9 Favored 'General case' 0 C--N 1.308 -1.2 0 C-N-CA 119.25 -0.98 . . . . 0.0 109.9 179.433 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 77.6 p -150.06 45.96 0.91 Allowed 'General case' 0 C--N 1.3 -1.576 0 C-N-CA 119.125 -1.03 . . . . 0.0 111.495 -179.169 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.439 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 1.7 mm-40 -142.46 113.29 7.45 Favored 'General case' 0 N--CA 1.488 1.441 0 C-N-CA 119.098 -1.041 . . . . 0.0 110.448 179.557 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.466 ' CG ' ' O ' ' A' ' 75' ' ' LYS . 0.6 OUTLIER -52.45 119.33 4.35 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.268 -0.973 . . . . 0.0 111.058 -179.322 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 163.36 -147.87 13.91 Favored Glycine 0 N--CA 1.483 1.78 0 C-N-CA 119.254 -1.451 . . . . 0.0 110.142 179.86 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.74 130.18 23.9 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.752 -179.938 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.53 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 2.6 m-85 -114.86 123.8 50.08 Favored 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.923 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . 0.516 ' N ' ' CD ' ' A' ' 79' ' ' LYS . 0.5 OUTLIER -103.97 121.03 42.29 Favored 'General case' 0 N--CA 1.49 1.572 0 C-N-CA 119.133 -1.027 . . . . 0.0 111.76 -178.949 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.478 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 4.2 p90 -129.54 173.19 10.81 Favored 'General case' 0 N--CA 1.485 1.317 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.212 178.295 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 42.2 p90 -171.11 -174.29 1.46 Allowed 'General case' 0 C--N 1.292 -1.894 0 C-N-CA 119.531 -0.868 . . . . 0.0 110.814 -178.576 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -108.89 132.07 54.41 Favored 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 119.898 -0.721 . . . . 0.0 110.49 179.209 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.496 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 2.2 mt-10 -73.38 -47.18 7.61 Favored Pre-proline 0 N--CA 1.485 1.286 0 C-N-CA 119.432 -0.907 . . . . 0.0 112.472 -179.914 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.496 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 3.2 Cg_exo -64.54 -47.18 5.94 Favored 'Trans proline' 0 C--O 1.214 -0.704 0 C-N-CA 120.89 1.06 . . . . 0.0 111.953 -179.227 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . 0.619 ' CD2' HD13 ' A' ' 12' ' ' LEU . 37.6 m80 -90.51 21.42 3.95 Favored 'General case' 0 C--N 1.305 -1.36 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.971 -179.421 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -65.73 1.66 1.24 Allowed 'General case' 0 C--N 1.303 -1.449 0 C-N-CA 119.376 -0.93 . . . . 0.0 110.692 179.844 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.446 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -96.5 -20.94 23.41 Favored Glycine 0 N--CA 1.49 2.277 0 C-N-CA 119.471 -1.347 . . . . 0.0 110.412 -179.869 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -90.41 -9.87 45.95 Favored 'General case' 0 C--N 1.304 -1.37 0 C-N-CA 119.352 -0.939 . . . . 0.0 110.485 179.667 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 96.46 20.28 25.33 Favored Glycine 0 N--CA 1.488 2.102 0 C-N-CA 119.498 -1.334 . . . . 0.0 110.462 179.817 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.31 102.72 0.7 Allowed 'General case' 0 C--N 1.304 -1.377 0 C-N-CA 119.151 -1.02 . . . . 0.0 110.982 -179.829 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.07 162.1 26.86 Favored 'General case' 0 N--CA 1.498 1.928 0 C-N-CA 119.862 -0.735 . . . . 0.0 111.003 179.826 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -142.96 153.26 24.6 Favored Glycine 0 N--CA 1.491 2.359 0 C-N-CA 119.436 -1.364 . . . . 0.0 111.468 -178.587 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -155.62 144.87 20.85 Favored 'General case' 0 N--CA 1.486 1.36 0 C-N-CA 119.429 -0.908 . . . . 0.0 111.078 179.629 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 2.4 p -141.78 123.32 13.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 C-N-CA 119.241 -0.984 . . . . 0.0 110.193 178.461 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 92.3 m -101.14 108.2 19.81 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.158 -179.526 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 23.2 t -88.93 148.15 4.72 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 C-N-CA 118.771 -1.172 . . . . 0.0 110.764 -179.329 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.5 m-80 . . . . . 0 N--CA 1.485 1.317 0 CA-C-O 116.341 -1.79 . . . . 0.0 110.868 -179.903 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.14 0 N-CA-C 110.073 -0.343 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 19.8 mt-10 -135.26 127.38 29.87 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 120.027 -0.669 . . . . 0.0 110.574 179.741 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 2.7 t -115.72 131.86 66.85 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.406 0 C-N-CA 119.864 -0.735 . . . . 0.0 110.991 -179.745 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 19.7 mtpp -104.72 118.9 37.71 Favored 'General case' 0 C--N 1.306 -1.295 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.205 -179.749 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.429 HD12 HD22 ' A' ' 31' ' ' ASN . 2.9 mt -81.52 108.22 14.93 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 118.956 -1.098 . . . . 0.0 109.672 178.269 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.531 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 110.41 125.64 4.91 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.649 -1.381 . . . . 0.0 109.649 -179.1 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . 0.525 ' OG ' ' N ' ' A' ' 11' ' ' GLY . 3.2 p -78.57 22.72 0.34 Allowed 'General case' 0 C--N 1.299 -1.588 0 C-N-CA 119.162 -1.015 . . . . 0.0 110.934 -179.746 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.422 ' H ' ' C ' ' A' ' 6' ' ' GLY . 1.3 m-20 57.23 2.64 0.13 Allowed 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 119.829 -0.749 . . . . 0.0 111.395 179.585 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.485 ' H ' ' C ' ' A' ' 7' ' ' SER . 0.3 OUTLIER 175.62 -41.87 0.01 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.738 -179.965 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -54.44 -32.2 52.25 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.353 -1.403 . . . . 0.0 110.094 179.869 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.525 ' N ' ' OG ' ' A' ' 7' ' ' SER . . . 142.29 -136.1 7.04 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.518 -1.325 . . . . 0.0 110.556 179.978 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 10.6 mt -117.96 104.56 11.02 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 120.103 -0.639 . . . . 0.0 110.67 -179.728 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 17.4 m -150.01 154.25 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.122 0 C-N-CA 118.777 -1.169 . . . . 0.0 111.268 179.749 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.433 ' O ' ' O ' ' A' ' 16' ' ' PRO . 11.1 m-85 -78.6 108.57 12.09 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 177.818 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 53.3 m -114.76 112.31 45.29 Favored Pre-proline 0 CA--C 1.559 1.303 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.248 -177.176 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.433 ' O ' ' O ' ' A' ' 14' ' ' PHE . 1.8 Cg_endo -65.56 176.79 18.52 Favored 'Cis proline' 0 C--N 1.36 1.178 0 C-N-CA 125.188 -0.755 . . . . 0.0 111.702 -0.936 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 7.9 t -93.86 -55.97 3.05 Favored 'General case' 0 N--CA 1.487 1.381 0 C-N-CA 119.637 -0.825 . . . . 0.0 110.453 179.212 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.4 p -128.92 142.65 50.87 Favored 'General case' 0 N--CA 1.486 1.356 0 CA-C-N 115.569 -0.741 . . . . 0.0 109.814 179.212 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 35.7 p90 -163.9 143.01 7.83 Favored 'General case' 0 N--CA 1.489 1.509 0 C-N-CA 118.663 -1.215 . . . . 0.0 111.782 -179.278 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.431 HG23 ' H ' ' A' ' 20' ' ' THR . 0.1 OUTLIER -90.76 153.59 20.15 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 119.465 -0.894 . . . . 0.0 110.903 179.533 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 4.7 m -145.95 -176.75 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 C-N-CA 119.494 -0.882 . . . . 0.0 110.585 179.617 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.409 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -97.53 147.09 24.62 Favored 'General case' 0 N--CA 1.484 1.274 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.716 179.773 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.3 74.03 0.14 Allowed 'General case' 0 C--N 1.304 -1.396 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.836 179.741 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.411 ' H ' ' H ' ' A' ' 25' ' ' GLU . . . 155.54 18.09 0.04 OUTLIER Glycine 0 N--CA 1.487 2.087 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.913 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.411 ' H ' ' H ' ' A' ' 24' ' ' GLY . 14.7 tt0 -99.65 156.1 17.25 Favored 'General case' 0 C--N 1.306 -1.32 0 C-N-CA 119.767 -0.773 . . . . 0.0 110.881 -179.783 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 2.0 mptp? -93.81 119.28 32.56 Favored 'General case' 0 C--N 1.303 -1.446 0 C-N-CA 119.537 -0.865 . . . . 0.0 110.722 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 13.1 mt -100.06 106.5 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.254 179.6 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 72.2 p -104.26 117.7 34.85 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.582 -0.847 . . . . 0.0 112.888 -177.893 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -84.38 149.0 26.31 Favored 'General case' 0 C--N 1.307 -1.266 0 C-N-CA 119.408 -0.917 . . . . 0.0 108.548 177.893 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 6.4 ttpp -141.19 133.39 27.98 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 118.965 -1.094 . . . . 0.0 111.664 -178.445 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.438 ' OD1' ' O ' ' A' ' 66' ' ' GLU . 0.0 OUTLIER -89.48 104.02 16.61 Favored 'General case' 0 C--N 1.301 -1.505 0 C-N-CA 119.08 -1.048 . . . . 0.0 109.735 178.946 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.531 ' ND2' ' O ' ' A' ' 6' ' ' GLY . 2.3 p-10 -91.56 -31.72 15.8 Favored 'General case' 0 N--CA 1.484 1.229 0 C-N-CA 118.864 -1.134 . . . . 0.0 111.846 -178.584 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . . . . . . . . . . . -175.21 139.78 0.48 Allowed 'General case' 0 N--CA 1.488 1.447 0 C-N-CA 118.96 -1.096 . . . . 0.0 111.138 -179.693 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 99.26 15.35 33.02 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.495 -1.335 . . . . 0.0 111.784 178.784 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.404 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -58.55 163.24 5.26 Favored Pre-proline 0 N--CA 1.481 1.113 0 C-N-CA 117.96 -1.496 . . . . 0.0 109.2 179.557 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -74.53 -174.48 13.85 Favored 'Cis proline' 0 C--O 1.206 -1.091 0 C-N-CA 124.481 -1.05 . . . . 0.0 112.195 -0.382 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 36.3 m-70 -149.7 -178.71 6.6 Favored 'General case' 0 C--N 1.298 -1.645 0 CA-C-N 115.661 -0.7 . . . . 0.0 109.885 178.544 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.726 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.2 OUTLIER -156.75 137.22 13.05 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.197 -1.001 . . . . 0.0 110.375 179.166 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.726 ' N ' HD22 ' A' ' 38' ' ' ASN . 7.6 mt -122.0 85.27 0.92 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 C-N-CA 119.866 -0.734 . . . . 0.0 111.479 -179.516 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 t -103.34 157.94 5.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.316 0 C-N-CA 119.922 -0.711 . . . . 0.0 109.484 178.755 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 16.3 m-85 -112.29 138.97 48.25 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 119.285 -0.966 . . . . 0.0 111.949 -179.42 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.512 ' C ' ' H ' ' A' ' 44' ' ' ASP . 4.4 t70 -82.36 105.95 13.85 Favored 'General case' 0 C--N 1.303 -1.441 0 C-N-CA 119.457 -0.897 . . . . 0.0 110.003 179.162 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 9.6 pt-20 -70.81 32.92 0.04 OUTLIER 'General case' 0 N--CA 1.486 1.339 0 C-N-CA 119.536 -0.866 . . . . 0.0 111.378 -179.451 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.512 ' H ' ' C ' ' A' ' 42' ' ' ASP . 82.5 m-20 -108.95 -15.13 14.43 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 120.032 -0.667 . . . . 0.0 110.693 179.518 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 3.8 mm-40 -139.79 16.33 2.5 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.418 -0.913 . . . . 0.0 110.718 179.491 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -93.41 143.7 27.09 Favored Pre-proline 0 C--N 1.296 -1.735 0 N-CA-C 108.779 -0.822 . . . . 0.0 108.779 179.31 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.403 ' C ' ' H ' ' A' ' 49' ' ' GLY . 3.0 Cg_exo -48.45 140.74 20.69 Favored 'Trans proline' 0 C--O 1.214 -0.682 0 C-N-CA 120.754 0.97 . . . . 0.0 111.961 -179.392 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -77.32 43.16 0.37 Allowed 'General case' 0 N--CA 1.484 1.259 0 C-N-CA 119.551 -0.86 . . . . 0.0 110.67 179.973 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.403 ' H ' ' C ' ' A' ' 47' ' ' PRO . . . -148.78 -26.51 0.07 OUTLIER Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 179.828 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . 0.441 ' O ' HG12 ' A' ' 50' ' ' VAL . 46.7 t -101.83 93.95 3.06 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 C-N-CA 119.913 -0.715 . . . . 0.0 110.458 179.746 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -44.88 139.62 2.97 Favored 'General case' 0 C--N 1.305 -1.35 0 C-N-CA 119.302 -0.959 . . . . 0.0 110.741 -179.919 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -90.81 3.42 54.47 Favored 'General case' 0 C--N 1.303 -1.439 0 C-N-CA 119.263 -0.975 . . . . 0.0 110.502 179.851 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -90.3 -31.63 16.86 Favored 'General case' 0 C--N 1.305 -1.357 0 C-N-CA 119.517 -0.873 . . . . 0.0 110.933 179.909 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 37.0 mttt -69.68 -32.52 71.18 Favored 'General case' 0 C--N 1.306 -1.286 0 C-N-CA 119.421 -0.912 . . . . 0.0 111.32 -179.762 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . . . . . . . . . 2.0 pt -93.22 -35.07 6.26 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.431 0 C-N-CA 119.123 -1.031 . . . . 0.0 111.148 -179.885 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 12.4 m -56.27 163.88 1.51 Allowed 'General case' 0 C--N 1.308 -1.237 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.198 179.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.642 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 63.3 mt-30 -124.97 84.59 58.76 Favored Pre-proline 0 N--CA 1.487 1.42 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.231 179.713 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -60.37 -22.71 72.25 Favored 'Trans proline' 0 C--O 1.216 -0.612 0 C-N-CA 120.995 1.13 . . . . 0.0 111.834 -178.761 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -96.35 115.93 28.22 Favored 'General case' 0 N--CA 1.486 1.373 0 C-N-CA 119.349 -0.94 . . . . 0.0 110.858 179.868 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . 0.533 ' CE1' ' OD1' ' A' ' 38' ' ' ASN . 55.0 m-85 -56.34 177.37 0.07 Allowed 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.624 179.879 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.7 pp -148.33 132.75 17.6 Favored 'General case' 0 N--CA 1.486 1.367 0 C-N-CA 119.283 -0.967 . . . . 0.0 110.8 179.93 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -128.99 39.03 3.85 Favored 'General case' 0 N--CA 1.493 1.721 0 C-N-CA 119.976 -0.69 . . . . 0.0 110.955 -179.745 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -102.27 125.52 8.55 Favored Glycine 0 N--CA 1.494 2.512 0 C-N-CA 119.632 -1.271 . . . . 0.0 110.388 179.985 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -70.52 103.3 2.44 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.295 -0.962 . . . . 0.0 110.532 179.748 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 100.38 -0.24 55.76 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.614 -1.279 . . . . 0.0 110.458 -179.884 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' A' ' 31' ' ' ASN . 17.6 tt0 -72.99 106.99 5.1 Favored 'General case' 0 N--CA 1.49 1.562 0 C-N-CA 119.062 -1.055 . . . . 0.0 110.569 179.863 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 1.1 p -96.43 161.99 13.68 Favored 'General case' 0 C--N 1.305 -1.361 0 C-N-CA 119.483 -0.887 . . . . 0.0 111.702 -179.169 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.642 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 24.2 t80 -135.75 136.04 40.45 Favored 'General case' 0 N--CA 1.491 1.592 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.517 179.185 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.4 mt-10 -98.13 152.23 19.57 Favored 'General case' 0 N--CA 1.492 1.665 0 C-N-CA 119.256 -0.978 . . . . 0.0 112.547 -178.428 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 1.4 t -151.85 132.78 4.55 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.633 178.951 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 6.6 m -123.52 107.29 11.39 Favored 'General case' 0 N--CA 1.487 1.377 0 C-N-CA 119.622 -0.831 . . . . 0.0 112.023 -178.683 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . 0.424 ' CD1' HG11 ' A' ' 94' ' ' VAL . 50.5 mt -89.58 160.88 16.45 Favored 'General case' 0 C--N 1.304 -1.372 0 C-N-CA 119.513 -0.875 . . . . 0.0 109.348 178.749 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -151.21 41.09 0.72 Allowed 'General case' 0 C--N 1.3 -1.57 0 C-N-CA 118.66 -1.216 . . . . 0.0 111.754 -178.918 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . 0.462 ' CB ' ' OH ' ' A' ' 78' ' ' TYR . 0.6 OUTLIER -141.85 116.76 9.88 Favored 'General case' 0 N--CA 1.489 1.503 0 C-N-CA 118.874 -1.13 . . . . 0.0 110.981 179.784 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -55.7 106.18 0.23 Allowed 'General case' 0 C--N 1.305 -1.336 0 C-N-CA 119.452 -0.899 . . . . 0.0 111.167 -179.685 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 173.93 -163.06 33.93 Favored Glycine 0 N--CA 1.484 1.843 0 C-N-CA 119.353 -1.403 . . . . 0.0 109.831 -179.987 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.6 125.7 45.3 Favored 'General case' 0 N--CA 1.485 1.308 0 C-N-CA 119.807 -0.757 . . . . 0.0 111.071 -179.881 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.547 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.6 m-85 -109.3 153.73 23.49 Favored 'General case' 0 N--CA 1.483 1.213 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.018 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 81.1 mttt -115.63 134.49 54.99 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 119.402 -0.919 . . . . 0.0 112.469 -179.394 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.503 ' O ' ' N ' ' A' ' 92' ' ' GLY . 0.9 OUTLIER -143.57 154.98 44.15 Favored 'General case' 0 C--N 1.303 -1.443 0 C-N-CA 119.492 -0.883 . . . . 0.0 110.058 176.917 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 36.5 p90 -168.45 -174.51 2.24 Favored 'General case' 0 C--N 1.284 -2.259 0 C-N-CA 119.577 -0.849 . . . . 0.0 110.582 -178.666 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.3 t -110.94 122.57 48.21 Favored 'General case' 0 C--N 1.308 -1.239 0 C-N-CA 119.842 -0.743 . . . . 0.0 109.832 179.732 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.582 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 1.5 tm-20 -72.74 -35.58 3.09 Favored Pre-proline 0 N--CA 1.483 1.182 0 C-N-CA 119.056 -1.058 . . . . 0.0 113.292 -178.885 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.582 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 1.1 Cg_endo -71.43 -38.48 4.56 Favored 'Trans proline' 0 C--O 1.213 -0.728 0 C-N-CA 120.52 0.814 . . . . 0.0 111.111 179.855 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 32.8 m80 -102.17 21.05 15.55 Favored 'General case' 0 N--CA 1.488 1.474 0 C-N-CA 119.785 -0.766 . . . . 0.0 111.049 -179.771 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.78 -12.9 8.22 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.612 179.766 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . -92.5 -13.47 57.0 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.324 179.821 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -87.59 -20.44 26.39 Favored 'General case' 0 C--N 1.306 -1.306 0 C-N-CA 119.323 -0.951 . . . . 0.0 110.549 179.933 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 110.21 14.82 12.47 Favored Glycine 0 N--CA 1.496 2.654 0 C-N-CA 119.853 -1.165 . . . . 0.0 110.83 179.673 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.3 mtp -72.27 98.4 2.18 Favored 'General case' 0 N--CA 1.485 1.307 0 C-N-CA 119.259 -0.976 . . . . 0.0 110.689 179.875 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 21.0 mmtt -130.37 150.33 51.65 Favored 'General case' 0 N--CA 1.496 1.843 0 C-N-CA 119.962 -0.695 . . . . 0.0 110.835 179.538 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.503 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -140.3 155.92 24.85 Favored Glycine 0 N--CA 1.501 3.021 0 C-N-CA 119.283 -1.437 . . . . 0.0 112.456 -177.914 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 26.5 tt0 -158.64 146.43 18.04 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 120.259 -0.576 . . . . 0.0 110.203 179.014 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.542 HG13 ' O ' ' A' ' 94' ' ' VAL . 11.9 p -138.29 122.25 21.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 C-N-CA 119.265 -0.974 . . . . 0.0 111.001 179.974 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 89.5 m -97.19 97.03 8.84 Favored 'General case' 0 C--N 1.303 -1.427 0 C-N-CA 119.428 -0.909 . . . . 0.0 110.673 179.885 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 24.0 t -81.95 154.17 4.06 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 C-N-CA 119.034 -1.066 . . . . 0.0 110.907 -179.051 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 2.2 p30 . . . . . 0 C--N 1.306 -1.318 0 CA-C-O 116.348 -1.787 . . . . 0.0 110.651 179.872 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.197 0 N-CA-C 110.086 -0.339 . . . . 0.0 110.086 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 9.4 mt-10 -104.77 123.98 48.61 Favored 'General case' 0 N--CA 1.488 1.458 0 C-N-CA 119.8 -0.76 . . . . 0.0 110.986 179.948 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 4.6 t -117.28 128.54 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 C-N-CA 119.888 -0.725 . . . . 0.0 110.404 179.494 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . . . . . . . . . 77.1 mttt -103.76 117.92 35.49 Favored 'General case' 0 C--N 1.301 -1.522 0 C-N-CA 119.814 -0.754 . . . . 0.0 111.155 -179.49 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . . . . . . . . . 5.2 mt -78.18 109.14 12.03 Favored 'General case' 0 C--N 1.307 -1.259 0 C-N-CA 118.727 -1.189 . . . . 0.0 109.529 177.964 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.406 ' O ' ' ND2' ' A' ' 32' ' ' ASN . . . 107.47 120.47 4.55 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.061 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 7' ' ' SER . . . . . . . . . . . . . 31.9 p -79.45 166.03 22.43 Favored 'General case' 0 C--N 1.305 -1.355 0 C-N-CA 119.582 -0.847 . . . . 0.0 110.992 -179.808 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -82.93 -29.65 28.98 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.497 -0.881 . . . . 0.0 110.998 179.928 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.6 p-10 -65.84 -4.93 7.59 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 119.408 -0.917 . . . . 0.0 111.043 -179.885 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.64 61.07 1.02 Allowed Glycine 0 N--CA 1.492 2.396 0 C-N-CA 119.37 -1.395 . . . . 0.0 110.468 179.988 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -154.02 154.2 25.35 Favored Glycine 0 N--CA 1.489 2.213 0 C-N-CA 119.459 -1.353 . . . . 0.0 110.295 -179.995 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 73.5 mt -101.14 99.91 10.4 Favored 'General case' 0 N--CA 1.488 1.451 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.041 -179.885 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 33.9 m -150.07 157.44 6.17 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.158 0 C-N-CA 119.036 -1.066 . . . . 0.0 110.73 179.325 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' PHE . . . . . 0.415 ' O ' ' O ' ' A' ' 16' ' ' PRO . 14.2 m-85 -78.44 112.02 15.05 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 178.135 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 54.6 m -116.03 108.79 45.69 Favored Pre-proline 0 CA--C 1.558 1.26 0 C-N-CA 119.375 -0.93 . . . . 0.0 111.824 -177.861 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . 0.415 ' O ' ' O ' ' A' ' 14' ' ' PHE . 2.6 Cg_endo -65.76 177.84 16.68 Favored 'Cis proline' 0 C--N 1.362 1.244 0 C-N-CA 125.353 -0.686 . . . . 0.0 111.75 -0.49 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -93.65 -51.64 4.83 Favored 'General case' 0 N--CA 1.488 1.47 0 C-N-CA 119.509 -0.877 . . . . 0.0 110.423 179.437 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 94.5 p -140.02 141.89 36.27 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.782 179.385 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' N ' ' A' ' 19' ' ' PHE . 22.4 p90 -162.71 149.42 12.95 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 118.743 -1.183 . . . . 0.0 111.183 -179.169 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . 0.422 HG23 ' H ' ' A' ' 20' ' ' THR . 0.7 OUTLIER -91.01 159.26 16.23 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.388 -0.925 . . . . 0.0 111.169 -179.972 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . . . . . . . . . 27.6 m -149.95 172.01 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 C-N-CA 119.515 -0.874 . . . . 0.0 110.858 179.697 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.503 ' O ' ' N ' ' A' ' 24' ' ' GLY . . . -88.83 147.79 24.23 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 119.459 -0.897 . . . . 0.0 110.662 179.9 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -61.85 76.3 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.371 0 C-N-CA 119.48 -0.888 . . . . 0.0 110.943 179.802 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . 0.503 ' N ' ' O ' ' A' ' 22' ' ' ALA . . . 147.18 22.28 0.09 OUTLIER Glycine 0 N--CA 1.49 2.268 0 C-N-CA 119.537 -1.315 . . . . 0.0 109.933 179.968 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -96.3 145.97 25.13 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 119.646 -0.821 . . . . 0.0 111.01 -179.787 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.8 mttm -87.12 128.68 35.11 Favored 'General case' 0 C--N 1.303 -1.436 0 C-N-CA 119.345 -0.942 . . . . 0.0 110.863 -179.971 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 5.8 mt -118.55 131.97 69.79 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 179.432 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 25.1 p -128.7 116.96 20.35 Favored 'General case' 0 N--CA 1.492 1.647 0 C-N-CA 119.354 -0.938 . . . . 0.0 112.384 -178.55 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 76.5 m-85 -84.82 109.72 18.3 Favored 'General case' 0 C--N 1.303 -1.442 0 C-N-CA 119.453 -0.899 . . . . 0.0 108.855 177.905 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 22.3 tttm -106.05 138.06 42.89 Favored 'General case' 0 N--CA 1.486 1.362 0 C-N-CA 119.719 -0.792 . . . . 0.0 111.445 -178.103 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.446 HD21 ' CD1' ' A' ' 61' ' ' LEU . 4.3 m-20 -83.26 106.9 15.42 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.062 179.404 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 32' ' ' ASN . . . . . 0.663 ' O ' ' HB2' ' A' ' 33' ' ' ALA . 1.0 OUTLIER -90.19 -30.75 17.39 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 118.88 -1.128 . . . . 0.0 111.774 -178.865 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 33' ' ' ALA . . . . . 0.663 ' HB2' ' O ' ' A' ' 32' ' ' ASN . . . 167.81 114.62 0.01 OUTLIER 'General case' 0 N--CA 1.484 1.263 0 C-N-CA 118.827 -1.149 . . . . 0.0 111.144 179.916 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 139.37 -0.96 2.34 Favored Glycine 0 N--CA 1.487 2.087 0 C-N-CA 119.587 -1.292 . . . . 0.0 110.559 179.858 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 35' ' ' PHE . . . . . 0.426 ' CD1' ' N ' ' A' ' 35' ' ' PHE . 0.0 OUTLIER -48.0 161.83 0.35 Allowed Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 118.749 -1.18 . . . . 0.0 110.071 -179.65 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -77.62 144.05 75.89 Favored 'Cis proline' 0 C--O 1.216 -0.587 0 C-N-CA 124.113 -1.203 . . . . 0.0 112.271 -1.022 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 37' ' ' HIS . . . . . . . . . . . . . 42.5 m-70 -112.85 175.56 5.39 Favored 'General case' 0 N--CA 1.495 1.782 0 C-N-CA 119.915 -0.714 . . . . 0.0 110.135 179.42 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.691 HD22 ' N ' ' A' ' 39' ' ' ILE . 0.1 OUTLIER -151.64 148.97 28.6 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 119.156 -1.018 . . . . 0.0 110.529 179.493 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.691 ' N ' HD22 ' A' ' 38' ' ' ASN . 4.0 mp -134.86 103.47 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 C-N-CA 119.616 -0.833 . . . . 0.0 111.351 -179.502 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.8 t -119.08 144.65 26.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 C-N-CA 120.075 -0.65 . . . . 0.0 110.123 179.22 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.689 ' CD2' HD12 ' A' ' 55' ' ' ILE . 9.9 m-85 -99.88 114.67 28.05 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 119.526 -0.87 . . . . 0.0 111.443 -179.338 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 42' ' ' ASP . . . . . 0.519 ' O ' ' N ' ' A' ' 44' ' ' ASP . 32.8 t0 -55.6 88.41 0.01 OUTLIER 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 119.441 -0.903 . . . . 0.0 110.48 179.676 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . 0.467 ' N ' ' O ' ' A' ' 41' ' ' PHE . 16.0 pt-20 -46.71 -13.25 0.03 OUTLIER 'General case' 0 N--CA 1.487 1.404 0 C-N-CA 119.515 -0.874 . . . . 0.0 111.357 -179.688 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . 0.519 ' N ' ' O ' ' A' ' 42' ' ' ASP . 0.9 OUTLIER -87.97 13.11 11.66 Favored 'General case' 0 C--N 1.305 -1.337 0 C-N-CA 119.308 -0.957 . . . . 0.0 111.388 -179.594 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -151.66 15.32 0.67 Allowed 'General case' 0 C--N 1.309 -1.181 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.114 179.843 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.588 HG22 ' HD2' ' A' ' 47' ' ' PRO . 0.5 OUTLIER -104.06 154.87 37.85 Favored Pre-proline 0 N--CA 1.491 1.624 0 N-CA-C 108.911 -0.774 . . . . 0.0 108.911 179.838 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . 0.588 ' HD2' HG22 ' A' ' 46' ' ' VAL . 6.1 Cg_exo -52.83 149.79 24.69 Favored 'Trans proline' 0 C--O 1.216 -0.594 0 C-N-CA 120.887 1.058 . . . . 0.0 111.236 179.646 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 48' ' ' ALA . . . . . . . . . . . . . . . -83.06 40.78 0.72 Allowed 'General case' 0 C--N 1.307 -1.252 0 C-N-CA 119.293 -0.963 . . . . 0.0 110.716 -179.899 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -142.89 -40.09 0.07 OUTLIER Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 179.804 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 50' ' ' VAL . . . . . . . . . . . . . 70.3 t -92.48 90.8 3.19 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 119.56 -0.856 . . . . 0.0 110.146 179.449 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.2 m-80 -44.8 146.5 0.77 Allowed 'General case' 0 N--CA 1.486 1.354 0 C-N-CA 119.314 -0.955 . . . . 0.0 110.877 -179.641 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -90.84 -29.58 17.46 Favored 'General case' 0 C--N 1.306 -1.323 0 C-N-CA 119.544 -0.862 . . . . 0.0 111.076 -179.728 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 3.9 pt-20 -60.74 -5.43 1.28 Allowed 'General case' 0 C--N 1.302 -1.468 0 C-N-CA 119.28 -0.968 . . . . 0.0 110.995 -179.719 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 22.2 mtmt -99.55 -38.39 8.78 Favored 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 119.605 -0.838 . . . . 0.0 111.486 -179.828 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 55' ' ' ILE . . . . . 0.689 HD12 ' CD2' ' A' ' 41' ' ' PHE . 2.1 pt -90.49 -29.25 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.208 -179.562 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 56' ' ' SER . . . . . . . . . . . . . 58.8 m -56.23 172.34 0.22 Allowed 'General case' 0 C--N 1.305 -1.342 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.107 179.909 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.64 ' NE2' ' CG ' ' A' ' 68' ' ' TYR . 60.9 mt-30 -134.45 71.92 70.96 Favored Pre-proline 0 N--CA 1.491 1.601 0 C-N-CA 119.981 -0.688 . . . . 0.0 110.815 179.757 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -59.29 -6.81 4.31 Favored 'Trans proline' 0 C--N 1.32 -0.927 0 C-N-CA 121.074 1.183 . . . . 0.0 111.209 -179.664 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -100.25 106.48 18.15 Favored 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.651 179.577 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 60' ' ' TYR . . . . . . . . . . . . . 31.1 m-85 -52.34 168.3 0.11 Allowed 'General case' 0 C--N 1.306 -1.312 0 C-N-CA 119.594 -0.842 . . . . 0.0 110.471 -179.993 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.446 ' CD1' HD21 ' A' ' 31' ' ' ASN . 1.7 pp -148.26 141.73 25.35 Favored 'General case' 0 N--CA 1.487 1.38 0 C-N-CA 119.12 -1.032 . . . . 0.0 110.877 179.85 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -137.85 8.09 2.76 Favored 'General case' 0 N--CA 1.488 1.44 0 C-N-CA 119.721 -0.792 . . . . 0.0 111.088 -179.835 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 63' ' ' GLY . . . . . . . . . . . . . . . -65.52 127.47 31.65 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 119.091 -1.528 . . . . 0.0 110.302 179.892 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -72.0 120.81 18.13 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.179 -1.008 . . . . 0.0 110.266 179.659 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 65' ' ' GLY . . . . . . . . . . . . . . . 86.29 -14.69 53.45 Favored Glycine 0 N--CA 1.487 2.047 0 C-N-CA 119.111 -1.519 . . . . 0.0 110.657 -179.664 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -62.19 152.08 34.22 Favored 'General case' 0 N--CA 1.489 1.483 0 C-N-CA 119.169 -1.012 . . . . 0.0 110.469 179.762 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -142.93 171.97 13.33 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.368 -0.933 . . . . 0.0 111.592 -179.615 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.64 ' CG ' ' NE2' ' A' ' 57' ' ' GLN . 34.2 t80 -135.73 128.41 30.86 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.145 179.218 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -99.23 155.79 17.31 Favored 'General case' 0 N--CA 1.49 1.562 0 C-N-CA 119.052 -1.059 . . . . 0.0 112.383 -178.604 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -156.34 142.94 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.023 178.93 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . . . . . . . . . 3.9 m -130.99 96.13 3.98 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 119.784 -0.766 . . . . 0.0 111.265 -179.287 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 11.7 mt -79.58 161.3 26.02 Favored 'General case' 0 C--N 1.308 -1.23 0 C-N-CA 119.045 -1.062 . . . . 0.0 109.134 179.172 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -150.46 45.47 0.87 Allowed 'General case' 0 C--N 1.302 -1.486 0 C-N-CA 118.596 -1.242 . . . . 0.0 112.242 -178.688 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 74' ' ' GLU . . . . . . . . . . . . . 29.2 mm-40 -143.82 105.7 4.34 Favored 'General case' 0 N--CA 1.489 1.521 0 C-N-CA 118.876 -1.13 . . . . 0.0 110.269 179.279 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -43.51 109.93 0.17 Allowed 'General case' 0 N--CA 1.484 1.247 0 C-N-CA 119.51 -0.876 . . . . 0.0 110.816 -179.296 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 175.98 -147.89 8.95 Favored Glycine 0 N--CA 1.486 1.989 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.417 -179.918 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 77' ' ' THR . . . . . 0.461 HG23 HG23 ' A' ' 95' ' ' THR . 0.0 OUTLIER -143.55 131.65 21.81 Favored 'General case' 0 C--N 1.305 -1.338 0 C-N-CA 119.598 -0.841 . . . . 0.0 110.807 -179.898 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 78' ' ' TYR . . . . . 0.595 ' CD1' ' N ' ' A' ' 78' ' ' TYR . 1.0 OUTLIER -119.6 129.61 54.7 Favored 'General case' 0 N--CA 1.486 1.336 0 CA-C-N 115.547 -0.751 . . . . 0.0 109.578 -179.942 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 79' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -101.3 121.21 41.48 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 119.424 -0.91 . . . . 0.0 111.827 -179.49 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . 0.54 ' CD1' ' N ' ' A' ' 80' ' ' PHE . 1.7 p90 -131.48 166.34 21.55 Favored 'General case' 0 N--CA 1.488 1.435 0 C-N-CA 119.816 -0.753 . . . . 0.0 110.009 178.161 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 81' ' ' TYR . . . . . . . . . . . . . 29.6 p90 -170.29 -176.85 2.31 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 119.105 -1.038 . . . . 0.0 111.409 -178.355 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 82' ' ' CYS . . . . . . . . . . . . . 1.8 t -102.21 130.75 48.96 Favored 'General case' 0 N--CA 1.482 1.154 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.301 179.16 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.55 ' N ' ' CD ' ' A' ' 84' ' ' PRO . 0.9 OUTLIER -77.3 -44.64 2.68 Favored Pre-proline 0 N--CA 1.485 1.279 0 C-N-CA 119.328 -0.949 . . . . 0.0 112.713 -179.71 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 84' ' ' PRO . . . . . 0.55 ' CD ' ' N ' ' A' ' 83' ' ' GLU . 4.1 Cg_exo -65.57 -52.91 0.88 Allowed 'Trans proline' 0 C--O 1.216 -0.596 0 C-N-CA 120.914 1.076 . . . . 0.0 111.535 -179.096 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . 0.466 ' C ' ' H ' ' A' ' 87' ' ' GLY . 37.4 m80 -81.94 15.58 2.22 Favored 'General case' 0 C--N 1.302 -1.46 0 C-N-CA 119.487 -0.885 . . . . 0.0 110.804 -179.874 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.65 -0.94 0.32 Allowed 'General case' 0 C--N 1.305 -1.346 0 C-N-CA 119.552 -0.859 . . . . 0.0 111.107 -179.938 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . 0.466 ' H ' ' C ' ' A' ' 85' ' ' HIS . . . -95.15 -14.14 49.73 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.324 -1.417 . . . . 0.0 110.361 179.951 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -93.14 -51.89 4.82 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.596 179.925 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . 142.26 24.75 0.2 Allowed Glycine 0 N--CA 1.488 2.166 0 C-N-CA 119.537 -1.316 . . . . 0.0 110.502 179.901 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 90' ' ' MET . . . . . . . . . . . . . 8.1 mtp -73.16 97.99 2.51 Favored 'General case' 0 C--N 1.307 -1.256 0 C-N-CA 119.148 -1.021 . . . . 0.0 110.962 -179.95 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.3 ptpt -119.7 154.99 33.28 Favored 'General case' 0 N--CA 1.491 1.6 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.507 179.22 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 80' ' ' PHE . . . -141.4 145.66 16.31 Favored Glycine 0 N--CA 1.496 2.64 0 C-N-CA 119.396 -1.383 . . . . 0.0 111.399 -178.764 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -152.2 143.78 23.49 Favored 'General case' 0 N--CA 1.489 1.499 0 C-N-CA 119.486 -0.886 . . . . 0.0 111.062 179.636 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.499 HG13 ' O ' ' A' ' 94' ' ' VAL . 12.3 p -137.16 125.2 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 C-N-CA 119.112 -1.035 . . . . 0.0 110.678 179.159 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.461 HG23 HG23 ' A' ' 77' ' ' THR . 46.2 m -102.56 99.18 9.17 Favored 'General case' 0 N--CA 1.489 1.482 0 C-N-CA 119.489 -0.884 . . . . 0.0 110.549 179.408 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 40.3 t -79.69 147.84 6.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.295 0 C-N-CA 118.763 -1.175 . . . . 0.0 110.633 -178.843 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 97' ' ' ASN . . . . . . . . . . . . . 3.9 m-80 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 116.285 -1.816 . . . . 0.0 110.75 -179.697 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 100' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_